PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chen, N; Szentirmay, MN; Pawar, SA; Sirito, M; Wang, J; Wang, Z; Zhai, Q; Yang, HX; Peehl, DM; Ware, JL; Sawadogo, M				Chen, N; Szentirmay, MN; Pawar, SA; Sirito, M; Wang, J; Wang, Z; Zhai, Q; Yang, HX; Peehl, DM; Ware, JL; Sawadogo, M			Tumor-suppression function of transcription factor USF2 in prostate carcinogenesis	ONCOGENE			English	Article						USF; transcription factor; tumor-suppressor gene; prostate cancer	HELIX-LOOP-HELIX; EPITHELIAL-CELLS; CANCER CELLS; DNA-BINDING; RECEPTOR; PROMOTER; TUMORIGENICITY; PROLIFERATION; EXPRESSION; NKX3.1	Although the transcription factor USF2 has been implicated in the regulation of cellular growth and proliferation, it is unknown whether alterations in USF2 contribute to tumorigenesis and tumor development. We examined the role of USF2 in prostate tumorigenesis. Western blot analysis revealed markedly decreased USF2 levels in three androgen-independent prostate cancer cell lines, PC-3, DU145, and M12, as compared to nontumorigenic prostate epithelial cells or the androgen-dependent cell line, LNCaP. Ectopic expression of USF2 in PC-3 cells did not affect the cell proliferation rate of PC-3 cells on plastic surfaces. However, it dramatically decreased anchorage-independent growth of PC-3 cells in soft agar (90-98% inhibition) and the invasion capability (80% inhibition) of PC-3 cells in matrix gel assay. Importantly, expression of USF2 in PC-3 cells inhibited the tumorigenicity of PC-3 cells in an in vivo nude mice xenograft model (80-90% inhibition). These results suggest that USF2 has tumor-suppression function. Consistent with its function in tumor suppression, we found that the USF2 protein is present in normal prostate epithelial cells but absent in 18 of 42 (43%) human prostate cancer tissues (P = 0.015). To further examine the functional role of USF2 in vivo, we generated mice with genetic deletion of USF2 gene. We found that USF2-null mice displayed marked prostate hyperplasia at a young age, suggesting that USF2 is involved in the normal growth and differentiation of prostate. Together, these studies demonstrate that USF2 has tumor-suppressor function and plays a role in prostate carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Methodist Hosp, Dept Pathol, Houston, TX 77030 USA; Stanford Univ, Dept Urol, Stanford, CA 94305 USA; Virginia Commonwealth Univ, Sch Med, Dept Pathol, Richmond, VA USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; The Methodist Hospital System; The Methodist Hospital - Houston; Stanford University; Virginia Commonwealth University	Chen, N (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	nanchen@mdanderson.org	Pawar, Snehalata/ABD-4557-2020	Pawar, Snehalata/0000-0003-3992-2494	NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aperlo C, 1996, EUR J BIOCHEM, V241, P249, DOI 10.1111/j.1432-1033.1996.0249t.x; Astbury C, 2001, GENE CHROMOSOME CANC, V31, P143, DOI 10.1002/gcc.1128; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Bookstein R, 2001, CONT CANC RES, P61; Bowen C, 2000, CANCER RES, V60, P6111; Choe C, 2005, EXP CELL RES, V302, P1, DOI 10.1016/j.yexcr.2004.08.013; Colella R, 2004, BIOTECH HISTOCHEM, V79, P121, DOI 10.1080/10520290400010572; Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990; Dehm SM, 2005, EXPERT REV ANTICANC, V5, P63, DOI 10.1586/14737140.5.1.63; GAO X, 1999, ADV ONCOBIOL, V3, P85; Gonzalgo ML, 2003, J UROLOGY, V170, P2444, DOI 10.1097/01.ju.0000085381.20139.b6; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Isaacs W, 2001, EPIDEMIOL REV, V23, P36, DOI 10.1093/oxfordjournals.epirev.a000794; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; Jaiswal AS, 2001, J CELL BIOCHEM, V81, P262, DOI 10.1002/1097-4644(20010501)81:2<262::AID-JCB1041>3.0.CO;2-R; Karayi MK, 2004, PROSTATE CANCER P D, V7, P6, DOI 10.1038/sj.pcan.4500697; Kivinen A, 2004, PROSTATE, V59, P190, DOI 10.1002/pros.20015; KOZLOWSKI JM, 1999, HUMAN CELL CULTURE, V2, P305; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; Macleod K, 2000, CURR OPIN GENET DEV, V10, P81, DOI 10.1016/S0959-437X(99)00041-6; Maddison LA, 2004, CANCER RES, V64, P6018, DOI 10.1158/0008-5472.CAN-03-2509; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Pawar SA, 2004, ONCOGENE, V23, P6125, DOI 10.1038/sj.onc.1207806; Peehl DM, 2002, CULTURE EPITHELIAL C, P171; Plymate SR, 2004, PROSTATE, V61, P276, DOI 10.1002/pros.20099; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; RUDDON RW, 1995, CANC BIOL, P96; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMID HP, 1992, AM J SURG PATHOL, V16, P184, DOI 10.1097/00000478-199202000-00012; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; STEINGRIMSSON E, 1995, GENOMICS, V28, P179, DOI 10.1006/geno.1995.1129; Szentirmay MN, 2003, J BIOL CHEM, V278, P37231, DOI 10.1074/jbc.M305791200; Vakar-Lopez F, 2004, J PATHOL, V203, P688, DOI 10.1002/path.1568; Voeller HJ, 1997, CANCER RES, V57, P4455	44	23	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					579	587		10.1038/sj.onc.1209079	http://dx.doi.org/10.1038/sj.onc.1209079			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16186802				2022-12-17	WOS:000234897400009
J	Ivanova, IA; D'Souza, SJA; Dagnino, L				Ivanova, IA; D'Souza, SJA; Dagnino, L			E2F1 stability is regulated by a novel-PKC/p38 beta MAP kinase signaling pathway during keratinocyte differentiation	ONCOGENE			English	Article						keratinocyte; E2F; differentiation	ACTIVATED PROTEIN-KINASE; UBIQUITIN-PROTEASOME PATHWAY; EPIDERMAL-KERATINOCYTES; MESSENGER-RNA; DEGRADATION; DELTA; RETINOBLASTOMA; GROWTH; PROLIFERATION; EXPRESSION	E2F transcription factors regulate proliferation, differentiation, DNA repair and apoptosis. Tight E2F regulation is crucial for epidermal formation and regeneration. However, virtually nothing is known about the molecular events modulating E2F during epidermal keratinocyte differentiation. Elucidation of these events is essential to understand epidermal morphogenesis, transformation and repair. Here we show that, in differentiating keratinocytes, Ca2(+) -induced protein kinase C (PKC) activation downregulates E2F1 protein levels. Further, we have identified PKC delta and eta as those isoforms specifically involved in induction of E2F1 proteasomal degradation. We also demonstrate that E2F1 downregulation by novel PKC isozymes requires activation of p38 beta mitogenactivated protein kinase ( MAPK). This is the first example of regulation in the E2F transcription factor family by activation of PKC and MAPK in the context of biologically significant differentiation stimuli in epithelia.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; Univ Western Ontario, Dept Paediat, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada.	ldagnino@uwo.ca		Dagnino, Lina/0000-0003-1483-5159				Alt A, 2001, CANCER RES, V61, P4591; Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Carpenter L, 2001, J BIOL CHEM, V276, P5368, DOI 10.1074/jbc.M010036200; Cazzolli R, 2002, AM J PHYSIOL-ENDOC M, V282, pE1204, DOI 10.1152/ajpendo.00487.2001; Chang WY, 2004, J BIOL CHEM, V279, P51343, DOI 10.1074/jbc.M408635200; Chida K, 2003, CANCER RES, V63, P2404; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Dashti SR, 2001, J BIOL CHEM, V276, P8059, DOI 10.1074/jbc.C000862200; Denning MF, 2004, INT J BIOCHEM CELL B, V36, P1141, DOI 10.1016/j.biocel.2003.12.004; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Eckert RL, 2004, J INVEST DERMATOL, V123, P13, DOI 10.1111/j.0022-202X.2004.22723.x; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Faigle R, 2004, MOL CELL BIOL, V24, P280, DOI 10.1128/MCB.24.1.280-293.2004; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kashiwagi M, 2000, ONCOGENE, V19, P6334, DOI 10.1038/sj.onc.1204028; Koster MI, 2004, EUR J CELL BIOL, V83, P625, DOI 10.1078/0171-9335-00387; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Li LW, 1999, MOL CELL BIOL, V19, P8547; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Penuelas S, 2003, EUR J BIOCHEM, V270, P4809, DOI 10.1046/j.1432-1033.2003.03874.x; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; REYNOLDS NJ, 1994, J INVEST DERMATOL, V103, P364, DOI 10.1111/1523-1747.ep12394957; Romanova LY, 1998, BIOCHEMISTRY-US, V37, P5558, DOI 10.1021/bi9731807; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Scheijen B, 2003, MOL CELL BIOL, V23, P3656, DOI 10.1128/MCB.23.10.3656-3668.2003; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280	44	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					430	437		10.1038/sj.onc.1208999	http://dx.doi.org/10.1038/sj.onc.1208999			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16116476				2022-12-17	WOS:000234714100011
J	Mohr, I				Mohr, I			To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control	ONCOGENE			English	Review						translational control; oncolytic virus	HERPES-SIMPLEX-VIRUS; VESICULAR STOMATITIS-VIRUS; HOST SHUTOFF PROTEIN; CAP-DEPENDENT TRANSLATION; INITIATION-FACTOR 4E; RNA-BINDING-PROTEIN; TYPE-1 MUTANT G207; MESSENGER-RNA; GAMMA(1)34.5 PROTEIN; WILD-TYPE	To ensure that their mRNAs are translated and that the viral proteins necessary for assembling the next generation of infectious progeny are produced, viruses must effectively seize control of the translational machinery within their host cells. In many cases, the ability to productively engage host translational components can determine if a given cell type can support viral replication, illustrating the critical importance of this task in the viral life cycle. Failure to interface properly with the host translational apparatus can compromise the productive growth cycle, resulting in an abortive infection and radically restricting viral replication. Not only have viruses become facile at commandeering this machinery, they are also particularly adept at manipulating cellular translation control pathways for their own ends. In this review, the mechanisms by which numerous viruses manipulate host translational control circuits are discussed. Furthermore, particular attention is devoted to understanding how interfering with the ability of a virus to properly regulate translation in its host can be exploited to generate oncolytic strains that selectively replicate in cancer cells.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University	Mohr, I (corresponding author), NYU, Sch Med, Dept Microbiol, MSB-214,550 1st Ave, New York, NY 10016 USA.	ian.mohr@med.nyu.edu						Advani SJ, 1999, CANCER RES, V59, P2055; Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Ahmed M, 2004, VIROLOGY, V330, P34, DOI 10.1016/j.virol.2004.08.039; Andreansky S, 1997, CANCER RES, V57, P1502; Andreansky SS, 1996, P NATL ACAD SCI USA, V93, P11313, DOI 10.1073/pnas.93.21.11313; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Barber GN, 2005, ONCOGENE, V24, P7710, DOI 10.1038/sj.onc.1209042; BARTKOSKI M, 1976, J VIROL, V20, P583, DOI 10.1128/JVI.20.3.583-588.1976; BOLOVAN CA, 1994, J VIROL, V68, P48, DOI 10.1128/JVI.68.1.48-55.1994; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; CAI WH, 1993, J VIROL, V67, P7501, DOI 10.1128/JVI.67.12.7501-7512.1993; Caron S, 2004, MOL CELL BIOL, V24, P4920, DOI 10.1128/MCB.24.11.4920-4928.2004; Cerveny M, 2003, VIROLOGY, V307, P290, DOI 10.1016/S0042-6822(02)00075-2; CHAMBERS R, 1995, P NATL ACAD SCI USA, V92, P1411, DOI 10.1073/pnas.92.5.1411; Cheng GF, 2001, VIROLOGY, V290, P115, DOI 10.1006/viro.2001.1148; CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; Chung RY, 1999, J VIROL, V73, P7556, DOI 10.1128/JVI.73.9.7556-7564.1999; Connor JH, 2004, J VIROL, V78, P8960, DOI 10.1128/JVI.78.17.8960-8970.2004; Connor JH, 2002, J VIROL, V76, P10177, DOI 10.1128/JVI.76.20.10177-10187.2002; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Cuesta R, 2000, EMBO J, V19, P3465, DOI 10.1093/emboj/19.13.3465; Doepker RC, 2004, J VIROL, V78, P4684, DOI 10.1128/JVI.78.9.4684-4699.2004; Duerst RJ, 2004, VIROLOGY, V322, P158, DOI 10.1016/j.virol.2004.01.019; ELSHIEKH NA, 1991, J VIROL, V65, P6430, DOI 10.1128/JVI.65.12.6430-6437.1991; Everett RD, 2000, BIOESSAYS, V22, P761, DOI 10.1002/1521-1878(200008)22:8<761::AID-BIES10>3.0.CO;2-A; Everly DN, 2002, J VIROL, V76, P8560, DOI 10.1128/JVI.76.17.8560-8571.2002; Faria PA, 2005, MOL CELL, V17, P93, DOI 10.1016/j.molcel.2004.11.023; Feng PH, 2001, J VIROL, V75, P10272, DOI 10.1128/JVI.75.21.10272-10280.2001; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gromeier M, 1996, P NATL ACAD SCI USA, V93, P2370, DOI 10.1073/pnas.93.6.2370; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Gross JD, 2003, CELL, V115, P739, DOI 10.1016/S0092-8674(03)00975-9; Hagglund R, 2004, J VIROL, V78, P2169, DOI 10.1128/JVI.78.5.2169-2178.2004; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Halford WP, 2001, J VIROL, V75, P3240, DOI 10.1128/JVI.75.7.3240-3249.2001; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; Hunter WD, 1999, J VIROL, V73, P6319, DOI 10.1128/JVI.73.8.6319-6326.1999; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; JACQUEMONT B, 1975, J VIROL, V15, P707, DOI 10.1128/JVI.15.4.707-713.1975; Kahvejian A, 2001, COLD SPRING HARB SYM, V66, P293, DOI 10.1101/sqb.2001.66.293; Kahvejian A, 2005, GENE DEV, V19, P104, DOI 10.1101/gad.1262905; Kauder SE, 2004, J CLIN INVEST, V113, P1743, DOI 10.1172/JCI200421323; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KESARI S, 1995, LAB INVEST, V73, P636; Kesari S, 1998, J GEN VIROL, V79, P525, DOI 10.1099/0022-1317-79-3-525; Khaleghpour K, 2001, MOL CELL, V7, P205, DOI 10.1016/S1097-2765(01)00168-X; Khoo D, 2002, J VIROL, V76, P11971, DOI 10.1128/JVI.76.23.11971-11981.2002; Kramm CM, 1997, HUM GENE THER, V8, P2057, DOI 10.1089/hum.1997.8.17-2057; Lasner TM, 1998, J NEUROVIROL, V4, P100, DOI 10.3109/13550289809113487; Leib DA, 2000, P NATL ACAD SCI USA, V97, P6097, DOI 10.1073/pnas.100415697; Leib DA, 1999, J EXP MED, V189, P663, DOI 10.1084/jem.189.4.663; Lichtenstein DL, 2004, CANCER GENE THER, V11, P819, DOI 10.1038/sj.cgt.7700765; Lichty BD, 2004, TRENDS MOL MED, V10, P210, DOI 10.1016/j.molmed.2004.03.003; Liu BL, 2003, GENE THER, V10, P292, DOI 10.1038/sj.gt.3301885; Lium EK, 1997, J VIROL, V71, P8602, DOI 10.1128/JVI.71.11.8602-8614.1997; MACLEAN AR, 1991, J GEN VIROL, V72, P631, DOI 10.1099/0022-1317-72-3-631; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Marissen WE, 2000, CELL DEATH DIFFER, V7, P1234, DOI 10.1038/sj.cdd.4400750; MARKERT JM, 1993, NEUROSURGERY, V32, P597, DOI 10.1227/00006123-199304000-00016; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Markovitz NS, 1997, J VIROL, V71, P5560, DOI 10.1128/JVI.71.7.5560-5569.1997; MEIGNIER B, 1990, J INFECT DIS, V162, P313, DOI 10.1093/infdis/162.2.313; MEIGNIER B, 1988, J INFECT DIS, V158, P602, DOI 10.1093/infdis/158.3.602; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Mohr I, 2004, INT REV IMMUNOL, V23, P199, DOI 10.1080/08830180490265600; Mohr I, 2003, EXPERT OPIN BIOL TH, V3, P113, DOI 10.1517/eobt.3.1.113.20950; Mohr I, 1996, EMBO J, V15, P4759, DOI 10.1002/j.1460-2075.1996.tb00853.x; Mohr I, 2001, J VIROL, V75, P5189, DOI 10.1128/JVI.75.11.5189-5196.2001; Mulvey M, 2004, J VIROL, V78, P10193, DOI 10.1128/JVI.78.18.10193-10196.2004; Mulvey M, 2003, J VIROL, V77, P10917, DOI 10.1128/JVI.77.20.10917-10928.2003; Mulvey M, 1999, J VIROL, V73, P3375, DOI 10.1128/JVI.73.4.3375-3385.1999; Murphy JA, 2003, J VIROL, V77, P9337, DOI 10.1128/JVI.77.17.9337-9345.2003; Nakamura H, 2002, J CLIN INVEST, V109, P871, DOI 10.1172/JCI10623; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Pe'ery T, 2000, COLD SPRING HARBOR M, V39, P371; Peters GA, 2002, J VIROL, V76, P11054, DOI 10.1128/JVI.76.21.11054-11064.2002; Poppers J, 2000, J VIROL, V74, P11215, DOI 10.1128/JVI.74.23.11215-11221.2000; Pyles RB, 1997, HUM GENE THER, V8, P533, DOI 10.1089/hum.1997.8.5-533; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; QUIROZ E, 1988, AM J TROP MED HYG, V39, P312, DOI 10.4269/ajtmh.1988.39.312; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; RANDAZZO BP, 1995, VIROLOGY, V211, P94, DOI 10.1006/viro.1995.1382; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; READ GS, 1983, J VIROL, V46, P498, DOI 10.1128/JVI.46.2.498-512.1983; Rodriguez LL, 2002, VIRUS RES, V85, P211, DOI 10.1016/S0168-1702(02)00026-6; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; ROIZMAN B, 2001, FIELDS VIROLOGY, P2239; SACKS WR, 1987, J VIROL, V61, P829, DOI 10.1128/JVI.61.3.829-839.1987; Sandri-Goldin RM, 2004, J VIROL, V78, P4389, DOI 10.1128/JVI.78.9.4389-4396.2004; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; SINKOVICS J, 1993, INTERVIROLOGY, V36, P193, DOI 10.1159/000150339; Smith TJ, 2002, J VIROL, V76, P2054, DOI 10.1128/JVI.76.5.2054-2061.2002; STANNERS CP, 1971, J CELL PHYSIOL, V77, P31, DOI 10.1002/jcp.1040770105; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; STOW ND, 1986, J GEN VIROL, V67, P2571, DOI 10.1099/0022-1317-67-12-2571; STRELOW LI, 1995, J VIROL, V69, P6779, DOI 10.1128/JVI.69.11.6779-6786.1995; Sundaresan P, 2000, J VIROL, V74, P3832, DOI 10.1128/JVI.74.8.3832-3841.2000; Taneja S, 2001, P NATL ACAD SCI USA, V98, P8804, DOI 10.1073/pnas.161011798; THOMAS G, 1986, J CELL BIOL, V103, P2137, DOI 10.1083/jcb.103.6.2137; THOMAS G, 1979, CELL BIOL INT REP, V3, P307, DOI 10.1016/S0309-1651(79)80001-6; THOMAS G, 1981, P NATL ACAD SCI-BIOL, V78, P5712, DOI 10.1073/pnas.78.9.5712; Todo T, 2001, P NATL ACAD SCI USA, V98, P6396, DOI 10.1073/pnas.101136398; Walsh D, 2005, J VIROL, V79, P8057, DOI 10.1128/JVI.79.13.8057-8064.2005; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Xi QR, 2005, J VIROL, V79, P5676, DOI 10.1128/JVI.79.9.5676-5683.2005; Xi QR, 2004, GENE DEV, V18, P1997, DOI 10.1101/gad.1212504; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557	127	23	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7697	7709		10.1038/sj.onc.1209053	http://dx.doi.org/10.1038/sj.onc.1209053			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299530	Bronze			2022-12-17	WOS:000233372600006
J	Narita, N; Fujieda, S; Tokuriki, M; Takahashi, N; Tsuzuki, H; Ohtsubo, T; Matsumoto, H				Narita, N; Fujieda, S; Tokuriki, M; Takahashi, N; Tsuzuki, H; Ohtsubo, T; Matsumoto, H			Inhibition of histone deacetylase 3 stimulates apoptosis induced by heat shock under acidic conditions in human maxillary cancer	ONCOGENE			English	Article						cDNA array; hyperthermia; low pH; HDAC3; head and neck cancer	HISTONE DEACETYLASE INHIBITOR; EPIDERMAL-GROWTH-FACTOR; IN-VITRO; SIGNAL-TRANSDUCTION; RANDOMIZED-TRIAL; NITRIC-OXIDE; TUMOR-GROWTH; EXPRESSION; CELLS; P53	To elucidate the molecular mechanisms for the enhancement of heat-induced apoptosis on exposure to acidic conditions, human maxillary carcinoma IMC-3 cells were heat-shocked at 44 degrees C for 30 min at either pH 7.4 or 6.7. Analyses with cDNA arrays, the reverse transcription polymerase chain reaction (RT-PCR), and Western blotting were performed. We found that histone deacetylase 3 (HDAC3) was specifically induced after hyperthermia at 44 degrees C for 30 min at pH 6.7. Although the cytotoxicity of heating at 44 degrees C for 30 min was enhanced by decreasing the pH from 7.4 to 6.7, it was enhanced even more by antisense RNA oligonucleotides for HDAC3. The induction of G(2)/M arrest after heating occurred earlier at pH 6.7 than at pH 7.4. The inhibition of HDAC3 by the antisense RNA oligonucleotides suppressed partially the induction of G2/M arrest, resulting in an enhancement of the apoptosis caused by the heating under acidic conditions. Antisense RNA oligonucleotides for HDAC3 enhanced apoptosis 48 h after hyperthermia at 43 degrees C for 30 min in vivo. Analyses of p65 activity suggested that NF-KB is involved in this enhancement of hyperthermia. HDAC3 may be a novel target enhancing hyperthermia and combined treatment with hyperthermia and HDAC inhibitors is a possible modality for cancer therapy.	Univ Fukui, Dept Otorhinolaryngol, Matsuoka, Fukui 9101193, Japan; Univ Fukui, Fac Med Sci, Dept Expt Radiol & Hlth Phys, Matsuoka, Fukui 9101193, Japan	University of Fukui; University of Fukui	Narita, N (corresponding author), Univ Fukui, Dept Otorhinolaryngol, Matsuoka, Fukui 9101193, Japan.	norihiko@fmsrsa.fukui-med.ac.jp	Narita, Norihiko/AAA-4801-2022	Narita, Norihiko/0000-0001-9765-9669				AKIN RE, 2004, J BIOL CHEM, V297, P51218; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Dahl O, 2002, INT J HYPERTHER, V18, P25, DOI 10.1080/02656730110083756; ENGIN K, 1995, CLIN CANCER RES, V1, P139; FUJIEDA S, 1995, J IMMUNOL, V155, P2318; Gan YH, 2005, J BIOL CHEM, V280, P16467, DOI 10.1074/jbc.M412960200; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; HARMON BV, 1990, INT J RADIAT BIOL, V58, P845, DOI 10.1080/09553009014552221; Huang YH, 2002, CANCER RES, V62, P2913; Jin ZH, 2004, INT J RADIAT ONCOL, V59, P852, DOI 10.1016/j.ijrobp.2004.01.033; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Levenson VV, 2000, CANCER RES, V60, P5027; Liu F, 2004, J BIOL CHEM, V279, P34537, DOI 10.1074/jbc.M402475200; Marshall John L, 2002, J Exp Ther Oncol, V2, P325, DOI 10.1046/j.1359-4117.2002.01039.x; Matsumoto H, 1997, INT J RADIAT ONCOL, V38, P1089, DOI 10.1016/S0360-3016(97)00300-3; Matsumoto H, 1998, INT J ONCOL, V13, P741; Matsumoto H, 1998, INT J RADIAT ONCOL, V41, P915, DOI 10.1016/S0360-3016(98)00121-7; Matsumoto H, 1999, CANCER RES, V59, P3239; MIZOGUCHI H, 1991, INT J CANCER, V49, P738, DOI 10.1002/ijc.2910490518; MORONI MC, 1992, J BIOL CHEM, V267, P2714; Mukhopadhyay T, 1996, CRIT REV ONCOGENESIS, V7, P151, DOI 10.1615/CritRevOncog.v7.i3-4.20; Murata M, 2000, JPN J CANCER RES, V91, P1154, DOI 10.1111/j.1349-7006.2000.tb00899.x; Narita N, 2002, INT J RADIAT ONCOL, V53, P190, DOI 10.1016/S0360-3016(02)02727-X; Ohnishi K, 2001, INT J HYPERTHER, V17, P415, DOI 10.1080/02656730110063604; Ohtsubo T, 2001, INT J RADIAT ONCOL, V49, P1391, DOI 10.1016/S0360-3016(00)01590-X; Ohtsubo T, 2000, INT J HYPERTHER, V16, P481, DOI 10.1080/02656730050199331; OVERGAARD J, 1995, LANCET, V345, P540, DOI 10.1016/S0140-6736(95)90463-8; Park HJ, 1999, BRIT J CANCER, V80, P1892, DOI 10.1038/sj.bjc.6690617; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; RHEE JG, 1984, INT J RADIAT ONCOL, V10, P393, DOI 10.1016/0360-3016(84)90060-9; Ru K, 1999, ONCOL RES, V11, P505; Sasakawa Y, 2002, BIOCHEM PHARMACOL, V64, P1079, DOI 10.1016/S0006-2952(02)01261-3; Sneed PK, 1998, INT J RADIAT ONCOL, V40, P287, DOI 10.1016/S0360-3016(97)00731-1; Sugimoto C, 1999, INT J CANCER, V82, P860, DOI 10.1002/(SICI)1097-0215(19990909)82:6<860::AID-IJC15>3.0.CO;2-6; Takahashi A, 2003, INT J HYPERTHER, V19, P145, DOI 10.1080/02656730210166131; Takahashi I, 2002, SURGERY, V131, pS78, DOI 10.1067/msy.2002.119308; Takasu T, 1998, CANCER RES, V58, P2504; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yu XD, 2002, J NATL CANCER I, V94, P504	43	23	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7346	7354		10.1038/sj.onc.1208879	http://dx.doi.org/10.1038/sj.onc.1208879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16044157				2022-12-17	WOS:000233142100011
J	Cai, Y; Stafford, LJ; Bryan, BA; Mitchell, D; Liu, MY				Cai, Y; Stafford, LJ; Bryan, BA; Mitchell, D; Liu, MY			G-protein-activated phospholipase C-beta, new partners for cell polarity proteins Par3 and Par6	ONCOGENE			English	Article						PLC-beta; cell polarity; cell asymmetric division; PDZ domain; G-protein	CAENORHABDITIS-ELEGANS EMBRYOS; KINASE-C; DROSOPHILA NEUROBLASTS; PLANAR POLARITY; GENE-EXPRESSION; DIRECT BINDING; G-ALPHA; DIVISION; CDC42; LOCALIZATION	Cell polarity and asymmetric cell division are fundamental traits of all living cells and play an essential role in embryonic development, neuronal cell chirality formation, and maintenance of mammalian epithelial cell morphology. Heterotrimeric GTP-binding proteins ( G proteins) are involved in directing cell polarity and asymmetric cell division in different organisms. However, the mechanism for G-protein-mediated cell polarity and asymmetric cell division is poorly understood. In this study, we have demonstrated that G-protein-activated phospholipase C-beta (PLC-beta) interacts with cell polarity proteins Par3 and Par6 ( Par: partition-defective) to form protein complexes and to mediate downstream signal transduction. The interactions between PLC-beta and Par proteins are direct and require the extreme C-terminal-specific sequence motifs of PLC-beta and the PDZ (PSD95/Dlg/ZO-1) domains of Par proteins. Binding of Par proteins with PLC-beta stimulates PLC-beta enzymatic activity, leading to the hydrolysis of phosphatidylinositol-4,5-bisphosphate, and the production of diacylglycerol and inositol 1,4, 5-triphosphate, important mediators in cell polarity and cell asymmetric division processes. Furthermore, we have shown that coexpression of PLC-beta with Par proteins induces transcriptional activation coupled to intracellular Ca2+ and the Wnt signaling pathway. Therefore, our data suggest that the interaction of PLC-beta with cell polarity Par proteins may serve as a nexus to transduce extracellular signals to transcriptional regulation through G-protein-mediated signaling pathway in cell polarity and cell asymmetric division.	Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Alkek Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Liu, MY (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Alkek Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamhsc.edu		Liu, Mingyao/0000-0001-7339-5048	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064792] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL64792] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basham SE, 1999, DEV BIOL, V215, P253, DOI 10.1006/dbio.1999.9447; Bohm H, 1997, CURR BIOL, V7, P603, DOI 10.1016/S0960-9822(06)00260-0; Brandt D, 2002, J BIOL CHEM, V277, P20903, DOI 10.1074/jbc.M200946200; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Chant T, 1999, ANNU REV CELL DEV BI, V15, P365, DOI 10.1146/annurev.cellbio.15.1.365; Cocco L, 2001, MARC MALPIG SYMP SER, V7, P31; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Fanto M, 2004, J CELL SCI, V117, P527, DOI 10.1242/jcs.00973; Fanto M, 1999, NATURE, V397, P523, DOI 10.1038/17389; Gomes JE, 2002, CURR BIOL, V12, pR444, DOI 10.1016/S0960-9822(02)00939-9; Gong Y, 2004, NATURE, V430, P689, DOI 10.1038/nature02796; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Herman MA, 2002, SEMIN CELL DEV BIOL, V13, P233, DOI 10.1016/S1084-9521(02)00051-4; Jan YN, 2001, NAT REV NEUROSCI, V2, P772, DOI 10.1038/35097516; Jan YN, 2003, NEURON, V40, P229, DOI 10.1016/S0896-6273(03)00631-7; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kemphues K, 2000, CELL, V101, P345, DOI 10.1016/S0092-8674(00)80844-2; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kerschbaum HH, 1997, J IMMUNOL, V159, P1628; Kim SK, 2000, NAT CELL BIOL, V2, pE143, DOI 10.1038/35019620; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Manzoli L, 1999, ANTICANCER RES, V19, P3753; Meili R, 2003, CELL, V114, P153, DOI 10.1016/S0092-8674(03)00553-1; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Roegiers F, 2004, CURR OPIN CELL BIOL, V16, P195, DOI 10.1016/j.ceb.2004.02.010; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schneider SQ, 2003, ANNU REV GENET, V37, P221, DOI 10.1146/annurev.genet.37.110801.142443; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; van Haasteren G, 1999, J RECEPT SIGNAL TR R, V19, P481, DOI 10.3109/10799899909036666; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Xia CZ, 2001, J BIOL CHEM, V276, P19770, DOI 10.1074/jbc.M006266200; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	46	23	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4293	4300		10.1038/sj.onc.1208593	http://dx.doi.org/10.1038/sj.onc.1208593			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15782111				2022-12-17	WOS:000229815300012
J	Koreth, J; van den Heuvel, S				Koreth, J; van den Heuvel, S			Cell-cycle control in Caenorhabditis elegans: how the worm moves from G1 to S	ONCOGENE			English	Review						C. elegans cell cycle; G1-S; cyclin D; Cdk4/6; lin-35 Rb; cki-1; Cip/Kip	DEPENDENT KINASE INHIBITOR; C-ELEGANS; DEVELOPMENTAL REGULATION; PHOSPHATASE CDC14; LIN-35 RB; NEMATODE; GENE; EXIT; PROLIFERATION; PROGRESSION	The nematode Caenorhabditis elegans offers a powerful model system to study cell division control during animal development. Progress from the one- cell zygote to adult stage follows a nearly invariant pattern of divisions. This, combined with a transparent body and efficient genetics, allows for sensitive identification and quantitative analysis of cell- cycle mutants. Nearly all G1 control genes identified in C. elegans have mammalian homologs. Examples include a D- type cyclin and CDK4/ 6- related kinase, a member of the retinoblastoma protein family and CDK inhibitors of the Cip/ Kip family. Genetic studies have placed the currently known G1 regulators into pathways similar to those in mammals. Together, this validates the use of C. elegans in identifying additional regulators of cell- cycle entry and exit. For instance, we recently found that the CDC- 14 phosphatase promotes maintenance of the quiescent state. Here, we describe cell-cycle control as an integral part of C. elegans development, summarize current knowledge of G1 control genes in the worm, compare the results with those obtained in other species, and discuss the possible implications of cellcycle studies in C. elegans for higher organisms, including humans.	Harvard Univ, Sch Med, MGH Canc Ctr, Charlestown, MA 02129 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Harvard University; Dana-Farber Cancer Institute	van den Heuvel, S (corresponding author), Harvard Univ, Sch Med, MGH Canc Ctr, Charlestown, MA 02129 USA.	heuvel@helix.mgh.harvard.edu	van den Heuvel, Sander J.L./B-8892-2011	van den Heuvel, Sander J.L./0000-0001-9015-7463				Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Boxem M, 2002, CURR BIOL, V12, P906, DOI 10.1016/S0960-9822(02)00844-8; Boxem M, 1999, DEVELOPMENT, V126, P2227; Boxem M, 2001, DEVELOPMENT, V128, P4349; BRENNER S, 1974, GENETICS, V77, P71; Brodigan TM, 2003, DEV BIOL, V254, P102, DOI 10.1016/S0012-1606(02)00032-5; Ceol CJ, 2004, DEV CELL, V6, P563, DOI 10.1016/S1534-5807(04)00065-6; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; Fay DS, 2000, DEVELOPMENT, V127, P4049; Fay DS, 2002, GENE DEV, V16, P503, DOI 10.1101/gad.952302; Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; FERGUSON EL, 1989, GENETICS, V123, P109; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fukuyama M, 2003, DEV BIOL, V260, P273, DOI 10.1016/S0012-1606(03)00239-2; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Gruneberg U, 2002, J CELL BIOL, V158, P901, DOI 10.1083/jcb.200202054; HEDGECOCK EM, 1985, DEV BIOL, V107, P128, DOI 10.1016/0012-1606(85)90381-1; Hong Y, 1998, DEVELOPMENT, V125, P3585; HORVITZ HR, 1980, GENETICS, V96, P435; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; KEMPHUES KJ, 1997, C ELEGANS, V0002, P00335; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kipreos ET, 2000, DEVELOPMENT, V127, P5071; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kostic I, 2003, DEV BIOL, V263, P242, DOI 10.1016/S0012-1606(03)00452-4; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lambie EJ, 2002, BIOESSAYS, V24, P38, DOI 10.1002/bies.10019; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Meyer CA, 2002, CURR BIOL, V12, P661, DOI 10.1016/S0960-9822(02)00770-4; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Park M, 1999, DEVELOPMENT, V126, P4849; Riddle DL, 1997, C ELEGANS, P739; Rual JF, 2004, GENOME RES, V14, P2162, DOI 10.1101/gr.2505604; Saito RM, 2004, NAT CELL BIOL, V6, P777, DOI 10.1038/ncb1154; SCHEDL T, 1997, C ELEGANS, V2, P241; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEYDOUX G, 1993, DEV BIOL, V157, P423, DOI 10.1006/dbio.1993.1146; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Solari F, 2000, CURR BIOL, V10, P223, DOI 10.1016/S0960-9822(00)00343-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5	55	23	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2756	2764		10.1038/sj.onc.1208607	http://dx.doi.org/10.1038/sj.onc.1208607			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838512				2022-12-17	WOS:000228465800002
J	Provost, E; McCabe, A; Stern, J; Lizardi, I; D'Aquila, TG; Rimm, DL				Provost, E; McCabe, A; Stern, J; Lizardi, I; D'Aquila, TG; Rimm, DL			Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin	ONCOGENE			English	Article						adhesion; signaling; wnt; armadillo; ubiquitination; MDCK	PATHWAY; PHOSPHORYLATION; DEGRADATION; PROTEIN; UBIQUITINATION; SIAH-1; P53	beta-catenin is a multifunctional protein involved in both cadherin-mediated adhesion and the wnt signaling cascade. Mutations in exon 3 of beta-catenin have been identified in many cancers. In addition to disruption of key serine and threonine residues, mutations are frequently reported in other residues in exon 3 that are not kinase substrates. The most frequently mutated nonserine/threonine residues are D32 and G34. Since D32 and G34 are part of the ubiquitination destruction motif, DSG phi XS, we hypothesize that this motif may contribute to disruption of beta-catenin homeostasis and lead to cellular transformation. We demonstrate that the mutants D32A and G34A exhibit no change in phosphorylation by GSK3 beta, but display reduced ubiquitination compared to wild- type and S33A mutant beta-catenin. To assess the functional implications of these mutations, we created stable MDCK cell lines expressing these constructs. We found that stable cell lines harboring D32A- mutated beta-catenin were highly transformed, while S33A and G34 demonstrated only weak transforming properties in our assays. Despite altered ubiquitination status and increased transformation, the D32A mutant cell line does not display transcriptional activation of standard target genes. Therefore, D32A mutation may mediate transformation by an alternative beta-catenin-mediated signaling pathway.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Rimm, DL (corresponding author), Yale Univ, Sch Med, Dept Pathol, 333 Cedar St,POB 208023, New Haven, CT 06520 USA.	david.rimm@yale.edu		Rimm, David/0000-0001-5820-4397				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Al-Fageeh M, 2004, ONCOGENE, V23, P4839, DOI 10.1038/sj.onc.1207634; Besnard-Guerin C, 2004, J BIOL CHEM, V279, P788, DOI 10.1074/jbc.M308068200; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Provost E, 2003, J BIOL CHEM, V278, P31781, DOI 10.1074/jbc.M304953200; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Zou JX, 2002, J BIOL CHEM, V277, P1824, DOI 10.1074/jbc.M103133200	15	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2667	2676		10.1038/sj.onc.1208346	http://dx.doi.org/10.1038/sj.onc.1208346			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829978				2022-12-17	WOS:000228356700008
J	Cornelis, S; Bruynooghe, Y; Van Loo, G; Saelens, X; Vandenabeele, P; Beyaert, R				Cornelis, S; Bruynooghe, Y; Van Loo, G; Saelens, X; Vandenabeele, P; Beyaert, R			Apoptosis of hematopoietic cells induced by growth factor withdrawal is associated with caspase-9 mediated cleavage of Raf-1	ONCOGENE			English	Article						apoptosis; caspase; IL-3; mitochondria; Raf-1	PROTEIN-KINASE; SIGNALING PATHWAYS; CYTOCHROME-C; MITOCHONDRIA; ACTIVATION; DEATH; PHOSPHORYLATION; RECEPTOR; SURVIVAL; RELEASE	The Raf-1 serine/threonine kinase is a key protein that is implicated in the transmission of many growth and cell survival signals. In the present study we demonstrate that apoptosis of hematopoietic cells induced by IL-3-deprivation is associated with the cleavage of Raf-1, resulting in the separation of the N-terminal regulatory domain and the C-terminal kinase domain. Raf-1 cleavage specifically occurs upon triggering of the mitochondrial death pathway, and coincides with the activation of specific caspases. Moreover, Bcl-2 overexpression or treatment with the caspase inhibitor z-VAD.fmk completely prevented Raf-1 cleavage, whereas caspase inhibition by treatment of cells with Ac-DEVD.fmk or z-IETD.fmk, or CrmA overexpression had no effect. Furthermore, in vitro cleavage studies indicate that caspase-9, which is the apical protease in the mitochondrial death pathway, is able to cleave Raf-1 at position D279. Cell fractionation studies showed that the Raf-1 C-terminal fragment that is generated upon IL-3 withdrawal is localized predominantly to the mitochondria. In addition, constitutive expression of this C-terminal Raf-1 fragment fused to a mitochondrial targeting sequence in Ba/F3 pre-B cells significantly delays apoptosis induced by IL-3 withdrawal. These results suggest an important role for caspase-9 mediated cleavage of Raf-1 in the negative feedback regulation of hematopoietic cell apoptosis induced by growth factor withdrawal.	State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Belgium; State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signaling & Cell Death, B-9052 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University	Beyaert, R (corresponding author), State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technol Pk 927, B-9052 Ghent, Belgium.	rudi.beyaert@dmbr.ugent.be	Saelens, Xavier/N-5728-2015; Vandenabeele, Peter/C-8597-2009; , van Loo Geert/AAD-1220-2019; Vandenabeele, Peter/AAD-5793-2022; Beyaert, Rudi/B-2589-2009; van Loo, Geert/C-1505-2009	, van Loo Geert/0000-0002-8427-4775; Vandenabeele, Peter/0000-0002-6669-8822; , Xavier/0000-0002-3861-6965; Beyaert, Rudi/0000-0002-5704-582X				Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bojes HK, 1999, CELL DEATH DIFFER, V6, P61, DOI 10.1038/sj.cdd.4400452; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Costantini P, 2002, CELL DEATH DIFFER, V9, P82, DOI 10.1038/sj.cdd.4400932; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; HAPEL AJ, 1984, BLOOD, V64, P786; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jesenberger V, 2001, J EXP MED, V193, P353, DOI 10.1084/jem.193.3.353; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Le Mellay V, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-14; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Majewski M, 1999, CANCER RES, V59, P2815; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Potokar M, 2003, FEBS LETT, V544, P153, DOI 10.1016/S0014-5793(03)00494-0; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; Troppmair J, 2003, BIOCHEM PHARMACOL, V66, P1341, DOI 10.1016/S0006-2952(03)00483-0; van Loo G, 2002, CELL DEATH DIFFER, V9, P1207, DOI 10.1038/sj.cdd.4401101; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	52	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2005	24	9					1552	1562		10.1038/sj.onc.1208401	http://dx.doi.org/10.1038/sj.onc.1208401			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674327				2022-12-17	WOS:000227218200008
J	Gaggero, A; De Ambrosis, A; Mezzanzanica, D; Piazza, T; Rubartelli, A; Figini, M; Canevari, S; Ferrini, S				Gaggero, A; De Ambrosis, A; Mezzanzanica, D; Piazza, T; Rubartelli, A; Figini, M; Canevari, S; Ferrini, S			A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and-4 processing	ONCOGENE			English	Article						IL-18 isoform; alternative splicing; caspase-1; caspase-4	GAMMA-INDUCING FACTOR; ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA ISOFORMS; NECROSIS-FACTOR-ALPHA; CANCER CELL-LINES; 2 IL-15 ISOFORMS; INTERFERON-GAMMA; HUMAN INTERLEUKIN-18; FIBRONECTIN ISOFORM; EPITHELIAL-CELLS	Interleukin-18 (IL-18) is a proinflammatory cytokine synthesized as a 24 kDa inactive precursor (pro-IL-18) by several cell types, and is processed to a bioactive molecule of 18 kDa by the proteinases caspase-1 or caspase-4. All ovarian carcinoma cell lines express pro-IL-18, only in some instances coexpress caspase-1, and always express caspase-4; in any case, they display a defective processing of IL-18. We analysed whether pro-IL-18, present in two ovarian carcinoma cell lysates, could be processed 'in vitro' by recombinant active caspase-1. While most of pro-IL-18 could be cleaved by caspase-1, a residual of pro-IL-18 appeared to be resistant. Cloning and sequence analysis of the whole pro-IL-18 open reading frame demonstrated the existence of an alternatively spliced mRNA variant, which lacked exon-3 (Delta3pro-IL-18). The 12 bp exon-3 encodes for the AEDD amino-acid sequence, which is N-terminal with respect to the cleavage site of caspase-1. Both pro-IL-18 and D3pro-IL-18 mRNA isoforms were detected in all ovarian cancer cell lines analysed, while Delta3pro-IL-18 mRNA was undetectable in normal ovarian epithelial cells. The Delta3pro-IL-18 cDNA induced synthesis of an alternative Delta3pro-IL-18 protein upon transfection into a murine cell line. The Delta3pro-IL-18 protein was resistant to proteolytic activation by caspase-1 and -4, although it was capable to bind caspase-1. Aternative splicing of pro-IL-18 exon-3 may represent a novel mechanism of regulation of bioactive IL-18 production in human ovarian tumors.	Ist Nazl Ric Canc, Ctr Biotecnol Avanzate, I-16132 Genoa, Italy; Ist Nazl Tumori, I-20133 Milan, Italy	University of Genoa; IRCCS AOU San Martino IST; Fondazione IRCCS Istituto Nazionale Tumori Milan	Ferrini, S (corresponding author), Ist Nazl Ric Canc, Ctr Biotecnol Avanzate, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.	silvano.ferrini@istge.it	Rubartelli, Anna/AAA-1259-2021; Figini, Mariangela/K-8753-2016; Mezzanzanica, Delia/C-2607-2017	Figini, Mariangela/0000-0001-9001-8754; Mezzanzanica, Delia/0000-0002-9664-6871; Ferrini, Silvano/0000-0001-7254-2616				Akita K, 1997, J BIOL CHEM, V272, P26595, DOI 10.1074/jbc.272.42.26595; Bufler P, 2002, P NATL ACAD SCI USA, V99, P13723, DOI 10.1073/pnas.212519099; Cameron LA, 1999, EUR RESPIR J, V14, P553, DOI 10.1034/j.1399-3003.1999.14c12.x; Carnemolla B, 1996, J BIOL CHEM, V271, P8157, DOI 10.1074/jbc.271.14.8157; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; Coughlin CM, 1998, J CLIN INVEST, V101, P1441, DOI 10.1172/JCI1555; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Fantuzzi G, 1999, J CLIN IMMUNOL, V19, P1, DOI 10.1023/A:1020506300324; FANTUZZI G, 1999, EUR CYTOKIN E NETW, V9; Gaggero A, 1999, EUR J IMMUNOL, V29, P1265, DOI 10.1002/(SICI)1521-4141(199904)29:04<1265::AID-IMMU1265>3.0.CO;2-V; Galmozzi E, 2001, FEBS LETT, V502, P31, DOI 10.1016/S0014-5793(01)02659-X; Gardella S, 1999, J LEUKOCYTE BIOL, V66, P237, DOI 10.1002/jlb.66.2.237; Gardella S, 2000, FEBS LETT, V481, P245, DOI 10.1016/S0014-5793(00)02015-9; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Hartenbach EM, 1997, CANCER LETT, V121, P169, DOI 10.1016/S0304-3835(97)00350-9; Kalina U, 2002, EUR J IMMUNOL, V32, P2635, DOI 10.1002/1521-4141(200209)32:9<2635::AID-IMMU2635>3.0.CO;2-N; Kalina U, 2000, SCAND J IMMUNOL, V52, P525, DOI 10.1046/j.1365-3083.2000.00836.x; Kim SH, 2000, P NATL ACAD SCI USA, V97, P1190, DOI 10.1073/pnas.97.3.1190; Kohno K, 1997, J IMMUNOL, V158, P1541; Kost ER, 1999, GYNECOL ONCOL, V72, P392, DOI 10.1006/gyno.1998.5257; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; Lu H, 2000, J IMMUNOL, V165, P1463, DOI 10.4049/jimmunol.165.3.1463; Meazza R, 1997, EUR J IMMUNOL, V27, P1049, DOI 10.1002/eji.1830270502; Meazza R, 2000, INT J CANCER, V87, P574, DOI 10.1002/1097-0215(20000815)87:4<574::AID-IJC18>3.3.CO;2-K; Meazza R, 1996, ONCOGENE, V12, P2187; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; Naik SM, 1999, J INVEST DERMATOL, V113, P766, DOI 10.1046/j.1523-1747.1999.00750.x; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Nash MA, 1998, CLIN EXP IMMUNOL, V112, P172; NAYLOR MS, 1993, J CLIN INVEST, V91, P2194, DOI 10.1172/JCI116446; NICOLO G, 1990, CELL DIFFER DEV, V32, P401, DOI 10.1016/0922-3371(90)90056-3; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Onu A, 1997, J IMMUNOL, V158, P255; Osaki T, 1999, GENE THER, V6, P808, DOI 10.1038/sj.gt.3300908; Pages F, 1999, INT J CANCER, V84, P326, DOI 10.1002/(SICI)1097-0215(19990621)84:3<326::AID-IJC22>3.0.CO;2-K; Stoll S, 1997, J IMMUNOL, V159, P298; Sugawara S, 2001, J IMMUNOL, V167, P6568, DOI 10.4049/jimmunol.167.11.6568; Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9; Tatsumi T, 2002, CANCER RES, V62, P5853; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; USHIO S, 1996, J IMMUNOL, V156, P4272; Wang ZY, 2002, INT J CANCER, V98, P873, DOI 10.1002/ijc.10268; Windbichler GH, 2000, BRIT J CANCER, V82, P1138; WU S, 1993, CANCER RES, V53, P1939; Xiang Y, 2001, J VIROL, V75, P9947, DOI 10.1128/JVI.75.20.9947-9954.2001; Young JL, 2000, J EXP MED, V191, P1535, DOI 10.1084/jem.191.9.1535	49	23	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7552	7560		10.1038/sj.onc.1208036	http://dx.doi.org/10.1038/sj.onc.1208036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326478				2022-12-17	WOS:000224176500012
J	Degl'Innocenti, D; Arighi, E; Popsueva, A; Sangregorio, R; Alberti, L; Rizzetti, MG; Ferrario, C; Sariola, H; Pierotti, MA; Borrello, MG				Degl'Innocenti, D; Arighi, E; Popsueva, A; Sangregorio, R; Alberti, L; Rizzetti, MG; Ferrario, C; Sariola, H; Pierotti, MA; Borrello, MG			Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branching	ONCOGENE			English	Article						RET isoforms; Tyr1062; cell branching; cell scattering; cell transformation	RECEPTOR TYROSINE KINASE; URETERAL BUD DEVELOPMENT; ENTERIC NERVOUS-SYSTEM; NEUROTROPHIC FACTOR; C-RET; TRANSFORMING ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; DOCKING SITE; GDNF FAMILY; AUTOPHOSPHORYLATION SITES	The receptor tyrosine kinase RET is alternatively spliced to yield two main isoforms, RET9 and RET51, which differ in their carboxyl terminal. Activated RET induces different biological responses such as morphological transformation, neurite outgrowth, proliferation, cell migration and branching. The two isoforms have been suggested to have separate intracellular signaling pathways and different roles in mouse development. Here we show that both isoforms are able to induce cell scattering of SK-N-MC neuroepithelioma cell line and branching tubule formation in MDCK cell line. However, the Y1062F mutation, which abrogates the transforming activity of both activated RET isoforms in NIH3T3 cells, does not abolish scattering and branching morphogenesis of RET51, whereas impairs these biological effects of RET9. The GDNF-induced biological effects of RET51 are inhibited by the simultaneous abrogation of both Tyr1062 and Tyr1096 docking sites. Thus, Tyr1096 may substitute the functions of Tyr1062. GRB2 is the only known adaptor protein binding to Tyr1096. Dominant-negative GRB2 expressed in MDCK cells together with RET9 or RET51 significantly reduces branching. Therefore, GRB2 is necessary for RET-mediated branching of MDCK cells.	Ist Nazl Tumori, Dept Expt Oncol, Res Unit 3, I-20133 Milan, Italy; Univ Helsinki, Biomedicum Helsinki, Inst Biomed, FIN-0014 Helsinki, Finland; Univ Helsinki, Cent Hosp, HUCH Diagnost Dept Pathol, FIN-00290 Helsinki, Finland; FIRC, Inst Mol Oncol IFOM, I-20139 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; IFOM - FIRC Institute of Molecular Oncology	Borrello, MG (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Res Unit 3, Via G Venezian 1, I-20133 Milan, Italy.	marco.pierotti@istitutotumori.mi.it; mariagrazia.borrello@istitutotumori.mi.it	Borrello, Maria Grazia/C-3161-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Borrello, Maria Grazia/0000-0002-6854-2848; Pierotti, Marco Alessandro/0000-0002-7431-8332				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Albert L, 2003, J CELL PHYSIOL, V195, P168, DOI 10.1002/jcp.10252; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Andreozzi F, 2003, ONCOGENE, V22, P2942, DOI 10.1038/sj.onc.1206475; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 2002, BIOCHEM BIOPH RES CO, V296, P515, DOI 10.1016/S0006-291X(02)00886-0; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Carter MT, 2001, CYTOGENET CELL GENET, V95, P169, DOI 10.1159/000059341; Coulpier M, 2002, J BIOL CHEM, V277, P1991, DOI 10.1074/jbc.M107992200; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; De Vita G, 2000, CANCER RES, V60, P3727; Durbec PL, 1996, DEVELOPMENT, V122, P349; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hayashi Y, 2001, J NEURO-ONCOL, V55, P51, DOI 10.1023/A:1012946812930; Hennige AM, 2000, MOL CELL ENDOCRINOL, V167, P69, DOI 10.1016/S0303-7207(00)00283-5; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; Iwahashi N, 2002, BIOCHEM BIOPH RES CO, V294, P642, DOI 10.1016/S0006-291X(02)00528-4; Iwashita T, 2001, GASTROENTEROLOGY, V121, P24, DOI 10.1053/gast.2001.25515; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; KAWAMOTO Y, 2004, J BIOL CHEM     0106; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lanzi C, 2000, INT J CANCER, V85, P384, DOI 10.1002/(SICI)1097-0215(20000201)85:3<384::AID-IJC15>3.3.CO;2-P; Lee DCW, 2002, ONCOGENE, V21, P5582, DOI 10.1038/sj.onc.1205741; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Mercalli E, 2001, ONCOGENE, V20, P3475, DOI 10.1038/sj.onc.1204462; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Mograbi B, 2001, MOL CELL BIOL, V21, P6719, DOI 10.1128/MCB.21.20.6719-6730.2001; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Schedl A, 2000, CURR OPIN GENET DEV, V10, P543, DOI 10.1016/S0959-437X(00)00125-8; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Srinivas S, 1999, DEVELOPMENT, V126, P1375; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tang MJ, 1998, J CELL BIOL, V142, P1337, DOI 10.1083/jcb.142.5.1337; Taraviras S, 1999, CURR OPIN GENET DEV, V9, P321, DOI 10.1016/S0959-437X(99)80048-3; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; TSUZUKI T, 1995, ONCOGENE, V10, P191; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249	60	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7297	7309		10.1038/sj.onc.1207862	http://dx.doi.org/10.1038/sj.onc.1207862			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326489				2022-12-17	WOS:000224021400001
J	Sumigama, S; Ito, T; Kajiyama, H; Shibata, K; Tamakoshi, K; Kikkawa, F; Williams, T; Tainsky, MA; Nomura, S; Mizutani, S				Sumigama, S; Ito, T; Kajiyama, H; Shibata, K; Tamakoshi, K; Kikkawa, F; Williams, T; Tainsky, MA; Nomura, S; Mizutani, S			Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2 alpha	ONCOGENE			English	Article						tumorigenicity; erbB2; Akt; ERK; E-cadherin; matrix metalloproteinase; peritoneal dissemination	TRANSCRIPTION FACTOR AP-2; HUMAN BREAST-CANCER; SIGNALING PATHWAYS; PROSTATE-CANCER; DOWN-REGULATION; UP-REGULATION; TUMOR-GROWTH; DNA-BINDING; EXPRESSION; GENE	A previous report demonstrated that AP-2alpha favors the survival of ovarian cancer patients by clinical findings. However, the functional roles of AP-2alpha in human ovarian cancers have not been determined. To clarify the roles, we overexpressed AP-2alpha in SKOV3 human ovarian cancer cells, which originally possess little AP-2alpha. AP-2alpha overexpression changed cell morphology from spindle to epithelioid type and suppressed cell proliferation and invasion, which would be partially correlated with decreased phosphorylation levels of the erbB2, Akt and ERK pathways, increased E-cadherin and reduced pro-matrix metalloproteinase-2 levels. Moreover, nude mice intraperitoneally injected with AP-2alpha-overexpressing cells survived longer than those with neotransfected cells. The present data represent the first direct evidence that AP-2alpha plays a tumor suppressive role in ovarian cancer.	Nagoya Grad Univ, Dept Obstet & Gynecol, Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Grad Univ, Dept Publ Hlth, Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Colorado, Hlth Sci Ctr, Dept Craniofacial Biol, Denver, CO 80262 USA; Wayne State Univ, Program Mol Biol & Genet, Karmanos Canc Inst, Detroit, MI 48201 USA	Nagoya University; Nagoya University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Barbara Ann Karmanos Cancer Institute; Wayne State University	Ito, T (corresponding author), Nagoya Grad Univ, Dept Obstet & Gynecol, Sch Med, Showa Ku, Tsurumai Cho 65, Nagoya, Aichi 4668550, Japan.	itoto@med.nagoya-u.ac.jp	KIKKAWA, Fumitaka/I-7341-2014; Kotani, Tomomi/I-7360-2014; Sumigama, Seiji/AAR-9926-2020	Sumigama, Seiji/0000-0001-6913-3731; Kotani, Tomomi/0000-0002-3082-6116; Tainsky, Michael/0000-0002-0261-831X				Agus DB, 2000, SEMIN ONCOL, V27, P53; Anttila MA, 2000, BRIT J CANCER, V82, P1974; Auman HJ, 2002, DEVELOPMENT, V129, P2733; BACUS SS, 1994, AM J CLIN PATHOL S1, V102, P13; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; Bosher JM, 1996, ONCOGENE, V13, P1701; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CLIBY W, 1993, CANCER RES, V53, P2393; Daly RJ, 1999, GROWTH FACTORS, V16, P255, DOI 10.3109/08977199909069144; Davidson B, 2001, ANAL CELL PATHOL, V23, P107, DOI 10.1155/2001/418547; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ENOMOTO T, 1990, CANCER RES, V50, P6139; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GAYNOR RB, 1991, GENOMICS, V10, P1100, DOI 10.1016/0888-7543(91)90209-W; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Hayakawa A, 1999, CANCER LETT, V140, P113, DOI 10.1016/S0304-3835(99)00062-2; Ho AT, 2001, J BIOL CHEM, V276, P40215, DOI 10.1074/jbc.M101647200; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Kajiyama H, 2002, CANCER RES, V62, P2753; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIKKAWA F, 1993, ANTICANCER RES, V13, P891; Kikkawa F, 2000, GYNECOL OBSTET INVES, V50, P269, DOI 10.1159/000010330; Klapper LN, 2000, ADV CANCER RES, V77, P25; Levkowitz G, 1996, ONCOGENE, V12, P1117; Luo J, 1999, CANCER RES, V59, P3552; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; MIZUNO K, 1992, ANTICANCER RES, V12, P21; MIZUTANI S, 1985, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V37, P769; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Nawrocki-Raby B, 2003, AM J PATHOL, V163, P653, DOI 10.1016/S0002-9440(10)63692-9; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Qvist H, 1998, BIOL CHEM, V379, P75; Schmalfeldt B, 2001, CLIN CANCER RES, V7, P2396; SLAMON DJ, 1987, NEW ENGL J MED, V317, P955, DOI 10.1056/NEJM198710083171509; Turner BC, 1998, CANCER RES, V58, P5466; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; Vernimmen D, 2003, BRIT J CANCER, V89, P899, DOI 10.1038/sj.bjc.6601200; VIKHANSKAYA F, 1994, NUCLEIC ACIDS RES, V22, P1012, DOI 10.1093/nar/22.6.1012; West-Mays JA, 2003, DIFFERENTIATION, V71, P206, DOI 10.1046/j.1432-0436.2003.710302.x; Williams TM, 1999, J MOL DIAGN, V1, P5; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200; Zhu CH, 2002, BREAST CANCER RES TR, V71, P47, DOI 10.1023/A:1013378113916	49	23	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5496	5504		10.1038/sj.onc.1207723	http://dx.doi.org/10.1038/sj.onc.1207723			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15146170				2022-12-17	WOS:000222588400009
J	Schwindling, SL; Noll, A; Montenarh, M; Gotz, C				Schwindling, SL; Noll, A; Montenarh, M; Gotz, C			Mutation of a CK2 phosphorylation site in cdc25C impairs importin alpha/beta binding and results in cytoplasmic retention	ONCOGENE			English	Article						protein kinase CK2; phosphorylation; importin alpha/beta; nuclear import; cdc25C	CASEIN KINASE-II; NUCLEAR-LOCALIZATION SEQUENCE; CYCLIN-DEPENDENT KINASES; PORE-TARGETING COMPLEX; 14-3-3 PROTEIN-BINDING; POLO-LIKE KINASE; CELL-CYCLE; T-ANTIGEN; BETA-SUBUNIT; MITOTIC PHOSPHORYLATION	cdc25C is a phosphatase, which activates the mitosis-promoting factor cyclin B1/cdc2 by dephosphorylation, and thus triggers G(2)/M transition. The activity of cdc25C itself is controlled by phosphorylation of certain amino-acid residues, which among other things determines the subcellular localization of the enzyme. Here, we describe a new phosphorylation site at threonine 236 of cdc25C, which is phosphorylated by protein kinase CK2. This phosphorylation site is located near the nuclear localization signal ( amino acids 239 - 245). We demonstrate that cdc25C interacts with importin beta and the importin alpha/beta heterodimer but not with importin a. We further found that a cdc25C phosphorylation mutant where threonine 236 was replaced by aspartic acid as well as cdc25C phosphorylated by CK2 binds importin b or the importin alpha/beta heterodimer less efficiently than wild type or the corresponding alanine mutant. Furthermore, the cdc25C(T236D) shows a retarded uptake into the nucleus in a cell import assay. Inhibition of protein kinase CK2 enzyme activity in vivo resulted in an enhanced nuclear localization of cdc25C. Thus, phosphorylation of cdc25C at threonine 236 is an important signal for the retention of cdc25C in the cytoplasm.	Univ Saarland, D-66421 Homburg, Germany	Saarland University	Gotz, C (corresponding author), Univ Saarland, Gebaude 44, D-66421 Homburg, Germany.	bccgoe@uniklinik-saarland.de	Montenarh, Mathias/AAB-6689-2020					ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; Briggs LJ, 2001, BIOCHEM J, V353, P69, DOI 10.1042/bj3530069; Bureik M, 1997, BIOL CHEM, V378, P1361, DOI 10.1515/bchm.1997.378.11.1361; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; Dotan I, 2001, BIOCHEM BIOPH RES CO, V288, P603, DOI 10.1006/bbrc.2001.5804; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; Faust M, 2002, CELL MOL LIFE SCI, V59, P2155, DOI 10.1007/s000180200022; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Fontes MRM, 2003, BIOCHEM J, V375, P339, DOI 10.1042/BJ20030510; Forwood JK, 1999, BIOCHEM BIOPH RES CO, V257, P731, DOI 10.1006/bbrc.1999.0370; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gotz C, 1999, EUR J BIOCHEM, V266, P493, DOI 10.1046/j.1432-1327.1999.00882.x; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, J CELL SCI, P75; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kasahara H, 1999, MOL CELL BIOL, V19, P526; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam MHC, 1999, J BIOL CHEM, V274, P18559, DOI 10.1074/jbc.274.26.18559; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Li Y, 2002, BIOCHEM BIOPH RES CO, V298, P439, DOI 10.1016/S0006-291X(02)02470-1; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LITCHFIELD DW, 1995, BBA-MOL CELL RES, V1269, P69, DOI 10.1016/0167-4889(95)00100-7; LORENZ A, 1992, INT J ONCOL, V1, P571; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1993, BIOCHIM BIOPHYS ACTA, V1164, P223, DOI 10.1016/0167-4838(93)90252-M; Miller ME, 2001, J CELL SCI, V114, P1811; Montenarh M, 2003, ADV CLIN EXP MED, V12, P15; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PIWNICAWORMS H, 1991, COLD SH Q B, V56, P567; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Quimby BB, 2001, CELL MOL LIFE SCI, V58, P1766, DOI 10.1007/PL00000816; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Schneider E, 2002, ONCOGENE, V21, P5031, DOI 10.1038/sj.onc.1205690; Seger D, 1998, J BIOL CHEM, V273, P24805, DOI 10.1074/jbc.273.38.24805; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Xiao CY, 1998, FEBS LETT, V440, P297, DOI 10.1016/S0014-5793(98)01478-1; Yim H, 1999, PLANTA MED, V65, P9, DOI 10.1055/s-1999-13953; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	71	23	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4155	4165		10.1038/sj.onc.1207566	http://dx.doi.org/10.1038/sj.onc.1207566			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064744				2022-12-17	WOS:000221520200014
J	Warming, S; Suzuki, T; Yamaguchi, TP; Jenkins, NA; Copeland, NG				Warming, S; Suzuki, T; Yamaguchi, TP; Jenkins, NA; Copeland, NG			Early B-cell factor-associated zinc-finger gene is a frequent target of retroviral integration in murine B-cell lymphomas	ONCOGENE			English	Article						EBFAZ; EVI3; B-cell lymphoma	ACUTE LYMPHOBLASTIC-LEUKEMIA; PRE-B; PROTEIN; MOUSE; IDENTIFICATION; EXPRESSION; LAMBDA-5; STRAINS; CLONING; LOCUS	The early B-cell factor (EBF)-associated zinc-finger protein (EBFAZ) binds to and negatively regulates EBF, a basic helix-loop-helix transcription factor required for B-cell lineage commitment and development of the olfactory epithelium. It also binds to SMA- and MAD-related protein 1 (SMAD1) and SMAD4 in response to bone morphogenic protein 2 (BMP2) signaling. It is highly related to ecotropic viral integration site 3 (EVI3), a protein that, like EBFAZ, contains 30 Kruppel-like zinc finger repeats. In previous studies, we showed that Evi3 is a frequent target of retroviral integration in AKXD27 B-cell lymphomas. Here, we show that EBFAZ is also a frequent target. Integrations at Ebfaz and Evi3 are mutually exclusive, suggesting that they function in the same tumor pathway. Lymphomas with integrations at Ebfaz or Evi3 express the pre-B-cell-specific marker immunoglobulin lambda chain 5, and contain immunoglobulin heavy-chain rearrangements, suggesting that they are blocked at an early B-cell stage. Unlike Evi3, which is expressed at low levels in normal B cells, or Ebfaz, which is not expressed in B cells, both genes are highly expressed following viral integration. Collectively, our results suggest that ectopic expression of Ebfaz can substitute for the upregulated expression of Evi3 in B-cell disease and highlight the importance of this gene family in hematopoietic cancer.	NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21702 USA; NCI, Canc & Dev Lab, Ctr Canc Res, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Copeland, NG (corresponding author), NCI, Mouse Canc Genet Program, Ctr Canc Res, W 7th St & Ft Detrick, Frederick, MD 21702 USA.	copeland@ncifcrf.gov	Warming, Soren/ABD-5729-2021	Warming, Soren/0000-0002-5721-0741	NATIONAL CANCER INSTITUTE [ZIABC010345, Z01BC010345] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Heerema NA, 1999, LEUKEMIA, V13, P679, DOI 10.1038/sj.leu.2401413; Hiai H, 2003, CANCER SCI, V94, P847, DOI 10.1111/j.1349-7006.2003.tb01365.x; HILDEN JM, 1995, BLOOD, V86, P3876, DOI 10.1182/blood.V86.10.3876.bloodjournal86103876; JUSTICE MJ, 1994, J VIROL, V68, P1293, DOI 10.1128/JVI.68.3.1293-1300.1994; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Seong C, 1998, BRIT J HAEMATOL, V101, P189, DOI 10.1046/j.1365-2141.1998.00657.x; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Smadja NV, 2001, BLOOD, V98, P2229, DOI 10.1182/blood.V98.7.2229; SUZUKI T, 2002, NAT GENET, V19, P19; Tsai RYL, 1998, MOL CELL BIOL, V18, P6447, DOI 10.1128/MCB.18.11.6447; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Warming S, 2003, BLOOD, V101, P1934, DOI 10.1182/blood-2002-08-2652	19	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2727	2731		10.1038/sj.onc.1207452	http://dx.doi.org/10.1038/sj.onc.1207452			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048087				2022-12-17	WOS:000220714900014
J	Lee, S; Roy, F; Galmarini, CM; Accardi, R; Michelon, J; Viller, A; Cros, E; Dumontet, C; Sylla, BS				Lee, S; Roy, F; Galmarini, CM; Accardi, R; Michelon, J; Viller, A; Cros, E; Dumontet, C; Sylla, BS			Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia	ONCOGENE			English	Article						Dok1; chronic lymphocytic leukemia; frameshift mutation; NLS; Lck; tyrosine phosphorylation	RASGAP-BINDING PROTEIN; GTPASE-ACTIVATING PROTEIN; TYROSINE PHOSPHORYLATION; NEGATIVE REGULATION; MOLECULAR-CLONING; DOCKING PROTEIN; P62(DOK) DOK1; V-SRC; KINASE; APOPTOSIS	B-cell chronic lymphocytic leukemia (B-CLL) is a malignant disease characterized by an accumulation of monoclonal CD5+ mature B cells, with a high percentage of cells arrested in the G0/G1 phase of the cell cycle, and a particular resistance toward apoptosis-inducing agents. Dok1 ( downstream of tyrosine kinases) is an abundant Ras-GTPase-activating protein (Ras-GAP)-associated tyrosine kinase substrate, which negatively regulates cell proliferation, downregulates MAP kinase activation and promotes cell migration. The gene encoding Dok1 maps to human chromosome 2p13, a region previously found to be rearranged in B-CLL. We have screened the Dok1 gene for mutations from 46 individuals with B-CLL using heteroduplex analysis. A four-nucleotide GGCC deletion in the coding region was found in the leukemia cells from one patient. This mutation causes a frameshift leading to protein truncation at the carboxyl-terminus, with the acquisition of a novel amino-acid sequence. In contrast to the wild-type Dok1 protein, which has cytoplasmic/membrane localization, the mutant Dok1 is a nuclear protein containing a functional bipartite nuclear localization signal. Whereas overexpression of wild-type Dok1 inhibited PDGF-induced MAP kinase activation, this inhibition was not observed with the mutant Dok1. Furthermore the mutant Dok1 forms heterodimers with Dok1 wild type and the association can be enhanced by Lck-mediated tyrosine-phosphorylation. This is the first example of a Dok1 mutation in B-CLL and the data suggest that Dok1 might play a role in leukemogenesis.	Int Agcy Res Canc, F-69008 Lyon, France; INSERM, U590, F-69008 Lyon, France; Hospices Civils Lyon, F-69008 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon	Sylla, BS (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	sylla@iarc.fr		Galmarini, Carlos Maria/0000-0001-5494-6617; Dumontet, Charles/0000-0003-1875-134X				ABTS H, 1991, LEUKEMIA RES, V15, P987, DOI 10.1016/0145-2126(91)90103-Z; Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cheng GF, 2002, J VIROL, V76, P9434, DOI 10.1128/JVI.76.18.9434-9445.2002; Cong F, 1999, MOL CELL BIOL, V19, P8314; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; ELROUBY S, 1993, BLOOD, V82, P3452; Favre C, 2003, GENES IMMUN, V4, P40, DOI 10.1038/sj.gene.6363891; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hall T.A., 1999, NUCLC ACIDS S, V41, P95, DOI citeulike-article-id:691774; Hosooka T, 2001, MOL CELL BIOL, V21, P5437, DOI 10.1128/MCB.21.16.5437-5446.2001; Hubert P, 2000, EUR J IMMUNOGENET, V27, P145, DOI 10.1046/j.1365-2370.2000.00203.x; INABA T, 1991, LEUKEMIA, V5, P719; JUCKER M, 1991, LEUKEMIA, V5, P528; Kato I, 2002, J IMMUNOL, V168, P629, DOI 10.4049/jimmunol.168.2.629; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Liang XQ, 2002, J BIOL CHEM, V277, P13732, DOI 10.1074/jbc.M200277200; Martelli MP, 2001, J BIOL CHEM, V276, P45654, DOI 10.1074/jbc.M105777200; Munzert G, 2002, BLOOD, V100, P3749, DOI 10.1182/blood.V100.10.3749; NEET K, 1995, MOL CELL BIOL, V15, P4908; Nelms K, 1998, GENOMICS, V53, P243, DOI 10.1006/geno.1998.5514; Nemorin JG, 2000, J BIOL CHEM, V275, P14590, DOI 10.1074/jbc.275.19.14590; Nemorin JG, 2001, J IMMUNOL, V166, P4408, DOI 10.4049/jimmunol.166.7.4408; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RICHARDSON AL, 1992, ONCOGENE, V7, P961; Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539; Sattler M, 2001, J BIOL CHEM, V276, P2451, DOI 10.1074/jbc.M006250200; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; SCHROEDER HW, 1994, IMMUNOL TODAY, V15, P288, DOI 10.1016/0167-5699(94)90009-4; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; SONNIER JA, 1983, NEW ENGL J MED, V309, P590, DOI 10.1056/NEJM198309083091005; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Sylla BS, 2000, P NATL ACAD SCI USA, V97, P7470, DOI 10.1073/pnas.130193097; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; van Dijk TB, 2000, BLOOD, V96, P3406; VonKnethen A, 1997, LEUKEMIA LYMPHOMA, V26, P551; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wick MJ, 2001, J BIOL CHEM, V276, P42843, DOI 10.1074/jbc.M102116200; Wyatt W, 2000, BLOOD, V96, p367A; Yamakawa N, 2002, EMBO J, V21, P1684, DOI 10.1093/emboj/21.7.1684; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YOFFE G, 1990, J PEDIATR-US, V116, P114, DOI 10.1016/S0022-3476(05)81658-0; Zhao MM, 2001, J EXP MED, V194, P265, DOI 10.1084/jem.194.3.265	52	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2287	2297		10.1038/sj.onc.1207385	http://dx.doi.org/10.1038/sj.onc.1207385			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14730347				2022-12-17	WOS:000220427700002
J	Bossi, G; Mazzaro, G; Porrello, A; Crescenzi, M; Soddu, S; Sacchi, A				Bossi, G; Mazzaro, G; Porrello, A; Crescenzi, M; Soddu, S; Sacchi, A			Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy	ONCOGENE			English	Article						p53; gene therapy; tumor targeting; normal cells; retrovirus vector	HEMATOPOIETIC STEM-CELLS; SUPPRESSOR GENE; RETROVIRAL VECTORS; EXOGENOUS WT-P53; 32D CELLS; CANCER; DIFFERENTIATION; TRANSPLANTATION; EXPRESSION; ONCOGENES	The p53 oncosuppressor is strictly maintained in an inactive form under normal conditions, while it is post-translationally activated by a variety of stresses, enacting different protective biological functions. Since one critical issue in cancer gene therapy is tumor specificity, we asked whether the tight p53 regulation applies also to exogenously transferred p53. In principle, this type of regulation could allow p53 gene transfer in both normal and tumor cells to produce detrimental effects only in the latter ones. Here, we report that primary bone marrow cells infected with a p53 recombinant retrovirus and transplanted into irradiated mice reconstitute the hematopoietic system, with no detectable alterations in any of its compartments. Furthermore, simultaneous infection of leukemia and bone marrow cells depleted the neoplastic contamination, allowing lifelong, disease-free survival of 65% of the transplanted animals. These results show that exogenous p53 is controlled as tightly as the endogenous one, and opens the way to p53 gene therapy, without requiring tumor targeting.	Regina Elena Inst Canc Res, Dept Expt Oncol, Mol Oncogenesis Lab, I-00158 Rome, Italy; Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS)	Soddu, S (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Mol Oncogenesis Lab, Via Messi Oro 156, I-00158 Rome, Italy.	soddu@ifo.it; sacchi@ifo.it	Bossi, Gianluca/G-8375-2016; Bossi, Gianluca/ABH-6846-2020; Soddu, Silvia/K-2467-2018; Soddu, Silvia/ABH-6774-2020; Crescenzi, Marco/J-3603-2018; Bossi, Gianluca/B-9394-2017	Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; Crescenzi, Marco/0000-0003-0156-1494; Bossi, Gianluca/0000-0002-2947-1063	Telethon [GP0234Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; Appella E, 2000, PATHOL BIOL, V48, P227; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BLANDINO G, 1995, ONCOGENE, V10, P731; BODINE DM, 1991, EXP HEMATOL, V19, P206; Bossi G, 2000, CANCER GENE THER, V7, P135, DOI 10.1038/sj.cgt.7700101; CLAYMAN GL, 1995, CANCER RES, V55, P1; D'Orazi G, 2000, J GENE MED, V2, P11; Domen J, 1999, MOL MED TODAY, V5, P201, DOI 10.1016/S1357-4310(99)01464-1; Favrot M, 1998, GENE THER, V5, P728, DOI 10.1038/sj.gt.3300661; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Gorin NC, 2002, CURR OPIN ONCOL, V14, P152, DOI 10.1097/00001622-200203000-00003; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Heslop HE, 1995, BLOOD REV, V9, P220, DOI 10.1016/S0268-960X(95)90013-6; Karlsson S, 1997, J INTERN MED, V242, P95, DOI 10.1111/joim.1997.242.s740.95; KASTAN MB, 1991, CANCER RES, V51, P4279; LaCasse EC, 1999, BLOOD, V94, P2901; Martinelli R, 1997, ONCOGENE, V15, P607, DOI 10.1038/sj.onc.1201218; Mazzaro G, 1999, ONCOGENE, V18, P5831, DOI 10.1038/sj.onc.1202962; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nielsen LL, 1998, CANCER GENE THER, V5, P52; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Scardigli R, 1997, GENE THER, V4, P1371, DOI 10.1038/sj.gt.3300530; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; Soddu S, 1996, MOL CELL BIOL, V16, P487; Soddu S, 1998, CYTOKINES CELL MOL T, V4, P177; TAKAHASHI T, 1992, CANCER RES, V52, P2340; Williams David A., 2000, Hematology Am Soc Hematol Educ Program, P376; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155	34	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					418	425		10.1038/sj.onc.1207042	http://dx.doi.org/10.1038/sj.onc.1207042			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724570				2022-12-17	WOS:000188098300012
J	Conlan, LA; McNees, CJ; Heierhorst, J				Conlan, LA; McNees, CJ; Heierhorst, J			Proteasome-dependent dispersal of PML nuclear bodies in response to alkylating DNA damage	ONCOGENE			English	Article						PML; Sp100; DNA alkylation; proteasome	PROTEIN; LOCALIZATION; P53	Promyelocytic leukemia protein (PML) nuclear bodies (NBs) are present in variable number in most human cell types and have been linked to various cellular functions, including roles as depots for DNA repair proteins. Here, we show that treatment of human cells with DNA methylating agents leads to redistribution of PML from NBs to a diffuse nuclear localization. Biochemically, this correlates with a specific reduction of PML levels in the nuclear matrix fraction without affecting total PML levels. Similar results were obtained for the other major PML NB component, the Sp100 protein, indicating that DNA methylating agents lead to a general disassembly of PML NBs. Similar to the dispersal of PML NBs in response to some viral infections, PML redistribution after DNA damage was inhibited by the proteasome inhibitor MG132. We propose that the regulated dispersal of PML NBs may facilitate the enhanced release of DNA repair proteins from NB depots in order to respond adequately to extensive DNA damage.	Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia	St Vincent's Hospital Melbourne; St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne	Heierhorst, J (corresponding author), Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.	heier@ariel.its.unimelb.edu.au						Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; De Lucia F, 2001, BIOCHEM J, V358, P447, DOI 10.1042/0264-6021:3580447; Everett RD, 1999, J CELL SCI, V112, P3443; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seker H, 2003, ONCOGENE, V22, P1620, DOI 10.1038/sj.onc.1206140; Venere M, 2002, NAT CELL BIOL, V4, pE255, DOI 10.1038/ncb1102-e255; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Xu ZX, 2003, MOL CELL BIOL, V23, P4247, DOI 10.1128/MCB.23.12.4247-4256.2003; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869	16	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					307	310		10.1038/sj.onc.1207119	http://dx.doi.org/10.1038/sj.onc.1207119			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712236				2022-12-17	WOS:000187895300033
J	Dazy, S; Damiola, F; Parisey, N; Beug, H; Gandrillon, O				Dazy, S; Damiola, F; Parisey, N; Beug, H; Gandrillon, O			The MEK-1/ERKs signalling pathway is differentially involved in the self-renewal of early and late avian erythroid progenitor cells	ONCOGENE			English	Article						MEK-1; self-renewal; TGF-alpha; erythropoiesis	P38 MAP KINASE; V-ERBA; STEM-CELLS; GLUCOCORTICOID-RECEPTOR; TYROSINE KINASE; C-KIT; APOPTOSIS; ACTIVATION; GROWTH; PROLIFERATION	Making decisions between self-renewal and differentiation is a central ability of stem cells. Elucidation of molecular networks governing this decision is therefore of prime importance. A model of choice to explore this question is represented by chicken erythroid progenitors, in which self-renewal versus differentiation as well as progenitor maturation are regulated by external factor combinations. We used this system to study whether similar or different signalling pathways were involved in the self-renewal of early, immature or more mature erythroid progenitors. We show that a transforming growth factor (TGF)-alpha-activated Ras/MEK-1/ERK1/2 pathway is strictly required for immature self-renewing cells but becomes fully dispensable when those cells are induced to differentiate. Consequently, pharmacological inhibition of this pathway led to spontaneous differentiation, only dependent on the presence of survival signals. Conversely, ectopic expression of a constitutive form of MEK-1 stimulates renewal and arrests differentiation process. Finally, we demonstrate that the ERK/MAPK signalling pathway is required in early but not in late primary erythroid progenitors, which can be turned into each other by different growth factor combinations specifically driving their renewal. To the best of our knowledge, this is the first description of a central role of ERK/MAPK signalling in regulating progenitor plasticity in the same cell type under different environmental conditions.	Univ Lyon 1, Ctr Genet Mol & Cellulaire, Lab Signalisat & Ident Cellulaires, CNRS,UMR 5534, F-69622 Villeurbanne, France; Inst Mol Pathol, A-1030 Vienna, Austria	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Gandrillon, O (corresponding author), Univ Lyon 1, Ctr Genet Mol & Cellulaire, Lab Signalisat & Ident Cellulaires, CNRS,UMR 5534, Bat Gregoire Mendel,16 Rue Dubois, F-69622 Villeurbanne, France.	Gandrillon@cgmc.univ-lyon1.fr		Parisey, Nicolas/0000-0003-2439-3809; Damiola, Francesca/0000-0002-0238-1252				Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, HEMATOPOIESIS DEV AP, P368; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; Bourgin C, 2000, FEBS LETT, V480, P113, DOI 10.1016/S0014-5793(00)01906-2; BRUNET A, 1994, ONCOGENE, V9, P3379; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; Dolznig H, 2002, CURR BIOL, V12, P1076, DOI 10.1016/S0960-9822(02)00930-2; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; GANDRILLON O, 1994, ONCOGENE, V9, P749; Gandrillon O, 1998, ONCOGENE, V16, P563, DOI 10.1038/sj.onc.1201550; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; LACOSTEELEAUME AS, 1994, EXP CELL RES, V213, P198, DOI 10.1006/excr.1994.1191; Lesault I, 2002, EMBO J, V21, P694, DOI 10.1093/emboj/21.4.694; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuzaki T, 2000, ONCOGENE, V19, P1500, DOI 10.1038/sj.onc.1203461; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374; STEINLEIN P, 1994, GROWTH FACTORS, V10, P1, DOI 10.3109/08977199409019599; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; Tamir A, 2000, CELL GROWTH DIFFER, V11, P269; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Verfaillie CM, 2002, TRENDS CELL BIOL, V12, P502, DOI 10.1016/S0962-8924(02)02386-3; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wessely O, 1999, BIOL CHEM, V380, P187, DOI 10.1515/BC.1999.027; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; Witt O, 2000, BLOOD, V95, P2391, DOI 10.1182/blood.V95.7.2391.007k21_2391_2396; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	52	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9205	9216		10.1038/sj.onc.1207049	http://dx.doi.org/10.1038/sj.onc.1207049			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681680				2022-12-17	WOS:000187400400002
J	Gillgrass, A; Cardiff, RD; Sharan, N; Kannan, S; Muller, WJ				Gillgrass, A; Cardiff, RD; Sharan, N; Kannan, S; Muller, WJ			Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression	ONCOGENE			English	Article						epidermal growth factor receptor; Gab-1; waved-2; ErbB-2; transgenic	HUMAN-BREAST-CANCER; TRANSGENIC MICE; TYROSINE KINASE; PROTO-ONCOGENE; NEU ONCOGENE; TGF-ALPHA; INDUCTION; OVEREXPRESSION; AMPLIFICATION; TUMORIGENESIS	Activation of the epidermal growth factor receptor (EGFR) family is thought to play an important role in mammary tumorigenesis and metastasis. The potent transforming activity of the EGFR family is due to their ability to heterodimerize with each other in response to a number of mitogenic ligands. The formation of EGFR and ErbB-2 heterodimers has been recently implicated as an important factor in the induction of sporadic human breast cancers. To directly assess whether the catalytic activity of EGFR is required for ErbB-2 induction of mammary tumors, we have interbred transgenic mice expressing ErbB-2 oncogene under the transcriptional control of the mouse mammary tumor virus (MMTV) promoter/enhancer to a naturally occurring mouse mutant carrying a catalytically impaired EGFR (waved-2 mice). Although the female transgenic mice possessing mutant EGFR developed mammary tumors, the tumors occurred only after a delayed latency period, and were fewer in number. The impaired tumor phenotype was further correlated with debilitated phosphorylation of the Gab1 multisubstrate adapter. These observations provide evidence that efficient ErbB-2-induced mammary tumor progression requires EGFR-dependent activation of Gab1.	McMaster Univ, MOBIX, Hamilton, ON L8S 4K1, Canada; Univ Calif Davis, Davis, CA 95616 USA; McGill Univ, Dept Med, Mol Oncol Grp, Montreal, PQ, Canada; McGill Univ, Dept Biochem, Montreal, PQ, Canada	McMaster University; University of California System; University of California Davis; McGill University; McGill University	Muller, WJ (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Biochem, 687 Pne Ave W,Rm H-5-21, Montreal, PQ H3A 1A1, Canada.							Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Rowse GJ, 1998, CANCER RES, V58, P2675; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276	22	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9151	9155		10.1038/sj.onc.1206983	http://dx.doi.org/10.1038/sj.onc.1206983			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668796				2022-12-17	WOS:000187149100005
J	Ricaud, S; Vernus, B; Duclos, M; Bernardi, H; Ritvos, O; Carnac, G; Bonnieu, A				Ricaud, S; Vernus, B; Duclos, M; Bernardi, H; Ritvos, O; Carnac, G; Bonnieu, A			Inhibition of autocrine secretion of myostatin enhances terminal differentiation in human rhabdomyosarcoma cells	ONCOGENE			English	Article						myostatin; rhabdomyosarcoma; autocrine secretion; inhibition of myostatin; inhibition of differentiation; MyoD activity	HUMAN ALVEOLAR RHABDOMYOSARCOMA; FIBROBLAST GROWTH-FACTOR; MYOGENIC DIFFERENTIATION; GENE-EXPRESSION; MUSCLE-CELLS; REGULATORY FACTORS; PROTEIN-SYNTHESIS; PROLIFERATION; MYOD; INDUCTION	Rhabdomyosarcomas (RMSs) are one of the most common solid tumor of childhood. Rhabdomyosarcoma (RMS) cells fail to both complete the skeletal muscle differentiation program and irreversibly exit the cell cycle as a consequence of an active repression exerted on the muscle-promoting factor MyoD. Myostatin is a negative regulator of normal muscle growth, we have thus studied its possible role in RMS cells. Here, we present evidence that overexpression of myostatin is a common feature of RMS since both subtypes of RMS (embryonal RD and alveolar Rh30 cells) express high levels of myostatin when compared to nontumoral skeletal muscle cells. Interestingly, we found that inactivation of myostatin through overexpression of antisense myostatin or of follistatin (a myostatin antagonist) constructs enhanced differentiation of RD cells. In addition, RD and Rh30 cells treated with blocking antimyostatin antibodies progress into the myogenic terminal differentiation program. Finally, our results suggest that high levels of myostatin could impair MyoD function in RMS cells. These results show that an autocrine myostatin loopcontributes to maintain RMS cells in an undifferentiating stage and suggest that new therapeutic approaches could be exploited for the treatment of RMS based on inactivation of myostatin protein.	INRA, UMR Differenciat Cellulaire & Croissance 866, F-34060 Montpellier 1, France; INRA, Rech Avicoles Stn, F-37380 Nouzilly, France; Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland; Univ Helsinki, Programme Dev & Reprod Biol, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; CNRS, FRE 2593, CRBM, F-34293 Montpellier 5, France	INRAE; INRAE; University of Helsinki; University of Helsinki; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Bonnieu, A (corresponding author), INRA, UMR Differenciat Cellulaire & Croissance 866, F-34060 Montpellier 1, France.		DUCLOS, Michel/AAQ-3957-2021; Bonnieu, Anne/ABA-7182-2020; Ritvos, Olli/GWC-2442-2022; Carnac, Gilles/N-6744-2018	DUCLOS, Michel/0000-0002-9305-3982; Carnac, Gilles/0000-0002-3518-8774; Bernardi, Henri/0000-0003-3570-8925; Ritvos, Olli/0000-0001-7017-6931				Alric S, 1998, ONCOGENE, V16, P273, DOI 10.1038/sj.onc.1201484; Artaza JN, 2002, J CELL PHYSIOL, V190, P170, DOI 10.1002/JCP.10044; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Bouche M, 2000, FASEB J, V14, P1147, DOI 10.1096/fasebj.14.9.1147; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; DeGiovanni C, 1996, CANCER RES, V56, P3898; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; Froeschle A, 1998, ONCOGENE, V16, P3369, DOI 10.1038/sj.onc.1201894; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; JIN P, 1991, J BIOL CHEM, V266, P1245; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; Kitzmann M, 1998, J CELL BIOL, V142, P1447, DOI 10.1083/jcb.142.6.1447; Knudsen ES, 1998, CANCER RES, V58, P2042; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Puri PL, 2000, GENE DEV, V14, P574; Rios R, 2002, AM J PHYSIOL-CELL PH, V282, pC993, DOI 10.1152/ajpcell.00372.2001; Rios R, 2001, BIOCHEM BIOPH RES CO, V280, P561, DOI 10.1006/bbrc.2000.4159; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Taylor WE, 2001, AM J PHYSIOL-ENDOC M, V280, pE221, DOI 10.1152/ajpendo.2001.280.2.E221; Thies RS, 2001, GROWTH FACTORS, V18, P251; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; TONIN PN, 1991, CANCER RES, V51, P5100; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	44	23	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8221	8232		10.1038/sj.onc.1207177	http://dx.doi.org/10.1038/sj.onc.1207177			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614446				2022-12-17	WOS:000186541500001
J	Milosevic, J; Hoffarth, S; Huber, C; Schuler, M				Milosevic, J; Hoffarth, S; Huber, C; Schuler, M			The DNA damage-induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspases	ONCOGENE			English	Article						Bcl-2; apoptosis; DNA damage; Bax caspases	CYTOCHROME-C RELEASE; TRIGGERS APOPTOSIS; CELL-DEATH; BAX; PATHWAYS; FAMILY; REQUIREMENT; CLEAVAGE; MEMBER; APAF1	Apoptosis induced by DNA-damaging agents or radiation mainly proceeds through death receptor-independent caspase activation. The release of mitochondrial apoptogenic proteins, such as cytochrome c, into the cytoplasm leading to Apaf1-dependent activation of caspase-9 is a key event in this pathway. The permeability of the mitochondrial outer membrane is regulated by the various pro- and antiapoptotic Bcl-2 family proteins, and it is thought that DNA damage triggers apoptosis through the downregulation of antiapoptotic Bcl-2. Using murine embryonic fibroblasts (MEF) deficient and proficient in Apaf1, we show that DNA-damaging agents and radiation lead to a decline in Bcl-2 protein only in wt MEF, but not in apaf1(-/-) MEF, which are defective in the activation of effector caspases and apoptosis. In contrast, the induction of proapoptotic Noxa, the activation of Bax, the cytoplasmic release of cytochrome c, as well as a drop of the mitochondrial transmembrane potential DeltaPsi(m) are equally observed in wt and apaf1(-/-) MEF following DNA damage. Moreover, the loss of Bcl-2 protein occurring in wt MEF can be prevented by caspase inhibition. Hence, the activation of proapoptotic Bcl-2 family proteins rather than the downregulation of antiapoptotic Bcl-2 mediates the primary signal in the DNA damage-induced release of mitochondrial apoptogenic proteins in MEF.	Johannes Gutenberg Univ Mainz, Dept Med 3, D-55101 Mainz, Germany; Johannes Gutenberg Univ Mainz, Gene Therapy Lab, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Schuler, M (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med 3, Bldg 302, D-55101 Mainz, Germany.	m.schuler@3-med.klinik.uni-mainz.de						Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; CHEN M, 1995, CANCER RES, V55, P991; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	32	23	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6852	6856		10.1038/sj.onc.1206716	http://dx.doi.org/10.1038/sj.onc.1206716			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534531				2022-12-17	WOS:000185843400005
J	Nagano, H; Noguchi, T; Inagaki, K; Yoon, S; Matozaki, T; Itoh, H; Kasuga, M; Hayashi, Y				Nagano, H; Noguchi, T; Inagaki, K; Yoon, S; Matozaki, T; Itoh, H; Kasuga, M; Hayashi, Y			Downregulation of stomach cancer-associated protein tyrosine phosphatase-1 (SAP-1) in advanced human hepatocellular carcinoma	ONCOGENE			English	Article						tyrosine phosphatase; cell migration; dedifferentiation; hepatoma	FOCAL ADHESION KINASE; CELL INVASION; HUMAN LUNG; EXPRESSION; RECEPTOR; GROWTH; GENE; LIVER; OVEREXPRESSION; AMPLIFICATION	SAP-1 (stomach cancer-associated protein tyrosine phosphatase-1) is a transmembrane-type protein tyrosine phosphatase that has been implicated as a negative regulator of integrin-mediated signaling. The potential role of this enzyme in hepatocarcinogenesis has now been investigated by examining its expression in 32 surgically excised human hepatocellular carcinoma (HCC) specimens. Both immunohistochemical and immunoblot analyses revealed that normal liver tissue, as well as tissue affected by chronic hepatitis or cirrhosis, contained substantial amounts of SAP-1. The expression level of SAP-1 in 75% of well-differentiated HCCs was similar to or higher than that observed in the surrounding non-cancerous tissue. In contrast, the abundance of SAP-1 in 85.7% of moderately differentiated HCCs and in all poorly differentiated HCCs was greatly reduced compared with that in the adjacent tissue. Indeed, SAP-1 was almost undetectable in 83.3% of poorly differentiated HCCs. Furthermore, expression of recombinant SAP-1 in two highly motile human HCC cell lines resulted in a change in morphology and a marked reduction in both migratory activity and growth rate. In conclusion, these results indicate that SAP-1 expression is downregulated during the dedifferentiation of human HCC, and that this downregulation may play a causal role in disease progression.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Dept Biomed Informat, Div Surg Pathol,Chuo Ku, Kobe, Hyogo 6500017, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Maebashi, Gumma 3718512, Japan	Kobe University; Kobe University; Gunma University	Noguchi, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.							Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DEVRIES L, 1991, FEBS LETT, V282, P285; DOI I, 1975, GANN, V66, P385; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IKUTA S, 1994, J GASTROENTEROL, V29, P727, DOI 10.1007/BF02349278; Imamura F, 2000, JPN J CANCER RES, V91, P811, DOI 10.1111/j.1349-7006.2000.tb01018.x; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; KAMEDA T, 1990, CANCER RES, V50, P8002; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; Keane MM, 1996, CANCER RES, V56, P4236; KIM SR, 1995, J GASTROEN HEPATOL, V10, P498, DOI 10.1111/j.1440-1746.1995.tb01338.x; KITAMURA T, 1995, JPN J CANCER RES, V86, P811, DOI 10.1111/j.1349-7006.1995.tb03090.x; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; Morita Y, 1997, HEPATOLOGY, V25, P856, DOI 10.1002/hep.510250412; NISHIDA N, 1993, CANCER RES, V53, P368; Noguchi T, 2001, J BIOL CHEM, V276, P15216, DOI 10.1074/jbc.M007208200; Ojakian GK, 2001, J CELL SCI, V114, P941; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Palmer HJ, 1999, J BIOL CHEM, V274, P11424, DOI 10.1074/jbc.274.16.11424; ROGLER CE, 1992, SEMIN LIVER DIS, V12, P265, DOI 10.1055/s-2007-1007398; Saito S, 1996, BIOCHEM BIOPH RES CO, V227, P406, DOI 10.1006/bbrc.1996.1520; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Seo Y, 1997, BIOCHEM BIOPH RES CO, V231, P705, DOI 10.1006/bbrc.1997.6139; SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570; TAHARA H, 1995, CANCER RES, V55, P2734; Takada T, 2002, J BIOL CHEM, V277, P34359, DOI 10.1074/jbc.M206541200; Tamura M, 1999, CANCER RES, V59, P442; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; Tonks N K, 1993, Semin Cell Biol, V4, P373, DOI 10.1006/scel.1993.1044; TSUKAMOTO T, 1992, CANCER RES, V52, P3506; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101	41	23	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4656	4663		10.1038/sj.onc.1206588	http://dx.doi.org/10.1038/sj.onc.1206588			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879010				2022-12-17	WOS:000184157000006
J	Alpy, F; Boulay, A; Moog-Lutz, C; Andarawewa, KL; Degot, S; Stoll, I; Rio, MC; Tomasetto, C				Alpy, F; Boulay, A; Moog-Lutz, C; Andarawewa, KL; Degot, S; Stoll, I; Rio, MC; Tomasetto, C			Metastatic lymph node 64 (MLN64), a gene overexpressed in breast cancers, is regulated by Sp/KLF transcription factors	ONCOGENE			English	Article						erbB-2; MLN64; MENTHO; StAR; Sp1	HIGHLY EXPRESSED GENES; PROTEIN STAR; ESOPHAGEAL-CARCINOMA; CHROMOSOMAL DOMAINS; DNA AMPLIFICATION; FACTOR RECEPTOR; IN-VITRO; FAMILY; GENOME; REVEALS	MLN64, is invariably coamplified and coexpressed with erbB-2 in breast cancers. The human MLN64 and ERBB2 genes are positioned at less than 50 kb from each other, on chromosome 17q12. To understand the molecular basis of MLN64 overexpression in cancer, the genomic region containing the MLN64 and ERBB2 genes was isolated and mapped. The two genes, DARPP32 and Telethonin, flanking MLN64 respectively on its centromeric and telomeric sides, although coamplified, are not over-expressed in breast cancer cells, indicating that gene amplification is not sufficient to allow overexpression. The MLN64 minimal promoter was isolated and found to be a housekeeping gene promoter containing four potential Sp1 binding elements. Using Sp1-deficient Drosophila SL2 cells, MLN64 promoter activity was induced in a dose-dependent manner by exogenous Sp1 addition. Furthermore, mutation of each individual Sp1 element resulted in a significant decrease in reporter gene activity, indicating that all the Sp1 binding elements are functional and act together to promote gene expression. Since the ERBB2 promoter is also positively regulated by Sp1, this study indicates that MLN64 and ERBB2 genes share common transcriptional controls together with a physical link on chromosome 17q. We speculate that, in addition to the oncogenic potential of erbB-2 overexpression, the unbalanced action of MLN64 contributes to the poor clinical outcome of breast tumors bearing this amplified region.	Univ Louis Pasteur Strasbourg 1, CNRS INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tomasetto, C (corresponding author), IGBMC, Dept Mol Pathol, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, France.		Alpy, Fabien/ABD-5893-2020; MOOG-LUTZ, Christel/F-1975-2011; Alpy, Fabien/H-8941-2016; Tomasetto, Catherine Laure/J-2783-2014	Alpy, Fabien/0000-0002-0526-0720; Alpy, Fabien/0000-0002-0526-0720; Tomasetto, Catherine Laure/0000-0002-1811-5848				Alpy F, 2002, J BIOL CHEM, V277, P50780, DOI 10.1074/jbc.M208290200; Alpy F, 2001, J BIOL CHEM, V276, P4261, DOI 10.1074/jbc.M006279200; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Bates NP, 1997, J MAMMARY GLAND BIOL, V2, P153, DOI 10.1023/A:1026303814855; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bieche I, 1996, CANCER RES, V56, P3886; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blumenthal T, 2002, NATURE, V417, P851, DOI 10.1038/nature00831; Boutanaev AM, 2002, NATURE, V420, P666, DOI 10.1038/nature01216; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; CHEN YY, 1994, ONCOGENE, V9, P2269; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Foster KW, 2000, CANCER RES, V60, P6488; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Hyman E, 2002, CANCER RES, V62, P6240; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; Kauraniemi P, 2001, CANCER RES, V61, P8235; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; Mayerhofer A, 1999, J CLIN ENDOCR METAB, V84, P257, DOI 10.1210/jc.84.1.257; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Pegram MD, 1998, BREAST CANCER RES TR, V52, P65, DOI 10.1023/A:1006111117877; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Soury E, 2001, IMMUNOGENETICS, V53, P634, DOI 10.1007/s00251-001-0374-z; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tanaka S, 2000, J CELL PHYSIOL, V183, P411, DOI 10.1002/(SICI)1097-4652(200006)183:3<411::AID-JCP14>3.0.CO;2-Z; Tanaka S, 1997, CANCER RES, V57, P28; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Valle G, 1997, FEBS LETT, V415, P163, DOI 10.1016/S0014-5793(97)01108-3; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462	52	23	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3770	3780		10.1038/sj.onc.1206500	http://dx.doi.org/10.1038/sj.onc.1206500			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802284				2022-12-17	WOS:000183551000011
J	Kunapuli, P; Somerville, R; Still, IH; Cowell, JK				Kunapuli, P; Somerville, R; Still, IH; Cowell, JK			ZNF198 protein, involved in rearrangement in myeloproliferative disease, forms complexes with the DNA repair-associated HHR6A/6B and RAD18 proteins	ONCOGENE			English	Article						ZNF198; myeloproliferative disease; post replication repair; RAD6; RAD18	UBIQUITIN-CONJUGATING ENZYME; GROWTH-FACTOR RECEPTOR-1; SACCHAROMYCES-CEREVISIAE; POSTREPLICATION REPAIR; DISORDER FUSES; YEAST RAD6; GENE RAD6; TRANSLOCATION; CHROMOSOME-13; BINDING	A highly specific t(8;13)(p11;q12) translocation has been consistently identified in bone marrow cells from patients with an atypical myeloproliferative disease that is associated with peripheral blood eosinophila and T- or B-cell leukemias. In all patients analysed to date, the translocation event results in a chimeric gene in which the atypical zinc-finger domain of ZNF198 is fused to the N-terminal end of the catalytic domain of the FGFR1 receptor tyrosine kinase. To understand more about the consequences of this rearrangement we have investigated the normal function of the ZNF198 gene. Using yeast two-hybrid analysis we identified HHR6 as a protein binding partner an confirmed this using immunoprecipitation studies. The ZNF198/FGFRI fusion protein also binds to HHR6. We demonstrate here that the human RAD18 is also present in the ZNF198/HHR6 protein complex, although it does not coimmunoprecipitate with the fusion kinase. Cells expressing the fusion kinase gene show a marked increased sensitivity to UVB irradiation, suggesting that it acts in a dominant-negative way to affect DNA repair. These observations support the idea that ZNF198, through its interaction with HHR6 and RAD18, may be involved in the DNA repair process.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA	Roswell Park Cancer Institute; Cleveland Clinic Foundation	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.			Cowell, John/0000-0002-2079-5950	NATIONAL CANCER INSTITUTE [P30CA016056, R01CA076167] Funding Source: NIH RePORTER; NCI NIH HHS [CA76167, P30 CA16056-26] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRUZZO LV, 1992, AM J SURG PATHOL, V16, P236, DOI 10.1097/00000478-199203000-00003; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; BAUMANN H, 2003, IN PRESS J BIOL CHEM; Chervin RD, 2000, SLEEP MED, V1, P21, DOI 10.1016/S1389-9457(99)00009-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HARPER JW, 1993, CELL, V75, P805; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; KEMPSKI H, 1995, GENE CHROMOSOME CANC, V12, P283, DOI 10.1002/gcc.2870120408; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Ollendorff V, 1999, J BIOL CHEM, V274, P26922, DOI 10.1074/jbc.274.38.26922; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; Shekhar MPV, 2002, CANCER RES, V62, P2115; Smedley D, 1998, HUM MOL GENET, V7, P637, DOI 10.1093/hmg/7.4.637; SMEDLEY D, 1999, NEOPLASIA, V1, P249; Still IH, 1997, BLOOD, V90, P3136, DOI 10.1182/blood.V90.8.3136; Still IH, 1998, BLOOD, V92, P1456, DOI 10.1182/blood.V92.4.1456.splL3_1456_1458; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Tateishi S, 2000, P NATL ACAD SCI USA, V97, P7927, DOI 10.1073/pnas.97.14.7927; van der Laan R, 2000, GENOMICS, V69, P86, DOI 10.1006/geno.2000.6220; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Xin H, 2000, NUCLEIC ACIDS RES, V28, P2847, DOI 10.1093/nar/28.14.2847	29	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3417	3423		10.1038/sj.onc.1206408	http://dx.doi.org/10.1038/sj.onc.1206408			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776193				2022-12-17	WOS:000183128500008
J	Wei, YK; Sun, MH; Nilsson, G; Dwight, T; Xie, YT; Wang, J; Hou, YY; Larsson, O; Larsson, C; Zhu, XZ				Wei, YK; Sun, MH; Nilsson, G; Dwight, T; Xie, YT; Wang, J; Hou, YY; Larsson, O; Larsson, C; Zhu, XZ			Characteristic sequence motifs located at the genomic breakpoints of the translocation t(X;18) in synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; translocation; DNA sequence; breakpoints	TOPOISOMERASE-II CLEAVAGE; ACUTE MYELOID-LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; CLUSTER REGION; DNA-SEQUENCE; ILLEGITIMATE RECOMBINATION; ALVEOLAR RHABDOMYOSARCOMA; BCR GENE; TUMORS; SITES	The SYT-SSXI and SYT-SSX2 fusion genes, derived by reciprocal translocations t(X;18), are acquired genetic events strongly associated with the tumorigenesis of synovial sarcoma. In approaching the mechanisms underlying the formation of these fusion oncogenes, we have analysed the genomic sequences surrounding the SYT-SSX breakpoints in 10 tumors, two expressing SYT-SSXI and eight expressing SYT-SSX2 fusion transcripts. The breakpoints were found to be clustered in the 5' end of intron 10 of SYT, and in two cluster regions within intron 4 of SSX2, whereas the two breakpoints in SSX1 intron 4 were 0.5 kb apart. SYT intron 10 is abundant in repetitive regions with the interspersed repeats occupying 66% of the whole intron. Nine of the 10 breakpoints in intron 10 of SYT and six of the eight breakpoints in intron 4 of SSX2 were at or near repetitive regions. These findings suggest that repetitive regions may contribute to the distribution of genomic breakpoints. Several of the fusion sequences exhibited characteristic signs of nonhomologous end joining, including microhomologies at the end points as well as deletions. Sequences highly homologous (83-94%) to consensus topoisomerase II cleavage sites were identified at or near the breakpoints in all 10 tumors, suggesting a role of this enzyme in creating staggered ends at the breakpoint. Furthermore, sequences highly homologous to consensus Translin binding sequences were found at the breakpoints in two cases, and an Alu-Alu fusion and an insertion of a 206-bp LINE-1 element were found at the breakpoint in one case each. The demonstration of characteristic sequences at the SYT-SSX breakpoint regions is expected to improve our understanding of the molecular genetic mechanisms behind translocations in general, and of the SYT-SSX fusions in synovial sarcoma in particular.	Fudan Univ, Canc Hosp, Dept Pathol, Shanghai 200032, Peoples R China; Karolinska Hosp, CCK R8 04, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Karolinska Hosp, Dept Surg Sci, Sect Orthoped, SE-17176 Stockholm, Sweden; Karolinska Hosp, CMM L8 01, Dept Mol Med, SE-17176 Stockholm, Sweden	Fudan University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Zhu, XZ (corresponding author), Fudan Univ, Canc Hosp, Dept Pathol, 270 Dongan Rd, Shanghai 200032, Peoples R China.			Dwight, Trisha/0000-0003-1943-4514				AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; Barr FG, 1998, CANCER GENET CYTOGEN, V102, P32, DOI 10.1016/S0165-4608(97)00287-2; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; Chalk JG, 1997, ONCOGENE, V15, P1199, DOI 10.1038/sj.onc.1201285; CHEN SJ, 1989, ONCOGENE, V4, P195; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; Hosaka T, 2000, ONCOGENE, V19, P5821, DOI 10.1038/sj.onc.1203943; Ishida S, 1998, CYTOGENET CELL GENET, V82, P278, DOI 10.1159/000015119; Kanoe H, 1999, ONCOGENE, V18, P721, DOI 10.1038/sj.onc.1202364; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; Kolomietz E, 2002, GENE CHROMOSOME CANC, V35, P97, DOI 10.1002/gcc.10111; KROWCZYNSKA AM, 1986, NUCLEIC ACIDS RES, V14, P7071; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; Liu J, 1997, GENE CHROMOSOME CANC, V18, P232, DOI 10.1002/(SICI)1098-2264(199703)18:3<232::AID-GCC10>3.0.CO;2-K; Lovett BD, 2001, P NATL ACAD SCI USA, V98, P9802, DOI 10.1073/pnas.171309898; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; Nilsson G, 1999, CANCER RES, V59, P3180; Panagopoulos I, 1997, ONCOGENE, V15, P1357, DOI 10.1038/sj.onc.1201281; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; SOWERBY SJ, 1993, ONCOGENE, V8, P1679; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SREEKANTAIAH C, 1994, AM J PATHOL, V144, P1121; TOTH G, 1994, GENE, V140, P285, DOI 10.1016/0378-1119(94)90559-2; Villablanca A, 2002, EUR J ENDOCRINOL, V147, P313, DOI 10.1530/eje.0.1470313; WEISS SW, 2001, SOFT TISSUE TUMORS; Zhang YM, 2002, P NATL ACAD SCI USA, V99, P3070, DOI 10.1073/pnas.042702899; Zucman-Rossi J, 1998, P NATL ACAD SCI USA, V95, P11786, DOI 10.1073/pnas.95.20.11786	38	23	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2215	2222		10.1038/sj.onc.1206343	http://dx.doi.org/10.1038/sj.onc.1206343			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687023				2022-12-17	WOS:000182066900015
J	Dong, S; Qiu, JH; Stenoien, DL; Brinkley, WR; Mancini, MA; Tweardy, DJ				Dong, S; Qiu, JH; Stenoien, DL; Brinkley, WR; Mancini, MA; Tweardy, DJ			Essential role for the dimerization domain of NuMA-RAR alpha in its oncogenic activities and localization to NuMA sites within the nucleus	ONCOGENE			English	Article						NuMA-RAR alpha; dimerization domain; coiled-coil domain; acute promyclocytic leukemia	ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTORS; FUSION; PROTEINS; TRANSLOCATION; HOMODIMERS; GENE	Nuclear mitotic apparatus protein-retinoic acid receptor alpha (NuMA-RARalpha) is the fourth of five fusion proteins identified in acute promyelocytic leukemia (APL) patients. The molecular basis for its oncogenic activity has not been delineated. In gel-shift assays, NuMA-RARalpha bound to retinoic acid response elements (RAREs) both as a homodimer and as a heterodimer with RXRalpha. The binding profile of NuMA-RARalpha to a panel of RAREs was very similar to PML-RARalpha and PLZF-RARalpha. In transient transfection assays using HepG2 cells, NuMA-RARalpha inhibited wild-type RARalpha transcriptional activity, while it augmented STAT3 transcriptional activity. In GST-pull down experiments, NuMA-RARalpha formed a complex with the corepressor SMRT, was released from the NuMA-RARalpha/SMRT complexes by all-trans retinoic acid (ATRA) at 10(-7)-10(-6) (M) and became associated with the coactivator TRAM-1 at 10(-8) (M) ATRA. Studies comparing NuMA-RARalpha with NuMA-RARalpha(DeltaCC) demonstrated that the dimerization or alpha-helical coiled-coil domain of NuMA was required for homodimer formation, transcriptional repression of wild-type RARalpha, transcriptional activation of STAT3, and stability of the NuMA-RARalpha/SMRT complex. Confocal fluorescent microscopy of HeLa cells was performed following transient expression of cyan fluorescent protein (CFP)-tagged proteins and incubation of cells with or without ATRA. Within the nucleus, CFP-NuMA-RARalpha exhibited a speckled pattern identical to that observed in cells transfected with CFP-NuMA. Furthermore, CFP-NuMA-RARalpha colocalized with yellow fluorescent protein-tagged (YFP)-NuMA. In contrast, CFP-NuMA-RARalpha(DeltaCC) exhibited a diffuse granular pattern within the nucleus, similar to RARalpha. These results indicate that the dimerization domain of NuMA-RARalpha is critical for each of the known oncogenic activities of NuMA fusion proteins as well as its sequestration to nuclear sites normally occupied by NuMA and is distinct from RARalpha.	Baylor Coll Med, Infect Dis Sect, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Tweardy, DJ (corresponding author), Baylor Coll Med, Infect Dis Sect, Dept Med, 1 Baylor Plaza,BCM 286,Room N1319, Houston, TX 77030 USA.		Tweardy, David/L-3929-2019					Benekli M, 2002, BLOOD, V99, P252, DOI 10.1182/blood.V99.1.252; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; Dong S, 2002, BLOOD, V99, P2637, DOI 10.1182/blood.V99.8.2637; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Hummel JL, 2002, CELL GROWTH DIFFER, V13, P173; Kawasaki A, 2000, BLOOD, V96, p684A; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Xia Z, 1998, CANCER RES, V58, P3173; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766	20	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					858	868		10.1038/sj.onc.1206182	http://dx.doi.org/10.1038/sj.onc.1206182			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584566				2022-12-17	WOS:000180864300009
J	Millan, O; Ballester, A; Castrillo, A; de la Oliva, JL; Traves, PG; Rojas, JM; Bosca, L				Millan, O; Ballester, A; Castrillo, A; de la Oliva, JL; Traves, PG; Rojas, JM; Bosca, L			H-Ras-specific activation of NF-kappa B protects NIH 3T3 cells against stimulus-dependent apoptosis	ONCOGENE			English	Article						survival; nuclear factor kappa B; apoptosis; TNF alpha; staurosporine	NITRIC-OXIDE SYNTHASE; ONCOGENIC RAS; TRANSCRIPTIONAL ACTIVITY; KINASE; INDUCTION; EXPRESSION; TRANSFORMATION; INHIBITION; PROTEINS; SUBUNIT	Ras signaling involves the activation of several downstream pathways that exhibit isoform specificity. In this study, the basal and tumor necrosis factor alpha (TNFalpha)-induced activation. of NF-kappaB has been examined in cells overexpressing H-Ras, K-Ras or N-Ras. Cells expressing H-Ras exhibited a basal kappaB activity that correlated with sustained IkappaB kinase activation and lower steady-state levels of IkappaBalpha in the cytosol. Upon activation with TNFalpha, the cells expressing the distinct Ras. isoforms behaved similarly in terms of binding of nuclear proteins to a kappaB sequence and induction of a kappaB-dependent reporter gene. The basal activation of NF-kappaB in cells expressing H-Ras impaired staurosporine-induced apoptosis in these cells, through a mechanism that was NF-kappaB-dependent and inhibitable in the presence of z-VAD. Moreover, titration of caspase activation in response to staurosporine showed a significant resistance in cells expressing H-Ras when compared with the void vector or the N-Ras counterparts. These results indicate that the distinct Ras proteins have specific effects on the NF-kappaB pathway and that this action contributes to protect cells against apoptosis.	Univ Complutense, Fac Farm, Inst Bioquim, Ctr Mixto CSIC UCM, Madrid 28040, Spain; Univ Complutense, Fac Farm, Inst Bioquim, Ctr Nacl Invest Cardiovasc, Madrid 28040, Spain; Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Biol Celular, Majadahonda, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Complutense University of Madrid; Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM)	Bosca, L (corresponding author), Univ Complutense, Fac Farm, Inst Bioquim, Ctr Mixto CSIC UCM, Madrid 28040, Spain.	boscal@farm.ucm.es	Rojas, José M/D-3718-2018; Rojas, José M./AAA-3354-2021; G. Traves, Paqui/L-5693-2014; Bosca, Lisardo/A-2059-2008	Rojas, José M/0000-0002-5383-3482; Rojas, José M./0000-0002-7547-2825; G. Traves, Paqui/0000-0001-5749-8426; Bosca, Lisardo/0000-0002-0253-5469; Ballester Jareno, Alicia/0000-0002-6474-7248				Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Downward J, 1996, CANCER SURV, V27, P87; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; Grana TM, 2002, CANCER RES, V62, P4142; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Hortelano S, 2002, CELL DEATH DIFFER, V9, P643, DOI 10.1038/sj.cdd.4401017; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Ludwig L, 2001, CANCER RES, V61, P4526; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; Prior IA, 2001, J CELL SCI, V114, P1603; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Yan F, 2001, CANCER RES, V61, P8668; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	44	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					477	483		10.1038/sj.onc.1206179	http://dx.doi.org/10.1038/sj.onc.1206179			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555061				2022-12-17	WOS:000180538200001
J	Bhanoori, M; Yellaturu, CR; Ghosh, SK; Hassid, A; Jennings, LK; Rao, GN				Bhanoori, M; Yellaturu, CR; Ghosh, SK; Hassid, A; Jennings, LK; Rao, GN			Thiol alkylation inhibits the mitogenic effects of platelet-derived growth factor and renders it proapoptotic via activation of STATs and p53 and induction of expression of caspase1 and p21(waf1/cip1)	ONCOGENE			English	Article						apoptosis; cell growth; protein tyrosine phosphatases; protein tyrosine kinases; thiols; transcription factors	SMOOTH-MUSCLE CELLS; NF-KAPPA-B; PROTEIN-TYROSINE-PHOSPHATASE; DISULFIDE BOND FORMATION; NECROSIS-FACTOR-ALPHA; HYDROGEN-PEROXIDE; TRANSCRIPTION FACTOR; REDOX REGULATION; SIGNALING PATHWAY; KINASE ACTIVATION	Thiols provide the major intracellular redox milieu and can undergo reversible oxidation and reduction. To understand the role of thiols in redox signaling events, we have studied the effect of N-ethylmaleimide, a specific thiol alkylating agent, on platelet-derived growth factor-BB (PDGF-BB)-induced mitogenesis in vascular smooth muscle cells (VSMC). Thiol alkylation inhibited PDGF-BB-induced expression of the Fos and Jun family proteins and AP-1 activity in VSMC. Thiol alkylation also inhibited PDGF-BB-induced expression of cyclin A and growth in these cells. In contrast, thiol alkylation enhanced and sustained the effect of PDGF-BB on the activation of the Jak STAT pathway, and this event was correlated with inhibition of protein tyrosine phosphatase 1B activity. Thiol alkylation via inducing the expression of p21(waf1/cip1) in a STAT1- and p53-dependent manner antagonized the downregulation of this cell cycle inhibitory molecule by PDGF-BB. The inhibition of AP-1 and activation of STATs, particularly STAT1, by thiol alkylation correlated with increased production of active caspase 1 and apoptosis in VSMC. Together, these findings suggest a role for thiols in mediating mitogenic and/or apoptotic signaling events in VSMC. These results also show that a sustained change in the intracellular thiol redox state can convert a mitogen into a death promoter.	Univ Tennessee, Hlth Sci Ctr, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Ctr Vasc Biol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.		Bhanoori, Manjula/ACH-9333-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064165] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64165] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; Chen B, 2000, CANCER RES, V60, P3290; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; Chernoff J, 1999, J CELL PHYSIOL, V180, P173; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Clottes E, 1998, J BIOL CHEM, V273, P19391, DOI 10.1074/jbc.273.31.19391; Coffey RNT, 2000, CANCER-AM CANCER SOC, V88, P2092, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2092::AID-CNCR15>3.0.CO;2-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; DICK LR, 1992, BIOCHEMISTRY-US, V31, P7347, DOI 10.1021/bi00147a020; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Ghosh SK, 2002, J BIOL CHEM, V277, P21325, DOI 10.1074/jbc.M201608200; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HANDEL ML, 1995, P NATL ACAD SCI USA, V92, P4497, DOI 10.1073/pnas.92.10.4497; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOSHI T, 2001, J PHYSL, V15, P1; Huang YQ, 2000, J BIOL CHEM, V275, P6462, DOI 10.1074/jbc.275.9.6462; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Kwaw I, 2001, BIOCHEMISTRY-US, V40, P10491, DOI 10.1021/bi010866x; Lee SL, 2001, AM J PHYSIOL-LUNG C, V281, pL646, DOI 10.1152/ajplung.2001.281.3.L646; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Preston TJ, 2001, J BIOL CHEM, V276, P9558, DOI 10.1074/jbc.M004617200; Qin SF, 2000, P NATL ACAD SCI USA, V97, P7118, DOI 10.1073/pnas.130198197; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; Rao GN, 1996, J BIOL CHEM, V271, P27760, DOI 10.1074/jbc.271.44.27760; Rao GN, 1996, ONCOGENE, V13, P713; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; Schmidt KN, 1996, ADV EXP MED BIOL, V387, P63; Schnelldorfer T, 2000, CANCER-AM CANCER SOC, V89, P1440, DOI 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.3.CO;2-S; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Verdier F, 2000, J BIOL CHEM, V275, P18375, DOI 10.1074/jbc.275.24.18375; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wei SJ, 2000, CANCER RES, V60, P6688; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	69	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					117	130		10.1038/sj.onc.1206065	http://dx.doi.org/10.1038/sj.onc.1206065			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527914				2022-12-17	WOS:000180166900013
J	Arlinghaus, RB				Arlinghaus, RB			Bcr: a negative regulator of the Bcr-Abi oncoprotein in leukemia	ONCOGENE			English	Article						chronic myelogenous leukemia (CML); Bcr-Abl oncoprotein; phosphoserine Bcr; inhibition of Bcr-Abl	PHOSPHOTYROSINE-DEPENDENT MANNER; MUSCLE PYRUVATE-KINASE; SH2 DOMAIN; C-ABL; TYROSINE PHOSPHORYLATION; FIRST EXON; P160 BCR; PROTEIN; SEQUENCES; CELLS	The fusion of 5' parts of the BCR gene to the ABL gene at the second exon yields several forms of an oncogenic Bcr-Abl oncoprotein observed in several types of Philadelphia chromosome positive leukemia patients. The first exon of the BCR gene is a critical part of this fusion, as the coiled-coil domain at the amino terminal domain of the Bcr protein causes oligomerization of the Bcr-Abl oncoprotein forming tetramers, thereby activating the tyrosine kinase activity of the normally silent c-Abl protein. Another consequence of this Ber-Abl fusion is the extensive autophosphorylation of the cis Bcr protein sequences on tyrosine residues. This review will summarize the effects of Bcr-Abl autophosphorylation on tyrosines as they relate to the oncogenic activity of Bcr-Abl, and as a means to inactivate the serine/threonine kinase activity of the Bcr protein. The review also discusses our findings that show that phosphoserine Bcr by means of a unique structure, binds to the Abl SH2 domain of the Bcr-Abl oncoprotein, and as a result this SH2 binding inhibits the oncogenic effects of the oncoprotein. Our results indicate that one effect of this binding is inhibition of the Bcr-Abl tyrosine kinase. Serine 354 of Bcr plays a major role in this inhibition. In the case of Bcr(64-413), serine 354 is required for the formation of the unique Bcr structure that binds to the Abl SH2 domain.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA49639, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA049639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNAMALAI AE, 1981, J BIOL CHEM, V256, P276; Arlinghaus RB, 1998, CRIT REV ONCOGENESIS, V9, P1; CAMPBELL ML, 1990, ONCOGENE, V5, P773; Che W, 2001, CIRCULATION, V104, P1399, DOI 10.1161/hc3701.095581; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; Hawk N, 2002, CANCER RES, V62, P386; He YP, 2002, BLOOD, V99, P2957, DOI 10.1182/blood.V99.8.2957; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LI WJ, 1989, ONCOGENE, V4, P127; Lin F, 2001, ONCOGENE, V20, P1873, DOI 10.1038/sj.onc.1204409; Liu JX, 1996, CANCER RES, V56, P5120; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Sun T, 2001, BIOPOLYMERS, V60, P61, DOI 10.1002/1097-0282(2001)60:1<61::AID-BIP1004>3.0.CO;2-4; TOMICH JM, 1981, BIOCHEMISTRY-US, V20, P6711, DOI 10.1021/bi00526a029; Wang Y, 2001, CANCER RES, V61, P138; Wu Y, 1999, ONCOGENE, V18, P4416, DOI 10.1038/sj.onc.1202828; Wu Y, 1998, ONCOGENE, V16, P141, DOI 10.1038/sj.onc.1201524; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001	32	23	26	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2002	21	56					8560	8567		10.1038/sj.onc.1206083	http://dx.doi.org/10.1038/sj.onc.1206083			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476302				2022-12-17	WOS:000179734300005
J	Marziali, G; Perrotti, E; Ilari, R; Lulli, V; Coccia, EM; Moret, R; Kuhn, LC; Testa, U; Battistini, A				Marziali, G; Perrotti, E; Ilari, R; Lulli, V; Coccia, EM; Moret, R; Kuhn, LC; Testa, U; Battistini, A			Role of Ets-1 in transcriptional regulation of transferrin receptor and erythroid differentiation	ONCOGENE			English	Article						Friend leukemia cells; transferrin receptor; Ets-1; transcription; differentiation	ERYTHROLEUKEMIC CELL-LINES; HEMATOPOIETIC PROGENITORS; IRON-METABOLISM; MESSENGER-RNA; PROMOTER REGION; HEME-SYNTHESIS; DNA-BINDING; MYB-ETS; T-CELLS; GENE	High expression of transferrin receptor (TfR) on the membrane of erythroid cells accounts for the high level of iron required to sustain heme synthesis. Several studies indicate that during erythroid differentiation TfR expression is highly dependent on transcriptional regulation. In this study we characterized the minimal region able to confer transcriptional regulation during erythroid differentiation in Friend leukemia cells (FLC). This region of 120 bp, upstream the transcription start site, contains an overlapping consensus recognition sequence for AP1/CREB/ATF transcription factors and for proteins of the Ets family and a GC rich region. Here, we report that both the Ets and the Ap1/CRE like sites are essential for promoter activity during erythroid differentiation. We showed that Ets-1 binds to the EBS-TfR and its binding activity decreases in FLC induced to differentiate and during normal erythroid differentiation. Consistent with this, FLC constitutively expressing Ets-1 show a decrease in TfR gene expression, globin mRNA and hemoglobin synthesis. We conclude that Ets-1 binding activity is modulated during erythroid maturation and that a deregulated expression of this transcription factor interferes with terminal erythroid differentiation.	Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; Ist Super Sanita, Lab Hematol & Oncol, I-00161 Rome, Italy; Ist Super Sanita, Immunol Lab, I-00161 Rome, Italy; Swiss Inst Expt Canc Res, ISREC, CH-1066 Epalinges, Switzerland	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Swiss Institute Experimental Cancer Research	Battistini, A (corresponding author), Ist Super Sanita, Virol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.		Coccia, Eliana M/B-4752-2013; BATTISTINI, ANGELA/C-2944-2016; PERROTTI, EDVIGE/C-2956-2016; Lulli, Valentina/J-9189-2016; Marziali, Giovanna/J-9808-2016; Testa, Ugo/J-6472-2016	Coccia, Eliana M/0000-0002-1606-2949; Lulli, Valentina/0000-0002-2143-4436; Marziali, Giovanna/0000-0001-7450-1017; Testa, Ugo/0000-0001-7900-8942; PERROTTI, EDVIGE/0000-0002-4041-2910; Ilari, Ramona/0000-0001-7380-522X				Bartelsman EJ, 1998, J PROD ANAL, V9, P5, DOI 10.1023/A:1018383629341; BATTISTINI A, 1991, J BIOL CHEM, V266, P528; BEARD P, 1991, NUCLEIC ACIDS RES, V19, P7117, DOI 10.1093/nar/19.25.7117; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Busfield SJ, 1997, EUR J BIOCHEM, V249, P77, DOI 10.1111/j.1432-1033.1997.t01-1-00077.x; CASEY JL, 1988, NUCLEIC ACIDS RES, V16, P629, DOI 10.1093/nar/16.2.629; CHAN RYY, 1994, EUR J BIOCHEM, V220, P683, DOI 10.1111/j.1432-1033.1994.tb18669.x; Clausen PA, 1997, LEUKEMIA, V11, P1224, DOI 10.1038/sj.leu.2400735; Cowley DO, 2000, GENE DEV, V14, P366; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; Grignani F, 1998, CANCER RES, V58, P14; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIRSCH S, 1995, CELL GROWTH DIFFER, V6, P719; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Lok CN, 2000, J BIOL CHEM, V275, P24185, DOI 10.1074/jbc.M000944200; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MARZIALI G, 1999, MOL BIOL HEMATOPOIES, V6, P391; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; ORKIN SH, 1975, J BIOL CHEM, V250, P8753; OUYANG Q, 1993, MOL CELL BIOL, V13, P1796, DOI 10.1128/MCB.13.3.1796; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Ponka P, 1999, INT J BIOCHEM CELL B, V31, P1111, DOI 10.1016/S1357-2725(99)00070-9; Ponka P, 1997, BLOOD, V89, P1; QUEVA C, 1993, ONCOGENE, V8, P2511; Rameil P, 2000, ONCOGENE, V19, P2086, DOI 10.1038/sj.onc.1203542; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rossi F, 1996, CURR BIOL, V6, P866, DOI 10.1016/S0960-9822(02)00610-3; SETH A, 1993, ONCOGENE, V8, P1783; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; Starck J, 1999, MOL CELL BIOL, V19, P121; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1997, TRANSCRIPTION FACTOR, P253; WATSON DK, 2000, ETS GENE FAMILY ONCO; Weiss G, 1997, BLOOD, V89, P680, DOI 10.1182/blood.V89.2.680; WERNERT N, 1992, AM J PATHOL, V140, P119; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383	43	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					7933	7944		10.1038/sj.onc.1205925	http://dx.doi.org/10.1038/sj.onc.1205925			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439744				2022-12-17	WOS:000179097200003
J	Rockwood, LD; Torrey, TA; Kim, JS; Coleman, AE; Kovalchuk, AL; Xiang, S; Ried, T; Morse, HC; Janz, S				Rockwood, LD; Torrey, TA; Kim, JS; Coleman, AE; Kovalchuk, AL; Xiang, S; Ried, T; Morse, HC; Janz, S			Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations	ONCOGENE			English	Article						in vivo mutant rates; MYC; mutator phenotype; B-cell neoplasia; genomic instability	DOUBLE TRANSGENIC MICE; IN-VIVO MUTATIONS; DNA; SELECTION; TARGET; MODEL	lambda-MYC-induced mouse Burkitt lymphoma (BL) harboring the shuttle vector pUR288, which includes a lacZ reporter gene to study mutagenesis, was employed to assess genomic instability associated with MYC deregulation. The frequency of lacZ mutations in lymphomas was elevated only 1.75-fold above that in normal tissue, indicating that mouse BL does not exhibit a phenotype of hypermutability. However, the nature of lacZ mutations was strikingly different in normal tissues and lymphomas. While point mutations comprised approximately 75% of the mutations found in normal tissues, apparent translocations, deletions and inversions constituted the majority of mutations (similar to65%) in lymphomas. Genomic instability in mouse BL thus seems characterized by a preponderance of illegitimate genetic rearrangements in the context of near-background mutant frequencies. SKY analyses of cell lines from primary BL tumors revealed substantial changes in chromosomal structure, confirming the lacZ studies. Bi-allelic deletions of the tumor suppressor p16(Ink4a) were detected in six out of 16 cell lines, illustrating cellular selection of advantageous mutations. Together, these approaches indicate that MYC may contribute to lymphomagenesis through the dominant mutator effect of inducing chromosomal instability. The results further suggest that a phenotype of hypermutability (elevated mutant frequency) may not always be required for oncogenesis to occur.	NCI, Genet Lab, CCR, Bethesda, MD 20892 USA; NIAID, Immunopathol Lab, Bethesda, MD 20892 USA; NCI, Genet Branch, CCR, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Janz, S (corresponding author), NCI, Genet Lab, CCR, Bldg 37,Room 2B10, Bethesda, MD 20892 USA.			Morse, Herbert/0000-0002-9331-3705; Kovalchuk, Alexander/0000-0003-2761-0442	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000858, Z01AI000858] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baross-Francis A, 1998, P NATL ACAD SCI USA, V95, P8739, DOI 10.1073/pnas.95.15.8739; BOERRIGTER METI, 1995, NATURE, V377, P657, DOI 10.1038/377657a0; Buettner VL, 1996, ONCOGENE, V13, P2407; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coleman AE, 2000, GENE CHROMOSOME CANC, V29, P70, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1009>3.0.CO;2-C; Davis CD, 1996, MUTAT RES-FUND MOL M, V356, P287, DOI 10.1016/0027-5107(96)00074-7; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; GOSSEN JA, 1989, P NATL ACAD SCI USA, V86, P7971, DOI 10.1073/pnas.86.20.7971; Jakubczak JL, 1996, P NATL ACAD SCI USA, V93, P9073, DOI 10.1073/pnas.93.17.9073; KOHLER SW, 1991, ENVIRON MOL MUTAGEN, V18, P316, DOI 10.1002/em.2850180421; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; LOEB LA, 1991, CANCER RES, V51, P3075; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; MUSHINSKI JF, 2002, IN PRESS CRIT REV ON; Roth D., 1988, GENETIC RECOMBINATIO, P621; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687	19	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7235	7240		10.1038/sj.onc.1205697	http://dx.doi.org/10.1038/sj.onc.1205697			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370814				2022-12-17	WOS:000178504600012
J	Mamane, Y; Grandvaux, N; Hernandez, E; Sharma, S; Innocente, SA; Lee, JM; Azimi, N; Lin, R; Hiscott, J				Mamane, Y; Grandvaux, N; Hernandez, E; Sharma, S; Innocente, SA; Lee, JM; Azimi, N; Lin, R; Hiscott, J			Repression of IRF-4 target genes in human T cell leukemia virus-1 infection	ONCOGENE			English	Review						human T cell leukemia virus; interferon regulatory factors; cyclin B1; transcription	INTERFERON REGULATORY FACTOR-4; NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; REPLICATION PROTEIN-A; TYPE-1 TAX PROTEIN; I HTLV-I; CYCLIN B1; TRANSCRIPTION FACTOR; KINASE IKK; MOLECULAR MECHANISM	The human T cell leukemia/lymphotropic virus-1 (HTLV-I) is the etiologic agent of adult T cell leukemia (ATL), an aggressive and fatal leukemia of CD4+ T lymphocytes. Interferon regulatory factor-4 (IRF-4) was shown previously to be constitutively expressed in T cells infected with HTLV-1. In this study, we investigated the role of IRF-4 gene regulation in the context of HTLV-1 infection using gene array technology and IRF-4 expressing T cells. Many potential IRF-4 regulated genes were identified, the vast majority of which were repressed by IRF-4 expression. Cyclin B1, a G2-M checkpoint protein identified as an IRF-4 repressed gene in the array, was further characterized in the context of HTLV-1 infection. All HTLV-1 infected cell lines and ATL patient lymphocytes demonstrated a dramatic decrease in cyclin B1 levels; subsequent analysis of the cyclin B1 promoter identified two sites important in IRF-4 binding and repression of cyclin B1 expression. Furthermore, IRF-4-mediated repression of cyclin B1 led to a significant decrease in CDC2 kinase activity in HTLV-1 infected T cells. IRF-4 expression in HTLV-1 infected T cells also downregulated other genes implicated in the mitotic checkpoint as well as genes involved in actin cytoskeletal rearrangement, DNA repair, apoptosis, metastasis and immune recognition. Several of the identified genes are dysregulated in ATL and may provide important mechanistic information concerning pathways critical to the emergence of ATL.	McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; Hamilton Reg Canc Ctr, Hamilton, ON L8V 1C3, Canada; NCI, NIH, Bethesda, MD 20892 USA	Lady Davis Institute; McGill University; McGill University; McMaster University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hiscott, J (corresponding author), McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.		Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Bochkareva E, 2000, J BIOL CHEM, V275, P27332; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; Brien TP, 1998, MODERN PATHOL, V11, P870; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Campbell MS, 2001, J CELL SCI, V114, P953; CANN AJ, 1996, FIELDS VIROLOGY; Cannavo G, 2001, BLOOD, V97, P1756, DOI 10.1182/blood.V97.6.1756; Carbone A, 2001, BLOOD, V97, P744, DOI 10.1182/blood.V97.3.744; Carbone A, 2000, BRIT J HAEMATOL, V111, P247, DOI 10.1046/j.1365-2141.2000.02329.x; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; Chatterjee D, 2000, ANTICANCER RES, V20, P4477; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Clark PR, 2001, CELL STRESS CHAPERON, V6, P121, DOI 10.1379/1466-1268(2001)006<0121:TIHAAM>2.0.CO;2; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Dianov GL, 1999, BIOCHEMISTRY-US, V38, P11021, DOI 10.1021/bi9908890; Dib K, 2000, FRONT BIOSCI-LANDMRK, V5, pD438, DOI 10.2741/Pathology; Duell EJ, 2001, CANCER EPIDEM BIOMAR, V10, P217; Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Gaidano G, 2000, LEUKEMIA, V14, P563, DOI 10.1038/sj.leu.2401748; Grumont RJ, 2000, J EXP MED, V191, P1281, DOI 10.1084/jem.191.8.1281; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Gupta S, 2001, J IMMUNOL, V166, P6104, DOI 10.4049/jimmunol.166.10.6104; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hapke S, 2001, MOL CELL BIOL, V21, P2118, DOI 10.1128/MCB.21.6.2118-2132.2001; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Imaizumi Y, 2001, JPN J CANCER RES, V92, P1284, DOI 10.1111/j.1349-7006.2001.tb02151.x; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Itoyama A, 2001, BLOOD, V97, P3612, DOI 10.1182/blood.V97.11.3612; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Jackman MR, 1997, CANCER SURV, V29, P47; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Kaida A, 2000, ONCOGENE, V19, P827, DOI 10.1038/sj.onc.1203387; KAMADA N, 1992, CANCER RES, V52, P1481; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KASAI T, 2001, J BIOL CHEM, V29, P29; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Lacana E, 1997, J IMMUNOL, V158, P5129; Lemasson I, 2001, J BIOL CHEM, V276, P15720, DOI 10.1074/jbc.M100131200; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Lin RT, 1999, MOL CELL BIOL, V19, P959; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Lo KWH, 1999, BIOCHEMISTRY-US, V38, P7498, DOI 10.1021/bi990034n; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Mamane Y, 2000, IMMUNITY, V12, P129, DOI 10.1016/S1074-7613(00)80166-1; Mamane Y, 2002, J INTERF CYTOK RES, V22, P135, DOI 10.1089/107999002753452746; Manjili MH, 2002, FRONT BIOSCI-LANDMRK, V7, pD43, DOI 10.2741/manjili; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; Mashal RD, 1996, CANCER RES, V56, P4159; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Meraro D, 1999, J IMMUNOL, V163, P6468; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Murakami H, 1999, VIRCHOWS ARCH, V434, P153, DOI 10.1007/s004280050319; Nagulapalli S, 1998, MOL CELL BIOL, V18, P4639, DOI 10.1128/MCB.18.8.4639; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; OConnor PM, 1997, CANCER SURV, V29, P151; Ohshima K, 1999, J PATHOL, V189, P539, DOI 10.1002/(SICI)1096-9896(199912)189:4&lt;539::AID-PATH465&gt;3.0.CO;2-T; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 2000, AIDS RES HUM RETROV, V16, P1669, DOI 10.1089/08892220050193128; Porter LA, 2000, BLOOD, V95, P2645; Poullet P, 2001, J BIOL CHEM, V276, P37686, DOI 10.1074/jbc.M106175200; Rosenbauer F, 1999, BLOOD, V94, P4274, DOI 10.1182/blood.V94.12.4274.424k05_4274_4281; SADAMORI N, 1991, CANCER GENET CYTOGEN, V51, P131, DOI 10.1016/0165-4608(91)90019-Q; SADAMORI N, 1991, ACTA HAEMATOL-BASEL, V86, P14; Satoh S, 2001, J BIOL CHEM, V276, P39290, DOI 10.1074/jbc.M107026200; Schmidt M, 2000, J CLIN ONCOL, V18, P3331, DOI 10.1200/JCO.2000.18.19.3331; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Sharma S, 2000, AIDS RES HUM RETROV, V16, P1613, DOI 10.1089/08892220050193047; SHARMA S, 2002, IN PRESS J IMMUNOL; Song YH, 2000, J CELL BIOCHEM, V80, P229; Soria JC, 2000, CANCER RES, V60, P4000; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Tanaka Y, 1998, BLOOD, V91, P3909; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Tsukasaki K, 2001, BLOOD, V97, P3875, DOI 10.1182/blood.V97.12.3875; Tsukasaki K, 2000, BEST PRACT RES CL HA, V13, P231, DOI 10.1053/beha.1999.0070; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Wang IK, 2000, PHARMACOL TOXICOL, V86, P83, DOI 10.1034/j.1600-0773.2000.d01-16.x; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; Yao J, 2000, FRONT BIOSCI-LANDMRK, V5, pD138, DOI 10.2741/Yao; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	108	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6751	6765		10.1038/sj.onc.1205843	http://dx.doi.org/10.1038/sj.onc.1205843			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360402				2022-12-17	WOS:000178315800005
J	Toft, NJ; Curtis, LJ; Sansom, OJ; Leitch, AL; Wyllie, AH; Riele, HT; Arends, MJ; Clarke, AR				Toft, NJ; Curtis, LJ; Sansom, OJ; Leitch, AL; Wyllie, AH; Riele, HT; Arends, MJ; Clarke, AR			Heterozygosity for p53 promotes microsatellite instability and tumorigenesis on a Msh2 deficient background	ONCOGENE			English	Article						mismatch repair; p53; tumorigenesis; microsatellite instability; apoptosis	FEMALE EMBRYONIC LETHALITY; MURINE SMALL-INTESTINE; CELL-CYCLE CHECKPOINT; WILD-TYPE P53; MISMATCH REPAIR; P53-DEFICIENT MICE; COLORECTAL-CANCER; DNA-DAMAGE; IONIZING-RADIATION; MUTATION FREQUENCY	In colorectal tumorigenesis, loss of function of the mismatch repair genes is closely associated with genomic instability at the nucleotide level whereas p53 deficiency has been linked with gross chromosomal instability. We have addressed the contribution of these two forms of genetic instability to tumorigenesis using mice mutant for Msh2 and p53. As previously reported, deficiency of both genes leads to rapid lymphomagenesis Here we show that heterozygosity for p53 also markedly reduces survival on an Msh2 null background. We characterized the patterns of genomic instability in a small set of tumours and showed that, as predicted p53 deficiency predisposes to aneuploidy and Msh2 deficiency leads to microsatellite instability (MSI). However, heterozygosity for p53 in the absence of Msh2 resulted in increased MSI and not aneuploidy. This implied role for p53 in modulating MSI was confirmed using a large cohort of primary fibroblast clones. The differences observed were highly significant (P < 0.01) in both the fibroblast clones (which all retained p53 functionality) and the tumours, a proportion of which retained p53 functionality. Our results therefore demonstrate a dose sensitive role for p53 in the maintenance of genomic integrity at the nucleotide level.	Cardiff Univ, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	Cardiff University; University of Edinburgh; Netherlands Cancer Institute; University of Cambridge	Clarke, AR (corresponding author), Cardiff Univ, Sch Biosci, POB 911, Cardiff CF10 3US, S Glam, Wales.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010				ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Bubb VJ, 1996, ONCOGENE, V12, P2641; CARDER P, 1993, ONCOGENE, V8, P1397; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cottu PH, 1996, ONCOGENE, V13, P2727; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Cranston A, 1999, MAMM GENOME, V10, P1020, DOI 10.1007/s003359901151; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DONCHOWER LA, 1992, NATURE, V356, P215; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Gong JG, 1999, NATURE, V399, P806; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY M, 1993, ONCOGENE, V8, P2457; HAWN MT, 1995, CANCER RES, V55, P3721; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; KALLIONIEMI OP, 1993, SEMIN CANCER BIOL, V4, P41; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; OZBUN MA, 1993, CANCER RES, V53, P1646; PURDIE CA, 1994, ONCOGENE, V9, P603; Rafferty JA, 1996, ONCOGENE, V12, P693; REICHMANN A, 1981, INT J CANCER, V28, P431, DOI 10.1002/ijc.2910280407; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2001, ONCOGENE, V20, P3580, DOI 10.1038/sj.onc.1204449; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; Toft NJ, 1998, NAT GENET, V18, P17, DOI 10.1038/ng0198-17; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; VINDELOV LL, 1983, CYTOMETRY, V3, P321; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	45	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6299	6306		10.1038/sj.onc.1205727	http://dx.doi.org/10.1038/sj.onc.1205727			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214270				2022-12-17	WOS:000177829000006
J	Zhou, XY; Wang, X; Wang, HY; Chen, DJ; Li, GC; Iliakis, G; Wang, Y				Zhou, XY; Wang, X; Wang, HY; Chen, DJ; Li, GC; Iliakis, G; Wang, Y			Ku affects the ATM-dependent S phase checkpoint following ionizing radiation	ONCOGENE			English	Article						ku; ATM; S phase checkpoint; ionizing radiation	DOUBLE-STRAND BREAKS; DNA END BINDING; PROTEIN-KINASE; V(D)J RECOMBINATION; ATAXIA-TELANGIECTASIA; REPAIR; DAMAGE; CELLS; INVOLVEMENT; SENSITIVITY	Following exposure to genotoxic stress, proliferating cells actively slow down DNA replication through an S phase checkpoint to provide time for repair. The ATM-dependent pathway plays an important role in the S phase checkpoint response following ionizing irradiation. We report that there is a stronger S phase checkpoint response in irradiated Ku80(-/-) cells as compared with their wild-type counterparts, which has no relationship to DNA-dependent protein kinase (DNA-PK) activity but correlates with a higher ATM activity and with more ATM bound to chromatin DNA in such cells. Wortmannin, a nonspecific inhibitor of ATM, not only reduces the higher activity of ATM kinase, but also abolishes the stronger S phase checkpoint response in Ku80(-/-) cells. Furthermore, a specific ATM antisense oligonucleotide abolishes the stronger S checkpoint response in Ku80(-/-) cells and renders these cells practically indistinguishable from Ku80(+/+) cells for this endpoint. These results in aggregate indicate that the stronger S checkpoint in irradiated Ku80(-/-) cells is due to the higher ATM kinase activity.	Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Jefferson Med Coll, Philadelphia, PA 19107 USA; Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA; Univ Essen Gesamthsch, Sch Med, Inst Med Radiat Biol, D-45122 Essen, Germany	Jefferson University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Duisburg Essen	Wang, Y (corresponding author), Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Jefferson Med Coll, Thompson Bldg,B1,1020 Sansom St, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA 56909, CA 50519, CA76203, T32-CA09137, P30-CA56036] Funding Source: Medline; NIA NIH HHS [AG18949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050519, T32CA009137, R37CA050519, R29CA076203, R01CA056909, P30CA056036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Dibiase SJ, 2000, CANCER RES, V60, P1245; DYCK EV, 1999, NATURE, V401, P728; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; GETTS RC, 1994, J BIOL CHEM, V269, P15981; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; JEGGO PA, 1985, MUTAT RES, V145, P171, DOI 10.1016/0167-8817(85)90024-0; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; Sarkaria JN, 1998, CANCER RES, V58, P4375; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Wachsberger PR, 1999, RADIAT RES, V151, P398, DOI 10.2307/3579826; Wang HC, 2001, NUCLEIC ACIDS RES, V29, P1653, DOI 10.1093/nar/29.8.1653; WANG Y, 1992, CANCER RES, V52, P508; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou XY, 2002, CANCER RES, V62, P1598; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	32	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6377	6381		10.1038/sj.onc.1205782	http://dx.doi.org/10.1038/sj.onc.1205782			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214278				2022-12-17	WOS:000177829000014
J	Xu, CW; Luo, ZJ				Xu, CW; Luo, ZJ			Inactivation of Ras function by allele-specific peptide aptamers	ONCOGENE			English	Article						allele-specific; Ras; functional genomics; peptide aptamer	SIGNAL-TRANSDUCTION; GENETIC SELECTION; PLASMA-MEMBRANE; ACTIVATION; PROTEINS; CONNECTIONS; DROSOPHILA; SEQUENCE; C-RAF-1; SWITCH	One challenge facing biology is the elucidation of the function of the estimated 30000 human genes and their polymorphic variants. Reagents that affect the activity of specific genes will be useful in the dissection of cellular regulatory networks. Here, as a test case, we used a two-bait two-hybrid system to identify peptide aptamers that distinguish allelic forms of H-Ras. Some of these anti-Ras aptamters inhibit the interaction of oncogenic Ras with c-Raf1 in vitro, and abolish EGF-stimulated activation of c-Raf1 in vivo. These experiments show that the inactivation of protein function by peptide aptamers represents a viable approach to the understanding and control of signaling pathways and oncogenic missense alleles.	Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA; Boston Univ, Sch Med, Dept Med, Diabet & Metab Unit, Boston, MA 02118 USA	Memorial Sloan Kettering Cancer Center; Boston University	Xu, CW (corresponding author), Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, 1275 York Ave, New York, NY 10021 USA.	w-xu@ski.mskcc.org	Luo, Zhijun/AAE-9302-2019	Luo, Zhijun/0000-0001-8105-5289	NIGMS NIH HHS [GM57959] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057959] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE, V377, P3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Geyer CR, 1999, P NATL ACAD SCI USA, V96, P8567, DOI 10.1073/pnas.96.15.8567; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Xu CW, 1997, P NATL ACAD SCI USA, V94, P12473, DOI 10.1073/pnas.94.23.12473	21	23	25	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5753	5757		10.1038/sj.onc.1205680	http://dx.doi.org/10.1038/sj.onc.1205680			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173045	Bronze			2022-12-17	WOS:000177463400010
J	Zeng, JZ; Wang, HY; Chen, ZJ; Ullrich, A; Wu, MC				Zeng, JZ; Wang, HY; Chen, ZJ; Ullrich, A; Wu, MC			Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma	ONCOGENE			English	Article						differential expression; cancer-related protein; proline-rich motif; antisense technology; metastasis; tumor marker	EUKARYOTIC MESSENGER-RNAS; GROWTH-FACTOR-ALPHA; C-MYC; PROTEIN EXPRESSION; DNA METHYLATION; HIGH-FREQUENCY; SH3 DOMAINS; MUTATIONS; HETEROZYGOSITY; HEPATITIS	To gain new insight into the molecular mechanism underlying the pathogenesis of human primary hepatocellular carcinoma (HCC), we searched for HCC-specific molecules through screening genes that are differentially expressed between cancerous and noncancerous counterparts of liver and identified a novel HCC-associated gene, HCCA1 encoding a similar to80 kDa cytoplasmic protein that contains several proline-rich motifs likely for SH3-binding. HCCA1 transcript, albeit present in some adult tissues, is up-regulated selectively in HCC but not in other tumor cells. High expression of HCCA1 occurs as a late event frequently (89.2%) in HCCs and correlated significantly with the degree of tumor progression. When treated with antisense oligonucleotides to HCCA1, HCCA1 expression in HCC cells (HuH-7) was effectively suppressed and cell growth was down-regulated in a time- and dose-dependent manner. Furthermore, HuH-7 cells harboring the HCCA1 antisense expression clone displayed a remarkably reduced efficiency in colony formation. Together, these data strongly suggest that HCCA1 is a positive effector in cell proliferation and contributes to HCC carcinogenesis and progression. We believe that this protein will serve as a novel useful marker for HCC and is a potential target for pharmaceutical intervention of this malignant disease.	Secondary Mil Med Univ, Int Corp Lab Signal Transduct, Eastern Hepatobiliary Surg Inst, Shanghai 200438, Peoples R China; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Naval Medical University; Max Planck Society	Wang, HY (corresponding author), Secondary Mil Med Univ, Int Corp Lab Signal Transduct, Eastern Hepatobiliary Surg Inst, 225 Changhai Rd, Shanghai 200438, Peoples R China.		Wang, Hongyang/B-1340-2010	Zeng, Jin-Zhang/0000-0003-1252-2351				Bouchier-Hayes L, 2001, J BIOL CHEM, V276, P44069, DOI 10.1074/jbc.M107373200; Chen TC, 2000, CANCER LETT, V153, P169, DOI 10.1016/S0304-3835(00)00366-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chung YH, 2000, CANCER, V89, P977, DOI 10.1002/1097-0142(20000901)89:5<977::AID-CNCR6>3.0.CO;2-I; COLLIER JD, 1992, J HEPATOL, V14, P377, DOI 10.1016/0168-8278(92)90186-S; COLOMBO M, 1992, J HEPATOL, V15, P225, DOI 10.1016/0168-8278(92)90041-M; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; De Petro G, 1998, CANCER RES, V58, P2234; deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167; Duffy MJ, 2001, CLIN CHEM, V47, P624; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Endo K, 2000, LIVER, V20, P209, DOI 10.1034/j.1600-0676.2000.020003209.x; Ferrell L, 2000, MODERN PATHOL, V13, P679, DOI 10.1038/modpathol.3880119; Fujiwara Y, 2000, JPN J CANCER RES, V91, P287, DOI 10.1111/j.1349-7006.2000.tb00943.x; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; Hsu HC, 1997, CANCER RES, V57, P5179; Huang GT, 1999, HEPATO-GASTROENTEROL, V46, P1923; Hui AM, 1999, SCAND J GASTROENTERO, V34, P737; Hui AM, 2000, CANCER LETT, V154, P93, DOI 10.1016/S0304-3835(00)00385-2; Ince N, 1999, NEW ENGL J MED, V340, P798, DOI 10.1056/NEJM199903113401009; Johnson P J, 2001, Clin Liver Dis, V5, P145, DOI 10.1016/S1089-3261(05)70158-6; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Keck CL, 1999, CANCER GENET CYTOGEN, V111, P37, DOI 10.1016/S0165-4608(98)00210-6; KENMOCHI K, 1987, LIVER, V7, P18; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; King KL, 1998, J GASTROEN HEPATOL, V13, P273, DOI 10.1111/j.1440-1746.1998.01555.x; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; Kondoh N, 1999, CANCER RES, V59, P4990; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Liao C, 2000, HEPATOLOGY, V32, P721, DOI 10.1053/jhep.2000.17967; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Miyake H, 2000, CANCER RES, V60, P3058; Musso O, 1997, J HEPATOL, V26, P593, DOI 10.1016/S0168-8278(97)80425-4; OGATA N, 1991, HEPATOLOGY, V13, P31, DOI 10.1002/hep.1840130106; Ponder KP, 1996, FASEB J, V10, P673, DOI 10.1096/fasebj.10.7.8635684; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Shen LL, 1998, HEPATO-GASTROENTEROL, V45, P1753; Shi YZ, 2000, BRIT J CANCER, V83, P50; Shimizu Y, 1999, INT J CANCER, V82, P187, DOI 10.1002/(SICI)1097-0215(19990719)82:2&lt;187::AID-IJC6&gt;3.0.CO;2-1; Tahara K, 1999, CANCER, V85, P1234, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1234::AID-CNCR4>3.3.CO;2-Z; Takayama T, 1998, HEPATOLOGY, V28, P1241, DOI 10.1002/hep.510280511; Takeda S, 1996, ONCOGENE, V12, P1589; Tannapfel A, 2000, INT J CANCER, V89, P350, DOI 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0.CO;2-3; Teeguarden JG, 2000, MOL CARCINOGEN, V28, P51, DOI 10.1002/(SICI)1098-2744(200005)28:1<51::AID-MC7>3.0.CO;2-3; Ueki T, 1997, HEPATOLOGY, V25, P862, DOI 10.1002/hep.510250413; Wang HY, 1996, ONCOGENE, V12, P2555; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Yuen MF, 2001, CANCER, V91, P106, DOI 10.1002/1097-0142(20010101)91:1<106::AID-CNCR14>3.0.CO;2-2; Zimmermann U, 1997, HEPATOLOGY, V26, P1492; Zondervan PE, 2000, J PATHOL, V192, P207, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH690&gt;3.0.CO;2-#	59	23	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4932	4943		10.1038/sj.onc.1205652	http://dx.doi.org/10.1038/sj.onc.1205652			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118372				2022-12-17	WOS:000176874800008
J	Billecke, CA; Ljungman, ME; McKay, BC; Rehemtulla, A; Taneja, N; Ethier, SP				Billecke, CA; Ljungman, ME; McKay, BC; Rehemtulla, A; Taneja, N; Ethier, SP			Lack of functional pRb results in attenuated recovery of mRNA synthesis and increased apoptosis following UV radiation in human breast cancer cells	ONCOGENE			English	Article						retinoblastoma protein; UV radiation; apoptosis; DNA damage repair	NUCLEOTIDE EXCISION-REPAIR; MAMMARY EPITHELIAL-CELLS; LIGHT-INDUCED APOPTOSIS; RNA-POLYMERASE-II; ULTRAVIOLET-IRRADIATION; RETINOBLASTOMA PROTEIN; IONIZING-RADIATION; CASPASE ACTIVATION; SUPPRESSOR GENES; E7 PROTEIN	Lack of functional pRb results in attenuated recovery of mRNA synthesis and increased apoptosis following UV radiation in human breast cancer cells. We have previously demonstrated that a human breast cancer cell line, MDA-MB-468, which lacks the retinoblastoma protein (pRb), is particularly sensitive to low doses of ultraviolet (UV) radiation. These cells are 15-20-fold more sensitive to UV radiation than cells with wild-type pRb. In order to understand the mechanisms of the high apoptotic response of MDA-MB-468 cells to UV radiation, we examined the effects of UV on these cells with regards to both membrane-mediated events and DNA damage. We found that MDA-MB-468 cells were resistant to all ligand-induced death receptor signaling. In addition, although UV activated caspase 8 in MDA-MB-468 cells, a peptide inhibitor of caspase 8 failed to inhibit UV-induced apoptosis. We then tested the possibility that nuclear events mediated the enhanced sensitivity to UV-induced apoptosis in these cells. Unlike UV-resistant cells, MDA-MB-468 cells were unable to recover mRNA synthesis after 5 J/m(2) UVC. We also found that the pRb-null DU-145 cells similarly had attenuated recovery of mRNA synthesis after UV radiation. In UV-resistant cells with wild-type pRb, the inactivation of pRb with HPV-16 E7 resulted in significant inhibition in their ability to recover mRNA synthesis and increased levels of apoptosis following UV radiation. Furthermore, pRb-null cells were deficient in repair of UV radiation-induced DNA damage. These data suggest that the sensitivity of MDA-MB-468 cells to UV radiation is due to defects in repair of DNA damage and recovery of mRNA synthesis rather than to membrane death receptor pathways. Inactivation of pRb may contribute to an increased sensitivity to UV radiation by attenuating repair of DNA lesions and recovery of mRNA synthesis following UV radiation.	Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Radiat & Canc Biol, Ann Arbor, MI 48109 USA; Univ Ottawa, Ottawa Reg Canc Ctr, Dept Radiol, Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada	University of Michigan System; University of Michigan; University of Ottawa; Ottawa Hospital Research Institute	Ethier, SP (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Radiat & Canc Biol, Ann Arbor, MI 48109 USA.	spethier@umich.edu	McKay, Bruce C/I-4081-2013	McKay, Bruce C/0000-0002-7921-1331				Addison CL, 1997, J GEN VIROL, V78, P1653, DOI 10.1099/0022-1317-78-7-1653; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Boyer SN, 1996, CANCER RES, V56, P4620; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Carlson CA, 2000, RADIAT RES, V154, P590, DOI 10.1667/0033-7587(2000)154[0590:LORPCW]2.0.CO;2; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Conforti G, 2000, ONCOGENE, V19, P2714, DOI 10.1038/sj.onc.1203583; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Fan GS, 1997, J BIOL CHEM, V272, P19413, DOI 10.1074/jbc.272.31.19413; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Game JC, 1999, GENETICS, V151, P485; Havre PA, 1998, CANCER RES, V58, P4733; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; McDougall J K, 1994, Curr Top Microbiol Immunol, V186, P101; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; McKay BC, 2001, MUTAT RES-DNA REPAIR, V485, P93, DOI 10.1016/S0921-8777(00)00064-1; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sartor CI, 1997, CANCER RES, V57, P978; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Taneja N, 2001, ONCOGENE, V20, P167, DOI 10.1038/sj.onc.1204054; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; Webber MM, 1997, PROSTATE, V30, P136, DOI 10.1002/(SICI)1097-0045(19970201)30:2<136::AID-PROS9>3.0.CO;2-M; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492	43	23	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4481	4489		10.1038/sj.onc.1205546	http://dx.doi.org/10.1038/sj.onc.1205546			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085226				2022-12-17	WOS:000176476700002
J	Smith, AJH; Xian, J; Richardson, M; Johnstone, KA; Rabbitts, PH				Smith, AJH; Xian, J; Richardson, M; Johnstone, KA; Rabbitts, PH			Cre-loxP chromosome engineering of a targeted deletion in the mouse corresponding to the 3p21.3 region of homozygous loss in human tumours	ONCOGENE			English	Article						Cre-loxP; Luca region; chromosome 3; deletion; breast cancer; lung cancer	EMBRYONIC STEM-CELLS; FREQUENT EPIGENETIC INACTIVATION; SUPPRESSOR GENE; LUNG-CANCER; ALLELE LOSS; RASSF1A; BREAST; MICE; RECOMBINATION; GENERATION	Chromosomal deletions are a common feature of epithelial tumours and when further defined by homozygous deletions, are often the location of tumour suppressor genes. Deletions within the short arm of chromosome 3 occur very frequently in human carcinomas: a minimal region of loss at 3p21.3 (the Luca) region has been defined by overlapping homozygous deletions in lung and breast cancer cell lines. Using a rapid strategy for Cre-loxP chromosome engineering, a deletion of approximately 370 kb was created in the mouse germline corresponding to the deleted region at 3p21.3. The deletion when homozygous is embryonic lethal. Heterozygotes develop normally despite being haplo-insufficient for twelve genes including the candidate tumour suppressor gene Rassf1. Because damage to 3p21.3 often occurs very early in the sequence of genetic changes that lead to malignancy, particularly in lung and breast cancer, further genetic damage to these mice will provide the opportunity to model multi-step tumorigenesis of these tumours.	Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; Univ Cambridge, Ctr Mrc, Dept Oncol, Cambridge CB2 2QH, England	University of Edinburgh; University of Cambridge	Smith, AJH (corresponding author), Univ Edinburgh, Ctr Genome Res, W Mains Rd, Edinburgh EH9 3JQ, Midlothian, Scotland.		Johnstone, Karen/E-2369-2011	Johnstone, Karen/0000-0002-3183-8397				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Chung GTY, 1995, ONCOGENE, V11, P2591; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Hesketh R., 1997, ONCOGENE TUMOUR SUPP; Justice MJ, 1997, METHODS, V13, P423, DOI 10.1006/meth.1997.0548; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; Lee MG, 2001, CANCER RES, V61, P6688; LePage DF, 2000, P NATL ACAD SCI USA, V97, P10471, DOI 10.1073/pnas.97.19.10471; Lerman MI, 2000, CANCER RES, V60, P6116; Li ZW, 1996, P NATL ACAD SCI USA, V93, P6158, DOI 10.1073/pnas.93.12.6158; Macleod K, 2000, CURR OPIN GENET DEV, V10, P81, DOI 10.1016/S0959-437X(99)00041-6; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Mitelman F, 1991, CATALOGUE CHROMOSOME; Morrissey C, 2001, CANCER RES, V61, P7277; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Thomas JW, 1998, P NATL ACAD SCI USA, V95, P1114, DOI 10.1073/pnas.95.3.1114; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wistuba II, 2000, CANCER RES, V60, P1949; Zheng BH, 2000, MOL CELL BIOL, V20, P648, DOI 10.1128/MCB.20.2.648-655.2000; Zhu YW, 2000, P NATL ACAD SCI USA, V97, P1137, DOI 10.1073/pnas.97.3.1137	27	23	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4521	4529		10.1038/sj.onc.1205530	http://dx.doi.org/10.1038/sj.onc.1205530			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085230				2022-12-17	WOS:000176476700006
J	Wheeler, DL; Reddig, PJ; Dreckschmidt, NE; Leitges, M; Verma, AK				Wheeler, DL; Reddig, PJ; Dreckschmidt, NE; Leitges, M; Verma, AK			Protein kinase C delta-mediated signal to ornithine decarboxylase induction is independent of skin tumor suppression	ONCOGENE			English	Article						tumor promotion; protein kinase C; transgenic mice; ornithine decarboxylase; skin carcinogenesis	PHORBOL ESTER; TRANSGENIC MICE; MOUSE SKIN; PROTEOLYTIC ACTIVATION; IRREVERSIBLE INHIBITOR; INDUCED APOPTOSIS; GENE-EXPRESSION; OKADAIC ACID; DBA/2 MICE; PROMOTION	Protein Kinase Cdelta (PKCdelta), a Call-independent, phospholipid-dependent serine/threonine kinase, is among the PKC isoforms expressed in mouse epidermis. We reported that FVB/N transgenic mice that overexpress (similar to eightfold) PKCdelta protein in basal epidermal cells are resistant to skin tumor formation by the 7,12-dimethylbenz(a)anthracene (DMBA)-initiation and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promotion protocol. However, despite being resistant to skin tumor promotion by TPA, PKCdelta transgenic mice elicited a 3-4-fold increase in TPA-induced epidermal ODC activity and putrescine levels than their wild-type littermates. PKCdelta was observed to be the key component of the TPA signal transduction pathways to the induction of mouse epidermal ODC activity. To determine if TPA-induced ODC activity and associated putrescine levels in PKCdelta transgenic mice contributed to PKCdelta-mediated suppression of skin tumor promotion by TPA, the irreversible inhibitor of ODC, alpha-difluoromethylornithine (DFMO), was used. PKCdelta transgenic mice and their wild-type littermates were initiated with 100 nmol DMBA and then promoted twice weekly with 5 nmol TPA. The experimental group was given 0.5% DFMO in their drinking water, while the control group was given tap water. After 25 weeks, the number of papillomas (> 2 mm) per mouse was counted. The DFMO treatment did not affect the skin tumor multiplicity of PKCdelta transgenic mice. These results indicate that PKCdelta-induced ODC activity is not involved in PKCdelta-mediated tumor suppression. Thus, the signaling pathways via PKCdelta to epidermal ODC induction and skin tumor suppression appear to be independent.	Univ Wisconsin, Med Sch,Ctr Comprehens Canc, CSC, Dept Human Oncol, Madison, WI 53792 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Max Planck Inst Expt Endocrinol, D-30625 Hannover, Germany	University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; University of North Carolina Chapel Hill; Max Planck Society	Verma, AK (corresponding author), Univ Wisconsin, Med Sch,Ctr Comprehens Canc, CSC, Dept Human Oncol, K4-532,, Madison, WI 53792 USA.	akverma@facstaff.wisc.edu	Leitges, Michael/AAN-1953-2021					ALDAZ CM, 1985, CANCER RES, V45, P2753; ARGYRIS TS, 1985, CRC CR REV TOXICOL, V14, P211, DOI 10.3109/10408448509037459; ASHENDEL CL, 1983, CANCER RES, V43, P4327; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DIGIOVANNI J, 1984, CARCINOGENESIS, V5, P1493, DOI 10.1093/carcin/5.11.1493; DRIEDGER PE, 1980, P NATL ACAD SCI-BIOL, V77, P567, DOI 10.1073/pnas.77.1.567; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FISCHER SM, 1988, CANCER RES, V48, P658; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; FURSTENBERGER G, 1985, SCIENCE, V230, P76, DOI 10.1126/science.3929385; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GILMOUR SK, 1987, CANCER RES, V47, P1221; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; HIRABAYASHI N, 1988, CARCINOGENESIS, V9, P2215, DOI 10.1093/carcin/9.12.2215; Hobbs CA, 2000, J CELL BIOCHEM, V77, P345, DOI 10.1002/(SICI)1097-4644(20000601)77:3<345::AID-JCB1>3.3.CO;2-G; Hu RH, 1997, BIOCHEM J, V328, P307, DOI 10.1042/bj3280307; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; IMAMOTO A, 1992, CARCINOGENESIS, V13, P177, DOI 10.1093/carcin/13.2.177; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; Jansen AP, 2001, INT J CANCER, V93, P635, DOI 10.1002/ijc.1395; Jansen AP, 2001, CANCER RES, V61, P808; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KOZA RA, 1991, CARCINOGENESIS, V12, P1619, DOI 10.1093/carcin/12.9.1619; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OBrien TG, 1997, CANCER RES, V57, P2630; Otieno MA, 2000, CANCER RES, V60, P4391; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Rajesh D, 1999, MOL PHARMACOL, V56, P515, DOI 10.1124/mol.56.3.515; Reddig PJ, 1999, CANCER RES, V59, P5710; Reddig PJ, 2000, CANCER RES, V60, P595; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Sawai H, 1997, J BIOL CHEM, V272, P2452; SISSKIN EF, 1982, CARCINOGENESIS, V3, P403, DOI 10.1093/carcin/3.4.403; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TAKIGAWA M, 1982, BIOCHEM BIOPH RES CO, V105, P969, DOI 10.1016/0006-291X(82)91065-8; TSENG CP, 1994, CARCINOGENESIS, V15, P707, DOI 10.1093/carcin/15.4.707; VERMA AK, 1988, CANCER RES, V48, P1736; VERMA AK, 1992, CELLULAR AND MOLECULAR TARGETS FOR CHEMOPREVENTION, P207; VERMA AK, 1980, CARCINOGENESIS, V1, P271, DOI 10.1093/carcin/1.3.271; VERMA AK, 1986, CANCER RES, V46, P6149; VERMA AK, 1995, SKIN CANC MECH HUMAN, P383; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang HQ, 1999, J CELL SCI, V112, P3497; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755	56	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3620	3630		10.1038/sj.onc.1205451	http://dx.doi.org/10.1038/sj.onc.1205451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032864				2022-12-17	WOS:000175793700013
J	Kabsch, K; Alonso, A				Kabsch, K; Alonso, A			The human papillomavirus type 16 (HPV-16) E5 protein sensitizes human keratinocytes to apoptosis induced by osmotic stress	ONCOGENE			English	Article						fpapillomavirus; keratinocytes; apoptosis; osmotic shock	GROWTH-FACTOR RECEPTOR; EPITHELIAL-CELL LINE; ACTIVATION; GENE; CASPASES; FIBROBLASTS; ONCOPROTEIN; KINASE; HACAT; DEATH	We have studied the role of the HPV-16 E5 protein in apoptosis, using HaCaT cell lines stably transfected with either E5 (HaCaT/E5) or the empty vector (HaCaT/ pMSG) as control. When subjected to a hyperosmolar concentration of sorbitol, HaCaT/E5 cells respond with cytochrome e release, activation of caspase-3, -8, and -9, and PARP-cleavage, showing that the mitochondria and death-receptor mediated apoptotic pathways are involved in subsequent cell death. Similar effects are observed for the control cells only after extended sorbitol treatment. Thus, E5-expressing cells are more sensitive to osmotic stress, perhaps because of modifications of the cellular membranes caused by this strongly hydrophobic molecule.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Kabsch, K (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	k.kabsch@dkfz-heidelberg.de						Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1999, ONCOGENE, V18, P6714, DOI 10.1038/sj.onc.1203075; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; Crusius K, 2000, VIRUS GENES, V20, P65, DOI 10.1023/A:1008112207824; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; FAULKNERVALLE G, 1995, J GEN VIROL, V76, P1239; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; HACHISUKA H, 1990, CELL TISSUE RES, V260, P207, DOI 10.1007/BF00297507; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jost M, 2001, J INVEST DERMATOL, V116, P860, DOI 10.1046/j.1523-1747.2001.01356.x; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KELL B, 1994, J GEN VIROL, V75, P2451, DOI 10.1099/0022-1317-75-9-2451; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; LEPTAK C, 1992, J VIROL, V66, P1833; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PIM D, 1992, ONCOGENE, V7, P27; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; ULLMAN CG, 1994, BIOCHEM SOC T, V22, pS439, DOI 10.1042/bst022439s; Wang J, 2000, J CELL SCI, V113, P753	33	23	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					947	953		10.1038/sj.onc.1205147	http://dx.doi.org/10.1038/sj.onc.1205147			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840340				2022-12-17	WOS:000173427100010
J	Comtesse, N; Niedermayer, I; Glass, B; Heckel, D; Maldener, E; Nastainczyk, W; Feiden, W; Meese, E				Comtesse, N; Niedermayer, I; Glass, B; Heckel, D; Maldener, E; Nastainczyk, W; Feiden, W; Meese, E			MGEA6 is tumor-specific overexpressed and frequently recognized by patient-serum antibodies	ONCOGENE			English	Article						tumor antigen; overexpression; central nervous-system neoplasm; meningioma; glioma	CANCER PATIENTS; ANTIGENS; MENINGIOMA; CLONING; PROTEIN	Tumorigenesis of meningioma has been associated with chromosome 22, most notably the NF2 gene, but additional genes have also been implicated in meningioma development. Previously, we have cloned the cDNAs for the meningioma expressed antigen 6 (MGEA6) and its splice variant MGEA11. Here, we show that antibodies against recombinantly expressed MGEA6/11 are found in 41.7% (10/24) of the sera from meningioma patients and in 2/8 sera of glioblastoma patients, whereas no response was seen in 12 sera from healthy persons. Western-blot analyses using generated polyclonal antibodies, revealed overexpression in meningioma and glioma tumor samples compared to normal brain. Immunohistochemical staining of tissue sections confirms reactivity in meningioma tumor cells and tumor cells of glial origin. We found no reactivity to normal astrocytes and only faint reactivity to normal leptomeninges. Sequence analysis predicted membranic localization of MGEA6/11, that was confirmed by cell fractionation. The immune response to MGEA6/11 is frequent in both meningioma and glioma patients and may likely be attributed to overexpression of the MGEA6/11 protein in the tumor cells.	Univ Saarlandes Kliniken, Inst Humangenet, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Abt Neuropathol, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Inst Med Biochem, D-66421 Homburg, Germany	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes	Meese, E (corresponding author), Univ Saarland, Dept Human Genet, Bldg 60, D-66421 Homburg, Germany.		Meese, Eckart Ulrich/ABD-1983-2021					AKAGI K, 1995, INT J CANCER, V60, P178, DOI 10.1002/ijc.2910600208; BARKER CF, 1977, ADV IMMUNOL, V25, P1; BECKER I, 1989, J NEUROIMMUNOL, V25, P161, DOI 10.1016/0165-5728(89)90133-1; BENMAHREZ K, 1990, INT J CANCER, V46, P35, DOI 10.1002/ijc.2910460109; Boon T, 1997, CURR OPIN IMMUNOL, V9, P681, DOI 10.1016/S0952-7915(97)80049-0; Comtesse N, 2001, GENOMICS, V75, P43, DOI 10.1006/geno.2001.6576; Comtesse N, 1999, CLIN CANCER RES, V5, P3560; Disis ML, 1996, CURR OPIN IMMUNOL, V8, P637, DOI 10.1016/S0952-7915(96)80079-3; DISIS ML, 1994, CANCER RES, V54, P16; GALLAGER G, 1991, BRIT J CANCER, V61, P35; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Heckel D, 1997, HUM MOL GENET, V6, P2031, DOI 10.1093/hmg/6.12.2031; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; Kleihues P, 2000, PATHOLOGY GENETICS T; MARCIAS MJ, 1996, NATURE, V382, P646; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; PEES HW, 1979, ACTA NEUROCHIR, V50, P217, DOI 10.1007/BF01808518; PEES HW, 1976, CLIN EXP IMMUNOL, V24, P310; PUPA SM, 1993, CANCER RES, V53, P5864; REAL FX, 1988, P NATL ACAD SCI USA, V85, P3965, DOI 10.1073/pnas.85.11.3965; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; TABUCHI K, 1979, ACTA NEUROCHI WIEN, V55, P201; Yamamoto A, 1996, INT J CANCER, V69, P283, DOI 10.1002/(SICI)1097-0215(19960822)69:4<283::AID-IJC8>3.3.CO;2-D	23	23	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					239	247		10.1038/sj.onc.1205005	http://dx.doi.org/10.1038/sj.onc.1205005			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803467				2022-12-17	WOS:000173026200008
J	Dagon, Y; Dovrat, S; Vilchik, S; Hacohen, D; Shlomo, G; Sredni, B; Salzberg, S; Nir, U				Dagon, Y; Dovrat, S; Vilchik, S; Hacohen, D; Shlomo, G; Sredni, B; Salzberg, S; Nir, U			Double-stranded RNA-dependent protein kinase, PKR, down-regulates CDC2/cyclin B1 and induces apoptosis in non-transformed but not in v-mos transformed cells	ONCOGENE			English	Article						PKR; v-mos; cell cycle; CDC2	TUMOR-SUPPRESSOR P53; BREAST-CANCER CELLS; NF-KAPPA-B; XENOPUS-OOCYTES; MALIGNANT TRANSFORMATION; MAP KINASE; INTERFERON; EXPRESSION; ACTIVATION; P68	The interferon (IFN)-induced, double stranded RNA (dsRNA)-activated serine/threonine kinase, PKR, is a potent negative regulator of cell growth when overexpressed in yeast or mammalian cells. Paradoxically, while it can function as a tumor suppressor and inducer of apoptosis, it is overexpressed in a variety of human cancers. To resolve this enigma, we established cell-lines that overexpress PKR in non-transformed and in v-mos transformed CHO cells. Overexpression of PKR suppressed the proliferation of CHO cells by inducing a transient G0/G1 arrest, followed by a delayed G2/M arrest, which attenuated cell cycle progression. These effects were accompanied by early induction of p21/ WAF-1 and delayed downregulation of CDC2 and cyclin B1. Induction of proapoptotic activity of the ectopic PKR paralleled the onset of G2/M arrest in CHO cells. However, while transiently inducing p21/WAF-1, PKR did not impose G2/M arrest or apoptosis in v-mos-transformed cells, nor was CDC2 or cyclin B1 downregulated in those cells. These findings link the proapoptotic activity of PKR to the arrest of cell cycle at the G2/M phase. Consequently, the apoptotic activity of PKR could be counter-acted by an oncogene-like v-mos that overrides the G2/M arrest induced by PKR.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Nir, U (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.		Salzberg, Steven L/F-6162-2011; Dagon, Yossi/AAI-5882-2020; Salzberg, Steven/Q-6514-2019	Salzberg, Steven L/0000-0002-8859-7432; Salzberg, Steven/0000-0002-8859-7432				Afshari CA, 1997, ONCOGENE, V14, P3029, DOI 10.1038/sj.onc.1201157; BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; Chen F W, 1999, Int Rev Immunol, V18, P429, DOI 10.3109/08830189909088492; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CRADDOCK BL, 1995, BIOCHEM J, V309, P1009, DOI 10.1042/bj3091009; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; deMoor CH, 1997, MOL CELL BIOL, V17, P6419, DOI 10.1128/MCB.17.11.6419; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gil J, 1999, MOL CELL BIOL, V19, P4653; Gil J, 2000, BIOCHEMISTRY-US, V39, P7521, DOI 10.1021/bi992868b; HAINES GK, 1993, VIRCHOWS ARCH B, V63, P289, DOI 10.1007/BF02899275; HAINES GK, 1992, VIRCHOWS ARCH B, V62, P151, DOI 10.1007/BF02899677; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Haines GK, 1998, TUMOR BIOL, V19, P52, DOI 10.1159/000029974; HAINES GK, 1993, ARCH OTOLARYNGOL, V119, P1142; HANNIGAN G, 1986, EMBO J, V5, P1607, DOI 10.1002/j.1460-2075.1986.tb04403.x; HENRY GL, 1994, J BIOL REG HOMEOS AG, V8, P15; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; KERR IM, 1977, NATURE, V268, P540, DOI 10.1038/268540a0; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; Kishimoto T, 1999, DEV BIOL, V214, P1, DOI 10.1006/dbio.1999.9393; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; Kronfeld-Kinar Y, 1999, CELL GROWTH DIFFER, V10, P201; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; Li SY, 2000, EUR J BIOCHEM, V267, P1598, DOI 10.1046/j.1432-1327.2000.01134.x; Li SY, 2001, J BIOL CHEM, V276, P13881, DOI 10.1074/jbc.M008140200; LOHKA MJ, 1989, J CELL SCI, V92, P131; LORCA T, 1993, PATHOL BIOL, V41, P260; Lu JF, 1999, J BIOL CHEM, V274, P32198, DOI 10.1074/jbc.274.45.32198; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; Melville MW, 2000, CELL MOL LIFE SCI, V57, P311, DOI 10.1007/PL00000692; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MEURS EF, 1992, J VIROL, V66, P5804; MUNDSCHAU LJ, 1994, BIOCHIMIE, V76, P792, DOI 10.1016/0300-9084(94)90083-3; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAULES RS, 1992, ONCOGENE, V7, P2489; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Rhodes N, 1997, ONCOGENE, V14, P3017, DOI 10.1038/sj.onc.1201158; Rivas C, 1999, J INTERF CYTOK RES, V19, P1229, DOI 10.1089/107999099312885; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; Salzberg S, 2000, EXP CELL RES, V254, P45, DOI 10.1006/excr.1999.4721; Shang YF, 1998, J BIOL CHEM, V273, P30608, DOI 10.1074/jbc.273.46.30608; Singh A, 1997, ENVIRON PROG, V16, P281, DOI 10.1002/ep.3300160417; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; SQUIRE J, 1993, GENOMICS, V16, P768, DOI 10.1006/geno.1993.1263; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Ueda K, 1999, ONCOL RES, V11, P125; Vojdani A, 1997, J INTERN MED, V242, P465, DOI 10.1111/j.1365-2796.1997.tb00019.x; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Yoshida N, 2000, MOL REPROD DEV, V57, P88, DOI 10.1002/1098-2795(200009)57:1<88::AID-MRD12>3.0.CO;2-9; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293	67	23	24	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8045	8056		10.1038/sj.onc.1204945	http://dx.doi.org/10.1038/sj.onc.1204945			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781817				2022-12-17	WOS:000172396800001
J	Lefevre, SH; Vogt, N; Dutrillaux, AM; Chauveinc, K; Stoppa-Lyonnet, D; Doz, F; Desjardins, L; Dutrillaux, B; Chevillard, S; Malfoy, B				Lefevre, SH; Vogt, N; Dutrillaux, AM; Chauveinc, K; Stoppa-Lyonnet, D; Doz, F; Desjardins, L; Dutrillaux, B; Chevillard, S; Malfoy, B			Genome instability in secondary solid tumors developing after radiotherapy of bilateral retinoblastoma	ONCOGENE			English	Article						ionizing radiation; secondary cancers; retinoblastoma; chromosome instability; TP53; predisposition	P53 GENE-MUTATIONS; THYROID CARCINOMAS; MICROSATELLITE INSTABILITY; HODGKINS-DISEASE; MAMMALIAN-CELLS; HIGH PREVALENCE; RET GENES; RADIATION; CANCER; DNA	Genome alterations of seven secondary tumors (five osteosarcomas, one malignant peripheral sheath nerve tumor, one leiomyosarcoma) occurring in the field of irradiation of patients treated for bilateral retinoblastoma have been studied. These patients were predisposed to develop radiation-induced tumors because of the presence of a germ line mutation in the retinoblastoma gene (RB1). Tumor cells were characterized by a high chromosome instability whereas microsatellites and minisatellites were found to be stable. In all tumors, the normal RBI allele was lost with the corresponding chromosome 13, whereas the germ line mutated allele was retained. The two alleles of TP53 were inactivated, one by deletion of the short arm of chromosome 17, the other by mutation. As compared with non-radiation induced tumors, the observed panel of TP53 mutations was uncommon with sites not recurrently found otherwise and a high rate of deletions (3/7). In these predisposed patients, the loss of the single normal allele of RB1 is rather due to the radiation-induced chromosome instability than a direct effect of ionizing radiation.	Inst Curie, CNRS UMR 147, F-75248 Paris 05, France; Inst Curie, Serv Radiotherapie, F-75248 Paris, France; Inst Curie, Serv Genet Oncol, F-75248 Paris 05, France; Inst Curie, Serv Pediat, F-75248 Paris 05, France; Inst Curie, Serv Ophthalmol, F-75248 Paris 05, France; CEA, DSV, DRR, F-92265 Fontenay Aux Roses, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CEA	Malfoy, B (corresponding author), Inst Curie, CNRS UMR 147, 26 Rue Ulm, F-75248 Paris 05, France.			Doz, Francois/0000-0001-9286-4831; Chevillard, Sylvie/0000-0001-5889-4041				ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Behrens C, 2000, CANCER EPIDEM BIOMAR, V9, P1027; Bernardino J, 1997, CANCER GENET CYTOGEN, V96, P123, DOI 10.1016/S0165-4608(96)00258-0; Boland CR, 1998, CANCER RES, V58, P5248; Bongarzone I, 1997, GENOMICS, V42, P252, DOI 10.1006/geno.1997.4685; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; BRACHMAN DG, 1991, CANCER RES, V51, P6393; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brat DJ, 1999, AM J PATHOL, V154, P1431, DOI 10.1016/S0002-9440(10)65397-7; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; CAHAN WG, 1948, CANCER, V1, P3, DOI 10.1002/1097-0142(194805)1:1<3::AID-CNCR2820010103>3.0.CO;2-7; Calvo R, 1998, J NATL CANCER I, V90, P1095, DOI 10.1093/jnci/90.14.1095; Chauveinc L, 1999, CANCER GENET CYTOGEN, V114, P1, DOI 10.1016/S0165-4608(99)00038-2; Chevillard S, 1997, CLIN CANCER RES, V3, P2471; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; DeBenedetti VMG, 1996, CANCER EPIDEM BIOMAR, V5, P93; DEVATHAIRE F, 1992, BRIT J CANCER, V65, P425, DOI 10.1038/bjc.1992.87; DRAPER GJ, 1992, BRIT J CANCER, V66, P211, DOI 10.1038/bjc.1992.244; Dutrillaux B, 1981, PRATIQUE ANAL CHROMO; Fennelly J, 1997, LEUKEMIA, V11, P807, DOI 10.1038/sj.leu.2400674; Fogelfeld L, 1996, J CLIN ENDOCR METAB, V81, P3039, DOI 10.1210/jc.81.8.3039; Gafanovich A, 1999, CANCER-AM CANCER SOC, V85, P504; Gamble SC, 1999, MUTAT RES-FUND MOL M, V425, P231, DOI 10.1016/S0027-5107(99)00045-7; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jeffreys AJ, 1997, ELECTROPHORESIS, V18, P1501, DOI 10.1002/elps.1150180903; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Klugbauer S, 1995, ONCOGENE, V11, P2459; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Le Page F, 1999, BIOCHIMIE, V81, P147, DOI 10.1016/S0300-9084(99)80047-9; LEFRANCOIS D, 1989, INT J CANCER, V44, P871, DOI 10.1002/ijc.2910440521; LEPAGE F, 1995, CARCINOGENESIS, V16, P2779; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Little JB, 1997, RADIAT RES, V148, P299, DOI 10.2307/3579514; Lohmann DR, 1999, HUM MUTAT, V14, P283, DOI 10.1002/(SICI)1098-1004(199910)14:4<283::AID-HUMU2>3.0.CO;2-J; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MARTINS MB, 1993, MUTAT RES, V285, P229, DOI 10.1016/0027-5107(93)90111-R; Mertens F, 2000, CANCER GENET CYTOGEN, V116, P89, DOI 10.1016/S0165-4608(99)00105-3; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Nakanishi H, 1998, LAB INVEST, V78, P727; Nikiforov YE, 1999, ONCOGENE, V18, P6330, DOI 10.1038/sj.onc.1203019; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 1996, ONCOGENE, V13, P687; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P155, DOI 10.1016/S0027-5107(00)00022-1; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; Richter HE, 1999, CARCINOGENESIS, V20, P2247, DOI 10.1093/carcin/20.12.2247; ROBINSON E, 1988, JNCI-J NATL CANCER I, V80, P233, DOI 10.1093/jnci/80.4.233; SAJANTILA A, 1992, AM J HUM GENET, V50, P816; Shoshan Y, 2000, J NEUROPATH EXP NEUR, V59, P614, DOI 10.1093/jnen/59.7.614; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; SOUSSI T, 1990, ONCOGENE, V5, P945; Tada M, 1997, NEUROSURGERY, V40, P393, DOI 10.1097/00006123-199702000-00034; United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), 1993, REP SOURC EFF RISKS; VOGEL F, 1979, HUM GENET, V52, P1; Wallace SS, 1998, RADIAT RES, V150, pS60, DOI 10.2307/3579809; Wong FL, 1997, JAMA-J AM MED ASSOC, V278, P1262, DOI 10.1001/jama.278.15.1262; Wright E G, 2000, Med Confl Surviv, V16, P117, DOI 10.1080/13623690008409501	63	23	23	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8092	8099		10.1038/sj.onc.1205009	http://dx.doi.org/10.1038/sj.onc.1205009			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781822				2022-12-17	WOS:000172396800006
J	Lin, SCJ; Skapek, SX; Papermaster, DS; Hankin, M; Lee, EYHP				Lin, SCJ; Skapek, SX; Papermaster, DS; Hankin, M; Lee, EYHP			The proliferative and apoptotic activities of E2F1 in the mouse retina	ONCOGENE			English	Article						E2F1; p53; RB and retinoblastoma	S-PHASE ENTRY; RETINOBLASTOMA GENE FAMILY; TRANSCRIPTION FACTOR E2F1; SKELETAL-MUSCLE CELLS; ADIPOCYTE DIFFERENTIATION; DEREGULATED EXPRESSION; FIBROBLASTS LEADS; TRANSGENIC MICE; PROTEIN; RB	The E2F1 transcription factor controls cell proliferation and apoptosis. E2F1 activity is negatively regulated by the retinoblastoma (RB) protein. To study how inactivation of Rb and dysregulated E2F1 affects the developing retina, we analysed wild-type and Rb-/- embryonic retinas and retinal transplants and we established transgenic mice expressing human E2F1 in retinal photoreceptor cells under the regulation of the IRBP promoter (TgIRBPE2F1). A marked increase in cell proliferation and apoptosis was observed in the retinas of Rb-/- mice and TgIRBPE2F1 transgenic mice. In the transgenic mice, photoreceptor cells formed rosette-like arrangements at postnatal days 9 through 28. Complete loss of photoreceptors followed in the TgIRBPE2F1 mice but not in the Rb-/- retinal transplants. Both RB-deficient and E2F1-overexpressing photoreceptor cells expressed rhodopsin, a marker of terminal differentiation. Loss of p53 partially reduced the apoptosis and resulted in transient hyperplasia of multiple cell types in the TgIRBPE2F1 retinas at postnatal day 6. Our findings support the concept that cross-talk occurs between different retinal cell types and that multiple genetic pathways must become dysregulated for the full oncogenic transformation of neuronal retinal cells.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Connecticut, Hlth Sci Ctr, Dept Neurosci, Farmington, CT 06030 USA; Med Coll Ohio, Dept Anat & Neurobiol, Toledo, OH 43614 USA	University of Texas System; University of Texas Health San Antonio; St Jude Children's Research Hospital; University of Connecticut	Lee, EYHP (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.	Leee@uthscsa.edu			NCI NIH HHS [P30 CA 54174, CA49649] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA054174, R29CA049649, R37CA049649, R01CA049649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ALUBAIDI MR, 1992, P NATL ACAD SCI USA, V89, P1194, DOI 10.1073/pnas.89.4.1194; Belliveau MJ, 1999, DEVELOPMENT, V126, P555; Belliveau MJ, 2000, J NEUROSCI, V20, P2247; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen G, 1999, DNA CELL BIOL, V18, P305, DOI 10.1089/104454999315367; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANKIN M, 1993, DEV BRAIN RES, V75, P146, DOI 10.1016/0165-3806(93)90075-L; HANKIN MH, 1987, J COMP NEUROL, V263, P455, DOI 10.1002/cne.902630310; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HU NP, 1994, ONCOGENE, V9, P1021; Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; LIOU GI, 1990, J BIOL CHEM, V265, P8373; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; McCaffrey J, 1999, MOL CELL BIOL, V19, P6458; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; NIR I, 1984, J CELL BIOL, V98, P1788, DOI 10.1083/jcb.98.5.1788; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Skapek SX, 2000, J BIOL CHEM, V275, P7212, DOI 10.1074/jbc.275.10.7212; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Udovichenko IP, 1998, J BIOL CHEM, V273, P7181, DOI 10.1074/jbc.273.13.7181; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215; YOUNG RW, 1984, CELL, V85, P537; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	64	23	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7073	7084		10.1038/sj.onc.1204932	http://dx.doi.org/10.1038/sj.onc.1204932			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704831				2022-12-17	WOS:000171739300010
J	Reese, JS; Allay, E; Gerson, SL				Reese, JS; Allay, E; Gerson, SL			Overexpression of human O-6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice	ONCOGENE			English	Article						MGMT; p53; MNU; lymphomagenesis	TRANSGENIC MICE; N-METHYLNITROSOUREA; THYMIC LYMPHOMAS; KNOCKOUT MICE; HUMAN MGMT; GENE; MUTATIONS; EXPRESSION; REPAIR; TUMORS	O-6-alkylguanine DNA alkyltransferase (AGT) is a key mechanism in the prevention against MNU induced malignant transformation by removal of O-6 methyl guanine (O(6)mG) adducts. We asked whether heterozygous p53 deficient mice (p53+/-) would be more susceptible to MNU induced lymphomas than wild type mice, and whether O(6)mG adducts were responsible for this susceptibility. To determine whether MGMT overexpression would be protective, p53+/- mice were bred to human MGMT transgenic mice (MGMT+) and treated with 50 mg/kg MNU. MNU increased the incidence of thymic lymphomas in non-transgenic p53 + / - mice from 23% (n = 13) to 68% (n = 22) and decreased the mean latency from 433 to 106 days (P=0.01 compared to untreated mice). Wild type mice had an incidence of 30% (n = 38) and a mean latency of 135 days after MNU. Overexpression of MGMT in the thymus of p53 + / - mice significantly reduced the lymphoma incidence from 68 to 28% (n = 17) and increased the latency from 106 to 167 days (P=0.003). Similarly, the lymphoma incidence in MGMT + /wild type mice decreased from 30 to 8% (n = 12) and the latency increased to 297 days (P=0.2). Loss of the wild type allele was found in only 2/17 lymphomas occurring in p53 + / - mice and there were no significant point mutations in exons 5-8 of p53. Furthermore, there was no loss of p53 function in these mice. These data demonstrate that unrepaired O(6)mG lesions act cooperatively with the reduced p53 dose and lead to lymphomagenesis in p53+/- mice, but AGT overexpression and rapid removal of O(6)mG adducts is protective.	Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Div Hematol Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland	Gerson, SL (corresponding author), Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, BRB-3,10900 Euclid Ave, Cleveland, OH 44106 USA.				NCI NIH HHS [CA63193] Funding Source: Medline; NIEHS NIH HHS [ES06288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allay E, 1999, ONCOGENE, V18, P3783, DOI 10.1038/sj.onc.1202697; Allay E, 1997, ONCOGENE, V15, P2127, DOI 10.1038/sj.onc.1201384; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; Glassner BJ, 1999, MUTAGENESIS, V14, P339, DOI 10.1093/mutage/14.3.339; GOODROW TL, 1992, MOL CARCINOGEN, V5, P9; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSONO S, 1991, ONCOGENE, V6, P237; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; LIU LL, 1994, CANCER RES, V54, P4648; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; NEALE GAM, 1995, BLOOD, V86, P3060; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Offer H, 2001, CANCER RES, V61, P88; Ohgaki H, 2000, MOL CARCINOGEN, V28, P97, DOI 10.1002/1098-2744(200006)28:2<97::AID-MC5>3.0.CO;2-O; PEGG AE, 1990, CANCER RES, V50, P6119; Qin XS, 1999, ONCOGENE, V18, P4394, DOI 10.1038/sj.onc.1202798; Qin XS, 1999, CARCINOGENESIS, V20, P1667, DOI 10.1093/carcin/20.9.1667; SAYLORS RL, 1991, CANCER RES, V51, P4721; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215	23	23	27	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5258	5263		10.1038/sj.onc.1204700	http://dx.doi.org/10.1038/sj.onc.1204700			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536039				2022-12-17	WOS:000170575500002
J	Yoon, DS; Li, L; Zhang, RD; Kram, A; Ro, JY; Johnston, D; Grossman, HB; Scherer, S; Czerniak, B				Yoon, DS; Li, L; Zhang, RD; Kram, A; Ro, JY; Johnston, D; Grossman, HB; Scherer, S; Czerniak, B			Genetic mapping and DNA sequence-based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease	ONCOGENE			English	Article						tumor suppressor gene loci; chromosome 16; bladder cancer	HUMAN-BREAST-CARCINOMA; URINARY-BLADDER; MICROSATELLITE ANALYSIS; PROSTATE-CANCER; ALLELIC LOSS; E-CADHERIN; EXPRESSION; CARCINOGENESIS; HETEROZYGOSITY; ALLELOTYPE	Histologic and genetic mapping with 30 hypervariable markers mapped to chromosome 16 were performed on 234 DNA samples of five cystectomy specimens from patients with invasive bladder cancer. Allelic losses of individual markers were related to microscopically identified precursor conditions in the entire bladder mucosa and invasive cancer. Their significance for the development and progression of neoplasia from in situ preneoplastic conditions to invasive disease was analysed by the nearest neighbor algorithm and binomial maximum likelihood analysis. Using this approach we identified five distinct regions of allelic losses defined by their flanking markers and predicted size as follows. p13.3(D16S418-D16S406, 1.2 cM), p13.1(D16S748-D16S287, 12.9 cM), q12 1(D16S409-D16S514, 24.0 cM), q22.1 (D16S496-D16S515, 5.4 cM), and q24 (D16S507-D16S511, 5.9 cM and D16S402-D16S413, 17.4 cM). The regions mapping to p13.1 and q24 were involved in early intraurothelial phases of bladder neoplasia such as mild to moderate dysplasia. On the other hand the deleted region mapping to p13.3 was involved in progression of severe dysplasia/carcinoma in situ to invasive bladder cancer. Testing of markers that exhibited statistically significant LOH in relation to progression of neoplasia from precursor conditions to invasive cancer on 28 tumors and voided urine samples from 25 patients with bladder cancer revealed that q12.1 showed LOH in 46.4% of tumor and 32.0% of voided urine samples. The LOH of a single marker D16S541 could be detected in approximately 28% of tumors and 20% of voided urine samples of patients with bladder cancer. These data imply that the deleted region centered around marker D16S541 spanning approximately 10 cM and flanked by D16S409 and D16S415 contains a novel putative tumor suppressor gene or genes playing an important role in the development of human bladder cancer. To facilitate more precise positional mapping and identification of pathogenetically relevent genes, we analysed of human genome contig and sequence databases spanning the deleted regions. Multiple known candidate genes and several smaller gene-rich areas mapping to the target regions of chromosome 16 were identified Oncogene (2001) 20, 5005-5014.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Baylor Coll Med, Human Genome Sequencing Ctr, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Czerniak, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Kram, Andrzej/0000-0003-0621-0204	NCI NIH HHS [R29CA66723, UO-1 CA85078] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA085078, R29CA066723] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1997, J CLIN PATHOL; Asgeirsson KS, 2000, EUR J CANCER, V36, P1098, DOI 10.1016/S0959-8049(00)00062-9; Brownlee K.A., 1965, STAT THEORY METHODOL; CAIRNS P, 1994, CANCER RES, V54, P1422; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHANG WYH, 1995, CANCER RES, V55, P3246; Chaturvedi V, 1997, ONCOGENE, V14, P2059, DOI 10.1038/sj.onc.1201044; Czerniak B, 1999, ONCOGENE, V18, P1185, DOI 10.1038/sj.onc.1202385; Czerniak B, 2000, GENE CHROMOSOME CANC, V27, P392, DOI 10.1002/(SICI)1098-2264(200004)27:4<392::AID-GCC9>3.3.CO;2-E; CZERNIAK B, 1992, HUM PATHOL, V23, P1199, DOI 10.1016/0046-8177(92)90285-B; Czerniak B, 1995, DIAGNOSTIC CYTOLOGY, P345; DEVILEE P, 1991, ONCOGENE, V6, P1705; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hartigan J.A., 1975, CLUSTERING ALGORITHM; Hughes TR, 2000, NAT GENET, V25, P333, DOI 10.1038/77116; KOSS L G, 1977, Urology, V9, P442, DOI 10.1016/0090-4295(77)90227-8; KOSS LG, 1991, NEW ENGL J MED, V324, P125; KOSS LG, 1974, JAMA-J AM MED ASSOC, V227, P281; KOSS LG, 1979, HUM PATHOL, V10, P533, DOI 10.1016/S0046-8177(79)80097-0; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; Lininger RA, 1998, HUM PATHOL, V29, P1113, DOI 10.1016/S0046-8177(98)90422-1; Lucito R, 2000, GENOME RES, V10, P1726, DOI 10.1101/gr.138300; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; Mostofi F, 1999, HISTOLOGICAL TYPING; Ott J., 1991, ANAL HUMAN GENETICS; Pan Y, 1998, PROSTATE, V36, P31, DOI 10.1002/(SICI)1097-0045(19980615)36:1<31::AID-PROS5>3.0.CO;2-E; RODGERS CS, 1984, CANCER GENET CYTOGEN, V13, P95, DOI 10.1016/0165-4608(84)90052-9; Sato M, 1998, GENE CHROMOSOME CANC, V22, P1; SATO T, 1990, CANCER RES, V50, P7184; SPRUCK CH, 1994, CANCER RES, V54, P784; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316	34	23	25	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5005	5014		10.1038/sj.onc.1204612	http://dx.doi.org/10.1038/sj.onc.1204612			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526485				2022-12-17	WOS:000170439800010
J	Zhou, WL; Carpenter, G				Zhou, WL; Carpenter, G			Heregulin-dependent translocation and hyperphosphorylation of ErbB-2	ONCOGENE			English	Article						ErbB-2; heregulin; detergent-insoluble fraction	LIPID RAFTS; ACTIN CYTOSKELETON; SIGNALING NETWORK; MEMBRANE DOMAINS; RECEPTOR; ONCOGENESIS; TRAFFICKING; RECRUITMENT; ENGAGEMENT; CAVEOLAE	Previous data have shown that in several tumor cells lines the addition of heregulin results in the translocation of ErbB-4 to a detergent-insoluble membrane fraction where it is hypertyrosine phosphorylated, The data herein demonstrate that heregulin or betacellulin, but not EGF, promotes the rapid translocation of ErbB-2, the heterodimerization partner for ErbB-4, to the same detergent-insoluble fraction in T47 D mammary carcinoma cells. The translocation of ErbB-2 and ErbB-4, but not ErbB-3, to this detergent-insoluble fraction is readily detected 2 min after the addition of heregulin, ErbB-2 present in this detergent-insoluble membrane fraction is tyrosine phosphorylated to a level fourfold greater than the majority of cellular ErbB-2 present in the detergent-soluble membrane fraction. These results suggest the ligand-dependent formation of hyperphosphorylated ErbB-4/ErbB-2 dimers coordinate with translocation to a putative membrane microdomain,	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R01CA024071, T32CA009582] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09582, R01 CA24071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Dunbar AJ, 2000, INT J BIOCHEM CELL B, V32, P805, DOI 10.1016/S1357-2725(00)00028-5; Holowka D, 2000, J CELL SCI, V113, P1009; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Leupin O, 2000, CURR BIOL, V10, P277, DOI 10.1016/S0960-9822(00)00362-6; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhao YY, 1999, CIRC RES, V84, P1380; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200	17	23	23	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3918	3920		10.1038/sj.onc.1204517	http://dx.doi.org/10.1038/sj.onc.1204517			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439355				2022-12-17	WOS:000169494700017
J	Ikeda, W; Nakanishi, H; Tanaka, Y; Tachibana, K; Takai, Y				Ikeda, W; Nakanishi, H; Tanaka, Y; Tachibana, K; Takai, Y			Cooperation of Cdc42 small G protein-activating and actin filament-binding activities of frabin in microspike formation	ONCOGENE			English	Article						frabin; Cdc42; microspikes; actin cytoskeleton; F-actin-binding activity	NUCLEOTIDE EXCHANGE FACTOR; CELL-CELL ADHESION; AARSKOG-SYNDROME; SYNDROME GENE; MDCK CELLS; N-WASP; RAC; DOMAIN; EXPRESSION; INVASION	Frabin is a GDP/GTP exchange protein for Cdc42 with actin filament (F-actin)-binding activity. Cdc42 is a small GTP-binding protein that forms filopodia-like microspikes in a variety of cells. Expression of frabin indeed forms microspikes through at Least activation of Cdc42 in MDCK cells and fibroblasts such as COS7, L, and NIH3T3 cells. However, the role of the F-actin-binding activity of frabin in the microspike formation remains unknown. We have examined here this role of frabin by expressing various frabin mutants, which have lost Cdc42-activating or F-actin-binding activity, with or without a dominant active mutant of Cdc42 in MDCK and COS7 cells. We show here that for the microspike formation, either of the Cdc42-activating and F- actin-binding activities of frabin alone is not sufficient and both the activities are necessary and that both the activities play a cooperative role in the microspike formation, The present results, together with the earlier finding that Cdc42 reorganizes the actin cytoskeleton at least through the N-WASP-Arp2/3 complex, suggest that frabin directly and indirectly reorganizes the actin cytoskeleton through its F-actin-binding and Cdc42-activating activities, respectively, in a cooperative manner, eventually leading to microspike formation.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan.		Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058; Nakanishi, Hiroyuki/0000-0002-9765-0266				Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Gorski JL, 2000, DEV DYNAM, V218, P573, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1015>3.3.CO;2-6; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Obaishi H, 1998, J BIOL CHEM, V273, P18697, DOI 10.1074/jbc.273.30.18697; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pasteris NG, 1999, GENOMICS, V60, P57, DOI 10.1006/geno.1999.5903; Pasteris NG, 2000, GENE, V242, P237, DOI 10.1016/S0378-1119(99)00518-1; PASTERIS NG, 1994, CELL, V79, P669; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Umikawa M, 1999, J BIOL CHEM, V274, P25197, DOI 10.1074/jbc.274.36.25197; Yasuda T, 2000, GENES CELLS, V5, P583, DOI 10.1046/j.1365-2443.2000.00349.x	26	23	23	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3457	3463		10.1038/sj.onc.1204463	http://dx.doi.org/10.1038/sj.onc.1204463			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429692				2022-12-17	WOS:000169478300001
J	Rietveld, LEG; Caldenhoven, E; Stunnenberg, HG				Rietveld, LEG; Caldenhoven, E; Stunnenberg, HG			Avian erythroleukemia: a model for corepressor function in cancer	ONCOGENE			English	Review						erythroleukemia; corepressor; v-ErbA; histone deacetylase; carbonic anhydrase II; methylation	THYROID-HORMONE-RECEPTOR; RECRUIT HISTONE DEACETYLASE; TRANSCRIPTION FACTOR GATA-1; PLZF-RAR-ALPHA; V-ERBA; N-COR; BINDING PROTEIN; DNA METHYLTRANSFERASE; SMRT COREPRESSOR; C-ERBA	Transcriptional regulation at the level of chromatin plays crucial roles during eukaryotic development and differentiation. A plethora of studies revealed that the acetylation status of histones is controlled by multiprotein complexes containing (de)acetylase activities. In the current model, histone deacetylases and acetyltransferases are recruited to chromatin by DNA-bound repressors and activators, respectively. Shifting the balance between deacetylation, i.e. repressive chromatin and acetylationl i.e. active chromatin can lead to aberrant gene transcription and cancer, In human acute promyelocytic leukemia (APL) and avian erythroleukemia (AEL), chromosomal translocations and/or mutations in nuclear hormone receptors, RAR alpha [NR1B1] and TR alpha [NR1A1], yielded oncoproteins that deregulate transcription and alter chromatin structure. The oncogenic receptors are locked in their 'off' mode thereby constitutively repressing transcription of genes that are critical for differentiation of hematopoietic cells. AEL involves an oncogenic version of the chicken TR alpha, v-ErbA, Apart from repression by v-ErbA, ia recruitment of corepressor compleses, other repressors and corepressors appear to be involved in repression of v-ErbA target genes, such as carbonic anhydrase II (CAII), Reactivation of repressed genes in APL and AEL by chromatin modifying agents such as inhibitors of histone deacetylase or of methylation provides nem therapeutic strategies in the treatment of acute myeloid leukemia.	NCMLS, Dept Mol Biol, NL-6500 HB Nijmegen, Netherlands		Stunnenberg, HG (corresponding author), NCMLS, Dept Mol Biol, Geert Grootepl Zuid 26,POB 9101, NL-6500 HB Nijmegen, Netherlands.		Stunnenberg, Hendrik G./D-6875-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Ballestar E, 2000, BIOCHEMISTRY-US, V39, P7100, DOI 10.1021/bi0001271; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Boyer LA, 2000, J BIOL CHEM, V275, P18864, DOI 10.1074/jbc.M002810200; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BRALIOU GG, 2000, IN PRESS ONCOGENE; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CASINI T, 1995, ONCOGENE, V11, P1019; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Goldhirsch A, 1996, SEMIN ONCOL, V23, P494; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guenther MG, 2000, GENE DEV, V14, P1048; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HERMANN T, 1993, ONCOGENE, V8, P55; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Huang EY, 2000, GENE DEV, V14, P45; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kao HY, 2000, GENE DEV, V14, P55; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; LIMONTA M, 1993, LEUKEMIA RES, V17, P977, DOI 10.1016/0145-2126(93)90045-M; Lubbert M, 2000, CURR TOP MICROBIOL, V249, P135; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutz M, 2000, BIOCHEM SOC T, V28, P386, DOI 10.1042/0300-5127:0280386; Lutz M, 2000, NUCLEIC ACIDS RES, V28, P1707, DOI 10.1093/nar/28.8.1707; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; PAIN B, 1990, New Biologist, V2, P284; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; RASCLE A, 1994, ONCOGENE, V9, P2853; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; RICHEL DJ, 1991, BRIT J CANCER, V64, P144, DOI 10.1038/bjc.1991.258; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Willard HF, 1999, NAT GENET, V23, P127, DOI 10.1038/13751; Wolffe AP, 1999, P NATL ACAD SCI USA, V96, P5894, DOI 10.1073/pnas.96.11.5894; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zamir I, 1996, MOL CELL BIOL, V16, P5458; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056	123	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2001	20	24					3100	3109		10.1038/sj.onc.1204335	http://dx.doi.org/10.1038/sj.onc.1204335			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420726				2022-12-17	WOS:000169308500014
J	Brem, R; Certa, U; Neeb, M; Nair, APK; Moroni, C				Brem, R; Certa, U; Neeb, M; Nair, APK; Moroni, C			Global analysis of differential gene expression after transformation with the v-H-ras oncogene in a murine tumor model	ONCOGENE			English	Article						ras transformation; DNA microarray; transcript imaging	MAST-CELLS; CANCER; IDENTIFICATION; PROLIFERATION; FIBROBLASTS; PROGRESSION; INTEGRIN; DISPLAY; CLONING; BCL-2	Mouse PB-3c mast cells stably transfected with the v-H-ras oncogene induce tumor formation in vivo when implanted into mice. Such tumor cells are characterized by an autocrine IL-3 loop. DNA microarrays allow simultaneous transcript imaging of several thousand genes and the technique was applied in this tumor model to analyse gene expression following malignant transformation. Using three independent tumor lines derived from the same precursor the expression of about 400 out of 11000 genes was modulated in each tumor. A subset of only 75 genes (0.68%) is shared and up- or downregulated in all three lines. A significant portion of this gene pool possesses functions related to tumorigenesis such as cell adhesion, signaling or transcriptional regulation. Apart from a number of expressed sequence tags (EST's) we find downregulation of four interferon-inducible genes in the tumor lines. Finally, when we extrapolate our data to the complete mouse genome, we estimate that about 500 genes are differentially expressed in tumor cells compared to the precursor cell PB-3c.	F Hoffmann La Roche & Co Ltd, Dept Roche Genet, CH-4070 Basel, Switzerland; Inst Med Microbiol, CH-4051 Basel, Switzerland	Roche Holding	Certa, U (corresponding author), F Hoffmann La Roche & Co Ltd, Dept Roche Genet, CH-4070 Basel, Switzerland.			Brem, Reto/0000-0002-0171-1248				ASHLEY DJB, 1969, BRIT J CANCER, V23, P313, DOI 10.1038/bjc.1969.41; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1989, CANCER RES, V49, P4682; Buess M, 1999, ONCOGENE, V18, P1487, DOI 10.1038/sj.onc.1202445; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CERTA U, 2001, IN PRESS DNA ARRAYS; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DOUGHERTY GJ, 1989, J BIOL CHEM, V264, P6509; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; JALANKO H, 1978, INT J CANCER, V21, P453, DOI 10.1002/ijc.2910210409; Kleeff J, 1998, CANCER RES, V58, P3769; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Puthier D, 1999, LEUKEMIA, V13, P289, DOI 10.1038/sj.leu.2401302; RA C, 1989, J BIOL CHEM, V264, P15323; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; SMITH TJ, 1994, IMMUNITY, V1, P393, DOI 10.1016/1074-7613(94)90070-1; Vasavada RC, 2000, J BIOL CHEM, V275, P15399, DOI 10.1074/jbc.275.20.15399; Yan SQ, 1998, BIOL CHEM, V379, P113; ZIEGLER I, 1993, J BIOL CHEM, V268, P12544; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	30	23	24	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2854	2858		10.1038/sj.onc.1204403	http://dx.doi.org/10.1038/sj.onc.1204403			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420697				2022-12-17	WOS:000168712000013
J	Santos, J; Herranz, M; Fernandez, M; Vaquero, C; Lopez, P; Fernandez-Piqueras, J				Santos, J; Herranz, M; Fernandez, M; Vaquero, C; Lopez, P; Fernandez-Piqueras, J			Evidence of a possible epigenetic inactivation mechanism operating on a region of mouse chromosome 19 in gamma-radiation-induced thymic lymphomas	ONCOGENE			English	Article						Pten; Cd95; Jak2; epigenetic inactivation; gamma-irradiation; mouse thymic lymphomas; chromosome 19	TUMOR-SUPPRESSOR GENE; T-CELL LYMPHOMAS; INHIBITOR P15(INK4B); PROSTATE-CANCER; FREQUENT LOSS; DISTAL PART; PTEN/MMAC1; MUTATION; PTEN; MICE	Loss of heterozygosity (LOH) analysis, performed in 68 gamma -radiation-induced primary thymic lymphomas of F1 hybrid mice, provided evidence of significant LOH on chromosome 19 in a region defined by the D19Mit106 (22 cM) and D19Mit100 (27 cM) markers (Thymic Lymphoma Suppressor Region 8, TLSR8), Cd95 and Pten, two genes mapped at this region, were inactivated in a vast majority of these tumors (85.3% for Cd95 and 61.8% for Pten), Moreover, altered expression of Cd95 and Pten occurred concomitantly in 34 of 68 (50%) thymic lymphomas suggesting a coordinated mechanism of inactivation of these genes. Surprisingly, we also found that Jak2, a proto-oncogene located between Cd95 and Pten, was simultaneously inactivated in a significant fraction of the tumors analysed (24 of 34, 70.6%). Taken together these findings and the lack of mutations in the coding sequences of the mentioned genes clearly suggest a possible regional epigenetic inactivation mechanism on mouse chromosome 19 operating during the development of these tumors.	Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain	Autonomous University of Madrid	Fernandez-Piqueras, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain.		LORENZO, CONCEPCION VAQUERO/L-2827-2017; Herranz, Michel/L-2561-2016; Santos, Javier/ABF-5755-2021	Santos, Javier/0000-0002-4168-6251				Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Butler LM, 2000, BRIT J CANCER, V82, P131; Cairns P, 1997, CANCER RES, V57, P4997; Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FEINBERG AP, 1995, J NATL CANC I MONOGR, V17, P21; Herranz M, 1999, CANCER RES, V59, P2068; Liu R, 2000, ONCOGENE, V19, P571, DOI 10.1038/sj.onc.1203364; Malumbres M, 1999, ONCOGENE, V18, P385, DOI 10.1038/sj.onc.1202299; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; Melendez B, 1999, ONCOGENE, V18, P4166, DOI 10.1038/sj.onc.1202826; Okumoto M, 1999, CANCER LETT, V135, P223, DOI 10.1016/S0304-3835(98)00305-X; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Sachs RK, 2000, TRENDS GENET, V16, P143, DOI 10.1016/S0168-9525(99)01960-5; Santos J, 1998, ONCOGENE, V17, P925, DOI 10.1038/sj.onc.1202009; Santos J, 1996, ONCOGENE, V12, P669; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Yu CL, 1997, J IMMUNOL, V159, P5206	24	23	23	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2186	2189		10.1038/sj.onc.1204297	http://dx.doi.org/10.1038/sj.onc.1204297			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360203				2022-12-17	WOS:000168116700014
J	Brodie, SG; Xu, XL; Li, CL; Kuo, A; Leder, P; Deng, CX				Brodie, SG; Xu, XL; Li, CL; Kuo, A; Leder, P; Deng, CX			Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis	ONCOGENE			English	Article						p53; erbB2; cyclin D1; tumorigenesis; cooperation; parotid gland	TRANSGENIC MICE; BREAST-CANCER; CELL-CYCLE; CARCINOMAS; AMPLIFICATION; EXPRESSION; NEOPLASMS; HER-2/NEU; DEATH; D1	Transgenic mice expressing specific oncogenes usually develop tumors in a stochastic fashion suggesting that tumor progression is a multi-step process. To gain further understanding of the interactions between oncogenes and tumor suppressor genes during tumorigenesis, we have crossed a transgenic strain (TG,NK) carrying an activated c-neu oncogene driven by the MMTV enhancer/promoter with p53-deficient mice. c-neu transgenic mice have stochastic breast tumor formation and normal appearing salivary glands. However, c-neu mice heterozygous for a p53 deletion develop parotid gland tumors and loose their wild type p53 allele, c-neu mice with a homozygous p53 deletion have increased rates of parotid tumor onset suggesting that inactivation of p53 is required and sufficient for parotid gland transformation in the presence of activated c-neu. In contrast to the dramatic effect of p53 in parotid gland transformation, p53 loss has little effect on the rate or stochastic appearance of mammary tumors. In addition, p53 loss was accompanied by the down regulation of p21 in parotid gland tumors but not breast tumors, The parotid gland tumors were aneuploid and demonstrated increased levels of Cyclin D1 expression. These observations suggest that in c-neu transgenic mice, p53 alterations have differential tissue effects and may be influenced by the tissue specific expression of genes influencing p53 activity.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Califano J, 1999, OTOLARYNG CLIN N AM, V32, P861, DOI 10.1016/S0030-6665(05)70178-X; CARDIFF RD, 1991, AM J PATHOL, V139, P495; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1997, CANCER SURV, V29, P329; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELSON A, 1995, ONCOGENE, V11, P181; EVANS E P, 1987, P93; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; Hand AR, 1999, ARCH ORAL BIOL, V44, pS3, DOI 10.1016/S0003-9969(99)00042-4; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Hynes NE, 1996, J MAMMARY GLAND BIOL, V1, P199, DOI 10.1007/BF02013643; Isola J, 1999, CLIN CANCER RES, V5, P4140; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jimenez RE, 2000, MODERN PATHOL, V13, P37, DOI 10.1038/modpathol.3880007; Kamio N, 1996, VIRCHOWS ARCH, V428, P75; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1997, CANCER RES, V57, P1171; LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MULLER S, 1994, MODERN PATHOL, V7, P628; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OSWALD F, 1994, ONCOGENE, V9, P2029; Pignataro L, 1998, ANTICANCER RES, V18, P1287; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRESS MF, 1994, CANCER RES, V54, P5675; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Rice DH, 1999, OTOLARYNG CLIN N AM, V32, P875, DOI 10.1016/S0030-6665(05)70179-1; Samuelson LC, 1996, ANNU REV PHYSIOL, V58, P209, DOI 10.1146/annurev.physiol.58.1.209; SCHULZE A, 1994, ONCOGENE, V9, P3475; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STAL O, 1994, CYTOMETRY, V16, P160, DOI 10.1002/cyto.990160210; Tonin PN, 2000, SEMIN SURG ONCOL, V18, P281, DOI 10.1002/(SICI)1098-2388(200006)18:4<281::AID-SSU2>3.0.CO;2-Q; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEBSTER MA, 1994, SEMIN CANCER BIOL, V5, P69; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P	57	23	23	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1445	1454		10.1038/sj.onc.1204222	http://dx.doi.org/10.1038/sj.onc.1204222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313888				2022-12-17	WOS:000167595200005
J	Berry, DM; Benn, SJ; Cheng, AM; McGlade, CJ				Berry, DM; Benn, SJ; Cheng, AM; McGlade, CJ			Caspase-dependent cleavage of the hematopoietic specific adaptor protein Gads alters signalling from the T cell receptor	ONCOGENE			English	Article						Gads; caspase; T cell receptor; SH2 domain; SH3 domain	PHOSPHOLIPASE C-GAMMA-1; TYROSINE PHOSPHOPROTEIN; MAMMALIAN CASPASES; MOLECULAR-CLONING; ACTIVATION; SLP-76; LAT; APOPTOSIS; GRB2; DEATH	Gads is a SH2 and SH3 domain-containing, hematopoietic-specific adaptor protein that functions in signalling from the T cell receptor. Gads acts by linking SLP-76, bound by the carboxy-terminal Gads SH3 domain, to tyrosine phosphorylated LAT which contains binding sites for the Gads SH2 domain. Gads is distinguished from Grb2 and the closely related Grap protein by the presence of a 120 amino acid unique region between the SH2 domain and the carboxy terminal SH3 domain. Here we demonstrate that the unique region of Gads contains a capase cleavage site. Induction of apoptosis in lymphocytes results in detectable Gads cleavage by 60 min. Gads cleavage is blocked in vivo by treating cells with a caspase 3 inhibitor. A putative caspase 3 cleavage site was identified within the unique region and mutation of this site prevented Gads cleavage in vitro, and in vivo. The Gads cleavage products retained the predicted binding specificity for SLP-76 and LAT, Expression of the Gads cleavage products in Jurkat T cells inhibited NFAT activation following TCR cross linking. These findings indicate that cleavage of Gads in vivo could function to alter signalling downstream of the T cell receptor by disrupting cross talk between SLP-76 and LAT.	Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Washington University (WUSTL)	McGlade, CJ (corresponding author), Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fadeel B, 2000, LEUKEMIA, V14, P1514, DOI 10.1038/sj.leu.2401871; Fang N, 1996, J IMMUNOL, V157, P3769; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Hofmann TG, 2000, ONCOGENE, V19, P1153, DOI 10.1038/sj.onc.1203406; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	39	23	24	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1203	1211		10.1038/sj.onc.1204218	http://dx.doi.org/10.1038/sj.onc.1204218			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313864				2022-12-17	WOS:000167570100007
J	Hart, AH; Reventar, R; Bernstein, A				Hart, AH; Reventar, R; Bernstein, A			Genetic analysis of ETS genes in C-elegans	ONCOGENE			English	Article						LIN-1; ETS; C. elegans; transcription factor	DNA-BINDING DOMAIN; TERNARY COMPLEX FACTORS; TRANSCRIPTION FACTOR; CAENORHABDITIS-ELEGANS; VULVAR INDUCTION; MAP-KINASE; REVERSE GENETICS; CELL FATES; FLI-1 GENE; EXPRESSION	The recent completion of the Caenorhabditis elegans genome has revealed that this nematode worm has 10 members of the ETS gene family. Isolation and analysis of C. elegans mutants and subsequent screens to identify interacting genes can proceed very quickly in this model organism. Molecular genetic analysis of the receptor tyrosine kinase-Ras-MAP kinase signaling pathway in C, elegans identified the ETS family transcription factor Lin-1 as a nuclear effector of this evolutionarily conserved signal transduction pathway. Here we review classical genetic approaches used to discover the role of Lin-1 in the Ras-MAP kinase signaling pathway and describe new technologies that can be applied to the analyses of signaling pathways and transcription factor regulatory networks in C. elegans.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Canadian Inst Hlth Res, Ottawa, ON K1A 0W9, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Institute for Work & Health	Hart, AH (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, 600 Univ Ave,Room 983, Toronto, ON M5G 1X5, Canada.		Hart, Adam/C-1196-2011	Hart, Adam/0000-0001-8129-3877				AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BEN DY, 1991, GENE DEV, V5, P908; BENIAN GM, 1993, GENETICS, V134, P1097; Bochert MA, 1998, BIOCHEM BIOPH RES CO, V246, P176, DOI 10.1006/bbrc.1998.8560; BRETONGORIUS J, 1995, BLOOD, V85, P1805, DOI 10.1182/blood.V85.7.1805.bloodjournal8571805; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chang C, 1999, CANCER METAST REV, V18, P203, DOI 10.1023/A:1006317206443; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; FERGUSON EL, 1985, GENETICS, V110, P17; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gengyo-Ando K, 2000, BIOCHEM BIOPH RES CO, V269, P64, DOI 10.1006/bbrc.2000.2260; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; HART AH, 1995, ONCOGENE, V10, P1423; Hodgkin J, 1998, TRENDS GENET, V14, P352, DOI 10.1016/S0168-9525(98)01543-1; Jacobs D, 1998, GENETICS, V149, P1809; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; Kaji H, 2000, ELECTROPHORESIS, V21, P1755, DOI 10.1002/(SICI)1522-2683(20000501)21:9&lt;1755::AID-ELPS1755&gt;3.0.CO;2-S; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KOIZUMI S, 1990, ONCOGENE, V5, P675; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; Kuwabara PE, 1997, TRENDS GENET, V13, P455, DOI 10.1016/S0168-9525(97)01253-5; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LELIEVRECHOTTEAU A, 1994, FEBS LETT, V354, P62, DOI 10.1016/0014-5793(94)01091-9; Liu LX, 1999, GENOME RES, V9, P859, DOI 10.1101/gr.9.9.859; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Martinelli SD, 1997, SEMIN CELL DEV BIOL, V8, P459, DOI 10.1006/scdb.1997.0171; MAVROTHALASSITIS G, 1994, ONCOGENE, V9, P425; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MEYER D, 1993, MECH DEVELOP, V44, P109, DOI 10.1016/0925-4773(93)90061-2; Michaelis RC, 1998, AM J MED GENET, V76, P222, DOI 10.1002/(SICI)1096-8628(19980319)76:3<222::AID-AJMG5>3.0.CO;2-S; Miller DM, 1999, BIOTECHNIQUES, V26, P914, DOI 10.2144/99265rr01; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; Miyazaki Y, 1996, ONCOGENE, V13, P1721; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; PLASTERK RHA, 1992, BIOESSAYS, V14, P629, DOI 10.1002/bies.950140911; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Qi S., 1992, DNA Sequence, V3, P127, DOI 10.3109/10425179209034008; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Sarafi-Reinach TR, 2000, GENE DEV, V14, P2472, DOI 10.1101/gad.832300; SCHOLZ H, 1993, GENETICS, V135, P455; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; TYMMS MJ, 1994, MOL REPROD DEV, V39, P208, DOI 10.1002/mrd.1080390214; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Wood WB., 1988, NEMATODE CAENORHABDI; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zhou J, 1998, ONCOGENE, V17, P2719, DOI 10.1038/sj.onc.1202198; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	76	23	23	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6400	6408		10.1038/sj.onc.1204040	http://dx.doi.org/10.1038/sj.onc.1204040			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175356				2022-12-17	WOS:000166595000002
J	He, HL; McColl, K; Distelhorst, CW				He, HL; McColl, K; Distelhorst, CW			Involvement of c-Fos in signaling grp78 induction following ER calcium release	ONCOGENE			English	Article						GRP78; c-Fos; calcium; thapsigargin	ENDOPLASMIC-RETICULUM STRESS; PROGRAMMED CELL-DEATH; CA2+-ATPASE INHIBITOR THAPSIGARGIN; UNFOLDED PROTEIN RESPONSE; MOUSE LYMPHOMA-CELLS; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; GLUCOCORTICOID RECEPTOR; DNA-BINDING; IN-VIVO	Release of calcium from the endoplasmic reticulum (ER) signals an increase in transcription of both the early response gene, c-fos, and the late response gene, grp78. We hale used thapsigargin (TG), an ER calcium-ATPase pump inhibitor that induces calcium release from the ER, to investigate the possible involvement of c-Fos, a component of the AP-1 transcription factor, in grp78 induction. Tno cell lines with markedly different responses to TG treatment were employed: the WEHI7,2 mouse lymphoma line in which TG fails to induce grp78, and the MDA-MB-468 mammary epithelial line in which TG induces grp78. In WEHI7,2 cells, TG-induced calcium release triggers a rapid increase in c-fos mRNA, but the level of c-Fos protein decreases due to degradation by the multicatalytic proteasome, C-Fos DeltaC, a proteasome resistant c-Fos mutant with AP-1 activity similar to that of wild type c-Pos, restores grp78 induction in WEHI7.2 cells, detected by both Northern hybridization and a grp78 promoter-luciferase reporter assay. In MDA-MB-468 cells, TG-mediated calcium release induces a sustained elevation of c-Fos protein that precedes grp78 induction. A region of the grp78 promoter containing both ERSE and CORE regions, but missing TRE and CRE regions, is sufficient to mediate induction of reporter luciferase activity, Induction of this reporter was blocked by A-Fos, a dominant negative inhibitor of c-Fos, Also, the induction of grp78-luciferase reporter activity was inhibited by c-fos antisense mRNA. In summary, the findings indicate that c-Fos is involved in signaling grp78 induction following TG treatment, and that grp78 induction is inhibited by proteasome-mediated c-Fos degradation.	Case Western Reserve Univ, Div Hematol Oncol, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, Dept Med, BRB 329,10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA079806] Funding Source: NIH RePORTER; NCI NIH HHS [CA79806] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chen LY, 2000, J CELL BIOCHEM, V78, P404, DOI 10.1002/1097-4644(20000901)78:3<404::AID-JCB6>3.0.CO;2-8; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Duval DL, 1997, MOL ENDOCRINOL, V11, P1814, DOI 10.1210/me.11.12.1814; Foti DM, 1999, J BIOL CHEM, V274, P30402, DOI 10.1074/jbc.274.43.30402; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Ivanov VN, 1997, J BIOL CHEM, V272, P8558; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kaina B, 1997, CANCER RES, V57, P2721; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LI WWF, 1993, J BIOL CHEM, V268, P12003; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; LODISH HF, 1992, J BIOL CHEM, V267, P12753; McColl KS, 1998, MOL CELL ENDOCRINOL, V139, P229, DOI 10.1016/S0303-7207(98)00051-3; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Preston GA, 1996, MOL CELL BIOL, V16, P211; Qi XM, 1997, ONCOGENE, V15, P2849, DOI 10.1038/sj.onc.1201463; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Tabuchi A, 1996, J BIOL CHEM, V271, P31061, DOI 10.1074/jbc.271.49.31061; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	57	23	23	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5936	5943		10.1038/sj.onc.1203994	http://dx.doi.org/10.1038/sj.onc.1203994			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127825				2022-12-17	WOS:000165563100013
J	Komatsu, K; Wharton, W; Hang, HY; Wu, C; Singh, S; Lieberman, HB; Pledger, WJ; Wang, HG				Komatsu, K; Wharton, W; Hang, HY; Wu, C; Singh, S; Lieberman, HB; Pledger, WJ; Wang, HG			PCNA interacts with hHus1/hRad9 in response to DNA damage and replication inhibition	ONCOGENE			English	Article						hRad9; hHus1; PCNA; DNA damage; cell-cycle checkpoints	CELL NUCLEAR ANTIGEN; CHECKPOINT CONTROL GENE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; POLYMERASE-DELTA; HUMAN HOMOLOG; PROTEIN-PCNA; CYCLE; REPAIR; RAD1	The hHus1 and several hRad proteins are involved in the control of DNA integrity checkpoints, although the mechanisms underlying these processes are unknown. Using a yeast two-hybrid system to detect protein-protein interactions, we found that human proliferating cell nuclear antigen (PCNA), a protein known to function in both DNA replication and repair, interacts with the human checkpoint-related protein Hus1 (hHus1). In human skin fibroblast cells, exposure to ionizing radiation of hydroxyurea triggers translocation of hHus1 from the cytosol to the nucleus, where it associates with PCNA as well as another checkpoint protein, hRad9. This nuclear translocation and the complex formation or hHus1 with PCNA and hRad9 correlate closely with changes in cell cycle distribution in response to radiation exposure. These results suggest that this multi-protein complex may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.	H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA; Imgenex Corp, San Diego, CA 92121 USA	Columbia University	Wang, HG (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Wu, Chun-Fang/0000-0002-4973-2021	NATIONAL CANCER INSTITUTE [R01CA072694, R01CA082197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052493] Funding Source: NIH RePORTER; NCI NIH HHS [CA72694, CA82197] Funding Source: Medline; NIGMS NIH HHS [GM52493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Kondo T, 1999, MOL CELL BIOL, V19, P1136; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kostrub CF, 1997, MOL GEN GENET, V254, P389, DOI 10.1007/PL00008606; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Nojima H, 1997, Hum Cell, V10, P221; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tsurimoto Toshiki, 1999, Frontiers in Bioscience, V4, pd849, DOI 10.2741/Tsurimoto; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x	35	23	25	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5291	5297		10.1038/sj.onc.1203901	http://dx.doi.org/10.1038/sj.onc.1203901			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077446				2022-12-17	WOS:000165059700010
J	Petrocelli, T; Slingerland, J				Petrocelli, T; Slingerland, J			UVB induced cell cycle checkpoints in an early stage human melanoma line, WM35	ONCOGENE			English	Article						UVB; cell cycle; checkpoint; DNA damage; Cdc25A	PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3-BETA; DNA-DAMAGE CHECKPOINT; D-DEPENDENT KINASE; RETINOBLASTOMA PROTEIN; TYROSINE PHOSPHORYLATION; FISSION YEAST; INHIBITORY PHOSPHORYLATION; ULTRAVIOLET-IRRADIATION; PHASE PROGRESSION	The activation of cell cycle checkpoints in response to genotoxic stressors is essential for the maintenance of genomic integrity. Although most prior studies of cell cycle effects of UV irradiation have used UVC, this UV range does not penetrate the earth's atmosphere. Thus, we have investigated the mechanisms of ultraviolet B (UVB) irradiation-induced cell cycle arrest in biologically relevant target cell type, the early stage human melanoma cell line, WM35. Irradiation of WM35 cells with UVB resulted in arrests throughout the cell cycle: at the G1/S transition, in S phase and in G2. G1 arrest was accompanied by increased association of p21 with cyclin E/cdk2 and cyclin A/cdk2, increased binding of p27 to cyclin E/cdk2 and inhibition of these Kinases, A loss of Cdc25A expression was associated with an increased inhibitory phosphotyrosine content of cyclin and cyclin A-associated cdk2 and may also contribute to G1 arrest following UVB irradiation. The association of Cdc25A with 14-3-3 was increased by UVB, Reduced cyclin D1 protein and increased binding of p21 and p27 to cyclin D1/cdk4 complexes were also observed. The loss of cyclin D1 could not be attributed to inhibition of either MAPK or PI3K/PKB pathways, since both were activated by UVB. Cdc25B levels fell and the remaining protein showed an increased association with 14-3-3 in response to UVB, Losses in cyclin B1 expression and an increased binding of p21 to cyclin B1/cdk1 complexes also contributed to inhibition of this kinase activity, and G2/M arrest.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto Sunnybrook Reg Canc Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Slingerland, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto Sunnybrook Reg Canc Ctr, Div Canc Biol Res, Res Bldg,S-218,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARKER D, 1995, CANCER RES, V55, P4041; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EPSTEIN JH, 1983, J AM ACAD DERMATOL, V9, P487, DOI 10.1016/S0190-9622(83)70160-X; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Florenes VA, 1996, ONCOGENE, V13, P2447; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERZINGER T, 1995, ONCOGENE, V11, P2151; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO J, 1993, GENE DEV, V7, P331; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAU CC, 1994, P NATL ACAD SCI USA, V79, P7491; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LIU M, 1995, ONCOGENE, V10, P1955; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pedley J, 1996, ONCOGENE, V13, P1335; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petrocelli T, 1996, ONCOGENE, V12, P1387; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; REED SI, 1994, J CELL SCI, P69; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rigel DS, 1996, J AM ACAD DERMATOL, V35, P1012, DOI 10.1016/S0190-9622(96)90139-5; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XQ, 1994, EXP CELL RES, V212, P176, DOI 10.1006/excr.1994.1133; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	82	23	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2000	19	39					4480	4490		10.1038/sj.onc.1203808	http://dx.doi.org/10.1038/sj.onc.1203808			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002421				2022-12-17	WOS:000089236800005
J	Renshaw, MW; Lewis, JM; Schwartz, MA				Renshaw, MW; Lewis, JM; Schwartz, MA			The c-Abl tyrosine kinase contributes to the transient activation of MAP kinase in cells plated on fibronectin	ONCOGENE			English	Article						Erk2; Ras; signal transduction; extracellular matrix; cell adhesion	FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; GROWTH-FACTOR; V-ABL; SHC; RAS; MIGRATION; INTEGRINS; MOTILITY	Previous work showed that integrin stimulation triggers activation of the c-Abl tyrosine kinase and its transient localization to focal adhesions. We now report that plating cells on fibronectin triggers association of Grb2 with c-Abl, suggesting possible involvement of c-Abl with integrin activation of the MAP kinase pathway. Expression of a kinase-defective c-Abl specifically inhibited the transient induction of Erk2 activity following cell adhesion, Together with the known ability of activated, oncogenic forms of c-Abl to activate Ras and the MAP kinase pathway, these data suggest that c-myc contributes to the integrin induction of MAP kinase activity.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schwartz, MA (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Lewis, Jean/0000-0001-6978-5166; schwartz, martin/0000-0002-2071-1243	NCI NIH HHS [R29 CA74230] Funding Source: Medline; NHLBI NIH HHS [P01 HL57900] Funding Source: Medline; NIGMS NIH HHS [F32 GM18298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074230] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agami R, 1999, NATURE, V399, P809; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; CHANG JH, 1995, METHOD ENZYMOL, V254, P430; CHEN QM, 1994, J BIOL CHEM, V269, P26602; GOGA A, 1995, CELL, V82, P891; Gong JG, 1999, NATURE, V399, P806; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; KAMASHITA I, 1989, ANAL BIOCHEM, V183, P139; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lin TH, 1997, J BIOL CHEM, V272, P8849; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Raffel GD, 1996, J BIOL CHEM, V271, P4640; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZHAO X, 1999, J BIOL CHEM, V272, P18141	30	23	23	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 29	2000	19	28					3216	3219		10.1038/sj.onc.1203667	http://dx.doi.org/10.1038/sj.onc.1203667			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918577				2022-12-17	WOS:000088019200011
J	Garcia-Cuellar, MP; Schreiner, SA; Birke, M; Hamacher, M; Fey, GH; Slany, RK				Garcia-Cuellar, MP; Schreiner, SA; Birke, M; Hamacher, M; Fey, GH; Slany, RK			ENL, the MLL fusion partner in t(11;19), binds to the c-Abl interactor protein 1 (ABI1) that is fused to MLL in t(10;11)(+)	ONCOGENE			English	Article						leukemia; MLL; translocation; ENL; ABI1	ACUTE MYELOID-LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; TRANSCRIPTION FACTORS; 11Q23 TRANSLOCATIONS; DROSOPHILA-TRITHORAX; MUTANT MICE; HRX-ENL; GENE; CLONING; ALL-1	Translocations of the chromosomal locus 11q23 that disrupt the MLL gene (alternatively ALL-I or HRX) are frequently found in children's leukemias. These events fuse the MLL amino terminus in frame with a variety of unrelated proteins, Up to date, 16 different fusion partners have been characterized and more are likely to exist. No general unifying property could yet be detected amongst these proteins. We show here that the frequent MLL fusion partner ENL at 19p13.1 interacts with the human homologue of the mouse Abl-Interactor 1 (ABI1) protein. ABI1 in turn, is fused to MLL in the t(10:ll)(p11.2;q23) translocation, ABI1 was identified as an ENL binding protein by a yeast two-hybrid screen. The interaction of ENL and ABI1 could be verified in vitro by far-Western blot assays and GST-pulldown studies as well as in vivo by co-immunoprecipitation experiments. A structure-function analysis identified an internal region of ENL and a composite motif of ABI1 including an SH3 domain as mutual binding partners. These data introduce novel aspects that might contribute to the understanding of the process of leukemogenesis by MLL fusion proteins.	Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Staudtstr 5, D-91058 Erlangen, Germany.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERNARD OA, 1994, ONCOGENE, V9, P1039; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; James P, 1996, GENETICS, V144, P1425; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; PRASAD R, 1993, CANCER RES, V53, P5624; Rogaia D, 1997, CANCER RES, V57, P799; RUBNITZ JE, 1994, BLOOD, V84, P1747; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Taki T, 1998, BLOOD, V92, P1125, DOI 10.1182/blood.V92.4.1125.416k40_1125_1130; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735; Ziemnicka-Kotula D, 1998, J BIOL CHEM, V273, P13681, DOI 10.1074/jbc.273.22.13681	38	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1744	1751		10.1038/sj.onc.1203506	http://dx.doi.org/10.1038/sj.onc.1203506			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777208				2022-12-17	WOS:000086292500002
J	Machida, K; Matsuda, S; Yamaki, K; Senga, T; Thant, AA; Kurata, H; Miyazaki, K; Hayashi, K; Okuda, T; Kitamura, T; Hayakawa, T; Hamaguchi, M				Machida, K; Matsuda, S; Yamaki, K; Senga, T; Thant, AA; Kurata, H; Miyazaki, K; Hayashi, K; Okuda, T; Kitamura, T; Hayakawa, T; Hamaguchi, M			v-Src suppresses SHPS-1 expression via the Ras-MAP kinase pathway to promote the oncogenic growth of cells	ONCOGENE			English	Article						SHPS-1; SIRP; v-Src; transformation; tumor suppressor; signal transduction	CHICKEN-EMBRYO FIBROBLASTS; MAMMARY EPITHELIAL-CELLS; PLASMA-MEMBRANE MATRIX; MORPHOLOGICAL TRANSFORMATION; TYROSINE PHOSPHORYLATION; C-RAS; PROTEIN; ADHESION; P60SRC; ASSOCIATION	We investigated the effect of cell transformation by v-src on the expression and tyrosine phosphorylation of SHPS-1, a putative docking protein for SHP-1 and SHP-2. We found that transformation by v-sle virtually inhibited the SHPS-1 expression at mRNA level. While nontransforming Src kinases including c-Src, nonmyristoylated forms of v-Src had no inhibitory effect on SHPS-1 expression, transforming Src kinases including wild-type v-Src and chimeric mutant of c-Src bearing v-Src SH3 substantially suppressed the SHPS-1 expression. In cells expressing temperature sensitive mutant of v-Src, suppression of the SHPS-1 expression was temperature-dependent. In contrast, tyrosine phosphorylation of SHPS-1 was rather activated in cells expressing c-Src or nonmyristoylated forms of v-Src, SHPS-1 expression in SR3Y1 was restored by treatment with herbimycin A, a potent inhibitor of tyrosine kinase, or by the expression of dominant negative form of Ras. Contrary, active form of Mek1 markedly suppressed SHPS-1 expression. Finally, overexpression of SHPS-1 in SR3Y1 led to the drastic reduction of anchorage independent growth of the cells. Taken together, our results suggest that the suppression of SHPS-1 expression is a pivotal event for cell transformation by v-src, and the Ras-MAP kinase cascade plays a critical role in the suppression.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med 2, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Surg 1, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, Tokyo 1080071, Japan	Nagoya University; Nagoya University; Nagoya University; University of Tokyo	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Kitamura, Toshio/AAA-2071-2021					Comu S, 1997, J NEUROSCI, V17, P8702; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CROW DS, 1992, ONCOGENE, V7, P999; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GOTOH Y, 1994, ONCOGENE, V9, P1891; HAMAGUCHI M, 1989, ONCOGENE RES, V4, P29; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; KOZUMA LM, 1990, MOL CELL BIOL, V10, P837; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; Lin XY, 1997, CANCER RES, V57, P2304; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; Miyazaki K, 1999, BIOCHEM BIOPH RES CO, V263, P759, DOI 10.1006/bbrc.1999.1464; OZAKI T, 1994, CANCER RES, V54, P646; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; Sano S, 1997, FEBS LETT, V411, P327, DOI 10.1016/S0014-5793(97)00724-2; Senga T, 2000, ONCOGENE, V19, P273, DOI 10.1038/sj.onc.1203296; Shibata K, 1998, CANCER RES, V58, P900; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; Thant AA, 1997, FEBS LETT, V406, P28, DOI 10.1016/S0014-5793(97)00230-5; ZHANG M, 1995, CANCER RES, V55, P2537; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	40	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1710	1718		10.1038/sj.onc.1203497	http://dx.doi.org/10.1038/sj.onc.1203497			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763828				2022-12-17	WOS:000086083800011
J	Liu, JB; Estes, ML; Drazba, JA; Liu, HY; Prayson, R; Kondo, S; Jacobs, BS; Barnett, GH; Barna, BP				Liu, JB; Estes, ML; Drazba, JA; Liu, HY; Prayson, R; Kondo, S; Jacobs, BS; Barnett, GH; Barna, BP			Anti-sense oligonucleotide of p21(waf1/cip1) prevents Interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells	ONCOGENE			English	Article						antisense oligonucleotide; astrocytoma; cytokine; p21(waf1/cip1)	DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR; CYCLE ARREST; CDK INHIBITOR; DNA-SYNTHESIS; MICE LACKING; TGF-BETA; EXPRESSION; PROLIFERATION; P21	Elevation of the cyclin-dependent kinase (cdk) inhibitor, p27(kip1) is necessary for Interleukin (IL)-4-mediated growth arrest of human low grade astrocytoma (RTLGA) cells and occurs at 24 h of treatment. Pathways involved in IL-4 alteration of p27(kip1) are unknown, however. Here we investigated whether other cdk inhibitors contributed to the actions of IL-4 on RTLGA cells. By 12 h of IL-4 treatment, both cdk4 and cdk2 kinase activities against the retinoblastoma protein (pRb) were reduced and nuclear entry of pRb was prohibited. Twelve-hour cdk complexes contained elevated p21(waf1/cip1) but not p27(kip1), p15(ink4B) or p16(ink4A), IL-4 increased p21(waf1/cip1) but not p27(kip1) mRNA levels, and stimulated luciferase activity of a p21(waf1/cip1) promoter-luciferase reporter. In p53-mutant WITG3 cells, IL-4 did not alter p21(waf1/cip1) mRNA and promoter-luciferase activity or p27(kip1) protein, suggesting a need for functional p53. STAT6 phosphorylation by IL-4, however, occurred in both p53-mutant WITG3 and p53-functional RTLGA cells. Pre-treatment of RTLGA with anti-sense but not missense p21(waf1/cip1) oligonucleotide prior to IL-4: (a) restored cdk activities; (b) reduced cdk4-associated p21(waf1/cip1) levels; (c) prevented p27(kip1) elevation; and (d) reversed growth arrest. These results are the first to suggest that p21(waf1/cip1) is essential for IL-4-mediated elevation of p27(kip1) and growth arrest of astrocytoma cells.	Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res 653, Cleveland, OH 44109 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pathol Anat, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurol Surg, Cleveland, OH 44195 USA	MetroHealth System; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Barna, BP (corresponding author), Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res 653, 2500 MetroHlth Dr, Cleveland, OH 44109 USA.				NINDS NIH HHS [R01NS-33932] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033932] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; BARNA BP, 1995, J NEUROIMMUNOL, V60, P75, DOI 10.1016/0165-5728(95)00055-7; Benedetti S, 1999, CANCER RES, V59, P645; Blanchard DA, 1997, J IMMUNOL, V158, P3054; Brodie C, 1998, J NEUROIMMUNOL, V81, P20, DOI 10.1016/S0165-5728(97)00154-9; BRODIE C, 1994, J NEUROIMMUNOL, V55, P91, DOI 10.1016/0165-5728(94)90150-3; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DAMELL JE, 1997, SCIENCE, V277, P1630; DRAETTA G, 1996, TOPICS BIOL, P241; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EL DW, 1993, CELL, V75, P817; ELDEIRY WS, 1995, CANCER RES, V55, P2910; ESTES ML, 1993, AM J PATHOL, V143, P337; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; HALLEVY O, 1995, SCIENCE, V267, P1018; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1997, CANCER SURV, V29, P91; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEM SE, 1992, SCIENCE, V256, P827; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Koff A, 1995, Prog Cell Cycle Res, V1, P141; Kondo S, 1996, ONCOGENE, V13, P1279; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; Kwon TK, 1997, J IMMUNOL, V158, P5642; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu JB, 1997, J IMMUNOL, V159, P812; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LOIS AF, 1995, CANCER RES, V55, P4010; Lu BF, 1997, J IMMUNOL, V159, P1255; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; MITCHELL LC, 1989, J IMMUNOL, V142, P1548; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Noffz G, 1998, J IMMUNOL, V160, P345; OConnor PM, 1997, CANCER RES, V57, P4285; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Paul WE, 1997, CIBA F SYMP, V204, P208; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Puri R K, 1995, Cancer Treat Res, V80, P143; REIFENBERGER G, 1993, CANCER RES, V53, P2736; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sampson JH, 1997, NEUROSURGERY, V41, P1365, DOI 10.1097/00006123-199712000-00024; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; SUZUMURA A, 1994, J NEUROIMMUNOL, V53, P209, DOI 10.1016/0165-5728(94)90031-0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1997, J MOL MED-JMM, V75, P317, DOI 10.1007/s001090050117; Tikoo R, 1997, J BIOL CHEM, V272, P442; Toms SA, 1998, J NEUROSURG, V88, P884, DOI 10.3171/jns.1998.88.5.0884; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WALDMAN T, 1995, CANCER RES, V55, P5187; Wei MX, 1998, J NEUROVIROL, V4, P237, DOI 10.3109/13550289809114523; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng YX, 1996, ONCOGENE, V12, P1557	72	23	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2000	19	5					661	669		10.1038/sj.onc.1203373	http://dx.doi.org/10.1038/sj.onc.1203373			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698511				2022-12-17	WOS:000085192000008
J	Micouin, A; Wietzerbin, J; Steunou, V; Martyre, MC				Micouin, A; Wietzerbin, J; Steunou, V; Martyre, MC			p95(vav) associates with the type I interferon (IFN) receptor and contributes to the antiproliferative effect of IFN-alpha in megakaryocytic cell lines	ONCOGENE			English	Article						vav; type IIFN receptor; megakaryocytic cells; IFN antiproliferative effect	VAV PROTOONCOGENE PRODUCT; PROTEIN-TYROSINE KINASE; HEMATOPOIETIC-CELLS; T-CELL; MYELOID METAPLASIA; BETA RECEPTOR; STEEL FACTOR; B-CELLS; PHOSPHORYLATION; EXPRESSION	The vav proto-oncogene product is a 95 kDa protein predominantly expressed in hematopoietic cells. Vav presents a wide range of functional domains, including structural domains known to be involved in signal transduction, Triggering of various cytokine receptors among which type I interferon receptor induces a rapid and transient tyrosine phosphorylation of p95(vav). Nevertheless, the biological functions of p95(vav) are still unclear, This report is the first documentation on the physical association of p95(vav) With both alpha and beta type I interferon receptor chains, as demonstrated by co-immunoprecipitation and Western blot analysis in megakaryocytic cells (Dami and UT7), This interaction is increased by interferon-alpha/beta stimulation, Moreover, p95(vav) phosphorylated subsequently to type I interferon treatment, is translocated in the nucleus; a concomitant increase of its association with the regulatory subunit of the nuclear DNA-dependent protein kinase, KU-70 is observed in the nucleus. To determine whether p95(vav) participates in the biological response to type I interferons, we studied the effects of non modified Vav oligodeoxynucleotides on the antiproliferative effect of interferon-alpha on megakaryocytic cells, By this oligodeoxynucleotide strategy, we show that p95(vav) contributes greatly to the cell proliferation inhibition induced by type I IFN.	Inst Curie, U365 INSERM, Sect Rech, F-75231 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Micouin, A (corresponding author), Inst Curie, U365 INSERM, Sect Rech, 26 Rue Ulm, F-75231 Paris, France.							ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CARLOSTELLA C, 1987, BLOOD, V70, P1014; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; COHEN B, 1995, MOL CELL BIOL, V15, P4208; COLAMONICI OR, 1994, J BIOL CHEM, V269, P5660; Croze E, 1996, J BIOL CHEM, V271, P33165, DOI 10.1074/jbc.271.52.33165; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1998, J BIOL CHEM, V273, P3144, DOI 10.1074/jbc.273.6.3144; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; GREENBERG SM, 1988, BLOOD, V72, P1968; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HU P, 1993, BIOESSAYS, V15, P179, DOI 10.1002/bies.950150306; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KATZAV S, 1995, CRIT REV ONCOGEN, V6, P82; KOMATSU N, 1991, CANCER RES, V51, P341; Lewerenz M, 1998, J MOL BIOL, V282, P585, DOI 10.1006/jmbi.1998.2026; Luger SM, 1996, BLOOD, V87, P1326, DOI 10.1182/blood.V87.4.1326.bloodjournal8741326; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MARTYRE MC, 1994, BRIT J HAEMATOL, V86, P244, DOI 10.1111/j.1365-2141.1994.tb04722.x; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; Miyakawa Y, 1997, BLOOD, V89, P2789, DOI 10.1182/blood.V89.8.2789; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; REEVES WH, 1994, MANUAL BIOL MARKERS; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; Romero F, 1996, MOL CELL BIOL, V16, P37; Romero F, 1998, J BIOL CHEM, V273, P5923, DOI 10.1074/jbc.273.10.5923; SACCHI S, 1995, LEUKEMIA LYMPHOMA, V19, P13, DOI 10.3109/10428199509059658; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Uddin S, 1997, FEBS LETT, V403, P31, DOI 10.1016/S0014-5793(97)00023-9; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Williams EA, 1997, J CHEM TECHNOL BIOT, V70, P9; WU J, 1995, MOL CELL BIOL, V15, P4337; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	43	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					387	394		10.1038/sj.onc.1203314	http://dx.doi.org/10.1038/sj.onc.1203314			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656686				2022-12-17	WOS:000084873700009
J	Noda, A; Toma-Aiba, Y; Fujiwara, Y				Noda, A; Toma-Aiba, Y; Fujiwara, Y			A unique, short sequence determines p53 gene basal and UV-inducible expression in normal human cells	ONCOGENE			English	Article						p53; UV; X-ray; stress response; transcription; promoter	DEPENDENT PROTEIN-KINASE; CELLULAR TUMOR-ANTIGEN; KAPPA-B ACTIVATION; RNA POLYMERASE-II; DNA-DAMAGE; NUCLEAR ACCUMULATION; IONIZING-RADIATION; GLIOBLASTOMA CELLS; TRANSCRIPTION; GROWTH	The p53 tumor suppressor protein plays a central role in the cellular defence against agents which cause genetic damage. The induction and activation of p53 upon stress has been shown at post-transcription level by multiple mechanisms, while the regulatory role of p53 gene transcription is still poorly understood. Here we show that the causative mechanisms underlying this activation are attributed in part to the promoter function of p53, In various normal human cells, p53 gene expression is induced transcriptionally by ultraviolet (UV) but not X-ray irradiation. We determined that, by p53 promoter dissection, the 21 bp element (PE21) responsible for this UV activation resides adjacent to, and upstream to the putative NF kappa B binding site. Moreover, the PE21 sequence,vas found to be a primary determinant for human p53 gene basal expression carrying bi-directional transcriptional initiation activity, which controls the initiation of RNA synthesis about 50 bases downstream, indicating that the sequence plays a critical role in both basal and inducible transcription. Finally, we detected the putative PE21 binding factor(s) in nuclear extracts from non-irradiated and irradiated cells, Since the PE21 sequence does not show any homologies to the conventional TATA or GC box, or to an 'initiatior', all of which determine the initiation site for transcription, the PE21 sequence appears to be a new class in eukaryotic promoter elements. Our results indicate that the mechanism of PE21-directed p53 mRNA transcription has an important role in the cellular stress response as well as tumor suppression.	Kobe Univ, Sch Med, Dept Radiat Biophys & Genet, Chuo Ku, Kobe, Hyogo 6500017, Japan; Meiji Cell Technol Ctr, Odawara 250, Japan	Kobe University; Meiji Holdings Co., Ltd.	Noda, A (corresponding author), Kobe Univ, Sch Med, Dept Radiat Biophys & Genet, Chuo Ku, 7-5-1 Kusunokicho, Kobe, Hyogo 6500017, Japan.			Noda, Asao/0000-0002-9029-9813				Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHODOSH LA, 1991, CURRENT PROTOCOLS MO, V2; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FORNACE AJ, 1982, MUTAT RES, V94, P263, DOI 10.1016/0027-5107(82)90290-1; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FRITSCHE M, 1993, ONCOGENE, V8, P307; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JAYARAMAN L, 1997, GENE DEV, V11, P588; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MALZMAN W, 1984, MOL CELL BIOL, V4, P1689; MCKNIGHT SL, 1984, CELL, V37, P253, DOI 10.1016/0092-8674(84)90321-0; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MONSNER J, 1995, EMBO J, V14, P4442; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PORTER MB, 1990, J CELL PHYSIOL, V142, P425, DOI 10.1002/jcp.1041420228; Rathmell WK, 1997, CANCER RES, V57, P68; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Sambrook J, 1989, MOL CLONING LAB MANU; SCHMID P, 1991, DEVELOPMENT, V113, P857; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; SUN XG, 1995, MOL CELL BIOL, V15, P4489; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU HY, 1994, J BIOL CHEM, V269, P20067; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; XU LC, 1991, NUCLEIC ACIDS RES, V19, P6699, DOI 10.1093/nar/19.24.6699; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	56	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					21	31		10.1038/sj.onc.1203230	http://dx.doi.org/10.1038/sj.onc.1203230			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644976				2022-12-17	WOS:000084844300003
J	Na, SQ; Li, BY; Grewal, IS; Enslen, H; Davis, RJ; Hanke, JH; Flavell, RA				Na, SQ; Li, BY; Grewal, IS; Enslen, H; Davis, RJ; Hanke, JH; Flavell, RA			Expression of activated CDC42 induces T cell apoptosis in thymus and peripheral lymph organs via different pathways	ONCOGENE			English	Article						apoptosis; thymus; T cells; CDC42; Fas; Fas ligand	PROTEIN-KINASE ACTIVATION; NEGATIVE SELECTION; SIGNALING PATHWAY; TRANSGENIC MICE; GTPASE CDC42; FAS LIGAND; IN-VIVO; LYMPHOCYTES; RHO; DEATH	CDC42, a Ras-related small GTP binding protein, is involved in diverse cellular functions in lymphocytes. We generated transgenic mice expressing constitutively active murine CDC42 (Q61L) under the control of the human CD2 promoter. Transgenic mice showed smaller thymi with a dramatic reduction of CD4(+)CD8(+), CD4(+) and CD8(+) thymocytes and with increase of CD4(-)CD8(-) thymocytes at CD25(-)CD44(+) and CD25(+) stage. A high percentage of the transgenic thymocytes were apoptotic, explaining the reduction of cellularity and size of the thymus, Mature T cells (TCR alpha beta(+)) in peripheral lymph organs, spleen and lymph node, were also dramatically reduced, and exhibited massive apoptosis, Expression of Fas and Fas ligand on both thymocytes and peripheral T cells was upregulated in transgenic mice, but the increased apoptosis in the thymus was independent of Fas (CD95), whereas peripheral spleen and lymph node T cell apoptosis was Fas dependent. Thus, activated CDC42 triggers distinct apoptotic pathways in thymocytes and peripheral T cells.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Pfizer; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Flavell, RA (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, POB 20811, New Haven, CT 06520 USA.		Enslen, Hervé/M-3400-2017; Enslen, Hervé/AAH-4492-2021	Enslen, Hervé/0000-0001-9741-5293; Enslen, Hervé/0000-0001-9741-5293; Grewal, Iqbal S/0000-0002-4775-055X	NCI NIH HHS [CA72009, CA65861] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072009, R01CA065861] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; ALAN A, 1997, J EXP MED, V186, P1503; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Avraham A, 1998, EUR J IMMUNOL, V28, P2320, DOI 10.1002/(SICI)1521-4141(199808)28:08<2320::AID-IMMU2320>3.0.CO;2-K; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Faris M, 1998, J IMMUNOL, V160, P134; Galandrini R, 1997, IMMUNITY, V7, P163, DOI 10.1016/S1074-7613(00)80519-1; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GODFREY DI, 1993, J IMMUNOL, V150, P4244; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOGAN B, 1986, MANIPULATING MOUSE E, P217; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; Kaga S, 1998, J IMMUNOL, V160, P4182; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; LINETTE GP, 1994, CURR OPIN CELL BIOL, V6, P809, DOI 10.1016/0955-0674(94)90049-3; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mehal WZ, 1998, J IMMUNOL, V161, P1686; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moorman JP, 1996, J IMMUNOL, V156, P4146; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; vonFreedenJeffry U, 1997, IMMUNITY, V7, P147, DOI 10.1016/S1074-7613(00)80517-8; WEBB SR, 1994, J IMMUNOL, V152, P586; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	49	23	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7966	7974		10.1038/sj.onc.1203122	http://dx.doi.org/10.1038/sj.onc.1203122			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637507				2022-12-17	WOS:000084634600005
J	Dermott, JM; Reddy, MVR; Onesime, D; Reddy, EP; Dhanasekaran, N				Dermott, JM; Reddy, MVR; Onesime, D; Reddy, EP; Dhanasekaran, N			Oncogenic mutant of G alpha(12) stimulates cell proliferation through cycloxygenase-2 signaling pathway	ONCOGENE			English	Article						G protein; G alpha(12); oncogene; transformation; signal transduction; COX-2, celebrex, celecoxib	CYTOSOLIC PHOSPHOLIPASE A(2); G-PROTEINS; COOPERATIVE TRANSFORMATION; NIH3T3 CELLS; 3T3 CELLS; EXPRESSION; KINASE; CYCLOOXYGENASE-2; GENE; FIBROBLASTS	Expression of the GTPase-deficient, activated mutant alpha-subunit of the heterotrimeric G protein G12 (G alpha(12)QL) leads to the neoplastic transformation of fibroblast cell lines. The mitogenic pathway regulated by G alpha(12)QL includes an extensive signaling network involving several small GTPases and various kinases. In addition, G alpha(12)QL has been shown to potentiate the serum-induced phospholipase-A(2) activity in NIH3T3 cells. In the present study, we demonstrate that cycloxygenase-2 (COX-2) pathway is involved in the mitogenic pathway activated by G alpha(12)QL Expression of G alpha(12)QL and not G alpha(13)QL, stimulates the serum-induced release of arachidonic acid in NIH3T3 cells. Furthermore, expression of G alpha(12)QL or the stimulation of wild-type G alpha(12) induces the expression of COX-2. Our results also indicate that the COX-2 inhibitor acutely disrupts the DNA-synthesis stimulated by G alpha(12)QL in NIH3T3 cells. These studies, for the first time, identify the crucial role of COX-2 in Gait-mediated regulation of cell proliferation and suggest a role for prostaglandin-derived autocrine loop in G alpha(12)-mediated signaling pathways.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011		NIGMS NIH HHS [GM 49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Dennis M, 1997, CEREBROVASC DIS, V7, P22, DOI 10.1159/000108159; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gebauer G, 1999, J CELL BIOCHEM, V75, P547, DOI 10.1002/(SICI)1097-4644(19991215)75:4<547::AID-JCB1>3.3.CO;2-X; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; JIANG H, 1993, FEBS LETT, V3, P319; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; XU N, 1993, P NATL ACAD SCI USA, V90, P11354; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Zhang YH, 1996, ONCOGENE, V12, P2377	30	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7185	7189		10.1038/sj.onc.1203345	http://dx.doi.org/10.1038/sj.onc.1203345			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602471				2022-12-17	WOS:000084119400001
J	Kiermaier, A; Gawn, JM; Desbarats, L; Saffrich, R; Ansorge, W; Farrell, PJ; Eilers, M; Packham, G				Kiermaier, A; Gawn, JM; Desbarats, L; Saffrich, R; Ansorge, W; Farrell, PJ; Eilers, M; Packham, G			DNA binding of USF is required for specific E-box dependent gene activation in vivo	ONCOGENE			English	Article						Myc; Max; USF; prothymosin-alpha; IgH enhancer; EBV	HEAVY-CHAIN ENHANCER; C-MYC; TRANSCRIPTION FACTOR; COOPERATIVE INTERACTION; HISTONE DEACETYLASE; TARGET GENE; CELL-GROWTH; PROTEINS; TRANSFORMATION; RECOGNITION	Although USF-1 and -2 are the major proteins that bind to Myc-regulated E-box (CACGTG) elements in many cells, there is no clear role for USF during Myc-dependent gene regulation. Using dominant negative alleles of USF-1 we now show that DNA binding by USF at a MSc-regulated E-box limits the ability of another E-box binding factor, TFE-3, to activate a target gene of Myc in vivo and to stimulate S phase entry in resting fibroblasts, Similarly, dominant negative alleles of USF-1 relieve the restriction that presents activation of the IgH enhancer by TFE-3 in non B-cells, DNA binding activity of USF complexes is abundant in primary human B-cells and is significantly downregulated during B-cell immortalization, Re-expression of USF-1 in immortalized B-cells retards proliferation. Our data establish an essential role for USF in restricting E-box dependent gene activation in vivo and suggest that this control is relaxed during cellular immortalization.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med Microbiol, London W2 1PG, England; EMBL, Biochem Instrumentat Programme, D-69117 Heidelberg, Germany; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ Marburg, Inst Mol Biol & Tumour Res, D-35033 Marburg, Germany	Imperial College London; European Molecular Biology Laboratory (EMBL); Imperial College London; Ludwig Institute for Cancer Research; Philipps University Marburg	Packham, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med Microbiol, St Marys Campus,Norfolk Pl, London W2 1PG, England.		Ansorge, Wilhelm/AAN-8780-2020	Saffrich, Rainer/0000-0002-0547-4550; Eilers, Martin/0000-0002-0376-6533				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Aperlo C, 1996, EUR J BIOCHEM, V241, P249, DOI 10.1111/j.1432-1033.1996.0249t.x; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Berger A, 1998, BBA-LIPID LIPID MET, V1390, P225, DOI 10.1016/S0005-2760(97)00180-X; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; DAMARE ARF, 1994, EMBO J, V13, P180; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Galibert MD, 1997, J IMMUNOL, V159, P6176; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MAEKAWA T, 1991, NUCLEIC ACIDS RES, V19, P4689, DOI 10.1093/nar/19.17.4689; Merrell K, 1997, MOL CELL BIOL, V17, P3335, DOI 10.1128/MCB.17.6.3335; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sinclair Alison J., 1995, V7, P89; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; TOBIAS KE, 1995, ONCOGENE, V11, P1721; Tsuneoka M, 1997, ONCOGENE, V14, P2301, DOI 10.1038/sj.onc.1201067; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803	34	23	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7200	7211		10.1038/sj.onc.1203166	http://dx.doi.org/10.1038/sj.onc.1203166			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602473				2022-12-17	WOS:000084119400003
J	Chen, G; Templeton, D; Suttle, DP; Stacey, DW				Chen, G; Templeton, D; Suttle, DP; Stacey, DW			Ras stimulates DNA topoisomerase II alpha through MEK: A link between oncogenic signaling and a therapeutic target	ONCOGENE			English	Article						topoisomerase II alpha; Ras; ERK; JNK; MEKK; cell cycle	ACTIVATED PROTEIN-KINASE; C-JUN; REGULATED KINASE; NIH-3T3 CELLS; MAP KINASES; TRANSFORMATION; GROWTH; EXPRESSION; PATHWAY; GENE	Topoisomerase II alpha (topo II alpha) is a major target of antitumor treatments. In an effort to determine why this protein might be a better target in tumor cells than in normal cells, we attempted to determine if the altered proliferative signaling in a tumor cell might effect the levels of expression of the topo II alpha gene. In support of this idea, it was found that topo II alpha was elevated following microinjection of oncogenic Ras protein. Oncogenic was was further shown to stimulate the topo II alpha promoter. Stimulation by pas was independent of the normal cell cycle regulation of this promoter. Transactivation of topo II alpha by ras required both the MEK/ERK pathway, and the stress-associated protein kinase (SAPK) signaling pathway. As a direct confirmation that both ERK and SAPK were involved in topo II alpha regulation, a constitutively active MEKK that stimulates these two kinases simultaneously was shown to strongly induce topo II alpha promoter activity. Activation of either pathway alone, on the other hand, only slightly stimulated the topo II alpha promoter. Deletion analyses showed that elements near both the 5' and 3' ends of the promoter were responsible for the ras stimulation. Site-directed mutagenesis further demonstrated that an Ets-like binding site near the 5' end (-480 to -475) was one of the responsive elements. Taken together, these studies demonstrate the direct role of Ras signaling in stimulation of topo II alpha expression, and thereby establish a link between the action of a common tumor mutation and the target of multiple anti-tumor reagents.	Cleveland Clin Fdn, Dept Mol Biol, Cleveland, OH 44195 USA; Univ Tennessee, Dept Pharmacol, Memphis, TN 38163 USA; Vet Adm Med Ctr, Res Serv, Memphis, TN 38104 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Case Western Reserve University	Stacey, DW (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, NC2-150, Cleveland, OH 44195 USA.		Templeton, Dennis J/F-7695-2011		NATIONAL CANCER INSTITUTE [R01CA047941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052271] Funding Source: NIH RePORTER; NCI NIH HHS [CA47941] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BOS JL, 1989, CANCER RES, V49, P4682; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DOBROWOLSKI S, 1994, MOL CELL BIOL, V10, P5314; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HSIANG YH, 1988, CANCER RES, V48, P3230; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KAUFMANN SH, 1991, CANCER RES, V51, P3534; Koo HM, 1996, CANCER RES, V56, P5211; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NELSON WG, 1987, CANCER RES, V47, P3246; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1994, EMBO J, V13, P6107, DOI 10.1002/j.1460-2075.1994.tb06957.x; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WOESSNER RD, 1990, CANCER RES, V50, P2901; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067	55	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7149	7160		10.1038/sj.onc.1203149	http://dx.doi.org/10.1038/sj.onc.1203149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597316				2022-12-17	WOS:000083901900022
J	Jonkers, J; Weening, JJ; van der Valk, M; Bobeldijk, R; Berns, A				Jonkers, J; Weening, JJ; van der Valk, M; Bobeldijk, R; Berns, A			Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression	ONCOGENE			English	Article						insertional mutagenesis; Moloney leukemia virus; transgenic mice; T cell lymphoma; oncogenes; glomerulosclerosis	E-MU-MYC; MURINE LEUKEMIA-VIRUS; EPITHELIAL TRANSFORMATION; METANEPHRIC MESENCHYME; DEVELOPING KIDNEY; B-CELL; C-MYC; N-MYC; GENE; DNA	The proto-oncogene Frat1 was originally identified as a common site of proviral insertion in transplanted tumors of Moloney murine leukemia virus (M-MuLV)-infected E mu-Pim1 transgenic mice. Contrary to most common insertion sites implicated in mouse T cell lymphomagenesis, retroviral insertional mutagenesis of Frat1 constitutes a relatively late event in M-MuLV-induced tumor development, suggesting that proviral activation of Frat1 contributes to progression of T cell lymphomas rather than their genesis, To substantiate this notion we have generated transgenic mice that overexpress Frat1 in various organs, including lymphoid tissues, Frat1 trans; genic mice develop focal glomerulosclerosis and a nephrotic syndrome, but they do not exhibit an increased incidence of spontaneous lymphomas, Conversely, these mice are highly susceptible to M-MuLV-induced lymphomagenesis, and Frat/Pim1 bitransgenic animals develop lymphomas with increased frequency compared to Pim1 transgenic littermates, These data support a role for Frat1 in tumor progression.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Jonkers, Jos/AAG-3246-2019	Jonkers, Jos/0000-0002-9264-9792				AARDEN LA, 1979, NY ACAD SCI US, V254, P505; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; COUSER WG, 1994, WESTERN J MED, V160, P440; CUYPERS HT, 1984, CELL, V37, P141; HARRISON PTC, 1984, LAB ANIM, V18, P325, DOI 10.1258/002367784780865324; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Izui S, 1994, Int Rev Immunol, V11, P211, DOI 10.3109/08830189409061728; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kispert A, 1996, DEVELOPMENT, V122, P3627; Klein J B, 1993, Curr Opin Nephrol Hypertens, V2, P225, DOI 10.1097/00041552-199303000-00008; Kotzin BL, 1996, CELL, V85, P303, DOI 10.1016/S0092-8674(00)81108-3; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NISHIMURA M, 1994, J EXP MED, V179, P1053, DOI 10.1084/jem.179.3.1053; RENAULD JC, 1994, ONCOGENE, V9, P1327; Sambrook J, 1989, MOL CLONING LAB MANU; Sheehan D.C., 1980, THEORY PRACTICE HIST, VSecond; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERPUTTEN H, 1979, CELL, V18, P109, DOI 10.1016/0092-8674(79)90359-3; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WEENING JJ, 1986, KIDNEY INT, V29, P789, DOI 10.1038/ki.1986.68; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	38	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					5982	5990		10.1038/sj.onc.1202995	http://dx.doi.org/10.1038/sj.onc.1202995			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557087				2022-12-17	WOS:000083359100004
J	De Medina, SGD; Popov, Z; Chopin, DK; Southgate, J; Tucker, GC; Delouvee, A; Thiery, JP; Radvanyi, F				De Medina, SGD; Popov, Z; Chopin, DK; Southgate, J; Tucker, GC; Delouvee, A; Thiery, JP; Radvanyi, F			Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas	ONCOGENE			English	Article						bladder; E-cadherin; fibroblast growth factor receptor; human, transitional cell carcinoma	CELL CELL-ADHESION; GENE-MUTATIONS; TUMOR-CELLS; IN-VITRO; INVASION; CANCERS; BREAST; LINES	E-cadherin is a cell-cell adhesion molecule expressed predominantly by epithelial cells. Reduction or loss of E-cadherin immunoreactivity has been associated with tumour progression in many epithelial cancers, including bladder carcinomas. The fibroblast growth factor receptor 2b (FGFR2b) recognized specifically by FGF7 is expressed only by epithelial cells. Recently, decreased expression of FGFR2b protein and mRNA,vas found to be associated with tumour progression in bladder carcinomas. The purpose of this investigation was to look for a possible relationship between E-cadherin and FGFR2b expression in bladder carcinomas, As decreased E-cadherin immunoreactivity was found to correlate directly with decreased expression at the mRNA level, the possible relationship between E-cadherin and FGFR2b was investigated at the mRNA le, el using semi-quantitative RT-PCR in 92 transitional cell carcinomas (TCCs) and four lymph node metastases, All tumours with low E-cadherin expression had low expression of FGFR2b, whereas tumours with low FGFR2b mRNA could express any level of E-cadherin mRNA, The same observation was equally valid for bladder and colon cancer cell lines suggesting that, besides bladder tumours, this relationship could apply to other carcinomas types. These results suggest that a relationship exists between the transcription of the E-cadherin and FGFR2b genes preventing high expression of FGFR2b where expression of E-cadherin is lon. We suggest that reduced expression of FGFR2b in conjunction with decreased expression of E-cadherin mag contribute to the aggressive behaviour attributable to high grade TCCs.	Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France; CHU Henri Mondor, Grp Etud Tumeurs Urol, CRCHM, F-94010 Creteil, France; CHU Henri Mondor, Serv Urol, F-94010 Creteil, France; Univ St Cyril & Methudius, Fac Med, Urol Clin, Skopje 9100, Macedonia; St James Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England; Inst Rech Servier, Div Cancerol Expt, F-92150 Suresnes, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Saints Cyril & Methodius University of Skopje; Saint James's University Hospital; Servier; Institut de Recherches Internationales Servier	Radvanyi, F (corresponding author), Inst Curie, CNRS, UMR 144, 26 Rue Ulm, F-75248 Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Popov, Zivko/Q-9497-2017; Popov, Zivko/AAG-1481-2021; Southgate, Jennifer/AAJ-9089-2021; Thiery, Jean Paul/H-1550-2011	Popov, Zivko/0000-0002-7178-0927; Popov, Zivko/0000-0002-7178-0927; Southgate, Jennifer/0000-0002-0135-480X; Thiery, Jean Paul/0000-0003-0478-5020; Radvanyi, Francois/0000-0002-5696-6424	NCI NIH HHS [2RO1 CA 49417-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1996, ONCOGENE, V13, P1919; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; BRINGUIER PP, 1993, CANCER RES, V53, P3241; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GIROLDI LA, 1994, INVAS METAST, V14, P71; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HENNIG G, 1995, ONCOGENE, V11, P475; Matsubara A, 1998, CANCER RES, V58, P1509; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OTTO T, 1994, CANCER RES, V54, P3120; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Rubin J. S., 1995, V74, P191; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	22	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5722	5726		10.1038/sj.onc.1202958	http://dx.doi.org/10.1038/sj.onc.1202958			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523852				2022-12-17	WOS:000083016500014
J	Toledano-Katchalski, H; Elson, A				Toledano-Katchalski, H; Elson, A			The transmembranal and cytoplasmic forms of protein tyrosine phosphatase epsilon physically associate with the adaptor molecule Grb2	ONCOGENE			English	Article						breast cancer; phosphatase; SH2 domain; Jurkat; T-cell receptor	T-CELL ACTIVATION; RECEPTOR SIGNAL-TRANSDUCTION; V-HA-RAS; PHOSPHOTYROSINE PHOSPHATASES; HEMATOPOIETIC-CELLS; CATALYTIC DOMAINS; KINETIC-ANALYSIS; TRANSGENIC MICE; EGF RECEPTOR; SH3 DOMAINS	The protein tyrosine phosphatase Epsilon (PTP epsilon) gene gives rise to two physiologically-distinct protein products-a transmembranal, receptor-like form and a cytoplasmic, non-receptor form. Previous studies have suggested a link between expression of transmembranal PTP epsilon and transformation of mouse mammary epithelium specifically by ras or neu, although little is known about the underlying molecular mechanisms; cytoplasmic PTP epsilon is believed to function mainly in hematopoietic tissues. As part of our efforts to understand PTP epsilon function at the molecular level, we demonstrate here that both forms of PTP epsilon associate with the adaptor molecule Grb2 in vivo. Binding is mediated by the SH2 domain of Grb2; this domain binds exclusively to the carboxy-terminal phosphotyrosine of cytoplasmic PTP epsilon(Y638), and probably to additional phosphotyrosine. residues in transmembranal PTP epsilon. Through its SH2 domain, Grb2 can constitutively associate with transmembranal PTP epsilon in mammary tumors initiated by ras or neu, and can be induced to associate with cytoplasmic PTP epsilon in Jurkat T-cells following stimulation of T-cell receptor signaling by pervanadate. These findings indicate that tyrosine phosphorylation of PTP epsilon and subsequent binding to Grb may link this phosphatase to downstream events which transduce signals from the cell membrane to its interior.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		Toledano, Hila/AGY-6574-2022	Elson, Ari/0000-0001-9808-9135				Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; Elson A, 1996, GENOMICS, V31, P373, DOI 10.1006/geno.1996.0061; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; HAO L, 1997, J BIOL CHEM, V272, P29332; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; IMBODEN JB, 1995, CURR BIOL, V5, P727, DOI 10.1016/S0960-9822(95)00145-X; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lee JM, 1996, ONCOGENE, V12, P253; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lim KL, 1997, EUR J BIOCHEM, V245, P693, DOI 10.1111/j.1432-1033.1997.00693.x; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Mukouyama Y, 1997, MOL BRAIN RES, V50, P230, DOI 10.1016/S0169-328X(97)00193-9; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SU J, 1994, J BIOL CHEM, V269, P18731; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Vogel W, 1996, CELL GROWTH DIFFER, V7, P1589; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994	50	23	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5024	5031		10.1038/sj.onc.1202883	http://dx.doi.org/10.1038/sj.onc.1202883			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490839				2022-12-17	WOS:000082497100002
J	Shen, ZW; Batzer, A; Koehler, JA; Polakis, P; Schlessinger, J; Lydon, NB; Moran, MF				Shen, ZW; Batzer, A; Koehler, JA; Polakis, P; Schlessinger, J; Lydon, NB; Moran, MF			Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src	ONCOGENE			English	Article						p68; SH3; Src; kinase	FAMILY TYROSINE KINASES; C-SRC; PROTEIN; MITOSIS; RNA; P62; PURIFICATION; ASSOCIATION; SH2-DOMAIN; PEPTIDES	Sam68 is a 68 kDa protein that associates with and is phosphorylated by the c-Src kinase at mitosis. It contains a KH domain implicated in RNA binding and several proline-rich motifs that resemble known SH3 binding sites. The SH3 domains of c-Src, phosphatidylinositol 3-OH kinase, phospholipase C-gamma and Grb2 protein (containing two SH3 domains), but not other SH3 domains tested, were capable of binding Sam68 in vitro. Synthetic peptides corresponding to the proline motifs of Sam68 inhibited with different efficiencies the binding of SH3 domains to Sam68 suggesting that the proline motifs of Sam68 function as specific SH3 domain binding sites. Mutation of Sam68 SH3 binding sites further indicated that the SRC SH3 domain mediates binding of Src to unphosphorylated Sam68. Phosphorylation of Sam68 by Src kinase was inhibited when the Src SH3 binding site of Sam68 was mutated or when corresponding peptides were added to in vitro kinase reactions indicating that binding of the Src SH3 domain to a specific site near the amino-terminus of Sam68 (including residues 38-45: PPLPHRSR) facilitates phosphorylation of Sam68 by the Src kinase domain. Sam68-based proline peptides had no effect on the phosphorylation of another in vitro substrate of Src, enolase. These results suggest that Src effectively mounts Sam68 through its SH3 domain, possibly as a mechanism to position the kinase domain close to substrate tyrosine residues in the carboxyl-half of the protein.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON, Canada; Univ Toronto, Dept Med & Mol Genet, Toronto, ON, Canada; NYU, Dept Pharmacol, New York, NY 10016 USA; ONYX Pharmaceut, Richmond, CA USA; Kinetix Pharmaceut Inc, Medford, MA USA	University of Toronto; University of Toronto; New York University	Moran, MF (corresponding author), Hoechst Marion Roussel Deutschland GMBH, DG Rheumatol, H528,Postfach 35 40, D-65174 Wiesbaden, Germany.		Moran, Michael/GYD-3631-2022					BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LYDON NB, 1992, BIOCHEM J, V287, P985, DOI 10.1042/bj2870985; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STONE JC, 1991, METHOD ENZYMOL, V200, P673; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	30	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4647	4653		10.1038/sj.onc.1203079	http://dx.doi.org/10.1038/sj.onc.1203079			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467411				2022-12-17	WOS:000082154400001
J	McIntyre, M; Desdouets, C; Senamaud-Beaufort, C; Laurent-Winter, C; Lamas, E; Brechot, C				McIntyre, M; Desdouets, C; Senamaud-Beaufort, C; Laurent-Winter, C; Lamas, E; Brechot, C			Differential expression of the cyclin-dependent kinase inhibitor P27 in primary hepatocytes in early-mid G1 and G1/S transitions	ONCOGENE			English	Article						cell cycle; p27; hepatocyte proliferation; cyclin dependent kinase; phosphorylation	CELL-CYCLE; LIVER-REGENERATION; CDK INHIBITOR; GROWTH-FACTOR; MICE LACKING; 3T3 CELLS; S-PHASE; P27(KIP1); ACTIVATION; PROGRESSION	P27, an inhibitor of cyclin-dependent kinases, plays an important role in the control of cell adhesion and contact inhibition-dependent cell cycle regulation, Hepatocytes, maintained in primary culture, offer a model of synchronized primary epithelial cells which retain a differentiated profile while stimulated to proliferate, We therefore investigated the pattern of endogenous p27 expression in cyclin rat hepatocytes isolated by collagenase perfusion followed by mitogenic stimulation, P27 mas expressed in whole normal liver and freshly isolated hepatocytes. We then observed a sharp decrease in p27 levels, concomitant with the progression in early-mid G1, followed by reaccumulation in late G1 and the G1/S transition, Immunochemistry and BrdU labelling demonstrated nuclear localization of p27 and its expression in cells engaged in both G1 and S phase, P27 was detected in late G1 in complexes containing cyclins D1, E and A, Cyclin E- and A-associated kinase activities, however, mere detected at the G1/S transition and depletion experiments confirmed that most active complexes were free of p27, Phosphorylated forms of p27 mere detected in unstimulated and stimulated hepatocytes in both early-mid G1 and G1/S, Finally, two-dimensional gel electrophoresis showed evidence for several forms of p27 with a distinct profile of distribution in quiescent and stimulated hepatocytes, Collectively, our data offer a model in which p27 shows a biphasic profile of accumulation, with the early decrease possibly involved in the progression through early and mid G1, In contrast with most cell types tested so far, the late G1 accumulation did not impair formation of active cyclin E- and a associated kinases, and thus G1/S transition.	Necker Inst, INSERM, U370, F-75015 Paris, France; Inst Pasteur, Lab Chim Struct Macromol Electrophorese Bidimensi, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Brechot, C (corresponding author), Necker Inst, INSERM, U370, 156 Rue Vaugirard, F-75015 Paris, France.		Desdouets, Chantal/M-3430-2017; Lamas, Eugenia/L-9654-2018	Lamas, Eugenia/0000-0001-7677-9442				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; ALBRECHT JH, 1993, AM J PHYSIOL, V265, P857; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CHENG M, 1998, P NATL ACAD SCI USA, V95, P1; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; deMora JF, 1997, ONCOGENE, V15, P2541, DOI 10.1038/sj.onc.1201420; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; Glaise D, 1998, CELL GROWTH DIFFER, V9, P165; GRANA X, 1995, ONCOGENE, V11, P211; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Katayose Y, 1997, CANCER RES, V57, P5441; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; LaurentWinter C, 1997, EUR J BIOCHEM, V244, P767, DOI 10.1111/j.1432-1033.1997.00767.x; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loyer P, 1996, Prog Cell Cycle Res, V2, P37; LOYER P, 1994, J BIOL CHEM, V269, P2491; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; LU XP, 1992, J BIOL CHEM, V267, P2844; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; McGowan J.A, 1986, RES ISOLATED CULTURE, P13; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; MURPHY D, 1994, J INFECT DIS, V169, P473, DOI 10.1093/infdis/169.2.473; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Reed SI, 1997, CANCER SURV, V29, P7; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Sanchez JC, 1997, ELECTROPHORESIS, V18, P638, DOI 10.1002/elps.1150180349; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Tikoo R, 1997, J BIOL CHEM, V272, P442; TOYASHIMA H, 1994, CELL, V78, P67; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	56	23	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4577	4585		10.1038/sj.onc.1202815	http://dx.doi.org/10.1038/sj.onc.1202815			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467402				2022-12-17	WOS:000082018600007
J	Brakebusch, C; Wennerberg, K; Krell, HW; Weidle, UH; Sallmyr, A; Johansson, S; Fassler, R				Brakebusch, C; Wennerberg, K; Krell, HW; Weidle, UH; Sallmyr, A; Johansson, S; Fassler, R			beta 1 integrin promotes but is not essential for metastasis of ras-myc transformed fibroblasts	ONCOGENE			English	Article						beta 1 integrin; tumor; metastasis; extracellular matrix; knockout cell line	BREAST-CARCINOMA CELLS; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODY; SYNTHETIC PEPTIDES; CANCER; FIBRONECTIN; MELANOMA; ADHESION; INVASION	To investigate the role of beta 1 integrin during tumor metastasis, we established a ras-myc transformed fibroblastoid cell line with a disrupted beta 1 integrin gene on both alleles (GERM 11), Stable transfection of this cell line with an expression vector encoding beta 1A integrin resulted in beta 1A integrin-expressing sublines. Tumors were induced by subcutaneous injection of GERM 11 cells and 3 independent beta 1 integrin expressing sublines (GERM 116, 1A10, 2F2) into syngeneic mice. After 10 days tumors were surgically removed. While average weights of GERM 11 and GERM 116 tumors were similar, tumors induced by the high expressing clones 1A10 and 2F2 were markedly smaller, suggesting an inverse correlation of tumor growth and beta 1 integrin expression. The metastasis potential of all three beta 1 integrin-expressing GERM 11 sublines tested was significantly higher than that of the beta 1-deficient GERM 11 cells. GERM 116 tumors led in all animals to severe metastasis in lung and liver, while GERM 11 tumors induced only a few metastatic foci in the lung. Stroma of both tumors contained nidogen and high amounts of tenascin C, but only a few very low levels of fibronectin, laminin-1, and collagen type I. beta 1 integrin, therefore, increases but is not essential for metastasis of ras-myc transformed fibroblasts.	Univ Lund Hosp, Dept Expt Pathol, S-22185 Lund, Sweden; Biomed Ctr, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Boehringer Mannheim GmbH, D-82372 Penzberg, Germany	Lund University; Skane University Hospital	Fassler, R (corresponding author), Univ Lund Hosp, Dept Expt Pathol, S-22185 Lund, Sweden.		Wennerberg, Krister/AFM-0539-2022; Wennerberg, Krister/AAH-2919-2022	Wennerberg, Krister/0000-0002-1352-4220; Wennerberg, Krister/0000-0002-1352-4220; Brakebusch, Cord/0000-0002-9342-1634				ALBELDA SM, 1990, CANCER RES, V50, P6757; Bloch W, 1997, J CELL BIOL, V139, P265, DOI 10.1083/jcb.139.1.265; BOTTGER BA, 1989, DIFFERENTIATION, V41, P158, DOI 10.1111/j.1432-0436.1989.tb00743.x; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; Coopman PJ, 1996, MOL BIOL CELL, V7, P1789, DOI 10.1091/mbc.7.11.1789; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; ELLIOTT BE, 1994, CELL ADHES COMMUN, V1, P319, DOI 10.3109/15419069409097263; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FUJITA S, 1995, CANCER LETT, V91, P145, DOI 10.1016/0304-3835(95)03735-F; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gui GPH, 1997, BRIT J CANCER, V75, P623, DOI 10.1038/bjc.1997.113; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HUMPHRIES MJ, 1988, J CLIN INVEST, V81, P782, DOI 10.1172/JCI113384; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KADLER K, 1994, PROTEIN PROFILE, V1, P519; KOUKOULIS GK, 1991, HUM PATHOL, V22, P636, DOI 10.1016/0046-8177(91)90285-W; LARJAVA H, 1993, J CELL PHYSIOL, V157, P190, DOI 10.1002/jcp.1041570125; LESSEY BA, 1995, AM J PATHOL, V146, P717; Matsuura N, 1996, AM J PATHOL, V148, P55; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; NEWTON SA, 1995, INT J ONCOL, V6, P1063; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Peters D. M. P., 1994, EXTRACELLULAR MATRIX, P315; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; RUIZ P, 1993, CELL ADHES COMMUN, V1, P67, DOI 10.3109/15419069309095682; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SMILENOV L, 1992, FEBS LETT, V302, P227, DOI 10.1016/0014-5793(92)80447-O; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Stroeken PJM, 1998, CANCER RES, V58, P1569; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; YAMADA KM, 1990, CANCER RES, V50, P4485; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	37	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3852	3861		10.1038/sj.onc.1202770	http://dx.doi.org/10.1038/sj.onc.1202770			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445848				2022-12-17	WOS:000081171700006
J	Wurfel, J; Rosel, M; Seiter, S; Claas, C; Herlevsen, M; Weth, R; Zoller, M				Wurfel, J; Rosel, M; Seiter, S; Claas, C; Herlevsen, M; Weth, R; Zoller, M			Metastasis-association of the rat ortholog of the human epithelial glycoprotein antigen EGP314	ONCOGENE			English	Article						rat; metastasis; epithelial glycoprotein; adhesion	CARCINOMA-ASSOCIATED ANTIGEN; CELL ADHESION MOLECULE; HUMAN-BREAST-CANCER; MONOCLONAL-ANTIBODY; EP-CAM; SURFACE GLYCOPROTEIN; COLORECTAL-CARCINOMA; MURINE HOMOLOG; COMPLEMENTARY-DNA; TUMOR INVASION	Screening for surface molecules expressed by metastasizing rat tumors had revealed evidence for metastasis-association of a molecule also expressed on epithelial cells. The similarity to the expression profile of the panepithelial glycoprotein EGP314 prompted us to isolate and sequence the gene and to explore functional features of the molecule in transfected tumor lines. The molecule D5.7A, named according to the antibody, D5.7, used for selection, indeed, is the ortholog of EGP314 with 92% and 80% identity to the murine and the human molecules. Like EGP314, D5.7A has a particular cleavage site, a small cleavage product being resolved under reducing conditions from the membrane anchored part of the molecule. Transfection of a low metastasizing fibrosarcoma, pheochromoblastoma and adenocarcinoma revealed that expression of D5.7A facilitates tumor progression. Depending on the origin of the tumor, D5.7A transfectants either metastasized via the lymphatic system (pheochromoblastoma, adenocarcinoma) or hematogeneously (fibrosarcoma). Particularly after proteolytic cleavage, D5.7A facilitated cell - cell adhesion and provided a proliferative signal upon crosslinking. Thus, the rat ortholog of EGP314 is involved in metastasis formation. Importantly, its functional activities apparently rely on proteolytic cleavage. These findings provide a first evidence on how a panepithelial marker can be involved in tumor progression.	German Canc Res Ctr, Dept Tumor Progress & Immune Def, D-69120 Heidelberg, Germany; Univ Hosp Homburg, Dept Dermatol, Homburg, Germany; Univ Karlsruhe, Dept Appl Genet, Karlsruhe, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Universitatsklinikum des Saarlandes; Helmholtz Association; Karlsruhe Institute of Technology	Zoller, M (corresponding author), German Canc Res Ctr, Dept Tumor Progress & Immune Def, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.			Wuerfel, Jens/0000-0002-0034-8053				Basak S, 1998, JNCI-J NATL CANCER I, V90, P691, DOI 10.1093/jnci/90.9.691; BEHRENS J, 1993, BREAST CANCER RES TR, V24, P175, DOI 10.1007/BF01833258; BERGSAGEL PL, 1992, J IMMUNOL, V148, P590; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BJORK P, 1993, J BIOL CHEM, V268, P24232; Borkowski TA, 1996, EUR J IMMUNOL, V26, P110, DOI 10.1002/eji.1830260117; BUMOL TF, 1988, HYBRIDOMA, V7, P407, DOI 10.1089/hyb.1988.7.407; Claas C, 1996, CELL GROWTH DIFFER, V7, P663; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DELEIJ L, 1994, INT J CANCER, P60; EDWARDS DP, 1986, CANCER RES, V46, P1306; EVANS CW, 1992, CELL BIOL INT REP, V16, P1, DOI 10.1016/S0309-1651(06)80150-5; FAGERBERG J, 1995, P NATL ACAD SCI USA, V92, P4773, DOI 10.1073/pnas.92.11.4773; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FERNSTEN PD, 1990, CANCER RES, V50, P4656; FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166; FORNARO M, 1995, INT J CANCER, V62, P610, DOI 10.1002/ijc.2910620520; GLINSKY GV, 1993, CRIT REV ONCOL HEMAT, V14, P229, DOI 10.1016/1040-8428(93)90011-R; GOTTLINGER H, 1986, HYBRIDOMA, V5, pS29; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HELFRICH W, 1994, INT J CANCER, P70; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDO PA, 1993, CANCER IMMUNOL IMMUN, V36, P223, DOI 10.1007/BF01740903; LARSON LN, 1988, INT J CANCER, V42, P877, DOI 10.1002/ijc.2910420615; Li WP, 1997, J IMMUNOL, V159, P763; LINNENBACH AJ, 1993, MOL CELL BIOL, V13, P1507, DOI 10.1128/MCB.13.3.1507; LIOTTA LA, 1983, LAB INVEST, V49, P636; Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; Litvinov SV, 1996, AM J PATHOL, V148, P865; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; Mareel M. M., 1991, MECH INVASION METAST; MAREEL MM, 1993, CRIT REV ONCOGENESIS, V4, P559; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATZKU S, 1983, INVAS METAST, V3, P109; MATZKU S, 1989, CANCER RES, V49, P1294; MATZKU S, 1985, INVAS METAST, V5, P356; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOMBURG F, 1987, CANCER RES, V47, P2883; Nelson AJ, 1996, EUR J IMMUNOL, V26, P401, DOI 10.1002/eji.1830260220; OSSOWSKI L, 1992, CANCER RES, V52, P6754; PEREZ MS, 1989, J IMMUNOL, V142, P3662; REISSER D, 1993, INT J CANCER, V53, P651, DOI 10.1002/ijc.2910530421; RemacleBonnet MM, 1997, INT J CANCER, V72, P835, DOI 10.1002/(SICI)1097-0215(19970904)72:5<835::AID-IJC21>3.0.CO;2-6; ROSEL M, 1998, IN PRESS ONCOGENE; ROSS AH, 1984, BIOCHEM BIOPH RES CO, V135, P297; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHON MP, 1993, INT J CANCER, V55, P988, DOI 10.1002/ijc.2910550619; SCHON MP, 1995, BRIT J DERMATOL, V133, P176, DOI 10.1111/j.1365-2133.1995.tb02613.x; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHETYE J, 1988, CANCER IMMUNOL IMMUN, V27, P154; SIMON B, 1990, P NATL ACAD SCI USA, V87, P2755, DOI 10.1073/pnas.87.7.2755; SPURR NK, 1986, INT J CANCER, V38, P631, DOI 10.1002/ijc.2910380503; STEIN R, 1994, INT J CANCER, P98; STRNAD J, 1989, CANCER RES, V49, P314; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; SZALA S, 1990, P NATL ACAD SCI USA, V87, P3542, DOI 10.1073/pnas.87.9.3542; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takes RP, 1997, ARCH OTOLARYNGOL, V123, P412; TANDON AK, 1990, CANCER RES, V50, P3317; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUBURA A, 1992, J CUTAN PATHOL, V19, P73, DOI 10.1111/j.1600-0560.1992.tb01562.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Zaloudik J, 1997, BRIT J CANCER, V76, P909, DOI 10.1038/bjc.1997.483; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; ZOLLER M, 1978, BRIT J CANCER, V37, P61, DOI 10.1038/bjc.1978.9; ZOLLER M, 1992, J NUCL MED, V33, P1366; ZORAS J, 1995, EUR UROL, V28, P251	74	23	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	1999	18	14					2323	2334		10.1038/sj.onc.1202542	http://dx.doi.org/10.1038/sj.onc.1202542			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327052				2022-12-17	WOS:000079595500004
J	Jang, JS; Lee, SJ; Choi, YH; Nguyen, P; Lee, J; Hwang, SG; Wu, ML; Takano, E; Maki, M; Henkart, PA; Trepel, JB				Jang, JS; Lee, SJ; Choi, YH; Nguyen, P; Lee, J; Hwang, SG; Wu, ML; Takano, E; Maki, M; Henkart, PA; Trepel, JB			Posttranslational regulation of the retinoblastoma gene family member p107 by calpain protease	ONCOGENE			English	Article						proteolysis; p107; calpain; proteasome	LARGE T-ANTIGEN; ACTIVATED NEUTRAL PROTEASE; CELL-CYCLE; PROTEINS P130; KAPPA-B; IN-VIVO; C-JUN; UBIQUITIN; DEGRADATION; PATHWAY	The retinoblastoma protein plays a critical role in regulating the G1/S transition. Less is known about the function and regulation of the homologous pocket protein p107. Here we present evidence for the posttranslational regulation of p107 by the Ca2+-activated protease calpain. Three negative growth regulators, the HMG-CoA reductase inhibitor lovastatin, the antimetabolite 5-fluorouracil, and the cyclic nucleotide dibutyryl cAMP were found to induce cell type-specific loss of p107 protein which was reversible by the calpain inhibitor leucyl-leucyl-norleucinal but not by the serine protease inhibitor phenylmethylsulfonylfluoride, caspase inhibitors, or lactacystin, a specific inhibitor of the 26S proteasome, Purified calpain induced Ca2+-dependent p107 degradation in cell lysates. Transient expression of the specific calpain inhibitor calpastatin blocked the loss of p107 protein in lovastatin-treated cells, and the half-life of p107 was markedly lengthened in lovastatian-treated cells stably transfected with a calpastatin expression vector versus cells transfected with vector alone. The data presented here demonstrate downregulation of p107 protein in response to various antiproliferative signals, and implicate calpain in p107 posttranslational regulation.	NCI, Med Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA; NCI, Expt Immunol Branch, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Natl Kyoto Hosp, Kyoto 612, Japan; Nagoya Univ, Nagoya, Aichi 46401, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Nagoya University	Trepel, JB (corresponding author), NCI, Med Branch, Div Clin Sci, NIH, Bldg 10,Room 12N226, Bethesda, MD 20892 USA.		Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491	DIVISION OF BASIC SCIENCES - NCI [Z01BC009263] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Boyer SN, 1996, CANCER RES, V56, P4620; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KATO J, 1993, GENE DEV, V7, P331; KAVITA U, 1995, J BIOL CHEM, V270, P27758, DOI 10.1074/jbc.270.46.27758; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Lee MJ, 1996, FASEB J, V10, P16; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Liu ZQ, 1996, FEBS LETT, V385, P109, DOI 10.1016/0014-5793(96)00360-2; Maki CG, 1996, CANCER RES, V56, P2649; MAYOL X, 1993, ONCOGENE, V8, P2561; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MOHAN PS, 1995, J NEUROCHEM, V64, P859; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; TORTORA G, 1994, ONCOGENE, V9, P3233; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Walowitz JL, 1998, J BIOL CHEM, V273, P6656, DOI 10.1074/jbc.273.12.6656; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	68	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1789	1796		10.1038/sj.onc.1202497	http://dx.doi.org/10.1038/sj.onc.1202497			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086333				2022-12-17	WOS:000079090000002
J	de Lera, TL; Folgueira, L; Martin, AG; Dargemont, C; Pedraza, MA; Bermejo, M; Bonay, P; Fresno, M; Alcami, J				de Lera, TL; Folgueira, L; Martin, AG; Dargemont, C; Pedraza, MA; Bermejo, M; Bonay, P; Fresno, M; Alcami, J			Expression of I kappa B alpha in the nucleus of human peripheral blood T lymphocytes	ONCOGENE			English	Article						IKB alpha; NF-kappa B; nuclear; T lymphocytes	TUMOR-NECROSIS-FACTOR; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; REL ONCOGENE; C-REL; P50; PROTEIN; SUBUNIT; SIGNAL; PHOSPHORYLATION	According to current models the inhibitory capacity of I kappa B alpha would be mediated through the retention of Rel/NF-kappa B proteins in the cytosol. However, I kappa B alpha has also been detected in the nucleus of cell lines and when overexpressed by transient transfection. To gain better insight into the potential role of nuclear I kappa B alpha in a physiological context we have analysed its presence in the nucleus of human peripheral blood T lymphocytes (PBL). We demonstrate the nuclear localization of I kappa B alpha in PBL by different techniques: Western blot, indirect immunofluorescence and electron microscopy. Low levels of nuclear I kappa B alpha were detected in resting cells whereas a superinduction was obtained after PMA activation. The nuclear pool of I kappa B alpha showed a higher stability than cytosolic I kappa B alpha and was partially independent of the resynthesis of the protein. Unexpectedly, the presence of nuclear I kappa B alpha did not inhibit NF-kappa B binding to DNA and this phenomenon was not due to the presence of I kappa B beta at the nuclear level. Immunoprecipitation experiments failed to demonstrate an association between nuclear I kappa B alpha and NF-kappa B proteins. Our results demonstrate that in resting and PMA-activated human PBL, I kappa B alpha is present in the nucleus in an apparently inactive form unable to disrupt NF-kappa B binding from DNA.	Hosp 12 Octubre, Ctr Invest, Microbiol Serv, E-28041 Madrid, Spain; Inst Curie, CNRS, UMR 144, Lab Transport Nucleocytoplasm, F-75231 Paris, France; Univ Autonoma Madrid, Ctr Biol Mol, E-28049 Madrid, Spain	Hospital Universitario 12 de Octubre; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; Autonomous University of Madrid	Alcami, J (corresponding author), Hosp 12 Octubre, Ctr Invest, Microbiol Serv, E-28041 Madrid, Spain.		Folgueira, Lola/C-7958-2016; Alcami, Pepe/T-2242-2018	Folgueira, Lola/0000-0002-3730-015X; Alcami, Pepe/0000-0003-0023-7377; Fresno Escudero, Manuel/0000-0002-9223-5477; Bermejo, Mercedes/0000-0001-9909-8578				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BACHELERIE F, 1991, NATURE, V350, P709, DOI 10.1038/350709a0; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LAI JH, 1994, J BIOL CHEM, V269, P30077; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P4516, DOI 10.1093/nar/21.19.4516; MOORE NC, 1995, J IMMUNOL, V155, P4653; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PIMENTELMUINOS FX, 1995, EUR J IMMUNOL, V25, P179, DOI 10.1002/eji.1830250130; PIMENTELMUINOS FX, 1994, J BIOL CHEM, V269, P24424; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413	49	23	23	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1581	1588		10.1038/sj.onc.1202455	http://dx.doi.org/10.1038/sj.onc.1202455			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102628				2022-12-17	WOS:000078770700008
J	Falchetti, ML; Falcone, G; D'Ambrosio, E; Verna, R; Alema, S; Levi, A				Falchetti, ML; Falcone, G; D'Ambrosio, E; Verna, R; Alema, S; Levi, A			Induction of telomerase activity in v-myc-transformed avian cells	ONCOGENE			English	Article						telomerase; v-Myc; v-Src; transformation; TRAP	DIFFERENTIATION PROGRAM; MYOGENIC CELLS; IMMORTAL CELLS; STEM-CELLS; ONCOGENES; CANCER; TRANSCRIPTION; PROTEIN; LINES; GENE	Telomerase activity is detectable in the majority of tumors or immortalized cell lines, but is repressed in most normal human somatic cells. It is generally assumed that reactivation of telomerase prevents the erosion of chromosome ends which occurs in cycling cells and, hence, hinders cellular replicative senescence. Here, we show that the expression of v-Myc oncoprotein by retroviral infection of telomerase-negative embryonal quail myoblasts and chicken neuroretina cells is sufficient for reactivating telomerase activity, earlier than telomere shortening could occur. Furthermore, the use of a conditional v-Myc-estrogen receptor protein (v-MycER) causes estrogen-dependent expression of detectable levels of telomerase activity in recently infected chick embryo fibroblasts and neuroretina cells. We conclude that the high levels of telomerase activity in v-Myc-expressing avian cells are not the mere consequence of transformation or of a differentiative block, since v-Src tyrosine kinase, which prevents terminal differentiation and promotes cell transformation, fails to induce telomerase activity.	Univ Roma La Sapienza, Ist Neurobiol, Rome, Italy; Univ Roma La Sapienza, Ist Biol Cellulare, Rome, Italy; Univ Roma La Sapienza, CNR, Ist Med Sperimentale, Rome, Italy; Univ Roma La Sapienza, Dipartimento Med Sperimentale, Rome, Italy	Sapienza University Rome; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Sapienza University Rome	Levi, A (corresponding author), Univ Roma La Sapienza, Ist Neurobiol, Rome, Italy.		falchetti, maria laura/AAA-5586-2019; Falcone, Germana/A-3735-2016	Alema, Stefano/0000-0002-9869-6354; VERNA, Roberto/0000-0002-1869-3912; Falcone, Germana/0000-0002-3508-7623				ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; BISTER K, 1987, ONCOGENE, V1, P97; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CASALBORE P, 1987, NATURE, V326, P188, DOI 10.1038/326188a0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1995, TELOMERES, P265; Falchetti ML, 1998, NUCLEIC ACIDS RES, V26, P862, DOI 10.1093/nar/26.3.862; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greaves M, 1996, TRENDS GENET, V12, P127, DOI 10.1016/0168-9525(96)30016-4; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1995, TELOMERES, P247; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Holt SE, 1996, MOL CELL BIOL, V16, P2932; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lustig AJ, 1997, TRENDS CELL BIOL, V7, P299, DOI 10.1016/S0962-8924(97)01110-0; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Pain B, 1996, DEVELOPMENT, V122, P2339; POLLERBERG GE, 1995, J NEUROSCI RES, V41, P427, DOI 10.1002/jnr.490410402; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; Strahl C, 1996, MOL CELL BIOL, V16, P53; Tahara H, 1995, CLIN CANCER RES, V1, P1245; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; WEINBERG RA, 1989, CANCER RES, V49, P3713; WHITAKER NJ, 1995, ONCOGENE, V11, P971	49	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	1999	18	7					1515	1519		10.1038/sj.onc.1202438	http://dx.doi.org/10.1038/sj.onc.1202438			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050888				2022-12-17	WOS:000078651600013
J	Qing, J; Wei, D; Maher, VM; McCormick, JJ				Qing, J; Wei, D; Maher, VM; McCormick, JJ			Cloning and characterization of a novel gene encoding a putative transmembrane protein with altered expression in some human transformed and tumor-derived cell lines	ONCOGENE			English	Article						differential display; cell transformation; gene expression	EUKARYOTIC MESSENGER-RNAS; MALIGNANT TRANSFORMATION; DIFFERENTIAL DISPLAY; HUMAN FIBROBLASTS; CARCINOGENESIS; RECEPTOR; GROWTH; MODEL; STRAIN	Identification and characterization of genes expressed in normal cells and decreased in their malignant counterparts is an important method for detecting candidate tumor suppressors. Using differential display of mRNAs from nontumorigenic infinite life span human fibroblast cell strain MSU-1.1 and an isogenic fibrosarcoma-derived cell line, 6A/SB1, which was derived from chemical carcinogen transformed MSU-1.1 cells, we identified a no, el gene, ST7, showing sixfold lower expression in 6A/SB1 cells compared with parental MSU-1.1 cells. Molecular cloning of a near full-length cDNA revealed that the no, el gene encodes a putative transmembrane protein composed of 859 amino acids: the 492 N-terminal amino acids including a fivefold cysteine-rich repeat of 40 amino acids homologous to the ligand binding repeat of the known low density Lipoprotein receptor, a 24 hydrophobic amino acid stretch spanning the plasma membrane, and a C-terminal domain of 343 residues, ST7 is located on human chromosome 8, band q22.2-23.1, the same locus as the genes involved in acute myeloid leukemia and a locus of high polymorphism in cancer biopsies. The ST7 gene is widely expressed in normal human tissues and is particularly abundant in human heart and skeletal muscle. Northern analysis of 15 tumor cell lines derived from patients and 16 cell lines established from tumors formed in athymic mice by MSU-1.1 cells transformed in culture by various methods showed that 16 of the 31 cell lines ha,le low or undetectable levels of ST7 mRNA. Furthermore, Western blotting analysis using a specific anti-peptide antibody demonstrated that the level of ST7 protein is high in normal fibroblasts and low in 12 sarcoma-derived cell lines tested. Altered expression of ST7 appears to occur at both the transcriptional and post-transcriptional levels. These studies are a first step in characterizing a novel putative receptor protein, whose expression is downregulated in some malignantly transformed cells, and which may play an important role in the transformation process of these cells.	Michigan State Univ, Dept Microbiol, Carcinogenesis Lab, E Lansing, MI 48824 USA; Michigan State Univ, Ctr Canc, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	McCormick, JJ (corresponding author), Michigan State Univ, Dept Microbiol, Carcinogenesis Lab, FST Bldg, E Lansing, MI 48824 USA.				NCI NIH HHS [CA60907] Funding Source: Medline; NIA NIH HHS [AG11026] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011026] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; FARBER E, 1984, CANCER RES, V44, P4217; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1996, BIOCHIM BIOPHYS ACTA, V1288, P17; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURUYA T, 1989, CANCER GENET CYTOGEN, V43, P131, DOI 10.1016/0165-4608(89)90136-2; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MCCORMICK JJ, 1994, RISK ANAL, V14, P257, DOI 10.1111/j.1539-6924.1994.tb00240.x; Miyazaki S, 1997, GENOMICS, V46, P155, DOI 10.1006/geno.1997.4996; MORGAN TL, 1991, EXP CELL RES, V197, P125, DOI 10.1016/0014-4827(91)90489-H; PARK NH, 1995, ONCOGENE, V10, P2145; Peto R, 1977, ORIGINS HUMAN CANC C, P1403; Qing J, 1997, ONCOGENE, V15, P2159, DOI 10.1038/sj.onc.1201385; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reinhold DS, 1996, INT J RADIAT BIOL, V69, P707, DOI 10.1080/095530096145454; REZNIKOFF CA, 1993, SEMIN CANCER BIOL, V4, P143; RHIM JS, 1994, P NATL ACAD SCI USA, V91, P11874, DOI 10.1073/pnas.91.25.11874; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; Sambrook J, 1989, MOL CLONING LAB MANU; SHABTAI F, 1988, CANCER GENET CYTOGEN, V31, P113, DOI 10.1016/0165-4608(88)90018-0; STANLEY KK, 1985, EMBO J, V4, P375, DOI 10.1002/j.1460-2075.1985.tb03639.x; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; STONER GD, 1991, CANCER RES, V51, P365; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; YANG DJ, 1992, P NATL ACAD SCI USA, V89, P2237, DOI 10.1073/pnas.89.6.2237	33	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					335	342		10.1038/sj.onc.1202290	http://dx.doi.org/10.1038/sj.onc.1202290			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927190				2022-12-17	WOS:000078166500006
J	van der Reijden, BA; Dauwerse, HG; Giles, RH; Jagmohan-Changur, S; Wijmenga, C; Liu, PP; Smit, B; Wessels, HW; Beverstock, GC; Jotterand-Bellomo, M; Martinet, D; Muhlematter, D; Lafage-Pochitaloff, M; Gabert, J; Reiffers, J; Bilhou-Nabera, C; van Ommen, GJB; Hagemeijer, A; Breuning, MH				van der Reijden, BA; Dauwerse, HG; Giles, RH; Jagmohan-Changur, S; Wijmenga, C; Liu, PP; Smit, B; Wessels, HW; Beverstock, GC; Jotterand-Bellomo, M; Martinet, D; Muhlematter, D; Lafage-Pochitaloff, M; Gabert, J; Reiffers, J; Bilhou-Nabera, C; van Ommen, GJB; Hagemeijer, A; Breuning, MH			Genomic acute myeloid leukemia-associated inv(16)(p13q22) breakpoints are tightly clustered	ONCOGENE			English	Article						inv(16)(p13q22); CBFB; MYH11; AML; genomic; breakpoints	ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ABNORMAL MARROW EOSINOPHILS; ACUTE MYELOGENOUS LEUKEMIA; MYOSIN HEAVY-CHAIN; MOLECULAR CHARACTERIZATION; FUSION; GENE; TRANSLOCATION; CHROMOSOME-16	The inv(16) and related t(16;16) are found in 10% of all cases with ne novo acute myeloid leukemia. In these rearrangements the core binding factor beta (CBFB) gene on 16q22 is fused to the smooth muscle myosin heavy chain gene (MYH11) on 16p13, To gain insight into the mechanisms causing the inv(16) ne have analysed 24 genomic CBFB-MYH11 breakpoints. All breakpoints in CBFB are located in a 15-Kb intron, More than 50% of the sequenced 6.2 Kb of this intron consists of human repetitive elements. Twenty-one of the 24 breakpoints in MYH11 are located in a 370-hp intron, The remaining three breakpoints in MYH11 ape located more upstream, The localization of three breakpoints adjacent to a V(D)J recombinase signal sequence in MYH11 suggests a V(D)J recombinase-mediated rearrangement in these cases, V(D)J recombinase-associated characteristics (small nucleotide deletions and insertions of random nucleotides) were detected in six other cases. CBFB and MYH11 duplications were detected in four of six cases tested.	Erasmus Univ, Inst Hematol, Dept Cell Biol & Genet, Rotterdam, Netherlands; Leiden Univ, Dept Human Genet, Sylvius Labs, NL-2300 RA Leiden, Netherlands; Natl Ctr Human Genome Res, Lab Gene Transfer, NIH, Bethesda, MD USA; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; CHU Vaudois, Div Autonome Genet Med, CH-1011 Lausanne, Switzerland; Inst J Paoli I Calmettes, Hematol Lab, F-13009 Marseille, France; Univ Bordeaux, Lab Univ Hematol, Bordeaux, France	Erasmus University Rotterdam; Leiden University; Leiden University - Excl LUMC; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Erasmus University Rotterdam; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Universite de Bordeaux	van der Reijden, BA (corresponding author), Erasmus Univ, Inst Hematol, Dept Cell Biol & Genet, Rotterdam, Netherlands.		Liu, Paul/A-7976-2012; Breuning, Martijn H/E-3429-2010; van der Reijden, Bert A/A-3543-2014; Wijmenga, Cisca/D-2173-2009; Wijmenga, Cisca/AAE-7719-2019	Liu, Paul/0000-0002-6779-025X; Wijmenga, Cisca/0000-0002-5635-1614; Giles, Rachel/0000-0001-9133-2008				ADRIAANSEN HJ, 1993, BLOOD, V81, P3043; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; CLAXTON DF, 1994, BLOOD, V83, P1750; DAUWERSE HG, 1989, NUCLEIC ACIDS RES, V17, P3603, DOI 10.1093/nar/17.9.3603; DAUWERSE JG, 1993, HUM MOL GENET, V2, P1527, DOI 10.1093/hmg/2.10.1527; DONG WF, 1995, LEUKEMIA, V9, P1812; GELLERT M, 1992, TRENDS GENET, V8, P408, DOI 10.1016/0168-9525(92)90322-U; HEBERT J, 1994, BLOOD, V84, P2291, DOI 10.1182/blood.V84.7.2291.bloodjournal8472291; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; JURKA J, 1992, J MOL EVOL, V35, P286, DOI 10.1007/BF00161166; KUSS BJ, 1994, LANCET, V343, P1531, DOI 10.1016/S0140-6736(94)92938-6; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; MARLTON P, 1995, BLOOD, V85, P772, DOI 10.1182/blood.V85.3.772.bloodjournal853772; MATSUOKA R, 1993, AM J MED GENET, V46, P61, DOI 10.1002/ajmg.1320460110; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OHNO H, 1993, LEUKEMIA, V7, P2057; PAPADOPOULOS PC, 1990, GENE CHROMOSOME CANC, V1, P233, DOI 10.1002/gcc.2870010308; POIREL H, 1995, BLOOD, V85, P1313, DOI 10.1182/blood.V85.5.1313.bloodjournal8551313; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; SMIT AFA, 1995, NUCLEIC ACIDS RES, V23, P98, DOI 10.1093/nar/23.1.98; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; VANDERREIJDEN BA, 1993, BLOOD, V82, P2948; VANDERREIJDEN BA, 1995, BLOOD, V86, P277, DOI 10.1182/blood.V86.1.277.bloodjournal861277; vanderReijden BA, 1996, LEUKEMIA, V10, P1459; VONLINDERN M, 1992, GENE CHROMOSOME CANC, V5, P227, DOI 10.1002/gcc.2870050309; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WIJMENGA C, 1993, HUM GENET, V92, P198; YANAGISAWA K, 1991, BLOOD, V78, P451	33	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					543	550		10.1038/sj.onc.1202321	http://dx.doi.org/10.1038/sj.onc.1202321			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927211				2022-12-17	WOS:000078166500027
J	Ioannidis, P; Courtis, N; Havredaki, M; Michailakis, E; Tsiapalis, CM; Trangas, T				Ioannidis, P; Courtis, N; Havredaki, M; Michailakis, E; Tsiapalis, CM; Trangas, T			The polyadenylation inhibitor cordycepin (3 ' dA) causes a decline in c-MYC mRNA levels without affecting c-MYC protein levels	ONCOGENE			English	Article						c-myc mRNA; translation; poly(A) tail; cordycepin	MESSENGER-RNA DEGRADATION; AU-RICH ELEMENTS; TUMOR NECROSIS FACTOR; POLY(A) TAIL; 3'-UNTRANSLATED REGION; UNTRANSLATED REGION; CELL-CYCLE; TRANSLATIONAL EFFICIENCY; INITIATION; SEQUENCE	Study of the distribution of the poly(A) tail length of c-myc mRNA in several cell lines revealed a distinct, prevailing population with short poly(A) tails, derived through sequential deadenylation, To elucidate the possible in vivo function of this distinct short failed c-myc mRNA population, the polyadenylation inhibitor cordycepin was used, This resulted in a decline in steady state c-myc mRNA levels with the remaining messenger mostly oligoadenylated, However, c-MYC proteins did not follow the reduction of the c-myc mRNA, On the other hand, in cells exposed to physiological agents known to downregulate c-myc expression, the reduction of mRNA steady state levels, was reflected upon c-MYC protein levels, The dissociation between c-myc mRNA and protein levels caused by cordycepin was not dare to the stabilization of the c-MYC proteins and was not an indiscriminate effect since in the presence of cordycepin, c-fos mRNA and protein levels concomitantly declined, Our data indicate that under these conditions, a long poly(A) tail is not instrumental for c-myc mRNA translation and furthermore, the discrepancy in the steady state of c-myc mRNA level: c-MYC protein ratio between control cells and cells treated with cordycepin indicates that c-myc mRNA is subjected to translational control.	St Savvas Hosp, Papanikolaou Res Ctr Oncol, Athens 11522, Greece; NCSR Democritos, Athens, Greece; Athens Gen Hosp, Oncol Unit, Athens, Greece	National Centre of Scientific Research "Demokritos"	Trangas, T (corresponding author), St Savvas Hosp, Papanikolaou Res Ctr Oncol, 171 Alexandras Ave, Athens 11522, Greece.							BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BALLANTINE JEM, 1985, FEBS LETT, V180, P224, DOI 10.1016/0014-5793(85)81075-9; BEACH LR, 1978, J BIOL CHEM, V253, P2628; BERNSTEIN J, 1995, J BIOL CHEM, V270, P10559, DOI 10.1074/jbc.270.18.10559; Black BL, 1997, MOL CELL BIOL, V17, P2756, DOI 10.1128/MCB.17.5.2756; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BREWER G, 1990, METHOD ENZYMOL, V181, P202; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTENSEN AK, 1987, AM J ANAT, V178, P1, DOI 10.1002/aja.1001780102; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; Dehlin E, 1996, MOL CELL BIOL, V16, P468; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Ioannidis P, 1996, NUCLEIC ACIDS RES, V24, P4969, DOI 10.1093/nar/24.24.4969; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KLEENE KC, 1989, DEVELOPMENT, V106, P367; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KRUYS VI, 1988, GENE, V72, P191, DOI 10.1016/0378-1119(88)90144-8; LIN JX, 1987, J BIOL CHEM, V262, P11908; Lorenzini EC, 1997, BIOCHEM J, V326, P361, DOI 10.1042/bj3260361; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; MACIEJEWSKILENOIR D, 1993, P NATL ACAD SCI USA, V90, P1435, DOI 10.1073/pnas.90.4.1435; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; NABRU C, 1997, J BIOL CHEM, V272, P32061; Paulin FEM, 1996, ONCOGENE, V13, P505; Ranganathan G, 1997, J BIOL CHEM, V272, P2515; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS A, 1993, J BIOL CHEM, V268, P22955; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STOECKLE MY, 1993, BIOTECHNIQUES, V15, P227; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; Yang Q, 1997, J BIOL CHEM, V272, P15466, DOI 10.1074/jbc.272.24.15466; ZEEVI M, 1982, MOL CELL BIOL, V2, P517, DOI 10.1128/MCB.2.5.517; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	60	23	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					117	125		10.1038/sj.onc.1202255	http://dx.doi.org/10.1038/sj.onc.1202255			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926926				2022-12-17	WOS:000078166000013
J	White, GRM; Varley, JM; Heighway, J				White, GRM; Varley, JM; Heighway, J			Isolation and characterization of a human homologue of the latrophilin gene from a region of 1p31.1 implicated in breast cancer	ONCOGENE			English	Article						latrophilin; breast cancer; chromosome 1; alternative splicing	ALPHA-LATROTOXIN; RECEPTOR; PROTEIN; HETEROZYGOSITY; CLONING	We have identified a region of chromosome 1p31.1 that shows high frequency loss of heterozygosity (LOH) in human breast cancer. This region forms part of a 7 Mb YAC/BAC contig, In order to identify candidate sequences, mutation of which might contribute to the development of disease, we have carried out mapping studies of ESTs localized to 1p31.1. This analysis, coupled with library screening and a modified 5' RACE-PCR strategy, resulted in the identification and characterization of a novel gene (LPHH1) which is located adjacent to the smallest region of overlapping loss (SRO) seen in tumours, The 4209 bp open reading frame of the 7 kb LPHH1 transcript encodes a peptide which shows approximately 65% identity to rat latrophilin, a G-coupled, seven span transmembrane protein, which binds alpha-latrotoxin. In the human sequence, whilst conservation of the transmembrane domain is high, the intra- and extracellular domains show two regions of variable structure, which are presumably generated by alternative splicing. Surprisingly, while expression of the rat gene is tightly restricted to neurological and perhaps some endocrine cells, the human sequence appears to be expressed very widely in all normal tissues tested. Northern and RT-PCR analysis of a panel of tumour cell lines showed that LPHH1 expression was variable, apparently elevated in some lines and absent or markedly reduced in others. Furthermore, characterization of the range of transcripts encoded in a breast tumour cell line, compared to normal breast, suggested that gene product variability was higher in the tumour.	Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Mol Genet Sect, Manchester M20 4BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Varley, JM (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Mol Genet Sect, Wilmslow Rd, Manchester M20 4BX, Lancs, England.							Bittner MA, 1998, J NEUROSCI, V18, P2914; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; HOGGARD N, 1995, GENOMICS, V30, P233, DOI 10.1006/geno.1995.9882; HOGGARD N, 1995, GENE CHROMOSOME CANC, V12, P24, DOI 10.1002/gcc.2870120105; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lang JC, 1998, EMBO J, V17, P648, DOI 10.1093/emboj/17.3.648; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; NACHEVA E, 1990, BRIT J HAEMATOL, V74, P70, DOI 10.1111/j.1365-2141.1990.tb02540.x; NAGAI H, 1995, CANCER RES, V55, P1752; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Yamamichi K, 1998, INT J CANCER, V79, P256, DOI 10.1002/(SICI)1097-0215(19980619)79:3<256::AID-IJC8>3.0.CO;2-O	14	23	26	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3513	3519		10.1038/sj.onc.1202487	http://dx.doi.org/10.1038/sj.onc.1202487			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030676				2022-12-17	WOS:000078086200013
J	You, XL; Yen, LY; Zeng-Rong, N; Al Moustafa, AE; Alaoui-Jamali, MA				You, XL; Yen, LY; Zeng-Rong, N; Al Moustafa, AE; Alaoui-Jamali, MA			Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells	ONCOGENE			English	Article						erbB-2 receptor; DNA repair; cell cycle; apoptosis	NEU DIFFERENTIATION FACTOR; EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; BREAST-CARCINOMA CELLS; TUMOR-CELLS; INHIBITOR P27(KIP1); SIGNAL-TRANSDUCTION; C-ERBB-2 GENE; G(1) ARREST; PROTEIN	Overexpression of the erbB-2 tyrosine kinase receptor, p185(crbB-2), is a common alteration in non-small cell lung cancer (NSCLC) and has been associated with poor prognosis and a tumor drug resistance phenotype, In this study, we have examined the consequences of crbB-2 depletion on DNA repair, cell cycle, and apoptosis using a panel of NSCLC cell lines constitutively overexpressing er erbB-2 receptor. Depletion of the erbB-2 was achieved using the tyrosine kinase inhibitor CP127,374 which promotes erbB-2 degradation. Treatment with CP127,374 concentrations which deplete erbB-2 and inhibit tyrosine phosphorylation resulted in downregulation of DNA repair mechanisms and cell accumulation at G1 phase of the cell cycle. G1 arrest was observed in cells with mutated p53 as well as cells lacking p53 protein, suggesting a p53-independent mechanisms, NSCLC cells which overexpress erbB-2 were more resistant to cisplatin-induced cytotoxicity in comparison to cells expressing low levels of erbB-2. Treatment with CP127,374 alone did not result in any induction of apoptosis, A combination of CP127,374 and cisplatin, however, was more potent in cell growth inhibition and induction of apoptosis compared to treatment with cisplatin alone. Together, our results further support a pivotal role of erbB-2 signaling in the regulatory balance between DNA repair, cell cycle checkpoints and apoptosis; all these mechanisms are essential determinants for tumor cell destiny following chemotherapy stress.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, McGill Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Lady Davis Institute; McGill University; McGill University; National Research Council Canada	Alaoui-Jamali, MA (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, 3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.							Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALAOUIJAMALI MA, 1997, J BIOCH CELL BIOL, V75, P315; ALIMANDI M, 1995, ONCOGENE, V10, P1813; ARTEAGA CL, 1994, CANCER RES, V54, P3758; Bacus SS, 1996, ONCOGENE, V12, P2535; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Chavany C, 1996, J BIOL CHEM, V271, P4974; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENG D, 1996, CANCER RES, V56, P3666; Deshane J, 1996, CANCER GENE THER, V3, P89; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOUGALL WC, 1994, ONCOGENE, V9, P2109; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Ford JM, 1998, CANCER RES, V58, P599; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HYNES EN, 1994, BIOCHIM BIOPHYS ACTA, V1198, P165; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KERN JA, 1990, CANCER RES, V50, P5184; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Lewis GD, 1996, CANCER RES, V56, P1457; LIU C, 1993, AM J PATHOL, V142, P413; McDonald E, 1996, CANCER RES, V56, P2250; MILLER P, 1994, CANCER RES, V54, P2724; NIE ZR, 1995, CANCER RES, V55, P4760; NOGUCHI M, 1993, CANCER RES, V53, P2035; Paterson J., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P363; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; Smit EF, 1996, THORAX, V51, P638, DOI 10.1136/thx.51.6.638; StCroix B, 1996, NAT MED, V2, P1204; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; SUDA Y, 1990, EMBO J, V9, P181, DOI 10.1002/j.1460-2075.1990.tb08094.x; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; VAUGHN JP, 1995, P NATL ACAD SCI USA, V92, P8338, DOI 10.1073/pnas.92.18.8338; Vreeswijk MPG, 1998, CANCER RES, V58, P1978; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; Wu XP, 1996, ONCOGENE, V12, P1397; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yen L, 1997, ONCOGENE, V14, P1827, DOI 10.1038/sj.onc.1201019; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhang LS, 1996, ONCOGENE, V12, P571	61	23	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3177	3186		10.1038/sj.onc.1202246	http://dx.doi.org/10.1038/sj.onc.1202246			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872333				2022-12-17	WOS:000077517400011
J	Bogenmann, E; Peterson, S; Maekawa, K; Matsushima, H				Bogenmann, E; Peterson, S; Maekawa, K; Matsushima, H			Regulation of NGF responsiveness in human neuroblastoma	ONCOGENE			English	Article						neuroblastoma; trkA; differentiation	NERVE GROWTH-FACTOR; HUMAN NEURO-BLASTOMA; RETINOIC ACID; CELL-LINE; NEUROTROPHIN RECEPTOR; TRK PROTOONCOGENE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; HIGH-AFFINITY	Functional nerve growth factor (NGF) responsiveness was investigated in human neuroblastoma (NB) cell lines in vitro and retinoic acid (RA) was found to transcriptionally enhance expression of the trkA, but not the trkB gene in GOTO cells, while the reverse was found in HTLA230 NE cells. Ciliary neurotrophic factor (CNTF) specifically induced trkA gene transcription in both cell lines. Transcriptional activation of the trkA gene increased total trkA protein and surface bound receptor, which was tyrosine phosphorylated upon NGF stimulation inducing immediate early response gene transcription (i.e. c-fos, Egr-1). Newly synthesized trkA protein had a molecular weight of 110 kDa and was post-translationally modified. Rapid down regulation of the receptor protein occurred upon NGF stimulation, despite the presence of high levels of trkA mRNA, due to an increased rate of receptor degradation. Transient DNA synthesis and cell proliferation upon NGF treatment occurred in GOTO cells with elevated trkA expression. In contrast, NGF induced neuronal differentiation in HTLA230 cells expressing the endogenous trkA receptor gene, despite the lack of p75 expression. Hence, transcriptional activation of trkA gene expression can be achieved by different signal pathways in human NE cells, but NGF can act either as mitogen or inducer of cell differentiation, depending on the tumor from which cells are derived.	Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA; Jikei Univ, Sch Med, Inst DNA Med, Dept Pediat,Minato Ku, Tokyo 105, Japan; Jikei Univ, Sch Med, Inst DNA Med, Dept Gene Therapy,Minato Ku, Tokyo 105, Japan	Children's Hospital Los Angeles; Jikei University; Jikei University	Bogenmann, E (corresponding author), Childrens Hosp Los Angeles, Div Hematol Oncol, 4650 Sunset Blvd, Los Angeles, CA 90027 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034940] Funding Source: NIH RePORTER; NINDS NIH HHS [1R01NS34940] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBACID M, 1993, ONCOGENE, V8, P2033; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BASU T, 1994, ONCOGENE, V9, P3483; BIRREN SJ, 1992, SCIENCE, V257, P395, DOI 10.1126/science.1321502; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BOGENMANN E, 1995, ONCOGENE, V10, P1915; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KUMAR S, 1993, MOL BRAIN RES, V17, P163, DOI 10.1016/0169-328X(93)90086-5; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MATSUSHIMA H, 1992, INT J CANCER, V51, P250, DOI 10.1002/ijc.2910510214; MATSUSHIMA H, 1992, INT J CANCER, V51, P727, DOI 10.1002/ijc.2910510511; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1982, ANN INTERN MED, V97, P873, DOI 10.7326/0003-4819-97-6-873; Seeger Robert C., 1993, P2172; SEKIGUCHI M, 1979, JPN J EXP MED, V49, P67; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAIJI M, 1992, MOL CELL BIOL, V12, P2193, DOI 10.1128/MCB.12.5.2193; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Torres M, 1996, ONCOGENE, V12, P77; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VERDI JM, 1994, NEURON, V13, P1359, DOI 10.1016/0896-6273(94)90421-9; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WYATT S, 1995, J CELL BIOL, V130, P1435, DOI 10.1083/jcb.130.6.1435	64	23	27	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2367	2376		10.1038/sj.onc.1202160	http://dx.doi.org/10.1038/sj.onc.1202160			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811468				2022-12-17	WOS:000076723300011
J	Burstein, ES; Hesterberg, DJ; Gutkind, JS; Brann, MR; Currier, EA; Messier, TL				Burstein, ES; Hesterberg, DJ; Gutkind, JS; Brann, MR; Currier, EA; Messier, TL			The ras-related GTPase rac1 regulates a proliferative pathway selectively utilized by G-protein coupled receptors	ONCOGENE			English	Article						rac; ras; G-protein coupled receptor; tyrosine kinase linked receptor; JAK/STAT linked receptor	NIH 3T3 CELLS; HETEROTRIMERIC G-PROTEINS; KINASE KINASE KINASE; C-JUN; MUSCARINIC RECEPTORS; SIGNALING PATHWAY; BINDING PROTEINS; TYROSINE PHOSPHORYLATION; ALPHA-SUBUNIT; HA-RAS	Ras and rac are each members of the superfamily of monomeric GTPases and both function as molecular switches to link cell-surface signals to intracellular responses. Using a novel assay of cellular proliferation called R-SAT(TM) (Receptor Selection and Amplification Technology), we examined the roles of ras and rac in mediating the proliferative responses to a variety of cell-surface receptors, Activated, wild-type and dominant-negative mutants of rac and ras were tested for their effects on cellular proliferation either alone or in combination with receptors, Activated rac (rac Q61L, henceforth rac*) and ras (ras G12V, henceforth ras*) each induced strong proliferative responses. Dominant-negative rac (rac T17N, henceforth rac(-)) dramatically suppressed proliferative responses to G-protein coupled receptors (GPCR's) including the m5 muscarinic receptor and the alpha 1B adrenergic receptor. In contrast, rac(-) had little or no effect upon responses to the tyrosine kinase receptor TrkC, and only partially suppressed responses to the Janus kinase (JAK/STAT) linked granulocyte macrophage colony stimulating factor (GM-CSF) receptor. Dominant-negative ras (ras T17N, henceforth ras(-)) blocked the proliferative responses to all of the tested receptors, Compared to rac(-) and ras(-), wild-type rac and ras had only modest effects on the tested receptors, Overall these results demonstrate that rac mediates the proliferative effects of G-protein coupled receptors through a pathway that is distinct from the proliferative signaling pathway utilized by tyrosine kinase linked and JAK-linked receptors.	ACADIA Pharmaceut Inc, San Diego, CA 92121 USA; NIDR, Mol Signaling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Burstein, ES (corresponding author), ACADIA Pharmaceut Inc, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482				ARECES LB, 1993, P NATL ACAD SCI USA, V90, P3963, DOI 10.1073/pnas.90.9.3963; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; Burstein ES, 1997, J NEUROCHEM, V68, P525; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YAN MH, 1994, NATURE, V372, P798	58	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1617	1623		10.1038/sj.onc.1202067	http://dx.doi.org/10.1038/sj.onc.1202067			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794239				2022-12-17	WOS:000076089900014
J	Guo, XYD; Cuillerot, JM; Wang, T; Wu, Y; Arlinghaus, R; Claxton, D; Bachier, C; Greenberger, J; Colombowala, I; Deisseroth, AB				Guo, XYD; Cuillerot, JM; Wang, T; Wu, Y; Arlinghaus, R; Claxton, D; Bachier, C; Greenberger, J; Colombowala, I; Deisseroth, AB			Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210(bcr-abl) positive 32D myeloid leukemia cells	ONCOGENE			English	Article						p210(bcr-abl) oncoprotein; tetramerization; BCR; CML	ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; C-ABL; PHILADELPHIA-CHROMOSOME; ONCOGENIC ACTIVATION; HEMATOPOIETIC-CELLS; FUSION PROTEINS; GENE-PRODUCT; BINDING; INHIBITION	We first showed that the introduction of a bcr-abl transcription unit into the 32D murine myeloid cell line (P210bcrab132D) converts this cell line from an IL3 dependent cell line to an IL3 growth independent cell line, We next cloned a fragment of the bcr-abl cDNA, which codes for the bcr oligomerization domain and neighboring regions, To test for a transformation inhibitory effect of this oligomerization inhibitory peptide transcription unit on the p210(bcr-abl) mediated IL3 independent growth of the P210bcrab132D cell line, we transiently co-electroporated into the growth factor dependent 32D cells, mixtures of plasmids which contained varying ratios of the plasmid expression vectors for the bcr oligomerization inhibitory peptide along with a smaller amount of the plasmid expression vector for the full length p210(bcr-abl). (The P210(bcr-abl) protein converts the 32D from a growth factor dependent into a growth factor independent cell line.) We then showed that the oligomerization domain containing fragment from the bcr and bcr-abl proteins, can be used to inhibit the IL3 independent growth of p210(bcr-abl) positive 32D cells, These studies may be of eventual interest for those investigators whose goal is to design molecular therapeutic approaches to CML based on the use of peptidomimetic chemical functionalities, which mimic the structure and the inhibitory binding properties of the oligomerization domain containing fragment so as to inhibit the transforming function of the P210(bcr-abl) oncoprotein.	Yale Univ, Sch Med, Dept Internal Med, Med Oncol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Canc Ctr, Gene Therapy Program, New Haven, CT 06520 USA; Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA; Univ Pittsburgh, Med Ctr, Hanover, NH USA; Dartmouth Coll, Hanover, NH 03755 USA; S Texas Canc Inst, San Antonio, TX USA	Yale University; Yale University; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Dartmouth College	Deisseroth, AB (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Med Oncol Sect, 333 Cedar St, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 55162, P01 CA49639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDI A, 1994, BLOOD, V83, P2038; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; CARLESSO N, 1994, ONCOGENE, V9, P149; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBERGER JS, 1983, P NATL ACAD SCI USA, V80, P2391; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HOEVE J, 1994, BLOOD, V86, P1731; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Liu JX, 1996, MOL CELL BIOL, V16, P998; LU D, 1993, BLOOD, V82, P1257; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MITINORI S, 1995, NATURE, V374, P159; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUVRE C, 1989, CELL, V56, P777; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; USALA SJ, 1988, MOL ENDOCRINOL, V2, P1217, DOI 10.1210/mend-2-12-1217; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZAVACKI AM, 1993, MOL ENDOCRINOL, V7, P1319, DOI 10.1210/me.7.10.1319	55	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	1998	17	7					825	833		10.1038/sj.onc.1201999	http://dx.doi.org/10.1038/sj.onc.1201999			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9779999				2022-12-17	WOS:000075448800004
J	Castagnino, P; Soriano, JV; Montesano, R; Bottaro, DP				Castagnino, P; Soriano, JV; Montesano, R; Bottaro, DP			Induction of tissue inhibitor of metalloproteinases-3 is a delayed early cellular response to hepatocyte growth factor	ONCOGENE			English	Article						hepatocyte growth factor; TIMP-3; metalloproteinase; cell proliferation; gene induction	ERYTHROID-POTENTIATING ACTIVITY; FACTOR SCATTER FACTOR; RECEPTOR TYROSINE KINASE; CHICKEN-EMBRYO FIBROBLASTS; MET PROTOONCOGENE PRODUCT; HUMAN SKIN FIBROBLASTS; KIDNEY-CELLS REQUIRES; TIMP GENE FAMILY; NIH 3T3 CELLS; EPITHELIAL-CELLS	Hepatocyte growth factor (HGF) stimulates mitogenic, motogenic, and morphogenic responses in various cell types. We analysed HGF-responsive cells by differential display PCR to identify HGF-induced genes that mediate these biological events. One of the genes identified encoded a member of the tissue inhibitor of metalloproteinases (TIMP) family, TIMP3. HGF transiently induced TIMP-3 mRNA in keratinocytes as well as kidney and mammary epithelial cells maximally between 4 and 6 h post-stimulation. Increased TIMP3 protein secretion returned to basal levels within 18 h, while the expression of gelatinases A and B remained unchanged, suggesting that temporary suppression of matrix degradation is a delayed early response to HGF. Ectopic overexpression of TIMP-3 in cultured leiomyosarcoma cells conferred an epithelial morphology, reduced cell growth rate, anchorage-independent growth, and matrix invasion in vitro. Antisense suppression of TIMP3 was associated with a scattered, fibroblastic cell morphology, as well as enhanced proliferation, anchorage-independent growth, and matrix invasion. A survey of tumor cell lines revealed an inverse relationship between metastatic potential and TIMP3 expression level. These data suggest that early, transient TIMP3 expression mediates specific HGF-induced phenotypic changes, and that loss of TIMP3 expression may enhance the invasion potential of certain tumors.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Ctr Med Univ Geneva, Dept Morphol, Geneva, Switzerland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Geneva	Bottaro, DP (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.		Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				ALBINI A, 1987, CANCER RES, V47, P3239; ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; AVALOS BR, 1988, BLOOD, V71, P1721; BARDELLI A, 1992, ONCOGENE, V7, P1973; BERTAUX B, 1990, PATHOL BIOL, V38, P1029; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; BLENIS J, 1984, J BIOL CHEM, V259, P1563; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; Dunsmore SE, 1996, J BIOL CHEM, V271, P24576, DOI 10.1074/jbc.271.40.24576; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GOHDA E, 1994, CYTOKINE, V6, P633, DOI 10.1016/1043-4666(94)90051-5; GOLDE DW, 1980, P NATL ACAD SCI-BIOL, V77, P593, DOI 10.1073/pnas.77.1.593; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Hurskainen T, 1996, J HISTOCHEM CYTOCHEM, V44, P1379, DOI 10.1177/44.12.8985130; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JONES SE, 1994, FEBS LETT, V352, P171, DOI 10.1016/0014-5793(94)00951-1; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LONGATI P, 1994, ONCOGENE, V9, P49; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; PELICCI G, 1995, ONCOGENE, V10, P1631; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PONZETTO C, 1991, J BIOL CHEM, V266, P22087; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RON D, 1993, J BIOL CHEM, V268, P2984; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SAKURAI H, 1997, AM J PHYSIOL, V272, P139; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Soloway PD, 1996, ONCOGENE, V13, P2307; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SPONSEL HT, 1994, AM J PHYSIOL, V267, pF257, DOI 10.1152/ajprenal.1994.267.2.F257; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; STASKUS PW, 1991, J BIOL CHEM, V266, P449; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; STOKER M, 1985, J CELL SCI, V77, P209; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WATANABE S, 1994, BIOCHEM BIOPH RES CO, V199, P1453, DOI 10.1006/bbrc.1994.1394; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WESTBROOK CA, 1984, J BIOL CHEM, V259, P9992; WICK M, 1994, J BIOL CHEM, V269, P18953; WOJTA J, 1994, BLOOD, V84, P151; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZHU H, 1994, J BIOL CHEM, V269, P29943	81	23	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					481	492		10.1038/sj.onc.1201957	http://dx.doi.org/10.1038/sj.onc.1201957			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696042	Green Published			2022-12-17	WOS:000075043000011
J	Carson-Walter, EB; Smith, DP; Ponder, BAJ; Baylin, SB; Nelkin, BD				Carson-Walter, EB; Smith, DP; Ponder, BAJ; Baylin, SB; Nelkin, BD			Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells	ONCOGENE			English	Article						RET; raf-1; differentiation	ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; NEOPLASIA TYPE 2B; PC12 CELLS; NEURONAL DIFFERENTIATION; TRANSFORMING GENE; RAS ONCOGENE; PROTOONCOGENE; MUTATIONS	Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor of the calcitonin secreting thyroid C-cells, Somatic and germline mutations in the RET proto-oncogene are associated with sporadic and inherited cases of MTC, respectively. The human MTC cell Line, TT, can be differentiated by activated raf-1, This differentiation is characterized, in part, by down-regulation of the RET proto-oncogene, We now show that raf-1 induction is followed by activation of the downstream kinases MEK1/2 and ERK1/2 and that differentiation is dependent on activation of MEK1/2, The concurrent down-regulation of RET appears to involve altered nuclear compartmentalization and transport of RET mRNA, Although RET is down-regulated during raf-1 mediated differentiation, overexpression of activated RET alleles which resist down-regulation does not alter the raf-1 mediated differentiation response. These data suggest that RET down-regulation is associated with, but not required, for raf-1 mediated MTC cell differentiation and that the raf-1 signal transduction pathway plays a dominant role in promoting MTC cell differentiation.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Program Human Genet & Mol Biol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Univ Cambridge, Human Canc Genet Grp, Cambridge CB2 2OQ, England	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of Cambridge	Nelkin, BD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA.				NCI NIH HHS [R01-CA47480] Funding Source: Medline; PHS HHS [2T32G07814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; CALIFANO D, 1995, ONCOGENE, V11, P107; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARSON EB, 1995, CANCER RES, V55, P2048; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HAZARD JB, 1959, J CLIN ENDOCR METAB, V19, P152, DOI 10.1210/jcem-19-1-152; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Holt KH, 1996, MOL CELL BIOL, V16, P577; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P249, DOI 10.1046/j.1365-2265.1996.681503.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NELKIN BD, 1990, BIOCHEM BIOPH RES CO, V170, P140, DOI 10.1016/0006-291X(90)91251-M; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Richardson GM, 1996, HUM ECOL RISK ASSESS, V2, P44, DOI 10.1080/10807039.1996.10387459; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	41	23	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					367	376		10.1038/sj.onc.1201938	http://dx.doi.org/10.1038/sj.onc.1201938			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690518				2022-12-17	WOS:000074947500011
J	Goller, ME; Iacovoni, JS; Vogt, PK; Kruse, U				Goller, ME; Iacovoni, JS; Vogt, PK; Kruse, U			Glutaredoxin is a direct target of oncogenic jun	ONCOGENE			English	Article						jun; target gene; glutaredoxin; cytochrome P450; growth associated protein (GAP)-43; differential expression; subtractive hybridization	MESSENGER-RNAS; LEUCINE ZIPPER; TRANSFORMATION; DNA; FAMILY; FOS; TRANSACTIVATION; FIBROBLASTS; PROTEINS	We have analysed differential gene expression in v-jun-transformed chicken embryo fibroblasts (CEF) compared to normal CEF by using the directional tag PCR subtraction method. From a first generation of putative Jun targets four clones were selected for study; they are upregulated in jun-transformed cells. Three of these clones showed homology to known genes: glutaredoxin, growth associated protein (GAP)-43/neuromodulin, and phenobarbital-induced cytochrome P450. The expression of these genes was analysed in fibroblasts transformed by various oncogenes. Expression of the glutaredoxin mRNA could be induced by a Jun-estrogen receptor chimaera in the absence of de novo protein biosynthesis. Based on this observation we conclude that glutaredoxin is a direct target of v-Jun.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, BCC239,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAIZER L, 1990, MOL BRAIN RES, V7, P61, DOI 10.1016/0169-328X(90)90074-N; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BUSSLINGER M, 1994, FOS JUN FAMILIES TRA, P1833; Hadman M, 1996, ONCOGENE, V12, P135; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HANSEN AJ, 1989, DNA-J MOLEC CELL BIO, V8, P179, DOI 10.1089/dna.1.1989.8.179; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1992, ONCOGENE, V7, P1119; Picard Didier, 1993, Trends in Cell Biology, V3, P278, DOI 10.1016/0962-8924(93)90057-8; Sambrook J, 1989, MOL CLONING LAB MANU; USUI H, 1994, J NEUROSCI, V14, P4915	20	23	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2945	2948		10.1038/sj.onc.1201819	http://dx.doi.org/10.1038/sj.onc.1201819			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671415				2022-12-17	WOS:000073988200013
J	McCarty, JH; Feinstein, SC				McCarty, JH; Feinstein, SC			Activation loop tyrosines contribute varying roles to TrkB autophosphorylation and signal transduction	ONCOGENE			English	Article						Shc; phospholipase C; Erk; proliferation; receptor tyrosine kinase	NERVE GROWTH-FACTOR; INSULIN-RECEPTOR; NEUROTROPHIC FACTOR; PROTEIN-KINASE; PHOSPHOLIPASE C-GAMMA-1; CRYSTAL-STRUCTURE; BINDING-SITES; BETA-SUBUNIT; NGF RECEPTOR; DOMAIN	The TrkB receptor tyrosine kinase (RTK) is a high affinity receptor for the neurotrophins brain derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5), Following exposure to BDNF or NT-4/5, TrkB is autophosphorylated on five cytoplasmic tyrosines: Y384, Y670, Y674, Y675, and Y785. Based on crystallographic analyses for others RTKs, TrkB tyrosines Y670, Y674, and Y675 are expected to lie within a putative kinase activation loop, Phosphorylation of these activation loop tyrosines is postulated to be a conserved event required for complete RTK activation, Here, we have assessed the importance these activation loop tyrosines play in regulating TrkB autophosphorylation, cytoplasmic signal transduction, and cell proliferation, We show that while tyrosine 670 is dispensable for BDNF-inducible TrkB autophosphorylation and the activation of certain signal transduction events, it is required for complete TrkB-mediated cellular proliferation, Combinatorial mutagenesis of tyrosines 674 and 675 only moderately affects TrkB autophosphorylation, but significantly impairs the BDNF-inducible stimulation of cytoplasmic signaling events and cellular proliferation, The combined mutation of all three activation loop tyrosines results in an inactive receptor, which is unable to autophosphorylate, stimulate signaling events, or induce mitogenesis, The data highlight the varying degrees of importance of the three activation loop tyrosines in TrkB mediated biological responses.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Feinstein, SC (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.				NATIONAL EYE INSTITUTE [R01EY010739] Funding Source: NIH RePORTER; NEI NIH HHS [EY 10739] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BORG P, 1995, CELL, V80, P693; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GUITON M, 1994, J BIOL CHEM, V269, P30370; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HEFTI F, 1994, J NEUROBIOL, V25, P1418, DOI 10.1002/neu.480251109; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Iwasaki Y, 1997, BIOCHEMISTRY-US, V36, P2694, DOI 10.1021/bi962057x; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LONGATI P, 1994, ONCOGENE, V9, P49; MARSH HN, 1993, J NEUROSCI, V13, P4281; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P43; MITRA G, 1991, ONCOGENE, V6, P2237; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PURVES D, 1988, BODY BRAIN; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Segal RA, 1996, J BIOL CHEM, V271, P20175, DOI 10.1074/jbc.271.33.20175; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3655; WATTS JD, 1992, J BIOL CHEM, V267, P901; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WIGLER M, 1979, CELL, V11, P223; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541; ZHANG B, 1991, J BIOL CHEM, V266, P990	54	23	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1691	1700		10.1038/sj.onc.1201688	http://dx.doi.org/10.1038/sj.onc.1201688			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582017				2022-12-17	WOS:000072807600007
J	Canman, CE; Kastan, MB				Canman, CE; Kastan, MB			Small contribution of G1 checkpoint control manipulation to modulation of p53-mediated apoptosis	ONCOGENE			English	Article						apoptosis; p53; p21; E2F	CELL-CYCLE ARREST; S-PHASE ENTRY; GROWTH ARREST; G(1) ARREST; TRANSCRIPTION FACTOR; P53-DEPENDENT APOPTOSIS; RETINOBLASTOMA PROTEIN; P53-INDUCED APOPTOSIS; HEMATOPOIETIC-CELLS; DEPENDENT KINASES	Deregulation of the S-phase promoting E2F-1 transcription factor has been shown to cooperate with p53 to induce apoptosis, BaF3 cells undergo rapid, p53-dependent apoptosis when irradiated in the absence of IL-3, Rapid apoptosis induced by ionizing radiation (IR) coincides with attenuated p21(WAF1/Cip1) induction, Failure to adequately induce p21 could result in inappropriate release of E2F from Rb which may then cooperate with p53 to induce apoptosis in cells deprived of growth factor, We engineered BaF3 cells to express exogenous p21 and tested whether overexpressing p21 in cells irradiated in the absence of IL-3 protects from IR-induced apoptosis. Enforced p21 expression resulted in a consistent, but partial, protection of cells from undergoing IR-induced apoptosis. However, deregulating E2F activity through expression of HPV E7 failed to sensitize cells to IR-induced apoptosis in the presence of IL-3. Together, these data strongly suggest that the IL-3-responsive factors which modulate p53-mediated apoptosis in BaF3 cells are largely independent of G1 cell cycle checkpoint control mediated by p21.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Canman, CE (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, 345 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.			, Christine/0000-0001-8892-7430	NATIONAL CANCER INSTITUTE [R01CA061949, T32CA060441] Funding Source: NIH RePORTER; NCI NIH HHS [CA61949, CA60441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DULLIC V, 1994, CELL, V76, P1013; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GORCZYCA W, 1993, CANCER RES, V54, P2591; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HARPER JW, 1993, CELL, V75, P805; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Liu Y, 1996, CANCER RES, V56, P31; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; Minshall C, 1996, J IMMUNOL, V156, P939; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHAUNG H, 1995, J BIOL CHEM, V270, P14500	75	23	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					957	966		10.1038/sj.onc.1201612	http://dx.doi.org/10.1038/sj.onc.1201612			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519869				2022-12-17	WOS:000072335900001
J	Lin, JC; Naujokas, M; Zhu, H; Nolet, S; Park, M				Lin, JC; Naujokas, M; Zhu, H; Nolet, S; Park, M			Intron-exon structure of the MET gene and cloning of an alternatively-spliced Met isoform reveals frequent exon-skipping of a single large internal exon	ONCOGENE			English	Article						MET receptor tyrosine kinase; genomic structure; alternative splicing; exon-skipping; hepatocyte growth factor receptor	HEPATOCYTE GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; TYROSINE KINASE RECEPTOR; C-MET; SCATTER FACTOR; PROTOONCOGENE PRODUCT; FACTOR/SCATTER FACTOR; HGF RECEPTOR; EXPRESSION; OVEREXPRESSION	Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional factor that stimulates epithelial cell mitogenesis, motility, invasion, and morphogenesis. Its receptor is encoded by the MET proto-oncogene, a transmembrane receptor tyrosine kinase. Several studies have suggested a role for MET as a dominant oncogene in tumor development and progression. Conversely, MET is located at a region on chromosome 7q31 frequently deleted in carcinomas, suggesting that recessive mutations in MET may exist in certain cancers. To facilitate a search for mutations in MET, we have obtained the intron-exon structure of the human MET gene. We present the genomic structure of the first member of the Met receptor family to be characterized. Interestingly, MET contains a large second exon of 1214 nucleotides. We show that this exon, containing the AUG for the Met receptor, is frequently skipped in normal human tissues and cell lines, and corresponds to a ubiquitously expressed 7 kb Met transcript. This transcript yields no detectable protein product in vivo. Thus, unlike other genes, in which alternative splicing often gives rise to proteins,vith distinct activities, exon-skipping of MET exon 2 is predicted to decrease the abundance of a Met mRNA encoding a functional Met receptor.	McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Biochem, Montreal, PQ, Canada	McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.							BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORDANO S, 1989, ONCOGENE, V4, P1983; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; JUCKER M, 1994, LEUKEMIA RES, V18, P7, DOI 10.1016/0145-2126(94)90003-5; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE CC, 1995, J BIOL CHEM, V270, P507, DOI 10.1074/jbc.270.2.507; Lin JC, 1996, ONCOGENE, V13, P2001; LIU C, 1992, ONCOGENE, V7, P181; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maniatis T., 1992, MOL CLONING LAB MANU; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MOTOYAMA T, 1979, Acta Medica et Biologica, V27, P49; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PIAO XH, 1994, BLOOD, V83, P476; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RONSIN C, 1993, ONCOGENE, V8, P1195; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Scotlandi K, 1996, AM J PATHOL, V149, P1209; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Sterner DA, 1996, P NATL ACAD SCI USA, V93, P15081, DOI 10.1073/pnas.93.26.15081; TAKAHASHI S, 1995, CANCER RES, V55, P4114; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Yang XM, 1996, DEVELOPMENT, V122, P2163; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yonemura Y, 1996, INT J ONCOL, V8, P555; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	51	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					833	842		10.1038/sj.onc.1201599	http://dx.doi.org/10.1038/sj.onc.1201599			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484774				2022-12-17	WOS:000072053200002
J	Ahmed, M; Dusanter-Fourt, I; Bernard, M; Mayeux, P; Hawley, RG; Bennardo, T; Novault, S; Bonnet, ML; Gisselbrecht, S; Varet, B; Turhan, AG				Ahmed, M; Dusanter-Fourt, I; Bernard, M; Mayeux, P; Hawley, RG; Bennardo, T; Novault, S; Bonnet, ML; Gisselbrecht, S; Varet, B; Turhan, AG			BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line	ONCOGENE			English	Article						BCR-ABL; apoptosis; EpoR	DNA-BINDING ACTIVITY; CHRONIC MYELOGENOUS LEUKEMIA; FACTOR-DEPENDENT CELLS; TYROSINE KINASE; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; POSITIVE CELLS; SH2 DOMAIN; TRANSFORMATION	The interleukin-3 dependent murine Ba/F3 cell line has been widely used as an experimental model of cell transformation by BCR-ABL oncogenes as assessed by induction of growth-factor-independence and inhibition of apoptosis in vitro. The signaling pathways used by BCR-ABL oncogenes to exert these effects are unknown, To gain insights into this phenomenon, we have introduced the p190- and p210-encoding BCR-ABL oncogenes as well as the constitutively activated oncogenic murine erythropoietin receptor (cEpoR) into Ba/F3 and compared the behavior of individual clones in response to apoptotic stimuli, Both p210 and p190 BCR-ABL vectors induced IL-3-independent growth and the same result was obtained with the cEpo-R vector, Individual clones of Ba/F3 cells expressing BCR-ABL exhibited significant resistance to apoptosis induced by either etoposide, serum deprivation or growth-factor withdrawal. In contrast, Ba/F3 cells expressing the constitutively active cEpoR behaved like parental Ba/F3 cells undergoing apoptosis when similarly treated with etoposide or upon serum deprivation, Bc12 and Bas levels were similar in all BCR-ABL and cEpoR-transfected clones, However, in band-shift assays, nuclear extracts from growth-factor-independent Ba/F3 clones expressing cEpoR had no detectable STAT activity as opposed to the constitutive STAT activation detected in all Ba/F3 clones expressing p210 or p190 BCR-ABL. Our results indicate that although both constitutively activated cEpoR and BCR-ABL oncogenes induce growth-factor independence in Ba/F3 cells, only BCR-ABL is able to protect cells from etoposide and serum-deprivation-induced apoptosis and induce a strong constitutive activation of STAT factors, suggesting a role for these molecules in the anti-apoptotic activity of BCR-ABL.	Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Hop Necker Enfants Malad, CNRS, URA 1461, F-75743 Paris, France; Hop Necker Enfants Malad, Serv Hematol Adulte, F-75743 Paris, France; Hop Cochin, ICGM, INSERM, U363, F-75674 Paris, France; Toronto Hosp, Oncol Gene Therapy Program, Toronto, ON M5G 2M1, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Turhan, AG (corresponding author), Inst Gustave Roussy, INSERM, U362, PR-1 Rue Camille Desmoulins, F-94805 Villejuif, France.		Dusanter-Fourt, Isabelle/P-4558-2017	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Hawley, Robert/0000-0003-3512-5818; TURHAN, Ali/0000-0002-4861-0137				BEDI A, 1994, BLOOD, V83, P2038; Bright JJ, 1997, J IMMUNOL, V159, P175; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; EAVES CJ, 1987, CHRONIC MYELOID LEUK, V1, P931; Esteve P, 1995, ONCOGENE, V11, P2657; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HAWLEY RG, 1994, GENE THER, V1, P136; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; ISSAAD C, 1994, BLOOD, V84, P3447; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANEUVILLE P, 1994, CANCER RES, V54, P1360; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OFarrell AM, 1996, BLOOD, V87, P3655, DOI 10.1182/blood.V87.9.3655.bloodjournal8793655; OKUDA K, 1994, J BIOL CHEM, V269, P24602; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; SIRARD C, 1994, BLOOD, V83, P1575; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	48	23	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					489	496		10.1038/sj.onc.1201556	http://dx.doi.org/10.1038/sj.onc.1201556			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484838				2022-12-17	WOS:000071739400007
J	Chen, SL; Zhang, XK; Halverson, DO; Byeon, MK; Schweinfest, CW; Ferris, DK; Bhat, NK				Chen, SL; Zhang, XK; Halverson, DO; Byeon, MK; Schweinfest, CW; Ferris, DK; Bhat, NK			Characterization of human N8 protein	ONCOGENE			English	Article						leucine zipper protein; homodimerization; phosphorylation; cytoplasmic protein; epithelial cells	DNA-BINDING DOMAIN; LEUCINE ZIPPER; DIMERIZATION; EXPRESSION; SEQUENCE; COMPLEX; FAMILY; GENES; MYC; MAX	We have shown before that the N8 mRNA is expressed at higher levels in lung tumor and lung tumor-derived cell lines than normal lung cells. In this paper, we have characterized the N8 protein, and studied its properties. The N8 gene encodes a major 24 kDa protein and its expression correlates well with the N8 mRNA expression pattern observed in different cell lines. N8 protein is capable of forming a homodimer or multimeter in vitro. It is a phosphorylated cytoplasmic protein and phosphorylation occurs mainly at serine residues, N8 protein is expressed at higher levels in epithelial cells than in mesenchymal cells, Ns protein expression is induced in a fibroblast cell line expressing adenoviral Ela protein, which acquired epithelial-like characteristics. Furthermore, ectopic expression of N8 protein in NIH3T3 cells converts them into a spheroid form. These spheroids also have some of the characteristic features of epithelial cells. Taken together, these results suggest that the N8 protein may be associated with the development or maintenance of epithelial cell phenotype.	NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,FREDERICK,MD 21702; NCI,MOL ONCOL LAB,FREDERICK,MD 21702; MED UNIV S CAROLINA,HOLLINGS CANC CTR,CTR MOL & STRUCT BIOL,CHARLESTON,SC 29425	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Medical University of South Carolina								ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BHAT NK, 1992, HYBRIDOMA, V11, P277, DOI 10.1089/hyb.1992.11.277; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BYRNE JA, 1995, CANCER RES, V55, P2896; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; Chen SL, 1996, ONCOGENE, V12, P741; Coligan JKA, 1991, CURRENT PROTOCOLS IM; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872	15	23	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2577	2588		10.1038/sj.onc.1201437	http://dx.doi.org/10.1038/sj.onc.1201437			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399645				2022-12-17	WOS:A1997YG73200007
J	Tolkacheva, T; Feuer, B; Lorenzi, MV; Saez, R; Chan, AML				Tolkacheva, T; Feuer, B; Lorenzi, MV; Saez, R; Chan, AML			Cooperative transformation of NIH3T3 cells by G alpha 12 and Rac1	ONCOGENE			English	Article						Rac1; RhoA; Cdc42Hs; G alpha 12; oncogene; transformation	ACTIN STRESS FIBERS; GENE-PRODUCT; G-PROTEINS; RAS TRANSFORMATION; ALPHA-SUBUNITS; CDC42 GTPASES; RHO; BINDING; KINASE; FAMILY	The heterotrimeric G-protein, G alpha 12, together with the closely-related G alpha 13, are members of the G12 class of alpha-subunits important in mediating the signaling from seven transmembrane domain-spanning receptors, Recent evidence implicating both G alpha 12 and G alpha 13 in the activation of signaling pathways involving members of the RHO gene family led us to examine the role of Rad, RhoA and Cdc42Hs in the transforming properties of G alpha 12. Asparagine 17 (Asn 17) dominant inhibitory mutants of Rad, and to a lesser extent RhoA, block focus forming ability of the GTPase-deficient mutant of G alpha 12 (G alpha 12 Leu 229) in NIH3T3 cells, In turn, wild-type G alpha 12 cooperates well with Rad Val 12 but not with RhoA Leu 63 mutant in transforming NIH3T3 cells, Interestingly, the morphology of foci induced by G alpha 12 and RhoA mutants are strikingly similar and is distinct from those displayed by Rad Val 12 mutant, The fact that G alpha 12's ability to induce mitogenesis in NIH3T3 cells is not significantly perturbed by C3 ribosyltransferase suggested that RhoA does not play a major role in G alpha 12-induced mitogenic events, Activated mutant of Rad has previously been demonstrated to stimulate the activity of the stress-induced c-Jun IV-terminal kinase/stress-activated protein kinases (JNK/SAPKs), Transient co-transfection of Rad Val 12 mutant with the wild-type G alpha 12 in COS7 cells leads to the further activation of an exogenously expressed hemagglutinin(HA)-tagged JNK. Furthermore, the cooperation between G alpha 12 and Rad in cellular transformation is correlated with their ability to stimulate transcription from c-fos serum response element (SRE).	CUNY MT SINAI SCH MED,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464				ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Li WQ, 1996, ONCOGENE, V13, P731; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Zhang YH, 1996, ONCOGENE, V12, P2377	36	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					727	735		10.1038/sj.onc.1201229	http://dx.doi.org/10.1038/sj.onc.1201229			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264413				2022-12-17	WOS:A1997XP68300012
J	Weinberg, WC; Montano, NE; Deng, C				Weinberg, WC; Montano, NE; Deng, C			Loss of p21(CIP1/WAF1) does not recapitulate accelerated malignant conversion caused by p53 loss in experimental skin carcinogenesis	ONCOGENE			English	Article						p53; p21(CIP1/WAF1); epidermal carcinogenesis	P53-MEDIATED G(1) ARREST; HARVEY SARCOMA-VIRUS; P53-INDEPENDENT PATHWAY; PRIMARY KERATINOCYTES; GENE DOSAGE; EXPRESSION; P21; PROGRESSION; INHIBITOR; WAF1/CIP1	The p21(CIP1/WAF1) protein is considered a downstream effector of tumor suppression by p53, We have previously demonstrated that p53 null keratinocytes have lower basal p21(CIP1/WAF1) mRNA levels and that tumors derived from these cells following transduction with the v-ras(Ha) oncogene grow faster than wildtype keratinocytes and rapidly progress to undifferentiated carcinomas (Cancer Res 54: 5584-5592, 1994), In this study, primary keratinocytes differing in p21(CIP1/WAF1) gene dose were transduced with v-ras(Ha) encoding retrovirus and grafted to nude mouse hosts to test whether the p53 null phenotype is mediated through p21(CIP1/WAF1). Resulting tumors from all genotypes were well differentiated papillomas; focal carcinomas were observed in 43, 30 and 44% of papillomas derived from +/+, +/- and -/- keratinocytes, respectively, p21(CIP1/WAF1) deficient keratinocytes expressing v-ras(Ha) do not display the degree of increased growth observed in p53 deficient tumors irt vivo or the decreased responsiveness to negative growth regulation by Ca2+ in vitro. These results suggest that p21(CIP1/WAF1) does not regulate the differentiated phenotype or malignant progression of v-ras(Ha) initiated keratinocytes and that additional functions of the p53 protein other than transcriptional regulation Of the p21(CIP1/WAF1) gene are required for p53 mediated tumor suppression.	NIDDKD,BIOCHEM & METAB LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Weinberg, WC (corresponding author), NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,NIH,BETHESDA,MD 20892, USA.		Weinberg, Wendy/A-8920-2009; deng, chuxia/N-6713-2016					Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAE IS, 1995, CANCER RES, V55, P2387; BRISSETTE JL, 1993, MOL CARCINOGEN, V7, P21, DOI 10.1002/mc.2940070105; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CONWAY K, 1992, CANCER RES, V52, P6487; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Doglioni C, 1996, J PATHOL, V179, P248, DOI 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO;2-6; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIU M, 1995, ONCOGENE, V10, P1955; Matsushita K, 1996, INT J CANCER, V69, P259, DOI 10.1002/(SICI)1097-0215(19960822)69:4<259::AID-IJC3>3.3.CO;2-D; MICHIELI P, 1994, CANCER RES, V54, P3391; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Reiners JJ, 1997, CARCINOGENESIS, V18, P593, DOI 10.1093/carcin/18.3.593; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; TENNENBAUM T, 1993, CANCER RES, V53, P4803; WALDMAN T, 1995, CANCER RES, V55, P5187; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WEINBERG WC, 1994, CANCER RES, V54, P5584; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng YX, 1996, ONCOGENE, V12, P1557	33	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					685	690		10.1038/sj.onc.1201230	http://dx.doi.org/10.1038/sj.onc.1201230			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264409				2022-12-17	WOS:A1997XP68300008
J	Luan, XD; Shi, GP; Zohouri, M; Paradee, W; Smith, DI; Decker, HJ; Cannizzaro, LA				Luan, XD; Shi, GP; Zohouri, M; Paradee, W; Smith, DI; Decker, HJ; Cannizzaro, LA			The FHIT gene is alternatively spliced in normal kidney and renal cell carcinoma	ONCOGENE			English	Article						FHIT; renal cell carcinoma	CHROMOSOME-TRANSLOCATION; TUMOR-CELLS; BREAKPOINT; FRA3B	FHIT (Fragile Histidine Triad), a putative tumor suppressor gene, was cloned from fetal brain and colon cDNA libraries, Portions of this gene are deleted in esophageal, colon, lung and breast tumors, but this gene has not been found altered in sporadic renal cell carcinomas, We report here an alternatively spliced form of this gene cloned from a kidney cDNA library, This cDNA is 1189 bp in length, and contains an additional 94 bp exon, designated exon 2a (E2a), This novel sequence is located between exon 2 and exon 3 of the FHIT gene's untranslated region and exon 2a is present in all normal kidney tissues and cell Lines, Analyses performed on sporadic renal cell carcinoma (RCC) tissues and cell Lines, show consistent loss of exon 8 of the FHIT cDNA in almost 60% of the cases, Interestingly, in a familial, as well as, in a metastatic RCC, derived from a patient with the sporadic form, exon 2a and exon 3 are also deleted, Northern analyses with the exon 2a of the familial and the metastatic RCC demonstrates concurrent loss of expression of a 4.4 kb transcript with the loss of the E2a sequence, suggesting that exon 2a of the FHIT gene may play an important role in the oncogenesis of renal cell carcinoma.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PATHOL, BRONX, NY 10461 USA; WAYNE STATE UNIV, SCH MED, DEPT INTERNAL MED, DIV HEMATOL & ONCOL, DETROIT, MI 48201 USA; UNIV MAINZ, DEPT MED, DIV HEMATOL ONCOL, D-55313 MAINZ, GERMANY	Yeshiva University; Albert Einstein College of Medicine; Wayne State University; Johannes Gutenberg University of Mainz								ANGLARD P, 1991, CANCER RES, V51, P1071; ATCHISON L, 1995, CYTOGENET CELL GENET, V71, P136, DOI 10.1159/000134092; BOGHOSIANSELL L, 1992, CYTOGENET CELL GENET, V60, P268; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Fallon B, 1989, Semin Urol, V7, P228; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRAMZA AW, 1995, BIOTECHNIQUES, V18, P228; ISHIKAWA I, 1993, HISTOPATHOLOGY, V22, P135, DOI 10.1111/j.1365-2559.1993.tb00091.x; KOVACS G, 1988, HUM GENET, V78, P148, DOI 10.1007/BF00278186; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P256, DOI 10.1002/gcc.2870030404; KOVACS G, 1989, CANCER RES, V49, P651; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAFORGIA S, 1993, CANCER RES, V53, P3118; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; Moch H, 1996, CANCER RES, V56, P27; MORITA R, 1991, CANCER RES, V51, P820; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OLSON S, 1984, TUMORS KIDNEY URINAR, P15; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; Sambrook J., 1989, MOL CLONING; Shi G, 1996, CYTOGENET CELL GENET, V75, P180, DOI 10.1159/000134473; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; WILKE CM, 1994, GENOMICS, V22, P319, DOI 10.1006/geno.1994.1390; YAMAKAWA K, 1992, GENOMICS, V14, P412, DOI 10.1016/S0888-7543(05)80234-4	27	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					79	86		10.1038/sj.onc.1201164	http://dx.doi.org/10.1038/sj.onc.1201164			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233780				2022-12-17	WOS:A1997XH58600009
J	Ryan, KM; Birnie, GD				Ryan, KM; Birnie, GD			Cell-cycle progression is not essential for c-Myc to block differentiation	ONCOGENE			English	Article						cell-cycle progression; DNA binding; Max; c-Myc; myeloid differentiation; ornithine decarboxylase	NERVE GROWTH-FACTOR; ORNITHINE DECARBOXYLASE; TRANSCRIPTIONAL ACTIVATION; HL-60 CELLS; DNA-BINDING; EXPRESSION; PROTEIN; MAX; PROLIFERATION; APOPTOSIS	The c-myc proto-oncogene has been shown to cause blockages to differentiation in many cell lineages, Although the mechanism by which c-Myc affects this process remains unknown, it is considered that it might result indirectly as an outcome of the continued cell-cycle progression invoked by c-Myc in cells which must growth arrest in order to differentiate, However, as there is little evidence to support this hypothesis, it is equally possible that a differentiation blockage occurs through a mechanism independent of c-Myc's involvement in cell-cycle progression, To explore this possibility me utilised a differentiation-defective variant of the U937 cell line, which still responds to the differentiation inducer by undergoing rapid growth Analysis of this line during growth arrest revealed that, although the expression of the Myc target gene, ornithine decarboxylase (ODC) was down-regulated, the cells differed from those of the parental line in that they continued to express high levels of c-Myc protein, did not but maintain levels of expression of the Myc antagonists, mad1 and mxi1. Moreover, antisense down-regulation of the c-Myc protein levels in these growth-arrested cells revealed that this continued c-Myc expression was essential for their differentiation blockage, These data therefore indicate that c-Myc can block differentiation by a mechanism dissociated from its ability to direct cell-cycle progression or the expression of ODC.	BEATSON INST CANC RES, CANC RES CAMPAIGN, BEATSON LABS, GLASGOW G61 1BD, LANARK, SCOTLAND	Beatson Institute				Ryan, Kevin M./0000-0002-1059-9681				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASKEW DS, 1991, ONCOGENE, V6, P1915; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BACON TA, 1991, ONCOGENE RES, V6, P21; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CHAVANY C, 1995, MOL PHARMACOL, V48, P738; CROUCH DH, 1993, ONCOGENE, V8, P1849; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FIELD JK, 1990, ANTICANCER RES, V10, P1; FINKLESTEIN R, 1988, ONCOGENE RES, V3, P287; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HAYASHI SI, 1995, BIOCHEM J, V306, P1; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HICKOK NJ, 1990, GENE, V93, P257, DOI 10.1016/0378-1119(90)90233-H; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Ingvarsson S, 1990, Semin Cancer Biol, V1, P359; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LARSSON LG, 1994, ONCOGENE, V9, P1247; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUK GD, 1982, SCIENCE, V216, P75, DOI 10.1126/science.6950518; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARUYAMA K, 1987, ONCOGENE, V1, P361; MITCHELL LS, 1992, DIFFERENTIATION, V49, P119, DOI 10.1111/j.1432-0436.1992.tb00776.x; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; ROY AL, 1993, NATURE, V365, P356; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STACEY G, 1992, CYTOTECHNOLOGY, V9, P211, DOI 10.1007/BF02521748; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	49	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	1997	14	23					2835	2843		10.1038/sj.onc.1201124	http://dx.doi.org/10.1038/sj.onc.1201124			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190900				2022-12-17	WOS:A1997XD64300012
J	Strobel, T; Swanson, L; Korsmeyer, S; Cannistra, SA				Strobel, T; Swanson, L; Korsmeyer, S; Cannistra, SA			Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells	ONCOGENE			English	Article						apoptosis; p53; BAX; radiation; ovarian; cancer	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; IN-VIVO; BCL-2; DEATH; GENE; RADIOSENSITIVITY; CHECKPOINT; INDUCTION	The p53 protein is known to play a central role in mediating G(1) arrest or apoptosis in response to ionizing radiation in some cell types, It has been proposed that the Link between p53 and induction of apoptosis is provided in part by p53-mediated upregulation of BAX. In this study, we used the human SW626 ovarian cancer cell line, which lacks functional p53, to further investigate the relationship between wildtype p53, BAX, and apoptosis, SW626 cells expressing a temperature sensitive (ts) p53 mutant did not undergo G(1) arrest or apoptosis and did not exhibit enhanced sensitivity to radiation at the permissive temperature of 32 degrees C, The tsp53 protein was functional in these cells as evidenced by rapid induction of p21 at 32 degrees C, but not at 37 degrees C, Interestingly, restoration of wildtype p53 function at 32 degrees C was not associated with BAS upregulation. In addition, stable overexpression of BAX in SW626 cells was not capable of enhancing apoptotic cell death in response to radiation, Thus, failure of p53 to upregulate BAS is not the sole reason for its inability to promote radiation-induced apoptosis in SW626 cells, Taken together, our data suggest that neither p53 nor BAX upregulation is sufficient for the induction of apoptosis in response to genotoxic damage in some cell types.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV NEOPLAST DIS MECHANISMS,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,DIV MOL ONCOL,ST LOUIS,MO	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [R01CA060670] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60670] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD JM, 1995, ONCOGENE, V11, P1921; BRACHMAN DG, 1993, CANCER RES, V53, P3667; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; HALDAR S, 1994, CANCER RES, V54, P2095; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kobayashi T, 1995, ONCOGENE, V11, P2311; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIU TJ, 1994, CANCER RES, V54, P3662; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	22	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2753	2758		10.1038/sj.onc.1201132	http://dx.doi.org/10.1038/sj.onc.1201132			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190890				2022-12-17	WOS:A1997XD64300002
J	Liao, XB; Du, YB; Morse, HC; Jenkins, NA; Copeland, NG				Liao, XB; Du, YB; Morse, HC; Jenkins, NA; Copeland, NG			Proviral integrations at the Evi5 locus disrupt a novel 90 kDa protein with homology to the Tre2 oncogene and cell-cycle regulatory proteins	ONCOGENE			English	Article						Evi5; Gfi1; leukemia; oncogene; Tre2	GENETIC-LINKAGE MAP; ZINC-FINGER PROTEIN; CHROMOSOMAL LOCALIZATION; SACCHAROMYCES-CEREVISIAE; MOUSE CHROMOSOME-5; MOLECULAR-CLONING; MESSENGER-RNA; LYMPHOMAS; SEQUENCE; FAMILY	Evi5 is a common site of retroviral integration in T-cell lymphomas of AKXD mice. Mapping studies have localized Evi5 to a region approximately 18 kb upstream of another common viral integration site, Gfi1, on mouse chromosome 5 (Liao X, Jenkins NA and Copeland NG, (1995a). J. Virol., 69, 7132-7137). Gfi1 encodes a zinc finger transcription factor involved in interleukin-2 signaling. To determine if Evi5 encodes a gene separate from Gfi1 that might also be involved in T-cell disease, we have searched within the Evi5 locus for novel transcripts. A 6.0 kb transcript was identified in these studies that spans the Evi5 locus and is disrupted by viral integration at Evi5. This transcript is expressed in all embryonic and adult mouse tissues examined. While blast searches indicated that Evi5 is a novel gene, homologies were detected between Evi5 and a known oncogene, Tre2, as well as mammalian and yeast cell cycle regulatory proteins. Evi5 thus encodes a gene separate from Gfi1 that may also be involved in T-cell disease.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702; NIAID,IMMUNOPATHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Morse, Herbert/0000-0002-9331-3705				BELL DW, 1995, CYTOGENET CELL GENET, V70, P263, DOI 10.1159/000134048; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; CHANG F, 1993, TRENDS GENET, V9, P333, DOI 10.1016/0168-9525(93)90022-A; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRANKHAUSER C, 1994, EMBO J, V13, P3011; FRANKHAUSER C, 1993, EMBO J, V12, P2697; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Green E., 1981, GENETICS PROBABILITY, DOI 10.1007/978-1-349-04904-2; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HULSEBOS TJM, 1995, GENOMICS, V29, P712, DOI 10.1006/geno.1995.9947; IHLE JN, 1990, PROG CLIN BIOL RES, V352, P329; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; JUSTICE MJ, 1992, GENOMICS, V13, P1281, DOI 10.1016/0888-7543(92)90047-V; JUSTICE MJ, 1990, GENETICS, V125, P855; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; Maniatis T., 1982, MOL CLONING; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; MIYATANI S, 1992, P NATL ACAD SCI USA, V89, P8443, DOI 10.1073/pnas.89.18.8443; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NAZAROV V, 1995, J VIROL, V69, P3885, DOI 10.1128/JVI.69.6.3885-3888.1995; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RICHARDSON PM, 1995, ONCOGENE, V11, P1139; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schmidt T, 1996, NUCLEIC ACIDS RES, V24, P2528, DOI 10.1093/nar/24.13.2528; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; WANG YC, 1995, MOL CELL BIOL, V15, P6838; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; ZHU XL, 1995, MOL CELL BIOL, V15, P5017; Zornig M, 1996, ONCOGENE, V12, P1789	49	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1023	1029		10.1038/sj.onc.1200929	http://dx.doi.org/10.1038/sj.onc.1200929			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070650				2022-12-17	WOS:A1997WM07000003
J	Mumberg, D; Haas, K; Moroy, T; Niedenthal, R; Hegemann, JH; Funk, M; Muller, R				Mumberg, D; Haas, K; Moroy, T; Niedenthal, R; Hegemann, JH; Funk, M; Muller, R			Uncoupling of DNA replication and cell cycle progression by human cyclin E	ONCOGENE			English	Article						cyclin E; DNA-replication; Saccharomyces cerevisiae; oncogene co-operation; ras oncogene	SACCHAROMYCES-CEREVISIAE; G1 CYCLIN; S-PHASE; DROSOPHILA EMBRYOGENESIS; RETINOBLASTOMA PROTEIN; SIGNAL-TRANSDUCTION; POTENTIAL MEDIATOR; DEPENDENT KINASES; DIVISION CYCLE; BUDDING YEAST	The G(1)-specific D- and E-type cyclins are among the most crucial factors controlling cell cycle progression in mammalian cells and are therefore thought to play an important role in tumorigenisis, D-type cyclins have indeed been shown to be endowed with an oncogenic potential, Here, we report that the ectopic expression of human cyclin E, but not cyclin D1, deregulates DNA synthesis in both yeast and mammalian cells, In yeast, induction of DNA synthesis by cyclin E occurs even under conditions of cell cycle arrest in G(1) or G(2)/M, indicating an uncoupling of DNA replication from cell cycle progression, In rat embryo fibroblasts, the cooperative action of Ras and cyclin E induces transformation, These cells, in contrast to those transformed by Ras and cyclin D1, show aberrant levels of DNA synthesis, Since cyclin E is commonly overexpressed in a variety of human tumors, these findings may point to a link between the uncontrolled proliferation and the genomic instability typically seen in malignant tumors, Furthermore they reveal significant differences in the functional properties of cyclin E and D1.	UNIV MARBURG, INST MOL BIOL & TUMORFORSCH, D-35033 MARBURG, GERMANY; UNIV GIESSEN, INST MIKROBIOL & MOL BIOL, D-35392 GIESSEN, GERMANY	Philipps University Marburg; Justus Liebig University Giessen			Müller, Rolf/L-4997-2016; Moroy, Tarik/D-9923-2011	Müller, Rolf/0000-0003-3339-4248; Funk, Martin/0000-0003-2721-4036				ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BASCO RD, 1995, MOL CELL BIOL, V15, P5030; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KERJAN P, 1986, NUCLEIC ACIDS RES, V14, P7861, DOI 10.1093/nar/14.20.7861; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOVEC H, 1994, ONCOGENE, V9, P323; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEWING A, 1993, J CELL SCI, V104, P545; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, TRENDS GENET, V7, P393, DOI 10.1016/0168-9525(91)90262-O; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMMEL A, 1994, ONCOGENE, V9, P995; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2	48	23	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2493	2497						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957094				2022-12-17	WOS:A1996VX10800025
J	Kudoh, T; Ishidate, T; Nakamura, T; Toyoshima, K; Akiyama, T				Kudoh, T; Ishidate, T; Nakamura, T; Toyoshima, K; Akiyama, T			Constitutive expression of the Wilms tumor suppressor gene WT1 in F9 embryonal carcinoma cells induces apoptotic cell death in response to retinoic acid	ONCOGENE			English	Article						WT1; Wilms tumor; tumor suppressor gene; apoptosis; F9	TERATOCARCINOMA STEM-CELLS; PROMOTER ACTIVITY; BAX GENE; C-MYC; DIFFERENTIATION; P53; PRODUCT; INDUCTION; PROTEIN; LOCUS	The product of the Wilms tumor suppressor gene, WT1, is thought to be a tissue specific transcription factor regulating cell growth and differentiation. To elucidate the function of WT1 in cellular differentiation, we examined the changes in the level of WT1 expression during retinoic acid induced-differentiation of embryonal carcinoma F9 cells into parietal endoderm cells. We found that, in response to retinoic acid addition, the expression of WT1 increased significantly after 12-24 h of incubation, then decreased and finally disappeared after 4 days, by which time most of the cells had differentiated into primitive endoderm cells. To examine the significance of these changes in WT1 expression, we established cell lines constitutively expressing one of the WT1 splicing variants. These cell lines showed a phenotype very similar to parental F9 cells in the absence of retinoic acid. However, in the presence of retinoic acid, they failed to differentiate into primitive endoderm cells and underwent apoptotic death 36 h after the addition of retinoic acid. These results suggest that downregulation of WT1 expression is necessary for normal differentiation of F9 cells into parietal endoderm cells.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,OSAKA 565,JAPAN; OSAKA MED CTR CANC & CARDIOVASC DIS,OSAKA 537,JAPAN	Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases								BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KLINKEN SP, 1988, EXP CELL RES, V178, P185, DOI 10.1016/0014-4827(88)90390-4; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MIWA H, 1992, LEUKEMIA, V6, P405; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORRIS JF, 1991, ONCOGENE, V6, P2339; OSHIMA RG, 1981, J BIOL CHEM, V256, P8124; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUCHER FJ, 1990, SCIENCE, V250, P1259; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SEKIYA M, 1994, BLOOD, V83, P1876; SELLINS KS, 1987, J IMMUNOL, V139, P3199; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	45	23	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1431	1439						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875981				2022-12-17	WOS:A1996VL38400008
J	Harwood, FG; Frazier, MW; Krajewski, S; Reed, JC; Houghton, JA				Harwood, FG; Frazier, MW; Krajewski, S; Reed, JC; Houghton, JA			Acute and delayed apoptosis induced by thymidine deprivation correlates with expression of p53 and p53-regulated genes in colon carcinoma cells	ONCOGENE			English	Article						p53 heterozygosity; apoptosis; cytostasis	WILD-TYPE P53; COLORECTAL-CARCINOMA; MUTANT CONFORMATION; DNA DAMAGE; BCL-2; RESISTANCE; PROTEIN; FLUOROURACIL; AMPLIFICATION; CYTOTOXICITY	The endogenous expression of p53 and p53-regulated genes has been examined in a thymidylate synthase-deficient colon carcinoma cell line (TS-) and a derived mutant clone (Thy4) that exhibit acute or delayed apoptotic responses, respectively, when released from G0 synchrony under conditions of dThd starvation. These cell clones demonstrate heterozygosity in p53, thereby expressing one wt allele and one with an A-->C point mutation at codon 240. Following release from G0, upregulated expression of both alleles occurred. During apoptosis in TS-, a wtp53 phenotype was expressed and in Thy4 during cytostasis, a mp53 phenotype was manifested, as determined from the ratios of wtp53/mp53 proteins, transactivation of p50-2 (a wtp53-responsive CAT reporter construct) and the endogenous expression of MDM2. Neither cytotoxicity nor cytostasis correlated with expression of p21(Waf1/Cip1) ThY4 cells sustained accumulation of high levels of Bax in a wtp53-independent and dThd-independent manner and survival was associated with upregulated expression of Bcl-2. In contrast, Bax expression decreased in TS- during apoptosis, except in a highly resistant subpopulation that retained high levels of Bax. Data suggest that resistant cells (Thy4) can sustain high Bax expression and that Bcl-2 is upregulated in response to an apoptotic stimulus due to the absence of negative regulation by wtp53.	ST JUDE CHILDRENS RES HOSP, DEPT MOLEC PHARMACOL, MEMPHIS, TN 38105 USA; LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	St Jude Children's Research Hospital; Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [R37 CA32613, CA60181, CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060181, P30CA021765, R37CA032613] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRISTOW RG, 1994, ONCOGENE, V9, P1527; BRONNER MP, 1995, AM J PATHOL, V146, P20; CANMAN CE, 1992, P NATL ACAD SCI USA, V89, P10474, DOI 10.1073/pnas.89.21.10474; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DOLE M, 1994, CANCER RES, V54, P3253; DONCHOWER LA, 1992, NATURE, V356, P215; DOROSHOW JH, 1990, J CLIN ONCOL, V8, P491, DOI 10.1200/JCO.1990.8.3.491; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERLICHMAN C, 1988, J CLIN ONCOL, V6, P469, DOI 10.1200/JCO.1988.6.3.469; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHER TC, 1993, CANCER RES, V53, P3321; FREBOURG T, 1994, CANCER RES, V54, P878; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HOCKENBERY D, 1991, NATURE, V349, P254; HOUGHTON JA, 1994, CANCER RES, V54, P4967; Houghton JA, 1995, CLIN CANCER RES, V1, P723; HOUGHTON PJ, 1989, P NATL ACAD SCI USA, V86, P1377, DOI 10.1073/pnas.86.4.1377; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KAMESAKI S, 1993, CANCER RES, V53, P4251; KASTAN MB, 1991, CANCER RES, V51, P6304; KEURBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEONARDO AD, 1994, GENE DEV, V8, P2540; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; OLIVER FJ, 1993, BIOCHEM BIOPH RES CO, V194, P126, DOI 10.1006/bbrc.1993.1794; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OTLVAI ZN, 1993, CELL, V74, P609; PETRELLI N, 1987, J CLIN ONCOL, V5, P1559, DOI 10.1200/JCO.1987.5.10.1559; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1994, CANCER RES, V54, P3714; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALTON MI, 1993, CANCER RES, V53, P1853; WANG YS, 1993, ONCOGENE, V8, P3427; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHAN QM, 1994, ONCOGENE, V9, P3743	63	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2057	2067						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668331				2022-12-17	WOS:A1996UP28300004
J	Brezden, CB; Rauth, AM				Brezden, CB; Rauth, AM			Differential cell death in immortalized and non-immortalized cells at confluency	ONCOGENE			English	Article						apoptosis; necrosis; confluency; immortalized; non-immortalized; p53-independence	P53; APOPTOSIS	Rat embryo fibroblast cells that have been immortalized by viral transfection have an altered cell cycle control. These cells have been observed to die via an apoptotic death when grown to confluency which, in at least one of the cell line pairs studied, was independent of the presence of wildtype or mutant p53. This confluency-dependent apoptotic cell death was observed in thirteen of fourteen rodent and human cell lines tested. In contrast, primary rodent and human cell strains (fibroblasts) entered a quiescent G(1)/G(0) state at confluency. Two weeks later, these non-immortalized cells underwent necrosis, not apoptosis. As the medium was not replenished during this two week period, cell necrosis was probably due to deprivation of nutrients and growth factors. These results indicate that mechanisms of cell death may differ between transformed and non-transformed cells under physiological stressed situations, such as high cell density. It may be possible to exploit these differences to increase the efficacy of chemotherapeutic compounds towards neoplastic cells.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON,CANADA; ONTARIO CANC INST,DIV EXPTL THERAPEUT,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto								BOWEN ID, 1993, CELL BIOL INT, V17, P365, DOI 10.1006/cbir.1993.1075; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GANNOUNZAKI L, 1994, EXP CELL RES, V213, P375, DOI 10.1006/excr.1994.1212; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KARNOVSKY MJ, 1964, J CELL BIOL, V23, P217, DOI 10.1083/jcb.23.2.217; KASTAN MB, 1991, CANCER RES, V51, P6304; LING V, 1974, J CELL PHYSIOL, V83, P103, DOI 10.1002/jcp.1040830114; LOCK RB, 1994, CANCER RES, V54, P4933; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIRZAYANS R, 1994, BRIT J CANCER, V68, P838; MYMRYK JS, 1994, ONCOGENE, V9, P1187; PEACOCK JW, 1994, EMBO J, V13, P1084, DOI 10.1002/j.1460-2075.1994.tb06357.x; PRICE TNC, 1994, ONCOGENE, V9, P2897; SMETS LA, 1994, ANTI-CANCER DRUG, V5, P3, DOI 10.1097/00001813-199402000-00001; TOMEI LD, 1993, P NATL ACAD SCI USA, V90, P853, DOI 10.1073/pnas.90.3.853; WYLLIE AH, 1973, J PATHOL, V111, P2552; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	24	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					201	206						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552393				2022-12-17	WOS:A1996TQ01400025
J	BRAUNINGER, A; STREBHARDT, K; RUBSAMENWAIGMANN, H				BRAUNINGER, A; STREBHARDT, K; RUBSAMENWAIGMANN, H			IDENTIFICATION AND FUNCTIONAL-CHARACTERIZATION OF THE HUMAN AND MURINE POLO-LIKE KINASE (PLK) PROMOTER	ONCOGENE			English	Article						SERINE THERONINE KINASE; PROMOTER; POLO-LIKE KINASE (PLK)	PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTORS; BINDING PROTEINS; ENHANCER-BINDING; DNA-BINDING; GENE; DROSOPHILA; CLONING; ENCODES	The Plk gene encodes a serine/theronine kinase which is located in the nucleus. Northern blot analysis linked Plk expression to the proliferative activity of cells and tissues. To analyse the transcriptional regulation of the Plk gene we have isolated several human genomic clones containing the Plk promoter. RNAse protection assays revealed three major transcription start sites within a 40 bp region centered around the 5' end of the known human cDNA and 6 minor Cap sites. A genomic fragment of 2.3 kb located 5' to the translation start sites drives the expression of the CAT-reporter in transient transfections in human (EPLC, HeLa) and mouse (NIH3T3, 32D) cell lines in an orientation dependent fashion. The 2.3 kb genomic fragment contains a CCAAT motif located 30-70 bp upstream of the Cap sites and two overlapping Spl sites 20 bp further upstream. Additional sequence motif homologues to binding sites of known transcription factors could be identified. In addition to the human Plk promoter, the mouse Plk promoter was isolated. The sequence alignment of the human and murine promoter revealed three regions with extensive sequence homology within a region of 300 bp immediately upstream of the Cap sites. A fourth region of homology encompassing 90 bp about 2.1 kb 5' of the Cap sites was identified as web. Deletion of various regions within the 2.3 kb promoter fragment identified several domains involved in the regulation of the human Plk promoter. The 300 bp region immediately 5' of the Cap sites which is highly conserved between mouse and man is essential for promoter activity. 3' deletions including the CCAAT site abolished promoter activity. Growing 5' deletions within the core region of the promoter reduces transcriptional activity. Furthermore, using deletion clones we identified regions 5' of the core region which enhance or silence the transcriptional activity of the core promoter.	CHEMOTHERAPEUT FORSCHUNGSINST,D-60596 FRANKFURT,GERMANY; BAYER AG,D-42113 WUPPERTAL,GERMANY	Bayer AG			Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Ausubel F. M., 1993, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; BEPLER G, 1988, DIFFERENTIATION, V37, P158, DOI 10.1111/j.1432-0436.1988.tb00806.x; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; COPERTINO DW, 1995, P NATL ACAD SCI USA, V92, P2131, DOI 10.1073/pnas.92.6.2131; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MILLIGAN JF, 1987, NUC ACIDS RES, V15, P8789; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Sambrook J., 1989, MOL CLONING LAB MANU; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHARON G, 1990, GENETICS, V125, P487; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SUNKEL CE, 1988, J CELL SCI, V89, P25; WHITE MRA, 1992, ONCOGENE, V7, P677; WRITH T, 1988, EMBO J, V7, P3109; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343	40	23	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1793	1800						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478607				2022-12-17	WOS:A1995TD09400014
J	BAKER, SJ; REDDY, EP				BAKER, SJ; REDDY, EP			B-CELL DIFFERENTIATION - ROLE OF E2A AND PAX5/BSAP TRANSCRIPTION FACTORS	ONCOGENE			English	Review						B-CELL DIFFERENTIATION; E2A; PAX5; BSAP	DNA-BINDING PROTEINS; HEAVY-CHAIN ENHANCER; LOOP-HELIX PROTEINS; LYMPHOCYTES-PRE-B; IMMUNOGLOBULIN ENHANCER; GENE-TRANSCRIPTION; NUCLEAR-LOCALIZATION; V(D)J RECOMBINATION; SWITCH REGIONS; CIRCULAR DNA	Transcriptional regulation of lineage specific genes has the ability to dictate both the proliferative and differentiative potentials of a pulipotent precursor cell. The E2A and Pax5/BSAP genes encode transcription factors which bind to B cell specific promoters and enhancers and guide the development of immature, but committed cells into mature B lymphocytes which express and secrete immunoglobulins. In vitro analysis has consistently suggested that these proteins regulate distinct classes of genes during B cell differentiation; however, recent targeted gene disruption and transgene expression in mice has indicated that these genes may actually be components of a single regulatory mechanism which is essential for both B lymphocyte differentiation and proliferation.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011					ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ALESSANDRINI A, 1991, MOL CELL BIOL, V11, P2096, DOI 10.1128/MCB.11.4.2096; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARBERIS A, 1989, GENE DEV, V3, P663, DOI 10.1101/gad.3.5.663; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DERIE MA, 1989, CELL IMMUNOL, V118, P368, DOI 10.1016/0008-8749(89)90385-7; DORN A, 1989, MOL CELL BIOL, V9, P312, DOI 10.1128/MCB.9.1.312; DORSHKIND K, 1994, CELL, V79, P751, DOI 10.1016/0092-8674(94)90065-5; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; GERONDAKIS S, 1990, P NATL ACAD SCI USA, V87, P1581, DOI 10.1073/pnas.87.4.1581; GOLAY JT, 1987, IMMUNOLOGY, V62, P279; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HERMANSON GG, 1989, P NATL ACAD SCI USA, V86, P7341, DOI 10.1073/pnas.86.19.7341; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; JACOBS Y, 1994, MOL CELL BIOL, V14, P4087, DOI 10.1128/MCB.14.6.4087; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P1897, DOI 10.1073/pnas.85.6.1897; LIAO F, 1994, J IMMUNOL, V152, P2904; LIAO F, 1992, J IMMUNOL, V148, P2909; LIEBERSON R, 1991, NUC ACIDS RES, V19, P165; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; LUTZKER S, 1988, MOL CELL BIOL, V8, P1849, DOI 10.1128/MCB.8.4.1849; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOSS LG, 1988, MOL CELL BIOL, V8, P2620, DOI 10.1128/MCB.8.6.2620; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEURATH MF, 1994, J IMMUNOL, V153, P730; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OKABE T, 1992, EUR J IMMUNOL, V22, P31, DOI 10.1002/eji.1830220106; PEREZMUTUL J, 1988, NUCLEIC ACIDS RES, V16, P6085, DOI 10.1093/nar/16.13.6085; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; PEZZUTTO A, 1987, J IMMUNOL, V138, P2793; RADCLIFFE G, 1990, MOL CELL BIOL, V10, P382, DOI 10.1128/MCB.10.1.382; RAJEWSKY K, 1992, CURR OPIN IMMUNOL, V4, P171, DOI 10.1016/0952-7915(92)90008-3; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; SAISANIT S, 1995, MOL CELL BIOL, V15, P1513; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2788, DOI 10.1073/pnas.88.7.2788; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; SU LK, 1990, MOL CELL BIOL, V10, P2619, DOI 10.1128/MCB.10.6.2619; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TANAKA M, 1993, CELL, V60, P275; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSAO BP, 1988, NUCLEIC ACIDS RES, V16, P3239, DOI 10.1093/nar/16.8.3239; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WATERS SH, 1989, MOL CELL BIOL, V9, P5594, DOI 10.1128/MCB.9.12.5594; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS M, 1991, GENE DEV, V5, P2353, DOI 10.1101/gad.5.12a.2353; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; XIN XQ, 1993, J IMMUNOL, V151, P5398; XU LZ, 1992, INT IMMUNOL, V4, P875, DOI 10.1093/intimm/4.8.875; Xu M, 1990, Dev Immunol, V1, P11, DOI 10.1155/1990/47659; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310	101	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					413	426						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630627				2022-12-17	WOS:A1995RN53000001
J	MULLER, E; SCHEIDTMANN, KH				MULLER, E; SCHEIDTMANN, KH			PURIFICATION AND CHARACTERIZATION OF A PROTEIN-KINASE WHICH IS ACTIVATED BY SV40 LARGE T-ANTIGEN AND PHOSPHORYLATES THE TUMOR-SUPPRESSOR PROTEIN P53	ONCOGENE			English	Article						T-ANTIGEN; LT-ACTIVATED KINASE; P53 PHOSPHORYLATION; CELL CYCLE; TRANSFORMATION	WILD-TYPE P53; CELL-CYCLE CONTROL; DNA-REPLICATION; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; GENE AMPLIFICATION; 3T3 CELLS; SITE; TRANSFORMATION; BINDING	In SV40-transformed or infected rat cells phosphorylation of the tumor suppressor protein p53 is enhanced due to activation of kinases. At least three different kinases can be co-precipitated with p53-large T (LT) immune complexes, casein kinase II representing the major activity, a cyclin dependent kinase (Cdk), and a kinase which appears to be specifically activated by LT (E Muller, B Boldyreff and KH Scheidtmann, Oncogene 8: 2193-2205, 1993). In this paper we describe the purification and identification of the LT-activated kinase that phosphorylates a site adjacent to the Cdk site in rat p53. To monitor the activity a synthetic peptide was used containing glutamic acid at the position of Ser-313, thus mimicking a phosphorylated Cdk site, With a combination of Mono Q chromatography and subsequent affinity chromatographies with p13(suc1) and a p53-fragment as ligands a 42 kDa protein kinase was purified to near homogeneity from SV40-transformed rat cells, This kinase phosphorylated both the peptide substrate and the native rat p53, Interestingly, phosphorylation of the specific site seemed to depend on prior phosphorylation of the Cdk site. On the other hand, the kinase seemed to be activated by LT, as the activity towards the peptide substrate was significantly higher in extracts from wildtype LT-transformed cells than from normal or mutant LT-transformed cells, This activation was not restricted to rat cells but occurred in SV40-transformed mouse and infected monkey cells as well, Phosphorylation of the specific site by LT-activated kinase was not dependent on the presence of LT in vitro suggesting that activation of the LT-activated kinase is probably indirect rather than through direct interaction with LT. Cell cycle studies revealed that the LT-activated kinase is cell cycle regulated, since its activity was not detectable in M phase but increased during G1 phase after which it remained relatively constant.	UNIV BONN, INST GENET, DEPT MOLEC GENET, D-53117 BONN, GERMANY	University of Bonn								BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FISCELLA M, 1993, ONCOGENE, V8, P1519; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALL PA, 1993, ONCOGENE, V8, P203; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE HA, 1991, METHOD ENZYMOL, V200, P268; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO K, 1990, ONCOGENE, V5, P921; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MULLER E, 1993, ONCOGENE, V8, P2193; OREN M, 1992, CANCER METAST REV, V11, P141, DOI 10.1007/BF00048060; OROURKE RW, 1990, ONCOGENE, V5, P1829; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHEIDTMANN KH, 1994, INT J ONCOL, V5, P1353; SCHEIDTMANN KH, 1989, CURR TOP MICROBIOL, V144, P85; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUSSI T, 1990, ONCOGENE, V5, P945; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YU JS, 1994, J BIOL CHEM, V269, P14341; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	74	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1175	1185						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700642				2022-12-17	WOS:A1995QN35300019
J	WOLKOWICZ, R; ELKIND, NB; RONEN, D; ROTTER, V				WOLKOWICZ, R; ELKIND, NB; RONEN, D; ROTTER, V			THE DNA-BINDING ACTIVITY OF WILD-TYPE P53 IS MODULATED BY BLOCKING ITS VARIOUS ANTIGENIC EPITOPES	ONCOGENE			English	Article						DNA-BINDING; P53; ANTIGENIC EPITOPES	CELL-CYCLE CONTROL; A MOUSE CELLS; MUTANT P53; MONOCLONAL-ANTIBODY; GROWTH SUPPRESSION; CONTROL PROTEIN; TUMOR-ANTIGEN; NORMAL 3T3; EXPRESSION; GENE	Interaction of wild type p53 with specific DNA target sequences, which is dictated by several structural domains, can be modified by blocking the different antigenic epitopes of the protein. Comparison of p53 protein expressed by recombinant bacteria (wtp53-Bac) to that produced in an eukaryotic system by a vaccinia expression vector (wtp53-Vac), indicated that only the later exhibited spontaneous DNA-binding activity. Furthermore, DNA-binding patterns of these wild type p53 proteins were affected differently by their interactions with monoclonal anti-p53 antibodies recognizing individual antigenic epitopes of the molecule. While the vaccinia derived p53 that spontaneously bound DNA is supershifted by the N'-terminal specific antibodies PAb-248, the bacterial derived p53 protein that retains this antigenic epitope but does not bind DNA spontaneously, is not affected. The C'-terminal specific PAb-421 antibodies accelerated binding of the bacterial p53 protein and modified the pattern of the interaction of the vaccinia derived p53 DNA. DNA-binding patterns generated by PAb-421 and PAb-248, suggest that either interaction of wild type p53 is dependent on modification of the p53 protein or that it interacts with cellular factors which their activity can be mimicked by PAb-421. Saturation of both types of wild type p53 with several anti-p53 monoclonal antibodies directed against the wild type p53 specific epitope that maps to the N'-terminal border of the DNA-binding region, blocked specific DNA-binding. The fact that most p53 mutants have lost the wild type p53 conformation specific epitope coupled with the observation that blocking of this site by binding specific antibodies, prevents the interaction of wild type p53 with DNA, suggests that maintaining the correct structural conformation of this site is central for DNA-binding activity. The wild type specific epitope which maps to the N'-terminal border of the DNA-binding region is neighboring the first P-strand detected by the recent crystallographic analysis.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DEPPERT W, 1990, ONCOGENE, V5, P1701; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRISON SC, 1991, NATURE, V353; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KELMAN Z, 1989, BLOOD, V74, P2318; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHALOVITZ D, 1989, P NATL ACAD SCI USA, V86, P8763; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RONEN D, 1992, NUCLEIC ACIDS RES, V20, P3435, DOI 10.1093/nar/20.13.3435; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; Rotter Varda, 1993, Trends in Cell Biology, V3, P46, DOI 10.1016/0962-8924(93)90151-P; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TARUNINA M, 1993, ONCOGENE, V8, P3165; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, J IMMUNOL METHODS, V151, P237; WADEHARPER J, 1993, CELL, V75, P805; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	73	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1167	1174						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7535417				2022-12-17	WOS:A1995QN35300018
J	COX, LS; MIDGLEY, CA; LANE, DP				COX, LS; MIDGLEY, CA; LANE, DP			XENOPUS P53 IS BIOCHEMICALLY SIMILAR TO THE HUMAN TUMOR-SUPPRESSOR PROTEIN P53 AND IS INDUCED UPON DNA-DAMAGE IN SOMATIC-CELLS	ONCOGENE			English	Article							WILD-TYPE P53; CASEIN KINASE-II; LARGE T-ANTIGEN; PURIFIED DNA; FREE-EXTRACT; SV40-TRANSFORMED CELLS; REPLICATION OCCURS; GENE AMPLIFICATION; NUCLEAR-ENVELOPE; BINDING FUNCTION	Xenopus p53 cDNA, homologous to the human tumour suppressor p53, has previously been cloned from oocyte and gastrula libraries. In this report, we describe a polyclonal antibody 2674 raised against Xenopus p53 (Xp53) expressed in bacteria, that recognises proteins of approximately 52, 46 and 35 kDa present in Xenopus oocytes, parthenogenically activated eggs and in somatic tissue culture cells. We report here purification of Xp53 from insect cells infected with XpS3-baculovirus, and this protein is shown to be phosphorylated by casein kinase II but has low sequence-specific DNA binding activity. Using similar purification conditions, we have isolated endogenous Xp53, shelving that Xenopus eggs contain high levels of p53 protein. Xp53 from eggs binds to the p53-specific DNA-binding consensus sequence. Two dimensional gel analysis indicates that Xp53 from eggs may exist in various states of phosphorylation. u.v.-induced DNA damage of somatic Xenopus cells results in accumulation of Xp53. We suggest that the high levels of putative Xp53 detected in eggs may represent maternal stockpiles of a protein necessary to protect rapidly dividing cells from the effects of DNA damage.			COX, LS (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,CRC,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND.		Cox, Lynne/AAT-2047-2021; Lane, David P/C-4920-2008	Cox, Lynne/0000-0002-5306-285X; Lane, David/0000-0003-0551-3545				BACHVAROVA R, 1966, J EXP ZOOL, V163, P285, DOI 10.1002/jez.1401630307; BLOW JJ, 1990, J CELL SCI, V95, P383; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX LS, 1992, J CELL SCI, V101, P43; COX LS, 1991, CELL, V66, P271, DOI 10.1016/0092-8674(91)90617-8; COX LS, 1990, J CELL SCI, V97, P177; Davidson E. H., 1986, GENE ACTIVITY EARLY; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARVEY M, 1993, ONCOGENE, V8, P2457; HOEVER M, 1994, ONCOGENE, V9, P109; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HUTCHISON C, 1989, J CELL SCI, V93, P605; HUTCHISON CJ, 1988, DEVELOPMENT, V103, P553; HUTCHISON CJ, 1987, EMBO J, V6, P2003, DOI 10.1002/j.1460-2075.1987.tb02464.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILLS AD, 1989, J CELL SCI, V94, P471; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	58	23	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2951	2959						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084598				2022-12-17	WOS:A1994PG82200021
J	SEWING, A; MULLER, R				SEWING, A; MULLER, R			PROTEIN-KINASE-A PHOSPHORYLATES CYCLIN D1 AT 3 DISTINCT SITES WITHIN THE CYCLIN BOX AND AT THE C-TERMINUS	ONCOGENE			English	Note							RETINOBLASTOMA PROTEIN; NUCLEAR-PROTEIN; CELL-CYCLE; BINDING; ACTIVATION; SEQUENCES; PHASE; G(1)	Cyclin D1 is a nuclear phosphoprotein that is thought to play a major role in the control of G(0)/G(1)-->S progression. The fact that its expression is not tightly regulated during cell cycle progression suggests that its activity might be modulated by post-translational mechanisms. In the present study, we show that out of five serine-threonine kinases tested only protein kinase A (PKA) was able to phosphorylate cyclin D1 in vitro. In agreement with this observation, forskolin treatment, but not TPA stimulation, led to increased phosphorylation of cyclin D1 in vivo. Phosphoamino acid analysis and two-dimensional phosphopeptide mapping of wild-type and truncated cyclin D1 proteins showed that PKA phosphorylates three distinct serine residues in cyclin D1 at positions 90, 197 and 234. Serine-90 is located within the cyclin box, raising the possibility that phosphorylation of cyclin D1 might play a role in regulating the interaction with other proteins.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KATO J, 1993, GENE DEV, V7, P331; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SEWING A, 1994, J CELL SCI, V107, P581; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	20	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2733	2736						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058338				2022-12-17	WOS:A1994PC05400036
J	TIEMANN, F; DEPPERT, W				TIEMANN, F; DEPPERT, W			IMMORTALIZATION OF BALB/C MOUSE EMBRYO FIBROBLASTS ALTERS SV40 LARGE T-ANTIGEN INTERACTIONS WITH THE TUMOR-SUPPRESSOR P53 AND RESULTS IN A REDUCED SV40 TRANSFORMATION-EFFICIENCY	ONCOGENE			English	Article							ADENOVIRUS E1A PROTEINS; SIMIAN VIRUS-40; MONOCLONAL-ANTIBODIES; WILD-TYPE; ONCOGENIC TRANSFORMATION; CELLULAR-TRANSFORMATION; BINDING-SITES; MUTANT P53; CELLS; COOPERATION	In order to analyse the immortalizing and transforming potential of simian virus 40 (SV40), we compared the transformation efficiencies of SV40 in primary and in established BALB/c mouse fibroblasts. Five independently isolated clones of freshly immortalized normal fibroblasts (FTE cells) were established from precrisis BALB/c mouse embryo fibroblasts (pMEF cells) according to the protocol for establishing 3T3 cells (Todaro & Green, 1963). These cells expressed a wild-type p53 and were indistinguishable in all parameters analysed from original 3T3 cells kept in our laboratory. Using abortive infection to control gene dosage, followed by selection of transformed cells by cloning in soft agar, SV40 was able to transform primary cells with a much higher efficiency than 3T3 or FTE cells. Analysis of this unexpected result revealed that the different transformation efficiencies of SV40 in primary and established cells correlated with an altered cellular response to SV40 infection regarding metabolic stabilization of p53 complexed to large T during abortive infection. Whereas p53 in pMEF cells became stabilized upon abortive infection with SV40, p53 in 3T3 and FTE cells remained unstable. Our results strongly favour the hypothesis that metabolic stabilization and the ensuing higher levels of p53 in abortively infected cells enhance the transforming competence of large T.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY	Heinrich Pette Institute; University of Hamburg								AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1989, ONCOGENE, V4, P1103; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DEPPERT W, 1989, NATO ASI SERIES; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ECKHART W, 1989, ONCOGENES MOL ORIGIN, P223; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUKUSAWA K, 1991, MOL CELL BIOL, V11, P3472; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MANFREDI JJ, 1993, J VIROL, V67, P4750, DOI 10.1128/JVI.67.8.4750-4759.1993; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MONTENARH M, 1985, EMBO J, V4, P2941, DOI 10.1002/j.1460-2075.1985.tb04027.x; OLSON DC, 1993, ONCOGENE, V8, P2353; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; PRIVES C, 1991, COLD SH Q B, V56, P227; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; REIHSAUS E, 1992, EXP CELL RES, V199, P10, DOI 10.1016/0014-4827(92)90456-I; RICHTER W, 1990, VIROLOGY, V174, P543, DOI 10.1016/0042-6822(90)90108-4; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRMBECK R, 1987, J VIROL, V61, P3561, DOI 10.1128/JVI.61.11.3561-3569.1987; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WALSER A, 1986, EMBO J, V5, P883, DOI 10.1002/j.1460-2075.1986.tb04299.x; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERG RA, 1989, CANCER RES, V49, P3713; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZERRAHN J, 1992, ONCOGENE, V7, P1371; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	74	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1907	1915						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208537				2022-12-17	WOS:A1994NR68500014
J	OHTANIFUJITA, N; FUJITA, T; TAKAHASHI, R; ROBBINS, PD; DRYJA, TP; SAKAI, T				OHTANIFUJITA, N; FUJITA, T; TAKAHASHI, R; ROBBINS, PD; DRYJA, TP; SAKAI, T			A SILENCER ELEMENT IN THE RETINOBLASTOMA TUMOR-SUPPRESSOR GENE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; SITE-DIRECTED MUTAGENESIS; POLYMERASE CHAIN-REACTION; LARGE T-ANTIGEN; CELL-CYCLE; SUSCEPTIBILITY GENE; E2F-BINDING SITE; BINDING PROTEIN; CARCINOMA-CELLS; REPORTER GENE	We have previously identified two positive regulatory elements in the retinoblastoma gene (RB) promoter. One is an ATF site and the other we have called a retinoblastoma binding factor 1 site. In addition, a consensus E2F site is located directly 3' to the ATF site. Here we demonstrate with gel shift assays that E2F and E2F-dependent complexes can bind in vitro to the E2F site of the RB promoter (RB-E2F site). Moreover, we demonstrate that deletion of the RB-E2F site results in stimulation of RB promoter activity in transient transfection assays in several cell lines. Specific point mutations in the E2F site that inhibit the binding of E2F and its complexes also stimulate the RB promoter activity, suggesting that a factor(s) that can bind to the RB-E2F site could be a silencer. RB promoter activity was also stimulated two- to four-fold by mutation of the E2F site in the RB-negative cell lines, J82 and HTB9. Taken together, our results show that the E2F site in the promoter of the RB tumor-suppressor gene acts as a silencer element and that the silencer effect of the E2F site is not necessarily dependent on the presence of the RB protein.	KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; KYOTO UNIV,FAC MED,DEPT PATHOL 2,KYOTO 606,JAPAN; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261; HARVARD UNIV,SCH MED,MASSACHUSETTS EYE & EAR INFIRM,DEPT OPHTHALMOL,BOSTON,MA 02114	Kyoto Prefectural University of Medicine; Kyoto University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary								BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISTCHENKO AS, 1993, INT J CANCER, V53, P87, DOI 10.1002/ijc.2910530117; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SLACK RS, 1993, ONCOGENE, V8, P1585; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YOKOTA J, 1988, ONCOGENE, V3, P471; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	55	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1703	1711						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183566				2022-12-17	WOS:A1994NL81500023
J	TONISSEN, KF; KRIEG, PA				TONISSEN, KF; KRIEG, PA			ANALYSIS OF A VARIANT MAX SEQUENCE EXPRESSED IN XENOPUS-LAEVIS	ONCOGENE			English	Article							C-MYC; DNA-BINDING; RAS COTRANSFORMATION; TRANSCRIPTION; PROTEIN; REQUIRES; ONCOGENE; CELLS; FORMS	Max is a small helix-loop-helix protein which forms heterodimers with members of the Myc protein family. Myc/Max heterodimers exhibit sequence-specific DNA binding with much greater affinity than Myc homodimers. The Xenopus laevis homologue of Max, XMax, is shorter than the equivalent mammalian protein. This difference results from the deletion of a 24 amino acid sequence located near the C-terminus of the protein. Xenopus max transcripts undergo alternative splicing. In addition to the 27 base alternatively spliced sequence (exon A) previously detected in mice and humans, some Xmax transcripts also contain an 81 base sequence (exon B) at a second site within the coding sequence. Although exon B insertion alters part of the leucine zipper protein/protein interaction domain, the resulting XMax protein retains the ability to form stable heterodimers with both c-Myc acid N-Myc. Xmax mRNA is present at approximately constant levels during early development. This contrasts with the rapidly changing levels of c-myc and N-myc mRNA in the embryo and has implications for regulation of gene expression during differentiation. All four alternatively spliced forms of Xmax mRNA are present during development and in all adult tissue examined.	UNIV TEXAS,CTR DEV BIOL,DEPT ZOOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin			Tonissen, Kathryn F/E-9424-2010	Tonissen, Kathryn F/0000-0002-1018-2798	NICHD NIH HHS [HD25179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025179] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Battey, 1986, BASIC METHODS MOL BI; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DEAN M, 1986, J BIOL CHEM, V261, P9161; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; GERHART JG, 1980, MECHANISMS REGULATIN, P133; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HOURDRY J, 1988, DEVELOPMENT, V104, P631; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MELTON DA, 1979, CELL, V18, P1165, DOI 10.1016/0092-8674(79)90229-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VASTRIK I, 1993, ONCOGENE, V8, P503; VIZE PD, 1990, DEVELOPMENT, V110, P885	30	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					33	38						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302600				2022-12-17	WOS:A1994MW24700005
J	MAXWELL, SA; ROTH, JA				MAXWELL, SA; ROTH, JA			BINDING OF CELLULAR PROTEINS TO A CONFORMATIONAL DOMAIN OF TUMOR-SUPPRESSOR PROTEIN P53	ONCOGENE			English	Note							WILD-TYPE P53; T-ANTIGEN; ACTIVATING MUTATIONS; DNA-REPLICATION; GENE-PRODUCT; LUNG-CANCER; TRANSFORMATION; MUTANT; SEQUENCE; WILD-TYPE-P53	The genes regulated by p53, as well as the factors modulating its function, need to be identified before the mechanism of action of p53 in control of cell growth can be adequately understood, Binding of the SV40 large T-antigen protein to an evolutionally conserved (conformational) domain of p53 inhibits p53's DNA-binding and transcription activation activities. Cellular proteins might also bind to this same region of p53 to regulate its function. A hybrid protein composed of protein A fused to the conformational domain (amino acids 115-295) of p53 was expressed in Escherichia coli and used as an affinity probe for binding proteins in detergent lysates of non-small cell lung carcinoma (NSCLC) cells. The wildtype p53 hybrid protein associated with several major proteins of molecular weights 45 K, 56 K, and 70 K, as web as other minor species ranging in molecular weight from 30 K to 90 K. These proteins bound specifically to the p53 sequence of the hybrid protein. Protein A did not associate with these proteins and the two p53 hybrid proteins containing missense mutations at codons 273 and 175 exhibited a 40-80% weaker association. In addition, T antigen competed with the cellular proteins for binding to the conformational domain. The conditions of cell growth had a profound effect on the expression of the p53 binding proteins. Considerably more p53 binding proteins were expressed in actively growing cells than in culture's maintained under conditions for slow growth. Quantitative differences in expression of p53-binding proteins were observed among different NSCLC cell lines. The expression of p53-binding proteins was not restricted to NSCLC cell lines; detergent extracts of an osteosarcoma cell line yielded similar p53-binding proteins.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CARDIOVASC SURG,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	MAXWELL, SA (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT THORAC SURG,1515 HOLCOMBE BLVD,BOX 109,HOUSTON,TX 77030, USA.				NCI NIH HHS [2P30-CA16672-018, NCI CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1993, EUR J CANCER, V29A, P101, DOI 10.1016/0959-8049(93)90584-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1992, CANCER SURV, V12, P59; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, VIROLOGY, V98, P308, DOI 10.1016/0042-6822(79)90554-3; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEDCALF EA, 1992, ONCOGENE, V7, P71; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER CW, 1990, CANCER RES, V50, P7950; MILNER J, 1990, ONCOGENE, V5, P1683; MITSUDOMI T, 1992, ONCOGENE, V7, P171; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	47	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3421	3426						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247546				2022-12-17	WOS:A1993MG78200028
J	PICHEL, JG; LAKSO, M; WESTPHAL, H				PICHEL, JG; LAKSO, M; WESTPHAL, H			TIMING OF SV40 ONCOGENE ACTIVATION BY SITE-SPECIFIC RECOMBINATION DETERMINES SUBSEQUENT TUMOR PROGRESSION DINING MURINE LENS DEVELOPMENT	ONCOGENE			English	Article							TRANSGENIC MICE; ANTIGEN EXPRESSION; DNA RECOMBINATION; MAMMALIAN-CELLS; MOUSE LENS; GENE; CRYSTALLIN; PROMOTER; DIFFERENTIATION; TUMORIGENESIS	We generated mice that carry copies of a dormant transgene encoding the SV40 tumor antigens. The transgenes are specifically targeted to the lens and contain features that render their expression dependent on the action of Cre, a site-specific bacteriophage DNA recombinase. Timing of oncogene activation was controlled by making Cre available either prior to, or coincident with, the onset of primary fiber differentiation in the embryonic lens vesicle. Early expression of Cre resulted in oncogene activation in undifferentiated lens epithelial cells that rapidly proliferated inside the lens capsule. By contrast, when Cre accumulation was delayed to coincide with the onset of primary lens fiber differentiation, SV40 oncogenes were activated in cells that had begun to elongate and to accumulate lens-specific crystallins. During subsequent proliferation inside the lens capsule, transformed progeny cells maintained the profile of fiber differentiation that their parent cells had acquired at the time of oncogenic conversion. Developing lens tumors were confined within the capsule of the embryonic lens. However, if the capsule was perforated in an embryonic eye in organ culture, cells rapidly grew out while still maintaining features of differentiation. Our findings show that the differentiated state of the primary target cells is an important parameter of subsequent lens oncogenesis, and that an intact lens capsule can restrict invasive neoplastic growth.	NICHHD, MAMMALIAN GENES & DEV LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Pichel, Jose G/AAF-2255-2019	Pichel, Jose G/0000-0001-8580-0952				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; BUTEL JS, 1990, INTERVIROLOGY, V31, P85, DOI 10.1159/000150142; CHEN JD, 1992, ONCOGENE, V7, P1167; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FUKUSHIGE S, 1992, P NATL ACAD SCI USA, V89, P7905, DOI 10.1073/pnas.89.17.7905; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hogan B., 1986, MANIPULATING MOUSE E; KHILLAN JS, 1987, GENE DEV, V1, P1327, DOI 10.1101/gad.1.10.1327; KOTHARY R, 1991, MECH DEVELOP, V35, P25, DOI 10.1016/0925-4773(91)90038-8; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCAVOY JW, 1980, DIFFERENTIATION, V17, P137, DOI 10.1111/j.1432-0436.1980.tb01091.x; NAKAMURA T, 1989, New Biologist, V1, P193; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; SAUER B, 1987, MOL CELL BIOL, V7, P2087, DOI 10.1128/MCB.7.6.2087; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; TRETON JA, 1991, DIFFERENTIATION, V47, P143, DOI 10.1111/j.1432-0436.1991.tb00232.x; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; WESTPHAL H, 1992, ADV DEV BIOL, V1, P183; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZWAAN J, 1983, DEV BIOL, V96, P173, DOI 10.1016/0012-1606(83)90320-2	28	23	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3333	3342						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247535				2022-12-17	WOS:A1993MG78200017
J	BRADBURY, JM; ARNO, J; EDWARDS, PAW				BRADBURY, JM; ARNO, J; EDWARDS, PAW			INDUCTION OF EPITHELIAL ABNORMALITIES THAT RESEMBLE HUMAN BREAST-LESIONS BY THE EXPRESSION OF THE NEU/ERBB-2 ONCOGENE IN RECONSTITUTED MOUSE MAMMARY-GLAND	ONCOGENE			English	Article							DUCTAL CARCINOMA INSITU; NEU ONCOGENE; PROTEIN OVEREXPRESSION; C-ERBB-2 PROTEIN; CELL-LINE; TUMORS; CANCER; RECEPTOR; GENE; PROTOONCOGENE	We have developed a transplantation system that allows us to introduce oncogenes into mouse mammary epithelial cells in culture and then to reconstitute an epithelial tree in vivo from the genetically altered cells. Introduction of the neu oncogene, a transforming homologue of the human proto-oncogene c-erbB-2, produced a variety of abnormal patterns of epithelial growth, many of which resembled lesions found in human breasts. In four of 43 oncogene-bearing glands, areas of ductal carcinoma in situ were found, an abnormality previously observed in transgenic neu-bearing mice. Six glands developed localized areas of dense stroma containing excess ductal structures comprised of mildly hyperplastic epithelium. These areas resembled the human breast lesion termed sclerosing adenosis. Other glands developed hyperplastic epithelium, sometimes with multilayering of the cells and/or atypical changes such as abnormally large nuclei. In human breasts such lesions would be termed mild or atypical hyperplasia. In all the abnormal areas examined, levels of neu protein above background level were detected by immunohistochemistry. Some staining was localized to membranes (as observed in ductal carcinoma in situ in humans) but cytoplasmic staining was also common in the lesions induced in mice by the neu oncogene. The range of abnormalities seen in the reconstituted glands carrying the neu oncogene suggests that the matching lesions in the human breast may be stages on one pathway to tumour development.			BRADBURY, JM (corresponding author), UNIV CAMBRIDGE, DEPT PATHOL, TENNIS COURT RD, CAMBRIDGE CB2 1QP, ENGLAND.		Edwards, Paul A/M-8291-2014	Edwards, Paul A/0000-0002-4789-3374				BANERJEE M R, 1976, TCA (Tissue Culture Association) Manual, V2, P457, DOI 10.1007/BF00918341; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARTKOVA J, 1990, HUM PATHOL, V21, P1164, DOI 10.1016/0046-8177(90)90154-W; BATTIFORA H, 1990, HISTOPATHOLOGY, V16, P105, DOI 10.1111/j.1365-2559.1990.tb01076.x; BERGER MS, 1988, CANCER RES, V48, P1238; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRADBURY JM, 1988, INT J CANCER, V42, P923, DOI 10.1002/ijc.2910420623; BRADBURY JM, 1991, INT J CANCER, V48, P908, DOI 10.1002/ijc.2910480619; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEOME KB, 1959, CANCER RES, V19, P515; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; EDWARDS PAW, 1988, ONCOGENE, V2, P407; EDWARDS PAW, 1993, IN PRESS CANCER SURV; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GULLICK WJ, 1990, INT J CANCER, P55; GUSTERSON BA, 1988, BRIT J CANCER, V58, P453, DOI 10.1038/bjc.1988.239; GUSTERSON BA, 1987, MOL CELL PROBE, V1, P383, DOI 10.1016/0890-8508(87)90019-3; GUSTERSON BA, 1988, INT J CANCER, V42, P842, DOI 10.1002/ijc.2910420608; HANNA W, 1990, MODERN PATHOL, V3, P455; LACROIX H, 1989, ONCOGENE, V4, P145; LEMOINE NR, 1990, ONCOGENE, V5, P237; LIU E, 1992, ONCOGENE, V7, P1027; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NIELSEN LL, 1991, CANCER RES, V51, P3762; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; PORTER PL, 1991, CANCER, V68, P331, DOI 10.1002/1097-0142(19910715)68:2<331::AID-CNCR2820680221>3.0.CO;2-X; PRESS MF, 1990, ONCOGENE, V5, P953; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; STRANGE R, 1992, DEVELOPMENT, V115, P49; SUDA Y, 1990, EMBO J, V9, P181, DOI 10.1002/j.1460-2075.1990.tb08094.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VATTEN LJ, 1992, EUR J CANCER, V28A, P1148, DOI 10.1016/0959-8049(92)90476-I; WANG BC, 1991, CANCER RES, V51, P5649; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	41	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1551	1558						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8099220				2022-12-17	WOS:A1993LE06400018
J	BRAUNINGER, A; KARN, T; STREBHARDT, K; RUBSAMENWAIGMANN, H				BRAUNINGER, A; KARN, T; STREBHARDT, K; RUBSAMENWAIGMANN, H			CHARACTERIZATION OF THE HUMAN CSK LOCUS	ONCOGENE			English	Note							PROTEIN-TYROSINE KINASE; RECEPTOR GENE; SEQUENCE; PHOSPHORYLATION; PP60C-SRC; PROTOONCOGENE; EXPRESSION; ONCOGENES; CLONING; DOMAINS	The CSK-gene encodes an intracellular protein-tyrosine kinase (PTK). In contrast to members of the src-family, an autophosphorylation site corresponding to Tyr416, as well as the equivalent of the regulatory Tyr527 in p60c-src are missing in the amino acid sequence deduced from the gene. CSK phosphorylates other members of the src-family of tyrosine kinases at their regulatory carboxy-terminus. By regulating the activity of these kinases, CSK may play an important role in cell growth and development. Here we describe the structure of the human CSK gene. The entire coding region spans a genomic distance of only 4.9 kb. It encompasses 12 exons ranging between 66 and 220 bp in size. The introns between coding exons vary between 76 and 920 bp in length. An exon coding for the 5'-untranslated region of CSK is separated from the first coding exon by an intron of more than 6400 bp. Based on comparisons of sequence homologies within the catalytic domains, the intracellular PTKs are divided into the src-family, the fes/fer- and the abl/arg-group. The genomic structure of four members of the SRC-family revealed nearly identical exon/intron boundaries within the catalytic domain of this family. They differ from those described for FES. Comparing the genomic structure of CSK with the exon/intron organisation of both, it is obvious that the exon/intron boundaries are in common either with those of the SRC-type or the FES boundaries. This intermediate exon/intron structure of CSK between FES and the SRC-family agrees with the position of CSK in a phylogenetic tree based on sequence homology within the kinase domain.	CHEMOTHERAPEUT FORSCHUNGSINST,GEORG SPEYER HAUS,PAUL EHRLICH STR 42-44,W-6000 FRANKFURT 70,GERMANY	Octapharma			karn, t/C-7452-2013; Karn, Thomas/AAE-7723-2019; Strebhardt, Klaus/E-8765-2011	karn, t/0000-0002-3264-6573; Karn, Thomas/0000-0002-3264-6573; Strebhardt, Klaus/0000-0003-2173-9763				AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; ANDRE C, 1992, ONCOGENE, V7, P685; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HRADETZKY D, 1992, GENE, V113, P275, DOI 10.1016/0378-1119(92)90407-G; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PARTANEN J, 1991, ONCOGENE, V6, P2013; PATEL M, 1990, ONCOGENE, V5, P201; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0	37	23	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1365	1369						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	7683131				2022-12-17	WOS:A1993KY32800030
J	KWONG, YY; HUSAIN, Z; BISWAS, DK				KWONG, YY; HUSAIN, Z; BISWAS, DK			C-HA-RAS GENE MUTATION AND ACTIVATION PRECEDE PATHOLOGICAL-CHANGES IN DMBA-INDUCED INVIVO CARCINOGENESIS	ONCOGENE			English	Article							MULTISTEP CARCINOGENESIS; CELLULAR ONCOGENES; COLORECTAL CANCERS; CARCINOMA; NEOPLASIA; MODEL; DNA	We have previously reported a stage-specific and sequential overexpression of the c-Ha-ras and c-erhB genes in 7, 12-dimethylbenzanthracene (DMBA)-induced in vivo carcinogenesis in hamster buccal pouch epithelium (HBPE). In this investigation, the immunoreactive protein product of the c-Ha-ras gene (p21 protein) was identified in HBPE cells, specifically in treated tissues and cultured cells established after 3 weeks of DMBA treatment. Microscopic examination did not show any histopathological changes in these tissues. The p21 protein was detected in a few selective cells, which were dispersed away from the more densely populated basal layer. The overexpression of the c-Ha-ras gene was accompanied by a point mutation of A --> T in codon 61 (CAA), inducing an amino acid substitution from the wild-type glutamine to leucine in the- peptide. The concurrent molecular modifications preceded any detectable histopathological changes. The cellular morphology and orientation in treated HBPE at this early stage was indistinguishable from the control tissue. Yet the genetic alterations, such as the point mutation and overexpression of the gene, were evident at the predysplastic stage. Amplification and overexpression of the second proto-oncogene, c-erbB, and its product, epidermal growth factor receptor (EGFR), were detected in HBPE cells at the later stages of extensive cell proliferation and invasion. By using double antibodies and two immunoreporter systems, we demonstrated overexpression of both c-Ha-ras and c-erbB genes in the same HBPE cells during this chemically induced in vivo carcinogenesis.	HARVARD UNIV,SCH DENT MED,MOLEC BIOL LAB,188 LONGWOOD AVE,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED,BOSTON,MA 02115	Harvard University; Harvard School of Dental Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HEIM, 1987, CANCER CYTOGENETICS; HUSAIN Z, 1989, P NATL ACAD SCI USA, V86, P1264, DOI 10.1073/pnas.86.4.1264; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; KUMAR R, 1990, ONCOGENE, V5, P1271; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; MIYAMOTO S, 1990, MOL CELL BIOL, V10, P1593, DOI 10.1128/MCB.10.4.1593; NUZUM EO, 1990, MOL CARCINOGEN, V3, P287, DOI 10.1002/mc.2940030509; POLVERINI PJ, 1986, LAB INVEST, V54, P432; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SOLT DB, 1988, CARCINOGENESIS, V9, P2173, DOI 10.1093/carcin/9.12.2173; SUKUMAR S, 1990, CANCER CELL-MON REV, V2, P199; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; WONG DTW, 1987, ONCOGENE, V2, P67	31	23	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1481	1489						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630811				2022-12-17	WOS:A1992JE81300003
J	SELS, FT; LANGER, S; SCHULZ, AS; SILVER, J; SITBON, M; FRIEDRICH, RW				SELS, FT; LANGER, S; SCHULZ, AS; SILVER, J; SITBON, M; FRIEDRICH, RW			FRIEND MURINE LEUKEMIA-VIRUS IS INTEGRATED AT A COMMON SITE IN MOST PRIMARY SPLEEN TUMORS OF ERYTHROLEUKEMIC ANIMALS	ONCOGENE			English	Article							MOUSE MYELOBLASTIC LEUKEMIAS; PUTATIVE ONCOGENE; THYMIC LYMPHOMAS; CELL-LINES; DNA; ACTIVATION; SPI-1; PROGRESSION; EXPRESSION; POLYMERASE	A common proviral integration site was identified and characterized in erythroleukaemias induced by Friend murine leukaemia virus (F-MuLV). Using inverse polymerase chain reaction, we found a proviral integration site common to at least 90% of 20 primary tumours tested. This site was identical to Fli-1, a locus recently reported by others to be rearranged in 75% (9/12) of cell lines established from spleens of erythroleukaemic mice and to code for a member of the ets gene family. Our data suggest that about half of the F-MuLV-induced erythroleukaemias contained more than one cell clone with a proviral integration in Fli-1, with different individual integration sites within Fli-1 in each cell clone. All proviruses were found to be integrated in the same transcriptional orientation with respect to flanking cellular DNA. We discuss these findings in relation to multistage models of neoplasm.	UNIV GIESSEN,INST MED VIROL,FRANKFURTER STR 107,W-6300 GIESSEN,GERMANY; HOP COCHIN,INSERM,U152,ICGM,IMMUNOL & ONCOL MALADIES RETROVIRALES LAB,F-75674 PARIS 14,FRANCE; NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892	Justus Liebig University Giessen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Sitbon, Marc/A-6771-2010	Sitbon, Marc/0000-0003-3616-2338				BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BEAR SE, 1989, P NATL ACAD SCI USA, V86, P7495, DOI 10.1073/pnas.86.19.7495; BELLACOSA A, 1991, MOL CELL BIOL, V11, P2864, DOI 10.1128/MCB.11.5.2864; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERGERON D, 1991, J VIROL, V65, P7, DOI 10.1128/JVI.65.1.7-15.1991; BORDEREAUX D, 1987, J VIROL, V61, P4043, DOI 10.1128/JVI.61.12.4043-4045.1987; CHATTOPADHYAY SK, 1981, VIROLOGY, V113, P465, DOI 10.1016/0042-6822(81)90175-6; CHATTOPADHYAY SK, 1982, NATURE, V295, P25, DOI 10.1038/295025a0; CHESEBRO B, 1983, VIROLOGY, V128, P221, DOI 10.1016/0042-6822(83)90332-X; CUYPERS HTM, 1986, J VIROL, V60, P230, DOI 10.1128/JVI.60.1.230-241.1986; DREYFUS F, 1990, LEUKEMIA, V4, P590; DUGAICZYK A, 1975, J MOL BIOL, V96, P171, DOI 10.1016/0022-2836(75)90189-8; FAMULARI NG, 1983, CURR TOP MICROBIOL, V103, P75; FRIEDRICH RW, 1990, EMBL GENBANK NUCLEOT; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; KABAT D, 1990, CURR TOP MICROBIOL I, V148, P1; KELLY M, 1983, J VIROL, V45, P291, DOI 10.1128/JVI.45.1.291-298.1983; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; OLIFF A, 1984, P NATL ACAD SCI-BIOL, V81, P5464, DOI 10.1073/pnas.81.17.5464; OLIFF A, 1981, BLOOD, V58, P244; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; RANDS E, 1981, VIROLOGY, V108, P445, DOI 10.1016/0042-6822(81)90451-7; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULZ AS, 1988, J GEN VIROL, V69, P2663, DOI 10.1099/0022-1317-69-10-2663; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; SHIBUYA T, 1982, CELL, V31, P483, DOI 10.1016/0092-8674(82)90141-6; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; SILVER J, 1990, J VIROL, V64, P3150; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; SITBON M, 1986, CELL, V47, P851, DOI 10.1016/0092-8674(86)90800-7; SITBON M, 1990, J VIROL, V64, P2135, DOI 10.1128/JVI.64.5.2135-2140.1990; SOLA B, 1986, J VIROL, V60, P718, DOI 10.1128/JVI.60.2.718-725.1986; TSICHLIS PN, 1985, J VIROL, V56, P258, DOI 10.1128/JVI.56.1.258-267.1985; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L	39	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					643	652						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565463				2022-12-17	WOS:A1992HQ68200005
J	GAUTHIERROUVIERE, C; BASSET, M; LAMB, NJC; FERNANDEZ, A				GAUTHIERROUVIERE, C; BASSET, M; LAMB, NJC; FERNANDEZ, A			ROLE OF FOS-AP-1 BINDING SEQUENCE (FAP) IN THE INDUCTION OF C-FOS EXPRESSION BY PURIFIED C-KINASE AND IN C-FOS DOWN-REGULATION FOLLOWING SERUM INDUCTION	ONCOGENE			English	Article							RESPONSE ELEMENT; PROTO-ONCOGENE; AUTO-REGULATION; DNA-BINDING; GENE; TRANSCRIPTION; AP-1; JUN; IDENTIFICATION; PROMOTER	Microinjection of purified calcium phospholipid-dependent protein kinase (C-kinase) resulted in the rapid and transient induction of c-fos in quiescent rat embryo fibroblast. This C-kinase-induced expression of c-fos was prevented by in vivo competition using co-injection of oligonucleotides corresponding to the sequence of either the serum response element (SRE) or the fos AP-1 binding sequence (FAP) adjacent to SRE. This indicates that both these sequences must be involved in the binding/activation of protein factors required for the induction of c-fos by C-kinase. In contrast, the induction of c-fos by serum or by casein kinase II microinjection, which is also inhibited by injection of SRE oligonucleotides, is only delayed and then markedly prolonged by injecting TRE/FAP sequence, demonstrating that the FAP site plays a prominent role in vivo in the down-regulation of the endogenous c-fos gene expression.	CNRS,INSERM,BP5051,CRBM,CELL BIOL,ROUTE MENDE,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier				GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, GENE DEV, V7, P4305; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P324; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	26	23	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					363	369						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549354				2022-12-17	WOS:A1992HG98200023
J	LEPRINCE, D; CREPIEUX, P; STEHELIN, D				LEPRINCE, D; CREPIEUX, P; STEHELIN, D			C-ETS-1 DNA-BINDING TO THE PEA3 MOTIF IS DIFFERENTIALLY INHIBITED BY ALL THE MUTATIONS FOUND IN V-ETS	ONCOGENE			English	Article							LONG TERMINAL REPEAT; C-ETS; LEUKEMIA-VIRUS; PROTO-ONCOGENE; LYMPHOID-CELLS; E26 RETROVIRUS; SEQUENCE; PROTEINS; GENE; EXPRESSION	The proto-oncogene c-ets-1, one of the two cellular sequences transduced by the avian retrovirus E26, encodes for two transcription factors that activate through a purine-rich motif. The v-ets oncogene differs from its cellular progenitor p68c-ets-1 (i) by its fusion to gag- and myb-derived sequences in the E26 P135gag-myb-ets fusion protein, (ii) by two point mutations, and (iii) by the replacement of the 13 C-terminal amino acids present in c-ets-1 by 16 unrelated residues in v-ets. A 35 kDa protein which binds to the purine-rich PEA3 motif in a sequence-specific manner has been obtained by expression in Escherichia coli of the 311 carboxy-terminal amino acids of c-ets-1. Using various v-/c-ets-1 chimeric 35 kDa proteins expressed in bacteria, we have shown that all the mutations found in v-ets, when introduced into this c-ets-1 protein, diminish or even abolish its sequence-specific DNA binding. These results demonstrate that, in addition to the previously defined 85 amino acids located near the carboxy terminus of the c-ets-1 protein (the ETS domain), other sequences are required for sequence-specific DNA binding. In addition, the c-ets-1 35 kDa polypeptide carrying the two point mutations and the viral-specific carboxy terminus, and thus similar to the v-ets-encoded domain of the E26 P135gag-myb-ets, does not bind to the PEA3 motif.			LEPRINCE, D (corresponding author), INST PASTEUR,INSERM,U186,CNRS,URA 1160,1 RUE CALMETTE,F-59019 LILLE,FRANCE.		Crepieux, Pascale/X-3217-2019	Leprince, Dominique/0000-0002-1999-0775				BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Ivanov X, 1962, B I PATHOL COMP ANIM, V9, P5; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; POGNONEC P, 1989, ONCOGENE, V4, P691; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; REDDY ESP, 1990, CANCER RES, V50, P5013; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TREISMAN J, 1989, CELL, V59, P553; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	38	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					9	17						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741168				2022-12-17	WOS:A1992HC22700002
J	HAMANN, U; WENZEL, A; FRANK, R; SCHWAB, M				HAMANN, U; WENZEL, A; FRANK, R; SCHWAB, M			THE MYCN PROTEIN OF HUMAN NEUROBLASTOMA-CELLS IS PHOSPHORYLATED BY CASEIN KINASE-II IN THE CENTRAL REGION AND AT SERINE 367	ONCOGENE			English	Article							SV40 LARGE-T; RETINOBLASTOMA SUSCEPTIBILITY GENE; EPIDERMAL GROWTH-FACTOR; BALB/C 3T3 FIBROBLASTS; AMINO-ACID-SEQUENCE; HUMAN C-MYC; N-MYC; DNA-BINDING; ADENOVIRUS E1A; NUCLEAR-LOCALIZATION	The MYCN gene has been implicated in certain neuronal tumours, such as neuroblastomas and retinoblastomas. These tumours express high levels of mRNA and protein of MYCN as a result of amplification. MYCN encodes a short-lived nuclear phosphoprotein whose function has not yet been elucidated. This study was undertaken to determine the pattern of MYCN protein (pMYCN) phosphorylation in human neuroblastoma cells. We report that pMYCN is phosphorylated in vitro by purified casein kinase II (CK-II). Two-dimensional phosphopeptide maps showed that most of the phosphopeptides of pMYCN phosphorylated in vitro by CK-II correspond to those phosphorylated in vivo. Fine mapping of the phosphorylation sites was performed using two synthetic MYCN peptides corresponding to pMYCN CK-II consensus sequences. Both peptides were found to be phosphorylated by CK-II and competitively inhibited CK-II phosphorylation of pMYCN in vitro. Thus, we have localized two major CK-II phosphorylation sites in pMYCN, one to the highly acidic central region and the second to serine 367 proximal to the C-terminus. Our data demonstrate that pMYCN is a physiological substrate for CK-II and, since CK-II activity is stimulated in response to mitogens, CK-II phosphorylation of pMYCN may, therefore, represent one signal transduction pathway used by neuroblastoma cells.	UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	HAMANN, U (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,INST EXPTL PATHOL,W-6900 HEIDELBERG,GERMANY.							ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BISTER K, 1987, ONCOGENE, V1, P97; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; CAVALIERI F, 1988, ONCOGENE, V2, P289; CHAN PK, 1986, J BIOL CHEM, V261, P1868; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; FIGGE J, 1988, NATURE, V334, P109, DOI 10.1038/334109a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FIRZLAFF J M, 1989, New Biologist, V1, P44; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1987, ANN REV BIOCH, V56, P567; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MA A, 1989, GROWTH REGULATION CA, V2, P17; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINNA LA, 1979, BIOCHEM BIOPH RES CO, V87, P114, DOI 10.1016/0006-291X(79)91654-1; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SPECTOR DL, 1987, ONCOGENE, V1, P5; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; WALTON GM, 1983, J BIOL CHEM, V258, P4440; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	66	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1745	1751						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923500				2022-12-17	WOS:A1991GX11800004
J	KUHAR, SG; LEHMAN, JM				KUHAR, SG; LEHMAN, JM			T-ANTIGEN AND P53 IN PRECRISIS AND POSTCRISIS SIMIAN VIRUS-40-TRANSFORMED HUMAN CELL-LINES	ONCOGENE			English	Article							TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; TRANSFORMED-CELLS; HUMAN-FIBROBLASTS; VIRUS-40; PROTEIN; SV40; GROWTH; FORMS	Infection of normal human diploid fibroblasts (HF) with the DNA tumor virus simian virus 40 (SV) leads to an extension of lifespan and concomitant increase in' the levels of the viral large tumor antigen (T antigen) and the cellular protein p53. The intracellular localization of T antigen and p53 was mostly nuclear in both SVpre-crisis and SVpost-crisis cells, however certain population doubling (PD) of the SVpre-crisis cells exhibited some cytoplasmic staining. The DNA content of SVpre-crisis cells shifted to tetraploidy and the SVpost-crisis cells were near-tetraploid. Quantitation of T antigen and p53 in single cells by flow cytometry demonstrated that for all antibodies tested the levels of T antigen were higher in the SVpre-crisis HF than in the SVpost-crisis. The quantity of p53 increased with increasing age of SVpre-crisis HF, and the levels of p53 were higher in the SVpost-crisis HF populations. Immunoprecipitation of p53, T antigen and complexes demonstrated that all p53 was bound to T antigen in SVpre-crisis HF and SVpost-crisis HF. The SVpre-crisis HF cells showed that 33% of all T antigen was bound to p53, while 67% was free, and the SVpost-crisis HF exhibited 50% free T antigen and 50% bound to p53. The half-life of p53 was similar in all SVpre-crisis HF; however, the half-life was 2-3 times greater in SVpost-crisis HF than in SVpre-crisis HF. These results suggest that the interaction of DNA (ploidy), T antigen, p53 and complexes may be involved in formation of a stable SV40-transformed human cell line.	UNION UNIV,DEPT MICROBIOL & IMMUNOL,A-68,ALBANY,NY 12208	Union College			Lehman, John M./AAU-4849-2020		NCI NIH HHS [CA41608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA041608, R01CA041608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1989, ONCOGENE, V4, P1103; GIRARDI AJ, 1966, ANN MED EXP BIOL FEN, V44, P242; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARA H, 1987, EXP CELL RES, V168, P531, DOI 10.1016/0014-4827(87)90025-5; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; JACOBBERGER JW, 1986, CYTOMETRY, V7, P356, DOI 10.1002/cyto.990070410; JENKINS JR, 1988, ONCOGENE HDB; KOPROWSKI H, 1962, J CELL COMPAR PHYSL, V59, P281, DOI 10.1002/jcp.1030590308; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LAFFIN J, 1989, CYTOMETRY, V10, P205, DOI 10.1002/cyto.990100212; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMAN JM, 1979, J SUPRAMOLEC STRUCT, V10, P25; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; SACK GH, 1981, EXP CELL RES, V134, P425, DOI 10.1016/0014-4827(81)90442-0; SACK GH, 1981, IN VITRO CELL DEV B, V17, P1; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHEIN HM, 1962, P SOC EXP BIOL MED, V109, P495, DOI 10.3181/00379727-109-27246; TACK LC, 1989, J VIROL, V63, P2352, DOI 10.1128/JVI.63.5.2352-2356.1989; TACK LC, 1988, J VIROL, V62, P1028, DOI 10.1128/JVI.62.3.1028-1037.1988; Tooze J, 1981, MOL BIOL TUMOR VIRUS; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0	32	23	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1499	1506						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1656367				2022-12-17	WOS:A1991GX27400002
J	RIGHI, M; SASSANO, M; VALSASNINI, P; SHAMMAH, S; RICCIARDICASTAGNOLI, P				RIGHI, M; SASSANO, M; VALSASNINI, P; SHAMMAH, S; RICCIARDICASTAGNOLI, P			ACTIVATION OF THE M-CSF GENE IN MOUSE MACROPHAGES IMMORTALIZED BY RETROVIRUSES CARRYING A V-MYC ONCOGENE	ONCOGENE			English	Article							AVIAN LEUKEMIA VIRUSES; C-MYC; NUCLEOTIDE-SEQUENCE; MURINE RETROVIRUSES; MESSENGER-RNA; GROWTH-FACTOR; CELL-LINES; MONOCLONAL-ANTIBODY; TUMORS INVIVO; TRANSFORMATION	We have recently immortalized murine brain macrophages (microglial cells) with a complex of retroviruses (3RV) transducing separately the myc and mil oncogenes. Surprisingly, the immortalized cells harboured an exogenous v-myc oncogene, but no v-mil sequences. The transformed macrophage cell lines grew in vitro without the addition of exogenous growth factors and were also able to grow in vivo in nude mice. In addition, they released oncogenic retroviruses able to immortalize mouse macrophages from primary splenic or thymic cultures. Molecular cloning of the provirus (VN-11) harboured in a microglial clone demonstrated that no cell-derived sequences apart from an avian v-myc gene were transduced by the recombinant retrovirus. When cells were tested for production of myeloid growth factors, they were found to transcribe and synthesize the Macrophage-Colony Stimulating Factor (M-CSF). The correlation between viral infection and activation of the M-CSF gene was tested using a M-CSF dependent cells line from which growth factor independent clones could be readily obtained after infection. The synthesis of M-CSF was detected only in cells expressing the avian v-myc protein. These data support the hypothesis that, in our conditions, macrophages can be immortalized by the expression of v-myc and the concomitant establishment of an autocrine loop triggered by viral infection.			RIGHI, M (corresponding author), UNIV MILAN,DEPT PHARMACOL,CNR,CTR CYTOPHARMACOL,VIA VANVITELLI 32,I-20129 MILAN,ITALY.		Righi, Marco/P-4332-2019; Righi, Marco Giovanni Enea/M-9003-2019; Righi, Marco Giovanni Enea/G-5171-2011	Righi, Marco Giovanni Enea/0000-0003-1181-0327; Righi, Marco Giovanni Enea/0000-0003-1181-0327				AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BIRCHENALLROBERTS MC, 1989, ONCOGENE, V4, P731; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; CORY S, 1987, ONCOGENE RES, V1, P61; DEAN M, 1987, ONCOGENE RES, V1, P279; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1982, BIOCHIM BIOPHYS ACTA, V651, P245, DOI 10.1016/0304-419X(82)90014-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GREEN SM, 1989, ONCOGENE, V4, P737; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HERR W, 1984, J VIROL, V49, P471, DOI 10.1128/JVI.49.2.471-478.1984; HOLLON T, 1989, J VIROL, V63, P3353, DOI 10.1128/JVI.63.8.3353-3361.1989; JANSEN HW, 1985, VIROLOGY, V142, P248, DOI 10.1016/0042-6822(85)90333-2; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; KAN NC, 1983, P NATL ACAD SCI USA, V81, P3004; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; METCALF D, 1982, INT J CANCER, V30, P773, DOI 10.1002/ijc.2910300616; METCALF D, 1984, HEMOPOIETIC COLONIES; MORI L, 1985, EMBO J, V4, P2025, DOI 10.1002/j.1460-2075.1985.tb03887.x; NEDOSPASOV SA, 1986, NUCLEIC ACIDS RES, V14, P7713, DOI 10.1093/nar/14.19.7713; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RIGHI M, 1989, ONCOGENE, V4, P223; RIGHI M, 1989, EUR J IMMUNOL, V19, P1443, DOI 10.1002/eji.1830190815; SAULE S, 1982, J VIROL, V42, P71, DOI 10.1128/JVI.42.1.71-82.1982; SAULE S, 1984, EXP CELL RES, V155, P496, DOI 10.1016/0014-4827(84)90209-X; SHER E, 1989, J CELL BIOL, V108, P2291, DOI 10.1083/jcb.108.6.2291; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SYMONDS G, 1989, ONCOGENE, V4, P285; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; VOGT M, 1989, ONCOGENE RES, V4, P19; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7	44	23	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					103	111						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1825138				2022-12-17	WOS:A1991EY03900014
J	RE, GG; ANTOUN, GR; ZIPF, TF				RE, GG; ANTOUN, GR; ZIPF, TF			MODULATION OF A CONSTITUTIVE TRANSCRIPTIONAL BLOCK AT EXON-1 CONTROLS HUMAN C-MYC ONCOGENE EXPRESSION	ONCOGENE			English	Note									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DIV LAB MED,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	RE, GG (corresponding author), UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DIV PEDIAT,PEDIAT LEUKEMIA RES PROGRAM,HOUSTON,TX 77030, USA.							ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BUTTURINI A, 1988, INT J CELL CLONING, V6, P2, DOI 10.1002/stem.5530060103; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DOEFLER W, 1981, J GEN VIROL, V47, P1; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOURNEY RM, 1987, FOCUS, V10, P5; HUEBNER K, 1989, CANCER RES, V49, P4071; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KELLY K, 1988, J BIOL CHEM, V263, P4828; LEE WMF, 1989, ONCOGENES, P37; LIEBERMANN DA, 1989, ONCOGENE, V4, P589; RE GG, 1985, VIROLOGY, V146, P27, DOI 10.1016/0042-6822(85)90050-9; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0	21	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1247	1250						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	1697411				2022-12-17	WOS:A1990DX36100019
J	HART, PA; MARSHALL, CJ				HART, PA; MARSHALL, CJ			AMINO-ACID 61 IS A DETERMINANT OF SENSITIVITY OF RAP PROTEINS TO THE RAS GTPASE ACTIVATING PROTEIN	ONCOGENE			English	Note									INST CANC RES,CHESTER BEATTY LABS,FULHAM RD,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HALL A, 1990, G PROTEINS MEDIATORS, P173; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PIZON V, 1988, ONCOGENE, V3, P201; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646	23	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1099	1101						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2115644				2022-12-17	WOS:A1990DP41500025
J	SUKEGAWA, J; AKATSUKA, T; SUGAWARA, I; MORI, S; YAMAMOTO, T; TOYOSHIMA, K				SUKEGAWA, J; AKATSUKA, T; SUGAWARA, I; MORI, S; YAMAMOTO, T; TOYOSHIMA, K			MONOCLONAL-ANTIBODIES TO THE AMINO-TERMINAL SEQUENCE OF THE C-YES GENE-PRODUCT AS SPECIFIC PROBES OF ITS EXPRESSION	ONCOGENE			English	Note									UNIV TOKYO,INST MED SCI,DEPT ONCOL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MED SCI,DEPT PATHOL,MINATO KU,TOKYO 108,JAPAN; NATL INST HLTH,DEPT ENTEROVIRUSES,SHINAGAWA KU,TOKYO 141,JAPAN	University of Tokyo; University of Tokyo								CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COLLET MS, 1987, P NATL ACAD SCI USA, V75, P2021; COOPER JA, 1990, IN PRESS PROTEIN PEP; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MAGOTA K, 1984, J BACTERIOL, V157, P909, DOI 10.1128/JB.157.3.909-917.1984; MCKEARN TJ, 1980, MONOCLONAL ANTIBODIE, P368; MORI S, 1989, LAB INVEST, V61, P93; OHASHI M, 1980, EXP GERONTOL, V15, P121, DOI 10.1016/0531-5565(80)90083-2; SEMBA K, 1985, SCIENCE, V227, P1038, DOI 10.1126/science.2983418; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMAMOTO T, 1989, IN PRESS MECHANISMS; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538	21	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					611	614						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2183163				2022-12-17	WOS:A1990DB85300023
J	DUTT, K; SCOTT, M; DELMONTE, M; AGARWAL, N; STERNBERG, P; SRIVASTAVA, SK; SRINIVASAN, A				DUTT, K; SCOTT, M; DELMONTE, M; AGARWAL, N; STERNBERG, P; SRIVASTAVA, SK; SRINIVASAN, A			ESTABLISHMENT OF HUMAN RETINAL-PIGMENT EPITHELIAL-CELL LINES BY ONCOGENES	ONCOGENE			English	Article									W KELLOG EYE CTR,DEPT OPHTHALMOL,ANN ARBOR,MI 48105; UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814; WISTAR INST,PHILADELPHIA,PA 19104; EMORY UNIV,SCH MED,DEPT OPHTHALMOL,ATLANTA,GA 30322; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284	Uniformed Services University of the Health Sciences - USA; The Wistar Institute; Emory University; University of Texas System; University of Texas Health San Antonio	DUTT, K (corresponding author), MOREHOUSE SCH MED,DEPT PATHOL,ATLANTA,GA 30310, USA.			Del Monte, Monte/0000-0002-3153-959X	NCRR NIH HHS [RR-08248, G12-RR-03034-03S1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003034, S06RR008248] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAYLEY SA, 1988, EXP CELL RES, V177, P232, DOI 10.1016/0014-4827(88)90042-0; BUITENWERF J, 1982, INTERVIROLOGY, V17, P222, DOI 10.1159/000149292; BUTEL JS, 1984, EXP MOL PATHOL, V40, P79, DOI 10.1016/0014-4800(84)90068-6; CHANG S E, 1986, Biochimica et Biophysica Acta, V823, P161, DOI 10.1016/0304-419X(86)90001-6; CHANG SE, 1982, CANCER RES, V42, P2040; COWELL JK, 1981, CANCER RES, V41, P1508; DAYAGROSJEAN L, 1984, INT J CANCER, V33, P319, DOI 10.1002/ijc.2910330308; DELMONTE MA, 1981, VISION RES, V21, P137, DOI 10.1016/0042-6989(81)90147-4; DELMONTE MA, 1980, IN VITRO EPITHELIAL, V16, P327; DELMONTE MA, 1985, INVEST OPHTHALMOL  S, V26, P339; EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718; FLOOD MT, 1981, VISION RES, V21, P119, DOI 10.1016/0042-6989(81)90144-9; FOREST C, 1983, CELL BIOL INT REP, V7, P73, DOI 10.1016/0309-1651(83)90106-6; FROST E, 1978, VIROLOGY, V91, P39, DOI 10.1016/0042-6822(78)90353-7; GOODING LR, 1982, J IMMUNOL, V129, P1306; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGGERTY JG, 1988, P NATL ACAD SCI USA, V85, P6797, DOI 10.1073/pnas.85.18.6797; HAYATA I, 1983, CANCER RES, V43, P367; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAVAIL MM, 1976, EXP EYE RES, V23, P227, DOI 10.1016/0014-4835(76)90206-2; LAVAIL MM, 1975, J HERED, V66, P242, DOI 10.1093/oxfordjournals.jhered.a108621; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; Namba M, 1981, GANN MONOGR CANCER R, V27, P221; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PATHAK S, 1981, GENES CHROMOSOMES NE, P405; Ponten J, 1971, Virol Monogr, V8, P1; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; TEVETHIA MJ, 1984, VIROLOGY, V137, P414, DOI 10.1016/0042-6822(84)90234-4; TOPP WC, 1980, DNA TUMOR VIRUSES, P205; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; VOGT M, 1986, MOL CELL BIOL, V6, P3545, DOI 10.1128/MCB.6.10.3545; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3864, DOI 10.1128/MCB.8.9.3864; WOODWORTH C, 1986, CANCER RES, V46, P4018	40	23	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					195	200						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	2320373				2022-12-17	WOS:A1990CU02900005
J	LIU, JX; SINGH, B; WLODEK, D; ARLINGHAUS, RB				LIU, JX; SINGH, B; WLODEK, D; ARLINGHAUS, RB			CELL CYCLE-MEDIATED STRUCTURAL AND FUNCTIONAL ALTERATION OF P85GAG-MOS PROTEIN-KINASE ACTIVITY	ONCOGENE			English	Article									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT MOLEC PATHOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT MED ONCOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA45125, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARLINGHAUS RB, 1985, J GEN VIROL, V66, P1845, DOI 10.1099/0022-1317-66-9-1845; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BLAIR DG, 1979, VIROLOGY, V95, P303, DOI 10.1016/0042-6822(79)90486-0; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; FRIED J, 1976, J CELL BIOL, V71, P172, DOI 10.1083/jcb.71.1.172; GALLICK GE, 1984, VIROLOGY, V139, P366, DOI 10.1016/0042-6822(84)90382-9; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GALLICK GE, 1984, MODERN APPROACHES VA, P407; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERZOG NK, 1988, ONCOGENE, V3, P225; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1986, ENZYMES, V17, P191; KESHET E, 1988, ONCOGENE, V2, P235; KLOETZER WS, 1984, VIROLOGY, V138, P143, DOI 10.1016/0042-6822(84)90154-5; KLOETZER WS, 1983, P NATL ACAD SCI-BIOL, V80, P412, DOI 10.1073/pnas.80.2.412; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MAXWELL SA, 1985, J VIROL, V55, P874, DOI 10.1128/JVI.55.3.874-876.1985; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; Meistrich ML, 1983, CELL SEPARATION METH, V2, P33; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, ONCOGENE, V2, P227; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHOJI S, 1981, P NATL ACAD SCI-BIOL, V78, P848, DOI 10.1073/pnas.78.2.848; SINGH B, 1986, P NATL ACAD SCI USA, V83, P3629, DOI 10.1073/pnas.83.11.3629; SINGH B, 1986, VIROLOGY, V152, P502, DOI 10.1016/0042-6822(86)90156-X; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; SINGH B, 1989, IN PRESS VIROLOGY, V172; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WEINMASTER G, 1983, J VIROL, V46, P29, DOI 10.1128/JVI.46.1.29-41.1983	47	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					171	178						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	2138725				2022-12-17	WOS:A1990CU02900002
J	GRAND, RJA; BYRD, PJ; GRABHAM, PW; GREGORY, CD; HUEN, DS; MERRICK, RM; YOUNG, LS; GALLIMORE, PH				GRAND, RJA; BYRD, PJ; GRABHAM, PW; GREGORY, CD; HUEN, DS; MERRICK, RM; YOUNG, LS; GALLIMORE, PH			THE EXPRESSION OF THE RETINOBLASTOMA GENE-PRODUCT RB1 IN PRIMARY AND ADENOVIRUS-TRANSFORMED HUMAN-CELLS	ONCOGENE			English	Article											GRAND, RJA (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT CANC STUDIES,CANCER RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		Young, Lawrence S/B-7213-2009; Huen, David/F-3676-2014	Young, Lawrence S/0000-0003-3919-4298; Huen, David/0000-0002-9900-2297				BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; BYRD PJ, 1988, ONCOGENE, V2, P477; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOORBAR J, 1986, EMBO J, V5, P355, DOI 10.1002/j.1460-2075.1986.tb04219.x; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; FIGGE J, 1988, NATURE, V334, P109, DOI 10.1038/334109a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; Gallimore PH, 1984, CANCER CELL, V2, P519; GLUZMAN Y, 1980, P NATL ACAD SCI-BIOL, V77, P3898, DOI 10.1073/pnas.77.7.3898; GODBOUT R, 1983, NATURE, V304, P451, DOI 10.1038/304451a0; GRABHAM PW, 1988, EXP EYE RES, V47, P123, DOI 10.1016/0014-4835(88)90029-2; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; GRAND RJA, 1986, EMBO J, V5, P1253, DOI 10.1002/j.1460-2075.1986.tb04354.x; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MANOS MM, 1985, J VIROL, V53, P120, DOI 10.1128/JVI.53.1.120-127.1985; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; PARASKEVA C, 1982, J GEN VIROL, V58, P73, DOI 10.1099/0022-1317-58-1-73; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; YOKOTA J, 1988, ONCOGENE, V3, P471	37	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1291	1298						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682458				2022-12-17	WOS:A1989AX65900004
J	DOLCETTI, R; RIZZO, S; VIEL, A; MAESTRO, R; DE RE, V; FERIOTTO, G; BOIOCCHI, M				DOLCETTI, R; RIZZO, S; VIEL, A; MAESTRO, R; DE RE, V; FERIOTTO, G; BOIOCCHI, M			N-MYC ACTIVATION BY PROVIRAL INSERTION IN MCF 247-INDUCED MURINE T-CELL LYMPHOMAS	ONCOGENE			English	Article									CTR RIFERIMENTO ONCOL, DIV EXPTL ONCOL 1, VIA PEDEMONTANA OCCIDENTALE, I-33081 AVIANO, ITALY	IRCCS Aviano (CRO)			Viel, Alessandra/J-7116-2018; Maestro, Roberta/M-1846-2015; DE RE, VALLI/AAA-1374-2019; Dolcetti, Riccardo/O-3832-2015; Maestro, Roberta/P-9748-2019; De Re, Valli/K-4121-2016; Rizzo, Silvana/AAW-1132-2020	Viel, Alessandra/0000-0003-2804-0840; Maestro, Roberta/0000-0002-6642-5592; DE RE, VALLI/0000-0001-6100-9373; Dolcetti, Riccardo/0000-0003-1625-9853; Maestro, Roberta/0000-0002-6642-5592; De Re, Valli/0000-0001-6100-9373; Rizzo, Silvana/0000-0002-7156-1783				ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; AMY CM, 1987, CANCER RES, V47, P6310; BOIOCCHI M, 1984, TUMORI, V70, P467, DOI 10.1177/030089168407000601; CHATTOPADHYAY SK, 1982, NATURE, V295, P25, DOI 10.1038/295025a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; CUYPERS HT, 1984, CELL, V37, P141; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DOLCETTI R, 1988, EUR J CANCER CLIN ON, V24, P1321, DOI 10.1016/0277-5379(88)90223-4; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FUNG YK, 1983, CELL, V33, P37; HARTLEY JW, 1977, P NATL ACAD SCI USA, V74, P789, DOI 10.1073/pnas.74.2.789; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; KAWASHIMA K, 1976, P NATL ACAD SCI USA, V73, P4680, DOI 10.1073/pnas.73.12.4680; KELLY M, 1983, J VIROL, V45, P291, DOI 10.1128/JVI.45.1.291-298.1983; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LI Y, 1984, P NATL ACAD SCI-BIOL, V81, P6808, DOI 10.1073/pnas.81.21.6808; LOWY DR, 1980, P NATL ACAD SCI-BIOL, V77, P614, DOI 10.1073/pnas.77.1.614; Maniatis T., 1982, MOL CLONING; MEIER R, 1980, NUCLEIC ACIDS, V16, P2340; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; NEIL JC, 1983, NATURE, V108, P814; NISEN PD, 1986, CANCER RES, V46, P6217; NOWINSKI RC, 1978, J VIROL, V27, P13, DOI 10.1128/JVI.27.1.13-18.1978; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; ODONNELL PV, 1985, J VIROL, V55, P500, DOI 10.1128/JVI.55.2.500-503.1985; ONEILL RR, 1986, J VIROL, V58, P359, DOI 10.1128/JVI.58.2.359-366.1986; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; PEDERSEN FS, 1981, J VIROL, V35, P211; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WIRSCHUBSKY Z, 1986, INT J CANCER, V38, P739, DOI 10.1002/ijc.2910380518	43	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					1009	1014						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2548143				2022-12-17	WOS:A1989AJ29700010
J	CARLONI, G; PATERSON, H; MAREEL, M; AUGERYBOURGET, Y; SAHRAOUI, J; RUBINSTEIN, E; SUAREZ, H; AZZARONE, B				CARLONI, G; PATERSON, H; MAREEL, M; AUGERYBOURGET, Y; SAHRAOUI, J; RUBINSTEIN, E; SUAREZ, H; AZZARONE, B			N-RAS DEPENDENT REVERTANT PHENOTYPE IN HUMAN HT1080 FIBRO-SARCOMA CELLS IS ASSOCIATED WITH LOSS OF PROLIFERATION WITHIN NORMAL-TISSUES AND EXPRESSION OF AN ADULT MEMBRANE ANTIGENIC PHENOTYPE	ONCOGENE			English	Article									INST RECH SCI CANC,GENET MOLEC LAB,F-94802 VILLEJUIF,FRANCE; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; DEPT RADIOTHERAPY & NUCL MED,EXPTL CANCEROL LAB,GHENT,BELGIUM; INSERM,U268,F-94824 VILLEJUIF,FRANCE	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Institut National de la Sante et de la Recherche Medicale (Inserm)			Rubinstein, Eric/B-4650-2019; Azzarone, Bruno/AAH-9251-2019	Rubinstein, Eric/0000-0001-7623-9665; Azzarone, Bruno/0000-0002-5962-3849				ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; AZZARONE B, 1984, J CELL BIOL, V98, P1133, DOI 10.1083/jcb.98.3.1133; AZZARONE B, 1984, INT J CANCER, V33, P759, DOI 10.1002/ijc.2910330608; AZZARONE B, 1985, EXP CELL RES, V159, P451, DOI 10.1016/S0014-4827(85)80018-5; AZZARONE B, 1986, INT J CANCER, V38, P177, DOI 10.1002/ijc.2910380206; AZZARONE B, 1987, J CELL SCI, V87, P155; AZZARONE B, 1988, MUTAT RES, V199, P313, DOI 10.1016/0027-5107(88)90211-4; AZZARONE B, 1985, RETROVIRUSES HUMAN P, P473; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; CARLONI G, 1988, FEBS LETT, V229, P333, DOI 10.1016/0014-5793(88)81151-7; CHO HY, 1976, SCIENCE, V194, P951, DOI 10.1126/science.62397; DUESBERG PH, 1983, NATURE, V304, P219, DOI 10.1038/304219a0; Favaloro J, 1980, Methods Enzymol, V65, P718; FRAZIERSCOTT K, 1988, J CLIN INVEST, V82, P1877; GAMBKE C, 1984, NATURE, V307, P476, DOI 10.1038/307476a0; GREENE WC, 1987, CANCER INVEST, V5, P369; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HAYNES BF, 1981, J IMMUNOL, V126, P1409; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; LEONARD WJ, 1984, NATURE, V311, P26; MAREEL M, 1979, VIRCHOWS ARCH B, V30, P197; Mareel M M, 1987, J Cell Sci Suppl, V8, P141; MAREEL M M, 1981, Invasion and Metastasis, V1, P195; MAREEL MM, 1986, ANTICANCER RES, V6, P419; MAREEL MM, 1982, MEMBRANES TUMOUR GRO, P223; MAREEL MMK, 1982, TUMOR INVASION METAS, P207; MARSHALL CJ, 1984, CANCER CELL, V2, P441; MICHALAK M, 1986, J BIOL CHEM, V261, P92; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; RUBIN H, 1984, NATURE, V309, P518, DOI 10.1038/309518a0; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SARAGOVI H, 1987, J IMMUNOL, V139, P1918; SHARON M, 1988, J EXP MED, V167, P1265, DOI 10.1084/jem.167.3.1265; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; STORME G, 1981, ONCOLOGY, V38, P182, DOI 10.1159/000225547; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VARMUS HE, 1984, ANNU REV GENET, V18, P553; VOUSDEN KH, 1984, EMBO J, V3, P913, DOI 10.1002/j.1460-2075.1984.tb01905.x; WELTE K, 1984, J EXP MED, V160, P1390, DOI 10.1084/jem.160.5.1390; YAGITA H, 1986, CANCER RES, V46, P1478	43	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					873	880						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666908				2022-12-17	WOS:A1989AE58400009
J	HARVEY, RC; MARTENEIRE, C; SUN, LHK; WILLIAMS, D; SHOWE, LC				HARVEY, RC; MARTENEIRE, C; SUN, LHK; WILLIAMS, D; SHOWE, LC			TRANSLOCATIONS AND REARRANGEMENTS IN T-CELL ACUTE LEUKEMIAS WITH THE T(11-14) (P13-Q11) CHROMOSOMAL TRANSLOCATIONS	ONCOGENE			English	Article									WISTAR INST ANAT & BIOL,36TH & SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute				Harvey, Richard/0000-0002-4904-9767	NCI NIH HHS [T32 CA09485, CA25875-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009485, P01CA025875] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; BAER R, 1988, EMBO J, V7, P1661, DOI 10.1002/j.1460-2075.1988.tb02993.x; BAER R, 1985, CELL, V43, P705, DOI 10.1016/0092-8674(85)90243-0; BIRD J, 1988, J EXP MED, V168, P229, DOI 10.1084/jem.168.1.229; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; CACCIA N, 1985, J EXP MED, V161, P1255, DOI 10.1084/jem.161.5.1255; CALMAN AF, 1986, J EXP MED, V164, P1940, DOI 10.1084/jem.164.6.1940; CHAMPAGNE E, 1988, EUR J IMMUNOL, V18, P1033, DOI 10.1002/eji.1830180710; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; DENNY CT, 1986, SCIENCE, V234, P197, DOI 10.1126/science.3092355; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVILLARTAY JP, 1988, NATURE, V335, P170, DOI 10.1038/335170a0; DEVILLARTAY JP, 1987, P NATL ACAD SCI USA, V84, P8608; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; ERIKSON J, 1985, SCIENCE, V229, P784, DOI 10.1126/science.3875152; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; FOA R, 1984, J CLIN INVEST, V74, P1756, DOI 10.1172/JCI111594; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; HATA S, 1988, SCIENCE, V240, P1541, DOI 10.1126/science.3259726; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; KIMURA N, 1987, EUR J IMMUNOL, V17, P375, DOI 10.1002/eji.1830170312; KIRSH IR, 1988, T CELL RECEPTORS, P651; KITCHINGMAN GR, 1986, BLOOD, V67, P698; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; LEWIS WH, 1985, NATURE, V317, P544, DOI 10.1038/317544a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LURIA S, 1987, EMBO J, V6, P3307, DOI 10.1002/j.1460-2075.1987.tb02650.x; Maniatis T., 1982, MOL CLONING; MAROLLEAU JP, 1988, CELL, V55, P291, DOI 10.1016/0092-8674(88)90052-9; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; PONCZ M, 1982, HEMOGLOBIN, V6, P27, DOI 10.3109/03630268208996930; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCOTT AF, 1979, P NATL ACAD SCI USA, V76, P4563, DOI 10.1073/pnas.76.9.4563; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SEIDMAN JG, 1980, NATURE, V286, P779, DOI 10.1038/286779a0; SHOWE LC, 1987, ANNU REV IMMUNOL, V5, P253, DOI 10.1146/annurev.iy.05.040187.001345; UESHIMA Y, 1984, BLOOD, V63, P1028; WEISS A, 1986, P NATL ACAD SCI USA, V83, P6998, DOI 10.1073/pnas.83.18.6998; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; WINOTO A, 1985, NATURE, V316, P832, DOI 10.1038/316832a0; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIKAI Y, 1986, J EXP MED, V164, P90, DOI 10.1084/jem.164.1.90	51	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					341	349						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2523031				2022-12-17	WOS:A1989U567600010
J	WENDLER, PA; BOSCHELLI, F				WENDLER, PA; BOSCHELLI, F			SRC HOMOLOGY-2 DOMAIN DELETION MUTANTS OF P60V-SRC DO NOT PHOSPHORYLATE CELLULAR PROTEINS OF 120-150 KDA	ONCOGENE			English	Article									MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NCI NIH HHS [5RO1-CO-36928] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRYANT D, 1982, J VIROL, V44, P683, DOI 10.1128/JVI.44.2.683-691.1982; BURR JG, 1981, COLD SPRING HARBOR C, V8, P1217; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P41; HARTMAN S, 1988, IN PRESS P NAT ACAD; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KATZ RA, 1982, J VIROL, V42, P346, DOI 10.1128/JVI.42.1.346-351.1982; LAU AF, 1986, VIROLOGY, V151, P86, DOI 10.1016/0042-6822(86)90106-6; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUSKY M, 1981, NATURE, V293, P79, DOI 10.1038/293079a0; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; PARSONS JT, 1984, CANCER CELL, V2, P37; PIWINICAWORMS H, 1987, CELL, V49, P75; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SEFTON BM, 1982, J VIROL, V41, P813, DOI 10.1128/JVI.41.3.813-820.1982; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; WAYE MMY, 1983, EMBO J, V2, P1827, DOI 10.1002/j.1460-2075.1983.tb01665.x; WEBER MJ, 1979, CELL, V16, P25, DOI 10.1016/0092-8674(79)90184-3	29	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					231	236						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2494631				2022-12-17	WOS:A1989U567500015
J	SINGH, B; HERZOG, NK; LIU, J; ARLINGHAUS, RB				SINGH, B; HERZOG, NK; LIU, J; ARLINGHAUS, RB			P-37MOS ENCODED BY THE HT-1 STRAIN OF MOLONEY MURINE SARCOMA-VIRUS HAS AN ASSOCIATED PROTEIN-KINASE ACTIVITY	ONCOGENE			English	Article											SINGH, B (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ARLINGHAUS RB, 1985, J GEN VIROL, V66, P1845, DOI 10.1099/0022-1317-66-9-1845; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; BROW MAD, 1984, J VIROL, V49, P579, DOI 10.1128/JVI.49.2.579-582.1984; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; ESCOBEDO J, 1986, VIRUS RES, V6, P75, DOI 10.1016/0168-1702(86)90058-4; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GALLICK GE, 1984, MODERN APPROACHES VA, P407; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; HUNTER T, 1986, ENZYMES, V17, P191; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KLOETZER WS, 1984, VIROLOGY, V138, P143, DOI 10.1016/0042-6822(84)90154-5; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; MAXWELL SA, 1985, J VIROL, V55, P874, DOI 10.1128/JVI.55.3.874-876.1985; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PROPST F, 1987, MOL CELL BIOL, V7, P1623; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; SINGH B, 1986, P NATL ACAD SCI USA, V83, P3629, DOI 10.1073/pnas.83.11.3629; SINGH B, 1986, VIROLOGY, V152, P502, DOI 10.1016/0042-6822(86)90156-X; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	37	23	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					79	85						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400011
J	PANTAZIS, P; SARIBAN, E; BOHAN, CA; ANTONIADES, HN; KALYANARAMAN, VS				PANTAZIS, P; SARIBAN, E; BOHAN, CA; ANTONIADES, HN; KALYANARAMAN, VS			SYNTHESIS OF PDGF BY CULTURED HUMAN-T CELLS TRANSFORMED WITH HTLV-I AND HTLV-II	ONCOGENE			English	Article									HARVARD UNIV,SCH MED,DANA FARBER CANC INST,CLIN PHARMACOL LAB,BOSTON,MA 02115; CTR DIS CONTROL,AIDS SECT,ATLANTA,GA 30333; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Centers for Disease Control & Prevention - USA; Harvard University; Harvard T.H. Chan School of Public Health	PANTAZIS, P (corresponding author), CTR BLOOD RES,800 HUNTINGDON AVE,BOSTON,MA 02115, USA.				NCI NIH HHS [CA38784, CA30301] Funding Source: Medline; NHLBI NIH HHS [HL29583] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038784] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029583] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONIADES HN, 1981, P NATL ACAD SCI-BIOL, V78, P7314, DOI 10.1073/pnas.78.12.7314; ANTONIADES HN, 1983, SCIENCE, V220, P963, DOI 10.1126/science.6844921; ANTONIADES HN, 1979, P NATL ACAD SCI USA, V76, P1809, DOI 10.1073/pnas.76.4.1809; ANTONIADES HN, 1986, ONCOGENES GENES GROW, P1; ANTONIADES HN, 1987, IN PRESS METHODS ENZ, V147; ARYA SK, 1984, SCIENCE, V223, P1086, DOI 10.1126/science.6320374; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BRONZERT D, 1987, IN PRESS P NATL ACAD; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALLAFAVERA R, 1982, SCIENCE, V218, P686, DOI 10.1126/science.6291150; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRANCHINI G, 1984, J INVEST DERMATOL S1, V83, P63; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; GRAVES DT, 1985, BIOCHEM BIOPH RES CO, V129, P56, DOI 10.1016/0006-291X(85)91402-0; HELDIN CH, 1981, BIOCHEM J, V193, P907, DOI 10.1042/bj1930907; HOSHINO H, 1983, P NATL ACAD SCI-BIOL, V80, P6061, DOI 10.1073/pnas.80.19.6061; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; KALYANARAMAN VS, 1985, EMBO J, V4, P1455, DOI 10.1002/j.1460-2075.1985.tb03802.x; MANIATIS T, 1982, MOL CLONING LABORATO; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; OWEN AJ, 1984, SCIENCE, V225, P54, DOI 10.1126/science.6328659; PANTAZIS P, 1986, P NATL ACAD SCI USA, V83, P6455, DOI 10.1073/pnas.83.17.6455; PANTAZIS P, 1985, P NATL ACAD SCI USA, V82, P2404, DOI 10.1073/pnas.82.8.2404; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519; RAINES EW, 1982, J BIOL CHEM, V257, P5154; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; ROMERO P, 1986, BLOOD, V67, P839; ROZENGURT E, 1985, INT J CANCER, V36, P247, DOI 10.1002/ijc.2910360218; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SEIGEL LJ, 1986, VIROLOGY, V154, P67, DOI 10.1016/0042-6822(86)90430-7; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOTOHNO K, 1984, P NATL ACAD SCI-BIOL, V81, P1079, DOI 10.1073/pnas.81.4.1079; SHIMOTOHNO K, 1984, P NATL ACAD SCI-BIOL, V81, P6657, DOI 10.1073/pnas.81.21.6657; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SWAN DC, 1982, P NATL ACAD SCI-BIOL, V79, P4691, DOI 10.1073/pnas.79.15.4691; THIELEN GJ, 1971, J NATL CANCER I, V47, P881; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467	44	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	3					285	289						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	2838779				2022-12-17	WOS:A1987J970500008
J	Galbraith, LCA; Mui, E; Nixon, C; Hedley, A; Strachan, D; MacKay, G; Sumpton, D; Sansom, OJ; Leung, HY; Ahmad, I				Galbraith, Laura C. A.; Mui, Ernest; Nixon, Colin; Hedley, Ann; Strachan, David; MacKay, Gillian; Sumpton, David; Sansom, Owen J.; Leung, Hing Y.; Ahmad, Imran			PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer	ONCOGENE			English	Article								Peroxisome Proliferator-Activated Receptor Gamma (PPARG) is one of the three members of the PPAR family of transcription factors. Besides its roles in adipocyte differentiation and lipid metabolism, we recently demonstrated an association between PPARG and metastasis in prostate cancer. In this study a functional effect of PPARG on AKT serine/threonine kinase 3 (AKT3), which ultimately results in a more aggressive disease phenotype was identified. AKT3 has previously been shown to regulate PPARG co-activator 1 alpha (PGC1 alpha) localisation and function through its action on chromosome maintenance region 1 (CRM1). AKT3 promotes PGC1 alpha localisation to the nucleus through its inhibitory effects on CRM1, a known nuclear export protein. Collectively our results demonstrate how PPARG over-expression drives an increase in AKT3 levels, which in turn has the downstream effect of increasing PGC1 alpha localisation within the nucleus, driving mitochondrial biogenesis. Furthermore, this increase in mitochondrial mass provides higher energetic output in the form of elevated ATP levels which may fuel the progression of the tumour cell through epithelial to mesenchymal transition (EMT) and ultimately metastasis.	[Galbraith, Laura C. A.; Mui, Ernest; Nixon, Colin; Hedley, Ann; Strachan, David; MacKay, Gillian; Sumpton, David; Sansom, Owen J.; Leung, Hing Y.; Ahmad, Imran] Canc Res UK Beatson Inst, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland; [Galbraith, Laura C. A.; Sansom, Owen J.; Leung, Hing Y.; Ahmad, Imran] Univ Glasgow, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland	Beatson Institute; University of Glasgow	Ahmad, I (corresponding author), Canc Res UK Beatson Inst, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.; Ahmad, I (corresponding author), Univ Glasgow, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland.	imran.ahmad@glasgow.ac.uk	Ahmad, Imran/GRJ-0536-2022	Galbraith, Laura/0000-0002-1396-4226; Sumpton, David/0000-0002-9004-4079; Sansom, Owen J./0000-0001-9540-3010; Ahmad, Imran/0000-0002-4404-1926; Leung, Hing Y./0000-0002-3933-3975	Cancer Research UK Clinician Scientist Fellowship award [C49745/A19661]; CRUK core award [A17196]	Cancer Research UK Clinician Scientist Fellowship award; CRUK core award	This work was supported by Cancer Research UK Clinician Scientist Fellowship award to (C49745/A19661; IA) and CRUK core award to CRUK Beatson Institute A17196 (OJS, CN, AH, DS, DS, & GM).	Ahmad I, 2016, P NATL ACAD SCI USA, V113, P8290, DOI 10.1073/pnas.1601571113; BHALLA K, 2011, BBA-MOL CELL BIOL L, V71, P6888; Brunmeir R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061738; Burns KA, 2007, BBA-MOL CELL BIOL L, V1771, P952, DOI 10.1016/j.bbalip.2007.04.018; CHURCH D, 2011, GENOME BIOL, V9; Corum DG, 2014, FASEB J, V28, P395, DOI 10.1096/fj.13-235382; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Ding LA, 2017, J BIOL CHEM, V292, P9283, DOI 10.1074/jbc.M116.773739; Ding L, 2012, CELL METAB, V15, P861, DOI 10.1016/j.cmet.2012.04.020; Fan WW, 2015, CURR OPIN CELL BIOL, V33, P49, DOI 10.1016/j.ceb.2014.11.002; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917; FISHER S, 2011, FASEB J, V12; Floyd ZE, 2012, BBA-MOL BASIS DIS, V1822, P1090, DOI 10.1016/j.bbadis.2012.03.014; FORNEROD M, 1997, BBA-REV CANCER, V16, P807; Galbraith L, 2018, PHARMACOL RES, V131, P177, DOI 10.1016/j.phrs.2018.02.022; Geiger TR, 2009, BBA-REV CANCER, V1796, P293, DOI 10.1016/j.bbcan.2009.07.006; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Huggins C, 1941, CANCER RES, V1, P293; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Kaminski L, 2019, CANCER RES, V79, P3268, DOI 10.1158/0008-5472.CAN-18-2043; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim M, 2016, ACTA BIOCH BIOPH SIN, V48, P447, DOI 10.1093/abbs/gmw014; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; LOVE M, 2014, NAT METHODS, V15; Madhunapantula SV, 2009, PIGM CELL MELANOMA R, V22, P400, DOI 10.1111/j.1755-148X.2009.00585.x; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; March HN, 2011, NAT GENET, V43, P1202, DOI 10.1038/ng.990; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Phung TL, 2015, CANCER RES, V75, P40, DOI 10.1158/0008-5472.CAN-13-2961; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; PUIGSERVER P, 1998, AM J CLIN NUTR, V92, P829; Siegel R., 2015, CA-CANCER J CLIN, V65, P29, DOI [10.3322/caac.21254, DOI 10.3322/CAAC.21254, DOI 10.3322/caac.21208]; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Torrano V, 2016, NAT CELL BIOL, V18, P645, DOI 10.1038/ncb3357; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wright GL, 2008, FASEB J, V22, P3264, DOI 10.1096/fj.08-106468; WU Z, 1999, NAT GENET, V98, P115; Wu ZG, 2013, J CELL SCI, V126, P3417, DOI 10.1242/jcs.126854; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	41	22	22	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2355	2366		10.1038/s41388-021-01707-7	http://dx.doi.org/10.1038/s41388-021-01707-7		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33654198	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000624398900005
J	Abril, YLN; Fernandez, IR; Hong, JY; Chiang, YL; Kutateladze, DA; Zhao, QJ; Yang, M; Hu, J; Sadhukhan, S; Li, B; He, B; Remick, B; Bai, JJ; Mullmann, J; Wang, FY; Maymi, V; Dhawan, R; Auwerx, J; Southard, T; Cerione, RA; Lin, HN; Weiss, RS				Abril, Yashira L. Negron; Fernandez, Irma R.; Hong, Jun Young; Chiang, Ying-Ling; Kutateladze, Dennis A.; Zhao, Qingjie; Yang, Min; Hu, Jing; Sadhukhan, Sushabhan; Li, Bo; He, Bin; Remick, Brenna; Bai, Jessica Jingyi; Mullmann, James; Wang, Fangyu; Maymi, Viviana; Dhawan, Ravi; Auwerx, Johan; Southard, Teresa; Cerione, Richard A.; Lin, Hening; Weiss, Robert S.			Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer	ONCOGENE			English	Article							PROTEIN; DESUCCINYLATION; ANTIOXIDANT; SUCCINYLATION; MALONYLATION; DEMALONYLASE; PROGRESSION; METABOLISM; EXPRESSION; REGULATORS	SIRT5 is a member of the sirtuin family of NAD(+)-dependent protein lysine deacylases implicated in a variety of physiological processes. SIRT5 removes negatively charged malonyl, succinyl, and glutaryl groups from lysine residues and thereby regulates multiple enzymes involved in cellular metabolism and other biological processes. SIRT5 is overexpressed in human breast cancers and other malignancies, but little is known about the therapeutic potential of SIRT5 inhibition for treating cancer. Here we report that genetic SIRT5 disruption in breast cancer cell lines and mouse models caused increased succinylation of IDH2 and other metabolic enzymes, increased oxidative stress, and impaired transformation and tumorigenesis. We, therefore, developed potent, selective, and cell-permeable small-molecule SIRT5 inhibitors. SIRT5 inhibition suppressed the transformed properties of cultured breast cancer cells and significantly reduced mammary tumor growth in vivo, in both genetically engineered and xenotransplant mouse models. Considering that Sirt5 knockout mice are generally normal, with only mild phenotypes observed, these data establish SIRT5 as a promising target for treating breast cancer. The new SIRT5 inhibitors provide useful probes for future investigations of SIRT5 and an avenue for targeting SIRT5 as a therapeutic strategy.	[Abril, Yashira L. Negron; Fernandez, Irma R.; Remick, Brenna; Mullmann, James; Maymi, Viviana; Dhawan, Ravi; Southard, Teresa; Weiss, Robert S.] Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA; [Fernandez, Irma R.; Hong, Jun Young; Chiang, Ying-Ling; Kutateladze, Dennis A.; Zhao, Qingjie; Yang, Min; Hu, Jing; Sadhukhan, Sushabhan; Li, Bo; He, Bin; Bai, Jessica Jingyi; Cerione, Richard A.; Lin, Hening] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; [Li, Bo; Mullmann, James; Wang, Fangyu; Cerione, Richard A.] Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; [Auwerx, Johan] Ecole Polytech Fed Lausanne EPFL, Inst Bioengn, Lab Integrat Syst Physiol, CH-1015 Lausanne, Switzerland; [Lin, Hening] Cornell Univ, Howard Hughes Med Inst, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; [He, Bin] Guizhou Med Univ, Sch Pharm, Guiyang 550004, Peoples R China	Cornell University; Cornell University; Cornell University; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Cornell University; Howard Hughes Medical Institute; Guizhou Medical University	Weiss, RS (corresponding author), Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA.; Lin, HN (corresponding author), Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.; Lin, HN (corresponding author), Cornell Univ, Howard Hughes Med Inst, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.	hl379@cornell.edu; rsw26@cornell.edu	Auwerx, Johan/ABE-9307-2021; Chiang, Ying-Ling/N-3259-2014	Wang, Fangyu/0000-0002-6388-1461; Hong, Jun Young/0000-0002-5257-6525; Weiss, Robert/0000-0003-3327-1379; Chiang, Ying-Ling/0000-0001-5591-6209; Maymi, Viviana/0000-0002-1575-3510; Sadhukhan, Sushabhan/0000-0002-3302-5875; Dhawan, Ravi/0000-0002-2544-341X; Negron Abril, Yashira/0000-0002-5922-9999; Kutateladze, Dennis/0000-0002-5706-7092; Auwerx, Johan/0000-0002-5065-5393	NIH [CA163255, CA223534]; NIH/NIGMS [T32GM007273, 5T32GM008500]; Cornell Deans Excellence Fellowship; HHMI Gilliam Fellowship; Ecole Polytechnique Federale de Lausanne (EPFL); Swiss National Science Foundation (SNSF) [31003A_179435]; NSF through MRI award [CHE-1531632]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Cornell Deans Excellence Fellowship; HHMI Gilliam Fellowship; Ecole Polytechnique Federale de Lausanne (EPFL); Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); NSF through MRI award	The authors thank the NCI Physical SciencesOncology Network Bioresource Core Facility (PBCF) for MDAMB-231 cells, and Drs. Ruchika Bhawal and Sheng Zhang from the Cornell Proteomics and Metabolomics Facility for technical assistance. This work was supported in part by NIH R01 grants CA163255 and CA223534. YLNA was supported by NIH/NIGMS grant 5T32GM008500, and IRF was supported by NIH/NIGMS grant T32GM007273, a Cornell Deans Excellence Fellowship, and an HHMI Gilliam Fellowship. JA was supported by grants from the Ecole Polytechnique Federale de Lausanne (EPFL), and the Swiss National Science Foundation (SNSF 31003A_179435). This work utilized the Cornell University NMR facility, which is supported in part by the NSF through MRI award CHE-1531632.	Bheda P, 2016, ANNU REV BIOCHEM, V85, P405, DOI 10.1146/annurev-biochem-060815-014537; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chang L, 2018, MOL MED REP, V17, P342, DOI 10.3892/mmr.2017.7875; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Du JT, 2011, SCIENCE, V334, P806, DOI 10.1126/science.1207861; Farooqi AS, 2019, J MED CHEM, V62, P4131, DOI 10.1021/acs.jmedchem.9b00191; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Greene KS, 2019, P NATL ACAD SCI USA, V116, P26625, DOI 10.1073/pnas.1911954116; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]; He B, 2012, J AM CHEM SOC, V134, P1922, DOI 10.1021/ja2090417; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hirschey MD, 2015, MOL CELL PROTEOMICS, V14, P2308, DOI 10.1074/mcp.R114.046664; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Igci M, 2016, GENE, V586, P123, DOI 10.1016/j.gene.2016.04.023; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jiang L, 2016, NATURE, V532, P255, DOI 10.1038/nature17393; Jiang YH, 2020, MED CHEM, V16, P358, DOI 10.2174/1573406415666190603101937; Jing H, 2016, CANCER CELL, V29, P297, DOI 10.1016/j.ccell.2016.02.007; Kalbas D, 2018, J MED CHEM, V61, P2460, DOI 10.1021/acs.jmedchem.7b01648; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Liem Minh Phan, 2014, Cancer Biology Medicine, V11, P1, DOI 10.7497/j.issn.2095-3941.2014.01.001; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Lin HN, 2012, ACS CHEM BIOL, V7, P947, DOI 10.1021/cb3001793; Lin ZF, 2013, BIOCHEM BIOPH RES CO, V441, P191, DOI 10.1016/j.bbrc.2013.10.033; Liu JJ, 2016, MOLECULES, V21, DOI 10.3390/molecules21091217; Lu WD, 2014, TUMOR BIOL, V35, P10699, DOI 10.1007/s13277-014-2372-4; Maurer B, 2012, ACS MED CHEM LETT, V3, P1050, DOI 10.1021/ml3002709; Nishida Y, 2015, MOL CELL, V59, P321, DOI 10.1016/j.molcel.2015.05.022; Park J, 2013, MOL CELL, V50, P919, DOI 10.1016/j.molcel.2013.06.001; Peng C, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.012658; Polletta L, 2015, AUTOPHAGY, V11, P253, DOI 10.1080/15548627.2015.1009778; Rajabi N, 2017, ANGEW CHEM INT EDIT, V56, P14836, DOI 10.1002/anie.201709050; Rardin MJ, 2013, CELL METAB, V18, P920, DOI 10.1016/j.cmet.2013.11.013; Sadhukhan S, 2016, P NATL ACAD SCI USA, V113, P4320, DOI 10.1073/pnas.1519858113; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Smith BC, 2007, BIOCHEMISTRY-US, V46, P14478, DOI 10.1021/bi7013294; Spiegelman NA, 2019, CHEMMEDCHEM, V14, P744, DOI 10.1002/cmdc.201800715; Spiegelman NA, 2018, CHEMMEDCHEM, V13, P1890, DOI 10.1002/cmdc.201800391; Tan MJ, 2014, CELL METAB, V19, P605, DOI 10.1016/j.cmet.2014.03.014; Unterlass JE, 2019, EXPERT REV MOL MED, V21, DOI 10.1017/erm.2019.4; Wagner GR, 2017, CELL METAB, V25, P823, DOI 10.1016/j.cmet.2017.03.006; Wagner GR, 2014, MOL CELL, V54, P5, DOI 10.1016/j.molcel.2014.03.027; Wang YQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02951-4; Xu L, 2018, ONCOL REP, V39, P2315, DOI 10.3892/or.2018.6319; Yang X, 2018, CANCER RES, V78, P372, DOI 10.1158/0008-5472.CAN-17-1912; Ye XY, 2017, ONCOTARGET, V8, P6984, DOI 10.18632/oncotarget.14346; Yu JJ, 2013, SCI REP-UK, V3, DOI 10.1038/srep02806; Zhou LS, 2016, EMBO REP, V17, P811, DOI 10.15252/embr.201541643	52	22	24	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1644	1658		10.1038/s41388-020-01637-w	http://dx.doi.org/10.1038/s41388-020-01637-w		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33479498	Green Accepted			2022-12-17	WOS:000609352300002
J	Zhang, Y; Yan, Q; Gong, LQ; Xu, H; Liu, BL; Fang, XN; Yu, DD; Li, L; Wei, T; Wang, Y; Wong, CN; Lyu, Z; Tang, Y; Sham, PC; Guan, XY				Zhang, Yu; Yan, Qian; Gong, Lanqi; Xu, Hang; Liu, Beilei; Fang, Xiaona; Yu, Dandan; Li, Lei; Wei, Ting; Wang, Ying; Wong, Ching Ngar; Lyu, Zhaojie; Tang, Ying; Sham, Pak Chung; Guan, Xin-Yuan			C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism	ONCOGENE			English	Article							VIRUS X PROTEIN; HEPATOCELLULAR-CARCINOMA; AEROBIC GLYCOLYSIS; TUMOR-SUPPRESSOR; LIVER-CANCER; METASTASIS; ACTIVATION; INTEGRATION; EXPRESSION; PATHWAY	Chronic hepatitis B virus (HBV) infection is strongly associated with the initiation and development of hepatocellular carcinoma (HCC). However, the genetic alterations and pathogenesis mechanisms remain significantly unexplored, especially for HBV-induced metabolic reprogramming. Analysis of integration breakpoints in HBV-positive HCC samples revealed the preferential clustering pattern within the 3 '-end of X gene in the HBV genome, leading to the production of C-terminal truncated X protein (Ct-HBx). In this study, we not only characterized the oncogenic role of two Ct-HBx (HBx-120 and HBx-134) via in vitro and in vivo functional assays but also deciphered their underlying molecular mechanisms. Gene expression profiling by transcriptome sequencing identified potential targets of Ct-HBx and novel malignant hallmarks such as glycolysis, cell cycle, and m-TORC1 signaling in Ct-HBx-expressing cells. TXNIP, a well-established regulator of glucose metabolism, was shown to be downregulated by Ct-HBx and play a pivotal role in Ct-HBx-mediated HCC progression. Suppression of TXNIP is frequently observed in HCC patients with Ct-HBx expression and significantly (P = 0.015) correlated to a poorer prognosis. Re-introduction of TXNIP attenuated the metabolic reprogramming induced by the Ct-HBx and inhibited the tumor growth in the mice model. Further study suggested that Ct-HBx could downregulate TXNIP via a transcriptional repressor nuclear factor of activated T cells 2 (NFACT2). Collectively, our findings indicate that TXNIP plays a critical role in Ct-HBx-mediated hepatocarcinogenesis, serving as a novel therapeutic strategy in HCC treatment.	[Zhang, Yu; Gong, Lanqi; Liu, Beilei; Fang, Xiaona; Yu, Dandan; Li, Lei; Wang, Ying; Wong, Ching Ngar; Lyu, Zhaojie; Tang, Ying; Guan, Xin-Yuan] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China; [Zhang, Yu; Gong, Lanqi; Liu, Beilei; Fang, Xiaona; Yu, Dandan; Li, Lei; Wang, Ying; Wong, Ching Ngar; Lyu, Zhaojie; Tang, Ying; Guan, Xin-Yuan] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China; [Yan, Qian] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Res Ctr Med Sci, Guangzhou 510030, Peoples R China; [Yan, Qian; Guan, Xin-Yuan] Univ Hong Kong, Shenzhen Hosp, Dept Clin Oncol, Shenzhen 518053, Peoples R China; [Xu, Hang; Sham, Pak Chung] Univ Hong Kong, Li Ka Shing Fac Med, Dept Psychiat, Hong Kong, Peoples R China; [Yu, Dandan] Southern Univ Sci & Technol, Dept Biol, Shenzhen 518055, Peoples R China; [Wei, Ting] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou 510282, Peoples R China; [Guan, Xin-Yuan] Sun Yat Sen Univ, State Key Lab Oncol Southern China, Canc Ctr, Guangzhou 510060, Peoples R China	University of Hong Kong; University of Hong Kong; Guangdong Academy of Medical Sciences & Guangdong General Hospital; University of Hong Kong; University of Hong Kong; Southern University of Science & Technology; Southern Medical University - China; State Key Lab Oncology South China; Sun Yat Sen University	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, Shenzhen Hosp, Dept Clin Oncol, Shenzhen 518053, Peoples R China.; Guan, XY (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol Southern China, Canc Ctr, Guangzhou 510060, Peoples R China.	xyguan@hku.hk			Hong Kong Research Grant Council (RGC) [C7065-18GF, C7026-18GF, T12-704/16-R]; Research Grant Council (RGC) [17143716]; National Key R&D Program of China [2017YFC1309000]; National Natural Science Foundation of China [81903049, 81772554]; Shenzhen Peacock Team Project [KQTD201533117210153, KQTD2018041118502879]	Hong Kong Research Grant Council (RGC)(Hong Kong Research Grants Council); Research Grant Council (RGC)(Hong Kong Research Grants Council); National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Peacock Team Project	This project was supported by grants from the Hong Kong Research Grant Council (RGC) grants including Collaborative Research Funds (C7065-18GF and C7026-18GF), Theme-based Research Scheme (T12-704/16-R), Research Grant Council (RGC) grants including GRF (17143716), the National Key R&D Program of China (2017YFC1309000), National Natural Science Foundation of China (81903049, 81772554), and The Shenzhen Peacock Team Project (KQTD201533117210153, KQTD2018041118502879). Professor Xin-Yuan Guan is Sophie YM Chan Professor in Cancer Research.	Arzumanyan A, 2011, CANCER RES, V71, P3701, DOI 10.1158/0008-5472.CAN-10-3951; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Chambers JW, 2010, J VIROL, V84, P1867, DOI 10.1128/JVI.02123-09; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Delgado T, 2010, P NATL ACAD SCI USA, V107, P10696, DOI 10.1073/pnas.1004882107; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Hardie DG, 2015, CLIN CANCER RES, V21, P3836, DOI 10.1158/1078-0432.CCR-14-3300; He L, 2018, MOL CELL, V70, P949, DOI 10.1016/j.molcel.2018.04.024; He ZL, 2017, ONCOL LETT, V14, P1323, DOI 10.3892/ol.2017.6296; Huang JF, 2013, HEPATOLOGY, V57, P1882, DOI 10.1002/hep.26195; Hui STY, 2008, P NATL ACAD SCI USA, V105, P3921, DOI 10.1073/pnas.0800293105; Ishikawa T, 2010, WORLD J GASTROENTERO, V16, P2463, DOI 10.3748/wjg.v16.i20.2463; Jeon JH, 2005, CANCER RES, V65, P4485, DOI 10.1158/0008-5472.CAN-04-2271; Ji SR, 2016, CLIN CANCER RES, V22, P3950, DOI 10.1158/1078-0432.CCR-15-2380; Jin HO, 2011, ONCOGENE, V30, P3792, DOI 10.1038/onc.2011.102; Kaadige MR, 2009, P NATL ACAD SCI USA, V106, P14878, DOI 10.1073/pnas.0901221106; Keng VW, 2011, HEPATOLOGY, V53, P781, DOI 10.1002/hep.24091; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Li XJ, 2014, J HEPATOL, V60, P975, DOI 10.1016/j.jhep.2013.12.014; Liu XW, 2016, MOL MED REP, V14, P2311, DOI 10.3892/mmr.2016.5472; Liu Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14813-y; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; Lo AKF, 2015, J PATHOL, V237, P238, DOI 10.1002/path.4575; Ma NF, 2008, CLIN CANCER RES, V14, P5061, DOI 10.1158/1078-0432.CCR-07-5082; Ma T, 2015, ANGIOGENESIS, V18, P477, DOI 10.1007/s10456-015-9475-4; Malone CF, 2017, CANCER DISCOV, V7, P1450, DOI 10.1158/2159-8290.CD-17-0177; Noch E, 2012, MOL CANCER THER, V11, P14, DOI 10.1158/1535-7163.MCT-11-0517; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pusapati RV, 2016, CANCER CELL, V29, P548, DOI 10.1016/j.ccell.2016.02.018; Quetier I, 2015, J GEN VIROL, V96, P614, DOI 10.1099/vir.0.070680-0; Schoder H, 2007, J NUCL MED, V48, p4S; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Sheth SS, 2006, ONCOGENE, V25, P3528, DOI 10.1038/sj.onc.1209394; Sung WK, 2012, NAT GENET, V44, P765, DOI 10.1038/ng.2295; Suzuki J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05854-6; Sze KMF, 2013, HEPATOLOGY, V57, P131, DOI 10.1002/hep.25979; Thai M, 2014, CELL METAB, V19, P694, DOI 10.1016/j.cmet.2014.03.009; Wang Y, 2002, J PATHOL, V197, P610, DOI 10.1002/path.1150; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wu N, 2013, MOL CELL, V49, P1167, DOI 10.1016/j.molcel.2013.01.035; Xiao L, 2014, ONCOGENE, V33, P4568, DOI 10.1038/onc.2014.32; Yang WJ, 2009, HEPATOLOGY, V49, P1515, DOI 10.1002/hep.22833; Ye JB, 2014, CANCER DISCOV, V4, P1406, DOI 10.1158/2159-8290.CD-14-0250; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Zhang R, 2016, AM J CANCER RES, V6, P312; Zhou Q, 2011, FUTURE ONCOL, V7, P1149, DOI [10.2217/FON.11.95, 10.2217/fon.11.95]	50	22	23	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1147	1161		10.1038/s41388-020-01593-5	http://dx.doi.org/10.1038/s41388-020-01593-5		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323975	hybrid, Green Published			2022-12-17	WOS:000599126500007
J	Vantaku, V; Putluri, V; Bader, DA; Maity, S; Ma, J; Arnold, JM; Rajapakshe, K; Donepudi, SR; von Rundstedt, FC; Devarakonda, V; Dubrulle, J; Karanam, B; McGuire, SE; Stossi, F; Jain, AK; Coarfa, C; Cao, Q; Sikora, AG; Villanueva, H; Kavuri, SM; Lotan, Y; Sreekumar, A; Putluri, N				Vantaku, Venkatrao; Putluri, Vasanta; Bader, David A.; Maity, Suman; Ma, Jing; Arnold, James M.; Rajapakshe, Kimal; Donepudi, Sri Ramya; von Rundstedt, Friedrich-Carl; Devarakonda, Vaishnavi; Dubrulle, Julien; Karanam, Balasubramanyam; McGuire, Sean E.; Stossi, Fabio; Jain, Abhinav K.; Coarfa, Cristian; Cao, Qi; Sikora, Andrew G.; Villanueva, Hugo; Kavuri, Shyam M.; Lotan, Yair; Sreekumar, Arun; Putluri, Nagireddy			Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression	ONCOGENE			English	Article							GROUP PROTEIN EZH2; BREAST-CANCER; DNA METHYLATION; CELLULAR FUNCTIONS; METASTASIS; PROSTATE; GENES; HYPERMETHYLATION; IDENTIFICATION; SUPPRESSOR	Advanced Bladder Cancer (BLCA) remains a clinical challenge that lacks effective therapeutic measures. Here, we show that distinct, stage-wise metabolic alterations in BLCA are associated with the loss of function of aldehyde oxidase (AOX1). AOX1 associated metabolites have a high predictive value for advanced BLCA and our findings demonstrate that AOX1 is epigenetically silenced during BLCA progression by the methyltransferase activity of EZH2. Knockdown (KD) of AOX1 in normal bladder epithelial cells re-wires the tryptophan-kynurenine pathway resulting in elevated NADP levels which may increase metabolic flux through the pentose phosphate (PPP) pathway, enabling increased nucleotide synthesis, and promoting cell invasion. Inhibition of NADP synthesis rescues the metabolic effects of AOX1 KD. Ectopic AOX1 expression decreases NADP production, PPP flux and nucleotide synthesis, while decreasing invasion in cell line models and suppressing growth in tumor xenografts. Further gain and loss of AOX1 confirm the EZH2-dependent activation, metabolic deregulation, and tumor growth in BLCA. Our findings highlight the therapeutic potential of AOX1 and provide a basis for the development of prognostic markers for advanced BLCA.	[Vantaku, Venkatrao; Bader, David A.; Rajapakshe, Kimal; Dubrulle, Julien; McGuire, Sean E.; Stossi, Fabio; Coarfa, Cristian; Sreekumar, Arun; Putluri, Nagireddy] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Putluri, Vasanta; Donepudi, Sri Ramya; Dubrulle, Julien; McGuire, Sean E.; Stossi, Fabio; Coarfa, Cristian; Sikora, Andrew G.; Villanueva, Hugo; Sreekumar, Arun; Putluri, Nagireddy] Baylor Coll Med, Dan L Duncan Canc Ctr, Alkek Ctr Mol Discovery, Adv Technol Core, Houston, TX 77030 USA; [Maity, Suman] Univ Texas Houston, Sch Publ Hlth, Dept Biostat, Houston, TX USA; [Ma, Jing] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA; [Arnold, James M.; Sreekumar, Arun] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [von Rundstedt, Friedrich-Carl] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; [von Rundstedt, Friedrich-Carl] Friedrich Schiller Univ, Jena Univ Hosp, Dept Urol, Jena, Germany; [Devarakonda, Vaishnavi; Kavuri, Shyam M.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Karanam, Balasubramanyam] Tuskegee Univ, Dept Biol, Tuskegee, AL 36088 USA; [Karanam, Balasubramanyam] Tuskegee Univ, Ctr Canc Res, Tuskegee, AL 36088 USA; [Jain, Abhinav K.] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Ctr Canc Epigenet, Houston, TX 77030 USA; [Cao, Qi] Houston Methodist Res Inst, Inst Acad Med, Ctr Inflammat & Epigenet, Houston, TX USA; [Sikora, Andrew G.; Villanueva, Hugo] Baylor Coll Med, Dept Otolaryngol Head Neck Surg, Houston, TX 77030 USA; [Lotan, Yair] Univ Texas SouthWestern, Dept Urol, Dallas, TX USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Fred Hutchinson Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Friedrich Schiller University of Jena; Baylor College of Medicine; Tuskegee University; Tuskegee University; University of Texas System; UTMD Anderson Cancer Center; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; University of Texas System; University of Texas Southwestern Medical Center Dallas	Putluri, N (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Putluri, N (corresponding author), Baylor Coll Med, Dan L Duncan Canc Ctr, Alkek Ctr Mol Discovery, Adv Technol Core, Houston, TX 77030 USA.	putluri@bcm.edu	; Cao, Qi/A-5517-2010	Bader, David/0000-0003-0514-7346; Putluri, Nagireddy/0000-0003-4488-7400; Donepudi, Sri Ramya/0000-0002-2845-1212; Ma, Jing/0000-0001-6294-227X; Cao, Qi/0000-0002-5140-3681				Ablain J, 2014, INT J CANCER, V135, P2262, DOI 10.1002/ijc.29081; Agledal L, 2010, REDOX REP, V15, P2, DOI 10.1179/174329210X12650506623122; [Anonymous], 2018, CANCER DISCOV, V8, pOF15, DOI [10.1158/2159-8290.CD-RW2018-067, DOI 10.1158/2159-8290.CD-RW2018-067]; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Baylin SB, 1998, ADV CANCER RES, V72, P141; BEACONSFIELD P, 1964, Dev Med Child Neurol, V6, P469; Bhowmik SK, 2015, ONCOTARGET, V6, P42651, DOI 10.18632/oncotarget.4765; Blecher-Gonen R, 2013, NAT PROTOC, V8, P539, DOI 10.1038/nprot.2013.023; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Chalkiadaki A, 2015, NAT REV CANCER, V15, DOI 10.1038/nrc3985; Chen YG, 2009, INT J COMPUT INT SYS, V2, P1, DOI 10.2991/jnmp.2009.2.1.1; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; D'Amato NC, 2015, CANCER RES, V75, P4651, DOI 10.1158/0008-5472.CAN-15-2011; Davidson B, 2014, HUM PATHOL, V45, P691, DOI 10.1016/j.humpath.2013.11.003; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Deryugina EI, 2008, HISTOCHEM CELL BIOL, V130, P1119, DOI 10.1007/s00418-008-0536-2; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; Dudziec E, 2011, EPIGENOMICS-UK, V3, P35, DOI 10.2217/EPI.10.71; Estecio MRH, 2007, GENOME RES, V17, P1529, DOI 10.1101/gr.6417007; Esteller M, 2000, CANCER RES, V60, P129; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Garattini E, 2008, CELL MOL LIFE SCI, V65, P1019, DOI 10.1007/s00018-007-7398-y; Garattini Enrico, 2009, Human Genomics, V4, P119; Haldrup C, 2013, J CLIN ONCOL, V31, P3250, DOI 10.1200/JCO.2012.47.1847; Hurst CD, 2017, CANCER CELL, V32, P701, DOI 10.1016/j.ccell.2017.08.005; Hussain M, 2009, CANCER RES, V69, P3570, DOI 10.1158/0008-5472.CAN-08-2807; Icard P, 2012, BBA-REV CANCER, V1825, P111, DOI 10.1016/j.bbcan.2011.10.007; Jin F, 2017, CANCER PREV RES, V10, P588, DOI [10.1158/1940-6207.CAPR-17-0198, 10.1158/1940-6207.capr-17-0198]; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kim WJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-3; Kitamura S, 2006, DRUG METAB PHARMACOK, V21, P83, DOI 10.2133/dmpk.21.83; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kompier LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013821; Li M, 2015, JOVE-J VIS EXP, DOI 10.3791/52411; Ma J, 2016, BIOINFORMATICS, V32, P3165, DOI 10.1093/bioinformatics/btw410; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Oster B, 2011, INT J CANCER, V129, P2855, DOI 10.1002/ijc.25951; Ozturk S, 2016, P NATL ACAD SCI USA, V113, P638, DOI 10.1073/pnas.1514663113; Park JS, 2014, IEEE ENG MED BIO, P3430, DOI 10.1109/EMBC.2014.6944360; Piyarathna DWB, 2018, EUR UROL FOCUS, V4, P907, DOI 10.1016/j.euf.2017.04.005; Platten M, 2012, CANCER RES, V72, P5435, DOI 10.1158/0008-5472.CAN-12-0569; Prendergast GC, 2011, NATURE, V478, P192, DOI 10.1038/478192a; Putluri N, 2014, NEOPLASIA, V16, P390, DOI 10.1016/j.neo.2014.05.007; Putluri N, 2011, CANCER RES, V71, P7376, DOI 10.1158/0008-5472.CAN-11-1154; Putluri N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021417; Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659; SALTER M, 1985, BIOCHEM J, V229, P499, DOI 10.1042/bj2290499; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sievert KD, 2009, WORLD J UROL, V27, P295, DOI 10.1007/s00345-009-0395-z; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Sun SS, 2016, CELL SIGNAL, V28, P481, DOI 10.1016/j.cellsig.2016.02.004; Tan JZ, 2014, ACTA PHARMACOL SIN, V35, P161, DOI 10.1038/aps.2013.161; Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180; Thoma C, 2018, NAT REV UROL, V15, P1, DOI 10.1038/nrurol.2017.207; Vantaku V, 2019, CLIN CANCER RES, V25, P3689, DOI 10.1158/1078-0432.CCR-18-1515; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wolff EM, 2010, CANCER RES, V70, P8169, DOI 10.1158/0008-5472.CAN-10-1335; Yan JL, 2013, BLOOD, V121, P4512, DOI 10.1182/blood-2012-08-450494; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang M, 2013, CANCER CELL, V23, P709, DOI 10.1016/j.ccr.2013.05.015; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672; Zhai LJ, 2015, CLIN CANCER RES, V21, P5427, DOI 10.1158/1078-0432.CCR-15-0420	69	22	22	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6265	6285		10.1038/s41388-019-0902-7	http://dx.doi.org/10.1038/s41388-019-0902-7			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	31383940	Green Accepted			2022-12-17	WOS:000574357500001
J	Rose, M; Maurer, A; Wirtz, J; Bleilevens, A; Waldmann, T; Wenz, M; Eyll, M; Geelvink, M; Gereitzig, M; Ruchel, N; Denecke, B; Eltze, E; Herrmann, E; Toma, M; Horst, D; Grimm, T; Denzinger, S; Ecke, T; Vogeli, TA; Knuechel, R; Maurer, J; Gaisa, NT				Rose, Michael; Maurer, Angela; Wirtz, Julia; Bleilevens, Andreas; Waldmann, Tanja; Wenz, Maximilian; Eyll, Marie; Geelvink, Mirja; Gereitzig, Melanie; Ruechel, Nadine; Denecke, Bernd; Eltze, Elke; Herrmann, Edwin; Toma, Marieta; Horst, David; Grimm, Tobias; Denzinger, Stefan; Ecke, Thorsten; Voegeli, Thomas Alexander; Knuechel, Ruth; Maurer, Jochen; Gaisa, Nadine T.			EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer	ONCOGENE			English	Article							TRANSITIONAL-CELL CARCINOMA; COMPREHENSIVE MOLECULAR CHARACTERIZATION; PHASE-II; UROTHELIAL CARCINOMA; LUNG-CANCER; 1ST-LINE TREATMENT; MASS-ACTION; FAMILY; CHEMOTHERAPY; EXPRESSION	Recent findings suggested a benefit of anti-EGFR therapy for basal-like muscle-invasive bladder cancer (MIBC). However, the impact on bladder cancer with substantial squamous differentiation (Sq-BLCA) and especially pure squamous cell carcinoma (SCC) remains unknown. Therefore, we comprehensively characterized pure and mixed Sq-BLCA (n = 125) on genetic and protein expression level, and performed functional pathway and drug-response analyses with cell line models and isolated primary SCC (p-SCC) cells of the human urinary bladder. We identified abundant EGFR expression in 95% of Sq-BLCA without evidence for activatingEGFRmutations. Both SCaBER and p-SCC cells were sensitive to EGFR tyrosine kinase inhibitors (TKIs: erlotinib and gefitinib). Combined treatment with anti-EGFR TKIs and varying chemotherapeutics led to a concentration-dependent synergism in SCC cells according to the Chou-Talalay method. In addition, the siRNA knockdown of EGFR impaired SCaBER viability suggesting a putative "Achilles heel" of Sq-BLCA. The observed effects seem Sq-BLCA-specific since non-basal urothelial cancer cells were characterized by poor TKI sensitivity associated with a short-term feedback response potentially attenuating anti-tumor activity. Hence, our findings give further insights into a crucial, Sq-BLCA-specific role of the ERBB signaling pathway proposing improved effectiveness of anti-EGFR based regimens in combination with chemotherapeutics in squamous bladder cancers with wild-type EGFR-overexpression.	[Rose, Michael; Maurer, Angela; Wirtz, Julia; Wenz, Maximilian; Eyll, Marie; Geelvink, Mirja; Gereitzig, Melanie; Ruechel, Nadine; Knuechel, Ruth; Gaisa, Nadine T.] Rhein Westfal TH Aachen, Inst Pathol, Aachen, Germany; [Bleilevens, Andreas; Waldmann, Tanja; Maurer, Jochen] Univ Clin RWTH, Dept Gynecol, Aachen, Germany; [Denecke, Bernd] Rhein Westfal TH Aachen, Med Fac, IZKF Aachen, Aachen, Germany; [Eltze, Elke] Saarbrucken Rastpfuhl, Inst Pathol, Saarbrucken, Germany; [Herrmann, Edwin] Univ Hosp Munster, Dept Urol, Munster, Germany; [Toma, Marieta] Tech Univ Dresden, Inst Pathol, Univ Hosp Gustav Carus, Dresden, Germany; [Horst, David] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany; [Grimm, Tobias] Ludwig Maximilians Univ Munchen, Dept Urol, Munich, Germany; [Denzinger, Stefan] Univ Regensburg, Dept Urol, Regensburg, Germany; [Ecke, Thorsten] Helios Hosp Bad Saarow, Dept Urol, Bad Saarow Pieskow, Germany; [Voegeli, Thomas Alexander] Rhein Westfal TH Aachen, Dept Urol, Aachen, Germany; [Toma, Marieta] Univ Hosp Bonn, Inst Pathol, Bonn, Germany	RWTH Aachen University; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; University of Munster; Technische Universitat Dresden; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich; University of Regensburg; RWTH Aachen University; University of Bonn	Gaisa, NT (corresponding author), Rhein Westfal TH Aachen, Inst Pathol, Aachen, Germany.	ngaisa@ukaachen.de	Maurer, Jochen/G-4832-2018; Toma, Marieta/AAI-8022-2021	Maurer, Jochen/0000-0003-3962-3128; Wirtz, Julia/0000-0003-0220-6312; Ruchel, Nadine/0000-0001-9657-8787	Medical Faculty of the RWTH Aachen University [42/13]	Medical Faculty of the RWTH Aachen University	The authors appreciate the contributions of all pathologists and urologists sending cases for study material, the German Study Group of Bladder Cancers (DFBK e.V.), as well as the excellent technical support of Uschi Schneider, Patrick Kuhl and Anja Steinle. We thank Timon Heide for his great support in analyzing TCGA data sets and are grateful for the publicly available TCGA research Network data sets (http://cancergenome.nih.gov). We further thank Dr. Kathrin Scheckenbach (Dusseldorf University Hospital, Germany), Prof. Wolfgang Schulz (Dusseldorf University Hospital, Germany) and Dr. Alexander Buchner (LMU Munchen, Germany) for providing cell lines. We also thank Pia Dinger and Franziska Lammert for proofreading the manuscript. Furthermore, we thank Dr. Olbrich for supporting our study. This project was partly funded by START-funds of the Medical Faculty of the RWTH Aachen University (NTG grant number: 42/13).	Ahsan A, 2010, CANCER RES, V70, P2862, DOI 10.1158/0008-5472.CAN-09-4294; Baldia PH, 2016, ONCOTARGET, V7, P71429, DOI 10.18632/oncotarget.12198; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Bergman AM, 1996, CLIN CANCER RES, V2, P521; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Casalini P, 2004, J CELL PHYSIOL, V200, P343, DOI 10.1002/jcp.20007; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen LF, 2010, CLIN CANCER RES, V16, P2489, DOI 10.1158/1078-0432.CCR-09-2318; Chin TM, 2008, CLIN CANCER RES, V14, P6867, DOI 10.1158/1078-0432.CCR-08-0093; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Chow NH, 1997, VIRCHOWS ARCH, V430, P461, DOI 10.1007/s004280050056; Chow NH, 2001, CLIN CANCER RES, V7, P1957; Eriksson P, 2017, ONCOTARGET, V8, P48905, DOI 10.18632/oncotarget.16554; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Ferner RE, 2016, BRIT J CLIN PHARMACO, V81, P52, DOI 10.1111/bcp.12721; Freed DM, 2017, CELL, V171, P683, DOI 10.1016/j.cell.2017.09.017; Gaisa NT, 2011, J PATHOL, V225, P172, DOI 10.1002/path.2959; Gaisa NT, 2011, VIRCHOWS ARCH, V458, P301, DOI 10.1007/s00428-010-1017-2; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hasinoff BB, 2010, TOXICOL APPL PHARM, V249, P132, DOI 10.1016/j.taap.2010.08.026; Herbst RS, 2007, J CLIN ONCOL, V25, P4743, DOI 10.1200/JCO.2007.12.3026; Humphrey PA, 2016, EUR UROL, V70, P106, DOI 10.1016/j.eururo.2016.02.028; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Kamoun A, 2019, EUR UROL; Kenakin T, 2016, BRIT J CLIN PHARMACO, V81, P41, DOI 10.1111/bcp.12810; Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817; Kramer C, 2007, CANCER-AM CANCER SOC, V109, P2016, DOI 10.1002/cncr.22627; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072; Longton E, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00432; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Metzger E, 2017, CANCER RES, V77, P5900, DOI 10.1158/0008-5472.CAN-17-1754; Minato A, 2018, CANCER CONTROL, V25, DOI 10.1177/1073274818800269; Minato A, 2017, CLIN GENITOURIN CANC, V15, pE1063, DOI 10.1016/j.clgc.2017.07.008; Miyabayashi K, 2013, CANCER RES, V73, P2221, DOI 10.1158/0008-5472.CAN-12-1453; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Mooso BA, 2015, J UROLOGY, V193, P19, DOI 10.1016/j.juro.2014.07.121; O-Charoenrat P, 2000, INT J CANCER, V88, P759, DOI 10.1002/1097-0215(20001201)88:5<759::AID-IJC12>3.0.CO;2-0; Petrylak DP, 2010, BJU INT, V105, P317, DOI 10.1111/j.1464-410X.2009.08799.x; Pirker Robert, 2010, J Thorac Oncol, V5, P1706, DOI 10.1097/JTO.0b013e3181f1c8de; Pruthi RS, 2010, BJU INT, V106, P349, DOI 10.1111/j.1464-410X.2009.09101.x; Rebouissou S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008970; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Rose M, 2018, METHODS MOL BIOL, V1655, P43, DOI 10.1007/978-1-4939-7234-0_4; Rose M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0610-2; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Seiler R, 2017, EUR UROL, V72, P544, DOI 10.1016/j.eururo.2017.03.030; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559; Tsai CM, 2011, J THORAC ONCOL, V6, P559, DOI 10.1097/JTO.0b013e3182021ff5; Weickhardt AJ, 2012, J CLIN ONCOL, V30, P1505, DOI 10.1200/JCO.2011.38.6599; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wilson KJ, 2012, GROWTH FACTORS, V30, P107, DOI 10.3109/08977194.2011.649918; Wirth LJ, 2016, ORAL ONCOL, V61, P31, DOI 10.1016/j.oraloncology.2016.07.005; Yan XT, 2019, LUNG CANCER, V128, P6, DOI 10.1016/j.lungcan.2018.12.007; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309	59	22	22	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6856	6870		10.1038/s41388-020-01465-y	http://dx.doi.org/10.1038/s41388-020-01465-y		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32978523	Green Published, hybrid			2022-12-17	WOS:000572714000004
J	Xia, Q; Zhang, HW; Zhang, P; Li, Y; Xu, MC; Li, XB; Li, XJ; Dong, L				Xia, Qin; Zhang, Hanwen; Zhang, Pei; Li, Yang; Xu, Mengchuan; Li, Xiaobo; Li, Xuejun; Dong, Lei			Oncogenic Smurf1 promotes PTEN wild-type glioblastoma growth by mediating PTEN ubiquitylation	ONCOGENE			English	Article							MAMMALIAN TARGET; UBIQUITIN LIGASE; STEM-CELLS; RESISTANCE; RAPAMYCIN; GLIOMA; RECEPTOR; COMPLEX; SMAD7	PI3K/Akt/mTOR signaling pathway activity is highly elevated in glioblastoma (GBM). Although rapamycin is known to inhibit this pathway, GBM patients are resistant to rapamycin monotherapy. This may be related to mutations of tumor suppressor phosphatase and tensin homolog (PTEN). Here, we show that higher expression of E3 ligase Smad ubiquitylation regulatory factor 1 (Smurf1) in GBM is correlated with poor prognosis. Smurf1 promotes cell growth and colony formation by accelerating cell cycle and aberrant signaling pathways. In addition, we show that Smurf1 ubiquitylates and degrades PTEN. We further demonstrate that the oncogenic role of Smurf1 is dependent on PTEN. Upregulated Smurf1 impairs PTEN activity, leading to consistent activation of PI3K/Akt/mTOR signaling pathway; and depletion of Smurf1 dramatically inhibits cell proliferation and tumor growth. Moreover, loss of Smurf1 abolishes the aberrant regulation of PTEN, causing negative feedback on PI3K/Akt/mTOR signaling pathway, and thus leading to rescue of tumor sensitivity to rapamycin in an orthotopic GBM model. Taken together, we show that Smurf1 promotes tumor progression via PTEN, and combined treatment of Smurf1 knockdown with mammalian target of rapamycin (mTOR) inhibition reduces tumor progression. These results identify a unique role of Smurf1 in mTOR inhibitor resistance and provide a strong rationale for combined therapy targeting GBM.	[Xia, Qin; Zhang, Hanwen; Zhang, Pei; Li, Yang; Xu, Mengchuan; Dong, Lei] Beijing Inst Technol, Sch Life Sci, Beijing, Peoples R China; [Li, Xiaobo] Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Collaborat Innovat Ctr Tianjin Med Epigenet, Tianjin Key Lab Med Epigenet,Dept Immunol, Tianjin, Peoples R China; [Li, Xuejun] Cent South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Hunan, Peoples R China	Beijing Institute of Technology; Tianjin Medical University; Central South University	Dong, L (corresponding author), Beijing Inst Technol, Sch Life Sci, Beijing, Peoples R China.	ldong@bit.edu.cn	Zhang, Hanwen/AAG-1299-2022; Zhang, Hanwen/AFK-2928-2022; dong, lei/O-9654-2016	Zhang, Hanwen/0000-0001-8955-7494; Zhang, Hanwen/0000-0001-8955-7494; dong, lei/0000-0001-7530-7427	Beijing Natural Science Foundation [Z190018]; Natural Science Foundation of China [81870123]; China Postdoctoral Science Foundation [2018M641206]; National Science Foundation for Young Scientists of China [81902545]	Beijing Natural Science Foundation(Beijing Natural Science Foundation); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Science Foundation for Young Scientists of China	This work was supported by grants from Beijing Natural Science Foundation (Z190018), The Natural Science Foundation of China (81870123), China Postdoctoral Science Foundation Grant (2018M641206), and the National Science Foundation for Young Scientists of China (81902545).	Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Bassi C, 2013, SCIENCE, V341, P395, DOI 10.1126/science.1236188; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chang H, 2018, CELL MOL NEUROBIOL, V38, P421, DOI 10.1007/s10571-017-0485-1; Chen A, 2009, MOL CELL BIOL, V29, P5348, DOI 10.1128/MCB.00407-09; Cheng PL, 2011, NEURON, V69, P231, DOI 10.1016/j.neuron.2010.12.021; Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008; Cloughesy TF, 2014, ANNU REV PATHOL-MECH, V9, P1, DOI 10.1146/annurev-pathol-011110-130324; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Edinger AL, 2003, CANCER RES, V63, P8451; Endersby R, 2008, ONCOGENE, V27, P5416, DOI 10.1038/onc.2008.239; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Grunwald V, 2002, CANCER RES, V62, P6141; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Holmes B, 2019, J NEURO-ONCOL, V145, P11, DOI 10.1007/s11060-019-03274-0; Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992; Iwanami A, 2013, P NATL ACAD SCI USA, V110, P4339, DOI 10.1073/pnas.1217602110; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Khammanivong A, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-260; Knobbe CB, 2002, NEURO-ONCOLOGY, V4, P196; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Lee JJ, 2011, CELL DEATH DIFFER, V18, P666, DOI 10.1038/cdd.2010.139; Lee MG, 2016, CANCER RES, V76, P1847, DOI 10.1158/0008-5472.CAN-15-1752; Lee YR, 2019, SCIENCE, V364, P651, DOI 10.1126/science.aau0159; Lee YR, 2018, NAT REV MOL CELL BIO, V19, P547, DOI 10.1038/s41580-018-0015-0; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li H, 2017, ONCOGENE, V36, P5668, DOI 10.1038/onc.2017.166; Lin F, 2014, CLIN CANCER RES, V20, P2703, DOI 10.1158/1078-0432.CCR-14-0084; Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mondal S, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0126-6; Narimatsu M, 2009, CELL, V137, P295, DOI 10.1016/j.cell.2009.02.025; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Song MS, 2011, CELL, V144, P187, DOI 10.1016/j.cell.2010.12.020; Stichel D, 2018, ACTA NEUROPATHOL, V136, P793, DOI 10.1007/s00401-018-1905-0; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Wang J, 2019, NAT NEUROSCI, V22, P91, DOI 10.1038/s41593-018-0285-z; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wiedemeyer R, 2008, CANCER CELL, V13, P355, DOI 10.1016/j.ccr.2008.02.010; Xie P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4733; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yu L, 2015, CANCER RES, V75, P1275, DOI 10.1158/0008-5472.CAN-14-2387; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	48	22	22	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5902	5915		10.1038/s41388-020-01400-1	http://dx.doi.org/10.1038/s41388-020-01400-1		JUL 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32737433				2022-12-17	WOS:000554333300001
J	Ricciardiello, F; Gang, Y; Palorini, R; Li, QX; Giampa, M; Zhao, FY; You, L; La Ferla, B; De Vitto, H; Guan, WF; Gu, J; Zhang, TP; Zhao, YP; Chiaradonna, F				Ricciardiello, Francesca; Gang, Yang; Palorini, Roberta; Li, Quanxiao; Giampa, Marco; Zhao, Fangyu; You, Lei; La Ferla, Barbara; De Vitto, Humberto; Guan, Wenfang; Gu, Jin; Zhang, Taiping; Zhao, Yupei; Chiaradonna, Ferdinando			Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; O-GLCNAC; GLCNACYLATION; CELLS	Different evidence has indicated metabolic rewiring as a necessity for pancreatic cancer (PC) growth, invasion, and chemotherapy resistance. A relevant role has been assigned to glucose metabolism. In particular, an enhanced flux through the Hexosamine Biosynthetic Pathway (HBP) has been tightly linked to PC development. Here, we show that enhancement of the HBP, through the upregulation of the enzyme Phosphoacetylglucosamine Mutase 3 (PGM3), is associated with the onset of gemcitabine (GEM) resistance in PC. Indeed, mRNA profiles of GEM sensitive and resistant patient-derived tumor xenografts (PDXs) indicate that PGM3 expression is specifically increased in GEM-resistant PDXs. Of note, PGM3 results also overexpressed in human PC tissues as compared to paired adjacent normal tissues and its higher expression in PC patients is associated with worse median overall survival (OS). Strikingly, genetic or pharmacological PGM3 inhibition reduces PC cell growth, migration, invasion, in vivo tumor growth and enhances GEM sensitivity. Thus, combined treatment between a specific inhibitor of PGM3, named FR054, and GEM results in a potent reduction of xenograft tumor growth without any obvious side effects in normal tissues. Mechanistically, PGM3 inhibition, reducing protein glycosylation, causes a sustained Unfolded Protein Response (UPR), a significant attenuation of the pro-tumorigenic Epidermal Growth Factor Receptor (EGFR)-Akt axis, and finally cell death. In conclusion this study identifies the HBP as a metabolic pathway involved in GEM resistance and provides a strong rationale for a PC therapy addressing the combined treatment with the PGM3 inhibitor and GEM.	[Ricciardiello, Francesca; Palorini, Roberta; Giampa, Marco; La Ferla, Barbara; De Vitto, Humberto; Chiaradonna, Ferdinando] Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; [Gang, Yang; Li, Quanxiao; Zhao, Fangyu; You, Lei; Zhang, Taiping; Zhao, Yupei] Chinese Acad Med Sci & Peking Union Med Coll, Dept Gen Surg, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China; [Guan, Wenfang; Gu, Jin] Tsinghua Univ, MOE Key Lab Bioinformat, Beijing 100084, Peoples R China; [Guan, Wenfang; Gu, Jin] Tsinghua Univ, Bioinformat Div, Ctr Synthet & Syst Biol, BNRist, Beijing 100084, Peoples R China; [Guan, Wenfang; Gu, Jin] Tsinghua Univ, Dept Automat, Beijing 100084, Peoples R China; [De Vitto, Humberto] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA	University of Milano-Bicocca; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Tsinghua University; Tsinghua University; Tsinghua University; University of Minnesota System	Chiaradonna, F (corresponding author), Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy.; Zhang, TP; Zhao, YP (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Dept Gen Surg, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.	tpingzhang@yahoo.com; zhao8028@263.net; ferdinando.chiaradonna@unimib.it	ricciardiello, francesca/AAO-3804-2020; CHIARADONNA, Ferdinando/K-4959-2016; La Ferla, Barbara/AAM-3452-2020	CHIARADONNA, Ferdinando/0000-0001-8529-2732; La Ferla, Barbara/0000-0002-4340-9717	MAECI (Executive Programme of Scientific and Technological Cooperation Italy-China) [CN19GR03]; Associazione Italiana per la Ricerca sul Cancro [15364]; Fondo individuale FFABBR_NAT 2017 (MIUR, Italy); Chinese Government [2018YFE0118600]; National Natural Science Foundation of China [81772639]; Natural Science Foundation of Beijing [7192157]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-001]; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2018PT32014]; MIUR; National Brazilian Institution of Science (CAPES) [9281-13-4]; Italian Government [2018YFE0118600]	MAECI (Executive Programme of Scientific and Technological Cooperation Italy-China); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Fondo individuale FFABBR_NAT 2017 (MIUR, Italy); Chinese Government; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Beijing(Beijing Natural Science Foundation); CAMS Innovation Fund for Medical Sciences (CIFMS); Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences; MIUR(Ministry of Education, Universities and Research (MIUR)); National Brazilian Institution of Science (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Italian Government	FC was supported by grants from MAECI (Executive Programme of Scientific and Technological Cooperation Italy-China 2019-2021, #CN19GR03), from Associazione Italiana per la Ricerca sul Cancro (A.I.R.C., IG2014 Id.15364) and Fondo individuale FFABBR_NAT 2017 (MIUR, Italy). TZ was supported by grants from Key Projects of International Scientific and Technological Innovation Cooperation Between Chinese and Italian Governments (2018YFE0118600), from the National Natural Science Foundation of China (No. 81772639), from Natural Science Foundation of Beijing (No. 7192157) and CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2016-I2M-1-001). YZ was supported by grants from Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2018PT32014). FR is supported by fellowship from MIUR. RP and HDV were supported by fellowship from MIUR and National Brazilian Institution of Science (CAPES 9281-13-4), respectively. We thank Neil Campbell for English editing.	ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491; Akella NM, 2019, BMC BIOL, V17, DOI 10.1186/s12915-019-0671-3; Amrutkar M, 2017, CANCERS, V9, DOI 10.3390/cancers9110157; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Avril T, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.72; Binenbaum Y, 2015, DRUG RESIST UPDATE, V23, P55, DOI 10.1016/j.drup.2015.10.002; Cavalcante LD, 2014, EUR J PHARMACOL, V741, P8, DOI [10.1010/j.ejphar.2014.07.041, 10.1016/j.ejphar.2014.07.041]; Chatham JC, 2010, CURR SIGNAL TRANSD T, V5, P49, DOI 10.2174/157436210790226492; Chen RR, 2017, SCI REP-UK, V7, DOI 10.1038/srep41463; Chiaradonna F, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7060053; Dauer P, 2018, MOL ONCOL, V12, P1498, DOI 10.1002/1878-0261.12322; de Queiroz RM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00116; Du YX, 2017, CANCER RES, V77, P2661, DOI 10.1158/0008-5472.CAN-16-2339; Fang B, 2001, EXP CELL RES, V263, P243, DOI 10.1006/excr.2000.5110; Feng MY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0947-4; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Guillaumond F, 2013, P NATL ACAD SCI USA, V110, P3919, DOI 10.1073/pnas.1219555110; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Liu CF, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00415; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Liu YC, 2011, P NATL ACAD SCI USA, V108, P11332, DOI 10.1073/pnas.1107385108; Lopez-Sambrooks C, 2016, NAT CHEM BIOL, V12, P1023, DOI 10.1038/nchembio.2194; Luo WH, 2019, CANCER MED-US, V8, P6403, DOI 10.1002/cam4.2384; Ma ZY, 2013, J BIOL CHEM, V288, P15121, DOI 10.1074/jbc.M113.470047; Munkley J, 2019, ONCOL LETT, V17, P2569, DOI 10.3892/ol.2019.9885; Nagaraj NS, 2011, CLIN CANCER RES, V17, P483, DOI 10.1158/1078-0432.CCR-10-1670; Namba T, 2015, MAR DRUGS, V13, P2376, DOI 10.3390/md13042376; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Paiotta A, 2018, EUR J ORG CHEM, V2018, P1946, DOI 10.1002/ejoc.201800183; Palam LR, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.264; Qian WK, 2018, LIFE SCI, V208, P253, DOI 10.1016/j.lfs.2018.07.046; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Ricciardiello F, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0405-4; Rodrigues JG, 2018, CELL IMMUNOL, V333, P46, DOI 10.1016/j.cellimm.2018.03.007; Shukla SK, 2017, CANCER CELL, V32, P392, DOI 10.1016/j.ccell.2017.08.008; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stichelen SOV, 2012, AM J PHYSIOL-ENDOC M, V302, pE417, DOI 10.1152/ajpendo.00390.2011; Tadros S, 2017, CANCER RES, V77, P5503, DOI 10.1158/0008-5472.CAN-16-3062; Thakur PC, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1562-z; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Vaziri-Gohar A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00617; Wellen KE, 2012, NAT REV MOL CELL BIO, V13, P270, DOI 10.1038/nrm3305; Yang G, 2019, SCI CHINA LIFE SCI, V62, P791, DOI 10.1007/s11427-018-9495-2; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	45	22	23	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4103	4117		10.1038/s41388-020-1260-1	http://dx.doi.org/10.1038/s41388-020-1260-1		MAR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32235891	Green Submitted			2022-12-17	WOS:000522606000001
J	Vessoni, AT; Filippi-Chiela, EC; Lenz, G; Batista, LFZ				Vessoni, Alexandre Teixeira; Filippi-Chiela, Eduardo Cremonese; Lenz, Guido; Batista, Luis Francisco Zirnberger			Tumor propagating cells: drivers of tumor plasticity, heterogeneity, and recurrence	ONCOGENE			English	Review							CANCER STEM-CELLS; ACUTE MYELOID-LEUKEMIA; INITIATING CELLS; OXIDATIVE-PHOSPHORYLATION; INTRATUMOR HETEROGENEITY; PHENOTYPIC HETEROGENEITY; MESENCHYMAL TRANSITION; CLONAL EVOLUTION; DRUG-RESISTANCE; MELANOMA-CELLS	Tumorigenesis is associated with the development of a highly variable pattern of cellular diversity, consequence of genetic and epigenetic diversification, followed by clonal selection and expansion. This process is shaped by the microenvironment and leads to intratumoral heterogeneity, which is characterized by differences between cancer cells in terms of gene expression, phenotypic markers, growth dynamics, and resistance to treatment. Another relevant aspect in intratumor heterogeneity is cell plasticity-the ability of a cell to switch to new identities. In this review, we focus on the mechanisms that regulate cancer cell plasticity within a tumor, and explore the concept of tumor propagating cells, or TPCs, a cancer cell able to propagate/phenocopy the parental tumor and recapitulate tumor heterogeneity. We discuss the influence of the microenvironment and driver mutations on TPCs formation and function, the existence of phenotypically distinct TPC clones within a tumor, the evolution of TPCs with disease progression, and their implications for therapy.	[Vessoni, Alexandre Teixeira; Batista, Luis Francisco Zirnberger] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Filippi-Chiela, Eduardo Cremonese] Univ Fed Rio Grande do Sul, Dept Ciencias Morfol, Inst Ciencias Basicas Saude, Porto Alegre, RS, Brazil; [Lenz, Guido] Univ Fed Rio Grande do Sul, Dept Biofis, Porto Alegre, RS, Brazil; [Lenz, Guido] Univ Fed Rio Grande do Sul, Ctr Biotecnol, Porto Alegre, RS, Brazil; [Batista, Luis Francisco Zirnberger] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA; [Batista, Luis Francisco Zirnberger] Washington Univ, Sch Med, Ctr Regenerat Med, St Louis, MO 63110 USA	Washington University (WUSTL); Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Washington University (WUSTL); Washington University (WUSTL)	Vessoni, AT; Batista, LFZ (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Batista, LFZ (corresponding author), Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.; Batista, LFZ (corresponding author), Washington Univ, Sch Med, Ctr Regenerat Med, St Louis, MO 63110 USA.	alexandre.vessoni@wustl.edu; lbatista@wustl.edu	Filippi-Chiela, Eduardo/F-1959-2014; Vessoni, Alexandre/L-5754-2013	Filippi-Chiela, Eduardo/0000-0001-8192-3779; Vessoni, Alexandre/0000-0001-9170-5185	Philip Majerus Fellowship Fund; NHLBI [4R00HL114732, 1R01HL137793]; V Foundation for Cancer Research; AA&MDS International Foundation; CONCERN Foundation; Department of Defense Bone Marrow Failure Research Program [BM160054]; American Cancer Society; Edward Mallinckrodt Jr. Foundation	Philip Majerus Fellowship Fund; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); V Foundation for Cancer Research; AA&MDS International Foundation; CONCERN Foundation; Department of Defense Bone Marrow Failure Research Program; American Cancer Society(American Cancer Society); Edward Mallinckrodt Jr. Foundation	ATV was supported by the Philip Majerus Fellowship Fund. LFZB is supported by the NHLBI (4R00HL114732; 1R01HL137793) and grants from the V Foundation for Cancer Research, the Edward Mallinckrodt Jr. Foundation, the AA&MDS International Foundation, the CONCERN Foundation, the Department of Defense Bone Marrow Failure Research Program (BM160054) and the American Cancer Society. We thank Sapiens Scientific Illustrations for the artistic work on Figs. 1-3.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Auffinger B, 2014, CELL DEATH DIFFER, V21, P1119, DOI 10.1038/cdd.2014.31; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Bai F, 2014, CANCER RES, V74, P6161, DOI 10.1158/0008-5472.CAN-14-1119; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Barrett LE, 2012, CANCER CELL, V21, P11, DOI 10.1016/j.ccr.2011.11.025; Blazek ER, 2007, INT J RADIAT ONCOL, V67, P1, DOI 10.1016/j.ijrobp.2006.09.037; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Bridges HR, 2014, BIOCHEM J, V462, P475, DOI 10.1042/BJ20140620; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chen RH, 2010, CANCER CELL, V17, P362, DOI 10.1016/j.ccr.2009.12.049; Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021; Corces MR, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00263; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; De Luca A, 2015, ONCOTARGET, V6, P14777, DOI 10.18632/oncotarget.4401; Denise C, 2015, ONCOTARGET, V6, P41706, DOI 10.18632/oncotarget.5991; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344; Egan JB, 2012, BLOOD, V120, P1060, DOI 10.1182/blood-2012-01-405977; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Engle EK, 2015, LEUKEMIA, V29, P869, DOI 10.1038/leu.2014.289; Ge YJ, 2017, CELL, V169, P636, DOI 10.1016/j.cell.2017.03.042; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Giesen C, 2014, NAT METHODS, V11, P417, DOI [10.1038/NMETH.2869, 10.1038/nmeth.2869]; Giessler KM, 2017, J EXP MED, V214, P2073, DOI 10.1084/jem.20162017; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbst K, 2016, CANCER RES, V76, P4765, DOI 10.1158/0008-5472.CAN-15-3476; Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hughes AEO, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004462; Ischenko I, 2013, P NATL ACAD SCI USA, V110, P3937, DOI 10.1073/pnas.1219592110; Jacoby MA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98962; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jeon HM, 2014, CANCER RES, V74, P4482, DOI 10.1158/0008-5472.CAN-13-1597; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kim SY, 2016, J CELL BIOCHEM, V117, P2289, DOI 10.1002/jcb.25527; Kim TM, 2015, CLIN CANCER RES, V21, P4461, DOI 10.1158/1078-0432.CCR-14-2413; Klco JM, 2014, CANCER CELL, V25, P379, DOI 10.1016/j.ccr.2014.01.031; Krause DS, 2006, NAT MED, V12, P1175, DOI 10.1038/nm1489; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Kurtova AV, 2015, NATURE, V517, P209, DOI 10.1038/nature14034; Lagadec C, 2012, STEM CELLS, V30, P833, DOI 10.1002/stem.1058; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Lamb R, 2014, ONCOTARGET, V5, P11029, DOI 10.18632/oncotarget.2789; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lapouge G, 2012, EMBO J, V31, P4563, DOI 10.1038/emboj.2012.312; Ledur PF, 2016, NEURO-ONCOLOGY, V18, P1413, DOI 10.1093/neuonc/now062; Ledur PF, 2017, ONCOTARGET, V8, P69185, DOI 10.18632/oncotarget.20193; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009; Li S, 2016, NAT MED, V22, P792, DOI 10.1038/nm.4125; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Liu K, 2017, MOL CELL, V68, P281, DOI 10.1016/j.molcel.2017.09.022; Liu XJ, 2017, CELL RES, V27, P764, DOI 10.1038/cr.2017.41; Lotti F, 2013, J EXP MED, V210, P2851, DOI 10.1084/jem.20131195; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Lu R, 2016, CANCER CELL, V30, P92, DOI 10.1016/j.ccell.2016.05.008; Maenhaut C, 2010, CARCINOGENESIS, V31, P149, DOI 10.1093/carcin/bgp259; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mazumdar C, 2015, CELL STEM CELL, V17, P1, DOI 10.1016/j.stem.2015.09.017; McClellan JS, 2015, P NATL ACAD SCI USA, V112, P4074, DOI 10.1073/pnas.1413383112; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Medyouf H, 2014, CELL STEM CELL, V14, P824, DOI 10.1016/j.stem.2014.02.014; Miller CA, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003665; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oshimori N, 2015, CELL, V160, P963, DOI 10.1016/j.cell.2015.01.043; Pagotto A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.327; Park SM, 2015, J CLIN INVEST, V125, P1286, DOI 10.1172/JCI78440; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Piccirillo SGM, 2015, STEM CELL REP, V4, P7, DOI 10.1016/j.stemcr.2014.11.003; Quek L, 2018, NAT MED, V24, P1167, DOI 10.1038/s41591-018-0115-6; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Read TA, 2009, CANCER CELL, V15, P135, DOI 10.1016/j.ccr.2008.12.016; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Rycaj K, 2015, CANCER RES, V75, P4003, DOI 10.1158/0008-5472.CAN-15-0798; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Schapiro D, 2017, NAT METHODS, V14, P873, DOI [10.1038/nmeth.4391, 10.1038/NMETH.4391]; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Schober M, 2011, P NATL ACAD SCI USA, V108, P10544, DOI 10.1073/pnas.1107807108; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Shalapour S, 2015, J CLIN INVEST, V125, P3347, DOI 10.1172/JCI80007; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080; Shih AH, 2015, CANCER CELL, V27, P502, DOI 10.1016/j.ccell.2015.03.009; Shimoda M, 2014, NAT CELL BIOL, V16, P889, DOI 10.1038/ncb3021; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Stewart JM, 2011, P NATL ACAD SCI USA, V108, P6468, DOI 10.1073/pnas.1005529108; Sun YQ, 2018, CANCER CELL, V34, P643, DOI 10.1016/j.ccell.2018.08.018; Taussig DC, 2008, BLOOD, V112, P568, DOI 10.1182/blood-2007-10-118331; Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood-2009-02-206565; Tehranchi R, 2010, NEW ENGL J MED, V363, P1025, DOI 10.1056/NEJMoa0912228; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Trissal MC, 2018, CANCER RES, V78, P3510, DOI 10.1158/0008-5472.CAN-17-3592; Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Venkataramani V, 2019, NATURE, V573, P532, DOI 10.1038/s41586-019-1564-x; Venkatesh HS, 2019, NATURE, V573, P539, DOI 10.1038/s41586-019-1563-y; Venteicher AS, 2017, SCIENCE, V355, DOI 10.1126/science.aai8478; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Vlashi E, 2014, BREAST CANCER RES TR, V146, P525, DOI 10.1007/s10549-014-3051-2; Vlashi E, 2011, P NATL ACAD SCI USA, V108, P16062, DOI 10.1073/pnas.1106704108; Volonte A, 2014, J IMMUNOL, V192, P523, DOI 10.4049/jimmunol.1301342; Walker BA, 2014, LEUKEMIA, V28, P384, DOI 10.1038/leu.2013.199; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Wei J, 2010, MOL CANCER THER, V9, P67, DOI 10.1158/1535-7163.MCT-09-0734; Weng QJ, 2019, CELL STEM CELL, V24, P707, DOI 10.1016/j.stem.2019.03.006; Wong TN, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02858-0; Wulf GG, 2001, BLOOD, V98, P1166, DOI 10.1182/blood.V98.4.1166; Xu J, 2019, ELIFE, V8, DOI 10.7554/eLife.45105; Xue RD, 2016, GASTROENTEROLOGY, V150, P998, DOI 10.1053/j.gastro.2015.12.033; Yan C, 2017, CANCER LETT, V388, P34, DOI 10.1016/j.canlet.2016.11.018; Yang Y, 2017, INT J ONCOL, V51, P515, DOI 10.3892/ijo.2017.4044; Ye HB, 2016, CELL STEM CELL, V19, P23, DOI 10.1016/j.stem.2016.06.001; You Y, 2018, CLIN EXP IMMUNOL, V191, P60, DOI 10.1111/cei.13044; Zamarron BF, 2011, INT J BIOL SCI, V7, P651, DOI 10.7150/ijbs.7.651; Zeng QQ, 2019, NATURE, V573, P526, DOI 10.1038/s41586-019-1576-6	148	22	22	4	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2055	2068		10.1038/s41388-019-1128-4	http://dx.doi.org/10.1038/s41388-019-1128-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31801972				2022-12-17	WOS:000518584000003
J	Du, F; Li, XW; Feng, WB; Qiao, CY; Chen, J; Jiang, MZ; Qiu, ZY; Qian, MR; Tian, D; Nie, YZ; Fan, DM; Wu, KC; Xia, LM				Du, Feng; Li, Xiaowei; Feng, Weibo; Qiao, Chenyang; Chen, Jie; Jiang, Mingzuo; Qiu, Zhaoyan; Qian, Meirui; Tian, Dean; Nie, Yongzhan; Fan, Daiming; Wu, Kaichun; Xia, Limin			SOX13 promotes colorectal cancer metastasis by transactivating SNAI2 and c-MET	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR; PANCREATIC-CANCER; EXPRESSION; STEM; CHEMOTHERAPY; PRINCIPLES; CRIZOTINIB; RESISTANCE; REGULATORS	Metastasis is a major cause of high recurrence and poor survival of patients with colorectal cancer (CRC), although the mechanisms associated with this process remain poorly understood. In this study, we report a novel mechanism by which SOX13 promotes CRC metastasis by transactivating SNAI2 and c-MET. SOX13 overexpression was significantly correlated with more aggressive clinicopathological features of CRC and indicated poor prognosis in two independent cohorts of CRC patients (cohort I, n = 363; cohort II, n = 390). Overexpression of SOX13-promoted CRC migration, invasion, and metastasis, whereas SOX13 downregulation caused the opposite effects. Further mechanistic investigation identified SNAI2 and MET as important target genes of SOX13 using serial deletion and site-directed mutagenesis luciferase reporter and chromatin immunoprecipitation (ChIP) assays, as well as functional complementation analyses. In addition, SOX13 was shown to be a direct target of HGF/STAT3 signaling, and the c-MET inhibitor crizotinib blocked the HGF/STAT3/SOX13/c-MET axis, significantly inhibiting SOX13-mediated CRC migration, invasion and metastasis. Moreover, in clinical CRC tissues, SOX13 expression was positively correlated with the expression of SNAI2, c-MET, and HGF. CRC patients with positive coexpression of SOX13/SNAI2, SOX13/c-MET, or HGF/SOX13 exhibited a worse prognosis. In summary, SOX13 is a promising prognostic biomarker in patients with CRC, and blocking the HGF/STAT3/SOX13/c-MET axis with crizotinib could be a new therapeutic strategy to prevent SOX13-mediated CRC metastasis.	[Du, Feng; Tian, Dean; Xia, Limin] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Gastroenterol, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; [Du, Feng; Feng, Weibo; Qiao, Chenyang; Chen, Jie; Jiang, Mingzuo; Qian, Meirui; Nie, Yongzhan; Fan, Daiming; Wu, Kaichun; Xia, Limin] Fourth Mil Med Univ, State Key Lab Canc Biol, Natl Clin Res Ctr Digest Dis, Xian 710032, Shaanxi, Peoples R China; [Du, Feng; Feng, Weibo; Qiao, Chenyang; Chen, Jie; Jiang, Mingzuo; Qian, Meirui; Nie, Yongzhan; Fan, Daiming; Wu, Kaichun; Xia, Limin] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Shaanxi, Peoples R China; [Du, Feng] Chinese People Liberat Army 306th Hosp, Dept Gastroenterol, Beijing, Peoples R China; [Li, Xiaowei] Navy Gen Hosp, Dept Gastroenterol, Beijing 100048, Peoples R China; [Qiu, Zhaoyan] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Fuxing Rd 28, Beijing 100853, Peoples R China; [Tian, Dean; Xia, Limin] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Liver & Gastrointestinal Dis, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Air Force Military Medical University; Air Force Military Medical University; Sixth Medical Center of Chinese PLA General Hospital; Chinese People's Liberation Army General Hospital; Huazhong University of Science & Technology	Xia, LM (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Gastroenterol, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.; Xia, LM (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, Natl Clin Res Ctr Digest Dis, Xian 710032, Shaanxi, Peoples R China.; Xia, LM (corresponding author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Shaanxi, Peoples R China.; Xia, LM (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Inst Liver & Gastrointestinal Dis, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.	xialimin@fmmu.edu.cn			National Key Research and Development Program of China [SQ2017YFSF090132, 2018YFC1312103]; National Natural Science Foundation of China [81972237, 81772623, 81627807, 81430072, 81421003]; National Center for Clinical Research of Digestive Diseases [2015BAI13B07]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Center for Clinical Research of Digestive Diseases	Research was supported by grants from the National Key Research and Development Program of China 2018YFC1312103 (LX), National Natural Science Foundation of China No. 81972237 (LX), No. 81772623 (LX), No. 81627807 (KW), No.81430072 (DF) and No. 81421003 (KW), National Key Research and Development Program of China SQ2017YFSF090132 (KW), and National Center for Clinical Research of Digestive Diseases 2015BAI13B07 (DF). We also would like to thank Qingling An and Jianhua Dou from the Fourth Military Medical University for providing excellent technical assistance.	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Balsas P, 2017, BLOOD, V130, P501, DOI 10.1182/blood-2017-04-776740; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Du F, 2019, CANCER LETT, V452, P103, DOI 10.1016/j.canlet.2019.03.035; Du F, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1481-9; Emaduddin M, 2008, P NATL ACAD SCI USA, V105, P2358, DOI 10.1073/pnas.0712176105; Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hu Y, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0592-y; Huang WJ, 2015, HEPATOLOGY, V61, P1920, DOI 10.1002/hep.27756; Kamachi Y, 2013, DEVELOPMENT, V140, P4129, DOI 10.1242/dev.091793; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008; Lee SJ, 2018, CLIN COLORECTAL CANC, V17, P165, DOI 10.1016/j.clcc.2018.02.013; Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009; Li CX, 2017, P NATL ACAD SCI USA, V114, pE2852, DOI 10.1073/pnas.1618297114; Man CH, 2015, BLOOD, V125, P3928, DOI 10.1182/blood-2014-06-580993; McQuade RM, 2017, CURR MED CHEM, V24, P1537, DOI 10.2174/0929867324666170111152436; Moore AE, 2009, CARCINOGENESIS, V30, P1796, DOI 10.1093/carcin/bgp183; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795; Pietrantonio F, 2016, CANCER DISCOV, V6, P963, DOI 10.1158/2159-8290.CD-16-0297; Prior HM, 1996, MOL MED, V2, P405, DOI 10.1007/BF03401900; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; Tchougounova E, 2009, ONCOGENE, V28, P1537, DOI 10.1038/onc.2009.9; Thu KL, 2014, ONCOGENE, V33, P279, DOI 10.1038/onc.2012.595; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Tsao CM, 2012, HEPATOLOGY, V56, P2277, DOI 10.1002/hep.25933; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Zarour LR, 2017, CELL MOL GASTROENTER, V3, P163, DOI 10.1016/j.jcmgh.2017.01.006; Zeng ZS, 2008, CANCER LETT, V265, P258, DOI 10.1016/j.canlet.2008.02.049; Zhang R, 2018, EUR REV MED PHARMACO, V22, P6801, DOI 10.26355/eurrev_201810_16146	38	22	22	2	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3522	3540		10.1038/s41388-020-1233-4	http://dx.doi.org/10.1038/s41388-020-1233-4		FEB 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32111984				2022-12-17	WOS:000517049100003
J	Tong, X; Wang, SJ; Lei, Z; Li, C; Zhang, CJ; Su, ZY; Liu, X; Zhao, J; Zhang, HT				Tong, Xin; Wang, Shengjie; Lei, Zhe; Li, Chang; Zhang, Cuijuan; Su, Zhiyue; Liu, Xia; Zhao, Jun; Zhang, Hong-Tao			MYOCD and SMAD3/SMAD4 form a positive feedback loop and drive TGF-beta-induced epithelial-mesenchymal transition in non-small cell lung cancer	ONCOGENE			English	Article							GENE-EXPRESSION; MYOCARDIN FAMILY; DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; SNAIL; TRANSFORMATION; INDUCTION; PROTEINS; BINDING	Myocardin (MYOCD) promotes Smad3-mediated transforming growth factor-beta (TGF-beta) signaling in mouse fibroblast cells. Our previous studies show that TGF-beta/SMADs signaling activation enhances epithelial-mesenchymal transition (EMT) in human non-small cell lung cancer (NSCLC) cells. However, whether and how MYOCD contributes to TGF-beta-induced EMT of NSCLC cells are poorly elucidated. Here, we found that TGF-beta-induced EMT was accompanied by increased MYOCD expression. Interestingly, MYOCD overexpression augmented EMT and invasion of NSCLC cells induced by TGF-beta, whereas knockdown of MYOCD expression attenuated these effects. Overexpression and knockdown of MYOCD resulted in the upregulation and downregulation of TGF-beta-induced Snail mRNA, respectively. Moreover, MYOCD overexpression promoted TGF-beta-stimulated NSCLC cell metastasis in vivo. MYOCD was highly expressed and positively correlated with Snail in metastatic NSCLC tissues. Mechanistically, MYOCD directly interacted with SMAD3 and sustained the formation of TGF-beta-induced nuclear SMAD3/SMAD4 complex, facilitating TGF-beta/SMAD3-induced transactivation of Snail. Importantly, MYOCD was transcriptionally activated by TGF-beta-induced SMAD3/SMAD4 complex and CRISPR/Cas9-mediated silencing of SMAD3/SMAD4 led to a reduction in MYOCD mRNA expression. Taken together, our findings indicate that MYOCD promotes TGF-beta-induced EMT and metastasis of NSCLC and identify a positive feedback loop between MYOCD and SMAD3/SMAD4 driving TGF-beta-induced EMT.	[Tong, Xin; Wang, Shengjie; Lei, Zhe; Zhang, Cuijuan; Su, Zhiyue; Liu, Xia; Zhang, Hong-Tao] Soochow Univ, Med Coll, Lab Canc Mol Genet, Suzhou 215123, Jiangsu, Peoples R China; [Tong, Xin; Wang, Shengjie; Lei, Zhe; Zhang, Cuijuan; Su, Zhiyue; Liu, Xia; Zhang, Hong-Tao] Soochow Univ, Med Coll, Sch Biol & Basic Med Sci, Dept Genet, Suzhou 215123, Jiangsu, Peoples R China; [Wang, Shengjie] Nanjing Med Univ, Kangda Coll, Dept Basic Med, Lianyungang 222000, Peoples R China; [Li, Chang; Zhao, Jun] Soochow Univ, Med Coll, Affiliated Hosp 1, Dept Thorac Surg, Suzhou 215006, Jiangsu, Peoples R China; [Zhang, Hong-Tao] Suzhou Key Lab Mol Canc Genet, Suzhou 215123, Jiangsu, Peoples R China	Soochow University - China; Soochow University - China; Nanjing Medical University; Soochow University - China	Zhang, HT (corresponding author), Soochow Univ, Med Coll, Lab Canc Mol Genet, Suzhou 215123, Jiangsu, Peoples R China.; Zhang, HT (corresponding author), Soochow Univ, Med Coll, Sch Biol & Basic Med Sci, Dept Genet, Suzhou 215123, Jiangsu, Peoples R China.; Zhang, HT (corresponding author), Suzhou Key Lab Mol Canc Genet, Suzhou 215123, Jiangsu, Peoples R China.	htzhang@suda.edu.cn	Zhang, Hong-Tao/P-9661-2017; Lei, Zhe/AGZ-4963-2022	Zhang, Hong-Tao/0000-0003-4182-421X; 	National Natural Science Foundation of China [81872343, 81672277]; Suzhou Key Laboratory for Molecular Cancer Genetics [SZS201209]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Suzhou Key Laboratory for Molecular Cancer Genetics; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	We are grateful for participation and cooperation from the patients with NSCLC. Funding was provided by grants from National Natural Science Foundation of China (81872343, 81672277), and Suzhou Key Laboratory for Molecular Cancer Genetics (SZS201209), and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Ackers-Johnson M, 2015, ARTERIOSCL THROM VAS, V35, P817, DOI 10.1161/ATVBAHA.114.305218; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bunn PA, 2008, ONCOLOGIST, V13, P1, DOI 10.1634/theoncologist.13-S1-1; Chen J, 2011, ARTERIOSCL THROM VAS, V31, P368, DOI 10.1161/ATVBAHA.110.218149; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Deheuninck J, 2009, CELL RES, V19, P47, DOI 10.1038/cr.2008.324; Donatelli SS, 2014, P NATL ACAD SCI USA, V111, P4203, DOI 10.1073/pnas.1319269111; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kimura Y, 2010, CANCER RES, V70, P501, DOI 10.1158/0008-5472.CAN-09-1469; Kurpinski K, 2010, STEM CELLS, V28, P734, DOI 10.1002/stem.319; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Macias MJ, 2015, TRENDS BIOCHEM SCI, V40, P296, DOI 10.1016/j.tibs.2015.03.012; Marwitz S, 2016, CANCER RES, V76, P3785, DOI 10.1158/0008-5472.CAN-15-1326; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; McDonald OG, 2006, J CLIN INVEST, V116, P36, DOI 10.1172/JCI26505; Milyavsky M, 2007, CANCER CELL, V11, P133, DOI 10.1016/j.ccr.2006.11.022; Mitra P, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7080097; Molchadsky A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003707; Morita T, 2007, J CELL BIOL, V179, P1027, DOI 10.1083/jcb.200708174; Morita T, 2018, MOL CANCER RES, V16, P880, DOI 10.1158/1541-7786.MCR-17-0715; O'Connor JW, 2015, J CELL PHYSIOL, V230, P1829, DOI 10.1002/jcp.24895; Perot G, 2009, CANCER RES, V69, P2269, DOI 10.1158/0008-5472.CAN-08-1443; Ponten F, 2008, J PATHOL, V216, P387, DOI 10.1002/path.2440; Qiu P, 2005, CIRC RES, V97, P983, DOI 10.1161/01.RES.0000190604.90049.71; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sartor MA, 2010, BIOINFORMATICS, V26, P456, DOI 10.1093/bioinformatics/btp683; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith AP, 2009, ONCOGENE, V28, P422, DOI 10.1038/onc.2008.395; Sward K, 2016, J PHYSIOL-LONDON, V594, P4741, DOI 10.1113/JP271913; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang DZ, 2004, CURR OPIN GENET DEV, V14, P558, DOI 10.1016/j.gde.2004.08.003; Wang L, 2016, ONCOGENE, V35, P867, DOI 10.1038/onc.2015.141; Wang LQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0889-7; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Wu JY, 2017, CANCER LETT, V400, P18, DOI 10.1016/j.canlet.2017.04.021; Xia XD, 2017, ATHEROSCLEROSIS, V257, P266, DOI 10.1016/j.atherosclerosis.2016.12.002; Xie WB, 2011, J BIOL CHEM, V286, P15050, DOI 10.1074/jbc.M110.202747; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xue JF, 2014, J CLIN INVEST, V124, P564, DOI 10.1172/JCI71104; Yang HP, 2015, LUNG CANCER, V87, P249, DOI 10.1016/j.lungcan.2014.12.015	50	22	24	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2890	2904		10.1038/s41388-020-1189-4	http://dx.doi.org/10.1038/s41388-020-1189-4		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32029901				2022-12-17	WOS:000511540800005
J	Kouzi, F; Zibara, K; Bourgeais, J; Picou, F; Gallay, N; Brossaud, J; Dakik, H; Roux, B; Hamard, S; Le Nail, LR; Hleihel, R; Foucault, A; Ravalet, N; Rouleux-Bonnin, F; Gouilleux, F; Mazurier, F; Bene, MC; Akl, H; Gyan, E; Domenech, J; El-Sabban, M; Herault, O				Kouzi, Farah; Zibara, Kazem; Bourgeais, Jerome; Picou, Frederic; Gallay, Nathalie; Brossaud, Julie; Dakik, Hassan; Roux, Benjamin; Hamard, Sophie; Le Nail, Louis-Romee; Hleihel, Rita; Foucault, Amelie; Ravalet, Noemie; Rouleux-Bonnin, Florence; Gouilleux, Fabrice; Mazurier, Frederic; Bene, Marie C.; Akl, Haidar; Gyan, Emmanuel; Domenech, Jorge; El-Sabban, Marwan; Herault, Olivier			Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells	ONCOGENE			English	Article							AML CELLS; STEM-CELLS; INCREASE PROLIFERATION; CARBENOXOLONE SODIUM; INHIBIT APOPTOSIS; UP-REGULATION; CONNEXIN-43; EXPRESSION; PROTEIN; IDENTIFICATION	The bone marrow (BM) niche impacts the progression of acute myeloid leukemia (AML) by favoring the chemoresistance of AML cells. Intimate interactions between leukemic cells and BM mesenchymal stromal cells (BM-MSCs) play key roles in this process. Direct intercellular communications between hematopoietic cells and BM-MSCs involve connexins, components of gap junctions. We postulated that blocking gap junction assembly could modify cell-cell interactions in the leukemic niche and consequently the chemoresistance. The comparison of BM-MSCs from AML patients and healthy donors revealed a specific profile of connexins in BM-MSCs of the leukemic niche and the effects of carbenoxolone (CBX), a gap junction disruptor, were evaluated on AML cells. CBX presents an antileukemic effect without affecting normal BM-CD34(+) progenitor cells. The proapoptotic effect of CBX on AML cells is in line with the extinction of energy metabolism. CBX acts synergistically with cytarabine (Ara-C) in vitro and in vivo. Coculture experiments of AML cells with BM-MSCs revealed that CBX neutralizes the protective effect of the niche against the Ara-C-induced apoptosis of leukemic cells. Altogether, these results suggest that CBX could be of therapeutic interest to reduce the chemoresistance favored by the leukemic niche, by targeting gap junctions, without affecting normal hematopoiesis.	[Kouzi, Farah; Bourgeais, Jerome; Picou, Frederic; Gallay, Nathalie; Dakik, Hassan; Roux, Benjamin; Hamard, Sophie; Foucault, Amelie; Ravalet, Noemie; Rouleux-Bonnin, Florence; Gouilleux, Fabrice; Mazurier, Frederic; Gyan, Emmanuel; Domenech, Jorge; Herault, Olivier] CNRS, ERL7001, LNOx Leukem Niche & Redox Metab, Tours, France; [Kouzi, Farah; Bourgeais, Jerome; Picou, Frederic; Gallay, Nathalie; Dakik, Hassan; Roux, Benjamin; Hamard, Sophie; Foucault, Amelie; Ravalet, Noemie; Rouleux-Bonnin, Florence; Gouilleux, Fabrice; Mazurier, Frederic; Gyan, Emmanuel; Domenech, Jorge; Herault, Olivier] Univ Tours, Fac Med, EA7501, GICC, Tours, France; [Kouzi, Farah; Zibara, Kazem; Akl, Haidar] Lebanese Univ, DSST, PRASE, Beirut, Lebanon; [Zibara, Kazem; Akl, Haidar] Lebanese Univ, Fac Sci, Biol Dept, Beirut, Lebanon; [Bourgeais, Jerome; Picou, Frederic; Gallay, Nathalie; Roux, Benjamin; Foucault, Amelie; Ravalet, Noemie; Domenech, Jorge; Herault, Olivier] Tours Univ Hosp, Dept Biol Hematol, Tours, France; [Brossaud, Julie] Bordeaux Univ Hosp, Dept Nucl Med, Pessac, France; [Le Nail, Louis-Romee] Tours Univ Hosp, Dept Surg Orthopedia, Tours, France; [Hleihel, Rita; El-Sabban, Marwan] Amer Univ Beirut, Fac Med, Dept Anat Cell Biol & Physiol Sci, Beirut, Lebanon; [Hleihel, Rita] Amer Univ Beirut, Fac Med, Dept Internal Med, Beirut, Lebanon; [Bene, Marie C.] CRCINA, Nantes Univ Hosp, Dept Biol Hematol, Nantes, France; [Gyan, Emmanuel] Tours Univ Hosp, Dept Hematol & Cell Therapy, Tours, France	Centre National de la Recherche Scientifique (CNRS); Universite de Tours; Lebanese University; Lebanese University; CHU Tours; CHU Bordeaux; CHU Tours; American University of Beirut; American University of Beirut; Nantes Universite; CHU de Nantes; CHU Tours	Herault, O (corresponding author), CNRS, ERL7001, LNOx Leukem Niche & Redox Metab, Tours, France.; Herault, O (corresponding author), Univ Tours, Fac Med, EA7501, GICC, Tours, France.; Herault, O (corresponding author), Tours Univ Hosp, Dept Biol Hematol, Tours, France.	olivier.herault@univ-tours.fr	Rouleux, Florence/AFT-8675-2022; DAKIK, Hassan/E-3153-2015; PICOU, FREDERIC/AAC-4695-2022; Le Nail, Louis-Romée/CAH-0851-2022; Hleihel, Rita/GON-7341-2022; Ravalet, Noémie/AAC-7874-2022	DAKIK, Hassan/0000-0003-0270-8195; PICOU, FREDERIC/0000-0002-2066-2146; Ravalet, Noémie/0000-0001-5779-337X; Herault, Olivier/0000-0002-7419-1124; Zibara, Kazem/0000-0002-9887-072X; , Nathalie GALLAY/0000-0002-4236-4780; Foucault, Amelie/0000-0003-4225-2006; Hamard, Sophie/0000-0002-8537-2713; Le Nail, Louis-Romee/0000-0003-1642-4935; Mazurier, Frederic/0000-0002-6984-7096; Gouilleux, Fabrice/0000-0001-6047-1718; Roux, Benjamin/0000-0002-0400-5672; Bourgeais, Jerome/0000-0002-2557-9624	Association of Specialization and Scientific Orientation (Lebanon); Ligue Nationale Contre le Cancer (France); International Rotary Club of Blois; les Sapins de l'Espoir Contre le Cancer; CANCEN; Tours-Autogreffe; AHB associations; UL; L-CNRS	Association of Specialization and Scientific Orientation (Lebanon); Ligue Nationale Contre le Cancer (France)(Ligue nationale contre le cancer); International Rotary Club of Blois; les Sapins de l'Espoir Contre le Cancer; CANCEN; Tours-Autogreffe; AHB associations; UL; L-CNRS	The authors acknowledge Philippe Rosset for the collect of healthy donors' samples, Lamya Haddaoui, and all the participants to the FILOtheque. This work is supported by grants awarded to FK from the Association of Specialization and Scientific Orientation (Lebanon) and the Ligue Nationale Contre le Cancer (France). The research program was supported by the International Rotary Club of Blois, les Sapins de l'Espoir Contre le Cancer, CANCEN, Tours-Autogreffe, and AHB associations. The authors would particularly like to thank Prof. Philippe Rosset for having provided the BM samples as well as Elfi Ducrocq, Jorge Khamis, from LNOx (CNRS ERL 7001), and Marie-Therese Georget from the Department of Hematology Biology (Tours University Hospital) for their technical help. This research was also supported by grants to KZ (UL and L-CNRS).	Aasen T, 2016, NAT REV CANCER, V16, P775, DOI 10.1038/nrc.2016.105; ARCHAMBAULT A, 1977, CAN MED ASSOC J, V117, P1155; BENDALL LJ, 1994, EXP HEMATOL, V22, P1252; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Bruserud O, 2004, HAEMATOLOGICA, V89, P391; Bruserud O, 1998, CYTOKINES CELL MOL T, V4, P187; Cairns RA, 2011, COLD SH Q B, V76, P299, DOI 10.1101/sqb.2011.76.012856; Chapuis N, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00405; Chen WL, 2014, BLOOD, V124, P1645, DOI 10.1182/blood-2014-02-554204; Chen Z, 2007, J BIOENERG BIOMEMBR, V39, P267, DOI 10.1007/s10863-007-9086-x; Colmone A, 2008, SCIENCE, V322, P1861, DOI 10.1126/science.1164390; Delorme Bruno, 2007, V140, P67; Desbourdes L, 2017, STEM CELLS DEV, V26, P709, DOI 10.1089/scd.2016.0295; Dhanesha N, 2012, CLIN EXP PHARMACOL P, V39, P69, DOI 10.1111/j.1440-1681.2011.05640.x; Fares I, 2017, BLOOD, V129, P3344, DOI 10.1182/blood-2016-11-750729; Gao FH, 2007, BIOCHEM BIOPH RES CO, V356, P505, DOI 10.1016/j.bbrc.2007.03.009; Hatfield K, 2006, INT J CANCER, V119, P2313, DOI 10.1002/ijc.22180; HAUSMANN W, 1966, BRIT J PHARM CHEMOTH, V26, P412, DOI 10.1111/j.1476-5381.1966.tb01921.x; Herault O, 1999, BRIT J HAEMATOL, V104, P530, DOI 10.1046/j.1365-2141.1999.01203.x; Herault O, 2012, J EXP MED, V209, P895, DOI 10.1084/jem.20102386; Hundertmark S, 1997, J ENDOCRINOL, V155, P171, DOI 10.1677/joe.0.1550171; Ishikawa ET, 2012, P NATL ACAD SCI USA, V109, P9071, DOI 10.1073/pnas.1120358109; Jensen K, 2011, ENDOCR-RELAT CANCER, V18, P613, DOI 10.1530/ERC-10-0289; Kaushik AK, 2014, J PROTEOME RES, V13, P1088, DOI 10.1021/pr401106h; Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Kotini M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06368-x; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159; Li X, 2006, J CELL PHYSIOL, V208, P594, DOI 10.1002/jcp.20695; Liu Y, 2010, LEUKEMIA RES, V34, P631, DOI 10.1016/j.leukres.2009.10.013; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Mason EF, 2011, BBA-MOL CELL RES, V1813, P645, DOI 10.1016/j.bbamcr.2010.08.011; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; MONTGOMERY RD, 1968, GUT, V9, P704, DOI 10.1136/gut.9.6.704; Moschoi R, 2016, BLOOD, V128, P253, DOI 10.1182/blood-2015-07-655860; Pabst C, 2014, NAT METHODS, V11, P436, DOI 10.1038/nmeth.2847; Paraguassu-Braga FH, 2003, CELL DEATH DIFFER, V10, P1101, DOI 10.1038/sj.cdd.4401279; Picou F, 2018, PHARMACOL RES, V136, P45, DOI 10.1016/j.phrs.2018.08.015; Raza A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08058-y; Reikvam H, 2015, INT J MOL MED, V35, P645, DOI 10.3892/ijmm.2014.2045; Rozental R, 2001, METH MOL B, V154, P447; Ryningen A, 2005, LEUKEMIA RES, V29, P185, DOI 10.1016/j.leukres.2004.06.008; Samudio I, 2008, CANCER RES, V68, P5198, DOI 10.1158/0008-5472.CAN-08-0555; Shiozawa Y, 2008, LEUKEMIA, V22, P941, DOI 10.1038/leu.2008.48; Sinyuk M, 2015, ONCOTARGET, V6, P31508, DOI 10.18632/oncotarget.5226; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Sriskanthadevan S, 2015, BLOOD, V125, P2120, DOI 10.1182/blood-2014-08-594408; Stolzel F, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2015.114; Thuma F, 2014, SEMIN CANCER BIOL, V28, P39, DOI 10.1016/j.semcancer.2014.02.011; Traub RD, 2017, NETWORK FUNCTIONS AND PLASTICITY: PERSPECTIVES FROM STUDYING NEURONAL ELECTRICAL COUPLING IN MICROCIRCUITS, P301, DOI 10.1016/B978-0-12-803471-2.00013-8; Trovato-Salinaro A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-122; Vignon C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068425; Wang AD, 2018, HEMATOLOGY, V23, P729, DOI 10.1080/10245332.2018.1486064; WEBER MC, 1994, BLOOD, V83, P2221; Ye HB, 2016, CELL STEM CELL, V19, P23, DOI 10.1016/j.stem.2016.06.001; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Yi S, 2012, ONCOL LETT, V4, P1003, DOI 10.3892/ol.2012.884; Yulyana Y, 2013, STEM CELLS DEV, V22, P1870, DOI 10.1089/scd.2012.0529; Zeng ZH, 2012, BLOOD, V120, P2679, DOI 10.1182/blood-2011-11-393934; Zhang X, 2012, LEUKEMIA RES, V36, P198, DOI 10.1016/j.leukres.2011.10.001; Zhou HS, 2016, CANCER BIOL MED, V13, P248, DOI 10.20892/j.issn.2095-3941.2016.0023	62	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1198	1212		10.1038/s41388-019-1069-y	http://dx.doi.org/10.1038/s41388-019-1069-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31649334	Green Published, hybrid			2022-12-17	WOS:000526714600003
J	Yu, SR; Sha, HH; Qin, XB; Chen, Y; Li, XY; Shi, MQ; Feng, JF				Yu, Shaorong; Sha, Huanhuan; Qin, Xiaobing; Chen, Yan; Li, Xiaoyou; Shi, Meiqi; Feng, Jifeng			EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells	ONCOGENE			English	Article							TUMOR-DERIVED EXOSOMES; CHECKPOINT INHIBITORS; DOCETAXEL; CARCINOMA; BLOCKADE; PATHWAY; ALTERS	EGFR-mutant lung cancer (LC) patients display a poor response to PD-1/PD-L1 blockade. In the absence of independent genetic validation, whether EGFR mutation distorts host antitumor immunity is unknown. Here, we showed that in the clinic, LC with the E746-A750 deletion mutation (EGFR-19del) displayed a temporal association with the loss of intratumoral CD8+ T cells. In a xenograft model, EGFR-19del-expressing Lewis lung cancer (LLC) tumors had a low T cell density at the early stage of tumor development, along with dendritic cells (DCs) exhibiting variant phenotypes in the tumors and draining lymph nodes (LNs). Importantly, EGFR-19del DCs were observed in the LNs of tumor-bearing mice and LC patients. The proliferative activity of T cells within the LN was significantly dampened. In vitro experiments indicated that the function of DCs was repressed by EGFR-19del LLC cells through exosome uptake in which exosomes derived from the EGFR-19del LLC cells could efficiently transfer active EGFR-19del to the surface of the DCs. Injection of EGFR-19del tumor-derived exosomes promoted LLC tumor progression and induced immunosuppression. The combination of gefitinib and GM-CSF treatment recovered tumor T cell infiltration in EGFR-19del tumors by rescuing the function of DCs and increasing the efficacy of anti-PD-L1 treatment. Together, these results indicated that LC with the EGFR E746-A750 deletion mutation induced anergic DCs to repress antitumor immunity through exosomes.	[Yu, Shaorong; Sha, Huanhuan; Qin, Xiaobing; Li, Xiaoyou; Shi, Meiqi; Feng, Jifeng] Nanjing Med Univ, Affiliated Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China; [Yu, Shaorong; Sha, Huanhuan; Qin, Xiaobing; Chen, Yan; Li, Xiaoyou; Shi, Meiqi; Feng, Jifeng] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China; [Yu, Shaorong; Sha, Huanhuan; Qin, Xiaobing; Chen, Yan; Li, Xiaoyou; Shi, Meiqi; Feng, Jifeng] Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China; [Qin, Xiaobing] Xuzhou Med Univ, Affiliated Hosp, Dept Med Oncol, Xuzhou, Jiangsu, Peoples R China; [Chen, Yan] Nanjing Med Univ, Affiliated Canc Hosp, Dept Pathol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Xuzhou Medical University; Nanjing Medical University	Feng, JF (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China.; Feng, JF (corresponding author), Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China.; Feng, JF (corresponding author), Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China.	fjif@vip.sina.com			National Natural Science Foundation of China [81871873]; Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Youth Talent [QNRC2016646]; China Postdoctoral Science Foundation [2017M621680]; Six talent peaks project in Jiangsu Province [WSN-039]; talents program of Jiangsu Cancer Hospital [YC201807]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Youth Talent; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Six talent peaks project in Jiangsu Province; talents program of Jiangsu Cancer Hospital	This work was supported by grants from the National Natural Science Foundation of China (81871873); the Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Youth Talent (QNRC2016646); the China Postdoctoral Science Foundation (2017M621680); the Six talent peaks project in Jiangsu Province (WSN-039); and the talents program of Jiangsu Cancer Hospital (YC201807).	Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Anguille S, 2015, PHARMACOL REV, V67, P731, DOI 10.1124/pr.114.009456; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Choi D, 2018, MOL CELL PROTEOMICS, V17, P1948, DOI 10.1074/mcp.RA118.000644; Conejo-Garcia JR, 2016, PHARMACOL THERAPEUT, V164, P97, DOI 10.1016/j.pharmthera.2016.04.003; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Dong ZY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356145; Donnem T, 2015, CLIN CANCER RES, V21, P2635, DOI 10.1158/1078-0432.CCR-14-1905; Dresch C, 2012, TRENDS IMMUNOL, V33, P381, DOI 10.1016/j.it.2012.04.009; Eisenbarth SC, 2019, NAT REV IMMUNOL, V19, P89, DOI 10.1038/s41577-018-0088-1; Enamorado M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16073; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Gao L, 2018, NAT IMMUNOL, V19, P233, DOI 10.1038/s41590-017-0043-5; Jameson SC, 2018, IMMUNITY, V48, P214, DOI 10.1016/j.immuni.2018.02.010; Lee CK, 2018, JAMA ONCOL, V4, P210, DOI 10.1001/jamaoncol.2017.4427; Lee CK, 2017, J THORAC ONCOL, V12, P403, DOI 10.1016/j.jtho.2016.10.007; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Mascia F, 2016, INT J CANCER, V139, P2593, DOI 10.1002/ijc.30376; Mondanelli G, 2017, IMMUNITY, V46, P233, DOI 10.1016/j.immuni.2017.01.005; Park SL, 2018, NAT IMMUNOL, V19, P183, DOI 10.1038/s41590-017-0027-5; Qin XB, 2017, INT J NANOMED, V12, P3721, DOI 10.2147/IJN.S131516; Raulf N, 2018, EUR J CANCER, V102, P52, DOI 10.1016/j.ejca.2018.07.123; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Sanderson MP, 2008, J CELL BIOCHEM, V103, P1783, DOI 10.1002/jcb.21569; van de Laar L, 2012, BLOOD, V119, P3383, DOI 10.1182/blood-2011-11-370130; Wang SH, 2016, J BIOL CHEM, V291, P21085, DOI 10.1074/jbc.M116.717892; Zhang HY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15016; Zhang LL, 2019, THERANOSTICS, V9, P2541, DOI 10.7150/thno.32655; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020	33	22	22	4	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2643	2657		10.1038/s41388-020-1182-y	http://dx.doi.org/10.1038/s41388-020-1182-y		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32001818				2022-12-17	WOS:000510328400002
J	Wu, XQ; Zhang, X; Yu, L; Zhang, C; Ye, LP; Ren, D; Li, Y; Sun, XQ; Yu, LF; Ouyang, Y; Chen, XF; Song, LB; Liu, P; Lin, X				Wu, Xianqiu; Zhang, Xin; Yu, Liang; Zhang, Chen; Ye, Liping; Ren, Dong; Li, Yue; Sun, Xiaoqing; Yu, Lefan; Ouyang, Ying; Chen, Xiangfu; Song, Libing; Liu, Pian; Lin, Xi			Zinc finger protein 367 promotes metastasis by inhibiting the Hippo pathway in breast cancer	ONCOGENE			English	Article							CIRCULATING TUMOR-CELLS; YES-ASSOCIATED PROTEIN; YAP; ANOIKIS; MECHANISMS; SUPPRESSOR; DORMANCY	Circulating tumor cells (CTC) disseminating is an important cause of distant metastasis. However, the mechanism involved in increasing the numbers of CTCs in breast cancer is unclear. Herein, Zinc finger protein 367 (ZNF367) was identified as a potential prometastatic gene in an integrative breast cancer datasets. ZNF367 was upregulated in breast cancer tissues and cell lines, and significantly correlated with poorer metastasis-free and overall survivals in patients. ZNF367 promoted tumor metastasis accompanied with increase of CTC numbers. Mechanistically, ZNF367 interacted with chromatin remodeling protein BRG1 and transcriptionally activated CIT and TP53BP2, leading to the inhibition of the Hippo pathway and activation of YAP1, which gave rise to the resistance of anoikis and increased CTCs in the blood circulation. More importantly, administration of a YAP1 inhibitor Verteporfin resensitized ZNF367-overexpressing breast cancer cells to anoikis and abrogated metastasis. Our findings addressed the importance of ZNF367 in breast cancer as a prognostic biomarker and offered a potential therapeutic strategy for the treatment of a subset of metastatic breast cancer with ZNF367 overexpression.	[Wu, Xianqiu; Zhang, Xin; Ye, Liping; Li, Yue; Sun, Xiaoqing; Ouyang, Ying; Chen, Xiangfu; Song, Libing; Lin, Xi] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Expt Res,State Key Lab Oncol Southern China, Guangzhou 510060, Peoples R China; [Wu, Xianqiu] Sun Yat Sen Univ, Affiliated Jiangmen Hosp, Jiangmen Cent Hosp, Dept Gastrointestinal Surg, Jiangmen 529030, Peoples R China; [Zhang, Xin; Ren, Dong] Sun Yat Sen Univ, Affiliated Jiangmen Hosp, Jiangmen Cent Hosp, Clin Expt Ctr, Jiangmen 529030, Peoples R China; [Yu, Liang] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Vasc & Breast Surg, Guangzhou 510080, Guangdong, Peoples R China; [Zhang, Chen] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hepatobiliary Surg, Wuhan 430022, Peoples R China; [Yu, Lefan] UCL, Inst Struct & Mol Biol, Div Biosci, London WC1E 6BT, England; [Liu, Pian] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China; [Lin, Xi] Sun Yat Sen Univ, Canc Ctr, Ultrason Dept, Guangzhou 510060, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Huazhong University of Science & Technology; University of London; Birkbeck University London; University College London; Huazhong University of Science & Technology; Sun Yat Sen University	Lin, X (corresponding author), Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Expt Res,State Key Lab Oncol Southern China, Guangzhou 510060, Peoples R China.; Liu, P (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China.; Lin, X (corresponding author), Sun Yat Sen Univ, Canc Ctr, Ultrason Dept, Guangzhou 510060, Peoples R China.	liupianamazing@126.com; linxi@sysucc.org.cn	Zhang, Xin/C-2464-2017; Song, LB/AAL-1968-2020	Zhang, Xin/0000-0001-6036-2685; Ye, Liping/0000-0002-2263-0631	National Natural Science Foundation of China [81772800]; Fundamental Research Funds for the Central Universities [2017KFYXJJ258]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by National Natural Science Foundation of China (No. 81772800); Fundamental Research Funds for the Central Universities (No. 2017KFYXJJ258).	Asano H, 2004, BIOCHEM J, V384, P647, DOI 10.1042/BJ20040394; Aslan B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8351; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756; Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940; Cristofanilli M, 2005, J CLIN ONCOL, V23, P1420, DOI 10.1200/JCO.2005.08.140; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; de Groot AF, 2017, CANCER TREAT REV, V60, P130, DOI 10.1016/j.ctrv.2017.09.003; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; Gao Y, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0340-0; Gibault F, 2017, CHEMMEDCHEM, V12, P954, DOI 10.1002/cmdc.201700063; Giuliano M, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0440-8; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Jain M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101423; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lin E, 2018, ANNU REV BIOMED ENG, V20, P329, DOI 10.1146/annurev-bioeng-062117-120947; Lu C, 2017, NAT GENET, V49, P178, DOI 10.1038/ng.3779; Lucci A, 2012, LANCET ONCOL, V13, P688, DOI 10.1016/S1470-2045(12)70209-7; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; McCarthy N, 2014, NAT REV CANCER, V14, DOI 10.1038/nrc3746; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Rack B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju066; Ren CL, 2016, INT J CANCER, V138, P1586, DOI 10.1002/ijc.29679; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Sinn HP, 2010, PATHOLOGE, V31, P361, DOI 10.1007/s00292-010-1307-0; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Tseng LM, 2013, NEOPLASMA, V60, P290, DOI 10.4149/neo_2013_038; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Wang WQ, 2014, MOL CELL PROTEOMICS, V13, P119, DOI 10.1074/mcp.M113.030049; Wong CW, 2001, CANCER RES, V61, P333; Yu SJ, 2013, CLIN CANCER RES, V19, P1389, DOI 10.1158/1078-0432.CCR-12-1959; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zhang X, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0717-5; Zhang XP, 2017, ONCOTARGET, V8, P38863, DOI 10.18632/oncotarget.16408; Zhang ZL, 2009, CANCER EPIDEM BIOMAR, V18, P2685, DOI 10.1158/1055-9965.EPI-09-0097	39	22	23	3	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2568	2582		10.1038/s41388-020-1166-y	http://dx.doi.org/10.1038/s41388-020-1166-y		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31988454				2022-12-17	WOS:000509655100001
J	Bruno, G; Cencetti, F; Pini, A; Tondo, A; Cuzzubbo, D; Fontani, F; Strinna, V; Buccoliero, AM; Casazza, G; Donati, C; Filippi, L; Bruni, P; Favre, C; Calvani, M				Bruno, Gennaro; Cencetti, Francesca; Pini, Alessandro; Tondo, Annalisa; Cuzzubbo, Daniela; Fontani, Filippo; Strinna, Vanessa; Buccoliero, Anna Maria; Casazza, Gabriella; Donati, Chiara; Filippi, Luca; Bruni, Paola; Favre, Claudio; Calvani, Maura			beta 3-adrenoreceptor blockade reduces tumor growth and increases neuronal differentiation in neuroblastoma via SK2/S1P(2) modulation	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN-MELANOMA; MESSENGER-RNA; BETA-BLOCKERS; COLON-CANCER; BONE-MARROW; CELL LINES; EXPRESSION; CLASSIFICATION; ADRENOCEPTORS	Neuroblastoma (NB) is the most frequently observed among extracranial pediatric solid tumors. It displays an extreme clinical heterogeneity, in particular for the presentation at diagnosis and response to treatment, often depending on cancer cell differentiation/stemness. The frequent presence of elevated hematic and urinary levels of catecholamines in patients affected by NB suggests that the dissection of adrenergic system is crucial for a better understanding of this cancer. beta 3-adrenoreceptor (beta 3-AR) is the last identified member of adrenergic receptors, involved in different tumor conditions, such as melanoma. Multiple studies have shown that the dysregulation of the bioactive lipid sphingosine 1-phosphate (S1P) metabolism and signaling is involved in many pathological diseases including cancer. However, whether S1P is crucial for NB progression and aggressiveness is still under investigation. Here we provide experimental evidence that beta 3-AR is expressed in NB, both human specimens and cell lines, where it is critically involved in the activation of proliferation and the regulation between stemness/differentiation, via its functional cross-talk with sphingosine kinase 2 (SK2)/S1P receptor 2 (S1P(2)) axis. The specific antagonism of beta 3-AR by SR59230A inhibits NB growth and tumor progression, by switching from stemness to cell differentiation both in vivo and in vitro through the specific blockade of SK2/S1P(2) signaling.	[Bruno, Gennaro; Fontani, Filippo] Univ Florence, Dept Hlth Sci, Florence, Italy; [Bruno, Gennaro; Tondo, Annalisa; Cuzzubbo, Daniela; Fontani, Filippo; Strinna, Vanessa; Favre, Claudio; Calvani, Maura] A Meyer Univ, Dept Paediat Haematol Oncol, Childrens Hosp, Florence, Italy; [Cencetti, Francesca; Donati, Chiara; Bruni, Paola] Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Florence, Italy; [Pini, Alessandro] Univ Florence, Dept Expt & Clin Med, Florence, Italy; [Buccoliero, Anna Maria] A Meyer Univ, Pathol Unit, Childrens Hosp, Florence, Italy; [Casazza, Gabriella] Santa Chiara Hosp, Pediat Hematol Oncol & Bone Marrow Transplant Uni, Pisa, Italy; [Filippi, Luca] A Meyer Univ, Med Surg Feto Neonatal Dept, Neonatal Intens Care Unit, Childrens Hosp, Florence, Italy	University of Florence; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; University of Florence; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; Santa Chiara Hospital; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER	Calvani, M (corresponding author), A Meyer Univ, Dept Paediat Haematol Oncol, Childrens Hosp, Florence, Italy.; Cencetti, F (corresponding author), Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Florence, Italy.	francesca.cencetti@unifi.it; maura.calvani@meyer.it	Filippi, Luca/AAD-5019-2021; Bruni, Paola/A-1151-2008; donati, chiara/AAN-2682-2021; Bruno, Gennaro/AAL-6465-2020	donati, chiara/0000-0003-2224-4199; Bruno, Gennaro/0000-0001-6252-3825; Bruni, Paola/0000-0002-1151-3413	Fondazione Ospedale Pediatrico Meyer; FFARB2017 - Fondi Finanziamento Ateneo Ricerca di Base anno 2017; Fondi Ateneo (RICATEN, ex-60%)	Fondazione Ospedale Pediatrico Meyer; FFARB2017 - Fondi Finanziamento Ateneo Ricerca di Base anno 2017; Fondi Ateneo (RICATEN, ex-60%)	This work was supported by funds from Fondazione Ospedale Pediatrico Meyer to CF, FFARB2017 - Fondi Finanziamento Ateneo Ricerca di Base anno 2017 to FC, Fondi Ateneo (RICATEN, ex-60%) to PB, CD, FC.	Bossard F, 2011, AM J RESP CELL MOL, V44, P91, DOI 10.1165/rcmb.2009-0372OC; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Bruno G, 2018, CELL SIGNAL, V45, P110, DOI 10.1016/j.cellsig.2018.02.001; Buhagiar Alfred, 2015, ANAL CELL PATHOL, V2015, P1; Calvani M, 2015, ONCOTARGET, V6, P4615, DOI 10.18632/oncotarget.2652; Cannavo A, 2017, J AM COLL CARDIOL, V70, P182, DOI 10.1016/j.jacc.2017.05.020; Cencetti F, 2010, MOL BIOL CELL, V21, P1111, DOI 10.1091/mbc.E09-09-0812; Chisholm KM, 2012, MODERN PATHOL, V25, P1446, DOI 10.1038/modpathol.2012.108; Choi HS, 2005, PEDIATR BLOOD CANCER, V45, P68, DOI 10.1002/pbc.20315; Chumanevich AA, 2010, CARCINOGENESIS, V31, P1787, DOI 10.1093/carcin/bgq158; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Daguze Justine, 2016, JAAD Case Rep, V2, P497, DOI 10.1016/j.jdcr.2016.10.005; Dal Monte M, 2013, J MOL MED, V91, P1407, DOI 10.1007/s00109-013-1073-6; Garaventa A, 2009, EUR J CANCER, V45, P2835, DOI 10.1016/j.ejca.2009.06.010; Hafer R, 1999, J NEUROIMMUNOL, V96, P201, DOI 10.1016/S0165-5728(99)00030-2; Hansford LM, 2007, CANCER RES, V67, P11234, DOI 10.1158/0008-5472.CAN-07-0718; Huang P, 2011, CANCER RES, V71, P2938, DOI 10.1158/0008-5472.CAN-10-3524; Lamkin DM, 2012, BRAIN BEHAV IMMUN, V26, P635, DOI 10.1016/j.bbi.2012.01.013; Leaute-Labreze C, 2008, NEW ENGL J MED, V358, P2649, DOI 10.1056/NEJMc0708819; Li MH, 2013, PEDIATR BLOOD CANCER, V60, P1418, DOI 10.1002/pbc.24564; Li MH, 2011, CANCER PREV RES, V4, P1325, DOI 10.1158/1940-6207.CAPR-11-0017; London WB, 2017, CANCER-AM CANCER SOC, V123, P4914, DOI 10.1002/cncr.30934; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925; Montoya A, 2017, ONCOTARGET, V8, P6446, DOI 10.18632/oncotarget.14119; Mora J, 2001, CANCER RES, V61, P6892; Moretti S, 2013, LAB INVEST, V93, P279, DOI 10.1038/labinvest.2012.175; Pasquier E, 2013, BRIT J CANCER, V108, P2485, DOI 10.1038/bjc.2013.205; Perez-Sayans M, 2010, ONCOL RES, V19, P45, DOI 10.3727/096504010X12828372551867; Perrone MG, 2008, ONCOLOGY-BASEL, V75, P224, DOI 10.1159/000163851; Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Rains Steven L, 2017, Oncoscience, V4, P95, DOI 10.18632/oncoscience.357; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Stiles J, 2012, EXP THER MED, V4, P594, DOI 10.3892/etm.2012.654; Strub GM, 2010, ADV EXP MED BIOL, V688, P141; Takenobu H, 2011, ONCOGENE, V30, P97, DOI 10.1038/onc.2010.383; Takuwa N, 2010, CANCER RES, V0008-5472.CAN-09-2722; Tong QS, 2008, WORLD J PEDIATR, V4, P58, DOI 10.1007/s12519-008-0012-z; Voigt A, 1997, J NEUROIMMUNOL, V78, P117, DOI 10.1016/S0165-5728(97)00088-X; Wallington-Beddoe CT, 2014, CANCER RES, V74, P2803, DOI 10.1158/0008-5472.CAN-13-2732; Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310; Watkins JL, 2015, CANCER-AM CANCER SOC, V121, P3444, DOI 10.1002/cncr.29392; Weigert A, 2009, INT J CANCER, V125, P2114, DOI 10.1002/ijc.24594; Wolter JK, 2014, ONCOTARGET, V5, P161, DOI 10.18632/oncotarget.1083; Yang EV, 2009, BRAIN BEHAV IMMUN, V23, P267, DOI 10.1016/j.bbi.2008.10.005; Zhang WL, 2014, J BIOL CHEM, V289, P32178, DOI 10.1074/jbc.M114.601096	50	22	22	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					368	384		10.1038/s41388-019-0993-1	http://dx.doi.org/10.1038/s41388-019-0993-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477835	hybrid, Green Published			2022-12-17	WOS:000507766400009
J	Hsu, YL; Huang, MS; Hung, JY; Chang, WA; Tsai, YM; Pan, YC; Lin, YS; Tsai, HP; Kuo, PL				Hsu, Ya-Ling; Huang, Ming-Shyan; Hung, Jen-Yu; Chang, Wei-An; Tsai, Ying-Ming; Pan, Yi-Chung; Lin, Yi-Shiuan; Tsai, Hung-Pei; Kuo, Po-Lin			Bone-marrow-derived cell-released extracellular vesicle miR-92a regulates hepatic pre-metastatic niche in lung cancer	ONCOGENE			English	Article							BREAST-CANCER; LIVER METASTASIS; STELLATE CELLS; MICROENVIRONMENT; HEMATOPOIESIS; ACTIVATION; EXPRESSION; FIBROSIS; INITIATE	Metastatic tumors have been shown to establish a supportive pre-metastatic niche (PMN) in distant organs, which in turn determines disseminated tumor cells' targeting of such organs. PMN is formed through the recruitment of bone-marrow-derived cells (BMDCs); however, the role of BMDCs in PMN formation is not fully understood. On the basis of RNA-seq data and bioinformatic analysis, secretion of extracellular vesicle (EV) miR-92a by BMDCs of lung cancer-bearing mice contributes to the establishment of liver PMN. Both BMDC-derived EVs and miR-92a mimics potentiate the activation of hepatic stellate cells (HSCs), subsequently increasing extracellular matrix (ECM) deposition in mice. Consequently, remodeling of the liver microenvironment enhanced immunosuppressive cell accumulation and cancer cell attachment. EVs miR-92a directly suppressed its target SMAD7, leading to the enhancement of transforming growth factor-beta signaling in HSC. Elevated levels of circulating miR-92a are found in the sera of lung cancer patients, and EVs isolated from these patients have a similar ability to increase HSCs activation and ECM protein expression. Our study reveals the sequential steps of liver PMN formation in lung cancer, providing critical mediators that prepare PMN in the liver, and identifies new targets that offer valuable options for diagnosis and therapeutic intervention.	[Hsu, Ya-Ling; Tsai, Ying-Ming] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 807, Taiwan; [Huang, Ming-Shyan] E DA Canc Hosp, Dept Internal Med, Kaohsiung 840, Taiwan; [Huang, Ming-Shyan] I Shou Univ, Sch Med, Kaohsiung 840, Taiwan; [Hung, Jen-Yu; Chang, Wei-An; Tsai, Ying-Ming] Kaohsiung Med Univ Hosp, Div Pulm & Crit Care Med, Kaohsiung 807, Taiwan; [Hung, Jen-Yu; Chang, Wei-An; Tsai, Ying-Ming] Kaohsiung Med Univ, Sch Med, Coll Med, Kaohsiung 807, Taiwan; [Chang, Wei-An; Pan, Yi-Chung; Lin, Yi-Shiuan; Kuo, Po-Lin] Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Kaohsiung 807, Taiwan; [Tsai, Hung-Pei] Kaohsiung Med Univ Hosp, Div Neurosurg, Dept Surg, Kaohsiung 807, Taiwan; [Kuo, Po-Lin] Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung 807, Taiwan; [Kuo, Po-Lin] Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Kaohsiung 804, Taiwan	Kaohsiung Medical University; E-Da Hospital; I Shou University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; National Sun Yat Sen University	Kuo, PL (corresponding author), Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Kaohsiung 807, Taiwan.; Kuo, PL (corresponding author), Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung 807, Taiwan.; Kuo, PL (corresponding author), Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Kaohsiung 804, Taiwan.	kuopolin@seed.net.tw			Ministry of Science and Technology [MOST 107-2320-B-037-011-MY3, MOST 104-2314-B-037-053-MY4]; Kaohsiung Medical University Hospital [KMUHS10701, KMUHS10712]; Kaohsiung Medical University [KMU-DK108003, KMU-DK108008, KMU-TC108A04]; E-DA Cancer Hospital Research Foundation [EDCHI107001]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Kaohsiung Medical University Hospital; Kaohsiung Medical University; E-DA Cancer Hospital Research Foundation	The authors gratefully acknowledge the support of research grants from the Ministry of Science and Technology (MOST 107-2320-B-037-011-MY3; MOST 104-2314-B-037-053-MY4), the Kaohsiung Medical University Hospital (KMUHS10701; KMUHS10712), the Kaohsiung Medical University (KMU-DK108003; KMU-DK108008; KMU-TC108A04), and the E-DA Cancer Hospital Research Foundation (EDCHI107001). The authors thank the Center for Research Resources and Development of Kaohsiung Medical University.	Adler BJ, 2014, NAT REV ENDOCRINOL, V10, P737, DOI 10.1038/nrendo.2014.169; Barbazan J, 2017, CANCER RES, V77, P3431, DOI 10.1158/0008-5472.CAN-16-1917; Bian EB, 2014, TOXICOL LETT, V224, P175, DOI 10.1016/j.toxlet.2013.10.038; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brodt P, 2016, CLIN CANCER RES, V22, P5971, DOI 10.1158/1078-0432.CCR-16-0460; Burnier JV, 2011, ONCOGENE, V30, P3766, DOI 10.1038/onc.2011.89; Chang YP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178676; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Deng Z, 2017, ONCOGENE, V36, P639, DOI 10.1038/onc.2016.229; Dooley S, 2003, GASTROENTEROLOGY, V125, P178, DOI 10.1016/S0016-5085(03)00666-8; Engblom C, 2017, SCIENCE, V358, DOI 10.1126/science.aal5081; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Hara T, 2017, BIOCHEM BIOPH RES CO, V490, P688, DOI 10.1016/j.bbrc.2017.06.102; Hashimoto M, 2016, INT J CANCER, V139, P812, DOI 10.1002/ijc.30118; Houg DS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0842-9; Huang AL, 2014, ASIAN PAC J CANCER P, V15, P8143, DOI 10.7314/APJCP.2014.15.19.8143; Jiang T, 2017, CLIN LUNG CANCER, V18, P631, DOI 10.1016/j.cllc.2017.04.015; Kang NL, 2011, HEPATOLOGY, V54, P707, DOI 10.1002/hep.24384; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kim KW, 2017, CANCER RES TREAT, V49, P1, DOI 10.4143/crt.2016.606; Lin LY, 2016, ONCOGENE, V35, P6038, DOI 10.1038/onc.2016.131; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Mederacke I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3823; Nielsen SR, 2016, NAT CELL BIOL, V18, P549, DOI 10.1038/ncb3340; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Rana S, 2013, NEOPLASIA, V15, P281, DOI 10.1593/neo.122010; Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084; Ren YJ, 2016, ONCOTARGET, V7, P53245, DOI 10.18632/oncotarget.10644; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Taylor D, 2011, J IMMUNOL, V186, P5956, DOI 10.4049/jimmunol.1003558; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Tsao AS, 2016, J THORAC ONCOL, V11, P613, DOI 10.1016/j.jtho.2016.03.012; Tsuchida T, 2017, NAT REV GASTRO HEPAT, V14, P397, DOI 10.1038/nrgastro.2017.38; Xu R, 2018, NAT REV CLIN ONCOL, V15, P617, DOI 10.1038/s41571-018-0036-9; Xu WW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14399; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376	39	22	23	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					739	753		10.1038/s41388-019-1024-y	http://dx.doi.org/10.1038/s41388-019-1024-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KQ3JF	31558801				2022-12-17	WOS:000516822100001
J	Ghosh, JC; Seo, JH; Agarwal, E; Wang, Y; Kossenkov, AV; Tang, HY; Speicher, DW; Altieri, DC				Ghosh, Jagadish C.; Seo, Jae Ho; Agarwal, Ekta; Wang, Yuan; Kossenkov, Andrew V.; Tang, Hsin-Yao; Speicher, David W.; Altieri, Dario C.			Akt phosphorylation of mitochondrial Lonp1 protease enables oxidative metabolism and advanced tumor traits	ONCOGENE			English	Article							STRESS; PROTEOSTASIS; CANCER; CLPP; DEGRADATION; DYNAMICS; DISEASE; ROS	Tumor mitochondria have heightened protein folding quality control, but the regulators of this process and how they impact cancer traits are not completely understood. Here we show that the ATP-directed mitochondrial protease, LonP1 is upregulated by stress conditions, including hypoxia, in tumor, but not normal cells. In mitochondria, LonP1 is phosphorylated by Akt on Ser173 and Ser181, enhancing its protease activity. Interference with this pathway induces accumulation of misfolded subunits of electron transport chain complex II and complex V, resulting in impaired oxidative bioenergetics and heightened ROS production. Functionally, this suppresses mitochondrial trafficking to the cortical cytoskeleton, shuts off tumor cell migration and invasion, and inhibits primary and metastatic tumor growth, in vivo. These data identify LonP1 as a key effector of mitochondrial reprogramming in cancer and potential therapeutic target.	[Ghosh, Jagadish C.; Seo, Jae Ho; Agarwal, Ekta; Wang, Yuan; Speicher, David W.; Altieri, Dario C.] Prostate Canc Discovery & Dev Program, Philadelphia, PA 19107 USA; [Ghosh, Jagadish C.; Seo, Jae Ho; Agarwal, Ekta; Wang, Yuan; Altieri, Dario C.] Wistar Inst Anat & Biol, Immunol Microenvironm & Metastasis Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Kossenkov, Andrew V.; Tang, Hsin-Yao; Speicher, David W.] Wistar Inst Anat & Biol, Ctr Syst & Computat Biol, 3601 Spruce St, Philadelphia, PA 19104 USA; [Speicher, David W.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA	The Wistar Institute; The Wistar Institute; The Wistar Institute	Altieri, DC (corresponding author), Prostate Canc Discovery & Dev Program, Philadelphia, PA 19107 USA.; Altieri, DC (corresponding author), Wistar Inst Anat & Biol, Immunol Microenvironm & Metastasis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	daltieri@wistar.org		Agarwal, Ekta/0000-0002-5992-3358; Tang, Hsin-Yao/0000-0003-1838-018X	National Institutes of Health (NIH) [P01 CA140043, R35 CA220446, R50 CA221838, R50 CA211199]; Cancer Center Support Grant (CCSG) [CA010815]; NATIONAL CANCER INSTITUTE [R35CA220446, P01CA140043, P30CA010815] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant (CCSG); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank James Hayden and Frederick Keeney for assistance with time-lapse videomicroscopy and Sandra Harper for performing the HPLC gel filtration experiments. This work was supported by the National Institutes of Health (NIH) grants P01 CA140043 (DCA and DWS), R35 CA220446 (D.C.A.) R50 CA221838 (H-YT), and R50 CA211199 (AVK). and Support for Core Facilities utilized in this study was provided by Cancer Center Support Grant (CCSG) CA010815 to The Wistar Institute.	Altieri DC, 2013, CELL MOL LIFE SCI, V70, P2463, DOI 10.1007/s00018-012-1177-0; Anderson RG, 2018, BBA-REV CANCER, V1870, P96, DOI 10.1016/j.bbcan.2018.05.005; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Bezawork-Geleta A, 2015, SCI REP-UK, V5, DOI 10.1038/srep17397; Bota DA, 2016, FREE RADICAL BIO MED, V100, P188, DOI 10.1016/j.freeradbiomed.2016.06.031; Caino MC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13730; Caino MC, 2015, P NATL ACAD SCI USA, V112, P8638, DOI 10.1073/pnas.1500722112; Calvo SE, 2016, NUCLEIC ACIDS RES, V44, pD1251, DOI 10.1093/nar/gkv1003; Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004; Chae YC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3139; Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490; Ciechanover A, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.117; Cole A, 2015, CANCER CELL, V27, P864, DOI 10.1016/j.ccell.2015.05.004; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Desai SP, 2013, BIOPHYS J, V104, P2077, DOI 10.1016/j.bpj.2013.03.025; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Ghosh JC, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju502; Gibellini L, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00254; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Granot Z, 2007, MOL ENDOCRINOL, V21, P2164, DOI 10.1210/me.2005-0458; Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317; Haynes CM, 2010, J CELL SCI, V123, P3849, DOI 10.1242/jcs.075119; Hetz C, 2015, NAT CELL BIOL, V17, P829, DOI 10.1038/ncb3184; Janku F, 2018, NAT REV CLIN ONCOL, V15, P273, DOI 10.1038/nrclinonc.2018.28; Kang BH, 2007, CELL, V131, P257, DOI 10.1016/j.cell.2007.08.028; Kao TY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.9; Liu KY, 2014, CRIT REV BIOCHEM MOL, V49, P400, DOI 10.3109/10409238.2014.925421; Lu B, 2017, ADV EXP MED BIOL, V1038, P173, DOI 10.1007/978-981-10-6674-0_12; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Marchi S, 2019, EMBO J, V38, DOI 10.15252/embj.201899435; Pinti M, 2015, CELL MOL LIFE SCI, V72, P4807, DOI 10.1007/s00018-015-2039-3; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Potter M, 2016, BIOCHEM SOC T, V44, P1499, DOI 10.1042/BST20160094; Pryde KR, 2016, CELL REP, V17, P2522, DOI 10.1016/j.celrep.2016.11.027; Quiros PM, 2014, CELL REP, V8, P541, DOI 10.1016/j.celrep.2014.06.018; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Sanchez-Alvarez M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16662-1; Santi SA, 2010, AM J PHYSIOL-CELL PH, V298, pC580, DOI 10.1152/ajpcell.00375.2009; Senft D, 2016, CURR OPIN CELL BIOL, V39, P43, DOI 10.1016/j.ceb.2016.02.001; Seo JH, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002507; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; van Oosten-Hawle P, 2014, GENE DEV, V28, P1533, DOI 10.1101/gad.241125.114; Vieux EF, 2013, P NATL ACAD SCI USA, V110, pE2002, DOI 10.1073/pnas.1307066110; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494	49	22	22	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2019	38	43					6926	6939		10.1038/s41388-019-0939-7	http://dx.doi.org/10.1038/s41388-019-0939-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JH4GX	31406245	Green Accepted			2022-12-17	WOS:000492728000004
J	Wang, JC; Jiang, J; Chen, H; Wang, LY; Guo, H; Yang, LK; Xiao, DB; Qing, GL; Liu, HD				Wang, Jingchao; Jiang, Jue; Chen, Hui; Wang, Liyuan; Guo, Hao; Yang, Likun; Xiao, Daibiao; Qing, Guoliang; Liu, Hudan			FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma	ONCOGENE			English	Article							AMINO-ACID-METABOLISM; CELL-DEATH; N-MYC; STRESS; STABILIZATION; ATF4; BAX; TRANSFORMATION; AMPLIFICATION; ACETYLATION	MYCN amplification in neuroblastoma predicts poor prognosis and resistance to therapy. Yet pharmacological strategies of direct MYC inhibition remain unsuccessful due to its "undruggable" protein structure. We herein developed a synthetic lethal screen against MYCN-amplified neuroblastomas using clinically approved therapeutic reagents. We performed a high-throughput screen, from a library of 938 FDA-approved drugs, for candidates that elicit synthetic lethal effects in MYC-driven neuroblastoma cells. The proteasome inhibitors, which are FDA approved for the first-line treatment of multiple myeloma, emerge as top hits to elicit MYC-mediated synthetic lethality. Proteasome inhibition activates the PERK-eIF2 alpha-ATF4 axis in MYC-transformed cells and induces BAX-mediated apoptosis through ATF4-dependent NOXA and TRIB3 induction. A combination screen reveals the proteasome inhibitor bortezomib (BTZ) and the histone deacetylase (HDAC) inhibitor vorinostat (SAHA) concertedly induce dramatic cell death in part through synergistic activation of BAX. This combination causes marked tumor suppression in vivo, supporting dual proteasome/HDAC inhibition as a potential therapeutic approach for MYC-driven cancers. This FDA-approved drug screen with in vivo validation thus provides a rationale for clinical evaluation of bortezomib, alone or in combination with vorinostat, in MYC-driven neuroblastoma patients.	[Wang, Jingchao; Qing, Guoliang; Liu, Hudan] Wuhan Univ, Hubei Canc Clin Study Ctr, Dept Radiat & Med Oncol, Hubei Key Lab Tumor Biol Behav,Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China; [Wang, Jingchao; Jiang, Jue; Chen, Hui; Wang, Liyuan; Guo, Hao; Xiao, Daibiao; Qing, Guoliang; Liu, Hudan] Wuhan Univ, Med Res Inst, Wuhan 430071, Hubei, Peoples R China; [Yang, Likun] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol, Wuhan 430022, Hubei, Peoples R China	Wuhan University; Wuhan University; Huazhong University of Science & Technology	Qing, GL; Liu, HD (corresponding author), Wuhan Univ, Hubei Canc Clin Study Ctr, Dept Radiat & Med Oncol, Hubei Key Lab Tumor Biol Behav,Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.; Qing, GL; Liu, HD (corresponding author), Wuhan Univ, Med Res Inst, Wuhan 430071, Hubei, Peoples R China.	qingguoliang@whu.edu.cn; hudanliu@whu.edu.cn			National Key R&D Program of China [2017YFA0505600]; National Natural Science Foundation of China [81830084, 81572736, 81770177]; National Science Fund for Distinguished Young Scholars [81725013]; Hubei Provincial Natural Science Fund for Distinguished Young Scholars [2017CFA072]; Hubei Provincial Natural Science Fund for Creative Research Groups [2018CFA018]; Innovative Research Grant from Wuhan University [2042017kf0282]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); Hubei Provincial Natural Science Fund for Distinguished Young Scholars; Hubei Provincial Natural Science Fund for Creative Research Groups; Innovative Research Grant from Wuhan University	We are grateful to HL and GQ lab members for technical support and critical reading of the paper. We would like to thank the Core Facility of Medical Research Institute at Wuhan University for confocal microscopy and histological analysis. This study was supported by grants from the National Key R&D Program of China (2017YFA0505600 to GQ), the National Natural Science Foundation of China (81830084 and 81572736 to GQ, 81770177 to HL), National Science Fund for Distinguished Young Scholars (81725013 to GQ), Hubei Provincial Natural Science Fund for Distinguished Young Scholars (2017CFA072 to HL), Hubei Provincial Natural Science Fund for Creative Research Groups (2018CFA018 to GQ), and Innovative Research Grant from Wuhan University (2042017kf0282 to GQ).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Ameri K, 2008, INT J BIOCHEM CELL B, V40, P14, DOI 10.1016/j.biocel.2007.01.020; Bhatt S, 2013, J CLIN INVEST, V123, P2616, DOI 10.1172/JCI64503; Braso-Maristany F, 2016, NAT MED, V22, P1303, DOI 10.1038/nm.4198; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Carracedo A, 2006, CANCER CELL, V9, P301, DOI 10.1016/j.ccr.2006.03.005; Carroll PA, 2015, CANCER CELL, V27, P271, DOI 10.1016/j.ccell.2014.11.024; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Gan L, 2016, ONCOGENE, V35, P3037, DOI 10.1038/onc.2015.360; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Hui KF, 2013, MOL CANCER THER, V12, P747, DOI 10.1158/1535-7163.MCT-12-0811; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Kilberg MS, 2009, TRENDS ENDOCRIN MET, V20, P436, DOI 10.1016/j.tem.2009.05.008; Lange PS, 2008, J EXP MED, V205, P1227, DOI 10.1084/jem.20071460; Liu X, 2008, ONCOGENE, V27, P1478, DOI 10.1038/sj.onc.1210769; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; O'Neil NJ, 2017, NAT REV GENET, V18, P613, DOI 10.1038/nrg.2017.47; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Porro A, 2010, J BIOL CHEM, V285, P19532, DOI 10.1074/jbc.M109.078584; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Raedler Lisa, 2015, Am Health Drug Benefits, V8, P135; Ren P, 2015, J PATHOL, V235, P90, DOI 10.1002/path.4429; Sato A, 2012, BJU INT, V109, P1258, DOI 10.1111/j.1464-410X.2011.10533.x; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Suraweera A, 2012, MOL CELL, V48, P242, DOI 10.1016/j.molcel.2012.08.003; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Voorhees PM, 2006, ANNU REV PHARMACOL, V46, P189, DOI 10.1146/annurev.pharmtox.46.120604.141300; Wang ZJ, 2017, CLIN CANCER RES, V23, P3834, DOI 10.1158/1078-0432.CCR-16-2880; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Xiao DB, 2016, MOL CELL, V64, P493, DOI 10.1016/j.molcel.2016.09.016; Xie H, 2018, J CLIN INVEST, V128, P1300, DOI 10.1172/JCI95864; Yue M, 2017, CELL REP, V21, P3819, DOI 10.1016/j.celrep.2017.12.002	43	22	22	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6737	6751		10.1038/s41388-019-0912-5	http://dx.doi.org/10.1038/s41388-019-0912-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31406244				2022-12-17	WOS:000489552900002
J	Stetka, J; Vyhlidalova, P; Lanikova, L; Koralkova, P; Gursky, J; Hlusi, A; Flodr, P; Hubackova, S; Bartek, J; Hodny, Z; Divoky, V				Stetka, J.; Vyhlidalova, P.; Lanikova, L.; Koralkova, P.; Gursky, J.; Hlusi, A.; Flodr, P.; Hubackova, S.; Bartek, J.; Hodny, Z.; Divoky, V			Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation	ONCOGENE			English	Article							STEM-CELL FUNCTION; REACTIVE OXYGEN; REPLICATION STRESS; OXIDATIVE STRESS; HEMATOPOIETIC PROGENITORS; IFN-GAMMA; EXPRESSION; DISEASE; ACTIVATION; PROGRESSION	Inflammatory and oncogenic signaling converge in disease evolution of BCR-ABL-negative myeloproliferative neoplasms, clonal hematopoietic stem cell disorders characterized by gain-of-function mutation in JAK2 kinase (JAK2V617F), with highest prevalence in patients with polycythemia vera (PV). Despite the high risk, DNA-damaging inflammatory microenvironment, PV progenitors tend to preserve their genomic stability over decades until their progression to post-PV myelofibrosis/acute myeloid leukemia. Using induced pluripotent stem cells-derived CD34(+) progenitor-enriched cultures from JAK2V617F(+) PV patient and from JAK2 wild-type healthy control, CRISPR-modified HEL cells and patients' bone marrow sections from different disease stages, we demonstrate that JAK2V617F induces an intrinsic IFN gamma- and NF-kappa B associated inflammatory program, while suppressing inflammation-evoked DNA damage both in vitro and in vivo. We show that cells with JAK2V617F tightly regulate levels of inflammatory cytokines-induced reactive oxygen species, do not fully activate the ATM/p53/p21waf1 checkpoint and p38/JNK MAPK stress pathway signaling when exposed to inflammatory cytokines, suppress DNA single-strand break repair genes' expression yet overexpress the dual-specificity phosphatase (DUSP) 1. RNAi-mediated knock-down and pharmacological inhibition of DUSP1, involved in p38/JNK deactivation, in HEL cells reveals growth addiction to DUSP1, consistent with enhanced DNA damage response and apoptosis in DUSP1inhibited parental JAK2V617F(+) cells, but not in CRISPR-modified JAK2 wild-type cells. Our results indicate that the JAK2V617F+ PV progenitors utilize DUSP1 activity as a protection mechanism against DNA damage accumulation, promoting their proliferation and survival in the inflammatory microenvironment, identifying DUSP1 as a potential therapeutic target in PV.	[Stetka, J.; Vyhlidalova, P.; Lanikova, L.; Koralkova, P.; Divoky, V] Palacky Univ, Dept Biol, Fac Med & Dent, Olomouc, Czech Republic; [Vyhlidalova, P.] Palacky Univ, Dept Histol & Embryol, Fac Med & Dent, Olomouc, Czech Republic; [Lanikova, L.] Inst Mol Genet ASCR Vvi, Lab Cell & Dev Biol, Prague, Czech Republic; [Gursky, J.; Bartek, J.] Palacky Univ, Inst Mol & Translat Med, Fac Med & Dent, Olomouc, Czech Republic; [Hlusi, A.; Divoky, V] Palacky Univ, Dept Hematooncol, Univ Hosp, Olomouc, Czech Republic; [Hlusi, A.; Flodr, P.; Divoky, V] Palacky Univ, Fac Med & Dent, Olomouc, Czech Republic; [Flodr, P.] Palacky Univ, Dept Clin & Mol Pathol, Univ Hosp, Olomouc, Czech Republic; [Hubackova, S.] Czech Acad Sci, Lab Mol Therapy, Inst Biotechnol, BIOCEV, Prague 25250, Czech Republic; [Bartek, J.] Danish Canc Soc Res Ctr, DK-2100 Copenhagen, Denmark; [Bartek, J.; Hodny, Z.] Inst Mol Genet ASCR Vvi, Lab Genome Integr, Prague, Czech Republic; [Bartek, J.] Karolinska Inst, Div Genome Biol, Dept Biochem & Biophys, Sci Life Lab, Stockholm, Sweden	Palacky University Olomouc; Palacky University Olomouc; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Palacky University Olomouc; Palacky University Olomouc; University Hospital Olomouc; University Hospital Plzen; Palacky University Olomouc; Palacky University Olomouc; University Hospital Olomouc; Czech Academy of Sciences; Institute of Biotechnology of the Czech Academy of Sciences; Danish Cancer Society; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Karolinska Institutet	Divoky, V (corresponding author), Palacky Univ, Dept Biol, Fac Med & Dent, Olomouc, Czech Republic.; Bartek, J (corresponding author), Palacky Univ, Inst Mol & Translat Med, Fac Med & Dent, Olomouc, Czech Republic.; Divoky, V (corresponding author), Palacky Univ, Dept Hematooncol, Univ Hosp, Olomouc, Czech Republic.; Divoky, V (corresponding author), Palacky Univ, Fac Med & Dent, Olomouc, Czech Republic.; Bartek, J (corresponding author), Danish Canc Soc Res Ctr, DK-2100 Copenhagen, Denmark.; Bartek, J; Hodny, Z (corresponding author), Inst Mol Genet ASCR Vvi, Lab Genome Integr, Prague, Czech Republic.; Bartek, J (corresponding author), Karolinska Inst, Div Genome Biol, Dept Biochem & Biophys, Sci Life Lab, Stockholm, Sweden.	jb@cancer.dk; zdenek.hodny@img.cas.cz; vladimir.divoky@upol.cz	Flodr, Patrik/GLS-0074-2022; Vyhlidalova, Pavla/O-8178-2019; Koralkova, Pavla/AAL-2965-2020	Vyhlidalova, Pavla/0000-0002-2522-6749; Lanikova, Lucie/0000-0002-2845-8692; Stetka, Jan/0000-0003-4301-2856; Stemberkova Hubackova, Sona/0000-0002-3454-6840	Czech Science Foundation [14-10687P]; Internal Grant Agency of Palacky University [IGA_LF_2018_010]; Danish Council for Independent Research; Swedish Research Council; European Regional Development Fund [ENOCH/CZ.02.1.01/0.0/0.0/16_019/0000868];  [LTAUSA17142]	Czech Science Foundation(Grant Agency of the Czech Republic); Internal Grant Agency of Palacky University; Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Swedish Research Council(Swedish Research CouncilEuropean Commission); European Regional Development Fund(European Commission); 	Czech Science Foundation Project 14-10687P (PV), LTAUSA17142 project (JS, LL, and VD), Internal Grant Agency of Palacky University, Project IGA_LF_2018_010 (JS and PK), Danish Council for Independent Research (JB), Swedish Research Council (JB), and European Regional Development Fund-Project ENOCH/CZ.02.1.01/0.0/0.0/16_019/0000868 (ZH and JB).	Algood HMS, 2004, J IMMUNOL, V172, P6846, DOI 10.4049/jimmunol.172.11.6846; Andersson AC, 2006, J HISTOCHEM CYTOCHEM, V54, P1413, DOI 10.1369/jhc.6A7001.2006; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Baba T, 2016, BLOOD, V127, P2607, DOI 10.1182/blood-2015-10-673087; Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419; Bagnyukova TV, 2013, BRIT J CANCER, V109, P1063, DOI 10.1038/bjc.2013.353; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2010, ONCOGENE, V29, P5095, DOI 10.1038/onc.2010.249; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bennett BT, 2009, METHODS, V48, P63, DOI 10.1016/j.ymeth.2009.02.009; Berglund UW, 2016, ANN ONCOL, V27, P2275, DOI 10.1093/annonc/mdw429; Besancenot R, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000476; BEUTLER E, 1977, BRIT J HAEMATOL, V35, P331, DOI 10.1111/j.1365-2141.1977.tb00589.x; Bock O, 2005, J PATHOL, V205, P548, DOI 10.1002/path.1744; Campbell PJ, 2006, NEW ENGL J MED, V355, P2452, DOI 10.1056/NEJMra063728; Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431; Cerquozzi S, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.95; Chagraoui H, 2002, BLOOD, V100, P3495, DOI 10.1182/blood-2002-04-1133; Chen E, 2015, CELL REP, V13, P2345, DOI 10.1016/j.celrep.2015.11.037; Chen E, 2014, P NATL ACAD SCI USA, V111, P15190, DOI 10.1073/pnas.1401873111; Chen E, 2010, CANCER CELL, V18, P524, DOI 10.1016/j.ccr.2010.10.013; Desterke C, 2011, CANCER RES, V71, P2901, DOI 10.1158/0008-5472.CAN-10-1731; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; Fleischman AG, 2011, BLOOD, V118, P6392, DOI 10.1182/blood-2011-04-348144; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Hasselbalch HC, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/102476; Heaton WL, 2018, LEUKEMIA, V32, P2399, DOI 10.1038/s41375-018-0131-z; Herwig R, 2016, NAT PROTOC, V11, P1889, DOI 10.1038/nprot.2016.117; Horvathova M, 2012, HAEMATOL-HEMATOL J, V97, P1480, DOI 10.3324/haematol.2011.059550; Hu P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05955-2; Hubackova S, 2016, ONCOGENE, V35, P1236, DOI 10.1038/onc.2015.162; Hubackova S, 2012, AGING-US, V4, P932, DOI 10.18632/aging.100520; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karigane D, 2016, CELL STEM CELL, V19, P192, DOI 10.1016/j.stem.2016.05.013; Kennedy M, 2012, CELL REP, V2, P1722, DOI 10.1016/j.celrep.2012.11.003; Kesarwani M, 2017, NAT MED, V23, P472, DOI 10.1038/nm.4310; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; Kleppe M, 2017, CELL STEM CELL, V21, P489, DOI 10.1016/j.stem.2017.08.011; Koledova Z, 2010, STEM CELLS DEV, V19, P181, DOI 10.1089/scd.2009.0065; Kozlov SV, 2016, MOL CELL PROTEOMICS, V15, P1032, DOI 10.1074/mcp.M115.055723; Lee J, 2019, CURR GENET, V65, P417, DOI 10.1007/s00294-018-0898-5; Li JA, 2010, BLOOD, V116, P1528, DOI 10.1182/blood-2009-12-259747; Lu M, 2010, EXP HEMATOL, V38, P472, DOI 10.1016/j.exphem.2010.03.005; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Majumder S, 1998, J IMMUNOL, V161, P4736; Manshouri T, 2011, CANCER RES, V71, P3831, DOI 10.1158/0008-5472.CAN-10-4002; Marty C, 2013, LEUKEMIA, V27, P2187, DOI 10.1038/leu.2013.102; Mills RJ, 2017, P NATL ACAD SCI USA, V114, pE8372, DOI 10.1073/pnas.1707316114; Molina G, 2009, NAT CHEM BIOL, V5, P680, DOI 10.1038/nchembio.190; Pearl LH, 2015, NAT REV CANCER, V15, P166, DOI 10.1038/nrc3891; Pietras EM, 2017, BLOOD, V130, P1693, DOI 10.1182/blood-2017-06-780882; Plo I, 2008, BLOOD, V112, P1402, DOI 10.1182/blood-2008-01-134114; Rasmussen RD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13398; Schepers K, 2013, CELL STEM CELL, V13, P285, DOI 10.1016/j.stem.2013.06.009; Schnoder TM, 2017, J CANCER RES CLIN, V143, P807, DOI 10.1007/s00432-017-2354-1; Smith C, 2015, MOL THER, V23, P570, DOI 10.1038/mt.2014.226; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takacova S, 2012, CANCER CELL, V21, P517, DOI 10.1016/j.ccr.2012.01.021; Tefferi A, 2014, BLOOD, V124, P2507, DOI 10.1182/blood-2014-05-579136; Turpie AGG, 2017, BLOOD, V130; Vaidya R, 2012, AM J HEMATOL, V87, P1003, DOI 10.1002/ajh.23295; Vainchenker W, 2017, BLOOD, V129, P667, DOI 10.1182/blood-2016-10-695940; van Dekken H, 2008, AM J CLIN PATHOL, V130, P745, DOI 10.1309/AJCPO31THGVEUIDH; Vener C, 2010, EXP HEMATOL, V38, P1058, DOI 10.1016/j.exphem.2010.07.005; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Walter D, 2015, NATURE, V520, P549, DOI 10.1038/nature14131; Wernig G, 2017, P NATL ACAD SCI USA, V114, P4757, DOI 10.1073/pnas.1621375114; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Wu XF, 2018, CELL, V172, P423, DOI 10.1016/j.cell.2017.11.018; Ye ZH, 2014, STEM CELLS, V32, P269, DOI 10.1002/stem.1545; Zambetti NA, 2016, CELL STEM CELL, V19, P613, DOI 10.1016/j.stem.2016.08.021; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262; Zidova Z, 2014, CELL PHYSIOL BIOCHEM, V34, P2221, DOI 10.1159/000369665; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	82	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5627	5642		10.1038/s41388-019-0813-7	http://dx.doi.org/10.1038/s41388-019-0813-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	30967632	Green Published, hybrid			2022-12-17	WOS:000474845100006
J	Schwiebs, A; San Juan, MH; Schmidt, KG; Wiercinska, E; Anlauf, M; Ottenlinger, F; Thomas, D; Elwakeel, E; Weigert, A; Farin, HF; Bonig, H; Scholich, K; Geisslinger, G; Pfeilschifter, JM; Radeke, HH				Schwiebs, Anja; San Juan, Martina Herrero; Schmidt, Katrin G.; Wiercinska, Eliza; Anlauf, Martin; Ottenlinger, Florian; Thomas, Dominique; Elwakeel, Eiman; Weigert, Andreas; Farin, Henner F.; Bonig, Halvard; Scholich, Klaus; Geisslinger, Gerd; Pfeilschifter, Josef M.; Radeke, Heinfried H.			Cancer-induced inflammation and inflammation-induced cancer in colon: a role for S1P lyase	ONCOGENE			English	Article							PERSISTENT STAT3 ACTIVATION; SPHINGOSINE KINASE 1; BOWEL-DISEASE; INTESTINAL INFLAMMATION; COLORECTAL-CANCER; LYMPHOCYTE EGRESS; TUMOR PROGRESSION; DOWN-REGULATION; SPHINGOSINE-1-PHOSPHATE; RECEPTOR	A role of sphingolipids for inflammatory bowel disease and cancer is evident. However, the relative and separate contribution of sphingolipid deterioration in inflammation versus carcinogenesis for the pathophysiology of colitis-associated colon cancer (CAC) was unknown and therefore examined in this study. We performed isogenic bone marrow transplantation of inducible sphingosine-1-phosphate (S1P) lyase knockout mice to specifically modulate sphingolipids and associated genes and proteins in a compartment-specific way in a DSS/AOM mediated CAC model. 3D organoid cultures were used in vitro. S1P lyase (SGPL1) knockout in either immune cells or tissue, caused local sphingolipid accumulation leading to a dichotomic development of CAC: Immune cell SGPL1 knockout (I-SGPL(-/-)) augmented massive immune cell infiltration initiating colitis with lesions and calprotectin increase. Pathological crypt remodeling plus extracellular S1P-signaling caused delayed tumor formation characterized by S1P receptor 1, STAT3 mRNA increase, as well as programmed cell death ligand 1 expression, accompanied by a putatively counter regulatory STAT1(S727) phosphorylation. In contrast, tissue SGPL1 knockout (T-SGPL(-/-)) provoked immediate occurrence of epithelial-driven tumors with upregulated sphingosine kinase 1, S1P receptor 2 and epidermal growth factor receptor. Here, progressing carcinogenesis was accompanied by an IL-12 to IL-23 shift with a consecutive development of a Th2/GATA3-driven, tumor-favoring microenvironment. Moreover, the knockout models showed distinct lymphopenia and neutrophilia, different from the full SGPL1 knockout. This study shows that depending on the initiating cellular S1P source, the pathophysiology of inflammation-induced cancer versus cancer-induced inflammation develops through separate, discernible molecular steps.	[Schwiebs, Anja; San Juan, Martina Herrero; Schmidt, Katrin G.; Ottenlinger, Florian; Pfeilschifter, Josef M.; Radeke, Heinfried H.] Hosp Goethe Univ, ZAFES, Pharmazentrum Frankfurt, Inst Gen Pharmacol & Toxicol, Frankfurt, Germany; [Wiercinska, Eliza; Bonig, Halvard] German Red Cross Blood Serv Inst, Frankfurt, Germany; [Wiercinska, Eliza; Bonig, Halvard] Goethe Univ, Inst Transfus Med & Immunohematol, Frankfurt, Germany; [Anlauf, Martin] St Vincenz Hosp, Inst Pathol & Cytol, Limburg, Germany; [Thomas, Dominique; Scholich, Klaus; Geisslinger, Gerd] Hosp Goethe Univ, Pharmazentrum Frankfurt, Inst Clin Pharmacol, Frankfurt, Germany; [Elwakeel, Eiman; Weigert, Andreas] Hosp Goethe Univ, Pharmazentrum Frankfurt, Inst Biochem 1, Frankfurt, Germany; [Farin, Henner F.] Inst Tumor Biol & Expt Therapy, Georg Speyer Haus, Frankfurt, Germany; [Farin, Henner F.] German Canc Consortium DKTK, Heidelberg, Germany; [Farin, Henner F.] German Canc Res Ctr, Heidelberg, Germany; [Bonig, Halvard] Univ Washington, Dept Med Hematol, Seattle, WA 98195 USA; [Geisslinger, Gerd] Fraunhofer Inst Mol Biol & Appl Ecol IME, Project Grp Translat Med & Pharmacol TMP, Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Washington; University of Washington Seattle; Fraunhofer Gesellschaft	Schwiebs, A; Radeke, HH (corresponding author), Hosp Goethe Univ, ZAFES, Pharmazentrum Frankfurt, Inst Gen Pharmacol & Toxicol, Frankfurt, Germany.	schwiebs@med.uni-frankfurt.de; radeke@em.uni-frankfurt.de	Weigert, Andreas/E-6540-2010; Radeke, Heinfried H/E-3772-2013; Bönig, Halvard/AAG-3029-2021; Farin, Henner/AAC-2574-2021	Weigert, Andreas/0000-0002-7529-1952; Radeke, Heinfried H/0000-0002-4499-2510; Bönig, Halvard/0000-0003-0088-2675; Farin, Henner/0000-0003-1558-5366; Elwakeel, Eiman/0000-0002-0219-9653; Wiercinska, Eliza/0000-0002-8434-6492	Deutsche Forschungsgemeinschaft [SFB1039]; Else-Kroner-Fresenius-Graduiertenkolleg; Translational Research Innovation Pharma graduate school - Else-Kroner-Fresenius Foundation; LOEWE Cell and Gene Therapy Frankfurt faculty [III L 4 518/17.004]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Else-Kroner-Fresenius-Graduiertenkolleg; Translational Research Innovation Pharma graduate school - Else-Kroner-Fresenius Foundation; LOEWE Cell and Gene Therapy Frankfurt faculty	This work was supported by the Deutsche Forschungsgemeinschaft (grant number: SFB1039) to (HHR, AS, KGS, DT, EE, AW, KS, GG, JMP). We also acknowledge the support of the Else-Kroner-Fresenius-Graduiertenkolleg for (FO), the Translational Research Innovation Pharma graduate school for (KGS) funded by the Else-Kroner-Fresenius Foundation both awarded to (HHR), and the LOEWE Cell and Gene Therapy Frankfurt faculty (grant number: III L 4 518/17.004) for EW, awarded to HB.	Allende ML, 2011, J BIOL CHEM, V286, P7348, DOI 10.1074/jbc.M110.171819; Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128; [Anonymous], 2010, WOODHEAD PUBL MATER; Arlt O, 2014, CELL PHYSIOL BIOCHEM, V34, P27, DOI 10.1159/000362982; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Begagne E, 2014, J CLIN INVEST, V124, P5368, DOI 10.1172/JCI74188; Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; Beswick EJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01125; Billich A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059630; Brizuela L, 2012, MOL CANCER THER, V11, P1841, DOI 10.1158/1535-7163.MCT-12-0227; Caini S, 2016, DIGEST LIVER DIS, V48, P1162, DOI 10.1016/j.dld.2016.07.008; Chumanevich AA, 2010, CARCINOGENESIS, V31, P1787, DOI 10.1093/carcin/bgq158; Cyster JG, 2012, ANNU REV IMMUNOL, V30, P69, DOI 10.1146/annurev-immunol-020711-075011; Daniel C, 2007, MOL IMMUNOL, V44, P3305, DOI 10.1016/j.molimm.2007.02.026; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Degagne E, 2014, CLIN EXP GASTROENTER, V7, P205, DOI 10.2147/CEG.S43453; Dillmann C, 2016, J IMMUNOL, V196, P1579, DOI 10.4049/jimmunol.1403168; Doll F, 2005, BBA-MOL CELL BIOL L, V1738, P72, DOI 10.1016/j.bbalip.2005.12.001; Duan RD, 2009, PROG LIPID RES, V48, P62, DOI 10.1016/j.plipres.2008.04.003; Foerster S, 2013, PROTEOMICS, V13, P3131, DOI 10.1002/pmic.201300154; Gandy KAO, 2013, FASEB J, V27, P3155, DOI 10.1096/fj.13-228460; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gu YP, 2011, J CELL BIOL, V193, P667, DOI 10.1083/jcb.201010075; Helbling M, 2014, ONCOTARGET, V5, P4671, DOI 10.18632/oncotarget.2069; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; Kim JJ, 2012, JOVE-J VIS EXP, DOI 10.3791/3678; Kroemer G, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1058597; Kumar A, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/7685142; Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250; Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Linke B, 2009, J PROTEOME RES, V8, P4851, DOI 10.1021/pr900106v; Liu SQ, 2013, INT J ONCOL, V42, P617, DOI 10.3892/ijo.2012.1733; Minn AJ, 2016, CELL, V165, P272, DOI 10.1016/j.cell.2016.03.031; Monteleone G, 2012, INT J MOL SCI, V13, P11071, DOI 10.3390/ijms130911071; Nitulescu II, 2017, EBIOMEDICINE, V26, P112, DOI 10.1016/j.ebiom.2017.11.013; Oskouian B, 2006, P NATL ACAD SCI USA, V103, P17384, DOI 10.1073/pnas.0600050103; Ottenlinger FM, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00412; Pathria P, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.998529; Patmanathan SN, 2017, CELL SIGNAL, V34, P66, DOI 10.1016/j.cellsig.2017.03.002; Richter C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00044; Rizzo A, 2011, WORLD J GASTROENTERO, V17, P3092, DOI 10.3748/wjg.v17.i26.3092; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640; Schwab SR, 2007, NAT IMMUNOL, V8, P1295, DOI 10.1038/ni1545; Schwiebs A, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00094; Shalapour S, 2015, J CLIN INVEST, V125, P3347, DOI 10.1172/JCI80007; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Shida D, 2004, FEBS LETT, V577, P333, DOI 10.1016/j.febslet.2004.10.024; Siso S, 2010, PRION, V4, P134; Snider AJ, 2009, FASEB J, V23, P143, DOI 10.1096/fj.08-118109; Suh JH, 2015, TRANSL CANCER RES, V4, P469, DOI 10.3978/j.issn.221-676X.2015.10.06; Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x; Timofeeva OA, 2006, ONCOGENE, V25, P7555, DOI 10.1038/sj.onc.1209742; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; Vogel P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004112; Wang KP, 2015, ADV CANCER RES, V128, P173, DOI 10.1016/bs.acr.2015.04.014; Zamora-Pineda J, 2016, J EXP MED, V213, P2773, DOI 10.1084/jem.20160287; Zhang WW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01699; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051	62	22	26	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4788	4803		10.1038/s41388-019-0758-x	http://dx.doi.org/10.1038/s41388-019-0758-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30816345				2022-12-17	WOS:000471160500010
J	Zhang, L; Li, WL; Cao, L; Xu, JY; Qian, Y; Chen, HR; Zhang, YQ; Kang, W; Gou, HY; Wong, CC; Yu, J				Zhang, Li; Li, Weilin; Cao, Lei; Xu, Jiaying; Qian, Yun; Chen, Huarong; Zhang, Yanquan; Kang, Wei; Gou, Hongyan; Wong, Chi Chun; Yu, Jun			PKNOX2 suppresses gastric cancer through the transcriptional activation of IGFBP5 and p53	ONCOGENE			English	Article							FACTOR-BINDING PROTEIN-5; EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH; DIFFERENTIATION; TUMORIGENESIS; PROGRESSION; EXPRESSION; PBX1	Promoter methylation plays a vital role in tumorigenesis through transcriptional silencing of tumor suppressive genes. Using genome-wide methylation array, we first identified PBX/Knotted Homeobox 2 (PKNOX2) as a candidate tumor suppressor in gastric cancer. PKNOX2 mRNA expression is largely silenced in gastric cancer cell lines and primary gastric cancer via promoter methylation. Promoter methylation of PKNOX2 was associated with poor survival in gastric cancer patients. A series of in vitro and in vivo functional studies revealed that PKNOX2 functions as a tumor suppressor. Ectopic PKNOX2 expression inhibited cell proliferation in GC cell lines and suppressed growth of tumor xenografts in mice via induction of apoptosis and cell cycle arrest; and suppressed cell migration and invasion by blocking epithelial-to-mesenchymal transition. On the other hand, knockdown PKNOX2 in normal gastric epithelial cells triggered diverse malignant phenotypes. Mechanistically, PKNOX2 exerts its tumor suppressive effect by promoting the up-regulation of Insulin like Growth Factor Binding Protein 5 (IGFBP5) and TP53. PKNOX2 binds to the promoter regions of IGFBP5 and TP53 and transcriptionally activated their expression by chromatin immunoprecipitation (ChIP)-PCR assay. IGFBP5 knockdown partly abrogated tumor suppressive effect of PKNOX2, indicating that the function(s) of PKNOX2 are dependent on IGFBP5. IGFBP5 promoted PKNOX2-mediated up-regulation of p53. As a consequence, p53 transcription target genes were coordinately upregulated in PKNOX2-expressing GC cells, leading to tumor suppression. In summary, our results identified PKNOX2 as a tumor suppressor in gastric cancer by activation of IGFBP5 and p53 signaling pathways. PKNOX2 promoter hypermethylation might be a biomarker for the poor survival of gastric cancer patients.	[Zhang, Li; Li, Weilin; Cao, Lei; Xu, Jiaying; Chen, Huarong; Zhang, Yanquan; Gou, Hongyan; Wong, Chi Chun; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Zhang, Li; Li, Weilin; Cao, Lei; Xu, Jiaying; Chen, Huarong; Zhang, Yanquan; Gou, Hongyan; Wong, Chi Chun; Yu, Jun] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, State Key Lab Digest Dis,Dept Med & Therapeut, Hong Kong, Peoples R China; [Li, Weilin] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China; [Qian, Yun] Shenzhen Univ Hosp, Dept Gastroenterol, Shenzhen, Peoples R China; [Kang, Wei] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Shenzhen University; Chinese University of Hong Kong	Wong, CC; Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Wong, CC; Yu, J (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, State Key Lab Digest Dis,Dept Med & Therapeut, Hong Kong, Peoples R China.	chichun.wong@cuhk.edu.hk; junyu@cuhk.edu.hk	Wong, Chi Chun/C-4636-2016; Chen, Huarong/ABZ-5810-2022; KANG, Wei/C-5451-2016; Li, Weilin/ABG-9032-2021; Yu, Jun/D-8569-2015; chen, huarong/ABH-8561-2020; Zhang, Yanquan/D-5615-2017; xu, jia/GSD-6347-2022	KANG, Wei/0000-0002-4651-677X; Yu, Jun/0000-0001-5008-2153; chen, huarong/0000-0003-2192-1864; Zhang, Yanquan/0000-0003-3527-9972; 	National Key R&D Program of China [2018YFC135000/2018YFC1315004]; RGC/GRF Hong Kong [14114615, 14101917, 14111216, 14106145, 14108718]; National Natural Science Foundation of China (NSFC) [81772501, 81502064]; HMRF Hong Kong [03140856]; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme; CUHK direct grant	National Key R&D Program of China; RGC/GRF Hong Kong(Hong Kong Research Grants Council); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); HMRF Hong Kong; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme; CUHK direct grant(Chinese University of Hong Kong)	This project was supported by research funds from National Key R&D Program of China (No. 2018YFC135000/2018YFC1315004), RGC/GRF Hong Kong (14114615, 14101917, 14111216, 14106145, and 14108718); National Natural Science Foundation of China (NSFC) (81772501 and 81502064); HMRF Hong Kong (03140856); Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute; CUHK direct grant.	Adrien D, 2010, LANGENBECK ARCH SURG, V395, P261, DOI 10.1007/s00423-009-0465-0; Ahn BY, 2010, CANCER RES, V70, P3013, DOI 10.1158/0008-5472.CAN-09-3108; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Banno K, 2012, INT J ONCOL, V41, P793, DOI 10.3892/ijo.2012.1528; Brendolan A, 2005, DEVELOPMENT, V132, P3113, DOI 10.1242/dev.01884; Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200; Capellini TD, 2006, DEVELOPMENT, V133, P2263, DOI 10.1242/dev.02395; Castro AC, 2007, J PATHOL, V211, P507, DOI DOI 10.1002/PATH.2138; Choi YJ, 2015, CARCINOGENESIS, V36, P553, DOI 10.1093/carcin/bgv022; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fernandez LC, 2008, CANCER LETT, V266, P144, DOI 10.1016/j.canlet.2008.02.042; Gullu G, 2012, CHIN J CANCER, V31, P266, DOI 10.5732/cjc.011.10405; Haller K, 2002, DEV DYNAM, V225, P358, DOI 10.1002/dvdy.10167; Hung PS, 2008, J PATHOL, V214, P368, DOI 10.1002/path.2280; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kim KS, 2007, MOL BIOL CELL, V18, P4543, DOI 10.1091/mbc.E07-03-0280; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Li WL, 2018, ONCOGENE, V37, P6383, DOI 10.1038/s41388-018-0402-1; Mao BJ, 2015, INT J ONCOL, V46, P459, DOI 10.3892/ijo.2014.2765; Natalwala A, 2008, WORLD J GASTROENTERO, V14, P3792, DOI 10.3748/wjg.14.3792; Pirini F, 2017, ONCOTARGET, V8, P38501, DOI 10.18632/oncotarget.16258; Qian Y, 2017, CANCER RES, V77, P1968, DOI 10.1158/0008-5472.CAN-16-1595; Qin P, 2004, J BIOL CHEM, V279, P16263, DOI 10.1074/jbc.M313938200; Saavedra K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125834; Shah N, 2014, CLIN CANCER RES, V20, P4400, DOI 10.1158/1078-0432.CCR-13-1486; Shersher DD, 2011, ANN THORAC SURG, V92, P1805, DOI 10.1016/j.athoracsur.2011.06.058; Sureshbabu A, 2012, J CELL SCI, V125, P1693, DOI 10.1242/jcs.092882; Yamashita H, 2009, CANCER SCI, V100, P2028, DOI 10.1111/j.1349-7006.2009.01274.x; Zhang L, 2010, MOL BIOL REP, V37, P2579, DOI 10.1007/s11033-009-9777-y	30	22	22	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4590	4604		10.1038/s41388-019-0743-4	http://dx.doi.org/10.1038/s41388-019-0743-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30745575	Green Published, hybrid			2022-12-17	WOS:000470240300011
J	Villafanez, F; Garcia, IA; Carbajosa, S; Pansa, MF; Mansilla, S; Llorens, MC; Angiolini, V; Guantay, L; Jacobs, H; Madauss, KP; Gloger, I; Gottifredi, V; Bocco, JL; Soria, G				Villafanez, Florencia; Alejandra Garcia, Iris; Carbajosa, Sofia; Florencia Pansa, Maria; Mansilla, Sabrina; Candelaria Llorens, Maria; Angiolini, Virginia; Guantay, Laura; Jacobs, Heinz; Madauss, Kevin P.; Gloger, Israel; Gottifredi, Vanesa; Luis Bocco, Jose; Soria, Gaston			AKT inhibition impairs PCNA ubiquitylation and triggers synthetic lethality in homologous recombination-deficient cells submitted to replication stress	ONCOGENE			English	Article							PROTEIN-KINASE B; NUCLEAR ANTIGEN UBIQUITINATION; DNA-DAMAGE RESPONSE; SIGNALING PATHWAY; P21 DEGRADATION; REPAIR; ETA; POLYMERASES; AKT/PKB; CANCER	Translesion DNA synthesis (TLS) and homologous recombination (HR) cooperate during S-phase to safeguard replication forks integrity. Thus, the inhibition of TLS becomes a promising point of therapeutic intervention in HR-deficient cancers, where TLS impairment might trigger synthetic lethality (SL). The main limitation to test this hypothesis is the current lack of selective pharmacological inhibitors of TLS. Herein, we developed a miniaturized screening assay to identify inhibitors of PCNA ubiquitylation, a key post-translational modification required for efficient TLS activation. After screening a library of 627 kinase inhibitors, we found that targeting the pro-survival kinase AKT leads to strong impairment of PCNA ubiquitylation. Mechanistically, we found that AKT-mediated modulation of Proliferating Cell Nuclear Antigen (PCNA) ubiquitylation after UV requires the upstream activity of DNA PKcs, without affecting PCNA ubiquitylation levels in unperturbed cells. Moreover, we confirmed that persistent AKT inhibition blocks the recruitment of TLS polymerases to sites of DNA damage and impairs DNA replication forks processivity after UV irradiation, leading to increased DNA replication stress and cell death. Remarkably, when we compared the differential survival of HR-proficient vs HR-deficient cells, we found that the combination of UV irradiation and AKT inhibition leads to robust SL induction in HR-deficient cells. We link this phenotype to AKT ability to inhibit PCNA ubiquitylation, since the targeted knockdown of PCNA E3-ligase (RAD18) and a non-ubiquitylable (PCNA K164R) knock-in model recapitulate the observed SL induction. Collectively, this work identifies AKT as a novel regulator of PCNA ubiquitylation and provides the proof-of-concept of inhibiting TLS as a therapeutic approach to selectively kill HR-deficient cells submitted to replication stress.	[Villafanez, Florencia; Alejandra Garcia, Iris; Carbajosa, Sofia; Florencia Pansa, Maria; Candelaria Llorens, Maria; Angiolini, Virginia; Guantay, Laura; Luis Bocco, Jose; Soria, Gaston] Consejo Nacl Invest Cient & Tecn, CIBICI, Ctr Invest Bioquim Clin & Inmunol, Cordoba, Argentina; [Villafanez, Florencia; Alejandra Garcia, Iris; Carbajosa, Sofia; Florencia Pansa, Maria; Candelaria Llorens, Maria; Angiolini, Virginia; Guantay, Laura; Luis Bocco, Jose; Soria, Gaston] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, Cordoba, Argentina; [Mansilla, Sabrina; Gottifredi, Vanesa] Fdn Inst Leloir, Buenos Aires, DF, Argentina; [Jacobs, Heinz] Netherlands Canc Inst, Tumor Biol & Immunol, Amsterdam, Netherlands; [Madauss, Kevin P.] GlaxoSmithKline Trust Sci, Global Hlth R&D, Upper Providence, PA USA; [Gloger, Israel] GlaxoSmithKline Trust Sci, Global Hlth R&D, Stevenage, Herts, England	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba; Leloir Institute; Netherlands Cancer Institute	Soria, G (corresponding author), Consejo Nacl Invest Cient & Tecn, CIBICI, Ctr Invest Bioquim Clin & Inmunol, Cordoba, Argentina.; Soria, G (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, Cordoba, Argentina.	gsoria29@gmail.com	Carbajosa, Sofía/AAB-1554-2020; Gottifredi, Vanesa/AAI-1788-2019	Mansilla, Sabrina Florencia/0000-0001-7752-3377; Villafanez, Florencia/0000-0001-9835-2343; Gottifredi, Vanesa/0000-0001-9656-5951; Carbajosa Gonzalez, Sofia/0000-0002-0133-8287	Start-up grant from the Fondo para la Investigacion Cientifica y Tecnologica (FONCyT PICT start-up) [2013-1553]; KWF [10796/2016-2, 10032/2016-1]; FONCyT; Trust in Science (Global Health R& D) from GlaxoSmithKline [PAE-GLAXO 2014-0005]; National Institute of Cancer; CONICET	Start-up grant from the Fondo para la Investigacion Cientifica y Tecnologica (FONCyT PICT start-up); KWF; FONCyT(FONCyT); Trust in Science (Global Health R& D) from GlaxoSmithKline; National Institute of Cancer; CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET))	We thank the flow cytometry, microscopy and cell culture facilities of CIBICI-CONICET for technical support. We thank Nicolas Nieto Moreno for careful reading of the manuscript and helpful suggestions. We would like to thank Gerard Drewes of CellZome (a GSK company) for his scientific advice. This work was supported by a Start-up grant from the Fondo para la Investigacion Cientifica y Tecnologica (FONCyT PICT start-up 2013-1553), by KWF projects 10796/2016-2 and 10032/2016-1 to HJ and by a consortium grant of FONCyT and the Trust in Science (Global Health R& D) from GlaxoSmithKline (PAE-GLAXO 2014-0005). S.M, V.G., J.L.B. and G.S. are researchers from CONICET. FV, IAG, SC, and MCL were supported by fellowships from FONCyT, MFP and LG were supported by fellowships from the National Institute of Cancer and CONICET.	Joray MB, 2017, FOOD CHEM TOXICOL, V109, P888, DOI 10.1016/j.fct.2017.04.039; Bertolin AP, 2015, DNA REPAIR, V32, P158, DOI 10.1016/j.dnarep.2015.04.027; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Boehme KA, 2008, P NATL ACAD SCI USA, V105, P7785, DOI 10.1073/pnas.0703423105; Branzei D, 2016, DNA REPAIR, V44, P68, DOI 10.1016/j.dnarep.2016.05.008; Brown JS, 2017, PHARMACOL THERAPEUT, V172, P101, DOI 10.1016/j.pharmthera.2016.12.001; Brun Jan, 2010, BMC Res Notes, V3, P85, DOI 10.1186/1756-0500-3-85; Ceppi P, 2009, CLIN CANCER RES, V15, P1039, DOI 10.1158/1078-0432.CCR-08-1227; Cipolla L, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00105; Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292; Despras E, 2012, ENVIRON MOL MUTAGEN, V53, P752, DOI 10.1002/em.21741; Despras E, 2010, HUM MOL GENET, V19, P1690, DOI 10.1093/hmg/ddq046; Han EKH, 2007, ONCOGENE, V26, P5655, DOI 10.1038/sj.onc.1210343; Hendel A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002262; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jia JH, 2013, CELL SIGNAL, V25, P1498, DOI 10.1016/j.cellsig.2013.02.021; Langerak P, 2007, J EXP MED, V204, P1989, DOI 10.1084/jem.20070902; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Liu Q, 2014, NEURO-ONCOLOGY, V16, P1313, DOI 10.1093/neuonc/nou058; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Madia F, 2009, J CELL BIOL, V186, P509, DOI 10.1083/jcb.200906011; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Mansilla SF, 2013, NUCLEIC ACIDS RES, V41, P6942, DOI 10.1093/nar/gkt475; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; McIntyre J, 2015, DNA REPAIR, V29, P166, DOI 10.1016/j.dnarep.2015.02.011; Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003; Niimi A, 2008, P NATL ACAD SCI USA, V105, P16125, DOI 10.1073/pnas.0802727105; Nitulescu GM, 2016, INT J ONCOL, V48, P869, DOI 10.3892/ijo.2015.3306; Park J, 2009, J BIOL CHEM, V284, P6169, DOI 10.1074/jbc.C800210200; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Sabbioneda S, 2008, MOL BIOL CELL, V19, P5193, DOI 10.1091/mbc.E08-07-0724; Sale JE, 2012, J CELL SCI, V125, P1633, DOI 10.1242/jcs.094748; Sale JE, 2012, NAT REV MOL CELL BIO, V13, P141, DOI 10.1038/nrm3289; Sharma S, 2012, MOL PHARMACOL, V81, P778, DOI 10.1124/mol.111.076828; Sokol AM, 2013, SCI REP-UK, V3, DOI 10.1038/srep03277; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Soria G, 2006, ONCOGENE, V25, P2829, DOI 10.1038/sj.onc.1209315; Soria G, 2008, J CELL SCI, V121, P3271, DOI 10.1242/jcs.027730; Soria G, 2013, CELL CYCLE, V12, P422, DOI 10.4161/cc.23215; Soria G, 2010, DNA REPAIR, V9, P358, DOI 10.1016/j.dnarep.2009.12.003; Soria G, 2009, CELL CYCLE, V8, P3340, DOI 10.4161/cc.8.20.9836; Srivastava AK, 2015, P NATL ACAD SCI USA, V112, P4411, DOI 10.1073/pnas.1421365112; Surucu B, 2008, J BIOL CHEM, V283, P30025, DOI 10.1074/jbc.M803053200; Tu Y, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-172; Vaisman A, 2017, CRIT REV BIOCHEM MOL, V52, P274, DOI 10.1080/10409238.2017.1291576; Wang SC, 2014, TRENDS PHARMACOL SCI, V35, P178, DOI 10.1016/j.tips.2014.02.004; Wang ZF, 2016, J CELL SCI, V129, P1223, DOI 10.1242/jcs.179408; Wit N, 2015, NUCLEIC ACIDS RES, V43, P282, DOI 10.1093/nar/gku1301; Wu YT, 2011, J BIOL CHEM, V286, P14190, DOI 10.1074/jbc.M111.219923; Yamanaka K, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006842; Zhang WW, 2011, FEBS LETT, V585, P2786, DOI 10.1016/j.febslet.2011.04.044	54	22	22	8	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4310	4324		10.1038/s41388-019-0724-7	http://dx.doi.org/10.1038/s41388-019-0724-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30705406	Green Published, hybrid			2022-12-17	WOS:000469339100008
J	Fang, S; Liu, M; Li, L; Zhang, FF; Li, Y; Yan, Q; Cui, YZ; Zhu, YH; Yuan, YF; Guan, XY				Fang, Shuo; Liu, Ming; Li, Lei; Zhang, Fei-Fei; Li, Yun; Yan, Qian; Cui, Yu-Zhu; Zhu, Ying-Hui; Yuan, Yun-Fei; Guan, Xin-Yuan			Lymphoid enhancer-binding factor-1 promotes stemness and poor differentiation of hepatocellular carcinoma by directly activating the NOTCH pathway	ONCOGENE			English	Article							SIGNALING PATHWAY; GENE-EXPRESSION; WNT; CELLS; SURVIVAL; LEF-1; TRANSLOCATION; LEUKEMIA; TARGET; SPLIT	The poorly differentiated hepatocellular carcinoma (HCC) cells are usually characterized by immature hepatic progenitor cell-like properties, such as enhanced self-renewal ability, resistance to chemotherapeutic drugs, and a loss of mature hepatocyte proteins. However, the molecular mechanisms governing this process still remain unclear. In this study, we found the lymphoid enhancer-binding factor-1 (LEF1), a transcriptional factor, was frequently overexpressed in HCCs, which was significantly associated with poor prognosis and tumor cell differentiation. Functional studies have found that LEF1 enhanced cell growth, foci formation, colony formation in soft agar, and tumor formation in nude mice. Different from its canonical roles in the WNT signaling pathway, we found that LEF1 could activate the critical members (e.g., NOTCH1 and NOTCH2) of the NOTCH signaling pathway through directly binding to their promoter regions. Further studies have found that LEF1 could enhance the self-renewal ability, drug resistance, dedifferentiation, and invasion of HCC cells. The oncogenic functions and the effects of LEF1 on cancer stemness could be effectively inhibited by NOTCH inhibitor. Further characterization of LEF1 may lead to the development of novel therapeutic strategies for HCC treatment.	[Fang, Shuo; Zhang, Fei-Fei; Li, Yun; Yan, Qian; Cui, Yu-Zhu; Guan, Xin-Yuan] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China; [Fang, Shuo; Zhang, Fei-Fei; Li, Yun; Yan, Qian; Cui, Yu-Zhu; Guan, Xin-Yuan] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China; [Fang, Shuo] Sun Yat Sen Univ, Affiliated Hosp 7, Shenzhen, Peoples R China; [Liu, Ming] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Sch Basic Med Sci, Key Lab Prot Modificat & Degradat, Guangzhou, Guangdong, Peoples R China; [Li, Lei; Zhu, Ying-Hui; Yuan, Yun-Fei; Guan, Xin-Yuan] Sun Yat Sen Univ, State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China	University of Hong Kong; University of Hong Kong; Sun Yat Sen University; Guangzhou Medical University; State Key Lab Oncology South China; Sun Yat Sen University	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China.; Guan, XY (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China.	xyguan@hku.hk	SHUO, FANG/GQP-5192-2022; /A-3639-2009	SHUO, FANG/0000-0002-1724-404X; Yuan, Yunfei/0000-0003-2467-3683; LIU, MING/0000-0003-3222-8715; /0000-0003-1874-9805	Hong Kong Research Grant Council (RGC) [17143716, 767313, C7038-14G, C7027-14G, T12-704/16-R]; National Natural Science Foundation of China [81772554, 81272416, 81372583]; Shenzhen Peacock Team Project [KQTD 2015033117210153]	Hong Kong Research Grant Council (RGC)(Hong Kong Research Grants Council); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Peacock Team Project	This work was supported by grants from the Hong Kong Research Grant Council (RGC), including GRF (17143716 and 767313), Collaborative Research Funds (C7038-14G and C7027-14G), Theme-based Research Scheme (T12-704/16-R), and National Natural Science Foundation of China (81772554, 81272416, and 81372583). This work was also supported by the Shenzhen Peacock Team Project (KQTD 2015033117210153). Professor XY Guan is a Sophie YM Chan Professor in Cancer Research.	Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen LL, 2011, GUT, V60, P534, DOI 10.1136/gut.2010.224071; Chen LL, 2010, J CLIN INVEST, V120, P1178, DOI 10.1172/JCI40665; Chen LL, 2009, HEPATOLOGY, V50, P122, DOI 10.1002/hep.22933; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Collu GM, 2014, CELL MOL LIFE SCI, V71, P3553, DOI 10.1007/s00018-014-1644-x; Cook JJ, 2010, J NEUROSCI, V30, P6743, DOI 10.1523/JNEUROSCI.1381-10.2010; Dhanasekaran R., 2016, F1000 RES, V5, P879; Fu L, 2007, CANCER RES, V67, P10720, DOI 10.1158/0008-5472.CAN-07-2411; Galceran J, 2004, GENE DEV, V18, P2718, DOI 10.1101/gad.1249504; Heitzler P, 1996, DEVELOPMENT, V122, P161; Ji JF, 2012, SEMIN ONCOL, V39, P461, DOI 10.1053/j.seminoncol.2012.05.011; Kabos P, 2002, J BIOL CHEM, V277, P8763, DOI 10.1074/jbc.C100758200; Kim K, 2002, CELL BIOL INT, V26, P463, DOI 10.1006/cbir.2002.0901; Kohn A, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.21; Kopan R, 2002, J CELL SCI, V115, P1095; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Liu M, 2016, HEPATOLOGY, V63, P1544, DOI 10.1002/hep.28437; Ma NF, 2008, HEPATOLOGY, V47, P503, DOI 10.1002/hep.22072; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; McGregor SM, 2009, THESIS; Mishra L, 2009, HEPATOLOGY, V49, P318, DOI 10.1002/hep.22704; Nakahara F, 2014, BLOOD, V123, P3932, DOI 10.1182/blood-2013-01-476747; Okamura RM, 1998, IMMUNITY, V8, P11, DOI 10.1016/S1074-7613(00)80454-9; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Park HJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132992; Petropoulos K, 2008, J EXP MED, V205, P515, DOI 10.1084/jem.20071875; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Sekiya S, 2012, J CLIN INVEST, V122, P3914, DOI 10.1172/JCI63065; Si-Tayeb K, 2010, DEV CELL, V18, P175, DOI 10.1016/j.devcel.2010.01.011; Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360; Tong MJ, 2010, J CLIN GASTROENTEROL, V44, pE63, DOI 10.1097/MCG.0b013e3181b4b68b; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Ungerback J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017957; Valenti L, 2013, DIABETES, V62, P4052, DOI 10.2337/db13-0769; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Waterman ML, 2004, CANCER METAST REV, V23, P41, DOI 10.1023/A:1025858928620; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Wu W, 2016, ONCOTARGET, V7, P21631, DOI 10.18632/oncotarget.7795; Zhang Y, 2013, INT J MED SCI, V10, P738, DOI 10.7150/ijms.5693	46	22	23	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4061	4074		10.1038/s41388-019-0704-y	http://dx.doi.org/10.1038/s41388-019-0704-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30696957				2022-12-17	WOS:000468740200007
J	Mancuso, P; Tricarico, R; Bhattacharjee, V; Cosentino, L; Kadariya, Y; Jelinek, J; Nicolas, E; Einarson, M; Beeharry, N; Devarajan, K; Katz, RA; Dorjsuren, DG; Sun, H; Simeonov, A; Giordano, A; Testa, JR; Davidson, G; Davidson, I; Larue, L; Sobol, RW; Yen, TJ; Bellacosa, A				Mancuso, Pietro; Tricarico, Rossella; Bhattacharjee, Vikram; Cosentino, Laura; Kadariya, Yuwaraj; Jelinek, Jaroslav; Nicolas, Emmanuelle; Einarson, Margret; Beeharry, Neil; Devarajan, Karthik; Katz, Richard A.; Dorjsuren, Dorjbal G.; Sun, Hongmao; Simeonov, Anton; Giordano, Antonio; Testa, Joseph R.; Davidson, Guillaume; Davidson, Irwin; Larue, Lionel; Sobol, Robert W.; Yen, Timothy J.; Bellacosa, Alfonso			Thymine DNA glycosylase as a novel target for melanoma	ONCOGENE			English	Article							BASE EXCISION-REPAIR; TRANSCRIPTION FACTOR; READ ALIGNMENT; SENESCENCE; DEMETHYLATION; MUTATIONS; GENES; 5-HYDROXYMETHYLCYTOSINE; 5-CARBOXYLCYTOSINE; DISCOVERY	Melanoma is an aggressive neoplasm with increasing incidence that is classified by the NCI as a recalcitrant cancer, i.e., a cancer with poor prognosis, lacking progress in diagnosis and treatment. In addition to conventional therapy, melanoma treatment is currently based on targeting the BRAF/MEK/ERK signaling pathway and immune checkpoints. As drug resistance remains a major obstacle to treatment success, advanced therapeutic approaches based on novel targets are still urgently needed. We reasoned that the base excision repair enzyme thymine DNA glycosylase (TDG) could be such a target for its dual role in safeguarding the genome and the epigenome, by performing the last of the multiple steps in DNA demethylation. Here we show that TDG knockdown in melanoma cell lines causes cell cycle arrest, senescence, and death by mitotic alterations; alters the transcriptome and methylome; and impairs xenograft tumor formation. Importantly, untransformed melanocytes are minimally affected by TDG knockdown, and adult mice with conditional knockout of Tdg are viable. Candidate TDG inhibitors, identified through a high-throughput fluorescence-based screen, reduced viability and clonogenic capacity of melanoma cell lines and increased cellular levels of 5-carboxylcytosine, the last intermediate in DNA demethylation, indicating successful on-target activity. These findings suggest that TDG may provide critical functions specific to cancer cells that make it a highly suitable anti-melanoma drug target. By potentially disrupting both DNA repair and the epigenetic state, targeting TDG may represent a completely new approach to melanoma therapy.	[Mancuso, Pietro; Tricarico, Rossella; Cosentino, Laura; Nicolas, Emmanuelle; Einarson, Margret; Katz, Richard A.; Bellacosa, Alfonso] Fox Chase Canc Ctr, Canc Epigenet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA; [Mancuso, Pietro; Giordano, Antonio] Univ Siena, Dept Med Biotechnol, Siena, Italy; [Mancuso, Pietro] PSL Res Univ, Inst Curie, INSERM, U1021 Normal & Pathol Dev Melanocytes, F-91405 Orsay, France; [Bhattacharjee, Vikram; Kadariya, Yuwaraj; Beeharry, Neil; Testa, Joseph R.; Yen, Timothy J.] Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave, Philadelphia, PA 19111 USA; [Jelinek, Jaroslav] Temple Univ, Sch Med, Fels Inst Canc & Mol Biol, Philadelphia, PA 19140 USA; [Devarajan, Karthik] Fox Chase Canc Ctr, Dept Biostat, 333 Cottman Ave, Philadelphia, PA 19111 USA; [Dorjsuren, Dorjbal G.; Sun, Hongmao; Simeonov, Anton] NIH, Div Preclin Innovat, Natl Ctr Adv Translat Sci, Rockville, MD 20850 USA; [Giordano, Antonio] Temple Univ, Coll Sci & Technol, Dept Biol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; [Davidson, Guillaume; Davidson, Irwin] ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; [Davidson, Irwin; Larue, Lionel] Equipe Labellisee Ligue Canc, Orsay, France; [Larue, Lionel] Univ Paris Saclay, Univ Paris Sud, CNRS, UMR3347, Orsay, France; [Sobol, Robert W.] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA	Fox Chase Cancer Center; University of Siena; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Fox Chase Cancer Center; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; University of South Alabama	Bellacosa, A (corresponding author), Fox Chase Canc Ctr, Canc Epigenet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Alfonso.Bellacosa@fccc.edu	Mancuso, Pietro/J-1636-2019; Sobol, Robert/E-4125-2013; Giordano, Antonio/F-1927-2010	Davidson, Irwin/0000-0001-5533-1171; TRICARICO, ROSSELLA/0000-0001-7055-7208; Sobol, Robert/0000-0001-7385-3563; Giordano, Antonio/0000-0002-5959-016X; Davidson, Guillaume/0000-0001-9272-3924	Edwards Family; David A. Hungerford Endowed Fund in Basic Chromosome Research; NIH [CA78412, CA191956, CA06927]; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH); PA Department of Health C.U.R.E.; Commonwealth of Pennsylvania; INCa Project [PLBIO11-027]; William J. Avery Endowed Postdoctoral Fellowship; National Institutes of Health [CA148629, ES025138]; Ligue Nationale Contre le Cancer; INCa; ITMO cancer; program "Investissements d'Avenir" [ANR-11-LBX-0038, ANR-10-IDEX-0001-02 PSL]; Ligue National contre le cancer; Labex INRT [ANR-10-IDEX-0001-02]; IGBMC high-throughput sequencing facility, a member of "France Genomique" consortium [ANR10-INBS-09-08]; NATIONAL CANCER INSTITUTE [R21CA191956, R01CA175691, R50CA211479, P30CA006927, R01CA148629] Funding Source: NIH RePORTER	Edwards Family; David A. Hungerford Endowed Fund in Basic Chromosome Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); PA Department of Health C.U.R.E.; Commonwealth of Pennsylvania; INCa Project; William J. Avery Endowed Postdoctoral Fellowship; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); INCa(Institut National du Cancer (INCA) France); ITMO cancer; program "Investissements d'Avenir"(French National Research Agency (ANR)); Ligue National contre le cancer(Ligue nationale contre le cancer); Labex INRT; IGBMC high-throughput sequencing facility, a member of "France Genomique" consortium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. P. Abbosh and Dr. I. Astsaturov for critical reading of the manuscript; Dr. R. Zaidi for comments and advice; L. Cathay for secretarial assistance; and John and Robin Spurlino and the Edwards Family for their generous support of this research. We would like to thank Alice M. Hungerford for her philanthropic funding through the David A. Hungerford Endowed Fund in Basic Chromosome Research, honoring her late husband's legacy as a renowned scientist and the co-discoverer of the Philadelphia Chromosome. We thank the following core services at Fox Chase Cancer Center: Genomics, Cell Culture, Cell Sorting, Biological Imaging, High-Throughput Screening, Biostatistics and Bioinformatics, and Laboratory Animal Facilities. This study was supported by NIH grants CA78412 (to A. Bellacosa), CA191956 (to A. Bellacosa and T. Yen), and CA06927; the intramural research program of the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), PA Department of Health C.U.R.E. and an appropriation from the Commonwealth of Pennsylvania to the Fox Chase Cancer Center. PM was supported in part by INCa Project PLBIO11-027. RT was supported in part by a William J. Avery Endowed Postdoctoral Fellowship. RWS was supported by grants from the National Institutes of Health (CA148629 and ES025138) and is an Abraham A. Mitchell Distinguished Investigator. LL was supported by a grant from Ligue Nationale Contre le Cancer, INCa, ITMO cancer, and is under the program "Investissements d'Avenir" launched by the French Government and implemented by ANR Labex CelTisPhyBio (ANR-11-LBX-0038 and ANR-10-IDEX-0001-02 PSL). Work in the laboratory of ID was supported by grants from the INCa, the Ligue National contre le cancer, and the Labex INRT (ANR-10-IDEX-0001-02). RNA-seq was performed at the IGBMC high-throughput sequencing facility, a member of "France Genomique" consortium (ANR10-INBS-09-08). LL and ID are "equipes labelisees of the Ligue National Contre le cancer." AB would like to dedicate this article to the memory of his mother Maria, who showed that strength and tenderness, elegance and simplicity, resilience and joyfulness can coexist, and who will be missed tremendously.	Arantes-Rodrigues R, 2012, LAB ANIMAL, V41, P129, DOI 10.1038/laban0512-129; Bandyopadhyay D, 2002, CANCER RES, V62, P6231; Beeharry N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040342; Bellacosa A, 2015, DNA REPAIR, V32, P33, DOI 10.1016/j.dnarep.2015.04.011; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chong CR, 2006, NAT CHEM BIOL, V2, P415, DOI 10.1038/nchembio806; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Cortazar D, 2007, DNA REPAIR, V6, P489, DOI 10.1016/j.dnarep.2006.10.013; Cortazar D, 2011, NATURE, V470, P419, DOI 10.1038/nature09672; Cortellino S, 2011, CELL, V146, P67, DOI 10.1016/j.cell.2011.06.020; Dalton SR, 2012, EPIGENOMICS-UK, V4, P459, DOI [10.2217/EPI.12.36, 10.2217/epi.12.36]; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Eichenbaum G, 2011, J APPL TOXICOL, V31, P342, DOI 10.1002/jat.1592; Fitzgerald ME, 2008, J BIOL CHEM, V283, P32680, DOI 10.1074/jbc.M805504200; Gambichler T, 2013, MELANOMA RES, V23, P218, DOI 10.1097/CMR.0b013e32835f9bd4; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giuliano S, 2011, PIGM CELL MELANOMA R, V24, P295, DOI 10.1111/j.1755-148X.2010.00820.x; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Goding CR, 2016, CANCER CELL, V29, P619, DOI 10.1016/j.ccell.2016.04.010; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Ha GH, 2009, CELL DEATH DIFFER, V16, P483, DOI 10.1038/cdd.2008.182; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Henry RA, 2016, BIOCHEMISTRY-US, V55, P6766, DOI 10.1021/acs.biochem.6b00841; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Huang JM, 2017, DERMATOL CLIN, V35, P85, DOI 10.1016/j.det.2016.08.001; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Jelinek J, 2012, EPIGENETICS-US, V7, P1368, DOI 10.4161/epi.22552; Joshi S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006600; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maiti A, 2011, J BIOL CHEM, V286, P35334, DOI 10.1074/jbc.C111.284620; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Ohanna M, 2011, GENE DEV, V25, P1245, DOI 10.1101/gad.625811; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; Prieur A, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1473; Rambow F, 2015, CELL REP, V13, P840, DOI 10.1016/j.celrep.2015.09.037; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Sato T, 2017, CANCER RES, V77, P470, DOI 10.1158/0008-5472.CAN-16-0834; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Song FJ, 2014, CARCINOGENESIS, V35, P2097, DOI 10.1093/carcin/bgu140; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Svilar D, 2012, JOVE-J VIS EXP, DOI 10.3791/4168; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Turner DP, 2006, CANCER RES, V66, P7686, DOI 10.1158/0008-5472.CAN-05-4488; Xu JF, 2017, ONCOTARGET, V8, P89988, DOI 10.18632/oncotarget.21219; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; 2003, AM J PATHOL, V163, P333	61	22	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3710	3728		10.1038/s41388-018-0640-2	http://dx.doi.org/10.1038/s41388-018-0640-2			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30674989	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000467379600011
J	Wagner, S; Vlachogiannis, G; Brandon, AD; Valenti, M; Box, G; Jenkins, L; Mancusi, C; Self, A; Manodoro, F; Assiotis, I; Robinson, P; Chauhan, R; Rust, AG; Matthews, N; Eason, K; Khan, K; Starling, N; Cunningham, D; Sadanandam, A; Isacke, CM; Kirkin, V; Valeri, N; Whittaker, SR				Wagner, Steve; Vlachogiannis, Georgios; Brandon, Alexis De Haven; Valenti, Melanie; Box, Gary; Jenkins, Liam; Mancusi, Caterina; Self, Annette; Manodoro, Floriana; Assiotis, Ioannis; Robinson, Penny; Chauhan, Ritika; Rust, Alistair G.; Matthews, Nik; Eason, Kate; Khan, Khurum; Starling, Naureen; Cunningham, David; Sadanandam, Anguraj; Isacke, Clare M.; Kirkin, Vladimir; Valeri, Nicola; Whittaker, Steven R.			Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer	ONCOGENE			English	Article							NF-KAPPA-B; INTRINSIC RESISTANCE; PLUS IRINOTECAN; DOSE-ESCALATION; INFLAMMATION; DRIVEN; COLON; FLUOROURACIL; ACTIVATION; LEUCOVORIN	Despite showing clinical activity in BRAF-mutant melanoma, the MEK inhibitor (MEKi) trametinib has failed to show clinical benefit in KRAS-mutant colorectal cancer. To identify mechanisms of resistance to MEKi, we employed a pharmacogenomic analysis of MEKi-sensitive versus MEKi-resistant colorectal cancer cell lines. Strikingly, interferon- and inflammatory-related gene sets were enriched in cell lines exhibiting intrinsic and acquired resistance to MEK inhibition. The bromodomain inhibitor JQ1 suppressed interferon-stimulated gene (ISG) expression and in combination with MEK inhibitors displayed synergistic effects and induced apoptosis in MEKi-resistant colorectal cancer cell lines. ISG expression was confirmed in patient-derived organoid models, which displayed resistance to trametinib and were resensitized by JQ1 co-treatment. In in vivo models of colorectal cancer, combination treatment significantly suppressed tumor growth. Our findings provide a novel explanation for the limited response to MEK inhibitors in KRAS-mutant colorectal cancer, known for its inflammatory nature. Moreover, the high expression of ISGs was associated with significantly reduced survival of colorectal cancer patients. Excitingly, we have identified novel therapeutic opportunities to overcome intrinsic and acquired resistance to MEK inhibition in colorectal cancer.	[Wagner, Steve; Brandon, Alexis De Haven; Valenti, Melanie; Box, Gary; Mancusi, Caterina; Self, Annette; Kirkin, Vladimir; Whittaker, Steven R.] Inst Canc Res, Div Canc Therapeut, London, England; [Vlachogiannis, Georgios; Eason, Kate; Sadanandam, Anguraj; Valeri, Nicola] Inst Canc Res, Div Mol Pathol, London, England; [Jenkins, Liam; Isacke, Clare M.] Inst Canc Res, Breast Canc Now Res Ctr, London, England; [Manodoro, Floriana; Assiotis, Ioannis; Robinson, Penny; Chauhan, Ritika; Rust, Alistair G.; Matthews, Nik] Inst Canc Res, Tumour Profiling Unit, London, England; [Khan, Khurum; Starling, Naureen; Cunningham, David; Valeri, Nicola] Royal Marsden NHS Fdn Trust, Dept Med, London, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Whittaker, SR (corresponding author), Inst Canc Res, Div Canc Therapeut, London, England.	steven.whittaker@icr.ac.uk	Whittaker, Steven/AAS-9874-2020	Sadanandam, Anguraj/0000-0001-8485-5150; valeri, nicola/0000-0002-5426-5683; Whittaker, Steven/0000-0001-9062-7947; Eason, Katherine/0000-0001-6903-9067; Isacke, Clare/0000-0002-9222-3345; Jenkins, Liam/0000-0002-0560-0182; Cunningham, David/0000-0001-5158-1069; Rust, Alistair/0000-0001-7287-192X; Starling, Naureen/0000-0002-1496-6792; Kirkin, Vladimir/0000-0002-8049-3663	Institute of Cancer Research start-up funds; Cancer Research UK (Cancer Research UK) [C2739/A22897]; Biotechnology and Biological Sciences Research Council (BBSRC CASE Studentship) [1650206]; National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Royal Marsden NHS Foundation Trust; Institute of Cancer Research [A62, A100, A101, A159]; Cancer Research UK [CEA A18052]; European Union FP7 [CIG 334261]; NIHR BRC at the Royal Marsden NHS Foundation Trust; BBSRC [1650206] Funding Source: UKRI	Institute of Cancer Research start-up funds; Cancer Research UK (Cancer Research UK); Biotechnology and Biological Sciences Research Council (BBSRC CASE Studentship)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Royal Marsden NHS Foundation Trust; Institute of Cancer Research; Cancer Research UK(Cancer Research UK); European Union FP7(European Commission); NIHR BRC at the Royal Marsden NHS Foundation Trust; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work has been funded by the Institute of Cancer Research start-up funds (to SRW), Cancer Research UK (Cancer Research UK grant number C2739/A22897 to VK, Cancer Research UK Cancer Therapeutics Unit), Biotechnology and Biological Sciences Research Council (BBSRC CASE Studentship 1650206 to LJ and CMI), by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Royal Marsden NHS Foundation Trust, and the Institute of Cancer Research (grant numbers A62, A100, A101, A159), Cancer Research UK (grant number CEA A18052) and the European Union FP7 (grant number CIG 334261) to NV. KE, AS, KK, NS, and DC acknowledge support from the NIHR BRC at the Royal Marsden NHS Foundation Trust, and the Institute of Cancer Research.	Ancrile B, 2007, GENE DEV, V21, P1714, DOI 10.1101/gad.1549407; Ancrile BB, 2008, MOL INTERV, V8, P22, DOI 10.1124/mi.8.1.6; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Blagg J, 2017, CANCER CELL, V32, P9, DOI 10.1016/j.ccell.2017.06.005; Boutin AT, 2017, GENE DEV, V31, P370, DOI 10.1101/gad.293449.116; Brown JD, 2014, MOL CELL, V56, P219, DOI 10.1016/j.molcel.2014.08.024; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gelfo V, 2016, ONCOTARGET, V7, P72167, DOI 10.18632/oncotarget.12354; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; Golay HG, 2014, EXPERT REV ANTICANC, V14, P869, DOI 10.1586/14737140.2014.928596; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Hickish T, 2017, LANCET ONCOL, V18, P192, DOI 10.1016/S1470-2045(17)30006-2; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X; Jamieson T, 2012, J CLIN INVEST, V122, P3127, DOI 10.1172/JCI61067; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Luo WJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-161; Ma YF, 2017, CLIN CANCER RES, V23, P2027, DOI 10.1158/1078-0432.CCR-16-0453; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; NAGARKATTI M, 1990, J IMMUNOL, V144, P4898; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Romano M, 2016, ANTICANCER RES, V36, P1447; Roumeliotis TI, 2017, CELL REP, V20, P2201, DOI 10.1016/j.celrep.2017.08.010; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Shouval DS, 2016, GASTROENTEROLOGY, V151, P1100, DOI 10.1053/j.gastro.2016.08.055; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091; Vlachogiannis G, 2018, SCIENCE, V359, P920, DOI 10.1126/science.aao2774; Whittaker SR, 2004, CANCER RES, V64, P262, DOI 10.1158/0008-5472.CAN-03-0110; Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470; Wislez M, 2006, CANCER RES, V66, P4198, DOI 10.1158/0008-5472.CAN-05-3842; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Zawistowski JS, 2017, CANCER DISCOV, V7, P302, DOI 10.1158/2159-8290.CD-16-0653; Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179	53	22	22	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1717	1733		10.1038/s41388-018-0554-z	http://dx.doi.org/10.1038/s41388-018-0554-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30353166	Green Published, hybrid			2022-12-17	WOS:000460423800011
J	Vargas, G; Bouchet, M; Bouazza, L; Reboul, P; Boyault, C; Gervais, M; Kan, C; Benetollo, C; Brevet, M; Croset, M; Mazel, M; Cayrefourcq, L; Geraci, S; Vacher, S; Pantano, F; Filipits, M; Driouch, K; Bieche, I; Gnant, M; Jacot, W; Aubin, JE; Duterque-Coquillaud, M; Alix-Panabieres, C; Clezardin, P; Bonnelye, E				Vargas, G.; Bouchet, M.; Bouazza, L.; Reboul, P.; Boyault, C.; Gervais, M.; Kan, C.; Benetollo, C.; Brevet, M.; Croset, M.; Mazel, M.; Cayrefourcq, L.; Geraci, S.; Vacher, S.; Pantano, F.; Filipits, M.; Driouch, K.; Bieche, I.; Gnant, M.; Jacot, W.; Aubin, J. E.; Duterque-Coquillaud, M.; Alix-Panabieres, C.; Clezardin, P.; Bonnelye, E.			ERR alpha promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors	ONCOGENE			English	Article							ESTROGEN-RELATED RECEPTOR; OSTEOCLAST DIFFERENTIATION; METASTASIS; ORPHAN; GAMMA; IDENTIFICATION; GENE; PGC-1-ALPHA; BIOMARKERS; ACTIVATOR	Bone is the most common metastatic site for breast cancer. Estrogen-related-receptor alpha (ERR alpha) has been implicated in cancer cell invasiveness. Here, we established that ERR alpha promotes spontaneous metastatic dissemination of breast cancer cells from primary mammary tumors to the skeleton. We carried out cohort studies, pharmacological inhibition, gain-of-function analyses in vivo and cellular and molecular studies in vitro to identify new biomarkers in breast cancer metastases. Meta-analysis of human primary breast tumors revealed that high ERR alpha expression levels were associated with bone but not lung metastases. ERR alpha expression was also detected in circulating tumor cells from metastatic breast cancer patients. ERR alpha overexpression in murine 4T1 breast cancer cells promoted spontaneous bone micro-metastases formation when tumor cells were inoculated orthotopically, whereas lung metastases occurred irrespective of ERR alpha expression level. In vivo, Rank was identified as a target for ERR alpha. That was confirmed in vitro in Rankl stimulated tumor cell invasion, in mTOR/pS6K phosphorylation, by transactivation assay, ChIP and bioinformatics analyses. Moreover, pharmacological inhibition of ERR alpha reduced primary tumor growth, bone micro-metastases formation and Rank expression in vitro and in vivo. Transcriptomic studies and meta-analysis confirmed a positive association between metastases and ERR alpha/RANK in breast cancer patients and also revealed a positive correlation between ERR alpha and BRCA1(mut) carriers. Taken together, our results reveal a novel ERR alpha/RANK axis by which ERR alpha in primary breast cancer promotes early dissemination of cancer cells to bone. These findings suggest that ERR alpha may be a useful therapeutic target to prevent bone metastases.	[Vargas, G.; Bouchet, M.; Bouazza, L.; Gervais, M.; Kan, C.; Brevet, M.; Croset, M.; Geraci, S.; Clezardin, P.; Bonnelye, E.] INSERM, UMR1033, Lyon, France; [Vargas, G.; Bouchet, M.; Bouazza, L.; Gervais, M.; Kan, C.; Benetollo, C.; Croset, M.; Geraci, S.; Clezardin, P.; Bonnelye, E.] Univ Lyon 1, Lyon, France; [Bouchet, M.] IGFL, Lyon, France; [Reboul, P.] Univ Lorraine, CNRS, UMR7365, Nancy, France; [Boyault, C.] Inst Adv Biosci, Grenoble, France; [Kan, C.] Univ Sydney, Ctr Canc Res, Sydney, NSW, Australia; [Benetollo, C.] CNRS, INSERM, U1028, UMR5292, Lyon, France; [Brevet, M.] Ctr Biol & Pathol Est, Bron, France; [Mazel, M.; Cayrefourcq, L.; Alix-Panabieres, C.] Inst Univ Rech Clin, EA2415, Montpellier, France; [Vacher, S.; Driouch, K.; Bieche, I.] Inst Curie, Dept Genet, Paris, France; [Pantano, F.] Univ Campus Biomed, I-00128 Rome, Italy; [Filipits, M.; Gnant, M.] Med Univ Vienna, Dept Surg, Vienna, Austria; [Filipits, M.; Gnant, M.] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria; [Jacot, W.] Montpellier Canc Inst, Montpellier, France; [Aubin, J. E.] Univ Toronto, Toronto, ON, Canada; [Duterque-Coquillaud, M.] Inst Biol Lille, CNRS, UMR8161, Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Lorraine; University of Sydney; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University Campus Bio-Medico - Rome Italy; Medical University of Vienna; Medical University of Vienna; Universite de Montpellier; University of Toronto; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Bonnelye, E (corresponding author), INSERM, UMR1033, Lyon, France.; Bonnelye, E (corresponding author), Univ Lyon 1, Lyon, France.	edith.bonnelye@inserm.fr	Croset, Martine/S-4784-2019; Gnant, Michael/AAN-7054-2020; Pantano, Francesco/D-8459-2012; Bonnelye, Edith/AAT-9134-2021; Clezardin, Philippe/M-8071-2014; REBOUL, Pascal/ABA-3774-2021	Gnant, Michael/0000-0003-1002-2118; Pantano, Francesco/0000-0002-2894-9686; Clezardin, Philippe/0000-0003-0149-4463; REBOUL, Pascal/0000-0003-3546-2152; Duterque-Coquillaud, Martine/0000-0003-3943-5629; VACHER, Sophie/0000-0002-0042-6023; Cayrefourcq, Laure/0000-0002-6124-7029; Bouazza, Lamia/0000-0001-8487-2655; Boyault, Cyril/0000-0001-9614-4292; Filipits, Martin/0000-0003-2847-4534; BREVET, Marie/0000-0003-2275-691X	National Center for Scientific Research (CNRS); National Institute of Health and Medical Research (INSERM); University of Lyon1, La Ligue Nationale (Drome), Inserm-Transfert; Labex DEVweCAN; French National Cancer Institute (INCa); Marie-Curie-Individual-Fellowship [655777-miR-OMeS]; CANCER-ID (FP7/2007-2013); EFPIA	National Center for Scientific Research (CNRS)(Centre National de la Recherche Scientifique (CNRS)); National Institute of Health and Medical Research (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Lyon1, La Ligue Nationale (Drome), Inserm-Transfert; Labex DEVweCAN; French National Cancer Institute (INCa)(Institut National du Cancer (INCA) France); Marie-Curie-Individual-Fellowship; CANCER-ID (FP7/2007-2013); EFPIA	This work was supported by the National Center for Scientific Research (CNRS) to EB, the National Institute of Health and Medical Research (INSERM), the University of Lyon1, La Ligue Nationale (Drome), Inserm-Transfert (EB). GV was supported by the Labex DEVweCAN, MG, MB by the French National Cancer Institute (INCa), CK by the Marie-Curie-Individual-Fellowship (655777-miR-OMeS). CAP, LC, and MM by CANCER-ID (FP7/2007-2013) and EFPIA.	Ariazi EA, 2002, CANCER RES, V62, P6510; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Audet-Walsh E, 2015, ACTA PHARMACOL SIN, V36, P51, DOI 10.1038/aps.2014.121; Bae S, 2017, J CLIN INVEST, V127, P2555, DOI 10.1172/JCI89935; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bartkowiak K, 2015, CANCER RES, V75, P5367, DOI 10.1158/0008-5472.CAN-14-3728; Benoit G, 2006, PHARMACOL REV, V58, P798, DOI 10.1124/pr.58.4.10; Bieche I, 2001, CANCER RES, V61, P1652; Blake ML, 2014, CLIN EXP METASTAS, V31, P233, DOI 10.1007/s10585-013-9624-3; Bonnelye E, 2013, J BONE MINER RES, V28, P225, DOI 10.1002/jbmr.1836; Bonnelye E, 2010, J MOL ENDOCRINOL, V45, P365, DOI 10.1677/JME-10-0024; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Brodowicz T, 2017, CANCER TREAT REV, V61, P23, DOI 10.1016/j.ctrv.2017.09.008; Campbell JP, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001363; Carnesecchi J, 2017, P NATL ACAD SCI USA, V114, P3909, DOI 10.1073/pnas.1614664114; Castet A, 2006, MOL ENDOCRINOL, V20, P1035, DOI 10.1210/me.2005-0227; Chaveroux C, 2013, CELL METAB, V17, P586, DOI 10.1016/j.cmet.2013.03.003; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; D'Oronzo S, 2017, J BONE ONCOL, V9, P1, DOI 10.1016/j.jbo.2017.09.001; David M, 2012, INT J ONCOL, V40, P1133, DOI 10.3892/ijo.2011.1309; Deblois G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12156; Deblois G, 2013, NAT REV CANCER, V13, P27, DOI 10.1038/nrc3396; Delhon I, 2009, ENDOCRINOLOGY, V150, P4463, DOI 10.1210/en.2009-0121; Delliaux C, 2018, CANCER LETT, V438, P32, DOI 10.1016/j.canlet.2018.08.027; Dirckx N, 2018, J CLIN INVEST, V128, P1087, DOI 10.1172/JCI97794; Dwyer MA, 2010, CANCER RES, V70, P9298, DOI 10.1158/0008-5472.CAN-10-0226; Fradet A, 2016, ONCOTARGET, V7, P77071, DOI 10.18632/oncotarget.12787; Fradet A, 2011, CANCER RES, V71, P5728, DOI 10.1158/0008-5472.CAN-11-1431; GARCIA CMS, 2014, BRAZ J VET PATHOL, V7, P158; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Hong EJ, 2013, P NATL ACAD SCI USA, V110, P17975, DOI 10.1073/pnas.1315319110; Ishibashi H, 2003, J CLIN ENDOCR METAB, V88, P2309, DOI 10.1210/jc.2002-021353; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Kan C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101674; Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118; PANTEL K, 1995, JNCI-J NATL CANCER I, V87, P1162, DOI 10.1093/jnci/87.15.1162; Patch RJ, 2011, J MED CHEM, V54, P788, DOI 10.1021/jm101063h; Rakha EA, 2008, J CLIN ONCOL, V26, P3153, DOI 10.1200/JCO.2007.15.5986; Salatino S, 2016, MOL ENDOCRINOL, V30, P809, DOI 10.1210/me.2016-1036; Santini D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019234; Schmid M, 2003, J CLIN ONCOL, V21, P984, DOI 10.1200/JCO.2003.01.138; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sigl V, 2016, CELL RES, V26, P761, DOI 10.1038/cr.2016.69; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Stein RA, 2009, J STEROID BIOCHEM, V114, P106, DOI 10.1016/j.jsbmb.2009.02.010; Sumi D, 2005, BIOCHEM BIOPH RES CO, V328, P165, DOI 10.1016/j.bbrc.2004.12.165; Takeno A, 2018, AM J PHYSIOL-ENDOC M, V314, pE115, DOI 10.1152/ajpendo.00159.2017; Tam IS, 2016, J STEROID BIOCHEM, V157, P13, DOI 10.1016/j.jsbmb.2015.06.009; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015; Willy PJ, 2004, P NATL ACAD SCI USA, V101, P8912, DOI 10.1073/pnas.0401420101; Wu DL, 2016, BBA-REV CANCER, V1866, P23, DOI 10.1016/j.bbcan.2016.06.001; Yevshin I, 2017, NUCLEIC ACIDS RES, V45, pD61, DOI 10.1093/nar/gkw951; Zeng R, 2015, J BONE MINER RES, V30, P2287, DOI 10.1002/jbmr.2584; Zhang LY, 2012, J CLIN PATHOL, V65, P36, DOI 10.1136/jclinpath-2011-200312; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	61	22	23	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					950	964		10.1038/s41388-018-0579-3	http://dx.doi.org/10.1038/s41388-018-0579-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30478447	Green Accepted, Green Published			2022-12-17	WOS:000458624900003
J	Zhao, L; Zhang, DJ; Shen, Q; Jin, M; Lin, ZY; Ma, H; Huang, SY; Zhou, PF; Wu, G; Zhang, T				Zhao, Lei; Zhang, Dejun; Shen, Qiong; Jin, Min; Lin, Zhenyu; Ma, Hong; Huang, Shaoyi; Zhou, Pengfei; Wu, Gang; Zhang, Tao			KIAA1199 promotes metastasis of colorectal cancer cells via microtubule destabilization regulated by a PP2A/stathmin pathway	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; PP2A INHIBITOR; POOR-PROGNOSIS; TUMOR INVASION; STATHMIN; OVEREXPRESSION; EXPRESSION; GROWTH; PHOSPHORYLATION; APOPTOSIS	Tumor metastasis is the main cause of death in advanced colorectal cancer. Our previous research showed that upregulation of KIAA1199 predicted poorer outcomes, and promoted cell motility and tumor metastasis in colorectal cancer, with the mechanisms not being fully elucidated. Here, we demonstrate that silencing of KIAA1199 results in reduced tumor metastasis in the orthotopic transplantation tumor model of colorectal cancer. Importantly, we find that KIAA1199 interacts with protein phosphatase 2A (PP2A) through the C-terminal domain and increases phosphatase activity of PP2A, which is essential for KIAA1199-mediated cell motility. Moreover, we identify stathmin, a microtubule-destabilizing protein, as a downstream of KIAA1199-PP2A complex. KIAA1199-induced dephosphorylation of stathmin results in microtubule destabilization and leads to enhanced cell motility. Furthermore, a microtubule-stabilizing drug paclitaxel could prevent KIAA1199-induced microtubule destabilization, and inhibit cell migration and invasion in vitro and tumor metastasis in vivo in colorectal cancer. Collectively, our study reveals that KIAA1199 promotes metastasis of colorectal cancer cells via microtubule destabilization regulated by a PP2A/stathmin pathway, and suggests that KIAA1199 may be a promising target for preventing metastasis in colorectal cancer.	[Zhao, Lei; Zhang, Dejun; Jin, Min; Lin, Zhenyu; Ma, Hong; Wu, Gang; Zhang, Tao] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Canc, Wuhan 430022, Hubei, Peoples R China; [Shen, Qiong] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Surg, Wuhan 430030, Hubei, Peoples R China; [Huang, Shaoyi; Zhou, Pengfei] Wuhan YZY Med Sci & Technol Co Ltd, Wuhan 430075, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Zhang, T (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Canc, Wuhan 430022, Hubei, Peoples R China.	taozhangxh@hust.edu.cn			National Natural Science Foundation of China [81702392, 81874061]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work is supported by the National Natural Science Foundation of China (81702392 to LZ and 81874061 to TZ). The authors acknowledge Liang Zeng, Jingjing Wu, and Yan Xue for technical assistance, and thank Dr. Shuangbing Xu for critical review of the paper. Data deposition The authors agree to submit the author's version of the accepted paper to public repositories.	Abe S, 2003, J HUM GENET, V48, P564, DOI 10.1007/s10038-003-0079-2; Ajay AK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-204; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Boudreau RM, 2007, CELL SIGNAL, V19, P139, DOI 10.1016/j.cellsig.2006.05.030; Byrne FL, 2014, ONCOGENE, V33, P882, DOI 10.1038/onc.2013.11; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chen J, 2013, ONCOGENE, V32, P1330, DOI 10.1038/onc.2012.141; Cortes J, 2012, BREAST CANCER RES TR, V133, P821, DOI 10.1007/s10549-011-1875-6; Cristobal I, 2012, HAEMATOL-HEMATOL J, V97, P543, DOI 10.3324/haematol.2011.050542; Duong FHT, 2014, CARCINOGENESIS, V35, P114, DOI 10.1093/carcin/bgt258; Etienne-Manneville S, 2013, ANNU REV CELL DEV BI, V29, P471, DOI 10.1146/annurev-cellbio-101011-155711; Evensen NA, 2013, JNCI-J NATL CANCER I, V105, P1402, DOI 10.1093/jnci/djt224; Fink SP, 2015, ONCOTARGET, V6, P30500, DOI 10.18632/oncotarget.5921; Jami MS, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-194; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jia SQ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175058; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Kaverina I, 2011, SEMIN CELL DEV BIOL, V22, P968, DOI 10.1016/j.semcdb.2011.09.017; Knight LM, 2015, J VIROL, V89, P35, DOI 10.1128/JVI.02317-14; Koga A, 2017, PANCREATOLOGY, V17, P115, DOI 10.1016/j.pan.2016.12.007; Kuang XY, 2015, ONCOTARGET, V6, P22227, DOI 10.18632/oncotarget.4276; Lee E, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.2; Li N, 2011, P NATL ACAD SCI USA, V108, P12851, DOI 10.1073/pnas.1017372108; Li W, 2010, CANCER SCI, V101, P1226, DOI 10.1111/j.1349-7006.2010.01523.x; Liu CY, 2016, ONCOTARGET, V7, P9135, DOI 10.18632/oncotarget.7035; Liu P, 2013, ONCOL REP, V29, P419, DOI 10.3892/or.2012.2157; Lu J, 2010, J NEUROSURG, V113, P225, DOI 10.3171/2009.11.JNS091272; Lu J, 2009, P NATL ACAD SCI USA, V106, P11697, DOI 10.1073/pnas.0905930106; Manna T, 2009, J BIOL CHEM, V284, P15640, DOI 10.1074/jbc.M900343200; Matsuzaki S, 2009, ANN SURG ONCOL, V16, P2042, DOI 10.1245/s10434-009-0469-6; McDermott MSJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-157; Mistry SJ, 1998, BIOCHEM J, V334, P23, DOI 10.1042/bj3340023; Nemunaitis J, 2012, EXPERT OPIN THER TAR, V16, P631, DOI 10.1517/14728222.2012.696101; Perrotti D, 2013, LANCET ONCOL, V14, pE229, DOI 10.1016/S1470-2045(12)70558-2; Rong BX, 2016, ONCOTARGET, V7, P78980, DOI 10.18632/oncotarget.12982; Schweyer S, 2007, J PATHOL, V213, P72, DOI 10.1002/path.2203; Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036; Shostak K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6232; Spano D, 2012, SEMIN CANCER BIOL, V22, P234, DOI 10.1016/j.semcancer.2012.03.006; Suh HN, 2016, SCI REP-UK, V6, DOI 10.1038/srep38273; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Xu J, 2015, INT J CLIN EXP PATHO, V8, P2909; Zhang DJ, 2017, INT J CANCER, V140, P2298, DOI 10.1002/ijc.30656; Zimmerman R, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.31	46	22	23	5	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					935	949		10.1038/s41388-018-0493-8	http://dx.doi.org/10.1038/s41388-018-0493-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30202098				2022-12-17	WOS:000458624900002
J	Lee, E; Ouzounova, M; Piranlioglu, R; Ma, MT; Guzel, M; Marasco, D; Chadli, A; Gestwicki, JE; Cowell, JK; Wicha, MS; Hassan, KA; Korkaya, H				Lee, Eunmi; Ouzounova, Maria; Piranlioglu, Raziye; Ma, Minh Thu; Guzel, Mustafa; Marasco, Daniela; Chadli, Ahmed; Gestwicki, Jason E.; Cowell, John K.; Wicha, Max S.; Hassan, Khaled A.; Korkaya, Hasan			The pleiotropic effects of TNF alpha in breast cancer subtypes is regulated by TNFAIP3/A20	ONCOGENE			English	Article							TUMOR-NECROSIS-FACTOR; ZINC-FINGER PROTEIN; NF-KAPPA-B; HSP70 PROTECTS; A20; CELLS; EXPRESSION; PROMOTES; BASAL; UBIQUITINATION	TNF alpha is a pleiotropic cytokine which fuels tumor cell growth, invasion, and metastasis in some malignancies, while in others it induces cytotoxic cell death. However, the molecular mechanism by which TNF alpha exerts its diverse effects on breast cancer subtypes remains elusive. Using in vitro assays and mouse xenografts, we show here that TNF alpha contributes to the aggressive properties of triple negative breast cancer (TNBC) cell lines via upregulation of TNFAIP3(A20). In a striking contrast, TNF alpha induces a potent cytotoxic cell death in luminal (ER+) breast cancer cell lines which fail to upregulate A20 expression. Overexpression of A20 not only protects luminal breast cancer cell lines from TNF alpha-induced cell death via inducing HSP70-mediated anti-apoptotic pathway but also promotes a robust EMT/CSC phenotype by activating the pStat3-mediated inflammatory signaling. Furthermore, A20 overexpression in luminal breast cancer cells induces aggressive metastatic properties in mouse xenografts via generating a permissive inflammatory microenvironment constituted by granulocytic-MDSCs. Collectively, our results reveal a mechanism by which A20 mediates pleiotropic effects of TNF alpha playing role in aggressive behaviors of TNBC subtype while its deficiency results in TNF alpha-induced apoptotic cell death in luminal breast cancer subtype.	[Lee, Eunmi; Ouzounova, Maria; Piranlioglu, Raziye; Ma, Minh Thu; Chadli, Ahmed; Cowell, John K.; Korkaya, Hasan] Augusta Univ, Dept Biochem & Mol Biol, Georgia Canc Ctr, Augusta, GA 30912 USA; [Guzel, Mustafa] Medipol Univ, Regenerat & Restorat Res Ctr REMER, Istanbul, Turkey; [Marasco, Daniela] Univ Naples Federico II, Dept Pharm, I-80134 Naples, Italy; [Gestwicki, Jason E.; Hassan, Khaled A.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Wicha, Max S.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Ouzounova, Maria] CRCL, Dept Canc Cell Plast, Lyon, France	University System of Georgia; Augusta University; Istanbul Medipol University; University of Naples Federico II; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie (CRCL)	Korkaya, H (corresponding author), Augusta Univ, Dept Biochem & Mol Biol, Georgia Canc Ctr, Augusta, GA 30912 USA.	hkorkaya@augusta.edu	Wicha, Max/AAE-7268-2019; Korkaya, Hasan/ABD-6282-2020; Ouzounova, Maria/B-7189-2014; Korkaya, Hasan/GRY-1016-2022	Korkaya, Hasan/0000-0002-0719-5862; Ouzounova, Maria/0000-0001-8934-3461; Piranlioglu, Raziye/0000-0003-2450-3887; Guzel, Prof. Mustafa/0000-0002-1423-0435	NATIONAL CANCER INSTITUTE [R35CA197585] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA197585] Funding Source: Medline; NINDS NIH HHS [R01 NS059690] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Bocchini Claire E, 2014, JAKSTAT, V3, pe970459, DOI 10.4161/21623988.2014.970459; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Catrysse L, 2014, TRENDS IMMUNOL, V35, P22, DOI 10.1016/j.it.2013.10.005; da Silva CG, 2013, HEPATOLOGY, V57, P2014, DOI 10.1002/hep.26197; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Diao JJ, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0453-2; Gabai VL, 2016, CANCER RES, V76, P5926, DOI 10.1158/0008-5472.CAN-16-0800; Hadisaputri YE, 2017, INT J ONCOL, V50, P1002, DOI 10.3892/ijo.2017.3869; Hartman ZC, 2013, CANCER RES, V73, P3470, DOI 10.1158/0008-5472.CAN-12-4524-T; Hjelmeland AB, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000319; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jia DY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.319; Kampinga HH, 2010, NAT REV MOL CELL BIO, V11, P579, DOI 10.1038/nrm2941; Kim G, 2015, ONCOGENE, V34, P671, DOI 10.1038/onc.2014.4; Komander D, 2008, BIOCHEM J, V409, P77, DOI 10.1042/BJ20071399; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kundrat L, 2010, J MOL BIOL, V395, P587, DOI 10.1016/j.jmb.2009.11.017; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee JH, 2017, NAT CELL BIOL, V19, P1260, DOI 10.1038/ncb3609; Mahat DB, 2016, MOL CELL, V62, P63, DOI 10.1016/j.molcel.2016.02.025; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Meng XZ, 2002, SHOCK, V17, P345, DOI 10.1097/00024382-200205000-00001; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Ouzounova M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14979; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Petrocca F, 2013, CANCER CELL, V24, P182, DOI 10.1016/j.ccr.2013.07.008; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Qian SB, 2006, NATURE, V440, P551, DOI 10.1038/nature04600; Rakha EA, 2009, CLIN CANCER RES, V15, P2302, DOI 10.1158/1078-0432.CCR-08-2132; Reeg S, 2016, FREE RADICAL BIO MED, V99, P153, DOI 10.1016/j.freeradbiomed.2016.08.002; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Van Molle W, 2002, IMMUNITY, V16, P685, DOI 10.1016/S1074-7613(02)00310-2; Vereecke L, 2009, TRENDS IMMUNOL, V30, P383, DOI 10.1016/j.it.2009.05.007; Wang YF, 2015, MOBILE SOCIAL NETWORKING AND COMPUTING: A MULTIDISCIPLINARY INTEGRATED PERSPECTIVE, P3; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Zhong HH, 2016, CANCER RES, V76, P480, DOI 10.1158/0008-5472.CAN-15-0883	43	22	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					469	482		10.1038/s41388-018-0472-0	http://dx.doi.org/10.1038/s41388-018-0472-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30166590	Green Accepted			2022-12-17	WOS:000456589800002
J	Kim, IK; McCutcheon, JN; Rao, GH; Liu, SV; Pommier, Y; Skrzypski, M; Zhang, YW; Giaccone, G				Kim, In-Kyu; McCutcheon, Justine N.; Rao, Guanhua; Liu, Stephen V.; Pommier, Yves; Skrzypski, Marcin; Zhang, Yu-Wen; Giaccone, Giuseppe			Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer	ONCOGENE			English	Article							ELEMENT-BINDING-PROTEIN; TUMOR-SUPPRESSOR GENE; MEK INHIBITOR; METHYLTRANSFERASE; IDENTIFICATION; CHEMOTHERAPY; TRANSCRIPTION; EXPRESSION; CARCINOMA; EVOLUTION	Resistance to chemotherapy remains a critical barrier to effective cancer treatment. Although cisplatin is one of the most commonly used chemotherapeutic agents in the treatment of non-small cell lung cancer (NSCLC), mechanisms of resistance to this drug are not fully understood. Here, we report a novel cisplatin-resistance mechanism involving SET Domain Containing 2 (SETD2), a histone H3 lysine 36 (H3K36) trimethyltransferase, and cAMP-responsive element-binding protein 1 (CREB1). A549 cells selected in vivo to give brain metastases exhibited cisplatin resistance and decreased expression of phosphorylated CREB1. Next-generation sequencing (NGS) analysis identified a missense mutation in SETD2 (p.T1171K), and we demonstrated that SETD2-mediated trimethylation of H3K36 (H3K36me3) and CREB1 phosphorylation are critical for cellular sensitivity to cisplatin. Moreover, we showed that suppression of SETD2 or CREB1 and ectopic expression of mutant SETD2 conferred cisplatin resistance through inhibition of H3K36me3 and ERK activation in NSCLC cells. Our results provide evidence that SETD2 and CREB1 contribute to cisplatin cytotoxicity via regulation of the ERK signaling pathway, and their inactivation may lead to cisplatin resistance.	[Kim, In-Kyu; McCutcheon, Justine N.; Rao, Guanhua; Liu, Stephen V.; Zhang, Yu-Wen; Giaccone, Giuseppe] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; [Pommier, Yves] NCI, Lab Mol Pharmacol, Dev Therapeut Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; [Skrzypski, Marcin] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fahrenheit Universities; Medical University Gdansk	Zhang, YW; Giaccone, G (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA.	yz457@georgetown.edu; gg496@georgetown.edu	Liu, Stephen/E-5688-2019	Liu, Stephen/0000-0002-4852-3914; Skrzypski, Marcin/0000-0002-4391-4318; Kim, In-Kyu/0000-0002-8427-8311	NATIONAL CANCER INSTITUTE [ZIABC006150] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA BC006150] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abol-Enein H, 2003, LANCET, V361, P1927; Al Sarakbi W, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-290; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005; Choi EB, 2016, ONCOGENE, V35, P4569, DOI 10.1038/onc.2016.3; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Crans-Vargas HN, 2002, BLOOD, V99, P2617, DOI 10.1182/blood.V99.7.2617; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Duns G, 2010, CANCER RES, V70, P4287, DOI 10.1158/0008-5472.CAN-10-0120; Fontebasso AM, 2013, ACTA NEUROPATHOL, V125, P659, DOI 10.1007/s00401-013-1095-8; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Giaccone G, 2018, LANCET ONCOL, V19, P347, DOI 10.1016/S1470-2045(18)30062-7; Hainsworth JD, 2010, J THORAC ONCOL, V5, P1630, DOI 10.1097/JTO.0b013e3181e8b3a3; Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jiang MR, 2008, BBA-MOL CELL RES, V1783, P1055, DOI 10.1016/j.bbamcr.2008.02.007; Jo SK, 2005, KIDNEY INT, V67, P458, DOI 10.1111/j.1523-1755.2005.67102.x; Kachnic LA, 2010, CANCER LETT, V292, P73, DOI 10.1016/j.canlet.2009.11.009; Kovach SJ, 2006, J CELL PHYSIOL, V206, P411, DOI 10.1002/jcp.20474; Maione P, 2015, THER ADV MED ONCOL, V7, P263, DOI 10.1177/1758834015595048; Mar BG, 2017, BLOOD, V130, P2631, DOI 10.1182/blood-2017-03-775569; Mar BG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4469; Mizumoto Y, 2007, CANCER SCI, V98, P652, DOI 10.1111/j.1349-7006.2007.00445.x; Moon YW, 2015, CELL DEATH DIFFER, V22, P1341, DOI 10.1038/cdd.2014.228; Nagao K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049926; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; Ossovskaya V, 2010, GENES CANC, V1, P812, DOI 10.1177/1947601910383418; Park IY, 2016, CELL, V166, P950, DOI 10.1016/j.cell.2016.07.005; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Rao GH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06128-9; ROSENBERG B, 1969, NATURE, V222, P385, DOI 10.1038/222385a0; Sandler AB, 2000, J CLIN ONCOL, V18, P122, DOI 10.1200/JCO.2000.18.1.122; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Seo HS, 2008, CANCER RES, V68, P6065, DOI 10.1158/0008-5472.CAN-07-5376; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; Shenoy K, 2009, CANCER RES, V69, P1941, DOI 10.1158/0008-5472.CAN-08-1996; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Sun XJ, 2005, J BIOL CHEM, V280, P35261, DOI 10.1074/jbc.M504012200; Verlinsky Y, 2001, JAMA-J AM MED ASSOC, V285, P3130, DOI 10.1001/jama.285.24.3130; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wu D, 2007, ONCOGENE, V26, P5070, DOI 10.1038/sj.onc.1210316; Xiang W, 2015, ONCOTARGET, V6, P4066, DOI 10.18632/oncotarget.2926; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang R, 2008, CLIN CANCER RES, V14, P6396, DOI 10.1158/1078-0432.CCR-07-5113; Yu ZY, 2010, AM J PHYSIOL-RENAL, V298, pF617, DOI 10.1152/ajprenal.00636.2009; Zhang YL, 2014, CELL REP, V8, P1989, DOI 10.1016/j.celrep.2014.08.031; Zhu XF, 2014, NAT GENET, V46, P287, DOI 10.1038/ng.2894	49	22	25	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					180	193		10.1038/s41388-018-0429-3	http://dx.doi.org/10.1038/s41388-018-0429-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30093630	Green Accepted			2022-12-17	WOS:000455366700003
J	Yuan, JM; Ng, WH; Lam, PYP; Wang, Y; Xia, HP; Yap, JJ; Guan, SP; Lee, ASG; Wang, M; Baccarini, M; Hu, JC				Yuan, Jimin; Ng, Wan Hwa; Lam, Paula Y. P.; Wang, Yu; Xia, Hongping; Yap, Jiajun; Guan, Shou Ping; Lee, Ann S. G.; Wang, Mei; Baccarini, Manuela; Hu, Jiancheng			The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants	ONCOGENE			English	Article							LANGERHANS CELL HISTIOCYTOSIS; B-RAF; PROTEIN-KINASES; WILD-TYPE; ACTIVATION MECHANISM; INHIBITOR RESISTANCE; METASTATIC MELANOMA; MAPK PATHWAY; GENE FUSIONS; C-RAF	Although extensively studied for three decades, the molecular mechanisms that regulate the RAF/MEK/ERK kinase cascade remain ambiguous. Recent studies identified the dimerization of RAF as a key event in the activation of this cascade. Here, we show that in-frame deletions in the beta 3-alpha C loop activate ARAF as well as BRAF and other oncogenic kinases by enforcing homodimerization. By characterizing these RAF mutants, we find that ARAF has less allosteric and catalytic activity than the other two RAF isoforms, which arises from its non-canonical APE motif. Further, these RAF mutants exhibit a strong oncogenic potential, and a differential inhibitor resistance that correlates with their dimer affinity. Using these unique mutants, we demonstrate that active RAFs, including the BRAF(V600E) mutant, phosphorylate MEK in a dimer-dependent manner. This study characterizes a special category of oncogenic kinase mutations, and elucidates the molecular basis that underlies the differential ability of RAF isoforms to stimulate MEK-ERK pathway. Further, this study reveals a unique catalytic feature of RAF family kinases that can be exploited to control their activities for cancer therapies.	[Yuan, Jimin; Ng, Wan Hwa; Lam, Paula Y. P.; Wang, Yu; Xia, Hongping; Yap, Jiajun; Guan, Shou Ping; Hu, Jiancheng] Div Cellular & Mol Res, Singapore, Singapore; [Lam, Paula Y. P.; Wang, Mei; Hu, Jiancheng] Duke NUS Med Sch, Canc & Stem Cell Program, 8 Coll Rd, Singapore 169857, Singapore; [Lee, Ann S. G.] Natl Canc Ctr Singapore, Div Med Sci, 11 Hosp Dr, Singapore 169610, Singapore; [Lee, Ann S. G.] Duke NUS Med Sch, Off Clin & Acad Fac Affairs, 8 Coll Rd, Singapore 169857, Singapore; [Lee, Ann S. G.] Natl Univ Singapore, Dept Physiol, 2 Med Dr, Singapore 117597, Singapore; [Baccarini, Manuela] Univ Vienna, Max F Perutz Labs, Doktor Bohr Gasse 9, A-1030 Vienna, Austria	National University of Singapore; National Cancer Centre Singapore (NCCS); National University of Singapore; National University of Singapore; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Hu, JC (corresponding author), Div Cellular & Mol Res, Singapore, Singapore.; Hu, JC (corresponding author), Duke NUS Med Sch, Canc & Stem Cell Program, 8 Coll Rd, Singapore 169857, Singapore.	hu.jiancheng@nccs.com.sg	XIA, HONGPING/AAK-7100-2020; Hu, Jiancheng/ABE-8133-2021; Baccarini, Manuela/B-6481-2014	Hu, Jiancheng/0000-0003-1615-0030; Wang, Mei/0000-0001-6887-6840; Baccarini, Manuela/0000-0002-3033-391X	NCCRF startup grant (NCCRF-SUG-JH); NCCRF bridging grant [NCCRF-YR2016-JUL-BG1]; NMRC seeding grants [NCCSPG-YR2015-JUL-14, NCCSPG-YR2016-JAN-17]; Duke-NUS Khoo Bridge Funding Award [Duke-NUS-KBrFA/2017/0003]; Asia Fund Cancer Research [AFCR2017/2019-JH]; SHF Research Grant [SHF/FG692S/2016]	NCCRF startup grant (NCCRF-SUG-JH); NCCRF bridging grant; NMRC seeding grants; Duke-NUS Khoo Bridge Funding Award; Asia Fund Cancer Research; SHF Research Grant	We thank the laboratories of Dr. Hui, Dr. Sabapathy, Dr. Virshup, and Dr. Anand for their help in experimental technologies. We also thank Dr. Andrey Shaw and Dr. Susan Taylor for their assistances. This study is supported by NCCRF startup grant (NCCRF-SUG-JH), NCCRF bridging grant (NCCRF-YR2016-JUL-BG1), NMRC seeding grants (NCCSPG-YR2015-JUL-14 and NCCSPG-YR2016-JAN-17), and Duke-NUS Khoo Bridge Funding Award (Duke-NUS-KBrFA/2017/0003), Asia Fund Cancer Research (AFCR2017/2019-JH) and SHF Research Grant (SHF/FG692S/2016).	Baccarini M, 2005, FEBS LETT, V579, P3271, DOI 10.1016/j.febslet.2005.03.024; Beenstock J, 2016, TRENDS BIOCHEM SCI, V41, P938, DOI 10.1016/j.tibs.2016.08.006; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chakraborty R, 2016, BLOOD, V128, P2533, DOI 10.1182/blood-2016-08-733790; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Cseh B, 2014, FEBS LETT, V588, P2398, DOI 10.1016/j.febslet.2014.06.025; Desideri E, 2015, CELL, V161, P967, DOI 10.1016/j.cell.2015.04.045; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Diedrich B, 2017, EMBO J, V36, P646, DOI 10.15252/embj.201694732; Estep AL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001279; Fabrini R, 2009, BIOCHEMISTRY-US, V48, P10473, DOI 10.1021/bi901238t; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Galabova-Kovacs G, 2006, P NATL ACAD SCI USA, V103, P1325, DOI 10.1073/pnas.0507399103; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Haling JR, 2014, CANCER CELL, V26, P402, DOI 10.1016/j.ccr.2014.07.007; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hibino K, 2009, BIOPHYS J, V97, P1277, DOI 10.1016/j.bpj.2009.05.048; Hu JC, 2008, MOL IMMUNOL, V45, P1825, DOI 10.1016/j.molimm.2007.11.002; Hu J, 2015, MOL CELL BIOL, V35, P264, DOI 10.1128/MCB.00943-14; Hu JC, 2013, CELL, V154, P1036, DOI 10.1016/j.cell.2013.07.046; Hu JC, 2011, P NATL ACAD SCI USA, V108, P6067, DOI 10.1073/pnas.1102554108; Jain P, 2017, ONCOGENE, V36, P6348, DOI 10.1038/onc.2017.276; Jesenberger V, 2001, J EXP MED, V193, P353, DOI 10.1084/jem.193.3.353; Jin T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01274-0; Kornev AP, 2006, P NATL ACAD SCI USA, V103, P17783, DOI 10.1073/pnas.0607656103; Kumar-Sinha C, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0252-1; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Lavoie H, 2014, TRENDS BIOCHEM SCI, V39, P475, DOI 10.1016/j.tibs.2014.08.004; Luker KE, 2004, P NATL ACAD SCI USA, V101, P12288, DOI 10.1073/pnas.0404041101; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Mooz J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005484; Nan XL, 2015, P NATL ACAD SCI USA, V112, P7996, DOI 10.1073/pnas.1509123112; Nelson DS, 2014, BLOOD, V123, P3152, DOI 10.1182/blood-2013-06-511139; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Rebocho AP, 2013, ONCOGENE, V32, P3207, DOI 10.1038/onc.2012.330; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Shaw AS, 2014, MOL CELL BIOL, V34, P1538, DOI 10.1128/MCB.00057-14; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Taylor SS, 2013, BIOCHEM SOC T, V41, P981, DOI 10.1042/BST20130120; Taylor SS, 2011, TRENDS BIOCHEM SCI, V36, P65, DOI 10.1016/j.tibs.2010.09.006; Thevakumaran N, 2015, NAT STRUCT MOL BIOL, V22, P37, DOI 10.1038/nsmb.2924; Valley CC, 2015, MOL BIOL CELL, V26, P4087, DOI 10.1091/mbc.E15-05-0269; Wan LX, 2017, CANCER DISCOV, V7, P424, DOI 10.1158/2159-8290.CD-16-0647; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang XX, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005147; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Yang J, 2012, J MOL BIOL, V415, P666, DOI 10.1016/j.jmb.2011.11.035	61	22	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5719	5734		10.1038/s41388-018-0365-2	http://dx.doi.org/10.1038/s41388-018-0365-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29930381	hybrid, Green Published, Green Submitted			2022-12-17	WOS:000448288200002
J	Lee, S; Axelsen, TV; Jesse, N; Pedersen, SF; Vahi, P; Boedtkjer, E				Lee, Soojung; Axelsen, Trine, V; Jesse, Nicolai; Pedersen, Stine F.; Vahi, Pernille; Boedtkjer, Ebbe			Na+,HCO3--cotransporter NBCn1 (Slc4a7) accelerates ErbB2-induced breast cancer development and tumor growth in mice	ONCOGENE			English	Article							INTRACELLULAR PH TRANSIENTS; EXPRESSION; CELLS; NHE1; MIGRATION; NA+; EPITHELIUM; EVOLUTION; ARTERIES; HYPOXIA	Metabolic acid production challenges cellular pH homeostasis in solid cancer tissue, and mechanisms of net acid extrusion represent promising new targets for breast cancer therapy. Here, we used genetically engineered mice to investigate the contribution of the Na+,HCO3--cotransporter NBCn1 (Slc4a7) to intracellular acid-base regulation in ErbB2-induced breast cancer tissue and the consequences of NBCn1 knockout for breast tumor development and growth. We demonstrate an approximately 2-fold increase of NBCn1 protein abundance in ErbB2-induced breast cancer tissue compared to normal breast tissue despite a 4-fold decrease in the NBCn1 mRNA level. In congruence, we show that NBCn1 facilitates net acid extrusion and elevates steady-state intracellular pH in breast cancer tissue. Disruption of NBCn1 expression delayed ErbB2-induced breast carcinogenesis from a median tumor-free survival of 9.5 months in wild-type mice to 12 months in NBCn1-knockout mice and decelerated the tumor growth rate by approximately 1/3. Glycolytic metabolism-evaluated based on the interstitial concentrations of lactate and glucose measured in microdialysates-was increased in breast cancer tissue compared to normal breast tissue, but was unaffected by NBCn1 knockout. Disruption of NBCn1 expression inhibited cell proliferation-evaluated by staining for the proliferative marker Ki67-particularly in central tumor areas with predicted increase in acid loading from glycolytic metabolism. In conclusion, NBCn1 regulates intracellular pH in ErbB2-induced breast cancer tissue by providing a pathway for cellular uptake of HCO3-, which can neutralize metabolic acidic waste products. Disrupting NBCn1 expression delays ErbB2-induced breast cancer development, inhibits cancer cell proliferation, and decelerates tumor growth.	[Lee, Soojung; Axelsen, Trine, V; Jesse, Nicolai; Boedtkjer, Ebbe] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Pedersen, Stine F.] Univ Copenhagen, Dept Biol, Copenhagen, Denmark; [Vahi, Pernille] Aarhus Univ Hosp, Dept Pathol, Aarhus, Denmark	Aarhus University; University of Copenhagen; Aarhus University	Boedtkjer, E (corresponding author), Aarhus Univ, Dept Biomed, Aarhus, Denmark.	eb@biomed.au.dk	Pedersen, Stine Falsig/O-1133-2019; Boedtkjer, Ebbe/O-8449-2019	Pedersen, Stine Falsig/0000-0002-3044-7714; Boedtkjer, Ebbe/0000-0002-5078-9279	Danish Cancer Society [R42-A4273]; Novo Nordisk Foundation [NNF13OC0007393, NNF15OC0017344, NNF16OC0023194]; Danish Council for Independent Research [7025-00050B]	Danish Cancer Society(Danish Cancer Society); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish Council for Independent Research(Det Frie Forskningsrad (DFF))	This work was supported by the Danish Cancer Society (grant no. R42-A4273 to EB), the Novo Nordisk Foundation (grant no. NNF13OC0007393 and NNF15OC0017344 to EB and grant no. NNF16OC0023194 to SFP), and the Danish Council for Independent Research (grant no. 7025-00050B to EB).	Aalkjaer C, 2014, COMPR PHYSIOL, V4, P1605, DOI 10.1002/cphy.c130005; Amith SR, 2017, SEMIN CANCER BIOL, V43, P35, DOI 10.1016/j.semcancer.2017.01.004; Andersen AP, 2018, INT J CANCER, V142, P2529, DOI 10.1002/ijc.31276; Boedtkjer E, 2006, CIRC RES, V98, P515, DOI 10.1161/01.RES.0000204750.04971.76; Boedtkjer E, 2012, CURR PHARM DESIGN, V18, P1345, DOI 10.2174/138161212799504830; Boedtkjer E, 2008, AM J PHYSIOL-CELL PH, V294, pC591, DOI 10.1152/ajpcell.00281.2007; Boedtkjer E, 2016, CARDIOVASC RES, V111, P227, DOI 10.1093/cvr/cvw079; Boedtkjer E, 2013, INT J CANCER, V132, P1288, DOI 10.1002/ijc.27782; Boedtkjer E, 2011, CIRCULATION, V124, P1819, DOI 10.1161/CIRCULATIONAHA.110.015974; Bonde L, 2017, ACTA PHYSIOL, V219, P227, DOI 10.1111/apha.12685; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Bouzinova EV, 2005, AM J PHYSIOL-CELL PH, V289, pC1448, DOI 10.1152/ajpcell.00313.2005; Brockton NT, 2012, ORAL ONCOL, V48, P615, DOI 10.1016/j.oraloncology.2012.01.018; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Counillon L, 2016, BBA-MOL CELL RES, V1863, P2465, DOI 10.1016/j.bbamcr.2016.02.018; Damkier HH, 2006, AM J PHYSIOL-HEART C, V290, pH172, DOI 10.1152/ajpheart.00713.2005; Flinck M, 2018, ACTA PHYSIOL, V223, DOI 10.1111/apha.13068; Froelunde AS, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0952-8; Gatenby RA, 2007, BRIT J CANCER, V97, P646, DOI 10.1038/sj.bjc.6603922; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gerweck LE, 1996, CANCER RES, V56, P1194; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gorbatenko A, 2016, BIOCHEM J, V473, P4027, DOI 10.1042/BCJ20160054; Gorbatenko A, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00130; Gorbatenko A, 2014, FASEB J, V28, P350, DOI 10.1096/fj.13-233288; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Helmlinger G, 2002, CLIN CANCER RES, V8, P1284; Landis MD, 2006, ONCOGENE, V25, P3325, DOI 10.1038/sj.onc.1209365; Larsen AM, 2012, CHEMMEDCHEM, V7, P1808, DOI 10.1002/cmdc.201200335; Lauritzen G, 2010, EXP CELL RES, V316, P2538, DOI 10.1016/j.yexcr.2010.06.005; Lee S, 2016, ONCOGENE, V35, P2112, DOI 10.1038/onc.2015.273; Lee S, 2015, PFLUG ARCH EUR J PHY, V467, P367, DOI 10.1007/s00424-014-1524-0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McIntyre A, 2016, CANCER RES, V76, P3744, DOI 10.1158/0008-5472.CAN-15-1862; Morais-Santos F, 2015, ONCOTARGET, V6, P19177, DOI 10.18632/oncotarget.3910; Parakh S, 2017, CANCER TREAT REV, V59, P1, DOI 10.1016/j.ctrv.2017.06.005; Parks SK, 2015, J CELL PHYSIOL, V230, P1954, DOI 10.1002/jcp.24930; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; Pedersen SF, 2006, PFLUG ARCH EUR J PHY, V452, P249, DOI 10.1007/s00424-006-0044-y; Rasmussen JK, 2018, J CEREBR BLOOD F MET, V38, P492, DOI 10.1177/0271678X17699224; Rodriguez-Enriquez S, 2008, J CELL PHYSIOL, V216, P189, DOI 10.1002/jcp.21392; Romero Q, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-341; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Stransky L, 2016, PHYSIOL REV, V96, P1071, DOI 10.1152/physrev.00035.2015; Swietach P, 2008, J BIOL CHEM, V283, P20473, DOI 10.1074/jbc.M801330200; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; VAUPEL P, 1989, CANCER RES, V49, P6449	48	22	22	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5569	5584		10.1038/s41388-018-0353-6	http://dx.doi.org/10.1038/s41388-018-0353-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29907770				2022-12-17	WOS:000446991200007
J	Heinicke, U; Haydn, T; Kehr, S; Vogler, M; Fulda, S				Heinicke, Ulrike; Haydn, Tinka; Kehr, Sarah; Vogler, Meike; Fulda, Simone			BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis	ONCOGENE			English	Article							MITOCHONDRIAL PATHWAY; ANTITUMOR-ACTIVITY; CANCER-THERAPY; MCL-1; JNJ-26481585; DISCOVERIES; RESISTANCE; CHILDREN; LEUKEMIA; OVERCOME	BH3 mimetics are emerging novel anticancer therapeutics that potently and specifically inhibit antiapoptotic BCL-2 proteins and thereby induce cell death in many cancer entities. Previously, we demonstrated that JNJ-26481585 (JNJ), a second-generation histone deacetylase inhibitor (HDACI), engages mitochondrial apoptosis via upregulation of several BH3-only proteins. In the present study, we describe synergistic interactions of JNJ with BH3 mimetics (i.e. ABT-737, ABT-199) in rhabdomyosarcoma (RMS) cells. Importantly, JNJ synergizes with ABT-199 to trigger apoptosis in primary-derived RMS cells isolated from tumor samples, underlining the translational importance of combining these compounds and their potential to improve cancer therapy. Importantly, JNJ/ABT-199 cotreatment also significantly inhibits long-term survival of RMS cells. Mechanistically, JNJ increases expression levels of the BH3-only protein BIM, while exposure to ABT-199 displaces BIM from BCL-2 and shuttles BIM to MCL-1, which also constitutively sequesters NOXA. Both BIM and NOXA contribute to JNJ/ABT-199-mediated cell death, as individual knockdown of NOXA or BIM significantly prevents cell death. Further, JNJ and ABT-199 act in concert to activate BAK and BAX, resulting in loss of the mitochondrial membrane potential (MMP) and caspase activation. These events are required for JNJ/ABT-199-mediated apoptosis, since BAK or BAX silencing or inhibition of caspases significantly protects from JNJ/ABT-199-induced cell death. Rescue experiments demonstrate that overexpression of MCL-1, but not overexpression of BCL-2, blocks JNJ/ABT-199-induced apoptosis. In conclusion, this study provides the first demonstration of ABT-199-induced priming, which sensitizes RMS cells to HDACI, such as JNJ, by engaging mitochondrial apoptosis, highlighting that BH3 mimetics show great promise for the treatment of RMS.	[Heinicke, Ulrike; Haydn, Tinka; Kehr, Sarah; Vogler, Meike; Fulda, Simone] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Germany; [Haydn, Tinka; Fulda, Simone] German Canc Consortium DKTK Partner Site, Frankfurt, Germany; [Haydn, Tinka; Fulda, Simone] German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ)	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Germany.; Fulda, S (corresponding author), German Canc Consortium DKTK Partner Site, Frankfurt, Germany.; Fulda, S (corresponding author), German Canc Res Ctr, Heidelberg, Germany.	simone.fulda@kgu.de		Vogler, Meike/0000-0003-2650-586X; Fulda, Simone/0000-0002-0459-6417	BMBF; Deutsche Krebshilfe; Deutsche Kinderkrebsstiftung; Medical Faculty, Goethe-University Frankfurt	BMBF(Federal Ministry of Education & Research (BMBF)); Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Kinderkrebsstiftung; Medical Faculty, Goethe-University Frankfurt	We thank D. Bruecher for expert technical assistance and C. Hugenberg for excellent secretarial assistance. This work has been partially supported by grants from the BMBF, the Deutsche Krebshilfe and the Deutsche Kinderkrebsstiftung (to SF) and a grant from the Medical Faculty, Goethe-University Frankfurt (to MV).	Arts J, 2009, CLIN CANCER RES, V15, P6841, DOI 10.1158/1078-0432.CCR-09-0547; Ashkenazi A, 2017, NAT REV DRUG DISCOV, V16, P273, DOI 10.1038/nrd.2016.253; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Carol H, 2014, PEDIATR BLOOD CANCER, V61, P245, DOI 10.1002/pbc.24724; Carter BZ, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.512.512; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Choudhary GS, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.525; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dagher R, 1999, Oncologist, V4, P34; Dantonello TM, 2009, J CLIN ONCOL, V27, P1446, DOI 10.1200/JCO.2007.15.0466; Delbridge ARD, 2016, NAT REV CANCER, V16, P99, DOI 10.1038/nrc.2015.17; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dewson Grant, 2015, Cold Spring Harb Protoc, V2015, P481, DOI 10.1101/pdb.prot086470; Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; Heinicke U, 2016, ONCOGENE, V35, P3729, DOI 10.1038/onc.2015.440; Heinicke U, 2015, ONCOTARGET, V6, P37836, DOI 10.18632/oncotarget.6097; Heinicke U, 2014, CANCER LETT, V351, P50, DOI 10.1016/j.canlet.2014.04.021; Hugle M, 2015, CELL DEATH DIFFER, V22, P1946, DOI 10.1038/cdd.2015.59; Khaw SL, 2014, LEUKEMIA, V28, P1207, DOI 10.1038/leu.2014.1; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Matthews GM, 2012, ADV CANCER RES, V116, P165, DOI 10.1016/B978-0-12-394387-3.00005-7; Michels J, 2014, BIOCHEM PHARMACOL, V92, P55, DOI 10.1016/j.bcp.2014.07.029; MILLER RW, 1995, CANCER, V75, P395, DOI 10.1002/1097-0142(19950101)75:1+<395::AID-CNCR2820751321>3.0.CO;2-W; Niu XJ, 2016, CLIN CANCER RES, V22, P4440, DOI 10.1158/1078-0432.CCR-15-3057; Pan RQ, 2014, CANCER DISCOV, V4, P362, DOI 10.1158/2159-8290.CD-13-0609; Pazzaglia L, 2009, HISTOL HISTOPATHOL, V24, P61, DOI 10.14670/HH-24.61; Peirs S, 2014, BLOOD, V124, P3738, DOI 10.1182/blood-2014-05-574566; Phillips DC, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.88; Portell CA, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.509.509; Preuss E, 2013, J BIOL CHEM, V288, P35287, DOI 10.1074/jbc.M113.495986; Sarosiek KA, 2016, FEBS J, V283, P3523, DOI 10.1111/febs.13714; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Tong JS, 2017, CANCER RES, V77, P2512, DOI 10.1158/0008-5472.CAN-16-3242	39	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5325	5339		10.1038/s41388-018-0212-5	http://dx.doi.org/10.1038/s41388-018-0212-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29858601				2022-12-17	WOS:000445759700006
J	Klein, ME; Dickson, MA; Antonescu, C; Qin, LX; Dooley, SJ; Barlas, A; Manova, K; Schwartz, GK; Crago, AM; Singer, S; Koff, A; Tap, WD				Klein, Mary E.; Dickson, Mark A.; Antonescu, Cristina; Qin, Li-Xuan; Dooley, Scott J.; Barlas, Afsar; Manova, Katia; Schwartz, Gary K.; Crago, Aimee M.; Singer, Samuel; Koff, Andrew; Tap, William D.			PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence	ONCOGENE			English	Article							BREAST-CANCER; DEDIFFERENTIATED LIPOSARCOMA; TUMOR-GROWTH; PALBOCICLIB; COMPLEXES; CDK6; SUPPRESSION; PROGRESSION; SURVIVAL; SARCOMA	CDK4/6 inhibitors are being used to treat a variety of human malignancies. In well-differentiated and dedifferentiated liposarcoma their clinical promise is associated with their ability to downregulate the MDM2 protein. The downregulation of MDM2 following treatment with CDK4/6 inhibitors also induces many cultured tumor cell lines derived from different types of malignancies to progress from quiescence into senescence. Here we used cultured human cell lines and defined a role for PDLIM7 and CDH18, regulating MDM2 protein in CDK4/6 inhibitor-treated cells. Materials from our previous phase II trials with palbociclib were then used to demonstrate that expression of CDH18 protein was associated with response, measured as both progression-free survival and overall survival. This supports the hypothesis that the biologic transition from quiescence to senescence has clinical relevance for this class of drugs.	[Klein, Mary E.; Koff, Andrew] Mem Sloan Kettering Canc Ctr, Louis V Gerstner Grad Sch Biomed Sci, 1275 York Ave, New York, NY 10065 USA; [Klein, Mary E.; Koff, Andrew] Mem Sloan Kettering Canc Ctr, Programs Mol, 1275 York Ave, New York, NY 10065 USA; [Dickson, Mark A.; Tap, William D.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA; [Dickson, Mark A.; Tap, William D.] Weill Cornell Med Coll, Dept Med, New York, NY 10021 USA; [Antonescu, Cristina] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Qin, Li-Xuan] Mem Sloan Kettering Canc Ctr, Dept Epidemiol, 1275 York Ave, New York, NY 10065 USA; [Qin, Li-Xuan] Mem Sloan Kettering Canc Ctr, Dept Biostat, 1275 York Ave, New York, NY 10065 USA; [Dooley, Scott J.] Univ Penn, Perelman Sch Med, Dept Ophthalmol, Ctr Adv Retinal & Ocular Therapeut, Philadelphia, PA 19104 USA; [Barlas, Afsar; Manova, Katia] Mem Sloan Kettering Canc Ctr, Dev Biol, 1275 York Ave, New York, NY 10065 USA; [Schwartz, Gary K.] Columbia Univ, Med Ctr, Div Hematol & Oncol, Herbert Irving Pavil 9th Floor, New York, NY 10032 USA; [Crago, Aimee M.; Singer, Samuel] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA; [Crago, Aimee M.; Singer, Samuel] Weill Cornell Med Coll, Dept Surg, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center; Columbia University; Memorial Sloan Kettering Cancer Center; Cornell University	Koff, A (corresponding author), Mem Sloan Kettering Canc Ctr, Louis V Gerstner Grad Sch Biomed Sci, 1275 York Ave, New York, NY 10065 USA.; Koff, A (corresponding author), Mem Sloan Kettering Canc Ctr, Programs Mol, 1275 York Ave, New York, NY 10065 USA.	koffa@mskcc.org			NIH/NCI Cancer Center Support Grant [P30 CA008748]; NCI Soft Tissue Sarcoma SPORE [CA140146]; Maloris Foundation; Linn Fund from Cycle For Survival; Heidi Connery Memorial Research Grant from the Sarcoma Foundation of America; NATIONAL CANCER INSTITUTE [P50CA140146, P50CA217694, P30CA008748] Funding Source: NIH RePORTER	NIH/NCI Cancer Center Support Grant; NCI Soft Tissue Sarcoma SPORE; Maloris Foundation; Linn Fund from Cycle For Survival; Heidi Connery Memorial Research Grant from the Sarcoma Foundation of America; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Annalee Tai for technical assistance, Maura Dickler for discussions on the clinical impact of palbociclib in breast cancer, and Marta Kovatcheva, Caroline Gleason, Andrew Schade (Eli Lilly and Company), Michael Overholtzer and others in our laboratories for discussions during the course of these studies. The research was funded in part through NIH/NCI Cancer Center Support Grant P30 CA008748 and the NCI Soft Tissue Sarcoma SPORE CA140146 (AK, WDT, MD, GKS). Additional funding was provided by the Maloris Foundation, The Linn Fund from Cycle For Survival, and a Heidi Connery Memorial Research Grant from the Sarcoma Foundation of America to AK.	Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Baughn LB, 2006, CANCER RES, V66, P7661, DOI 10.1158/0008-5472.CAN-06-1098; Bollard J, 2017, GUT, V66, P1286, DOI 10.1136/gutjnl-2016-312268; Brooks CL, 2007, ONCOGENE, V26, P7262, DOI 10.1038/sj.onc.1210531; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Choi YJ, 2012, CANCER CELL, V22, P438, DOI 10.1016/j.ccr.2012.09.015; Dickson MA, 2016, JAMA ONCOL, V2, P937, DOI 10.1001/jamaoncol.2016.0264; Dickson MA, 2013, J CLIN ONCOL, V31, P2024, DOI 10.1200/JCO.2012.46.5476; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303; Gong XQ, 2017, CANCER CELL, V32, P761, DOI 10.1016/j.ccell.2017.11.006; Guschin DY, 2010, METHODS MOL BIOL, V649, P247, DOI 10.1007/978-1-60761-753-2_15; Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Jung CR, 2010, J CLIN INVEST, V120, P4493, DOI 10.1172/JCI42674; Kanojia D, 2015, ONCOTARGET, V6, P42429, DOI 10.18632/oncotarget.6464; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Kovatcheva M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00540-5; Kovatcheva M, 2015, ONCOTARGET, V6, P8226, DOI 10.18632/oncotarget.3364; Krcmery J, 2010, BIOESSAYS, V32, P100, DOI 10.1002/bies.200900148; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138; Riley Maurisa F, 2012, Genes Cancer, V3, P226, DOI 10.1177/1947601912455322; Shapiro GI, 2017, CANCER CELL, V32, P721, DOI 10.1016/j.ccell.2017.11.013; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Tan MCB, 2016, ANN SURG, V263, P593, DOI 10.1097/SLA.0000000000001149; Urban AE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164042; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Witkiewicz AK, 2015, ONCOTARGET, V6, P15788, DOI 10.18632/oncotarget.3819; Yang C, 2017, ONCOGENE, V36, P2255, DOI 10.1038/onc.2016.379; Yoshida A, 2016, CANCER RES, V76, P2990, DOI 10.1158/0008-5472.CAN-15-2931	38	22	23	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5066	5078		10.1038/s41388-018-0332-y	http://dx.doi.org/10.1038/s41388-018-0332-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29789718	hybrid, Green Published			2022-12-17	WOS:000444405300003
J	Abdoul-Azize, S; Buquet, C; Li, H; Picquenot, JM; Vannier, JP				Abdoul-Azize, Souleymane; Buquet, Catherine; Li, Hong; Picquenot, Jean-Michel; Vannier, Jean-Pierre			Integration of Ca2+ signaling regulates the breast tumor cell response to simvastatin and doxorubicin	ONCOGENE			English	Article							CANCER-CELLS; INDUCED CARDIOTOXICITY; NEURONAL APOPTOSIS; LEUKEMIA-CELLS; STATINS; STORE; BIM; ACTIVATION; PATHWAY; INDUCE	Recent studies have suggested that the lipid-lowering agent simvastatin holds great promise as a cancer therapeutic; it inhibits the growth of multiple tumors, including triple-negative breast cancer. Doxorubicin-and simvastatin-induced cytotoxicity has been associated with the modulation of Ca2+ signaling, but the underlying mechanisms remain incompletely understood. Here we identify how Ca2+ signaling regulates the breast tumor cell response to doxorubicin and simvastatin. These two drugs inhibit cell survival while increasing apoptosis in two human breast cancer cell lines and five primary breast tumor specimens through the modulation of Ca2+ signaling. Signal transduction and functional studies revealed that both simvastatin and doxorubicin trigger persistent cytosolic Ca2+ release, thereby stimulating the proapoptotic BIM pathway and mitochondrial Ca2+ overload, which are responsible for metabolic dysfunction and apoptosis induction. Simvastatin and doxorubicin suppress the prosurvival ERK1/2 pathway in a Ca2+-independent and Ca2+-dependent manner, respectively. In addition, reduction of the Ca2+ signal by chelation or pharmacological inhibition significantly prevents drug-mediated anticancer signaling. Unexpectedly, a scratch-wound assay indicated that these two drugs induce rapid cell migration, while inhibiting cell invasion and colony formation in a Ca2+-dependent manner. Further, the in vivo data for MDA-MB-231 xenografts demonstrate that upon chelation of Ca2+, the ability of both drugs to reduce the tumor burden was significantly reduced via caspase-3 deactivation. Our results establish a calcium-based mechanism as crucial for executing the cell death process triggered by simvastatin and doxorubicin, and suggest that combining simvastatin with doxorubicin may be an effective regimen for the treatment of breast cancer.	[Abdoul-Azize, Souleymane; Buquet, Catherine; Li, Hong; Vannier, Jean-Pierre] Univ Rouen, Fac Med & Pharm, IRIB, Unite Inserm,U1234, F-76183 Rouen, France; [Picquenot, Jean-Michel] Ctr Henri Becquerel Lutte Canc CLCC Normandie, Serv Anat & Cytol Pathol, F-76038 Rouen 1, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Abdoul-Azize, S (corresponding author), Univ Rouen, Fac Med & Pharm, IRIB, Unite Inserm,U1234, F-76183 Rouen, France.	souleymane.abdoul-azize@univ-rouen.fr	Abdoul-Azize, Souleymane/AAB-2181-2021	Abdoul-Azize, Souleymane/0000-0003-2065-9091	French Ministry of Higher Education and Research; Association Vie et Espoir	French Ministry of Higher Education and Research; Association Vie et Espoir	This work was supported by grants from the French Ministry of Higher Education and Research, and the Association Vie et Espoir. We thank members of the LIONS CLUB Les Andelys association for their support with equipment.	Abdoul-Azize S, 2017, ONCOTARGET, V8, P27339, DOI 10.18632/oncotarget.16039; Ansari L, 2017, CANCER GENE THER, V24, P189, DOI 10.1038/cgt.2017.9; Borahay MA, 2014, J BIOL CHEM, V289, P35075, DOI 10.1074/jbc.M114.583575; Buranrat B, 2017, ONCOL LETT, V14, P6243, DOI 10.3892/ol.2017.6783; Burridge PW, 2016, NAT MED, V22, P547, DOI 10.1038/nm.4087; Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008-5472.CAN-05-4061; Cheng HY, 2016, ONCOTARGET, V7, P16866, DOI 10.18632/oncotarget.7619; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; David L, 2004, MATRIX BIOL, V23, P183, DOI 10.1016/j.matbio.2004.05.005; David L, 2008, ACTA BIOMATER, V4, P256, DOI 10.1016/j.actbio.2007.08.012; Einbond LS, 2016, FITOTERAPIA, V109, P146, DOI 10.1016/j.fitote.2015.12.005; Gajek Arkadiusz, 2015, Asian Pac J Cancer Prev, V16, P8503; Gao JQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168219; Gazzerro P, 2012, PHARMACOL REV, V64, P102, DOI 10.1124/pr.111.004994; Giorgi C, 2015, P NATL ACAD SCI USA, V112, P1779, DOI 10.1073/pnas.1410723112; Gogebakan B, 2014, TUMOR BIOL, V35, P8033, DOI 10.1007/s13277-014-1752-0; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Huang XX, 2015, CURR CANCER DRUG TAR, V15, P481, DOI 10.2174/156800961506150805151905; Kato S, 2010, J CELL MOL MED, V14, P1180, DOI 10.1111/j.1582-4934.2009.00771.x; Katz MS, 2005, NAT CLIN PRACT ONCOL, V2, P82, DOI 10.1038/ncponc0097; Lavik AR, 2015, ONCOTARGET, V6, P27388, DOI 10.18632/oncotarget.4489; Leung YM, 1999, JPN J PHARMACOL, V81, P253, DOI 10.1254/jjp.81.253; Li Y, 2013, INT J MOL MED, V31, P1234, DOI 10.3892/ijmm.2013.1292; Liao YY, 2009, P NATL ACAD SCI USA, V106, P3202, DOI 10.1073/pnas.0813346106; Liu CX, 2016, ONCOTARGET, V7, P7534, DOI 10.18632/oncotarget.7183; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marchi S, 2016, CURR OPIN PHARMACOL, V29, P1, DOI 10.1016/j.coph.2016.03.002; Mattson MP, 2003, NAT CELL BIOL, V5, P1041, DOI 10.1038/ncb1203-1041; Mebratu Y, 2009, CELL CYCLE, V8, P1168, DOI 10.4161/cc.8.8.8147; MORTIMER JE, 2003, P AN M AM SOC CLIN, V22, P93; Motiani RK, 2010, J BIOL CHEM, V285, P19173, DOI 10.1074/jbc.M110.102582; Ouadid-Ahidouch H, 2013, TRENDS MOL MED, V19, P117, DOI 10.1016/j.molmed.2012.11.004; Parekh AB, 2010, NAT REV DRUG DISCOV, V9, P399, DOI 10.1038/nrd3136; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Rambal AA, 2009, LEUKEMIA, V23, P1744, DOI 10.1038/leu.2009.80; Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412; Safwat S, 2017, J PHARM PHARMACOL, V69, P613, DOI 10.1111/jphp.12707; Shi J, 2017, J PHYSIOL-LONDON, V595, P1039, DOI 10.1113/JP273302; Simon T, 2014, NEUROMOL MED, V16, P752, DOI 10.1007/s12017-014-8324-8; Szwed M, 2016, CELL ONCOL, V39, P107, DOI 10.1007/s13402-015-0256-2; Tanwar J, 2018, CELL CALCIUM, V69, P19, DOI 10.1016/j.ceca.2017.06.002; Tiwari M, 2017, J CELL PHYSIOL, V232, P976, DOI 10.1002/jcp.25670; Tombal B, 2002, CELL DEATH DIFFER, V9, P561, DOI 10.1038/sj.cdd.4400999; Vashisht A, 2015, AM J PHYSIOL-CELL PH, V309, pC457, DOI 10.1152/ajpcell.00064.2015; Wu QJ, 2015, ONCOTARGET, V6, P42988, DOI 10.18632/oncotarget.5557; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Yao H, 2017, ONCOTARGET, V8, P1913, DOI 10.18632/oncotarget.12284; Zhang HT, 2016, CELL PHYSIOL BIOCHEM, V40, P1079, DOI 10.1159/000453163; Zhang S, 2016, MOL NEUROBIOL, V53, P7078, DOI 10.1007/s12035-015-9573-8; Zhang S, 2012, NAT MED, V18, P1639, DOI 10.1038/nm.2919	51	22	23	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4979	4993		10.1038/s41388-018-0329-6	http://dx.doi.org/10.1038/s41388-018-0329-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29795329				2022-12-17	WOS:000443823600006
J	Imamaki, R; Ogawa, K; Kizuka, Y; Komi, Y; Kojima, S; Kotani, N; Honke, K; Honda, T; Taniguchi, N; Kitazume, S				Imamaki, Rie; Ogawa, Kazuko; Kizuka, Yasuhiko; Komi, Yusuke; Kojima, Soichi; Kotani, Norihiro; Honke, Koichi; Honda, Takashi; Taniguchi, Naoyuki; Kitazume, Shinobu			Glycosylation controls cooperative PECAM-VEGFR2-beta 3 integrin functions at the endothelial surface for tumor angiogenesis	ONCOGENE			English	Article							CELL ADHESION MOLECULE; PRECURSOR PROTEIN 770; HOMOPHILIC INTERACTIONS; PLATELET; CANCER; SIALYLATION; RECEPTOR; PECAM-1; GLYCANS; APOPTOSIS	Most of the angiogenesis inhibitors clinically used in cancer treatment target the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) pathway. However, the current strategies for treating angiogenesis have limited efficacy. The issue of how to treat angiogenesis and endothelial dysfunction in cancer remains a matter of substantial debate. Here we demonstrate a glycosylation-dependent regulatory mechanism for tumor angiogenesis. St6gal1(-/-) mice, lacking the alpha 2,6-sialylation enzyme, were shown to exhibit impaired tumor angiogenesis through enhanced endothelial apoptosis. In a previous study, St6gal1(-/-) endothelial cells exhibited a reduction in the cell surface residency of platelet endothelial cell adhesion molecule (PECAM). In this study, we found that cooperative functionality of PECAM-VEGFR2-integrin beta 3 was disturbed in St6gal1(-/-) mice. First, cell surface PECAM-VEGFR2 complexes were lost, and both VEGFR2 internalization and the VEGFR-dependent signaling pathway were enhanced. Second, enhanced anoikis was observed, suggesting that the absence of alpha 2,6-sialic acid leads to dysregulated integrin signaling. Notably, ectopic expression of PECAM increased cell surface integrin-beta 3, indicating that the reduction of cell surface integrin-beta 3 involves loss-of-endothelial PECAM. The results suggest that the cell surface stability of these glycoproteins is significantly reduced by the lack of alpha 2,6-sialic acid, leading to abnormal signal transduction. The present findings highlight that alpha 2,6-sialylation is critically involved in endothelial survival by controlling the cell surface stability and signal transduction of angiogenic molecules, and could be a novel target for anti-angiogenesis therapy.	[Imamaki, Rie; Ogawa, Kazuko; Kizuka, Yasuhiko; Taniguchi, Naoyuki; Kitazume, Shinobu] RIKEN, Dis Glyc Team, Syst Glycobiol Res Grp, Saitama 3510198, Japan; [Komi, Yusuke; Kojima, Soichi] RIKEN, Mol Ligand Biol Res Team, Wako, Saitama 3510198, Japan; [Kotani, Norihiro] Saitama Med Univ, Dept Biochem, Saitama 3500495, Japan; [Honke, Koichi] Kochi Univ, Dept Biochem, Med Sch, Kochi 7838505, Japan; [Honda, Takashi] Fukushima Med Univ, Sch Nursing, Dept Human Life Sci, Fukushima 9601295, Japan; [Kitazume, Shinobu] Fukushima Med Univ, Preparing Sect New Fac Med Sci, Fukushima 9601295, Japan	RIKEN; RIKEN; Saitama Medical University; Kochi University; Fukushima Medical University; Fukushima Medical University	Kitazume, S (corresponding author), RIKEN, Dis Glyc Team, Syst Glycobiol Res Grp, Saitama 3510198, Japan.; Kitazume, S (corresponding author), Fukushima Med Univ, Preparing Sect New Fac Med Sci, Fukushima 9601295, Japan.	shinobuk@fmu.ac.jp	Taniguchi, Naoyuki/I-4182-2014; Kojima, Soichi/N-7104-2015	Taniguchi, Naoyuki/0000-0001-5889-5968; Kotani, Norihiro/0000-0003-3739-6478; Kojima, Soichi/0000-0002-5252-1612; Kizuka, Yasuhiko/0000-0002-3181-9743	Systems Glycobiology Research Project; Strategic Programs for RD of RIKEN; MEXT/JSPS KAKENHI grant [16K08601, 25430122]; Mitsubishi Foundation; Grants-in-Aid for Scientific Research [16K08601] Funding Source: KAKEN	Systems Glycobiology Research Project; Strategic Programs for RD of RIKEN; MEXT/JSPS KAKENHI grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Mitsubishi Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by grants from the Systems Glycobiology Research Project and the Strategic Programs for R&D of RIKEN (to N.T.), MEXT/JSPS KAKENHI grant numbers 16K08601 and 25430122 (to S.K.), and a grant from the Mitsubishi Foundation (to S.K.). The authors would like to acknowledge Dr. Jamey D. Marth for providing the St6gal1<SUP>-/-</SUP> mice and the RIKEN BSI-Olympus Collaboration Center for technical support.	Abe Y, 1999, J IMMUNOL, V163, P2867; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bird IN, 1999, J CELL SCI, V112, P1989; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Croci DO, 2014, GLYCOBIOLOGY, V24, P1283, DOI 10.1093/glycob/cwu083; Croci DO, 2014, CELL, V156, P744, DOI 10.1016/j.cell.2014.01.043; Dennis JW, 2009, CELL, V139, P1229, DOI 10.1016/j.cell.2009.12.008; Domingues I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025668; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Frentzas S, 2016, NAT MED, V22, P1294, DOI 10.1038/nm.4197; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Gao CJ, 2003, BLOOD, V102, P169, DOI 10.1182/blood-2003-01-0003; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kitazume S, 2014, GLYCOBIOLOGY, V24, P1260, DOI 10.1093/glycob/cwu094; Kitazume S, 2014, J BIOL CHEM, V289, P27604, DOI 10.1074/jbc.M114.563585; Kitazume S, 2012, J BIOL CHEM, V287, P40817, DOI 10.1074/jbc.M112.398578; Kitazume S, 2010, J BIOL CHEM, V285, P40097, DOI 10.1074/jbc.M110.144626; Kitazume S, 2010, J BIOL CHEM, V285, P6515, DOI 10.1074/jbc.M109.073106; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; Komi Y, 2007, JPN J CLIN ONCOL, V37, P867, DOI 10.1093/jjco/hym115; Kotani N, 2008, P NATL ACAD SCI USA, V105, P7405, DOI 10.1073/pnas.0710346105; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee C, 2014, J BIOL CHEM, V289, P9121, DOI 10.1074/jbc.M114.555888; Lertkiatmongkol P, 2016, J BIOL CHEM, V291, P26216, DOI 10.1074/jbc.M116.756502; Lurje G, 2009, ONCOLOGY-BASEL, V77, P400, DOI 10.1159/000279388; Mahabeleshwar GH, 2006, J EXP MED, V203, P2495, DOI 10.1084/jem.20060807; Markowska AI, 2010, J EXP MED, V207, P1981, DOI 10.1084/jem.20090121; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; McIntyre A, 2015, EMBO MOL MED, V7, P368, DOI 10.15252/emmm.201404271; Morello V, 2011, ONCOGENE, V30, P4087, DOI 10.1038/onc.2011.107; Nakayama M, 2013, NAT CELL BIOL, V15, P249, DOI 10.1038/ncb2679; Newman PJ, 2003, ARTERIOSCL THROM VAS, V23, P953, DOI 10.1161/01.ATV.0000071347.69358.D9; Paddock C, 2016, BLOOD, V127, P1052, DOI 10.1182/blood-2015-07-660092; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8; Sata M, 2000, ARTERIOSCL THROM VAS, V20, P309, DOI 10.1161/01.ATV.20.2.309; Schutze S, 2008, NAT REV MOL CELL BIO, V9, P655, DOI 10.1038/nrm2430; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sugimoto I, 2007, J BIOL CHEM, V282, P34896, DOI 10.1074/jbc.M704766200; Swindall AF, 2011, J BIOL CHEM, V286, P22982, DOI 10.1074/jbc.M110.211375; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; Ungewiss C, 2016, SCI REP-UK, V6, DOI 10.1038/srep18652; Woodfin A, 2007, ARTERIOSCL THROM VAS, V27, P2514, DOI 10.1161/ATVBAHA.107.151456; Xu D, 2011, J BIOL CHEM, V286, P737, DOI 10.1074/jbc.M110.177006; Zhuo Y, 2008, J BIOL CHEM, V283, P22177, DOI 10.1074/jbc.M8000015200	50	22	23	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4287	4299		10.1038/s41388-018-0271-7	http://dx.doi.org/10.1038/s41388-018-0271-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29717262	Green Published			2022-12-17	WOS:000440566100007
J	Lu, JQ; Liu, LS; Zheng, MJ; Li, XL; Wu, AL; Wu, QZ; Liao, C; Zou, J; Song, H				Lu, Jinqiu; Liu, Liansheng; Zheng, Mingjie; Li, Xiaoling; Wu, Ailing; Wu, Qingzhe; Liao, Cheng; Zou, Jian; Song, Hai			MEKK2 and MEKK3 suppress Hedgehog pathway-dependent medulloblastoma by inhibiting GLI1 function	ONCOGENE			English	Article							ACTIVATOR FUNCTION; PROTEINS; CANCER; OVEREXPRESSION; EXPRESSION; SITE	Hedgehog (Hh) pathway plays a pivotal role in diverse aspects of development and postnatal physiology. Perturbation of Hh signaling and activation of GLI1 (glioma-associated oncogene 1), a dedicated transcription factor for Hh pathway, are highly associated with several cancers, such as medulloblastoma and basal cell carcinoma. Dynamic and precise control of GLI1 activity is thus important to ensure proper homeostasis and tumorigenesis. Here we show that MEKK2 (MAP3K2) and MEKK3 (MAP3K3) inhibit GLI1 transcriptional activity and oncogenic function through phosphorylation on multiple Ser/Thr sites of GLI1, which reduces GLI1 protein stability, DNA-binding ability, and increases the association of GLI1 with SUFU. Interestingly, MEKK2 and MEKK3 are responsible for FGF2-mediated inhibition on Hh signaling. Moreover, expression of MEKK2 and MEKK3 inhibits medulloblastoma cell proliferation and negatively correlates with Hh pathway activity in medulloblastoma clinical samples. Together, these findings reveal a novel noncanonical GLI1 regulation and provide a potential therapeutic target for the treatment of cancers with aberrant Hh pathway activation, such as medulloblastoma.	[Lu, Jinqiu; Liu, Liansheng; Li, Xiaoling; Wu, Ailing; Wu, Qingzhe; Song, Hai] Zhejiang Univ, Inst Life Sci, Hangzhou 310058, Zhejiang, Peoples R China; [Lu, Jinqiu; Liu, Liansheng; Li, Xiaoling; Wu, Ailing; Wu, Qingzhe; Song, Hai] Zhejiang Univ, Innovat Ctr Cell Signaling Network, Hangzhou 310058, Zhejiang, Peoples R China; [Zheng, Mingjie; Zou, Jian] Zhejiang Univ, Inst Translat Med, Affiliated Hosp 2, Eye Ctr,Sch Med, Hangzhou 310058, Zhejiang, Peoples R China; [Liao, Cheng] Janssen China Res & Dev Ctr, Lung Canc Translat Res, Discovery Ctr, 5F,Bldg 1 North,Jinchuang Mans 4560 Jinke, Shanghai 201210, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Song, H (corresponding author), Zhejiang Univ, Inst Life Sci, Hangzhou 310058, Zhejiang, Peoples R China.; Song, H (corresponding author), Zhejiang Univ, Innovat Ctr Cell Signaling Network, Hangzhou 310058, Zhejiang, Peoples R China.	haisong@zju.edu.cn		Li, Xiaoling/0000-0002-1554-1569; Zheng, Mingjie/0000-0003-0735-3995	National Natural Science Foundation of China [31471368]; Zhejiang Provincial Natural Science Foundation of China [LR16C120001, LZ15H120001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province)	We thank Bin Zhao and Zongping Xia (both Zhejiang University, China) for reagents, members of the Song laboratory for discussion, and Pao-Tien Chuang for critical reading of the manuscript. This work was supported by the National Natural Science Foundation of China (grant number 31471368), the Zhejiang Provincial Natural Science Foundation of China (grant number LR16C120001) to HS, and the Zhejiang Provincial Natural Science Foundation of China (grant number LZ15H120001) to JZ. HS is a scholar in the National 1000 Young Talents Program.	Aberger F, 2014, SEMIN CELL DEV BIOL, V33, P93, DOI 10.1016/j.semcdb.2014.05.003; Bai CB, 2004, DEV CELL, V6, P103, DOI 10.1016/S1534-5807(03)00394-0; Barakat MT, 2010, TRENDS MOL MED, V16, P337, DOI 10.1016/j.molmed.2010.05.003; Barnfield PC, 2005, DIFFERENTIATION, V73, P397, DOI 10.1111/j.1432-0436.2005.00042.x; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Cuevas BD, 2007, ONCOGENE, V26, P3159, DOI 10.1038/sj.onc.1210409; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Fan YH, 2014, J PATHOL, V232, P75, DOI 10.1002/path.4283; Fogarty MP, 2007, P NATL ACAD SCI USA, V104, P2973, DOI 10.1073/pnas.0605770104; Gotschel F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065403; Greenblatt MB, 2016, P NATL ACAD SCI USA, V113, pE1226, DOI 10.1073/pnas.1600813113; Hasan R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-2; Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Infante P, 2015, TRENDS PHARMACOL SCI, V36, P547, DOI 10.1016/j.tips.2015.05.006; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Jiang L, 2013, ONCOL LETT, V6, P1333, DOI 10.3892/ol.2013.1553; Karlstrom RO, 2003, DEVELOPMENT, V130, P1549, DOI 10.1242/dev.00364; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Lewis KE, 1999, DEV BIOL, V216, P469, DOI 10.1006/dbio.1999.9519; Lin CW, 2014, DEV BIOL, V392, P324, DOI 10.1016/j.ydbio.2014.05.014; Mao JH, 2002, J BIOL CHEM, V277, P35156, DOI 10.1074/jbc.M206743200; Mazur PK, 2014, NATURE, V510, P283, DOI 10.1038/nature13320; Murone M, 2000, NAT CELL BIOL, V2, P310, DOI 10.1038/35010610; Neumann CJ, 1999, DEVELOPMENT, V126, P4817; Petrova R, 2014, DEVELOPMENT, V141, P3445, DOI 10.1242/dev.083691; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Umapathy G, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005470; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wilson CW, 2010, DEVELOPMENT, V137, P2079, DOI 10.1242/dev.045021; Zhang DY, 2006, EMBO J, V25, P97, DOI 10.1038/sj.emboj.7600913; Zhang WY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031450	35	22	23	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3864	3878		10.1038/s41388-018-0249-5	http://dx.doi.org/10.1038/s41388-018-0249-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29662197	Green Published, hybrid			2022-12-17	WOS:000438465600008
J	Zhu, ZC; Liu, JW; Li, K; Zheng, J; Xiong, ZQ				Zhu, Zhi-Chuan; Liu, Ji-Wei; Li, Kui; Zheng, Jing; Xiong, Zhi-Qi			KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells	ONCOGENE			English	Article							IMPORTIN-BETA; NUCLEAR IMPORT; MYELOMA CELLS; RECEPTOR; TRANSPORT; DEATH; PROLIFERATION; KPN-BETA-1; PHOSPHORYLATION; INDUCTION	The nuclear import receptor karyopherin beta 1 (KPNB1) is involved in the nuclear import of most proteins and in the regulation of multiple mitotic events. Upregulation of KPNB1 has been observed in cancers including glioblastoma. Depletion of KPNB1 induces mitotic arrest and apoptosis in cancer cells, but the underlying mechanism is not clearly elucidated. Here, we found that downregulation and functional inhibition of KPNB1 in glioblastoma cells induced growth arrest and apoptosis without apparent mitotic arrest. KPNB1 inhibition upregulated Puma and Noxa and freed Mcl-1-sequestered Bax and Bak, leading to mitochondrial outer membrane permeabilization (MOMP) and apoptosis. Moreover, combination of Bcl-xL inhibitors and KPNB1 inhibition enhanced apoptosis in glioblastoma cells. KPNB1 inhibition promoted cytosolic retention of its cargo and impaired cellular proteostasis, resulting in elevated polyubiquitination, formation of aggresome-like-induced structure (ALIS), and unfolded protein response (UPR). Ubiquitination elevation and UPR activation in KPNB1-deficient cells were reversed by KPNB1 overexpression or inhibitors of protein synthesis but aggravated by inhibitors of autophagylysosome or proteasome, indicating that rebalance of cytosolic/nuclear protein distribution and alleviation of protein overload favor proteostasis and cell survival. Chronic activation of eIF2 alpha/ATF4 cascade of UPR was responsible for the upregulation of Puma and Noxa, apoptosis and ABT-263 sensitivity. Taken together, our findings demonstrate that KPNB1 is required for proteostasis maintenance and its inhibition induces apoptosis in glioblastoma cells through UPR-mediated deregulation of Bcl-2 family members.	[Zhu, Zhi-Chuan; Li, Kui; Xiong, Zhi-Qi] Chinese Acad Sci, Inst Neurosci, CAS Ctr Excellence Brain Sci & Intelligence Techn, State Key Lab Neurosci, Shanghai 200031, Peoples R China; [Liu, Ji-Wei; Zheng, Jing] East China Univ Sci & Technol, Sch Pharm, Shanghai 200237, Peoples R China; [Xiong, Zhi-Qi] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Xiong, Zhi-Qi] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China	Chinese Academy of Sciences; East China University of Science & Technology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; ShanghaiTech University	Xiong, ZQ (corresponding author), Chinese Acad Sci, Inst Neurosci, CAS Ctr Excellence Brain Sci & Intelligence Techn, State Key Lab Neurosci, Shanghai 200031, Peoples R China.; Xiong, ZQ (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Xiong, ZQ (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.	xiongzhiqi@ion.ac.cn	Zhu, Zhichuan/GYV-0605-2022	Zhu, Zhichuan/0000-0003-0327-9978	National Natural Science Foundation of China [31021063, 91332203, 31490591]; Chinese Academy of Sciences [XDB02020007, QYZDJ-SSW-SMC010]; Ministry of Science and Technology [2016YFA0501002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This work was supported by grants from National Natural Science Foundation of China (31021063, 91332203, and 31490591), Chinese Academy of Sciences (XDB02020007, QYZDJ-SSW-SMC010), and Ministry of Science and Technology (2016YFA0501002).	Angus L, 2014, CARCINOGENESIS, V35, P1121, DOI 10.1093/carcin/bgt491; Cang SD, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0224-3; Chen S, 2012, CANCER RES, V72, P4225, DOI 10.1158/0008-5472.CAN-12-1118; Ciciarello M, 2004, J CELL SCI, V117, P6511, DOI 10.1242/jcs.01569; Cimica V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020188; Cory S, 2016, TRENDS CANCER, V2, P443, DOI 10.1016/j.trecan.2016.07.001; Dai HM, 2018, CELL DEATH DIFFER, V25, P282, DOI 10.1038/cdd.2017.156; Dai HM, 2014, J BIOL CHEM, V289, P89, DOI 10.1074/jbc.M113.505701; De Corte V, 2004, J CELL SCI, V117, P5283, DOI 10.1242/jcs.01410; Dikovskaya D, 2010, J CELL SCI, V123, P736, DOI 10.1242/jcs.060806; Ding WX, 2007, APOPTOSIS, V12, P2233, DOI 10.1007/s10495-007-0142-0; El Fajoui Z, 2011, GASTROENTEROLOGY, V141, P663, DOI 10.1053/j.gastro.2011.04.055; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Gomes DA, 2008, J BIOL CHEM, V283, P4344, DOI 10.1074/jbc.M706550200; Han CC, 2013, CELL SIGNAL, V25, P144, DOI 10.1016/j.cellsig.2012.09.023; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/j.molcel.2004.10.026; He S, 2016, J CANCER RES CLIN, V142, P561, DOI 10.1007/s00432-015-2057-4; Kojima Y, 2011, J BIOL CHEM, V286, P43383, DOI 10.1074/jbc.M111.309377; Kuusisto HV, 2015, BBA-MOL CELL RES, V1853, P1870, DOI 10.1016/j.bbamcr.2015.05.002; Lara-Gonzalez P, 2012, CURR BIOL, V22, pR966, DOI 10.1016/j.cub.2012.10.006; Leverson JD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.561; Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642; Liang PZ, 2013, TRAFFIC, V14, P1132, DOI 10.1111/tra.12097; Lieu KG, 2014, J CELL BIOL, V205, P301, DOI 10.1083/jcb.201304055; Liu XD, 2012, J BIOL CHEM, V287, P19687, DOI 10.1074/jbc.M112.350934; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lopez H, 2010, J BIOL CHEM, V285, P15016, DOI 10.1074/jbc.M109.086231; Lu XL, 2010, J BIOL CHEM, V285, P33281, DOI 10.1074/jbc.M110.102368; Madhavan S, 2009, MOL CANCER RES, V7, P157, DOI 10.1158/1541-7786.MCR-08-0435; Mingot JM, 2009, J CELL SCI, V122, P1452, DOI 10.1242/jcs.041749; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Polier G, 2015, INT J CANCER, V136, P688, DOI 10.1002/ijc.29009; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Quadroni M, 2015, J PROTEOMICS, V120, P215, DOI 10.1016/j.jprot.2015.02.020; Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141; Rodriguez D, 2011, BBA-MOL CELL RES, V1813, P564, DOI 10.1016/j.bbamcr.2010.11.012; Roscioli E, 2012, J CELL BIOL, V196, P435, DOI 10.1083/jcb.201109104; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Schmitz MHA, 2010, NAT CELL BIOL, V12, P886, DOI 10.1038/ncb2092; Shao DC, 2015, EUR J PHARMACOL, V758, P89, DOI 10.1016/j.ejphar.2015.03.069; Soderholm JF, 2011, ACS CHEM BIOL, V6, P700, DOI 10.1021/cb2000296; Szczepny A, 2014, BIOCHEM J, V461, P469, DOI 10.1042/BJ20130709; Uvarov AV, 2008, BBA-MOL CELL RES, V1783, P1237, DOI 10.1016/j.bbamcr.2008.03.004; van der Watt PJ, 2016, MOL CANCER THER, V15, P560, DOI 10.1158/1535-7163.MCT-15-0052; van der Watt PJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027723; Vela L, 2013, J BIOL CHEM, V288, P4935, DOI 10.1074/jbc.M112.422204; Vogler Meike, 2014, Adv Med, V2014, P943648, DOI 10.1155/2014/943648; Wong E, 2012, CURR BIOL, V22, pR966; Yan WQ, 2015, CELL SIGNAL, V27, P851, DOI 10.1016/j.cellsig.2015.01.013; Yang LL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0559-1; Yang WD, 2006, J CELL BIOL, V174, P951, DOI 10.1083/jcb.200605053; Zhang CM, 2002, CURR BIOL, V12, P498, DOI 10.1016/S0960-9822(02)00714-5; Zhang PY, 2014, J PATHOL, V232, P308, DOI 10.1002/path.4294; Zhu ZC, 2013, J NEURO-ONCOL, V112, P17, DOI 10.1007/s11060-012-1032-z	54	22	23	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2936	2952		10.1038/s41388-018-0180-9	http://dx.doi.org/10.1038/s41388-018-0180-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29520102	hybrid, Green Published			2022-12-17	WOS:000433936300003
J	Cho, HJ; Hwang, YS; Yoon, J; Lee, M; Lee, HG; Daar, IO				Cho, H. J.; Hwang, Y-S; Yoon, J.; Lee, M.; Lee, H. G.; Daar, I. O.			EphrinB1 promotes cancer cell migration and invasion through the interaction with RhoGDI1	ONCOGENE			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEINS; EPH RECEPTORS; RHO-GTPASES; GASTRIC-CANCER; EXPRESSION; ACTIVATION; COMPLEX; PHOSPHORYLATION; REGULATORS	Eph receptors and their corresponding ephrin ligands have been associated with regulating cell-cell adhesion and motility, and thus have a critical role in various biological processes including tissue morphogenesis and homeostasis, as well as pathogenesis of several diseases. Aberrant regulation of Eph/ephrin signaling pathways is implicated in tumor progression of various human cancers. Here, we show that a Rho family GTPase regulator, Rho guanine nucleotide dissociation inhibitor 1 (RhoGDI1), can interact with ephrinB1, and this interaction is enhanced upon binding the extracellular domain of the cognate EphB2 receptor. Deletion mutagenesis revealed that amino acids 327-334 of the ephrinB1 intracellular domain are critical for the interaction with RhoGDI1. Stimulation with an EphB2 extracellular domain-Fc fusion protein (EphB2-Fc) induces RhoA activation and enhances the motility as well as invasiveness of wild-type ephrinB1-expressing cells. These Eph-Fc-induced effects were markedly diminished in cells expressing the mutant ephrinB1 construct (Delta 327-334) that is ineffective at interacting with RhoGDI1. Furthermore, ephrinB1 depletion by siRNA suppresses EphB2-Fc-induced RhoA activation, and reduces motility and invasiveness of the SW480 and Hs578T human cancer cell lines. Our study connects the interaction between RhoGDI1 and ephrinB1 to the promotion of cancer cell behavior associated with tumor progression. This interaction may represent a therapeutic target in cancers that express ephrinB1.	[Cho, H. J.; Lee, H. G.] Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon 34141, South Korea; [Cho, H. J.; Hwang, Y-S; Yoon, J.; Lee, M.; Daar, I. O.] NCI, Cancer & Dev Biol Lab, NIH, Frederick, MD 21702 USA	Korea Research Institute of Bioscience & Biotechnology (KRIBB); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cho, HJ (corresponding author), Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon 34141, South Korea.; Daar, IO (corresponding author), NCI, Canc & Dev Biol Lab, Bldg 560,Room 22-90D, Frederick, MD 21702 USA.	hjcho@kribb.re.kr; daari@mail.nih.gov	Lee, Moonsup/AAK-2333-2020	Daar, Ira/0000-0003-2657-526X; Yoon, Jaeho/0000-0003-2730-8606	Intramural Research Program of the NIH, National Cancer Institute; National Research Council of Science and Technology (NST) grant by the Korea government (MSIP) [CRC-15-02-KRIBB]; NATIONAL CANCER INSTITUTE [ZIABC010006, ZIABC010958] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Research Council of Science and Technology (NST) grant by the Korea government (MSIP); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank our colleagues Dr Giovanna Tosato for critically reading of this manuscript, Dr Brad St Croix and Dr Deborah Morrison for cell lines. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, and the National Research Council of Science and Technology (NST) grant by the Korea government (MSIP) (CRC-15-02-KRIBB).	Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; Astin JW, 2010, NAT CELL BIOL, V12, P1194, DOI 10.1038/ncb2122; Barquilla A, 2015, ANNU REV PHARMACOL, V55, P465, DOI 10.1146/annurev-pharmtox-011112-140226; Bong YS, 2007, P NATL ACAD SCI USA, V104, P17305, DOI 10.1073/pnas.0702337104; Boyd AW, 2014, NAT REV DRUG DISCOV, V13, P39, DOI 10.1038/nrd4175; Brunet N, 2002, TRAFFIC, V3, P342, DOI 10.1034/j.1600-0854.2002.30504.x; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Cho HJ, 2014, J BIOL CHEM, V289, P18556, DOI 10.1074/jbc.M114.558809; Cho HJ, 2010, EXPERT OPIN THER TAR, V14, P67, DOI 10.1517/14728220903449251; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Colbert PL, 2015, ONCOTARGET, V6, P953, DOI 10.18632/oncotarget.2823; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; Daar IO, 2012, SEMIN CELL DEV BIOL, V23, P65, DOI 10.1016/j.semcdb.2011.10.012; Davy A, 2006, PLOS BIOL, V4, P1763, DOI 10.1371/journal.pbio.0040315; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; DerMardirossian C, 2006, MOL BIOL CELL, V17, P4760, DOI 10.1091/mbc.E06-06-0533; Donnelly SK, 2014, CELL ADHES MIGR, V8, P526, DOI 10.4161/cam.29712; Dovas A, 2010, J BIOL CHEM, V285, P23294, DOI 10.1074/jbc.M109.098129; Faure J, 1999, EUR J BIOCHEM, V262, P879, DOI 10.1046/j.1432-1327.1999.00458.x; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Garcia-Mata R, 2011, NAT REV MOL CELL BIO, V12, P493, DOI 10.1038/nrm3153; Gee HY, 2013, J CLIN INVEST, V123, P3243, DOI 10.1172/JCI69134; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Heroult M, 2006, EXP CELL RES, V312, P642, DOI 10.1016/j.yexcr.2005.10.028; Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67; Kandouz M, 2012, CANCER METAST REV, V31, P353, DOI 10.1007/s10555-012-9352-1; Kataoka H, 2002, J CANCER RES CLIN, V128, P343, DOI 10.1007/s00432-002-0355-0; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Lee HS, 2006, NAT CELL BIOL, V8, P55, DOI 10.1038/ncb1344; Lee HS, 2008, NAT CELL BIOL, V10, P979, DOI 10.1038/ncb1758; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; Lu Y, 2013, J BIOL CHEM, V288, P34276, DOI 10.1074/jbc.M113.519744; Maeda M, 1999, ONCOGENE, V18, P4788, DOI 10.1038/sj.onc.1202871; McKinney N, 2015, J NEURO-ONCOL, V121, P109, DOI 10.1007/s11060-014-1618-8; Merlos-Suarez A, 2008, CURR OPIN CELL BIOL, V20, P194, DOI 10.1016/j.ceb.2008.01.011; Pandya P, 2017, CURR OPIN CELL BIOL, V48, P87, DOI 10.1016/j.ceb.2017.06.006; Parri M, 2009, CANCER RES, V69, P2072, DOI 10.1158/0008-5472.CAN-08-1845; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Porter Andrew P, 2016, Small GTPases, V7, P123, DOI 10.1080/21541248.2016.1173767; Sabbatini ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066029; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sawai Y, 2003, J HEPATOL, V39, P991, DOI 10.1016/S0168-8278(03)00498-7; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Tanaka M, 2003, EMBO J, V22, P847, DOI 10.1093/emboj/cdg088; Tanaka M, 2010, CANCER SCI, V101, P87, DOI 10.1111/j.1349-7006.2009.01352.x; Varelias A, 2002, CANCER, V95, P862, DOI 10.1002/cncr.10749; Wu C, 2009, J NEUROSCI, V29, P7404, DOI 10.1523/JNEUROSCI.5841-08.2009; Xi HQ, 2012, J CELL MOL MED, V16, P2894, DOI 10.1111/j.1582-4934.2012.01612.x; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045	53	22	22	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					861	872		10.1038/onc.2017.386	http://dx.doi.org/10.1038/onc.2017.386			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059157	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000425281800004
J	Luo, W; Xu, C; Ayello, J; Dela Cruz, F; Rosenblum, JM; Lessnick, SL; Cairo, MS				Luo, W.; Xu, C.; Ayello, J.; Dela Cruz, F.; Rosenblum, J. M.; Lessnick, S. L.; Cairo, M. S.			Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis	ONCOGENE			English	Article							THERAPEUTIC TARGET; CELL-MIGRATION; GENE; EXPRESSION; CANCER; TUMOR; PHOSPHORYLATION; INHIBITOR-1; DEGRADATION; MECHANISMS	Protein phosphatase inhibitors are often considered as tumor promoters. Protein phosphatase 1 regulatory subunit 1A (PPP1R1A) is a potent protein phosphatase 1 (PP1) inhibitor; however, its role in tumor development is largely undefined. Here we characterize, for the first time, the functions of PPP1R1A in Ewing sarcoma (ES) pathogenesis. We found that PPP1R1A is one of the top ranked target genes of EWS/FLI, the master regulator of ES, and is upregulated by EWS/FLI via a GGAA microsatellite enhancer element. Depletion of PPP1R1A resulted in a significant decrease in oncogenic transformation and cell migration in vitro as well as xenograft tumor growth and metastasis in an orthotopic mouse model. RNA-sequencing and functional annotation analyses revealed that PPP1R1A regulates genes associated with various cellular functions including cell junction, adhesion and neurogenesis. Interestingly, we found a significant overlap of PPP1R1A-regulated gene set with that of ZEB2 and EWS, which regulates metastasis and neuronal differentiation in ES, respectively. Further studies for characterization of the molecular mechanisms revealed that activation of PPP1R1A by PKA phosphorylation at Thr35, and subsequent PP1 binding and inhibition, was required for PPP1R1A-mediated tumorigenesis and metastasis, likely by increasing the phosphorylation levels of various PP1 substrates. Furthermore, we found that a PKA inhibitor impaired ES cell proliferation, tumor growth and metastasis, which was rescued by the constitutively active PPP1R1A. Together, these results offered new insights into the role and mechanism of PPP1R1A in tumor development and identified an important kinase and phosphatase pathway, PKA/PPP1R1A/PP1, in ES pathogenesis. Our findings strongly suggest a potential therapeutic value of inhibition of the PKA/PPP1R1A/PP1 pathway in the treatment of primary and metastatic ES.	[Luo, W.; Ayello, J.; Rosenblum, J. M.; Cairo, M. S.] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA; [Luo, W.; Cairo, M. S.] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA; [Xu, C.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA; [Dela Cruz, F.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Lessnick, S. L.] Nationwide Childrens Hosp, Columbus, OH USA; [Cairo, M. S.] New York Med Coll, Dept Med, Valhalla, NY 10595 USA; [Cairo, M. S.] New York Med Coll, Dept Immunol & Microbiol, Valhalla, NY 10595 USA; [Cairo, M. S.] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA	New York Medical College; New York Medical College; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; Memorial Sloan Kettering Cancer Center; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; New York Medical College; New York Medical College; New York Medical College	Luo, W (corresponding author), New York Med Coll Grasslands Reservat, Dept Pediat, Vosburgh Room 101, Valhalla, NY 10595 USA.; Luo, W (corresponding author), New York Med Coll Grasslands Reservat, Dept Pathol, Vosburgh Room 101, Valhalla, NY 10595 USA.; Cairo, MS (corresponding author), New York Med Coll, Skyline Off 1N D12, Pediat Med Pathol Microbiol & Immunol & Cell Biol, 40 Sunshine Cottage Rd, Valhalla, NY 10595 USA.	Wen_Luo@nymc.edu; mitchell_cairo@nymc.edu			Pediatric Cancer Research Foundation; Association for Research of Childhood Cancer	Pediatric Cancer Research Foundation; Association for Research of Childhood Cancer	We thank Drs David Virshup, Shirish Shenolikar, Angus Nairn and James Bibb for helpful discussion. We would also like to thank the members of the Cairo and Lessnick laboratories for technical assistance and helpful discussion, and Erin Morris RN for her administrative assistance in the preparation of this manuscript. This work is supported by funds from Pediatric Cancer Research Foundation (MSC) and Association for Research of Childhood Cancer (WL).	Castro ME, 2008, CARCINOGENESIS, V29, P491, DOI 10.1093/carcin/bgm246; Chaturvedi Aashi, 2012, Genes Cancer, V3, P102, DOI 10.1177/1947601912457024; Chi LM, 2016, ACTA NEUROL BELG, V116, P543, DOI 10.1007/s13760-016-0613-6; Chu YY, 2015, CANCER IMMUNOL RES, V3, P333, DOI 10.1158/2326-6066.CIR-14-0114; Cohen PTW, 2002, J CELL SCI, V115, P241; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; Croft DR, 2006, METHOD ENZYMOL, V406, P541, DOI 10.1016/S0076-6879(06)06042-3; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; Dela Cruz F, 2012, DIFFERENTIATION, V83, P220, DOI 10.1016/j.diff.2012.01.001; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; El-Rifai W, 2002, CANCER RES, V62, P4061; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Finger EC, 2015, P NATL ACAD SCI USA, V112, P4441, DOI 10.1073/pnas.1418164112; Fleuren EDG, 2016, NAT REV CANCER, V16, P83, DOI 10.1038/nrc.2015.18; Franzetti GA, 2017, ONCOGENE, V36, P3505, DOI 10.1038/onc.2016.498; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Howe AK, 2004, BBA-MOL CELL RES, V1692, P159, DOI 10.1016/j.bbamcr.2004.03.005; Huang X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133152; HURTA RAR, 1992, BIOCHEM CELL BIOL, V70, P1081, DOI 10.1139/o92-153; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Ladenstein R, 2010, J CLIN ONCOL, V28, P3284, DOI 10.1200/JCO.2009.22.9864; Li FR, 2012, J NEUROSCI RES, V90, P2237, DOI 10.1002/jnr.23121; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Luo W, 2009, ONCOGENE, V28, P4126, DOI 10.1038/onc.2009.262; Luo W, 2007, EMBO J, V26, P1511, DOI 10.1038/sj.emboj.7601607; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; McKenzie AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026552; Mouravlev A, 2007, BRAIN RES, V1130, P31, DOI 10.1016/j.brainres.2006.10.076; Naviglio S, 2009, EXPERT OPIN THER TAR, V13, P83, DOI [10.1517/14728220802602349, 10.1517/14728220802602349 ]; Nicolaou P, 2009, J MOL CELL CARDIOL, V47, P365, DOI 10.1016/j.yjmcc.2009.05.010; Niedan S, 2014, ONCOGENE, V33, P3927, DOI 10.1038/onc.2013.361; Ohali A, 2004, ONCOGENE, V23, P8997, DOI 10.1038/sj.onc.1208060; Patel M, 2012, GENOME RES, V22, P259, DOI 10.1101/gr.125666.111; Postel-Vinay S, 2012, NAT GENET, V44, P323, DOI 10.1038/ng.1085; Potratz J, 2016, MOL ONCOL, V10, P677, DOI 10.1016/j.molonc.2015.12.009; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sainz-Jaspeado M, 2010, MOL CANCER RES, V8, P1489, DOI 10.1158/1541-7786.MCR-10-0060; Sand LGL, 2015, EUR J CANCER, V51, P2624, DOI 10.1016/j.ejca.2015.08.020; Sankar S, 2013, MOL CELL BIOL, V33, P4448, DOI 10.1128/MCB.00241-13; Sankar Savita, 2013, Genes Cancer, V4, P213, DOI 10.1177/1947601913489569; Schaefer KL, 2008, EUR J CANCER, V44, P699, DOI 10.1016/j.ejca.2008.01.020; Scotlandi K, 1996, CANCER RES, V56, P4570; Sechler M, 2017, ONCOGENE, V36, P4150, DOI 10.1038/onc.2017.44; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Volchenboum SL, 2015, J PATHOL CLIN RES, V1, P83, DOI 10.1002/cjp2.9; von Heyking K, 2017, MOL ONCOL, V11, P1288, DOI 10.1002/1878-0261.12057; Waisberg J, 2014, ANTICANCER RES, V34, P5599; Westerlund N, 2011, NAT NEUROSCI, V14, P305, DOI 10.1038/nn.2755; Wiles Elizabeth T, 2013, Genes Cancer, V4, P486, DOI 10.1177/1947601913506115	53	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					798	809		10.1038/onc.2017.378	http://dx.doi.org/10.1038/onc.2017.378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059150				2022-12-17	WOS:000424628100011
J	Otani, Y; Ichikawa, T; Kurozumi, K; Inoue, S; Ishida, J; Oka, T; Shimizu, T; Tomita, Y; Hattori, Y; Uneda, A; Matsumoto, Y; Michiue, H; Date, I				Otani, Y.; Ichikawa, T.; Kurozumi, K.; Inoue, S.; Ishida, J.; Oka, T.; Shimizu, T.; Tomita, Y.; Hattori, Y.; Uneda, A.; Matsumoto, Y.; Michiue, H.; Date, I.			Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion	ONCOGENE			English	Article							INCREASED EXPRESSION; GLIOBLASTOMA; PHENOTYPES; CANCER; TEMOZOLOMIDE; TRANSITION; RESISTANT; THERAPY; TARGETS; MODELS	Glioblastoma has the poorest prognosis, and is characterized by excessive invasion and angiogenesis. To determine the invasive mechanisms, we previously used two glioma cell lines (J3T-1 and J3T-2) with different invasive phenotypes. The J3T-1 showed abundant angiogenesis and tumor cell invasion around neovasculature, while J3T-2 showed diffuse cell infiltration into surrounding healthy parenchyma. Microarray analyses were used to identify invasion-related genes in J3T-2 cells, and the expressed genes and their intracellular and intratumoral distribution patterns were evaluated in J3T-2 cell lines, human glioma cell lines, human glioblastoma stem cells and human glioblastoma specimens. To determine the role of the invasion-related genes, invasive activities were evaluated in vitro and in vivo. Fibroblast growth factor 13 (FGF13) was overexpressed in J3T-2 cells compared to J3T-1 cells, and in human glioma cell lines, human glioblastoma stem cells and human glioblastoma specimens, when compared to that of normal human astrocytes. Immunohistochemical staining and the RNA-seq (sequencing) data from the IVY Glioblastoma Atlas Project showed FGF13 expression in glioma cells in the invasive edges of tumor specimens. Also, the intracellular distribution was mainly in the cytoplasm of tumor cells and colocalized with tubulin. Overexpression of FGF13 stabilized tubulin dynamics in vitro and knockdown of FGF13 decreased glioma invasion both in vitro and in vivo and prolonged overall survival of several xenograft models. FGF13 was negatively regulated by hypoxic condition. Silencing of FGF13 also decreased in vivo bevacizumab-induced glioma invasion. In conclusion, FGF13 regulated glioma cell invasion and bevacizumab-induced glioma invasion, and could be a novel target for glioma treatment.	[Otani, Y.; Ichikawa, T.; Kurozumi, K.; Ishida, J.; Oka, T.; Shimizu, T.; Tomita, Y.; Hattori, Y.; Uneda, A.; Matsumoto, Y.; Date, I.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Okayama, Japan; [Inoue, S.] Okayama City Hosp, Dept Neurosurg, Okayama, Japan; [Michiue, H.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Physiol, Okayama, Japan	Okayama University; Okayama University	Ichikawa, T (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Kita Ku, 2-5-1 Shikata, Okayama 7008558, Japan.	tomoichi@cc.okayama-u.ac.jp	Otani, Yoshihiro/AEG-1263-2022; MICHIUE, Hiroyuki/B-2320-2011; Uneda, Atsuhito/ABB-2477-2021; Kurozumi, Kazuhiko/AGT-1723-2022	Otani, Yoshihiro/0000-0002-1615-5125; Kurozumi, Kazuhiko/0000-0002-6942-9919; Matsumoto, Yuji/0000-0001-8798-381X; Uneda, Atsuhito/0000-0001-9709-6034	Japanese Ministry of Education, Culture, Sports, Science, and Technology [22591611, 25462261, 23592125, 26462182]	Japanese Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by grants-in-aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology to TI (No. 22591611 and No. 25462261) and KK (No. 23592125 and No. 26462182). We thank Dr H Wakimoto at Massachusetts General Hospital for providing the human glioblastoma-derived cancer stem cell line.<SUP>18,42</SUP> We thank M Arao and U Ukai in the Department of Neurological Surgery and A Ueda in the Department of Physiology for their technical assistance. The following medical students also contributed to our experiments: K Yamamoto and Y Inoue. The accession number for the gene expression data reported in this paper is GSE88740.	Barker CA, 2013, INT J RADIAT ONCOL, V86, P504, DOI 10.1016/j.ijrobp.2013.02.012; BERENS ME, 1993, IN VITRO CELL DEV-AN, V29A, P310, DOI 10.1007/BF02633959; Berezovsky AD, 2014, NEOPLASIA, V16, pe19; Berges R, 2012, MOL THER, V20, P1367, DOI 10.1038/mt.2012.45; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Delay M, 2012, CLIN CANCER RES, V18, P2930, DOI 10.1158/1078-0432.CCR-11-2390; Draberova E, 2011, J NEUROPATH EXP NEUR, V70, P811, DOI 10.1097/NEN.0b013e31822c256d; Fang XF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-11; Fife CM, 2014, BRIT J PHARMACOL, V171, P5507, DOI 10.1111/bph.12704; Fujimura A, 2013, NEOPLASIA, V15, P1272, DOI 10.1593/neo.131440; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Hampl JA, 2003, HUM GENE THER, V14, P611, DOI 10.1089/104303403321618137; Hayashi K, 2016, SCI REP-UK, V6, DOI 10.1038/srep23372; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ichikawa T, 2002, NEOPLASIA, V4, P523, DOI 10.1038/sj.neo.7900266; Ichikawa T, 2016, NEUROL MED-CHIR, V56, P387, DOI 10.2176/nmc.ra.2016-0077; Inoue S, 2012, WORLD NEUROSURG, V78, P670, DOI 10.1016/j.wneu.2011.09.005; Ishida J, 2014, TRANSL ONCOL, V7, P292, DOI 10.1016/j.tranon.2014.02.016; Katsetos CD, 2015, SEMIN PEDIATR NEUROL, V22, P49, DOI 10.1016/j.spen.2015.03.009; Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Maruo T, 2013, NEUROPATHOLOGY, V33, P264, DOI 10.1111/j.1440-1789.2012.01361.x; Nagai Shoichi, 2011, Genes Cancer, V2, P859, DOI 10.1177/1947601911431839; Nishimoto S, 2007, J BIOL CHEM, V282, P24255, DOI 10.1074/jbc.M704277200; Oehler C, 2012, ONCOLOGY-BASEL, V83, P1, DOI 10.1159/000339152; Oka T, 2016, SCI REP-UK, V6, DOI 10.1038/srep33319; Okada T, 2013, SCI REP-UK, V3, DOI 10.1038/srep02899; Onishi M, 2015, BRAIN TUMOR PATHOL, V32, P184, DOI 10.1007/s10014-015-0216-6; Onishi M, 2013, NEUROPATHOLOGY, V33, P162, DOI 10.1111/j.1440-1789.2012.01344.x; Onishi M, 2011, BRAIN TUMOR PATHOL, V28, P13, DOI 10.1007/s10014-010-0007-z; Piao Y, 2016, NEURO-ONCOLOGY, V18, P1230, DOI 10.1093/neuonc/now030; Piao YJ, 2012, NEURO-ONCOLOGY, V14, P1379, DOI 10.1093/neuonc/nos158; Saito N, 2014, STEM CELLS, V32, P301, DOI 10.1002/stem.1528; Scherer HJ, 1940, J NEUROL PSYCHIATRY, V3, P147, DOI 10.1136/jnnp.3.2.147; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Song YW, 2014, ACTA BIOCH BIOPH SIN, V46, P1034, DOI 10.1093/abbs/gmu099; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669; Wakimoto H, 2012, NEURO-ONCOLOGY, V14, P132, DOI 10.1093/neuonc/nor195; Wakimoto H, 2009, CANCER RES, V69, P3472, DOI 10.1158/0008-5472.CAN-08-3886; Wang F, 2015, ONCOTARGET, V6, P21468, DOI 10.18632/oncotarget.4097; Wittmack EK, 2004, J NEUROSCI, V24, P6765, DOI 10.1523/JNEUROSCI.1628-04.2004; Wu QF, 2012, CELL, V149, P1549, DOI 10.1016/j.cell.2012.04.046; Yu L, 2016, INT J CANCER, V139, P140, DOI 10.1002/ijc.30048	44	22	24	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					777	786		10.1038/onc.2017.373	http://dx.doi.org/10.1038/onc.2017.373			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059154	Green Submitted			2022-12-17	WOS:000424628100009
J	Gelato, KA; Schockel, L; Klingbeil, O; Ruckert, T; Lesche, R; Toedling, J; Kalfon, E; Heroult, M; Lejeune, P; Monning, U; Fernandez-Montalvan, AE; Baurle, S; Siegel, S; Haendler, B				Gelato, K. A.; Schoeckel, L.; Klingbeil, O.; Rueckert, T.; Lesche, R.; Toedling, J.; Kalfon, E.; Heroult, M.; Lejeune, P.; Moenning, U.; Fernandez-Montalvan, A. E.; Baeurle, S.; Siegel, S.; Haendler, B.			Super-enhancers define a proliferative PGC-1 alpha-expressing melanoma subgroup sensitive to BET inhibition	ONCOGENE			English	Article							INTEGRATIVE GENOMICS VIEWER; TRANSCRIPTION FACTORS; SELECTIVE-INHIBITION; EXPRESSION PROFILES; BROMODOMAIN; SUPPRESSES; PGC1-ALPHA; APOPTOSIS; LYMPHOMA; I-BET151	Metabolic changes are linked to epigenetic reprogramming and play important roles in several tumor types. PGC-1 alpha is a transcriptional coactivator controlling mitochondrial biogenesis and is linked to oxidative phosphorylation. We provide evidence that melanoma models with elevated PGC-1 alpha levels are characteristic of the proliferative phenotype and are sensitive to bromodomain and extra-terminal domain (BET) inhibitor treatment. A super-enhancer region highly occupied by the BET family member BRD4was identified for the PGC-1 alpha gene. BET inhibitor treatment prevented this interaction, leading to a dramatic reduction of PGC-1 alpha expression. Accordingly, BET inhibition diminished respiration and mitochondrial function in cells. In vivo, melanoma models with high PGC-1 alpha expression strongly responded to BET inhibition by reduction of PGC-1 alpha and impaired tumor growth. Altogether, our findings identify epigenetic regulatory elements that define a subset of melanomas with high sensitivity to BET inhibition, which opens up the opportunity to define melanoma patients most likely to respond to this treatment, depending on their tumor characteristics.	[Gelato, K. A.; Schoeckel, L.; Klingbeil, O.; Rueckert, T.; Lesche, R.; Toedling, J.; Kalfon, E.; Lejeune, P.; Moenning, U.; Fernandez-Montalvan, A. E.; Baeurle, S.; Siegel, S.; Haendler, B.] Bayer AG, Drug Discovery, Mullerstr 178, D-13353 Berlin, Germany; [Rueckert, T.] Deutsch Rheuma Forschungszentrum, Innate Immun, Berlin, Germany; [Toedling, J.] Charite, Dept Pediat Oncol & Hematol, Berlin, Germany; [Heroult, M.] Bayer AG, Corp Res & Dev, Leverkusen, Germany; [Klingbeil, O.] Cold Spring Harbor Lab, Canc Ctr, Cold Spring Harbor, NY 11724 USA	Bayer AG; Deutsches Rheuma-Forschungszentrum (DRFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Bayer AG; Cold Spring Harbor Laboratory	Haendler, B (corresponding author), Bayer AG, Drug Discovery, Mullerstr 178, D-13353 Berlin, Germany.	bernard.haendler@bayer.com		Toedling, Joern/0000-0003-1471-1295; Klingbeil, Olaf/0000-0001-7248-7506; Fernandez-Montalvan, Amaury/0000-0001-9156-0000				Abildgaard C, 2015, TRENDS MOL MED, V21, P164, DOI 10.1016/j.molmed.2014.12.007; Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bernasconi E, 2017, BRIT J HAEMATOL, V178, P936, DOI 10.1111/bjh.14803; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Bhagwat AS, 2016, CELL REP, V15, P519, DOI 10.1016/j.celrep.2016.03.054; Caro P, 2012, CANCER CELL, V22, P547, DOI 10.1016/j.ccr.2012.08.014; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Gallagher SJ, 2014, PIGM CELL MELANOMA R, V27, P1126, DOI 10.1111/pcmr.12282; Gallagher SJ, 2014, J INVEST DERMATOL, V134, P2795, DOI 10.1038/jid.2014.243; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gelato KA, 2016, EXPERT OPIN THER TAR, V20, P783, DOI 10.1517/14728222.2016.1134490; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Heinemann A, 2015, ONCOTARGET, V6, P21507, DOI 10.18632/oncotarget.4242; Ho JH, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-76; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Jung M, 2015, EPIGENOMICS-UK, V7, P487, DOI 10.2217/epi.14.91; Klingbeil O, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.271; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Leiter Ulrike, 2014, Adv Exp Med Biol, V810, P120; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Lo JA, 2014, SCIENCE, V346, P945, DOI 10.1126/science.1253735; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Luo C, 2016, NATURE, V537, P422, DOI 10.1038/nature19347; Mochizuki K, 2008, J BIOL CHEM, V283, P9040, DOI 10.1074/jbc.M707603200; Nagarajan S, 2014, CELL REP, V8, P459, DOI 10.1016/j.celrep.2014.06.016; Niezgoda A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/851387; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Roe JS, 2015, MOL CELL, V58, P1028, DOI 10.1016/j.molcel.2015.04.011; Salmon-Divon M, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-415; Schockel L, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0138-0; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Shakhova O, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004877; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Villena JA, 2015, FEBS J, V282, P647, DOI 10.1111/febs.13175; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Zhang WJ, 2015, CURR OPIN PHARMACOL, V23, P68, DOI 10.1016/j.coph.2015.05.015	45	22	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					512	521		10.1038/onc.2017.325	http://dx.doi.org/10.1038/onc.2017.325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28991225	Green Published, hybrid			2022-12-17	WOS:000423331600009
J	Chiang, WF; Cheng, TM; Chang, CC; Pan, SH; Changou, CA; Chang, TH; Lee, KH; Wu, SY; Chen, YF; Chuang, KH; Shieh, DB; Chen, YL; Tu, CC; Tsui, WL; Wu, MH				Chiang, W-F; Cheng, T-M; Chang, C-C; Pan, S-H; Changou, C. A.; Chang, T-H; Lee, K-H; Wu, S-Y; Chen, Y-F; Chuang, K-H; Shieh, D-B; Chen, Y-L; Tu, C-C; Tsui, W-L; Wu, M-H			Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation	ONCOGENE			English	Article							SINGLE-DOMAIN ANTIBODY; CANCER PROGRESSION; PROTEIN; ADENOCARCINOMA; INVASIVENESS; DIMERIZATION; ACTIVATION; FRAGMENTS; INVASION; THERAPY	Aberrant protein glycosylation could be a distinct surface-marker of cancer cells that influences cancer progression and metastasis because glycosylation can regulate membrane protein folding which alters receptor activation and changes epitope exposure for antibody (Ab) recognition. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), a glycophosphoinositol-anchored protein, is a heavily glycosylated tumor antigen. However, the clinical significance and biological effect of CEACAM6 glycosylation has not been addressed in cancers. We recently developed an anti-CEACAM6 Ab (TMU) from an immune llama library which can be engineered to a single-domain (sd)Ab or a heavy-chain (HC)Ab. The TMU HCAb specifically recognized glycosylated CEACAM6 compared to the conventional antibodies. Using the TMU HCAb, we found that glycosylated CEACAM6 was a tumor marker associated with recurrence in early-stage OSCC (oral squamous cell carcinoma) patients. CEACAM6 promoted OSCC cell invasion, migration, cytoskeletal rearrangement, and metastasis via interaction with epidermal growth factor (EGF) receptor (EGFR) and enhancing EGFR activation, clustering and intracellular signaling cascades. These functions were modulated by N-acetylglucosaminyltransferase 5 (MGAT5) which mediated N-glycosylation at Asn(256) (N256) of CEACAM6. Finally, the TMU sdAb and HCAb treatment inhibited the migration, invasion and EGF-induced signaling in CEACAM6-overexpressing cells. In conclusion, the complex N-glycosylation of CEACAM6 is critical for EGFR signaling of OSCC invasion and metastasis. Targeting glycosylated CEACAM6 with the TMU sdAb or TMU HCAb could be a feasible therapy for OSCC.	[Chiang, W-F; Cheng, T-M; Chang, C-C; Changou, C. A.; Tsui, W-L; Wu, M-H] Taipei Med Univ, Grad Inst Translat Med, Coll Med Sci & Technol, 250 Wuxing St, Taipei 11031, Taiwan; [Chiang, W-F] Chi Mei Med Ctr, Oral & Maxillofacial Sect, Tainan, Taiwan; [Chiang, W-F] Natl Yang Ming Univ, Sch Dent, Taipei, Taiwan; [Chang, C-C] Taipei Med Univ, Coll Pharm, PhD Program Biotechnol Res & Dev, Taipei, Taiwan; [Pan, S-H] Natl Taiwan Univ, Grad Inst Med Genom & Prote, Coll Med, Taipei, Taiwan; [Pan, S-H] Natl Taiwan Univ, PhD Program Translat Med, Taipei, Taiwan; [Pan, S-H] Acad Sinica, Taipei, Taiwan; [Pan, S-H] Natl Taiwan Univ, Genome & Syst Biol Degree Program, Taipei, Taiwan; [Changou, C. A.; Lee, K-H] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan; [Chang, T-H; Wu, M-H] Taipei Med Univ, Grad Inst Biomed Informat, Coll Med Sci & Technol, Taipei, Taiwan; [Wu, S-Y] Taipei Med Univ, Wan Fang Hosp, Dept Radiat Oncol, Taipei, Taiwan; [Wu, S-Y] Taipei Med Univ, Sch Med, Coll Med, Dept Internal Med, Taipei, Taiwan; [Chen, Y-F] Kaohsiung Med Univ, Grad Inst Nat Prod, Coll Pharm, Kaohsiung, Taiwan; [Chuang, K-H] Taipei Med Univ, Grad Inst Pharmacognosy, Coll Pharm, Taipei, Taiwan; [Shieh, D-B; Chen, Y-L] Natl Cheng Kung Univ & Hosp, Inst Basic Med Sci, Inst Oral Med, Tainan, Taiwan; [Shieh, D-B; Chen, Y-L] Natl Cheng Kung Univ & Hosp, Dept Stomatol, Coll Med, Tainan, Taiwan; [Shieh, D-B] Natl Cheng Kung Univ, Adv Optoelect Technol Ctr, Tainan, Taiwan; [Shieh, D-B] Natl Cheng Kung Univ, Ctr Micro Nano Sci & Technol, Tainan, Taiwan; [Tu, C-C] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Wu, M-H] Taipei Med Univ, Ctr Cell Therapy & Regenerat Med, Taipei, Taiwan	Taipei Medical University; Chi Mei Hospital; National Yang Ming Chiao Tung University; Taipei Medical University; National Taiwan University; National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Kaohsiung Medical University; Taipei Medical University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; Taipei Medical University; Taipei Medical University	Wu, MH (corresponding author), Taipei Med Univ, Grad Inst Translat Med, Coll Med Sci & Technol, 250 Wuxing St, Taipei 11031, Taiwan.	mhwu1015@tmu.edu.tw	Chiang, Wei-Fan/L-6537-2019; CHEN, YIH-FUNG/CAH-9367-2022; Chen, Yuh-Ling/AAS-7957-2021	Chiang, Wei-Fan/0000-0002-9240-1404; CHEN, YIH-FUNG/0000-0002-5595-1319; Pan, Szu-Hua/0000-0002-0138-0434; Wu, Szu-Yuan/0000-0001-5637-558X	National Core Facility Program for Biotechnology Grants of the Ministry of Science and Technology [MOST 104-2319-B-001-001]; Ministry of Science and Technology, Taiwan [MOST 103-2320-B-038-013-MY3, MOST 104-2321-B-038-007]; Taipei Medical University [TMU101-AE3-Y20, 103CM-TMU-01, CLFHR10222, TMU-T104-06]; Chi-Mei Medical Center, Taiwan; National Health Research Institutes, Taiwan [NHRI-EX105-10409BC]	National Core Facility Program for Biotechnology Grants of the Ministry of Science and Technology; Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Taipei Medical University; Chi-Mei Medical Center, Taiwan; National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan)	RNAi reagents were obtained from the National Core Facility for Manipulation of Gene Function by RNAi, miRNA, miRNA sponges, and the CRISPR/Genomic Research Center, Academia Sinica, supported by the National Core Facility Program for Biotechnology Grants of the Ministry of Science and Technology (MOST 104-2319-B-001-001). The human samples were from the Human Tumor Tissue Bank, Chi-Mei Medical Center (Liouying, Tainan, Taiwan). We thank the Image and Bioinformatics Core Facility of Taipei Medical University which provided assistance with deconvolution microscopy and the microarray analysis. This work was supported by grants MOST 103-2320-B-038-013-MY3 and MOST 104-2321-B-038-007 from the Ministry of Science and Technology, Taiwan; grants TMU101-AE3-Y20, 103CM-TMU-01, CLFHR10222 and TMU-T104-06 from Taipei Medical University and Chi-Mei Medical Center, Taiwan; and grant NHRI-EX105-10409BC from the National Health Research Institutes, Taiwan.	Balk-Moller E, 2014, AM J PATHOL, V184, P1198, DOI 10.1016/j.ajpath.2013.12.013; Baral TN, 2011, J IMMUNOL METHODS, V371, P70, DOI 10.1016/j.jim.2011.06.017; Beauchemin N, 2013, CANCER METAST REV, V32, P643, DOI 10.1007/s10555-013-9444-6; Blumenthal RD, 2005, CANCER RES, V65, P8809, DOI 10.1158/0008-5472.CAN-05-0420; Bonsor DA, 2015, P NATL ACAD SCI USA, V112, P13561, DOI 10.1073/pnas.1509511112; Camacho-Leal P, 2007, J CELL PHYSIOL, V211, P791, DOI 10.1002/jcp.20989; Cameron S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-74; Chan CHF, 2004, MOL THER, V9, P775, DOI 10.1016/j.ymthe.2004.03.009; Chen YF, 2009, CANCER RES, V69, P8585, DOI 10.1158/0008-5472.CAN-09-2284; Cheng TM, 2012, EUR J CANCER, V50, P713; Cooper JB, 2009, HEAD NECK-J SCI SPEC, V31, P1086, DOI 10.1002/hed.21109; Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602; Duxbury MS, 2004, BRIT J CANCER, V91, P1384, DOI 10.1038/sj.bjc.6602113; Duxbury MS, 2004, ONCOGENE, V23, P5834, DOI 10.1038/sj.onc.1207775; Frenken LGJ, 2000, J BIOTECHNOL, V78, P11, DOI 10.1016/S0168-1656(99)00228-X; Gemei M, 2013, CANCER-AM CANCER SOC, V119, P729, DOI 10.1002/cncr.27794; Jacquemet G, 2015, CURR OPIN CELL BIOL, V36, P23, DOI 10.1016/j.ceb.2015.06.007; Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820; Khosroshahi SA, 2016, PROTEIN EXPRES PURIF, V120, P59, DOI 10.1016/j.pep.2015.12.005; Kobayashi M, 2012, BRIT J CANCER, V107, P1745, DOI 10.1038/bjc.2012.422; Kolla V, 2009, AM J PHYSIOL-LUNG C, V296, pL1019, DOI 10.1152/ajplung.90596.2008; Kuriyan J, 2007, NATURE, V450, P983, DOI 10.1038/nature06524; Lau KS, 2008, GLYCOBIOLOGY, V18, P750, DOI 10.1093/glycob/cwn071; Liu YC, 2011, P NATL ACAD SCI USA, V108, P11332, DOI 10.1073/pnas.1107385108; Monteiro LS, 2014, ORAL DIS, V20, P178, DOI 10.1111/odi.12087; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Riley CJ, 2009, CANCER RES, V69, P1933, DOI 10.1158/0008-5472.CAN-08-2707; Sato Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep24823; Sharafinski ME, 2010, HEAD NECK-J SCI SPEC, V32, P1412, DOI 10.1002/hed.21365; Takenaka Y, 2002, GLYCOCONJUGATE J, V19, P543, DOI 10.1023/B:GLYC.0000014084.01324.15; Taniguchi N, 2015, ADV CANCER RES, V126, P11, DOI 10.1016/bs.acr.2014.11.001; van Gisbergen KPJM, 2005, CANCER RES, V65, P5935, DOI 10.1158/0008-5472.CAN-04-4140; WONG DYK, 1990, J ORAL MAXIL SURG, V48, P385, DOI 10.1016/0278-2391(90)90436-6; Wu MH, 2011, CLIN CANCER RES, V17, P1306, DOI 10.1158/1078-0432.CCR-10-1824; Wu MH, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001143; Xu CC, 2015, NAT REV MOL CELL BIO, V16, P742, DOI 10.1038/nrm4073; Yang SC, 2003, J ORAL PATHOL MED, V32, P600, DOI 10.1034/j.1600-0714.2003.00199.x; Zang MD, 2015, BBA-MOL BASIS DIS, V1852, P1020, DOI 10.1016/j.bbadis.2015.02.005; Zang MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112908; Zhuo Y, 2016, J BIOL CHEM, V291, P20085, DOI 10.1074/jbc.M116.740050	40	22	23	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					116	127		10.1038/onc.2017.303	http://dx.doi.org/10.1038/onc.2017.303			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28892050				2022-12-17	WOS:000422625000012
J	Wang, Z; He, Y; Deng, W; Lang, L; Yang, H; Jin, B; Kolhe, R; Ding, HF; Zhang, J; Hai, T; Yan, C				Wang, Z.; He, Y.; Deng, W.; Lang, L.; Yang, H.; Jin, B.; Kolhe, R.; Ding, H-F; Zhang, J.; Hai, T.; Yan, C.			Atf3 deficiency promotes genome instability and spontaneous tumorigenesis in mice	ONCOGENE			English	Article							ACTIVATING TRANSCRIPTION FACTOR-3; DNA-DAMAGE RESPONSE; RADIATION-INDUCED APOPTOSIS; TUMOR SUPPRESSION; PROTEIN SUPPRESSES; P53-DEFICIENT MICE; CANCER DEVELOPMENT; ADAPTIVE-RESPONSE; P53 PROTEINS; LUNG-CANCER	Mice lacking genes involving in the DNA-damage response (DDR) are often tumor prone owing to genome instability caused by oncogenic challenges. Previous studies demonstrate that activating transcription factor 3 (ATF3), a common stress sensor, can activate the tumor suppressor p53 and regulate expression of p53 target genes upon DNA damage. However, whether ATF3 contributes to the maintenance of genome stability and tumor suppression remains unknown. Here we report that Atf3-deficient (Atf3(-/-)) mice developed spontaneous tumors, and died significantly earlier than wild-type (Atf3(+/+)) mice. Consistent with these results, Atf3(-/-) mouse embryonic fibroblasts (MEFs) had more aberrant chromosomes and micronuclei, and were genetically unstable. Whereas we demonstrated that ATF3 activated p53 and promoted its pro-apoptotic activity in mouse thymi and small intestines, the chromosomal instability caused by Atf3 deficiency was largely dependent on the regulation of p53 by ATF3. Interestingly, loss of Atf3 also promoted spontaneous tumorigenesis in Trp53(+/-) mice, but did not affect tumor formation in Trp53(-/-) mice. Our results thus provide the first genetic evidence linking ATF3 to the suppression of the early development of cancer, and underscore the importance of ATF3 in the maintenance of genome integrity.	[Wang, Z.; He, Y.; Lang, L.; Yang, H.; Ding, H-F; Yan, C.] Augusta Univ, Georgia Canc Ctr, 1410 Laney Walker Blvd,CN2134, Augusta, GA 30912 USA; [Deng, W.] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Jin, B.] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China; [Kolhe, R.; Ding, H-F] Augusta Univ, Dept Pathol, Med Coll Georgia, Augusta, GA USA; [Zhang, J.] Case Western Reserve Univ, Dept Radiat Oncol, Cleveland, OH 44106 USA; [Hai, T.] Ohio State Univ, Dept Biol Chem & Pharmacol, Columbus, OH 43210 USA; [Yan, C.] Augusta Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA USA	University System of Georgia; Augusta University; State Key Lab Oncology South China; Sun Yat Sen University; Dalian Medical University; University System of Georgia; Augusta University; Case Western Reserve University; University System of Ohio; Ohio State University; University System of Georgia; Augusta University	Yan, C (corresponding author), Augusta Univ, Georgia Canc Ctr, 1410 Laney Walker Blvd,CN2134, Augusta, GA 30912 USA.; Deng, W (corresponding author), Sun Yat Sen Univ, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China.	dengwg@sysucc.org.cn; cyan@augusta.edu	Lang, Liwei/I-7744-2019; Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Yan, Chunhong/0000-0002-3974-7991; Lang, Liwei/0000-0002-2374-645X; Ding, Han-Fei/0000-0001-5702-3439; KOLHE, RAVINDRA/0000-0002-8283-2403	NIH [R01CA139107]; National Science Foundation of China [81472178]; State 973 Program of China [2014CB542005]; NATIONAL CANCER INSTITUTE [R01CA139107, R01CA154625] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); State 973 Program of China(National Basic Research Program of China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the NIH grant R01CA139107 to CY, and the grants from the National Science Foundation of China (81472178) and the State 973 Program of China (2014CB542005) to WD.	Armata HL, 2007, CANCER RES, V67, P11696, DOI 10.1158/0008-5472.CAN-07-1610; Bar J, 2016, NEOPLASIA, V18, P525, DOI 10.1016/j.neo.2016.07.004; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Beleza-Meireles A, 2008, EUR J ENDOCRINOL, V158, P729, DOI 10.1530/EJE-07-0793; Beucher A, 2009, EMBO J, V28, P3413, DOI 10.1038/emboj.2009.276; Boehme KA, 2009, CRIT REV BIOCHEM MOL, V44, P367, DOI 10.3109/10409230903401507; Campbell MR, 2006, ONCOGENE, V25, P2531, DOI 10.1038/sj.onc.1209277; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cui HM, 2016, J BIOL CHEM, V291, P10847, DOI 10.1074/jbc.M115.713099; Cui HM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7752; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Gold ES, 2012, J EXP MED, V209, P807, DOI 10.1084/jem.20111202; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Hackl C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-668; Hai T, 1999, GENE EXPRESSION, V7, P321; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; HARVEY M, 1993, ONCOGENE, V8, P2457; Hoetzenecker W, 2012, NAT MED, V18, P128, DOI 10.1038/nm.2557; Ishiguro T, 1996, CANCER RES, V56, P875; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacquet K, 2016, MOL CELL, V62, P409, DOI 10.1016/j.molcel.2016.03.031; Jan YH, 2012, CANCER RES, V72, P5119, DOI 10.1158/0008-5472.CAN-12-1842; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kawauchi J, 2002, J BIOL CHEM, V277, P39025, DOI 10.1074/jbc.M202974200; Keyes WM, 2006, P NATL ACAD SCI USA, V103, P8435, DOI 10.1073/pnas.0602477103; Kim KH, 2010, NUCLEIC ACIDS RES, V38, P48, DOI 10.1093/nar/gkp865; Kool J, 2003, ONCOGENE, V22, P4235, DOI 10.1038/sj.onc.1206611; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; MERRITT AJ, 1994, CANCER RES, V54, P614; Mo PL, 2010, J BIOL CHEM, V285, P26908, DOI 10.1074/jbc.M110.132597; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Shin G, 2011, CANCER INFORM, V10, P149, DOI 10.4137/CIN.S7226; Sooraj D, 2016, MOL CANCER THER, V15, P1726, DOI 10.1158/1535-7163.MCT-15-0890; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Taketani K, 2012, ONCOGENE, V31, P2210, DOI 10.1038/onc.2011.397; Turchi L, 2008, CELL DEATH DIFFER, V15, P1472, DOI 10.1038/cdd.2008.74; Turchi L, 2009, CELL DEATH DIFFER, V16, P728, DOI 10.1038/cdd.2009.2; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang Z, 2016, ONCOGENE, V35, P3555, DOI 10.1038/onc.2015.417; Wang Z, 2015, ONCOGENE, V34, P4975, DOI 10.1038/onc.2014.426; Wang ZY, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1010948; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Wei SS, 2014, J BIOL CHEM, V289, P8947, DOI 10.1074/jbc.M113.503755; Wolford CC, 2013, J CLIN INVEST, V123, P2893, DOI 10.1172/JCI64410; Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996; Xie JJ, 2014, ONCOTARGET, V5, P8569, DOI 10.18632/oncotarget.2322; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yan CH, 2005, MOL CANCER THER, V4, P233; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yan CH, 2006, CELL CYCLE, V5, P926, DOI 10.4161/cc.5.9.2714; Yin X, 2008, ONCOGENE, V27, P2118, DOI 10.1038/sj.onc.1210861; Yoo YD, 2017, EMBO REP, V18, P150, DOI [10.15252/embr.201642360, 10.15252/embr.201744761]; Yuan XL, 2013, CANCER RES, V73, P3625, DOI 10.1158/0008-5472.CAN-12-3879; Zhang C, 2002, BIOCHEM BIOPH RES CO, V297, P1302, DOI 10.1016/S0006-291X(02)02382-3; Zhao J, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2664-8; Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026744	69	22	22	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					18	27		10.1038/onc.2017.310	http://dx.doi.org/10.1038/onc.2017.310			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869597	Green Accepted			2022-12-17	WOS:000422625000003
J	Hsu, FF; Chiang, MT; Li, FA; Yeh, CT; Lee, WH; Chau, LY				Hsu, F-F; Chiang, M-T; Li, F-A; Yeh, C-T; Lee, W-H; Chau, L-Y			Acetylation is essential for nuclear heme oxygenase-1-enhanced tumor growth and invasiveness	ONCOGENE			English	Article							SIGNAL PEPTIDE PEPTIDASE; CHRONIC MYELOID-LEUKEMIA; PROSTATE-CANCER CELLS; CONFERS RESISTANCE; HDAC INHIBITORS; LUNG-CANCER; PROLIFERATION; INVASION; JUND; TRANSCRIPTION	Overexpression of heme oxygenase-1 (HO-1), an endoplasmic reticulum-anchored enzyme, is observed in many cancers. HO-1 nuclear translocation has been shown to correlate with progression of several cancers. We recently reported that HO-1 is susceptible to intramembrane proteolysis and translocates to the nucleus to promote cancer growth and invasiveness without depending on its enzymatic activity. In the present study, we show that the HO-1 lacking C-terminal transmembrane segment (t-HO-1) was susceptible to acetylation by p300 and CREB-binding protein (CBP) histone acetyltransferase in the nucleus. Mass spectrometry analysis of HO-1 isolated from human embryonic kidney cells 293T (HEK293T) cells overexpressing CBP and t-HO-1 revealed two acetylation sites located at K243 and K256. Mutation of both lysine residues to arginine (R) abolished t-HO-1-enhanced tumor cell growth, migration and invasion. However, mutation of the lysine residues to glutamine (Q), a mimic of acetylated lysine, had no significant effect on t-HO-1-mediated tumorigenicity. Mechanistic studies demonstrated that transcriptional factor JunD interacted with wild-type (WT) t-HO-1 and mutant carrying K243/256Q but not K243/256 R mutation. Moreover, JunD-induced AP-1 transcriptional activity was significantly enhanced by coexpression with WT and acetylation-mimic but not acetylation-defective t-HO-1. Consistent with the in vitro observations, the implication of K243/256 acetylation in t-HO-1-enhanced tumorigenicity was also demonstrated in xenograft models. Immunohistochemistry performed with a specific antibody against acetyl-HO-1 showed the positive acetyl-HO-1 nuclear staining in human lung cancer tissues but not in the corresponding non-tumor tissues, supporting its clinical significance. Collectively, our findings highlight the importance of nuclear HO-1 post-translational modification in the induction of cancer progression.	[Hsu, F-F; Chiang, M-T; Li, F-A; Chau, L-Y] Acad Sinica, Inst Biomed Sci, 128,Sec 2,Acad Rd, Taipei 115, Taiwan; [Yeh, C-T; Lee, W-H] Taipei Med Univ, Shuang Ho Hosp, Canc Ctr, Taipei, Taiwan	Academia Sinica - Taiwan; Taipei Medical University; Shuang Ho Hospital	Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sec 2,Acad Rd, Taipei 115, Taiwan.	lyc@ibms.sinica.edu.tw	Chau, Lee-Young/N-7659-2018; Li, Fu-An/M-8506-2019	Chau, Lee-Young/0000-0002-6316-2328; Li, Fu-An/0000-0002-0580-7765	Ministry of Science and Technology Taiwan [MOST 103-2320-B-001-013-MY3]; IBMS proteomics core	Ministry of Science and Technology Taiwan(Ministry of Science and Technology, Taiwan); IBMS proteomics core	This work was supported by the Ministry of Science and Technology Taiwan (MOST 103-2320-B-001-013-MY3). We thank IBMS proteomics core for the LC-MS analysis.	Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; Biswas C, 2014, J BIOL CHEM, V289, P26882, DOI 10.1074/jbc.M114.567685; Boname JM, 2014, J CELL BIOL, V205, P847, DOI 10.1083/jcb.201312009; Chau LY, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0128-0; Collinson EJ, 2011, J BIOL CHEM, V286, P2205, DOI 10.1074/jbc.M110.187062; Das C, 2005, IUBMB LIFE, V57, P137, DOI 10.1080/15216540500090629; Degese MS, 2012, LUNG CANCER, V77, P168, DOI 10.1016/j.lungcan.2012.02.016; Di Biase S, 2016, CANCER CELL, V30, P136, DOI 10.1016/j.ccell.2016.06.005; Gandini NA, 2012, EXP MOL PATHOL, V93, P237, DOI 10.1016/j.yexmp.2012.05.001; Hanna Colton, 2016, J Vis Exp, DOI 10.3791/54944; Hernandez JM, 2008, ONCOGENE, V27, P4757, DOI 10.1038/onc.2008.120; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Hsu FF, 2015, ONCOGENE, V34, P2360, DOI 10.1038/onc.2014.166; Hwang HW, 2009, J BIOL CHEM, V284, P22672, DOI 10.1074/jbc.M109.028001; Kajanne R, 2009, INT J ONCOL, V35, P1175, DOI 10.3892/ijo_00000434; Kaypee S, 2016, PHARMACOL THERAPEUT, V162, P98, DOI 10.1016/j.pharmthera.2016.01.011; Li MY, 2008, EUR RESPIR J, V32, P911, DOI 10.1183/09031936.00064508; Lin KT, 2012, CLIN CANCER RES, V18, P4691, DOI 10.1158/1078-0432.CCR-12-0633; Lin PH, 2013, ONCOGENE, V32, P2325, DOI 10.1038/onc.2012.244; Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200; Liu XF, 2016, CELL REP, V14, P1169, DOI 10.1016/j.celrep.2015.12.104; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Mayerhofer M, 2004, CANCER RES, V64, P3148, DOI 10.1158/0008-5472.CAN-03-1200; Millena AC, 2016, J BIOL CHEM, V291, P17964, DOI 10.1074/jbc.M116.714899; Miyake M, 2011, ONCOL REP, V25, P653, DOI 10.3892/or.2010.1125; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; Otterbein LE, 2011, P NATL ACAD SCI USA, V108, P14491, DOI 10.1073/pnas.1102295108; Pulukuri SMK, 2007, J BIOL CHEM, V282, P35594, DOI 10.1074/jbc.M705867200; Sacca P, 2007, BRIT J CANCER, V97, P1683, DOI 10.1038/sj.bjc.6604081; Sunamura Makoto, 2003, Angiogenesis, V6, P15, DOI 10.1023/A:1025803600840; Tibullo D, 2016, ONCOTARGET, V7, P28868, DOI 10.18632/oncotarget.7563; Tibullo D, 2013, CURR PHARM DESIGN, V19, P2765, DOI 10.2174/1381612811319150012; Verdin E, 2015, NAT REV MOL CELL BIO, V16, P258, DOI 10.1038/nrm3931; Wang D, 2008, BIOTECH HISTOCHEM, V83, P179, DOI 10.1080/10520290802451085; Was H, 2006, AM J PATHOL, V169, P2181, DOI 10.2353/ajpath.2006.051365; Was H, 2010, CURR DRUG TARGETS, V11, P1551, DOI 10.2174/1389450111009011551; Wegiel B, 2013, CANCER RES, V73, P7009, DOI 10.1158/0008-5472.CAN-13-1075; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Wright PE, 2015, NAT REV MOL CELL BIO, V16, P18, DOI 10.1038/nrm3920; Xu L, 2015, ONCOL REP, V33, P1057, DOI 10.3892/or.2014.3680; Zerbini LF, 2011, CELL CYCLE, V10, P2583, DOI 10.4161/cc.10.15.16057; Zhang Y, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2350-x	44	22	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6805	6814		10.1038/onc.2017.294	http://dx.doi.org/10.1038/onc.2017.294			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28846111				2022-12-17	WOS:000417282500006
J	Hata, AN; Rowley, S; Archibald, HL; Gomez-Caraballo, M; Siddiqui, FM; Ji, F; Jung, J; Light, M; Lee, JS; Debussche, L; Sidhu, S; Sadreyev, RI; Watters, J; Engelman, JA				Hata, A. N.; Rowley, S.; Archibald, H. L.; Gomez-Caraballo, M.; Siddiqui, F. M.; Ji, F.; Jung, J.; Light, M.; Lee, J. S.; Debussche, L.; Sidhu, S.; Sadreyev, R. I.; Watters, J.; Engelman, J. A.			Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers	ONCOGENE			English	Article							CELL LUNG-CANCER; BH3-ONLY PROTEINS PUMA; P53 PATHWAY; EXPRESSION ANALYSIS; ANTAGONIST RG7112; IMPROVED SURVIVAL; FEEDBACK LOOP; TUMOR-GROWTH; MUTATIONS; ACTIVATION	There are currently no effective targeted therapies for KRAS mutant cancers. Therapeutic strategies that combine MEK inhibitors with agents that target apoptotic pathways may be a promising therapeutic approach. We investigated combining MEK and MDM2 inhibitors as a potential treatment strategy for KRAS mutant non-small cell lung cancers (NSCLC) and colorectal carcinomas that harbor wild-type TP53. The combination of pimasertib (MEK inhibitor) and SAR405838 (MDM2 inhibitor) was synergistic and induced the expression of PUMA and BIM, led to apoptosis and growth inhibition in vitro, and tumor regression in vivo. Acquired resistance to the combination commonly resulted from the acquisition of TP53 mutations, conferring complete resistance to MDM2 inhibition. In contrast, resistant clones exhibited marked variability in sensitivity to MEK inhibition, which significantly impacted sensitivity to subsequent treatment with alternative MEK inhibitor-based combination therapies. These results highlight both the potential promise and limitations of combining MEK and MDM2 inhibitors for treatment of KRAS mutant NSCLC and colorectal cancers.	[Hata, A. N.; Archibald, H. L.; Gomez-Caraballo, M.; Siddiqui, F. M.; Engelman, J. A.] Massachusetts Gen Hosp, Canc Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA; [Hata, A. N.; Engelman, J. A.] Harvard Med Sch, Dept Med, Boston, MA USA; [Rowley, S.; Jung, J.; Light, M.; Lee, J. S.; Watters, J.] Sanofi Oncol, Cambridge, MA USA; [Ji, F.; Sadreyev, R. I.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; [Debussche, L.; Sidhu, S.] Sanofi Oncol, 13 Quai Jules Guesde, Vitry Sur Seine, France; [Sadreyev, R. I.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Hata, AN (corresponding author), Massachusetts Gen Hosp, Canc Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	ahata@mgh.harvard.edu		Sidhu, Sukhvinder/0000-0002-2999-4358	NIH [R01CA14059408]; Uniting Against Lung Cancer; Conquer Cancer Foundation of ASCO; NATIONAL CANCER INSTITUTE [R01CA166480, R01CA140594] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Uniting Against Lung Cancer; Conquer Cancer Foundation of ASCO; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all members of the Engelman Lab for helpful discussions and feedback. We thank MercK KGaA, Darmstadt, Germany for provision of pimasertib for our research and for scientific review of this manuscript. This study was funded by support from the NIH R01CA14059408 (JAE), Uniting Against Lung Cancer (ANH), Conquer Cancer Foundation of ASCO (ANH).	Aziz MH, 2011, ONCOGENE, V30, P4678, DOI 10.1038/onc.2011.185; Blumenschein GR, 2015, ANN ONCOL, V26, P894, DOI 10.1093/annonc/mdv072; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hata AN, 2014, CANCER RES, V74, P3146, DOI 10.1158/0008-5472.CAN-13-3728; Hoffman-Luca CG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128807; Ji ZY, 2013, CLIN CANCER RES, V19, P4383, DOI 10.1158/1078-0432.CCR-13-0074; Ji ZY, 2012, J INVEST DERMATOL, V132, P356, DOI 10.1038/jid.2011.313; Jung J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12609; Kitai H, 2016, CANCER DISCOV, V6, P754, DOI 10.1158/2159-8290.CD-15-1377; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Michaelis M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.129; MIYASHITA T, 1995, CELL, V80, P293; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Mose LE, 2014, BIOINFORMATICS, V30, P2813, DOI 10.1093/bioinformatics/btu376; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; R Foundation for Statistical Computing, 2021, R LANG ENV STAT COMP; Ramos AH, 2015, HUM MUTAT, V36, pE2423, DOI 10.1002/humu.22771; Ray-Coquard I, 2012, LANCET ONCOL, V13, P1133, DOI 10.1016/S1470-2045(12)70474-6; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Saiki AY, 2014, ONCOTARGET, V5, P2030, DOI 10.18632/oncotarget.1918; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Streibig, 2014, SYNERGY, V1, P22, DOI [10.1016/j.synres.2014.07.010, DOI 10.1016/J.SYNRES.2014.07.010]; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Tovar C, 2013, CANCER RES, V73, P2587, DOI 10.1158/0008-5472.CAN-12-2807; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wang SM, 2014, CANCER RES, V74, P5855, DOI 10.1158/0008-5472.CAN-14-0799; Wilm A, 2012, NUCLEIC ACIDS RES, V40, P11189, DOI 10.1093/nar/gks918; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394; Zhang WG, 2010, CANCER RES, V70, P2424, DOI 10.1158/0008-5472.CAN-09-0878	56	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6581	6591		10.1038/onc.2017.258	http://dx.doi.org/10.1038/onc.2017.258			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783173	Green Submitted, Green Accepted			2022-12-17	WOS:000416049200007
J	Kuo, TF; Chen, TY; Jiang, ST; Chen, KW; Chiang, YM; Hsu, YJ; Liu, YJ; Chen, HM; Yokoyama, KK; Tsai, KC; Yeh, HH; Chen, YR; Yang, MT; Yang, CY; Yang, WC				Kuo, T-F; Chen, T-Y; Jiang, S-T; Chen, K-W; Chiang, Y-M; Hsu, Y-J; Liu, Y-J; Chen, H-M; Yokoyama, K. K.; Tsai, K-C; Yeh, H-H; Chen, Y-R; Yang, M-T; Yang, C-Y; Yang, W-C			Protein disulfide isomerase a4 acts as a novel regulator of cancer growth through the procaspase pathway	ONCOGENE			English	Article							INDUCED CELL-DEATH; INDUCED APOPTOSIS; STRESS; IDENTIFICATION; INHIBITION; EXPRESSION; VIABILITY; CARCINOMA; CASPASE-3; FAMILY	Protein disulfide isomerase a4 (PDIA4) is implicated in the growth and death of tumor cells; however, its molecular mechanism and therapeutic potential in cancer are unclear. Here, we found that PDIA4 expression was upregulated in a variety of tumor cell lines and human lung adenocarcinoma tissues. Knockdown and overexpression of PDIA4 in tumor cells showed that PDIA4 facilitated cell growth via the reduction of caspases 3 and 7 activity. Consistently, Lewis lung carcinoma cells overexpressing PDIA4 grew faster than did parental cells in tumor-bearing mice, as shown by a reduced survival rate, increased tumor size and metastasis, and decreased cell death and caspases 3 and 7 activity. PDIA4 knockdown resulted in opposite outcomes. Moreover, results obtained in mice with spontaneous hepatoma indicated that PDIA4 deficiency significantly reduced hepatic tumorigenesis and cyst formation and increased mouse survival, tumor death, and caspases 3 and 7 activity. Mechanistic studies illustrated that PDIA4 negatively regulated tumor cell death by inhibiting degradation and activation of procaspases 3 and 7 via their mutual interaction in a CGHC-dependent manner. Finally, we found that 1,2-dihydroxytrideca-5,7,9,11-tetrayne, a PDIA4 inhibitor, reduced tumor development via enhancement of caspase-mediated cell death in TSA tumor-bearing mice. These findings characterize PDIA4 as a negative regulator of cancer cell apoptosis and suggest that PDIA4 is a potential therapeutic target for cancer.	[Kuo, T-F; Chen, T-Y; Chen, K-W; Chiang, Y-M; Hsu, Y-J; Liu, Y-J; Chen, H-M; Chen, Y-R; Yang, M-T; Yang, C-Y; Yang, W-C] Acad Sinica, Agr Biotechnol Res Ctr, 128,Sect 2,Acad Rd, Taipei 11529, Taiwan; [Chen, T-Y] Natl Taiwan Univ, Inst Biotechnol, Taipei, Taiwan; [Jiang, S-T] Natl Appl Res Labs, Natl Lab Anim Ctr, Taipei, Taiwan; [Yokoyama, K. K.] Kaohsiung Med Univ, Grad Inst Med, Kaohsiung, Taiwan; [Tsai, K-C] Natl Res Inst Chinese Med, Minist Hlth & Welf, Taipei, Taiwan; [Tsai, K-C] Taipei Med Univ, PhD Program Biotechnol Med, Taipei, Taiwan; [Yeh, H-H] Chia Nan Univ Pharm & Sci, Drug Discovery & Dev Ctr, Tainan, Taiwan; [Yang, M-T] Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung, Taiwan; [Yang, M-T] Acad Sinica, Taiwan Int Grad Program, Mol & Biol Agr Sci, Taipei, Taiwan; [Yang, M-T] Natl Chung Hsing Univ, Taichung, Taiwan; [Yang, W-C] Natl Chung Hsing Univ, Dept Life Sci, Taichung, Taiwan; [Yang, W-C] Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan; [Yang, W-C] Natl Taiwan Ocean Univ, Dept Aquaculture, Keelung, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Applied Research Laboratories - Taiwan; Kaohsiung Medical University; National Research Institute of Chinese Medicine; Taipei Medical University; Chia Nan University of Pharmacy & Science; National Chung Hsing University; Academia Sinica - Taiwan; National Chung Hsing University; National Chung Hsing University; National Yang Ming Chiao Tung University; National Taiwan Ocean University	Yang, WC (corresponding author), Acad Sinica, Agr Biotechnol Res Ctr, 128,Sect 2,Acad Rd, Taipei 11529, Taiwan.	wcyang@gate.sinica.edu.tw	Yang, Wen-Chin/D-3441-2015	Yang, Wen-Chin/0000-0001-6410-2581; YANG, CHUN-YEN/0000-0002-8672-2981	MOST [104-2320-B-037-033-My2, 104-2314-B-033-002];  [NHRI-EX103-10109B1];  [NHRI-EX106-10416S1];  [KMU-TP104G00];  [KMU-TP104G01];  [KMU-TP104A04];  [KMU-TP105E23];  [KMU-TP105E00];  [KMU-DT105005]	MOST(Ministry of Science & Technology (MOST), Republic of Korea); ; ; ; ; ; ; ; 	We thank the animal facility and the metabolomics facility of the Agricultural Biotechnology Research Center, and the mouse clinics of Academia Sinica for their technical assistance. We thank Drs Jim Stauffer (NCI) and Xin Chen (UCSF) for their SB plasmids, and the National RNAi Core Facility (Academia Sinica) for RNAi reagents. We also thank Ms Miranda Loney for editing the manuscript. This work was supported in part by MOST 104-2320-B-037-033-My2, and MOST 104-2314-B-033-002; NHRI-EX103-10109B1, and NHRI-EX106-10416S1, and KMU-TP104G00, KMU-TP104G01, KMU-TP104A04, KMU-TP105E23, KMU-TP105E23, KMU-TP105E00, and KMU-DT105005.	Almeida S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026454; Andreu CI, 2012, FEBS LETT, V586, P2826, DOI 10.1016/j.febslet.2012.07.023; Bratton SB, 2010, J CELL SCI, V123, P3209, DOI 10.1242/jcs.073643; Burgess JK, 2000, J BIOL CHEM, V275, P9758, DOI 10.1074/jbc.275.13.9758; Carbone DL, 2005, CHEM RES TOXICOL, V18, P1324, DOI 10.1021/tx050078z; Ciaffi M, 2006, GENE, V366, P209, DOI 10.1016/j.gene.2005.07.032; Ellerman DA, 2006, DEV CELL, V10, P831, DOI 10.1016/j.devcel.2006.03.011; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Galligan JJ, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-6; Garbi N, 2006, NAT IMMUNOL, V7, P93, DOI 10.1038/ni1288; Goplen D, 2006, CANCER RES, V66, P9895, DOI 10.1158/0008-5472.CAN-05-4589; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hashida T, 2011, J TOXICOL SCI, V36, P1, DOI 10.2131/jts.36.1; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Krepela E, 2006, J CANCER RES CLIN, V132, P57, DOI 10.1007/s00432-005-0048-6; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; Liu XW, 2004, BIOL CHEM, V385, P633, DOI 10.1515/BC.2004.078; Lovat PE, 2008, CANCER RES, V68, P5363, DOI 10.1158/0008-5472.CAN-08-0035; Manukyan D, 2008, THROMB RES, V122, pS19, DOI 10.1016/S0049-3848(08)70013-6; Na KS, 2007, MOL CELLS, V24, P261; Naguleswaran A, 2005, INT J PARASITOL, V35, P1459, DOI 10.1016/j.ijpara.2005.06.006; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Norgaard P, 2001, J CELL BIOL, V152, P553, DOI 10.1083/jcb.152.3.553; Ou W, 2006, VIROLOGY, V350, P406, DOI 10.1016/j.virol.2006.01.041; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Pawar H, 2011, CANCER BIOL THER, V12, P510, DOI 10.4161/cbt.12.6.16833; Rodriguez-Hernandez A, 2006, APOPTOSIS, V11, P131, DOI 10.1007/s10495-005-3276-y; Santana-Codina N, 2013, MOL CELL PROTEOMICS, V12, P2111, DOI 10.1074/mcp.M112.022772; Satoh M, 2005, CELL STRESS CHAPERON, V10, P211, DOI 10.1379/CSC-109R.1; Schultz-Norton JR, 2006, MOL ENDOCRINOL, V20, P1982, DOI 10.1210/me.2006-0006; Severino A, 2007, J AM COLL CARDIOL, V50, P1029, DOI 10.1016/j.jacc.2007.06.006; Stauffer JK, 2011, CANCER RES, V71, P2718, DOI 10.1158/0008-5472.CAN-10-2705; Tao GZ, 2013, J BIOL CHEM, V288, P17214, DOI 10.1074/jbc.M112.445965; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; Tufo G, 2014, CELL DEATH DIFFER, V21, P685, DOI 10.1038/cdd.2013.193; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; Xiong Y., 2012, INT J CELL BIOL, V2012, P273549, DOI 10.1155/2012/273549; Xu SL, 2012, P NATL ACAD SCI USA, V109, P16348, DOI 10.1073/pnas.1205226109; Yu SJ, 2012, J BIOENERG BIOMEMBR, V44, P101, DOI 10.1007/s10863-012-9416-5; Zahedi P, 2012, J CONTROL RELEASE, V158, P379, DOI 10.1016/j.jconrel.2011.11.025; Zhu Y, 2014, MOL CELL PROTEOMICS, V13, P2593, DOI 10.1074/mcp.M114.038786	43	22	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5484	5496		10.1038/onc.2017.156	http://dx.doi.org/10.1038/onc.2017.156			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28534513				2022-12-17	WOS:000411960500005
J	Schito, L; Rey, S; Konopleva, M				Schito, L.; Rey, S.; Konopleva, M.			Integration of hypoxic HIF-alpha signaling in blood cancers	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW MICROENVIRONMENT; MODELING PO(2) DISTRIBUTIONS; ACUTE MYELOGENOUS LEUKEMIA; SCID-REPOPULATING CELLS; INDUCIBLE FACTOR-1-ALPHA; LYMPHOCYTIC-LEUKEMIA	Hypoxia (low O-2) is a fundamental microenvironmental determinant of bone marrow (BM) pathophysiology. Recent data from molecular and clinical studies indicate that hematopoiesis and leukemogenesis are dependent upon hypoxia-inducible factors (HIFs), a family of essential transcriptional activators mediating the metazoan hypoxic response. In blood cancers, the synergism between HIF overexpression and stabilization within the hypoxic BM microenvironment promotes disease progression, therapy resistance and relapse. In this review, we will summarize current advances in the understanding of HIF signaling in blood cancers and its translational implications for hypoxic-targeted therapy.	[Schito, L.; Rey, S.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Konopleva, M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA; [Konopleva, M.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Konopleva, M (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA.	mkonople@mdanderson.org	Rey, Sergio/I-4918-2017	Rey, Sergio/0000-0001-8954-7712				Abbas S, 2010, BLOOD, V116, P2122, DOI 10.1182/blood-2009-11-250878; Almarza E, 2004, EXP HEMATOL, V32, P360, DOI 10.1016/j.exphem.2004.01.005; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Asosingh K, 2005, HAEMATOLOGICA, V90, P810; Battisti V, 2008, CLIN BIOCHEM, V41, P511, DOI 10.1016/j.clinbiochem.2008.01.027; Blair A, 2000, EXP HEMATOL, V28, P660, DOI 10.1016/S0301-472X(00)00155-7; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bonnet D., 2015, TARGETED THERAPY ACU, P559; BUICK RN, 1984, CANCER RES, V44, P4909; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; CAMPOS L, 1993, BLOOD, V81, P3091; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chen H, 2015, CELL BIOCHEM BIOPHYS, V72, P179, DOI 10.1007/s12013-014-0434-2; Chen HJ, 2000, BLOOD, V96, P3181; Chen HX, 2016, LEUKEMIA RES, V42, P28, DOI 10.1016/j.leukres.2016.01.013; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Cho BS, 2015, BLOOD, V126, P222, DOI 10.1182/blood-2015-02-628677; Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795; Chow DC, 2001, BIOPHYS J, V81, P675, DOI 10.1016/S0006-3495(01)75732-3; Chow DC, 2001, BIOPHYS J, V81, P685, DOI 10.1016/S0006-3495(01)75733-5; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Chua YL, 2010, J BIOL CHEM, V285, P31277, DOI 10.1074/jbc.M110.158485; CIPOLLESCHI MG, 1993, BLOOD, V82, P2031; Colla S, 2010, LEUKEMIA, V24, P1967, DOI 10.1038/leu.2010.193; Coltella N, 2014, EMBO MOL MED, V6, P640, DOI 10.1002/emmm.201303065; Danet GH, 2003, J CLIN INVEST, V112, P126, DOI 10.1172/JCI200317669; Dash A, 2001, BEST PRACT RES CL HA, V14, P49, DOI 10.1053/beha.2000.0115; Deeb G, 2011, LEUKEMIA RES, V35, P579, DOI 10.1016/j.leukres.2010.10.020; Desplat V, 2002, STEM CELLS, V20, P347, DOI 10.1634/stemcells.20-4-347; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; DRAENERT K, 1980, Scanning Electron Microscopy, P113; Duan CM, 2016, AM J PHYSIOL-CELL PH, V310, pC260, DOI 10.1152/ajpcell.00315.2015; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Evans RG, 2008, AM J PHYSIOL-RENAL, V295, pF1259, DOI 10.1152/ajprenal.90230.2008; Fiegl M, 2009, BLOOD, V113, P1504, DOI 10.1182/blood-2008-06-161539; Forristal CE, 2015, LEUKEMIA, V29, P2075, DOI 10.1038/leu.2015.102; Forristal CE, 2015, LEUKEMIA, V29, P1366, DOI 10.1038/leu.2015.8; Frolova O, 2012, CANCER BIOL THER, V13, P858, DOI 10.4161/cbt.20838; Gari M, 1999, BRIT J HAEMATOL, V105, P894, DOI 10.1046/j.1365-2141.1999.01449.x; Geay JF, 2005, CANCER RES, V65, P2676, DOI 10.1158/0008-5472.CAN-04-2152; Ghosh AK, 2009, BLOOD, V113, P5568, DOI 10.1182/blood-2008-10-185686; Giambra V, 2015, BLOOD, V125, P3917, DOI 10.1182/blood-2014-10-609370; Giatromanolaki A, 2010, ANTICANCER RES, V30, P2831; Giuntoli S, 2007, STEM CELLS, V25, P1119, DOI 10.1634/stemcells.2006-0637; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Griessinger E, 2014, STEM CELL TRANSL MED, V3, P520, DOI 10.5966/sctm.2013-0166; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; Gross S, 2010, J EXP MED, V207, P339, DOI 10.1084/jem.20092506; Han ZB, 2008, CARCINOGENESIS, V29, P1853, DOI 10.1093/carcin/bgn066; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Hubbi ME, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003417; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; Hussong JW, 2000, BLOOD, V95, P309; IKEDA H, 1991, BLOOD, V78, P2962; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Ivanovic Z, 2004, STEM CELLS, V22, P716, DOI 10.1634/stemcells.22-5-716; Ivanovic Z, 2000, BRIT J HAEMATOL, V108, P424; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jin LH, 2008, MOL CANCER THER, V7, P48, DOI 10.1158/1535-7163.MCT-07-0042; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kirito K, 2005, BLOOD, V105, P4258, DOI 10.1182/blood-2004-07-2712; Kocabas F, 2012, BLOOD, V120, P4963, DOI 10.1182/blood-2012-05-432260; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Kong DH, 2005, CANCER RES, V65, P9047, DOI 10.1158/0008-5472.CAN-05-1235; Konoplev S, 2007, CANCER, V109, P1152, DOI 10.1002/cncr.22510; Konopleva M, 2015, BONE MARROW TRANSPL, V50, P939, DOI 10.1038/bmt.2015.58; Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Konopleva M, 2009, DRUG RESIST UPDATE, V12, P103, DOI 10.1016/j.drup.2009.06.001; Konopleva MY, 2011, J CLIN ONCOL, V29, P591, DOI 10.1200/JCO.2010.31.0904; Koomagi R, 2001, CLIN CANCER RES, V7, P3381; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lee YK, 2004, BLOOD, V104, P788, DOI 10.1182/blood-2003-08-2763; Lehmann-Che J, 2014, NEW ENGL J MED, V371, P1170, DOI 10.1056/NEJMc1409040; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Li L, 2011, CANCER CELL, V20, P591, DOI 10.1016/j.ccr.2011.09.011; LICHTMAN MA, 1981, EXP HEMATOL, V9, P391; Lo Celso C, 2009, NATURE, V457, P92, DOI 10.1038/nature07434; Lundberg LG, 2000, AM J PATHOL, V157, P15, DOI 10.1016/S0002-9440(10)64511-7; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Mantel CR, 2015, CELL, V161, P1553, DOI 10.1016/j.cell.2015.04.054; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Martin SK, 2010, HAEMATOL-HEMATOL J, V95, P776, DOI 10.3324/haematol.2009.015628; Matsunaga T, 2012, LEUKEMIA RES, V36, pE122, DOI 10.1016/j.leukres.2012.02.028; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078-0432.CCR-07-2223; Molica S, 1999, BRIT J HAEMATOL, V107, P605, DOI 10.1046/j.1365-2141.1999.01752.x; Ng KP, 2014, BLOOD, V123, P3316, DOI 10.1182/blood-2013-07-511907; Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293; Nombela-Arrieta C, 2013, NAT CELL BIOL, V15, P533, DOI 10.1038/ncb2730; Padro T, 2000, BLOOD, V95, P2637, DOI 10.1182/blood.V95.8.2637.008k07_2637_2644; Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104; Pedersen M, 2008, BIOCHEM BIOPH RES CO, V377, P98, DOI 10.1016/j.bbrc.2008.09.102; PerezAtayde AR, 1997, AM J PATHOL, V150, P815; Petit C, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2776-1; Reilly JT, 2003, BLOOD REV, V17, P241, DOI 10.1016/S0268-960X(03)00024-9; Rey S, 2017, ADV DRUG DELIVER REV, V109, P45, DOI 10.1016/j.addr.2016.10.002; Rey S, 2010, CARDIOVASC RES, V86, P236, DOI 10.1093/cvr/cvq045; Ria R, 2014, CLIN CANCER RES, V20, P847, DOI 10.1158/1078-0432.CCR-13-1950; Rombouts EJC, 2004, BLOOD, V104, P550, DOI 10.1182/blood-2004-02-0566; Rouault-Pierre K, 2013, CELL STEM CELL, V13, P549, DOI 10.1016/j.stem.2013.08.011; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; SCHOFIELD R, 1983, BIOMED PHARMACOTHER, V37, P375; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354; Simsek T, 2010, CELL STEM CELL, V7, P380, DOI 10.1016/j.stem.2010.07.011; Spencer JA, 2014, NATURE, V508, P269, DOI 10.1038/nature13034; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Storti P, 2013, LEUKEMIA, V27, P1697, DOI 10.1038/leu.2013.24; Suda T, 2011, CELL STEM CELL, V9, P298, DOI 10.1016/j.stem.2011.09.010; Takubo K, 2013, CELL STEM CELL, V12, P49, DOI 10.1016/j.stem.2012.10.011; Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Taussig DC, 2008, BLOOD, V112, P568, DOI 10.1182/blood-2007-10-118331; Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood-2009-02-206565; Terpstra W, 1996, BLOOD, V87, P2187, DOI 10.1182/blood.V87.6.2187.bloodjournal8762187; Tong HY, 2012, LEUKEMIA LYMPHOMA, V53, P2412, DOI 10.3109/10428194.2012.696637; Tothova Z, 2007, CELL STEM CELL, V1, P140, DOI 10.1016/j.stem.2007.07.017; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Valsecchi R, 2016, BLOOD, V127, P1987, DOI 10.1182/blood-2015-07-657056; Velasco-Hernandez T, 2014, BLOOD, V124, P3597, DOI 10.1182/blood-2014-04-567065; Verstovsek S, 2002, BLOOD, V99, P2265, DOI 10.1182/blood.V99.6.2265; Vukovic M, 2016, BLOOD, V127, P2841, DOI 10.1182/blood-2015-10-677138; Vukovic M, 2015, J EXP MED, V212, P2223, DOI 10.1084/jem.20150452; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wang Y, 2014, BLOOD, V124, P1127, DOI 10.1182/blood-2013-12-544221; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Warner JK, 2004, ONCOGENE, V23, P7164, DOI 10.1038/sj.onc.1207933; Wellmann S, 2004, LEUKEMIA, V18, P926, DOI 10.1038/sj.leu.2403332; Winkler IG, 2010, BLOOD, V116, P375, DOI 10.1182/blood-2009-07-233437; Zhang CC, 2014, ANTIOXID REDOX SIGN, V20, P1891, DOI 10.1089/ars.2012.5019; Zhang HJ, 2012, BLOOD, V119, P2595, DOI 10.1182/blood-2011-10-387381; Zhang J, 2009, CANCER RES, V69, P5082, DOI 10.1158/0008-5472.CAN-08-4603; Zhao F, 2010, ONCOGENE, V29, P2962, DOI 10.1038/onc.2010.67; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944; Zhou FL, 2010, J BIOL CHEM, V285, P15010, DOI 10.1074/jbc.M110.103713; Zhou FL, 2013, J LEUKOCYTE BIOL, V94, P423, DOI 10.1189/jlb.0113006; Zou J, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-3	156	22	23	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5331	5340		10.1038/onc.2017.119	http://dx.doi.org/10.1038/onc.2017.119			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534514				2022-12-17	WOS:000411382100001
J	Endo, H; Okami, J; Okuyama, H; Nishizawa, Y; Imamura, F; Inoue, M				Endo, H.; Okami, J.; Okuyama, H.; Nishizawa, Y.; Imamura, F.; Inoue, M.			The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations	ONCOGENE			English	Article							SIGNAL-REGULATED KINASE; GEFITINIB RESISTANCE; ACQUIRED-RESISTANCE; PROTEIN-SYNTHESIS; RECEPTOR; PATHWAY; QUIESCENCE; PROMOTES; SURVIVAL; MUTANT	The biologic activity of individual cancer cells is highly heterogeneous. Hypoxia, one of the prominent features of a tumor microenvironment, is thought to be causal in generating this cellular heterogeneity. In this study, we revealed that primary lung cancer cells harboring activating epidermal growth factor receptor (EGFR) mutations generally entered a dormant state when hypoxic. We found that heterodimer formation of the ERBB family receptor tyrosine kinases (RTKs), and their subsequent downstream signaling, was diminished under hypoxic conditions, although phosphorylation of the EGFR was retained. Dormant lung cancer cells were found to be resistant to EGFR tyrosine kinase inhibitor (TKI) treatment. In terms of mechanism, we found that a negative regulator of ERBB signaling, MIG6/ERRFI1/RALT/Gene33, was induced by hypoxia both in vitro and in vivo. MIG6 expression prevented heterodimer formation of ERBB family RTKs, and suppressed their downstream signaling. Knockdown of MIG6 enhanced tumor cell growth under hypoxic conditions, and promoted the phosphorylation of ERK and AKT via increased EGFR-HER3 binding. Critically, sensitivity to an EGFR-TKI, as well as to irradiation under hypoxic conditions, was increased in MIG6 knockdown cells. The expression of MIG6 was partly correlated with a pS6 negative zone in patient tumors. Analyses of tumor sections from 68 patients with activating EGFR mutations showed that patients with high MIG6 expression showed significantly shorter survival after EGFR-TKI treatment than other groups. Collectively, our data suggest that dormant cancer cells with a high MIG6 expression level might be one of the causes of EGFR-TKI resistance in EGFR mutant lung cancer cells.	[Endo, H.; Okuyama, H.; Inoue, M.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Biochem, Osaka, Japan; [Okami, J.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Thorac Surg, Osaka, Japan; [Nishizawa, Y.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Pathol, Osaka, Japan; [Imamura, F.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Thorac Oncol, Osaka, Japan	Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Medical Center for Cancer & Cardiovascular Diseases	Inoue, M (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Biochem, Higashinari Ku, 1-3-3 Nakamichi, Osaka 5378511, Japan.	inoue-ma2@mc.pref.osaka.jp	Okami, Jiro/AAE-3837-2021		JSPS [26111005]; KAKENHI [25461937]; Grants-in-Aid for Scientific Research [26111005] Funding Source: KAKEN	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr T Tabuchi and Dr K Fukui for statistical counseling, N Kanto and T Yasuda for technical assistance, and M Izutsu for secretarial assistance. This work was supported by JSPS Grant-in-Aid for Scientific Research on Innovative Areas (26111005) (to MI) and KAKENHI (25461937) (to HE).	Abravanel DL, 2015, J CLIN INVEST, V125, P2484, DOI 10.1172/JCI74883; Aguirre-Ghiso JA, 2004, CANCER RES, V64, P7336, DOI 10.1158/0008-5472.CAN-04-0113; Ameri K, 2015, CELL REP; Amin R, 2016, MOL ONCOL, V10, P575, DOI 10.1016/j.molonc.2015.11.009; Anastasi S, 2016, SEMIN CELL DEV BIOL, V50, P115, DOI 10.1016/j.semcdb.2015.10.001; Bui AT, 2015, CELL CYCLE, V14, P1218, DOI 10.1080/15384101.2015.1014145; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958; Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Chang XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068966; Crea F, 2015, TRENDS MOL MED, V21, P206, DOI 10.1016/j.molmed.2015.02.005; Endo H, 2007, CANCER RES, V67, P8095, DOI 10.1158/0008-5472.CAN-06-3389; Endo H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098858; Endo H, 2013, J THORAC ONCOL, V8, P131, DOI 10.1097/JTO.0b013e3182779ccf; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harada H, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1786; Izumchenko E, 2014, CANCER RES, V74, P3995, DOI 10.1158/0008-5472.CAN-14-0110; Kondo J, 2011, P NATL ACAD SCI USA, V108, P6235, DOI 10.1073/pnas.1015938108; Lafont JE, 2008, J BIOL CHEM, V283, P4778, DOI 10.1074/jbc.M707729200; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maity TK, 2015, CANCER DISCOV, V5, P534, DOI 10.1158/2159-8290.CD-14-0750; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Minakata K, 2012, CANCER SCI, V103, P1946, DOI 10.1111/j.1349-7006.2012.02408.x; Nakajima A, 2015, INT J CANCER, V136, P2949, DOI 10.1002/ijc.29349; Ohashi K, 2012, P NATL ACAD SCI USA, V109, pE2127, DOI 10.1073/pnas.1203530109; Okuyama H, 2010, CANCER RES, V70, P10213, DOI 10.1158/0008-5472.CAN-10-2720; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Peart T, 2015, ONCOTARGET, V6, P22424, DOI 10.18632/oncotarget.4211; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Sato Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep24823; Semenza GL, 2016, BBA-MOL CELL RES, V1863, P382, DOI 10.1016/j.bbamcr.2015.05.036; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Sosa MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7170; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Swinson DEB, 2003, J CLIN ONCOL, V21, P473, DOI 10.1200/JCO.2003.11.132; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Tiram G, 2016, ACS NANO, V10, P2028, DOI 10.1021/acsnano.5b06189; Uniacke J, 2012, NATURE, V486, P126, DOI 10.1038/nature11055; Wang N, 2015, FASEB J, V29, P3141, DOI 10.1096/fj.14-266379; Wang W, 2009, CLIN CANCER RES, V15, P6630, DOI 10.1158/1078-0432.CCR-09-1001; Xu DZ, 2006, MOL CELL BIOL, V26, P5043, DOI 10.1128/MCB.02387-05; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Young RM, 2008, J BIOL CHEM, V283, P16309, DOI 10.1074/jbc.M710079200; Zhang XW, 2007, NATURE, V450, P741, DOI 10.1038/nature05998; Zhang YW, 2007, ONCOGENE, V26, P269, DOI 10.1038/sj.onc.1209790	53	22	22	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2824	2834		10.1038/onc.2016.431	http://dx.doi.org/10.1038/onc.2016.431			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27893711				2022-12-17	WOS:000401697800005
J	Fan, H; Cui, Z; Zhang, H; Mani, SK; Diab, A; Lefrancois, L; Fares, N; Merle, P; Andrisani, O				Fan, H.; Cui, Z.; Zhang, H.; Mani, S. K.; Diab, A.; Lefrancois, L.; Fares, N.; Merle, P.; Andrisani, O.			DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection	ONCOGENE			English	Article							RNA-POLYMERASE-II; STEM-CELL PLURIPOTENCY; PROTEIN 4; METHYLATION; TRANSCRIPTION; EXPRESSION; PROMOTER; COMPLEX; ESBAF	Sal-like protein 4 (SALL4), an embryonic stem cell transcriptional regulator, is re-expressed by an unknown mechanism in poor prognosis hepatocellular carcinoma (HCC), often associated with chronic hepatitis B virus (HBV) infection. Herein, we investigated the mechanism of SALL4 re-expression in HBV-related HCCs. We performed bisulfite sequencing PCR of genomic DNA isolated from HBV-related HCCs and HBV replicating cells, and examined DNA methylation of a CpG island located downstream from SALL4 transcriptional start site (TSS). HBV-related HCCs expressing increased SALL4 exhibited demethylation of specific CpG sites downstream of SALL4 TSS. Similarly, SALL4 re-expression and demethylation of these CpGs was observed in HBV replicating cells. SALL4 is also re-expressed in poor prognosis HCCs of other etiologies. Indeed, increased SALL4 expression in hepatitis C virus-related HCCs correlated with demethylation of these CpG sites. To understand how CpG demethylation downstream of SALL4 TSS regulates SALL4 transcription, we quantified by chromatin immunoprecipitation (ChIP) assays RNA polymerase II occupancy of SALL4 gene, as a function of HBV replication. In absence of HBV replication, RNA polymerase II associated with SALL4 exon1. By contrast, in HBV replicating cells RNA polymerase II occupancy of all SALL4 exons increased, suggesting CpG demethylation downstream from SALL4 TSS influences SALL4 transcriptional elongation. Intriguingly, demethylated CpGs downstream from SALL4 TSS are within binding sites of octamer-binding transcription factor 4 (OCT4) and signal transducer and activator of transcription3 (STAT3). ChIP assays confirmed occupancy of these sites by OCT4 and STAT3 in HBV replicating cells, and sequential ChIP assays demonstrated co-occupancy with chromatin remodeling BRG1/Brahma-associated factors. BRG1 knockdown reduced SALL4 expression, whereas BRG1 overexpression increased SALL4 transcription in HBV replicating cells. We conclude demethylation of CpGs located within OCT4 and STAT3 cis-acting elements, downstream of SALL4 TSS, enables OCT4 and STAT3 binding, recruitment of BRG1, and enhanced RNA polymerase II elongation and SALL4 transcription.	[Fan, H.; Cui, Z.; Zhang, H.; Mani, S. K.; Diab, A.; Andrisani, O.] Dept Basic Med Sci, W Lafayette, IN USA; [Fan, H.; Cui, Z.; Zhang, H.; Mani, S. K.; Diab, A.; Andrisani, O.] Purdue Univ, Purdue Ctr Canc Res, 205 Hansen Bldg,201 South Univ St, W Lafayette, IN 47907 USA; [Lefrancois, L.; Fares, N.; Merle, P.] INSERM, UMR 1052, Ctr Rech Cancerol Lyon, Lyon, France	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Andrisani, O (corresponding author), Purdue Univ, Dept Basic Med Sci, 205 Hansen Bldg,201 South Univ St, W Lafayette, IN 47907 USA.	andrisao@purdue.edu	Diab, Ahmed/X-5165-2018; Kailasam Mani, Saravana Kumar/I-8731-2019	Diab, Ahmed/0000-0001-6626-7013; Kailasam Mani, Saravana Kumar/0000-0002-0407-2314; Andrisani, Ourania/0000-0002-6230-0303; Fares, Nadim/0000-0002-8954-3938	NIH [DK044533, P30CA023168]; French grants PAIR-CHC from Institute National du Cancer (INCa) [2009-143]; NATIONAL CANCER INSTITUTE [P30CA023168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044533] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); French grants PAIR-CHC from Institute National du Cancer (INCa); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grant DK044533 to OA, and French grants PAIR-CHC 2009 (contract #2009-143, project ENELIVI) from Institute National du Cancer (INCa) to PM. Shared Resources (flow cytometry and DNA sequencing) are supported by NIH grant P30CA023168 to Purdue Center for Cancer Research.	Adelman K, 2012, NAT REV GENET, V13, P720, DOI 10.1038/nrg3293; Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580; Bard JD, 2009, FASEB J, V23, P1405, DOI 10.1096/fj.08-117721; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Buganim Y, 2014, CELL STEM CELL, V15, P295, DOI 10.1016/j.stem.2014.07.003; Choi JK, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r89; Fan H, 2016, ONCOGENE, V35, P715, DOI 10.1038/onc.2015.122; Gong FD, 2015, GENE DEV, V29, P197, DOI 10.1101/gad.252189.114; He J, 2013, INT J BIOCHEM CELL B, V45, P1962, DOI 10.1016/j.biocel.2013.06.008; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ho L, 2011, NAT CELL BIOL, V13, P903, DOI 10.1038/ncb2285; Ho LN, 2009, P NATL ACAD SCI USA, V106, P5187, DOI 10.1073/pnas.0812888106; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Jung YK, 2016, ANN SURG TREAT RES, V91, P23, DOI 10.4174/astr.2016.91.1.23; Kidder BL, 2009, STEM CELLS, V27, P317, DOI 10.1634/stemcells.2008-0710; Kumaki Y, 2008, NUCLEIC ACIDS RES, V36, pW170, DOI 10.1093/nar/gkn294; Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liao HF, 2014, DEVELOPMENT, V141, P2402, DOI 10.1242/dev.105130; Liu H, 2004, BLOOD, V104, P2505, DOI 10.1182/blood-2004-02-0483; Mani SKK, 2016, J HEPATOL, V65, P888, DOI 10.1016/j.jhep.2016.05.022; Mansour AA, 2012, NATURE, V488, P409, DOI 10.1038/nature11272; Marquardt JU, 2013, NEW ENGL J MED, V368, P2316, DOI 10.1056/NEJMe1303026; Ni Y, 2014, GASTROENTEROLOGY, V146, P1070, DOI 10.1053/j.gastro.2013.12.024; Nishino K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013017; Oikawa T, 2013, HEPATOLOGY, V57, P1469, DOI 10.1002/hep.26159; Oikawa T, 2009, GASTROENTEROLOGY, V136, P1000, DOI 10.1053/j.gastro.2008.11.018; Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134; Park H, 2015, J PATHOL TRANSL MED, V49, P373, DOI 10.4132/jptm.2015.07.09; Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06; Selth LA, 2009, COLD SPRING HARBOR P, V2009; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Veloso A, 2014, GENOME RES, V24, P896, DOI 10.1101/gr.171405.113; Yang JC, 2012, J BIOL CHEM, V287, P1996, DOI 10.1074/jbc.M111.308734; Yang JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010766; Yin F, 2016, WORLD J GASTROENTERO, V22, P2837, DOI 10.3748/wjg.v22.i9.2837; Yong KJ, 2013, NEW ENGL J MED, V368, P2266, DOI 10.1056/NEJMoa1300297; Zeng SS, 2014, J HEPATOL, V60, P127, DOI 10.1016/j.jhep.2013.08.024; Zhang H, 2015, J CHEM-NY, V2015, DOI 10.1155/2015/175940; Zhang H, 2016, HEPATOLOGY, V64, P1033, DOI 10.1002/hep.28698; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481	41	22	23	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2435	2445		10.1038/onc.2016.399	http://dx.doi.org/10.1038/onc.2016.399			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27797380	Green Accepted			2022-12-17	WOS:000400268900009
J	Liu, S; Tackmann, NR; Yang, J; Zhang, Y				Liu, S.; Tackmann, N. R.; Yang, J.; Zhang, Y.			Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis	ONCOGENE			English	Article							MULTIPLE INTESTINAL NEOPLASIA; MYC-INDUCED LYMPHOMAGENESIS; B-CELL LINE; C-MYC; RIBOSOME BIOGENESIS; IN-VIVO; P53; CANCER; IDENTIFICATION; GENES	Inactivation of the adenomatous polyposis coli (APC) tumor suppressor is frequently found in colorectal cancer. Loss of APC function results in deregulation of the Wnt/beta-catenin signaling pathway causing overexpression of the c-MYC oncogene. In lymphoma, both p19ARF and ribosomal proteins RPL11 and RPL5 respond to c-MYC activation to induce p53. Their role in c-MYCdriven colorectal carcinogenesis is unclear, as p19ARF deletion does not accelerate APC loss-triggered intestinal tumorigenesis. To determine the contribution of the ribosomal protein (RP)-murine double minute 2 (MDM2)-p53 pathway to APC loss-induced tumorigenesis, we crossed mice bearing MDM2(C305F) mutation, which disrupts RPL11-and RPL5-MDM2 binding, with Apc(min/+) mice, which are prone to intestinal tumor formation. Interestingly, loss of RP-MDM2 binding significantly accelerated colorectal tumor formation while having no discernable effect on small intestinal tumor formation. Mechanistically, APC loss leads to overexpression of c-MYC, RPL11 and RPL5 in mouse colonic tumor cells irrespective of MDM2(C305F) mutation. However, notable p53 stabilization and activation were observed only in Apc(min/+); Mdm2(+/+) but not Apc(min/+); Mdm2(C305F/C305F) colon tumors. These data establish that the RP-MDM2-p53 pathway, in contrast to the p19ARF-MDM2-p53 pathway, is a critical mediator of colorectal tumorigenesis following APC loss.	[Liu, S.; Tackmann, N. R.; Yang, J.; Zhang, Y.] Univ N Carolina, Dept Radiat Oncol, 450 West Dr, Chapel Hill, NC 27514 USA; [Liu, S.; Tackmann, N. R.; Yang, J.; Zhang, Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, 450 West Dr, Chapel Hill, NC 27514 USA; [Tackmann, N. R.; Zhang, Y.] Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC USA; [Yang, J.; Zhang, Y.] Xuzhou Med Coll, Inst Canc, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Xuzhou, Jiangsu, Peoples R China	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Xuzhou Medical University	Zhang, Y (corresponding author), Univ N Carolina, Dept Radiat Oncol, 450 West Dr, Chapel Hill, NC 27514 USA.; Zhang, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, 450 West Dr, Chapel Hill, NC 27514 USA.	ypzhang@med.unc.edu			National Institutes of Health [CA127770, CA 100302, CA167637]; Natural Science Foundation of China (NSFC); National Institute of General Medical Sciences [5T32 GM007092]; NATIONAL CANCER INSTITUTE [R01CA100302, R01CA167637, R01CA155235, R01CA127770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by grants from the National Institutes of Health (CA127770, CA 100302 and CA167637) and Natural Science Foundation of China (NSFC) to YZ, and the National Institute of General Medical Sciences (5T32 GM007092) to NRT.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Chen DL, 2013, MOL CELL, V51, P46, DOI 10.1016/j.molcel.2013.05.006; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Elyada E, 2011, NATURE, V470, P409, DOI 10.1038/nature09673; Feng Y, 2013, AM J PATHOL, V183, P493, DOI 10.1016/j.ajpath.2013.04.013; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gibson SL, 2005, CANCER BIOL THER, V4, P1389, DOI 10.4161/cbt.4.12.2303; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hill RM, 2015, CANCER CELL, V27, P72, DOI 10.1016/j.ccell.2014.11.002; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Ji HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026057; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kim TH, 2014, ONCOTARGET, V5, P860, DOI 10.18632/oncotarget.1784; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Littlewood TD, 2012, CELL, V151, P11, DOI 10.1016/j.cell.2012.09.006; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Meng X, 2015, ONCOGENE, V34, P5709, DOI 10.1038/onc.2015.39; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Oliner JD, 1993, ONCOPROTEIN MDM2 CON, P53; Sabo A, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014191; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schlosser I, 2005, ONCOGENE, V24, P520, DOI 10.1038/sj.onc.1208198; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014; Toshiyuki M, 1995, CELL, V80, P293, DOI DOI 10.1016/0092-8674(95)90412-3; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	52	22	22	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1374	1383		10.1038/onc.2016.301	http://dx.doi.org/10.1038/onc.2016.301			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27617574	Green Submitted, Green Accepted			2022-12-17	WOS:000395862500006
J	Roy, P; Mukherjee, T; Chatterjee, B; Vijayaragavan, B; Banoth, B; Basak, S				Roy, P.; Mukherjee, T.; Chatterjee, B.; Vijayaragavan, B.; Banoth, B.; Basak, S.			Non-canonical NF kappa B mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB: p50 NF kappa B pathway	ONCOGENE			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTORS; INDUCED APOPTOSIS; ACTIVATION; ALPHA; CELLS; TARGET; ABNORMALITIES; INFLAMMATION; THALIDOMIDE	Environmental drug resistance constitutes a serious impediment for therapeutic intervention in multiple myeloma. Tumorpromoting cytokines, such as tumor necrosis factor (TNF), induce nuclear factor-kappa B (NF kappa B)-driven expression of pro-survival factors, which confer resistance in myeloma cells to apoptotic insults from TNF-related apoptosis-inducing ligand (TRAIL) and other chemotherapeutic drugs. It is thought that RelA: p50 dimer, activated from I.Ba-inhibited complex in response to TNF-induced canonical NF kappa B signal, mediates the pro-survival NF kappa B function in cancerous cells. Myeloma cells additionally acquire gain-offunction mutations in the non-canonical N kappa B module, which induces partial proteolysis of p100 into p52 to promote RelB: p52/NF kappa B activation from p100-inhibited complex during immune cell differentiation. However, role of non-canonical NF kappa B signaling in the drug resistance in multiple myeloma remains unclear. Here we report that myeloma-associated non-canonical aberrations reinforce pro-survival TNF signaling in producing a protracted TRAIL-refractory state. These mutations did not act through a typical p52 NF kappa B complex, but completely degraded p100 to reposition RelB under I kappa Ba control, whose degradation during TNF signaling induced an early RelB: p50 containing NF kappa B activity. More so, autoregulatory RelB synthesis prolonged this TNF-induced RelB: p50 activity in myeloma cells harboring non-canonical mutations. Intriguingly, TNF-activated RelB: p50 dimer was both necessary and sufficient, and RelA was not required, for NF kappa B-dependent pro-survival gene expressions and suppression of apoptosis. Indeed, high RelB mRNA expressions in myeloma patients correlated with the augmented level of pro-survival factors and resistance to therapeutic intervention. In sum, we provide evidence that cancer-associated mutations perpetuate TNF-induced pro-survival NF kappa B activity through autoregulatory RelB control and thereby exacerbate environmental drug resistance in multiple myeloma.	[Roy, P.; Mukherjee, T.; Chatterjee, B.; Vijayaragavan, B.; Banoth, B.; Basak, S.] Natl Inst Immunol, Syst Immunol Lab, Aruna Asaf Ali Marg, New Delhi 110067, India; [Chatterjee, B.] IIT Delhi, Kusuma Sch Biol Sci, Hauz Khas, New Delhi, India; [Vijayaragavan, B.] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi; Weizmann Institute of Science	Basak, S (corresponding author), Natl Inst Immunol, Syst Immunol Lab, Aruna Asaf Ali Marg, New Delhi 110067, India.	sobasak@nii.ac.in	Banoth, Balaji/ABF-7350-2020	Banoth, Balaji/0000-0002-7467-2198; MUKHERJEE, TAPAS/0000-0002-9433-3716; Chatterjee, Budhaditya/0000-0003-2260-8642; Basak, Soumen/0000-0002-3586-1279	SERB; Department of Science and Technology, Govt. of India [EMR/2015/000658]; Wellcome Trust DBT India Alliance [500094/Z/09/Z]; CSIR; UGC	SERB(Department of Science & Technology (India)Science Engineering Research Board (SERB), India); Department of Science and Technology, Govt. of India(Department of Science & Technology (India)); Wellcome Trust DBT India Alliance(Wellcome TrustWellcome Trust DBT India Alliance); CSIR(Council of Scientific & Industrial Research (CSIR) - India); UGC(University Grants Commission, India)	We sincerely thank Ranjan Sen, NIH, and Anna George, NII, for critical reading and constructive suggestions. We also thank Michael Kuehl, NCI, for providing us HMCLs and Dr Shao Cong Sun, University of Texas for p100<INF>S866A, S870A</INF> construct. We thank V Kumar, MVR Prasad, J Sanghani and S Goel for technical assistance. Multiple myeloma-related research was funded by SERB, Department of Science and Technology, Govt. of India (EMR/2015/000658). Research in PI's laboratory is funded by an intermediate fellowship (500094/Z/09/Z) to SB from Wellcome Trust DBT India Alliance and NII-Core. PR and BB thank CSIR, and BC and TM thank UGC for research fellowships.	Almaden JV, 2014, CELL REP, V9, P2098, DOI 10.1016/j.celrep.2014.11.024; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Annunziata CM, 2010, CANCER-AM CANCER SOC, V116, P3276, DOI 10.1002/cncr.25190; Authier H, 2014, P NATL ACAD SCI USA, V111, P14794, DOI 10.1073/pnas.1410124111; Banoth B, 2015, ELIFE, V4, DOI 10.7554/eLife.05648; Basak S, 2008, CYTOKINE GROWTH F R, V19, P187, DOI 10.1016/j.cytogfr.2008.04.005; Basak S, 2008, MOL CELL BIOL, V28, P3139, DOI 10.1128/MCB.01469-07; Basak S, 2007, CELL, V128, P369, DOI 10.1016/j.cell.2006.12.033; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chen XP, 2009, J BIOL CHEM, V284, P27857, DOI 10.1074/jbc.M109.000950; Cormier F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059127; Dai Y, 2004, BLOOD, V103, P2761, DOI 10.1182/blood-2003-09-3037; Demchenko YN, 2014, ONCOTARGET, V5, P4554, DOI 10.18632/oncotarget.2128; Demchenko YN, 2010, BLOOD, V115, P3541, DOI 10.1182/blood-2009-09-243535; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Dimberg LY, 2013, ONCOGENE, V32, P1341, DOI 10.1038/onc.2012.164; Geng CY, 2014, AM J HEMATOL, V89, P1037, DOI 10.1002/ajh.23822; Hengeveld PJ, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.3; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Jourdan M, 1999, EUR CYTOKINE NETW, V10, P65; Jurisic V, 2002, MED ONCOL, V19, P133, DOI 10.1385/MO:19:3:133; Kawano Y, 2015, IMMUNOL REV, V263, P160, DOI 10.1111/imr.12233; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Koslowski M, 2011, ONCOGENE, V30, P876, DOI 10.1038/onc.2010.481; Latif T, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-27; Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Perez LE, 2008, J IMMUNOL, V180, P1545, DOI 10.4049/jimmunol.180.3.1545; Rauert H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.78; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Sanda T, 2012, CANCER CELL, V22, P209, DOI 10.1016/j.ccr.2012.06.007; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shih VFS, 2012, NAT IMMUNOL, V13, P1162, DOI 10.1038/ni.2446; Siggers T, 2012, NAT IMMUNOL, V13, P95, DOI 10.1038/ni.2151; Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600-065X.2011.01088.x; Thu YM, 2010, CYTOKINE GROWTH F R, V21, P213, DOI 10.1016/j.cytogfr.2010.06.002; Vallabhapurapu SD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9428; Wang XS, 2015, LEUKEMIA LYMPHOMA, V56, P1335, DOI 10.3109/10428194.2014.956313; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Zhao B, 2014, CELL REP, V8, P1595, DOI 10.1016/j.celrep.2014.07.037; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	52	22	22	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1417	1429		10.1038/onc.2016.309	http://dx.doi.org/10.1038/onc.2016.309			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27641334	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000395862500010
J	Zhang, S; Zhou, B; Wang, L; Li, P; Bennett, B; Snyder, R; Garantziotis, S; Fargo, D; Cox, A; Chen, L; Hu, G				Zhang, S.; Zhou, B.; Wang, L.; Li, P.; Bennett, Bd; Snyder, R.; Garantziotis, S.; Fargo, Dc; Cox, Ad; Chen, L.; Hu, G.			INO80 is required for oncogenic transcription and tumor growth in non-small cell lung cancer	ONCOGENE			English	Article							CHROMATIN REMODELING COMPLEX; AMPLIFICATION; PLURIPOTENCY; REPLICATION; MECHANISMS; LANDSCAPE; BIOLOGY; ENZYME; GENES	Epigenetic regulators are attractive targets for the development of new cancer therapies. Among them, the ATP-dependent chromatin remodeling complexes control the chromatin architecture and have important roles in gene regulation. They are often found to be mutated and de-regulated in cancers, but how they influence the cancer gene expression program during cancer initiation and progression is not fully understood. Here we show that the INO80 chromatin remodeling complex is required for oncogenic transcription and tumor growth in non-small-cell lung cancer (NSCLC). Ino80, the SWI/SNF ATPase in the complex, is highly expressed in NSCLC cells compared with normal lung epithelia cells. Further, its expression, as well as that of another subunit Ino80B, negatively correlates with disease prognosis in lung cancer patients. Functionally, INO80 silencing inhibits NSCLC cell proliferation and anchorage-independent growth in vitro and tumor formation in mouse xenografts. It occupies enhancer regions near lung cancer-associated genes, and its occupancy correlates with increased genome accessibility and enhanced expression of downstream genes. Together, our study defines a critical role of INO80 in promoting oncogenic transcription and NSCLC tumorigenesis, and reveals a potential treatment strategy for inhibiting the cancer transcription network by targeting the INO80 chromatin remodeling complex.	[Zhang, S.; Chen, L.] Chinese Peoples Liberat Army Gen Hosp, Dept Pulm & Crit Care Med, Beijing 100853, Peoples R China; [Zhou, B.; Cox, Ad] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; [Zhou, B.; Wang, L.] Fuwai Hosp, Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis, Beijing, Peoples R China; [Zhou, B.; Wang, L.] Fuwai Hosp, Chinese Acad Med Sci, Peking Union Med Coll, Natl Ctr Cardiovasc Dis, Beijing, Peoples R China; [Wang, L.; Li, P.; Hu, G.] Natl Inst Environm Hlth Sci, Epigenet & Stem Cell Biol Lab, 111 TW Alexander Dr,Bldg 101,Room A314, Res Triangle Pk, NC 27709 USA; [Bennett, Bd; Fargo, Dc] Natl Inst Environm Hlth Sci, Integrat Bioinformat, Res Triangle Pk, NC USA; [Snyder, R.; Garantziotis, S.] Natl Inst Environm Hlth Sci, Clin Res Branch, Res Triangle Pk, NC USA	Chinese People's Liberation Army General Hospital; University of North Carolina; University of North Carolina Chapel Hill; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Chen, L (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Pulm & Crit Care Med, Beijing 100853, Peoples R China.; Hu, G (corresponding author), Natl Inst Environm Hlth Sci, Epigenet & Stem Cell Biol Lab, 111 TW Alexander Dr,Bldg 101,Room A314, Res Triangle Pk, NC 27709 USA.	CLA_301@163.com; hug4@niehs.nih.gov	Hu, Guang/E-7474-2016; Garantziotis, Stavros/A-6903-2009	Hu, Guang/0000-0003-0437-4723; Garantziotis, Stavros/0000-0003-4007-375X; Cox, Adrienne D./0000-0002-4901-2454; Chen, Liang-an/0000-0002-1829-3134	Intramural Research Program of the NIH; National Institute of Environmental Health Sciences [Z01ES102745]; National Institutes of Health Grants [CA042978, CA161494]; NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIDES102465, ZIAES102605, ZIAES102745] Funding Source: NIH RePORTER	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institutes of Health Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank the NIEHS Animal, Epigenomics and Bioinformatics core facilities for assistance with various techniques and experiments. This study was supported in part by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences Z01ES102745 (to GH) and by National Institutes of Health Grants CA042978 and CA161494 (to ADC).	Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674; Baykara O, 2015, J CANCER, V6, P270, DOI 10.7150/jca.10638; Belinsky SA, 2015, ANNU REV PHYSIOL, V77, P453, DOI 10.1146/annurev-physiol-021014-072018; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bender E, 2014, NATURE, V513, pS2, DOI 10.1038/513S2a; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Conaway RC, 2009, TRENDS BIOCHEM SCI, V34, P71, DOI 10.1016/j.tibs.2008.10.010; El-Telbany Ahmed, 2012, Genes Cancer, V3, P467, DOI 10.1177/1947601912465177; Gaspar-Maia A, 2011, NAT REV MOL CELL BIO, V12, P36, DOI 10.1038/nrm3036; Han L, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.013; Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Hu GQ, 2011, GENOME RES, V21, P1650, DOI 10.1101/gr.121145.111; Jakopovic M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00261; Job B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015145; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kim J, 2011, GENOME MED, V3, DOI 10.1186/gm291; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Laurette P, 2015, ELIFE, V4, DOI 10.7554/eLife.06857; Linxweiler M, 2012, AM J PATHOL, V180, P473, DOI 10.1016/j.ajpath.2011.10.039; Liu SV, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00135; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Min JN, 2013, CELL RES, V23, P1396, DOI 10.1038/cr.2013.113; Morrison AJ, 2009, NAT REV MOL CELL BIO, V10, P373, DOI 10.1038/nrm2693; Narlikar GJ, 2013, CELL, V154, P490, DOI 10.1016/j.cell.2013.07.011; Papamichos-Chronakis M, 2011, CELL, V144, P200, DOI 10.1016/j.cell.2010.12.021; Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Viktorsson K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.28; Wang L, 2014, CELL STEM CELL, V14, P575, DOI 10.1016/j.stem.2014.02.013; Watanabe S, 2010, COLD SH Q B, V75, P35, DOI 10.1101/sqb.2010.75.063; Watanabe S, 2013, SCIENCE, V340, P195, DOI 10.1126/science.1229758; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009	35	22	22	5	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1430	1439		10.1038/onc.2016.311	http://dx.doi.org/10.1038/onc.2016.311			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27641337	Green Accepted			2022-12-17	WOS:000395862500011
J	Apicella, M; Migliore, C; Capeloa, T; Menegon, S; Cargnelutti, M; Degiuli, M; Sapino, A; Sottile, A; Sarotto, I; Casorzo, L; Cassoni, P; De Simone, M; Comoglio, PM; Marsoni, S; Corso, S; Giordano, S				Apicella, M.; Migliore, C.; Capeloa, T.; Menegon, S.; Cargnelutti, M.; Degiuli, M.; Sapino, A.; Sottile, A.; Sarotto, I.; Casorzo, L.; Cassoni, P.; De Simone, M.; Comoglio, P. M.; Marsoni, S.; Corso, S.; Giordano, S.			Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort	ONCOGENE			English	Article							ACQUIRED-RESISTANCE; GENE AMPLIFICATION; LUNG-CANCER; ACTIVATION; MUTATIONS; ADENOCARCINOMA; SENSITIVITY; INHIBITORS; GEFITINIB; GROWTH	Amplification of the MET oncogene occurs in 2-4% of gastroesophageal cancers and defines a small and aggressive subset of tumors. Although in vitro studies have given very promising results, clinical trials with MET inhibitors have been disappointing, showing few and short lasting responses. The aim of the work was to exploit a MET-amplified patient-derived xenograft model to optimize anti-MET therapeutic strategies in gastroesophageal cancer. We found that despite the high MET amplification level ( 26 gene copies), in the absence of qualitative or quantitative alterations of EGFR, MET inhibitors induced only tumor growth inhibition, whereas dual MET/EGFR inhibition led to complete tumor regression. Importantly, the combo treatment completely prevented the onset of resistance, which quite rapidly appeared in tumors treated with MET monotherapy. We found that this secondary resistance was due to EGFR activation and could be overcome by dual MET/EGFR inhibition. Similar results were also obtained in a MET-addicted, established gastric cancer cell line. In vitro experiments performed on tumor-derived primary cells confirmed that MET inhibitors were not able to abrogate the activation of downstream transducers and that only the combined MET/EGFR treatment completely shut off the signaling. Previously reported cases, as well as those described here, showed only partial and transient sensitivity to anti-MET therapy. The finding that combined anti-MET/EGFR therapy-even in the absence of EGFR genetic alterations-induced complete and durable response, represents a proof of concept and guarantees further investigations, opening a new perspective of treatment for these patients.	[Apicella, M.; Migliore, C.; Corso, S.; Giordano, S.] Univ Torino, Dept Oncol, Candiolo, Italy; [Apicella, M.; Migliore, C.; Capeloa, T.; Menegon, S.; Cargnelutti, M.; Sapino, A.; Sottile, A.; Sarotto, I.; Casorzo, L.; De Simone, M.; Comoglio, P. M.; Marsoni, S.; Corso, S.; Giordano, S.] IRCCS, FPO, Candiolo Canc Inst, Candiolo, Italy; [Capeloa, T.] Univ Torino, Dept Clin & Biol Sci, Orbassano, Italy; [Degiuli, M.] Osped Molinette, Dept Surg, Turin, Italy; [Sapino, A.; Cassoni, P.] Univ Torino, Dept Med Sci, Turin, Italy	University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin	Corso, S; Giordano, S (corresponding author), Univ Torino, IRCCS, FPO, Candiolo Canc Inst,Dept Oncol, Str Prov 142, I-10060 Turin, Italy.	simona.corso@unito.it; silvia.giordano@unito.it	Sapino, Anna/AGY-9901-2022; Giordano, Silvia/J-9858-2018; Sapino, Anna/J-4113-2018; Casorzo, Laura/AAB-7684-2020; Cassoni, Paola/I-8544-2018; sarotto, ivana/AAB-7797-2020	Sapino, Anna/0000-0003-3542-9571; Giordano, Silvia/0000-0003-1854-1086; Sapino, Anna/0000-0003-3542-9571; Casorzo, Laura/0000-0002-2509-7369; CORSO, Simona/0000-0002-5069-1503; Menegon, Silvia/0000-0002-5078-2464; Migliore, Cristina/0000-0003-3722-2814; Marsoni, Silvia/0000-0002-5361-7122; sottile, antonino/0000-0003-4252-3240; Comoglio, Paolo/0000-0002-7056-5328	Italian Association for Cancer Research (AIRC) [15464]; Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute	We thank all our colleagues for helpful scientific discussion; Drs Martinoglio, Porporato and Buscarino for technical support with RT-PCR and sequencing; Dr Perra for tumor microdissection; Dr Giove for support with immunohistochemistry; animal facility employees; Dr Natale for critical manuscript reading. SG and SC are EuroPDX Consortium members. This work was funded by the Italian Association for Cancer Research (AIRC); IG grant 15464 to SG and Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute 2013.	Bachleitner-Hofmann T, 2008, MOL CANCER THER, V7, P3499, DOI 10.1158/1535-7163.MCT-08-0374; Bang YJ, 2010, LANCET, V376, P1302; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bertotti A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2102er11; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Breindel JL, 2013, CANCER RES, V73, P5053, DOI 10.1158/0008-5472.CAN-12-3775; Cepero V, 2010, CANCER RES, V70, P7580, DOI 10.1158/0008-5472.CAN-10-0436; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Corso S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-121; Crew KD, 2004, SEMIN ONCOL, V31, P450, DOI 10.1053/j.seminoncol.2004.04.021; Cunningham D, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.16; Doi T., 2015, J CLIN ONCOL S3, V33; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Lee J, 2015, ONCOTARGET, V6, P28211, DOI 10.18632/oncotarget.4721; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495; Paik PK, 2015, CANCER DISCOV, V5, P842, DOI 10.1158/2159-8290.CD-14-1467; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Puri Neelu, 2008, J Carcinog, V7, P9; Qi J, 2011, CANCER RES, V71, P1081, DOI 10.1158/0008-5472.CAN-10-1623; Shah AM, 2015, J CLIN ONCOL, V33; Shah MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054014; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Wild CP, 2003, NAT REV CANCER, V3, P676, DOI 10.1038/nrc1166	33	22	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1200	1210		10.1038/onc.2016.283	http://dx.doi.org/10.1038/onc.2016.283			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27524418				2022-12-17	WOS:000395861300004
J	Ki, DH; He, S; Rodig, S; Look, AT				Ki, D. H.; He, S.; Rodig, S.; Look, A. T.			Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SOX10; NEUROFIBROMATOSIS TYPE-1; SUPPRESSOR GENE; ZEBRAFISH; SENSITIVITY; IMATINIB; CANCER; MUTATIONS; MUTANT; GLIOBLASTOMAS	Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, frequently metastatic sarcomas that are associated with neurofibromatosis type 1 (NF1), a prominent inherited genetic disease in humans. Although loss of the NF1 gene predisposes to MPNST induction, relatively long tumor latency in NF1 patients suggests that additional genetic or epigenetic abnormalities are needed for the development of these nerve sheath malignancies. To study the molecular pathways contributing to the formation of MPNSTs in NF1 patients, we used a zebrafish tumor model defined by nf1 loss in a p53-deficient background together with the overexpression of either wild-type or constitutively activated PDGFRA (platelet-derived growth factor receptor-a) under control of the sox10 neural crest-specific promoter. Here we demonstrate the accelerated onset and increased penetrance of MPNST formation in fish overexpressing both the wild-type and the mutant PDGFRA transgenes in cells of neural crest origin. Interestingly, overexpression of the wild-type PDGFRA was even more potent in promoting transformation than the mutant PDGFRA, which is important because similar to 78% of human MPNSTs have expression of wild-type PDGFRA, whereas only 5% harbor activating mutations of the gene encoding this receptor. Further analysis revealed the induction of cellular senescence in zebrafish embryos overexpressing mutant, but not wild-type, PDGFRA, suggesting a mechanism through which the oncogenic activity of the mutant receptor is tempered by the activation of premature cellular senescence in an NF1-deficient background. Taken together, our study suggests a model in which overexpression of wild-type PDGFRA associated with NF1 deficiency leads to aberrant activation of downstream RAS signaling and thus contributes importantly to MPNST development-a prediction supported by the ability of the kinase inhibitor sunitinib alone and in combination with the MEK inhibitor trametinib to retard MPNST progression in transgenic fish overexpressing the wild-type receptor.	[Ki, D. H.; He, S.; Look, A. T.] Childrens Hosp Boston, Harvard Med School, Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,Mayer 630, Boston, MA 02115 USA; [Rodig, S.] Brigham & Womens Hosp, Boston, MA USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Look, AT (corresponding author), Childrens Hosp Boston, Harvard Med School, Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,Mayer 630, Boston, MA 02115 USA.	Thomas_look@dfci.harvard.edu	Rodig, Scott/Y-3889-2019	Ki, Dong Hyuk/0000-0002-1571-7077	Department of Defense [W81XWH-12-1-0125]; Children's Tumor Foundation; NF1 Research Consortium Fund; Latsis family fellowship from the Boston Children's Hospital Neurofibromatosis program	Department of Defense(United States Department of Defense); Children's Tumor Foundation; NF1 Research Consortium Fund; Latsis family fellowship from the Boston Children's Hospital Neurofibromatosis program	This work was supported by the Latsis family fellowship from the Boston Children's Hospital Neurofibromatosis program, a grant from Department of Defense (W81XWH-12-1-0125), a Drug Discovery Initiative Award from the Children's Tumor Foundation and the NF1 Research Consortium Fund. We thank John Gilbert for editorial review and critical comments, and Dr Donna Neuberg for biostatistical advice regarding the sample size, statistical power and most appropriate statistical tests. We are grateful to Hillary Layden and Shawna Chamberlin for their expert assistance with zebrafish husbandry and to Dr Eric Holland for providing the wildtype and mutant PDGFRA cDNAs.	Alexander A, 1998, Front Biosci, V3, pd729; Aoki M, 2007, LAB INVEST, V87, P767, DOI 10.1038/labinvest.3700591; Baker SA, 2013, J PHYSIOL-LONDON, V591, P6193, DOI 10.1113/jphysiol.2013.264747; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Clarke ID, 2003, ONCOGENE, V22, P722, DOI 10.1038/sj.onc.1206160; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Corless CL, 2005, J CLIN ONCOL, V23, P5357, DOI 10.1200/JCO.2005.14.068; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; Demoulin JB, 2012, AM J BLOOD RES, V2, P44; DiMauro T, 2010, CURR CANCER DRUG TAR, V10, P869, DOI 10.2174/156800910793357998; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dutton JR, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-105; Evans DGR, 2011, EUR J HUM GENET, V19, P1187, DOI 10.1038/ejhg.2011.113; Ferrari Andrea, 2007, Paediatr Drugs, V9, P239, DOI 10.2165/00148581-200709040-00005; Fortman BJ, 2001, RADIOGRAPHICS, V21, P601, DOI 10.1148/radiographics.21.3.g01ma05601; Holtkamp N, 2004, ACTA NEUROPATHOL, V107, P159, DOI 10.1007/s00401-003-0797-8; Holtkamp N, 2006, CARCINOGENESIS, V27, P664, DOI 10.1093/carcin/bgi273; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Karamchandani JR, 2012, APPL IMMUNOHISTO M M, V20, P445, DOI 10.1097/PAI.0b013e318244ff4b; Keng Vincent W., 2012, Sarcoma, V2012, P620834, DOI 10.1155/2012/620834; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Kourea HP, 1998, CANCER, V82, P2191, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2191::AID-CNCR14>3.0.CO;2-P; Langenau DM, 2008, ONCOGENE, V27, P4242, DOI 10.1038/onc.2008.56; Lee JS, 2010, HUM MOL GENET, V19, P4643, DOI 10.1093/hmg/ddq395; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; LEGIUS E, 1994, GENE CHROMOSOME CANC, V10, P250, DOI 10.1002/gcc.2870100405; Macdonald R, 1999, METH MOL B, V127, P77, DOI 10.1385/1-59259-678-9:77; Mantripragada KK, 2008, CLIN CANCER RES, V14, P1015, DOI 10.1158/1078-0432.CCR-07-1305; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Mashour GA, 2001, ONCOGENE, V20, P97, DOI 10.1038/sj.onc.1204026; Mautner VF, 2003, NEURORADIOLOGY, V45, P618, DOI 10.1007/s00234-003-0964-6; Medves S, 2012, J CELL MOL MED, V16, P237, DOI 10.1111/j.1582-4934.2011.01415.x; Nonaka D, 2008, AM J SURG PATHOL, V32, P1291, DOI 10.1097/PAS.0b013e3181658c14; Ozawa T, 2010, GENE DEV, V24, P2205, DOI 10.1101/gad.1972310; Perrone F, 2009, NEURO-ONCOLOGY, V11, P725, DOI 10.1215/15228517-2009-003; Rahrmann EP, 2013, NAT GENET, V45, P756, DOI 10.1038/ng.2641; Riemenschneider MJ, 2005, AM J PATHOL, V167, P1379, DOI 10.1016/S0002-9440(10)61225-4; Rubin JB, 2005, NAT REV CANCER, V5, P557, DOI 10.1038/nrc1653; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shin J, 2012, DIS MODEL MECH, V5, P881, DOI 10.1242/dmm.009779; Tao T, 2013, CELL RES, V23, P620, DOI 10.1038/cr.2013.16; Thway K, 2014, ANN DIAGN PATHOL, V18, P109, DOI 10.1016/j.anndiagpath.2013.10.007; Toffalini F, 2010, BLOOD, V116, P2429, DOI 10.1182/blood-2010-04-279752; Velghe AI, 2014, ONCOGENE, V33, P2568, DOI 10.1038/onc.2013.218; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE; Wong WW, 1998, INT J RADIAT ONCOL, V42, P351, DOI 10.1016/S0360-3016(98)00223-5; Zietsch J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011858	50	22	25	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1058	1068		10.1038/onc.2016.269	http://dx.doi.org/10.1038/onc.2016.269			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27477693	Green Published, hybrid			2022-12-17	WOS:000395371500004
J	Thompson, JM; Nguyen, QH; Singh, M; Pavesic, MW; Nesterenko, I; Nelson, LJ; Liao, AC; Razorenova, OV				Thompson, J. M.; Nguyen, Q. H.; Singh, M.; Pavesic, M. W.; Nesterenko, I.; Nelson, L. J.; Liao, A. C.; Razorenova, O. V.			Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR; UP-REGULATION; INTERFERON-ALPHA; ROCK-II; HYPOXIA; GENE; EXPRESSION; Y-27632; PROGRESSION	Clear cell renal cell carcinoma (CC-RCC) is the most lethal of all genitourinary cancers. The functional loss of the von Hippel-Lindau (VHL) gene occurs in 90% of CC-RCC, driving cancer progression. The objective of this study was to identify chemical compounds that are synthetically lethal with VHL deficiency in CC-RCC. An annotated chemical library, the library of pharmacologically active compounds (LOPAC), was screened in parallel on VHL-deficient RCC4 cells and RCC4VHL cells with re-introduced VHL. The ROCK inhibitor, Y-27632, was identified and validated for selective targeting of VHL-deficient CC-RCC in multiple genetic backgrounds by clonogenic assays. Downregulation of ROCK1 by small interfering RNA (siRNA) selectively reduced the colony-forming ability of VHL-deficient CC-RCC, thus mimicking the effect of Y-27632 treatment, whereas downregulation of ROCK2 had no effect. In addition, two other ROCK inhibitors, RKI 1447 and GSK 429286, selectively targeted VHL-deficient CC-RCC. CC-RCC treatment with ROCK inhibitors is cytotoxic and cytostatic based on bromodeoxyuridine (BrdU) assay, propidium iodide (PI) staining and growth curves, and blocks cell migration based on transwell assay. On the one hand, knockdown of hypoxia-inducible factor (HIF) beta in the VHL-deficient CC-RCC had a protective effect against Y-27632 treatment, mimicking VHL reintroduction. On the other hand, CC-RCCVHL cells were sensitized to Y-27632 treatment in hypoxia (2% O-2). These results suggest that synthetic lethality between ROCK inhibition and VHL deficiency is dependent on HIF activation. Moreover, HIF1 alpha or HIF2 alpha overexpression in CC-RCCVHL cells is sufficient to sensitize them to ROCK inhibition. Finally, Y-27632 treatment inhibited growth of subcutaneous 786-OT1 CC-RCC tumors in mice. Thus, ROCK inhibitors represent potential therapeutics for VHL-deficient CC-RCC.	[Thompson, J. M.; Nguyen, Q. H.; Singh, M.; Pavesic, M. W.; Nesterenko, I.; Nelson, L. J.; Liao, A. C.; Razorenova, O. V.] Univ Calif Irvine, Dept Mol Biol & Biochem, 845 Hlth Sci Rd,Gross Hall Room 3010, Irvine, CA 92717 USA	University of California System; University of California Irvine	Razorenova, OV (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 845 Hlth Sci Rd,Gross Hall Room 3010, Irvine, CA 92717 USA.	olgar@uci.edu			NCI [R03 CA202563-01]; NIH T32 [2T32CA009054-36A1]; NIH [T32 NS82174-3]; NIH ICTS [UL1 TR001414];  [ACS-IRG-98-279-10]; NATIONAL CANCER INSTITUTE [T32CA009054, R03CA202563] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR001415, UL1TR001414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS082174] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH T32(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH ICTS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was funded by ACS-IRG-98-279-10 and NCI R03 CA202563-01 to OVR, NIH T32 (2T32CA009054-36A1) to JMT, NIH T32 NS82174-3 to IN and NIH ICTS (UL1 TR001414) to LJN. We thank Dr David Fruman and Dr Hung Fan for critical reading of the manuscript and anonymous reviewers for constructive critique.	Abe H, 2008, BIOMED RES-TOKYO, V29, P155, DOI 10.2220/biomedres.29.155; Amin E, 2013, BIOL CHEM, V394, P1399, DOI 10.1515/hsz-2013-0181; Bommi-Reddy A, 2008, P NATL ACAD SCI USA, V105, P16484, DOI 10.1073/pnas.0806574105; Buczek M, 2014, BBA-REV CANCER, V1845, P31, DOI 10.1016/j.bbcan.2013.10.001; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; Cowey CL, 2009, CURR ONCOL REP, V11, P94, DOI 10.1007/s11912-009-0015-5; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Escudier B, 2011, DRUGS R&D, V11, P113, DOI 10.2165/11591240-000000000-00000; Gilkes DM, 2014, P NATL ACAD SCI USA, V111, pE384, DOI 10.1073/pnas.1321510111; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Inan SY, 2008, BRIT J PHARMACOL, V155, P44, DOI 10.1038/bjp.2008.225; Isler D, 2014, PHARMACOL REP, V66, P114, DOI 10.1016/j.pharep.2013.06.006; Jonasch E, 2012, MOL CANCER RES, V10, P859, DOI 10.1158/1541-7786.MCR-12-0117; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; Kapitsinou PP, 2008, CELL DEATH DIFFER, V15, P650, DOI 10.1038/sj.cdd.4402313; Lane J, 2008, INT J ONCOL, V33, P585, DOI 10.3892/ijo_00000044; Liao DK, 2007, J CARDIOVASC PHARM, V50, P17, DOI 10.1097/FJC.0b013e318070d1bd; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Liu XZ, 2011, J ORTHOP RES, V29, P1259, DOI 10.1002/jor.21403; Lochhead PA, 2010, ONCOGENE, V29, P2591, DOI 10.1038/onc.2010.3; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mizukami Y, 2006, J BIOL CHEM, V281, P13957, DOI 10.1074/jbc.M511763200; Mleczak A, 2013, CELL SIGNAL, V25, P1, DOI 10.1016/j.cellsig.2012.09.010; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Nagatoya K, 2002, KIDNEY INT, V61, P1684, DOI 10.1046/j.1523-1755.2002.00328.x; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Patel RA, 2012, CANCER RES, V72, P5025, DOI 10.1158/0008-5472.CAN-12-0954; Pinto A, 2014, CLIN GENITOURIN CANC, V12, P408, DOI 10.1016/j.clgc.2014.06.012; Razorenova OV, 2014, MOL CELL BIOL, V34, P739, DOI 10.1128/MCB.00644-12; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Razorenova OV, 2005, GENE, V350, P89, DOI 10.1016/j.gene.2005.02.006; Rikitake Y, 2005, STROKE, V36, P2251, DOI 10.1161/01.STR.0000181077.84981.11; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shi JJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.10; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764; Sutphin PD, 2007, CANCER RES, V67, P5896, DOI 10.1158/0008-5472.CAN-07-0604; Takata K, 2008, MOL CANCER THER, V7, P1551, DOI 10.1158/1535-7163.MCT-07-0428; Thompson Jordan M., 2015, Yale Journal of Biology and Medicine, V88, P145; Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427; Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004; Woldemichael GM, 2012, NEOPLASIA, V14, P771, DOI 10.1593/neo.12852; Wolff NC, 2015, ONCOTARGET, V6, P16951, DOI 10.18632/oncotarget.4773; Zhang C, 2014, ONCOGENE, V33, P5582, DOI 10.1038/onc.2013.505; Zhang QH, 2012, ADV DIFFER EQU-NY, DOI 10.1186/1687-1847-2012-136	54	22	22	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1080	1089		10.1038/onc.2016.272	http://dx.doi.org/10.1038/onc.2016.272			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27841867	Green Submitted, Green Accepted			2022-12-17	WOS:000395371500006
J	Rada, M; Vasileva, E; Lezina, L; Marouco, D; Antonov, AV; Macip, S; Melino, G; Barlev, NA				Rada, M.; Vasileva, E.; Lezina, L.; Marouco, D.; Antonov, A. V.; Macip, S.; Melino, G.; Barlev, N. A.			Human EHMT2/G9a activates p53 through methylation-independent mechanism	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE; GENOTOXIC STRESS; TRANSCRIPTIONAL REGULATION; LYSINE METHYLATION; TUMOR SUPPRESSION; DNA-DAMAGE; G9A; SET7/9; GLP; H3	p53 is a critical tumor suppressor in humans. It functions mostly as a transcriptional factor and its activity is regulated by numerous post-translational modifications. Among different covalent modifications found on p53 the most controversial one is lysine methylation. We found that human G9a (hG9a) unlike its mouse orthologue (mG9a) potently stimulated p53 transcriptional activity. Both ectopic and endogenous hG9a augmented p53-dependent transcription of pro-apoptotic genes, including Bax and Puma, resulting in enhanced apoptosis and reduced colony formation. Significantly, shRNA-mediated knockdown of hG9a attenuated p53-dependent activation of Puma. On the molecular level, hG9a interacted with histone acetyltransferase, p300/CBP, resulting in increased histone acetylation at the promoter of Puma. The bioinformatics data substantiated our findings showing that positive correlation between G9a and p53 expression is associated with better survival of lung cancer patients. Collectively, this study demonstrates that depending on the cellular and organismal context, orthologous proteins may exert both overlapping and opposing functions. Furthermore, this finding has important ramifications on the use of G9a inhibitors in combination with genotoxic drugs to treat p53-positive tumors.	[Rada, M.; Lezina, L.; Marouco, D.; Macip, S.] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; [Vasileva, E.; Lezina, L.; Antonov, A. V.; Barlev, N. A.] Inst Cytol, St Petersburg, Russia; [Antonov, A. V.; Melino, G.] MRC Toxicol Unit, Leicester, Leics, England	University of Leicester; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Barlev, NA (corresponding author), Inst Cytol, Gene Express Lab, St Petersburg 194064, Russia.	nick.a.barlev@gmail.com	Macip, Salvador/P-4233-2019; Lezina, Larissa/AAO-3574-2020; Barlev, Nikolai A/K-5268-2017; Macip, Salvador/S-6358-2019	Macip, Salvador/0000-0003-1963-8840; Barlev, Nikolai A/0000-0001-7111-2446; 	RSF [14-15-00816]; Kurdistan Regional Government (Iraq); MCB RAS programme; Medical Research Council; AIRC [IG15653, MCO9979, IG11955]; Fondazione Roma malattie Non trasmissibili Cronico-Degenerative (NCD); MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	RSF(Russian Science Foundation (RSF)); Kurdistan Regional Government (Iraq); MCB RAS programme; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Roma malattie Non trasmissibili Cronico-Degenerative (NCD)(Fondazione Roma); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Dr O. Binda (Newcastle University, UK), Dr MR. Stallcup (University of Southern California, USA), Dr C-M Chiang (University of Texas Southwestern Medical Center, USA), Dr SB Seo (Chung-Ang University, Korea), Dr P. Muller (MRC Toxicology Unit, UK) for providing various constructs and reagents. We also thank S Cowley lab (University of Leicester, UK) for providing E14 cells. This work was supported by grants from RSF 14-15-00816 to (E.V. and N.B.); M.R. was supported by a Doctoral Studentship from the Kurdistan Regional Government (Iraq); A.V.A. was supported by MCB RAS programme; G. M. acknowledges the grant support from Medical Research Council, AIRC 2014 IG15653, AIRC 5xmille MCO9979, AIRC 2011 IG11955 and Fondazione Roma malattie Non trasmissibili Cronico-Degenerative (NCD).	Antonov AV, 2014, ONCOGENE, V33, P1621, DOI 10.1038/onc.2013.119; Antonov AV, 2011, NUCLEIC ACIDS RES, V39, pW323, DOI 10.1093/nar/gkr372; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099; Bittencourt D, 2012, P NATL ACAD SCI USA, V109, P19673, DOI 10.1073/pnas.1211803109; Brooks CL, 2011, FEBS LETT, V585, P2803, DOI 10.1016/j.febslet.2011.05.022; Brown SE, 2001, MAMM GENOME, V12, P916, DOI 10.1007/s00335-001-3029-3; Campaner S, 2011, MOL CELL, V43, P681, DOI 10.1016/j.molcel.2011.08.007; Celardo I, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.175; Chang YQ, 2009, NAT STRUCT MOL BIOL, V16, P312, DOI 10.1038/nsmb.1560; Chaturvedi CP, 2012, P NATL ACAD SCI USA, V109, P18845, DOI 10.1073/pnas.1213951109; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Collins R, 2010, NUCLEIC ACIDS RES, V38, P3503, DOI 10.1093/nar/gkq081; Dong C, 2012, CANCER CELL, V23, P316; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fedorova OA, 2011, BIOCHEM BIOPH RES CO, V416, P258, DOI 10.1016/j.bbrc.2011.10.126; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Henry RA, 2013, BIOCHEMISTRY-US, V52, P5746, DOI 10.1021/bi400684q; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Ivanov GS, 2007, MOL CELL BIOL, V27, P6756, DOI 10.1128/MCB.00460-07; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Lee DY, 2006, J BIOL CHEM, V281, P8476, DOI 10.1074/jbc.M511093200; Lehnertz B, 2011, MOL CELL, V43, P673, DOI 10.1016/j.molcel.2011.08.006; Lezina L, 2014, CELL DEATH DIFFER, V21, P1889, DOI 10.1038/cdd.2014.108; Lezina L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.483; Lezina L, 2015, ONCOTARGET, V6, P25843, DOI 10.18632/oncotarget.4584; Liu XY, 2011, P NATL ACAD SCI USA, V108, P1925, DOI 10.1073/pnas.1019619108; Marouco D, 2013, ONCOTARGET, V4, P1556, DOI 10.18632/oncotarget.1436; Michalak EM, 2010, GENE DEV, V24, P1608, DOI 10.1101/gad.1940110; Moiseeva TN, 2013, ONCOTARGET, V4, P1338, DOI 10.18632/oncotarget.1060; Mulligan P, 2008, MOL CELL, V32, P718, DOI 10.1016/j.molcel.2008.10.025; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oh ST, 2014, FEBS LETT, V588, P685, DOI 10.1016/j.febslet.2014.01.039; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Purcell DJ, 2011, J BIOL CHEM, V286, P41963, DOI 10.1074/jbc.M111.298463; Shankar SR, 2013, EPIGENETICS-US, V8, P16, DOI 10.4161/epi.23331; Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012; Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411; Sims RJ, 2008, NAT REV MOL CELL BIO, V9, P815, DOI 10.1038/nrm2502; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Sullivan KD, 2012, BBA-REV CANCER, V1825, P229, DOI 10.1016/j.bbcan.2012.01.004; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Thandapani P, 2013, MOL CELL, V50, P613, DOI 10.1016/j.molcel.2013.05.021; Trojer P, 2009, J BIOL CHEM, V284, P8395, DOI 10.1074/jbc.M807818200; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Weiss T, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-7; Xie P, 2008, CELL SIGNAL, V20, P1671, DOI 10.1016/j.cellsig.2008.05.012; Yu YX, 2012, MOL CELL, V46, P7, DOI 10.1016/j.molcel.2012.01.019; Zhang A, 2014, J MOL CELL BIOL, V6, P181, DOI 10.1093/jmcb/mju013	54	22	23	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					922	932		10.1038/onc.2016.258	http://dx.doi.org/10.1038/onc.2016.258			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27452519	Green Submitted			2022-12-17	WOS:000394169100005
J	Eguchi, R; Nakano, T; Wakabayashi, I				Eguchi, R.; Nakano, T.; Wakabayashi, I.			Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells	ONCOGENE			English	Article							MALIGNANT PLEURAL MESOTHELIOMA; GROWTH-FACTOR; EPITHELIN PRECURSOR; TUMOR ANGIOGENESIS; PROGNOSTIC MARKER; CANCER; CISPLATIN; THERAPY; TUMORIGENESIS; EXPRESSION	Malignant mesothelioma is an aggressive tumor arising from the mesothelial cells of serous membranes and is associated with tumor angiogenesis, which is a prerequisite for tumor progression. Vascular endothelial growth factors (VEGFs) including VEGF-A have a crucial role in tumor angiogenesis. However, bevacizumab, a monoclonal antibody to VEGF-A, has recently been reported not to improve the progression-free survival of patients with malignant mesothelioma. Cell culture supernatant contains extracellular components such as serum, which can mask the existence of unknown cell-derived factors in the supernatant and make it difficult to detect the factors by subsequent protein analysis. We tried using serum-free culture for human mesothelioma cell lines, NCI-H28, NCI-H2452 and NCI-H2052, and only NCI-H2052 cells adapted to serum-free culture. We found that serum-free culture supernatant derived from NCI-H2052 cells induces the formation of capillary-like tube structures (tube formation) in three-dimensional culture, in which endothelial cells sandwiched between two layers of collagen or embedded in collagen are incubated with various angiogenic inducers. However, neither neutralization of VEGF-A nor RNA interference of VEGF receptor 2 (VEGFR2) suppressed the supernatant-induced tube formation. Using mass spectrometry, we identified a total of 399 proteins in the supernatant, among which interleukin-8 (IL-8), growth-regulated a-protein, midkine, IL-18, IL-6, hepatoma-derived growth factor, clusterin and granulin (GRN), also known as progranulin (PGRN), were included as a candidate protein inducing angiogenesis. Neutralizing assays and RNA interference showed that PGRN, but not the above seven candidate proteins, caused the supernatant-induced tube formation. We also found that NCI-H28 and NCI-H2452 cells express PGRN. Furthermore, we demonstrate that not only PGRN but also GRN-like protein have an important role in the supernatant-induced tube formation. Thus, mesothelioma-derived GRNs induce VEGF-independent angiogenesis.	[Eguchi, R.; Wakabayashi, I.] Hyogo Coll Med, Dept Environm & Prevent Med, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan; [Nakano, T.] Hyogo Coll Med, Dept Internal Med, Div Resp Med, Nishinomiya, Hyogo, Japan	Hyogo College of Medicine; Hyogo College of Medicine	Eguchi, R (corresponding author), Hyogo Coll Med, Dept Environm & Prevent Med, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	r-eguchi@hyo-med.ac.jp		Eguchi, Ryoji/0000-0002-2417-7578	Hyogo College of Medicine; MEXT-Supported Program for the Strategic Research Foundation at Private Universities; JSPS KAKENHI [16K14626]	Hyogo College of Medicine; MEXT-Supported Program for the Strategic Research Foundation at Private Universities(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Ms Naoko Hamaue and Mr Daiki Haruguchi for their excellent technical assistance. This work was supported by a Grant-in-Aid for Researchers, Hyogo College of Medicine, 2013, the MEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2012-2015 and JSPS KAKENHI Grant Number 16K14626.	Bao CH, 2014, FUTURE ONCOL, V10, P2675, DOI 10.2217/fon.14.194; BHANDARI V, 1992, BIOCHEM BIOPH RES CO, V188, P57, DOI 10.1016/0006-291X(92)92349-3; Cenik B, 2012, J BIOL CHEM, V287, P32298, DOI 10.1074/jbc.R112.399170; Davidson B, 2004, CANCER-AM CANCER SOC, V100, P2139, DOI 10.1002/cncr.20219; Dowell JE, 2012, LUNG CANCER, V77, P567, DOI 10.1016/j.lungcan.2012.05.111; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21; Edwards JG, 2001, BRIT J CANCER, V85, P863, DOI 10.1054/bjoc.2001.1997; Eguchi R, 2008, PROTEOMICS, V8, P2897, DOI 10.1002/pmic.200800055; Eguchi R, 2013, CELL SIGNAL, V25, P1731, DOI 10.1016/j.cellsig.2013.05.008; Eguchi R, 2012, CARCINOGENESIS, V33, P969, DOI 10.1093/carcin/bgs109; Eguchi R, 2010, INT J ONCOL, V37, P1289, DOI 10.3892/ijo_00000780; Gijselinck I, 2008, HUM MUTAT, V29, P1373, DOI 10.1002/humu.20785; Goudar Ranjit Kumar, 2005, Curr Oncol Rep, V7, P260, DOI 10.1007/s11912-005-0048-3; Gourlaouen M, 2013, J BIOL CHEM, V288, P7467, DOI 10.1074/jbc.M112.446401; Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; Ho JC, 2008, HEPATOLOGY, V47, P1524, DOI 10.1002/hep.22191; Kadomatsu K, 2014, BRIT J PHARMACOL, V171, P936, DOI 10.1111/bph.12537; Karch CM, 2013, NEUROBIOL AGING, V34, P2538, DOI 10.1016/j.neurobiolaging.2013.05.004; Keeley EC, 2010, ADV CANCER RES, V106, P91, DOI 10.1016/S0065-230X(10)06003-3; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Koltai T, 2014, ONCOTARGETS THER, V7, P447, DOI 10.2147/OTT.S58622; Kumar-Singh S, 1997, J PATHOL, V182, P211, DOI 10.1002/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Palma G, 2013, BBA-REV CANCER, V1836, P296, DOI 10.1016/j.bbcan.2013.09.001; Pan CX, 2004, CLIN CANCER RES, V10, P1333, DOI 10.1158/1078-0432.CCR-1123-03; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; Sun XJ, 2004, AM J RESP CELL MOL, V30, P510, DOI 10.1165/rcmb.2003-0266OC; Toh HS, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0075073, 10.1371/journal.pone.0064989]; Tsao AS, 2009, J CLIN ONCOL, V27, P2081, DOI 10.1200/JCO.2008.19.8523; Vogelzang NJ, 2008, LANCET, V371, P1640, DOI 10.1016/S0140-6736(08)60703-5; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Welti J, 2013, J CLIN INVEST, V123, P3190, DOI 10.1172/JCI70212; Yang D, 2015, AM J CANCER RES, V5, P3085; ZHOU J, 1993, J BIOL CHEM, V268, P10863	38	22	24	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					714	722		10.1038/onc.2016.226	http://dx.doi.org/10.1038/onc.2016.226			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27345409				2022-12-17	WOS:000394167700012
J	Liceras-Boillos, P; Garcia-Navas, R; Ginel-Picardo, A; Anta, B; Perez-Andres, M; Lillo, C; Gomez, C; Jimeno, D; Fernandez-Medarde, A; Baltanas, FC; Santos, E				Liceras-Boillos, P.; Garcia-Navas, R.; Ginel-Picardo, A.; Anta, B.; Perez-Andres, M.; Lillo, C.; Gomez, C.; Jimeno, D.; Fernandez-Medarde, A.; Baltanas, F. C.; Santos, E.			Sos1 disruption impairs cellular proliferation and viability through an increase in mitochondrial oxidative stress in primary MEFs	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; MEDIATED ERK ACTIVATION; RAS ACTIVATION; SIGNALING PATHWAYS; MALIGNANT-TRANSFORMATION; SUPEROXIDE-PRODUCTION; IN-VITRO; K-RAS; CELLS; ASSAY	Using a 4-hydroxytamoxifen (4OHT)-inducible, conditional Sos1-null mutation, we analyzed wild-type (WT), single Sos1-KO, Sos2-KO and double Sos1/2 KO primary mouse embryonic fibroblasts (MEF) with an aim at evaluating the functional specificity or redundancy of the Sos1 and Sos2 alleles at the cellular level. The 4OHT-induced Sos1-KO and Sos1/2-DKO MEFs exhibited distinct flat morphology, enlarged cell perimeter and altered cytoskeletal organization that were not observed in the WT and Sos2-KO counterparts. The Sos1-KO and Sos1/2-DKO MEFs also displayed significant accumulation, in comparison with WT and Sos2-KO MEFs, of cytoplasmic vesicular bodies identified as autophagosomes containing degraded mitochondria by means of electron microscopy and specific markers. Cellular proliferation and migration were impaired in Sos1-KO and Sos1/2-DKO MEFs in comparison with WT and Sos2-KO MEFs, whereas cell adhesion was only impaired upon depletion of both Sos isoforms. RasGTP formation was practically absent in Sos1/2-DKO MEFs as compared with the other genotypes and extracellular signal-regulated kinase phosphorylation showed only significant reduction after combined Sos1/2 depletion. Consistent with a mitophagic phenotype, in vivo labeling with specific fluorophores uncovered increased levels of oxidative stress (elevated intracellular reactive oxygen species and mitochondrial superoxide and loss of mitochondrial membrane potential) in the Sos1-KO and the Sos1/2-DKO cells as compared with Sos2-KO and WT MEFs. Interestingly, treatment of the MEF cultures with antioxidants corrected the altered phenotypes of Sos1-KO and Sos1/2-DKO MEFs by restoring their altered perimeter size and proliferative rate to levels similar to those of WT and Sos2-KO MEFs. Our data uncover a direct mechanistic link between Sos1 and control of intracellular oxidative stress, and demonstrate functional prevalence of Sos1 over Sos2 with regards to cellular proliferation and viability.	[Liceras-Boillos, P.; Garcia-Navas, R.; Ginel-Picardo, A.; Anta, B.; Perez-Andres, M.; Gomez, C.; Jimeno, D.; Fernandez-Medarde, A.; Baltanas, F. C.; Santos, E.] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Unamuno, Salamanca 37007, Spain; [Lillo, C.] Univ Salamanca, INCYL, Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca	Baltanas, FC; Santos, E (corresponding author), Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Unamuno, Salamanca 37007, Spain.	baltanas@usal.es; esantos@usal.es	Baltanas, Fernando C./D-4756-2018; Fernández-Medarde, Alberto/B-3839-2017; Lillo, Concepcion/A-6321-2009; Baltanas, Fernando C./AAU-7451-2021; Perez-Andres, Martin/B-3692-2019; Garcia Navas, Rosula/D-5135-2018; Jimeno, David/D-3096-2018	Baltanas, Fernando C./0000-0001-8110-0991; Fernández-Medarde, Alberto/0000-0002-1230-5501; Lillo, Concepcion/0000-0001-5814-9826; Baltanas, Fernando C./0000-0001-8110-0991; Perez-Andres, Martin/0000-0003-4599-0776; Garcia Navas, Rosula/0000-0002-8956-3904; Jimeno, David/0000-0001-7876-0083	ISCIII (MINECO) [FIS PI13/02846, RTICC RD12/0036/0001, RD12/0036/0048]; JCyL, Spain [SA181U13, BIO/SA03/14]; FEDER-JCyL; Fondo Social Europeo; AECC	ISCIII (MINECO); JCyL, Spain(Junta de Castilla y Leon); FEDER-JCyL; Fondo Social Europeo(European Social Fund (ESF)European Commission); AECC	This work was supported by grants FIS PI13/02846, RTICC RD12/0036/0001 and RD12/0036/0048 from ISCIII (MINECO) and grants SA181U13 and BIO/SA03/14 from JCyL, Spain. PL-B, RG-N and CG were supported by FEDER-JCyL, Fondo Social Europeo and AECC, respectively. Nuria Calzada is gratefully acknowledged for technical assistance.	Arai JA, 2009, NEUROSCI LETT, V455, P22, DOI 10.1016/j.neulet.2009.03.047; Azrak SS, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-731; Baltanas FC, 2013, MOL CELL BIOL, V33, P4562, DOI 10.1128/MCB.01026-13; Bellot GL, 2013, MITOCHONDRION, V13, P155, DOI 10.1016/j.mito.2012.06.007; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Boykevisch S, 2006, CURR BIOL, V16, P2173, DOI 10.1016/j.cub.2006.09.033; Buday L, 2008, BBA-REV CANCER, V1786, P178, DOI 10.1016/j.bbcan.2008.05.001; Cardoso CMP, 2003, TOXICOL IN VITRO, V17, P663, DOI 10.1016/S0887-2333(03)00106-1; Castellano Esther, 2011, Genes Cancer, V2, P216, DOI 10.1177/1947601911408081; Castellano E, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r123; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P55, DOI 10.1016/0891-5849(94)00098-5; Castro-Castro A, 2011, EMBO J, V30, P3913, DOI 10.1038/emboj.2011.310; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen PC, 2010, J CLIN INVEST, V120, P4353, DOI 10.1172/JCI43910; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Dodd S, 2008, EXPERT OPIN BIOL TH, V8, P1955, DOI [10.1517/14728220802517901, 10.1517/14728220802517901 ]; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Esteban LM, 2000, MOL CELL BIOL, V20, P6410, DOI 10.1128/MCB.20.17.6410-6413.2000; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Groves JT, 2010, NAT STRUCT MOL BIOL, V17, P659, DOI 10.1038/nsmb.1844; Guittard G., 2015, EUR J IMMUNOL; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; Hennig A, 2015, BIOL CHEM, V396, P831, DOI 10.1515/hsz-2014-0257; Hu YM, 2012, CELL RES, V22, P399, DOI 10.1038/cr.2011.145; Huang AC, 2009, IN VIVO, V23, P613; Hunter SG, 2006, MOL CELL BIOL, V26, P4830, DOI 10.1128/MCB.02215-05; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; Jeng HH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2173; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kohli L, 2013, CANCER RES, V73, P4395, DOI 10.1158/0008-5472.CAN-12-3765; Kortum RL, 2012, MOL CELL BIOL, V32, P2748, DOI 10.1128/MCB.00317-12; Kortum RL, 2011, P NATL ACAD SCI USA, V108, P12407, DOI 10.1073/pnas.1104295108; Kumkhaek C, 2013, BLOOD, V121, P3216, DOI 10.1182/blood-2011-10-385252; Lee EJ, 2006, J DENT RES, V85, P1050, DOI 10.1177/154405910608501115; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liang HL, 2010, FREE RADICAL BIO MED, V49, P1550, DOI 10.1016/j.freeradbiomed.2010.08.018; Lv ZH, 2013, MOL MED REP, V8, P345, DOI 10.3892/mmr.2013.1561; Mari M, 2009, ANTIOXID REDOX SIGN, V11, P2685, DOI [10.1089/ars.2009.2695, 10.1089/ARS.2009.2695]; Marino G, 2011, MOL CELL, V42, P1, DOI 10.1016/j.molcel.2011.03.003; Martin-Encabo S, 2007, EXP CELL RES, V313, P3881, DOI 10.1016/j.yexcr.2007.07.036; Moiseeva O, 2009, MOL CELL BIOL, V29, P4495, DOI 10.1128/MCB.01868-08; Mukhopadhyay P, 2007, BIOCHEM BIOPH RES CO, V358, P203, DOI 10.1016/j.bbrc.2007.04.106; Nakayama GR, 1997, J IMMUNOL METHODS, V204, P205, DOI 10.1016/S0022-1759(97)00043-4; Neuzil J, 2012, CELL RES, V22, P285, DOI 10.1038/cr.2011.160; Nimnual Anjaruwee, 2002, Sci STKE, V2002, ppe36, DOI 10.1126/stke.2002.145.pe36; Oh-Hora M, 2003, J EXP MED, V198, P1841, DOI 10.1084/jem.20031547; Park D, 2000, BIOCHEMISTRY-US, V39, P12513, DOI 10.1021/bi000995y; Pierre S, 2011, BIOCHEM PHARMACOL, V81, P304, DOI 10.1016/j.bcp.2010.10.003; Poltorak M, 2014, EUR J IMMUNOL, V44, P1535, DOI 10.1002/eji.201344046; Qian XL, 2000, EMBO J, V19, P642, DOI 10.1093/emboj/19.4.642; Rojas Jose M, 2011, Genes Cancer, V2, P298, DOI 10.1177/1947601911408078; Roose JP, 2007, MOL CELL BIOL, V27, P2732, DOI 10.1128/MCB.01882-06; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Scita G, 2001, J CELL BIOL, V154, P1031, DOI 10.1083/jcb.200103146; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Timofeeva OA, 2009, INT J ONCOL, V35, P751, DOI 10.3892/ijo_00000388; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Warnecke N, 2012, EMBO REP, V13, P386, DOI 10.1038/embor.2012.17; Yokosuka T, 2013, CANCER CHEMOTH PHARM, V72, P1335, DOI 10.1007/s00280-013-2303-x; Yoo SG, 2012, INT J DISTRIB SENS N, DOI 10.1155/2012/382810	65	22	23	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6389	6402		10.1038/onc.2016.169	http://dx.doi.org/10.1038/onc.2016.169			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27157612				2022-12-17	WOS:000390247600004
J	Montenegro, MF; Sanchez-del-Campo, L; Gonzalez-Guerrero, R; Martinez-Barba, E; Pinero-Madrona, A; Cabezas-Herrera, J; Rodriguez-Lopez, JN				Montenegro, M. F.; Sanchez-del-Campo, L.; Gonzalez-Guerrero, R.; Martinez-Barba, E.; Pinero-Madrona, A.; Cabezas-Herrera, J.; Rodriguez-Lopez, J. N.			Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; LYSINE METHYLATION; ESTROGEN-RECEPTOR; DNA METHYLATION; E2F1; METHYLTRANSFERASE; EXPRESSION; LSD1; REPRESSION	During the course of cancer progression, neoplastic cells undergo dynamic and reversible transitions between multiple phenotypic states, and this plasticity is enabled by underlying shifts in epigenetic regulation. Our results identified a negative feedback loop in which SET9 controls DNA methyltransferase-1 protein stability, which represses the transcriptional activity of the SET9 promoter in coordination with Snail. The modulation of SET9 expression in breast cancer cells revealed a connection with E2F1 and the silencing of SET9 was sufficient to complete an epigenetic program that favored epithelial-mesenchymal transition and the generation of cancer stem cells, indicating that SET9 plays a role in modulating breast cancer metastasis. SET9 expression levels were significantly higher in samples from patients with pathological complete remission than in samples from patients with disease recurrence, which indicates that SET9 acts as a tumor suppressor in breast cancer and that its expression may serve as a prognostic marker for malignancy.	[Montenegro, M. F.; Gonzalez-Guerrero, R.; Rodriguez-Lopez, J. N.] Univ Murcia, IMIB, Sch Biol, Dept Biochem & Mol Biol A, Murcia 30100, Spain; [Sanchez-del-Campo, L.] Univ Oxford, Nuffield Dept Clin Med, Ludwig Inst Canc Res, Oxford, England; [Martinez-Barba, E.] Univ Hosp Virgen Arrixaca, IMIB, Dept Pathol, Murcia, Spain; [Pinero-Madrona, A.] Univ Hosp Virgen Arrixaca, IMIB, Dept Surg, Murcia, Spain; [Cabezas-Herrera, J.] Univ Hosp Virgen Arrixaca, IMIB, Mol Therapy & Biomarkers Res Grp, Murcia 30120, Spain	University of Murcia; Ludwig Institute for Cancer Research; University of Oxford; Hospital Clinico Universitario Virgen de la Arrixaca; Hospital Clinico Universitario Virgen de la Arrixaca; Hospital Clinico Universitario Virgen de la Arrixaca	Rodriguez-Lopez, JN (corresponding author), Univ Murcia, IMIB, Sch Biol, Dept Biochem & Mol Biol A, Murcia 30100, Spain.; Cabezas-Herrera, J (corresponding author), Univ Hosp Virgen Arrixaca, IMIB, Mol Therapy & Biomarkers Res Grp, Murcia 30120, Spain.	juan.cabezas@carm.es; neptuno@um.es	del Campo, Luis Sanchez/R-1308-2018; CABEZAS-HERRERA, JUAN/J-9434-2015; Piñero-Madrona, Antonio/AAB-5138-2022; Montenegro, Maria Fernanda/AAF-2695-2021	CABEZAS-HERRERA, JUAN/0000-0001-9053-5380; Gonzalez Guerrero, Rebeca/0000-0003-1006-7658; Sanchez del Campo, Luis/0000-0002-9537-7761; Montenegro, Maria Fernanda/0000-0002-0064-0484; Rodriguez-Lopez, Jose Neptuno/0000-0001-6863-1173	Ministerio de Economia y Competitividad (MINECO); Fondos (FEDER) [SAF2013-48375-C2-1-R]; Fundacion Seneca, Region de Murcia (FS-RM) [15230/PI/10, 19304/PI/14]; Ludwig Institute for Cancer Research; FAECC	Ministerio de Economia y Competitividad (MINECO); Fondos (FEDER); Fundacion Seneca, Region de Murcia (FS-RM)(Fundacion Seneca); Ludwig Institute for Cancer Research; FAECC	This work was supported by grants from Ministerio de Economia y Competitividad (MINECO; Co-financing with Fondos FEDER) (SAF2013-48375-C2-1-R) to JNR-L and Fundacion Seneca, Region de Murcia (FS-RM) (15230/PI/10 and 19304/PI/14) to JNR-L, JC-H, and AP-M. JC-H is contracted by the FFIS. MFM is contracted by Fundacion de la Asociacion Espanola contra el Cancer (FAECC). LS-d-C is supported by the Ludwig Institute for Cancer Research and FAECC.	Alla V, 2010, JNCI-J NATL CANCER I, V102, P127, DOI 10.1093/jnci/djp458; Barsyte-Lovejoy D, 2014, P NATL ACAD SCI USA, V111, P12853, DOI 10.1073/pnas.1407358111; Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang HW, 2014, MOLECULES, V19, P3149, DOI 10.3390/molecules19033149; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Engelmann D, 2012, CANCER RES, V72, P571, DOI 10.1158/0008-5472.CAN-11-2575; Engelmann D, 2010, CELL MOL LIFE SCI, V67, P931, DOI 10.1007/s00018-009-0222-0; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Esteve PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106; Geng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054959; Gupta A, 2003, CANCER, V97, P2341, DOI 10.1002/cncr.11332; Guttilla IK, 2012, BREAST CANCER RES TR, V132, P75, DOI 10.1007/s10549-011-1534-y; Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Jaggupilli A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/708036; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Laine A, 2014, CLIN CANCER RES, V20, P3644, DOI 10.1158/1078-0432.CCR-13-1942; Laine A, 2013, CANCER DISCOV, V3, P182, DOI 10.1158/2159-8290.CD-12-0292; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Liu Z, 2013, ONCOGENE, V32, P4203, DOI 10.1038/onc.2012.441; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Iglesias JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077281; Montenegro MF, 2015, ONCOGENE, V34, P135, DOI 10.1038/onc.2013.605; Montenegro MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052231; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mukherjee D, 2013, AM J CANCER RES, V3, P46; Munoz P, 2012, MOL ONCOL, V6, P620, DOI 10.1016/j.molonc.2012.10.006; Nakshatri H, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2559; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Putzer BM, 2013, TRENDS MOL MED, V19, P89, DOI 10.1016/j.molmed.2012.10.009; Pyle AD, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-235; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Saez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009; Scheel C, 2011, INT J CANCER, V129, P2310, DOI 10.1002/ijc.26311; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; Singh JK, 2013, CLIN CANCER RES, V19, P643, DOI 10.1158/1078-0432.CCR-12-1063; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tao DY, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0412-y; Veronesi U, 2003, NEW ENGL J MED, V349, P546, DOI 10.1056/NEJMoa012782; Wang LF, 2007, WORLD J GASTROENTERO, V13, P5692, DOI 10.3748/wjg.v13.i43.5692; Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030; Xie Q, 2011, J RECEPT SIG TRANSD, V31, P139, DOI 10.3109/10799893.2011.552914; Yui S, 2005, CANCER SCI, V96, P560, DOI 10.1111/j.1349-7006.2005.00097.x	55	22	23	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6143	6152		10.1038/onc.2016.154	http://dx.doi.org/10.1038/onc.2016.154			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27132511				2022-12-17	WOS:000388509800010
J	Qin, H; Malek, S; Cowell, JK; Ren, M				Qin, H.; Malek, S.; Cowell, J. K.; Ren, M.			Transformation of human CD34+hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; EXPRESSION; DEK; T(6/9)(P23,Q34); PROTEIN; GENES; FGFR1	Acute myeloid leukemia (AML) is a heterogeneous disease comprising a large number of subtypes defined by specific chromosome abnormalities. One such subtype carries the t(6; 9)(p22;q34) chromosome rearrangement, which leads to expression of the DEK-NUP214 chimeric gene, and has a particularly poor outcome. To provide a better understanding of the molecular etiology of these relatively rare individual AML variants, it is necessary to generate in vivo models, which can also serve as a means to evaluate targeted therapies based on their specific genetic abnormalities. Here, we describe the development of a human cell AML, generated in CD34+ human hematopoietic progenitor cells xenografted into immunocompromised mice that express human myeloid cell growth factors. Within 6 months, these mice develop a human cell AML with phenotypic characteristics of the primary t(6; 9) disease and a CD45+CD13+CD34+CD38+ immunophenotype. Gene expression studies show that members of the HOX family of genes (HOXA9, 10, B3, B4 and PBX3) are highly upregulated in the AML from this mouse model as well as from primary human t(6; 9) AML. Gene expression analysis also identified several other significantly disregulated pathways involving KRAS, BRCA1 and ALK, for example. This is the first report of a humanized model of the DEK-NUP214 disease and provides a means to study the development and treatment of this particular subtype of AML.	[Qin, H.; Cowell, J. K.; Ren, M.] Georgia Regents Univ, Ctr Canc, CN2133,1120 15th St GRU, Augusta, GA 30912 USA; [Malek, S.] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA	University System of Georgia; Augusta University; University of Michigan System; University of Michigan	Ren, M (corresponding author), Georgia Regents Univ, Ctr Canc, CN2133,1120 15th St GRU, Augusta, GA 30912 USA.	mren@gru.edu			NATIONAL CANCER INSTITUTE [R01CA076167] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA076167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramovich C, 2005, CURR OPIN HEMATOL, V12, P210, DOI 10.1097/01.moh.0000160737.52349.aa; Ageberg M, 2006, HAEMATOL-HEMATOL J, V91, P268; Alharbi RA, 2013, LEUKEMIA, V27, P1000, DOI 10.1038/leu.2012.356; AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; Balgobind BV, 2011, HAEMATOL-HEMATOL J, V96, P221, DOI 10.3324/haematol.2010.029660; Billerbeck E, 2011, BLOOD, V117, P3076, DOI 10.1182/blood-2010-08-301507; Hamaguchi H, 1998, BRIT J HAEMATOL, V102, P1249, DOI 10.1046/j.1365-2141.1998.00900.x; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; Mills KI, 2009, BLOOD, V114, P1063, DOI 10.1182/blood-2008-10-187203; Oancea C, 2010, LEUKEMIA, V24, P1910, DOI 10.1038/leu.2010.180; Oyarzo MP, 2004, AM J CLIN PATHOL, V122, P348, DOI 10.1309/5DGB59KQA527PD47; PALACIOS R, 1984, NATURE, V309, P126, DOI 10.1038/309126a0; Ren M, 2013, LEUKEMIA, V27, P32, DOI 10.1038/leu.2012.188; Ren MQ, 2013, BLOOD, V122, P1007, DOI 10.1182/blood-2013-03-489823; Ren MQ, 2011, BLOOD, V117, P6837, DOI 10.1182/blood-2010-07-295725; Riveiro-Falkenbach E, 2010, CLIN CANCER RES, V16, P2932, DOI 10.1158/1078-0432.CCR-09-2330; Saito Y, 2011, LEUKEMIA, V25, P921, DOI 10.1038/leu.2011.36; Sanden C, 2015, LEUKEMIA, V29, P1632, DOI 10.1038/leu.2015.72; Sanden C, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-440; Slovak ML, 2006, LEUKEMIA, V20, P1295, DOI 10.1038/sj.leu.2404233; SOEKARMAN D, 1992, BLOOD, V79, P2990; Spencer DH, 2015, LEUKEMIA, V29, P1279, DOI 10.1038/leu.2015.6; Vinnedge LMP, 2013, CELL CYCLE, V12, P51, DOI 10.4161/cc.23121; Vinnedge LMP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046985; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Wise-Draper TM, 2009, CANCER RES, V69, P1792, DOI 10.1158/0008-5472.CAN-08-2304; Yamauchi K, 2002, CANCER-AM CANCER SOC, V94, P1739, DOI 10.1002/cncr.10399	27	22	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5686	5691		10.1038/onc.2016.118	http://dx.doi.org/10.1038/onc.2016.118			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27065320	Green Accepted			2022-12-17	WOS:000386998300011
J	Finisguerra, V; Prenen, H; Mazzone, M				Finisguerra, V.; Prenen, H.; Mazzone, M.			Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma	ONCOGENE			English	Review							HEPATOCYTE GROWTH-FACTOR; TIVANTINIB ARQ 197; ADVANCED SOLID TUMORS; FACTOR SCATTER FACTOR; RECEPTOR C-MET; RANDOMIZED PHASE-II; TOLEROGENIC DENDRITIC CELLS; PAPILLARY RENAL-CARCINOMAS; CHIMERIC ANTIGEN RECEPTORS; NEGATIVE BREAST-CANCER	A lot of attention has been dedicated to investigate the role of the tyrosine kinase receptor MET in tumors. The acquired notion that cancer cells from different histological origin strictly rely on the engagement of this specific oncogene for their growth and survival has certainly justified the development and the use of MET-targeted therapies in the clinic. However, the function and involvement of this pathway in the stroma (that often constitutes >50% of the global cellularity of the tumor) may offer the opportunity to conceive new patient stratification criteria, rational drug design and guided trials of new combination treatments. In this review, we will summarize and discuss the role of MET in cancer cells but especially in different stromal compartments, in light of the results showed by past and recent preclinical and clinical trials with anti-MET drugs.	[Finisguerra, V.] Ludwig Inst Canc Res, Brussels, Belgium; [Finisguerra, V.] Catholic Univ Louvain, de Duve Inst, Brussels, Belgium; [Prenen, H.] Univ Hosp Leuven, Digest Oncol, Leuven, Belgium; [Prenen, H.] Katholieke Univ Leuven, Dept Oncol, Leuven, Belgium; [Mazzone, M.] VIB, Lab Mol Oncol & Angiogenesis, Vesalius Res Ctr, Leuven, Belgium; [Mazzone, M.] Katholieke Univ Leuven, Dept Oncol, Vesalius Res Ctr, Lab Mol Oncol & Angiogenesis, Leuven, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; KU Leuven; University Hospital Leuven; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Mazzone, M (corresponding author), Katholieke Univ Leuven, VIB Vesalius Res Ctr, Herestr 49,Bus 912, B-3000 Leuven, Brabant, Belgium.	massimiliano.mazzone@vib-kuleuven.be	Finisguerra, Veronica/AGS-6956-2022	Prenen, Hans/0000-0001-8802-7352; Mazzone, Massimiliano/0000-0001-8824-4015	ERC Starting Grant (OxyMO); Televie F.R.S.-FNRS	ERC Starting Grant (OxyMO); Televie F.R.S.-FNRS(Fonds de la Recherche Scientifique - FNRS)	We thank Sandy Smets for administrative support. MM is holding an ERC Starting Grant (OxyMO). VF is supported by Televie F.R.S.-FNRS.	Abken H, 2015, IMMUNOTHERAPY-UK, V7, P535, DOI [10.2217/IMT.15.15, 10.2217/imt.15.15]; Abounader R, 2001, J NEUROCHEM, V76, P1497, DOI 10.1046/j.1471-4159.2001.00158.x; ADAMS DH, 1994, P NATL ACAD SCI USA, V91, P7144, DOI 10.1073/pnas.91.15.7144; Aftimos PG, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.2580; Aguilar-Valenzuela R, 2014, J GASTROEN HEPATOL, V29, P878, DOI 10.1111/jgh.12456; Baek JH, 2012, J IMMUNOL, V189, P1699, DOI 10.4049/jimmunol.1200729; Bang YJ, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.2520; Beilmann M, 2000, BLOOD, V95, P3964; Beilmann M, 1997, BLOOD, V90, P4450; Bendell JC, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.663; Benkhoucha M, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-154; Benkhoucha M, 2010, P NATL ACAD SCI USA, V107, P6424, DOI 10.1073/pnas.0912437107; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Borset M, 1996, J BIOL CHEM, V271, P24655, DOI 10.1074/jbc.271.40.24655; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Camussi G, 1997, J IMMUNOL, V158, P1302; Castoldi R, 2013, ONCOGENE, V32, P5593, DOI 10.1038/onc.2013.245; CHANG H, 1994, NEPHRON, V67, P497, DOI 10.1159/000188032; Chen CT, 2012, MOL CANCER THER, V11, P660, DOI 10.1158/1535-7163.MCT-11-0754; Chen PM, 2014, J LEUKOCYTE BIOL, V96, P295, DOI 10.1189/jlb.3A0513-242R; Chen QY, 1996, CELL GROWTH DIFFER, V7, P821; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Choueiri TK, 2013, J CLIN ONCOL, V31, P181, DOI 10.1200/JCO.2012.43.3383; Cloughesy TF, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.2015; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697; Corso S, 2013, CANCER DISCOV, V3, P978, DOI 10.1158/2159-8290.CD-13-0040; Cortner J, 1995, EXS, V74, P89; Coudriet GM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015384; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Dieras V, 2015, ANN ONCOL, V26, P1904, DOI 10.1093/annonc/mdv263; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Falchook GS, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.2591; Falenta K, 2013, J MICROSC-OXFORD, V250, P200, DOI 10.1111/jmi.12035; Feldman DR, 2013, INVEST NEW DRUG, V31, P1016, DOI 10.1007/s10637-013-9934-y; Feldman SA, 2015, SEMIN ONCOL, V42, P626, DOI 10.1053/j.seminoncol.2015.05.005; Finisguerra V, 2015, NATURE, V522, P349, DOI 10.1038/nature14407; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Futamatsu H, 2005, CIRC RES, V96, P823, DOI 10.1161/01.RES.0000163016.52653.2e; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; Galimi F, 2001, J IMMUNOL, V166, P1241, DOI 10.4049/jimmunol.166.2.1241; Gallo S, 2015, CLIN SCI, V129, P1173, DOI 10.1042/CS20150502; Gan HK, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.11111; Garber K, 2014, NAT REV DRUG DISCOV, V13, P563, DOI 10.1038/nrd4406; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Goldman JW, 2012, CANCER-AM CANCER SOC, V118, P5903, DOI 10.1002/cncr.27575; Gong RJ, 2006, J AM SOC NEPHROL, V17, P2464, DOI 10.1681/ASN.2006020185; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Haber DA, 2011, CELL, V145, P19, DOI 10.1016/j.cell.2011.03.026; Harrison P, 2000, BIOCHEM BIOPH RES CO, V271, P203, DOI 10.1006/bbrc.2000.2612; Hirashima T, 2014, J CLIN ONCOL; Hong DS, 2015, ONCOTARGET, V6, P18693, DOI 10.18632/oncotarget.4472; Hong DS, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.2508; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Hwang CI, 2011, P NATL ACAD SCI USA, V108, P14240, DOI 10.1073/pnas.1017536108; Ito W, 2005, AM J RESP CELL MOL, V32, P268, DOI 10.1165/rcmb.2004-0058OC; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Iveson T, 2014, LANCET ONCOL, V15, P1007, DOI 10.1016/S1470-2045(14)70023-3; Jensen MC, 2015, CURR OPIN IMMUNOL, V33, P9, DOI 10.1016/j.coi.2015.01.002; JIANG W, 1992, IMMUNOLOGY, V77, P147; Kang YK, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.167; Kang YK, 2014, INVEST NEW DRUG, V32, P355, DOI 10.1007/s10637-013-0057-2; Kentsis A, 2012, NAT MED, V18, P1118, DOI 10.1038/nm.2819; Kobayashi H, 2006, BLOOD, V108, P1260, DOI 10.1182/blood-2005-09-012807; Koeppen H, 2014, CLIN CANCER RES, V20, P4488, DOI 10.1158/1078-0432.CCR-13-1836; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; Komarowska I, 2015, IMMUNITY, V42, P1087, DOI 10.1016/j.immuni.2015.05.014; Kontermann RE, 2015, DRUG DISCOV TODAY, V20, P838, DOI 10.1016/j.drudis.2015.02.008; Koochekpour S, 1997, CANCER RES, V57, P5391; Kumai T, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.976077; Kuroiwa T, 2001, J CLIN INVEST, V107, P1365, DOI 10.1172/JCI11808; Kurz SM, 2002, EUR J IMMUNOL, V32, P1832, DOI 10.1002/1521-4141(200207)32:7<1832::AID-IMMU1832>3.0.CO;2-2; Kwak EL, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.tps3087; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Liu Y, 2007, J PATHOL, V212, P12, DOI 10.1002/path.2155; Liu YH, 2004, AM J PHYSIOL-RENAL, V287, pF7, DOI 10.1152/ajprenal.00451.2003; Lolkema MP, 2015, CLIN CANCER RES, V21, P2297, DOI 10.1158/1078-0432.CCR-14-3258; LYON M, 1994, J BIOL CHEM, V269, P11216; Ma JH, 2009, J CLIN INVEST, V119, P478, DOI 10.1172/JCI36640; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; MARS WM, 1993, AM J PATHOL, V143, P949; Matsumoto K, 2001, KIDNEY INT, V59, P2023, DOI 10.1046/j.1523-1755.2001.00717.x; Matsumoto K, 2005, BIOCHEM BIOPH RES CO, V333, P316, DOI 10.1016/j.bbrc.2005.05.131; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Matsumoto K, 2008, FRONT BIOSCI-LANDMRK, V13, P1943, DOI 10.2741/2813; McCoach CE, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.2587; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Migliore C, 2012, CLIN CANCER RES, V18, P737, DOI 10.1158/1078-0432.CCR-11-1699; Mine S, 1998, LAB INVEST, V78, P1395; Misra S, 2011, FEBS J, V278, P1429, DOI 10.1111/j.1742-4658.2011.08071.x; Mizuno S, 2005, FASEB J, V19, P580, DOI 10.1096/fj.04-1535fje; Mizuno S, 1998, J CLIN INVEST, V101, P1827, DOI 10.1172/JCI1709; Monk P, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.7_suppl.146; Moransard M, 2010, GLIA, V58, P559, DOI 10.1002/glia.20945; Mungunsukh O, 2013, MOL BIOL CELL, V24, P2088, DOI 10.1091/mbc.E13-01-0017; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; Nasser MW, 2008, J BIOL CHEM, V283, P33394, DOI 10.1074/jbc.M804788200; Oh K, 2005, AM J PHYSIOL-GASTR L, V288, pG729, DOI 10.1152/ajpgi.00438.2004; Okunishi K, 2005, J IMMUNOL, V175, P4745, DOI 10.4049/jimmunol.175.7.4745; Okunishi K, 2007, J IMMUNOL, V179, P5504, DOI 10.4049/jimmunol.179.8.5504; Ovali E, 2000, HAEMATOLOGICA, V85, P464; Pant S, 2014, ANN ONCOL, V25, P1416, DOI 10.1093/annonc/mdu157; Pant S, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.4065; Parikh RA, 2014, ONCOTARGETS THER, V7, P969, DOI 10.2147/OTT.S40241; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Patnaik A, 2014, BRIT J CANCER, V111, P272, DOI 10.1038/bjc.2014.290; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Rosen LS, 2011, CLIN CANCER RES, V17, P7754, DOI 10.1158/1078-0432.CCR-11-1002; Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355; Rutella S, 2006, BLOOD, V108, P1435, DOI 10.1182/blood-2006-03-006403; Sagiv JY, 2015, CELL REP, V10, P562, DOI 10.1016/j.celrep.2014.12.039; Salgia R, 2014, CLIN CANCER RES, V20, P1666, DOI 10.1158/1078-0432.CCR-13-2070; Santoro A, 2013, LANCET ONCOL, V14, P55, DOI 10.1016/S1470-2045(12)70490-4; Scagliotti GV, 2015, ANN ONCOL, V26, P2007, DOI 10.1093/annonc/mdv334; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Seidel C, 1998, MED ONCOL, V15, P145, DOI 10.1007/BF02821933; Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240; Sequist LV, 2011, J CLIN ONCOL, V29, P3307, DOI 10.1200/JCO.2010.34.0570; Shah MA, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.4012; Shah MA, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.2; SHIOTA G, 1995, HEPATOLOGY, V21, P106, DOI 10.1002/hep.1840210119; SILVAGNO F, 1995, ARTERIOSCL THROM VAS, V15, P1857, DOI 10.1161/01.ATV.15.11.1857; Skibinski G, 2001, IMMUNOLOGY, V102, P506, DOI 10.1046/j.1365-2567.2001.01186.x; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; Spigel DR, 2014, ASCO M, V32, P8000, DOI DOI 10.1200/jco.2014.32.15_suppl.8000; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Strickler JH, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.2507; Tabernero J, 2014, CLIN CANCER RES, V20, P2793, DOI 10.1158/1078-0432.CCR-13-1837; Takada S, 1996, TRANSPLANT INT, V9, P151, DOI 10.1007/BF00336393; Tamura S, 1998, SCAND J IMMUNOL, V47, P296; Tesio M, 2011, BLOOD, V117, P419, DOI 10.1182/blood-2009-06-230359; Tolaney SM, 2015, INVEST NEW DRUG, V33, P1108, DOI 10.1007/s10637-015-0269-8; TOMIYA T, 1992, GASTROENTEROLOGY, V103, P1621, DOI 10.1016/0016-5085(92)91186-8; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Tuck AB, 1996, AM J PATHOL, V148, P225; Twardowski P, 2015, J CLIN ONCOL, V33; Ueda H, 2001, CARDIOVASC RES, V51, P41, DOI 10.1016/S0008-6363(01)00272-3; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Ueno M, 2013, DEV CELL, V27, P373, DOI 10.1016/j.devcel.2013.10.019; Valente G, 2009, CELL ONCOL, V31, P423, DOI 10.3233/CLO-2009-0504; vanderVoort R, 1997, J EXP MED, V185, P2121, DOI 10.1084/jem.185.12.2121; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; Vokes EE, 2015, J CLIN ONCOL, V33; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wojta J, 1999, LAB INVEST, V79, P427; WU YL, 2014, J CLIN ONCOL, V32; Yamaura K, 2004, CIRCULATION, V110, P1650, DOI 10.1161/01.CIR.0000143052.45956.71; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Yap TA, 2011, J CLIN ONCOL, V29, P1271, DOI 10.1200/JCO.2010.31.0367; Yen BLJ, 2013, STEM CELL REP, V1, P139, DOI 10.1016/j.stemcr.2013.06.006; Yoshioka H, 2015, ANN ONCOL, V26, P2066, DOI 10.1093/annonc/mdv288; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zhao L, 2015, J PATHOL, V237, P319, DOI 10.1002/path.4578; Zhu XP, 2000, UROLOGY, V56, P1071, DOI 10.1016/S0090-4295(00)00795-0; Zucali PA, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.2549	166	22	22	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5457	5467		10.1038/onc.2016.36	http://dx.doi.org/10.1038/onc.2016.36			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	26996670				2022-12-17	WOS:000386998200001
J	Zhang, P; Feng, S; Liu, G; Wang, H; Fu, A; Zhu, H; Ren, Q; Wang, B; Xu, X; Bai, H; Dong, C				Zhang, P.; Feng, S.; Liu, G.; Wang, H.; Fu, A.; Zhu, H.; Ren, Q.; Wang, B.; Xu, X.; Bai, H.; Dong, C.			CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradation	ONCOGENE			English	Article							COLON-CARCINOMA CELLS; BREAST-CANCER CELLS; V600E B-RAF; E-SELECTIN; ENDOTHELIAL-CELLS; VARIANT ISOFORMS; MESSENGER-RNA; BINDING-KINETICS; TUMOR-CELLS; VE-CADHERIN	Melanoma is one of the most lethal forms of skin cancer because of its early metastatic spread. The variant form of CD44 CD44v), a cell surface glycoprotein, is highly expressed on metastatic melanoma. The mechanisms of regulation of CD44 alternative splicing in melanoma and its pathogenic contributions are so far poorly understood. Here, we investigated the expression level of CD44 in a large set of melanocytic lesions at different stages. We found that the expression of CD44v8-10 and a splicing factor, U2AF2, is significantly increased during melanoma progression, whereas CD82/KAI1, a tetraspanin family of tumor suppressor, is reduced in metastatic melanoma. CD44v8-10 and U2AF2 expression levels, which are negatively correlated with CD82 levels, are markedly elevated in primary melanoma compared with dysplastic nevi and further increased in metastatic melanoma. We also showed that patients with higher CD44v8-10 and U2AF2 expression levels tended to have shorter survival. By using both in vivo and in vitro assays, we demonstrated that CD82 inhibits the production of CD44v8-10 on melanoma. Mechanistically, U2AF2 is a downstream target of CD82 and in malignant melanoma facilitates CD44v8-10 alternative splicing. U2AF2-mediated CD44 isoform switch is required for melanoma migration in vitro and lung and liver metastasis in vivo. Notably, overexpression of CD82 suppresses U2AF2 activity by inducing U2AF2 ubiquitination. In addition, our data suggested that enhancement of melanoma migration by U2AF2-dependent CD44v8-10 splicing is mediated by Src/focal adhesion kinase/RhoA activation and formation of stress fibers, as well as CD44-E-selectin binding reinforcement. These findings uncovered a hitherto unappreciated function of CD82 in severing the linkage between U2AF2-mediated CD44 alternative splicing and cancer aggressiveness, with potential prognostic and therapeutic implications in melanoma.	[Zhang, P.; Feng, S.; Fu, A.; Zhu, H.; Ren, Q.; Xu, X.; Bai, H.] Southwest Univ, Coll Pharmaceut Sci, Key Lab Luminescence & Real Time Analyt Chem, Minist Educ, Chongqing 400715, Peoples R China; [Zhang, P.] Univ Alberta, Dept Physiol, Edmonton, AB, Canada; [Liu, G.; Wang, H.] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Shanghai, Peoples R China; [Wang, B.] Chongqing Univ, Coll Bioengn, Chongqing, Peoples R China; [Dong, C.] Penn State Univ, Dept Biomed Engn, University Pk, PA 16802 USA	Southwest University - China; University of Alberta; Tongji University; Chongqing University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Zhang, P (corresponding author), Southwest Univ, Coll Pharmaceut Sci, Key Lab Luminescence & Real Time Analyt Chem, Minist Educ, Chongqing 400715, Peoples R China.	pu1@ualberta.ca			Fundamental Research Funds for the Central Universities [XDJK2014C176, XDJK2012B010, XDJK2015C154, XDJK2015C155]; Start-up Foundation of Southwest University [SWU114017]; National Natural Science Foundation of China (NSFC) [NSFC-81402393, NSFC-81572678, NSFC-81272433, NSFC-81472732, NSFC-81073084]; National Science Foundation [CBET-0729091]; NATIONAL CANCER INSTITUTE [R01CA125707] Funding Source: NIH RePORTER	Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Start-up Foundation of Southwest University; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Science Foundation(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Go J Yoshida (Tokyo Medical and Dental University) for helpful discussion. This study was funded by Fundamental Research Funds for the Central Universities (XDJK2014C176 to PZ, XDJK2012B010 to HFZ, XDJK2015C154 to QR and XDJK2015C155 to FS), the Start-up Foundation of Southwest University (SWU114017 to PZ), National Natural Science Foundation of China (NSFC) (NSFC-81402393 to PZ, NSFC-81572678 to PZ, NSFC-81272433 to GTL, NSFC-81472732 to GTL and NSFC-81073084 to HFZ) and National Science Foundation grants (CBET-0729091 to CD).	Berditchevski F, 2007, TRAFFIC, V8, P89, DOI 10.1111/j.1600-0854.2006.00515.x; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Charrin S, 2009, BIOCHEM J, V420, P133, DOI 10.1042/BJ20082422; Cheng CH, 2006, MOL CELL BIOL, V26, P362, DOI 10.1128/MCB.26.1.362-370.2006; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; Fu CL, 2011, J BIOL CHEM, V286, P34777, DOI 10.1074/jbc.M111.281642; Hanley WD, 2005, CANCER RES, V65, P5812, DOI 10.1158/0008-5472.CAN-04-4557; Hanley WD, 2006, FASEB J, V20, P337, DOI 10.1096/fj.05-4574fje; Huh SJ, 2010, CANCER RES, V70, P6071, DOI 10.1158/0008-5472.CAN-09-4442; Ishii H, 2014, J BIOL CHEM, V289, P27386, DOI 10.1074/jbc.M114.589432; Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706; Jacobs PP, 2011, FEBS LETT, V585, P3148, DOI 10.1016/j.febslet.2011.07.039; Khanna P, 2014, ONCOGENE, V33, P2898, DOI 10.1038/onc.2013.249; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Konig H, 1996, EMBO J, V15, P4030, DOI 10.1002/j.1460-2075.1996.tb00776.x; Konstantopoulos K, 2009, ANNU REV BIOMED ENG, V11, P177, DOI 10.1146/annurev-bioeng-061008-124949; Liang SL, 2007, CANCER RES, V67, P5814, DOI 10.1158/0008-5472.CAN-06-4233; Mackereth CD, 2011, NATURE, V475, P408, DOI 10.1038/nature10171; Marzese DM, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12307; McEver RP, 2010, ANNU REV CELL DEV BI, V26, P363, DOI 10.1146/annurev.cellbio.042308.113238; Nagano O, 2013, ONCOGENE, V32, P5191, DOI 10.1038/onc.2012.638; Odintsova E, 2000, CURR BIOL, V10, P1009, DOI 10.1016/S0960-9822(00)00652-7; Odintsova E, 2013, J BIOL CHEM, V288, P26323, DOI 10.1074/jbc.M112.439380; Okamoto I, 1998, J NATL CANCER I, V90, P307, DOI 10.1093/jnci/90.4.307; Okamoto Y, 1998, BIOCHEM BIOPH RES CO, V249, P872, DOI 10.1006/bbrc.1998.9247; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Prochazka L, 2014, CELL SIGNAL, V26, P2234, DOI 10.1016/j.cellsig.2014.07.011; Reinke LM, 2012, J BIOL CHEM, V287, P36435, DOI 10.1074/jbc.M112.397125; Sharma A, 2006, CANCER RES, V66, P8200, DOI 10.1158/0008-5472.CAN-06-0809; Shirure VS, 2015, AM J PHYSIOL-CELL PH, V308, pC68, DOI 10.1152/ajpcell.00094.2014; Sridhar SC, 2006, ONCOGENE, V25, P2367, DOI 10.1038/sj.onc.1209269; Stoilov P, 2008, P NATL ACAD SCI USA, V105, P11218, DOI 10.1073/pnas.0801661105; Subbaram S, 2014, J CELL SCI, V127, P1179, DOI 10.1242/jcs.131227; Takahashi K, 1995, ONCOGENE, V11, P2223; Takeo K, 2009, AM J PHYSIOL-CELL PH, V297, pC330, DOI 10.1152/ajpcell.00009.2009; Tsai YC, 2011, FEBS LETT, V585, P3166, DOI 10.1016/j.febslet.2011.08.031; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; Wei Q, 2014, CIRCULATION, V130, P1493, DOI 10.1161/CIRCULATIONAHA.114.011096; Wei WJ, 2012, NUCLEIC ACIDS RES, V40, P8622, DOI 10.1093/nar/gks579; Wirtz D, 2011, NAT REV CANCER, V11, P512, DOI 10.1038/nrc3080; Xiong FY, 2012, MOL BIOL REP, V39, P1935, DOI 10.1007/s11033-011-0940-x; Yae T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1892; Yago T, 2010, BLOOD, V116, P485, DOI 10.1182/blood-2009-12-259556; Zeng Y, 2013, CANCER RES, V73, P4123, DOI 10.1158/0008-5472.CAN-12-1343; Zhang P, 2015, AM J PHYSIOL-HEART C, V308, pH1205, DOI 10.1152/ajpheart.00005.2015; Zhang P, 2014, FEBS LETT, V588, P4573, DOI 10.1016/j.febslet.2014.10.027; Zhang P, 2014, FASEB J, V28, P4591, DOI 10.1096/fj.11-202747; Zhang P, 2011, J IMMUNOL, V186, P242, DOI 10.4049/jimmunol.1000494; Zhou B, 2004, CANCER RES, V64, P7455, DOI 10.1158/0008-5472.CAN-04-1574; Zhu S, 2016, ONCOGENE, V35, P1847, DOI 10.1038/onc.2015.250; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	52	22	23	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5056	5069		10.1038/onc.2016.67	http://dx.doi.org/10.1038/onc.2016.67			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	27041584	Green Accepted			2022-12-17	WOS:000383965300009
J	Zheng, D; Gui, B; Gray, KP; Tinay, I; Rafiei, S; Huang, Q; Sweeney, CJ; Kibel, AS; Jia, L				Zheng, D.; Gui, B.; Gray, K. P.; Tinay, I.; Rafiei, S.; Huang, Q.; Sweeney, C. J.; Kibel, A. S.; Jia, L.			Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer	ONCOGENE			English	Article							RECEPTOR-MEDIATED TRANSCRIPTION; SERINE PROTEINASE-INHIBITORS; GRANULIN-EPITHELIN PRECURSOR; GROWTH-FACTOR; EXPRESSION; PROGRESSION; GENES; MODEL; OVEREXPRESSION; INFLAMMATION	Androgen receptor (AR)-mediated gene expression continues to have a critical role in promoting castration-resistant prostate cancer (CRPC) survival and growth even after androgen deprivation therapy. AR cistrome analyses in CRPC cells have identified a large number of AR target genes involved in proliferative and cell cycle-related functions, and hold promise for development of novel therapeutic approaches for CRPC. However, there is little understanding of how these genes function in vivo and what the clinical implications are. We previously reported that secretory leukocyte peptidase inhibitor (SLPI) is regulated by the AR in a ligand-independent manner in CRPC cells and required for CRPC cell proliferation under androgen-deprived conditions. SLPI is a secreted serine protease inhibitor, which is overexpressed in a number of cancers, including lung, breast and ovarian cancer, and involved in tumor progression. However, the oncogenic potential of SLPI in prostate cancer remains unknown. Here we provide the first evidence that SLPI is upregulated in a subset of CRPC cell lines and CRPC patient tumors. In addition, serum SLPI levels are significantly elevated in metastatic CRPC patients compared with hormone naive patients, raising the possibility that this could serve as a biomarker. We demonstrated that SLPI expression has functional significance, as it promotes CRPC cell survival and growth after androgen withdrawal in vivo and in vitro. Last, we demonstrated that the oncogenic effect of SLPI may be due to protection of growth factor progranulin from enzymatic cleavage or suppression of CRPC cell apoptosis independent of anti-protease activity of SLPI. These findings implicate SLPI as a potential biomarker of resistance to AR inhibition and therapeutic target for CRPC treatment.	[Zheng, D.; Huang, Q.] Washington Univ, Sch Med, Dept Med, Ctr Pharmacogen, St Louis, MO 63110 USA; [Gui, B.; Tinay, I.; Rafiei, S.; Kibel, A. S.; Jia, L.] Brigham & Womens Hosp, Dept Surg, Div Urol, 45 Francis St,ASB 2-3, Boston, MA 02115 USA; [Gui, B.; Tinay, I.; Rafiei, S.; Sweeney, C. J.; Kibel, A. S.; Jia, L.] Harvard Med Sch, 45 Francis St,ASB 2-3, Boston, MA 02115 USA; [Gray, K. P.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Gray, K. P.] Harvard Sch Publ Hlth, Boston, MA USA; [Sweeney, C. J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Washington University (WUSTL); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute	Jia, L (corresponding author), Brigham & Womens Hosp, Dept Surg, Div Urol, 45 Francis St,ASB 2-3, Boston, MA 02115 USA.; Jia, L (corresponding author), Harvard Med Sch, 45 Francis St,ASB 2-3, Boston, MA 02115 USA.	ljia@bwh.harvard.edu	Zheng, Dali/J-2973-2019	Zheng, Dali/0000-0003-2345-4040	Anthony DiNovi Fund; 'Turkiye Kanserle Savas Vakfi' Scholarship Program	Anthony DiNovi Fund; 'Turkiye Kanserle Savas Vakfi' Scholarship Program	This work was supported by Anthony DiNovi Fund. Ilker Tinay was partially supported by the 'Turkiye Kanserle Savas Vakfi' Scholarship Program.	American Cancer Society, 2015, CANC FACTS FIG 2015; Ameshima S, 2000, CANCER-AM CANCER SOC, V89, P1448, DOI 10.1002/1097-0142(20001001)89:7<1448::AID-CNCR6>3.0.CO;2-Q; Bernard B, 2015, CURR UROL REP, V16, DOI 10.1007/s11934-015-0488-8; Bouchard D, 2006, LANCET ONCOL, V7, P167, DOI 10.1016/S1470-2045(06)70579-4; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Cheng WL, 2008, INT J CANCER, V123, P1787, DOI 10.1002/ijc.23746; Chopra DP, 2004, CANCER LETT, V203, P145, DOI 10.1016/j.canlet.2003.09.016; Davis JS, 2011, MOL ENDOCRINOL, V25, P611, DOI 10.1210/me.2010-0312; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Decker KF, 2012, NUCLEIC ACIDS RES, V40, P10765, DOI 10.1093/nar/gks888; Devoogdt N, 2003, P NATL ACAD SCI USA, V100, P5778, DOI 10.1073/pnas.1037154100; Devoogdt N, 2009, CANCER SCI, V100, P434, DOI 10.1111/j.1349-7006.2009.01076.x; Flavin R, 2014, CLIN CANCER RES, V20, P4904, DOI 10.1158/1078-0432.CCR-13-1341; Gipson TS, 1999, J IMMUNOL, V162, P3653; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; HIGASHIYAMA M, 1995, CANCER-AM CANCER SOC, V76, P1368, DOI 10.1002/1097-0142(19951015)76:8<1368::AID-CNCR2820760812>3.0.CO;2-N; Ho JC, 2008, HEPATOLOGY, V47, P1524, DOI 10.1002/hep.22191; Hoskins E, 2011, GYNECOL ONCOL, V122, P656, DOI 10.1016/j.ygyno.2011.04.052; Hough CD, 2000, CANCER RES, V60, P6281; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jia L, 2006, MOL CELL BIOL, V26, P7331, DOI 10.1128/MCB.00581-06; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kataoka H, 2002, PATHOL INT, V52, P89, DOI 10.1046/j.1440-1827.2002.01320.x; Kluger HM, 2005, CANCER RES, V65, P5578, DOI 10.1158/0008-5472.CAN-05-0108; Kluger HM, 2004, LAB INVEST, V84, P320, DOI 10.1038/labinvest.3700044; Lee ECY, 2003, CELL DEATH DIFFER, V10, P761, DOI 10.1038/sj.cdd.4401228; Lentsch AB, 1999, GASTROENTEROLOGY, V117, P953, DOI 10.1016/S0016-5085(99)70355-0; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lovat F, 2009, CARCINOGENESIS, V30, P861, DOI 10.1093/carcin/bgp050; Lowe AW, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000323; MCELVANEY NG, 1992, J CLIN INVEST, V90, P1296, DOI 10.1172/JCI115994; Monami G, 2009, AM J PATHOL, V174, P1037, DOI 10.2353/ajpath.2009.080735; Nukiwa T, 2008, CANCER SCI, V99, P849, DOI 10.1111/j.1349-7006.2008.00772.x; Pan CX, 2004, CLIN CANCER RES, V10, P1333, DOI 10.1158/1078-0432.CCR-1123-03; Rasool N, 2010, CLIN CANCER RES, V16, P600, DOI 10.1158/1078-0432.CCR-09-1979; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Simpkins FA, 2008, CARCINOGENESIS, V29, P466, DOI 10.1093/carcin/bgm212; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Song XY, 1999, J EXP MED, V190, P535, DOI 10.1084/jem.190.4.535; Taggart CC, 2005, J EXP MED, V202, P1659, DOI 10.1084/jem.20050768; Tangkeangsirisin W, 2004, CANCER RES, V64, P1737, DOI 10.1158/0008-5472.CAN-03-2364; Tanner MM, 2000, CLIN CANCER RES, V6, P1833; THALMANN GN, 1994, CANCER RES, V54, P2577; Thompson M, 2008, PROSTATE, V68, P1248, DOI 10.1002/pros.20792; Tomlins SA, 2008, CANCER CELL, V13, P519, DOI 10.1016/j.ccr.2008.04.016; Treda CJ, 2014, CARCINOGENESIS, V35, P896, DOI 10.1093/carcin/bgt382; Tsukishiro S, 2005, GYNECOL ONCOL, V96, P516, DOI 10.1016/j.ygyno.2004.10.036; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wang DP, 2009, CANCER RES, V69, P9448, DOI 10.1158/0008-5472.CAN-09-1903; Zelvyte I, 2004, ANTICANCER RES, V24, P241; Zheng DL, 2013, MOL CANCER RES, V11, P482, DOI 10.1158/1541-7786.MCR-12-0520; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	59	22	23	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4807	4815		10.1038/onc.2016.13	http://dx.doi.org/10.1038/onc.2016.13			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876202				2022-12-17	WOS:000383324700013
J	Dey, A; Robitaille, M; Remke, M; Maier, C; Malhotra, A; Gregorieff, A; Wrana, JL; Taylor, MD; Angers, S; Kenney, AM				Dey, A.; Robitaille, M.; Remke, M.; Maier, C.; Malhotra, A.; Gregorieff, A.; Wrana, J. L.; Taylor, M. D.; Angers, S.; Kenney, A. M.			YB-1 is elevated in medulloblastoma and drives proliferation in Sonic hedgehog-dependent cerebellar granule neuron progenitor cells and medulloblastoma cells	ONCOGENE			English	Article							BOX-BINDING PROTEIN-1; GROWTH-FACTOR-II; TRANSCRIPTION FACTOR YB-1; NUCLEAR EXPRESSION; GENE-EXPRESSION; BREAST-CANCER; P-GLYCOPROTEIN; CYCLE PROGRESSION; TARGET; ALPHA	Postnatal proliferation of cerebellar granule neuron precursors (CGNPs), proposed cells of origin for the SHH-associated subgroup of medulloblastoma, is driven by Sonic hedgehog (Shh) and insulin-like growth factor (IGF) in the developing cerebellum. Shh induces the oncogene Yes-associated protein (YAP), which drives IGF2 expression in CGNPs and mouse Shh-associated medulloblastomas. To determine how IGF2 expression is regulated downstream of YAP, we carried out an unbiased screen for transcriptional regulators bound to IGF2 promoters. We report that Y-box binding protein-1 (YB-1), an onco-protein regulating transcription and translation, binds to IGF2 promoter P3. We observed that YB-1 is upregulated across human medulloblastoma subclasses as well as in other varieties of pediatric brain tumors. Utilizing the cerebellar progenitor model for the Shh subgroup of medulloblastoma in mice, we show for the first time that YB-1 is induced by Shh in CGNPs. Its expression is YAP-dependent and it is required for IGF2 expression in CGNPs. Finally, both gain-of function and loss-of-function experiments reveal that YB-1 activity is required for sustaining CGNP and medulloblastoma cell (MBC) proliferation. Collectively, our findings describe a novel role for YB-1 in driving proliferation in the developing cerebellum and MBCs and they identify the SHH:YAP:YB1:IGF2 axis as a powerful target for therapeutic intervention in medulloblastomas.	[Dey, A.; Maier, C.; Malhotra, A.; Kenney, A. M.] Emory Univ, Dept Pediat Oncol, 1760 Haygood Dr,Suite E390, Atlanta, GA 30322 USA; [Robitaille, M.; Angers, S.] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON, Canada; [Robitaille, M.; Angers, S.] Univ Toronto, Fac Med, Dept Biochem, Toronto, ON, Canada; [Remke, M.; Taylor, M. D.] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON, Canada; [Gregorieff, A.; Wrana, J. L.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Ctr Syst Biol, Toronto, ON, Canada	Emory University; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Kenney, AM (corresponding author), Emory Univ, Dept Pediat Oncol, 1760 Haygood Dr,Suite E390, Atlanta, GA 30322 USA.	anna.kenney@emory.edu	Angers, Stephane/E-1432-2014; Robitaille, Melanie/ABA-5861-2020; Wrana, Jeffrey/F-8857-2013	Angers, Stephane/0000-0001-7241-9044; Robitaille, Melanie/0000-0001-9354-5162; Malhotra, Anshu/0000-0002-0255-2680; Dey, Abhinav/0000-0003-0412-6236; Roe, Caroline/0000-0003-4680-9553; Taylor, Michael/0000-0001-7009-3466; Remke, Marc/0000-0002-9404-9993	NIH [NINDS R01 NS061070]; CURE Childhood Cancer Foundation; Winship Cancer Institute (P30 center grant) [CA138292]; Alex Lemonade Stand Foundation; Northwestern Mutual Foundation; Integrated Cellular Imaging (ICI) core at Emory University; NATIONAL CANCER INSTITUTE [P30CA138292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061070] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CURE Childhood Cancer Foundation; Winship Cancer Institute (P30 center grant); Alex Lemonade Stand Foundation; Northwestern Mutual Foundation; Integrated Cellular Imaging (ICI) core at Emory University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are grateful for the resources available from the Winship Cancer Institute (WCI)Pathology Core Lab for paraffin embedding of tissues. We acknowledge the assistance provided by Neil Anthony (Integrated Imaging Core, Emory University) during image acquisition and analysis. We thank Tobey Macdonald, Matthew Schniederjan and Megan Hamling from Children's Healthcare of Atlanta (CHOA) for providing human medulloblastoma tissue sections. We also thank Daniel Brat and Carol Tucker-Burden for assistance in slice culture experiments. We greatly appreciate the suggestions and feedback from Nada Jabado, Dan Brat, Sandra Dunn, Tracy Ann-Read, Renee Read and Tamara Caspary. This work has been supported by grants to AMK from the NIH (NINDS R01 NS061070), CURE Childhood Cancer Foundation and Winship Cancer Institute (P30 center grant-CA138292). AD acknowledges Alex Lemonade Stand Foundation and Northwestern Mutual Foundation for Young Investigator Award and Imaging studies were supported by a pilot grant to AD from the Integrated Cellular Imaging (ICI) core at Emory University.	Bai CB, 2002, DEVELOPMENT, V129, P4753; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bhatia B, 2009, CANCER RES, V69, P7224, DOI 10.1158/0008-5472.CAN-09-1299; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Chowdhury RP, 2007, J BACTERIOL, V189, P8973, DOI 10.1128/JB.01222-07; Corcoran RB, 2008, CANCER RES, V68, P8788, DOI 10.1158/0008-5472.CAN-08-2135; Corrales JMD, 2004, DEVELOPMENT, V131, P5581, DOI 10.1242/dev.01438; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dolfini D, 2013, CELL DEATH DIFFER, V20, P676, DOI 10.1038/cdd.2013.13; Eberhart CG, 2008, CANCER CELL, V14, P105, DOI 10.1016/j.ccr.2008.07.011; Eliseeva IA, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1402, DOI 10.1134/S0006297911130049; En-Nia A, 2005, J BIOL CHEM, V280, P7702, DOI 10.1074/jbc.M413353200; Faury D, 2007, J CLIN ONCOL, V25, P1196, DOI 10.1200/JCO.2006.07.8626; Fernandez A, 2012, ONCOGENE, V31, P1923, DOI 10.1038/onc.2011.379; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Finkbeiner MR, 2009, ONCOGENE, V28, P1421, DOI 10.1038/onc.2008.485; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; Gimenez-Bonafe P, 2004, PROSTATE, V59, P337, DOI 10.1002/pros.20023; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Gu CD, 2001, ANTICANCER RES, V21, P2357; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hartmann W, 2005, AM J PATHOL, V166, P1153, DOI 10.1016/S0002-9440(10)62335-8; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Homer C, 2005, ONCOGENE, V24, P8314, DOI 10.1038/sj.onc.1208998; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; Huang JX, 2005, INT J ONCOL, V26, P607; ITO K, 1994, NUCLEIC ACIDS RES, V22, P2036, DOI 10.1093/nar/22.11.2036; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Jung K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-328; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; Lasham A, 2013, BIOCHEM J, V449, P11, DOI 10.1042/BJ20121323; Lee J, 1997, DEVELOPMENT, V124, P2537; LEE JE, 1990, DEVELOPMENT, V110, P151; Lossi L, 2009, PROG NEUROBIOL, V88, P221, DOI 10.1016/j.pneurobio.2009.01.002; Mainwaring LA, 2011, ONCOGENE, V30, P1784, DOI 10.1038/onc.2010.564; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Mill P, 2005, DEV CELL, V9, P293, DOI 10.1016/j.devcel.2005.05.009; Miwa A, 2006, BBA-GEN SUBJECTS, V1760, P1675, DOI 10.1016/j.bbagen.2006.08.027; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Packer R J, 1999, Neuro Oncol, V1, P232, DOI 10.1093/neuonc/1.3.232; Parathath SR, 2008, DEVELOPMENT, V135, P3291, DOI 10.1242/dev.022871; Pham NV, 1998, BRAIN RES, V810, P1, DOI 10.1016/S0006-8993(98)00783-5; Pomeroy SL, 2011, FUTURE ONCOL, V7, P327, DOI [10.2217/fon.11.15, 10.2217/FON.11.15]; Reginensi A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003380; Reiss Krzysztof, 2002, Expert Opin Ther Targets, V6, P539, DOI 10.1517/14728222.6.5.539; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; Rubinstein DB, 2002, CANCER RES, V62, P4985; SABATH DE, 1990, J BIOL CHEM, V265, P12671; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Shibao K, 1999, INT J CANCER, V83, P732; Shih DJH, 2014, J CLIN ONCOL, V32, P886, DOI 10.1200/JCO.2013.50.9539; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Suresh Kp, 2011, J Hum Reprod Sci, V4, P8, DOI 10.4103/0974-1208.82352; Tiberi L, 2014, CANCER CELL, V26, P797, DOI 10.1016/j.ccell.2014.10.021; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; Uchiumi T, 2006, J BIOL CHEM, V281, P40440, DOI 10.1074/jbc.M605948200; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wu Joyce, 2007, Transl Oncogenomics, V2, P49; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Yahata H, 2002, J CANCER RES CLIN, V128, P621, DOI 10.1007/s00432-002-0386-6; Zhang C, 2003, DEVELOPMENT, V130, P5609, DOI 10.1242/dev.00798	75	22	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4256	4268		10.1038/onc.2015.491	http://dx.doi.org/10.1038/onc.2015.491			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26725322	Green Accepted			2022-12-17	WOS:000382149800010
J	Pinto, A; Mace, Y; Drouet, F; Bony, E; Boidot, R; Draoui, N; Lobysheva, I; Corbet, C; Polet, F; Martherus, R; Deraedt, Q; Rodriguez, J; Lamy, C; Schicke, O; Delvaux, D; Louis, C; Kiss, R; Kriegsheim, AV; Dessy, C; Elias, B; Quetin-Leclercq, J; Riant, O; Feron, O				Pinto, A.; Mace, Y.; Drouet, F.; Bony, E.; Boidot, R.; Draoui, N.; Lobysheva, I.; Corbet, C.; Polet, F.; Martherus, R.; Deraedt, Q.; Rodriguez, J.; Lamy, C.; Schicke, O.; Delvaux, D.; Louis, C.; Kiss, R.; Kriegsheim, A. V.; Dessy, C.; Elias, B.; Quetin-Leclercq, J.; Riant, O.; Feron, O.			A new ER-specific photosensitizer unravels O-1(2)-driven protein oxidation and inhibition of deubiquitinases as a generic mechanism for cancer PDT	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM; PHOTODYNAMIC THERAPY; MAMMALIAN TARGET; HYPOXIA; MTOR; PHOTOEXCITATION; MULTIMERIZATION; SENSITIZERS	Photosensitizers (PS) are ideally devoid of any activity in the absence of photoactivation, and rely on molecular oxygen for the formation of singlet oxygen (O-1(2)) to produce cellular damage. Off-targets and tumor hypoxia therefore represent obstacles for the use of PS for cancer photodynamic therapy. Herein, we describe the characterization of OR141, a benzophenazine compound identified through a phenotypic screening for its capacity to be strictly activated by light and to kill a large variety of tumor cells under both normoxia and hypoxia. This new class of PS unraveled an unsuspected common mechanism of action for PS that involves the combined inhibition of the mammalian target of rapamycin (mTOR) signaling pathway and proteasomal deubiquitinases (DUBs) USP14 and UCH37. Oxidation of mTOR and other endoplasmic reticulum (ER)-associated proteins drives the early formation of high molecular weight (MW) complexes of multimeric proteins, the concomitant blockade of DUBs preventing their degradation and precipitating cell death. Furthermore, we validated the antitumor effects of OR141 in vivo and documented its highly selective accumulation in the ER, further increasing the ER stress resulting from O-1(2) generation upon light activation.	[Pinto, A.; Draoui, N.; Lobysheva, I.; Corbet, C.; Polet, F.; Martherus, R.; Delvaux, D.; Louis, C.; Dessy, C.; Feron, O.] Catholic Univ Louvain, IREC, Pole Pharmacol & Therapeut FATH, Brussels, Belgium; [Mace, Y.; Drouet, F.; Boidot, R.; Deraedt, Q.; Lamy, C.; Schicke, O.; Elias, B.; Riant, O.] Catholic Univ Louvain, Inst Condensed Matter & Nanosci Mol Solids & Reac, 1 Pl Louis Pasteur,Bte 3, B-1348 Louvain La Neuve, Belgium; [Bony, E.; Quetin-Leclercq, J.] Catholic Univ Louvain, LDRI, Pharmacognosy Res Grp GNOS, Louvain La Neuve, Belgium; [Rodriguez, J.; Kriegsheim, A. V.] Conway Inst, Syst Biol Ireland, Dublin 4, Ireland; [Kiss, R.] Univ Libre Bruxelles, Fac Pharm, Lab Cancerol & Toxicol Expt, Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Universite Libre de Bruxelles	Riant, O (corresponding author), Catholic Univ Louvain, Inst Condensed Matter & Nanosci Mol Solids & Reac, 1 Pl Louis Pasteur,Bte 3, B-1348 Louvain La Neuve, Belgium.; Feron, O (corresponding author), UCLouvain, IREC, Pole Pharmacol & Therapeut FATH, 53 Ave E Mounier,B1-53-09, B-1200 Brussels, Belgium.	olivier.riant@uclouvain.be; olivier.feron@uclouvain.be	von Kriegsheim, Alex/C-2371-2016; FERON, Olivier/AAM-6395-2020; rodriguez, javier/AAB-1131-2019; riant, olivier/AAU-3567-2021	von Kriegsheim, Alex/0000-0002-4952-8573; FERON, Olivier/0000-0001-5360-0286; rodriguez, javier/0000-0001-7467-8533; Deraedt, Quentin/0000-0001-9226-2777; riant, olivier/0000-0003-4852-6469; Leclercq, Joelle/0000-0002-2278-6206	Region Bruxelles Capitale (Innoviris); Fonds national de la Recherche Scientifique (FRS-FNRS); Belgian Foundation against cancer; J Maisin Foundation; Belgian Science Policy Office (Belspo) [UP7-03]; Action de Recherche Concertee [ARC 14/19]	Region Bruxelles Capitale (Innoviris)(Innoviris); Fonds national de la Recherche Scientifique (FRS-FNRS)(Fonds de la Recherche Scientifique - FNRS); Belgian Foundation against cancer; J Maisin Foundation; Belgian Science Policy Office (Belspo)(Belgian Federal Science Policy Office); Action de Recherche Concertee	This work was supported by grants from the Region Bruxelles Capitale (Innoviris), the Fonds national de la Recherche Scientifique (FRS-FNRS), the Belgian Foundation against cancer, the J Maisin Foundation, the interuniversity attraction pole (IUAP) research program #UP7-03 from the Belgian Science Policy Office (Belspo) and an Action de Recherche Concertee (ARC 14/19).	Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114; Altun M, 2011, CHEM BIOL, V18, P1401, DOI 10.1016/j.chembiol.2011.08.018; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brodsky JL, 2012, CELL, V151, P1163, DOI 10.1016/j.cell.2012.11.012; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Cao YT, 2005, CANCER RES, V65, P5498, DOI 10.1158/0008-5472.CAN-04-4553; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; Corbet C, 2014, CANCER RES, V74, P5507, DOI 10.1158/0008-5472.CAN-14-0705; Davies MJ, 2004, PHOTOCH PHOTOBIO SCI, V3, P17, DOI 10.1039/b307576c; Davies MJ, 2005, BBA-PROTEINS PROTEOM, V1703, P93, DOI 10.1016/j.bbapap.2004.08.007; Diao YR, 2010, P NATL ACAD SCI USA, V107, P20974, DOI 10.1073/pnas.1007225107; Donohue E, 2011, J BIOL CHEM, V286, P7290, DOI 10.1074/jbc.M110.139915; Draoui N, 2014, MOL CANCER THER, V13, P1410, DOI 10.1158/1535-7163.MCT-13-0653; Hiraoka W, 2006, ULTRASON SONOCHEM, V13, P535, DOI 10.1016/j.ultsonch.2005.10.001; Hwang JY, 2012, J CONTROL RELEASE, V163, P368, DOI 10.1016/j.jconrel.2012.09.015; Jain A, 2014, P NATL ACAD SCI USA, V111, P17833, DOI 10.1073/pnas.1419425111; Li WM, 2007, CIRC RES, V100, P79, DOI 10.1161/01.RES.0000253094.03023.3f; Liu XY, 2007, MOL BIOL CELL, V18, P1073, DOI 10.1091/mbc.E06-05-0406; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mroz Pawel, 2011, Cancers (Basel), V3, P2516, DOI 10.3390/cancers3022516; Nadeau PJ, 2007, MOL BIOL CELL, V18, P3903, DOI 10.1091/mbc.E07-05-0491; Nakatsukasa K, 2008, TRAFFIC, V9, P861, DOI 10.1111/j.1600-0854.2008.00729.x; Nau W., 2011, CHEMPHYSCHEM, V12, P2496; Ng WY, 2007, J CELL SCI, V120, P682, DOI 10.1242/jcs.03351; Ormond AB, 2013, MATERIALS, V6, P817, DOI 10.3390/ma6030817; Poon E, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001173; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Seront E, 2013, BRIT J CANCER, V109, P1586, DOI 10.1038/bjc.2013.505; Sueishi Y, 2014, J CLIN BIOCHEM NUTR, V54, P67, DOI 10.3164/jcbn.13-53; Takahara T, 2006, J BIOL CHEM, V281, P28605, DOI 10.1074/jbc.M606087200; Udeshi ND, 2013, NAT PROTOC, V8, P1950, DOI 10.1038/nprot.2013.120; van der Wijk T, 2004, J BIOL CHEM, V279, P44355, DOI 10.1074/jbc.M407483200; Wilson BC, 2008, PHYS MED BIOL, V53, pR61, DOI 10.1088/0031-9155/53/9/R01; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Yoshii H, 2012, BIOCHEM BIOPH RES CO, V417, P640, DOI 10.1016/j.bbrc.2011.12.024	37	22	22	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3976	3985		10.1038/onc.2015.474	http://dx.doi.org/10.1038/onc.2015.474			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26686091				2022-12-17	WOS:000381013100009
J	Nie, D; Shan, X; Nie, L; Duan, Y; Chen, Z; Yang, Y; Li, Z; Tian, L; Gao, Q; Shan, Y; Tang, N				Nie, D.; Shan, X.; Nie, L.; Duan, Y.; Chen, Z.; Yang, Y.; Li, Z.; Tian, L.; Gao, Q.; Shan, Y.; Tang, N.			Hepatitis C virus core protein interacts with Snail and histone deacetylases to promote the metastasis of hepatocellular carcinoma	ONCOGENE			English	Article							E-CADHERIN EXPRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR SNAIL; B-VIRUS; REPRESSOR; PHOSPHORYLATION; REPLICATION; DIFFERENTIATION; AGGRESSIVENESS; HDAC2	Downregulation of E-cadherin by the transcriptional repressor Snail is associated with acquisition of metastatic potential. Although hepatitis C virus (HCV) core protein has been implicated in hepatocarcinogenesis, it is unclear whether Snail is involved in HCV core-induced dysregulation of E-cadherin. Herein, we investigated the mechanism by which HCV core induces E-cadherin repression and the role of Snail in HCV core-mediated invasiveness and metastasis. We found that HCV infection, especially HCV core expression, effectively induced the epithelial-mesenchymal transition (EMT) in hepatoma cells by repressing E-cadherin. HCV core interacted with Snail and enhanced its binding to the E-box in the promoter region of E-cadherin, leading to decreased E-cadherin promoter activity. We found that HCV core, Snail, and the histone deacetylases HDAC1/HDAC2 formed a co-repressor complex at the E-cadherin promoter. Moreover, HCV core was shown to stabilize Snail through activation of the PI3K/Akt/GSK3 beta pathway. Silencing Snail expression restored E-cadherin expression and inhibited HCV core-promoted tumor growth and distant lung metastasis in vivo. Collectively, these results demonstrated that HCV core induced EMT by interacting with the transcriptional repressor complex Snail/HDACs at the E-cadherin promoter, which led to E-cadherin repression and increased invasiveness of hepatoma cells. These findings increase understanding of factors regulating metastasis in hepatoma and may ultimately lead to the development of novel treatment strategies for HCV-associated hepatocellular carcinoma.	[Shan, Y.; Tang, N.] Chongqing Med Univ, Affiliated Hosp 2, Chongqing 400016, Peoples R China; Chongqing Med Univ, Key Lab Mol Biol Infect Dis, Chinese Minist Educ, Chongqing 400016, Peoples R China	Chongqing Medical University; Chongqing Medical University	Shan, Y; Tang, N (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Chongqing 400016, Peoples R China.; Shan, Y; Tang, N (corresponding author), Chongqing Med Univ, Key Lab Mol Biol Infect Dis, Chongqing 400016, Peoples R China.	shanyoulan11@163.com; nitang@cqmu.edu.cn	Tang, Ni/Z-5133-2019	Tang, Ni/0000-0001-5830-8786; Nie, Lizhu/0000-0001-6353-5211	Major National ST program [2013ZX10002002-005-003, 2012ZX10002005-003-002]; China National Natural Science Foundation [81572683, 81371827, 31171307, 81502062]; Innovation Fund Designated for Graduate Students of Chongqing Government [CYS14124]; Outstanding Young talent program of 2nd affiliated hospital of CQMU	Major National ST program; China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Innovation Fund Designated for Graduate Students of Chongqing Government; Outstanding Young talent program of 2nd affiliated hospital of CQMU	We would like to thank Dr T-C He (University of Chicago, USA) for the kind provision of adenoviruses AdGFP, AdRFP, and AdR-FLuc. We are also grateful to Dr Takaji Wakita (National Institute of Infectious Diseases, Tokyo) for providing an HCV JFH1 cDNA clone and to Dr Haizhen Zhu (Hunan University, China) for the HLCZ01 cells. This study was supported by research grants from Major National S&T program (2013ZX10002002-005-003, NT; 2012ZX10002005-003-002, NT), China National Natural Science Foundation (#81572683, #81371827, #31171307, NT; #81502062, DN), Innovation Fund Designated for Graduate Students of Chongqing Government (#CYS14124, LN) and the Outstanding Young talent program of 2nd affiliated hospital of CQMU (NT).	Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060; Akkari L, 2012, J HEPATOL, V57, P1021, DOI 10.1016/j.jhep.2012.06.027; Arzumanyan A, 2012, ONCOGENE, V31, P563, DOI 10.1038/onc.2011.255; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Battaglia S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004355; Bi Y, 2009, J CELL BIOCHEM, V108, P295, DOI 10.1002/jcb.22254; Bose SK, 2012, J VIROL, V86, P13621, DOI 10.1128/JVI.02016-12; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Garg Minal, 2013, World J Stem Cells, V5, P188, DOI 10.4252/wjsc.v5.i4.188; Giannini C, 2003, CELL DEATH DIFFER, V10, pS27, DOI 10.1038/sj.cdd.4401121; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hashiguchi M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-572; Hou ZY, 2010, CANCER RES, V70, P4385, DOI 10.1158/0008-5472.CAN-10-0070; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Li TY, 2010, ANN SURG ONCOL, V17, P1937, DOI 10.1245/s10434-010-0925-3; Lindenbach BD, 2005, NATURE, V436, P933, DOI 10.1038/nature04077; Liu JX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023098; Mingot JM, 2009, J CELL SCI, V122, P1452, DOI 10.1242/jcs.041749; Noh JH, 2014, CANCER RES, V74, P1728, DOI 10.1158/0008-5472.CAN-13-2109; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Quan H, 2014, ONCOGENE, V33, P2826, DOI 10.1038/onc.2013.225; MacPherson MR, 2010, MOL BIOL CELL, V21, P244, DOI 10.1091/mbc.E09-06-0504; Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001; Rosen HR, 2011, NEW ENGL J MED, V364, P2429, DOI 10.1056/NEJMcp1006613; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sideridou M, 2011, J CELL BIOL, V195, P1123, DOI 10.1083/jcb.201108121; Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97; Tacke RS, 2011, J BIOL CHEM, V286, P10847, DOI 10.1074/jbc.M110.217653; Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582-4934.2008.00569.x; Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109; Xie Q, 2014, INT J CANCER, V135, P635, DOI 10.1002/ijc.28697; Yang DR, 2014, P NATL ACAD SCI USA, V111, pE1264, DOI 10.1073/pnas.1320071111; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	40	22	24	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3626	3635		10.1038/onc.2015.428	http://dx.doi.org/10.1038/onc.2015.428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26549030	Bronze			2022-12-17	WOS:000379622800002
J	Lucchesi, C; Sheikh, MS; Huang, Y				Lucchesi, C.; Sheikh, M. S.; Huang, Y.			Negative regulation of RNA-binding protein HuR by tumor-suppressor ECRG2	ONCOGENE			English	Article							MESSENGER-RNA; DOWN-REGULATION; CANCER; INHIBITOR; TARGET; GENE; XIAP	Esophageal cancer-related gene 2 (ECRG2) is a newer tumor suppressor whose function in the regulation of cell growth and apoptosis remains to be elucidated. Here we show that ECRG2 expression was upregulated in response to DNA damage, and increased ECRG2 expression induced growth suppression in cancer cells but not in non-cancerous epithelial cells. ECRG2-mediated growth suppression was associated with activation of caspases and marked reduction in the levels of apoptosis inhibitor, X chromosome-linked inhibitor of apoptosis protein (XIAP). ECRG2, via RNA-binding protein human antigen R (HuR), regulated XIAP mRNA stability and expression. Furthermore, ECRG2 increased HuR ubiquitination and degradation but was unable to modulate the non-ubiquitinable mutant form of HuR. We also identified missense and frame-shift ECRG2 mutations in various human malignancies and noted that, unlike wild-type ECRG2, one cancer-derived ECRG2 mutant harboring glutamic acid instead of valine at position 30 (V30E) failed to induce cell death and activation of caspases. This naturally occurring V30E mutant also did not suppress XIAP and HuR. Importantly, the V30E mutant overexpressing cancer cells acquired resistance against multiple anticancer drugs, thus suggesting that ECRG2 mutations appear to have an important role in the acquisition of anticancer drug resistance in a subset of human malignancies.	[Lucchesi, C.; Sheikh, M. S.; Huang, Y.] SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@upstate.edu			Carol M Baldwin Breast Cancer Research Fund	Carol M Baldwin Breast Cancer Research Fund	We thank Dr Myriam Gorospe (NIH/NIA) for kindly providing the pTAP-HuR and pTAP-HuR-K182R as well as Ad-GFP and Ad-HuR expression vectors and Dr Bert Vogelstein's laboratory (Johns Hopkins University School of Medicine, Baltimore, MD, USA) for kindly providing the RKO p53<SUP>-/-</SUP> cell line. These studies are supported in part by the Carol M Baldwin Breast Cancer Research Fund to Dr Ying Huang.	Abdelmohsen K, 2007, CELL CYCLE, V6, P1288, DOI 10.4161/cc.6.11.4299; Abdelmohsen K, 2010, WIRES RNA, V1, P214, DOI 10.1002/wrna.4; Abdelmohsen K, 2009, EMBO J, V28, P1271, DOI 10.1038/emboj.2009.67; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Berthelet Jean, 2013, Cells, V2, P163, DOI 10.3390/cells2010163; Cheng XL, 2008, J BIOL CHEM, V283, P5888, DOI 10.1074/jbc.M708145200; Chu PC, 2012, J BIOL CHEM, V287, P43639, DOI 10.1074/jbc.M112.393678; Cui YP, 2010, INT J ONCOL, V37, P1521, DOI 10.3892/ijo_00000805; Cui YP, 2003, BIOCHEM BIOPH RES CO, V302, P904, DOI 10.1016/S0006-291X(03)00122-0; Danson S, 2007, CURR CANCER DRUG TAR, V7, P785, DOI 10.2174/156800907783220471; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81; Geng Y, 2008, ARCH BIOCHEM BIOPHYS, V479, P153, DOI 10.1016/j.abb.2008.08.023; Huang G, 2007, CARCINOGENESIS, V28, P2274, DOI 10.1093/carcin/bgm140; Kakuguchi W, 2010, MOL CANCER RES, V8, P520, DOI 10.1158/1541-7786.MCR-09-0367; Kim HH, 2008, GENE DEV, V22, P1804, DOI 10.1101/gad.1645808; Kotta-Loizou I, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0161-y; Lebedeva S, 2011, MOL CELL, V43, P340, DOI 10.1016/j.molcel.2011.06.008; Lui KMJ, 2011, J CELL BIOL, V126, P2436; Meisner NC, 2007, NAT CHEM BIOL, V3, P508, DOI 10.1038/nchembio.2007.14; Obexer P, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00197; Owens T.W., 2013, J CARCINOG MUTAG S14; Rong R, 2005, ONCOGENE, V24, P4867, DOI 10.1038/sj.onc.1208660; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Song H, 2012, CANCER GENE THER, V19, P875, DOI 10.1038/cgt.2012.77; Srikantan S, 2012, CURR PROTEIN PEPT SC, V13, P372, DOI 10.2174/138920312801619394; Su Tao, 1998, Zhonghua Zhongliu Zazhi, V20, P254; Sun H, 2013, ONCOGENE, V32, P234, DOI 10.1038/onc.2012.34; Wang J, 2013, INT J MOL SCI, V14, P10015, DOI 10.3390/ijms140510015; Yi J, 2010, NUCLEIC ACIDS RES, V38, P1547, DOI 10.1093/nar/gkp1114; Zhang X, 2009, NUCLEIC ACIDS RES, V37, P7623, DOI 10.1093/nar/gkp755	32	22	22	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2565	2573		10.1038/onc.2015.339	http://dx.doi.org/10.1038/onc.2015.339			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26434587				2022-12-17	WOS:000376165700003
J	Li, X; Liang, Q; Liu, W; Zhang, N; Xu, L; Zhang, X; Zhang, J; Sung, JJY; Yu, J				Li, X.; Liang, Q.; Liu, W.; Zhang, N.; Xu, L.; Zhang, X.; Zhang, J.; Sung, J. J. Y.; Yu, J.			Ras association domain family member 10 suppresses gastric cancer growth by cooperating with GSTP1 to regulate JNK/c-Jun/AP-1 pathway	ONCOGENE			English	Article							FUNCTIONAL TUMOR-SUPPRESSOR; CELL-CYCLE PROGRESSION; C-JUN; EPIGENETIC INACTIVATION; TRANSCRIPTION; RASSF10; METHYLATION; PROTEIN; GENE; AP-1	The Ras association domain family (RASSF) encodes several members with tumor-suppressive potentials. We aimed to investigate the biological function and clinical implication of RASSF10 in gastric cancer (GC). We found that RASSF10 was silenced in six of seven GC cell lines and in primary GC tissues, but was highly expressed in normal gastric tissues. The silence of RASSAF10 was mediated by promoter methylation as evaluated by bisulfite genomic sequencing. RASSF10 expression could be restored by demethylation treatment. A negative correlation between methylation and mRNA expression of RASSF10 was observed in 223 gastric samples of The Cancer Genome Atlas study (P<0.0001). Re-expression of RASSF10 in GC cell lines (AGS and MKN45) significantly suppressed cell viability, colony formation, migration and invasion, reduced cells in S phase, accumulated cells in G2 phase and induced cell apoptosis in vitro, and inhibited tumorigenicity in nude mice. These were confirmed by decreased expression of proliferation markers (proliferating cell nuclear antigen, p-CDC2 and p-CDC25) and increased apoptotic cascades (cleaved caspases-9, -8, -3 and cleaved poly (ADP-ribose) polymerase). Conversely, RASSF10 knockdown in normal gastric cell line yielded an opposing effect. Co-immunoprecipitation combined with mass spectrometry analyses were performed to reveal the downstream effectors of RASSF10. The result revealed that glutathione S-transferase Pi 1 (GSTP1) was a direct cooperator of RASSF10. The tumor-suppressive effect of RASSF10 was partially mediated by cooperating with GSTP1 to deregulate Jun N-terminal kinase (JNK)/c-Jun/AP-1 pathway. Importantly, RASSF10 methylation was detected in 56.6% (98/173) of primary GCs and is an independent risk factor for poor survival of GC patients (P = 0.001). In conclusions, RASSF10 functions as a tumor suppressor by cooperating with GSTP1 to deregulate JNK/c-Jun/AP-1 pathway in GC. Promoter methylation of RASSF10 is associated with poor survival of GC patients.	[Li, X.; Liang, Q.; Xu, L.; Zhang, X.; Zhang, J.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Institute Digest Dis,Dept Med & Therapeut,State K, Shatin, Hong Kong, Peoples R China; [Li, X.] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China; [Liu, W.] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Gastroenterol, Hangzhou 310003, Zhejiang, Peoples R China; [Zhang, N.; Xu, L.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China	Chinese University of Hong Kong; State Key Lab Oncology South China; Sun Yat Sen University; Zhejiang University; Sun Yat Sen University	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Li, Xiao-xing/B-9114-2008; Liang, Qiaoyi Jessie/G-9612-2019; ZHANG, Xiang/N-7918-2015; Sung, Joseph J. Y./R-3203-2018; Yu, Jun/D-8569-2015; ZHANG, Jingwan/AIC-2560-2022	Li, Xiao-xing/0000-0001-8791-7505; Liang, Qiaoyi Jessie/0000-0001-8496-3442; ZHANG, Xiang/0000-0002-3222-5824; Sung, Joseph J. Y./0000-0003-3125-5199; Yu, Jun/0000-0001-5008-2153; ZHANG, Jingwan/0000-0002-0344-3398	Natural Science Foundation of China (NSFC) [81201963, 81372600]; China 863 Program [2012AA02A504]; Shenzhen Municipal Science and Technology RD fund [JCYJ20130401151108652]; Pearl River SAMP;T Nova Program of Guangzhou [201506010050]; Shenzhen Virtual University Park Support Scheme; Natural Science Foundation of China (NSFC) [81201963, 81372600]; China 863 Program [2012AA02A504]; Shenzhen Municipal Science and Technology RD fund [JCYJ20130401151108652]; Pearl River SAMP;T Nova Program of Guangzhou [201506010050]; Shenzhen Virtual University Park Support Scheme	Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); China 863 Program(National High Technology Research and Development Program of China); Shenzhen Municipal Science and Technology RD fund; Pearl River SAMP;T Nova Program of Guangzhou; Shenzhen Virtual University Park Support Scheme; Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); China 863 Program(National High Technology Research and Development Program of China); Shenzhen Municipal Science and Technology RD fund; Pearl River SAMP;T Nova Program of Guangzhou; Shenzhen Virtual University Park Support Scheme	This project was supported by research funds of Natural Science Foundation of China (NSFC) (81201963 and 81372600), a China 863 Program (2012AA02A504), Shenzhen Municipal Science and Technology R&D fund (JCYJ20130401151108652), Pearl River S&T Nova Program of Guangzhou (201506010050) and Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute. The results shown here are in part based on data generated by the TCGA Research Network: http://cancergenome.nih.gov/.	Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CELIS JE, 1988, ARCH BIOL MED EXP, V21, P417; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hesson LB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-42; Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401; Lee JG, 2013, FOOD CHEM TOXICOL, V55, P214, DOI 10.1016/j.fct.2012.12.026; Li X, 2012, ONCOGENE, V31, P3419, DOI 10.1038/onc.2011.511; Li X, 2014, CANCER LETT, V348, P146, DOI 10.1016/j.canlet.2014.03.017; Li ZH, 2014, ONCOL REP, V31, P1661, DOI 10.3892/or.2014.3039; Liu WL, 2011, HEPATOLOGY, V53, P843, DOI 10.1002/hep.24124; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Otani K, 2013, EXPERT REV MOL DIAGN, V13, P445, DOI [10.1586/erm.13.32, 10.1586/ERM.13.32]; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Richter AM, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.18; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Takai Daiya, 2003, In Silico Biology, V3, P235; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tomita H, 2011, GASTROENTEROLOGY, V140, P879, DOI 10.1053/j.gastro.2010.11.037; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Volodko N, 2014, FEBS LETT, V588, P2671, DOI 10.1016/j.febslet.2014.02.041; Wang SY, 2013, GUT, V62, P833, DOI 10.1136/gutjnl-2011-301776; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Wei ZR, 2013, BIOCHEM BIOPH RES CO, V432, P632, DOI 10.1016/j.bbrc.2013.02.033; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Xu LX, 2012, GUT, V61, P977, DOI 10.1136/gutjnl-2011-300411; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zhang Y, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-145	35	22	22	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2453	2464		10.1038/onc.2015.300	http://dx.doi.org/10.1038/onc.2015.300			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26279301				2022-12-17	WOS:000376165500004
J	Ferrer, I; Verdugo-Sivianes, EM; Castilla, MA; Melendez, R; Marin, JJ; Munoz-Galvan, S; Lopez-Guerra, JL; Vieites, B; Ortiz-Gordillo, MJ; De Leon, JM; Praena-Fernandez, JM; Perez, M; Palacios, J; Carnero, A				Ferrer, I.; Verdugo-Sivianes, E. M.; Castilla, M. A.; Melendez, R.; Marin, J. J.; Munoz-Galvan, S.; Lopez-Guerra, J. L.; Vieites, B.; Ortiz-Gordillo, M. J.; De Leon, J. M.; Praena-Fernandez, J. M.; Perez, M.; Palacios, J.; Carnero, A.			Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors	ONCOGENE			English	Article							GENETIC-LINKAGE ANALYSIS; IN-VITRO PROPAGATION; BINDING-PROTEIN; CHROMOSOME 17Q12-21; DENDRITIC SPINES; FAMILIAL BREAST; POOR-PROGNOSIS; OVARIAN-CANCER; HETEROGENEITY; CARCINOMA	The spinophilin (Spn, PPP1R9B) gene is located at 17q21.33, a region frequently associated with microsatellite instability and loss of heterozygosity, especially in breast tumors. Spn is a regulatory subunit of phosphatase1a (PP1), which targets the catalytic subunit to distinct subcellular locations. Spn downregulation reduces PPP1CA activity against the retinoblastoma protein, pRb, thereby maintaining higher levels of phosphorylated pRb. This effect contributes to an increase in the tumorigenic properties of cells in certain contexts. Here, we explored the mechanism of how Spn downregulation contributes to the malignant phenotype and poor prognosis in breast tumors and found an increase in the stemness phenotype. Analysis of human breast tumors showed that Spn mRNA and protein are reduced or lost in 15% of carcinomas, correlating with a worse prognosis, a more aggressive tumor phenotype and triple-negative tumors, whereas luminal tumors showed high Spn levels. Downregulation of Spn by shRNA increased the stemness properties along with the expression of stem-related genes (Sox2, KLF4, Nanog and OCT4), whereas ectopic overexpression of Spn cDNA reduced these properties. Breast tumor stem cells appeared to have low levels of Spn mRNA, and Spn loss correlated with increased stem-like cell appearance in breast tumors as indicated by an increase in CD44+/CD24- cells. A reduction of the levels of PPP1CA mimicked the cancer stem-like cell phenotype of Spn downregulation, suggesting that the mechanism of Spn involves PP1a. These increased cancer stem cell-like properties with reduced Spn might account for the malignant phenotype observed in Spn-loss tumors and may contribute to a worse patient prognosis.	[Ferrer, I.; Verdugo-Sivianes, E. M.; Castilla, M. A.; Melendez, R.; Marin, J. J.; Munoz-Galvan, S.; Perez, M.; Carnero, A.] Univ Seville, CSIC, HUVR, Inst Biomed Sevilla,IBIS, Campus HUVR,Edificio IBIS,Avda Manuel Siurot S-N, Seville 41013, Spain; [Marin, J. J.] Univ Seville, Dept Prevent Med & Publ Hlth, Seville, Spain; [Lopez-Guerra, J. L.; Ortiz-Gordillo, M. J.] Univ Hosp Virgen Del Rocio, Dept Radiat Oncol, Seville, Spain; [Vieites, B.] Univ Hosp Virgen Del Rocio, Dept Pathol, Seville, Spain; [De Leon, J. M.] Univ Hosp Virgen Del Rocio, Unidad Func Patol Mamaria, Seville, Spain; [Praena-Fernandez, J. M.] Virgen del Rocio Univ Hosp, Methodol Unit, Fdn Publ Andaluza Gest Invest Salud Sevilla, Seville, Spain; [Palacios, J.] Univ Hosp Ramon y Cajal, Dept Pathol, Madrid, Spain; [Carnero, A.] CSIC, E-41080 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); University of Sevilla; Virgen del Rocio University Hospital; Virgen del Rocio University Hospital; Virgen del Rocio University Hospital; Virgen del Rocio University Hospital; Hospital Universitario Ramon y Cajal; Consejo Superior de Investigaciones Cientificas (CSIC)	Carnero, A (corresponding author), Univ Seville, CSIC, HUVR, Inst Biomed Sevilla,IBIS, Campus HUVR,Edificio IBIS,Avda Manuel Siurot S-N, Seville 41013, Spain.	acarnero-ibis@us.es	IBIS, BIOMARCADORES/P-3515-2015; IBIS, RADIOBIOLOGIA/H-7452-2016; IBIS, CANCER/P-3323-2015; PRAENA-FERNANDEZ, J M/GON-7040-2022; Ferrer, Irene/C-9418-2015; Palacios, Jose/AAV-3765-2020; Muñoz-Galván, Sandra/K-5827-2015; Marin-Lopez, Juan J./G-7123-2012	PRAENA-FERNANDEZ, J M/0000-0001-5728-1024; Ferrer, Irene/0000-0002-2748-2607; Carnero, Amancio/0000-0003-4357-3979; Perez, Marco/0000-0001-6997-9593; VERDUGO SIVIANES, EVA MARIA/0000-0002-0922-0371; Marin-Lopez, Juan J./0000-0001-6072-739X	Spanish Ministry of Economy and Competitivity; Consejeria de Ciencia e Innovacion [CTS-6844, CTS-1848]; Consejeria de Salud of the Junta de Andalucia [PI-0135-2010, PI-0306-2012]; ISCIII [PIE13/0004]; FEDER funds; Sara Borrel Fellowship [CD12/00596]; ISCIII (Fis) - FEDER from Regional Development European Funds (European Union) [PI12/00137, PI15/00045]; ISCIII (RTICC) - FEDER from Regional Development European Funds (European Union) [RD12/0036/0028]	Spanish Ministry of Economy and Competitivity(Spanish Government); Consejeria de Ciencia e Innovacion; Consejeria de Salud of the Junta de Andalucia(Junta de Andalucia); ISCIII(Instituto de Salud Carlos III); FEDER funds(European Commission); Sara Borrel Fellowship; ISCIII (Fis) - FEDER from Regional Development European Funds (European Union); ISCIII (RTICC) - FEDER from Regional Development European Funds (European Union)	AC lab was supported by grants from the Spanish Ministry of Economy and Competitivity, Plan Nacional de I+D+I 2008-2011, Plan Estatal de I+D+I 2013-2016, ISCIII (Fis: PI12/00137, PI15/00045, RTICC: RD12/0036/0028) co-funded by FEDER from Regional Development European Funds (European Union), Consejeria de Ciencia e Innovacion (CTS-6844 and CTS-1848) and Consejeria de Salud of the Junta de Andalucia (PI-0135-2010 and PI-0306-2012). This work has been also possible with the help of the Plan Estatal de I+D+i 2013-2016, Grant PIE13/0004 co-funded by the ISCIII and FEDER funds. We thank the donors and the CNIO tumor bank and HUVR-IBiS Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT13/0010/0056) for the human specimens used in this study. IF was funded by a Sara Borrel Fellowship (CD12/00596).	Abujiang P, 1998, ONCOGENE, V17, P3029, DOI 10.1038/sj.onc.1202230; Aigelsreiter A, 2013, BRIT J CANCER, V108, P1830, DOI 10.1038/bjc.2013.165; Aigelsreiter MM, 2014, HUM PATHOL, V45, P683, DOI 10.1016/j.humpath.2013.11.014; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Allen PB, 2006, NEUROSCIENCE, V140, P897, DOI 10.1016/j.neuroscience.2006.02.067; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Berndt Norbert, 1999, Frontiers in Bioscience, V4, pD22, DOI 10.2741/Berndt; Bielas SL, 2007, CELL, V129, P579, DOI 10.1016/j.cell.2007.03.023; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Brady AE, 2003, J BIOL CHEM, V278, P32405, DOI 10.1074/jbc.M304195200; Carnero A, 2012, CURR MOL MED, V12, P528, DOI 10.2174/156652412800619987; Castro ME, 2008, CARCINOGENESIS, V29, P491, DOI 10.1093/carcin/bgm246; Chang CC, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1385; COHEN BB, 1993, AM J HUM GENET, V52, P723; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; EASTON DF, 1993, AM J HUM GENET, V52, P678; Estevez-Garcia P, 2013, CLIN CANCER RES, V19, P3925, DOI 10.1158/1078-0432.CCR-13-0057; Ferrer I, 2011, CELL CYCLE, V10, P2751, DOI 10.4161/cc.10.16.16422; Ferrer I, 2011, CELL CYCLE, V10, P1948, DOI 10.4161/cc.10.12.15798; Galderisi U, 2006, ONCOGENE, V25, P5250, DOI 10.1038/sj.onc.1209736; Ghebeh H, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-289; Guijarro MV, 2007, CARCINOGENESIS, V28, P1646, DOI 10.1093/carcin/bgm083; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; Kuntziger T, 2011, CELL CYCLE, V10, P1356, DOI 10.4161/cc.10.9.15442; Locke M, 2005, CANCER RES, V65, P8944, DOI 10.1158/0008-5472.CAN-05-0931; Mannello F, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-169; Mannello F, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-344; Molina-Pinelo S, 2011, J PATHOL, V225, P73, DOI 10.1002/path.2905; Ouimet CC, 2004, J COMP NEUROL, V479, P374, DOI 10.1002/cne.20313; Pinto CA, 2013, CANCER LETT, V341, P56, DOI 10.1016/j.canlet.2013.06.003; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; PORTER DE, 1993, BRIT J SURG, V80, P1381, DOI 10.1002/bjs.1800801108; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Querzoli P, 2001, BREAST CANCER RES TR, V66, P135, DOI 10.1023/A:1010643515095; RESNICOFF M, 1987, P NATL ACAD SCI USA, V84, P7295, DOI 10.1073/pnas.84.20.7295; Ress AL, 2014, ONCOTARGET, V5, P8492; Santamaria D, 2011, CELL CYCLE, V10, P2831, DOI 10.4161/cc.10.17.16528; Santra M, 2006, CANCER RES, V66, P11726, DOI 10.1158/0008-5472.CAN-06-1978; Santra M, 2011, CANCER SCI, V102, P1350, DOI 10.1111/j.1349-7006.2011.01952.x; Sarrouilhe D, 2006, BIOCHIMIE, V88, P1099, DOI 10.1016/j.biochi.2006.04.010; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Setoguchi T, 2004, CELL CYCLE, V3, P414; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Siegle JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5511; SMITH SA, 1993, AM J HUM GENET, V52, P767; Tseng SL, 1997, GENE CHROMOSOME CANC, V20, P377; Tsukada M, 2003, MECH DEVELOP, V120, P1033, DOI 10.1016/S0925-4773(03)00177-1; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Wang Q, 2004, SCIENCE, V304, P1940, DOI 10.1126/science.1098274	52	22	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2777	2788		10.1038/onc.2015.341	http://dx.doi.org/10.1038/onc.2015.341			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26387546				2022-12-17	WOS:000377472700011
J	Stoll, SW; Stuart, PE; Swindell, WR; Tsoi, LC; Li, B; Gandarillas, A; Lambert, S; Johnston, A; Nair, RP; Elder, JT				Stoll, S. W.; Stuart, P. E.; Swindell, W. R.; Tsoi, L. C.; Li, B.; Gandarillas, A.; Lambert, S.; Johnston, A.; Nair, R. P.; Elder, J. T.			The EGF receptor ligand amphiregulin controls cell division via FoxM1	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; CONFIDENCE-INTERVALS; GENE-EXPRESSION; HUMAN KERATINOCYTES; SQUAMOUS-CELL; MICE LACKING; DIFFERENTIATION; CANCER; KINASE; ACTIVATION	Epidermal growth factor receptor (EGFR) is central to epithelial cell physiology, and deregulated EGFR signaling has an important role in a variety of human carcinomas. Here we show that silencing of the EGF-related factor amphiregulin (AREG) markedly inhibits the expansion of human keratinocytes through mitotic failure and accumulation of cells with >= 4n DNA content. RNA-sequencing-based transcriptome analysis revealed that tetracycline-mediated AREG silencing significantly altered the expression of 2331 genes, 623 of which were not normalized by treatment with EGF. Interestingly, genes irreversibly upregulated by suppression of AREG overlapped with genes involved in keratinocyte differentiation. Moreover, a significant proportion of the irreversibly downregulated genes featured upstream binding sites recognized by forkhead box protein M1 (FoxM1), a key transcription factor in the control of mitosis that is widely dysregulated in cancer. The downregulation of FoxM1 and its target genes preceded mitotic arrest. Constitutive expression of FoxM1 in AREG knockdown cells normalized cell proliferation, reduced the number of cells with >= 4n DNA content and rescued expression of FoxM1 target genes. These results demonstrate that AREG controls G2/M progression and cytokinesis in keratinocytes via activation of a FoxM1-dependent transcriptional program, suggesting new avenues for treatment of epithelial cancer.	[Stoll, S. W.; Stuart, P. E.; Swindell, W. R.; Lambert, S.; Johnston, A.; Nair, R. P.; Elder, J. T.] Univ Michigan, Dept Dermatol, 7415 Med Sci Bldg 1,1301 East Catherine, Ann Arbor, MI 48109 USA; [Tsoi, L. C.] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Li, B.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; [Gandarillas, A.] Fdn Inst Invest Marques de Valdecilla IDIVAL, Cell Cycle Stem Cell Fate & Canc Lab, Santander, Spain; [Elder, J. T.] Ann Arbor Vet Affairs Hlth Syst, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Vanderbilt University; Hospital Universitario Marques de Valdecilla (HUMV)	Stoll, SW (corresponding author), Univ Michigan, Dept Dermatol, 7415 Med Sci Bldg 1,1301 East Catherine, Ann Arbor, MI 48109 USA.	sstoll@umich.edu		Tsoi, Lam Cheung/0000-0003-1627-5722	National Institute for Arthritis, Musculoskeletal and Skin Disease (NIAMS), National Institutes of Health (NIH) [K01 AR050462, R03 AR049420, K01 AR064765, R01 AR052889]; Instituto de Salud Carlos III (Spain, ISCIII-FIS/FEDER) [PI11/02070]; Babcock Foundation Endowment; Ann Arbor Veterans Affairs Hospital; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR049420, K01AR050462, R01AR052889] Funding Source: NIH RePORTER	National Institute for Arthritis, Musculoskeletal and Skin Disease (NIAMS), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Instituto de Salud Carlos III (Spain, ISCIII-FIS/FEDER); Babcock Foundation Endowment; Ann Arbor Veterans Affairs Hospital; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Mahdu Prasad for assistance with RNA-seq assays and Dr James Rheinwald (Harvard Medical School, Boston, MA) for providing the N/TERT-2G keratinocyte cell line. This work was in part supported by the National Institute for Arthritis, Musculoskeletal and Skin Disease (NIAMS), National Institutes of Health (NIH award K01 AR050462 and R03 AR049420 to SWS, K01 AR064765 to AJ and R01 AR052889 to JTE) and Instituto de Salud Carlos III (Spain, ISCIII-FIS/FEDER, PI11/02070, to AG). AJ is supported by a Babcock Foundation Endowment. JTE is supported by the Ann Arbor Veterans Affairs Hospital.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; BOONSTRA J, 1985, EXP CELL RES, V161, P421, DOI 10.1016/0014-4827(85)90098-9; Busser B, 2011, BBA-REV CANCER, V1816, P119, DOI 10.1016/j.bbcan.2011.05.003; Chandler H, 2013, CURR OPIN CELL BIOL, V25, P765, DOI 10.1016/j.ceb.2013.07.005; Chen LF, 2010, CLIN CANCER RES, V16, P2489, DOI 10.1158/1078-0432.CCR-09-2318; Cousineau D, 2005, TUTOR QUANT METHODS, V1, P42, DOI 10.20982/tqmp.01.1.p042; Cumming G, 2007, J CELL BIOL, V177, P7, DOI 10.1083/jcb.200611141; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567; Fontanini G, 1998, CLIN CANCER RES, V4, P241; Fontijn RD, 2001, MOL CELL BIOL, V21, P2944, DOI 10.1128/MCB.21.8.2944-2955.2001; Gandarillas A, 2014, EXP DERMATOL, V23, P87, DOI 10.1111/exd.12287; Garber M, 2011, NAT METHODS, V8, P469, DOI [10.1038/NMETH.1613, 10.1038/nmeth.1613]; Gruenbaum Y, 2000, J STRUCT BIOL, V129, P313, DOI 10.1006/jsbi.2000.4216; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Jean GW, 2008, PHARMACOTHERAPY, V28, P742, DOI 10.1592/phco.28.6.742; Johnston A, 2011, J INVEST DERMATOL, V131, P329, DOI 10.1038/jid.2010.313; Jost M, 1999, J INVEST DERMATOL, V112, P443, DOI 10.1046/j.1523-1747.1999.00543.x; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Kansra S, 2004, MOL BIOL CELL, V15, P4299, DOI 10.1091/mbc.E04-03-0233; Kansra S, 2005, MOL PHARMACOL, V67, P1145, DOI 10.1124/mol.104.004689; Kong XY, 2013, CANCER RES, V73, P3987, DOI 10.1158/0008-5472.CAN-12-3859; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Lazic SE, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-5; Lens SMA, 2003, CELL CYCLE, V2, P507, DOI 10.4161/cc.2.6.559; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Lichtenberger BM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005886; Liu BG, 2008, CANCER CELL, V14, P212, DOI 10.1016/j.ccr.2008.07.017; LOFTUS GR, 1994, PSYCHON B REV, V1, P476, DOI 10.3758/BF03210951; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Mascia F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005773; Matthews L, 2009, NUCLEIC ACIDS RES, V37, pD619, DOI 10.1093/nar/gkn863; Maxwell SE, 2004, DESIGNING EXPT ANAL, P868; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Morey RD, 2008, TUTOR QUANT METHODS, V4, P61, DOI 10.20982/tqmp.04.2.p061; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Okabe H, 2001, CANCER RES, V61, P2129; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Peus D, 1997, J INVEST DERMATOL, V109, P751, DOI 10.1111/1523-1747.ep12340759; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; POUMAY Y, 1995, J INVEST DERMATOL, V104, P271, DOI 10.1111/1523-1747.ep12612810; Qin L, 2005, J BIOL CHEM, V280, P3974, DOI 10.1074/jbc.M409807200; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rittie L, 2007, AM J PATHOL, V170, P2089, DOI 10.2353/ajpath.2007.060537; Robertson ED, 2012, J CELL SCI, V125, P3320, DOI 10.1242/jcs.095125; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Sanderson MP, 2006, GROWTH FACTORS, V24, P121, DOI 10.1080/08977190600634373; Schelfhout VRJ, 2002, J PATHOL, V198, P523, DOI 10.1002/path.1240; Schuller U, 2007, MOL CELL BIOL, V27, P8259, DOI 10.1128/MCB.00707-07; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Sternlicht MD, 2008, J MAMMARY GLAND BIOL, V13, P181, DOI 10.1007/s10911-008-9084-6; Stoll S, 1997, J CLIN INVEST, V100, P1271, DOI 10.1172/JCI119641; Stoll SW, 2010, J INVEST DERMATOL, V130, P2031, DOI 10.1038/jid.2010.98; Stoll SW, 2010, J INVEST DERMATOL, V130, P295, DOI 10.1038/jid.2009.211; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Stoll SW, 2015, J INVEST DERMA UNPUB; Swindell WR, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-27; Swindell WR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079253; Swindell WR, 2013, SCI REP-UK, V3, DOI 10.1038/srep01215; Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559; Teh MT, 2002, CANCER RES, V62, P4773; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tinhofer I, 2011, CLIN CANCER RES, V17, P5197, DOI 10.1158/1078-0432.CCR-10-3338; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Wang HX, 2010, CARCINOGENESIS, V31, P1132, DOI 10.1093/carcin/bgq058; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Xie Z, 2010, BIOINFORMATICS, V26, P287, DOI 10.1093/bioinformatics/btp631; Xue JF, 2014, J CLIN INVEST, V124, P564, DOI 10.1172/JCI71104; Yang G, 2010, CLIN CANCER RES, V16, P3171, DOI 10.1158/1078-0432.CCR-09-3171; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Yoshida T, 2010, BIOCHEM PHARMACOL, V80, P613, DOI 10.1016/j.bcp.2010.05.014; Yu G, 2015, R PACKAGE VERSION 1	80	22	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2075	2086		10.1038/onc.2015.269	http://dx.doi.org/10.1038/onc.2015.269			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26234682	Green Accepted			2022-12-17	WOS:000374505600007
J	Wethmar, K; Schulz, J; Muro, EM; Talyan, S; Andrade-Navarro, MA; Leutz, A				Wethmar, K.; Schulz, J.; Muro, E. M.; Talyan, S.; Andrade-Navarro, M. A.; Leutz, A.			Comprehensive translational control of tyrosine kinase expression by upstream open reading frames	ONCOGENE			English	Article							INITIATION; DATABASE; GENE; CENSUS	Post-transcriptional control has emerged as a major regulatory event in gene expression and often occurs at the level of translation initiation. Although overexpression or constitutive activation of tyrosine kinases (TKs) through gene amplification, translocation or mutation are well-characterized oncogenic events, current knowledge about translational mechanisms of TK activation is scarce. Here, we report the presence of translational cis-regulatory upstream open reading frames (uORFs) in the majority of transcript leader sequences of human TK mRNAs. Genetic ablation of uORF initiation codons in TK transcripts resulted in enhanced translation of the associated downstream main protein-coding sequences (CDSs) in all cases studied. Similarly, experimental removal of uORF start codons in additional non-TK proto-oncogenes, and naturally occurring loss-of-uORF alleles of the c-met proto-oncogene (MET) and the kinase insert domain receptor (KDR), was associated with increased CDS translation. Based on genome-wide sequence analyses we identified polymorphisms in 15.9% of all human genes affecting uORF initiation codons, associated Kozak consensus sequences or uORF-related termination codons. Together, these data suggest a comprehensive role of uORF-mediated translational control and delineate how aberrant induction of proto-oncogenes through loss-of-function mutations at uORF initiation codons may be involved in the etiology of cancer. We provide a detailed map of uORFs across the human genome to stimulate future research on the pathogenic role of uORFs.	[Wethmar, K.; Schulz, J.; Leutz, A.] Max Delbrueck Ctr Mol Med, Dept Cell Differentiat & Tumorigenesis, Berlin, Germany; [Wethmar, K.] Univ Hosp Muenster, Dept Hematol Oncol & Pneumol, Albert Schweitzer Campus 1, D-48149 Munster, Germany; [Muro, E. M.; Andrade-Navarro, M. A.] Max Delbrueck Ctr Mol Med, Dept Computat Biol & Data Min, Berlin, Germany; [Muro, E. M.; Talyan, S.; Andrade-Navarro, M. A.] Johannes Gutenberg Univ Mainz, Dept Biol, Inst Mol Biol, D-55122 Mainz, Germany; [Leutz, A.] Humboldt Univ, Dept Biol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Munster; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Institute of Molecular Biology (IMB); Johannes Gutenberg University of Mainz; Humboldt University of Berlin	Wethmar, K (corresponding author), Univ Hosp Muenster, Dept Hematol Oncol & Pneumol, Albert Schweitzer Campus 1, D-48149 Munster, Germany.	klaus.wethmar@ukmuenster.de	Wethmar, Klaus/AAQ-7085-2021; Muro, Enrique M./AAX-3698-2021; Talyan, Sweta/AAR-1436-2021; Leutz, Achim/K-9643-2013	Talyan, Sweta/0000-0002-7160-6742; Leutz, Achim/0000-0001-8259-927X	Deutsche Krebshilfe e.V., Bonn, Germany [110525]	Deutsche Krebshilfe e.V., Bonn, Germany(Deutsche Krebshilfe)	This work was supported by the Deutsche Krebshilfe e.V., Bonn, Germany (grant 110525 to KW and AL).	Barbosa C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003529; Calkhoven CF, 2000, GENE DEV, V14, P1920; Calvo SE, 2009, P NATL ACAD SCI USA, V106, P7507, DOI 10.1073/pnas.0810916106; Chen HY, 2012, J MOL NEUROSCI, V47, P448, DOI 10.1007/s12031-012-9705-9; Churbanov A, 2005, NUCLEIC ACIDS RES, V33, P5512, DOI 10.1093/nar/gki847; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Glubb DM, 2011, CLIN CANCER RES, V17, P5257, DOI 10.1158/1078-0432.CCR-11-0379; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hampf M, 2006, ANAL BIOCHEM, V356, P94, DOI 10.1016/j.ab.2006.04.046; Iacono M, 2005, GENE, V349, P97, DOI 10.1016/j.gene.2004.11.041; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Ivanov IP, 2010, P NATL ACAD SCI USA, V107, P18056, DOI 10.1073/pnas.1009269107; Jackson RJ, 2012, ADV PROTEIN CHEM STR, V86, P45, DOI [10.1016/B978-0-12-386497-0.00002-5, 10.1016/B978-0-12.386497.000002-5]; Jin XP, 2003, J BIOL CHEM, V278, P25716, DOI 10.1074/jbc.M300316200; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Lee S, 2012, P NATL ACAD SCI USA, V109, pE2424, DOI 10.1073/pnas.1207846109; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; Mendell JT, 2004, NAT GENET, V36, P1073, DOI 10.1038/ng1429; Michel AM, 2014, NUCLEIC ACIDS RES, V42, pD859, DOI 10.1093/nar/gkt1035; Occhi G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003350; Pabst S, 2010, CHEST, V137, P156, DOI 10.1378/chest.09-1003; Pruitt KD, 2014, NUCLEIC ACIDS RES, V42, pD756, DOI 10.1093/nar/gkt1114; Rosenbloom KR, 2015, NUCLEIC ACIDS RES, V43, pD670, DOI 10.1093/nar/gku1177; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Somers J, 2013, INT J BIOCHEM CELL B, V45, P1690, DOI 10.1016/j.biocel.2013.04.020; Spevak CC, 2006, BIOCHEM BIOPH RES CO, V350, P834, DOI 10.1016/j.bbrc.2006.09.128; Uzunoglu FG, 2013, ANN ONCOL, V24, P1282, DOI 10.1093/annonc/mds634; Wethmar K, 2014, WIRES RNA, V5, P765, DOI 10.1002/wrna.1245; Wethmar K, 2014, NUCLEIC ACIDS RES, V42, pD60, DOI 10.1093/nar/gkt952; Wethmar K, 2010, BIOESSAYS, V32, P885, DOI 10.1002/bies.201000037	32	22	22	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1736	1742		10.1038/onc.2015.233	http://dx.doi.org/10.1038/onc.2015.233			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26096937	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000373064200012
J	Zhang, YW; Nasto, RE; Varghese, R; Jablonski, SA; Serebriiskii, IG; Surana, R; Calvert, VS; Bebu, I; Murray, J; Jin, L; Johnson, M; Riggins, R; Ressom, H; Petricoin, E; Clarke, R; Golemis, EA; Weiner, LM				Zhang, Y-W; Nasto, R. E.; Varghese, R.; Jablonski, S. A.; Serebriiskii, I. G.; Surana, R.; Calvert, V. S.; Bebu, I.; Murray, J.; Jin, L.; Johnson, M.; Riggins, R.; Ressom, H.; Petricoin, E.; Clarke, R.; Golemis, E. A.; Weiner, L. M.			Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation	ONCOGENE			English	Article							INTERACTING PROTEINS; SIGNALING PATHWAYS; RECEPTOR PATHWAY; ER-ALPHA; RESISTANCE; TOB; DATABASE; MUTATIONS; COMPLEXES; APOPTOSIS	Resistance to therapies targeting the estrogen pathway remains a challenge in the treatment of estrogen receptor-positive breast cancer. To address this challenge, a systems biology approach was used. A library of small interfering RNAs targeting an estrogen receptor (ER)- and aromatase-centered network identified 46 genes that are dispensable in estrogen-dependent MCF7 cells, but are selectively required for the survival of estrogen-independent MCF7-derived cells and multiple additional estrogen-independent breast cancer cell lines. Integration of this information identified a tumor suppressor gene TOB1 as a critical determinant of estrogen-independent ER-positive breast cell survival. Depletion of TOB1 selectively promoted G1 phase arrest and sensitivity to AKT and mammalian target of rapmycin (mTOR) inhibitors in estrogen-independent cells but not in estrogen-dependent cells. Phosphoproteomic profiles from reverse-phase protein array analysis supported by mRNA profiling identified a significant signaling network reprogramming by TOB1 that differed in estrogen-sensitive and estrogen-resistant cell lines. These data support a novel function for TOB1 in mediating survival of estrogen-independent breast cancers. These studies also provide evidence for combining TOB1 inhibition and AKT/mTOR inhibition as a therapeutic strategy, with potential translational significance for the management of patients with ER-positive breast cancers.	[Zhang, Y-W; Nasto, R. E.; Varghese, R.; Jablonski, S. A.; Surana, R.; Murray, J.; Jin, L.; Johnson, M.; Riggins, R.; Ressom, H.; Clarke, R.; Weiner, L. M.] Georgetown Univ, Sch Med, Dept Oncol, Georgetown Lombardi Comprehens Canc Ctr, Res Bldg E501,3970 Reservoir Rd NW, Washington, DC 20057 USA; [Nasto, R. E.; Serebriiskii, I. G.; Golemis, E. A.] Fox Chase Canc Ctr, Program Dev Therapeut, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Nasto, R. E.] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA; [Serebriiskii, I. G.] Kazan Fed Univ, Kazan, Russia; [Calvert, V. S.; Petricoin, E.] George Mason Univ, Ctr Appl Prote & Mol Med, Manassas, VA USA; [Bebu, I.] George Washington Univ, Biostat Ctr, Washington, DC USA	Georgetown University; Fox Chase Cancer Center; Drexel University; Kazan Federal University; George Mason University; George Washington University	Weiner, LM (corresponding author), Georgetown Univ, Sch Med, Dept Oncol, Georgetown Lombardi Comprehens Canc Ctr, Res Bldg E501,3970 Reservoir Rd NW, Washington, DC 20057 USA.	weinerl@georgetown.edu	Clarke, Robert/A-6485-2008; Riggins, Rebecca/GQH-4466-2022	Clarke, Robert/0000-0002-9278-0854; Golemis, Erica/0000-0003-3618-3673	NIH/NCI grant [P30-CA051008]; Russian Government;  [R01CA050633];  [CA51880];  [U54 CA149147];  [R01CA63366];  [R21CA181287]; NATIONAL CANCER INSTITUTE [R01CA050633, R21CA181287, R01CA063366, U54CA149147, P30CA006927, U01CA051880, T32CA009686, P30CA051008] Funding Source: NIH RePORTER	NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Russian Government; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to the Flow Cytometry and Cell Sorting Shared Resource at the Lombardi Comprehensive Cancer Center, which is partially supported by NIH/NCI grant P30-CA051008. We also thank Wei Xu, Alan Zwart, David Goldstein, Annie Zuo and Yuri Gusev for their technical assistance. This study was supported by R01CA050633, CA51880, U54 CA149147 (to LMW), R01CA63366 and R21CA181287 (to EAG), and by the subsidy of the Russian Government to support the program of competitive growth of Kazan Federal University (to IS).	Acevedo ML, 2003, MOL CELL BIOL, V23, P335, DOI 10.1128/MCB.23.1.335-348.2003; American Cancer Society, 2013, CANC FACTS FIG 2013; Astsaturov I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001083; Bader GD, 2000, BIOINFORMATICS, V16, P465, DOI 10.1093/bioinformatics/16.5.465; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bostner J, 2013, BREAST CANCER RES TR, V137, P397, DOI 10.1007/s10549-012-2376-y; Britton DJ, 2006, BREAST CANCER RES TR, V96, P131, DOI 10.1007/s10549-005-9070-2; Brunner N, 1997, CANCER RES, V57, P3486; Caravatta L, 2008, J CELL PHYSIOL, V214, P192, DOI 10.1002/jcp.21186; Childs BG, 2014, EMBO REP, V15, P1139, DOI 10.15252/embr.201439245; Chitre M, 2014, CLINICOECONOMIC OUTC, V6, P331, DOI 10.2147/CEOR.S57214; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649; Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295; Garcia-Becerra R, 2013, INT J MOL SCI, V14, P108, DOI 10.3390/ijms14010108; Gritsch David, 2011, J Exp Ther Oncol, V9, P37; Helms MW, 2009, CANCER RES, V69, P5049, DOI 10.1158/0008-5472.CAN-08-4154; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jansen MPHM, 2013, CANCER RES, V73, P6632, DOI 10.1158/0008-5472.CAN-13-0704; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Kim B, 2015, ONCOGENE, V34, P1083, DOI 10.1038/onc.2014.51; Kim SY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008979; Levin ER, 2009, J PHYSIOL-LONDON, V587, P5019, DOI 10.1113/jphysiol.2009.177097; Licata L, 2012, NUCLEIC ACIDS RES, V40, pD857, DOI 10.1093/nar/gkr930; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Marcotte R, 2012, CANCER DISCOV, V2, P172, DOI 10.1158/2159-8290.CD-11-0224; Matsuda S, 1996, ONCOGENE, V12, P705; Mishra GR, 2006, NUCLEIC ACIDS RES, V34, pD411, DOI 10.1093/nar/gkj141; Nair BC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2929; Nehra R, 2010, FASEB J, V24, P2040, DOI 10.1096/fj.09-138305; O'Malley S, 2009, INT J CANCER, V125, P1805, DOI 10.1002/ijc.24490; Orchard S, 2014, NUCLEIC ACIDS RES, V42, pD358, DOI 10.1093/nar/gkt1115; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Redon CE, 2010, CLIN CANCER RES, V16, P4532, DOI 10.1158/1078-0432.CCR-10-0523; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Saj A, 2010, DEV CELL, V18, P862, DOI 10.1016/j.devcel.2010.03.013; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Solimini NL, 2012, SCIENCE, V337, P104, DOI 10.1126/science.1219580; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Sun M, 2001, CANCER RES, V61, P5985; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Suzuki T, 2001, GENES CELLS, V6, P131, DOI 10.1046/j.1365-2443.2001.00406.x; Suzuki T, 2012, J BIOL CHEM, V287, P40256, DOI 10.1074/jbc.M112.353805; Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083; Tarcea VG, 2009, NUCLEIC ACIDS RES, V37, pD642, DOI 10.1093/nar/gkn722; Tateishi Y, 2004, EMBO J, V23, P4813, DOI 10.1038/sj.emboj.7600472; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Xenarios I, 2002, NUCLEIC ACIDS RES, V30, P303, DOI 10.1093/nar/30.1.303; Xia WL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3480; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003; Zhang YW, 2009, J BIOL CHEM, V284, P18085, DOI 10.1074/jbc.M109.003020	54	22	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1643	1656		10.1038/onc.2015.226	http://dx.doi.org/10.1038/onc.2015.226			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26165839	Green Accepted			2022-12-17	WOS:000373064200004
J	Shi, D; Dai, C; Qin, J; Gu, W				Shi, D.; Dai, C.; Qin, J.; Gu, W.			Negative regulation of the p300-p53 interplay by DDX24	ONCOGENE			English	Article							BOX RNA HELICASES; IN-VITRO; KAPPA-B; TRANSCRIPTIONAL REGULATION; P53 RESPONSE; ACETYLATION; CANCER; MUTATIONS; CELLS; ACTIVATION	Numerous studies indicate that p300 acts as a key transcriptional cofactor in vivo, at least, in part, by modulating activities of p53 by acetylation. Nevertheless, the regulation of the p53-p300 interplay is not completely understood. Here, we have identified the DEAD (Asp-Glu-Ala-Asp) box RNA helicase 24 (DDX24) as a novel regulator of the p300-p53 axis. We found that DDX24 interacts with p300, and this interaction leads to suppression of p300-mediated acetylation of p53. Notably, RNA interference-mediated knockdown of endogenous DDX24 significantly increases the acetylation levels of endogenous p53 in human cancer cells and subsequently promotes p53-mediated activation of its transcriptional targets such as p21 and p53 upregulated modulator of apoptosis (PUMA). In contrast, DDX24 expression inhibits the p300-p53 interaction and suppresses p300-mediated acetylation of p53. Moreover, DDX24 is overexpressed in human cancer cells and reduction of DDX24 protein levels by RNA interference induces cell cycle arrest and senescence in a p53-dependent manner. These results reveal DDX24 as an important regulator of p300 and suggest that the modulation of the p53-p300 interplay by DDX24 is critical in controlling p53 activities in human cancer cells.	[Shi, D.; Dai, C.; Gu, W.] Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, Inst Canc Genet,Herbert Irving Comprehens Canc Ct, New York, NY USA; [Qin, J.] Baylor Coll Med, Dept Biochem, One Baylor Plaza, Houston, TX 77030 USA; [Qin, J.] Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA	Columbia University; Baylor College of Medicine; Baylor College of Medicine	Gu, W (corresponding author), Columbia Univ, Dept Pathol & Cell Biol, ICRC BLDG 609A,1130 St Nicholas Ave, New York, NY 10032 USA.	wg8@columbia.edu			National Cancer Institute of the National Institutes of Health [5RO1 CA172023, 5RO1 CA166294, 5RO1CA085533, 2P01CA080058]; NIH cancer biology training grant [T32-CA09503]; NATIONAL CANCER INSTITUTE [R01CA085533, P01CA080058, R01CA166294, R01CA172023, R01CA169246] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH cancer biology training grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute of the National Institutes of Health under Award 5RO1 CA172023, 5RO1 CA166294, 5RO1CA085533 and 2P01CA080058 to WG. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. D Shi is also supported by NIH cancer biology training grant T32-CA09503. We especially thank Dr Ruping Sun for his help with the analysis of TCGA database.	Abdelhaleem M, 2004, BBA-REV CANCER, V1704, P37, DOI 10.1016/j.bbcan.2004.05.001; Busuttil V, 2010, P NATL ACAD SCI USA, V107, P18061, DOI 10.1073/pnas.1006163107; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; Charvet C, 2011, MOL CELL, V42, P584, DOI 10.1016/j.molcel.2011.03.033; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Coutts AS, 2005, BIOCHEM BIOPH RES CO, V331, P778, DOI 10.1016/j.bbrc.2005.03.150; Cruciat CM, 2013, SCIENCE, V339, P1436, DOI 10.1126/science.1231499; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Delvecchio M, 2013, NAT STRUCT MOL BIOL, V20, P1040, DOI 10.1038/nsmb.2642; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Fukawa T, 2012, CANCER RES, V72, P5867, DOI 10.1158/0008-5472.CAN-12-1645; Fuller-Pace FV, 2008, BIOCHEM SOC T, V36, P609, DOI 10.1042/BST0360609; Fuller-Pace FV, 2006, NUCLEIC ACIDS RES, V34, P4206, DOI 10.1093/nar/gkl460; Fuller-Pace FV, 2013, RNA BIOL, V10, P121, DOI 10.4161/rna.23312; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gustafson EA, 2010, BIOCHEM BIOPH RES CO, V395, P1, DOI 10.1016/j.bbrc.2010.02.172; Iyer NG, 2007, ONCOGENE, V26, P21, DOI 10.1038/sj.onc.1209771; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Johnson RF, 2012, TRENDS BIOCHEM SCI, V37, P317, DOI 10.1016/j.tibs.2012.04.002; Jung SY, 2005, MOL ENDOCRINOL, V19, P2451, DOI 10.1210/me.2004-0476; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Ma Z, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003721; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Nakagawa Y, 1999, BRIT J CANCER, V80, P914, DOI 10.1038/sj.bjc.6690441; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Oren M, 2002, ANN NY ACAD SCI, V973, P374, DOI 10.1111/j.1749-6632.2002.tb04669.x; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Payne EM, 2011, BLOOD, V118, P903, DOI 10.1182/blood-2010-11-318022; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Shi Dingding, 2012, Genes Cancer, V3, P240, DOI 10.1177/1947601912455199; Shi DD, 2009, P NATL ACAD SCI USA, V106, P16275, DOI 10.1073/pnas.0904305106; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Szerlong HJ, 2010, J BIOL CHEM, V285, P31954, DOI 10.1074/jbc.M110.148718; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Thomasova D, 2012, NEOPLASIA, V14, P1097, DOI 10.1593/neo.121534; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Yamauchi T, 2014, MOL CELL BIOL, V34, P3321, DOI 10.1128/MCB.00320-14; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhao Hong, 2013, Methods Mol Biol, V965, P83, DOI 10.1007/978-1-62703-239-1_5; Zhao Y, 2000, GENOMICS, V67, P351, DOI 10.1006/geno.2000.6255; Zhu YH, 2012, PROG MOL BIOL TRANSL, V106, P307, DOI 10.1016/B978-0-12-396456-4.00001-8	47	22	23	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					528	536		10.1038/onc.2015.77	http://dx.doi.org/10.1038/onc.2015.77			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25867071	Green Accepted			2022-12-17	WOS:000369056700012
J	Shalini, S; Puccini, J; Wilson, CH; Finnie, J; Dorstyn, L; Kumar, S				Shalini, S.; Puccini, J.; Wilson, C. H.; Finnie, J.; Dorstyn, L.; Kumar, S.			Caspase-2 protects against oxidative stress in vivo	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; CELL-DEATH; ANTIOXIDANT DEFENSE; APOPTOSIS; PARAQUAT; ACTIVATION; PATHWAY; PHOSPHORYLATION; AUTOPHAGY; LIVER	Caspase-2 belongs to the caspase family of cysteine proteases with established roles in apoptosis. Recently, caspase-2 has been implicated in nonapoptotic functions including maintenance of genomic stability and tumor suppression. Our previous studies demonstrated that caspase-2 also regulates cellular redox status and delays the onset of several ageing-related traits. In the current study, we tested stress tolerance ability in caspase-2-deficient (Casp2(-/-)) mice by challenging both young and old mice with a low dose of the potent reactive oxygen species (ROS) generator, PQ that primarily affects lungs. In both groups of mice, PQ induced pulmonary damage. However, the lesions in caspase-2 knockout mice were consistently and reproducibly more severe than those in wild-type (WT) mice. Furthermore, serum interleukin (IL)-1 beta and IL-6 levels were higher in PQ-exposed aged Casp2(-/-) mice indicating increased inflammation. Interestingly, livers from Casp2(-/-)mice displayed karyomegaly, a feature commonly associated with ageing and aneuploidy. Given that Casp2(-/-) mice show impaired antioxidant defense, we tested oxidative damage in these mice. Protein oxidation significantly increased in PQ-injected old Casp2(-/-) mice. Moreover, FoxO1, SOD2 and Nrf2 expression levels were reduced and induction of superoxide dismutase (SOD) and glutathione peroxidase activity was not observed in PQ-treated Casp2(-/-) mice. Strong c-Jun amino-terminal kinase (JNK) activation was observed in Casp2(-/-) mice, indicative of increased stress. Together, our data strongly suggest that caspase-2 deficiency leads to increased cellular stress largely because these mice fail to respond to oxidative stress by upregulating their antioxidant defense mechanism. This makes the mice more vulnerable to exogenous challenges and may partly explain the shorter lifespan of Casp2(-/-) mice.	[Shalini, S.; Puccini, J.; Wilson, C. H.; Dorstyn, L.; Kumar, S.] Univ S Australia, Ctr Canc Biol, Adelaide, SA 5001, Australia; [Finnie, J.] Univ Adelaide, SA Pathol, Adelaide, SA, Australia; [Finnie, J.] Univ Adelaide, Sch Med & Vet Sci, Adelaide, SA, Australia	Centre for Cancer Biology; University of South Australia; SA Pathology; University of Adelaide; University of Adelaide	Kumar, S (corresponding author), Univ S Australia, Ctr Canc Biol, Adelaide, SA 5001, Australia.	sharad.kumar@unisa.edu.au	Kumar, Sharad/AAX-7787-2020; Dorstyn, Loretta/F-3673-2013	Kumar, Sharad/0000-0001-7126-9814; Dorstyn, Loretta/0000-0001-9886-0989; Shah, Sonia Shalini/0000-0002-9106-2324	National Health and Medical Research Council (NHMRC) [1021456, 1002863]; Cancer Council Research Fellowship	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Research Fellowship(Cancer Council Australia)	We thank Jim Manavis for TUNEL, the staff at the SA Pathology animal resource facility for maintaining the mouse strains, and Swati Dawar for help with some of the immunoblots in Figure 4. This work was supported by the National Health and Medical Research Council (NHMRC) project grant (1021456), a Cancer Council Research Fellowship to LD and a NHMRC Senior Principal Research Fellowship (1002863) to SK.	Braga M, 2008, APOPTOSIS, V13, P822, DOI 10.1007/s10495-008-0216-7; Bryan HK, 2013, BIOCHEM PHARMACOL, V85, P705, DOI 10.1016/j.bcp.2012.11.016; BUS JS, 1976, TOXICOL APPL PHARM, V35, P501, DOI 10.1016/0041-008X(76)90073-9; BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dorstyn L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.342; Dorstyn L, 2012, CELL DEATH DIFFER, V19, P1288, DOI 10.1038/cdd.2012.36; Gentric G, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/282430; Gonzalez-Polo RA, 2009, J NEUROCHEM, V109, P889, DOI 10.1111/j.1471-4159.2009.06020.x; Gorla GR, 2001, J CELL SCI, V114, P2943; HASSAN HM, 1979, J BIOL CHEM, V254, P846; He XQ, 2012, J PHARMACOL EXP THER, V342, P81, DOI 10.1124/jpet.112.194142; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jang S, 2008, P NATL ACAD SCI USA, V105, P7534, DOI 10.1073/pnas.0802865105; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 2009, NAT REV CANCER, V9, P897, DOI 10.1038/nrc2745; Kurz T, 2007, ARCH BIOCHEM BIOPHYS, V462, P220, DOI 10.1016/j.abb.2007.01.013; Li J, 2003, FREE RADICAL BIO MED, V35, P292, DOI 10.1016/S0891-5849(03)00308-3; Li N, 2011, MECH AGEING DEV, V132, P75, DOI 10.1016/j.mad.2010.12.004; Matsuzawa A, 2008, BBA-GEN SUBJECTS, V1780, P1325, DOI 10.1016/j.bbagen.2007.12.011; Meng FY, 2012, AM J PATHOL, V181, P804, DOI 10.1016/j.ajpath.2012.06.010; Mercado N, 2011, BIOCHEM BIOPH RES CO, V406, P292, DOI 10.1016/j.bbrc.2011.02.035; Nakatani T, 1997, EXP CELL RES, V236, P137, DOI 10.1006/excr.1997.3715; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Panaretakis T, 2005, MOL BIOL CELL, V16, P3821, DOI 10.1091/mbc.E04-10-0862; Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624; Parsons MJ, 2013, CELL DEATH DIFFER, V20, P1174, DOI 10.1038/cdd.2013.38; Puccini J, 2013, CELL DEATH DIFFER, V20, P1133, DOI 10.1038/cdd.2013.87; Puccini J, 2013, P NATL ACAD SCI USA, V110, P19920, DOI 10.1073/pnas.1311947110; Res Lopez A., 2012, RESP SYSTEM MEDIASTI, V529; Sanz N, 1997, J HEPATOL, V27, P525, DOI 10.1016/S0168-8278(97)80358-3; Shalini S, 2012, CELL DEATH DIFFER, V19, P1370, DOI 10.1038/cdd.2012.13; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Smith P, 1975, J Clin Pathol Suppl (R Coll Pathol), V9, P81, DOI 10.1136/jcp.28.Suppl_9.81; Tan M, 2013, TOXICOL LETT, V223, P1, DOI 10.1016/j.toxlet.2013.08.011; Thiruchelvam M, 2000, BRAIN RES, V873, P225, DOI 10.1016/S0006-8993(00)02496-3; Tiwari M, 2014, AUTOPHAGY, V10, P1054, DOI 10.4161/auto.28528; Tiwari M, 2011, J BIOL CHEM, V286, P8493, DOI 10.1074/jbc.M110.163824; Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788; Zhang YP, 2007, MECH AGEING DEV, V128, P213, DOI 10.1016/j.mad.2006.11.030	48	22	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4995	5002		10.1038/onc.2014.413	http://dx.doi.org/10.1038/onc.2014.413			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25531319				2022-12-17	WOS:000361693000009
J	Golden, D; Cantley, LG				Golden, D.; Cantley, L. G.			Casein kinase 2 prevents mesenchymal transformation by maintaining Foxc2 in the cytoplasm	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; HEREDITARY LYMPHEDEMA; FORKHEAD BOX; CK2; TRANSITION; PHOSPHORYLATION; LOCALIZATION; CANCER; DOMAIN; CELLS	Nuclear Foxc2 is a transcriptional regulator of mesenchymal transformation during developmental epithelial-mesenchymal transition (EMT) and has been associated with EMT in malignant epithelia. Our laboratory has shown that in normal epithelial cells Foxc2 is maintained in the cytoplasm where it promotes an epithelial phenotype. The Foxc2 amino terminus has a consensus casein kinase 2 (CK2) phosphorylation site at serine 124, and we now show that CK2 associates with Foxc2 and phosphorylates this site in vitro. Knockdown or inhibition of the CK2 alpha/alpha a' kinase subunit in epithelial cells causes de novo accumulation of Foxc2 in the nucleus. Mutation of serine 124 to leucine promotes constitutive nuclear localization of Foxc2 and expression of mesenchymal genes, whereas an S124D phosphomimetic leads to constitutive cytoplasmic localization and epithelial maintenance. In malignant breast cancer cells, the CK2 beta regulatory subunit is downregulated and FOXC2 is found in the nucleus, correlating with an increase in a-smooth muscle actin (SMA) expression. Restoration of CK2 beta expression in these cells results in cytoplasmic localization of Foxc2, decreased alpha-SMA expression and reduced cell migration and invasion. In contrast, knockdown of CK2 beta in normal breast epithelial cells leads to FOXC2 nuclear localization, decreased E-cadherin expression, increased alpha-SMA and vimentin expression, and enhanced cell migration and invasion. Based on these findings, we propose that Foxc2 is functionally maintained in the cytoplasm of normal epithelial cells by CK2 alpha/alpha'-mediated phosphorylation at serine 124, which is dependent on proper targeting of the holoenzyme via the CK2 beta regulatory subunit.	[Golden, D.] Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA; [Cantley, L. G.] Yale Univ, Sch Med, Dept Internal Med, Sect Nephrol, Haven, CT USA	University of Connecticut; Yale University	Golden, D (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, 263 Farmington Ave,MC 3501, Farmington, CT 06030 USA.	dgolden@uchc.edu		Golden, Diana/0000-0002-1080-9175	NIH [DK65109]; DG [DK094589]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007276, R01DK065109, F32DK094589] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DG; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH awards to LGC (DK65109) and DG (DK094589).	Arden KC, 2006, EXP GERONTOL, V41, P709, DOI 10.1016/j.exger.2006.05.015; Bard JBL, 2008, DEV DYNAM, V237, P2748, DOI 10.1002/dvdy.21652; Barrett RMA, 2011, CELL CYCLE, V10, P538, DOI 10.4161/cc.10.3.14758; Berry FB, 2005, HUM MOL GENET, V14, P2619, DOI 10.1093/hmg/ddi295; Berry FB, 2002, J BIOL CHEM, V277, P10292, DOI 10.1074/jbc.M110266200; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Deshiere A, 2013, ONCOGENE, V32, P1373, DOI 10.1038/onc.2012.165; Fang JM, 2000, AM J HUM GENET, V67, P1382, DOI 10.1086/316915; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hader C, 2010, ONCOGENE, V29, P1031, DOI 10.1038/onc.2009.397; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Mueller T, 2009, HUM MOL GENET, V18, P3334, DOI 10.1093/hmg/ddp274; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Obsil T, 2008, ONCOGENE, V27, P2263, DOI 10.1038/onc.2008.20; Pagano MA, 2007, CHEMBIOCHEM, V8, P129, DOI 10.1002/cbic.200600293; MacPherson MR, 2010, MOL BIOL CELL, V21, P244, DOI 10.1091/mbc.E09-06-0504; Schwindling SL, 2004, ONCOGENE, V23, P4155, DOI 10.1038/sj.onc.1207566; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Tu YF, 2011, BBA-BIOENERGETICS, V1807, P1125, DOI 10.1016/j.bbabio.2011.04.015; von Knethen A, 2010, J CELL SCI, V123, P192, DOI 10.1242/jcs.055475; WALLIN A, 1992, LAB INVEST, V66, P474; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331	28	22	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4702	4712		10.1038/onc.2014.395	http://dx.doi.org/10.1038/onc.2014.395			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25486430	Green Accepted			2022-12-17	WOS:000360931500004
J	Bugide, S; David, D; Nair, A; Kannan, N; Samanthapudi, VSK; Prabhakar, J; Manavathi, B				Bugide, S.; David, D.; Nair, A.; Kannan, N.; Samanthapudi, V. S. K.; Prabhakar, J.; Manavathi, B.			Hematopoietic PBX-interacting protein (HPIP) is over expressed in breast infiltrative ductal carcinoma and regulates cell adhesion and migration through modulation of focal adhesion dynamics	ONCOGENE			English	Article							CALPAIN-MEDIATED PROTEOLYSIS; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; KINASE FAK; MICROTUBULE; CANCER; MOTILITY; SRC; INTEGRINS; SURVIVAL	The scaffolding protein, hematopoietic PBX-interacting protein (HPIP/PBXIP1), regulates cell migration necessary for cancer cell dissemination. However, the mechanism that governs this process remains unknown. We show here that HPIP expression is associated with stages of breast cancer where cell dissemination results in poor patient outcome. Our investigation finds a novel association of HPIP with focal adhesion kinase (FAK) regulating FA dynamics. Interestingly, this interaction that led to activation of FAK protein was mediated by the C-terminal domain of HPIP and not the typical integrin-binding motif. Further, short hairpin RNA-mediated knockdown of FAK expression significantly reduced HPIP-induced cell migration indicating participation of FAK pathway. Live-cell time-lapse imaging and biochemical analysis further established the role of HPIP in microtubule-induced FA disassembly. We also found that HPIP-mediated MAPK activation led to phosphorylation and subsequent activation of calpain2, and the activated calpain2 in turn proteolyses FA protein, talin. Interestingly, HPIP is also proteolysed by calpain2 in breast cancer cells. The proteolysis of HPIP and talin by calpain2, and the activation of calapin2 by HPIP-mediated MAPK phosphorylation, is a novel regulatory axis to modulate the cell migration signal. Together, we have determined HPIP as a novel activator of FAK and a new substrate of calpain2. These molecular interactions between HPIP and FAK, and HPIP and calpain2 regulate cell adhesion and migration through modulation of FA dynamics.	[Bugide, S.; Samanthapudi, V. S. K.; Manavathi, B.] Univ Hyderabad, Sch Life Sci, Dept Biochem, Mol & Cellular Oncol Lab, Hyderabad 500046, Telangana, India; [David, D.; Nair, A.] Rajiv Gandhi Ctr Biotechnol, Thiruvananthapuram, Kerala, India; [Kannan, N.] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; [Prabhakar, J.] Reg Canc Ctr, Thiruvananthapuram, Kerala, India	University of Hyderabad; Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB); British Columbia Cancer Agency	Manavathi, B (corresponding author), Univ Hyderabad, Sch Life Sci, Dept Biochem, Mol & Cellular Oncol Lab, Hyderabad 500046, Telangana, India.	manavathibsl@uohyd.ernet.in	Bugide, Suresh/AAD-6053-2022	Manavathi, Bramanandam/0000-0002-1797-398X; Kannan, Nagarajan/0000-0002-8825-2178	Department of Biotechnology (DBT), India [BT/01/IYBA/2009, BT/PR11114/BRB/10/635/2008, BT-BRB-TF-4-2013]; Department of Science and Technology (DST), India [SB/SO/BB/013/2013]	Department of Biotechnology (DBT), India(Department of Biotechnology (DBT) India); Department of Science and Technology (DST), India(Department of Science & Technology (India))	We are grateful to Dr Elaine Fuchs, Rockefeller University, New York, for providing pBABE-FAK, DsRed2-zyxin and pEGFP-paxillin constructs, and Dr Sam Aparicio, British Columbia Cancer Agency, Vancouver, Canada, for providing pGIPz-FAKshRNA clones. This work was supported by Department of Biotechnology (DBT), India Grant Nos: BT/01/IYBA/2009, BT/PR11114/BRB/10/635/2008 and BT-BRB-TF-4-2013, and Department of Science and Technology (DST), Grant Nos: SB/SO/BB/013/2013, India (to BM). SB is Senior Research Fellow, Council for Scientific and Industrial Research, India (CSIR), India. The authors also acknowledge DBT-CREBB, UGC-PURSE, DST-FIST and UOH-SAP-CAS for providing the research facilities at University of Hyderabad.	Abramovich C, 2000, J BIOL CHEM, V275, P26172, DOI 10.1074/jbc.M001323200; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Chan KT, 2010, J BIOL CHEM, V285, P11418, DOI 10.1074/jbc.M109.090746; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Golubovskaya VM, 2010, ANTI-CANCER AGENT ME, V10, P735; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hamadi A, 2005, J CELL SCI, V118, P4415, DOI 10.1242/jcs.02565; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Krylyshkina O, 2002, J CELL BIOL, V156, P349, DOI 10.1083/jcb.200105051; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Manavathi B, 2006, P NATL ACAD SCI USA, V103, P15981, DOI 10.1073/pnas.0607445103; Manavathi B, 2012, J BIOL CHEM, V287, P5600, DOI 10.1074/jbc.M111.289843; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Nagano M, 2010, J BIOL CHEM, V285, P21013, DOI 10.1074/jbc.M110.106443; OWENS LV, 1995, CANCER RES, V55, P2752; Panetti TS, 2002, FRONT BIOSCI-LANDMRK, V7, pD143, DOI 10.2741/panetti; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Ritt M, 2013, J BIOL CHEM, V288, P8875, DOI 10.1074/jbc.M112.421164; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Scolz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051259; Sieg DJ, 1999, J CELL SCI, V112, P2677; Stehbens S, 2012, J CELL BIOL, V198, P481, DOI 10.1083/jcb.201206050; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Wang XH, 2008, BBA-MOL CELL RES, V1783, P1220, DOI 10.1016/j.bbamcr.2008.01.026; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Wu XY, 2008, CELL, V135, P137, DOI 10.1016/j.cell.2008.07.045; Xu XJ, 2013, J CLIN INVEST, V123, P630, DOI 10.1172/JCI64265	42	22	26	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4601	4612		10.1038/onc.2014.389	http://dx.doi.org/10.1038/onc.2014.389			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25486428				2022-12-17	WOS:000360189300006
J	Chen, C; Wang, X; Xiong, X; Liu, Q; Huang, Y; Xu, Q; Hu, J; Ge, G; Ling, K				Chen, C.; Wang, X.; Xiong, X.; Liu, Q.; Huang, Y.; Xu, Q.; Hu, J.; Ge, G.; Ling, K.			Targeting type I. phosphatidylinositol phosphate kinase inhibits breast cancer metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LEPTIN RECEPTOR; TYROSINE KINASE; SPLICE VARIANTS; CELL-MIGRATION; C-MET; GAMMA; EXPRESSION; 5-KINASE; ANGIOGENESIS	Most deaths from breast cancer are caused by metastasis, a complex behavior of cancer cells involving migration, invasion, survival and microenvironment manipulation. Type I. phosphatidylinositol phosphate kinase ( PIPKI gamma) regulates focal adhesion assembly and its phosphorylation at Y639 is critical for cell migration induced by EGF. However, the role of this lipid kinase in tumor metastasis remains unclear. Here we report that PIPKI. is vital for breast cancer metastasis. Y639 of PIPKI gamma can be phosphorylated by stimulation of EGF and hepatocyte growth factor ( HGF), two promoting factors for breast cancer progression. Histological analysis revealed elevated Y639 phosphorylation of PIPKI gamma in invasive ductal carcinoma lesions and suggested a positive correlation with tumor grade. Orthotopically transplanted PIPKI.-depleted breast cancer cells showed substantially reduced growth and metastasis, as well as suppressed expression of multiple genes related to cell migration and microenvironment manipulation. Re-expression of wild-type PIPKI. in PIPKI.-depleted cells restored tumor growth and metastasis, reinforcing the importance of PIPKI gamma in breast cancer progression. Y639-to-F or a kinase-dead mutant of PIPKI gamma could not recover the diminished metastasis in PIPKI gamma-depleted cancer cells, suggesting that Y639 phosphorylation and lipid kinase activity are both required for development of metastasis. Further analysis with in vitro assays indicated that depleting PIPKI gamma inhibited cell proliferation, MMP9 secretion and cell migration and invasion, lending molecular mechanisms for the eliminated cancer progression. These results suggest that PIPKI gamma, downstream of EGF and/or HGF receptor, participates in breast cancer progression from multiple aspects and deserves further studies to explore its potential as a therapeutic target.	[Chen, C.; Huang, Y.; Xu, Q.; Hu, J.; Ling, K.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Wang, X.] Mayo Clin, Dept Med Genet, Rochester, MN 55905 USA; [Xiong, X.] Oklahoma Univ Med, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK USA; [Liu, Q.; Ge, G.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai, Peoples R China; [Hu, J.] Mayo Clin, Dept Hypertens & Nephrol, Rochester, MN 55905 USA; [Ling, K.] Mayo Clin, Canc Ctr, Coll Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; University of Oklahoma System; University of Oklahoma Health Sciences Center; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Mayo Clinic; Mayo Clinic	Ling, K (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Ctr Canc, Guggenheim 16-04,200 First St SW, Rochester, MN 55905 USA.	ling.kun@mayo.edu			National Cancer Institute [1R01CA149039-01A1]; Susan G Komen for the Cure [KG100902]; NATIONAL CANCER INSTITUTE [R01CA149039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK090038, R01DK099160] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Daniel Visscher (Mayo Clinic) for scoring the breast cancer tissue microarrays, Dr Wilma Lingle (Mayo Clinic) for providing human breast cancer tissue samples and tissue microarrays, Dr Vijayalakshmi Shridhar (Mayo Clinic) for sharing the 4T1 cells and Dr Kah Whye Peng (Mayo Clinic) for providing the luciferase system. This work was supported by research grants from the National Cancer Institute (1R01CA149039-01A1) and Susan G Komen for the Cure (KG100902).	Ali S, 2007, CANCER METAST REV, V26, P401, DOI 10.1007/s10555-007-9073-z; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Bhati R, 2008, AM J PATHOL, V172, P1381, DOI 10.2353/ajpath.2008.070988; Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648; Courtwright A, 2009, CANCER RES, V69, P4621, DOI 10.1158/0008-5472.CAN-08-3402; Datta D, 2006, CANCER RES, V66, P9509, DOI 10.1158/0008-5472.CAN-05-4345; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Doughman RL, 2003, J MEMBRANE BIOL, V194, P77, DOI 10.1007/s00232-003-2027-7; El Sayegh TY, 2007, MOL BIOL CELL, V18, P3026, DOI 10.1091/mbc.E06-12-1159; Garofalo C, 2006, CLIN CANCER RES, V12, P1447, DOI 10.1158/1078-0432.CCR-05-1913; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Giudici ML, 2006, FEBS LETT, V580, P6933, DOI 10.1016/j.febslet.2006.11.052; Giudici ML, 2004, BIOCHEM J, V379, P489, DOI 10.1042/BJ20031394; Gonzalez RR, 2006, J BIOL CHEM, V281, P26320, DOI 10.1074/jbc.M601991200; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Ishikawa M, 2004, CLIN CANCER RES, V10, P4325, DOI 10.1158/1078-0432.CCR-03-0749; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Jemal A, 2004, CANCER-AM CANCER SOC, V101, P3, DOI 10.1002/cncr.20288; Keshtgar MRS, 1999, EUR J NUCL MED, V26, P57, DOI 10.1007/s002590050360; Landi L, 2013, CURR OPIN ONCOL, V25, P130, DOI 10.1097/CCO.0b013e32835daf37; Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ling K, 2007, J CELL BIOL, V176, P343, DOI 10.1083/jcb.200606023; Ling K, 2006, TRENDS CELL BIOL, V16, P276, DOI 10.1016/j.tcb.2006.03.007; Lippitz BE, 2013, LANCET ONCOL, V14, pE218, DOI 10.1016/S1470-2045(12)70582-X; Liu JL, 2007, MOL BIOL CELL, V18, P4483, DOI 10.1091/mbc.E07-05-0461; Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955; McMurtry V, 2009, CLIN EXP METASTAS, V26, P197, DOI 10.1007/s10585-008-9231-x; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Mulligan AM, 2013, CLIN CANCER RES, V19, P336, DOI 10.1158/1078-0432.CCR-11-3314; Perera CN, 2008, J ENDOCRINOL, V199, P221, DOI 10.1677/JOE-08-0215; Ponzo MG, 2010, CELL CYCLE, V9, P1043, DOI 10.4161/cc.9.6.11033; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x; Schill NJ, 2009, BIOCHEM J, V422, P473, DOI 10.1042/BJ20090638; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Sun Y, 2007, J CELL BIOL, V178, P297, DOI 10.1083/jcb.200701078; Sun Y, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2471; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Wang YJ, 2004, J CELL BIOL, V167, P1005, DOI 10.1083/jcb.200408008; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Xiong XH, 2012, MOL BIOL CELL, V23, P87, DOI 10.1091/mbc.E11-05-0449; Yan D, 2012, J BIOL CHEM, V287, P8598, DOI 10.1074/jbc.M111.322800	50	22	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4635	4646		10.1038/onc.2014.393	http://dx.doi.org/10.1038/onc.2014.393			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25486426	Green Accepted			2022-12-17	WOS:000360189300009
J	Zhu, L; Lu, Z; Zhao, H				Zhu, L.; Lu, Z.; Zhao, H.			Antitumor mechanisms when pRb and p53 are genetically inactivated	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; RETINOBLASTOMA TUMOR-SUPPRESSOR; SYNTHETIC LETHAL INTERACTIONS; SMALL-MOLECULE INHIBITORS; SENESCENCE IN-VIVO; CELL-CYCLE ARREST; DNA-DAMAGE; P53-INDUCIBLE REGULATOR; GLUTAMINE-METABOLISM; TARGET GENES	pRb and p53 are the two major tumor suppressors. Their inactivation is frequent when cancers develop and their reactivation is rationale of most cancer therapeutics. When pRb and p53 are genetically inactivated, cells irreparably lose the antitumor mechanisms afforded by them. Cancer genome studies document recurrent genetic inactivation of RB1 and TP53, and the inactivation becomes more frequent in more advanced cancers. These findings may explain why more advanced cancers are more likely to resist current therapies. Finding successful treatments for more advanced and multi-therapy-resistant cancers will depend on finding antitumor mechanisms that remain effective when pRb and p53 are genetically inactivated. Here, we review studies that have begun to make progress in this direction.	[Zhu, L.] Albert Einstein Coll Med, Dept Dev & Mol Biol & Ophthalmol & Visual Sci & M, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA; [Zhu, L.] Albert Einstein Coll Med, Liver Res Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Zhu, L (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol & Ophthalmol & Visual Sci & M, Albert Einstein Comprehens Canc Ctr, 1300 Morris Pk Ave,Room U-521, Bronx, NY 10461 USA.	liang.zhu@einstein.yu.edu		Lu, Zhonglei/0000-0002-8915-4828	NIH [RO1CA127901, RO1CA131421]; DOD PCRP Postdoctoral Fellowship [PC121837]; Irma T Hirschl Career Scientist Award; NATIONAL CANCER INSTITUTE [R01CA131421, R01CA127901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD PCRP Postdoctoral Fellowship; Irma T Hirschl Career Scientist Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Work in the authors' laboratory was supported by NIH grants RO1CA127901 and RO1CA131421. HZ is a recipient of DOD PCRP Postdoctoral Fellowship (PC121837), and LZ acknowledges support from the Irma T Hirschl Career Scientist Award.	Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Aksoy O, 2012, GENE DEV, V26, P1546, DOI 10.1101/gad.196238.112; Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Astle MV, 2012, ONCOGENE, V31, P1949, DOI 10.1038/onc.2011.394; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Berkers CR, 2013, CELL METAB, V18, P617, DOI 10.1016/j.cmet.2013.06.019; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Binne UK, 2007, NAT CELL BIOL, V9, P225, DOI 10.1038/ncb1532; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Burd CE, 2013, CELL, V152, P340, DOI 10.1016/j.cell.2012.12.010; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Carvajal LA, 2012, GENE DEV, V26, P1533, DOI 10.1101/gad.184911.111; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Chen DL, 2013, MOL CELL, V51, P46, DOI 10.1016/j.molcel.2013.05.006; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheung EC, 2013, DEV CELL, V25, P463, DOI 10.1016/j.devcel.2013.05.001; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Clem BF, 2012, CLIN CANCER RES, V18, P6096, DOI 10.1158/1078-0432.CCR-11-3164; Clermont F, 2012, EMBO MOL MED, V4, P688, DOI 10.1002/emmm.201201509; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Conkrite K, 2011, GENE DEV, V25, P1734, DOI 10.1101/gad.17027411; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Emerling BM, 2013, CELL, V155, P844, DOI 10.1016/j.cell.2013.09.057; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Haley VL, 2012, EMBO MOL MED, V4, P705, DOI 10.1002/emmm.201101105; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Ianari A, 2009, CANCER CELL, V15, P184, DOI 10.1016/j.ccr.2009.01.026; Inuzuka H, 2012, CELL, V150, P179, DOI 10.1016/j.cell.2012.05.038; Jackson JG, 2013, ONCOGENE, V32, P4325, DOI 10.1038/onc.2012.610; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Jiang P, 2013, NATURE, V493, P689, DOI 10.1038/nature11776; Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Korenjak M, 2012, MOL CELL BIOL, V32, P4375, DOI 10.1128/MCB.00536-12; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Lee P, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-1; Li BH, 2010, CANCER CELL, V17, P469, DOI 10.1016/j.ccr.2010.03.019; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lin WC, 2011, P NATL ACAD SCI USA, V108, P13379, DOI 10.1073/pnas.1110104108; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Lu ZL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4463; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; McEvoy J, 2014, ONCOTARGET, V5, P438, DOI 10.18632/oncotarget.1686; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Morandell S, 2013, CELL REP, V5, P868, DOI 10.1016/j.celrep.2013.10.025; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muller PAJ, 2014, J BIOL CHEM, V289, P122, DOI 10.1074/jbc.M113.502138; Murphy BL, 2013, CANCER RES, V73, P7068, DOI 10.1158/0008-5472.CAN-13-0927; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nickeleit I, 2008, CANCER CELL, V14, P23, DOI 10.1016/j.ccr.2008.05.016; Nicolay BN, 2013, CURR OPIN CELL BIOL, V25, P735, DOI 10.1016/j.ceb.2013.07.012; Nicolay BN, 2013, GENE DEV, V27, P182, DOI 10.1101/gad.206227.112; Nittner D, 2012, NAT CELL BIOL, V14, P958, DOI 10.1038/ncb2556; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786; Ooi LC, 2013, CANCER SCI, V104, P1461, DOI 10.1111/cas.12246; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Reinhardt HC, 2009, CELL CYCLE, V8, P3112, DOI 10.4161/cc.8.19.9626; Reynolds MR, 2014, ONCOGENE, V33, P556, DOI 10.1038/onc.2012.635; Rico-Bautista E, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-153; Sangwan M, 2012, ONCOGENE, V31, P5019, DOI 10.1038/onc.2011.654; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Shats I, 2013, CANCER RES, V73, P6056, DOI 10.1158/0008-5472.CAN-13-0453; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107; Sylvestre Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200; Takahashi C, 2006, NAT GENET, V38, P118, DOI 10.1038/ng1703; Takahashi C, 2004, MOL CELL BIOL, V24, P10406, DOI 10.1128/MCB.24.23.10406-10415.2004; Talluri S, 2010, MOL CELL BIOL, V30, P948, DOI 10.1128/MCB.01168-09; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Ungermannova D, 2013, J BIOMOL SCREEN, V18, P910, DOI 10.1177/1087057113485789; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Wu L, 2012, CHEM BIOL, V19, P1515, DOI 10.1016/j.chembiol.2012.09.015; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yan HL, 2009, EMBO J, V28, P2719, DOI 10.1038/emboj.2009.214; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Young NP, 2010, P NATL ACAD SCI USA, V107, P10184, DOI 10.1073/pnas.1004796107; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733; Zhang JK, 2004, CELL CYCLE, V3, P952; Zhang TY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004357; Zhao HL, 2013, CANCER CELL, V24, P645, DOI 10.1016/j.ccr.2013.09.021; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	146	22	22	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4547	4557		10.1038/onc.2014.399	http://dx.doi.org/10.1038/onc.2014.399			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25486431	Green Accepted			2022-12-17	WOS:000360189300001
J	Deutzmann, A; Ganz, M; Schonenberger, F; Vervoorts, J; Kappes, F; Ferrando-May, E				Deutzmann, A.; Ganz, M.; Schoenenberger, F.; Vervoorts, J.; Kappes, F.; Ferrando-May, E.			The human oncoprotein and chromatin architectural factor DEK counteracts DNA replication stress	ONCOGENE			English	Article							DAMAGE RESPONSE; PROTEIN DEK; PROTOONCOGENE; PATHWAY; FORKS; POLY(ADP-RIBOSE); CHEMORESISTANCE; APOPTOSIS; RESTART; MITOSIS	DNA replication stress is a major source of DNA strand breaks and genomic instability, and a hallmark of precancerous lesions. In these hyperproliferative tissues, activation of the DNA damage response results in apoptosis or senescence preventing or delaying their development to full malignancy. In cells, in which this antitumor barrier is disabled by mutations ( for example, in p53), viability and further uncontrolled proliferation depend on factors that help to cope with replication-associated DNA damage. Replication problems preferentially arise in chromatin regions harboring complex DNA structures. DEK is a unique chromatin architectural factor which binds to non-B-form DNA structures, such as cruciform DNA or four-way junctions. It regulates DNA topology and chromatin organization, and is essential for the maintenance of heterochromatin integrity. Since its isolation as part of an oncogenic fusion in a subtype of AML, DEK has been consistently associated with tumor progression and chemoresistance. How DEK promotes cancer, however, is poorly understood. Here we show that DEK facilitates cellular proliferation under conditions of DNA replication stress by promoting replication fork progression. DEK also protects from the transmission of DNA damage to the daughter cell generation. We propose that DEK counteracts replication stress and ensures proliferative advantage by resolving problematic DNA and/or chromatin structures at the replication fork.	[Deutzmann, A.; Ganz, M.; Schoenenberger, F.; Ferrando-May, E.] Univ Konstanz, Dept Biol, Bioimaging Ctr, D-78464 Constance, Germany; [Vervoorts, J.; Kappes, F.] Rhein Westfal TH Aachen, Inst Biochem & Mol Biol, Sch Med, Aachen, Germany	University of Konstanz; RWTH Aachen University	Ferrando-May, E (corresponding author), Univ Konstanz, Dept Biol, Bioimaging Ctr, POB 604,Univ Str 10, D-78464 Constance, Germany.	elisa.may@uni-konstanz.de	Ferdinand, Kappes/H-4445-2014	Ferdinand, Kappes/0000-0002-0369-0065; Vervoorts, Jorg/0000-0002-3251-6496; Deutzmann, Anja/0000-0002-3271-1427	German Research Foundation (DFG) [SFB 969, RTG 1331]; DFG [KA 2799/1]; START program of the Faculty of Medicine, RWTH Aachen	German Research Foundation (DFG)(German Research Foundation (DFG)); DFG(German Research Foundation (DFG)); START program of the Faculty of Medicine, RWTH Aachen	We thank G Marra for U2-OS cells, Y Marquardt for NHD fibroblasts, J Schmidt for ImageJ Macro programming, D Hermann, K Weidele and F Teusel for technical assistance; S Burger and the FlowKon facility for support in flow cytometry and M Lopes, C Lukas, A Burkle and B Luscher for fruitful discussions. This work was supported by the German Research Foundation (DFG) through funds of the SFB 969, and of the RTG 1331. Work in the laboratory of FK is supported by a DFG grant (KA 2799/1) and by the START program of the Faculty of Medicine, RWTH Aachen.	Alexiadis V, 2000, GENE DEV, V14, P1308; Bartek J, 2012, NAT STRUCT MOL BIOL, V19, P5, DOI 10.1038/nsmb.2220; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bogliolo M, 2007, EMBO J, V26, P1340, DOI 10.1038/sj.emboj.7601574; Chan KL, 2009, NAT CELL BIOL, V11, P753, DOI 10.1038/ncb1882; Chaudhuri AR, 2012, NAT STRUCT MOL BIOL, V19, P417, DOI 10.1038/nsmb.2258; Cheung TH, 2012, NATURE, V482, P524, DOI 10.1038/nature10834; de Feraudy S, 2010, P NATL ACAD SCI USA, V107, P6870, DOI 10.1073/pnas.1002175107; Debatisse M, 2012, TRENDS GENET, V28, P22, DOI 10.1016/j.tig.2011.10.003; Fahrer J, 2010, BIOCHEMISTRY-US, V49, P7119, DOI 10.1021/bi1004365; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harrigan JA, 2011, J CELL BIOL, V193, P97, DOI 10.1083/jcb.201011083; Hashimoto Y, 2010, NAT STRUCT MOL BIOL, V17, P1305, DOI 10.1038/nsmb.1927; Kappes F, 2008, MOL CELL BIOL, V28, P3245, DOI 10.1128/MCB.01921-07; Kappes F, 2011, GENE DEV, V25, P673, DOI 10.1101/gad.2036411; Kappes F, 2011, HUM PATHOL, V42, P932, DOI 10.1016/j.humpath.2010.10.022; Kavanaugh GM, 2011, NUCLEIC ACIDS RES, V39, P7465, DOI 10.1093/nar/gkr454; Khodadoust MS, 2009, CANCER RES, V69, P6405, DOI 10.1158/0008-5472.CAN-09-1063; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Mor-Vaknin N, 2006, MOL CELL BIOL, V26, P9484, DOI 10.1128/MCB.01030-06; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Naim V, 2009, NAT CELL BIOL, V11, P761, DOI 10.1038/ncb1883; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Renaud E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053693; Riveiro-Falkenbach E, 2010, CLIN CANCER RES, V16, P2932, DOI 10.1158/1078-0432.CCR-09-2330; Saha AK, 2013, P NATL ACAD SCI USA, V110, P6847, DOI 10.1073/pnas.1220751110; Schlacher K, 2012, CANCER CELL, V22, P106, DOI 10.1016/j.ccr.2012.05.015; Sirbu BM, 2013, J BIOL CHEM, V288, P31458, DOI 10.1074/jbc.M113.511337; Trenz K, 2006, EMBO J, V25, P1764, DOI 10.1038/sj.emboj.7601045; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Waldmann T, 2003, NUCLEIC ACIDS RES, V31, P7003, DOI 10.1093/nar/gkg864; Waldmann T, 2002, J BIOL CHEM, V277, P24988, DOI 10.1074/jbc.M204045200; Wang LC, 2008, DNA REPAIR, V7, P1973, DOI 10.1016/j.dnarep.2008.08.005; Wilhelm T, 2014, P NATL ACAD SCI USA, V111, P763, DOI 10.1073/pnas.1311520111; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Wise-Draper TM, 2009, CANCER RES, V69, P1792, DOI 10.1158/0008-5472.CAN-08-2304; Wise-Draper TM, 2009, AM J PATHOL, V174, P71, DOI 10.2353/ajpath.2009.080330	39	22	22	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4270	4277		10.1038/onc.2014.346	http://dx.doi.org/10.1038/onc.2014.346			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25347734	Green Submitted			2022-12-17	WOS:000359199800013
J	Huhn, D; Kousholt, AN; Sorensen, CS; Sartori, AA				Huehn, D.; Kousholt, A. N.; Sorensen, C. S.; Sartori, A. A.			miR-19, a component of the oncogenic miR-17 similar to 92 cluster, targets the DNA-end resection factor CtIP	ONCOGENE			English	Article							DAMAGE RESPONSE; MICRORNAS; IDENTIFICATION; MODULATION; REPAIR; ROLES; SITES	MicroRNA-19 (miR-19) was recently identified as the key oncogenic component of the polycistronic miR-17 +/- 92 cluster, also known as oncomiR-1, which is frequently upregulated or amplified in multiple tumor types. However, the gene targets and the pathways underlying the tumor-promoting activity of miR-19 still remain largely elusive. CtIP/RBBP8 promotes DNA-end resection, a critical step in the repair of DNA double-strand breaks (DSBs) by homologous recombination (HR), and is considered to function as a tumor suppressor. In this study, we show that miR-19 downregulates CtIP expression by binding to two highly conserved sequences located in the 3'-untranslated region of CtIP mRNA. We further demonstrate that CtIP expression is repressed by miR-19 during continuous genotoxic stress in a p53-dependent manner. Finally, we report that miR-19 impairs CtIP-mediated DNA-end resection, which results in reduced HR levels and DNA damage hypersensitivity. By downregulating CtIP, miR-19 overexpression suppresses the faithful repair of DSBs that is crucial for genome maintenance. Our findings thus provide new mechanistic insight into the oncogenic role of the miR-17 similar to 92 cluster.	[Huehn, D.; Sartori, A. A.] Univ Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland; [Kousholt, A. N.; Sorensen, C. S.] Univ Copenhagen, BRIC, Copenhagen N, Denmark	University of Zurich; University of Copenhagen	Sartori, AA (corresponding author), Univ Zurich, Inst Mol Canc Res, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	sartori@imcr.uzh.ch	Sartori, Alessandro/AAK-7840-2021	Sartori, Alessandro/0000-0003-2770-0333; Kousholt, Arne Nedergaard/0000-0002-3972-1740; Sorensen, Claus/0000-0001-6022-9710	Zurich Cancer League; Sophien-Stiftung zur Forderung der klinischen Krebsforschung; Swiss Cancer League; Vontobel-Stiftung	Zurich Cancer League; Sophien-Stiftung zur Forderung der klinischen Krebsforschung; Swiss Cancer League; Vontobel-Stiftung	We are very grateful to M Menigatti, A Mueller and J Stark for providing reagents and cell lines. We wish to thank A Porro and J Jiricny for critical reading of the manuscript. This work was financially supported in part by grants of the Zurich Cancer League and the Sophien-Stiftung zur Forderung der klinischen Krebsforschung (to AAS). DH is supported by the Swiss Cancer League and AAS by the Vontobel-Stiftung.	Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; Bunting SF, 2013, NAT REV CANCER, V13, P443, DOI 10.1038/nrc3537; Castellano L, 2009, P NATL ACAD SCI USA, V106, P15732, DOI 10.1073/pnas.0906947106; Chen PL, 2005, MOL CELL BIOL, V25, P3535, DOI 10.1128/MCB.25.9.3535-3542.2005; Chowdhury D, 2013, NAT REV MOL CELL BIO, V14, P181, DOI 10.1038/nrm3523; Dimitrov SD, 2013, GENE DEV, V27, P2274, DOI 10.1101/gad.225045.113; Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005; Farazi TA, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-1-r9; Ferretti Lorenza P., 2013, Frontiers in Genetics, V4, P99, DOI 10.3389/fgene.2013.00099; Gravel S, 2008, GENE DEV, V22, P2767, DOI 10.1101/gad.503108; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Gunn Amanda, 2012, Methods Mol Biol, V920, P379, DOI 10.1007/978-1-61779-998-3_27; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jasin M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012740; Jin HY, 2013, EMBO J, V32, P2377, DOI 10.1038/emboj.2013.178; Kakarougkas A, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130685; Kousholt AN, 2012, J CELL BIOL, V197, P869, DOI 10.1083/jcb.201111065; Landthaler M, 2008, RNA, V14, P2580, DOI 10.1261/rna.1351608; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Martin NT, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003505; Mavrakis KJ, 2010, NAT CELL BIOL, V12, P372, DOI 10.1038/ncb2037; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Olive V, 2013, IMMUNOL REV, V253, P158, DOI 10.1111/imr.12054; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Saetrom P, 2007, NUCLEIC ACIDS RES, V35, P2333, DOI 10.1093/nar/gkm133; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Steger M, 2013, MOL CELL, V50, P333, DOI 10.1016/j.molcel.2013.03.023; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Wan GH, 2013, CELL REP, V3, P2100, DOI 10.1016/j.celrep.2013.05.038; Wang HL, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003277; Wang YM, 2013, CELL CYCLE, V12, P32, DOI 10.4161/cc.23051; Wu Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.110; You ZS, 2010, TRENDS CELL BIOL, V20, P402, DOI 10.1016/j.tcb.2010.04.002	44	22	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3977	3984		10.1038/onc.2014.329	http://dx.doi.org/10.1038/onc.2014.329			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25308476				2022-12-17	WOS:000358544200010
J	Loskutov, YV; Kozyulina, PY; Kozyreva, VK; Ice, RJ; Jones, BC; Roston, TJ; Smolkin, MB; Ivanov, AV; Wysolmerski, RB; Pugacheva, EN				Loskutov, Y. V.; Kozyulina, P. Y.; Kozyreva, V. K.; Ice, R. J.; Jones, B. C.; Roston, T. J.; Smolkin, M. B.; Ivanov, A. V.; Wysolmerski, R. B.; Pugacheva, E. N.			NEDD9/Arf6-dependent endocytic trafficking of matrix metalloproteinase 14: a novel mechanism for blocking mesenchymal cell invasion and metastasis of breast cancer	ONCOGENE			English	Article							NUCLEOTIDE EXCHANGE FACTORS; GROWTH-FACTOR; MEMBRANE TRAFFICKING; ARF6 GTPASE; WILD-TYPE; MT1-MMP; ACTIVATION; PROTEIN; NEDD9; MIGRATION	NEDD9 is an established marker of invasive and metastatic cancers. NEDD9 downregulation has been shown to dramatically reduce cell invasion and metastasis in multiple tumors. The mechanisms by which NEDD9 regulates invasion are largely unknown. In the current study, we have found that NEDD9 is required for matrix metalloproteinase 14 (MMP14) enzymatic recovery/recycling through the late endosomes to enable disengagement of tissue inhibitor of matrix metalloproteinase 2 (TIMP2) and tumor invasion. Depletion of NEDD9 decreases targeting of the MMP14/TIMP2 complex to late endosomes and increases trafficking of MMP14 from early/sorting endosomes back to the surface in a small GTPase ADP ribosylation factor-6 (Arf6)-dependent manner. NEDD9 directly binds to Arf6-GTPase-activating protein, ARAP3 and Arf6-effector GGA3, thereby facilitating the Arf6 inactivation required for MMP14/TIMP2 targeting to late endosomes. Re-expression of NEDD9 or a decrease in Arf6 activity is sufficient to restore MMP14 activity and the invasive properties of tumor cells. Importantly, NEDD9 inhibition by Vivo-Morpholinos, an antisense therapy, decreases primary tumor growth and metastasis in xenograft models of breast cancer. Collectively, our findings uncover a novel mechanism to control tumor-cell dissemination through NEDD9/Arf6-dependent regulation of MMP14/TIMP2 trafficking, and validate NEDD9 as a clinically relevant therapeutic target to treat metastatic cancer.	[Loskutov, Y. V.; Kozyreva, V. K.; Ice, R. J.; Ivanov, A. V.; Wysolmerski, R. B.; Pugacheva, E. N.] W Virginia Univ, Sch Med, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; [Kozyulina, P. Y.; Jones, B. C.; Roston, T. J.; Ivanov, A. V.; Pugacheva, E. N.] W Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA; [Smolkin, M. B.] W Virginia Univ, Sch Med, Dept Pathol, Morgantown, WV 26506 USA; [Wysolmerski, R. B.] W Virginia Univ, Sch Med, Dept Neurobiol & Anat, Morgantown, WV 26506 USA	West Virginia University; West Virginia University; West Virginia University; West Virginia University	Pugacheva, EN (corresponding author), Robert C Byrd Hlth Sci Ctr, MBRCC Rm 2823,1 Med Ctr Dr, Morgantown, WV 26506 USA.	epugacheva@hsc.wvu.edu	Jones, Brandon/AAB-6130-2019; Kozyulina, Polina/AAO-2762-2020	Jones, Brandon/0000-0002-3743-2590; Kozyulina, Polina/0000-0001-8520-3445; Ivanov, Alexey/0000-0002-8617-4604; Loskutov, Juergen/0000-0003-3472-4093; Kozyreva, Varvara/0000-0003-3447-0070	Mary Babb Randolph Cancer Center; NIH [P20 RR016440, P30 RR032138/GM103488, P20 RR016477, P30 GM103488, P30 RR032138, RCP1101809]; NIH-NCI [CA148671]; Susan G Komen For the Cure Foundation [KG100539]; NIH/NCRR [5 P20 RR016440-09]; NATIONAL CANCER INSTITUTE [R21CA208875, R01CA148671] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P30RR032138, P20RR016440, P20RR016477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103488] Funding Source: NIH RePORTER	Mary Babb Randolph Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen For the Cure Foundation(Susan G. Komen Breast Cancer Foundation); NIH/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Mrs Yoho and Drs Schaller and Weed for critically reading the manuscript and providing administrative support during manuscript preparation. We also thank the West Virginia University Microscope Imaging Facility, supported by the Mary Babb Randolph Cancer Center and NIH grants P20 RR016440, P30 RR032138/GM103488 and P20 RR016477. The WVU Flow Cytometry Core Facility was supported by NIH grants P30 GM103488, P30 RR032138 and RCP1101809. We also thank Mr Farrugia for his assistance in the analysis of the microarray data. This work was supported by grants from the NIH-NCI (CA148671 to ENP), the Susan G Komen For the Cure Foundation (KG100539 to ENP) and in part by NIH/NCRR (5 P20 RR016440-09).	Ahn J, 2012, J CELL SCI, V125, P1814, DOI 10.1242/jcs.101444; Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Anders N, 2008, CELL MOL LIFE SCI, V65, P3433, DOI 10.1007/s00018-008-8227-7; Anilkumar N, 2005, FASEB J, V19, P1326, DOI 10.1096/fj.04-3651fje; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Bravo-Cordero JJ, 2007, EMBO J, V26, P1499, DOI 10.1038/sj.emboj.7601606; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Cai DP, 2003, J IMMUNOL, V170, P969, DOI 10.4049/jimmunol.170.2.969; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Fang ZY, 2006, MOL CELL PROTEOMICS, V5, P1437, DOI 10.1074/mcp.M600050-MCP200; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Giampieri S, 2010, CANCER RES, V70, P3435, DOI 10.1158/0008-5472.CAN-10-0466; Gu JJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002632; Hafner M, 2006, NATURE, V444, P941, DOI 10.1038/nature05415; Hakulinen J, 2008, J CELL BIOCHEM, V105, P1211, DOI 10.1002/jcb.21923; Hattula K, 2006, J CELL SCI, V119, P4866, DOI 10.1242/jcs.03275; Hemmann S, 2007, J HEPATOL, V46, P955, DOI 10.1016/j.jhep.2007.02.003; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Ice RJ, 2013, CANCER RES, V73, P3168, DOI 10.1158/0008-5472.CAN-12-4008; Jin YJ, 2014, INT J CANCER, V134, P2294, DOI 10.1002/ijc.28568; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kondo S, 2012, CLIN CANCER RES, V18, P6326, DOI 10.1158/1078-0432.CCR-11-2162; Little JL, 2014, ONCOGENE, V33, P411, DOI 10.1038/onc.2012.607; Lucas JT, 2010, ONCOGENE, V29, P4449, DOI 10.1038/onc.2010.185; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; McLaughlin SL, 2014, MOL CANCER RES, V12, P69, DOI 10.1158/1541-7786.MCR-13-0300; NETZELARNETT S, 1991, ANAL BIOCHEM, V195, P86, DOI 10.1016/0003-2697(91)90299-9; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; Oblander SA, 2005, DEV BIOL, V277, P255, DOI 10.1016/j.ydbio.2004.09.033; Pahwa S, 2014, CANCERS, V6, P416, DOI 10.3390/cancers6010416; Paleotti O, 2005, J BIOL CHEM, V280, P21661, DOI 10.1074/jbc.m503099200; Parachoniak CA, 2011, DEV CELL, V20, P751, DOI 10.1016/j.devcel.2011.05.007; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Polette M, 2004, CRIT REV ONCOL HEMAT, V49, P179, DOI 10.1016/j.critrevonc.2003.10.008; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1999, J CELL SCI, V112, P855; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Remacle AG, 2006, ONCOGENE, V25, P5648, DOI 10.1038/sj.onc.1209572; Sabe H, 2009, TRAFFIC, V10, P982, DOI 10.1111/j.1600-0854.2009.00917.x; Sakagami H, 2008, TOHOKU J EXP MED, V214, P191, DOI 10.1620/tjem.214.191; Santy LC, 2005, CURR BIOL, V15, P1749, DOI 10.1016/j.cub.2005.08.052; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; Schweitzer JK, 2011, SEMIN CELL DEV BIOL, V22, P39, DOI 10.1016/j.semcdb.2010.09.002; Shteyn E, 2011, J CELL BIOL, V194, P873, DOI 10.1083/jcb.201106010; Spang A, 2010, FEBS LETT, V584, P2646, DOI 10.1016/j.febslet.2010.04.005; Speranza MC, 2012, ONCOTARGET, V3, P724; Strongin AY, 2010, BBA-MOL CELL RES, V1803, P133, DOI 10.1016/j.bbamcr.2009.04.009; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Vonderheit A, 2005, PLOS BIOL, V3, P1225, DOI 10.1371/journal.pbio.0030233; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Williams KC, 2011, J BIOL CHEM, V286, P43405, DOI 10.1074/jbc.M111.297069; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yu XZ, 2012, J CELL BIOL, V199, P527, DOI 10.1083/jcb.201203025; Zhong J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035058; Zucker S, 2004, EXP CELL RES, V293, P164, DOI 10.1016/j.yexcr.2003.10.007	61	22	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3662	3675		10.1038/onc.2014.297	http://dx.doi.org/10.1038/onc.2014.297			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241893	Green Accepted			2022-12-17	WOS:000357679100005
J	Merino, D; Best, SA; Asselin-Labat, ML; Vaillant, F; Pal, B; Dickins, RA; Anderson, RL; Strasser, A; Bouillet, P; Lindeman, GJ; Visvader, JE				Merino, D.; Best, S. A.; Asselin-Labat, M-L; Vaillant, F.; Pal, B.; Dickins, R. A.; Anderson, R. L.; Strasser, A.; Bouillet, P.; Lindeman, G. J.; Visvader, J. E.			Pro-apoptotic Bim suppresses breast tumor cell metastasis and is a target gene of SNAI2	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; CANCER CELLS; SURVIVAL SIGNALS; BCL-2 PROTEIN; ANOIKIS; EXPRESSION; RESISTANCE; INDUCTION; DISEASE; PUMA	Evasion of cell death is fundamental to the development of cancer and its metastasis. The role of the BCL-2-mediated (intrinsic) apoptotic program in these processes remains poorly understood. Here we have investigated the relevance of the pro-apoptotic protein BIM to breast cancer progression using the MMTV-Polyoma middle-T (PyMT) transgenic model. BIM deficiency in PyMT females did not affect primary tumor growth, but substantially increased the survival of metastatic cells within the lung. These data reveal a role for BIM in the suppression of breast cancer metastasis. Intriguingly, we observed a striking correlation between the expression of BIM and the epithelial to mesenchymal transition transcription factor SNAI2 at the proliferative edge of the tumors. Overexpression and knockdown studies confirmed that these two genes were coordinately expressed, and chromatin immunoprecipitation analysis further revealed that Bim is a target of SNAI2. Taken together, our findings suggest that SNAI2-driven BIM-induced apoptosis may temper metastasis by governing the survival of disseminating breast tumor cells.	[Merino, D.; Best, S. A.; Asselin-Labat, M-L; Vaillant, F.; Pal, B.; Dickins, R. A.; Strasser, A.; Bouillet, P.; Lindeman, G. J.; Visvader, J. E.] Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3052, Australia; [Merino, D.; Best, S. A.; Asselin-Labat, M-L; Vaillant, F.; Pal, B.; Dickins, R. A.; Strasser, A.; Bouillet, P.; Visvader, J. E.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia; [Anderson, R. L.] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia; [Lindeman, G. J.] Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3050, Australia; [Lindeman, G. J.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia	Walter & Eliza Hall Institute; University of Melbourne; Peter Maccallum Cancer Center; Royal Melbourne Hospital; University of Melbourne	Lindeman, GJ (corresponding author), Walter & Eliza Hall Inst Med Res, Stem Cells & Canc Div, 1G Royal Parade, Parkville, Vic 3052, Australia.	lindeman@wehi.edu.au; visvader@wehi.edu.au	Strasser, Andreas/C-7581-2013; Dickins, Ross A/K-2852-2012; Bouillet, Philippe/E-1241-2013; Merino, Delphine/L-9159-2017; Pal, Bhupinder/AAF-4011-2020; Anderson, Robin/K-6966-2019; Anderson, Robin/S-1005-2017	Strasser, Andreas/0000-0002-5020-4891; Dickins, Ross A/0000-0003-4112-5304; Bouillet, Philippe/0000-0002-9012-6058; Merino, Delphine/0000-0002-8075-6275; Best, Sarah/0000-0002-4232-9432; Lindeman, Geoffrey/0000-0001-9386-2416; Pal, Bhupinder/0000-0002-3684-4331; Anderson, Robin/0000-0002-6841-7422	National Health and Medical Research Council, Australia (NHMRC) [461221, 1016701]; NHMRC IRIISS; Victorian State Government through Victorian Cancer Agency funding of the Victorian Breast Cancer Research Consortium and Operational Infrastructure Support; Australian Cancer Research Foundation; National Breast Cancer Foundation; NBCF Early Career Fellowship; senior NBCF Fellowship; NHMRC Postgraduate Scholarship [1017256]; NHMRC Australia Fellowship [637307]; National Breast Cancer Foundation [ECF-13-06] Funding Source: researchfish	National Health and Medical Research Council, Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC IRIISS(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government through Victorian Cancer Agency funding of the Victorian Breast Cancer Research Consortium and Operational Infrastructure Support; Australian Cancer Research Foundation; National Breast Cancer Foundation; NBCF Early Career Fellowship; senior NBCF Fellowship; NHMRC Postgraduate Scholarship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Australia Fellowship(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation	We are grateful to K Rogers, L Whitehead, C Nowell for help with imaging, K Birchall, L Reid and G Siciliano for animal husbandry; B Helbert and C Young for mouse genotyping; K Breslin, M Robati and K Liu for technical assistance. We thank D Metcalf and JM Adams for useful discussion and advice, LA O'Reilly for antibodies and D Huang for knockout MEF cell lines. This work was supported by the National Health and Medical Research Council, Australia (NHMRC, 461221 and 1016701); NHMRC IRIISS; the Victorian State Government through Victorian Cancer Agency funding of the Victorian Breast Cancer Research Consortium and Operational Infrastructure Support; the Australian Cancer Research Foundation; and The National Breast Cancer Foundation. DM was supported by a NBCF Early Career Fellowship, RLA by a senior NBCF Fellowship, and SAB by a NHMRC Postgraduate Scholarship #1017256. JEV and GJL were supported by an NHMRC Australia Fellowship and Research Fellowship (637307), respectively.	Boisvert-Adamo K, 2009, MOL CANCER RES, V7, P549, DOI 10.1158/1541-7786.MCR-08-0358; Bouillet P, 2005, CELL DEATH DIFFER, V12, P831, DOI 10.1038/sj.cdd.4401603; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Buckle T, 2010, LAB ANIM-UK, V44, P40, DOI 10.1258/la.2009.009030; Chambers AF, 2000, BREAST CANCER RES, V2, P400, DOI 10.1186/bcr86; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963; Clybouw C, 2012, CELL DEATH DIFFER, V19, P1060, DOI 10.1038/cdd.2011.198; Dai DL, 2008, J INVEST DERMATOL, V128, P403, DOI 10.1038/sj.jid.5700989; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Fernandez Y, 2000, CELL DEATH DIFFER, V7, P350, DOI 10.1038/sj.cdd.4400662; Fukazawa H, 2004, MOL CANCER THER, V3, P1281; GASPARINI G, 1995, CLIN CANCER RES, V1, P189; Gogada R, 2013, J BIOL CHEM, V288, P368, DOI 10.1074/jbc.M112.386102; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Kim S, 2014, CANCER RES, V74, P3695, DOI 10.1158/0008-5472.CAN-13-2591; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; Li ZG, 2008, P NATL ACAD SCI USA, V105, P162, DOI 10.1073/pnas.0710905105; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Maamer-Azzabi A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.328; Martin SS, 2004, ONCOGENE, V23, P4641, DOI 10.1038/sj.onc.1207595; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Oakes SR, 2012, P NATL ACAD SCI USA, V109, P2766, DOI 10.1073/pnas.1104778108; Pinon JD, 2008, ONCOGENE, V27, pS41, DOI 10.1038/onc.2009.42; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Sheridan C, 2008, J BIOL CHEM, V283, P22128, DOI 10.1074/jbc.M800271200; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Townson JL, 2003, CURR MOL MED, V3, P631, DOI 10.2174/1566524033479483; Uehara N, 2008, MOL CANCER RES, V6, P186, DOI 10.1158/1541-7786.MCR-07-0254; Valastyan S, 2011, GENE DEV, V25, P646, DOI 10.1101/gad.2004211; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Voss AK, 2012, METHODS MOL BIOL, V809, P335, DOI 10.1007/978-1-61779-376-9_23; Wong CW, 2001, CANCER RES, V61, P333; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	55	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3926	3934		10.1038/onc.2014.313	http://dx.doi.org/10.1038/onc.2014.313			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25263453				2022-12-17	WOS:000358544200005
J	Ferguson, B; Ram, R; Handoko, HY; Mukhopadhyay, P; Muller, HK; Soyer, HP; Morahan, G; Walker, GJ				Ferguson, B.; Ram, R.; Handoko, H. Y.; Mukhopadhyay, P.; Muller, H. K.; Soyer, H. P.; Morahan, G.; Walker, G. J.			Melanoma susceptibility as a complex trait: genetic variation controls all stages of tumor progression	ONCOGENE			English	Article							CUTANEOUS MELANOMA; MELANOCYTIC LESIONS; MALIGNANT-MELANOMA; ATYPICAL NEVI; MUTATIONS; MICE; CLASSIFICATION; IDENTIFICATION; EXPRESSION; PATHWAYS	Susceptibility to most common cancers is likely to involve interaction between multiple low risk genetic variants. Although there has been great progress in identifying such variants, their effect on phenotype and the mechanisms by which they contribute to disease remain largely unknown. We have developed a mouse melanoma model harboring two mutant oncogenes implicated in human melanoma, CDK4(R24C) and NRAS(Q61K). In these mice, tumors arise from benign precursor lesions that are a recognized strong risk factor for this neoplasm in humans. To define molecular events involved in the pathway to melanoma, we have for the first time applied the Collaborative Cross (CC) to cancer research. The CC is a powerful resource designed to expedite discovery of genes for complex traits. We characterized melanoma genesis in more than 50 CC strains and observed tremendous variation in all traits, including nevus and melanoma age of onset and multiplicity, anatomical site predilection, time for conversion of nevi to melanoma and metastases. Intriguingly, neonatal ultraviolet radiation exposure exacerbated nevus and melanoma formation in most, but not all CC strain backgrounds, suggesting that genetic variation within the CC will help explain individual sensitivity to sun exposure, the major environmental skin carcinogen. As genetic variation brings about dramatic phenotypic diversity in a single mouse model, melanoma-related endophenotype comparisons provide us with information about mechanisms of carcinogenesis, such as whether melanoma incidence is dependent upon the density of pre-existing nevus cells. Mouse models have been used to examine the functional role of gene mutations in tumorigenesis. This work represents their next phase of development to study how biological variation greatly influences lesion onset and aggressiveness even in the setting of known somatic driver mutations.	[Ferguson, B.; Handoko, H. Y.; Mukhopadhyay, P.; Walker, G. J.] Queensland Inst Med Res, Herston, Qld 4006, Australia; [Ram, R.; Morahan, G.] Harry Perkins Inst Med Res, Ctr Diabet Res, Perth, WA, Australia; [Muller, H. K.] Univ Tasmania, Sch Med, Hobart, Tas, Australia; [Soyer, H. P.] Univ Queensland, Clin Res Ctr, Herston, Qld, Australia	QIMR Berghofer Medical Research Institute; Harry Perkins Institute of Medical Research; University of Tasmania; University of Queensland	Walker, GJ (corresponding author), Queensland Inst Med Res, 300 Herston Rd, Herston, Qld 4006, Australia.	Graeme.Walker@qimr.edu.au	Morahan, Grant/T-7501-2019; Soyer, H. Peter/W-3791-2017; Mukhopadhyay, Pamela/I-6373-2015; Ferguson, Blake/J-4158-2016; Soyer, H. Peter/E-6000-2010	Soyer, H. Peter/0000-0002-4770-561X; Mukhopadhyay, Pamela/0000-0002-5905-1350; Soyer, H. Peter/0000-0002-4770-561X; Ferguson, Blake/0000-0002-5643-6976	Melanoma Research Alliance, Washington DC, USA; Scott Kirkbride Melanoma Research Centre, Perth, Western Australia; Diabetes Research Foundation of Western Australia; Australian Research Council Project [DP11010206]; National Health and Medical Research Council of Australia [1037321]; Ride To Cure Cancer, Western Australia	Melanoma Research Alliance, Washington DC, USA; Scott Kirkbride Melanoma Research Centre, Perth, Western Australia; Diabetes Research Foundation of Western Australia; Australian Research Council Project(Australian Research Council); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Ride To Cure Cancer, Western Australia	This work was supported by a pilot study grant from the Melanoma Research Alliance, Washington DC, USA and a Discovery Research Priming Grant from the Scott Kirkbride Melanoma Research Centre, Perth, Western Australia. GM is supported by the Diabetes Research Foundation of Western Australia, by Australian Research Council Project DP11010206 and by Program Grant 1037321 from the National Health and Medical Research Council of Australia. RR is supported by RTCC funding from the Ride To Cure Cancer, Western Australia. We thank Geniad Pty Ltd for providing mice from the Collaborative Cross strains.	Abel EL, 2010, JNCI-J NATL CANCER I, V102, P1663, DOI 10.1093/jnci/djq392; Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Aoki H, 2011, PIGM CELL MELANOMA R, V24, P125, DOI 10.1111/j.1755-148X.2010.00801.x; Bradish JR, 2013, FUTURE ONCOL, V9, P245, DOI [10.2217/fon.12.179, 10.2217/FON.12.179]; Campagne C, 2013, PIGM CELL MELANOMA R, V26, P735, DOI 10.1111/pcmr.12115; Chai E, 2013, PIGM CELL MELANOMA R, V27, P317; Churchill G, 2004, NAT GENET, V36, P1133, DOI 10.1038/ng1104-1133; Crawford NPS, 2008, CLIN EXP METASTAS, V25, P357, DOI 10.1007/s10585-008-9146-6; de Snoo FA, 2008, EUR J HUM GENET, V16, P1135, DOI 10.1038/ejhg.2008.72; Falchi M, 2009, NAT GENET, V41, P915, DOI 10.1038/ng.410; Faraji F, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002926; Ferguson B, 2010, PIGM CELL MELANOMA R, V23, P771, DOI 10.1111/j.1755-148X.2010.00752.x; Gandini S, 2005, EUR J CANCER, V41, P45, DOI 10.1016/j.ejca.2004.10.016; Gandini S, 2005, EUR J CANC, V41, P28; Goldstein AM, 2002, MELANOMA RES, V12, P51, DOI 10.1097/00008390-200202000-00008; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Landsberg J, 2010, PIGM CELL MELANOMA R, V23, P649, DOI 10.1111/j.1755-148X.2010.00744.x; Law MH, 2012, J INVEST DERMATOL, V132, P1763, DOI 10.1038/jid.2012.75; Lee JH, 2011, BRIT J DERMATOL, V164, P776, DOI 10.1111/j.1365-2133.2010.10185.x; LeFur N, 1996, GENOMICS, V37, P245; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; LYNCH HT, 1980, BRIT J CANCER, V42, P58, DOI 10.1038/bjc.1980.203; Molven A, 2005, GENE CHROMOSOME CANC, V44, P10, DOI 10.1002/gcc.20202; Morahan G, 2008, MAMM GENOME, V19, P390, DOI 10.1007/s00335-008-9134-9; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Puig S, 1997, HUM GENET, V101, P359, DOI 10.1007/s004390050642; Quigley D, 2009, NAT REV GENET, V10, P651, DOI 10.1038/nrg2617; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Rigel DS, 2008, J AM ACAD DERMATOL, V58, pS129, DOI 10.1016/j.jaad.2007.04.034; Threadgill DW, 2012, G3-GENES GENOM GENET, V2, P153, DOI 10.1534/g3.111.001891; Viros A, 2008, PLOS MED, V5, P941, DOI 10.1371/journal.pmed.0050120; Walker G, 2008, FUTURE ONCOL, V4, P841, DOI 10.2217/14796694.4.6.841; Walker GJ, 2011, PIGM CELL MELANOMA R, V24, P1158, DOI 10.1111/j.1755-148X.2011.00923.x; Welsh CE, 2012, MAMM GENOME, V23, P706, DOI 10.1007/s00335-012-9410-6; Whiteman DC, 2003, J NATL CANCER I, V95, P806, DOI 10.1093/jnci/95.11.806; Winter SF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002735; Wurm EMT, 2012, EXP DERMATOL, V21, P676, DOI 10.1111/j.1600-0625.2012.01543.x	38	22	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2879	2886		10.1038/onc.2014.227	http://dx.doi.org/10.1038/onc.2014.227			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25088201				2022-12-17	WOS:000355324300007
J	Zhu, M; Yin, F; Fan, X; Jing, W; Chen, R; Liu, L; Zhang, L; Liu, Y; Liang, Y; Bu, F; Tong, X; Zheng, H; Zhao, J; Guo, Y				Zhu, M.; Yin, F.; Fan, X.; Jing, W.; Chen, R.; Liu, L.; Zhang, L.; Liu, Y.; Liang, Y.; Bu, F.; Tong, X.; Zheng, H.; Zhao, J.; Guo, Y.			Decreased TIP30 promotes Snail-mediated epithelial-mesenchymal transition and tumor-initiating properties in hepatocellular carcinoma	ONCOGENE			English	Article							DEPENDENT UP-REGULATION; E-CADHERIN EXPRESSION; NF-KAPPA-B; POOR-PROGNOSIS; NUCLEAR IMPORT; CANCER CELLS; STEM-CELLS; TGF-BETA; METASTASIS; TRANSCRIPTION	The poor prognosis of hepatocellular carcinoma (HCC) is mainly due to tumor recurrence and metastases. Recently, epithelial-mesenchymal transition (EMT) has been implicated in tumor invasion and metastasis. However, the underlying molecular mechanisms are yet to be elucidated. Here, we show that 30-kDa Tat-interacting protein (TIP30), also called CC3, is significantly downregulated during transforming growth factor-beta-induced EMT. In our in vitro and in vivo studies, we show that decreased TIP30 expression leads to EMT, as well as enhanced motility and invasion of HCC cells. Also, increased self-renewal ability and chemotherapeutic resistance are observed with TIP30 depletion. Moreover, Snail is one of the key transcription factors promoting EMT, and overexpression of TIP30 greatly decreased nucleic accumulation in Snail through the regulation of intracellular localization. Small interfering RNAs targeting Snail attenuated EMT and tumor-initiating properties induced by TIP30 deficiency. We further confirmed that TIP30 competitively interrupted the interaction of Snail with importin-beta 2 to block the nuclear import of Snail. Consistently, TIP30 expression significantly correlates with E-cadherin expression in HCC patients. TIP30 or combination of E-cadherin is a powerful marker in predicting the prognosis of HCC. Taken together, our results suggest a novel and critical role of TIP30 involved in HCC progression and aggressiveness.	[Zhu, M.; Yin, F.; Fan, X.; Chen, R.; Zhang, L.; Liu, Y.; Liang, Y.; Bu, F.; Tong, X.; Zhao, J.; Guo, Y.] Second Mil Med Univ, Int Joint Canc Res Inst, Shanghai 200433, Peoples R China; [Zhu, M.; Jing, W.; Liu, L.; Zheng, H.] Second Mil Med Univ, Changhai Hosp, Shanghai 200433, Peoples R China; [Yin, F.; Zhao, J.; Guo, Y.] Peoples Liberat Army Gen Hosp, Ctr Canc, PLA Postgrad Sch Med, Beijing, Peoples R China	Naval Medical University; Naval Medical University; Chinese People's Liberation Army General Hospital	Zheng, H (corresponding author), Second Mil Med Univ, Changhai Hosp, 800 Xiangyin Rd, Shanghai 200433, Peoples R China.	zheng_hl2004@163.com; zhaojian@smmu.edu.cn			Ministry of Science and Technology of China [2010CB945600, 2010CB833600, 2011CB966200]; National Nature Science Foundation of China; State Key Project for Infection Disease and New Drug Development and Programs of Shanghai Subject Chief Scientists; Municipal Commission of Education; Municipal Commission of Science and Technology	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Project for Infection Disease and New Drug Development and Programs of Shanghai Subject Chief Scientists; Municipal Commission of Education; Municipal Commission of Science and Technology	This work is supported in part by grants from Ministry of Science and Technology of China '973' and '863' programs (2010CB945600, 2010CB833600, 2011CB966200), National Nature Science Foundation of China, State Key Project for Infection Disease and New Drug Development and Programs of Shanghai Subject Chief Scientists, Municipal Commission of Education and Municipal Commission of Science and Technology.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Banerjee SK, 2012, J CELL COMMUN SIGNAL, V6, P63, DOI 10.1007/s12079-012-0158-2; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen XB, 2010, DIGEST DIS SCI, V55, P2219, DOI 10.1007/s10620-009-0992-0; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Coleman WB, 2003, CURR MOL MED, V3, P573, DOI 10.2174/1566524033479546; Dang HE, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-396; Fujiki K, 2013, ARCH TOXICOL, V87, P2119, DOI 10.1007/s00204-013-1077-6; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559; He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hwang WL, 2011, GASTROENTEROLOGY, V141, P279, DOI 10.1053/j.gastro.2011.04.008; Ito M, 2003, CANCER RES, V63, P8763; Jiang C, 2007, CANCER RES, V67, P3574, DOI 10.1158/0008-5472.CAN-06-0831; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim MS, 2013, MOL CELLS, V36, P177, DOI 10.1007/s10059-013-0061-6; King FW, 2004, MOL CELL BIOL, V24, P7091, DOI 10.1128/MCB.24.16.7091-7101.2004; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Li A, 2013, ONCOGENE, V32, P2273, DOI 10.1038/onc.2012.253; Lu B, 2008, CLIN CANCER RES, V14, P7405, DOI 10.1158/1078-0432.CCR-08-0409; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nakahara J, 2009, J CLIN INVEST, V119, P169, DOI 10.1172/JCI35440; NicAmhlaoibh R, 2001, ONCOGENE, V20, P270, DOI 10.1038/sj.onc.1204075; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Pecha J, 2007, ONCOGENE, V26, P7423, DOI 10.1038/sj.onc.1210548; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Poon RTP, 2001, J CLIN ONCOL, V19, P3037, DOI 10.1200/JCO.2001.19.12.3037; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Taura K, 2010, HEPATOLOGY, V51, P1027, DOI 10.1002/hep.23368; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tong X, 2009, AM J PATHOL, V174, P1931, DOI 10.2353/ajpath.2009.080846; Wang HT, 2013, PSYCHOPHARMACOLOGY, V228, P129, DOI 10.1007/s00213-013-3017-9; Wu KJ, 2012, CELL SIGNAL, V24, P2273, DOI 10.1016/j.cellsig.2012.08.004; Xue GD, 2012, CANCER DISCOV, V2, P248, DOI 10.1158/2159-8290.CD-11-0270; Yamasaki H, 2005, GENES CELLS, V10, P455, DOI 10.1111/j.1365-2443.2005.00850.x; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang XR, 2009, CLIN CANCER RES, V15, P5518, DOI 10.1158/1078-0432.CCR-09-0151; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Zhang CL, 2010, CANCER RES, V70, P10224, DOI 10.1158/0008-5472.CAN-10-3057; Zhang W, 2012, GASTROENTEROLOGY, V143, P1641, DOI 10.1053/j.gastro.2012.08.032; Zhao J, 2008, HEPATOLOGY, V48, P265, DOI 10.1002/hep.22280; Zhao J, 2008, CANCER RES, V68, P4133, DOI 10.1158/0008-5472.CAN-08-0432; Zhao J, 2007, HUM PATHOL, V38, P293, DOI 10.1016/j.humpath.2006.08.005	51	22	26	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1420	1431		10.1038/onc.2014.73	http://dx.doi.org/10.1038/onc.2014.73			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24681951				2022-12-17	WOS:000350806500008
J	Tomiyama, L; Sezaki, T; Matsuo, M; Ueda, K; Kioka, N				Tomiyama, L.; Sezaki, T.; Matsuo, M.; Ueda, K.; Kioka, N.			Loss of Dlg5 expression promotes the migration and invasion of prostate cancer cells via Girdin phosphorylation	ONCOGENE			English	Article							BINDING PROTEIN GIRDIN; G-ALPHA-I; DOWN-REGULATION; KINASE; METASTASIS; MOTILITY; RECEPTOR; GROWTH; GIV; DIFFERENTIATION	Dlg5 has been reported to participate in cancer progression; however, its role in prostate cancer still remains poorly understood. In this study, we demonstrate that Dlg5 is frequently downregulated in prostate cancer. We show here that Dlg5 is involved in the regulation of cell migration and cancer cell invasion. Knockdown of endogenous Dlg5 markedly increased prostate cancer cell migration and invasion. Our studies, for the first time, demonstrate the interaction between Dlg5 and Girdin, an actin-binding Akt substrate. Importantly, we found that levels of Akt-mediated Girdin phosphorylation (p-Girdin-Ser1416) are increased in Dlg5-depleted cells. Small interfering RNA directed against Girdin and wortmannin treatment, which was found to reduce Girdin phosphorylation, impaired the effect of Dlg5 depletion on cell migration. Taken together, our findings demonstrate that Dlg5 interacts with and inhibits the activity of Girdin, thereby suppressing the migration of prostate cancer cells.	[Tomiyama, L.; Sezaki, T.; Matsuo, M.; Ueda, K.; Kioka, N.] Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan; [Ueda, K.] Kyoto Univ, Inst Integrated Cell Mat Sci iCeMS, Kyoto 6068502, Japan	Kyoto University; Kyoto University	Kioka, N (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	nkioka@kais.kyoto-u.ac.jp		Ueda, Kazumitsu/0000-0003-2980-6078; Kioka, Noriyuki/0000-0002-2708-537X	Asahi Glass Foundation; Ministry of Education, Culture, Sports, Science and Technology of Japan; Bio-oriented Technology Research Advancement Institution; Grants-in-Aid for Scientific Research [26660291] Funding Source: KAKEN	Asahi Glass Foundation; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Bio-oriented Technology Research Advancement Institution; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by the Asahi Glass Foundation, a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and a grant from the Bio-oriented Technology Research Advancement Institution.	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Aranjuez G, 2012, G3-GENES GENOM GENET, V2, P1379, DOI 10.1534/g3.112.004093; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang YJ, 2010, CELL CYCLE, V9, P1990, DOI 10.4161/cc.9.10.11730; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Enomoto A, 2009, NEURON, V63, P774, DOI 10.1016/j.neuron.2009.08.015; Gan Y, 2010, ONCOGENE, V29, P4947, DOI 10.1038/onc.2010.240; Garcia-Marcos M, 2011, MOL BIOL CELL, V22, P673, DOI 10.1091/mbc.E10-08-0738; Garcia-Marcos M, 2011, FASEB J, V25, P590, DOI 10.1096/fj.10-167304; Garcia-Marcos M, 2009, P NATL ACAD SCI USA, V106, P3178, DOI 10.1073/pnas.0900294106; Ghosh P, 2008, J CELL BIOL, V182, P381, DOI 10.1083/jcb.200712066; Ghosh P, 2010, MOL BIOL CELL, V21, P2338, DOI 10.1091/mbc.E10-01-0028; Goel HL, 2008, ENDOCR-RELAT CANCER, V15, P657, DOI 10.1677/ERC-08-0019; Hong SK, 2011, EXP CELL RES, V317, P2671, DOI 10.1016/j.yexcr.2011.08.008; Jiang P, 2008, CANCER RES, V68, P1310, DOI 10.1158/0008-5472.CAN-07-5111; Kitamura T, 2008, NAT CELL BIOL, V10, P329, DOI 10.1038/ncb1695; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; Lee YC, 2013, MOL CANCER RES, V11, P405, DOI 10.1158/1541-7786.MCR-12-0551; Lopez-Sanchez I, 2013, P NATL ACAD SCI USA, V110, P5510, DOI 10.1073/pnas.1303392110; Miyake H, 2011, CIRC RES, V108, P1170, DOI 10.1161/CIRCRESAHA.110.236174; Nakamura H, 1998, FEBS LETT, V433, P63, DOI 10.1016/S0014-5793(98)00882-5; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Natsume A, 2012, ONCOGENE, V31, P2715, DOI 10.1038/onc.2011.466; Nechiporuk T, 2007, DEV CELL, V13, P338, DOI 10.1016/j.devcel.2007.07.017; Nechiporuk T, 2013, DEV BIOL, V377, P375, DOI 10.1016/j.ydbio.2013.02.019; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Sezaki T, 2013, FEBS LETT, V587, P1624, DOI 10.1016/j.febslet.2013.04.015; Sezaki T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035519; Shah C, 2002, BMC GENOMICS, V3; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Smolen GA, 2010, GENE DEV, V24, P2654, DOI 10.1101/gad.1989110; Stoll M, 2004, NAT GENET, V36, P476, DOI 10.1038/ng1345; Taniuchi K, 2005, CANCER RES, V65, P105; Umemoto T, 2009, BIOCHEM BIOPH RES CO, V387, P191, DOI 10.1016/j.bbrc.2009.07.009; Wakabayashi M, 2003, J BIOL CHEM, V278, P21709, DOI 10.1074/jbc.M211004200; Woollard DJ, 2013, PROSTATE, V73, P563, DOI 10.1002/pros.22596; Yamashita H, 2011, J BIOL CHEM, V286, P3907, DOI 10.1074/jbc.M110.145409	37	22	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1141	1149		10.1038/onc.2014.31	http://dx.doi.org/10.1038/onc.2014.31			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662825				2022-12-17	WOS:000350122100007
J	Heim, D; Cornils, K; Schulze, K; Fehse, B; Lohse, AW; Brummendorf, TH; Wege, H				Heim, D.; Cornils, K.; Schulze, K.; Fehse, B.; Lohse, A. W.; Bruemmendorf, T. H.; Wege, H.			Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis	ONCOGENE			English	Article						Hepatocarcinogenesis; hepatocellular carcinoma; retroviral insertional mutagenesis; telomerase	NF-KAPPA-B; HEMATOPOIETIC STEM-CELLS; PRECANCEROUS HEPATIC NODULES; HUMAN FETAL HEPATOCYTES; HEPATOCELLULAR-CARCINOMA; GENE-TRANSFER; INDUCED APOPTOSIS; LIVER-CANCER; PLAG1; PROTEIN	Carcinogenesis is a multistep process involving alterations in various cellular pathways. The critical genetic events driving the evolution of primary liver cancer, specifically hepatoblastoma and hepatocellular carcinoma (HCC), are still poorly understood. However, telomere stabilization is acknowledged as prerequisite for cancer progression in humans. In this project, human fetal hepatocytes were utilized as a cell culture model for untransformed, proliferating human liver cells, with telomerase activation as first oncogenic hit. To elucidate critical downstream genetic events driving further transformation of immortalized liver cells, we used retroviral insertional mutagenesis as an unbiased approach to induce genetic alterations. Following isolation of hyperproliferating, provirus-bearing cell clones, we monitored cancer-associated growth properties and characterized changes toward a malignant phenotype. Three transformed clones with the ability to form colonies in soft agar were expanded. As proof-ofprinciple for our experimental setup, we identified a transforming insertion on chromosome 8 within the pleiomorphic adenoma gene 1 (PLAG1), resulting in a 20-fold increase in PLAG1 expression. Upregulation of PLAG1 has already been described to promote human hepatoblastoma development. In a separate clone, a transforming insertion was detected in close proximity to the receptorinteracting serine-threonine kinase 4 (RIPK4) with an approximately eightfold suppression in RIPK4 expression. As validation for this currently unknown driver in hepatocarcinogenesis, we examined RIPK4 expression in human HCC samples and confirmed a significant suppression of RIPK4 in 80% of the samples. Furthermore, overexpression of RIPK4 in transformed human fetal hepatocytes resulted in an almost complete elimination of anchorage-independent growth. On the basis of these data, we propose RIPK4 as a novel putative tumor suppressor in human hepatocarcinogenesis.	[Heim, D.; Schulze, K.; Lohse, A. W.; Wege, H.] Univ Med Ctr Hamburg Eppendorf, Dept Gastroenterol & Hepatol, D-20246 Hamburg, Germany; [Cornils, K.; Fehse, B.] Univ Med Ctr Hamburg Eppendorf, Clin Stem Cell Transplantat, Res Dept Cell & Gene Therapy, D-20246 Hamburg, Germany; [Bruemmendorf, T. H.] Rhein Westfal TH Aachen, Univ Med Ctr, Dept Hematol & Oncol, D-52062 Aachen, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; RWTH Aachen University; RWTH Aachen University Hospital	Heim, D (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Gastroenterol & Hepatol, Martinistr 52, D-20246 Hamburg, Germany.	dheim@uke.de	Fehse, Boris/A-8721-2012	Fehse, Boris/0000-0001-9780-7211	Deutsche Forschungsgemeinschaft [SFB 841, C5, C7]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We acknowledge the valuable technical assistance provided by N Knuth, J Polke, P Zemke-Trautmann and the FACS Core Unit of the UMC Hamburg-Eppendorf. We are grateful for the financial support by the Deutsche Forschungsgemeinschaft (SFB 841, projects C5 and C7).	Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; Astrom AK, 2000, INT J ONCOL, V16, P1107; Baum C, 2003, BLOOD, V101, P2099, DOI 10.1182/blood-2002-07-2314; BRECHOT C, 1980, NATURE, V286, P533, DOI 10.1038/286533a0; Declercq J, 2005, CANCER RES, V65, P4544, DOI 10.1158/0008-5472.CAN-04-4041; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Gabriel R, 2009, NAT MED, V15, P1431, DOI 10.1038/nm.2057; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Greider CW, 1991, CURR OPIN CELL BIOL, V3, P444, DOI 10.1016/0955-0674(91)90072-7; Haker B, 2007, CANCER LETT, V256, P120, DOI 10.1016/j.canlet.2007.06.007; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; Hibbard MK, 2000, CANCER RES, V60, P4869; Hoshida Yujin, 2009, Expert Rev Gastroenterol Hepatol, V3, P101, DOI 10.1586/egh.09.5; Hytiroglou P, 1998, CANCER, V82, P1831, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1831::AID-CNCR4>3.0.CO;2-Q; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Keng VW, 2009, NAT BIOTECHNOL, V27, P264, DOI 10.1038/nbt.1526; KERMOUNI A, 1995, GENOMICS, V29, P371, DOI 10.1006/geno.1995.9992; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim SW, 2008, BLOOD, V111, P1644, DOI 10.1182/blood-2007-05-088591; KING W, 1985, SCIENCE, V228, P554, DOI 10.1126/science.3838595; Kojima H, 1997, GASTROENTEROLOGY, V112, P493, DOI 10.1053/gast.1997.v112.pm9024303; Komine F, 2000, J HEPATOL, V32, P235, DOI 10.1016/S0168-8278(00)80068-9; Kuhlcke K, 2002, MOL THER, V5, P473, DOI 10.1006/mthe.2002.0566; Kustikova O, 2005, SCIENCE, V308, P1171, DOI 10.1126/science.1105063; Kustikova Olga S., 2008, V430, P255, DOI 10.1007/978-1-59745-182-6_18; Kustikova OS, 2003, BLOOD, V102, P3934, DOI 10.1182/blood-2003-05-1424; Landrette SF, 2005, BLOOD, V105, P2900, DOI 10.1182/blood-2004-09-3630; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Meylan E, 2002, EMBO REP, V3, P1201, DOI 10.1093/embo-reports/kvf236; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Modlich U, 2005, BLOOD, V105, P4235, DOI 10.1182/blood-2004-11-4535; Oh BK, 2005, AM J PATHOL, V166, P73, DOI 10.1016/S0002-9440(10)62233-X; Oh BK, 2003, J HEPATOL, V39, P786, DOI 10.1016/S0168-8278(03)00395-7; Ranzani M, 2013, NAT METHODS, V10, P155, DOI [10.1038/NMETH.2331, 10.1038/nmeth.2331]; Sawey ET, 2011, CANCER CELL, V19, P347, DOI 10.1016/j.ccr.2011.01.040; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Takaishi H, 2000, CANCER, V88, P312, DOI 10.1002/(SICI)1097-0142(20000115)88:2<312::AID-CNCR10>3.3.CO;2-I; Thorgeirsson SS, 2006, HEPATOLOGY, V43, pS145, DOI 10.1002/hep.21063; Trevisani F, 2008, CARCINOGENESIS, V29, P1299, DOI 10.1093/carcin/bgn113; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wahlers A, 2001, GENE THER, V8, P477, DOI 10.1038/sj.gt.3301426; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Wege H, 2003, GASTROENTEROLOGY, V124, P432, DOI 10.1053/gast.2003.50064; Wege H, 2011, MOL CANCER RES, V9, P1222, DOI 10.1158/1541-7786.MCR-10-0474; Zatkova A, 2004, GENE CHROMOSOME CANC, V39, P126, DOI 10.1002/gcc.10307	52	22	25	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					385	393		10.1038/onc.2013.551	http://dx.doi.org/10.1038/onc.2013.551			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24413083				2022-12-17	WOS:000348145500012
J	Brundage, ME; Tandon, P; Eaves, DW; Williams, JP; Miller, SJ; Hennigan, RH; Jegga, A; Cripe, TP; Ratner, N				Brundage, M. E.; Tandon, P.; Eaves, D. W.; Williams, J. P.; Miller, S. J.; Hennigan, R. H.; Jegga, A.; Cripe, T. P.; Ratner, N.			MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1	ONCOGENE			English	Article						Neurofibromatosis; MPNST; Schwann; resistance; DEPTOR; differentiation	TUMOR-SUPPRESSOR; C-MAF; MAMMALIAN TARGET; EXPRESSION; CELLS; ACTIVATION; INHIBITION; PATHWAYS; SURVIVAL; GENE	Mutations in the neurofibromatosis type 1 (NF1) tumor suppressor gene are common in cancer and can cause resistance to therapy. Using transcriptome analysis we identified MAF as an NF1-regulated transcription factor and verified MAF regulation through RAS/MAPK/AP-1 signaling in malignant peripheral nerve sheath tumor (MPNST) cell lines. MAF was also downregulated in human MPNST. Acute re-expression of MAF promoted expression of glial differentiation markers in MPNST cells in vitro, decreased self-renewal of embryonic precursors and transiently affected tumor cell phenotypes in vitro by increasing MPNST cell death and reducing metabolic activity and anchorage-independent growth. Paradoxically, chronic MAF overexpression enhanced MPNST cell tumor growth in vivo, correlating with elevated pS6 in vitro and in vivo. RAD001 blocked MAF-mediated tumor growth, and MAF regulated the mTOR pathway through DEPTOR. MAPK inhibition with NF1 loss of function is predicted to show limited efficacy due to reactivation of mTOR signaling via MAF.	[Brundage, M. E.; Tandon, P.; Eaves, D. W.; Williams, J. P.; Miller, S. J.; Hennigan, R. H.; Ratner, N.] Univ Cincinnati, Div Expt Hematol & Canc Biol, Dept Pediat, Coll Med, Cincinnati, OH 45267 USA; [Jegga, A.] Univ Cincinnati, Div Expt Hematol & Canc Biol, Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat,Dept Pediat, Cincinnati, OH 45267 USA; [Cripe, T. P.] Univ Cincinnati, Div Expt Hematol & Canc Biol, Dept Pediat, Div Oncol, Cincinnati, OH 45267 USA; [Cripe, T. P.] Ohio State Univ, Nationwide Childrens Hosp, Div Hematol Oncol BMT, Columbus, OH 43210 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Ratner, N (corresponding author), Univ Cincinnati, Div Expt Hematol & Canc Biol, Cincinnati Childrens Hosp, Dept Pediat,Coll Med, 3333 Burnet Ave, Cincinnati, OH 45267 USA.	nancy.ratner@cchmc.org	Williams, Jon/AAP-2761-2020; Jegga, Anil/H-6140-2011	Jegga, Anil/0000-0002-4881-7752; RATNER, NANCY/0000-0001-5030-9354	NIH [AR-47363, DK78392, DK90971];  [R01 NS28840];  [T32HD07463];  [NIH-P50-NS057531]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007463] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA117846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090971, P30DK078392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS057531, F32NS083249, R01NS028840] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Frank McCormick (UCSF) for providing NF1 constructs and Kohsuke Kataoka for providing the MAF reporter. We thank the Viral Vector Core in the Translational Core Laboratories at Cincinnati Children's Hospital Medical Center for viral vector production. We thank Monica DeLay for assistance with flow cytometry from the Research Flow Cytometry Core in the Division of Rheumatology at Cincinnati Children's Hospital Medical Center, supported in part by NIH AR-47363, NIH DK78392 and NIH DK90971. This work was supported by R01 NS28840 (to NR) and NIH-P50-NS057531 (to NR and TPC). MB was partially supported by a training grant, T32HD07463.	Annunziata CM, 2011, BLOOD, V117, P2396, DOI 10.1182/blood-2010-04-278788; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Brems H, 2009, LANCET ONCOL, V10, P508, DOI 10.1016/S1470-2045(09)70033-6; Buchstaller J, 2012, CANCER CELL, V21, P240, DOI 10.1016/j.ccr.2011.12.027; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Cheung M, 2003, DEVELOPMENT, V130, P5681, DOI 10.1242/dev.00808; De Raedt T, 2011, CANCER CELL, V20, P400, DOI 10.1016/j.ccr.2011.08.014; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Donovan S, 2002, CANCER CELL, V2, P507, DOI 10.1016/S1535-6108(02)00214-3; Endo M, 2013, CLIN CANCER RES, V19, P450, DOI 10.1158/1078-0432.CCR-12-1067; Eychene A, 2008, NAT REV CANCER, V8, P683, DOI 10.1038/nrc2460; Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Holzel M, 2010, CELL, V142, P218, DOI 10.1016/j.cell.2010.06.004; Huang WD, 2002, J BIOL CHEM, V277, P50668, DOI 10.1074/jbc.M206544200; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Johannessen CM, 2008, CURR BIOL, V18, P56, DOI 10.1016/j.cub.2007.11.066; Johansson G, 2008, MOL CANCER THER, V7, P1237, DOI 10.1158/1535-7163.MCT-07-2335; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kataoka K, 2001, J BIOL CHEM, V276, P34074, DOI 10.1074/jbc.M105383200; Keng VW, 2012, CANCER RES, V72, P3405, DOI 10.1158/0008-5472.CAN-11-4092; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kraniak JM, 2010, MOL CELL BIOCHEM, V344, P267, DOI 10.1007/s11010-010-0551-1; Lau N, 2000, J NEUROPATH EXP NEUR, V59, P759, DOI 10.1093/jnen/59.9.759; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Miller SJ, 2010, ONCOGENE, V29, P368, DOI 10.1038/onc.2009.360; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Pouponnot C, 2006, ONCOGENE, V25, P1299, DOI 10.1038/sj.onc.1209171; Pytel P, 2010, INT J SURG PATHOL, V18, P449, DOI 10.1177/1066896909351698; Stowe IB, 2012, GENE DEV, V26, P1421, DOI 10.1101/gad.190876.112; Sun DC, 2013, MOL CANCER RES, V11, P616, DOI 10.1158/1541-7786.MCR-12-0593; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Wang ZW, 2012, NEOPLASIA, V14, P368, DOI 10.1593/neo.12542; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Wende H, 2012, SCIENCE, V335, P1373, DOI 10.1126/science.1214314; Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470; Williams JP, 2008, CELL STEM CELL, V3, P658, DOI 10.1016/j.stem.2008.10.003; Wu J, 2014, ONCOGENE, V33, P173, DOI 10.1038/onc.2012.579; Yin B, 2006, LEUKEMIA, V20, P151, DOI 10.1038/sj.leu.2404033; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029; Zou CYY, 2009, MOL CANCER THER, V8, P1157, DOI 10.1158/1535-7163.MCT-08-1008	49	22	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5626	5636		10.1038/onc.2013.506	http://dx.doi.org/10.1038/onc.2013.506			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24509877	Green Accepted, Green Submitted			2022-12-17	WOS:000346088700007
J	Antonello, ZA; Nucera, C				Antonello, Z. A.; Nucera, C.			Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF	ONCOGENE			English	Review						metastatic human thyroid cancer; orthotopic; BRAF(V600E); preclinical and translational model; vemurafenib; tyrosine kinase inhibitors	RECEPTOR TYROSINE KINASES; ENDOTHELIAL GROWTH-FACTOR; TUMOR-CELL PROLIFERATION; IN-VIVO; THERAPEUTIC TARGET; PROGNOSTIC-FACTORS; CANCER CELLS; INCREASING INCIDENCE; TRANSCRIPTION FACTOR; GENETIC ALTERATIONS	Molecular signature of advanced and metastatic thyroid carcinoma involves deregulation of multiple fundamental pathways activated in the tumor microenvironment. They include BRAF(V600E) and AKT that affect tumor initiation, progression and metastasis. Human thyroid cancer orthotopic mouse models are based on human cell lines that generally harbor genetic alterations found in human thyroid cancers. They can reproduce in vivo and in situ (into the thyroid) many features of aggressive and refractory human advanced thyroid carcinomas, including local invasion and metastasis. Humanized orthotopic mouse models seem to be ideal and commonly used for preclinical and translational studies of compounds and therapies not only because they may mimic key aspects of human diseases (e. g. metastasis), but also for their reproducibility. In addition, they might provide the possibility to evaluate systemic effects of treatments. So far, human thyroid cancer in vivo models were mainly used to test single compounds, non selective and selective. Despite the greater antitumor activity and lower toxicity obtained with different selective drugs in respect to non-selective ones, most of them are only able to delay disease progression, which ultimately could restart with similar aggressive behavior. Aggressive thyroid tumors (for example, anaplastic or poorly differentiated thyroid carcinoma) carry several complex genetic alterations that are likely cooperating to promote disease progression and might confer resistance to single-compound approaches. Orthotopic models of human thyroid cancer also hold the potential to be good models for testing novel combinatorial therapies. In this article, we will summarize results on preclinical testing of selective and nonselective single compounds in orthotopic mouse models based on validated human thyroid cancer cell lines harboring the BRAF(V600E) mutation or with wild-type BRAF. Furthermore, we will discuss the potential use of this model also for combinatorial approaches, which are expected to take place in the upcoming human thyroid cancer basic and clinical research.	[Antonello, Z. A.; Nucera, C.] Harvard Univ, Expt Div Canc Biol & Angiogenesis, Beth Israel Deaconess Med Ctr,Lab Human Thyroid C, Dept Pathol,Simon C Fireman Res Ctr,Med Sch, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Nucera, C (corresponding author), Harvard Univ, Expt Div Canc Biol & Angiogenesis, Beth Israel Deaconess Med Ctr, Dept Pathol,Simon C Fireman Res Ctr,Med Sch, Boston, MA 02215 USA.	cnucera@bidmc.harvard.edu		Antonello, Zeus/0000-0002-5933-6794	National Institutes of Health Grants [NIHR21CA165039-01A1]; American Thyroid Association funds for Thyroid Cancer Research to Carmelo Nucera; Guido Berlucchi research award (Brescia, Italy); NATIONAL CANCER INSTITUTE [R21CA165039] Funding Source: NIH RePORTER	National Institutes of Health Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Thyroid Association funds for Thyroid Cancer Research to Carmelo Nucera; Guido Berlucchi research award (Brescia, Italy); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health Grants NIHR21CA165039-01A1 and the American Thyroid Association funds for Thyroid Cancer Research to Carmelo Nucera (Principal Investigator: Human Thyroid Cancers Preclinical and Translational Research). Carmelo Nucera was also a recipient of the Guido Berlucchi research award (Brescia, Italy). Zeus A Antonello was a Masters Student at the BIDMC and is currently a PhD Student at the Instituto de Neurociencias (Alicante, Spain). We thank Mark Duquette and Neal Smith (BIDMC, Harvard Medical School) for critical reading of our manuscript. We thank those authors who we have neglected to cite owing to limitation on the number of references.	Abate-Shen Cory, 2013, Cold Spring Harb Protoc, V2013, DOI 10.1101/pdb.top078774; Araujo J, 2010, CANCER TREAT REV, V36, P492, DOI 10.1016/j.ctrv.2010.02.015; BANCROFT GJ, 1994, IMMUNOBIOLOGY, V191, P424, DOI 10.1016/S0171-2985(11)80448-1; Bellelli R, 2012, ENDOCR-RELAT CANCER, V19, P695, DOI 10.1530/ERC-12-0031; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Bos PD, 2010, CURR OPIN PHARMACOL, V10, P571, DOI 10.1016/j.coph.2010.06.003; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Brassard M, 2011, J CLIN ENDOCR METAB, V96, P1352, DOI 10.1210/jc.2010-2708; Brown RL, 2011, J CANCER, V2, P193, DOI 10.7150/jca.2.193; Carlomagno F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/jnci/djj069; Carlomagno F, 2011, NAT REV ENDOCRINOL, V7, P65, DOI 10.1038/nrendo.2010.232; Chakravarty D, 2011, J CLIN INVEST, V121, P4700, DOI 10.1172/JCI46382; Chan CM, 2012, CLIN CANCER RES, V18, P3580, DOI 10.1158/1078-0432.CCR-11-3359; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Charles RP, 2011, CANCER RES, V71, P3863, DOI 10.1158/0008-5472.CAN-10-4463; Ciampi R, 2007, ENDOCRINOLOGY, V148, P936, DOI 10.1210/en.2006-0921; Colston KW, 1997, BRIT J CANCER, V76, P1017, DOI 10.1038/bjc.1997.501; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Dackiw APB, 2004, ENDOCRINOLOGY, V145, P5840, DOI 10.1210/en.2004-0785; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Day E, 2008, EUR J PHARMACOL, V599, P44, DOI 10.1016/j.ejphar.2008.10.014; Deshpande HA, 2013, CURR OPIN ONCOL, V25, P44, DOI 10.1097/CCO.0b013e32835a448c; Dhar DK, 1998, AM J SURG, V176, P442, DOI 10.1016/S0002-9610(98)00238-4; Durante C, 2006, J CLIN ENDOCR METAB, V91, P2892, DOI 10.1210/jc.2005-2838; Ensinger C, 2004, ANN NY ACAD SCI, V1030, P69, DOI 10.1196/annals.1329.009; Fenton C, 2000, THYROID, V10, P349, DOI 10.1089/thy.2000.10.349; Fizazi K, 2007, ANN ONCOL, V18, P1765, DOI 10.1093/annonc/mdm086; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Franco AT, 2011, P NATL ACAD SCI USA, V108, P1615, DOI 10.1073/pnas.1015557108; Garcia-Rostan G, 2005, CANCER RES, V65, P10199, DOI 10.1158/0008-5472.CAN-04-4259; Girelli ME, 1998, THYROID, V8, P517, DOI 10.1089/thy.1998.8.517; Gule MK, 2011, CLIN CANCER RES, V17, P2281, DOI 10.1158/1078-0432.CCR-10-2762; Henderson YC, 2008, CLIN CANCER RES, V14, P4908, DOI 10.1158/1078-0432.CCR-07-1772; Henderson YC, 2014, HEAD NECK-J SCI SPEC, V36, P375, DOI 10.1002/hed.23316; Hershberger PA, 1999, CANCER RES, V59, P2644; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Ito Y, 2013, NAT REV ENDOCRINOL, V9, P178, DOI 10.1038/nrendo.2012.257; Johnson JI, 2001, BRIT J CANCER, V84, P1424, DOI 10.1054/bjoc.2001.1796; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kandil E, 2013, J SURG RES, V184, P898, DOI 10.1016/j.jss.2013.03.052; Kerbel RS, 2003, CANCER BIOL THER, V2, pS134; Khanna C, 2005, CARCINOGENESIS, V26, P513, DOI 10.1093/carcin/bgh261; Killion JJ, 1998, CANCER METAST REV, V17, P279, DOI 10.1023/A:1006140513233; Kim KB, 2013, THYROID, V17, P17; Kim KB, 2013, THYROID, V23, P1277, DOI 10.1089/thy.2013.0057; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; Knauf JA, 2009, CURR OPIN CELL BIOL, V21, P296, DOI 10.1016/j.ceb.2009.01.013; Kopetz S, 2007, CLIN CANCER RES, V13, P7232, DOI 10.1158/1078-0432.CCR-07-1902; Leboeuf R, 2008, J CLIN ENDOCR METAB, V93, P2194, DOI 10.1210/jc.2007-2825; Lee Jieun, 2013, Genomics & Informatics, V11, P68, DOI 10.5808/GI.2013.11.2.68; Liu DX, 2010, INT J CANCER, V127, P2965, DOI 10.1002/ijc.25304; Liu W, 2002, AM J PATHOL, V160, P511, DOI 10.1016/S0002-9440(10)64870-5; Liu W, 2008, CANCER RES, V68, P8104, DOI 10.1158/0008-5472.CAN-08-2132; Liu Z, 2008, J CLIN ENDOCR METAB, V93, P3106, DOI 10.1210/jc.2008-0273; Lu C, 2012, ONCOGENE, V31, P2007, DOI 10.1038/onc.2011.390; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; Mathiasen IS, 2002, J BIOL CHEM, V277, P30738, DOI 10.1074/jbc.M201558200; Maxon HR, 1999, THYROID, V9, P443, DOI 10.1089/thy.1999.9.443; MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2; McClatchey AI, 1999, ONCOGENE, V18, P5334, DOI 10.1038/sj.onc.1203086; McDonald MP, 1996, SURGERY, V120, P1000, DOI 10.1016/S0039-6060(96)80046-8; Miller KA, 2009, CANCER RES, V69, P3689, DOI 10.1158/0008-5472.CAN-09-0024; Modigliani E, 1998, CLIN ENDOCRINOL, V48, P265, DOI 10.1046/j.1365-2265.1998.00392.x; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531; Nehs MA, 2012, ENDOCRINOLOGY, V153, P985, DOI 10.1210/en.2011-1519; Nehs MA, 2010, SURGERY, V148, P1154, DOI 10.1016/j.surg.2010.09.001; Nucera C, 2011, ONCOLOGIST, V16, P296, DOI 10.1634/theoncologist.2010-0317; Nucera C, 2010, P NATL ACAD SCI USA, V107, P10649, DOI 10.1073/pnas.1004934107; Nucera C, 2009, THYROID, V19, P1077, DOI 10.1089/thy.2009.0055; Nucera C, 2009, BBA-REV CANCER, V1795, P152, DOI 10.1016/j.bbcan.2009.01.003; Orim F, 2013, THYROID, V7, P7; Pal SK, 2010, EXPERT OPIN INV DRUG, V19, P1355, DOI 10.1517/13543784.2010.520701; Palmer HG, 2003, CANCER RES, V63, P7799; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Priolo C, 2010, AM J PATHOL, V176, P1901, DOI 10.2353/ajpath.2010.090873; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Rosove MH, 2013, NEW ENGL J MED, V368, P684, DOI 10.1056/NEJMc1215697; Saji M, 2011, ONCOGENE, V30, P4307, DOI 10.1038/onc.2011.136; Saji M, 2010, MOL CELL ENDOCRINOL, V321, P20, DOI 10.1016/j.mce.2009.10.016; Salvatore G, 2006, CLIN CANCER RES, V12, P1623, DOI 10.1158/1078-0432.CCR-05-2378; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sanders LE, 1998, SURGERY, V124, P967, DOI 10.1067/msy.1998.92000; SCHOLZ CC, 1990, EUR J CANCER, V26, P901, DOI 10.1016/0277-5379(90)90196-Z; Schweppe RE, 2009, J CLIN ENDOCR METAB, V94, P2199, DOI 10.1210/jc.2008-2511; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; SHAHA AR, 1995, SURGERY, V118, P1131, DOI 10.1016/S0039-6060(05)80124-2; SHARKEY FE, 1979, INT J CANCER, V24, P733, DOI 10.1002/ijc.2910240605; Sharma V, 2010, THYROID, V20, P1103, DOI 10.1089/thy.2010.0096; Sherman SI, 2013, ORAL ONCOL, V49, P707, DOI 10.1016/j.oraloncology.2013.03.442; Shimamura M, 2013, ENDOCRINOLOGY, V154, P4423, DOI 10.1210/en.2013-1174; Smallridge RC, 2012, THYROID, V22, P1104, DOI 10.1089/thy.2012.0302; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Su F, 2012, CANCER RES, V72, P969, DOI 10.1158/0008-5472.CAN-11-1875; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Tisset H, 2013, J CLIN ENDOCR METAB, V98, P3981, DOI 10.1210/jc.2013-1357; Trunzer K, 2013, J CLIN ONCOL, V31, P1767, DOI 10.1200/JCO.2012.44.7888; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Tsimberidou AM, 2009, J CLIN ENDOCR METAB, V94, P4423, DOI 10.1210/jc.2009-0743; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Wilhelm S, 2002, CURR PHARM DESIGN, V8, P2255, DOI 10.2174/1381612023393026; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Xing JN, 2011, BIOCHEM BIOPH RES CO, V404, P958, DOI 10.1016/j.bbrc.2010.12.088; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Xing MZ, 2010, THYROID, V20, P697, DOI 10.1089/thy.2010.1646; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646; Yutan E, 2001, Curr Treat Options Oncol, V2, P331, DOI 10.1007/s11864-001-0026-4	113	22	22	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5397	5404		10.1038/onc.2013.544	http://dx.doi.org/10.1038/onc.2013.544			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24362526	Green Accepted			2022-12-17	WOS:000345120700001
J	Park, TJ; Curran, T				Park, T-J; Curran, T.			Essential roles of Crk and CrkL in fibroblast structure and motility	ONCOGENE			English	Article						Crk; CrkL; focal adhesion; actin; cytoskeleton; motility	ADAPTER PROTEIN CRK; KEY SIGNALING INTEGRATORS; MICE LACKING; V-CRK; CANCER; ONCOGENE; PAXILLIN; PHOSPHORYLATION; TRANSFORMATION; P130(CAS)	Cytosolic proteins containing SH2 and SH3 domains, such as Crk and Crk-like (CrkL), are broadly expressed adapters that interact with a variety of proteins to fulfill key roles in signal transduction pathways triggered by activation of receptor and non-receptor tyrosine kinases. Crk and CrkL are similar to each other in structure and biochemical function, although they provide both distinct, as well as overlapping, biological roles during development. We developed a systematic approach to investigate Crk family functions at the cellular level by generating a conditional knock-out system for ablation of Crk and CrkL in cultured fibroblasts. The loss of both Crk and CrkL from fibroblasts resulted in reduced cell surface area and adoption of a rounded, refractile cellular phenotype. These morphological alterations were accompanied by a decrease in focal adhesion sites, reduced actin stress fibers and a collapse of microtubule structures. In addition, cells exhibited decreases in spontaneous motility and wound-healing behavior. Reduced p130Cas phosphorylation and actin levels closely followed the loss of Crk and CrkL, and stabilization of polymerized actin by jasplakinolide suppressed the morphological conversion. Ablation of Crk or CrkL alone conferred a much more modest phenotype suggesting that Crk and CrkL have overlapping functions that are critical for maintaining cell structure. The morphological alterations could be partially rescued by reintroduction of CrkII, and, to a lesser extent, CrkL. Taken together, our results suggest that Crk and CrkL have critical roles in cell structure and motility by maintaining cytoskeletal integrity.	[Park, T-J; Curran, T.] Childrens Hosp Philadelphia, Res Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Curran, T (corresponding author), Childrens Hosp Philadelphia, Res Inst, Colket Translat Res Bldg,Room 4060, Philadelphia, PA 19104 USA.	currant@email.chop.edu	Curran, Tom/F-5234-2018; Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Park, Taeju/0000-0003-3897-3994	Pennsylvania Department of Health Cure Formulary grant (SAP) [4100047628]	Pennsylvania Department of Health Cure Formulary grant (SAP)	We thank Hanna Li and Erin Finn for their technical assistance and Mateusz Koptyra for critical reading of the manuscript. This work was supported by a Pennsylvania Department of Health Cure Formulary grant (SAP#4100047628 to TC).	Antoku S, 2009, J CELL SCI, V122, P4228, DOI 10.1242/jcs.054627; Birge RB, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-13; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Fathers KE, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3183; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; George B, 2012, J CLIN INVEST, V122, P674, DOI 10.1172/JCI60070; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hallock PT, 2010, GENE DEV, V24, P2451, DOI 10.1101/gad.1977710; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kim YH, 2010, ONCOGENE, V29, P1421, DOI 10.1038/onc.2009.437; Kobashigawa Y, 2007, NAT STRUCT MOL BIOL, V14, P503, DOI 10.1038/nsmb1241; Kong JY, 2004, CELL BIOL INT, V28, P781, DOI 10.1016/j.cellbi.2004.07.012; Linghu H, 2006, ONCOGENE, V25, P3547, DOI 10.1038/sj.onc.1209398; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Nishihara H, 2002, CANCER LETT, V180, P55, DOI 10.1016/S0304-3835(01)00763-7; Park TJ, 2006, MOL CELL BIOL, V26, P6272, DOI 10.1128/MCB.00472-06; Park TJ, 2008, J NEUROSCI, V28, P13551, DOI 10.1523/JNEUROSCI.4323-08.2008; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Rodrigues SP, 2005, MOL CANCER RES, V3, P183; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sarkar P, 2007, MOL CELL, V25, P413, DOI 10.1016/j.molcel.2007.01.004; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Sriram Ganapathy, 2010, Genes Cancer, V1, P1132, DOI 10.1177/1947601910397188; Tikhmyanova N, 2010, CELL MOL LIFE SCI, V67, P1025, DOI 10.1007/s00018-009-0213-1; Watanabe T, 2006, MOL CANCER RES, V4, P499, DOI 10.1158/1541-7786.MCR-05-0141	35	22	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5121	5132		10.1038/onc.2013.453	http://dx.doi.org/10.1038/onc.2013.453			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24166500				2022-12-17	WOS:000343768400007
J	Toska, E; Shandilya, J; Goodfellow, SJ; Medler, KF; Roberts, SGE				Toska, E.; Shandilya, J.; Goodfellow, S. J.; Medler, K. F.; Roberts, S. G. E.			Prohibitin is required for transcriptional repression by the WT1-BASP1 complex	ONCOGENE			English	Article						WT1; BASP1; prohibitin; transcription	TUMOR-SUPPRESSOR; WILMS-TUMOR; CHROMATIN; BASP1; ACTIVATION; GENE; BRG1; WT1; RB; IDENTIFICATION	The Wilms' tumor-1 protein (WT1) is a transcriptional regulator that can either activate or repress genes controlling cell growth, apoptosis and differentiation. The transcriptional corepressor BASP1 interacts with WT1 and mediates WT1's transcriptional repression activity. BASP1 is contained within large complexes, suggesting that it works in concert with other factors. Here we report that the transcriptional repressor prohibitin is part of the WT1-BASP1 transcriptional repression complex. Prohibitin interacts with BASP1, colocalizes with BASP1 in the nucleus, and is recruited to the promoter region of WT1 target genes to elicit BASP1-dependent transcriptional repression. We demonstrate that prohibitin and BASP1 cooperate to recruit the chromatin remodeling factor BRG1 to WT1-responsive promoters and that this results in the dissociation of CBP from the promoter region of WT1 target genes. As seen with BASP1, prohibitin can associate with phospholipids. We demonstrate that the recruitment of PIP2 and HDAC1 to WT1 target genes is also dependent on the concerted activity of BASP1 and prohibitin. Our findings provide new insights into the function of prohibitin in transcriptional regulation and uncover a BASP1-prohibitin complex that plays an essential role in the PIP2-dependent recruitment of chromatin remodeling activities to the promoter.	[Toska, E.; Shandilya, J.; Medler, K. F.; Roberts, S. G. E.] SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA; [Goodfellow, S. J.] Univ Dundee, Wellcome Trust Ctr Gene Regulat, Dundee, Scotland; [Roberts, S. G. E.] Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Dundee; University of Bristol	Roberts, SGE (corresponding author), SUNY Buffalo, Dept Biol Sci, Cooke Hall,North Campus, Buffalo, NY 14260 USA.	sr237@buffalo.edu	Toska, Eneda/AAQ-4369-2020; Roberts, Stefan GE/R-5537-2016; Toska, Eneda/AAO-1711-2020	Toska, Eneda/0000-0002-8974-9792; Roberts, Stefan GE/0000-0002-7535-6365; Medler, Kathryn/0000-0001-9664-3606; Shandilya, Jayasha/0000-0001-9911-8065	National Institute of General Medical Sciences [1R01GM098609]; Cancer Research UK [C1356/A6630]; National Science Foundation [DBI 0923133]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM098609] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Cancer Research UK(Cancer Research UK); National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was funded by the National Institute of General Medical Sciences (1R01GM098609) (to KFM and SGER) and Cancer Research UK (C1356/A6630) (to SGER). We thank Alan Siegel for help with the confocal microscopy and the facility funded by National Science Foundation (DBI 0923133).	Ande SR, 2009, BIOCHEM BIOPH RES CO, V390, P1023, DOI 10.1016/j.bbrc.2009.10.101; Carpenter B, 2004, MOL CELL BIOL, V24, P537, DOI 10.1128/MCB.24.2.537-549.2004; Choi D, 2008, ONCOGENE, V27, P1716, DOI 10.1038/sj.onc.1210806; Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Essafi A, 2011, DEV CELL, V21, P559, DOI 10.1016/j.devcel.2011.07.014; Gamble SC, 2007, ONCOGENE, V26, P1757, DOI 10.1038/sj.onc.1209967; Goodfellow SJ, 2011, BIOCHEM J, V435, P113, DOI 10.1042/BJ20101734; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Green LM, 2009, NUCLEIC ACIDS RES, V37, P431, DOI 10.1093/nar/gkn955; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Han BK, 2011, GENE DEV, V25, P984, DOI 10.1101/gad.1998611; Hartkamp J, 2010, MOL CELL, V37, P159, DOI 10.1016/j.molcel.2009.12.023; Hartl M, 2009, P NATL ACAD SCI USA, V106, P5604, DOI 10.1073/pnas.0812101106; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; He B, 2008, MOL ENDOCRINOL, V22, P344, DOI 10.1210/me.2007-0400; He B, 2011, ENDOCRINOLOGY, V152, P1047, DOI 10.1210/en.2010-0732; Hohenstein P, 2006, HUM MOL GENET, V15, pR196, DOI 10.1093/hmg/ddl196; Huff V, 2011, NAT REV CANCER, V11, P111, DOI 10.1038/nrc3002; Joshi B, 2003, BIOCHEM BIOPH RES CO, V312, P459, DOI 10.1016/j.bbrc.2003.10.148; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kim HS, 2007, J BIOL CHEM, V282, P16278, DOI 10.1074/jbc.M700215200; McKay LM, 1999, ONCOGENE, V18, P6546, DOI 10.1038/sj.onc.1203046; Millard CJ, 2013, MOL CELL, V51, P57, DOI 10.1016/j.molcel.2013.05.020; Mishra S, 2006, J CELL MOL MED, V10, P353, DOI 10.1111/j.1582-4934.2006.tb00404.x; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Moribe T, 2008, INT J ONCOL, V33, P949, DOI 10.3892/ijo_00000082; Morrow IC, 2005, TRAFFIC, V6, P725, DOI 10.1111/j.1600-0854.2005.00318.x; Mosevitsky MI, 2005, INT REV CYTOL, V245, P245, DOI 10.1016/S0074-7696(05)45007-X; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Roberts SGE, 2005, CURR OPIN GENET DEV, V15, P542, DOI 10.1016/j.gde.2005.08.004; Schneider M, 2010, DEVELOPMENT, V137, P4073, DOI 10.1242/dev.053405; Shandilya J, 2012, P NATL ACAD SCI USA, V10, P1073; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Toska E, 2012, CELL REP, V2, P462, DOI 10.1016/j.celrep.2012.08.005; Trotter Kevin W, 2008, Nucl Recept Signal, V6, pe004, DOI 10.1621/nrs.06004; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Wang WH, 2001, J BIOL CHEM, V276, P16810, DOI 10.1074/jbc.M009687200; Watson PJ, 2012, NATURE, V481, P335, DOI 10.1038/nature10728; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yildirim S, 2013, J CELL SCI, V126, P2730, DOI 10.1242/jcs.123661; Zhang B, 2007, ONCOGENE, V26, P7153, DOI 10.1038/sj.onc.1210509; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	48	22	23	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5100	5108		10.1038/onc.2013.447	http://dx.doi.org/10.1038/onc.2013.447			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24166496	Green Accepted			2022-12-17	WOS:000343768400005
J	Basova, P; Pospisil, V; Savvulidi, F; Burda, P; Vargova, K; Stanek, L; Dluhosova, M; Kuzmova, E; Jonasova, A; Steidl, U; Laslo, P; Stopka, T				Basova, P.; Pospisil, V.; Savvulidi, F.; Burda, P.; Vargova, K.; Stanek, L.; Dluhosova, M.; Kuzmova, E.; Jonasova, A.; Steidl, U.; Laslo, P.; Stopka, T.			Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice	ONCOGENE			English	Article						PU.1; leukemia; differentiation; microRNA; p53; AML	HEMATOPOIETIC STEM-CELLS; TRANSCRIPTION FACTOR; MYELODYSPLASTIC SYNDROMES; MICRORNA EXPRESSION; P53 MUTATIONS; MYB; DIFFERENTIATION; GENE; TUMORS		[Basova, P.; Pospisil, V.; Savvulidi, F.; Burda, P.; Vargova, K.; Stanek, L.; Dluhosova, M.; Kuzmova, E.; Jonasova, A.; Stopka, T.] Charles Univ Prague, Dept Pathophysiol, Fac Med 1, Prague 12853 2, Czech Republic; [Basova, P.] Charles Univ Prague, Dept Expt Biomodels, Fac Med 1, Prague 12853 2, Czech Republic; [Stanek, L.] Charles Univ Prague, Dept Pathol, Fac Med 1, Prague 12853 2, Czech Republic; [Jonasova, A.; Stopka, T.] Charles Univ Prague, Dept Med Hematol, Fac Med 1, Prague 12853 2, Czech Republic; [Steidl, U.] Yeshiva Univ, Albert Einstein Coll Med, Bronx, NY USA; [Laslo, P.] Univ Leeds, St Jamess Univ Hosp, Leeds Inst Canc & Pathol, Sect Expt Haematol, Leeds, W Yorkshire, England	Charles University Prague; Charles University Prague; Charles University Prague; Charles University Prague; Yeshiva University; Albert Einstein College of Medicine; Saint James's University Hospital; University of Leeds	Stopka, T (corresponding author), Charles Univ Prague, Dept Pathophysiol, Fac Med 1, U Nemocnice 5, Prague 12853 2, Czech Republic.	tstopka@lf1.cuni.cz	Dluhošová, Martina/AAQ-7694-2021; Anna, Jonasona/U-6166-2017; Pospisil, Vit/M-9429-2017; Basova, Petra/I-8930-2017; Burda, Pavel/K-8219-2017; Kužmová, Erika/H-1520-2014; Vargova, Karina/G-9642-2017; Savvulidi Vargova, Karina/ABE-7513-2021	Anna, Jonasona/0000-0003-0246-1524; Pospisil, Vit/0000-0003-2144-0438; Basova, Petra/0000-0003-0587-4471; Burda, Pavel/0000-0002-2841-792X; Vargova, Karina/0000-0002-4969-4133; Savvulidi Vargova, Karina/0000-0002-4969-4133; Savvulidi, Filipp Georgijevic/0000-0002-4889-837X; Kuzmova, Erika/0000-0002-0728-9578	BIOCEV-Biotechnology and Biomedicine Centre of the Academy of Sciences [GACR P305/12/1033, UNCE 204021, PRVOUK-P24/LF1/3, SVV-2013-266509]; Charles University, from the European Regional Development Fund [CZ.1.05/1.1.00/02.0109]; Leukemia and Lymphoma Research grant;  [GAUK 251135 82210];  [GACR P301/12/P380];  [GAUK 251070 45410];  [GACR 305 13-12449P]	BIOCEV-Biotechnology and Biomedicine Centre of the Academy of Sciences; Charles University, from the European Regional Development Fund; Leukemia and Lymphoma Research grant; ; ; ; 	Primary support: GACR P305/12/1033 Institutional: UNCE 204021, PRVOUK-P24/LF1/3, SVV-2013-266509, BIOCEV-Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (CZ.1.05/1.1.00/02.0109), from the European Regional Development Fund. Other: PB: GAUK 251135 82210, GACR P301/12/P380; MD: GAUK 251070 45410; VP: GACR 305 13-12449P; PL: Leukemia and Lymphoma Research grant.	Abbas HA, 2011, CELL CYCLE, V10, P3257, DOI 10.4161/cc.10.19.17721; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Burda P, 2009, MOL CANCER RES, V7, P1693, DOI 10.1158/1541-7786.MCR-09-0031; Curik N, 2012, LEUKEMIA, V26, P1804, DOI 10.1038/leu.2012.47; Dahl R, 2003, BLOOD CELL MOL DIS, V31, P229, DOI 10.1016/S1079-9796(03)00152-9; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Epstein CB, 1998, ONCOGENE, V16, P2115, DOI 10.1038/sj.onc.1201734; Ghani S, 2011, BLOOD, V118, P2275, DOI 10.1182/blood-2011-02-335141; Haferlach C, 2008, LEUKEMIA, V22, P1539, DOI 10.1038/leu.2008.143; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Leddin M, 2011, BLOOD, V117, P2827, DOI 10.1182/blood-2010-08-302976; Mannefeld M, 2009, CANCER RES, V69, P4073, DOI 10.1158/0008-5472.CAN-08-4156; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nakano Y, 2000, EUR J HAEMATOL, V65, P23, DOI 10.1034/j.1600-0609.2000.90138.x; Neiman PE, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000132; Noel G, 2012, J IMMUNOL METHODS, V382, P81, DOI 10.1016/j.jim.2012.05.008; O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108; O'Connell RM, 2011, BLOOD, V118, P2960, DOI 10.1182/blood-2011-03-291971; Pattabiraman DR, 2013, LEUKEMIA, V27, P269, DOI 10.1038/leu.2012.225; Pospisil V, 2011, EMBO J, V30, P4450, DOI 10.1038/emboj.2011.317; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Sokol L, 2011, BRIT J HAEMATOL, V153, P24, DOI 10.1111/j.1365-2141.2011.08581.x; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Vargova K, 2011, BLOOD, V117, P3816, DOI 10.1182/blood-2010-05-285064; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Zhao Z, 2010, GENE DEV, V24, P1389, DOI 10.1101/gad.1940710	29	22	23	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4735	4745		10.1038/onc.2013.414	http://dx.doi.org/10.1038/onc.2013.414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24121269				2022-12-17	WOS:000343239500004
J	Sagoo, MS; Harbour, JW; Stebbing, J; Bowcock, AM				Sagoo, M. S.; Harbour, J. W.; Stebbing, J.; Bowcock, A. M.			Combined PKC and MEK inhibition for treating metastatic uveal melanoma	ONCOGENE			English	Editorial Material							SOMATIC MUTATIONS; GNAQ; SF3B1	Uveal melanoma (UM) is the most common primary intraocular malignancy and the second most common form of melanoma. UM has a strong tendency for metastatic disease, and no effective treatments have yet been identified. Activating oncogenic mutations are commonly found in GNAQ and GNA11 in UM, and inhibiting key downstream effectors of the GNAQ/11 signaling pathway represents a rational therapeutic approach for treating metastatic UM. Chen et al., doi:10.1038/onc.2013.418, now confirm activation of the MAPK and PKC pathways as a result of GNAQ and GNA11 activating mutations in melanocytes, and they demonstrate that MAPK activation occurs downstream of PKC activation. PKC inhibitors disrupt MAPK signaling and block proliferation of GNAQ/11 mutant UM cell lines and slow the in vivo growth of xenografted UM tumors without inducing their shrinkage. However, a combination of PKC and MEK inhibition led to sustained MAPK pathway inhibition and tumor regression in vivo. Hence, the authors concluded that MEK and PKC inhibition is synergistic, with superior efficacy to treatment of GNAQ/GNA11 mutant UMs with either drug alone.	[Sagoo, M. S.] Moorfields Eye Hosp, Ocular Oncol Serv, London, England; [Sagoo, M. S.] St Bartholomews Hosp, London, England; [Sagoo, M. S.] UCL Inst Ophthalmol, London, England; [Harbour, J. W.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst & Sylvester Comprehens Can, Ocular Oncol Serv, Miami, FL 33136 USA; [Stebbing, J.] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London SW3 6LY, England; [Bowcock, A. M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; Queen Mary University London; University of London; University College London; Bascom Palmer Eye Institute; University of Miami; Imperial College London; Imperial College London	Bowcock, AM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Guy Scadding Bldg,Royal Brompton Campus, London SW3 6LY, England.	a.bowcock@imperial.ac.uk	Harbour, J. William/B-1448-2015	Harbour, J. William/0000-0002-1104-9809; Sagoo, Mandeep/0000-0003-1530-3824; Bowcock, Anne/0000-0001-8691-9090; Stebbing, Justin/0000-0002-1117-6947	NATIONAL CANCER INSTITUTE [R01CA125970] Funding Source: NIH RePORTER; Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish; NCI NIH HHS [5R01 CA12597007, 1R01 CA16187001, R01 CA125970] Funding Source: Medline; Department of Health [NIHR-RP-011-053] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Health		Chen X, 2014, ONCOGENE, V33, P4724, DOI 10.1038/onc.2013.418; Harbour J William, 2013, Am Soc Clin Oncol Educ Book, P388, DOI 10.1200/EdBook_AM.2013.33.388; Harbour JW, 2013, NAT GENET, V45, P133, DOI 10.1038/ng.2523; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Ho AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040439; Khalili JS, 2012, CLIN CANCER RES, V18, P4345, DOI 10.1158/1078-0432.CCR-11-3227; Landreville S, 2012, CLIN CANCER RES, V18, P408, DOI 10.1158/1078-0432.CCR-11-0946; Martin M, 2013, NAT GENET, V45, P933, DOI 10.1038/ng.2674; Onken MD, 2008, INVEST OPHTH VIS SCI, V49, P5230, DOI 10.1167/iovs.08-2145; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Wu XQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029622; Zuidervaart W, 2005, BRIT J CANCER, V92, P2032, DOI 10.1038/sj.bjc.6602598	13	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4722	4723		10.1038/onc.2013.555	http://dx.doi.org/10.1038/onc.2013.555			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24413085	Green Accepted			2022-12-17	WOS:000343239500002
J	Levanon, K; Sapoznik, S; Bahar-Shany, K; Brand, H; Shapira-Frommer, R; Korach, J; Hirsch, MS; Roh, MH; Miron, A; Liu, JF; Vena, N; Ligon, AH; Fotheringham, S; Bailey, D; Flavin, RJ; Birrer, MJ; Drapkin, RI				Levanon, K.; Sapoznik, S.; Bahar-Shany, K.; Brand, H.; Shapira-Frommer, R.; Korach, J.; Hirsch, M. S.; Roh, M. H.; Miron, A.; Liu, J. F.; Vena, N.; Ligon, A. H.; Fotheringham, S.; Bailey, D.; Flavin, R. J.; Birrer, M. J.; Drapkin, R. I.			FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis	ONCOGENE			English	Article						serous ovarian carcinoma; fallopian tube epithelium; FOXO3a; AKT; ERK; miRNA-182	LUNG-CANCER CELLS; TRANSCRIPTION FACTOR; OVARIAN-CANCER; FALLOPIAN-TUBE; PROMOTES TUMORIGENESIS; CANDIDATE PRECURSOR; EXPRESSION; INHIBITORS; CARCINOMA; CHEMOTHERAPY	Serous ovarian carcinoma is the most lethal gynecological malignancy in Western countries. The molecular events that underlie the development of the disease have been elusive for many years. The recent identification of the fallopian tube secretory epithelial cells (FTSECs) as the cell-of-origin for most cases of this disease has led to studies aimed at elucidating new candidate therapeutic pathways through profiling of normal FTSECs and serous carcinomas. Here we describe the results of transcriptional profiles that identify the loss of the tumor suppressive transcription factor FOXO3a in a vast majority of high-grade serous ovarian carcinomas. We show that FOXO3a loss is a hallmark of the earliest stages of serous carcinogenesis and occurs both at the DNA, RNA and protein levels. We describe several mechanisms responsible for FOXO3a inactivity, including chromosomal deletion (chromosome 6q21), upregulation of miRNA-182 and destabilization by activated PI3K and MEK. The identification of pathways involved in the pathogenesis of ovarian cancer can advance the management of this disease from being dependant on surgery and cytotoxic chemotherapy alone to the era of targeted therapy. Our data strongly suggest FOXO3a as a possible target for clinical intervention.	[Levanon, K.] Chaim Sheba Med Ctr, Sheba Canc Res Ctr, Dr Pinchas Borenstein Talpiot Med Leadership Prog, IL-52621 Ramat Gan, Israel; [Levanon, K.; Drapkin, R. I.] Dept Med Oncol, Boston, MA USA; [Levanon, K.; Drapkin, R. I.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Sapoznik, S.; Bahar-Shany, K.; Brand, H.] Sheba Canc Res Ctr, Ramat Gan, Israel; [Sapoznik, S.; Bahar-Shany, K.; Brand, H.] Chaim Sheba Med Ctr, IL-52621 Ramat Gan, Israel; [Brand, H.] Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel; [Shapira-Frommer, R.] Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Ramat Gan, Israel; [Korach, J.; Ligon, A. H.] Chaim Sheba Med Ctr, Dept Gynecol Oncol, IL-52621 Ramat Gan, Israel; [Hirsch, M. S.; Roh, M. H.; Drapkin, R. I.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Miron, A.; Liu, J. F.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Liu, J. F.; Ligon, A. H.; Drapkin, R. I.] Harvard Univ, Sch Med, Boston, MA USA; [Vena, N.; Ligon, A. H.; Fotheringham, S.; Bailey, D.; Flavin, R. J.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA; [Birrer, M. J.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA	Chaim Sheba Medical Center; Harvard University; Dana-Farber Cancer Institute; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital	Levanon, K (corresponding author), Chaim Sheba Med Ctr, Sheba Canc Res Ctr, Dr Pinchas Borenstein Talpiot Med Leadership Prog, IL-52621 Ramat Gan, Israel.	Keren.Levanon@sheba.health.gov.il	Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Flavin, Richard/0000-0002-4993-4563; Fotheringham, Susan/0000-0001-5440-8747; Levanon, Keren/0000-0002-5122-064X	National Institutes of Health/National Cancer Institute [P50 CA105009, U01 CA152990, R21 CA156021]; Ovarian Cancer Research Fund; Mary Kay Foundation; Tina Brozman Foundation; Robert and Debra First Fund; Gamel Family Fund for Ovarian Cancer; Marsha Rivkin Foundation Scientific Scholar Award; AACR- George and Patricia Sehl Fellowship; American Physicians Fellowship for Medicine in Israel-Claire and Emmanuel G. Rosenblatt Foundation Grant; Israel Science Foundation Legacy Heritage Clinical Research Initiative; Israel Cancer Research Fund Clinical Research Career Development Award; Chaim Sheba Medical Center Dr Pinchas Bornstein Talpiot Medical Leadership Program; NATIONAL CANCER INSTITUTE [R21CA156021, P50CA105009, U01CA152990] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ovarian Cancer Research Fund; Mary Kay Foundation; Tina Brozman Foundation; Robert and Debra First Fund; Gamel Family Fund for Ovarian Cancer; Marsha Rivkin Foundation Scientific Scholar Award; AACR- George and Patricia Sehl Fellowship; American Physicians Fellowship for Medicine in Israel-Claire and Emmanuel G. Rosenblatt Foundation Grant; Israel Science Foundation Legacy Heritage Clinical Research Initiative; Israel Cancer Research Fund Clinical Research Career Development Award; Chaim Sheba Medical Center Dr Pinchas Bornstein Talpiot Medical Leadership Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by research grants from the National Institutes of Health/National Cancer Institute (P50 CA105009, U01 CA152990, and R21 CA156021), the Ovarian Cancer Research Fund, The Mary Kay Foundation, The Tina Brozman Foundation, The Robert and Debra First Fund, the Gamel Family Fund for Ovarian Cancer, the Marsha Rivkin Foundation Scientific Scholar Award, the AACR- George and Patricia Sehl Fellowship for Cancer Genetics Research, the American Physicians Fellowship for Medicine in Israel-Claire and Emmanuel G. Rosenblatt Foundation Grant, The Israel Science Foundation Legacy Heritage Clinical Research Initiative, The Israel Cancer Research Fund Clinical Research Career Development Award and the Chaim Sheba Medical Center Dr Pinchas Bornstein Talpiot Medical Leadership Program. We thank Drs. John Quackenbush, Massimo Loda, Keith Ligon and Sekhar Duraisamy, Dana-Farber Cancer Institute, for their suggestions and generous assistance with reagents and bioinformatics; Dr Ravid Straussman, the Broad Institute, for his guidance with methylation detection; Dr Sol Efroni and Rotem Ben-Hamo, Bar Ilan University, Israel, for bioinformatic support; and The Chaim Sheba Tissue Bank.	Barreyro FJ, 2007, J BIOL CHEM, V282, P27141, DOI 10.1074/jbc.M704391200; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Carter ME, 2007, CURR BIOL, V17, pR113, DOI 10.1016/j.cub.2007.01.008; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Dejean AS, 2009, NAT IMMUNOL, V10, P504, DOI 10.1038/ni.1729; Fei M, 2009, CANCER INVEST, V27, P52, DOI 10.1080/07357900802146204; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Folkins AK, 2008, GYNECOL ONCOL, V109, P168, DOI 10.1016/j.ygyno.2008.01.012; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Gomes AR, 2008, CELL CYCLE, V7, P3133, DOI 10.4161/cc.7.20.6920; Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Jarboe EA, 2008, HISTOPATHOLOGY, V53, P127, DOI 10.1111/j.1365-2559.2007.02938.x; Karst AM, 2012, NAT PROTOC, V7, P1755, DOI 10.1038/nprot.2012.097; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Kim W, 2013, PHARMACOL RES, V70, P90, DOI 10.1016/j.phrs.2013.01.005; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kornblau SM, 2010, CLIN CANCER RES, V16, P1865, DOI 10.1158/1078-0432.CCR-09-2551; Kuhn RM, 2009, NUCLEIC ACIDS RES, V37, pD755, DOI 10.1093/nar/gkn875; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Lu MD, 2012, MED ONCOL, V29, P3409, DOI 10.1007/s12032-012-0275-z; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nakamura T, 2008, MOL CELL ENDOCRINOL, V281, P47, DOI 10.1016/j.mce.2007.10.007; Osuka S, 2013, STEM CELLS, V31, P627, DOI 10.1002/stem.1328; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Potente M, 2005, J CLIN INVEST, V115, P2382, DOI 10.1172/JCI23126; Rathbone CR, 2008, MUSCLE NERVE, V37, P84, DOI 10.1002/mus.20897; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Santo EE, 2007, CANCER RES, V73, P2189; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Su JL, 2011, CANCER RES, V71, P6878, DOI 10.1158/0008-5472.CAN-11-0295; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wilicox BJ, 2008, P NATL ACAD SCI USA, V105, P13987, DOI 10.1073/pnas.0801030105; Yamaguchi H, 2013, CLIN CANCER RES, V19, P845, DOI 10.1158/1078-0432.CCR-12-2621; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yap TA, 2009, NAT REV CANCER, V9, P167, DOI 10.1038/nrc2583; Zhao Fung, 2012, Front Med, V6, P376, DOI 10.1007/s11684-012-0228-0	47	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4424	4432		10.1038/onc.2013.394	http://dx.doi.org/10.1038/onc.2013.394			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24077281	Green Submitted, Green Accepted			2022-12-17	WOS:000341157800007
J	Shain, KH; Tao, J				Shain, K. H.; Tao, J.			The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies	ONCOGENE			English	Review						BCR; microenviroment; lymphoma; drug resistance	CHRONIC LYMPHOCYTIC-LEUKEMIA; SPLEEN TYROSINE KINASE; NF-KAPPA-B; BONE-MARROW MICROENVIRONMENT; MULTIPLE-MYELOMA; STROMAL CELLS; MANTLE-CELL; THERAPEUTIC TARGET; ACTIVATING FACTOR; TUMOR-CELLS	Specific niches within the lymphoma tumor microenvironment (TME) provide sanctuary for subpopulations of tumor cells through stromal cell-tumor cell interactions. These interactions notably dictate growth, response to therapy and resistance of residual malignant B cells to therapeutic agents. This minimal residual disease (MRD) remains a major challenge in the treatment of B-cell malignancies and contributes to subsequent disease relapse. B-cell receptor (BCR) signaling has emerged as essential mediator of B-cell homing, survival and environment-mediated drug resistance (EMDR). Central to EMDR are chemokine- and integrin-mediated interactions between lymphoma and the TME. Further, stromal cell-B cell adhesion confers a sustained BCR signaling leading to chemokine and integrin activation. Recently, the inhibitors of BCR signaling have garnered a substantial clinical interest because of their effectiveness in B-cell disorders. The efficacy of these agents is, at least in part, attributed to attenuation of BCR-dependent lymphoma-TME interactions. In this review, we discuss the pivotal role of BCR signaling in the integration of intrinsic and extrinsic determinants of TME-mediated lymphoma survival and drug resistance.	[Shain, K. H.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Med Program, Tampa, FL 33612 USA; [Shain, K. H.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol & Chem Biol, Tampa, FL 33612 USA; [Tao, J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematopathol, Tampa, FL 33612 USA; [Tao, J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Lab Med & Chem Biol, Tampa, FL 33612 USA; [Tao, J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Med Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Tao, J (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Med Program, Tampa, FL 33612 USA.	Jianguo.Tao@moffitt.org			NCI NIH HHS [P30 CA076292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA076292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Arana E, 2008, J CELL SCI, V121, P2279, DOI 10.1242/jcs.017905; Attal M, 2012, NEW ENGL J MED, V366, P1782, DOI 10.1056/NEJMoa1114138; Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood-2011-09-380410; Azab AK, 2009, BLOOD, V114, P619, DOI 10.1182/blood-2009-01-199281; Azab AK, 2009, BLOOD, V113, P4341, DOI 10.1182/blood-2008-10-186668; Baran-Marszak F, 2010, HAEMATOL-HEMATOL J, V95, P1865, DOI 10.3324/haematol.2009.019745; Bossen C, 2008, BLOOD, V111, P1004, DOI 10.1182/blood-2007-09-110874; Buchner M, 2009, CANCER RES, V69, P5424, DOI 10.1158/0008-5472.CAN-08-4252; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Burger JA, 2012, CURR OPIN ONCOL, V24, P643, DOI 10.1097/CCO.0b013e3283589950; Burger JA, 2009, BLOOD, V114, P3367, DOI 10.1182/blood-2009-06-225326; Byrd JC, 2012, BLOOD, V120, P21; Carrasco YR, 2006, EMBO J, V25, P889, DOI 10.1038/sj.emboj.7600944; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; de Gorter DJJ, 2007, IMMUNITY, V26, P93, DOI 10.1016/j.immuni.2006.11.012; de Gorter DJJ, 2007, J IMMUNOL, V178, P1405, DOI 10.4049/jimmunol.178.3.1405; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; de Rooij MFM, 2012, BLOOD, V119, P2590, DOI 10.1182/blood-2011-11-390989; Do RKG, 2000, J EXP MED, V192, P953, DOI 10.1084/jem.192.7.953; Friedberg JW, 2010, BLOOD, V115, P2578, DOI 10.1182/blood-2009-08-236471; Gilbert LA, 2012, GENE DEV, V26, P1758, DOI 10.1101/gad.197590.112; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Grzesiak JJ, 2007, SURGERY, V141, P804, DOI 10.1016/j.surg.2006.12.016; Hall BM, 2004, CANCER LETT, V207, P229, DOI 10.1016/j.canlet.2003.10.033; Hall BM, 2004, LEUKEMIA LYMPHOMA, V45, P35, DOI 10.1080/1042819031000139620; Hallek M, 1997, EXP HEMATOL, V25, P1367; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Herman SEM, 2012, ASH ANN M, V120, P185; Herreros B, 2008, LEUKEMIA, V22, P49, DOI 10.1038/sj.leu.2404970; Hoellenriegel J, 2012, LEUKEMIA, V26, P1576, DOI 10.1038/leu.2012.24; Hoellenriegel J., 2012, ASH ANN M, V120, P186; Hoellenriegel J, 2011, BLOOD, V118, P3603, DOI 10.1182/blood-2011-05-352492; Ikeda H, 2010, BLOOD, V116, P1460, DOI 10.1182/blood-2009-06-222943; Kern C, 2004, BLOOD, V103, P679, DOI 10.1182/blood-2003-02-0540; Khare SD, 2000, P NATL ACAD SCI USA, V97, P3370, DOI 10.1073/pnas.050580697; Kurtova AV, 2009, BLOOD, V114, P4441, DOI 10.1182/blood-2009-07-233718; Lam KP, 1998, P NATL ACAD SCI USA, V95, P13171, DOI 10.1073/pnas.95.22.13171; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; Lannutti BJ, 2011, BLOOD, V117, P591, DOI 10.1182/blood-2010-03-275305; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Lu Y, 2004, CLIN EXP METASTAS, V21, P399, DOI 10.1007/s10585-005-0056-6; Lwin T, 2007, LEUKEMIA, V21, P1521, DOI 10.1038/sj.leu.2404723; Lwin T, 2009, LEUKEMIA, V23, P170, DOI 10.1038/leu.2008.266; Lwin T, 2007, BLOOD, V110, P1631, DOI 10.1182/blood-2006-11-060350; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; McCaig AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048929; McCarthy PL, 2012, NEW ENGL J MED, V366, P1770, DOI 10.1056/NEJMoa1114083; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Medina DJ, 2012, HAEMATOL-HEMATOL J, V97, P1255, DOI 10.3324/haematol.2011.040659; Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood-2003-06-1984; Ngo HT, 2008, BLOOD, V112, P150, DOI 10.1182/blood-2007-12-129395; Niedermeier M, 2009, BLOOD, V113, P5549, DOI 10.1182/blood-2008-06-165068; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Perez LE, 2008, J IMMUNOL, V180, P1545, DOI 10.4049/jimmunol.180.3.1545; Quiroga MP, 2009, BLOOD, V114, P1029, DOI 10.1182/blood-2009-03-212837; Rushworth SA, 2013, CELL SIGNAL, V25, P106, DOI 10.1016/j.cellsig.2012.09.008; Saito K, 2003, IMMUNITY, V19, P669, DOI 10.1016/S1074-7613(03)00297-8; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; Schweighoffer E, 2013, IMMUNITY, V38, P475, DOI 10.1016/j.immuni.2012.11.015; Shain KH, 2009, EXPERT REV HEMATOL, V2, P649, DOI [10.1586/ehm.09.55, 10.1586/EHM.09.55]; Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008-5472.CAN-08-2419; Shain KH, 2001, MOL CANCER THER, V1, P69; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; Spaargaren M, 2003, J EXP MED, V198, P1539, DOI 10.1084/jem.20011866; Staudt LM, 2012, ASH ANN M, V120, pSCI; Stein R, 2010, BLOOD, V115, P5180, DOI 10.1182/blood-2009-06-228288; Tai YT, 2012, BLOOD, V120, P1877, DOI 10.1182/blood-2011-12-396853; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Thiel S, 2000, FEBS LETT, V470, P15, DOI 10.1016/S0014-5793(00)01276-X; Vij R, 2012, BLOOD, V120, P21; Vora KA, 2003, J IMMUNOL, V171, P547, DOI 10.4049/jimmunol.171.2.547; Woyach JA, 2012, BLOOD, V120, P1175, DOI 10.1182/blood-2012-02-362624; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Young RM, 2013, NAT REV DRUG DISCOV, V12, P229, DOI 10.1038/nrd3937; Zhang L, 2012, BLOOD, V120, P3783, DOI 10.1182/blood-2012-04-424630	81	22	23	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4107	4113		10.1038/onc.2013.379	http://dx.doi.org/10.1038/onc.2013.379			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24037527	Green Accepted			2022-12-17	WOS:000340595700001
J	Park, JW; Shin, MK; Lambert, PF				Park, J. W.; Shin, M-K; Lambert, P. F.			High incidence of female reproductive tract cancers in FA-deficient HPV16-transgenic mice correlates with E7's induction of DNA damage response, an activity mediated by E7's inactivation of pocket proteins	ONCOGENE			English	Article						HPV16 E7; HPV-positive cancer; Fanconi anemia	HUMAN-PAPILLOMAVIRUS TYPE-16; FANCONI-ANEMIA PATHWAY; FANCD2 KNOCKOUT MICE; CERVICAL-CANCER; MOUSE MODEL; NECK-CANCER; CELL-CYCLE; S-PHASE; GENOMIC INSTABILITY; LIFE-CYCLE	Fanconi anemia (FA) is a rare genetic disorder caused by defects in a DNA damage repair system, the FA pathway. FA patients frequently develop squamous cell carcinoma (SCC) at sites that are associated with human papillomavirus (HPV)-driven cancer including the female reproductive tract. To assess experimentally whether FA deficiency increases susceptibility to HPV-associated cervical/vaginal cancer, we monitored cancer incidence in the female lower reproductive tract of FA-deficient mice expressing HPV16 oncogenes, E6 and/or E7. FA deficiency specifically increased the incidence of cancers in mice expressing E7; but this effect was not observed in mice just expressing E6. We also observed that E7, but not E6, induced DNA damage as scored by induction of g-H2AX and 53BP1 (p53 binding protein 1) nuclear foci, and this induction was heightened in FA-deficient tissue. Finally, we discovered that this induction of DNA damage responses was recapitulated in mice deficient in expression of `pocket' proteins, pRb, p107 and p130, which are established targets of E7. Our findings support the hypothesis that E7 induces cancer by causing DNA damage at least in part through the inactivation of pocket proteins. This hypothesis explains why a deficiency in DNA damage repair would increase susceptibility to E7-driven cancer.	[Park, J. W.; Shin, M-K; Lambert, P. F.] Univ Wisconsin, McArdle Lab Canc Res, Sch Med & Publ Hlth, Dept Oncol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Lambert, PF (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	lambert@oncology.wisc.edu		Park, Jung Wook/0000-0003-4798-9621	NIH [CA098428, CA022443]; NATIONAL CANCER INSTITUTE [R01CA098428, P01CA022443] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Norman Drinkwater for advice on statistical analysis of the data reported in this study and Markus Grompe for the fancD2-null mouse strain. This study was supported by grants from the NIH (CA098428 and CA022443).	Alter BP, 2003, BLOOD, V101, P2072, DOI 10.1182/blood-2002-11-3597; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Begum S, 2005, CLIN CANCER RES, V11, P5694, DOI 10.1158/1078-0432.CCR-05-0587; Brake T, 2003, CANCER RES, V63, P8173; Chung SH, 2008, CANCER RES, V68, P9928, DOI 10.1158/0008-5472.CAN-08-2051; Collins AS, 2005, J VIROL, V79, P14769, DOI 10.1128/JVI.79.23.14769-14780.2005; Crossan GP, 2012, J PATHOL, V226, P326, DOI 10.1002/path.3002; de Araujo MR, 2011, ORAL DIS, V17, P572, DOI 10.1111/j.1601-0825.2011.01803.x; Duensing S, 2002, CANCER RES, V62, P7075; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; Garner E, 2011, FEBS LETT, V585, P2853, DOI 10.1016/j.febslet.2011.04.078; Genther SM, 2003, J VIROL, V77, P2832, DOI 10.1128/JVI.77.5.2832-2842.2003; Gillison ML, 2004, LANCET, V363, P1488, DOI 10.1016/S0140-6736(04)16194-1; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Ho VM, 2009, ONCOGENE, V28, P1393, DOI 10.1038/onc.2008.491; Hoskins EE, 2009, ONCOGENE, V28, P674, DOI 10.1038/onc.2008.416; Hoskins EE, 2012, J VIROL, V86, P8131, DOI 10.1128/JVI.00408-12; Houghtaling S, 2005, CANCER RES, V65, P85; Houghtaling S, 2003, GENE DEV, V17, P2021, DOI 10.1101/gad.1103403; Huh KW, 2005, P NATL ACAD SCI USA, V102, P11492, DOI 10.1073/pnas.0505337102; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Juko-Pecirep I, 2011, GYNECOL ONCOL, V122, P377, DOI 10.1016/j.ygyno.2011.04.014; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Knipscheer P, 2009, SCIENCE, V326, P1698, DOI 10.1126/science.1182372; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; Liu TX, 2003, DEV CELL, V5, P903, DOI 10.1016/S1534-5807(03)00339-3; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; MAYOL X, 1993, ONCOGENE, V8, P2561; McLaughlin-Drubin ME, 2009, VIROLOGY, V384, P335, DOI 10.1016/j.virol.2008.10.006; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Park JW, 2010, CANCER RES, V70, P9959, DOI 10.1158/0008-5472.CAN-10-1291; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Pyeon D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000318; Riley RR, 2003, CANCER RES, V63, P4862; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Schaffer BE, 2010, CANCER RES, V70, P3877, DOI 10.1158/0008-5472.CAN-09-4228; Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(13)60022-7; Shai A, 2008, CANCER RES, V68, P2622, DOI 10.1158/0008-5472.CAN-07-5266; Shai A, 2007, CANCER RES, V67, P1626, DOI 10.1158/0008-5472.CAN-06-3344; Shin MK, 2012, CANCER RES, V72, P5418, DOI 10.1158/0008-5472.CAN-12-2083; Shin MK, 2012, CANCER RES, V72, P1280, DOI 10.1158/0008-5472.CAN-11-2833; Shin MK, 2009, CANCER RES, V69, P5656, DOI 10.1158/0008-5472.CAN-08-3711; Simpson DS, 2009, CANCER RES, V69, P8733, DOI 10.1158/0008-5472.CAN-09-1359; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Spardy N, 2007, J VIROL, V81, P13265, DOI 10.1128/JVI.01121-07; Strati K, 2006, P NATL ACAD SCI USA, V103, P14152, DOI 10.1073/pnas.0606698103; Sun A, 2007, J CELL BIOCHEM, V102, P1400, DOI 10.1002/jcb.21609; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Wang SS, 2009, J INFECT DIS, V199, P20, DOI 10.1086/595563; Watson M, 2008, CANCER-AM CANCER SOC, V113, P2841, DOI 10.1002/cncr.23758; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Zhang QS, 2010, BLOOD, V116, P5140, DOI 10.1182/blood-2010-04-278226	59	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3383	3391		10.1038/onc.2013.327	http://dx.doi.org/10.1038/onc.2013.327			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	24013229	Green Accepted			2022-12-17	WOS:000338779300005
J	Garrido, G; Rabasa, A; Garrido, C; Lopez, A; Chao, L; Garcia-Lora, AM; Garrido, F; Fernandez, LE; Sanchez, B				Garrido, G.; Rabasa, A.; Garrido, C.; Lopez, A.; Chao, L.; Garcia-Lora, A. M.; Garrido, F.; Fernandez, L. E.; Sanchez, B.			Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms	ONCOGENE			English	Article						EGFR; monoclonal antibodies; resistance; MHC-I alterations	MHC CLASS-I; METASTATIC COLORECTAL-CANCER; COORDINATED DOWN-REGULATION; SQUAMOUS-CELL CARCINOMA; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; LUNG-CANCER; TUMOR-CELLS; PHASE-III; CETUXIMAB	To define the molecular basis of secondary resistance to epidermal growth factor receptor (EGFR)-specific antibodies is crucial to increase clinical benefit in patients. The limited access to posttreatment tumor samples constitutes the major barrier to conduct these studies, representing preclinical experimentation as a useful alternative. Anti-EGFR antibody-based therapy has been reported to mediate tumor regression by interrupting oncogenic signals and, more recently, by inducing antitumor immunological responses. However, resistance models have been focused only on tumor escape associated with EGFR blockade, whereas studies describing immune-associated escape mechanisms have not been reported thus far. To address this idea, we modeled resistance induction in D122 metastasis-bearing C57BL/6 mice treated with 7A7 (an anti-murine EGFR antibody). Similarly to patients receiving EGFR-specific antibodies, 7A7 resistance promotion represents an important drawback to successful therapy. Characterization of primary cultures derived from metastasis in 7A7-treated mice revealed a high frequency of tumor variants resistant to in vivo and in vitro antibody treatment. We showed, for the first time, the convergence of alterations in oncogenic and immunological pathways in 7A7-resistant variants. To identify key molecules behind resistance, seven 7A7-resistant variants were screened. HER3 overexpression and PTEN deficiency leading to hyperactivation of protumoral downstream signaling were found in these variants as a consequence of 7A7-mediated EGFR inhibition. Concomitantly, we found a high percentage of resistant variants carrying abnormalities in the constitutive and/or interferon gamma (IFN-gamma)-inducible major histocompatibility complex I (MHC-I) expression. A significant decrease in mRNA levels for MHC-I heavy chains, beta(2)-microglogulin and antigen processing machinery genes as well as transcriptional alterations in IFN-gamma pathway components were identified as the main mechanisms underlying MHC-I expression defects in 7A7-resistant variants. Notably, these defects have not been previously associated with EGFR-specific antibody resistance, providing novel immunological escape mechanisms. This study has strong implications for the development of new combination strategies to overcome anti-EGFR antibodies refractoriness.	[Garrido, G.; Rabasa, A.; Chao, L.; Sanchez, B.] Ctr Mol Immunol, Tumor Immunol Direct, Inst Mol Immunol, Havana 11600, Cuba; [Garrido, C.; Garcia-Lora, A. M.; Garrido, F.] Hosp Univ VirgenNieves, Dept Anal Clin & Inmunol, Granada, Spain; [Garrido, C.; Garrido, F.] Univ Granada, Fac Med, Dept Bioquim Biol Mol & Inmunol 3, Granada, Spain; [Lopez, A.] Ctr Mol Immunol, Syst Biol Direct, Inst Mol Immunol, Havana 11600, Cuba; [Fernandez, L. E.] Ctr Mol Immunol, Innovat Direct, Inst Mol Immunol, Havana 11600, Cuba	University of Granada	Sanchez, B (corresponding author), Ctr Mol Immunol, Tumor Immunol Direct, Inst Mol Immunol, 216 St & 15th Ave,POB 16040, Havana 11600, Cuba.	belinda@cim.sld.cu	Garrido, Cristina/H-5974-2015	Garrido, Cristina/0000-0002-6277-4920; Garcia Lora, Angel Miguel/0000-0002-8248-8235; Garrido Torres-Puchol, Federico/0000-0003-4770-9685; RABASA CAPOTE, AILEM/0000-0002-4250-2725	Cuban Government; Boehringer Ingelheim Fonds; Instituto de Salud Carlos III [CP03/0111, P112/02031, PI 08/1265, PI 11/01022, RETIC RD 06/020]; Junta de Andalucia, Spain [CTS-143, CTS-695, CTS-3952, CVI-4740]; MEC (FPU) [1631]; FPS [CP03/0111, I3]; ISCIII, Spain	Cuban Government; Boehringer Ingelheim Fonds(Boehringer Ingelheim); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Junta de Andalucia, Spain(Junta de AndaluciaEuropean Commission); MEC (FPU)(Spanish Government); FPS; ISCIII, Spain(Instituto de Salud Carlos III)	We thank Isabel Linares and Ignacio Algarra for technical assistance. This work was partially supported by Cuban Government, a grant from Boehringer Ingelheim Fonds and by grants from the Instituto de Salud Carlos III (CP03/0111, P112/02031, PI 08/1265, PI 11/01022, RETIC RD 06/020); Junta de Andalucia (Group CTS-143 and CTS-695, CTS-3952, CVI-4740 grants), Spain. CG was supported by the MEC (FPU, 1631). AMGL was supported by Miguel Servet Contract CP03/0111 and Contract I3 from FPS and ISCIII, Spain.	Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Aptsiauri N, 2007, INT REV CYTOL, V256, P139, DOI 10.1016/S0074-7696(07)56005-5; Bianchi F, 2006, P NATL ACAD SCI USA, V103, P18981, DOI 10.1073/pnas.0605821103; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Brand TM, 2011, CANCER BIOL THER, V11, P777, DOI 10.4161/cbt.11.9.15050; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Correale P, 2012, INT J CANCER, V130, P1577, DOI 10.1002/ijc.26181; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; Duncan TJ, 2007, CLIN CANCER RES, V13, P4139, DOI 10.1158/1078-0432.CCR-06-2833; EISENBACH L, 1984, INT J CANCER, V34, P567, DOI 10.1002/ijc.2910340421; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Erjala K, 2006, CLIN CANCER RES, V12, P4103, DOI 10.1158/1078-0432.CCR-05-2404; Garcia-Lora A, 2003, INT J CANCER, V106, P521, DOI 10.1002/ijc.11241; Garrido C, 2012, CARCINOGENESIS, V33, P687, DOI 10.1093/carcin/bgr318; Garrido C, 2010, CANCER IMMUNOL IMMUN, V59, P13, DOI 10.1007/s00262-009-0716-5; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; Garrido F, 2010, INT J CANCER, V127, P249, DOI 10.1002/ijc.25270; Garrido G, 2004, HYBRIDOMA HYBRIDOM, V23, P168, DOI 10.1089/1536859041224280; Garrido G, 2007, CANCER IMMUNOL IMMUN, V56, P1701, DOI 10.1007/s00262-007-0313-4; Garrido G, 2011, J IMMUNOL, V187, P4954, DOI 10.4049/jimmunol.1003477; Groettrup M, 1997, P NATL ACAD SCI USA, V94, P8970, DOI 10.1073/pnas.94.17.8970; Herrmann F, 2004, CANCER RES, V64, P215, DOI 10.1158/0008-5472.CAN-2522-2; Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kelly-Spratt KS, 2009, ONCOGENE, V28, P3652, DOI 10.1038/onc.2009.226; Kim SM, 2010, CANCER LETT, V296, P150, DOI 10.1016/j.canlet.2010.04.006; Meissner M, 2005, CLIN CANCER RES, V11, P2552, DOI 10.1158/1078-0432.CCR-04-2146; Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055; Perez Rolando, 2011, Cancers (Basel), V3, P2014, DOI 10.3390/cancers3022014; Pollack BP, 2011, CLIN CANCER RES, V17, P4400, DOI 10.1158/1078-0432.CCR-10-3283; PORGADOR A, 1991, INT J CANCER, P54; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Reichert JM, 2012, DRUG DISCOV TODAY, V17, P954, DOI 10.1016/j.drudis.2012.04.006; Romero I, 2012, J PATHOL, V227, P367, DOI 10.1002/path.4029; Romero JM, 2005, INT J CANCER, V113, P605, DOI 10.1002/ijc.20499; Seliger B, 2008, ADV CANCER RES, V101, P249, DOI 10.1016/S0065-230X(08)00407-7; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Srivastava RM, 2013, CLIN CANCER RES, V19, P1858, DOI 10.1158/1078-0432.CCR-12-2426; Talavera A, 2011, MOL IMMUNOL, V48, P1578, DOI 10.1016/j.molimm.2011.03.016; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009; Xi SC, 2006, JNCI-J NATL CANCER I, V98, P181, DOI 10.1093/jnci/djj020; Yang XM, 2013, MOL THER, V21, P91, DOI 10.1038/mt.2012.184; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309	48	22	22	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3129	3139		10.1038/onc.2013.288	http://dx.doi.org/10.1038/onc.2013.288			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23975426	Bronze			2022-12-17	WOS:000338410000006
J	Khanna, P; Chung, CY; Neves, RI; Robertson, GP; Dong, C				Khanna, P.; Chung, C-Y; Neves, R. I.; Robertson, G. P.; Dong, C.			CD82/KAI expression prevents IL-8-mediated endothelial gap formation in late-stage melanomas	ONCOGENE			English	Article						melanoma metastasis; CD82; IL-8; adhesion	DUFFY ANTIGEN RECEPTOR; CANCER-RELATED INFLAMMATION; TUMOR-SUPPRESSOR MECHANISM; METASTASIS SUPPRESSION; CELLULAR SENESCENCE; BARRIER FUNCTION; LUNG METASTASIS; CELLS; INTERLEUKIN-8; DARC	Melanoma cells facilitate endothelial gap formation, the first step during tumor transendothelial migration, which is mediated by both adhesion and endogenously produced chemokines (in particular, interleukin-8 ( IL- 8)). Tetraspanins are localized to the cell surface in cancer and participate in various functions including invasion of tissues mediated by secretion of cytokines and matrix metalloproteinases. However, little is known about the role of CD82 tetraspanins in malignant melanomas during cancer cell invasion. In this study, we investigated the functional importance of CD82 expression in melanoma-mediated gap formation by using cDNAs to induce CD82 expression in highly invasive melanoma cell lines. Results showed that CD82 expression inhibited melanoma cell-induced gap formation, melanoma cell extravasation in vitro and subsequent lung metastasis development in vivo. Mechanistic studies showed that inducible expression of CD82 in highly metastatic melanoma cells significantly increased p21 expression upon binding of Duffy antigen receptor group (DARC), inducing tumor cell senescence and interrupting IL-8-mediated vascular endothelial (VE)-cadherin disassembly. Taken together, these studies provide a rationale for using drug therapies that restore CD82 expression and inhibit IL-8 production to inhibit late-stage melanoma cell extravasation and subsequent metastasis development.	[Khanna, P.; Dong, C.] Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA; [Chung, C-Y; Neves, R. I.; Robertson, G. P.] Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA; [Neves, R. I.; Robertson, G. P.] Penn State Univ, Coll Med, Dept Dermatol, Hershey, PA 17033 USA; [Neves, R. I.; Robertson, G. P.] Penn State Univ, Coll Med, Penn State Melanoma Therapeut Program, Hershey, PA 17033 USA; [Neves, R. I.] Penn State Univ, Coll Med, Cutaneous Oncol Program, Hershey, PA 17033 USA; [Neves, R. I.] Penn State Univ, Coll Med, Div Plast Surg, Dept Surg, Hershey, PA 17033 USA; [Robertson, G. P.] Penn State Univ, Coll Med, Dept Pathol, Hershey, PA 17033 USA; [Robertson, G. P.; Dong, C.] Penn State Univ, Coll Med, Penn State Melanoma Ctr, Hershey, PA 17033 USA; [Robertson, G. P.] Penn State Univ, Coll Med, Foreman Fdn Melanoma Res, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Dong, C (corresponding author), Penn State Univ, Dept Bioengn, 205 Hallowell Bldg, University Pk, PA 16802 USA.	gprobertson@psu.edu; cxd23@psu.edu	Neves, Rogerio Izar/AAV-5842-2020; Robertson, Gavin P./A-6106-2017	Neves, Rogerio Izar/0000-0003-4866-5215; Robertson, Gavin P./0000-0003-0152-2997	NIH [CA-127892-01A1, CA-125707]; American Cancer Society [RSG-04-053-01-GMC]; Foreman Foundation for Melanoma Research; Johnson & Johnson Innovative Technology Research Seed Grant Program; NATIONAL CANCER INSTITUTE [R01CA127892, R01CA125707] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Foreman Foundation for Melanoma Research; Johnson & Johnson Innovative Technology Research Seed Grant Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Chris Goodrich who kindly provided technical support. We also acknowledge Dr Meenhard Herlyn for kindly providing WM35 and WM793 cells. We thank Dr Justin Brown for letting us use his Odyssey system to develop the western blots. This work was supported by NIH Grant CA-127892-01A1, American Cancer Society Grant RSG-04-053-01-GMC and The Foreman Foundation for Melanoma Research (GPR); NIH Grants CA-125707 (CD); and Johnson & Johnson Innovative Technology Research Seed Grant Program (CD and GPR).	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2009, CANCER RES, V69, P2167, DOI 10.1158/0008-5472.CAN-08-3772; Bandyopadhyay S, 2006, NAT MED, V12, P933, DOI 10.1038/nm1444; BRODLAND DG, 1992, J AM ACAD DERMATOL, V27, P1, DOI 10.1016/0190-9622(92)70146-7; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Criscuoli ML, 2005, BLOOD, V105, P1508, DOI 10.1182/blood-2004-06-2246; Dejana E, 1999, EXP CELL RES, V252, P13, DOI 10.1006/excr.1999.4601; Dong Cheng, 2005, Molecular & Cellular Biomechanics, V2, P145; Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511; Gabellini C, 2009, EUR J CANCER, V45, P2618, DOI 10.1016/j.ejca.2009.07.007; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gavard J, 2009, FEBS LETT, V583, P1, DOI 10.1016/j.febslet.2008.11.032; Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014; Giuliano S, 2011, PIGM CELL MELANOMA R, V24, P295, DOI 10.1111/j.1755-148X.2010.00820.x; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Houben R, 2009, J INVEST DERMATOL, V129, P406, DOI 10.1038/jid.2008.214; Huh SJ, 2010, CANCER RES, V70, P6071, DOI 10.1158/0008-5472.CAN-09-4442; Iiizumi M, 2007, CANCER RES, V67, P1411, DOI 10.1158/0008-5472.CAN-06-3801; Ishikawa F, 2003, CANCER SCI, V94, P944, DOI 10.1111/j.1349-7006.2003.tb01382.x; Khanna P, 2010, AM J PHYSIOL-CELL PH, V298, pC1140, DOI 10.1152/ajpcell.00242.2009; Leong SR, 1997, PROTEIN SCI, V6, P609; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Liang S, 2008, CELL MOL BIOENG, V1, P189, DOI 10.1007/s12195-008-0016-8; Liu SC, 2009, CANCER LETT, V286, P240, DOI 10.1016/j.canlet.2009.05.038; Liu WM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051797; LLeonart ME, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-3; Lombardi DP, 1999, CANCER RES, V59, P5724; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Murdoch C, 1999, CYTOKINE, V11, P704, DOI 10.1006/cyto.1998.0465; Nagasawa K, 2006, J CELL PHYSIOL, V208, P123, DOI 10.1002/jcp.20647; NICOLSON GL, 1982, J HISTOCHEM CYTOCHEM, V30, P214, DOI 10.1177/30.3.7061823; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; Peng HH, 2005, FRONT BIOSCI-LANDMRK, V10, P1597, DOI 10.2741/1643; Peng HH, 2007, EXP CELL RES, V313, P551, DOI 10.1016/j.yexcr.2006.10.030; Romanska HM, 2011, J PATHOL, V223, P4, DOI 10.1002/path.2779; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sharma A, 2006, CANCER RES, V66, P8200, DOI 10.1158/0008-5472.CAN-06-0809; Shevde LA, 2003, CANCER LETT, V198, P1, DOI 10.1016/S0304-3835(03)00304-5; Singethan Katrin, 2008, Commun Integr Biol, V1, P11; Singh RK, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-57; Singh RK, 2000, HISTOL HISTOPATHOL, V15, P843, DOI 10.14670/HH-15.843; SINGH RK, 1994, CANCER RES, V54, P3242; Singh S, 2009, CANCER RES, V69, P411, DOI 10.1158/0008-5472.CAN-08-3378; Takaoka A, 1998, JPN J CANCER RES, V89, P397, DOI 10.1111/j.1349-7006.1998.tb00577.x; Tran MA, 2008, CANCER RES, V68, P7638, DOI 10.1158/0008-5472.CAN-07-6614; Tsai YC, 2011, FEBS LETT, V585, P3166, DOI 10.1016/j.febslet.2011.08.031; VERIN AD, 1995, AM J PHYSIOL-LUNG C, V269, pL99, DOI 10.1152/ajplung.1995.269.1.L99; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Wu SW, 2012, ARCH IRAN MED, V15, P707, DOI 0121511/AIM.0012; Xu CF, 2009, FASEB J, V23, P3273, DOI 10.1096/fj.08-123414; Zarbock A, 2010, AM J PHYSIOL-LUNG C, V298, pL462, DOI 10.1152/ajplung.00224.2009; Zijlstra A, 2006, CANCER CELL, V10, P177, DOI 10.1016/j.ccr.2006.08.012; Zoller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543	55	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2898	2908		10.1038/onc.2013.249	http://dx.doi.org/10.1038/onc.2013.249			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23873025				2022-12-17	WOS:000337231800009
J	Devine, DJ; Rostas, JW; Metge, BJ; Das, S; Mulekar, MS; Tucker, JA; Grizzle, WE; Buchsbaum, DJ; Shevde, LA; Samant, RS				Devine, D. J.; Rostas, J. W.; Metge, B. J.; Das, S.; Mulekar, M. S.; Tucker, J. A.; Grizzle, W. E.; Buchsbaum, D. J.; Shevde, L. A.; Samant, R. S.			Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-beta/SMAD signaling	ONCOGENE			English	Article						N-Myc interactor; epithelial-mesenchymal transition; SMAD; breast cancer	GROWTH-FACTOR-BETA; CANCER STEM-CELLS; INTERFERON-GAMMA; BREAST; EMT; NMI; METASTASIS; SMAD7; TRANSCRIPTION; PROGRESSION	Epithelial-mesenchymal transition is one of the critical cellular programs that facilitate the progression of breast cancer to an invasive disease. We have observed that the expression of N-myc interactor (NMI) decreases significantly during progression of breast cancer, specifically in invasive and metastatic stages. Recapitulation of this loss in breast cell lines with epithelial morphology (MCF10A (non-tumorigenic) and T47D (tumorigenic)) by silencing NMI expression causes mesenchymal-like morphological changes in 3D growth, accompanied by upregulation of SLUG and ZEB2 and increased invasive properties. Conversely, we found that restoring NMI expression attenuated the mesenchymal attributes of metastatic breast cancer cells, accompanied by distinctly circumscribed 3D growth with basement membrane deposition and decreased invasion. Further investigations into the downstream signaling modulated by NMI revealed that NMI expression negatively regulates SMAD signaling, which is a key regulator of cellular plasticity. We demonstrate that NMI blocks TGF-beta/SMAD signaling via upregulation of SMAD7, a negative feedback regulator of the pathway. We also provide evidence that NMI activates STAT signaling, which negatively modulates TGF-beta/SMAD signaling. Taken together, our findings suggest that loss of NMI during breast cancer progression could be one of the driving factors that enhance the invasive ability of breast cancer by aberrant activation of TGF-beta/SMAD signaling.	[Devine, D. J.; Rostas, J. W.] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 35294 USA; [Rostas, J. W.] Univ S Alabama, Dept Surg, Mobile, AL 35294 USA; [Metge, B. J.; Das, S.; Grizzle, W. E.; Shevde, L. A.; Samant, R. S.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Metge, B. J.; Das, S.; Shevde, L. A.; Samant, R. S.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA; [Mulekar, M. S.] Univ S Alabama, Dept Math & Stat, Mobile, AL 35294 USA; [Tucker, J. A.] Univ S Alabama, Dept Pathol, Mobile, AL 35294 USA; [Buchsbaum, D. J.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL USA	University of South Alabama; University of South Alabama; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of South Alabama; University of South Alabama; University of Alabama System; University of Alabama Birmingham	Samant, RS (corresponding author), Univ S Alabama, Dept Pathol, WTI 320E,1720,Second Ave S, Mobile, AL 35294 USA.	rsamant@uab.edu		Samant, Rajeev/0000-0001-5681-4976; Buchsbaum, Donald/0000-0003-2797-5847	USPHS [CA140472, CA138850]; American Medical Association Seed Grant; NATIONAL CANCER INSTITUTE [R01CA140472, R01CA138850] Funding Source: NIH RePORTER	USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); American Medical Association Seed Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Grant support: USPHS grants CA140472 and Mayer Mitchell Award (RSS) and CA138850 (LAS). J. Rostas is a recipient of the American Medical Association Seed Grant 2011. We thank Dr Charles V. Clevenger (Northwestern University, Chicago, IL) for the gift of the beta-casein and lactogenic hormone response element reporters and Dr Robert Weinberg (Whitehead Institute, MA) for the gift of HME and HMEC cell lines.	Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Bao JX, 1996, ONCOGENE, V12, P2171; Baxley SE, 2010, CURR DRUG TARGETS, V11, P1089; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Cano C, 2010, THESCIENTIFICWORLDJO, V10, P1947, DOI 10.1100/tsw.2010.183; Cocolakis E, 2008, J BIOL CHEM, V283, P1293, DOI 10.1074/jbc.M707492200; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; De Wever O, 2008, HISTOCHEM CELL BIOL, V130, P481, DOI 10.1007/s00418-008-0464-1; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037; Fillmore RA, 2009, INT J CANCER, V125, P556, DOI 10.1002/ijc.24276; Fuxe J, 2010, CELL CYCLE, V9, P2363, DOI 10.4161/cc.9.12.12050; GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Iwamoto T, 2002, HISTOL HISTOPATHOL, V17, P887, DOI 10.14670/HH-17.887; Joseph MJ, 2009, J CELL BIOCHEM, V108, P726, DOI 10.1002/jcb.22309; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kang YB, 2006, J CELL BIOCHEM, V98, P1380, DOI 10.1002/jcb.20928; Krantz SB, 2012, J SURG RES, V173, P105, DOI 10.1016/j.jss.2011.09.020; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Miyazono K, 2009, P JPN ACAD B-PHYS, V85, P314, DOI 10.2183/pjab.85.314; Nawshad A, 2005, CELLS TISSUES ORGANS, V179, P11, DOI 10.1159/000084505; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Papageorgis P, CANC RES, V70, P968; Piek E, 1999, J CELL SCI, V112, P4557; Postigo AA, 2003, EMBO J, V22, P2443, DOI 10.1093/emboj/cdg225; PRICE JE, 1990, CANCER-AM CANCER SOC, V66, P1313, DOI 10.1002/1097-0142(19900915)66:14+<1313::AID-CNCR2820661403>3.0.CO;2-4; Saika S, 2004, LAB INVEST, V84, P1259, DOI 10.1038/labinvest.3700151; SCHMITT E, 1994, EUR J IMMUNOL, V24, P793, DOI 10.1002/eji.1830240403; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Takebe N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2876; Taylor MA, 2010, J MAMMARY GLAND BIOL, V15, P169, DOI 10.1007/s10911-010-9181-1; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Tian YC, 2003, AM J PHYSIOL-RENAL, V285, pF130, DOI 10.1152/ajprenal.00408.2002; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Vincent-Salomon A, 2003, BREAST CANCER RES, V5, P101, DOI 10.1186/bcr578; Wakefield LM, 2001, J MAMMARY GLAND BIOL, V6, P67, DOI 10.1023/A:1009568532177; Wang ZW, 2011, NAT REV GASTRO HEPAT, V8, P27, DOI 10.1038/nrgastro.2010.188; Weng HL, 2007, J HEPATOL, V46, P295, DOI 10.1016/j.jhep.2006.09.014; Xiao BG, 1996, CLIN EXP IMMUNOL, V103, P475; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yan XH, 2011, BIOCHEM J, V434, P1, DOI 10.1042/BJ20101827; Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018; Yao DB, 2011, MOL CANCER RES, V9, P1608, DOI 10.1158/1541-7786.MCR-10-0568; Yates C, 2012, ADV EXP MED BIOL, V720, P81, DOI 10.1007/978-1-4614-0254-1_7; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	57	22	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2620	2628		10.1038/onc.2013.215	http://dx.doi.org/10.1038/onc.2013.215			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23770854	Green Accepted			2022-12-17	WOS:000336502700008
J	Garcia-Murillas, I; Sharpe, R; Pearson, A; Campbell, J; Natrajan, R; Ashworth, A; Turner, NC				Garcia-Murillas, I.; Sharpe, R.; Pearson, A.; Campbell, J.; Natrajan, R.; Ashworth, A.; Turner, N. C.			An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer	ONCOGENE			English	Article						breast cancer; amplification; GNAS; siRNA	OVARIAN-CANCER; ALPHA-S; CELL-LINES; AMPLIFICATION; TUMORS; GROWTH; PHOSPHORYLATION; SENSITIVITY; ABERRATIONS; ACTIVATION	Poor-prognosis oestrogen receptor-positive breast cancer is characterised by the presence of high-level focal amplifications. We utilised a focused small interfering RNA screen in 14 breast cancer cell lines to define genes that were pathogenic in three genomic regions focally amplified in oestrogen receptor-positive breast cancer, 8p11-12, 11q13 and 20q. Silencing the GNAS locus, that encodes the G protein alpha stimulatory subunit Gas, specifically reduced the growth of 20q amplified breast cancer cell lines. Examination of a publically available small hairpin RNA data set confirmed GNAS silencing to be selective for 20q amplified cancer cell lines. Cell lines with 20q amplification were found to overexpress specifically the extra long Gas splice variant (XL alpha s). Overexpression of XL alpha s induced cAMP levels to a greater extent than Gas, suggesting that amplification of the GNAS locus, and overexpression of the XL alpha s variant in particular, enhanced cAMP signalling. GNAS silencing in amplified cell lines reduced extracellular-signal-regulated kinase 1/2 (ERK1/2) phosphorylation, and conversely overexpression of exogenous XL alpha s in a nonamplified cell line increased MEK-ERK1/2 phosphorylation, identifying one potential downstream consequence of enhanced cAMP signalling. Our data indicate that amplification of the GNAS locus may contribute to the pathogenesis of breast cancer, and highlight a previously unrecognised role for the GNAS XL alpha s variant in cancer.	[Garcia-Murillas, I.; Sharpe, R.; Pearson, A.; Campbell, J.; Natrajan, R.; Ashworth, A.; Turner, N. C.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Turner, N. C.] Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Turner, NC (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	nicholas.turner@icr.ac.uk		garcia-murillas, isaac/0000-0001-8183-7969; Natrajan, Rachael/0000-0002-9987-2946; Turner, Nicholas/0000-0001-8937-0873	Cancer Research UK; Breakthrough Breast Cancer; NIHR Biomedical Research Centre	Cancer Research UK(Cancer Research UK); Breakthrough Breast Cancer; NIHR Biomedical Research Centre(National Institute for Health Research (NIHR))	We thank Murat Bastepe for supplying cDNA contructs for G alpha s and XL alpha s. This work was supported by grants from Cancer Research UK and Breakthrough Breast Cancer. Dr Nicholas Turner is a CRUK Clinician Scientist. We acknowledge NHS funding to the NIHR Biomedical Research Centre.	Aydin C, 2009, ENDOCRINOLOGY, V150, P3567, DOI 10.1210/en.2009-0318; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Consonni SV, 2012, P NATL ACAD SCI USA, V109, P3814, DOI 10.1073/pnas.1117599109; Courjal F, 1997, CANCER RES, V57, P4360; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Freda PU, 2007, PITUITARY, V10, P275, DOI 10.1007/s11102-007-0058-2; Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128; Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407; Hodgson JG, 2003, BREAST CANCER RES TR, V78, P337, DOI 10.1023/A:1023085825042; Holland DG, 2011, EMBO MOL MED, V3, P167, DOI 10.1002/emmm.201100122; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Liu Z, 2011, J BIOL CHEM, V286, P38558, DOI 10.1074/jbc.M111.240150; Luttrell DK, 2004, ONCOGENE, V23, P7969, DOI 10.1038/sj.onc.1208162; Mackay A, 2009, BREAST CANCER RES TR, V118, P481, DOI 10.1007/s10549-008-0296-7; Mariot V, 2011, BONE, V48, P312, DOI 10.1016/j.bone.2010.09.032; Natrajan R, 2010, BREAST CANCER RES TR, V121, P575, DOI 10.1007/s10549-009-0501-3; Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nonet GH, 2001, CANCER RES, V61, P1250; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Press MF, 2011, J CLIN ONCOL, V29, P859, DOI 10.1200/JCO.2009.27.5644; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Sircoulomb F, 2011, EMBO MOL MED, V3, P153, DOI 10.1002/emmm.201100121; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith FD, 2010, NAT CELL BIOL, V12, P1242, DOI 10.1038/ncb2130; Stephens PJ, 2009, NATURE, V462, P1005, DOI 10.1038/nature08645; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61; Wadhawan S, 2008, MOL BIOL EVOL, V25, P2745, DOI 10.1093/molbev/msn229; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Wu J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002543; Zhang L, 2005, CANCER RES, V65, P925	42	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2478	2486		10.1038/onc.2013.202	http://dx.doi.org/10.1038/onc.2013.202			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23752180	Green Accepted			2022-12-17	WOS:000336033600007
J	Shatnawi, A; Norris, JD; Chaveroux, C; Jasper, JS; Sherk, AB; McDonnell, DP; Giguere, V				Shatnawi, A.; Norris, J. D.; Chaveroux, C.; Jasper, J. S.; Sherk, A. B.; McDonnell, D. P.; Giguere, V.			ELF3 is a repressor of androgen receptor action in prostate cancer cells	ONCOGENE			English	Article						ETS factor; ChIP; nuclear receptor; LNCaP cells; xenograft	ETS TRANSCRIPTION FACTOR; EXPRESSION; GENE; EPITHELIUM; ESE-1; RECURRENCE; MECHANISM; BINDING; FAMILY; DIFFERENTIATION	The androgen receptor (AR) has a critical role in the development and progression of prostate cancer (PC) and is a major therapeutic target in this disease. The transcriptional activity of AR is modulated by the coregulators with which it interacts, and consequently deregulation of cofactor expression and/or activity impacts the expression of genes whose products can have a role in PC pathogenesis. Here we report that E74-like factor 3 (ELF3), a member of the ETS family of transcription factors, is a repressor of AR transcriptional activity. Exogenous expression of ELF3 represses AR transcriptional activity when assessed using reporter-based transfection assays or when evaluated on endogenous AR target genes. Conversely, ELF3 knock down increases the AR transcriptional activity. Biochemical dissection of this activity indicates that it results from the physical interaction between ELF3 and AR and that this interaction inhibits the recruitment of AR to specific androgen response elements within target gene promoters. Significantly, we observed that depletion of ELF3 expression in LNCaP cells promotes cell migration, whereas increased ELF3 expression severely inhibits tumor growth in vitro and in a mouse xenograft model. Taken together, these results suggest that modulation of ELF3 expression and/or AR/ELF3 interaction may have utility in the treatment of PC.	[Shatnawi, A.; Chaveroux, C.; Giguere, V.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Norris, J. D.; Jasper, J. S.; Sherk, A. B.; McDonnell, D. P.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA; [Giguere, V.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; [Giguere, V.] McGill Univ, Dept Oncol, Montreal, PQ, Canada	McGill University; Duke University; McGill University; McGill University; McGill University	Giguere, V (corresponding author), McGill Univ, Goodman Canc Res Ctr, 1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada.	vincent.giguere@mcgill.ca	shatnawi, Aymen/AAF-5661-2020	Chaveroux, Cedric/0000-0002-4116-3354; Norris, John/0000-0001-6553-8053; Giguere, Vincent/0000-0001-9567-3694; Jasper, Jeff/0000-0003-3941-0018	US Department of Defense [W81XWH-09-1-0605]; Canadian Institutes of Health Research [MOP-64275]; Terry Fox Foundation Program Project Grant; NIH [5RO1 CA139818]; NATIONAL CANCER INSTITUTE [R01CA139818] Funding Source: NIH RePORTER	US Department of Defense(United States Department of Defense); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Terry Fox Foundation Program Project Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Angie Rizzino (University of Nebraska Medical Center) for providing the Flag-ELF3 construct and ELF3 mutants and Majid Ghahremani for technical help. This work was financially supported by a postdoctoral award (W81XWH-09-1-0605) from the US Department of Defense PC Research Program (to AS); the Canadian Institutes of Health Research (MOP-64275) and a Terry Fox Foundation Program Project Grant (to VG); and NIH Grant 5RO1 CA139818 (to DPMcD).	Agoulnik IU, 2006, CANCER RES, V66, P10594, DOI 10.1158/0008-5472.CAN-06-1023; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang CY, 2005, TRENDS PHARMACOL SCI, V26, P225, DOI 10.1016/j.tips.2005.03.002; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; Charest-Marcotte A, 2010, GENE DEV, V24, P537, DOI 10.1101/gad.1871610; Clegg NJ, 2012, CANCER RES, V72, P1494, DOI 10.1158/0008-5472.CAN-11-3948; Eckel KL, 2003, DNA CELL BIOL, V22, P79, DOI 10.1089/104454903321515896; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Frigo DE, 2009, MOL ENDOCRINOL, V23, P1385, DOI 10.1210/me.2009-0010; Gregory CW, 2001, CANCER RES, V61, P4315; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Knudsen KE, 2011, EXPERT REV ENDOCRINO, V6, P483, DOI 10.1586/EEM.11.33; Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002; Kopp JL, 2007, J BIOL CHEM, V282, P3027, DOI 10.1074/jbc.M609907200; Lessard L, 2012, CANCER RES, V72, P1529, DOI 10.1158/0008-5472.CAN-11-2602; Maniccia AW, 2009, J CELL PHYSIOL, V219, P634, DOI 10.1002/jcp.21708; Ng AYN, 2002, GASTROENTEROLOGY, V122, P1455, DOI 10.1053/gast.2002.32990; Norris JD, 2009, CHEM BIOL, V16, P452, DOI 10.1016/j.chembiol.2009.01.016; O'Malley BW, 2012, MOL ENDOCRINOL, V26, P1646, DOI 10.1210/me.2012-1114; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; Oliver JR, 2012, LAB INVEST, V92, P320, DOI 10.1038/labinvest.2011.186; Pienta KJ, 2006, CLIN CANCER RES, V12, P1665, DOI 10.1158/1078-0432.CCR-06-0067; Prescott JD, 2004, MOL CELL BIOL, V24, P5548, DOI 10.1128/MCB.24.12.5548-5564.2004; Reddy SPM, 2003, J BIOL CHEM, V278, P21378, DOI 10.1074/jbc.M212258200; Rudders S, 2001, J BIOL CHEM, V276, P3302, DOI 10.1074/jbc.M006507200; Ryan CJ, 2011, J CLIN ONCOL, V29, P3651, DOI 10.1200/JCO.2011.35.2005; Shatnawi A, 2007, MOL ENDOCRINOL, V21, P635, DOI 10.1210/me.2006-0274; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Yap TA, 2011, NAT REV CLIN ONCOL, V8, P597, DOI 10.1038/nrclinonc.2011.117; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076; Zong Y, 2009, P NATL ACAD SCI USA, V106, P12465, DOI 10.1073/pnas.0905931106	40	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					862	871		10.1038/onc.2013.15	http://dx.doi.org/10.1038/onc.2013.15			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23435425	Green Accepted			2022-12-17	WOS:000331626900007
J	Shiu, KK; Wetterskog, D; Mackay, A; Natrajan, R; Lambros, M; Sims, D; Bajrami, I; Brough, R; Frankum, J; Sharpe, R; Marchio, C; Horlings, H; Reyal, F; van der Vijver, M; Turner, N; Reis-Filho, JS; Lord, CJ; Ashworth, A				Shiu, K-K; Wetterskog, D.; Mackay, A.; Natrajan, R.; Lambros, M.; Sims, D.; Bajrami, I.; Brough, R.; Frankum, J.; Sharpe, R.; Marchio, C.; Horlings, H.; Reyal, F.; van der Vijver, M.; Turner, N.; Reis-Filho, J. S.; Lord, C. J.; Ashworth, A.			Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies	ONCOGENE			English	Article						HER2-positive breast cancer; microarrays; gene expression; comparative genomic hybridization; siRNA screens; TFAP2C	COMPARATIVE GENOMIC HYBRIDIZATION; PLUS ADJUVANT CHEMOTHERAPY; COPY-NUMBER ALTERATIONS; TRANSCRIPTION FACTOR; EXPRESSION LEVELS; FOLLOW-UP; TRASTUZUMAB; RESISTANCE; RECEPTOR; LAPATINIB	Overexpression of the receptor tyrosine kinase ERBB2 (also known as HER2) occurs in around 15% of breast cancers and is driven by amplification of the ERBB2 gene. ERBB2 amplification is a marker of poor prognosis, and although anti-ERBB2-targeted therapies have shown significant clinical benefit, de novo and acquired resistance remains an important problem. Genomic profiling has demonstrated that ERBB2+ve breast cancers are distinguished from ER+ve and 'triple-negative' breast cancers by harbouring not only the ERBB2 amplification on 17q12, but also a number of co-amplified genes on 17q12 and amplification events on other chromosomes. Some of these genes may have important roles in influencing clinical outcome, and could represent genetic dependencies in ERBB2+ve cancers and therefore potential therapeutic targets. Here, we describe an integrated genomic, gene expression and functional analysis to determine whether the genes present within amplicons are critical for the survival of ERBB2+ve breast tumour cells. We show that only a fraction of the ERBB2-amplified breast tumour lines are truly addicted to the ERBB2 oncogene at the mRNA level and display a heterogeneous set of additional genetic dependencies. These include an addiction to the transcription factor gene TFAP2C when it is amplified and overexpressed, suggesting that TFAP2C represents a genetic dependency in some ERBB2+ve breast cancer cells.	[Shiu, K-K; Wetterskog, D.; Mackay, A.; Natrajan, R.; Lambros, M.; Sims, D.; Bajrami, I.; Brough, R.; Frankum, J.; Turner, N.; Reis-Filho, J. S.; Lord, C. J.; Ashworth, A.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Marchio, C.] Univ Turin, Dept Biomed Sci & Human Oncol, I-10124 Turin, Italy; [Horlings, H.; Reyal, F.; van der Vijver, M.] Acad Med Ctr, Dept Pathol, Amsterdam, Netherlands	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Turin; University of Amsterdam; Academic Medical Center Amsterdam	Reis-Filho, JS (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	Jorge.Reis-Filho@icr.ac.uk; Chris.Lord@icr.ac.uk; Alan.Ashworth@icr.ac.uk	Marchio, Caterina/J-9152-2016; Lord, Christopher/AAX-7130-2021; Lord, Christopher J/B-3295-2012	Marchio, Caterina/0000-0003-2024-6131; Lord, Christopher J/0000-0002-3226-0515; Turner, Nicholas/0000-0001-8937-0873; Natrajan, Rachael/0000-0002-9987-2946	Cancer Research UK; AACR as part of the Stand Up To Cancer Breast Cancer Dream Team Initiative; Breakthrough Breast Cancer	Cancer Research UK(Cancer Research UK); AACR as part of the Stand Up To Cancer Breast Cancer Dream Team Initiative; Breakthrough Breast Cancer	This work was supported by grants from Cancer Research UK, AACR as part of the Stand Up To Cancer Breast Cancer Dream Team Initiative, and Breakthrough Breast Cancer. Dr Kai-Keen Shiu is an Avon Clinical Fellow.	Arriola E, 2008, LAB INVEST, V88, P491, DOI 10.1038/labinvest.2008.19; Baselga J, 2010, J CLIN ONCOL, V28, P1138, DOI 10.1200/JCO.2009.24.2024; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Boutros M, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r66; Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Chin SF, 2007, ONCOGENE, V26, P1959, DOI 10.1038/sj.onc.1209985; Cleator SJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1506; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Delacroix L, 2005, DNA CELL BIOL, V24, P582, DOI 10.1089/dna.2005.24.582; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Gee JMW, 2009, J PATHOL, V217, P32, DOI 10.1002/path.2430; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gianni L, 2011, LANCET ONCOL, V12, P236, DOI 10.1016/S1470-2045(11)70033-X; Guler G, 2007, CLIN CANCER RES, V13, P6115, DOI 10.1158/1078-0432.CCR-07-1282; Gunnarsson R, 2008, GENE CHROMOSOME CANC, V47, P697, DOI 10.1002/gcc.20575; Harris LN, 2007, CLIN CANCER RES, V13, P1198, DOI 10.1158/1078-0432.CCR-06-1304; He AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-279; Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106; Hollestelle A, 2010, BREAST CANCER RES TR, V121, P53, DOI 10.1007/s10549-009-0460-8; Kao J, 2006, GENE CHROMOSOME CANC, V45, P761, DOI 10.1002/gcc.20339; Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771; Lambros MBK, 2006, LAB INVEST, V86, P398, DOI 10.1038/labinvest.3700390; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Mackay A, 2009, BREAST CANCER RES TR, V118, P481, DOI 10.1007/s10549-008-0296-7; Marchio C, 2008, J PATHOL, V216, P399, DOI 10.1002/path.2423; Natrajan R, 2010, BREAST CANCER RES TR, V121, P575, DOI 10.1007/s10549-009-0501-3; Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878; O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171; Perez EA, 2011, J CLIN ONCOL, V29, P3366, DOI 10.1200/JCO.2011.35.0868; Pietersen AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2214; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Santarius T, 2009, NAT REV, V10, P59; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Schoeberl B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000352; Shiu KK, 2010, FUTURE ONCOL, V6, P967, DOI 10.2217/FON.10.56; Sims D, 2010, BREAST CANCER RES TR, V124, P567, DOI 10.1007/s10549-010-0945-5; Sircoulomb F, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-539; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Staaf J, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2568; Tan DSR, 2008, PATHOBIOLOGY, V75, P63, DOI 10.1159/000123844; Turner BC, 1998, CANCER RES, V58, P5466; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Vernimmen D, 2003, BIOCHEM J, V370, P323, DOI 10.1042/BJ20021238; Vogel C, 2001, EUR J CANCER, V37, pS25, DOI 10.1016/S0959-8049(00)00405-6; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Williams CMJ, 2009, EMBO J, V28, P3591, DOI 10.1038/emboj.2009.290; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhao C, 2003, CANCER, V98, P18, DOI 10.1002/cncr.11482	54	22	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					619	631		10.1038/onc.2012.625	http://dx.doi.org/10.1038/onc.2012.625			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23334330	Green Submitted			2022-12-17	WOS:000331125100010
J	Fallone, F; Britton, S; Nieto, L; Salles, B; Muller, C				Fallone, F.; Britton, S.; Nieto, L.; Salles, B.; Muller, C.			ATR controls cellular adaptation to hypoxia through positive regulation of hypoxia-inducible factor 1 (HIF-1) expression	ONCOGENE			English	Article						ATR; PIKK; hypoxia; HIF-1 alpha regulation; translation; replicative stress	DEPENDENT PROTEIN-KINASE; DNA-DAMAGE; MESSENGER-RNA; REQUIRES ATM; CANCER-CELLS; TUMOR-CELLS; PHOSPHORYLATION; HIF-1-ALPHA; INHIBITION; TRANSLATION	Tumor cells adaptation to severe oxygen deprivation (hypoxia) plays a major role in tumor progression. The transcription factor HIF-1 (hypoxia-inducible factor 1), whose alpha-subunit is stabilized under hypoxic conditions is a key component of this process. Recent studies showed that two members of the phosphoinositide 3-kinase-related kinases (PIKKs) family, ATM (ataxia telangiectasia mutated) and DNA-PK (DNA-dependent protein kinase), regulate the hypoxic-dependent accumulation of HIF-1. These proteins initiate cellular stress responses when DNA damage occurs. In addition, it has been demonstrated that extreme hypoxia induces a replicative stress resulting in regions of single-stranded DNA at stalled replication forks and the activation of ATR (ataxia telangiectasia and Rad3 related protein), another member of the PIKKs family. Here, we show that even less severe hypoxia (0.1% O-2) also induces activation of ATR through replicative stress. Importantly, in using either transiently silenced ATR cells, cells expressing an inactive form of ATR or cells exposed to an ATR inhibitor (CGK733), we demonstrate that hypoxic ATR activation positively regulates the key transcription factor HIF-1 independently of the checkpoint kinase Chk1. We show that ATR kinase activity regulates HIF-1 alpha at the translational level and we find that the elements necessary for the regulation of HIF-1 alpha translation are located within the coding region of HIF-1 alpha mRNA. Finally, by using three independent cellular models, we clearly show that the loss of ATR expression and/or kinase activity results in the decrease of HIF-1 DNA binding under hypoxia and consequently affects protein expression levels of two HIF-1 target genes, GLUT-1 and CAIX. Taken together, our data show a new function for ATR in cellular adaptation to hypoxia through regulation of HIF-1 alpha translation. Our work offers new prospect for cancer therapy using ATR inhibitors with the potential to decrease cellular adaptation in hypoxic tumors.	[Fallone, F.; Britton, S.; Nieto, L.; Salles, B.; Muller, C.] CNRS, IPBS, Toulouse, France; [Fallone, F.; Britton, S.; Nieto, L.; Salles, B.; Muller, C.] Univ Toulouse, UPS, IPBS, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Muller, C (corresponding author), CNRS, UMR5089, IPBS, 205 Route Narbonne,BP 6418231077, Toulouse, France.	muller@ipbs.fr	Nieto, Laurence/AAJ-5703-2021; Britton, Sébastien/AAL-1862-2020; MULLER, Catherine/E-2060-2011; MULLER, Catherine/M-2185-2018	Nieto, Laurence/0000-0002-1006-0168; Britton, Sébastien/0000-0002-7008-5316; 	'Ligue Nationale Contre le Cancer' (Equipe Labelisee); Canceropole GSO; Association contre le Cancer, ARC; Radioprotection Committee of EDF	'Ligue Nationale Contre le Cancer' (Equipe Labelisee)(Ligue nationale contre le cancer); Canceropole GSO; Association contre le Cancer, ARC; Radioprotection Committee of EDF	We thank Catherine Botanch, Emilie Mirey and Christine Bordier for their help, Dr Nathalie Mazure and Dr Delphine Larrieu for critical comments on the manuscript and Aymeric Poizot for English rereading. We acknowledge Dr P Calsou, Dr Y Martineau and Dr S Pyronnet for technical advices and reagents. This work was supported by the 'Ligue Nationale Contre le Cancer' (Equipe Labelisee, BS), the Canceropole GSO (BS and CM), the Association contre le Cancer, ARC (2008-1102, CM) and the Radioprotection Committee of EDF (CM).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Abraham RT, 2003, CURR TOP MICROBIOL, V279, P299; Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Airley RE, 2003, INT J CANCER, V104, P85, DOI 10.1002/ijc.10904; Bencokova Z, 2009, MOL CELL BIOL, V29, P526, DOI 10.1128/MCB.01301-08; Bouquet F, 2011, J CELL SCI, V124, P1943, DOI 10.1242/jcs.078030; Brahimi-Horn MC, 2007, BIOCHEM PHARMACOL, V73, P450, DOI 10.1016/j.bcp.2006.10.013; Brahimi-Horn MC, 2009, J CELL SCI, V122, P1055, DOI 10.1242/jcs.035022; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Crescenzi E, 2008, CLIN CANCER RES, V14, P1877, DOI 10.1158/1078-0432.CCR-07-4298; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; Dolt KS, 2007, GENE, V386, P73, DOI 10.1016/j.gene.2006.08.004; Economopoulou M, 2009, NAT MED, V15, P553, DOI 10.1038/nm.1947; Galban S, 2008, MOL CELL BIOL, V28, P93, DOI 10.1128/MCB.00973-07; Gibson SL, 2005, CANCER RES, V65, P10734, DOI 10.1158/0008-5472.CAN-05-1160; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hammond EM, 2004, CANCER RES, V64, P6556, DOI 10.1158/0008-5472.CAN-04-1520; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kang MJ, 2008, FEBS J, V275, P5969, DOI 10.1111/j.1742-4658.2008.06725.x; Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lei Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007629; Lopez-Contreras AJ, 2010, DNA REPAIR, V9, P1249, DOI 10.1016/j.dnarep.2010.09.012; Lou JJW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010522; Lovejoy CA, 2009, DNA REPAIR, V8, P1004, DOI 10.1016/j.dnarep.2009.04.006; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Martin L, 2012, ONCOGENE, V31, P4076, DOI 10.1038/onc.2011.585; Masuda K, 2009, J CELL MOL MED, V13, P2759, DOI 10.1111/j.1582-4934.2009.00842.x; Monferran S, 2004, EMBO J, V23, P3758, DOI 10.1038/sj.emboj.7600403; Monti Elena, 2011, Curr Mol Pharmacol, V4, P62; Moretti F, 2010, RNA, V16, P2493, DOI 10.1261/rna.2384610; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Onnis B, 2009, J CELL MOL MED, V13, P2780, DOI 10.1111/j.1582-4934.2009.00876.x; Ousset M, 2010, CELL CYCLE, V9, P2814, DOI 10.4161/cc.9.14.12253; Paulsen RD, 2007, DNA REPAIR, V6, P953, DOI 10.1016/j.dnarep.2007.02.015; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Rapisarda A, 2007, ONCOGENE, V26, P6875, DOI 10.1038/sj.onc.1210489; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2007, DRUG DISCOV TODAY, V12, P853, DOI 10.1016/j.drudis.2007.08.006; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; van Uden P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001285; Veuger SJ, 2003, CANCER RES, V63, P6008; Wan C, 2010, MUTAT RES-FUND MOL M, V686, P39, DOI 10.1016/j.mrfmmm.2009.12.012; Wang CX, 2011, J GASTROEN HEPATOL, V26, P1630, DOI 10.1111/j.1440-1746.2011.06758.x; Willmore E, 2004, BLOOD, V103, P4659, DOI 10.1182/blood-2003-07-2527; Zhong H, 2000, CANCER RES, V60, P1541; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430; Zundel W, 2000, GENE DEV, V14, P391	56	22	23	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4387	4396		10.1038/onc.2012.462	http://dx.doi.org/10.1038/onc.2012.462			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085754	Green Published			2022-12-17	WOS:000324404200007
J	Yamada, T; Takeuchi, S; Fujita, N; Nakamura, A; Wang, W; Li, Q; Oda, M; Mitsudomi, T; Yatabe, Y; Sekido, Y; Yoshida, J; Higashiyama, M; Noguchi, M; Uehara, H; Nishioka, Y; Sone, S; Yano, S				Yamada, T.; Takeuchi, S.; Fujita, N.; Nakamura, A.; Wang, W.; Li, Q.; Oda, M.; Mitsudomi, T.; Yatabe, Y.; Sekido, Y.; Yoshida, J.; Higashiyama, M.; Noguchi, M.; Uehara, H.; Nishioka, Y.; Sone, S.; Yano, S.			Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations	ONCOGENE			English	Article						Akt kinase-interacting protein1; EGFR mutation; novel therapeutic target; lung cancer	GROWTH-FACTOR RECEPTOR; ACQUIRED-RESISTANCE; INCREASED SENSITIVITY; SCAFFOLD PROTEINS; DRUG-RESISTANCE; MAPK SCAFFOLD; PHASE-II; INHIBITOR; GEFITINIB; PATHWAY	Despite initial dramatic response, epidermal growth factor receptor (EGFR) mutant lung cancer patients always acquire resistance to EGFR-tyrosine kinase inhibitors (TKIs). Gatekeeper T790M mutation in EGFR is the most prevalent genetic alteration underlying acquired resistance to EGFR-TKI, and EGFR mutant lung cancer cells are reported to be addictive to EGFR/Akt signaling even after acquired T790M mutation. Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinositide 3-kinase)/PDK1 (3-phosphoinositide-dependent protein kinase)/Akt that determines receptor signal selectivity for non-mutated EGFR, and assessed its role in EGFR mutant lung cancer with or without gatekeeper T790M mutation. Cell line-based assays showed that Aki1 constitutively associates with mutant EGFR in lung cancer cells with (H1975) or without (PC-9 and HCC827) T790M gatekeeper mutation. Silencing of Aki1 induced apoptosis of EGFR mutant lung cancer cells. Treatment with Aki1 siRNA dramatically inhibited growth of H1975 cells in a xenograft model. Moreover, silencing of Aki1 further potentiated growth inhibitory effect of new generation EGFR-TKIs against H1975 cells in vitro. Aki1 was frequently expressed in tumor cells of EGFR mutant lung cancer patients (53/56 cases), including those with acquired resistance to EGFR-TKI treatment (7/7 cases). Our data suggest that Aki1 may be a critical mediator of survival signaling from mutant EGFR to Akt, and may therefore be an ideal target for EGFR mutant lung cancer patients, especially those with acquired EGFR-TKI resistance due to EGFR T790M gatekeeper mutation.	[Yamada, T.; Takeuchi, S.; Wang, W.; Li, Q.; Yano, S.] Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa 9200934, Japan; [Fujita, N.; Nakamura, A.] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan; [Oda, M.] Kanazawa Univ, Dept Gen & Cardiothorac Surg, Kanazawa, Ishikawa 9200934, Japan; [Mitsudomi, T.] Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 464, Japan; [Yatabe, Y.] Aichi Canc Ctr Hosp, Dept Pathol, Nagoya, Aichi 464, Japan; [Sekido, Y.] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan; [Yoshida, J.] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan; [Higashiyama, M.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Thorac Surg, Osaka, Japan; [Noguchi, M.] Univ Tsukuba, Inst Basic Med Sci, Dept Pathol, Tsukuba, Ibaraki 305, Japan; [Uehara, H.] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Mol & Environm Pathol, Tokushima 770, Japan; [Nishioka, Y.; Sone, S.] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Resp Med & Rheumatol, Tokushima 770, Japan	Kanazawa University; Japanese Foundation for Cancer Research; Kanazawa University; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; National Cancer Center - Japan; Osaka Medical Center for Cancer & Cardiovascular Diseases; University of Tsukuba; Tokushima University; Tokushima University	Yamada, T (corresponding author), Kanazawa Univ, Canc Res Inst, Div Med Oncol, Takara Machi 13-1, Kanazawa, Ishikawa 9200934, Japan.	tadaakiy@med.kanazawa-u.ac.jp	Sekido, Yoshitaka/P-9756-2015; YATABE, Yasushi/J-6461-2014; Yamada, Tadaaki/L-5378-2015	YATABE, Yasushi/0000-0003-1788-559X; Yamada, Tadaaki/0000-0002-6945-281X; Yoshida, Junji/0000-0002-1433-9297; wang, wei/0000-0001-8887-8499; Sekido, Yoshitaka/0000-0002-2428-3848; Mitsudomi, Tetsuya/0000-0001-9860-8505	Ministry of Health, Labor and Welfare [16-1]; Scientific Research on Innovative Areas 'Integrative Research on Cancer Microenvironment Network' from the Ministry of Education, Culture, Sports, Science, and Technology of Japan [23790902, 21390256, 22112010]	Ministry of Health, Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); Scientific Research on Innovative Areas 'Integrative Research on Cancer Microenvironment Network' from the Ministry of Education, Culture, Sports, Science, and Technology of Japan	We thank Dr John D Minna (University of Texas Southwestern Medical Center) and Dr Isaiah J Fidler (MD Anderson Cancer Center, Houston, TX, USA) for kindly provided by H1975 and PC14PE6, respectively. We thank Mrs Takayuki Nakagawa and Kenji Kita (Cancer Research Institute, Kanazawa University) for technical assistance and fruitful discussion. This work was supported in part by the Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare (M Noguchi, 16-1) and was supported by Grants-in-Aid for Cancer Research (T Yamada, 23790902 and S Yano, 21390256) and Scientific Research on Innovative Areas 'Integrative Research on Cancer Microenvironment Network' (S Yano, 22112010) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; Claperon A, 2007, ONCOGENE, V26, P3143, DOI 10.1038/sj.onc.1210408; Dhanasekaran DN, 2007, ONCOGENE, V26, P3185, DOI 10.1038/sj.onc.1210411; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Godin-Heymann N, 2007, CANCER RES, V67, P7319, DOI 10.1158/0008-5472.CAN-06-4625; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Jackman D, 2010, J CLIN ONCOL, V28, P357, DOI 10.1200/JCO.2009.24.7049; Janjigian YY, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.7525; Karp DD, 2009, J CLIN ONCOL, V27, P2516, DOI 10.1200/JCO.2008.19.9331; Kobayashi S, 2005, CANCER RES, V65, P7096, DOI 10.1158/0008-5472.CAN-05-1346; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mitsudomi T, 2007, CANCER SCI, V98, P1817, DOI 10.1111/j.1349-7006.2007.00607.x; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Morrison DK, 2001, J CELL SCI, V114, P1609; Mouri A, 2012, J NEUROSCI, V32, P4562, DOI 10.1523/JNEUROSCI.6458-11.2012; Mulloy R, 2007, CANCER RES, V67, P2325, DOI 10.1158/0008-5472.CAN-06-4293; Nakamura A, 2008, MOL CELL BIOL, V28, P5996, DOI 10.1128/MCB.00114-08; Neal JW, 2010, CURR TREAT OPTION ON, V11, P36, DOI 10.1007/s11864-010-0120-6; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Sequist LV, 2010, J CLIN ONCOL, V28, P3076, DOI 10.1200/JCO.2009.27.9414; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Whitmarsh AJ, 2006, BIOCHEM SOC T, V34, P828, DOI 10.1042/BST0340828; Yano S, 2000, AM J PATHOL, V157, P1893, DOI 10.1016/S0002-9440(10)64828-6; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yu Z, 2007, CANCER RES, V67, P10417, DOI 10.1158/0008-5472.CAN-07-1248; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zhou WJ, 2009, NATURE, V462, P1070, DOI 10.1038/nature08622	38	22	24	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4427	4435		10.1038/onc.2012.446	http://dx.doi.org/10.1038/onc.2012.446			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23045273	Green Submitted			2022-12-17	WOS:000324404200011
J	Derbal-Wolfrom, L; Pencreach, E; Saandi, T; Aprahamian, M; Martin, E; Greferath, R; Tufa, E; Choquet, P; Lehn, JM; Nicolau, C; Duluc, I; Freund, JN				Derbal-Wolfrom, L.; Pencreach, E.; Saandi, T.; Aprahamian, M.; Martin, E.; Greferath, R.; Tufa, E.; Choquet, P.; Lehn, J-M; Nicolau, C.; Duluc, I.; Freund, J-N			Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2	ONCOGENE			English	Article						hypoxia; ITPP; colon cancer; xenograft; MAP kinase; homeobox gene	EXPRESSION; INHIBITOR	Preventing tumor neovascularisation is one of the strategies recently developed to limit the dissemination of cancer cells and apparition of metastases. Although these approaches could improve the existing treatments, a number of unexpected negative effects have been reported, mainly linked to the hypoxic condition and the subsequent induction of the pro-oncogenic hypoxia inducible factor(s) resulting from cancer cells' oxygen starvation. Here, we checked in vivo on colon cancer cells an alternative approach. It is based on treatment with myo-inositol trispyrophosphate (ITPP), a molecule that leads to increased oxygenation of tumors. We provide evidence that ITPP increases the survival of mice in a model of carcinomatosis of human colon cancer cells implanted into the peritoneal cavity. ITPP also reduced the growth of subcutaneous colon cancer cells xenografted in nu/nu mice. In the subcutaneous tumors, ITPP stimulated the expression of the homeobox gene Cdx2 that is crucial for intestinal differentiation and that also has an anti-tumoral function. On this basis, human colon cancer cells were cultured in vitro in hypoxic conditions. Hypoxia was shown to decrease the level of Cdx2 protein, mRNA and the activity of the Cdx2 promoter. This decline was unrelated to the activation of HIF1 alpha and HIF2 alpha by hypoxia. However, it resulted from the activation of a phosphatidylinositol 3-kinases-like mitogen-activated protein kinase pathway, as assessed by the fact that LY294002 and U0126 restored high Cdx2 expression in hypoxia. Corroborating these results, U0126 recapitulated the increase of Cdx2 triggered by ITPP in subcutaneous colon tumor xenografts. The present study provides evidence that a chemical compound that increases oxygen pressure can antagonize the hypoxic setting and reduce the growth of human colon tumors implanted in nu/nu mice.	[Derbal-Wolfrom, L.; Saandi, T.; Aprahamian, M.; Martin, E.; Duluc, I.; Freund, J-N] INSERM, U682, Strasbourg, France; [Pencreach, E.] CHU Hautepierre, Lab Biochim & Biol Mol, EA Physiopathol & Med Translat 4438, F-67098 Strasbourg, France; [Greferath, R.; Tufa, E.; Nicolau, C.] NormOxys Inc, Boston, MA USA; [Choquet, P.] CHU Hautepierre, Serv Biophys & Med Nucl, Fre3240, CNRS, F-67098 Strasbourg, France; [Greferath, R.; Tufa, E.; Lehn, J-M] CNRS, UMR 7006, ISIS, Strasbourg, France; [Nicolau, C.] Tufts Univ, Friedman Sch Nutr Sci, Boston, MA 02111 USA; [Derbal-Wolfrom, L.; Pencreach, E.; Saandi, T.; Aprahamian, M.; Martin, E.; Choquet, P.; Lehn, J-M; Duluc, I.; Freund, J-N] Univ Strasbourg, Fac Med, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; Centre National de la Recherche Scientifique (CNRS); CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Tufts University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Freund, JN (corresponding author), Univ Strasbourg, INSERM, U682, 3 Ave Moliere, F-67200 Strasbourg, France.	jean-noel.freund@inserm.fr	Duluc, Isabelle/O-1972-2017; DULUC, Isabelle/AAA-7062-2022; Freund, Jean-Noel/R-4383-2016; CHOQUET, Philippe/H-5868-2019; Pencreach, Erwan/R-3750-2016	Duluc, Isabelle/0000-0001-8396-6385; DULUC, Isabelle/0000-0001-8396-6385; Freund, Jean-Noel/0000-0002-0971-3774; CHOQUET, Philippe/0000-0003-0514-0726; 	INSERM (France); NormOxys Inc (USA); Ligue contre la Cancer du Haut-Rhin (France); AICR (UK); Departement of Mayotte (France)	INSERM (France)(Institut National de la Sante et de la Recherche Medicale (Inserm)); NormOxys Inc (USA); Ligue contre la Cancer du Haut-Rhin (France); AICR (UK); Departement of Mayotte (France)	This work was supported by the INSERM (France), NormOxys Inc (USA) and the Ligue contre la Cancer du Haut-Rhin (France). Ms Saandi was supported by the AICR (UK) and the Departement of Mayotte (France).	Aprahamian M, 2011, CHEMBIOCHEM, V12, P777, DOI 10.1002/cbic.201000619; Benahmed F, 2008, GASTROENTEROLOGY, V135, P1238, DOI 10.1053/j.gastro.2008.06.045; Benahmed F, 2007, AM J PATHOL, V170, P733, DOI 10.2353/ajpath.2007.060696; Biolo A, 2009, P NATL ACAD SCI USA, V106, P1926, DOI 10.1073/pnas.0812381106; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Gross I, 2008, ONCOGENE, V27, P107, DOI 10.1038/sj.onc.1210601; Gross I, 2005, ONCOGENE, V24, P7955, DOI 10.1038/sj.onc.1208945; Hinkel I, 2012, GASTROENTEROLOGY, V142, P875, DOI 10.1053/j.gastro.2011.12.037; Kieda C, 2006, P NATL ACAD SCI USA, V103, P15576, DOI 10.1073/pnas.0607109103; Loges S, 2009, CANCER CELL, V15, P167, DOI 10.1016/j.ccr.2009.02.007; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Marampon F, 2009, MOL CANCER THER, V8, P543, DOI 10.1158/1535-7163.MCT-08-0570; PEARSON JW, 1989, CANCER RES, V49, P3562; Pencreach E, 2009, CLIN CANCER RES, V15, P1297, DOI 10.1158/1078-0432.CCR-08-0889; Renouf B, 2012, NUCLEIC ACIDS RES, V40, P3456, DOI 10.1093/nar/gkr1242; Sihn G, 2007, FEBS LETT, V581, P962, DOI 10.1016/j.febslet.2007.01.079; Stringer EJ, 2012, DEVELOPMENT, V139, P465, DOI 10.1242/dev.070722; Turck N, 2005, EXP CELL RES, V303, P494, DOI 10.1016/j.yexcr.2004.10.025; Verzi MP, 2010, DEV CELL, V19, P713, DOI 10.1016/j.devcel.2010.10.006	19	22	23	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4313	4318		10.1038/onc.2012.445	http://dx.doi.org/10.1038/onc.2012.445			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045284				2022-12-17	WOS:000324168000013
J	Emmenegger, BA; Hwang, EI; Moore, C; Markant, SL; Brun, SN; Dutton, JW; Read, TA; Fogarty, MP; Singh, AR; Durden, DL; Yang, C; McKeehan, WL; Wechsler-Reya, RJ				Emmenegger, B. A.; Hwang, E. I.; Moore, C.; Markant, S. L.; Brun, S. N.; Dutton, J. W.; Read, T-A; Fogarty, M. P.; Singh, A. R.; Durden, D. L.; Yang, C.; McKeehan, W. L.; Wechsler-Reya, R. J.			Distinct roles for fibroblast growth factor signaling in cerebellar development and medulloblastoma	ONCOGENE			English	Article						basic FGF; cerebellum; medulloblastoma; granule; sonic hedgehog	HEDGEHOG PATHWAY INHIBITOR; FACTOR RECEPTOR; CELL-PROLIFERATION; STEM-CELLS; SUPPRESSOR; PRECURSORS; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; PROGRESSION	Cerebellar granule neurons are the most abundant neurons in the brain, and a critical element of the circuitry that controls motor coordination and learning. In addition, granule neuron precursors (GNPs) are thought to represent cells of origin for medulloblastoma, the most common malignant brain tumor in children. Thus, understanding the signals that control the growth and differentiation of these cells has important implications for neurobiology and neurooncology. Our previous studies have shown that proliferation of GNPs is regulated by Sonic hedgehog (Shh), and that aberrant activation of the Shh pathway can lead to medulloblastoma. Moreover, we have demonstrated that Shh-dependent proliferation of GNPs and medulloblastoma cells can be blocked by basic fibroblast growth factor (bFGF). But while the mitogenic effects of Shh signaling have been confirmed in vivo, the inhibitory effects of bFGF have primarily been studied in culture. Here, we demonstrate that mice lacking FGF signaling in GNPs exhibit no discernable changes in GNP proliferation or differentiation. In contrast, activation of FGF signaling has a potent effect on tumor growth: treatment of medulloblastoma cells with bFGF prevents them from forming tumors following transplantation, and inoculation of tumor-bearing mice with bFGF markedly inhibits tumor growth in vivo. These results suggest that activators of FGF signaling may be useful for targeting medulloblastoma and other Shh-dependent tumors.	[Emmenegger, B. A.; Markant, S. L.; Brun, S. N.; Wechsler-Reya, R. J.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA; [Emmenegger, B. A.; Markant, S. L.; Brun, S. N.; Wechsler-Reya, R. J.] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC USA; [Hwang, E. I.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Moore, C.; Markant, S. L.; Brun, S. N.; Wechsler-Reya, R. J.] Sanford Burnham Med Res Inst, Tumor Dev Program, La Jolla, CA 92037 USA; [Dutton, J. W.] N Carolina State Univ, Coll Vet Med, Raleigh, NC USA; [Read, T-A] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA; [Fogarty, M. P.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA; [Singh, A. R.; Durden, D. L.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Yang, C.; McKeehan, W. L.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc & Stem Cell Biol, Houston, TX USA	Duke University; Duke University; Children's National Health System; Sanford Burnham Prebys Medical Discovery Institute; University of North Carolina; North Carolina State University; Emory University; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Diego; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wechsler-Reya, RJ (corresponding author), Sanford Burnham Med Res Inst, Tumor Dev Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rwreya@sanfordburnham.org		Read, Tracy-Ann/0000-0002-5436-1296	National Institute of Mental Health [MH67916]; Pediatric Brain Tumor Foundation of the US; California Institute for Regenerative Medicine [LA1-01747]; NATIONAL CANCER INSTITUTE [P50CA140388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067916] Funding Source: NIH RePORTER	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Pediatric Brain Tumor Foundation of the US; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank Marcie Kritzik for help with the paper, Kerry Dorr for contributions to the early stages of this work, Albert Basson for helpful discussions, Chuxia Deng, David Ornitz and James Olson for providing mice, Matthias Lauth and Rune Toftgard for Sufu<SUP>-/-</SUP> MEFs, Sam Johnson for help with microscopy, Amanda Conway for help with western blotting, and Mike Cook and Beth Harvat for help with flow cytometry. This work was funded by grant number MH67916 from the National Institute of Mental Health, by funds from the Pediatric Brain Tumor Foundation of the US, and by a Leadership Award (LA1-01747) from the California Institute for Regenerative Medicine.	Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; Ballinger MD, 1999, NAT BIOTECHNOL, V17, P1199, DOI 10.1038/70746; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Corrales JD, 2006, DEVELOPMENT, V133, P1811, DOI 10.1242/dev.02351; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Debinski W, 2009, EXPERT REV NEUROTHER, V9, P1519, DOI 10.1586/ERN.09.99; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FISHELL G, 1991, DEVELOPMENT, V113, P755; Fogarty MP, 2007, P NATL ACAD SCI USA, V104, P2973, DOI 10.1073/pnas.0605770104; FUJITA S, 1966, J COMP NEUROL, V128, P191, DOI 10.1002/cne.901280206; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hamre KM, 1997, DEVELOPMENT, V124, P4201; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Hsu P, 2001, BRAIN RES, V896, P188, DOI 10.1016/S0006-8993(01)02173-4; Humke EW, 2010, GENE DEV, V24, P670, DOI 10.1101/gad.1902910; Jia J, 2006, CELL MOL LIFE SCI, V63, P1249, DOI 10.1007/s00018-005-5519-z; Kenigsberg RL, 1997, AM J PATHOL, V151, P867; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kofuji P, 1996, NEURON, V16, P941, DOI 10.1016/S0896-6273(00)80117-8; Komuro H, 1998, J NEUROSCI, V18, P1478; Lauth M, 2007, ONCOGENE, V26, P5163, DOI 10.1038/sj.onc.1210321; Lauth M, 2010, NAT STRUCT MOL BIOL, V17, P718, DOI 10.1038/nsmb.1833; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lee Y, 2007, ONCOGENE, V26, P6442, DOI 10.1038/sj.onc.1210467; Lewis PM, 2004, DEV BIOL, V270, P393, DOI 10.1016/j.ydbio.2004.03.007; Li SZ, 2009, DEV NEUROBIOL, V69, P837, DOI 10.1002/dneu.20740; Lumpkin EA, 2003, GENE EXPR PATTERNS, V3, P389, DOI 10.1016/S1567-133X(03)00089-9; MARES V, 1970, BRAIN RES, V23, P323, DOI 10.1016/0006-8993(70)90060-0; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; Mullen RJ, 1997, PERSPECT DEV NEUROBI, V5, P43; NICHOLSO.JL, 1972, BRAIN RES, V44, P13, DOI 10.1016/0006-8993(72)90362-9; Nicot A, 2002, J NEUROSCI, V22, P9244; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Olson DC, 1998, CELL GROWTH DIFFER, V9, P557; PASCUALCASTROVIEJO I, 1994, NEUROPEDIATRICS, V25, P183, DOI 10.1055/s-2008-1073020; Pons S, 2001, DEVELOPMENT, V128, P1481; Read TA, 2009, CANCER CELL, V15, P1; Rios I, 2004, DEVELOPMENT, V131, P3159, DOI 10.1242/dev.01188; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Song BW, 2002, J PHARMACOL EXP THER, V301, P605, DOI 10.1124/jpet.301.2.605; Spassky N, 2008, DEV BIOL, V317, P246, DOI 10.1016/j.ydbio.2008.02.026; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Traiffort E, 1999, EUR J NEUROSCI, V11, P3199, DOI 10.1046/j.1460-9568.1999.00777.x; Vachon P, 2004, J NEURO-ONCOL, V67, P139, DOI 10.1023/B:NEON.0000021824.41701.e5; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wang VY, 2001, NAT REV NEUROSCI, V2, P484, DOI 10.1038/35081558; Ward RJ, 2009, CANCER RES, V69, P4682, DOI 10.1158/0008-5472.CAN-09-0342; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Weinstein M, 1998, DEVELOPMENT, V125, P3615; Williams EJ, 2001, J BIOL CHEM, V276, P43879, DOI 10.1074/jbc.M105876200; Xu XL, 2002, GENESIS, V32, P85, DOI 10.1002/gene.10028; Yaguchi Y, 2009, DEV DYNAM, V238, P2058, DOI 10.1002/dvdy.22013; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Yu CD, 2005, J BIOL CHEM, V280, P17707, DOI 10.1074/jbc.M411771200; Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408	67	22	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4181	4188		10.1038/onc.2012.440	http://dx.doi.org/10.1038/onc.2012.440			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23045271	Green Accepted, Green Submitted			2022-12-17	WOS:000323748500013
J	Tripurani, SK; Cook, RW; Eldin, KW; Pangas, SA				Tripurani, S. K.; Cook, R. W.; Eldin, K. W.; Pangas, S. A.			BMP-specific SMADs function as novel repressors of PDGFA and modulate its expression in ovarian granulosa cells and tumors	ONCOGENE			English	Article						bone morphogenetic protein; platelet-derived growth factor; SMAD1; SMAD5; granulosa cell tumor	FACTOR-A-CHAIN; GROWTH-FACTORS; GENE-TRANSCRIPTION; RECEPTORS; BINDING; CANCER; PATHWAY; SP1	Platelet-derived growth factor alpha (PDGFA) is frequently upregulated in various cancers and thought to function as a key player in the development and progression of tumor growth by regulating aspects of cell proliferation, angiogenesis and metastasis. However, the mechanism by which it is upregulated is not fully understood. Previously, we demonstrated that conditional deletion of two transcription factors that signal for the bone morphogenetic proteins (Smad1 and Smad5) in ovarian granulosa cells causes metastatic granulosa cell tumors (GCTs) in female mice and phenocopies human juvenile GCTs (JGCTs). Smad1/5 double conditional knockout tumors, as well as human JGCTs, are highly vascularized, hemorrhagic and mitotically active. Expression analysis of these tumors and their metastases revealed a significant upregulation of key proliferation and pro-angiogenic factors such as Pdgfa, Pdgfb and Vegf. We examined whether these genes were direct targets of SMAD1 and SMAD5. Knockdown of SMAD1 and SMAD5 in mouse primary granulosa cells and a human GCT-derived cell line (COV434) resulted in upregulation of PDGFA, but not PDGFB nor VEGF. We identified several putative SMAD1/5-binding sites in the PDGFA promoter, and chromatin immunoprecipitation and reporter assays demonstrated that SMAD1/5 interact with the PDGFA promoter to regulate its activity. Further, SMAD1/5 antagonize the activity of the transcription factor Sp1, a well-known positive regulator of PDGFA, by inhibiting its occupancy at a key regulatory site on the proximal PDGFA promoter. Collectively, our studies establish that loss of SMAD1/5 leads to upregulation of PDGFA in ovarian granulosa cells, and that a novel regulatory interaction exists between the BR-SMADs and Sp1 in controlling PDGFA expression during granulosa cell tumorigenesis.	[Tripurani, S. K.; Cook, R. W.; Eldin, K. W.; Pangas, S. A.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Pangas, S. A.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Pangas, SA (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	spangas@bcm.edu		Pangas, Stephanie/0000-0001-5748-5844	Burroughs Wellcome Career award in Biomedical Sciences; NIH [CA138628]; NATIONAL CANCER INSTITUTE [R01CA138628] Funding Source: NIH RePORTER	Burroughs Wellcome Career award in Biomedical Sciences(Burroughs Wellcome Fund); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a Burroughs Wellcome Career award in Biomedical Sciences and a NIH CA138628 to SAP. We thank Dr David Kaetzel (University of Kentucky) for the PDGFA luciferase plasmids, Drs An Zwijsen (Leuven University), Elizabeth Robertson (University of Oxford), and Richard R Behringer (MD Anderson Cancer Center) for mouse lines, and Dr Xin-Hua Feng (Baylor College of Medicine) for the flag-tagged SMAD1 and SMAD5 expression plasmids. We thank Rebecca James, Hermann Piard and Yuxuan Lin for technical assistance and Nadera Mansouri-Attia, Krishna Jagarlamudi for critical reading of the manuscript.	Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Chu S, 2008, GYNECOL ONCOL, V108, P182, DOI 10.1016/j.ygyno.2007.09.017; Edson MA, 2010, MOL ENDOCRINOL, V24, P1251, DOI 10.1210/me.2009-0461; Fei T, 2010, GENOME RES, V20, P36, DOI 10.1101/gr.092114.109; Fortin J, 2010, CELL SIGNAL, V22, P936, DOI 10.1016/j.cellsig.2010.01.019; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; George D, 2003, ADV EXP MED BIOL, V532, P141; Gonfloni S, 2009, NAT MED, V15, P1179, DOI 10.1038/nm.2033; Hoffmann AC, 2008, NEOPLASIA, V10, P674, DOI 10.1593/neo.08292; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Iwamori T, 2010, MOL CELL BIOL, V30, P2280, DOI 10.1128/MCB.01392-09; Kaetzel DM, 2003, CYTOKINE GROWTH F R, V14, P427, DOI 10.1016/S1359-6101(03)00051-0; KAETZEL DM, 1994, BIOCHEM J, V301, P321, DOI 10.1042/bj3010321; Khachigian LM, 1999, CIRC RES, V84, P1258, DOI 10.1161/01.RES.84.11.1258; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Kodach LL, 2008, GASTROENTEROLOGY, V134, P1332, DOI 10.1053/j.gastro.2008.02.059; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Middlebrook BS, 2009, ENDOCRINOLOGY, V150, P5208, DOI 10.1210/en.2009-0644; Morikawa M, 2011, NUCLEIC ACIDS RES, V39, P8712, DOI 10.1093/nar/gkr572; Pangas SA, 2004, J BIOL CHEM, V279, P32281, DOI 10.1074/jbc.M403212200; Pangas SA, 2008, MOL CELL BIOL, V28, P248, DOI 10.1128/MCB.01404-07; Pinkas H, 2008, MOL HUM REPROD, V14, P199, DOI 10.1093/molehr/gan011; Rafty LA, 2002, EMBO J, V21, P334, DOI 10.1093/emboj/21.3.334; Rocconi RP, 2008, REPROD SCI, V15, P673, DOI 10.1177/1933719108317584; Schumer ST, 2003, J CLIN ONCOL, V21, P1180, DOI 10.1200/JCO.2003.10.019; Shih AH, 2006, CANCER LETT, V232, P139, DOI 10.1016/j.canlet.2005.02.002; Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2; Uhrbom L, 1998, CANCER RES, V58, P5275; Yamamoto S, 2008, MODERN PATHOL, V21, P115, DOI 10.1038/modpathol.3800984; Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54; Zhang H, 2000, MOL HUM REPROD, V6, P146, DOI 10.1093/molehr/6.2.146	35	22	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3877	3885		10.1038/onc.2012.392	http://dx.doi.org/10.1038/onc.2012.392			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22964636	Green Accepted			2022-12-17	WOS:000323210200010
J	Akbay, EA; Pena, CG; Ruder, D; Michel, JA; Nakada, Y; Pathak, S; Multani, AS; Chang, S; Castrillon, DH				Akbay, E. A.; Pena, C. G.; Ruder, D.; Michel, J. A.; Nakada, Y.; Pathak, S.; Multani, A. S.; Chang, S.; Castrillon, D. H.			Cooperation between p53 and the telomere-protecting shelterin component Pot1a in endometrial carcinogenesis	ONCOGENE			English	Article						endometrial cancer; shelterin; p53; telomeres; pot1a; mouse models	CELL-LINE; CANCER; DYSFUNCTION; COMPLEX; LENGTH; TRANSLOCATIONS; INSTABILITY; MUTATIONS; CARCINOMA; PTEN	Type II endometrial cancer (EMCA) represents only 10% of all EMCAs, but accounts for 40% of EMCA-related mortality. Previous studies of human tumors have shown an association between Type II tumors and damaged telomeres. We hypothesized that the lack of murine Type II EMCA models is due to the extremely long telomeres in laboratory mouse strains. We previously showed that telomerase-null mice with critically short telomeres developed endometrial lesions histologically resembling endometrial intraepithelial carcinoma (EIC), the accepted precursor for Type II EMCA. However, these mice did not develop invasive endometrial adenocarcinoma, and instead succumbed prematurely to multi-organ failure. Here, we modeled critical telomere attrition by conditionally inactivating Pot1a, a component of the shelterin complex that stabilizes telomeres, within endometrial epithelium. Inactivation of Pot1a by itself did not stimulate endometrial carcinogenesis, and did not result in detectable DNA damage or apoptosis in endometrium. However, simultaneous inactivation of Pot1a and p53 resulted in EIC-like lesions by 9 months indistinguishable from those seen in late generation telomerase-null mice. These lesions progressed to invasive endometrial adenocarcinomas as early as 9 months of age with metastatic disease in 100% of the animals by 15 months. These tumors were poorly differentiated endometrial adenocarcinomas with prominent nuclear atypia, resembling human Type II cancers. Furthermore, these tumors were aneuploid with double-stranded DNA breaks and end-to-end telomere fusions and most were tetraploid or near-tetraploid. These studies lend further support to the hypothesis that telomeric instability has a critical role in Type II endometrial carcinogenesis and provides an intriguing in-vivo correlate to recent studies implicating telomere-dependent tetraploidization as an important mechanism in carcinogenesis. Oncogene (2013) 32, 2211-2219; doi:10.1038/onc.2012.232; published online 11 June 2012	[Akbay, E. A.; Pena, C. G.; Ruder, D.; Michel, J. A.; Nakada, Y.; Castrillon, D. H.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Akbay, E. A.; Pena, C. G.; Ruder, D.; Michel, J. A.; Nakada, Y.; Castrillon, D. H.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Pathak, S.] Univ Texas MD Anderson Canc Ctr, Cellular Genet Lab, Houston, TX 77030 USA; [Multani, A. S.] Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX 77030 USA; [Chang, S.] Yale Univ, Sch Med, Dept Lab Med & Pathol, New Haven, CT USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Yale University	Castrillon, DH (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pathol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	diego.castrillon@utsouthwestern.edu		Akbay, Esra/0000-0002-4149-2529; Ruder, Dennis/0000-0001-7605-111X	MD Anderson Molecular Cytogenetics Core for cytogenetic services (under Cancer Center Support) [NCI CA016672]; NCI [RO1CA129037]; Michal and Betty Kadoorie Cancer Genetic Research Program; NIH [NCI R01CA137181, NCI U01CA141576]; Cancer Prevention Research Institute of Texas [RP100550]; NATIONAL CANCER INSTITUTE [R01CA129037, P30CA016672, R01CA137181, U01CA141576] Funding Source: NIH RePORTER	MD Anderson Molecular Cytogenetics Core for cytogenetic services (under Cancer Center Support); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Michal and Betty Kadoorie Cancer Genetic Research Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Florence Sibetya for help with the ploidy analyses, Teresa Gallardo for technical assistance, and the MD Anderson Molecular Cytogenetics Core for cytogenetic services (under Cancer Center Support Grant NCI CA016672). SC acknowledges support from the NCI (RO1CA129037) and the Michal and Betty Kadoorie Cancer Genetic Research Program. This work was supported by grants to DHC from the NIH (NCI R01CA137181, NCI U01CA141576) and the Cancer Prevention Research Institute of Texas (RP100550).	Akbay EA, 2008, AM J PATHOL, V173, P536, DOI 10.2353/ajpath.2008.071179; Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Baerlocher GM, 2004, METHOD CELL BIOL, V75, P719; Batista LFZ, 2009, CANCER CELL, V15, P455, DOI 10.1016/j.ccr.2009.05.006; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Bunch JT, 2005, MOL CELL BIOL, V25, P5567, DOI 10.1128/mcb.25.13.5567-5578.2005; Cirisano FD, 1999, GYNECOL ONCOL, V74, P385, DOI 10.1006/gyno.1999.5505; Clement PB, 2004, ADV ANAT PATHOL, V11, P117, DOI 10.1097/00125480-200405000-00001; Contreras CM, 2010, DIS MODEL MECH, V3, P181, DOI 10.1242/dmm.004440; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Davoli T, 2010, CELL, V141, P81, DOI 10.1016/j.cell.2010.01.031; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 2009, SCIENCE, V326, P948, DOI 10.1126/science.1170633; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Deng YB, 2008, NAT REV CANCER, V8, P450, DOI 10.1038/nrc2393; DePinho RA, 2003, J CLIN INVEST, V111, pS9; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2007, ANNU REV PATHOL-MECH, V2, P57, DOI 10.1146/annurev.pathol.2.010506.091905; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Friel Anne M, 2010, Front Biosci (Elite Ed), V2, P882; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Guo X, 2007, EMBO J, V26, P4709, DOI 10.1038/sj.emboj.7601893; HARKER WG, 1983, CANCER RES, V43, P4943; He H, 2006, EMBO J, V25, P5180, DOI 10.1038/sj.emboj.7601294; He H, 2009, MOL CELL BIOL, V29, P229, DOI 10.1128/MCB.01400-08; Hockemeyer D, 2008, GENE DEV, V22, P1773, DOI 10.1101/gad.1679208; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kendellen MF, 2009, MOL CELL BIOL, V29, P5611, DOI 10.1128/MCB.00286-09; Kim TH, 2010, J ONCOL, V2010, DOI 10.1155/2010/139087; Lax S F, 2002, Zentralbl Gynakol, V124, P10; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; MacDonald ND, 2000, CANCER RES, V60, P1750; Meyer LA, 2009, CANCER CONTROL, V16, P14, DOI 10.1177/107327480901600103; Multani AS, 2000, NEOPLASIA, V2, P339, DOI 10.1038/sj.neo.7900105; NOUMOFF JS, 1988, GYNECOL ONCOL, V31, P217, DOI 10.1016/0090-8258(88)90297-1; Okuda T, 2010, OBSTET GYNECOL INT, V2010, DOI 10.1155/2010/984013; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Pradhan M, 2006, MODERN PATHOL, V19, P1227, DOI 10.1038/modpathol.3800641; Qi L, 2005, NAT CELL BIOL, V7, P706, DOI 10.1038/ncb1276; Rai R, 2011, NAT STRUCT MOL BIOL, V18, P1400, DOI 10.1038/nsmb.2172; RISINGER JI, 1993, CANCER RES, V53, P5100; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Savage SA, 2008, AM J HUM GENET, V82, P501, DOI 10.1016/j.ajhg.2007.10.004; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Soliman PT, 2007, OBSTET GYN CLIN N AM, V34, P701, DOI 10.1016/j.ogc.2007.09.003; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tashiro H, 1997, AM J PATHOL, V150, P177; Thanasoula M, 2010, CURR BIOL, V20, P521, DOI 10.1016/j.cub.2010.01.046; Ueda SM, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.08.075; Wu L, 2006, CELL, V126, P49, DOI 10.1016/j.cell.2006.05.037	56	22	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2211	2219		10.1038/onc.2012.232	http://dx.doi.org/10.1038/onc.2012.232			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22689059	Green Published, hybrid			2022-12-17	WOS:000318062800010
J	Ribeiro, JD; Morey, L; Mas, A; Gutierrez, A; Luis, NM; Mejetta, S; Richly, H; Benitah, SA; Keyes, WM; Di Croce, L				Ribeiro, J. D.; Morey, L.; Mas, A.; Gutierrez, A.; Luis, N. M.; Mejetta, S.; Richly, H.; Benitah, S. A.; Keyes, W. M.; Di Croce, L.			ZRF1 controls oncogene-induced senescence through the INK4-ARF locus	ONCOGENE			English	Article						chromatin; Polycomb; senescence; ZRF1	DEMETHYLASE JMJD3 CONTRIBUTES; DEPENDENT KINASE INHIBITORS; HUMAN EMBRYONAL CARCINOMA; TUMOR-SUPPRESSOR LOCUS; NEURONAL DIFFERENTIATION; INK4A-ARF LOCUS; TRANSCRIPTIONAL ACTIVATION; CELLULAR SENESCENCE; CELLS; RAS	The reactivation of the INK4-ARF locus, which is epigenetically repressed by Polycomb proteins in healthy cells, is a hallmark of senescence. One mechanism of reactivating Polycomb-silenced genes is mediated by the epigenetic factor ZRF1, which associates with ubiquitinated histone H2A. We show that cells undergoing senescence following oncogenic Ras expression have increased ZRF1 levels, and that this binds to the p15INK4b, ARF and p16INK4a promoters. Furthermore, ZRF1 depletion in oncogenic Ras-expressing cells restores proliferation by preventing Arf and p16Ink4a expression, consequently bypassing senescence. Thus, ZRF1 regulates the INK4-ARF locus during cellular proliferation and senescence, and alterations in ZRF1 may contribute to tumorigenesis. Oncogene (2013) 32, 2161-2168; doi:10.1038/onc.2012.241; published online 25 June 2012	[Ribeiro, J. D.; Morey, L.; Mas, A.; Gutierrez, A.; Luis, N. M.; Mejetta, S.; Richly, H.; Benitah, S. A.; Keyes, W. M.; Di Croce, L.] CRG, Dept Differentiat & Canc, Barcelona 08003, Spain; [Ribeiro, J. D.; Morey, L.; Mas, A.; Gutierrez, A.; Luis, N. M.; Mejetta, S.; Richly, H.; Benitah, S. A.; Keyes, W. M.; Di Croce, L.] UPF, Barcelona 08003, Spain; [Benitah, S. A.; Di Croce, L.] ICREA, Barcelona, Spain	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; ICREA	Di Croce, L (corresponding author), CRG, Dept Differentiat & Canc, Barcelona 08003, Spain.	luciano.dicroce@crg.es	Luis, Nuno/F-2405-2012; Ribeiro, Jose Dirceu D/I-7308-2012; Di Croce, Luciano/E-7759-2015; Aznar-Benitah, Salvador/F-4761-2016; Gutierrez, Arantxa/K-8213-2015; Luis, Nuno Miguel/ABD-9784-2020; Ribeiro, Joana/K-3357-2014	Luis, Nuno/0000-0001-5438-9638; Ribeiro, Jose Dirceu D/0000-0002-3387-5642; Di Croce, Luciano/0000-0003-3488-6228; Aznar-Benitah, Salvador/0000-0002-9059-5049; Gutierrez, Arantxa/0000-0001-9033-3834; Luis, Nuno Miguel/0000-0001-5438-9638; Ribeiro, Joana/0000-0003-2221-4002; Morey, Lluis/0000-0001-9851-4066; Keyes, William M./0000-0002-8917-2268	Spanish 'Ministerio de Educacion y Ciencia' (CONSOLIDER) [BFU2010-18692]; European Commission FP7 project 4DCellFate [277899]; AICR [10-0177]; Foundation for Science and Technology (FCT) Portugal [SFRH/BD/15908/2005]; CRG-Novartis fellowship; ICREA Funding Source: Custom; Worldwide Cancer Research [10-0177] Funding Source: researchfish	Spanish 'Ministerio de Educacion y Ciencia' (CONSOLIDER)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Commission FP7 project 4DCellFate; AICR; Foundation for Science and Technology (FCT) Portugal(Portuguese Foundation for Science and Technology); CRG-Novartis fellowship; ICREA(ICREA); Worldwide Cancer Research	We thank VA Raker for help in preparing the manuscript, and to the CRG Genomic Unit. This work was supported by grants from the Spanish 'Ministerio de Educacion y Ciencia' (CONSOLIDER and BFU2010-18692), from the European Commission FP7 project 4DCellFate (277899), and from AICR (10-0177) to LDC. JDR was supported by grant SFRH/BD/15908/2005 from Foundation for Science and Technology (FCT) Portugal and is a fellow of the Graduate Program in Areas of Basic and Applied Biology (GABBA), University of Oporto, Portugal; LM was supported by a post-doctoral CRG-Novartis fellowship.	Adams PD, 2009, MOL CELL, V36, P2, DOI 10.1016/j.molcel.2009.09.021; Adler AS, 2007, GENE DEV, V21, P3244, DOI 10.1101/gad.1588507; Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Cruickshanks HA, 2011, CURR OPIN GENET DEV, V21, P100, DOI 10.1016/j.gde.2010.10.007; Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ferbeyre G, 2000, GENE DEV, V14, P2015; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Kia SK, 2008, MOL CELL BIOL, V28, P3457, DOI 10.1128/MCB.02019-07; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kotake Y, 2009, CANCER RES, V69, P1809, DOI 10.1158/0008-5472.CAN-08-2739; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; LOIS AF, 1995, CANCER RES, V55, P4010; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Maertens GN, 2010, EMBO J, V29, P2553, DOI 10.1038/emboj.2010.129; Maertens GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006380; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Resto VA, 2000, CANCER RES, V60, P5529; Richly H, 2011, CELL CYCLE, V10, P745, DOI 10.4161/cc.10.5.14795; Richly H, 2010, NATURE, V468, P1124, DOI 10.1038/nature09574; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Simboeck E, 2011, BIOCHEM PHARMACOL, V82, P1361, DOI 10.1016/j.bcp.2011.07.084; Smith JC, 2007, J PROTEOME RES, V6, P3174, DOI 10.1021/pr070122r; Thullberg M, 2000, FEBS LETT, V470, P161, DOI 10.1016/S0014-5793(00)01307-7; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	40	22	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 25	2013	32	17					2161	2168		10.1038/onc.2012.241	http://dx.doi.org/10.1038/onc.2012.241			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22733129				2022-12-17	WOS:000318062800005
J	Gu, Z; Zhang, F; Wang, ZQ; Ma, W; Davis, RE; Wang, Z				Gu, Z.; Zhang, F.; Wang, Z-Q; Ma, W.; Davis, R. E.; Wang, Z.			The p44/wdr77-dependent cellular proliferation process during lung development is reactivated in lung cancer	ONCOGENE			English	Article						lung; lung cancer; p44/wdr77; proliferation; differentiation	RECEPTOR COFACTOR P44; RETINOBLASTOMA PROTEIN; PHENOTYPIC DIFFERENTIATION; MYOGENIC DIFFERENTIATION; POTENTIAL MEDIATOR; ANALYSIS REVEALS; CYCLE ARREST; EXPRESSION; P21; IDENTIFICATION	During lung development, cells proliferate for a defined length of time before they begin to differentiate. Factors that control this proliferative process and how this growth process is related to lung cancer are currently unknown. Here, we found that the WD40-containing protein (p44/wdr77) was expressed in growing epithelial cells at the early stages of lung development. In contrast, p44/wdr77 expression was diminished in fully differentiated epithelial cells in the adult lung. Loss of p44/wdr77 gene expression led to cell growth arrest and differentiation. Re-expression of p44/wdr77 caused terminally differentiated cells to re-enter the cell cycle. Our findings suggest that p44/wdr77 is essential and sufficient for proliferation of lung epithelial cells. P44/Wdr77 was re-expressed in lung cancer, and silencing p44/wdr77 expression strongly inhibited growth of lung adenocarcinoma cells in tissue culture and abolished growth of lung adenocarcinoma tumor xenografts in mice. The growth arrest induced by loss of p44/wdr77 expression was partially through the p21-Rb signaling. Our results suggest that p44/wdr77 controls cellular proliferation during lung development, and this growth process is reactivated during lung tumorigenesis. Oncogene (2013) 32, 1888-1900; doi:10.1038/onc.2012.207; published online 4 June 2012	[Gu, Z.; Zhang, F.; Wang, Z.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Gu, Z.] Fourth Mil Med Univ, Tangdu Hosp, Dept Thorac Surg, Xian, Peoples R China; [Wang, Z-Q; Ma, W.; Davis, R. E.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Air Force Military Medical University; University of Texas System; UTMD Anderson Cancer Center	Wang, Z (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	zhenwang@mdanderson.org		Gu, Zhongping/0000-0002-7395-7888	National Institutes of Health through MD Anderson's Cancer Center [CA16672]; National Natural Science Foundation of China [81171922]; Key Project Research Fund of Shaanxi Provincial Science and Technology Program, China [2008K27G01]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	National Institutes of Health through MD Anderson's Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project Research Fund of Shaanxi Provincial Science and Technology Program, China; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Joe Munch in MD Anderson's Department of Scientific Publications for editing the manuscript and Shen Gao for performing the experiment as described in Supplementary Figure S1. This work was supported in part by the National Institutes of Health through MD Anderson's Cancer Center Support Grant CA16672, National Natural Science Foundation of China (81171922) and Key Project Research Fund of Shaanxi Provincial Science and Technology Program, China (2008K27G01). No additional external funding for this study was received. The funding agency had no role in study design, data collection or analysis, decision to publish, or manuscript preparation.	Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chen G, 1999, DNA CELL BIOL, V18, P305, DOI 10.1089/104454999315367; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Conlon I, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-36; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Conlon IJ, 2001, NAT CELL BIOL, V3, P918, DOI 10.1038/ncb1001-918; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gao S, 2010, ENDOCRINOLOGY, V151, P3941, DOI 10.1210/en.2009-1080; Gemma A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-174; Gonzalo S, 2005, CELL CYCLE, V4, P752, DOI 10.4161/cc.4.6.1720; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hosohata K, 2003, MOL CELL BIOL, V23, P7019, DOI 10.1128/MCB.23.19.7019-7029.2003; Jakt LM, 2001, GENOME RES, V11, P112, DOI 10.1101/gr.148301; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kuner R, 2009, LUNG CANCER, V63, P32, DOI 10.1016/j.lungcan.2008.03.033; Langley RR, 2003, CANCER RES, V63, P2971; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu J, 2004, DEV BIOL, V273, P418, DOI 10.1016/j.ydbio.2004.05.035; Ma WC, 2010, CANCER EPIDEM BIOMAR, V19, P2445, DOI 10.1158/1055-9965.EPI-10-0565; Mal A, 2000, J CELL BIOL, V149, P281, DOI 10.1083/jcb.149.2.281; Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875; Peng Y, 2008, P NATL ACAD SCI USA, V105, P5236, DOI 10.1073/pnas.0712262105; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Reymann S, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-46; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shi W, 2009, RESPIROLOGY, V14, P656, DOI 10.1111/j.1440-1843.2009.01565.x; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Wachi S, 2005, BIOINFORMATICS, V21, P4205, DOI 10.1093/bioinformatics/bti688; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zhou LR, 2006, J MOL ENDOCRINOL, V37, P283, DOI 10.1677/jme.1.02062	48	22	22	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1888	1900		10.1038/onc.2012.207	http://dx.doi.org/10.1038/onc.2012.207			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22665061	Green Accepted			2022-12-17	WOS:000317599900003
J	Klokov, D; Leskov, K; Araki, S; Zou, Y; Goetz, EM; Luo, X; Willson, D; Boothman, DA				Klokov, D.; Leskov, K.; Araki, S.; Zou, Y.; Goetz, E. M.; Luo, X.; Willson, D.; Boothman, D. A.			Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGF beta 1 signaling to confer a pro-survival bystander effect	ONCOGENE			English	Article						bystander effects; TGF beta 1; secretory clusterin; insulin-like growth factor-1; low-dose ionizing radiation; p53 suppression	GROWTH-FACTOR-I; CLUSTERIN GENE-EXPRESSION; IONIZING-RADIATION; DNA-DAMAGE; INDUCED SENESCENCE; FACTOR-BETA; CANCER; PROTEIN; APOPTOSIS; ACTIVATION	Inadvertent mammalian tissue exposures to low doses of ionizing radiation (IR) after radiation accidents, remediation of radioactive-contaminated areas, space travel or a dirty bomb represent an interesting trauma to an organism. Possible low-dose IR-induced bystander effects could impact our evaluation of human health effects, as cells within tissue are not equally damaged after doses of IR <= 10 cGy. To understand tissue responses after low IR doses, we generated a reporter system using the human clusterin promoter fused to firefly luciferase (hCLUp-Luc). Secretory clusterin (sCLU), an extracellular molecular chaperone, induced by low doses of cytotoxic agents, clears cell debris. Low-dose IR (>= 2 cGy) exposure induced hCLUp-Luc activity with peak levels at 96 h, consistent with endogenous sCLU levels. As doses increased (>= 1 Gy), sCLU induction amplitudes increased and time-to-peak response decreased. sCLU expression was stimulated by insulin-like growth factor-1, but suppressed by p53. Responses in transgenic hCLUp-Luc reporter mice after low IR doses showed that specific tissues (that is, colon, spleen, mammary, thymus and bone marrow) of female mice induced hCLUp-Luc activity more than male mice after whole body (>= 10 cGy) irradiation. Tissue-specific, non-linear dose- and time-responses of hCLUp-Luc and endogenous sCLU levels were noted. Colon maintained homeostatic balance after 10 cGy. Bone marrow responded with delayed, but prolonged and elevated expression. Intraperitoneal administration of alpha-transforming growth factor (TGF)beta 1 (1D11), but not control (13C4) antibodies, immediately following IR exposure abrogated CLU induction responses. Induction in vivo also correlated with Smad signaling by activated TGF beta 1 after IR. Mechanistically, media with elevated sCLU levels suppressed signaling, blocked apoptosis and increased survival of TGF beta 1-exposed tumor or normal cells. Thus, sCLU is a pro-survival bystander factor that abrogates TGF beta 1 signaling and most likely promotes wound healing. Oncogene (2013) 32, 479-490; doi:10.1038/onc.2012.64; published online 5 March 2012	[Leskov, K.] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Araki, S.; Zou, Y.; Goetz, E. M.; Luo, X.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Program Cell Stress & Canc Nanomed, Dept Pharmacol,Lab Mol Stress Responses, Dallas, TX 75390 USA; [Araki, S.; Zou, Y.; Goetz, E. M.; Luo, X.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Program Cell Stress & Canc Nanomed, Dept Radiat Oncol,Lab Mol Stress Response, Dallas, TX 75390 USA; [Willson, D.] Case Western Reserve Univ, Sch Med, Dept Biomed Engn, Lab Biomed Image Proc, Cleveland, OH USA	Case Western Reserve University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University	Boothman, DA (corresponding author), Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Program Cell Stress & Canc Nanomed, Dept Pharmacol,Lab Mol Stress Responses, Dallas, TX 75390 USA.	David.Boothman@UTSouthwestern.edu	Boothman, David/Q-7776-2019; Klokov, Dmitry/AAM-7316-2020; Leskov, Konstantin S/J-2339-2017	Klokov, Dmitry/0000-0003-1629-1431; Leskov, Konstantin S/0000-0001-6201-5660	DOE [DE-FG02-06ER64186]; NASA; DAB; DOD BCRP [W81XWH-06-0748]; DOD PCRP [X8IXWH-09-1-0168]; NATIONAL CANCER INSTITUTE [R01CA139217, R01CA078530, U24CA126608, P30CA142543] Funding Source: NIH RePORTER	DOE(United States Department of Energy (DOE)); NASA(National Aeronautics & Space Administration (NASA)); DAB; DOD BCRP(United States Department of Defense); DOD PCRP; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by DOE Grant #DE-FG02-06ER64186 to DAB, a pilot grant from NASA to develop BLI imaging of hCLUp-Luc to DW and DAB, a DOD BCRP pre-doctoral fellowship (W81XWH-06-0748) to E.M.G and a DOD PCRP post-doctoral fellowship (X8IXWH-09-1-0168) to XL We thank Ms Lakshmi Sampath and Mr Andrew Bruening for their help with this work. We are also grateful to Dr Mary Helen Barcellos-Hoff for her advice with the animal experiments. We are also grateful to the Robert B. and Virginia Payne Endowment to DAB. This is CSCN 065 and used the Flow Cytometry and Biostatistics Cores, Simmons Cancer Center.	Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; Araki S, 2005, BJR S, V27, P106, DOI [10.1259/bjr/18105113, DOI 10.1259/BJR/18105113]]; Araki S, 2010, J CLIN INVEST, V120, P290, DOI 10.1172/JCI39194; Arufe MC, 2011, STEM CELLS DEV, V20, P1199, DOI 10.1089/scd.2010.0315; Bhogal N, 2010, RADIAT RES, V173, P1, DOI 10.1667/RR1851.1; Cardona-Gomez GP, 2001, BRAIN RES REV, V37, P320, DOI 10.1016/S0165-0173(01)00137-0; Chi KN, 2010, J CLIN ONCOL, V28, P4247, DOI 10.1200/JCO.2009.26.8771; Cipriano R, 2011, P NATL ACAD SCI USA, V108, P8668, DOI 10.1073/pnas.1015022108; Cornelissen B, 2011, CANCER RES, V71, P4539, DOI 10.1158/0008-5472.CAN-10-4587; Criswell T, 2005, J BIOL CHEM, V280, P14212, DOI 10.1074/jbc.M412569200; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Criswell T, 2003, CANCER BIOL THER, V2, P372, DOI 10.4161/cbt.2.4.430; DASCH JR, 1989, J IMMUNOL, V142, P1536; Davis TW, 1998, CANCER RES, V58, P767; Doi S, 2011, J BIOL CHEM, V286, P8655, DOI 10.1074/jbc.M110.174037; Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69; Garkavtsev I, 2011, P NATL ACAD SCI USA, V108, P11596, DOI 10.1073/pnas.1104225108; Goetz EM, 2011, ONCOGENE, V30, P3745, DOI 10.1038/onc.2011.92; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; Jin G, 1999, EUR J BIOCHEM, V263, P534, DOI 10.1046/j.1432-1327.1999.00533.x; Kirshner J, 2006, CANCER RES, V66, P10861, DOI 10.1158/0008-5472.CAN-06-2565; Klokov D, 2004, MUTAT RES-FUND MOL M, V568, P97, DOI 10.1016/j.mrfmmm.2004.06.049; Lee TK, 2002, RADIAT RES, V157, P678, DOI 10.1667/0033-7587(2002)157[0678:POMILO]2.0.CO;2; Li LS, 2008, J BIOL CHEM, V283, P21394, DOI 10.1074/jbc.M709954200; Lindholm C, 2010, RADIAT RES, V173, P71, DOI 10.1667/RR1843.1; Nachtrab U, 1998, INT J RADIAT BIOL, V73, P279, DOI 10.1080/095530098142374; Nguyen DH, 2011, CANCER CELL, V19, P640, DOI 10.1016/j.ccr.2011.03.011; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Redon CE, 2009, ADV SPACE RES, V43, P1171, DOI 10.1016/j.asr.2008.10.011; Rodier F, 2011, J CELL SCI, V124, P68, DOI 10.1242/jcs.071340; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sfeir A, 2010, SCIENCE, V327, P1657, DOI 10.1126/science.1185100; Shahrabani-Gargir L, 2004, ENDOCRINOLOGY, V145, P5679, DOI 10.1210/en.2004-0613; Shannan B, 2006, CELL DEATH DIFFER, V13, P12, DOI 10.1038/sj.cdd.4401779; Snyder AR, 2004, HUM EXP TOXICOL, V23, P87, DOI 10.1191/0960327104ht423oa; Sutton D, 2006, INT J NANOMED, V1, P155, DOI 10.2147/nano.2006.1.2.155; Trougakos IP, 2009, CLIN CANCER RES, V15, P48, DOI 10.1158/1078-0432.CCR-08-1805; Trougakos IP, 2009, CANCER RES, V69, P403, DOI 10.1158/0008-5472.CAN-08-2912; Wagner MW, 2008, J BIOL CHEM, V283, P21382, DOI 10.1074/jbc.M709953200; Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291; Zoubeidi A, 2010, CLIN CANCER RES, V16, P1088, DOI 10.1158/1078-0432.CCR-09-2917	45	22	23	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2013	32	4					479	490		10.1038/onc.2012.64	http://dx.doi.org/10.1038/onc.2012.64			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22391565	Green Accepted			2022-12-17	WOS:000315551300009
J	Sanchez, M; Picard, N; Sauve, K; Tremblay, A				Sanchez, M.; Picard, N.; Sauve, K.; Tremblay, A.			Coordinate regulation of estrogen receptor beta degradation by Mdm2 and CREB-binding protein in response to growth signals	ONCOGENE			English	Article						ErbB2/Her-2/Neu; ErbB3; PI3-K/Akt pathway; 26S proteasome-ubiquitin system; CBP/p300; breast cancer	BREAST-CANCER CELLS; PHOSPHORYLATION; ACTIVATION; ALPHA; PATHWAY; KINASE; PROTEASOME; COACTIVATOR; GAMMA; CBP	The biological actions of estrogen are mediated via estrogen receptors ER alpha and ER beta. Yet, other cellular signaling events that also impact ER functions have an important role in breast carcinogenesis. Here, we show that activation of ErbB2/ErbB3 tyrosine kinase receptors with growth factor heregulin-beta prompts ER beta degradation by the 26S proteasome, a mechanism that requires the coactivator cAMP response element-binding (CREB)-binding protein (CBP). We found that CBP promotes ER beta ubiquitination and degradation through enhancement of the PI3-K/Akt pathway by heregulin-beta, an effect potentiated by a negatively charged hinge region of ER beta. Activated Akt triggered the recruitment of E3 ubiquitin ligase Mdm2 to ER beta, which was further stabilized by CBP, resulting in ER beta poly-ubiquitination. Mutation of CBP Thr-1872 or Mdm2 Ser-186/188 Akt sites resulted in a dissociation of the ER beta-CBP-Mdm2 complex and reduced ER beta turnover. We found that the decrease in ER beta induced by heregulin-beta was associated with reduced target gene promoter occupancy and enhanced proliferation of breast cancer cells. However, knockdown of Mdm2 restored endogenous ER beta levels resulting in reduction of breast cancer cell growth. These studies identify a tripartite Akt-regulated phosphorylation mechanism that functions to hamper normal ER beta activity and turnover through the concerted actions of CBP and Mdm2 in response to growth factor signaling pathways in breast cancer cells. Oncogene (2013) 32, 117-126; doi:10.1038/onc.2012.19; published online 20 February 2012	[Sanchez, M.; Picard, N.; Sauve, K.; Tremblay, A.] Univ Montreal, Ste Justine Hosp Res Ctr, Dept Biochem, Montreal, PQ H3T 1C5, Canada; [Tremblay, A.] Univ Montreal, Dept Obstet & Gynecol, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal	Tremblay, A (corresponding author), Univ Montreal, Ste Justine Hosp Res Ctr, Dept Biochem, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.	andre.tremblay.1@umontreal.ca			FHSJ (Fondation de l'Hopital Ste-Justine); FRSQ (Fonds de la Recherche en Sante du Quebec); GRUM (Groupe de Recherche sur le Medicament de l'Universite de Montreal); CIHR (Canadian Institutes of Health Research); NSERC (Natural Sciences and Engineering Research Council of Canada); Cancer Research Society Inc.; Canadian Foundation for Innovation; FHSJ	FHSJ (Fondation de l'Hopital Ste-Justine); FRSQ (Fonds de la Recherche en Sante du Quebec)(Fonds de la Recherche en Sante du Quebec); GRUM (Groupe de Recherche sur le Medicament de l'Universite de Montreal); CIHR (Canadian Institutes of Health Research)(Canadian Institutes of Health Research (CIHR)); NSERC (Natural Sciences and Engineering Research Council of Canada)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Cancer Research Society Inc.; Canadian Foundation for Innovation(Canada Foundation for Innovation); FHSJ	We thank members of the laboratory for critical reading and useful comments. MS is supported by a doctoral award from the FHSJ (Fondation de l'Hopital Ste-Justine), NP by the FRSQ (Fonds de la Recherche en Sante du Quebec) and the FHSJ, and KS by the GRUM (Groupe de Recherche sur le Medicament de l'Universite de Montreal), the FHSJ and the CIHR (Canadian Institutes of Health Research). AT is a New Investigator of the CIHR. This work was supported by grants from the CIHR, the NSERC (Natural Sciences and Engineering Research Council of Canada), the Cancer Research Society Inc. and the Canadian Foundation for Innovation.	Ariazi EA, 2002, CANCER RES, V62, P6510; Arpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045; Avallone R, 2006, MOL ENDOCRINOL, V20, P3165, DOI 10.1210/me.2006-0146; Berry NB, 2008, MOL ENDOCRINOL, V22, P1535, DOI 10.1210/me.2007-0449; Brekman A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2804; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Demers A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007728; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kim K, 2011, J MOL ENDOCRINOL, V46, P67, DOI 10.1677/JME-10-0110; Lazennec G, 2006, CANCER LETT, V231, P151, DOI 10.1016/j.canlet.2005.01.021; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Leygue E, 1998, CANCER RES, V58, P3197; Lindberg K, 2010, J CELL PHYSIOL, V222, P156, DOI 10.1002/jcp.21932; Loda M, 2010, CANCER CELL, V17, P311, DOI 10.1016/j.ccr.2010.03.013; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Ma YX, 2010, MOL ENDOCRINOL, V24, P76, DOI 10.1210/me.2009-0218; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2010, SEMIN CANCER BIOL, V20, P19, DOI 10.1016/j.semcancer.2009.10.005; Nair HB, 2011, STEROIDS, V76, P792, DOI 10.1016/j.steroids.2011.02.038; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Picard N, 2008, MOL ENDOCRINOL, V22, P317, DOI 10.1210/me.2007-0281; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Roger P, 2008, ADV EXP MED BIOL, V617, P139, DOI 10.1007/978-0-387-69080-3_13; Sakamoto G, 2009, BREAST CANCER-TOKYO, V16, P281, DOI 10.1007/s12282-009-0110-3; SANCHEZ M, 2005, MOL GENET CANC, V5, P149; Sanchez M, 2007, J BIOL CHEM, V282, P4830, DOI 10.1074/jbc.M607908200; Sanchez M, 2010, TRENDS ENDOCRIN MET, V21, P104, DOI 10.1016/j.tem.2009.09.007; Sauve K, 2009, CANCER RES, V69, P5793, DOI 10.1158/0008-5472.CAN-08-4924; Shao WL, 2004, P NATL ACAD SCI USA, V101, P11599, DOI 10.1073/pnas.0402997101; Shi DD, 2009, P NATL ACAD SCI USA, V106, P16275, DOI 10.1073/pnas.0904305106; St-Laurent V, 2005, J STEROID BIOCHEM, V94, P23, DOI 10.1016/j.jsbmb.2005.02.001; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; Treeck O, 2010, BREAST CANCER RES TR, V120, P557, DOI 10.1007/s10549-009-0413-2; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tremblay A, 2001, J STEROID BIOCHEM, V77, P19, DOI 10.1016/S0960-0760(01)00031-0; Weigel NL, 2007, MOL ENDOCRINOL, V21, P2311, DOI 10.1210/me.2007-0101	44	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2013	32	1					117	126		10.1038/onc.2012.19	http://dx.doi.org/10.1038/onc.2012.19			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22349818				2022-12-17	WOS:000313029500012
J	Berardi, S; Caivano, A; Ria, R; Nico, B; Savino, R; Terracciano, R; De Tullio, G; Ferrucci, A; De Luisi, A; Moschetta, M; Mangialardi, G; Catacchio, I; Basile, A; Guarini, A; Zito, A; Ditonno, P; Musto, P; Dammacco, F; Ribatti, D; Vacca, A				Berardi, S.; Caivano, A.; Ria, R.; Nico, B.; Savino, R.; Terracciano, R.; De Tullio, G.; Ferrucci, A.; De Luisi, A.; Moschetta, M.; Mangialardi, G.; Catacchio, I.; Basile, A.; Guarini, A.; Zito, A.; Ditonno, P.; Musto, P.; Dammacco, F.; Ribatti, D.; Vacca, A.			Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets	ONCOGENE			English	Article						angiogenesis; antiangiogenesis; endothelial cells; multiple myeloma; proteomic analysis	ALPHA-B-CRYSTALLIN; BONE-MARROW; LUNG-CANCER; VIMENTIN; ADHESION; FILAMIN; ANGIOGENESIS; NUCLEAR; MICROENVIRONMENT; LOCALIZATION	Bone marrow (BM) angiogenesis has an important role in the initiation and progression of multiple myeloma (MM). We looked at novel mechanisms of vessel formation in patients with MM through a comparative proteomic analysis between BM endothelial cells (ECs) of patients with active MM (MMECs) and ECs of patients with monoclonal gammopathy of undetermined significance (MGECs) and of subjects with benign anemia (normal ECs). Four proteins were found overexpressed in MMECs: filamin A, vimentin, alpha-crystallin B and 14-3-3 zeta/delta protein, not yet linked to overangiogenic phenotype. These proteins gave a typical distribution in the BM of MM patients and in MMECs versus MGECs, plausibly according to a different functional state. Their expression was enhanced by vascular endothelial growth factor, fibroblast growth factor 2, hepatocyte growth factor and MM plasma cell conditioned medium in step with enhancement of MMEC angiogenesis. Their silencing RNA knockdown affected critical MMEC angiogenesis-related functions, such as spreading, migration and tubular morphogenesis. A gradual stabilization of 14-33 zeta/delta protein was observed, with transition from normal ECs to MGECs and MMECs that may be a critical step for the angiogenic switch in MMECs and maintenance of the cell overangiogenic phenotype. These proteins were substantially impacted by anti-MM drugs, such as bortezomib, lenalidomide and panobinostat. Results suggest that these four proteins could be new targets for the antiangiogenic management of MM patients. Oncogene (2012) 31, 2258-2269; doi:10.1038/onc.2011.412; published online 3 October 2011	[Berardi, S.; Ria, R.; De Tullio, G.; Ferrucci, A.; De Luisi, A.; Moschetta, M.; Catacchio, I.; Basile, A.; Dammacco, F.; Vacca, A.] Univ Bari, Dept Biomed Sci & Human Oncol, Sch Med, I-70124 Bari, Italy; [Caivano, A.] IRCCS Referral Basilicata Canc Ctr, Dept Oncohematol, Mol Oncol Unit, Potenza, Italy; [Nico, B.; Ribatti, D.] Univ Bari, Dept Human Anat Histol & Embryol, Sch Med, I-70124 Bari, Italy; [Savino, R.; Terracciano, R.] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy; [Mangialardi, G.] Univ Bristol, Bristol Heart Inst, Dept Expt Cardiovasc Med, Bristol, Avon, England; [Guarini, A.] Natl Canc Inst Giovanni Paolo II, Hematol Unit, Bari, Italy; [Zito, A.] Di Venere Hosp, Pathol Unit, Bari, Italy; [Ditonno, P.] De Venere Hosp, Hematol Unit, Bari, Italy; [Musto, P.] IRCCS Referral Basilicata Canc Ctr, Unit Hematol & Stem Cell Transplantat, Potenza, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Magna Graecia University of Catanzaro; University of Bristol; IRCCS Istituto Tumori Bari Giovanni Paolo II	Vacca, A (corresponding author), Univ Bari, Dept Internal Med & Clin Oncol, Sch Med, Piazza Giulio Cesare 11, I-70124 Bari, Italy.	a.vacca@dimo.uniba.it	Vacca, Angelo/AAC-9558-2022; Terracciano, Rosa/AAO-8649-2020; DITONNO, PAOLO/AAG-5684-2020; Dammacco, Franco/ABG-5728-2020; Zito, Francesco/AAQ-8972-2020; CAIVANO, ANTONELLA/J-8120-2018; Guarini, Attilio/AAK-3156-2020; Ria, Roberto/I-4263-2015	Vacca, Angelo/0000-0002-4567-8216; Dammacco, Franco/0000-0003-2149-5471; Zito, Francesco/0000-0003-4140-4020; Guarini, Attilio/0000-0002-9304-6651; Musto, Pellegrino/0000-0003-3277-6594; Savino, Rocco/0000-0002-4046-1472; CAIVANO, ANTONELLA/0000-0003-2502-4060; Ria, Roberto/0000-0002-1515-0090; Terracciano, Rosa/0000-0002-5175-1758	Associazione Italiana per la Ricerca sul Cancro; Investigator Grant and Special Program Molecular Clinical Oncology 5 per mille, Milan [9965]; Ministry of Health, Progetto Oncologia, Humanitas Mirasole S.p.A., Rome, Italy	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Investigator Grant and Special Program Molecular Clinical Oncology 5 per mille, Milan; Ministry of Health, Progetto Oncologia, Humanitas Mirasole S.p.A., Rome, Italy	This work was supported by Associazione Italiana per la Ricerca sul Cancro, Investigator Grant and Special Program Molecular Clinical Oncology 5 per mille n. 9965, Milan, and the Ministry of Health, Progetto Oncologia 2006, Humanitas Mirasole S.p.A., Rome, Italy. The sponsors of this study are public or non-profit organizations that support science in general. They had no role in gathering, analyzing or interpreting the data. The authors are fully responsible for the content and editorial decisions for this manuscript. We thank Dr Maurilio Ponzoni, San Raffaele Institute, Milan, Italy, for collaboration on the mouse model.	Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae; Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Andley UP, 2007, PROG RETIN EYE RES, V26, P78, DOI 10.1016/j.preteyeres.2006.10.003; Arrigo AP, 2007, FEBS LETT, V581, P3665, DOI 10.1016/j.febslet.2007.04.033; Bedolla RG, 2009, CLIN CANCER RES, V15, P788, DOI 10.1158/1078-0432.CCR-08-1402; Chan W, 2002, EUR J CELL BIOL, V81, P692, DOI 10.1078/0171-9335-00281; Coluccia AML, 2008, BLOOD, V112, P1346, DOI 10.1182/blood-2007-10-116590; De Luisi A, 2011, CLIN CANCER RES, V17, P1935, DOI 10.1158/1078-0432.CCR-10-2381; Dimberg A, 2008, BLOOD, V111, P2015, DOI 10.1182/blood-2007-04-087841; Dutsch-Wicherek M, 2010, AM J REPROD IMMUNOL, V63, P181, DOI 10.1111/j.1600-0897.2009.00803.x; Eriksson JE, 2009, J CLIN INVEST, V119, P1763, DOI 10.1172/JCI38339; Fan T, 2007, CANCER RES, V67, P7901, DOI 10.1158/0008-5472.CAN-07-0090; Feng YY, 2006, P NATL ACAD SCI USA, V103, P19836, DOI 10.1073/pnas.0609628104; Ge F, 2009, J PROTEOME RES, V8, P3006, DOI 10.1021/pr9001004; Gilles C, 1999, J CELL SCI, V112, P4615; Gonzales M, 2001, MOL BIOL CELL, V12, P85, DOI 10.1091/mbc.12.1.85; Gruvberger Saal SK, 2006, J CLIN INVEST, V116, P30; Head MW, 2000, NEUROREPORT, V11, P361, DOI 10.1097/00001756-200002070-00028; Hellebrekers DMEI, 2006, CANCER RES, V66, P10770, DOI 10.1158/0008-5472.CAN-06-1609; Hishiya A, 2008, ONCOGENE, V27, P6489, DOI 10.1038/onc.2008.314; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095; Kim H, 2010, AM J PHYSIOL-CELL PH, V298, pC221, DOI 10.1152/ajpcell.00323.2009; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Lee JW, 2008, EUR J CELL BIOL, V87, P377, DOI 10.1016/j.ejcb.2008.03.006; Li ZG, 2008, P NATL ACAD SCI USA, V105, P162, DOI 10.1073/pnas.0710905105; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu CH, 2010, J PROTEOM BIOINFORM, V3, P5; Maiso P, 2006, CANCER RES, V66, P5781, DOI 10.1158/0008-5472.CAN-05-4186; Matrone MA, 2010, CANCER RES, V70, P7737, DOI 10.1158/0008-5472.CAN-10-1569; Meriane M, 2000, J BIOL CHEM, V275, P33046, DOI 10.1074/jbc.M001566200; Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003; Moyano JV, 2006, J CLIN INVEST, V116, P261, DOI 10.1172/JCI25888; Obermeyer N, 2003, ENDOTHELIUM-J ENDOTH, V10, P167, DOI 10.1080/713715224; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Popowicz GM, 2006, TRENDS BIOCHEM SCI, V31, P411, DOI 10.1016/j.tibs.2006.05.006; Ria R, 2009, CLIN CANCER RES, V15, P5369, DOI 10.1158/1078-0432.CCR-09-0040; Ribatti D, 2006, ONCOGENE, V25, P4257, DOI 10.1038/sj.onc.1209456; Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008-5472.CAN-05-1195; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Sluchanko NN, 2008, ARCH BIOCHEM BIOPHYS, V477, P305, DOI 10.1016/j.abb.2008.05.020; Tsuruta D, 2003, J CELL SCI, V116, P4977, DOI 10.1242/jcs.00823; Vacca A, 2003, BLOOD, V102, P3340, DOI 10.1182/blood-2003-04-1338; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; van den IJssel P, 2003, EXP CELL RES, V287, P249, DOI 10.1016/S0014-4827(03)00092-2; van Rijk AF, 2003, EUR J CELL BIOL, V82, P361, DOI 10.1078/0171-9335-00321; Wang ZH, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-308; Zhou AX, 2010, TRENDS CELL BIOL, V20, P113, DOI 10.1016/j.tcb.2009.12.001	49	22	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	18					2258	2269		10.1038/onc.2011.412	http://dx.doi.org/10.1038/onc.2011.412			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21963844				2022-12-17	WOS:000303610800002
J	Southern, SL; Collard, TJ; Urban, BC; Skeen, VR; Smartt, HJ; Hague, A; Oakley, F; Townsend, PA; Perkins, ND; Paraskeva, C; Williams, AC				Southern, S. L.; Collard, T. J.; Urban, B. C.; Skeen, V. R.; Smartt, H. J.; Hague, A.; Oakley, F.; Townsend, P. A.; Perkins, N. D.; Paraskeva, C.; Williams, A. C.			BAG-1 interacts with the p50-p50 homodimeric NF-kappa B complex: implications for colorectal carcinogenesis	ONCOGENE			English	Article						NF-kappa B; BAG-1; p50 homodimers; colorectal cancer; EGFR; COX2	ALTERNATIVE TRANSLATION INITIATION; SQUAMOUS-CELL CARCINOMA; DNA-BINDING; CANCER-CELLS; TRANSCRIPTIONAL ACTIVATION; ONCOPROTEIN BCL-3; P50 HOMODIMERS; PROTEIN; EXPRESSION; RECEPTOR	Understanding the mechanisms that promote aberrant tumour cell survival is critical for the determination of novel strategies to combat colorectal cancer (CRC). We have recently shown that the anti-apoptotic protein BAG-1, highly expressed in pre-malignant and CRC tissue, can potentiate cell survival through regulating NF-kappa B transcriptional activity. In this study, we identify a novel complex between BAG-1 and the p50-p50 NF-kappa B homodimers, implicating BAG-1 as a co-regulator of an atypical NF-kappa B pathway. Importantly, the BAG-1-p50 complex was detected at gene regulatory sequences including the epidermal growth factor receptor (EGFR) and COX-2 (PTGS2) genes. Suppression of BAG-1 expression using small interfering RNA was shown to increase EGFR and suppress COX-2 expression in CRC cells. Furthermore, mouse embryonic fibroblasts derived from the NF-kappa B1 (p105/p50) knock-out mouse were used to demonstrate that p50 expression was required for BAG-1 to suppress EGFR expression. This was shown to be functionally relevant as attenuation of BAG-1 expression increased ligand activated phosphorylation of EGFR in CRC cells. In summary, this paper identifies a novel role for BAG-1 in modulating gene expression through interaction with the p50-p50 NF-kappa B complexes. Data presented led us to propose that BAG-1 can act as a selective regulator of p50-p50 NF-kappa B responsive genes in colorectal tumour cells, potentially important for the promotion of cell survival in the context of the fluctuating tumour microenvironment. As BAG-1 expression is increased in the developing adenoma through to metastatic lesions, understanding the function of the BAG-1-p50 NF-kappa B complexes may aid in identifying strategies for both the prevention and treatment of CRC. Oncogene (2012) 31, 2761-2772; doi: 10.1038/onc.2011.452; published online 3 October 2011	[Southern, S. L.; Collard, T. J.; Urban, B. C.; Skeen, V. R.; Smartt, H. J.; Paraskeva, C.; Williams, A. C.] Univ Bristol, Sch Cellular & Mol Med, Bristol BS8 1TD, Avon, England; [Hague, A.] Univ Bristol, Sch Oral & Dent Sci, Bristol BS8 1TD, Avon, England; [Oakley, F.; Perkins, N. D.] Newcastle Univ, Sch Med, Inst Cell & Mol Biosci ICaMB, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Townsend, P. A.] Univ Southampton, Sch Med, Southampton Gen Hosp, Div Canc Sci, Southampton, Hants, England	University of Bristol; University of Bristol; Newcastle University - UK; University of Southampton	Williams, AC (corresponding author), Univ Bristol, Sch Cellular & Mol Med, Med Sci Bldg, Bristol BS8 1TD, Avon, England.	Ann.C.Williams@bristol.ac.uk	Townsend, Paul/AAF-8234-2020	Williams, Ann/0000-0002-6009-7137; Oakley, Fiona/0000-0001-8692-1836; Townsend, Paul/0000-0001-8956-9508; Urban, Bettina/0000-0002-9015-7583	Cancer Research UK; Citrina Foundation; Wellcome Trust; James Bristol Foundation; Medical Research Council; MRC [G0900535] Funding Source: UKRI; Cancer Research UK [11975] Funding Source: researchfish; Medical Research Council [G0900535] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Citrina Foundation; Wellcome Trust(Wellcome Trust); James Bristol Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was funded by a Cancer Research UK programme grant, the Citrina Foundation, The Wellcome Trust and by the John James Bristol Foundation. We thank the Medical Research Council for providing an Infrastructure Award to establish the School of Medical Sciences Cell Imaging Facility at the University of Bristol.	Arhel NJ, 2003, INT J CANCER, V106, P364, DOI 10.1002/ijc.11257; Arlt A, 2002, CANCER RES, V62, P910; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barnes JD, 2005, APOPTOSIS, V10, P301, DOI 10.1007/s10495-005-0804-8; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Cancer Research UK, 2007, BOW CANC FACTSH; Cao SJ, 2006, J BIOL CHEM, V281, P26041, DOI 10.1074/jbc.M602222200; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Clemo NK, 2008, CARCINOGENESIS, V29, P849, DOI 10.1093/carcin/bgn004; Cutress RI, 2003, ONCOGENE, V22, P4973, DOI 10.1038/sj.onc.1206688; Deng WG, 2003, J BIOL CHEM, V278, P4770, DOI 10.1074/jbc.M209286200; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Gehring U, 2009, INT J MOL SCI, V10, P906, DOI 10.3390/ijms10030906; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; Glass CK, 2000, GENE DEV, V14, P121; Hinitt CAM, 2010, EXP CELL RES, V316, P2042, DOI 10.1016/j.yexcr.2010.04.016; Hou SH, 2003, J BIOL CHEM, V278, P45994, DOI 10.1074/jbc.M307971200; Inan MS, 2000, AM J PHYSIOL-GASTR L, V279, pG1282, DOI 10.1152/ajpgi.2000.279.6.G1282; Jiang YX, 2009, CANCER-AM CANCER SOC, V115, P3609, DOI 10.1002/cncr.24434; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; Karst AM, 2009, INT J CANCER, V124, P494, DOI 10.1002/ijc.23973; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Kikuchi R, 2002, BRIT J CANCER, V87, P1136, DOI 10.1038/sj.bjc.6600579; Knowlden JM, 2008, BREAST CANCER RES TR, V111, P79, DOI 10.1007/s10549-007-9763-9; Lin Y, 2010, EXPERT OPIN THER TAR, V14, P45, DOI 10.1517/14728220903431069; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Maier JV, 2010, BIOCHEM BIOPH RES CO, V401, P406, DOI 10.1016/j.bbrc.2010.09.067; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Niyaz Y, 2001, J CELL SCI, V114, P1839; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pereira SG, 2008, INT J BIOCHEM CELL B, V40, P1425, DOI 10.1016/j.biocel.2007.05.004; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Rorke S, 2001, INT J CANCER, V95, P317, DOI 10.1002/1097-0215(20010920)95:5<317::AID-IJC1055>3.0.CO;2-J; Rosati A, 2007, J CELL PHYSIOL, V210, P676, DOI 10.1002/jcp.20865; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Sharp Adam, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404007537; Shindoh M, 2000, ORAL ONCOL, V36, P444, DOI 10.1016/S1368-8375(00)00025-7; Smartt HJM, 2003, BRIT J CANCER, V89, P1358, DOI 10.1038/sj.bjc.6601266; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Takayama S, 1998, CANCER RES, V58, P3116; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Thornburg NJ, 2003, CANCER RES, V63, P8293; Tong X, 2004, MOL CELL BIOCHEM, V265, P171, DOI 10.1023/B:MCBI.0000044394.66951.4d; Townsend PA, 2005, INT J BIOCHEM CELL B, V37, P251, DOI 10.1016/j.biocel.2004.03.016; Weldon CB, 2001, SURGERY, V130, P143, DOI 10.1067/msy.2001.115512; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; Wood J, 2009, ORAL ONCOL, V45, P94, DOI 10.1016/j.oraloncology.2008.07.013; Xiao GT, 2006, CYTOKINE GROWTH F R, V17, P281, DOI 10.1016/j.cytogfr.2006.04.005; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	66	22	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2761	2772		10.1038/onc.2011.452	http://dx.doi.org/10.1038/onc.2011.452			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21963853	Green Accepted			2022-12-17	WOS:000304769000006
J	Zeineldin, M; Cunningham, J; McGuinness, W; Alltizer, P; Cowley, B; Blanchat, B; Xu, W; Pinson, D; Neufeld, KL				Zeineldin, M.; Cunningham, J.; McGuinness, W.; Alltizer, P.; Cowley, B.; Blanchat, B.; Xu, W.; Pinson, D.; Neufeld, K. L.			A knock-in mouse model reveals roles for nuclear Apc in cell proliferation, Wnt signal inhibition and tumor suppression	ONCOGENE			English	Article						adenomatous polyposis coli; polyp; Wnt; nuclear; mouse model; NLS	ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN; SUBCELLULAR-LOCALIZATION; NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN; GENE; MUTATION; MICE; DNA; PHOSPHORYLATION	Mutation of the tumor suppressor adenomatous polyposis coli (APC) is considered an initiating step in the genesis of the vast majority of colorectal cancers. APC inhibits the Wnt-signaling pathway by targeting the proto-oncogene beta-catenin for destruction by cytoplasmic proteasomes. In the presence of a Wnt signal, or in the absence of functional APC, beta-catenin can serve as a transcription cofactor for genes required for cell proliferation such as cyclin-D1 and c-Myc. In cultured cells, APC shuttles between the nucleus and the cytoplasm, with nuclear APC implicated in the inhibition of Wnt target gene expression. Adopting a genetic approach to evaluate the functions of nuclear APC in the context of a whole organism, we generated a mouse model with mutations that inactivate the nuclear localization signals (NLSs) of Apc (Apc(mNLS)). Apc(mNLS/mNLS) mice are viable and fractionation of mouse embryonic fibroblasts (MEFs) isolated from these mice revealed a significant reduction in nuclear Apc as compared with Apc(+/+) MEFs. The levels of Apc and beta-catenin protein were not significantly altered in small intestinal epithelia from Apc(mNLS/mNLS) mice. Compared with Apc(+/+) mice, Apc(mNLS/mNLS) mice showed increased proliferation in epithelial cells from the jejunum, ileum and colon. These same tissues from Apc(mNLS/mNLS) mice showed more mRNA from three genes upregulated in response to canonical Wnt signal, c-Myc, axin-2 and cyclin-D1, and less mRNA from Hath-1, which is downregulated in response to Wnt. These observations suggest a role for nuclear Apc in the inhibition of canonical Wnt signaling and the control of epithelial proliferation in intestinal tissue. Furthermore, we found Apc(Min/+) mice, which harbor a mutation that truncates Apc, to have an increased polyp size and multiplicity if they also carry the Apc(mNLS) allele. Taken together, this analysis of the novel Apc(mNLS) mouse model supports a role for nuclear Apc in the control of Wnt target genes, intestinal epithelial cell proliferation and polyp formation. Oncogene (2012) 31, 2423-2437; doi: 10.1038/onc.2011.434; published online 26 September 2011	[Zeineldin, M.; McGuinness, W.; Alltizer, P.; Blanchat, B.; Neufeld, K. L.] Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; [Cowley, B.] Univ Utah, Eccles Inst Human Genet, Salt Lake City, UT USA; [Xu, W.] Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; [Pinson, D.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA	University of Kansas; Utah System of Higher Education; University of Utah; University of Virginia; University of Kansas; University of Kansas Medical Center	Neufeld, KL (corresponding author), Univ Kansas, Dept Mol Biosci, 7049 Haworth Hall,1200 Sunnyside Ave, Lawrence, KS 66045 USA.	klneuf@ku.edu	Zeineldin, Maged/AAU-1040-2021	Neufeld, Kristi/0000-0003-3653-9385	National Cancer Institute [RO1 CA10922];  [5P20 RR15563]; NATIONAL CANCER INSTITUTE [R01CA109220] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by RO1 CA10922 from the National Cancer Institute and 5P20 RR15563. We extend our gratitude to Alan Godwin, Kirk Thomas and Mario Capecchi for advice on the generation of the knock-in mouse and for the lambda phage library, and the tACE-Cre-Neo<SUP>r</SUP>- and Tk<SUP>HSV</SUP>-containing constructs. We thank Marc Roth, Areli Monarrez, Ashrita Abraham and Travis Friesen for technical assistance; the staff at the University of Kansas Animal Care Unit for excellent mouse husbandry and David Davido for critical reading of the manuscript. We also thank Reka Nagy and Drs Andras Nagy, Janet Rossant and Wanda Abramow-Newerly (Mount Sinai Hospital) for the mouse R1 ES cells.	Anderson CB, 2002, P NATL ACAD SCI USA, V99, P8683, DOI 10.1073/pnas.122235399; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; Cheung AF, 2010, ONCOGENE, V29, P1857, DOI 10.1038/onc.2009.457; Colnot S, 2004, LAB INVEST, V84, P1619, DOI 10.1038/labinvest.3700180; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; Fagman H, 2003, ONCOGENE, V22, P6013, DOI 10.1038/sj.onc.1206731; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Galea MA, 2001, J BIOL CHEM, V276, P45833, DOI 10.1074/jbc.M107149200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Ishikawa T, 2003, DEV BIOL, V253, P230, DOI 10.1016/S0012-1606(02)00020-9; Jaiswal AS, 2008, CANCER LETT, V271, P272, DOI 10.1016/j.canlet.2008.06.024; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Magnus HA, 1937, J PATHOL BACTERIOL, V44, P389, DOI 10.1002/path.1700440214; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 2003, MANIPULATING MOUSE E; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Neufeld KL, 2000, EMBO REP, V1, P519; Neufeld KL, 2009, ADV EXP MED BIOL, V656, P13, DOI 10.1007/978-1-4419-1145-2_2; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; Pollard P, 2009, GASTROENTEROLOGY, V136, P2204, DOI 10.1053/j.gastro.2009.02.058; Qian J, 2008, GASTROENTEROLOGY, V135, P152, DOI 10.1053/j.gastro.2008.03.074; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105; Sasai H, 2000, CARCINOGENESIS, V21, P953, DOI 10.1093/carcin/21.5.953; Sena P, 2006, CANCER LETT, V241, P203, DOI 10.1016/j.canlet.2005.10.011; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Taketo MM, 2006, CANCER SCI, V97, P355, DOI 10.1111/j.1349-7006.2006.00190.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wang Y, 2008, MOL BIOL CELL, V19, P4076, DOI 10.1091/mbc.E07-12-1296; Wang Y, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-75; Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6; Yang K, 1997, J EXP ZOOL, V277, P245, DOI 10.1002/(SICI)1097-010X(19970215)277:3<245::AID-JEZ5>3.3.CO;2-N; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	50	22	23	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2423	2437		10.1038/onc.2011.434	http://dx.doi.org/10.1038/onc.2011.434			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996741	Green Submitted, Green Accepted			2022-12-17	WOS:000303985300005
J	Wen, S; So, Y; Singh, K; Slingerland, JM; Resnick, MB; Zhang, S; Ruiz, V; Moss, SF				Wen, S.; So, Y.; Singh, K.; Slingerland, J. M.; Resnick, M. B.; Zhang, S.; Ruiz, V.; Moss, S. F.			Promotion of cytoplasmic mislocalization of p27 by Helicobacter pylori in gastric cancer	ONCOGENE			English	Article						gastric cancer; Helicobacter pylori; cell cycle regulation; cyclin-dependent kinase inhibitor	KINASE INHIBITOR P27(KIP1); EPITHELIAL-CELLS; PHOSPHORYLATION; EXPRESSION; APOPTOSIS; ACTIVATION; RISK; ERADICATION; PHENOTYPE; CARCINOMA	The cyclin-dependent kinase (CDK) inhibitor p27 has an important role in cell cycle regulation. Reduced expression of p27 is commonly associated with poor prognosis in many malignancies, including gastric cancer. Cytoplasmic p27 mislocalization may be an additional indicator of high-grade tumors and poor prognosis in cancer. As chronic infection by Helicobacter pylori is the most important risk factor for gastric cancer development, we evaluated the effects of H. pylori on p27 expression and localization in gastric cancer cells. Co-culture of gastric cells with H. pylori induced cytoplasmic p27 expression and reduced nuclear p27 expression in vitro. Cytoplasmic p27 expression was associated with and dependent upon phosphorylation of p27 at T157 and T198: wild-type p27 accumulated in the cytoplasm, but non-phosphorylatable mutants affecting T157 or T198 were nuclear in H. pylori-infected cells. These post-translational p27 changes were secondary to activation of cellular phosphoinositide-3 kinase (PI3K) and AKT signaling pathways, and dependent upon a functional H. pylori cag pathogenicity island. We investigated the clinical significance of cytoplasmic p27 mislocalization in 164 cases of resected gastric cancer in tissue microarrays. In 97 cases (59%), cytoplasmic p27 mislocalization was observed, and this was associated with increased mortality in multivariate analysis. These results show that H. pylori infection induces AKT/PI3K-mediated phosphorylation of p27 at T157 and T198 to cause cytoplasmic p27 mislocalization in gastric cancer, and that p27 mislocalization is an adverse prognostic feature in gastric cancer. This is the first demonstration of the translocation of a specific bacterial virulence factor that post-translationally regulates a host cell CDK inhibitor. This is of particular significance, because p27 has both tumor-suppressive and oncogenic activities, depending upon its subcellular localization. Cytoplasmic mislocalization of p27 induced by H. pylori may be an important mechanistic link between H. pylori infection and gastric carcinogenesis. Oncogene (2012) 31, 1771-1780; doi: 10.1038/onc.2011.362; published online 15 August 2011	[Wen, S.; So, Y.; Zhang, S.; Ruiz, V.; Moss, S. F.] Brown Univ, Dept Med, Div Gastroenterol, Rhode Isl Hosp, Providence, RI 02903 USA; [Wen, S.; So, Y.; Singh, K.; Resnick, M. B.; Zhang, S.; Ruiz, V.; Moss, S. F.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02903 USA; [Singh, K.; Resnick, M. B.] Brown Univ, Dept Pathol, Rhode Isl Hosp, Providence, RI 02903 USA; [Slingerland, J. M.] Univ Miami, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, Miami, FL USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Miami	Moss, SF (corresponding author), Brown Univ, Dept Med, Div Gastroenterol, Rhode Isl Hosp, 593 Eddy St,APC 414, Providence, RI 02903 USA.	Steven_Moss@Brown.edu	wen, sicheng/E-7676-2012; Resnick, Murray/U-2986-2019	Ruiz, Victoria/0000-0002-0121-4727; Singh, Kamaljeet/0000-0002-2506-5703	US Public Health Service [NIH R01CA111533, NIH P20RR17695]; NATIONAL CANCER INSTITUTE [R01CA111533] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017695] Funding Source: NIH RePORTER	US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We appreciate the help of Virginia Hovanesian for technical assistance with confocal microscopy, and Leila Noble and Rose Tavares for immunohistochemistry. The study was funded by US Public Health Service Grants NIH R01CA111533 (to SFM) and NIH P20RR17695 (to MBR).	Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Denicourt C, 2007, CANCER RES, V67, P9238, DOI 10.1158/0008-5472.CAN-07-1375; Duncan TJ, 2010, INT J GYNECOL PATHOL, V29, P8, DOI 10.1097/PGP.0b013e3181b64ec3; Eguchi H, 2004, GUT, V53, P797, DOI 10.1136/gut.2003.032144; Feakins RM, 2000, CANCER, V89, P1684, DOI 10.1002/1097-0142(20001015)89:8<1684::AID-CNCR6>3.0.CO;2-6; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fock KM, 2008, J GASTROEN HEPATOL, V23, P351, DOI 10.1111/j.1440-1746.2008.05314.x; Forman D, 2006, BEST PRACT RES CL GA, V20, P633, DOI 10.1016/j.bpg.2006.04.008; Fuccio L, 2009, ANN INTERN MED, V151, P121, DOI 10.7326/0003-4819-151-2-200907210-00009; Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6; Hidaka T, 2009, ANTICANCER RES, V29, P597; Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027; Jubelin G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004855; Kajihara R, 2010, BIOCHEM BIOPH RES CO, V401, P350, DOI 10.1016/j.bbrc.2010.09.051; Kim SS, 2006, MODERN PATHOL, V19, P49, DOI 10.1038/modpathol.3800476; Kossatz U, 2006, EMBO J, V25, P5159, DOI 10.1038/sj.emboj.7601388; Kuzushita N, 2005, GASTROENTEROLOGY, V129, P1544, DOI 10.1053/j.gastro.2005.07.056; Larrea MD, 2008, MOL CELL BIOL, V28, P6462, DOI 10.1128/MCB.02300-07; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Li R, 2006, J UROLOGY, V175, P528, DOI 10.1016/S0022-5347(05)00151-5; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Liu H, 2009, GASTROENTEROLOGY, V137, P1367, DOI 10.1053/j.gastro.2009.07.041; Mimuro H, 2007, CELL HOST MICROBE, V2, P250, DOI 10.1016/j.chom.2007.09.005; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Nagy TA, 2009, J INFECT DIS, V199, P641, DOI 10.1086/596660; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Resnick MB, 2005, HUM PATHOL, V36, P886, DOI 10.1016/j.humpath.2005.05.019; Saito Y, 2010, J EXP MED, V207, P2157, DOI 10.1084/jem.20100602; Schiappacassi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017673; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Shirin H, 2000, INFECT IMMUN, V68, P5321, DOI 10.1128/IAI.68.9.5321-5328.2000; Shirin H, 1999, CANCER RES, V59, P2277; Tabassam FH, 2009, CELL MICROBIOL, V11, P70, DOI 10.1111/j.1462-5822.2008.01237.x; Vervoorts J, 2008, CELL MOL LIFE SCI, V65, P3255, DOI 10.1007/s00018-008-8296-7; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wander SA, 2011, CLIN CANCER RES, V17, P12, DOI 10.1158/1078-0432.CCR-10-0752; Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304; Yasui W, 1997, JPN J CANCER RES, V88, P625, DOI 10.1111/j.1349-7006.1997.tb00428.x	43	22	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	14					1771	1780		10.1038/onc.2011.362	http://dx.doi.org/10.1038/onc.2011.362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21841827	Green Accepted			2022-12-17	WOS:000302785200003
J	De Cola, A; Bongiorno-Borbone, L; Bianchi, E; Barcaroli, D; Carletti, E; Knight, RA; Di Ilio, C; Melino, G; Sette, C; De Laurenzi, V				De Cola, A.; Bongiorno-Borbone, L.; Bianchi, E.; Barcaroli, D.; Carletti, E.; Knight, R. A.; Di Ilio, C.; Melino, G.; Sette, C.; De Laurenzi, V.			FLASH is essential during early embryogenesis and cooperates with p73 to regulate histone gene transcription	ONCOGENE			English	Article						Histone Locus Bodies; Cajal bodies; FLASH; NPAT	CYCLIN E/CDK2 SUBSTRATE; CELL-CYCLE; CAJAL BODIES; SELECTIVE DEGRADATION; MESSENGER-RNA; HINF-P; EXPRESSION; P220(NPAT); APOPTOSIS; TAP73	Replication-dependent histone gene expression is a fundamental process occurring in S-phase under the control of the cyclin-E/CDK2 complex. This process is regulated by a number of proteins, including Flice-Associated Huge Protein (FLASH) (CASP8AP2), concentrated in specific nuclear organelles known as HLBs. FLASH regulates both histone gene transcription and mRNA maturation, and its downregulation in vitro results in the depletion of the histone pull and cell-cycle arrest in S-phase. Here we show that the transcription factor p73 binds to FLASH and is part of the complex that regulates histone gene transcription. Moreover, we created a novel gene trap to disrupt FLASH in mice, and we show that homozygous deletion of FLASH results in early embryonic lethality, owing to arrest of FLASH(-/-) embryos at the morula stage. These results indicate that FLASH is an essential, non-redundant regulator of histone transcription and cell cycle during embryogenesis. Oncogene (2012) 31, 573-582; doi:10.1038/onc.2011.274; published online 4 July 2011	[De Laurenzi, V.] Univ G dAnnunzio, CeSI, Dipartimento Sci Biomed, I-66100 Chieti, Italy; [De Cola, A.; Bongiorno-Borbone, L.; Melino, G.] Univ Roma Tor Vergata, Dept Expt Med, IDI IRCCS Biochem Lab, Rome, Italy; [Bianchi, E.; Sette, C.] Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, Rome, Italy; [Bianchi, E.; Sette, C.] IRCCS Fdn Santa Lucia, Lab Neuroembryol, Rome, Italy; [Carletti, E.] Univ G dAnnunzio, Dipartimento Sci Movimento Umano, I-66100 Chieti, Italy; [Knight, R. A.; Melino, G.] Univ Leicester, Med Res Council, Toxicol Unit, Leicester, Leics, England; [Di Ilio, C.; De Laurenzi, V.] Fdn G DAnnunzio, CeSI, I-66100 Chieti, Italy	G d'Annunzio University of Chieti-Pescara; University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Santa Lucia; G d'Annunzio University of Chieti-Pescara; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Leicester; G d'Annunzio University of Chieti-Pescara	De Laurenzi, V (corresponding author), Univ G dAnnunzio, CeSI, Dipartimento Sci Biomed, Via Colle Ara 1, I-66100 Chieti, Italy.	delaurenzi@unich.it	Bianchi, Enrica/P-2379-2019; Sette, Claudio/S-4307-2019; De Laurenzi, Vincenzo/K-7471-2016	Bianchi, Enrica/0000-0001-8124-7328; Sette, Claudio/0000-0003-2864-8266; De Laurenzi, Vincenzo/0000-0002-7506-1743; De Cola, Antonella/0000-0002-3202-5339	AIRC; MIUR; AIRC, EU-EPISTEM; FIRB, MIUR; MinSan; Telethon; Alleanza Contro il Cancro; FIRC; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR)); AIRC, EU-EPISTEM(Fondazione AIRC per la ricerca sul cancro); FIRB, MIUR(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); MinSan; Telethon(Fondazione Telethon); Alleanza Contro il Cancro; FIRC(Fondazione AIRC per la ricerca sul cancro); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from AIRC, MIUR, to VDL, and AIRC, EU-EPISTEM; FIRB, MIUR; MinSan; Telethon and Alleanza Contro il Cancro to GM. DB is supported by a FIRC scholarship.	Alizadeh Z, 2005, MOL REPROD DEV, V72, P281, DOI 10.1002/mrd.20340; Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14802, DOI 10.1073/pnas.0604225103; Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14808, DOI 10.1073/pnas.0604227103; Bongiorno-Borbone L, 2010, ONCOGENE, V29, P802, DOI 10.1038/onc.2009.388; Bongiorno-Borbone L, 2008, CELL CYCLE, V7, P2357, DOI 10.4161/cc.6344; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DiFruscio M, 1997, MOL CELL BIOL, V17, P4080, DOI 10.1128/MCB.17.7.4080; Ghule PN, 2008, P NATL ACAD SCI USA, V105, P16964, DOI 10.1073/pnas.0809273105; Ghule PN, 2007, J CELL PHYSIOL, V213, P9, DOI 10.1002/jcp.21119; GIEBELHAUS DH, 1983, DEV BIOL, V98, P148, DOI 10.1016/0012-1606(83)90343-3; Gottifredi V, 1999, J VIROL, V73, P1427, DOI 10.1128/JVI.73.2.1427-1437.1999; GRAVES RA, 1985, P NATL ACAD SCI USA, V82, P5685, DOI 10.1073/pnas.82.17.5685; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hall C, 2001, MOL CELL BIOL, V21, P1854, DOI 10.1128/MCB.21.5.1854-1865.2001; Hamatani T, 2004, HUM MOL GENET, V13, P2263, DOI 10.1093/hmg/ddh241; HOGAN B, 1994, MANIPULATING MOUSE E; Joyner AL, 2000, GENE TARGETING PRACT; Levrero M, 2000, J CELL SCI, V113, P1661; Liu JL, 2006, J CELL BIOL, V172, P875, DOI 10.1083/jcb.200511038; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Maisse C, 2004, CELL DEATH DIFFER, V11, P685, DOI 10.1038/sj.cdd.4401376; Matera AG, 2006, J CELL BIOL, V172, P791, DOI 10.1083/jcb.200602002; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Miele A, 2005, MOL CELL BIOL, V25, P6140, DOI 10.1128/MCB.25.14.6140-6153.2005; Mitra P, 2003, MOL CELL BIOL, V23, P8110, DOI 10.1128/MCB.23.22.8110-8123.2003; Munarriz E, 2004, MOL CELL BIOL, V24, P10593, DOI 10.1128/MCB.24.24.10593-10610.2004; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Paynton BV, 1998, DEV GENET, V23, P285, DOI 10.1002/(SICI)1520-6408(1998)23:4&lt;285::AID-DVG4&gt;3.0.CO;2-W; Ramadan S, 2005, BIOCHEM BIOPH RES CO, V331, P713, DOI 10.1016/j.bbrc.2005.03.156; Sayan AE, 2005, BIOCHEM BIOPH RES CO, V330, P186, DOI 10.1016/j.bbrc.2005.02.145; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2008, TRENDS CELL BIOL, V18, P244, DOI 10.1016/j.tcb.2008.03.003; Tomasini R, 2009, P NATL ACAD SCI USA, V106, P797, DOI 10.1073/pnas.0812096106; Vernole P, 2009, CELL CYCLE, V8, P421, DOI 10.4161/cc.8.3.7623; Wei Y, 2003, MOL CELL BIOL, V23, P3669, DOI 10.1128/MCB.23.10.3669-3680.2003; Xie RL, 2009, P NATL ACAD SCI USA, V106, P12359, DOI 10.1073/pnas.0905651106; Yang XC, 2009, MOL CELL, V36, P267, DOI 10.1016/j.molcel.2009.08.016; Ye X, 2003, MOL CELL BIOL, V23, P8586, DOI 10.1128/MCB.23.23.8586-8600.2003; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zhao JY, 2004, CELL CYCLE, V3, P695	43	22	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					573	582		10.1038/onc.2011.274	http://dx.doi.org/10.1038/onc.2011.274			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21725362				2022-12-17	WOS:000300221800004
J	Giovinazzi, S; Lindsay, CR; Morozov, VM; Escobar-Cabrera, E; Summers, MK; Han, HS; McIntosh, LP; Ishov, AM				Giovinazzi, S.; Lindsay, C. R.; Morozov, V. M.; Escobar-Cabrera, E.; Summers, M. K.; Han, H. S.; McIntosh, L. P.; Ishov, A. M.			Regulation of mitosis and taxane response by Daxx and Rassf1	ONCOGENE			English	Article						Daxx; Rassf1A/C; taxane chemotherapy; mitosis; SAC; APC	TUMOR-SUPPRESSOR RASSF1A; TRANSCRIPTION REPRESSOR DAXX; SPINDLE ASSEMBLY CHECKPOINT; BREAST-CANCER PATIENTS; BETA-TUBULIN; PACLITAXEL RESISTANCE; INTERACTING PROTEIN; MITOTIC CHECKPOINT; NUCLEAR-STRUCTURE; DOWN-REGULATION	Current theories suggest that mitotic checkpoint proteins are essential for proper cellular response to taxanes, a widely used family of chemotherapeutic compounds. We recently showed that absence or depletion of protein Daxx increases cellular taxol (paclitaxel) resistance-a common trait of patients diagnosed with several malignancies, including breast cancer. Further investigation of Daxx-mediated taxol response revealed that Daxx is important for the proper timing of mitosis progression and cyclin B stability. Daxx interacts with mitotic checkpoint protein RAS-association domain family protein 1 (Rassf1) and partially colocalizes with this protein during mitosis. Rassf1/Daxx depletion or expression of Daxx-binding domain of Rassf1 elevates cyclin B stability and increases taxol resistance in cells and mouse xenograft models. In breast cancer patients, we observed the inverse correlation between Daxx and clinical response to taxane-based chemotherapy. These data suggest that Daxx and Rassf1 define a mitotic stress checkpoint that enables cells to exit mitosis as micronucleated cells (and eventually die) when encountered with specific mitotic stress stimuli, including taxol. Surprisingly, depletion of Daxx or Rassf1 does not change the activity of E3 ubiquitin ligase anaphase promotion complex/C in in vitro settings, suggesting the necessity of mitotic cellular environment for proper activation of this checkpoint. Daxx and Rassf1 may become useful predictive markers for the proper selection of patients for taxane chemotherapy. Oncogene (2012) 31, 13-26; doi: 10.1038/onc.2011.211; published online 6 June 2011	[Giovinazzi, S.; Lindsay, C. R.; Morozov, V. M.; Ishov, A. M.] Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Escobar-Cabrera, E.; McIntosh, L. P.] Univ British Columbia, Dept Chem, Vancouver, BC, Canada; [Escobar-Cabrera, E.; McIntosh, L. P.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada; [Summers, M. K.] Genentech Inc, Dept Cellular Regulat, San Francisco, CA 94080 USA; [Han, H. S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of Florida; University of British Columbia; University of British Columbia; Roche Holding; Genentech; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Ishov, AM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, 2033 Mowry Rd,Room 358, Gainesville, FL 32610 USA.	ishov@ufl.edu		Morozov, Viacheslav/0000-0002-4901-7722	NIH/NCI [R01 CA127378-01A1]; Canadian Cancer Society [017308]; NATIONAL CANCER INSTITUTE [R01CA127378] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canadian Cancer Society(Canadian Cancer Society (CCS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Gerd Pfeifer, Beckman Research Institute, for the generous gift of anti-Rassf1 antibodies and Dr Frank Rauscher, The Wistar Institute, for HP1 antibodies. This work was supported by NIH/NCI R01 CA127378-01A1 for CRL, SG, VMM and AMI, by the Canadian Cancer Society (017308) for EE and LPM. NMR spectroscopy support was provided by the Canadian Institutes for Health Research (CIHR), the Canadian Foundation for Innovation (CFI), the British Columbia Knowledge Development Fund (BCKDF), the UBC Blusson Fund and the Michael Smith Foundation for Health Research (MSFHR).	Aapro MS, 2001, ONCOLOGIST, V6, P36, DOI 10.1634/theoncologist.6-4-376; Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Amaar YG, 2005, J BONE MINER RES, V20, P1430, DOI 10.1359/JBMR.050311; Bonneterre J, 1999, EUR J CANCER, V35, P1431, DOI 10.1016/S0959-8049(99)00174-4; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Chang JC, 2005, J CLIN ONCOL, V23, P1169, DOI 10.1200/JCO.2005.03.156; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Crown J, 2004, ONCOLOGIST, V9, P24, DOI 10.1634/theoncologist.9-suppl_2-24; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; De Mulder P H, 1999, Acta Otorhinolaryngol Belg, V53, P247; Escobar-Cabrera E, 2010, STRUCTURE, V18, P1642, DOI 10.1016/j.str.2010.09.016; Estrabaud E, 2007, CANCER RES, V67, P1054, DOI 10.1158/0008-5472.CAN-06-2530; Hari M, 2003, CELL MOTIL CYTOSKEL, V56, P45, DOI 10.1002/cm.10132; Hari M, 2003, MOL CANCER THER, V2, P597; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Ishov AM, 2004, J CELL SCI, V117, P3807, DOI 10.1242/jcs.01230; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Iwao-Koizumi K, 2005, J CLIN ONCOL, V23, P422, DOI 10.1200/JCO.2005.09.078; Kitagawa D, 2006, EMBO J, V25, P3286, DOI 10.1038/sj.emboj.7601212; Kubota T, 1997, J SURG ONCOL, V64, P115, DOI 10.1002/(SICI)1096-9098(199702)64:2<115::AID-JSO5>3.3.CO;2-1; Lee EA, 2004, MOL CANCER THER, V3, P661; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Lindsay CR, 2008, FRONT BIOSCI-LANDMRK, V13, P7132, DOI 10.2741/3216; Lindsay CR, 2007, CELL CYCLE, V6, P1200, DOI 10.4161/cc.6.10.4244; Lindsay CR, 2009, CELL CYCLE, V8, P1544, DOI 10.4161/cc.8.10.8379; Liu L, 2007, CELL CYCLE, V6, P1663, DOI 10.4161/cc.6.13.4435; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Mantel C, 2008, CELL CYCLE, V7, P484, DOI 10.4161/cc.7.4.5316; Mauriac L, 2005, BREAST, V14, P617, DOI 10.1016/j.breast.2005.08.013; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Michaelson JS, 2000, APOPTOSIS, V5, P217, DOI 10.1023/A:1009696227420; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Miyoshi Y, 2004, CLIN CANCER RES, V10, P8163, DOI 10.1158/1078-0432.CCR-04-1310; Morozov VM, 2008, ONCOGENE, V27, P2177, DOI 10.1038/sj.onc.1210865; Niikura Y, 2007, J CELL BIOL, V178, P283, DOI 10.1083/jcb.200702134; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; O'Shaughnessy J, 2005, ONCOLOGIST, V10, P20, DOI 10.1634/theoncologist.10-90003-20; RAVDIN P, 2003, EJC SUPPL, V1, P32; Rong R, 2007, ONCOGENE, V26, P7700, DOI 10.1038/sj.onc.1210575; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Saffert RT, 2008, FUTURE VIROL, V3, P265, DOI 10.2217/17460794.3.3.265; Salomoni P, 2006, TRENDS CELL BIOL, V16, P97, DOI 10.1016/j.tcb.2005.12.002; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Song MS, 2008, EMBO J, V27, P1863, DOI 10.1038/emboj.2008.115; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; Summers MK, 2008, MOL CELL, V31, P544, DOI 10.1016/j.molcel.2008.07.014; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Wang YQ, 2005, BBA-MOL CELL RES, V1744, P245, DOI 10.1016/j.bbamcr.2004.12.003; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Wysong DR, 2009, CELL CYCLE, V8, P876, DOI 10.4161/cc.8.6.7897; Xia GH, 2004, EMBO J, V23, P3133, DOI 10.1038/sj.emboj.7600322	55	22	23	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	1					13	26		10.1038/onc.2011.211	http://dx.doi.org/10.1038/onc.2011.211			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21643015	Green Accepted, Bronze			2022-12-17	WOS:000299176200002
J	Lushnikova, T; Bouska, A; Odvody, J; Dupont, WD; Eischen, CM				Lushnikova, T.; Bouska, A.; Odvody, J.; Dupont, W. D.; Eischen, C. M.			Aging mice have increased chromosome instability that is exacerbated by elevated Mdm2 expression	ONCOGENE			English	Article						aging; Mdm2; p53; chromosome instability; aneuploidy	NIJMEGEN BREAKAGE SYNDROME; DOUBLE-STRAND BREAKS; GENOMIC INSTABILITY; DNA-DAMAGE; P53; CANCER; CELLS; NBS1; OVEREXPRESSION; TUMORIGENESIS	Aging is thought to negatively affect multiple cellular processes including the ability to maintain chromosome stability. Chromosome instability (CIN) is a common property of cancer cells and may be a contributing factor to cellular transformation. The types of DNA aberrations that arise during aging before tumor development and that contribute to tumorigenesis are currently unclear. Mdm2, a key regulator of the p53 tumor suppressor and modulator of DNA break repair, is frequently over-expressed in malignancies and contributes to CIN. To determine the relationship between aging and CIN and the role of Mdm2, precancerous wild-type C57Bl/6 and littermate-matched Mdm2 transgenic mice at various ages were evaluated. Metaphase analyses of wild-type cells showed a direct correlation between age and increased chromosome and chromatid breaks, chromosome fusions and aneuploidy, but the frequency of polyploidy remained stable over time. Elevated levels of Mdm2 in precancerous mice increased both the numerical and the structural chromosomal abnormalities observed. Chromosome and chromatid breaks, chromosome fusions, aneuploidy and polyploidy were increased in older Mdm2 transgenic mice compared with wild-type littermates. Unexpectedly, chromosome fusions, aneuploidy and polyploidy rates in Mdm2 transgenic mice, but not chromosome and chromatid breaks, showed cooperation between Mdm2 overexpression and age. Notably, Mdm2 overexpression promoted gains in one or more chromosomes with age, while it did not affect the rate of chromosome loss. Therefore, aging increased specific forms of genomic instability, and elevated Mdm2 expression cooperated with aging to increase the likelihood of gaining certain chromosomal abnormalities of the kind thought to lead to cancer development. Oncogene (2011) 30, 4622-4631; doi:10.1038/onc.2011.172; published online 23 May 2011	[Eischen, C. M.] Vanderbilt Univ, Dept Pathol, Med Ctr, Sch Med, Nashville, TN 37232 USA; [Bouska, A.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Dupont, W. D.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA	Vanderbilt University; University of Nebraska System; University of Nebraska Medical Center; Vanderbilt University	Eischen, CM (corresponding author), Vanderbilt Univ, Dept Pathol, Med Ctr, Sch Med, 1161 21st Ave S,C3321 MCN, Nashville, TN 37232 USA.	christine.eischen@vanderbilt.edu	Dupont, William D./I-4430-2012		NIH/NCI [R01 CA117935]; Vanderbilt Cancer Center [P30 CA068485]; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA117935] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Vanderbilt Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Eischen lab for thoughtful discussions. This work was supported by the NIH/NCI grants: R01 CA117935 (CME) and the Vanderbilt Cancer Center grant P30 CA068485.	Agresti A., 2003, CATEGORICAL DATA ANA; Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Aubert G, 2008, PHYSIOL REV, V88, P557, DOI 10.1152/physrev.00026.2007; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Bouska A, 2009, CANCER RES, V69, P1697, DOI 10.1158/0008-5472.CAN-08-3732; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Demuth I, 2007, ONCOGENE, V26, P7792, DOI 10.1038/sj.onc.1210876; DePinho RA, 2004, NAT GENET, V36, P932, DOI 10.1038/ng0904-932; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Diggle P., 2002, ANAL LONGITUDINAL DA, DOI DOI 10.2307/2983303; Dolle MET, 2002, GENOME RES, V12, P1732, DOI 10.1101/gr.125502; Feng ZH, 2007, P NATL ACAD SCI USA, V104, P16633, DOI 10.1073/pnas.0708043104; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Garagna S, 2001, P NATL ACAD SCI USA, V98, P171, DOI 10.1073/pnas.98.1.171; Garinis GA, 2008, NAT CELL BIOL, V10, P1241, DOI 10.1038/ncb1108-1241; Gorbunova V, 2007, NUCLEIC ACIDS RES, V35, P7466, DOI 10.1093/nar/gkm756; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Lin HJ, 2001, J CELL BIOL, V155, P1173, DOI 10.1083/jcb.200108119; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Morgan WF, 1998, MUTAT RES-FUND MOL M, V404, P125, DOI 10.1016/S0027-5107(98)00104-3; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; NISITANI S, 1990, MUTAT RES, V237, P221, DOI 10.1016/0921-8734(90)90003-A; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Storchova Z, 2008, J CELL SCI, V121, P3859, DOI 10.1242/jcs.039537; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Tucker JD, 1999, MUTAT RES-FUND MOL M, V425, P135, DOI 10.1016/S0027-5107(99)00036-6; Vitale I, 2010, EMBO J, V29, P1272, DOI 10.1038/emboj.2010.11; Wang P, 2008, ONCOGENE, V27, P1590, DOI 10.1038/sj.onc.1210788; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Wu XH, 2004, GENE DEV, V18, P1305, DOI 10.1101/gad.1182804; Zietkiewicz E, 2009, J APPL GENET, V50, P261, DOI 10.1007/BF03195682	38	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	46					4622	4631		10.1038/onc.2011.172	http://dx.doi.org/10.1038/onc.2011.172			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21602883	Green Accepted			2022-12-17	WOS:000297252100002
J	Ruptier, C; De Gasperis, A; Ansieau, S; Granjon, A; Taniere, P; Lafosse, I; Shi, H; Petitjean, A; Taranchon-Clermont, E; Tribollet, V; Voeltzel, T; Scoazec, JY; Maguer-Satta, V; Puisieux, A; Hainaut, P; Cavard, C; de Fromentel, CC				Ruptier, C.; De Gasperis, A.; Ansieau, S.; Granjon, A.; Taniere, P.; Lafosse, I.; Shi, H.; Petitjean, A.; Taranchon-Clermont, E.; Tribollet, V.; Voeltzel, T.; Scoazec, J-Y; Maguer-Satta, V.; Puisieux, A.; Hainaut, P.; Cavard, C.; de Fromentel, C. Caron			TP63 P2 promoter functional analysis identifies beta-catenin as a key regulator of Delta Np63 expression	ONCOGENE			English	Article						beta-catenin; p53 family; promoter; transcriptional regulation; tumour progression	SQUAMOUS-CELL CARCINOMA; STEM-CELLS; TRANSCRIPTIONAL ACTIVITY; DIFFERENTIAL REGULATION; SIGNALING PATHWAY; UP-REGULATION; P53 FAMILY; P63; CANCER; P73	The Delta Np63 protein, a product of the TP63 gene that lacks the N-terminal domain, has a critical role in the maintenance of self renewal and progenitor capacity in several types of epithelial tissues. Delta Np63 is frequently overexpressed in squamous cell carcinoma (SCC) and in some other epithelial tumours. This overexpression may contribute to tumour progression through dominant-negative effects on the transcriptionally active (TA) isoforms of the p53 family (TAp63, TAp73 and p53), as well as through independent mechanisms. However, the molecular basis of Delta Np63 overexpression is not fully understood. Here, we show that the expression of Delta Np63 is regulated by the Wnt/beta-catenin pathway in human hepatocellular carcinoma (HCC) and SCC cell lines. This regulation operates in particular through TCF/LEF sites present in the P2 promoter of TP63. In addition, we show that Delta Np63 and beta-catenin are frequently coexpressed and accumulated in oesophageal SCC, but not in HCC. These results suggest that activation of the b-catenin pathway may contribute to overexpression of Delta Np63 during tumour progression, in a cell type-specific manner. Oncogene (2011) 30, 4656-4665; doi:10.1038/onc.2011.171; published online 6 June 2011	[de Fromentel, C. Caron] CNRS5286, UMR INSERM U1052, Ctr Rech Cancerol Lyon, F-69008 Lyon, France; [Ruptier, C.; De Gasperis, A.; Ansieau, S.; Granjon, A.; Lafosse, I.; Tribollet, V.; Voeltzel, T.; Scoazec, J-Y; Maguer-Satta, V.; Puisieux, A.; de Fromentel, C. Caron] Univ Lyon, Lyon, France; [Ruptier, C.; De Gasperis, A.; Ansieau, S.; Granjon, A.; Lafosse, I.; Tribollet, V.; Voeltzel, T.; Scoazec, J-Y; Maguer-Satta, V.; Puisieux, A.; de Fromentel, C. Caron] Ctr Rech Cancerol Lyon, INSERM U1052, Lyon, France; [Taniere, P.; Shi, H.; Petitjean, A.; Taranchon-Clermont, E.; Hainaut, P.] Int Agcy Res Canc, F-69372 Lyon, France; [Scoazec, J-Y] Hop Edouard Herriot, Hosp Civils Lyon, Serv Cent Anat & Cytol Pathol, Lyon, France; [Puisieux, A.] Ctr Leon Berard, F-69373 Lyon, France; [Puisieux, A.] Inst Univ France, Paris, France; [Cavard, C.] Univ Paris 05, Inst Cochin, Dept Endocrinol Metab & Canc, CNRS UMR 8104, Paris, France; [Cavard, C.] INSERM U567, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; World Health Organization; International Agency for Research on Cancer (IARC); CHU Lyon; UNICANCER; Centre Leon Berard; Institut Universitaire de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	de Fromentel, CC (corresponding author), CNRS5286, UMR INSERM U1052, Ctr Rech Cancerol Lyon, 151 Cours Albert Thomas, F-69008 Lyon, France.	carondef@lyon.fnclcc.fr	Maguer-Satta, Veronique/U-8857-2019; de Fromentel, Claude Caron/Y-9715-2019; Hainaut, Pierre/B-6018-2012; Ansieau, Stephane/I-6195-2016	Maguer-Satta, Veronique/0000-0002-1556-068X; de Fromentel, Claude Caron/0000-0001-7566-3958; Hainaut, Pierre/0000-0002-1303-1610; ANSIEAU, Stephane/0000-0003-0989-2108; PUISIEUX, Alain/0000-0002-9938-3798	INSERM; Association pour la Recherche contre le Cancer [3117]; French Ligue Nationale Contre le Cancer; French Ministere de l'Enseignement et de la Recherche; International Agency for Research on Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); French Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); French Ministere de l'Enseignement et de la Recherche; International Agency for Research on Cancer	We thank Drs W Dinjens (University Medical Center, Rotterdam, The Netherlands) and A Costanzo (University of Rome, Italy) for the generous gift of TE-10 cells and pGL3-P2 plasmid, respectively; Drs J Zucmann-Rossi (INSERM U674, Paris, France) and B Terris (Institut Cochin, Paris, France) for the analysis of Delta Np63 expression in HCC samples; Dr B Abedi for her help for IHC experiments; Dr G Martel-Planche and A Masquelet and Ms A Durand and A Charnay for technical assistance; Drs S Sentis, G Hinkal and S and D Cox for critical reading of the manuscript. This project was supported by INSERM and the Association pour la Recherche contre le Cancer (grant number 3117). CR and HS were funded by the French Ligue Nationale Contre le Cancer, AP by the French Ministere de l'Enseignement et de la Recherche, and ET, PT, and VT by the International Agency for Research on Cancer.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Ai D, 2007, MOL CELL BIOL, V27, P5765, DOI 10.1128/MCB.01848-06; Ambler CA, 2009, J PATHOL, V217, P206, DOI 10.1002/path.2468; Auriol E, 2005, NUCLEIC ACIDS RES, V33, P4243, DOI 10.1093/nar/gki729; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Cavard C, 2006, ONCOGENE, V25, P599, DOI 10.1038/sj.onc.1208860; Cavard C, 2008, FUTURE ONCOL, V4, P647, DOI 10.2217/14796694.4.5.647; Chu WK, 2008, J BIOL CHEM, V283, P7328, DOI 10.1074/jbc.M800183200; Chu WK, 2006, BIOCHEM BIOPH RES CO, V342, P1356, DOI 10.1016/j.bbrc.2006.02.111; Drewelus I, 2010, CELL CYCLE, V9, P580, DOI 10.4161/cc.9.3.10593; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Hatzis P, 2008, MOL CELL BIOL, V28, P2732, DOI 10.1128/MCB.02175-07; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kudo Junjo, 2007, World J Surg Oncol, V5, P21, DOI 10.1186/1477-7819-5-21; Lanza M, 2006, CELL CYCLE, V5, P1996, DOI 10.4161/cc.5.17.3188; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Marcel V, 2009, CELL MOL LIFE SCI, V66, P391, DOI 10.1007/s00018-008-8336-3; Moll UM, 2004, MOL CANCER RES, V2, P371; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ninomiya I, 2000, INT J CANCER, V85, P757, DOI 10.1002/(SICI)1097-0215(20000315)85:6<757::AID-IJC3>3.0.CO;2-O; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Petitjean A, 2008, CARCINOGENESIS, V29, P273, DOI 10.1093/carcin/bgm258; Petitjean A, 2005, ONCOGENE, V24, P512, DOI 10.1038/sj.onc.1208215; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Romano RA, 2006, J INVEST DERMATOL, V126, P1469, DOI 10.1038/sj.jid.5700297; Senoo M, 2002, ONCOGENE, V21, P2455, DOI 10.1038/sj.onc.1205330; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Taniere P, 2001, BRIT J CANCER, V85, P721, DOI 10.1054/bjoc.2001.1990; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wu GJ, 2005, CANCER RES, V65, P758; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Zucchi I, 2008, P NATL ACAD SCI USA, V105, P16940, DOI 10.1073/pnas.0808978105	45	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	46					4656	4665		10.1038/onc.2011.171	http://dx.doi.org/10.1038/onc.2011.171			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21643019				2022-12-17	WOS:000297252100005
J	Nitzki, F; Zibat, A; Frommhold, A; Schneider, A; Schulz-Schaeffer, W; Braun, T; Hahn, H				Nitzki, F.; Zibat, A.; Frommhold, A.; Schneider, A.; Schulz-Schaeffer, W.; Braun, T.; Hahn, H.			Uncommitted precursor cells might contribute to increased incidence of embryonal rhabdomyosarcoma in heterozygous Patched1-mutant mice	ONCOGENE			English	Article						rhabdomyosarcoma; ERMS; time of initiation; hedgehog; patched1	HEDGEHOG SIGNALING PATHWAY; SONIC HEDGEHOG; ALVEOLAR RHABDOMYOSARCOMA; MUTANT MICE; GENE; PTCH; MEDULLOBLASTOMA; INACTIVATION; EXPRESSION; SPECIFICATION	Embryonal rhabdomyosarcoma (ERMS) is a tumor of the skeletal muscle in children and is frequently initiated by heterozygous germline mutations in the Hedgehog (Hh) receptor Patched1 (Ptch), both in humans and mice. Using a conditional knock-out strategy in Ptch(flox/+) mice, we demonstrate that early embryonic stages are more susceptible to ERMS development than later stages and that cells normally not committed to undergo myogenesis at this stage represent the major source of ERMS. We found that deletion of a single copy of the Ptch allele at E9.5 using the ubiquitously active Rosa26CreERT2 resulted in a tumor incidence of 88% but reached only 44% and 12% when the Ptch allele was inactivated at E11.5 and E13.5, respectively. Induction of the Ptch mutation at E9.5 did also significantly shorten ERMS-free survival and increased tumor multiplicity compared with tumor induction at E11.5 and E13.5. Interestingly, we observed a more that 10-fold reduction of ERMS incidence when the Ptch mutation was specifically introduced in Myf5-expressing cells, which is the myogenic factor expressed in all muscle cells at E9.5. We conclude that Myf5-negative cells are more susceptible to ERMS development than Myf5-positive embryonic precursors. As the propensity to undergo tumorigenic transformation declined with age, concomitant with the increase of stably committed muscle cells, it seems likely that the Ptch mutation favors tumor formation in progenitor cells, which have not yet acquired a muscle cell fate. Oncogene (2011) 30, 4428-4436; doi:10.1038/onc.2011.157; published online 23 May 2011	[Nitzki, F.; Zibat, A.; Hahn, H.] Univ Gottingen, Dept Human Genet, D-37073 Gottingen, Lower Saxony, Germany; [Schneider, A.; Braun, T.] Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodelling, Bad Nauheim, Germany; [Schulz-Schaeffer, W.] Univ Gottingen, Dept Neuropathol, D-37073 Gottingen, Lower Saxony, Germany	University of Gottingen; Max Planck Society; University of Gottingen	Hahn, H (corresponding author), Univ Gottingen, Dept Human Genet, Heinrich Dueker Weg 12, D-37073 Gottingen, Lower Saxony, Germany.	hhahn@gwdg.de	Braun, Thomas/B-2310-2008; Schneider, Andre/C-5270-2013	Braun, Thomas/0000-0002-6165-4804	Wilhelm Sander Stiftung [2003.112.3]	Wilhelm Sander Stiftung	We thank Susan Peter and Stefan Wolf for excellent animal care and Simone Fulda for critical comments on the manuscript. This work was supported by the grant 2003.112.3 of the Wilhelm Sander Stiftung to HH.	Asakura A, 1998, DEV BIOL, V203, P276, DOI 10.1006/dbio.1998.9050; Biressi S, 2007, DEV BIOL, V308, P281, DOI 10.1016/j.ydbio.2007.06.006; Biressi S, 2007, DEV BIOL, V304, P633, DOI 10.1016/j.ydbio.2007.01.016; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1994, DEVELOPMENT, V120, P3083; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; Diwan BA, 1997, CARCINOGENESIS, V18, P2009, DOI 10.1093/carcin/18.10.2009; Ecke I, 2009, CANCER RES, V69, P887, DOI 10.1158/0008-5472.CAN-08-0946; Evangelista M, 2006, CLIN CANCER RES, V12, P5924, DOI 10.1158/1078-0432.CCR-06-1736; Gensch N, 2008, DEVELOPMENT, V135, P1597, DOI 10.1242/dev.019331; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; Hahn H, 2004, GENOMICS, V84, P853, DOI 10.1016/j.ygeno.2004.07.002; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hameyer D, 2007, PHYSIOL GENOMICS, V31, P32, DOI 10.1152/physiolgenomics.00019.2007; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Kappler R, 2004, ONCOGENE, V23, P8785, DOI 10.1038/sj.onc.1208133; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kruger M, 2001, DEVELOPMENT, V128, P743; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; McDermott A, 2005, DEVELOPMENT, V132, P345, DOI 10.1242/dev.01537; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Merlino G, 2007, GENE DEV, V21, P1275, DOI 10.1101/gad.1563707; Nagao K, 2005, HUM MOL GENET, V14, P3379, DOI 10.1093/hmg/ddi369; Resende TP, 2010, P NATL ACAD SCI USA, V107, P12907, DOI 10.1073/pnas.1000979107; RIVERA OJ, 2006, 97 AACR ANN M 1 5 AP; Tallquist MD, 2000, DEVELOPMENT, V127, P5059; Taniguchi E, 2009, PEDIATR BLOOD CANCER, V53, P136, DOI 10.1002/pbc.21968; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Uhmann A, 2005, INT J ONCOL, V27, P1567; Uhmann A, 2007, BLOOD, V110, P1814, DOI 10.1182/blood-2007-02-075648; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Zibat A, 2010, ONCOGENE, V29, P6323, DOI 10.1038/onc.2010.368; Zibat A, 2009, CARCINOGENESIS, V30, P918, DOI 10.1093/carcin/bgp068	39	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	43					4428	4436		10.1038/onc.2011.157	http://dx.doi.org/10.1038/onc.2011.157			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21602886				2022-12-17	WOS:000296356500005
J	Roe, JS; Kim, HR; Hwang, IY; Cho, EJ; Youn, HD				Roe, J-S; Kim, H-R; Hwang, I-Y; Cho, E-J; Youn, H-D			von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage	ONCOGENE			English	Article						von Hippel-Lindau; Skp2; DNA damage; renal cell carcinoma; tumorigenesis	RENAL-CELL CARCINOMA; HYPOXIA-INDUCIBLE FACTOR-1; CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR; PROLYL HYDROXYLATION; TISSUE MICROARRAY; MOLECULAR-BASIS; INHIBITOR P27; TARGET GENE; HIF-ALPHA	Germline mutations in the von Hippel-Lindau (VHL) tumor suppressor gene cause VHL disease, a rare and autosomal-dominant genetic syndrome. Because VHL protein (pVHL) is the master regulator of hypoxia-inducible factor alpha (HIF alpha), the most prominent feature of VHL disease is the deregulation of HIF alpha proteins. However, the precise mechanism by which the loss of pVHL function contributes to tumorigenesis is not fully understood. Here, we show that pVHL destabilizes the F-box protein Skp2, a chief component of Skp, Cullin, F-box-containing complex that promotes DNA synthesis in the S phase. The beta-domain of pVHL interacts with Skp2, stimulating proteasome-dependent Skp2 degradation, but the destabilization of Skp2 does not depend on the E3 ubiquitin ligase activity of pVHL. Notably, the generation of DNA damage induces Skp2 degradation, which is attenuated by the suppression of endogenous pVHL expression. One possible mechanism of pVHL-dependent Skp2 degradation entails the antagonizing of Akt-mediated Skp2 phosphorylation, which maintains Skp2 stability. Reintroduction of VHL into VHL-null renal cell carcinoma (RCC) cells decreased Skp2 levels and restored DNA damage-dependent Skp2 degradation. These results identify the tumor suppressor function of pVHL in delaying the S-phase progression to inhibit cell proliferation on DNA damage. Clinically, this report explains as to why Skp2 accumulates abnormally in RCC tissues. Oncogene (2011) 30, 3127-3138; doi:10.1038/onc.2011.40; published online 28 February 2011	[Roe, J-S; Kim, H-R; Hwang, I-Y; Youn, H-D] Seoul Natl Univ, Coll Med, Natl Res Lab Metab Checkpoint, Dept Biomed Sci,Canc Res Inst, Seoul 110799, South Korea; [Roe, J-S; Kim, H-R; Hwang, I-Y; Youn, H-D] Seoul Natl Univ, Coll Med, Natl Res Lab Metab Checkpoint, Dept Biochem & Mol Biol,Canc Res Inst, Seoul 110799, South Korea; [Cho, E-J] Sungkyunkwan Univ, Coll Pharm, Natl Res Lab Chromatin Dynam, Suwon, South Korea	Seoul National University (SNU); Seoul National University (SNU); Sungkyunkwan University (SKKU)	Youn, HD (corresponding author), Seoul Natl Univ, Coll Med, Natl Res Lab Metab Checkpoint, Dept Biomed Sci,Canc Res Inst, 28 Yongon Dong, Seoul 110799, South Korea.	hdyoun@snu.ac.kr	Hwang, Inyoung/AAS-3325-2021; Cho, Eun-Jung/AAR-1785-2020; Youn, Hong-Duk/J-2774-2012	Hwang, Inyoung/0000-0002-4633-3658; Cho, Eun-Jung/0000-0002-6610-5329; Roe, Jae-Seok/0000-0002-9994-3062	Korea government (MEST) [0720460, A090281, NRF-2010-0018896, A080181, S2-2008-000-00400-1]	Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare (0720460), the Korea Healthcare Technology R&D Project (A090281), and National Research Foundation Grant (NRF-2010-0018896) to H-DY, a grant from the Korea Healthcare R&D Project (A080181) to E-JC and by the Korea Student Aid Foundation (KOSAF) grant, funded by the Korea government (MEST) (S2-2008-000-00400-1) to JSR. We thank Dr B Bruene (Johann Wolfgang Goethe-University) and Dr DS Lim (KAIST) for invaluable materials.	Balasubramanian S, 1999, ONCOGENE, V18, P1297, DOI 10.1038/sj.onc.1202417; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cohen HT, 1999, CURR OPIN NEPHROL HY, V8, P325, DOI 10.1097/00041552-199905000-00008; Cuadrado M, 2009, CANCER RES, V69, P8726, DOI 10.1158/0008-5472.CAN-09-0729; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feng X, 2009, ONCOGENE, V28, P3320, DOI 10.1038/onc.2009.185; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; He G, 2006, BRIT J CANCER, V95, P1514, DOI 10.1038/sj.bjc.6603448; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Ishizaki H, 2007, PATHOL INT, V57, P672, DOI 10.1111/j.1440-1827.2007.02156.x; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kawasaki T, 1999, ONCOL REP, V6, P329; Kim M, 2004, BIOCHEM BIOPH RES CO, V320, P945, DOI 10.1016/j.bbrc.2004.06.042; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; Kitagawa M, 2008, MOL CELL, V29, P217, DOI 10.1016/j.molcel.2007.11.036; Lam JS, 2005, UROLOGY, V66, P1, DOI 10.1016/j.urology.2005.06.112; Langner C, 2004, VIRCHOWS ARCH, V445, P631, DOI 10.1007/s00428-004-1121-2; Leonardi E, 2009, FEBS LETT, V583, P3704, DOI 10.1016/j.febslet.2009.10.070; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Liu Z, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-51; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; Maher ER, 2004, CURR MOL MED, V4, P833, DOI 10.2174/1566524043359827; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mizutani Y, 2007, INT J ONCOL, V30, P919; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Nho Richard Seonghun, 2003, Prog Cell Cycle Res, V5, P249; Nyhan MJ, 2008, BIOCHEM SOC T, V36, P472, DOI 10.1042/BST0360472; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Osipov V, 2002, APPL IMMUNOHISTO M M, V10, P344, DOI 10.1097/00022744-200212000-00010; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Vikhanskaya F, 1996, EXP CELL RES, V227, P380, DOI 10.1006/excr.1996.0288; Vivo C, 2003, BRIT J CANCER, V88, P388, DOI 10.1038/sj.bjc.6600736; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Zhou H, 2004, TOXICOL APPL PHARM, V200, P111, DOI 10.1016/j.taap.2004.04.003	52	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	28					3127	3138		10.1038/onc.2011.40	http://dx.doi.org/10.1038/onc.2011.40			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21358672				2022-12-17	WOS:000292726300002
J	Meyer, RD; Husain, D; Rahimi, N				Meyer, R. D.; Husain, D.; Rahimi, N.			c-Cbl inhibits angiogenesis and tumor growth by suppressing activation of PLC gamma 1	ONCOGENE			English	Article						VEGFR-2; PLC gammal; c-Cbl; angiogenesis; ubiquitination	ENDOTHELIAL-CELL PROLIFERATION; PHOSPHOLIPASE C-GAMMA-1; CHOROIDAL NEOVASCULARIZATION; NEGATIVE REGULATION; T-CELLS; MICE; VEGFR-2; PROTEINS; VASCULOGENESIS; RECEPTOR-2	Angiogenesis is regulated by highly coordinated function of various proteins with pro- and anti-angiogenic functions. Among the many cytoplasmic signaling proteins that are activated by VEGFR-2, activation of PLC gamma 1 is considered to have a pivotal role in angiogenic signaling. In previous study we have identified c-Cbl as a negative regulator of PLC gamma 1 in endothelial cells, the biochemical and biological significance of c-Cbl, however, in angiogenesis in vivo and molecular mechanisms involved were remained elusive. In this study, we report that genetic inactivation of c-Cbl in mice results in enhanced tumor angiogenesis and retinal neovascularization. Endothelial cells derived from c-Cbl null mice displayed elevated cell proliferation and tube formation in response to VEGF stimulation. Loss of c-Cbl also resulted in robust activation of PLC gamma 1 and increased intracellular calcium release. c-Cbl-dependent ubiquitination selectively inhibited tyrosine phosphorylation of PLC gamma 1 and mostly refrained from ubiquitin-mediated degradation. Hence, we propose c-Cbl as an angiogenic suppressor protein where upon activation it uniquely modulates PLC gamma 1 activation by ubiquitination and subsequently inhibits VEGF-driven angiogenesis. Oncogene (2011) 30, 2198-2206; doi:10.1038/onc.2010.597; published online 17 January 2011	[Meyer, R. D.; Rahimi, N.] Boston Univ, Dept Pathol, Boston, MA 02118 USA; [Husain, D.; Rahimi, N.] Boston Univ, Dept Ophthalmol, Boston, MA 02118 USA	Boston University; Boston University	Rahimi, N (corresponding author), Boston Univ, Dept Pathol, Med Campus,670 Albany St,Room 429, Boston, MA 02118 USA.	nrahimi@bu.edu		Rahimi, Nader/0000-0002-6745-1725; Husain, Deeba/0000-0002-8494-0950	National Institutes of Health (NIH/NEI); Department of Ophthalmology; BU; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR010888] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY017955] Funding Source: NIH RePORTER	National Institutes of Health (NIH/NEI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Department of Ophthalmology; BU(Bogazici University); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This study was supported by grants from the National Institutes of Health (NIH/NEI) to NR and Massachusetts Lions Foundation grant to Department of Ophthalmology, and also by BU CTSI grant (NR). The c-Cbl knockout mice were generously provided by Jeffrey Chiang (National Cancer Institute, Frederick, MD).	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Fang DY, 2001, NAT IMMUNOL, V2, P870, DOI 10.1038/ni0901-870; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Funakoshi T, 2006, EXP EYE RES, V83, P1102, DOI 10.1016/j.exer.2006.05.016; Graham LJ, 1998, BIOCHEM BIOPH RES CO, V249, P537, DOI 10.1006/bbrc.1998.9177; Graham LJ, 2003, ONCOGENE, V22, P2493, DOI 10.1038/sj.onc.1206318; Hochstrasser M, 2009, NATURE, V458, P422, DOI 10.1038/nature07958; Husain D, 2010, INVEST OPHTH VIS SCI, V51, P6803, DOI 10.1167/iovs.10-5255; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Lawson ND, 2003, GENE DEV, V17, P1346, DOI 10.1101/gad.1072203; Liao HJ, 2002, J BIOL CHEM, V277, P9335, DOI 10.1074/jbc.M109955200; Meyer RD, 2004, ONCOGENE, V23, P5523, DOI 10.1038/sj.onc.1207712; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; Meyer RD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003848; Miura-Shimura Y, 2003, J BIOL CHEM, V278, P38495, DOI 10.1074/jbc.M305656200; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 2002, NAT IMMUNOL, V3, P1192, DOI 10.1038/ni855; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Rahimi N, 2006, FRONT BIOSCI-LANDMRK, V11, P818; Rahimi N, 2009, CANCER RES, V69, P2607, DOI 10.1158/0008-5472.CAN-08-2905; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102; Schwartz AL, 2009, ANNU REV PHARMACOL, V49, P73, DOI 10.1146/annurev.pharmtox.051208.165340; Singh AJ, 2005, MOL BIOL CELL, V16, P2106, DOI 10.1091/mbc.E04-08-0749; Singh AJ, 2007, P NATL ACAD SCI USA, V104, P5413, DOI 10.1073/pnas.0700809104; Swaminathan G, 2006, J CELL PHYSIOL, V209, P21, DOI 10.1002/jcp.20694; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Teckchandani AM, 2005, EXP CELL RES, V307, P247, DOI 10.1016/j.yexcr.2005.03.010; Thien CBF, 2005, BIOCHEM J, V391, P153, DOI 10.1042/BJ20050892; Woodman SE, 2003, AM J PATHOL, V162, P2059, DOI 10.1016/S0002-9440(10)64337-4; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zhang HF, 2008, J CLIN INVEST, V118, P3904, DOI 10.1172/JCI36168	37	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	19					2198	2206		10.1038/onc.2010.597	http://dx.doi.org/10.1038/onc.2010.597			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242968	Green Accepted			2022-12-17	WOS:000290514600003
J	Hsu, JH; Lawlor, ER				Hsu, J. H.; Lawlor, E. R.			BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma	ONCOGENE			English	Article						BMI-1; polycomb; YAP; contact inhibition; Hippo pathway; Ewing sarcoma	POLYCOMB GROUP PROTEINS; CELL SELF-RENEWAL; GENE-PRODUCT; ORGAN SIZE; HIPPO; GROWTH; STEM; PROLIFERATION; MERLIN; KIBRA	The polycomb group family protein BMI-1 is over-expressed by and functions as an oncogene in many different human cancers. We have previously shown that BMI-1 promotes the tumorigenicity of Ewing sarcoma family tumors (ESFTs) and that this is mediated independently of CDKN2A repression. In this study, we have discovered that high levels of BMI-1 confer resistance to contact inhibition in ESFT cells. Using stable retroviral transduction, we evaluated the consequences of BMI-1 knockdown on the growth of CDKN2A wild-type and mutant ESFT cells in subconfluent and confluent conditions. Although knockdown of BMI-1 had no effect on proliferation in low-density cultures, at high cell densities it resulted in cell cycle arrest and death. The normal cell contact inhibition response is mediated, in large part, by the recently described Hippo pathway which functions to inhibit cell proliferation and promote cell death by inactivating the Yes-Associated Protein (YAP). Significantly, we found that YAP levels, activity and expression did not diminish in confluent ESFT cells that expressed high levels of BMI-1. In contrast, YAP expression and nuclear localization were reduced in confluent BMI-1 knockdown cells suggesting that silencing of BMI-1 restored contact inhibition by restoring normal activation of the Hippo-YAP growth-suppressor pathway. Importantly, knockdown of YAP in ESFT cells resulted in profound inhibition of cell proliferation and anchorage-independent colony formation suggesting that stabilization and continued expression of YAP is critical for ESFT growth and tumorigenicity. Together, these studies reveal a previously unrecognized link between BMI-1, contact inhibition and the Hippo-YAP pathway and suggest that resistance to contact inhibition in BMI-1 overexpressing cancer cells may be in part a result of Hippo inhibition and aberrant stabilization of YAP. Oncogene (2011) 30, 2077-2085; doi:10.1038/onc.2010.571; published online 20 December 2010	[Hsu, J. H.; Lawlor, E. R.] Univ Michigan, Dept Pediat, Div Hematol Oncol, Ann Arbor, MI 48109 USA; [Hsu, J. H.] Univ So Calif, Genet Mol & Cellular Biol Program, Los Angeles, CA USA; [Lawlor, E. R.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Southern California; University of Michigan System; University of Michigan	Lawlor, ER (corresponding author), Univ Michigan, Dept Pediat, Div Hematol Oncol, 1150 Med Ctr Dr,MSRBIII Room 1220A, Ann Arbor, MI 48109 USA.	elawlor@med.umich.edu			TJ Martell Foundation; NIH/NCI [1R01CA134604-01]; California Institute for Regenerative Medicine Training (CIRM) [1R01CA134604-01, T1-00004]; NATIONAL CANCER INSTITUTE [R01CA134604] Funding Source: NIH RePORTER	TJ Martell Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); California Institute for Regenerative Medicine Training (CIRM)(California Institute for Regenerative Medicine); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge Long Hung and Asim Beg for technical support, members of the Lawlor lab for helpful discussion, Dr T Triche and the Children's Oncology Cell Bank (COGCELL.org) for cell lines. This work was initiated at Childrens Hospital Los Angeles (CHLA) with support from the TJ Martell Foundation. JHH was supported by CIRM training Grant T1-00004 and ERL by NIH/NCI 1R01CA134604-01.; Grant support: California Institute for Regenerative Medicine Training Grant T1-00004 (JHH), 1R01CA134604-01 ( ERL).	ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; ABERCROMBIE M, 1954, EXP CELL RES, V6, P293, DOI 10.1016/0014-4827(54)90176-7; ABERCROMBIE M, 1958, EXP CELL RES, V15, P332, DOI 10.1016/0014-4827(58)90034-X; Badouel C, 2009, DEV CELL, V16, P411, DOI 10.1016/j.devcel.2009.01.010; Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4; Ban J, 2006, ADV EXP MED BIOL, V587, P41; Baumgartner R, 2010, DEV CELL, V18, P309, DOI 10.1016/j.devcel.2009.12.013; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chatoo W, 2009, J NEUROSCI, V29, P529, DOI 10.1523/JNEUROSCI.5303-08.2009; Datta S, 2007, CANCER RES, V67, P10286, DOI 10.1158/0008-5472.CAN-07-1636; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; EAGLE H, 1967, NATURE, V213, P1102, DOI 10.1038/2131102a0; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Lian I, 2010, GENE DEV, V24, P1106, DOI 10.1101/gad.1903310; LIM R, 1981, P NATL ACAD SCI-BIOL, V78, P4373, DOI 10.1073/pnas.78.7.4373; Liu J, 2009, NATURE, V459, P387, DOI 10.1038/nature08040; Meltzer Paul S, 2007, Cell Stem Cell, V1, P13, DOI 10.1016/j.stem.2007.05.011; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; Parrish JZ, 2007, GENE DEV, V21, P956, DOI 10.1101/gad.1514507; Pietersen AM, 2008, CURR BIOL, V18, P1094, DOI 10.1016/j.cub.2008.06.070; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; RODESCH F, 1973, EXP CELL RES, V76, P55, DOI 10.1016/0014-4827(73)90418-7; SILLETTI S, 1995, INT J CANCER, V63, P100, DOI 10.1002/ijc.2910630118; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Striedinger K, 2008, NEOPLASIA, V10, P1204, DOI 10.1593/neo.08642; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Wiederschain D, 2007, MOL CELL BIOL, V27, P4968, DOI 10.1128/MCB.02244-06; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810	40	22	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2077	2085		10.1038/onc.2010.571	http://dx.doi.org/10.1038/onc.2010.571			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21170084	Green Accepted			2022-12-17	WOS:000289977400011
J	Patrick, BA; Gong, X; Jaiswal, AK				Patrick, B. A.; Gong, X.; Jaiswal, A. K.			RETRACTED: Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to 20S proteasomal degradation of p63 resulting in thinning of epithelium and chemical-induced skin cancer (Retracted article. See vol. 36, pg. 2919, 2017)	ONCOGENE			English	Article; Retracted Publication						NQO1; p63; 20S proteasome; skin differentiation; carcinogenicity	QUINONE OXIDOREDUCTASE-1; INCREASES SUSCEPTIBILITY; EPIDERMAL MORPHOGENESIS; SKIN CARCINOGENESIS; MENADIONE TOXICITY; MOUSE SKIN; IN-VIVO; ACTIVATION; ROLES; NQO1	NAD(P)H:quinone oxidoreductase 1 (NQO1) is a cytosolic enzyme that protects cells against chemical and radiation-induced oxidative stress and skin cancer. Disruption of NQO1 gene in mice showed thinning of skin epithelium and loss of cytokeratin 14, an early marker of skin differentiation. Immunohistochemistry and western analysis demonstrated downregulation of p63 in NQO1-/- mouse skin, as compared with wild-type (WT) mouse. Further analysis including modulation of NQO1 expression revealed a direct correlation between the levels of NQO1 and p63 in skin-derived keratinocytes and dermal fibroblasts. Modulation of proteasomal activity revealed that p63 is degraded by 20S proteasome and that this degradation is significantly rescued by NQO1. Coimmunoprecipitation studies showed that NQO1 interacts directly with p63 but not 20S to protect against this degradation. In addition, benzo[a]pyrene treatment led to induction of NQO1 and stabilization of p63 in WT but not in NQO1-/- mouse skin and keratinocytes. These data suggest that NQO1 controls stabilization of p63 and progression towards keratinocyte differentiation leading to normal skin development and presumably skin carcinogenesis. Oncogene (2011) 30, 1098-1107; doi:10.1038/onc.2010.491; published online 1 November 2010	[Patrick, B. A.; Jaiswal, A. K.] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St,Howard Hall 404, Baltimore, MD 21201 USA; [Gong, X.] Baylor Coll Med, Houston, TX 77030 USA	University System of Maryland; University of Maryland Baltimore; Baylor College of Medicine	Jaiswal, AK (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St,Howard Hall 404, Baltimore, MD 21201 USA.	ajaiswal@som.umaryland.edu			NIH [RO1 ES007943]; NIEHS [ES007263]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007263, R01ES007943] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank our colleagues for helpful discussions and suggestions. This work was supported by NIH Grant RO1 ES007943. BAP was supported by Grant RO1 ES007943 and also in part is supported by NIEHS training Grant ES007263.	Ahn KS, 2006, J BIOL CHEM, V281, P19798, DOI 10.1074/jbc.M601162200; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Asher G, 2006, BIOCHEMISTRY-US, V45, P6372, DOI 10.1021/bi0600087; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Chen S, 2000, FREE RADICAL BIO MED, V29, P276, DOI 10.1016/S0891-5849(00)00308-7; Das A, 2006, FREE RADICAL BIO MED, V40, P1843, DOI 10.1016/j.freeradbiomed.2006.01.025; Fuchs E, 1996, ANNU REV GENET, V30, P197, DOI 10.1146/annurev.genet.30.1.197; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107, DOI 10.1152/physrev.1980.60.4.1107; Gong X, 2007, CANCER RES, V67, P5380, DOI 10.1158/0008-5472.CAN-07-0323; GUENGERICH FP, 1988, CANCER RES, V48, P2946; Iskander K, 2004, CANCER RES, V64, P5925, DOI 10.1158/0008-5472.CAN-04-0763; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Joseph P, 1998, BRIT J CANCER, V77, P709, DOI 10.1038/bjc.1998.117; Joseph P, 1998, BRIT J CANCER, V78, P312, DOI 10.1038/bjc.1998.492; JOSEPH P, 1994, P NATL ACAD SCI USA, V91, P8413, DOI 10.1073/pnas.91.18.8413; King KE, 2007, MOL CARCINOGEN, V46, P716, DOI 10.1002/mc.20337; Koster MI, 2007, CELL CYCLE, V6, P269, DOI 10.4161/cc.6.3.3792; Koster MI, 2007, P NATL ACAD SCI USA, V104, P3255, DOI 10.1073/pnas.0611376104; Long DJ, 2000, CANCER RES, V60, P5913; Long DJ, 2002, J BIOL CHEM, V277, P46131, DOI 10.1074/jbc.M208675200; Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166; Melino G, 2008, CELL DEATH DIFFER, V15, P1103, DOI 10.1038/cdd.2008.60; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Radjendirane Venugopal, 1997, P441; Romano RA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005623; Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X; Salvat C, 2000, EUR J BIOCHEM, V267, P3712, DOI 10.1046/j.1432-1327.2000.01404.x; Shen J, 2010, CANCER RES, V70, P1006, DOI 10.1158/0008-5472.CAN-09-2938; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539	34	22	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1098	1107		10.1038/onc.2010.491	http://dx.doi.org/10.1038/onc.2010.491			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21042282	Green Accepted			2022-12-17	WOS:000287964100008
J	Dwyer, J; Le Guelte, A; Moya, EMG; Sumbal, M; Carlotti, A; Douguet, L; Gutkind, JS; Grange, PA; Dupin, N; Gavard, J				Dwyer, J.; Le Guelte, A.; Moya, E. M. Galan; Sumbal, M.; Carlotti, A.; Douguet, L.; Gutkind, J. S.; Grange, P. A.; Dupin, N.; Gavard, J.			Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein coupled receptor	ONCOGENE			English	Article						cell junctions; permeability; rac; PI(3)K; VE-cadherin; kaposi sarcoma	SARCOMA-ASSOCIATED-HERPESVIRUS; KAPOSIS-SARCOMA; ENDOTHELIAL PERMEABILITY; VASCULAR-PERMEABILITY; PARACRINE NEOPLASIA; ADHERENS JUNCTIONS; GENE-EXPRESSION; GROWTH-FACTOR; CELL; VGPCR	Kaposi Sarcoma (KS) are opportunistic tumors, associated with human herpes virus 8 (HHV8) infection. KS development is highly favored by immune-depression and remains the second most frequent tumor in acquired immune deficiency syndrome patients. Although it has been shown that experimental expression of the HHV8 G-protein-coupled receptor (vGPCR) in the endothelial compartment is alone sufficient to recapitulate the formation and progression of KS-like lesions, its functional effects on endothelial homeostasis are not fully understood. Here we show that vGPCR expression in endothelial cells induces an increase in paracellular permeability both in vivo and in vitro. By using pharmacological inhibitors and small interference RNA-based knockdown, we demonstrate an essential role for the PI(3)Kinase-gamma/Rac nexus in vGPCR-mediated permeability. This was further accompanied by dramatic remodeling of VE-cadherin-dependent cell-cell junctions. Importantly, this in vitro vGPCR-initiated signaling signature was observed in a large panel of human KS. Altogether, our results support the hypothesis that endothelial vGPCR signaling is co-opted in KS, and unveil new key cellular targets for therapeutic intervention. Oncogene (2011) 30, 190-200; doi: 10.1038/onc.2010.411; published online 6 September 2010	[Dwyer, J.; Le Guelte, A.; Moya, E. M. Galan; Sumbal, M.; Douguet, L.; Gavard, J.] Univ Paris 05, Inst Cochin, CNRS UMR 8104, INSERM,U1016, F-75014 Paris, France; [Carlotti, A.] Univ Paris 05, Grp Hosp Cochin Port Royal, AP HP, Serv Anat & Cytol Pathol,Fac Med, F-75014 Paris, France; [Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA; [Grange, P. A.; Dupin, N.] Univ Paris 05, Lab Rech Dermatol, EA 1833, Fac Med, F-75014 Paris, France; [Dupin, N.] Univ Paris 05, Grp Hosp Cochin Port Royal Pavillon Tarnier, AP HP, Serv Dermatol,Fac Med, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Gavard, J (corresponding author), Univ Paris 05, Inst Cochin, CNRS UMR 8104, INSERM,U1016, 22 Rue Mechain,Rm 306, F-75014 Paris, France.	julie.gavard@inserm.fr	Gavard, Julie/I-5487-2012; Galan-Moya, Eva M/I-2912-2015; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Gavard, Julie/I-5487-2012; Grange, Philippe/W-3442-2017	Gavard, Julie/0000-0002-7985-9007; Galan-Moya, Eva M/0000-0001-5758-7592; Gutkind, J. Silvio/0000-0002-5150-4482; Dupin, Nicolas/0000-0002-6237-4951; Gavard, Julie/0000-0003-3107-2026; Grange, Philippe/0000-0001-8151-748X; Douguet, Laetitia/0000-0003-4319-491X	Ligue Nationale contre le Cancer, comite de Paris; European Community [PIRG04-GA-2008-239126]; Fondation pour la Recherche Medicale; Association pour la Recherche sur le Cancer; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER	Ligue Nationale contre le Cancer, comite de Paris; European Community(European Commission); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We would like to thank N. Bidere (Inserm U1014, Universite Paris-Sud, Hopital Paul Brousse, Villejuif, France) for helpful discussions and comments, A Schmitt (Institut Cochin, Paris, France) for technical help on electron microscopy experiments, Anne Audebourg and Brigitte Radenen (Service d'Anatomie et de Cytologie Pathologique, Hopital Cochin, Paris, France) for technical help on histological staining, and Nina Feinberg (OPCB, NIDCR, NIH, Bethesda, MD, USA) for technical help on the initial project. This research was funded by Ligue Nationale contre le Cancer, comite de Paris and by a Marie Curie International Reintegration Grant within the 7th European Community Framework Programme (PIRG04-GA-2008-239126). JD is supported by a post-doctoral fellowship from Fondation pour la Recherche Medicale, ALG by the PhD program from Universite Paris 5 and EMGM by a post-doctoral fellowship from Association pour la Recherche sur le Cancer.	Ascherl G, 1999, BLOOD, V93, P4232; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Barber DF, 2005, NAT MED, V11, P933, DOI 10.1038/nm1291; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Cesarman E, 2007, CURR TOP MICROBIOL, V312, P263; Chaisuparat R, 2008, CANCER RES, V68, P8361, DOI 10.1158/0008-5472.CAN-08-0878; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chiou CJ, 2002, J VIROL, V76, P3421, DOI 10.1128/JVI.76.7.3421-3439.2002; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Dupin N, 2006, J INVEST DERMATOL, V126, P545, DOI 10.1038/sj.jid.5700132; Gavard J, 2004, J CELL SCI, V117, P257, DOI 10.1242/jcs.00857; Gavard J, 2008, DEV CELL, V14, P25, DOI 10.1016/j.devcel.2007.10.019; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Gavard J, 2009, MOL CELL BIOL, V29, P2469, DOI 10.1128/MCB.01304-08; Grisotto MG, 2006, J CLIN INVEST, V116, P1264, DOI 10.1172/JCI26666; Grundhoff A, 2004, J CLIN INVEST, V113, P124, DOI 10.1172/JCI200417803; Martin D, 2008, ONCOGENE, V27, P1844, DOI [10.1038/sj.onc.1210817, 10.1038/onc.2009.351]; Maurer T, 2007, NEW ENGL J MED, V357, P1352, DOI 10.1056/NEJMc070508; Mitsuyasu RT, 2000, CURR OPIN ONCOL, V12, P174, DOI 10.1097/00001622-200003000-00013; Monini P, 2009, AIDS, V23, P534, DOI 10.1097/QAD.0b013e3283262a8d; Montaner S, 2006, CANCER RES, V66, P168, DOI 10.1158/0008-5472.CAN-05-1026; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2001, CANCER RES, V61, P2641; Montaner S, 2004, BLOOD, V104, P2903, DOI 10.1182/blood-2003-12-4436; Mutlu AD, 2007, CANCER CELL, V11, P245, DOI 10.1016/j.ccr.2007.01.015; Oksenhendler E, 2002, BLOOD, V99, P2331, DOI 10.1182/blood.V99.7.2331; Orenstein JM, 1997, AIDS, V11, pF35, DOI 10.1097/00002030-199705000-00001; Qian LW, 2008, J VIROL, V82, P11902, DOI 10.1128/JVI.01042-08; Sgadari C, 2002, NAT MED, V8, P225, DOI 10.1038/nm0302-225; Sodhi A, 2000, CANCER RES, V60, P4873; Sodhi A, 2004, P NATL ACAD SCI USA, V101, P4821, DOI 10.1073/pnas.0400835101; Sodhi A, 2004, NAT REV MOL CELL BIO, V5, P998, DOI 10.1038/nrm1529; Sodhi A, 2006, CANCER CELL, V10, P133, DOI 10.1016/j.ccr.2006.05.026; Stallone G, 2005, NEW ENGL J MED, V352, P1317, DOI 10.1056/NEJMoa042831; Szajerka T, 2007, AIDS REV, V9, P230; Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987	38	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					190	200		10.1038/onc.2010.411	http://dx.doi.org/10.1038/onc.2010.411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20818438				2022-12-17	WOS:000286438900007
J	Liu, W; Xin, H; Eckert, DT; Brown, JA; Gnarra, JR				Liu, W.; Xin, H.; Eckert, D. T.; Brown, J. A.; Gnarra, J. R.			Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor	ONCOGENE			English	Article						von Hippel-Lindau protein; renal cell carcinoma; anaphase-promoting complex/cyclosome; hypoxia; cell cycle	DNA-DAMAGE; GENE; ARREST; PROLIFERATION; TRANSLATION; EXPRESSION; COMPLEX; PROTEIN; GROWTH; DEGRADATION	Inactivation of von Hippel-Lindau tumor-suppressor protein (pVHL) is associated with von Hippel-Lindau disease, an inherited cancer syndrome, as well as the majority of patients with sporadic clear cell renal cell carcinoma (RCC). Although the involvement of pVHL in oxygen sensing through targeting hypoxia-inducible factor-alpha subunits to ubiquitin-dependent proteolysis has been well documented, less is known about pVHL regulation under both normoxic and hypoxic conditions. We found that pVHL levels decreased in hypoxia and that hypoxia-induced cell cycle arrest is associated with pVHL expression in RCC cells. pVHL levels fluctuate during the cell cycle, paralleling cyclin B1 levels, with decreased levels in mitosis and G1. pVHL contains consensus destruction (D) box sequences, and pVHL associates with Cdh1, an activator of the anaphase-promoting complex/cyclosome (APC/C) E3 ubiquitin ligase. We show that pVHL has a decreased half-life in G1, Cdh1 down-regulation results in increased pVHL expression, whereas Cdh1 overexpression results in decreased pVHL expression. Taken together, these results suggest that pVHL is a novel substrate of APC/C-Cdh1. D box-independent pVHL degradation was also detected, indicating that other ubiquitin ligases are also activated for pVHL degradation. Oncogene (2011) 30, 21-31; doi: 10.1038/onc.2010.395; published online 30 August 2010	[Gnarra, J. R.] Univ Pittsburgh, Sch Med, Dept Urol, Shadyside Med Ctr, Pittsburgh, PA 15232 USA; [Xin, H.; Brown, J. A.; Gnarra, J. R.] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA USA; [Gnarra, J. R.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gnarra, JR (corresponding author), Univ Pittsburgh, Sch Med, Dept Urol, Shadyside Med Ctr, Suite G37,5200 Ctr Ave, Pittsburgh, PA 15232 USA.	gnarrajr@upmc.edu	Liu, Weijun/D-5291-2017; Liu, Weijun/B-5896-2008	Gnarra, James/0000-0002-6369-3110; Liu, Weijun/0000-0002-4426-6148	Cancer Association of Greater New Orleans; LSUHSC-NO; NIH [CA125930];  [T32DK007774]; NATIONAL CANCER INSTITUTE [R01CA125930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007774] Funding Source: NIH RePORTER	Cancer Association of Greater New Orleans; LSUHSC-NO; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Arthur Haas, for support and discussions, Eric Hittle, Kimberlee Rankin, Mike Meyer, and Miki Katuwal for technical assistance, and the Cancer Association of Greater New Orleans for support to HX. This work was supported by the LSUHSC-NO Dean's Research Fund and NIH grant CA125930. DTE was supported by T32DK007774.	Baker DJ, 2007, CELL MOL LIFE SCI, V64, P589, DOI 10.1007/s00018-007-6443-1; Beroud C, 2000, HUM MUTAT, V15, P86, DOI 10.1002/(SICI)1098-1004(200001)15:1<86::AID-HUMU16>3.0.CO;2-4; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Fahling M, 2009, ACTA PHYSIOL, V195, P205, DOI 10.1111/j.1748-1716.2008.01894.x; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Hackenbeck T, 2009, CELL CYCLE, V8, P1386, DOI 10.4161/cc.8.9.8306; Harper Jane V., 2004, V296, P157; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jackson PK, 2004, TRENDS CELL BIOL, V14, P331, DOI 10.1016/j.tcb.2004.05.005; Jung CR, 2006, NAT MED, V12, P809, DOI 10.1038/nm1440; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kaelin WG, 2007, ANNU REV PATHOL-MECH, V2, P145, DOI 10.1146/annurev.pathol.2.010506.092049; Kaelin WG, 2007, CLIN CANCER RES, V13, p680S, DOI 10.1158/1078-0432.CCR-06-1865; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Lendahl U, 2009, NAT REV GENET, V10, P821, DOI 10.1038/nrg2665; Listovsky T, 2004, EMBO J, V23, P1619, DOI 10.1038/sj.emboj.7600149; Liu LP, 2004, CANCER BIOL THER, V3, P492, DOI 10.4161/cbt.3.6.1010; Liu WJ, 2008, CARCINOGENESIS, V29, P263, DOI 10.1093/carcin/bgm251; Liu WJ, 2007, MOL CELL BIOL, V27, P2967, DOI 10.1128/MCB.01830-06; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Semenza GL, 2009, BLOOD, V114, P2015, DOI 10.1182/blood-2009-05-189985; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stickle NH, 2005, MUTAT RES-FUND MOL M, V578, P23, DOI 10.1016/j.mrfmmm.2005.02.016; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Thoma CR, 2007, NAT CELL BIOL, V9, P588, DOI 10.1038/ncb1579; Thoma CR, 2009, NAT CELL BIOL, V11, P994, DOI 10.1038/ncb1912; van Leuken R, 2008, BBA-REV CANCER, V1786, P49, DOI 10.1016/j.bbcan.2008.05.002; Wasch R, 2010, ONCOGENE, V29, P1, DOI 10.1038/onc.2009.325; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Warnecke C, 2008, EXP CELL RES, V314, P2016, DOI 10.1016/j.yexcr.2008.03.003; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Young AP, 2008, NAT CELL BIOL, V10, P361, DOI 10.1038/ncb1699	43	22	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					21	31		10.1038/onc.2010.395	http://dx.doi.org/10.1038/onc.2010.395			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20802534	Green Accepted			2022-12-17	WOS:000285959300002
J	Neely, RJ; Brose, MS; Gray, CM; McCorkell, KA; Leibowitz, JM; Ma, C; Rothstein, JL; May, MJ				Neely, R. J.; Brose, M. S.; Gray, C. M.; McCorkell, K. A.; Leibowitz, J. M.; Ma, C.; Rothstein, J. L.; May, M. J.			The RET/PTC3 oncogene activates classical NF-kappa B by stabilizing NIK	ONCOGENE			English	Article						Hashimoto's thyroiditis; IKK; NIK; NF-kappa B; RET/PTC; thyroid cancer	GENE-EXPRESSION; FUSION GENE; IKK-ALPHA; RET; NUCLEAR; ONCOPROTEIN; CARCINOMA; PATHWAY; REARRANGEMENTS; LOCALIZATION	The oncogenic fusion protein RET/PTC3 (RP3) that is expressed in papillary thyroid carcinoma (PTC) and thyroid epithelia in Hashimoto's thyroiditis activates nuclear factor-kappa B (NF-kappa B) and induces pro-inflammatory gene expression; however, the mechanism of this activation is unknown. To address this, we expressed RP3 in murine embryonic fibroblasts (MEFs) lacking key classical and noncanonical NF-kappa B signaling components. In wild-type MEFs, RP3 upregulated CCL2, CXCL1, granulocyte-macrophage colony-stimulating factor and tumor necrosis factor expression and activated classical but not noncanonical NF-kappa B. RP3-activated NF-kappa B in I kappa B kinase (IKK)beta(-/-) MEFs but not IKK alpha- or NF-kappa B essential modulator (NEMO)-deficient cells and activation was inhibited by a peptide that blocks NEMO binding to the IKKs. RP3 increased the levels of NF-kappa B-inducing kinase (NIK) and did not activate NF-kappa B in NIK-deficient MEFs. Notably, NIK stabilization was not accompanied by TRAF3 degradation demonstrating that RP3 disrupts normal basal NIK regulation. Dominant-negative NIK blocked RP3-induced NF-kappa B activation and an RP3 signaling mutant (RP3(Y588F)) did not stabilize NIK. Finally, examination of PTC specimens revealed strong positive staining for NIK. We therefore conclude that RP3 activates classical NF-kappa B via NIK, NEMO and IKK alpha. Importantly, our findings reveal a novel mechanism for oncogene-induced NF-kappa B activation via stabilization of NIK. Oncogene (2011) 30, 87-96; doi: 10.1038/onc.2010.396; published online 6 September 2010	[Neely, R. J.; Gray, C. M.; McCorkell, K. A.; May, M. J.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [Neely, R. J.; Rothstein, J. L.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol Otolaryngol Head & Neck, Philadelphia, PA 19107 USA; [Brose, M. S.; Leibowitz, J. M.; Ma, C.] Univ Penn, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; [Rothstein, J. L.] Amgen Inc, Inflammat Res, Seattle, WA USA; [May, M. J.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; Jefferson University; University of Pennsylvania; Amgen; University of Pennsylvania	May, MJ (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St,OVH 200E, Philadelphia, PA 19104 USA.	maym@vet.upenn.edu		May, Michael/0000-0002-2485-3716	National Institutes of Health [RO1HL080612, R21CA135602, T32CA009683, T32GM07229]; Mari Lowe Center for Comparative Oncology; NATIONAL CANCER INSTITUTE [R21CA135602, T32CA009683] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mari Lowe Center for Comparative Oncology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the National Institutes of Health (RO1HL080612, R21CA135602 and T32CA009683, T32GM07229) and the Mari Lowe Center for Comparative Oncology.	Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Birbach A, 2004, J CELL SCI, V117, P3615, DOI 10.1242/jcs.01224; Borrello MG, 2005, P NATL ACAD SCI USA, V102, P14825, DOI 10.1073/pnas.0503039102; Bunone G, 2000, CANCER RES, V60, P2845; Ciampi R, 2007, ENDOCRINOLOGY, V148, P936, DOI 10.1210/en.2006-0921; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Eisenlohr LC, 2006, AUTOIMMUN REV, V6, P107, DOI 10.1016/j.autrev.2006.04.002; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; He JQ, 2007, J BIOL CHEM, V282, P3688, DOI 10.1074/jbc.M610271200; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Lam LT, 2008, P NATL ACAD SCI USA, V105, P20798, DOI 10.1073/pnas.0806491106; Lodyga M, 2009, ONCOGENE, V28, P937, DOI 10.1038/onc.2008.447; Ludwig L, 2001, CANCER RES, V61, P4526; Madge LA, 2008, J IMMUNOL, V180, P3467, DOI 10.4049/jimmunol.180.5.3467; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Monaco C, 2001, ONCOGENE, V20, P599, DOI 10.1038/sj.onc.1204127; Muzza M, 2010, CLIN ENDOCRINOL, V72, P702, DOI 10.1111/j.1365-2265.2009.03699.x; Nellore A, 2009, J CLIN ENDOCR METAB, V94, P1026, DOI 10.1210/jc.2008-1042; Nibu K, 2005, EUR ARCH OTO-RHINO-L, V262, P368, DOI 10.1007/s00405-004-0835-8; Nishina T, 2009, BIOCHEM BIOPH RES CO, V388, P96, DOI 10.1016/j.bbrc.2009.07.125; Pacifico F, 2004, J BIOL CHEM, V279, P54610, DOI 10.1074/jbc.M403492200; Pacifico F, 2010, MOL CELL ENDOCRINOL, V321, P29, DOI 10.1016/j.mce.2009.10.010; Pufnock JS, 2009, J IMMUNOL, V182, P5498, DOI 10.4049/jimmunol.0801284; Razani B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000778; Rhoden KJ, 2006, J CLIN ENDOCR METAB, V91, P2414, DOI 10.1210/jc.2006-0240; Russell JP, 2003, ONCOGENE, V22, P4569, DOI 10.1038/sj.onc.1206759; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sheils OM, 2000, INT J SURG PATHOL, V8, P185, DOI 10.1177/106689690000800305; Solt LA, 2007, J BIOL CHEM, V282, P8724, DOI 10.1074/jbc.M609613200; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; Veiga-Fernandes H, 2007, NATURE, V446, P547, DOI 10.1038/nature05597; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wells SA, 2009, CLIN CANCER RES, V15, P7119, DOI 10.1158/1078-0432.CCR-08-2742; Wharry CE, 2009, CANCER BIOL THER, V8, P1567, DOI 10.4161/cbt.8.16.8961; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Zarnegar B, 2008, P NATL ACAD SCI USA, V105, P3503, DOI 10.1073/pnas.0707959105	43	22	23	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					87	96		10.1038/onc.2010.396	http://dx.doi.org/10.1038/onc.2010.396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20818435	Green Accepted			2022-12-17	WOS:000285959300008
J	Mayeenuddin, LH; Yu, Y; Kang, Z; Helman, LJ; Cao, L				Mayeenuddin, L. H.; Yu, Y.; Kang, Z.; Helman, L. J.; Cao, L.			Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L)	ONCOGENE			English	Article						IGF1R therapeutic antibody; apoptosis; tumor regression; predictive biomarker; Bcl-x(L); Bcl-2	FACTOR-I RECEPTOR; MONOCLONAL-ANTIBODY; CYTOCHROME-C; TUMOR-GROWTH; IGF-I; APOPTOSIS; SURVIVAL; BCL-2; INHIBITION; THERAPY	Insulin-like growth factors (IGFs) and their receptor, IGF-1 receptor (IGF1R), have important roles in growth, development, stress response, aging and cancer. There are many agents that inhibit IGF1R in oncology clinical development, and in some cases, they have been associated with rapid tumor regression. However, it is not clear by which process these targeted agents induce cancer cell death and how to predict such tumor responses. Here, we showed that IGF1R antibody led to rapid cell death and tumor regression in some rhabdomyosarcoma (RMS) cells. Mechanistic analysis revealed a rapid onset of mitochondrial-dependent apoptosis, including mitochondrial depolarization, cytochrome C release and the activation of specific caspases. The antibody sensitive cells had greater dependence on AKT for maintaining downstream signaling and the expression of a constitutively active AKT, which restored AKT-signaling in these cells, inhibited anti-IGF1R induced cell death. Further analysis showed IGF1R antibody-induced hypophosphorylation of BAD and activation of downstream BAX. Interestingly, the examination of RMS cell lines and tumors revealed an inverse correlation between elevated IGF1R and Bcl-2 level (P = 0.033), with the sensitive cells lacking Bcl-2 expression. The overexpression of BAD specific target, Bcl-x(L), conferred resistance, whereas Bcl-x(L) knockdown sensitized cells lacking Bcl-2 to anti-IGF1R-induced cell death. We propose that RMS pathogenesis involves increased IGF1R expression that enhances AKT and Bcl-x(L)-mediated cell survival, and the blockage of IGF1R results in inhibition of survival signal from Bcl-x(L) and cell death in the sensitive Bcl-2 negative cells. Oncogene (2010) 29, 6367-6377; doi:10.1038/onc.2010.364; published online 6 September 2010	[Mayeenuddin, L. H.; Yu, Y.; Kang, Z.; Cao, L.] NCI, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Mayeenuddin, L. H.; Yu, Y.; Kang, Z.] NCI Frederick, Lab Prote & Analyt Technol, SAIC Frederick Inc, Frederick, MD USA; [Helman, L. J.] NCI, Pediat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cao, L (corresponding author), NCI, Genet Branch, Ctr Canc Res, 37 Convent Dr,MSC 4265,Bldg 37,Room 6134, Bethesda, MD 20892 USA.	caoli@mail.nih.gov	Cao, Liang/K-7806-2017	Cao, Liang/0000-0001-7293-8338; Kang, zhigang/0000-0003-3444-4315	US National Cancer Institute (NCI); NCI, NIH [N01-CO-12400]; NATIONAL CANCER INSTITUTE [ZIASC006892, ZICBC011048] Funding Source: NIH RePORTER	US National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Andrius Kazlauskas for providing the lentivirus expressing Bcl-x<INF>L</INF>, and Arnulfo Mendoza, Vanessa Moore, Susan Garfield and Barbara Taylor for excellent technical assistance. This research was supported by the Intramural Research Program of the US National Cancer Institute (NCI). This project was also funded in part with federal funds from the NCI, NIH, under contract N01-CO-12400.	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Barcia RN, 2007, AM J TRANSPLANT, V7, P2082, DOI 10.1111/j.1600-6143.2007.01897.x; Burtrum D, 2003, CANCER RES, V63, P8912; Cao L, 2008, CANCER RES, V68, P8039, DOI 10.1158/0008-5472.CAN-08-1712; Clemmons DR, 2007, NAT REV DRUG DISCOV, V6, P821, DOI 10.1038/nrd2359; Cohen BD, 2005, CLIN CANCER RES, V11, P2063, DOI 10.1158/1078-0432.CCR-04-1070; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Goetsch L, 2005, INT J CANCER, V113, P316, DOI 10.1002/ijc.20543; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172; Haluska P, 2007, CLIN CANCER RES, V13, P5834, DOI 10.1158/1078-0432.CCR-07-1118; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kooijman R, 2006, CYTOKINE GROWTH F R, V17, P305, DOI 10.1016/j.cytogfr.2006.02.002; Kurmasheva RT, 2006, BBA-REV CANCER, V1766, P1, DOI 10.1016/j.bbcan.2006.05.003; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Minshall C, 1997, J IMMUNOL, V159, P1225; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Phillips DC, 2007, CANCER RES, V67, P756, DOI 10.1158/0008-5472.CAN-06-2374; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Sachdev D, 2003, CANCER RES, V63, P627; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Tolcher AW, 2009, J CLIN ONCOL, V27, P5800, DOI 10.1200/JCO.2009.23.6745; Troiano L, 2007, NAT PROTOC, V2, P2719, DOI 10.1038/nprot.2007.405; Wang Y, 2005, MOL CANCER THER, V4, P1214, DOI 10.1158/1535-7163.MCT-05-0048; Wu JD, 2005, CLIN CANCER RES, V11, P3065, DOI 10.1158/1078-0432.CCR-04-1586; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang JH, 2004, DEV BRAIN RES, V152, P255, DOI 10.1016/j.devbrainres.2004.07.008	33	22	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6367	6377		10.1038/onc.2010.364	http://dx.doi.org/10.1038/onc.2010.364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20818434	Green Accepted			2022-12-17	WOS:000284874700007
J	Uberti, B; Dentelli, P; Rosso, A; Defilippi, P; Brizzi, MF				Uberti, B.; Dentelli, P.; Rosso, A.; Defilippi, P.; Brizzi, M. F.			Inhibition of beta 1 integrin and IL-3R beta common subunit interaction hinders tumour angiogenesis	ONCOGENE			English	Article						IL-3; IL-3 receptor; beta 1 integrin; endothelial progenitor cells; tumour angiogenesis	ENDOTHELIAL PROGENITOR CELLS; GROWTH-FACTOR; INTERLEUKIN-3; IL-3; RECRUITMENT; VASCULATURE; EXPRESSION; RECEPTORS; SURVIVAL; PROTEIN	Integrin/cytokine receptor interaction provides permissive signals leading to neoangiogenesis, and integrins are crucial for differentiation of endothelial progenitor cells (EPCs). It is known that the inflammatory interleukin-3 (IL-3), released in the tumoral microenvironment, contributes to both angiogenesis and vasculogenic processes. Herein, we generated IL-3 receptor beta common (IL-3R beta c) extracellular domain-derived fusion proteins (Fc) to elucidate the molecular mechanisms regulating these processes. Three different Fc were generated, containing the entire extracellular domain of IL-3R beta c (Fc1.4), a fragment corresponding to domains 1-3 (Fc1.3) and a fragment corresponding to domain 4 (Fc4), respectively. The ability of the fusion proteins to interfere with IL-3R beta c/beta 1 integrin interaction was assessed on endothelial cells (ECs), EPCs and murine-derived ECs. Pull-down experiments showed that Fc1.4 and Fc4 fusion proteins specifically interacted with beta 1 integrin. Fc4 and Fc1.4 fragments prevented IL-3-mediated EPC expansion, arterial morphogenesis and tumour-derived EC migration, without affecting cell adhesion. Fc4 in vivo inhibited the IL-3-mediated vasculogenic process, as well as inflammatory and tumour vascular growth. In conclusion, these data identify the b1 integrin-interacting domain in the juxta-membrane IL-3Rbc extracellular domain, and provide the rational for targeting this interaction to impair vascular growth. Oncogene (2010) 29, 6581-6590; doi:10.1038/onc.2010.384; published online 30 August 2010	[Uberti, B.; Dentelli, P.; Rosso, A.; Brizzi, M. F.] Univ Turin, Dept Internal Med, I-10126 Turin, Italy; [Defilippi, P.] Univ Turin, Ctr Mol Biotechnol, I-10126 Turin, Italy; [Defilippi, P.] Univ Turin, Ctr Expt Res & Med Studies, I-10126 Turin, Italy	University of Turin; University of Turin; University of Turin	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	mariafelice.brizzi@unito.it	DEFILIPPI, Paola/L-2232-2014; Brizzi, Maria Felice/J-7882-2016	Defilippi, Paola/0000-0001-6427-4906	Italian Association for Cancer Research (AIRC); Association for International Cancer Research (AICR); Regione Piemonte (OncoProt, Druidi, PIStem); EU	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Association for International Cancer Research (AICR); Regione Piemonte (OncoProt, Druidi, PIStem)(Regione Piemonte); EU(European Commission)	This work was supported by grants from the Italian Association for Cancer Research (AIRC) to MFB and PD, Association for International Cancer Research (AICR), Regione Piemonte (OncoProt, Druidi, PIStem) and EU FP7 Metafight to PD We thank Dr Alessandra Baragli and Dr Natalie Lassen for critical reading and final editing of the paper.	Ahn GO, 2009, ANGIOGENESIS, V12, P159, DOI 10.1007/s10456-009-9135-7; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; Bellik L, 2005, FEBS LETT, V579, P2731, DOI 10.1016/j.febslet.2005.04.003; Biancone L, 1999, J IMMUNOL, V162, P5263; Brizzi MF, 1999, CIRC RES, V84, P785; Buitenhuis M, 2004, INT J BIOCHEM CELL B, V36, P2120, DOI 10.1016/j.biocel.2003.11.008; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Carr PD, 2001, CELL, V104, P291, DOI 10.1016/S0092-8674(01)00213-6; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Defilippi P, 2005, J CELL BIOL, V168, P1099, DOI 10.1083/jcb.200405116; Dentelli P, 2005, ONCOGENE, V24, P6394, DOI 10.1038/sj.onc.1208786; Dentelli P, 2004, ONCOGENE, V23, P1681, DOI 10.1038/sj.onc.1207290; Dentelli P, 1999, J IMMUNOL, V163, P2151; Dentelli P, 2007, BLOOD, V109, P4264, DOI 10.1182/blood-2006-06-029603; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306; Furuya M, 2009, CURR PHARM DESIGN, V15, P1854, DOI 10.2174/138161209788453275; Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224; Gao DC, 2009, BBA-REV CANCER, V1796, P33, DOI 10.1016/j.bbcan.2009.05.001; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Giraudo E, 1996, J IMMUNOL, V157, P2618; Groger M, 2004, J IMMUNOL, V173, P7161, DOI 10.4049/jimmunol.173.12.7161; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Makinen T, 2005, GENE DEV, V19, P397, DOI 10.1101/gad.330105; MUI ALF, 1995, J LEUKOCYTE BIOL, V57, P799, DOI 10.1002/jlb.57.5.799; Naldini Antonella, 2005, Current Drug Targets - Inflammation and Allergy, V4, P3, DOI 10.2174/1568010053622830; Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P6547, DOI 10.1073/pnas.92.14.6547; Peters BA, 2005, NAT MED, V11, P261, DOI 10.1038/nm1200; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Schroeter MR, 2008, CIRC RES, V103, P536, DOI 10.1161/CIRCRESAHA.107.169375; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Shaked Y, 2007, CANCER RES, V67, P7055, DOI 10.1158/0008-5472.CAN-07-0905; Shojaei F, 2008, DRUG RESIST UPDATE, V11, P219, DOI 10.1016/j.drup.2008.09.001; Silva RAGD, 2008, ARTERIOSCL THROM VAS, V28, pE64; Streuli CH, 2009, BIOCHEM J, V418, P491, DOI 10.1042/BJ20081948; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Togliatto G, 2010, DIABETES, V59, P1016, DOI 10.2337/db09-0858; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zeoli A, 2008, BLOOD, V112, P350, DOI 10.1182/blood-2007-12-128215	45	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6581	6590		10.1038/onc.2010.384	http://dx.doi.org/10.1038/onc.2010.384			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20802515				2022-12-17	WOS:000285380200007
J	Ythier, D; Larrieu, D; Binet, R; Binda, O; Brambilla, C; Gazzeri, S; Pedeux, R				Ythier, D.; Larrieu, D.; Binet, R.; Binda, O.; Brambilla, C.; Gazzeri, S.; Pedeux, R.			Sumoylation of ING2 regulates the transcription mediated by Sin3A	ONCOGENE			English	Article						sumoylation; Sin3A; SUMO1; transcription	DNA-REPLICATION FORKS; PHD-FINGER; EXPRESSION; PROTEIN; GENE; SUMO; GROWTH; MOTIF; P53; ACETYLATION	ING2 (inhibitor of growth 2) is a candidate tumor-suppressor gene involved in cell cycle control, apoptosis and senescence. Although the functions of ING2 within the chromatin remodeling complex Sin3A/histone deacetylase (HDAC) and in the p53 pathway have been described, how ING2 itself is regulated remains unknown. In this study we report for the first time that ING2 can be sumoylated by small ubiquitin-like modifier 1 (SUMO1) on lysine 195 both in vitro and in vivo. Strikingly, ING2 sumoylation enhances its association with Sin3a. We provide evidences that ING2 can bind to the promoter of genes to mediate their expression and that sumoylation of ING2 is required for this binding to some of these genes. Among them, we identified the gene TMEM71 (transmembrane protein 71), whose expression is regulated by ING2 sumoylation. ING2 must be sumoylated to bind to the promoter of TMEM71 and to recruit the Sin3A chromatin-modifying complex to this promoter, in order to regulate TMEM71 transcription. Hence, sumoylation of ING2 enhances its binding to the Sin3A/HDAC complex and is required to regulate gene transcriptions. Oncogene (2010) 29, 5946-5956; doi:10.1038/onc.2010.325; published online 2 August 2010	[Ythier, D.; Larrieu, D.; Binet, R.; Brambilla, C.; Gazzeri, S.; Pedeux, R.] Univ Grenoble 1, INSERM, U823, Inst Albert Bonniot, Grenoble, France; [Binda, O.] Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; [Pedeux, R.] Univ Rennes 1, INSERM, U917, IFR140,Fac Med, Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Stanford University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes 1	Pedeux, R (corresponding author), INSERM, U917 MICA, Fac Med Rennes, Batiment 2,Piece 117,2 Ave Pr Leon Bernard, F-35043 Rennes, France.	remy.pedeux@univ-rennes1.fr	gazzeri, sylvie/U-4669-2019; PEDEUX, Rémy M/I-2603-2014; gazzeri, sylvie/M-1961-2013; Binda, Olivier/A-5941-2009; Binet, Romuald/I-7938-2012	gazzeri, sylvie/0000-0001-5817-1839; PEDEUX, Rémy M/0000-0002-2553-7934; gazzeri, sylvie/0000-0001-5817-1839; Binda, Olivier/0000-0002-1539-0828; Binet, Romuald/0000-0003-0636-2195	ARC; IASLC; Marie Curie International Reintegration Grant [MIRG-CT-2006-042148]; INCa; FRM; French Ministry of Education and Research; Agir a dom	ARC(Australian Research Council); IASLC; Marie Curie International Reintegration Grant(European Commission); INCa(Institut National du Cancer (INCA) France); FRM(Fondation pour la Recherche Medicale); French Ministry of Education and Research; Agir a dom	We thank D Nissou for technical assisstance; Dr O Gozani and C Harris for antibodies, plasmids and scientific discussion, and Dr Marc Piechaczyk and Dr Guillaume Bossis for scientific discussion and advising. RP was supported by ARC, the IASLC, an 'Agir a dom' grant and a Marie Curie International Reintegration Grant (MIRG-CT-2006-042148). DY, RB and DL were funded by the INCa, ARC, the FRM (Prix Mariane Josso) and the French Ministry of Education and Research, respectively.	Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001; Borkosky SS, 2009, J CANCER RES CLIN, V135, P703, DOI 10.1007/s00432-008-0507-y; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Farhana L, 2009, MOL CANCER THER, V8, P1625, DOI 10.1158/1535-7163.MCT-08-0964; Feng XL, 2006, MOL CELL BIOL, V26, P9244, DOI 10.1128/MCB.01538-06; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Gong W, 2006, MOL CELL BIOL, V26, P2947, DOI 10.1128/MCB.26.8.2947-2954.2006; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Larrieu D, 2009, CELL CYCLE, V8, P3623, DOI 10.4161/cc.8.22.9947; Larrieu D, 2009, EMBO REP, V10, P1168, DOI 10.1038/embor.2009.180; Lu F, 2006, BRIT J CANCER, V95, P80, DOI 10.1038/sj.bjc.6603205; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Mellor J, 2006, CELL, V126, P22, DOI 10.1016/j.cell.2006.06.028; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sarker KP, 2008, J BIOL CHEM, V283, P13269, DOI 10.1074/jbc.M708834200; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shiseki M, 2003, CANCER RES, V63, P2373; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Terui Y, 2004, J BIOL CHEM, V279, P28257, DOI 10.1074/jbc.M403153200; Ythier D, 2008, INT J CANCER, V123, P1483, DOI 10.1002/ijc.23790; Ythier D, 2010, LUNG CANCER, V69, P180, DOI 10.1016/j.lungcan.2009.11.006; Zhang HK, 2008, CANCER LETT, V261, P183, DOI 10.1016/j.canlet.2007.11.019	33	22	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5946	5956		10.1038/onc.2010.325	http://dx.doi.org/10.1038/onc.2010.325			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20676127				2022-12-17	WOS:000283843400008
J	Lu, Y; Bertran, S; Samuels, TA; Mira-y-Lopez, R; Farias, EF				Lu, Y.; Bertran, S.; Samuels, T-A; Mira-y-Lopez, R.; Farias, E. F.			Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RAR alpha agonist AM580	ONCOGENE			English	Article						RAR alpha; RAR gamma; AM580; MMTV-neu; MMTV-wnt1; breast cancer	HUMAN-BREAST-CANCER; ACID RECEPTOR-ALPHA; CHANGES FOLLOWING DEPRIVATION; SQUAMOUS-CELL CARCINOMA; RETINOIC ACID; BETA-CATENIN; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; EXPRESSION; GAMMA	We hypothesized that specific activation of a single retinoic acid receptor-alpha (RAR alpha), without direct and concurrent activation of RAR beta and gamma, will inhibit mammary tumor oncogenesis in murine models relevant to human cancer. A total of 50 uniparous mouse mammary tumor virus (MMTV)-neu and 50 nuliparous MMTV-wnt1 transgenic mice were treated with RAR alpha agonist (retinobenzoic acid, Am580) that was added to the diet for 40 (neu) and 35 weeks (wnt1), respectively. Among the shared antitumor effects was the inhibition of epithelial hyperplasia, a significant increase (P<0.05) in tumor-free survival and a reduction in tumor incidence and in the growth of established tumors. In both models, the mechanisms responsible for these effects involved inhibition of proliferation and survival pathways, and induction of apoptosis. The treatment was more effective in the MMTV-wnt1 model in which Am580 also induced differentiation, in both in vivo and three-dimensional (3D) cultures. In these tumors Am580 inhibited the wnt pathway, measured by loss of nuclear beta-catenin, suggesting partial oncogene dependence of therapy. Am580 treatment increased RAR beta and lowered the level of RAR gamma, an isotype whose expression we linked with tumor proliferation. The anticancer effect of RAR alpha, together with the newly discovered pro-proliferative role of RAR gamma, suggests that specific activation of RAR alpha and inhibition of RAR gamma might be effective in breast cancer therapy. Oncogene (2010) 29, 3665-3676; doi: 10.1038/onc.2010.119; published online 10 May 2010	[Lu, Y.; Bertran, S.; Samuels, T-A; Mira-y-Lopez, R.; Farias, E. F.] Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, Tisch Canc Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Farias, EF (corresponding author), Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, Tisch Canc Ctr, 1 Gustave Levy Pl, New York, NY 10029 USA.	Eduardo.farias@mssm.edu			NCI [R01-CA119018]; Samuel Waxman Cancer Research Foundation (SWCRF); NIH-NCI [5R24-CA095823-04]; NSF [DBI-972404]; NIH [1S10-RR0-9145-01]; NATIONAL CANCER INSTITUTE [R24CA095823, R01CA119018] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Samuel Waxman Cancer Research Foundation (SWCRF); NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Drs W Muller and HE Varmus, respectively, for the gift of MMTV-neu and MMTV-wnt1 mice, Dr K Shudo for generous gift of AM580 in amounts sufficient to complete these extensive in vivo studies, and Drs L Ossowski, S Waxman and J Aguirre-Ghiso for helpful advice. This work was supported by the NCI Grant R01-CA119018, the Samuel Waxman Cancer Research Foundation (SWCRF) and the NIH-NCI shared resources Grant 5R24-CA095823-04, NSF Major Research Instrumentation Grant DBI-972404, the NIH shared instrumentation Grant 1S10-RR0-9145-01 to MSSM's Microscopy Shared Resources Facility.	ASTROM A, 1990, BIOCHEM BIOPH RES CO, V173, P339, DOI 10.1016/S0006-291X(05)81062-9; Berry DC, 2007, PPAR RES, V2007, DOI 10.1155/2007/73256; Borriello A, 2006, CANCER RES, V66, P4240, DOI 10.1158/0008-5472.CAN-05-2759; Brennan KR, 2004, J MAMMARY GLAND BIOL, V9, P119, DOI 10.1023/B:JOMG.0000037157.94207.33; Bukholm IK, 2000, J PATHOL, V190, P15; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chapellier B, 2002, EMBO J, V21, P3402, DOI 10.1093/emboj/cdf331; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Collins SJ, 2008, CURR OPIN HEMATOL, V15, P346, DOI 10.1097/MOH.0b013e3283007edf; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Gantenbein-Ritter B, 2008, TISSUE ENG PART C-ME, V14, P353, DOI 10.1089/ten.tec.2008.0313; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Klaassen I, 2001, BRIT J CANCER, V85, P630, DOI 10.1054/bjoc.2001.1952; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; Marcotte R, 2008, J MAMMARY GLAND BIOL, V13, P323, DOI 10.1007/s10911-008-9087-3; MOON RC, 1990, METHOD ENZYMOL, V190, P395; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Noy N, 2007, BIOCHEMISTRY-US, V46, P13461, DOI 10.1021/bi7018699; Osanai M, 2005, MOL PHARMACOL, V67, P1808, DOI 10.1124/mol.104.005769; Ozpolat B, 2002, AM J HEMATOL, V70, P39, DOI 10.1002/ajh.10099; Paik J, 2003, CANCER INVEST, V21, P304, DOI 10.1081/CNV-120016425; Patatanian E, 2008, J CLIN PHARM THER, V33, P331, DOI 10.1111/j.1365-2710.2008.00935.x; Polakis P, 2000, GENE DEV, V14, P1837; Purton LE, 2006, J EXP MED, V203, P1283, DOI 10.1084/jem.20052105; Radu M, 2008, J CELL PHYSIOL, V217, P558, DOI 10.1002/jcp.21532; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Schneider SM, 2000, CANCER RES, V60, P5479; Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050; Shin DM, 2001, J CLIN ONCOL, V19, P3010, DOI 10.1200/JCO.2001.19.12.3010; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPORN MB, 1976, FED PROC, V35, P1332; Su D, 2008, BIOCHEM PHARMACOL, V75, P1129, DOI 10.1016/j.bcp.2007.11.006; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Van heusden J, 1998, BRIT J CANCER, V77, P26, DOI 10.1038/bjc.1998.5; Veeck J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2151; Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Walkley CR, 2007, CELL, V129, P1097, DOI 10.1016/j.cell.2007.05.014; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; WOLBACH SB, 1978, NUTR REV, V36, P16; Wolf G, 2000, NUTR REV, V58, P211, DOI 10.1111/j.1753-4887.2000.tb01865.x; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621	55	22	22	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3665	3676		10.1038/onc.2010.119	http://dx.doi.org/10.1038/onc.2010.119			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20453882	Green Accepted			2022-12-17	WOS:000279108600007
J	Ogba, N; Doughman, YQ; Chaplin, LJ; Hu, Y; Gargesha, M; Watanabe, M; Montano, MM				Ogba, N.; Doughman, Y. Q.; Chaplin, L. J.; Hu, Y.; Gargesha, M.; Watanabe, M.; Montano, M. M.			HEXIM1 modulates vascular endothelial growth factor expression and function in breast epithelial cells and mammary gland	ONCOGENE			English	Article						HEXIM1; VEGF; HIF-1 alpha; P-TEFb; angiogenesis; mammary tumors	ESTROGEN-RECEPTOR-ALPHA; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CANCER CELLS; GENE-EXPRESSION; DOWN-REGULATION; RAT UTERUS; IN-VIVO; VEGF; ESTRADIOL; TRANSCRIPTION	Recently, we found that mutation of the C-terminus of transcription factor hexamethylene bisacetamide-inducible protein 1 (HEXIM1) in mice leads to abnormalities in cardiovascular development because of aberrant vascular endothelial growth factor ( VEGF) expression. HEXIM1 regulation of some genes has also been shown to be positive transcription elongation factor b ( P-TEFb) dependent. However, it is not known whether HEXIM1 regulates VEGF in the mammary gland. We demonstrate that HEXIM1 regulates estrogen-induced VEGF transcription through inhibition of estrogen receptor-alpha recruitment to the VEGF promoter in a P-TEFb-independent manner in MCF-7 cells. Under hypoxic conditions, HEXIM1 inhibits estrogen-induced hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein expression and recruitment of HIF-1 alpha to the hypoxia-response element in the VEGF promoter. In the mouse mammary gland, increased HEXIM1 expression decreased estrogen-driven VEGF and HIF-1 alpha expression. Conversely, a mutation in the C-terminus of HEXIM1 ( HEXIM1(1- 312)) led to increased VEGF and HIF-1 alpha expression and vascularization in mammary glands of heterozygous HEXIM1(1-312) mice when compared with their wild-type littermates. In addition, HEXIM1(1-312) mice have a higher incidence of carcinogen-induced mammary tumors with increased vascularization, suggesting an inhibitory role for HEXIM1 during angiogenesis. Taken together, our data provide evidence to suggest a novel role for HEXIM1 in cancer progression. Oncogene ( 2010) 29, 3639-3649; doi: 10.1038/onc.2010.110; published online 10 May 2010	[Ogba, N.; Chaplin, L. J.; Hu, Y.; Montano, M. M.] Rainbow Babies & Childrens Hosp, Dept Pharmacol, Cleveland, OH 44106 USA; [Doughman, Y. Q.; Watanabe, M.] Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Gargesha, M.] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Dept Pharmacol, HG Wood Bldg W305,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@case.edu	Ogba, Ndiya/K-8429-2014	Ogba, Ndiya/0000-0003-0453-3763	National Institute of Health [CA92440]; American Heart Association; Department of Defense [W81XWH-06-1-0426]; NATIONAL CANCER INSTITUTE [R01CA092440] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Anthony J Berdis and Jay Prendergast for reagents and their help with kinase and ELISA assays. This work was supported by the National Institute of Health Grant CA92440 and the American Heart Association Grant to MMM and a Department of Defense predoctoral Fellowship W81XWH-06-1-0426 to NO.	Bogin L, 2002, CANCER RES, V62, P1948; Bos R, 2004, BREAST CANCER RES, V6, pR450, DOI 10.1186/bcr813; Buteau-Lozano H, 2002, CANCER RES, V62, P4977; Cho JY, 2005, MOL ENDOCRINOL, V19, P1191, DOI 10.1210/me.2004-0162; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Garvin S, 2005, BRIT J CANCER, V93, P1005, DOI 10.1038/sj.bjc.6602824; Higgins KJ, 2006, ENDOCRINOLOGY, V147, P3285, DOI 10.1210/EN.2006-0081; Hyder SM, 2006, ENDOCR-RELAT CANCER, V13, P667, DOI 10.1677/erc.1.00931; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kazi AA, 2005, MOL ENDOCRINOL, V19, P2006, DOI 10.1210/me.2004-0388; Kazi AA, 2007, ENDOCRINOLOGY, V148, P2363, DOI 10.1210/en.2006-1394; Kazi AA, 2009, BIOL REPROD, V81, P378, DOI 10.1095/biolreprod.109.076117; Kimbro KS, 2006, ENDOCR-RELAT CANCER, V13, P739, DOI 10.1677/erc.1.00728; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; LI BL, 1995, MOL CARCINOGEN, V14, P75, DOI 10.1002/mc.2940140203; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Lydon JP, 1999, CANCER RES, V59, P4276; Maity A, 2001, BREAST CANCER RES TR, V67, P51, DOI 10.1023/A:1010662905549; Molitoris KH, 2009, ENDOCRINOLOGY, V150, P5405, DOI 10.1210/en.2009-0884; Montano MM, 2008, CIRC RES, V102, P415, DOI 10.1161/CIRCRESAHA.107.157859; Ogba N, 2008, CANCER RES, V68, P7015, DOI 10.1158/0008-5472.CAN-08-0814; Qiang Z, 2006, MICROBIOL MOL BIOL R, V70, P646, DOI 10.1128/MMBR.00011-06; Rossiter H, 2007, FASEB J, V21, P3994, DOI 10.1096/fj.07-8720com; Rugo HS, 2004, ONCOLOGIST, V9, P43, DOI 10.1634/theoncologist.9-suppl_1-43; Seifeddine R, 2007, J STEROID BIOCHEM, V104, P169, DOI 10.1016/j.jsbmb.2007.03.025; Shimizu N, 2005, P NATL ACAD SCI USA, V102, P8555, DOI 10.1073/pnas.0409863102; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Stoner M, 2004, ONCOGENE, V23, P1052, DOI 10.1038/sj.onc.1207201; Wittmann BM, 2005, ONCOGENE, V24, P5576, DOI 10.1038/sj.onc.1208728; Wittmann BM, 2003, CANCER RES, V63, P5151; Woodfin A, 2007, ARTERIOSCL THROM VAS, V27, P2514, DOI 10.1161/ATVBAHA.107.151456	33	22	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3639	3649		10.1038/onc.2010.110	http://dx.doi.org/10.1038/onc.2010.110			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20453883	Green Accepted			2022-12-17	WOS:000279108600005
J	Wang, Y; Klumpp, S; Amin, HM; Liang, H; Li, J; Estrov, Z; Zweidler-McKay, P; Brandt, SJ; Agulnick, A; Nagarajan, L				Wang, Y.; Klumpp, S.; Amin, H. M.; Liang, H.; Li, J.; Estrov, Z.; Zweidler-McKay, P.; Brandt, S. J.; Agulnick, A.; Nagarajan, L.			SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability	ONCOGENE			English	Article						tumor suppressor; null mouse; LIM code; p53; lymphoma; SSBP2	DNA-BINDING PROTEINS; B-CELL; TRANSCRIPTION FACTOR; LIM-DOMAIN; MYELOGENOUS LEUKEMIA; GENE-EXPRESSION; DIFFERENTIATION; SURVIVAL; PROLIFERATION; ABUNDANCE	SSBP proteins bind and stabilize transcriptional cofactor LIM domain-binding protein1 (LDB1) from proteosomal degradation to promote tissue-specific transcription through an evolutionarily conserved pathway. The human SSBP2 gene was isolated as a candidate tumor suppressor from a critical region of loss in chromosome 5q14.1. By gene targeting, we show increased predisposition to B-cell lymphomas and carcinomas in Ssbp2(-/-) mice. Remarkably, loss of Ssbp2 causes increased LDB1 turnover in the thymus, a pathway exploited in Trp53(-/-) Ssbp2(-/-) mice to develop highly aggressive, immature thymic lymphomas. Using T-cell differentiation as a model, we report a stage-specific upregulation of Ssbp2 expression, which in turn regulates LDB1 turnover under physiological conditions. Furthermore, transcript levels of pT alpha, a target of LDB1-containing complex, and a critical regulator T-cell differentiation are reduced in Ssbp2(-/-) immature thymocytes. Our findings suggest that disruption of the SSBP2-regulated pathways may be an infrequent but critical step in malignant transformation of multiple tissues. Oncogene (2010) 29, 3044-3053; doi: 10.1038/onc.2010.78; published online 29 March 2010	[Wang, Y.; Liang, H.; Li, J.; Nagarajan, L.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA; [Klumpp, S.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA; [Amin, H. M.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Estrov, Z.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Zweidler-McKay, P.] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA; [Brandt, S. J.] Vanderbilt Univ, Dept Med, Nashville, TN USA; [Brandt, S. J.] Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN USA; [Brandt, S. J.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN USA; [Brandt, S. J.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Agulnick, A.] Novocell Inc, La Jolla, CA USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Nagarajan, L (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, Box 45,1515 Holcombe Blvd, Houston, TX 77030 USA.	lnagaraj@mdanderson.org		Zweidler-McKay, Patrick/0000-0001-6621-523X	NCI [CA16672];  [HL744409]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074449, R01HL049118] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Xiaoping Ma and Mayur Patel for expert technical assistance, Samuel Pfaff and Dong Er Zhang for housing the Ssbp2<SUP>-/-</SUP> mice in the early stages of these investigations, Gigi Lozano, Richard Behringer, present and former members of the Nagarajan laboratory for helpful discussions, Kim-Anh Vu for assistance with the histology photographs. These studies were supported by HL744409 to LN. The genotyping, flow cytometry facilities and veterinary services were supported by NCI core Grant CA16672.	Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630; Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; Baseta JG, 2000, J IMMUNOL, V165, P5621, DOI 10.4049/jimmunol.165.10.5621; Cai Y, 2008, BIOCHEM BIOPH RES CO, V373, P303, DOI 10.1016/j.bbrc.2008.06.027; Capron C, 2006, BLOOD, V107, P4678, DOI 10.1182/blood-2005-08-3145; Castro P, 2002, GENOMICS, V80, P78, DOI 10.1006/geno.2002.6805; Cerretini R, 2006, EUR J HAEMATOL, V76, P284, DOI 10.1111/j.1600-0609.2005.00616.x; Chen L, 2002, P NATL ACAD SCI USA, V99, P14320, DOI 10.1073/pnas.212532399; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; Fleisig HB, 2007, ONCOGENE, V26, P4797, DOI 10.1038/sj.onc.1210281; Goardon N, 2006, EMBO J, V25, P357, DOI 10.1038/sj.emboj.7600934; Gungor C, 2007, P NATL ACAD SCI USA, V104, P15000, DOI 10.1073/pnas.0703738104; Haks MC, 1999, IMMUNITY, V11, P91, DOI 10.1016/S1074-7613(00)80084-9; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnsen SA, 2009, CANCER RES, V69, P128, DOI 10.1158/0008-5472.CAN-08-1630; Koch JG, 2007, MAMM GENOME, V18, P300, DOI 10.1007/s00335-007-9028-2; Lecuyer E, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M703939200; Liang H, 2005, ONCOGENE, V24, P2625, DOI 10.1038/sj.onc.1208167; Liu JW, 2008, CLIN CANCER RES, V14, P3754, DOI 10.1158/1078-0432.CCR-07-4763; Majetl R, 2009, P NATL ACAD SCI USA, V106, P3396, DOI 10.1073/pnas.0900089106; Murre C, 2005, NAT IMMUNOL, V6, P1079, DOI 10.1038/ni1260; Nam CH, 2006, MOL THER, V13, P15, DOI 10.1016/j.ymthe.2005.09.010; Natkunam Y, 2008, J CLIN ONCOL, V26, P447, DOI 10.1200/JCO.2007.13.0690; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; Poitras JL, 2008, GENE CHROMOSOME CANC, V47, P884, DOI 10.1002/gcc.20585; Qian ZJ, 2002, P NATL ACAD SCI USA, V99, P14925, DOI 10.1073/pnas.222491799; Rothenberg EV, 2007, NAT IMMUNOL, V8, P441, DOI 10.1038/ni1461; Rothenberg EV, 2007, CURR OPIN HEMATOL, V14, P322, DOI 10.1097/MOH.0b013e3281de72a8; Ryu CJ, 2006, CANCER CELL, V9, P109, DOI 10.1016/j.ccr.2006.01.004; Smith KS, 1999, MOL CELL BIOL, V19, P4443; Sum EYM, 2005, P NATL ACAD SCI USA, V102, P7659, DOI 10.1073/pnas.0502990102; Tremblay M, 2003, J BIOL CHEM, V278, P12680, DOI 10.1074/jbc.M209870200; Uren AG, 2008, CELL, V133, P727, DOI 10.1016/j.cell.2008.03.021; van Meyel DJ, 2003, DEVELOPMENT, V130, P1915, DOI 10.1242/dev.00389; Wu HK, 1996, ONCOGENE, V12, P1205; Xu ZX, 2007, GENE DEV, V21, P942, DOI 10.1101/gad.1528507; Zhang XB, 2008, J CLIN INVEST, V118, P1502, DOI 10.1172/JCI34371	38	22	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3044	3053		10.1038/onc.2010.78	http://dx.doi.org/10.1038/onc.2010.78			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20348955	Green Accepted			2022-12-17	WOS:000278133100002
J	Watanabe, Y; Kojima, T; Kagawa, S; Uno, F; Hashimoto, Y; Kyo, S; Mizuguchi, H; Tanaka, N; Kawamura, H; Ichimaru, D; Urata, Y; Fujiwara, T				Watanabe, Y.; Kojima, T.; Kagawa, S.; Uno, F.; Hashimoto, Y.; Kyo, S.; Mizuguchi, H.; Tanaka, N.; Kawamura, H.; Ichimaru, D.; Urata, Y.; Fujiwara, T.			A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy	ONCOGENE			English	Article						telomerase; adenovirus; mesothelioma; heparanase; dual virotherapy	I CLINICAL-TRIAL; GENE-THERAPY; CANCER; REPLICATION; EXPRESSION; INCREASES; P14(ARF); METASTASIS; EFFICACY; IMPROVES	Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that is related to asbestos exposure. MPM is characterized by rapid and diffuse local growth in the thoracic cavity, and it has a poor prognosis because it is often refractory to conventional therapy. Although MPM is an extraordinarily challenging disease to treat, locoregional virotherapy may be useful against this aggressive disease because of the accessibility by intrapleural virus delivery. In this study, we show that telomerase-specific, replication-selective adenovirus OBP-301 can efficiently infect and kill human mesothelioma cells by viral replication. Intrathoracic administration of virus significantly reduced the number and size of human mesothelioma tumors intrathoracically implanted into nu/nu mice. A high-definition, fluorescence optical imaging system with an ultra-thin, flexible fibered microprobe clearly detected intracellular replication of green fluorescent protein-expressing oncolytic virus in intrathoracically established mesothelioma tumors. As the extracellular matrix (ECM) may contribute to the physiological resistance of a solid tumor by preventing the penetration of therapeutic agents (including oncolytic viruses), we also examined whether the co-expression of heparanase, an endoglucuronidase capable of specifically degrading heparan sulfate, that influences the physiological barrier to macromolecule penetration, can modify the permeability of the ECM, resulting in profound therapeutic efficacy. Co-injection of OBP-301 and a replication-defective adenovirus (Ad-S/hep)-expressing heparanase resulted in more profound antitumor effects without apparent toxicity in an orthotopic pleural dissemination model. Our results suggest that intrathoracic dual virotherapy with telomerase-specific oncolytic adenovirus in combination with heparanase-expressing adenovirus may be efficacious in the prevention and treatment of pleural dissemination of human malignant mesothelioma. Oncogene (2010) 29, 1145-1154; doi: 10.1038/onc.2009.415; published online 23 November 2009	[Fujiwara, T.] Okayama Univ, Ctr Gene & Cell Therapy, Grad Sch Med Dent & Pharmaceut Sci, Dept Surg, Okayama 7008558, Japan; [Watanabe, Y.; Kagawa, S.; Uno, F.; Fujiwara, T.] Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama, Japan; [Watanabe, Y.; Hashimoto, Y.; Kawamura, H.; Ichimaru, D.; Urata, Y.] Oncolys BioPharma Inc, Minato Ku, Tokyo, Japan; [Kyo, S.] Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 920, Japan; [Mizuguchi, H.] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Biochem & Mol Biol, Osaka, Japan	Okayama University; Okayama University; Oncolys BioPharma; Kanazawa University; Osaka University	Fujiwara, T (corresponding author), Okayama Univ, Ctr Gene & Cell Therapy, Grad Sch Med Dent & Pharmaceut Sci, Dept Surg, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	toshi_f@md.okayama-u.ac.jp	Kagawa, Shunsuke/B-2189-2011	Mizuguchi, Hiroyuki/0000-0003-0594-8178; Kagawa, Shunsuke/0000-0002-3610-8211				ALBERTS AS, 1988, J CLIN ONCOL, V6, P527, DOI 10.1200/JCO.1988.6.3.527; BALL DL, 1990, AM J CLIN ONCOL-CANC, V13, P4, DOI 10.1097/00000421-199002000-00002; Blackburn JS, 2007, CANCER RES, V67, P10849, DOI 10.1158/0008-5472.CAN-07-1791; CHAHINIAN AP, 1982, ANN INTERN MED, V96, P746, DOI 10.7326/0003-4819-96-6-746; CHAILLEUX E, 1988, CHEST, V93, P159, DOI 10.1378/chest.93.1.159; Cheng J, 2007, MOL THER, V15, P1982, DOI 10.1038/sj.mt.6300264; CONNELLY RR, 1987, JNCI-J NATL CANCER I, V78, P1053; Eikenes L, 2004, CANCER RES, V64, P4768, DOI 10.1158/0008-5472.CAN-03-1472; Fitzgerald M, 1999, ATHEROSCLEROSIS, V145, P97, DOI 10.1016/S0021-9150(99)00019-2; Fujiwara T, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3572; Ganesh S, 2007, CANCER RES, V67, P4399, DOI 10.1158/0008-5472.CAN-06-4260; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Hioki M, 2008, INT J CANCER, V122, P2628, DOI 10.1002/ijc.23438; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Kim JH, 2006, JNCI-J NATL CANCER I, V98, P1482, DOI 10.1093/jnci/djj397; Kishimoto H, 2006, NAT MED, V12, P1213, DOI 10.1038/nm1404; Kishimoto H, 2009, P NATL ACAD SCI USA, V106, P14514, DOI 10.1073/pnas.0906388106; Kuriyama N, 2001, CANCER RES, V61, P1805; McKee TD, 2006, CANCER RES, V66, P2509, DOI 10.1158/0008-5472.CAN-05-2242; McKenzie EA, 2007, BRIT J PHARMACOL, V151, P1, DOI 10.1038/sj.bjp.0707182; Molnar-Kimber KL, 1998, HUM GENE THER, V9, P2121, DOI 10.1089/hum.1998.9.14-2121; Murayama T, 2006, AM J IND MED, V49, P1, DOI 10.1002/ajim.20246; Price B, 1997, AM J EPIDEMIOL, V145, P211, DOI 10.1093/oxfordjournals.aje.a009093; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; RUFFIE P, 1989, J CLIN ONCOL, V7, P1157, DOI 10.1200/JCO.1989.7.8.1157; RUSCH VW, 1991, J THORAC CARDIOV SUR, V102, P1; Ryan CW, 1998, CHEST, V113, p66S, DOI 10.1378/chest.113.1_Supplement.66S; Sterman DH, 2007, CLIN CANCER RES, V13, P4456, DOI 10.1158/1078-0432.CCR-07-0403; Sterman DH, 2005, CLIN CANCER RES, V11, P7444, DOI 10.1158/1078-0432.CCR-05-0405; Sterman DH, 1998, HUM GENE THER, V9, P1083, DOI 10.1089/hum.1998.9.7-1083; Taki M, 2005, ONCOGENE, V24, P3130, DOI 10.1038/sj.onc.1208460; Tango Y, 2004, CANCER SCI, V95, P459, DOI 10.1111/j.1349-7006.2004.tb03232.x; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; Uno F, 2001, CANCER RES, V61, P7855; Yang CT, 2000, J NATL CANCER I, V92, P636, DOI 10.1093/jnci/92.8.636; Yang CT, 2001, CANCER RES, V61, P5959	36	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1145	1154		10.1038/onc.2009.415	http://dx.doi.org/10.1038/onc.2009.415			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935710				2022-12-17	WOS:000274912100006
J	Dujka, ME; Puebla-Osorio, N; Tavana, O; Sang, M; Zhu, C				Dujka, M. E.; Puebla-Osorio, N.; Tavana, O.; Sang, M.; Zhu, C.			ATM and p53 are essential in the cell-cycle containment of DNA breaks during V(D)J recombination in vivo	ONCOGENE			English	Article						V(D)J recombination; genomic instability; ATM; cell-cycle control	DOUBLE-STRAND BREAKS; ATAXIA-TELANGIECTASIA; GENOMIC INSTABILITY; CHROMOSOME BREAKS; HISTONE H2AX; C-MYC; DEFICIENT; MICE; RECEPTOR; LOCUS	V(D)J recombination is essential for the maturation of lymphocytes. Because of the involvement of cutting and joining DNA double strands, this recombination activity is strictly contained within the noncycling phases of the cell cycle. Such containment is crucial for the maintenance of genomic integrity. The ataxia telangiectasia mutated (ATM) gene is known to have a central role in sensing general DNA damage and mediating cell-cycle checkpoint. In this study, we investigated the role of ATM and its downstream targets in the cell-cycle control of V(D) J recombination in vivo. Our results revealed the persistence of double-strand breaks (DSBs) throughout the cell cycle in ATM(-/-) and p53(-/-) thymocytes, but the cell-cycle regulation of a V(D) J recombinase, Rag-2, was normal. The histone variant H2AX, which is phosphorylated during normal V(D) J recombination, was dispensable for containing DSBs. H2AX was still phosphorylated at V(D) J loci in the absence of ATM. Therefore, V(D) J recombination, a physiological DNA rearrangement process, activates the ATM/p53 pathway to contain DNA breaks within the noncycling cells and surprisingly this pathway is not important for containing Rag-2 activity. This study shows the dynamic multiple functions of ATM in maintaining genomic stability and preventing tumorigenesis in developing lymphocytes. Oncogene (2010) 29, 957-965; doi:10.1038/onc.2009.394; published online 16 November 2009	[Dujka, M. E.; Puebla-Osorio, N.; Tavana, O.; Sang, M.; Zhu, C.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Dujka, M. E.; Tavana, O.; Zhu, C.] Univ Texas Houston, Grad Sch Biomed Sci Houston, Program Immunol, Houston, TX USA	University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Zhu, C (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd,Unit 901, Houston, TX 77030 USA.	czhu@mdanderson.org		Tavana, Omid/0000-0001-8401-4546; Puebla, Nahum/0000-0001-6498-5230	NIH [CA116933, T32 CA009598-17]; Leukemia Research Foundation; American Cancer Society; NATIONAL CANCER INSTITUTE [T32CA009598, R01CA116933] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia Research Foundation; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge MD Anderson Flow Cytometry Core Facility for cell sorting and the Immune Imaging Core Facility for their assistance with confocal microscopy. This study was financially supported in part by NIH Grant CA116933, the Leukemia Research Foundation, the American Cancer Society-Bonnie Kies Lymphatic System Research Scholar grant (CZ) and NIH Grant T32 CA009598-17 (MED).	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bassing CH, 2008, BLOOD, V111, P2163, DOI 10.1182/blood-2007-08-104760; Borghesani PR, 2000, P NATL ACAD SCI USA, V97, P3336, DOI 10.1073/pnas.050584897; Bredemeyer AL, 2008, J IMMUNOL, V181, P2620, DOI 10.4049/jimmunol.181.4.2620; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Callen E, 2007, CELL, V130, P63, DOI 10.1016/j.cell.2007.06.016; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Desiderio S, 1996, CURR TOP MICROBIOL, V217, P45; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Huang CY, 2007, J EXP MED, V204, P1371, DOI 10.1084/jem.20061460; Jankovic M, 2007, NAT IMMUNOL, V8, P801, DOI 10.1038/ni1498; Jiang H, 2005, MOL CELL, V18, P699, DOI 10.1016/j.molcel.2005.05.011; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liao MJ, 1998, MOL CELL BIOL, V18, P3495, DOI 10.1128/MCB.18.6.3495; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Monroe RJ, 1999, IMMUNITY, V11, P201, DOI 10.1016/S1074-7613(00)80095-3; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Perkins EJ, 2002, GENE DEV, V16, P159, DOI 10.1101/gad.956902; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Savic V, 2009, MOL CELL, V34, P298, DOI 10.1016/j.molcel.2009.04.012; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tsai AG, 2008, CELL, V135, P1130, DOI 10.1016/j.cell.2008.10.035; Vacchio MS, 2007, P NATL ACAD SCI USA, V104, P6323, DOI 10.1073/pnas.0611222104; Widrow RJ, 1997, CYTOMETRY, V27, P250, DOI 10.1002/(SICI)1097-0320(19970301)27:3<250::AID-CYTO6>3.0.CO;2-I; Winrow CJ, 2005, HUM MOL GENET, V14, P2671, DOI 10.1093/hmg/ddi301; Yan MS, 2006, FREE RADICAL BIO MED, V41, P640, DOI 10.1016/j.freeradbiomed.2006.05.008; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	42	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					957	965		10.1038/onc.2009.394	http://dx.doi.org/10.1038/onc.2009.394			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19915617				2022-12-17	WOS:000274604400003
J	Cockrell, LM; Puckett, MC; Goldman, EH; Khuri, FR; Fu, H				Cockrell, L. M.; Puckett, M. C.; Goldman, E. H.; Khuri, F. R.; Fu, H.			Dual engagement of 14-3-3 proteins controls signal relay from ASK2 to the ASK1 signalosome	ONCOGENE			English	Article						ASK1; ASK2; 14-3-3; apoptosis; mitogen-activated protein kinase	KINASE KINASE KINASE; REGULATING KINASE-1; AMPHIPATHIC GROOVE; CELL-DEATH; APOPTOSIS; ACTIVATION; STRESS; 14-3-3-PROTEINS; PHOSPHORYLATION; DISSOCIATION	Faithful and efficient transmission of biological signals through mitogen-activated protein kinase (MAPK) pathways requires engagement of highly regulated cellular machinery in response to diverse environmental cues. Here, we report a novel mechanism controlling signal relay between two MAP3Ks, apoptosis signal-regulating kinase (ASK) 1 and ASK2. We show that ASK2 specifically interacts with 14-3-3 proteins through phosphorylated S964. Although a 14-3-3-binding defective mutant of ASK1 (S967A) has no effect on the ASK2/14-3-3 interaction, both overexpression of the analogous ASK2 (S964A) mutant and knockdown of ASK2 dramatically reduced the amount of ASK1 complexed with 14-3-3. These data suggest a dominant role of ASK2 in 14-3-3 control of ASK1 function. Indeed, ASK2 S964A-induced dissociation of 14-3-3 from ASK1 correlated with enhanced phosphorylation of ASK1 at T838 and increased c-Jun N-terminal kinase phosphorylation, the two biological readouts of ASK1 activation. Our results suggest a model in which upstream signals couple ASK2 S964 phosphorylation to the ASK1 signalosome through dual engagement of 14-3-3. Oncogene (2010) 29, 822-830; doi:10.1038/onc.2009.382; published online 23 November 2009	[Fu, H.] Emory Univ, Dept Pharmacol, Grad Div Biol & Biomed Sci, Program Mol & Syst Pharmacol,Rollins Res Ctr 5111, Atlanta, GA 30322 USA; [Cockrell, L. M.; Puckett, M. C.; Goldman, E. H.; Fu, H.] Emory Univ, Dept Pharmacol, Rollins Res Ctr, Atlanta, GA 30322 USA; [Khuri, F. R.; Fu, H.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Fu, H (corresponding author), Emory Univ, Dept Pharmacol, Grad Div Biol & Biomed Sci, Program Mol & Syst Pharmacol,Rollins Res Ctr 5111, 1510 Clifton Rd, Atlanta, GA 30322 USA.	hfu@emory.edu	Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618	National Cancer Institute [5F31CA117057]; National Science Foundation Facilitating Academic Careers in Engineering and Science Fellowship [0450303 (I6660663)]; NIH [T32 GM008602, RO1GM53165]; Emory URC; NIH/NCI [PO1CA116676, USAMRMC05075002]; NATIONAL CANCER INSTITUTE [F31CA117057, P01CA116676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053165, T32GM008602] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Science Foundation Facilitating Academic Careers in Engineering and Science Fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Emory URC; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the past and present members of the Fu laboratory for many stimulating discussions, as well as Zhengbin Yao for helpful suggestions. This work was supported by a National Cancer Institute National Research Service Award Grant 5F31CA117057 and a National Science Foundation Facilitating Academic Careers in Engineering and Science Fellowship 0450303 (I6660663) to LMC, an NIH Pharmacological Sciences Training Grant T32 GM008602 to MCP, NIH Grant RO1GM53165 and Emory URC grant to HF, and NIH/NCI Grant PO1CA116676 and USAMRMC05075002 to FRK and HF. HF is a Georgia Research Alliance Distinguished Investigator, and FRK and HF are Georgia Cancer Coalition Distinguished Cancer Scholars.	Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gardino AK, 2006, SEMIN CANCER BIOL, V16, P173, DOI 10.1016/j.semcancer.2006.03.007; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Imoto K, 2006, DIABETES, V55, P1197, DOI 10.2337/db05-1187; Iriyama T, 2009, EMBO J, V28, P843, DOI 10.1038/emboj.2009.32; Izumiya Y, 2003, CIRC RES, V93, P874, DOI 10.1161/01.RES.0000100665.67510.F5; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Min W, 2008, CIRC RES, V102, P840, DOI 10.1161/CIRCRESAHA.107.168153; Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003; Muslin AJ, 2005, CURR TOP DEV BIOL, V65, P211; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Osaka N, 2007, J CELL BIOL, V176, P903, DOI 10.1083/jcb.200611015; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Subramanian RR, 2004, EXP CELL RES, V294, P581, DOI 10.1016/j.yexcr.2003.12.009; Takeda K, 2008, ANNU REV PHARMACOL, V48, P199, DOI 10.1146/annurev.pharmtox.48.113006.094606; Takeda K, 2007, J BIOL CHEM, V282, P7522, DOI 10.1074/jbc.M607177200; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; Winter-Vann AM, 2007, J CELL BIOCHEM, V102, P848, DOI 10.1002/jcb.21522; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang LX, 1999, BIOCHEMISTRY-US, V38, P12159, DOI 10.1021/bi991019l; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790	34	22	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					822	830		10.1038/onc.2009.382	http://dx.doi.org/10.1038/onc.2009.382			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19935702				2022-12-17	WOS:000274397800005
J	Miao, L; Song, Z; Jin, L; Zhu, YM; Wen, LP; Wu, M				Miao, L.; Song, Z.; Jin, L.; Zhu, Y. M.; Wen, L. P.; Wu, M.			ARF antagonizes the ability of Miz-1 to inhibit p53-mediated transactivation	ONCOGENE			English	Article						p53; Miz-1; p14ARF; protein/protein interaction; transcription	CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; GENE-REGULATION; MYC; P53; ASSOCIATION; EXPRESSION; INK4A/ARF; P19(ARF); CANCER	Although Myc-interacting zinc-finger protein-1 (Miz-1) is known to be a poxvirus and zinc-finger (POZ) transcription factor required for Myc transcriptional repression, additional regulatory function of Miz-1 is less well understood. Using a yeast two-hybrid screen, we identified human alternate reading frame (ARF) protein as a novel interaction partner of Miz-1. The zinc-finger domain of Miz-1 is involved in its binding to ARF. In addition, we found that Miz-1 was able to interact with p53 through its DNA-binding domain, thus to diminish the binding of p53 to its target promoter and inhibit p53-mediated gene transcription. Interestingly, the Miz-1-regulated p53 transcriptional suppression does not require the presence of ARF or Mdm2. Importantly, ARF and p53 were found to competitively bind to Miz-1 in regulating p53-mediated transcription, and this conclusion was verified by both in vitro binding assay and competitive chromatin immunoprecipitation assay using a bona fide p53 endogenous Bax and Puma promoters. Thus, our study reveals that Miz-1 acts as a p53 suppressor by interfering with p53 DNA-binding ability, and ARF is able to counteract the suppression of Miz-1 on p53 by direct binding to Miz-1, suggesting that Miz-1 is a novel mediator in the ARF-p53 pathway. Oncogene (2010) 29, 711-722; doi: 10.1038/onc.2009.372; published online 9 November 2009	[Miao, L.; Jin, L.; Zhu, Y. M.; Wen, L. P.; Wu, M.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; [Miao, L.; Jin, L.; Zhu, Y. M.; Wen, L. P.; Wu, M.] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; [Song, Z.] CALTECH, Div Biol, Pasadena, CA 91125 USA	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; California Institute of Technology	Wu, M (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, 96 Huangshan Rd, Hefei 230027, Anhui, Peoples R China.	wumian@ustc.edu.cn	Jin, Lei/J-1896-2019; Wu, Mian/H-2494-2018	Jin, Lei/0000-0001-7187-9671; Wen, Longping/0000-0003-0384-4578; Wu, Mian/0000-0002-2714-0500	National Natural Science Foundation of China [30530200, 30728003, 30871290]; Ministry of Science and Technology of China [2006CB933300, 2006CB0N1402, 2006CB910300]; Chinese Academy of Sciences [KSCX1-YW-R-57]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Chinese Academy of Sciences(Chinese Academy of Sciences)	We thank Dr Nickie Chan for English checking and Dr Ratna B Ray for the plasmid pGL3-13-p53-Luc. This study was supported by grants from the National Natural Science Foundation of China (30530200, 30728003 and 30871290), the Ministry of Science and Technology of China (2006CB933300, 2006CB0N1402, and 2006CB910300) and the Chinese Academy of Sciences (KSCX1-YW-R-57).	Adhikary S, 2003, MOL CELL BIOL, V23, P7648, DOI 10.1128/MCB.23.21.7648-7657.2003; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Patel JH, 2007, J BIOL CHEM, V282, P5, DOI 10.1074/jbc.M609138200; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sakurai T, 2004, J BIOL CHEM, V279, P15505, DOI 10.1074/jbc.M310437200; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Suzuki H, 2005, BIOCHEM BIOPH RES CO, V326, P242, DOI 10.1016/j.bbrc.2004.11.016; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Zhao NX, 2004, J CELL BIOCHEM, V92, P65, DOI 10.1002/jcb.20025; Ziegelbauer J, 2004, P NATL ACAD SCI USA, V101, P458, DOI 10.1073/pnas.0307562100	39	22	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					711	722		10.1038/onc.2009.372	http://dx.doi.org/10.1038/onc.2009.372			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901969				2022-12-17	WOS:000274223700008
J	Zhang, J; Gonit, M; Salazar, MD; Shatnawi, A; Shemshedini, L; Trumbly, R; Ratnam, M				Zhang, J.; Gonit, M.; Salazar, M. D.; Shatnawi, A.; Shemshedini, L.; Trumbly, R.; Ratnam, M.			C/EBP alpha redirects androgen receptor signaling through a unique bimodal interaction	ONCOGENE			English	Article						androgen receptor; C/EBP alpha; prostate; prostate cancer	CCAAT/ENHANCER-BINDING-PROTEIN; PROSTATE-CANCER CELLS; GROWTH ARREST; DNA-BINDING; TRANSCRIPTIONAL COACTIVATOR; MOLECULAR-MECHANISMS; NUCLEAR RECEPTORS; MYELOID-LEUKEMIA; GENE-EXPRESSION; TERMINAL DOMAIN	Nuclear expression of CCAAT enhancer binding protein-alpha (C/EBP alpha), which supports tissue differentiation through several antiproliferative protein-protein interactions, augurs terminal differentiation of prostate epithelial cells. C/EBP alpha is also a tumor suppressor, but in many tumors its antiproliferative interactions may be attenuated by de-phosphorylation. C/EBP alpha acts as a corepressor of the classical androgen response element (ARE)-mediated gene activation by the androgen receptor (AR), but this is paradoxical as the genotropic actions of AR are crucial not only for the growth of the prostate but also for its maintenance and function. We show that DNA-bound C/EPB alpha recruits AR to activate transcription. C/EBP alpha-dependent trans-activation by AR also overrode suppression of AREs by C/EBP alpha elsewhere in a promoter. This mechanism was remarkable in that its androgen dependence was apparently for nuclear translocation of AR; it was otherwise androgen independent, flutamide insensitive and tolerant to disruption of AR dimerization. Gene response profiles and global chromatin associations in situ supported the direct bimodal regulation of AR transcriptional signaling by C/EBP alpha. This unique mechanism explains the functional coordination between AR and C/EPB alpha in the prostate and also shows that hormone-refractory AR signaling in prostate cancer could occur through receptor tethering. Oncogene (2010) 29, 723-738; doi: 10.1038/onc.2009.373; published online 9 November 2009	[Zhang, J.; Gonit, M.; Salazar, M. D.; Trumbly, R.; Ratnam, M.] Med Univ Ohio, Dept Biochem & Canc Biol, Toledo, OH 43614 USA; [Shatnawi, A.] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC USA; [Shemshedini, L.] Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; [Trumbly, R.] Med Univ Ohio, Bioinformat & Proteom Genom Core Div, Toledo, OH 43614 USA	Duke University; University System of Ohio; University of Toledo	Ratnam, M (corresponding author), Med Univ Ohio, Dept Biochem & Canc Biol, Block Hlth Sci Bldg,3000 Arlington Ave, Toledo, OH 43614 USA.	manohar.ratnam@utoledo.edu	Westall, Carol A/M-9646-2013; shatnawi, Aymen/AAF-5661-2020; Trumbly, Robert/AAF-6667-2020	Trumbly, Robert/0000-0001-5618-146X	NIH [CA 103964, CA 80183]; NATIONAL CANCER INSTITUTE [R01CA080183, R01CA103964] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by NIH R01 grants CA 103964 and CA 80183 to MR.	Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Baron S, 2004, J BIOL CHEM, V279, P14579, DOI 10.1074/jbc.M306143200; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Chattopadhyay S, 2006, MOL ENDOCRINOL, V20, P984, DOI 10.1210/me.2005-0240; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; Edwards J, 2005, BJU INT, V95, P1320, DOI 10.1111/j.1464-410X.2005.05526.x; Ettwiller L, 2007, NAT METHODS, V4, P563, DOI 10.1038/NMETH1061; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gery S, 2005, CLIN CANCER RES, V11, P3184, DOI 10.1158/1078-0432.CCR-04-2625; Glass CK, 2000, GENE DEV, V14, P121; Halmos B, 2002, CANCER RES, V62, P528; Han S, 2007, ANTI-CANCER DRUG, V18, P237, DOI 10.1097/CAD.0b013e328011e67d; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Jia L, 2005, CANCER RES, V65, P8003, DOI 10.1158/0008-5472.CAN-04-3679; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Loomis KD, 2007, CANCER RES, V67, P6768, DOI 10.1158/0008-5472.CAN-07-0139; Manolagas SC, 2001, ENDOCRINOLOGY, V142, P2200, DOI 10.1210/en.142.6.2200; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Miyamoto H, 2004, PROSTATE, V61, P332, DOI 10.1002/pros.20115; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Osada S, 1996, J BIOL CHEM, V271, P3891; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Paltoo D, 2003, CANCER LETT, V191, P67, DOI 10.1016/S0304-3835(02)00617-1; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/edrv-16-3-271; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Roy AK, 1999, VITAM HORM, V55, P309; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Safe S, 2004, PROG NUCLEIC ACID RE, V77, P1, DOI 10.1016/S0079-6603(04)77001-4; Schoenmakers E, 2000, J BIOL CHEM, V275, P12290, DOI 10.1074/jbc.275.16.12290; Schuster MB, 2006, BBA-REV CANCER, V1766, P88, DOI 10.1016/j.bbcan.2006.02.003; Shaffer PL, 2004, P NATL ACAD SCI USA, V101, P4758, DOI 10.1073/pnas.0401123101; Shand RL, 2006, CURR OPIN UROL, V16, P123, DOI 10.1097/01.mou.0000193384.39351.64; Shatnawi A, 2007, MOL ENDOCRINOL, V21, P635, DOI 10.1210/me.2006-0274; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Thomson AA, 2006, DIFFERENTIATION, V74, P382, DOI 10.1111/j.1432-0436.2006.00101.x; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Vlahopoulos S, 2005, J BIOL CHEM, V280, P7786, DOI 10.1074/JBC.m413992200; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Watkins PJ, 1996, CANCER RES, V56, P1063; Wettenhall JM, 2006, BIOINFORMATICS, V22, P897, DOI 10.1093/bioinformatics/btl025; Xu YY, 2006, CANCER RES, V66, P7783, DOI 10.1158/0008-5472.CAN-05-4472; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhang J, 2008, PROSTATE, V68, P1206, DOI 10.1002/pros.20779	68	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					723	738		10.1038/onc.2009.373	http://dx.doi.org/10.1038/onc.2009.373			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901962	Green Accepted			2022-12-17	WOS:000274223700009
J	Lin, KBL; Tan, P; Freeman, SA; Lam, M; McNagny, KM; Gold, MR				Lin, K. B. L.; Tan, P.; Freeman, S. A.; Lam, M.; McNagny, K. M.; Gold, M. R.			The Rap GTPases regulate the migration, invasiveness and in vivo dissemination of B-cell lymphomas	ONCOGENE			English	Article						B cells; lymphoma; Rap GTPase; cell migrationl extravasation	PYK2 TYROSINE PHOSPHORYLATION; CHEMOKINE; ACTIVATION; ADHESION; LYMPHOCYTES; RECEPTOR; POLARIZATION; MOTILITY	B-cell lymphomas are common malignancies in which transformed B cells enter the circulation, extravasate into tissues and form tumors in multiple organs. Lymphoma cells are thought to exit the vasculature and enter tissues through the same chemokine- and adhesion molecule-dependent mechanisms as normal B cells. We have previously shown that activation of the Rap GTPases, proteins that control cytoskeletal organization and integrin activation, is critical for chemokine-induced migration and adhesion in B-lymphoma cell lines. Using the A20 murine B-lymphoma cell line as a model, we now show that Rap activation is important for circulating lymphoma cells to enter tissues and form tumors in vivo. In vitro assays showed that Rap activation is required for A20 cells to efficiently adhere to vascular endothelial cells and undergo transendothelial migration. These findings suggest that Rap or its effectors could be novel targets for treating B-cell lymphomas. Oncogene (2010) 29, 608-615; doi: 10.1038/onc.2009.345; published online 19 October 2009	[Gold, M. R.] Univ British Columbia, Dept Microbiol & Immunol, Life Sci Ctr, Vancouver, BC V6T 1Z3, Canada; [Lin, K. B. L.; Freeman, S. A.; Gold, M. R.] Univ British Columbia, I3 Res Grp, Inst Life Sci, Vancouver, BC V6T 1Z3, Canada; [Lin, K. B. L.; Freeman, S. A.; Gold, M. R.] Univ British Columbia, CELL Res Grp, Inst Life Sci, Vancouver, BC V6T 1Z3, Canada; [Tan, P.; Lam, M.; McNagny, K. M.] Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Gold, MR (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, Life Sci Ctr, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mgold@interchange.ubc.ca	McNagny, Kelly/P-5239-2014; Gold, Michael/AAF-2081-2021	McNagny, Kelly/0000-0003-4737-3499; Gold, Michael/0000-0003-1222-3191	Canadian Institutes of Health Research [MOP-68865]; KMM [MOP-15477]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); KMM	We thank Andy Johnson of the UBC Flow Cytometry Facility and Goran Mansson of the LSI Imaging facility for technical assistance. This work was supported by grants from the Canadian Institutes of Health Research to MRG (GRANT MOP-68865) and KMM (GRANT MOP-15477). KMM is a Michael Smith Foundation for Health Research senior scholar.	Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Durand CA, 2006, EUR J IMMUNOL, V36, P2235, DOI 10.1002/eji.200535004; Gerard A, 2007, J CELL BIOL, V176, P863, DOI 10.1083/jcb.200608161; Goddard S, 2001, TRANSPLANTATION, V72, P1957, DOI 10.1097/00007890-200112270-00016; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; Jeon TJ, 2007, J CELL BIOL, V179, P833, DOI 10.1083/jcb.200705068; KIM KJ, 1979, J IMMUNOL, V122, P549; Krebs Danielle L., 1999, Methods in Cell Science, V21, P57, DOI 10.1023/A:1009843325770; Lin KBL, 2008, IMMUNITY, V28, P75, DOI 10.1016/j.immuni.2007.11.019; McLeod SJ, 2004, J BIOL CHEM, V279, P12009, DOI 10.1074/jbc.M313098200; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; McLeod SJ, 2002, J IMMUNOL, V169, P1365, DOI 10.4049/jimmunol.169.3.1365; Pals ST, 2007, BLOOD, V110, P3102, DOI 10.1182/blood-2007-05-075176; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; SIKORSKI EE, 1993, J IMMUNOL, V151, P5239; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; Thelen M, 2008, NAT IMMUNOL, V9, P953, DOI 10.1038/ni.f.207; Till KJ, 2008, CANCER RES, V68, P8429, DOI 10.1158/0008-5472.CAN-08-1758	20	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					608	615		10.1038/onc.2009.345	http://dx.doi.org/10.1038/onc.2009.345			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19838206				2022-12-17	WOS:000274084600013
J	Raimundo, N; Vanharanta, S; Aaltonen, LA; Hovatta, I; Suomalainen, A				Raimundo, N.; Vanharanta, S.; Aaltonen, L. A.; Hovatta, I.; Suomalainen, A.			Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas	ONCOGENE			English	Article						leiomyoma; mitochondria; fumarate hydratase; expression microarray; serum response factor	SERUM-RESPONSE FACTOR; RENAL-CELL CANCER; GENE-EXPRESSION; HEREDITARY LEIOMYOMATOSIS; GLUCOCORTICOID-RECEPTOR; TARGETED INACTIVATION; MITOCHONDRIAL DISEASE; HYPOXIA PATHWAY; KREBS CYCLE; PUR-BETA	Defects of metabolic enzymes result in a variety of manifestations not logically explained by the primary metabolic function. Dominant defects of fumarate hydratase (FH) result in predisposition to cutaneous and uterine leiomyomas, and renal cell cancer. FH is a metabolic enzyme of the tricarboxylic acid cycle, and its tumor-suppressor mechanism is not fully understood. We compared the consequences of FH deficiency and respiratory chain (RC) deficiency using global expression pattern of diploid primary fibroblasts. This approach utilized the information that RC defects do not seem to predispose to tumorigenesis, and the aim was to identify FH-specific signaling effects that might have relevance to tumor formation. These results were then compared to global expression patterns of FH-deficient and sporadic uterine leiomyoma data sets. We show here that FH-deficient fibroblasts share a common transcriptional fingerprint with FH-deficient and sporadic leiomyomas, highlighting the downregulation of serum response factor (SRF)-regulated transcripts, particularly the FOS-JUNB pathway. We confirmed the downregulation of this pathway at transcriptional and protein level. SRF has a fundamental function in the differentiation of smooth muscle progenitor cells, and its downregulation both in diploid FH-deficient primary fibroblasts and in leiomyomas suggests an early function in the mechanism of uterine leiomyoma formation in FH deficiency. Concordantly, the phosphorylated form of SRF, known to activate transcription, is undetectable in leiomyomas whereas clearly detected in several nuclei in the differentiated myometrium. A similar transcriptional SRF-pathway fingerprint in FH-deficient and sporadic leiomyomas emphasizes the potential importance of this pathway in primary events leading to leiomyomatosis.	[Raimundo, N.; Hovatta, I.; Suomalainen, A.] Univ Helsinki, Res Program Mol Neurol, FIN-00290 Helsinki, Finland; [Vanharanta, S.; Aaltonen, L. A.] Univ Helsinki, Res Program Genome Scale Biol, FIN-00290 Helsinki, Finland; [Vanharanta, S.; Aaltonen, L. A.; Hovatta, I.] Univ Helsinki, Dept Med Genet, FIN-00290 Helsinki, Finland; [Hovatta, I.] Natl Publ Hlth Inst, Dept Mol Med, Helsinki, Finland; [Hovatta, I.] Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, Helsinki, Finland; [Suomalainen, A.] Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00290 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital	Suomalainen, A (corresponding author), Univ Helsinki, Res Program Mol Neurol, Room c523B,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.	Anu.wartiovaara@helsinki.fi	Hovatta, Iiris/D-6871-2012; Aaltonen, Lauri/A-5375-2010; Raimundo, Nuno/AAD-9498-2020; Raimundo, Nuno/E-8357-2010	Hovatta, Iiris/0000-0002-5990-7892; Aaltonen, Lauri/0000-0001-6839-4286; Raimundo, Nuno/0000-0002-5988-9129; Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195	Helsinki Biomedical Graduate School; Sigrid Juselius Foundation; Centre of Excellence program of Academy of Finland; University of Helsinki; EMBO Young Investigator Program	Helsinki Biomedical Graduate School; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Centre of Excellence program of Academy of Finland(Academy of Finland); University of Helsinki; EMBO Young Investigator Program(European Molecular Biology Organization (EMBO))	We thank Heli Lehtonen for providing the paraffin sections and Markus Innila for skillful immunohistochemistry. The following funding sources are gratefully acknowledged: Helsinki Biomedical Graduate School (NR), Sigrid Juselius Foundation ( AS and LA), Centre of Excellence program of Academy of Finland and University of Helsinki ( AS and LA) and EMBO Young Investigator Program ( AS).; Financial support: Academy of Finland, Helsinki University, Sigrid Juselius Foundation ( for AS), Helsinki Biomedical Graduate School ( for NR).	Al Refae M, 2007, NAT CLIN PRACT ONCOL, V4, P256, DOI 10.1038/ncponc0773; Alam NA, 2003, HUM MOL GENET, V12, P1241, DOI 10.1093/hmg/ddg148; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Arslan AA, 2005, HUM REPROD, V20, P852, DOI 10.1093/humrep/deh698; Balza RO, 2006, J BIOL CHEM, V281, P6498, DOI 10.1074/jbc.M509487200; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; BOURGERON T, 1994, J CLIN INVEST, V93, P2514, DOI 10.1172/JCI117261; Campione E, 2007, J INVEST DERMATOL, V127, P2271, DOI 10.1038/sj.jid.5700851; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; Carvajal-Carmona LG, 2006, J CLIN ENDOCR METAB, V91, P3071, DOI 10.1210/jc.2006-0183; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Chai J, 2002, J PHYSIOL PHARMACOL, V53, P147; Chebotaev D, 2007, MOL CARCINOGEN, V46, P732, DOI 10.1002/mc.20349; Du KL, 2004, J BIOL CHEM, V279, P17578, DOI 10.1074/jbc.M400961200; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Hoffman PJ, 2004, FERTIL STERIL, V82, P639, DOI 10.1016/j.fertnstert.2004.01.047; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; Kelm RJ, 2003, J BIOL CHEM, V278, P38749, DOI 10.1074/jbc.M306163200; Le PP, 2005, PLOS GENET, V1, P159, DOI 10.1371/journal.pgen.0010016; Loeffen J, 2005, J INHERIT METAB DIS, V28, P799, DOI 10.1007/s10545-005-0044-7; Maradin M, 2006, J INHERIT METAB DIS, V29, P683, DOI 10.1007/s10545-006-0321-0; Marshall P, 2001, J BIOL CHEM, V276, P20719, DOI 10.1074/jbc.M102100200; MISRA RP, 1994, J BIOL CHEM, V269, P25483; Mittelstadt PR, 2003, MOL ENDOCRINOL, V17, P1534, DOI 10.1210/me.2002-0429; Parlakian A, 2004, MOL CELL BIOL, V24, P5281, DOI 10.1128/MCB.24.12.5281-5289.2004; Pipes GCT, 2006, GENE DEV, V20, P1545, DOI 10.1101/gad.1428006; Pollard P, 2005, J PATHOL, V205, P41, DOI 10.1002/path.1686; Pollard PJ, 2007, CANCER CELL, V11, P311, DOI 10.1016/j.ccr.2007.02.005; Pollard PJ, 2003, ANN MED, V35, P632, DOI 10.1080/07853890310018458; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Raimundo N, 2008, BBA-MOL BASIS DIS, V1782, P287, DOI 10.1016/j.bbadis.2008.01.008; Remes AM, 2004, J MOL MED, V82, P550, DOI 10.1007/s00109-004-0563-y; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Rustin P, 1997, BBA-MOL BASIS DIS, V1361, P185, DOI 10.1016/S0925-4439(97)00035-5; Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8; Shozu M, 2004, CANCER RES, V64, P4677, DOI 10.1158/0008-5472.CAN-03-0560; Smeitink JA, 2006, CELL METAB, V3, P9, DOI 10.1016/j.cmet.2005.12.001; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102; Vanharanta S, 2006, HUM MOL GENET, V15, P97, DOI 10.1093/hmg/ddi431; Walker CL, 2005, SCIENCE, V308, P1589, DOI 10.1126/science.1112063; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wei JJ, 2005, MODERN PATHOL, V18, P179, DOI 10.1038/modpathol.3800283; Weinhold B, 2000, EMBO J, V19, P5835, DOI 10.1093/emboj/19.21.5835; Ylisaukko-oja SK, 2006, EUR J HUM GENET, V14, P880, DOI 10.1038/sj.ejhg.5201630; Zhang SX, 2005, J BIOL CHEM, V280, P19115, DOI 10.1074/jbc.M413793200	52	22	22	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1261	1273		10.1038/onc.2008.472	http://dx.doi.org/10.1038/onc.2008.472			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151755				2022-12-17	WOS:000263906200010
J	Sagara, M; Kawasaki, Y; Iemura, S; Natsume, T; Takai, Y; Akiyama, T				Sagara, M.; Kawasaki, Y.; Iemura, S-i; Natsume, T.; Takai, Y.; Akiyama, T.			Asef2 and Neurabin2 cooperatively regulate actin cytoskeletal organization and are involved in HGF-induced cell migration	ONCOGENE			English	Article						APC; Asef2; Neurabin2/Spinophilin; HGF; filopodia; migration	TUMOR-SUPPRESSOR APC; EXCHANGE FACTOR; BINDING-PROTEIN; SPINOPHILIN; DOMAIN; CDC42; IDENTIFICATION; ACTIVATION; RELEASE; CANCER	The tumor suppressor adenomatous polyposis coli (APC) is mutated in sporadic and familial colorectal tumors. APC interacts with the Rac1- and Cdc42-specific guanine-nucleotide exchange factors (GEF), Asef and Asef2, which contain an APC-binding region (ABR) in addition to Dbl homology, Pleckstrin homology (PH) and Src homology 3 (SH3) domains. APC stimulates the GEF activity of Asef and Asef2, and thereby regulates cell adhesion and migration. Here we show that Asef2, but not Asef, interacts with Neurabin2/Spinophilin, a scaffold protein that binds to Filamentous actin (F-actin). In response to hepatocyte growth factor (HGF) treatment of HeLa cells, Asef2, Neurabin2 and APC were induced to accumulate and colocalize in lamellipodia and membrane ruffles. Neurabin2 did not affect the GEF activity of Asef2. RNA interference experiments showed that Asef2, Neurabin2 and APC are involved in HGF-induced cell migration. Furthermore, knockdown of Neurabin2 resulted in the suppression of Asef2-induced filopodia formation. These results suggest that Asef2, Neurabin2 and APC cooperatively regulate actin cytoskeletal organization and are required for HGF-induced cell migration.	[Akiyama, T.] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; [Iemura, S-i; Natsume, T.] Natl Inst Adv Ind Sci & Technol, Biomed Informat Res Ctr, Tokyo, Japan; [Takai, Y.] Kobe Univ, Grad Sch Med, Dept Biochem & Mol Biol, Div Mol & Cellular Biol, Kobe, Hyogo 657, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); Kobe University	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp	Natsume, Tohru/M-7627-2018	Natsume, Tohru/0000-0002-1510-2582	Japan Society for the Promotion of Science for Young Scientists	Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by Grants-in-Aid for Scientific Research on Priority Areas and the Organization for Pharmaceutical Safety and Research, Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists, and in part by Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan.	Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Futter M, 2005, P NATL ACAD SCI USA, V102, P3489, DOI 10.1073/pnas.0409802102; Hamann MJ, 2007, MOL CELL BIOL, V27, P1380, DOI 10.1128/MCB.01608-06; Itoh RE, 2008, J CELL SCI, V121, P2635, DOI 10.1242/jcs.028647; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kawasaki Y, 2007, ONCOGENE, V26, P7620, DOI 10.1038/sj.onc.1210574; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Mitin N, 2007, NAT STRUCT MOL BIOL, V14, P814, DOI 10.1038/nsmb1290; Murayama K, 2007, J BIOL CHEM, V282, P4238, DOI 10.1074/jbc.C600234200; Muroya K, 2007, BIOCHEM BIOPH RES CO, V355, P85, DOI 10.1016/j.bbrc.2007.01.131; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Polakis P, 2000, GENE DEV, V14, P1837; Ryan XZP, 2005, NEURON, V47, P85, DOI 10.1016/j.neuron.2005.05.013; Sarrouilhe D, 2006, BIOCHIMIE, V88, P1099, DOI 10.1016/j.biochi.2006.04.010; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Schuler H, 2008, FEBS J, V275, P59, DOI 10.1111/j.1742-4658.2007.06171.x; SU LK, 1995, CANCER RES, V55, P2972; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017	31	22	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1357	1365		10.1038/onc.2008.478	http://dx.doi.org/10.1038/onc.2008.478			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151759				2022-12-17	WOS:000264116000008
J	Moran, DM; Gawlak, G; Jayaprakash, MS; Mayar, S; Maki, CG				Moran, D. M.; Gawlak, G.; Jayaprakash, M. S.; Mayar, S.; Maki, C. G.			Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells	ONCOGENE			English	Article						HSP90; p53; micronuclei; radiation	INDUCED GENOMIC INSTABILITY; TUMOR-CELLS; CHROMOSOMAL INSTABILITY; IONIZING-RADIATION; G(2) CHECKPOINT; G1 CHECKPOINT; PHASE-I; S-PHASE; P53; INHIBITOR	P53 wild-type and p53-null or mutant cells undergo a G2-phase cell-cycle arrest in response to ionizing radiation (IR). In this study we examined the effect of heat-shock protein 90 (HSP90) inhibitor, geldanamycin (GA), on IR-induced G2 arrest in human colon adenocarcinoma cells with different p53 status. We show that GA treatment abrogates IR-induced G2-phase arrest in cells null or mutant for p53. Specifically, GA treatment pushed irradiated p53 signaling-defective cells into a premature mitosis characterized by aberrant mitotic figures, increased gamma H2AX expression and formation of micronucleated cells. Cells expressing wild-type p53 were resistant to GA-induced G2 checkpoint abrogation. Notably, GA treatment decreased levels of G2 regulatory proteins Wee1 and Chk1, and inhibitory phosphorylation of Cdc2, independent of p53 status. Further investigation identified p21 as the potential downstream effector of p53 that mediates resistance to G2 checkpoint abrogation. Clonogenic survival studies demonstrated higher sensitivity to GA alone or combination IR plus GA treatment in p53 and p21-null cells. Collectively, these data demonstrate potential mechanisms through which HSP90 inhibition can enhance the effects of ionizing radiation in p53compromised cancer cells. Combination IR plus HSP90 inhibitor therapies may be particularly useful in treating cancers that lack wild-type p53.	[Moran, D. M.; Gawlak, G.; Jayaprakash, M. S.; Mayar, S.; Maki, C. G.] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	University of Chicago	Maki, CG (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, 5841 S Maryland Ave,MC1105,Room G-06, Chicago, IL 60637 USA.	cmaki@rover.uchicago.edu			National Institutes of Health [RO1 CA080918]; NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health Grant RO1 CA080918.	Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612; Bisht KS, 2003, CANCER RES, V63, P8984; Bull EEA, 2004, CLIN CANCER RES, V10, P8077, DOI 10.1158/1078-0432.CCR-04-1212; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dixon H, 2002, CELL CYCLE, V1, P362, DOI 10.4161/cc.1.6.257; Dote H, 2006, CANCER RES, V66, P9211, DOI 10.1158/0008-5472.CAN-06-2181; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Goes FS, 2001, EUR J BIOCHEM, V268, P2281, DOI 10.1046/j.1432-1327.2001.02105.x; Grem JL, 2005, J CLIN ONCOL, V23, P1885, DOI 10.1200/JCO.2005.12.085; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Inoue T, 2001, J BIOL CHEM, V276, P45255, DOI 10.1074/jbc.M107477200; Jackson JR, 2000, CANCER RES, V60, P566; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kawabe T, 2004, MOL CANCER THER, V3, P513; Limoli CL, 1997, CANCER RES, V57, P5557; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Noguchi M, 2006, BIOCHEM BIOPH RES CO, V351, P658, DOI 10.1016/j.bbrc.2006.10.094; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005; Rahmani M, 2003, CANCER RES, V63, P8420; RIEDER CL, 1992, J CELL SCI, V102, P387; Robles AI, 2006, CLIN CANCER RES, V12, P6547, DOI 10.1158/1078-0432.CCR-06-1178; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Russell KJ, 1996, INT J RADIAT ONCOL, V36, P1099, DOI 10.1016/S0360-3016(96)00432-4; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sasaki M, 2007, J BIOL CHEM, V282, P14626, DOI 10.1074/jbc.M610514200; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shintani S, 2006, INT J ONCOL, V29, P1111; SUGIMOTO K, 2007, ONCOGENE; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YL, 2004, CANCER BIOL THER, V3, P305, DOI 10.4161/cbt.3.3.697; Wang YL, 2001, CANCER RES, V61, P8211; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716	42	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2008	27	42					5567	5577		10.1038/onc.2008.172	http://dx.doi.org/10.1038/onc.2008.172			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504430	Green Accepted			2022-12-17	WOS:000259280800003
J	Kouzmenko, AP; Takeyama, K; Kawasaki, Y; Akiyama, T; Kato, S				Kouzmenko, A. P.; Takeyama, K.; Kawasaki, Y.; Akiyama, T.; Kato, S.			Truncation mutations abolish chromatin-associated activities of adenomatous polyposis coli	ONCOGENE			English	Article						adenomatous polyposis coli; chromatin; nuclear protein complexes; DNA repair	DOUBLE-STRAND BREAKS; BETA-CATENIN DEGRADATION; COLORECTAL TUMOR-CELLS; GENETIC INSTABILITY; APC MUTATIONS; SUBCELLULAR-LOCALIZATION; CHROMOSOMAL INSTABILITY; NUCLEAR RECEPTOR; UBIQUITIN LIGASE; DIOXIN RECEPTOR	The adenomatous polyposis coli (APC) is a tumor suppressor whose loss of function leads to colon cancer. APC shuttles between the nucleus and cytoplasm, however its role in the nucleus remains elusive. We have found that nuclear APC specifically associates with transcriptionally active chromatin through structural elements located downstream to the region of frequent truncation mutations found in colorectal tumors. We show that a recombinant APC fragment comprising such elements associates in vivo with euchromatin and preferentially binds in vitro to acetylated histone H3. Induction of DNA double-strand breaks (DSB) stimulates accumulation of APC at the damaged DNA chromatin marked by histone H2AX and S139-phosphorylated histone H2AX. A nuclear complex containing the DNA-dependent protein kinase catalytic subunit (DNAPKcs) and APC associates with chromatin in response to DNA DSB. APC knockdown with siRNA decreased the rate of DNA DSB-induced S139 histone H2AX phosphorylation in cells expressing endogenous full-length APC, but not in colon cancer cells with its truncation mutants, whereas ectopic APC expression stimulated the H2AX phosphorylation regardless of the type of endogenous APC. Our data suggest that APC involves in the DSB DNA repair and that truncation mutations impair chromatin-associated functions of APC.	[Kouzmenko, A. P.; Takeyama, K.; Kawasaki, Y.; Akiyama, T.; Kato, S.] Univ Tokyo, Inst Mol & Cellular Biosci, Dept Nucl Signaling, Bunkyo Ku, Tokyo 1130032, Japan; [Kouzmenko, A. P.; Kato, S.] Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Dept Nucl Signaling, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.	alexk@iam.u-tokyo.ac.jp; uskato@mail.ecc.u-tokyo.ac.jp			Program for Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN); Ministry of Education, Culture, Sports, Science and Technology; Exploratory Research for Advanced Technology (ERATO); Japan Science and Technology Agency (JST)	Program for Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN); Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Exploratory Research for Advanced Technology (ERATO)(Japan Science & Technology Agency (JST)); Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST))	We thank Professor AW Burgess (Ludwig Institute for Cancer Research, Melbourne Branch) for critical reading of the paper and members of the Department of Nuclear Signaling for constructive discussions, advice and support. This study was funded in part by the Program for Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN) and priority areas from the Ministry of Education, Culture, Sports, Science and Technology (to SK), and by the Kato Nuclear Complex Project grant from the Exploratory Research for Advanced Technology (ERATO), Japan Science and Technology Agency (JST).	Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brocardo M, 2005, EMBO REP, V6, P184, DOI 10.1038/sj.embor.7400329; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Dempke W, 2000, ANTI-CANCER DRUG, V11, P225, DOI 10.1097/00001813-200004000-00001; Fagman H, 2003, ONCOGENE, V22, P6013, DOI 10.1038/sj.onc.1206731; Faux MC, 2004, J CELL SCI, V117, P427, DOI 10.1242/jcs.00862; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gaasenbeek M, 2006, CANCER RES, V66, P3471, DOI 10.1158/0008-5472.CAN-05-3285; Gounari F, 2005, NAT IMMUNOL, V6, P800, DOI 10.1038/ni1228; Green RA, 2003, J CELL BIOL, V163, P949, DOI 10.1083/jcb.200307070; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Homfray TFR, 1998, HUM MUTAT, V11, P114, DOI 10.1002/(SICI)1098-1004(1998)11:2<114::AID-HUMU3>3.0.CO;2-J; Ishiguro K, 2006, GUT, V55, P695, DOI 10.1136/gut.2005.079459; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kawasaki Y, 2007, ONCOGENE, V26, P7620, DOI 10.1038/sj.onc.1210574; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; KOUZMENKO AP, 2008, GENES CELLS IN PRESS; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Li ZY, 2005, CANCER RES, V65, P5195, DOI 10.1158/0008-5472.CAN-04-4609; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Memezawa A, 2007, ONCOGENE, V26, P5038, DOI 10.1038/sj.onc.1210320; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Morrison AJ, 2005, CELL CYCLE, V4, P568; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Nathke I, 2006, NAT REV CANCER, V6, P967, DOI 10.1038/nrc2010; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Neufeld KL, 2000, EMBO REP, V1, P519; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683; Osley MA, 2006, TRENDS GENET, V22, P671, DOI 10.1016/j.tig.2006.09.007; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Schneikert J, 2007, HUM MOL GENET, V16, P199, DOI 10.1093/hmg/ddl464; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shih IM, 2001, CANCER RES, V61, P818; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Steffensen IL, 2005, MUTAT RES-GEN TOX EN, V587, P73, DOI 10.1016/j.mrgentox.2005.07.004; Steffensen IL, 2006, MUTAT RES-GEN TOX EN, V611, P71, DOI 10.1016/j.mrgentox.2006.07.004; Strom A, 2007, DEVELOPMENT, V134, P2719, DOI 10.1242/dev.02875; Tighe A, 2004, J CELL SCI, V117, P6339, DOI 10.1242/jcs.01556; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	65	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4888	4899		10.1038/onc.2008.127	http://dx.doi.org/10.1038/onc.2008.127			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18454178				2022-12-17	WOS:000258596900003
J	van der Weyden, L; Arends, MJ; Dovey, OM; Harrison, HL; Lefebvre, G; Conte, N; Gergely, FV; Bradley, A; Adams, DJ				van der Weyden, L.; Arends, M. J.; Dovey, O. M.; Harrison, H. L.; Lefebvre, G.; Conte, N.; Gergely, F. V.; Bradley, A.; Adams, D. J.			Loss of Rassf1a cooperates with Apc(Min) to accelerate intestinal tumourigenesis	ONCOGENE			English	Article						adenoma; adenocarcinoma; RASSF; APC; beta-catenin	TUMOR-SUPPRESSOR RASSF1A; COLORECTAL-CANCER; CODING VARIATION; MOUSE; MUTATIONS; NEOPLASIA; COMPLEX; GENOME; MICE; HYPERMETHYLATION	Promoter methylation of the RAS-association domain family 1, isoform A gene (RASSF1A) is one of the most frequent events found in human tumours. In this study we set out to test the hypothesis that loss of Rassf1a can cooperate with inactivation of the adenomatous polyposis coli (Apc) gene to accelerate intestinal tumourigenesis using the Apc-Min (Apc(Min/+)) mouse model, as mutational or deletional inactivation of APC is a frequent early event in the genesis of intestinal cancer. Further, loss of RASSF1A has also been reported to occur in premalignant adenomas of the bowel. RASSF1A has been implicated in an array of pivotal cellular processes, including regulation of the cell cycle, apoptosis, microtubule stability and most recently in the beta-catenin signalling pathway. By interbreeding isoform specific Rassf1a knockout mice with Apc(+/Min) mice, we showed that loss of Rassf1a results in a significant increase in adenomas of the small intestine and accelerated intestinal tumourigenesis leading to the earlier death of adenocarcinoma-bearing mice and decreased overall survival. Comparative genomic hybridization of adenomas from Rassf1a(-/-); Apc(+/Min) mice revealed no evidence of aneuploidy or gross chromosomal instability (no difference to adenomas from Rassf1a(+/+); Apc(+/Min) mice). Immunohistochemical analysis of adenomas revealed increased nuclear beta-catenin accumulation in adenomas from Rassf1a(-/-); Apc(+/Min) mice, compared to those from Rassf1a(+/+); Apc(+/Min) mice, but no differences in proliferation marker (Ki67) staining patterns. Collectively these data demonstrate cooperation between inactivation of Rassf1a and Apc resulting in accelerated intestinal tumourigenesis, with adenomas showing increased nuclear accumulation of beta-catenin, supporting a mechanistic link via loss of the known interaction of Rassf1 with beta-TrCP that usually mediates degradation of beta-catenin.	[van der Weyden, L.; Dovey, O. M.; Harrison, H. L.; Lefebvre, G.; Conte, N.; Bradley, A.; Adams, D. J.] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; [Arends, M. J.] Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2QQ, England; [Gergely, F. V.] Cambridge Res Inst, Dept Oncol, Li Ka Shing Ctr, Cambridge, England	Wellcome Trust Sanger Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; CRUK Cambridge Institute; University of Cambridge	van der Weyden, L (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	lvdw@sanger.ac.uk	van der Weyden, Louise/AAV-5711-2021	van der Weyden, Louise/0000-0002-0645-1879; Harrison, Hannah/0000-0002-0054-8047; Conte, Nathalie/0000-0002-1010-3121; Adams, David/0000-0001-9490-0306; Bradley, Allan/0000-0002-2349-8839; Gergely, Fanni/0000-0002-2441-8095	Cancer Research UK [A8449] Funding Source: Medline; Wellcome Trust [079643] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Adams DJ, 2005, NAT GENET, V37, P532, DOI 10.1038/ng1551; Alberici P, 2007, AM J PATHOL, V170, P377, DOI 10.2353/ajpath.2007.060853; Carothers AM, 2001, J BIOL CHEM, V276, P39094, DOI 10.1074/jbc.M103450200; Chung YJ, 2004, GENOME RES, V14, P188, DOI 10.1101/gr.1878804; Cunningham F, 2006, NAT GENET, V38, P853, DOI 10.1038/ng0806-853a; Estrabaud E, 2007, CANCER RES, V67, P1054, DOI 10.1158/0008-5472.CAN-06-2530; GERDES J, 1984, J IMMUNOL, V133, P1710; Graubert TA, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030003; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Lee S, 2004, LAB INVEST, V84, P884, DOI 10.1038/labinvest.3700108; LUONGO C, 1994, CANCER RES, V54, P5947; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Oliveira C, 2005, ONCOGENE, V24, P7630, DOI 10.1038/sj.onc.1208906; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Tommasi S, 2005, CANCER RES, V65, P92; van Amerongen R, 2006, TRENDS GENET, V22, P678, DOI 10.1016/j.tig.2006.10.001; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466	25	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4503	4508		10.1038/onc.2008.94	http://dx.doi.org/10.1038/onc.2008.94			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391979	Green Accepted			2022-12-17	WOS:000257881700013
J	Goda, AE; Yoshida, T; Horinaka, M; Yasuda, T; Shiraishi, T; Wakada, M; Sakai, T				Goda, A. E.; Yoshida, T.; Horinaka, M.; Yasuda, T.; Shiraishi, T.; Wakada, M.; Sakai, T.			Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole	ONCOGENE			English	Article						dipyridamole; TRAIL; DR5; survivin; D-type cyclins; cdk6	APOPTOSIS-INDUCING LIGAND; DEATH RECEPTOR 5/TRAIL-R2; METHOTREXATE CYTOTOXICITY; IN-VITRO; SURVIVIN; TUMOR; PROLIFERATION; ACTIVATION; INHIBITION; CASPASE-3	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has emerged as an attractive cytokine that selectively targets cancer cells, however its efficacy has been challenged by a number of resistance mechanisms. Therefore, the current study investigated the potential of dipyridamole to enhance TRAIL efficacy and the probable underlying mechanisms. Dipyridamole dramatically sensitized p53-mutant human cancer cell lines: SW480, MG63 and DU145, to the antitumor activity of TRAIL, as evidenced by enabling TRAIL to efficiently cleave initiator and executioner caspases. Although dipyridamole upregulated both DR4 and DR5 and increased their cell surface expression, RNA interference revealed a preferential dependence on DR5. Moreover, dipyridamole inhibited survivin expression and its important consequences were confirmed by small interfering RNA. Mechanistically, dipyridamole induced transcriptional shutdown of survivin expression accompanying G(1) arrest that was characterized by downregulation of D-type cyclins and cdk6. In addition, a transcriptional mechanism powered by CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) induction was responsible for DR5 upregulation by dipyridamole. Importantly, dipyridamole-induced enhancement of TRAIL efficacy and alterations of protein expression were independent of either protein kinase A or protein kinase G. In conclusion, findings of the present study described novel mechanisms of dipyridamole action and highlighted its promising use as a potential enhancer of TRAIL efficacy.	[Goda, A. E.; Yoshida, T.; Horinaka, M.; Yasuda, T.; Wakada, M.; Sakai, T.] Kyoto Prefectural Univ Med, Dept Mol Targeting Canc Prevent, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan; [Goda, A. E.] Tanta Univ, Dept Pharmacol & Toxicol, Fac Pharm, Tanta, Egypt; [Yasuda, T.; Shiraishi, T.] Kyoto Prefectural Univ Med, Dept Urol, Grad Sch Med Sci, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine; Egyptian Knowledge Bank (EKB); Tanta University; Kyoto Prefectural University of Medicine	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Dept Mol Targeting Canc Prevent, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp	Goda, Ahmed/AAA-4688-2020	Goda, Ahmed/0000-0001-8200-6104				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Azuhata T, 2006, J PEDIATR SURG, V41, P1431, DOI 10.1016/j.jpedsurg.2006.04.020; Carlo-Stella C, 2007, CLIN CANCER RES, V13, P2313, DOI 10.1158/1078-0432.CCR-06-2774; CLARKE WR, 1994, PULM PHARMACOL, V7, P81, DOI 10.1006/pulp.1994.1009; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Hung KY, 2001, KIDNEY INT, V60, P872, DOI 10.1046/j.1523-1755.2001.060003872.x; Kappler M, 2004, CANCER GENE THER, V11, P186, DOI 10.1038/sj.cgt.7700677; Kelley RF, 2005, J BIOL CHEM, V280, P2205, DOI 10.1074/jbc.M410660200; KENNEDY DG, 1986, BIOCHEM PHARMACOL, V35, P3053, DOI 10.1016/0006-2952(86)90385-0; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin J, 2001, ONCOGENE, V20, P2000, DOI 10.1038/sj.onc.1204375; Lu ML, 2005, J BIOL CHEM, V280, P6742, DOI 10.1074/jbc.M411519200; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Pirnia F, 2002, CELL DEATH DIFFER, V9, P905, DOI 10.1038/sj.cdd.4401062; Ren YG, 2004, MOL BIOL CELL, V15, P5064, DOI 10.1091/mbc.e04-03-0184; Rodrigues M, 2004, BRAZ J MED BIOL RES, V37, P591, DOI 10.1590/S0100-879X2004000400017; Saito S, 2003, BIOCHEM BIOPH RES CO, V311, P17, DOI 10.1016/j.bbrc.2003.09.161; SALZMAN EW, 1972, ANN NY ACAD SCI, V201, P61, DOI 10.1111/j.1749-6632.1972.tb16287.x; SATO S, 1993, ANTI-CANCER DRUG DES, V8, P289; Shiraishi T, 2005, CANCER RES, V65, P6364, DOI 10.1158/0008-5472.CAN-05-0312; Thompson KL, 2003, TOXICOL SCI, V74, P260, DOI 10.1093/toxsci/kfg113; Van Geelen CMM, 2004, DRUG RESIST UPDATE, V7, P345, DOI 10.1016/j.drup.2004.11.002; VANMOUWERIK TJ, 1987, BIOCHEM PHARMACOL, V36, P809, DOI 10.1016/0006-2952(87)90168-7; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yoshida T, 2005, CANCER RES, V65, P5662, DOI 10.1158/0008-5472.CAN-05-0693; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Yoshida T, 2007, MOL CANCER RES, V5, P615, DOI 10.1158/1541-7786.MCR-06-0045; Zhang M, 2006, J EXP CLIN CANC RES, V25, P391; Zhuplatov SB, 2006, BASIC CLIN PHARMACOL, V99, P431, DOI 10.1111/j.1742-7843.2006.pto_516.x	35	22	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3435	3445		10.1038/sj.onc.1211008	http://dx.doi.org/10.1038/sj.onc.1211008			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193086				2022-12-17	WOS:000256309900008
J	Sugimoto, K; Sasaki, M; Isobe, Y; Tsutsui, M; Suto, H; Ando, J; Tamayose, K; Ando, M; Oshimi, K				Sugimoto, K.; Sasaki, M.; Isobe, Y.; Tsutsui, M.; Suto, H.; Ando, J.; Tamayose, K.; Ando, M.; Oshimi, K.			Hsp90-inhibitor geldanamycin abrogates G(2) arrest in p53-negative leukemia cell lines through the depletion of Chk1	ONCOGENE			English	Article						Hsp90; geldanamycin; Chk1; G(2) arrest	DNA-DAMAGE; ANSAMYCINS CAUSES; PROTEIN-KINASE; TUMOR-CELLS; HSP90; CHECKPOINT; INHIBITION; APOPTOSIS; CYCLE; RADIOSENSITIZATION	Checkpoint protein Chk1 has been identified as an Hsp90 client. Treatment with 100 nM geldanamycin (GM) for 24 h markedly reduced the Chk1 amount in Jurkat and ML-1 leukemia cell lines. Because Chk1 plays a central role in G(2) checkpoint, we added GM to G(2)-arrested Jurkat and HL-60 cells pretreated with 50 nM doxorubicin for 24 h. GM slowly released both cell lines from doxorubicin-induced G(2) arrest into G(1) phase. GM also abrogated ICRF-193-induced decatenation G(2) checkpoint in Jurkat and HL-60 cells. Western blot analysis showed that addition of GM attenuates doxorubicin-and ICRF193-induced Chk1 phosphorylation at Ser345. GM, however, failed to abrogate G(2) arrest in p53-positive ML-1 cells maybe due to the p21 induction. GM released HeLa cells from doxorubicin-induced G(2) arrest but trapped them at M phase. Flow cytometric analysis showed that addition of GM converted doxorubicin-induced necrosis into apoptosis in Jurkat cells. Colony assay indicated that although GM has a weak cytotoxic effect as a single agent, it dramatically intensifies the cytotoxicity of doxorubicin and ICRF-193 in Jurkat and HL-60 cells. These results suggest that abrogation of G(2) checkpoint by GM may play a central role in sensitizing p53-negative tumor cells to DNA-damaging and decate-nation-inhibiting agents.	[Sugimoto, K.; Sasaki, M.; Isobe, Y.; Tsutsui, M.; Suto, H.; Ando, J.; Tamayose, K.; Ando, M.; Oshimi, K.] Juntendo Univ, Sch Med, Dept Internal Med, Div Hematol,Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University	Sugimoto, K (corresponding author), Juntendo Univ, Sch Med, Dept Internal Med, Div Hematol,Bunkyo Ku, Hongo 2-1-1, Tokyo 1138421, Japan.	ksugimot@med.juntendo.ac.jp						ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Bisht KS, 2003, CANCER RES, V63, P8984; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Bull EEA, 2004, CLIN CANCER RES, V10, P8077, DOI 10.1158/1078-0432.CCR-04-1212; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; de Carcer G, 2004, CANCER RES, V64, P5106, DOI 10.1158/0008-5472.CAN-03-2214; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FAN SJ, 1995, CANCER RES, V55, P1649; Gorre ME, 2002, BLOOD, V100, P3041, DOI 10.1182/blood-2002-05-1361; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Jones DT, 2004, BLOOD, V103, P1855, DOI 10.1182/blood-2003-05-1603; Kawabe T, 2004, MOL CANCER THER, V3, P513; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kohn EA, 2003, CANCER RES, V63, P31; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Mesa RA, 2005, BLOOD, V106, P318, DOI 10.1182/blood-2004-09-3523; Minami Y, 2002, LEUKEMIA, V16, P1535, DOI 10.1038/sj.leu.2402558; Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood-2005-03-1158; Munster PN, 2001, CANCER RES, V61, P2945; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POWELL SN, 1995, CANCER RES, V55, P1643; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Srethapakdi M, 2000, CANCER RES, V60, P3940; Sugimoto K, 2000, BRIT J HAEMATOL, V110, P819, DOI 10.1046/j.1365-2141.2000.02304.x; Sugimoto K, 1998, BLOOD, V91, P1407, DOI 10.1182/blood.V91.4.1407; Sugimoto K, 2002, BRIT J HAEMATOL, V118, P229, DOI 10.1046/j.1365-2141.2002.03577.x; Tse AN, 2004, CANCER RES, V64, P6635, DOI 10.1158/0008-5472.CAN-04-0841; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200	44	22	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3091	3101		10.1038/sj.onc.1210978	http://dx.doi.org/10.1038/sj.onc.1210978			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071310				2022-12-17	WOS:000255897600002
J	Campanero, MR; Herrero, A; Calvo, V				Campanero, M. R.; Herrero, A.; Calvo, V.			The histone deacetylase inhibitor trichostatin A induces GADD45 gamma expression via Oct and NF-Y binding sites	ONCOGENE			English	Article						GADD45 gamma; HDAC inhibitor; TSA; Oct; NF-Y	TRANSCRIPTION FACTORS OCT-1; GROWTH-ARREST; CELL-GROWTH; P53-INDEPENDENT INDUCTION; GENOTOXIC STRESS; CANCER CELLS; GENE GADD45; DNA-DAMAGE; PROMOTER; RECRUITMENT	The GADD45 gamma protein is a potential tumor suppressor whose expression is reduced in several tumors. However, very little is known about the regulation of its expression. We have determined that the most relevant region of its promoter lies between nucleotides -112 and -54, relative to the transcription start site. Putative Oct and NF-Y elements were found in this region and factors belonging to these families interacted with these elements in vitro and with the promoter in vivo. Mutation of these elements reduced the basal activity of the promoter, suggesting that both sites are essential for basal expression. These factors interact with chromatin modifying proteins and we found that histone deacetylase 1 or silencing mediator for retinoid and thyroid hormone receptor overexpression reduced the basal activity of the promoter. In contrast, forced expression of the histone acetylase protein PCAF or cell treatment with the HDAC inhibitor trichostatin A increased GADD45 gamma mRNA levels and induced GADD45 gamma promoter activity through its Oct and NF-Y elements. Moreover, ectopic expression of a dominant-negative version of NF-YA strongly inhibited trichostatin A-induced activation of the promoter. Our data strongly suggest that inhibition of deacetylase activity could potentially be used for treatment of tumors where GADD45 gamma expression is reduced.	[Herrero, A.; Calvo, V.] Univ Autonoma Madrid, Fac Med, CSIC, E-28029 Madrid, Spain; [Campanero, M. R.] Univ Autonoma Madrid, Inst Invest Biomed, CSIC, Madrid, Spain; [Herrero, A.; Calvo, V.] Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Calvo, V (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Arzobiospo Morcillo 4, E-28029 Madrid, Spain.	vcalvo@iib.uam.es	HERRERO, ANA/GOV-3351-2022; Campanero, Miguel R/A-4052-2013; Calvo, Victor/L-5024-2014	HERRERO, ANA/0000-0001-8065-2225; Campanero, Miguel R/0000-0003-1410-8621; Calvo, Victor/0000-0002-5913-7058				Balliet AG, 2003, DNA CELL BIOL, V22, P457, DOI 10.1089/104454903322247334; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Brockman JL, 2005, MOL CELL ENDOCRINOL, V239, P45, DOI 10.1016/j.mce.2005.04.006; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Campanero MR, 1999, MOL CELL BIOL, V19, P8442; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; Chung HK, 2003, J CLIN ENDOCR METAB, V88, P3913, DOI 10.1210/jc.2002-022031; Constance CM, 1996, MOL CELL BIOL, V16, P3878; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Fan W, 1999, ONCOGENE, V18, P6573, DOI 10.1038/sj.onc.1203054; HINKLEY C, 1992, MOL CELL BIOL, V12, P4400, DOI 10.1128/MCB.12.10.4400; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jiang F, 2004, MOL CELL ENDOCRINOL, V213, P121, DOI 10.1016/j.mce.2003.10.050; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jung N, 2000, EUR J BIOCHEM, V267, P6180, DOI 10.1046/j.1432-1327.2000.01692.x; Kakizawa T, 2001, J BIOL CHEM, V276, P9720, DOI 10.1074/jbc.M008531200; Kojima S, 1999, FEBS LETT, V446, P313, DOI 10.1016/S0014-5793(99)00234-3; Liebermann DA, 2003, BLOOD CELL MOL DIS, V31, P213, DOI 10.1016/S1079-9796(03)00160-8; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; Lu BF, 2001, IMMUNITY, V14, P583, DOI 10.1016/S1074-7613(01)00141-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mariadason JM, 2000, CANCER RES, V60, P4561; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakayama K, 1999, J BIOL CHEM, V274, P24766, DOI 10.1074/jbc.274.35.24766; Osborne A, 2001, MOL CELL BIOL, V21, P6495, DOI 10.1128/MCB.21.19.6495-6506.2001; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Peng YW, 2003, J BIOL CHEM, V278, P8385, DOI 10.1074/jbc.M213156200; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Sun LH, 2003, MOL BIOL REP, V30, P249, DOI 10.1023/A:1026370726763; Takahashi S, 2001, CANCER RES, V61, P1187; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689; ZHAN QM, 1994, CANCER RES, V54, P2755; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885; Zhang W, 2001, INT J ONCOL, V18, P749; Zhang X, 2002, J CLIN ENDOCR METAB, V87, P1262, DOI 10.1210/jc.87.3.1262	50	22	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1263	1272		10.1038/sj.onc.1210735	http://dx.doi.org/10.1038/sj.onc.1210735			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724474				2022-12-17	WOS:000253407000008
J	Lee, JA; Park, JE; Lee, DH; Park, SG; Myung, PK; Park, BC; Cho, S				Lee, J. A.; Park, J. E.; Lee, D. H.; Park, S. G.; Myung, P. K.; Park, B. C.; Cho, S.			G(1) to S phase transition protein 1 induces apoptosis signal-regulating kinase 1 activation by dissociating 14-3-3 from ASK1	ONCOGENE			English	Article						apoptosis; apoptosis signal-regulating kinase 1; G(1) to S phase transition 1; mitogen-activated protein kinase	BINDING PROTEIN; TRANSLATION TERMINATION; CELL-DEATH; PROLIFERATION; THIOREDOXIN; INHIBITOR; STRESS; DAXX	Apoptosis signal-regulating kinase 1 (ASK1), a member of the mitogen-activated protein kinase kinase kinase family, plays a critical role in mediating apoptosis signals initiated by a variety of death stimuli such as hydrogen peroxide and tumor necrosis factor-a. Owing to its critical role in inducing apoptosis, the activity of ASK1 is tightly regulated by various mechanisms such as post-translational modi. cations and protein-protein interactions. Here we describe the identification of G(1) to S phase transition protein 1 (GSPT1), which is associated with protein translation, as a regulator of ASK1. GSPT1 interacts with ASK1 and enhances ASK1-induced apoptotic activity through the activation of caspase-3. In vitro kinase assay data show that GSPT1 enhances ASK1 autophosphorylation and its kinase activity. Cell cycle-dependent GSPT1 induction and small interfering RNA analyses show that ASK1 autophosphorylation is dependent on the expression level of endogenous GSPT1 in cells. GSPT1 inhibits the binding of ASK1 to the 14-3-3 protein, an ASK1 inhibitor, while GSPT1 has no effect on the interaction between ASK1 and TRAF2, a C-terminal-binding activator of ASK1. Thus, our results reveal a novel role of GSPT1 in the regulation of ASK1-mediated apoptosis.	[Park, J. E.; Lee, D. H.; Park, S. G.; Park, B. C.] Korea Res Inst Biosci & Biotechnol, Translat Res Ctr, Proteome Res Lab, Taejon 305600, South Korea; [Lee, J. A.; Cho, S.] Chung Ang Univ, Coll Pharm, Seoul 156756, South Korea; [Lee, J. A.; Cho, S.] Chung Ang Univ, Res Inst Translat Syst Biom, Seoul, South Korea; [Myung, P. K.] Chungnam Natl Univ, Coll Pharm, Taejon, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chung Ang University; Chung Ang University; Chungnam National University	Park, BC (corresponding author), Korea Res Inst Biosci & Biotechnol, Translat Res Ctr, Proteome Res Lab, POB 115 Yusong, Taejon 305600, South Korea.	parkbc@kribb.re.kr; sycho@cau.ac.kr						[Anonymous], 1999, HYBRID RICE; Bell R, 2004, EJC SUPPL, V2, P1, DOI 10.1016/J.EJCSUP.2004.01.001; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chauvin C, 2005, MOL CELL BIOL, V25, P5801, DOI 10.1128/MCB.25.14.5801-5811.2005; Cho SY, 2004, J BIOL CHEM, V279, P16050, DOI 10.1074/jbc.M305758200; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hegde R, 2003, J BIOL CHEM, V278, P38699, DOI 10.1074/jbc.M303179200; Hoshino S, 1998, J BIOL CHEM, V273, P22254, DOI 10.1074/jbc.273.35.22254; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KIKUCHI Y, 1988, EMBO J, V7, P1175, DOI 10.1002/j.1460-2075.1988.tb02928.x; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Malta-Vacas J, 2005, J CLIN PATHOL, V58, P621, DOI 10.1136/jcp.2004.021774; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	23	22	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1297	1305		10.1038/sj.onc.1210740	http://dx.doi.org/10.1038/sj.onc.1210740			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17700517				2022-12-17	WOS:000253407000012
J	Ying, H; Willingham, MC; Cheng, SY				Ying, H.; Willingham, M. C.; Cheng, S-Y			The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer	ONCOGENE			English	Article						thyroid carcinogenesis; SRC-3; apoptosis; cell cycles; thyroid hormone receptor mutant; mouse model of thyroid cancer	TRANSCRIPTIONAL ACTIVITY; HORMONE RESISTANCE; CELL-PROLIFERATION; SIGNALING PATHWAY; LIGAND-BINDING; BETA-RECEPTOR; GENE; CARCINOGENESIS; GROWTH; SRC-3	The molecular genetic events underlying thyroid carcinogenesis are not well understood. Mice harboring a dominant-negative mutant thyroid hormone receptor-beta (TR beta(PV/PV) mice) spontaneously develop follicular thyroid carcinoma similar to human cancer. The present study aimed to elucidate the role of the steroid receptor coactivator-3 (SRC-3) in thyroid carcinogenesis in vivo by using the offspring from the cross of TR beta(PV/PV) and SRC-3(-/-) mice. TR beta PV/PV mice deficient in SRC-3 (TRb beta(SRC)-S-PV/PV-3(-/-) mice) had significantly increased survival, decreased thyroid tumor growth, delayed tumor progression and lower incidence of distant metastasis as compared with TR beta(PV/PV) mice with SRC-3 (TR beta(SRC)-S-PV/PV-3(-/-) mice). Further, in vivo nd in vitro analyses of multiple signaling pathways indicated that SRC-3 deficiency could lead to (1) inhibition of cell cycle progression at the G(1)/S transition via controlling the expression of cell cycle regulators, such as E2F1; (2) induction of apoptosis by controlling the expression of the Bcl-2 and caspase-3 genes and (3) suppression of neovascularization and metastasis, at least in part, through modulating the vascular endothelial growth factor gene expression. Taken together, SRC-3 could play important roles through regulating multiple target genes and signaling pathways during thyroid carcinogenesis, understanding of which should direct future therapeutic options for thyroid cancer.	[Ying, H.; Cheng, S-Y] NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; [Willingham, M. C.] Wake Forest Univ, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bldg 37,Room 5128,37 Convent Dr, Bethesda, MD 20892 USA.	chengs@mail.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC008752, ZIABC008752] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Gillenwater A M, 1997, Cancer Treat Res, V90, P149; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kato Y, 2006, ONCOGENE, V25, P2736, DOI 10.1038/sj.onc.1209299; Kato Y, 2004, ENDOCRINOLOGY, V145, P4430, DOI 10.1210/en.2004-0612; Kim CS, 2007, CARCINOGENESIS, V28, P932, DOI 10.1093/carcin/bgl231; Liao L, 2002, J STEROID BIOCHEM, V83, P3, DOI 10.1016/S0960-0760(02)00254-6; Lonard DM, 2005, TRENDS BIOCHEM SCI, V30, P126, DOI 10.1016/j.tibs.2005.01.001; Louie MC, 2006, MOL CELL BIOL, V26, P3810, DOI 10.1128/MCB.26.10.3810-3823.2006; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; Olateju TO, 2006, ANN CLIN BIOCHEM, V43, P431, DOI 10.1258/000456306778904678; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yan J, 2006, ACTA PHARMACOL SIN, V27, P387, DOI 10.1111/j.1745-7254.2006.00315.x; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Ying H, 2005, MOL CELL BIOL, V25, P7687, DOI 10.1128/MCB.25.17.7687-7695.2005; Ying H, 2003, CANCER RES, V63, P5274; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	24	22	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					823	830		10.1038/sj.onc.1210680	http://dx.doi.org/10.1038/sj.onc.1210680			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653082				2022-12-17	WOS:000252884500011
J	de Bruijn, DRH; van Dijk, AHA; Willemse, MP; van Kessel, AG				de Bruijn, D. R. H.; van Dijk, A. H. A.; Willemse, M. P.; van Kessel, A. Geurts			The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4	ONCOGENE			English	Article						synovial sarcoma; SSX; LHX4; SS18-SSX; transcription regulation	CHRONIC MYELOGENOUS LEUKEMIA; KRUPPEL-ASSOCIATED BOX; CHROMOSOMAL LOCALIZATION; NUCLEAR-LOCALIZATION; ONCOPROTEIN SYT; FUSION TYPE; HOX GENE; EXPRESSION; TRANSLOCATION; IDENTIFICATION	As a result of the synovial sarcoma-associated t(X; 18) translocation, the SS18 gene on chromosome 18 is fused to either one of the three closely related SSX genes on the X chromosome. The SS18 protein is thought to act as a transcriptional co-activator, whereas the SSX proteins are thought to act as transcriptional corepressors. The main SSX-repression domain is located in its C terminus, a domain that is retained in the respective SS18-SSX fusion proteins. Both the SS18 and SSX proteins lack DNA-binding domains. Previously, we found that the SS18 and SS18-SSX fusion proteins may be tethered to DNA targets via the SS18-interacting protein AF10. Here, we set out to isolate proteins that interact with the SSX C-terminal repression domain using a yeast two-hybrid interaction trap. Of the positive clones isolated, two corresponded to the LIM homeobox protein LHX4, a DNA-binding protein that is involved in transcription regulation. An endogenous interaction was subsequently established in mammalian cells via colocalization and coimmunoprecipitation of the respective proteins. Interestingly, the LHX4 gene was previously found to be deregulated in various human leukemias. In addition, it was previously found that LIM homeobox proteins may bind to and activate the glycoprotein-alpha (CGA) promoter. Using LHX4 chromatin immunoprecipitation and CGA-promoter assays, we found that endogenous LHX4 binds to the CGA promoter and that LHX4-mediated CGA activation is enhanced by the SS18-SSX protein, but not by the SSX protein. Taken together, we conclude that this novel protein - protein interaction may have direct consequences for the (de) regulation of SSX and/or SS18-SSX target genes and, thus, for the development of human synovial sarcomas.	[de Bruijn, D. R. H.; van Dijk, A. H. A.; Willemse, M. P.; van Kessel, A. Geurts] Radboud Univ Nijmegen Med Ctr, Dept Human Genet 855, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	van Kessel, AG (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Human Genet 855, POB 9101, NL-6500 HB Nijmegen, Netherlands.	a.geurtsvankessel@antrg.umcn.nl	de Bruijn, D.R.H./L-4233-2015; van Kessel, Ad Geurts/A-2810-2010					Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Cronwright G, 2005, CANCER RES, V65, P2207, DOI 10.1158/0008-5472.CAN-04-1882; de Bruijn DRH, 2006, CANCER RES, V66, P9474, DOI 10.1158/0008-5472.CAN-05-3726; de Bruijn DRH, 2002, GENE CHROMOSOME CANC, V34, P285, DOI 10.1002/gcc.10073; de Bruijn DRH, 2001, CYTOGENET CELL GENET, V92, P310, DOI 10.1159/000056920; de Bruijn DRH, 2001, ONCOGENE, V20, P3281, DOI 10.1038/sj.onc.1204419; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; deBruijn DRH, 1996, ONCOGENE, V13, P643; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; Dong WF, 1997, DNA CELL BIOL, V16, P671, DOI 10.1089/dna.1997.16.671; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; dos Santos NR, 2000, CANCER RES, V60, P1654; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Guillou L, 2004, J CLIN ONCOL, V22, P4040, DOI 10.1200/JCO.2004.11.093; Gure AO, 2002, INT J CANCER, V101, P448, DOI 10.1002/ijc.10634; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Howard PW, 2000, J BIOL CHEM, V275, P13336, DOI 10.1074/jbc.275.18.13336; Huntley S, 2006, GENOME RES, V16, P669, DOI 10.1101/gr.4842106; Ito T, 2004, LAB INVEST, V84, P1484, DOI 10.1038/labinvest.3700174; Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kawai A, 2004, CANCER LETT, V204, P105, DOI 10.1016/j.canlet.2003.09.031; Kawamata N, 2002, ONCOGENE, V21, P4983, DOI 10.1038/sj.onc.1205628; Ladanyi M, 2002, CANCER RES, V62, P135; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Liu YB, 2002, BRAIN RES, V928, P147, DOI 10.1016/S0006-8993(01)03243-7; Machinis K, 2001, AM J HUM GENET, V69, P961, DOI 10.1086/323764; Mischo A, 2006, INT J CANCER, V118, P696, DOI 10.1002/ijc.21352; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Naka N, 2002, INT J CANCER, V98, P640, DOI 10.1002/ijc.10277; Perani M, 2003, ONCOGENE, V22, P8156, DOI 10.1038/sj.onc.1207031; Raetzman LT, 2002, DEVELOPMENT, V129, P4229; Richter K, 2003, HAEMATOLOGICA, V88, P1336; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; Saito T, 2006, CANCER RES, V66, P6919, DOI 10.1158/0008-5472.CAN-05-3697; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Taylor BJ, 2005, J IMMUNOTHER, V28, P564, DOI 10.1097/01.cji.0000175685.36239.e5; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Tureci O, 1996, CANCER RES, V56, P4766; Tureci O, 1998, INT J CANCER, V77, P19, DOI 10.1002/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2; Vogel MJ, 2006, GENOME RES, V16, P1493, DOI 10.1101/gr.5391806; Wu HK, 1997, BIOCHEM BIOPH RES CO, V233, P806, DOI 10.1006/bbrc.1997.6546; Wu HK, 1996, ONCOGENE, V12, P1205; Yamada S, 2003, INT J RELIAB APPL, V4, P1	56	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					653	662		10.1038/sj.onc.1210688	http://dx.doi.org/10.1038/sj.onc.1210688			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667940				2022-12-17	WOS:000252674900009
J	Hayes, NVL; Newsam, RJ; Baines, AJ; Gullick, WJ				Hayes, N. V. L.; Newsam, R. J.; Baines, A. J.; Gullick, W. J.			Characterization of the cell membrane-associated products of the Neuregulin 4 gene	ONCOGENE			English	Article						neuregulin 4; growth factor; tyrosine kinase	GROWTH-FACTOR; FACTOR-ALPHA; ISOFORMS; ACTIVATION; SYSTEM; FAMILY	The NRG4 gene is a member of a family of four genes that encode a class of epidermal growth factors. This gene has been reported to express a protein designated here as NRG4A1. We describe here a novel splice variant of the NRG4 gene, NRG4A2, which encodes a C-terminal region containing a predicted type I PDZ-binding peptide. Both NRG4A1 and NRG4A2 were shown to be expressed on the cell surface, as expected by the presence of a predicted transmembrane sequence, and were modified at a single N-linked glycosylation site in the extracellular domain. Significant stabilization of expression of both proteins was seen in the presence of the proteosome inhibitor MG-132 suggesting that they are normally degraded by this system. N-terminal cleavage was inhibited in both isotypes by the broad-spectrum matrix metalloproteinase inhibitor, galardin (GM 6001). A glycosylated, secreted form of NRG4A1 was detected in the cell medium which showed biological activity in two assays, phosphorylation of the HER4 receptor and stimulation of neurite formation in PC-12 cells stably expressing HER4. Transfection and expression of green fluorescent protein-tagged proteins and immunofluorescent staining with specific anti-peptide antibodies showed that NRG4A1 is localized to membrane ruffles, while NRG4A2 has a more punctate membrane distribution.	[Hayes, N. V. L.; Newsam, R. J.; Gullick, W. J.] Univ Kent, Res Sch Biosci, Canc Biol Lab, Canterbury CT2 7NJ, Kent, England; [Baines, A. J.] Univ Kent, Ctr Biomed Informat, Canterbury CT2 7NJ, Kent, England	University of Kent; University of Kent	Gullick, WJ (corresponding author), Univ Kent, Res Sch Biosci, Canc Biol Lab, Canterbury CT2 7NJ, Kent, England.	w.j.gullick@kent.ac.uk		Baines, Anthony/0000-0003-3068-7811				Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Carteron C, 2006, J CELL SCI, V119, P898, DOI 10.1242/jcs.02799; Dunn M, 2004, J PATHOL, V203, P672, DOI 10.1002/path.1561; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Harris BZ, 2001, J CELL SCI, V114, P3219; Harrison PJ, 2006, BIOL PSYCHIAT, V60, P132, DOI 10.1016/j.biopsych.2005.11.002; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; Hobbs SS, 2002, ONCOGENE, V21, P8442, DOI 10.1038/sj.onc.1205960; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; ROOBOL A, 1995, J CELL SCI, V108, P1477; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; Tastet C, 2003, ELECTROPHORESIS, V24, P1787, DOI 10.1002/elps.200305400; Vaskovsky A, 2000, J NEUROCHEM, V74, P979, DOI 10.1046/j.1471-4159.2000.0740979.x; von Heijne G, 2006, NAT REV MOL CELL BIO, V7, P909, DOI 10.1038/nrm2063; Wakatsuki S, 2004, J NEUROCHEM, V89, P119, DOI 10.1046/j.1471-4159.2003.02303.x; Yamada K, 2000, GENE, V255, P15, DOI 10.1016/S0378-1119(00)00309-7	18	22	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					715	720		10.1038/sj.onc.1210689	http://dx.doi.org/10.1038/sj.onc.1210689			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684490	Green Accepted			2022-12-17	WOS:000252674900015
J	Azoitei, N; Brey, A; Busch, T; Fulda, S; Adler, G; Seufferlein, T				Azoitei, N.; Brey, A.; Busch, T.; Fulda, S.; Adler, G.; Seufferlein, T.			Thirty-eight-negative kinase 1 (TNK1) facilitates TNF alpha-induced apoptosis by blocking NF-kappa B activation	ONCOGENE			English	Article						apoptosis; NF-kappa B; p65 transactivation; TNF alpha; TNK1	TUMOR-NECROSIS-FACTOR; PROTEIN-TYROSINE KINASE; GENE-EXPRESSION; P65 SUBUNIT; RECEPTOR; PHOSPHORYLATION; CELLS; TRANSCRIPTION; DEATH	Thirty-eight-negative kinase 1 (TNK1) is a member of the ACK-family of nonreceptor tyrosine kinases and was originally cloned from CD34+/Lin-/CD38-hematopoietic stem/progenitor cells. The signaling pathways induced by TNK1 are largely unknown. Here, we report that expression and consequent activation of TNK1 enables tumor necrosis factor a (TNF alpha)-induced apoptosis by selectively inhibiting TNF alpha-induced activation of nuclear factor-kappa B (NF-kappa B). TNK1 has no effect on NF-kappa B DNA binding or the composition of the NF-kappa B complex; however, the kinase markedly prevents TNFa-induced NF-kappa B transactivation. TNK1 therefore acts as a novel molecular switch that can determine the properties of TNFa signaling and therefore cell death.	Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Ulm, Childrens Hosp, Ulm, Germany	Ulm University; Ulm University	Seufferlein, T (corresponding author), Univ Ulm, Dept Internal Med 1, Robert Koch St 8, D-89081 Ulm, Germany.	thomas.seufferlein@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Seufferlein, Thomas TW/P-7147-2018	Fulda, Simone/0000-0002-0459-6417				Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; BEG AA, 1996, SCIENCE, V274, P784; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Eickhoff B, 2000, BIOL CHEM, V381, P1127, DOI 10.1515/BC.2000.138; Felschow DM, 2000, BIOCHEM BIOPH RES CO, V273, P294, DOI 10.1006/bbrc.2000.2887; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tibs.2004.11.001; Hoehn GT, 1996, ONCOGENE, V12, P903; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Mukhopadhyay A, 2002, J BIOL CHEM, V277, P30622, DOI 10.1074/jbc.M204748200; Navakauskiene R, 2004, PROTEOMICS, V4, P1029, DOI 10.1002/pmic.200300671; Neumann B, 1996, J EXP MED, V184, P259, DOI 10.1084/jem.184.1.259; Pasparakis M, 2000, CELL IMMUNOL, V201, P33, DOI 10.1006/cimm.2000.1636; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Taghiyev AF, 2005, CANCER BIOL THER, V4, P382; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	28	22	23	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	45					6536	6545		10.1038/sj.onc.1210476	http://dx.doi.org/10.1038/sj.onc.1210476			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471239				2022-12-17	WOS:000249919800007
J	Wu, J; Jin, YJ; Calaf, GM; Huang, WL; Yin, Y				Wu, J.; Jin, Y. J.; Calaf, G. M.; Huang, W-L; Yin, Y.			PAC1 is a direct transcription target of E2F-1 in apoptotic signaling	ONCOGENE			English	Article						E2F-1; PAC1; MAP kinases; 4-HPR; apoptosis; chemotherapeutics	STRESS-INDUCED APOPTOSIS; MAP KINASE; OXIDATIVE STRESS; E2F-1-INDUCED APOPTOSIS; CELL-PROLIFERATION; GROWTH SUPPRESSION; NITRIC-OXIDE; IN-VIVO; PHOSPHATASE; ACTIVATION	E2F-1 controls multiple cellular activities through transcriptional regulation of its target genes. As a mediator of cell death, E2F-1 can eliminate latent neoplastic cells through apoptosis. However, the mechanism by which E2F-1 mediates cancer cell killing is largely unknown. In this paper, we report that phosphatase of activated cells 1 (PAC1) phosphatase is a direct transcription target of E2F-1 in signaling apoptosis. We show that ectopic E2F-1 increases expression of PAC1 at both transcriptional and translational levels in breast cancer cells. E2F-1 physically interacts with the promoter of PAC1, binds to its consensus sequence in the promoter and transactivates the PAC1 promoter. E2F-1 suppresses extracellular signal-regulated kinase (ERK) phosphorylation through PAC1 and causes cancer cell death by apoptosis following treatment with a chemotherapeutic agent N-4-hydroxy-phenylretinamide (4-HPR). Furthermore, ectopic PAC1 inhibits ERK phosphorylation and mediates cell killing. Moreover, endogenous E2F-1 upregulates PAC1 and suppresses ERK activity, leading to cell death in response to 4-HPR. These results reveal a crucial role of PAC1 in E2F-1-directed apoptosis. Our study demonstrates that E2F-1 mediates apoptosis through transcriptional regulation of PAC1 and subsequent suppression of the ERK signaling. Our findings establish a functional link between E2F-1 and mitogen-activated protein kinases. The E2F-1 PAC1 cascade in cancer cell killing may provide a molecular basis for cancer therapeutic intervention.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, Dept Radiat Oncol, New York, NY 10032 USA; Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou, Peoples R China	Columbia University; Sun Yat Sen University	Yin, Y (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, Dept Radiat Oncol, VC11-213,630 W 168th St, New York, NY 10032 USA.	yy151@columbia.edu	huang, wen/GXW-0661-2022		NCI NIH HHS [CA102447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bednarek A, 1999, CARCINOGENESIS, V20, P879, DOI 10.1093/carcin/20.5.879; Bell R, 2004, EJC SUPPL, V2, P1, DOI 10.1016/J.EJCSUP.2004.01.001; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Conklin Kenneth A, 2004, Integr Cancer Ther, V3, P294, DOI 10.1177/1534735404270335; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Husain SS, 2001, LIFE SCI, V69, P3045, DOI 10.1016/S0024-3205(01)01411-4; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kim HJ, 2006, ONCOGENE, V25, P2785, DOI 10.1038/sj.onc.1209303; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Malone W, 2003, EXPERT OPIN INV DRUG, V12, P1829, DOI 10.1517/13543784.12.11.1829; Mates JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; MOON RC, 1989, PREV MED, V18, P576, DOI 10.1016/0091-7435(89)90031-5; Ookawa K, 1997, ONCOGENE, V14, P1389, DOI 10.1038/sj.onc.1200976; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Shen WH, 2006, CANCER RES, V66, P6033, DOI 10.1158/0008-5472.CAN-05-3878; Shen WH, 2004, J BIOL CHEM, V279, P7438, DOI 10.1074/jbc.M310264200; Simeone AM, 2003, ONCOGENE, V22, P6739, DOI 10.1038/sj.onc.1206786; Simeone AM, 2002, MOL CANCER THER, V1, P1009; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WHITMARSH AJ, 1999, SCI STKE; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yan WS, 2006, J BIOL CHEM, V281, P7856, DOI 10.1074/jbc.M512655200; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Zhang Q, 2005, J MOL BIOL, V354, P777, DOI 10.1016/j.jmb.2005.10.006; ZHU L, 1994, COLD SPRING HARB SYM, V59, P75, DOI 10.1101/SQB.1994.059.01.011	37	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6526	6535		10.1038/sj.onc.1210484	http://dx.doi.org/10.1038/sj.onc.1210484			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471234				2022-12-17	WOS:000249919800006
J	Kanome, T; Itoh, N; Ishikawa, F; Mori, K; Kim-Kaneyama, JR; Nose, K; Shibanuma, M				Kanome, T.; Itoh, N.; Ishikawa, F.; Mori, K.; Kim-Kaneyama, J-R; Nose, K.; Shibanuma, M.			Characterization of Jumping translocation breakpoint (JTB) gene product isolated as a TGF-beta 1-inducible clone involved in regulation of mitochondrial function, cell growth and cell death	ONCOGENE			English	Article						JTB; mitochondria; TGF-beta	BETA-INDUCED APOPTOSIS; CANCER-CELLS; ACTIVATION; EXPRESSION; PATHWAY; PROTEIN; CHEMOTHERAPY; RESPIRATION; MUTATIONS; TARGET	Jumping translocation breakpoint ( JTB) is a gene located on human chromosome 1 at q21 that suffers an unbalanced translocation in various types of cancers, and potentially encodes a transmembrane protein of unknown function. The results of cancer pro. ling indicated that its expression was suppressed in many cancers from different organs, implying a role in the neoplastic transformation of cells. Recently, we isolated JTB as a TGF-beta 1-inducible clone by differential screening. In this study, we characterized its product and biological functions. We found that it was processed at the N- terminus and located mostly in mitochondria. When expressed in cells, JTB- induced clustering of mitochondria around the nuclear periphery and swelling of each mitochondrion. In those mitochondria, membrane potential, as monitored with a JC- 1 probe, was significantly reduced. Coinciding with these changes in mitochondria, JTB retarded the growth of the cells and conferred resistance to TGF-beta 1-induced apoptosis. These activities were dependent on the N- terminal processing and induced by wild- type JTB but not by a mutant resistant to cleavage. These findings raised the possibility that aberration of JTB in structure or expression induced neoplastic changes in cells through dysfunction of mitochondria leading to deregulated cell growth and/or death.	Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Tokyo 1428555, Japan	Showa University	Shibanuma, M (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	smotoko@pharm.showa-u.ac.jp	Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305				Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Goldenthal MJ, 2004, MOL CELL BIOCHEM, V262, P1, DOI 10.1023/B:MCBI.0000038228.85494.3b; Hatakeyama S, 1999, ONCOGENE, V18, P2085, DOI 10.1038/sj.onc.1202510; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kaelin WG, 2005, CELL METAB, V1, P357, DOI 10.1016/j.cmet.2005.05.006; Keung YK, 1998, CANCER GENET CYTOGEN, V106, P135, DOI 10.1016/S0165-4608(97)00316-6; Kim SG, 2004, MOL BIOL CELL, V15, P420, DOI 10.1091/mbc.E03-04-0201; Kim-Kaneyama J, 2005, J CELL SCI, V118, P937, DOI 10.1242/jcs.01683; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kondoh H, 2005, CANCER RES, V65, P177; Kroemer G, 2003, CURR MED CHEM, V10, P1469, DOI 10.2174/0929867033457232; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Marchetti P, 2002, ANN BIOL CLIN-PARIS, V60, P391; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd; Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Rotem R, 2005, CANCER RES, V65, P1984, DOI 10.1158/0008-5472.CAN-04-3091; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Shibanuma M, 2003, MOL BIOL CELL, V14, P1158, DOI 10.1091/mbc.02-06-0099; Staniek K, 2002, FREE RADICAL RES, V36, P381, DOI 10.1080/10715760290021225; WARBURG O, 1956, SCIENCE, V124, P269; Wong N, 2003, J HEPATOL, V38, P298, DOI 10.1016/S0168-8278(02)00412-9	28	22	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					5991	6001		10.1038/sj.onc.1210423	http://dx.doi.org/10.1038/sj.onc.1210423			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17369841				2022-12-17	WOS:000249277200002
J	Manuylov, NL; Smagulova, FO; Tevosian, SG				Manuylov, N. L.; Smagulova, F. O.; Tevosian, S. G.			Fog2 excision in mice leads to premature mammary gland involution and reduced Esr1 gene expression	ONCOGENE			English	Article						GATA; FOG2; estrogen receptor; transcription factor; mammary; involution	ESTROGEN-RECEPTOR-ALPHA; HUMAN BREAST-CANCER; PROGESTERONE-RECEPTOR; COFACTOR; DIFFERENTIATION; PROTEIN; FAMILY; GATA-3; BCL-2; IDENTIFICATION	The critical role for GATA family proteins in maintaining the normal (non-transformed) cell state is corroborated by the recent findings of mutations or methylation in GATA genes both in primary cancers and tumor lines including breast. Previously, microarray pro. ling studies determined that the highest expression of both GATA3 and ESR1 ( estrogen receptor a) is seen in tumors associated with the most favorable survival outcomes, whereas the lowest expression of GATA3 is detected in tumor subtypes showing the worst outcomes. At this time, genes and pathways that are regulated by GATA3 in the mammary gland are not well defined. We have previously established a requirement for FOG ( Friend Of GATA) cofactors during mouse development. Here we report that in the murine mammary gland Fog2 gene expression is upregulated upon pregnancy and lactation with prominent expression in the epithelial cells of the gland during post-lactational regression. Mammary-specific deletion of Fog2 identified a role for this gene during gland involution; excision of the Fog2 gene leads to the accelerated involution of the gland despite diminished levels of the remodeling enzymes. Importantly, the levels of several genes linked to the control of cancerous transformation in the breast ( Esr1, Prg and Foxa1) are significantly reduced upon Fog2 excision. This implicates FOG2 in the maintenance of epithelial cell differentiation in the mammary gland and in performing a protective role in breast cancer.	Dartmouth Coll, Sch Med, Dept Genet, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Norris Cotton Canc Ctr, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Tevosian, SG (corresponding author), Dartmouth Coll, Sch Med, Dept Genet, Hanover, NH 03755 USA.	sergei.g.tevosian@dartmouth.edu	Smagulova, Fatima/K-5459-2015	Smagulova, Fatima/0000-0001-6883-1968				Adameyko II, 2005, DEV DYNAM, V233, P540, DOI 10.1002/dvdy.20368; Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Allar MA, 2004, ENDOCRINOLOGY, V145, P2467, DOI 10.1210/en.2003-1641; Amin DN, 2004, ONCOGENE, V23, P1428, DOI 10.1038/sj.onc.1207257; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Booth BW, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1538; Cantor AB, 2005, SEMIN CELL DEV BIOL, V16, P117, DOI 10.1016/j.semcdb.2004.10.006; Crispino JD, 2005, SEMIN CELL DEV BIOL, V16, P137, DOI 10.1016/j.semcdb.2004.11.002; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Gruvberger S, 2001, CANCER RES, V61, P5979; Han XY, 2003, J BIOL CHEM, V278, P47785, DOI 10.1074/jbc.M309482200; Hoch RV, 1999, INT J CANCER, V84, P122; Huggins GS, 2006, CANCER RES, V66, P1384, DOI 10.1158/0008-5472.CAN-05-2715; Jordan VC, 2004, CANCER CELL, V5, P207, DOI 10.1016/S1535-6108(04)00059-5; Kobayashi S, 2006, FASEB J, V20, P800, DOI 10.1096/fj.05-5426fje; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Lacroix M, 2004, MOL CELL ENDOCRINOL, V219, P1, DOI 10.1016/j.mce.2004.02.021; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; Master SR, 2002, MOL ENDOCRINOL, V16, P1185, DOI 10.1210/me.16.6.1185; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Mundschau G, 2003, BLOOD, V101, P4298, DOI 10.1182/blood-2002-12-3904; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Parikh P, 2005, J AM COLL SURGEONS, V200, P705, DOI 10.1016/j.jamcollsurg.2004.12.025; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polyak K, 2006, CANCER CELL, V9, P151, DOI 10.1016/j.ccr.2006.02.026; Schorr K, 1999, CANCER RES, V59, P2541; Shen DJ, 2005, BIOCHEM BIOPH RES CO, V326, P218, DOI 10.1016/j.bbrc.2004.10.214; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 2002, DEVELOPMENT, V129, P4627; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050; Thangaraju M, 2004, ONCOGENE, V23, P2548, DOI 10.1038/sj.onc.1207363; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Wolf I, 2007, INT J CANCER, V120, P1013, DOI 10.1002/ijc.22389	48	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5204	5213		10.1038/sj.onc.1210333	http://dx.doi.org/10.1038/sj.onc.1210333			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17310981				2022-12-17	WOS:000248674200004
J	van Wely, K; Meester-Smoor, MA; Janssen, MJFW; Aarnoudse, AJ; Grosveld, GC; Zwarthoff, EC				van Wely, Khm; Meester-Smoor, M. A.; Janssen, M. J. F. W.; Aarnoudse, A-J; Grosveld, G. C.; Zwarthoff, E. C.			The MN1-TEL myeloid leukemia-associated fusion protein has a dominant-negative effect on RAR-RXR-mediated transcription	ONCOGENE			English	Article						translocation; leukemia; retinoic acid; coactivator; mutant	HISTONE DEACETYLASE; CELL-GROWTH; DNA-BINDING; GENE; TRANSLOCATION; DEFECTS; SARCOMA; OVEREXPRESSION; COACTIVATORS; PATHWAYS	The translocation t(12;22)(p13;q11) creates an MN1-TEL fusion gene leading to acute myeloid leukemia. MN1 is a transcription coactivator of the retinoic acid and vitamin D receptors, and TEL (ETV6) is a member of the E26-transform ation-specific family of transcription factors. In MN1-TEL, the transactivating domains of MN1 are combined with the DNA-binding domain of TEL. We show that MN1-TEL inhibits retinoic acid receptor (RAR)-mediated transcription, counteracts coactivators such as p160 and p300, and acts as a dominant-negative mutant of MN1. Compared to MN1 the same transactivation domains in MIN1-TEL are poorly stimulated by p160, p300 or histone deacetylase inhibitors, indicating that the block of RAR-mediated transcription by MN1-TEL is caused by dysfunctional transactivation domains rather than by recruitment of corepressors. The mechanism leading to myeloid leukemia in t(12;22) thus differs from the translocations that involve RAR itself.	Erasmus MC, Josephine Nefkens Inst, Dept Pathol, NL-3000 CA Rotterdam, Netherlands; St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA	Erasmus University Rotterdam; Erasmus MC; St Jude Children's Research Hospital	Zwarthoff, EC (corresponding author), Erasmus MC, Josephine Nefkens Inst, Dept Pathol, POB 2040, NL-3000 CA Rotterdam, Netherlands.	e.zwarthoff@erasmusmc.nl		van Wely, Karel Hermanus Martinus/0000-0001-8431-8072				BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Beverloo HB, 2001, CANCER RES, V61, P5374; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; Bohlander SK, 2005, SEMIN CANCER BIOL, V15, P162, DOI 10.1016/j.semcancer.2005.01.008; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BUIJS A, 1995, ONCOGENE, V10, P1511; Buijs A, 2000, MOL CELL BIOL, V20, P9281, DOI 10.1128/MCB.20.24.9281-9293.2000; BUIJS A, 1995, IN PRESS ONCOGENE, P809; Carella C, 2006, LEUKEMIA, V20, P1582, DOI 10.1038/sj.leu.2404298; Cazzaniga G, 2001, CANCER RES, V61, P4666; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Goodman RH, 2000, GENE DEV, V14, P1553; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hisa T, 2004, EMBO J, V23, P450, DOI 10.1038/sj.emboj.7600038; Kawagoe H, 2005, BLOOD, V106, P4269, DOI 10.1182/blood-2005-04-1679; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Meester-Smoor MA, 2005, MOL CELL BIOL, V25, P4229, DOI 10.1128/MCB.25.10.4229-4236.2005; Mercader N, 2000, DEVELOPMENT, V127, P3961; Pattyn F, 2003, NUCLEIC ACIDS RES, V31, P122, DOI 10.1093/nar/gkg011; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; Sutton ALM, 2005, MOL ENDOCRINOL, V19, P2234, DOI 10.1210/me.2005-0081; van Wely KHM, 2003, ONCOGENE, V22, P699, DOI 10.1038/sj.onc.1206124; VANROOZENDAAL KEP, 1990, EXP CELL RES, V190, P137, DOI 10.1016/0014-4827(90)90155-4; Wan YJY, 1998, EXP CELL RES, V238, P241, DOI 10.1006/excr.1997.3851; Wang ZG, 1998, SCIENCE, V279, P1547; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	30	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5733	5740		10.1038/sj.onc.1210382	http://dx.doi.org/10.1038/sj.onc.1210382			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369854				2022-12-17	WOS:000248885100005
J	Fan, S; Meng, Q; Laterra, JJ; Rosen, EM				Fan, S.; Meng, Q.; Laterra, J. J.; Rosen, E. M.			Ras effector pathways modulate scatter factor-stimulated NF-kappa B signaling and protection against DNA damage	ONCOGENE			English	Article						scatter factor; ras; Ra1A; raf1; protection; adriamycin	ACTIVATED PROTEIN-KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; CELL-TRANSFORMATION; EPITHELIAL-CELLS; GENE-EXPRESSION; MET RECEPTOR; CANCER-CELLS; GROWTH; IDENTIFICATION; APOPTOSIS	Scatter factor (SF) (hepatocyte growth factor) is a pleiotrophic cytokine that accumulates within tumors in vivo and protects tumor cells against cytotoxicity and apoptosis due to DNA damaging agents in vitro. Previous studies have established that SF- mediated cell protection involves antiapoptotic signaling from its receptor (c-Met) to PI3 kinase -> c-Akt -> Pak1 (p21-activated kinase -1)-> NF- kappa B (nuclear factor-kappa B). Here, we found that Ras proteins (H-Ras and R-Ras) enhance SF-mediated activation of NF-kappa B and protection of DU-145 and MDCK (Madin-Darby canine kidney) cells against the topoisomerase II alpha inhibitor adriamycin. Studies of Ras effector loop mutants and their downstream effectors suggest that Ras/PI3 kinase and Ras/Raf1 pathways contribute to SF stimulation of NF-kappa B signaling and cell protection. Further studies revealed that Raf1 positively regulates the ability of SF to stimulate NF-kappa B activity and cell protection. The ability of Raf1 to stimulate NF-kappa B activity was not due to the classical Raf1 -> MEK1/2 -> ERK1/ 2 pathway. However, we found that a MEK3/6p -> 38 pathway contributes to SF-mediated activation of NF-kappa B. In contrast, RalA, a target of the Ras/RalGDS pathway negatively regulated the ability of SF to stimulate NF-kappa B activity and cell protection. Ras, Raf1 and RalA modulate SF stimulation of NF-kappa B activity, in part, by regulating I kappa B kinase (IKK)-kappa kinase activity. These findings suggest that Ras/ Raf1/ RalA pathways may converge to modulate NF-kappa B activation and SF-mediated survival signaling at the IKK complex and/or a kinase upstream of this complex.	Georgetown Univ, Dept Oncol, Lombard Comprehens Canc Ctr, Washington, DC 20057 USA; Kennedy Krieger Inst, Dept Neurol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Georgetown University; Kennedy Krieger Institute; Johns Hopkins University	Rosen, EM (corresponding author), Georgetown Univ, Dept Oncol, Lombard Comprehens Canc Ctr, 3970 Reservoir Rd NW,Box 571469, Washington, DC 20057 USA.	emr36@georgetown.edu			NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NINDS NIH HHS [R01-NS43987] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043987] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ALLEY MC, 1988, CANCER RES, V48, P589; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowers DC, 2000, CANCER RES, V60, P4277; Camonis JH, 2005, TRENDS CELL BIOL, V15, P327, DOI 10.1016/j.tcb.2005.04.002; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Costantini C, 2005, J MOL NEUROSCI, V25, P141, DOI 10.1385/JMN:25:2:141; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Fitzgerald EM, 2000, J PHYSIOL-LONDON, V527, P433, DOI 10.1111/j.1469-7793.2000.00433.x; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Herrmann C, 2003, CURR OPIN STRUC BIOL, V13, P122, DOI 10.1016/S0959-440X(02)00007-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hu MCT, 1998, GENE, V222, P31, DOI 10.1016/S0378-1119(98)00462-4; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Matteucci E, 2003, ONCOGENE, V22, P4062, DOI 10.1038/sj.onc.1206519; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; McFarlin DR, 2003, CARCINOGENESIS, V24, P99, DOI 10.1093/carcin/24.1.99; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Murai H, 1997, J BIOL CHEM, V272, P10483; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Rahman A, 2004, AM J PHYSIOL-LUNG C, V287, pL1017, DOI 10.1152/ajplung.00072.2004; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rosen EM, 1997, CIBA F SYMP, V212, P215; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Song KS, 2003, J BIOL CHEM, V278, P34890, DOI 10.1074/jbc.M303911200; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Stuckler D, 2005, CANCER RES, V65, P991; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Vitale N, 2005, J BIOL CHEM, V280, P29921, DOI 10.1074/jbc.M413748200; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wohlgemuth S, 2005, J MOL BIOL, V348, P741, DOI 10.1016/j.jmb.2005.02.048; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YAN MH, 1994, J BIOL CHEM, V269, P19067; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; Zhong H, 2000, CANCER RES, V60, P1541	60	22	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4774	4796		10.1038/sj.onc.1210271	http://dx.doi.org/10.1038/sj.onc.1210271			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297451				2022-12-17	WOS:000248170400003
J	Loffler, KA; Biondi, CA; Gartside, MG; Serewko-Auret, MM; Duncan, R; Tonks, ID; Mould, AW; Waring, P; Muller, HK; Kay, GF; Hayward, NK				Loffler, K. A.; Biondi, C. A.; Gartside, M. G.; Serewko-Auret, M. M.; Duncan, R.; Tonks, I. D.; Mould, A. W.; Waring, P.; Muller, H. K.; Kay, G. F.; Hayward, N. K.			Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice	ONCOGENE			English	Article						endocrine; pancreas; pituitary; parathyroid; thyroid	MULTIPLE ENDOCRINE NEOPLASIA; CELL-CYCLE; CONDITIONAL INACTIVATION; RETINOBLASTOMA GENE; TYPE-1; SUPPRESSOR; GROWTH; TUMORIGENESIS; EXPRESSION; PROTEIN	To identify possible genetic interactions between the mechanisms of tumor suppression of menin and pRb, we intercrossed mice with targeted deletions of Men1 and Rb1, and compared tumor development in cohorts of animals carrying single or dual mutations of these tumor-suppressor genes. In mice lacking one copy of Men1, pancreatic islet and anterior pituitary adenomas are common. In animals lacking one copy of Rb1, intermediate pituitary and thyroid tumors occur at high frequency, with less frequent development of pancreatic islet hyperplasia and parathyroid lesions. In mice heterozygous for both Men1 and Rb1, pancreatic hyperplasia and tumors of the intermediate pituitary and thyroid occurred at high frequency. Serum measurements of calcium and glucose did not vary significantly between genotypic groups. Loss of heterozygosity at the Rb1 locus was common in pituitary and thyroid tumors, whereas loss of menin was observed in pancreatic and parathyroid lesions. The tumor spectrum in the double heterozygotes was a combination of pathologies seen in each of the individual heterozygotes, without decrease in age of onset, indicating independent, non-additive effects of the two mutations. Together with the lack of increased tumor spectrum, this suggests that menin and pRb function in a common pathway of tumor suppression.	Queensland Inst Med Res, Canc & Cell Biol Div, Herston, Qld 4029, Australia; Peter MacCallum Canc Inst, Dept Pathol, Melbourne, Vic, Australia; Univ Tasmania, Sch Med, Hobart, Tas, Australia	QIMR Berghofer Medical Research Institute; Peter Maccallum Cancer Center; University of Tasmania	Hayward, NK (corresponding author), Queensland Inst Med Res, Canc & Cell Biol Div, 300 Herston Rd, Herston, Qld 4029, Australia.	Nick.Hayward@qimr.edu.au	hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020; Kay, Graham F/A-4130-2011	hayward, nicholas k/0000-0003-4760-1033; Loffler, Kelly/0000-0003-3302-5995; Mould, Arne/0000-0002-2004-4348				Agarwal SK, 2003, P NATL ACAD SCI USA, V100, P10770, DOI 10.1073/pnas.1834524100; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; Biondi C, 2002, GENESIS, V32, P150, DOI 10.1002/gene.10061; Biondi CA, 2004, MOL CELL BIOL, V24, P3125, DOI 10.1128/MCB.24.8.3125-3131.2004; Busygina V, 2004, HUM MOL GENET, V13, P2399, DOI 10.1093/hmg/ddh271; Casanovas O, 2005, ONCOGENE, V24, P6597, DOI 10.1038/sj.onc.1208823; CHANDRASEKHARAP.S, 2003, J INTERN MED, V253, P599; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; CRYNS VL, 1994, NEW ENGL J MED, V330, P757, DOI 10.1056/NEJM199403173301105; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jin SH, 2003, CANCER RES, V63, P4204; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Karnik SK, 2005, P NATL ACAD SCI USA, V102, P14659, DOI 10.1073/pnas.0503484102; Kim H, 2003, CANCER RES, V63, P6135; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; LOFFLER KA, 2006, INT J CANC      1016; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; Ratineau C, 2004, J BIOL CHEM, V279, P24477, DOI 10.1074/jbc.M401835200; Schnepp RW, 2004, J BIOL CHEM, V279, P10685, DOI 10.1074/jbc.M308073200; Sowa H, 2004, J BIOL CHEM, V279, P40267, DOI 10.1074/jbc.M401312200; Sowa H, 2003, J BIOL CHEM, V278, P21058, DOI 10.1074/jbc.M302044200; Tonks ID, 2005, PIGM CELL RES, V18, P252, DOI 10.1111/j.1600-0749.2005.00245.x; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480	31	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					4009	4017		10.1038/sj.onc.1210163	http://dx.doi.org/10.1038/sj.onc.1210163			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17173065	Bronze			2022-12-17	WOS:000247144500011
J	Kaur, M; Pop, M; Shi, D; Brignone, C; Grossman, SR				Kaur, M.; Pop, M.; Shi, D.; Brignone, C.; Grossman, S. R.			hHR23B is required for genotoxic-specific activation of p53 and apoptosis	ONCOGENE			English	Article						p53; hHR23; ubiquitin; proteasome; DNA damage; chromatin	NUCLEOTIDE EXCISION-REPAIR; UBIQUITIN-PROTEASOME SYSTEM; DNA-REPAIR; IN-VIVO; POLYUBIQUITIN CHAINS; UV-IRRADIATION; C PROTEIN; DEGRADATION; RAD23; DOMAINS	Rad23 proteins function in both DNA repair and protein stability regulation. As ubiquitinated forms of p53 are stabilized after DNA damage in concert with p53 functional activation, and human Rad23 proteins (hHR23A and B) regulate p53 stability in unstressed cells, the role of hHR23B in post-genotoxin regulation of p53 was investigated. Depletion of hHR23B by specific short interfering RNA before genotoxic exposure attenuated p53, p21 and bax induction, abrogated the accumulation of ubiquitinated p53 and suppressed apoptosis. Expression of ubiquitin derivatives with all lysines mutated except K48 or K63 demonstrated that K48-linked p53-ubiquitin conjugates were specifically induced after DNA damage. hHR23B, along with native and ubiquitinated p53, accumulated in chromatin after genotoxic exposure, and the accumulation of ubiquitinated p53 in chromatin was prevented by hHR23B depletion. Chromatin immunoprecipitation analysis demonstrated that hHR23B and p53 both localized to the p21 promoter shortly after DNA damage. hHR23B thus plays a critical role in the activation and function of p53 after specific genotoxic exposures.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Gastrointestinal Canc Program, Worcester, MA 01605 USA; Univ Massachusetts, Ctr Canc, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Grossman, SR (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB419,364 Plantat St, Worcester, MA 01605 USA.	steven.grossman@umassmed.edu			NATIONAL CANCER INSTITUTE [R01CA107532] Funding Source: NIH RePORTER; NCI NIH HHS [CA107532, R01 CA107532] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brignone C, 2004, ONCOGENE, V23, P4121, DOI 10.1038/sj.onc.1207540; Cutts SM, 2003, MOL CANCER THER, V2, P661; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hsieh HC, 2005, BIOCHEM BIOPH RES CO, V335, P181, DOI 10.1016/j.bbrc.2005.07.067; Itoh T, 2005, DNA REPAIR, V4, P1457, DOI 10.1016/j.dnarep.2005.08.008; Kruczynski A, 2004, CLIN CANCER RES, V10, P3156, DOI 10.1158/1078-0432.CCR-1305-2; Lee YJ, 2006, CARCINOGENESIS, V27, P446, DOI 10.1093/carcin/bgi254; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Ng JMY, 2003, GENE DEV, V17, P1630, DOI 10.1101/gad.260003; Ng JMY, 2002, MOL CELL BIOL, V22, P1233, DOI 10.1128/MCB.22.4.1233-1245.2002; Ortolan TG, 2004, NUCLEIC ACIDS RES, V32, P6490, DOI 10.1093/nar/gkh987; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Raasi S, 2004, J MOL BIOL, V341, P1367, DOI 10.1016/j.jmb.2004.06.057; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Robles AI, 1999, ONCOGENE, V18, P4681, DOI 10.1038/sj.onc.1202862; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Soria G, 2006, ONCOGENE, V25, P2829, DOI 10.1038/sj.onc.1209315; Sweder K., 2002, Journal of Biomedicine & Biotechnology, V2, P94, DOI 10.1155/S1110724302205033; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang XY, 2003, SPECTROSC SPECT ANAL, V23, P42; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xie ZW, 2004, NUCLEIC ACIDS RES, V32, P5981, DOI 10.1093/nar/gkh934	28	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1231	1237		10.1038/sj.onc.1209865	http://dx.doi.org/10.1038/sj.onc.1209865			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924240	Green Accepted			2022-12-17	WOS:000244406400013
J	Rokaeus, N; Klein, G; Wiman, KG; Szekely, L; Mattsson, K				Rokaeus, N.; Klein, G.; Wiman, K. G.; Szekely, L.; Mattsson, K.			PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins	ONCOGENE			English	Article						mutant p53; PRIMA-; nucleolus; PML odies; Hsp70	ACUTE PROMYELOCYTIC LEUKEMIA; POLYMERASE-I TRANSCRIPTION; DNA-DAMAGE; PREMATURE SENESCENCE; DEPENDENT APOPTOSIS; ONCOGENIC RAS; C-MYC; CELLS; DEGRADATION; INHIBITION	We have previously identified PRIMA-1, a low molecular weight compound that restores the transcriptional transactivation function to mutant p53 and induction of apoptosis. To explore the molecular mechanism for PRIMA-1-induced mutant p53-dependent apoptosis, we examined the intracellular distribution of mutant p53 upon treatment with PRIMA-1(MET) by immunofluorescence staining. We found that PRIMA-1(MET) induced nucleolar translocation of mutant p53 and the promyelocytic leukemia (PML) nuclear body-associated proteins PML, CBP and Hsp70. Levels of Hsp70 were significantly enhanced by PRIMA-1(MET) treatment. PRIMA-Dead, a compound structurally related to PRIMA-1 but unable to induce mutant p53-dependent apoptosis, failed to induce nucleolar translocation of mutant p53. Our results suggest that redistribution of mutant p53 to nucleoli plays a role in PRIMA-1-induced apoptosis.	Karolinska Univ Hosp, Karolinska Inst, CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; Karolinska Inst, MTC, Microbiol & Tumor Biol Ctr, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Univ Hosp, Karolinska Inst, CCK, Dept Oncol Pathol, R8-04, SE-17176 Stockholm, Sweden.	Klas.Wiman@ki.se	Szekely, Laszlo/B-1268-2009; Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Szekely, Laszlo/0000-0001-6144-6573				Amin HM, 2001, BRIT J HAEMATOL, V115, P287, DOI 10.1046/j.1365-2141.2001.03123.x; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Drouin A, 2001, EXP CELL RES, V271, P277, DOI 10.1006/excr.2001.5377; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olson MOJ, 2005, HISTOCHEM CELL BIOL, V123, P203, DOI 10.1007/s00418-005-0754-9; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pespeni M, 2005, METHODS, V35, P158, DOI 10.1016/j.ymeth.2004.08.006; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Rehman A, 2005, BREAST CANCER RES, V7, pR765, DOI 10.1186/bcr1290; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	48	22	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					982	992		10.1038/sj.onc.1209858	http://dx.doi.org/10.1038/sj.onc.1209858			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909106				2022-12-17	WOS:000244245400004
J	Kiyono, M; Shibuya, M				Kiyono, M.; Shibuya, M.			Inhibitory Smad transcription factors protect arterial endothelial cells from apoptosis induced by BMP4	ONCOGENE			English	Article						apoptosis; BMP4; endothelial cell; I-Smads	BONE MORPHOGENETIC PROTEIN; VENOUS DIFFERENTIATION; MEDIATES APOPTOSIS; ANGIOGENESIS; EXPRESSION; VASCULOGENESIS; RECEPTORS; GENES; FLOW	Arterial endothelial cells (EC) at the adult stage differ from capillary and venous EC in terms of resistance to stress; however, the molecular basis of this resistance is not clear. Here, we found that arterial EC are highly resistant to bone morphogenetic protein (BMP) 4-dependent apoptosis, whereas capillary and venous EC are not. The expression of inhibitory Smads (I-Smads) in arterial EC was well correlated with the resistance to this apoptosis. After the knockdown of I-Smad expression by short interfering RNA, the resistant arterial EC became sensitive to BMP4. In contrast, the ectopic expression of I-Smads in BMP4-sensitive cells suppressed BMP4-induced apoptosis. Furthermore, intravenous administration of BMP4 into mice caused hemorrhage of capillary EC in brain and lung. These results strongly suggest that BMP4/ I-Smads are a novel regulator for the stability of vascular EC.	Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	shibuya@ims.u-tokyo.ac.jp						Bourdeau A, 2000, TRENDS CARDIOVAS MED, V10, P279, DOI 10.1016/S1050-1738(01)00062-7; Duff SE, 2003, FASEB J, V17, P984, DOI 10.1096/fj.02-0634rev; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Gu K, 1996, ARCH ORAL BIOL, V41, P919, DOI 10.1016/S0003-9969(96)00052-0; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Herzog Y, 2001, MECH DEVELOP, V109, P115, DOI 10.1016/S0925-4773(01)00518-4; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Kiyono M, 2003, MOL CELL BIOL, V23, P4627, DOI 10.1128/MCB.23.13.4627-4636.2003; le Noble F, 2004, DEVELOPMENT, V131, P361, DOI 10.1242/dev.00929; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moyon D, 2001, DEVELOPMENT, V128, P3359; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Patan S, 2004, CANC TREAT, V117, P3; Shawber CJ, 2003, ANN NY ACAD SCI, V995, P162, DOI 10.1111/j.1749-6632.2003.tb03219.x; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59; Shin D, 2001, DEV BIOL, V230, P139, DOI 10.1006/dbio.2000.9957; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	25	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	54					7131	7137		10.1038/sj.onc.1209700	http://dx.doi.org/10.1038/sj.onc.1209700			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732319				2022-12-17	WOS:000242046900002
J	Parsons, MJ; Vertino, PM				Parsons, M. J.; Vertino, P. M.			Dual role of TMS1/ASC in death receptor signaling	ONCOGENE			English	Article						TNF alpha; TRAIL; apoptosis; NF-kappa B; epigenetic silencing; caspase-8	NF-KAPPA-B; CASPASE RECRUITMENT DOMAIN; CONTAINING APAF1-LIKE PROTEIN; FACTOR-INDUCED APOPTOSIS; INDUCED-PROXIMITY MODEL; SPECK-LIKE PROTEIN; ABERRANT METHYLATION; HUMAN BREAST; REGULATES ACTIVATION; TERMINAL KINASE	Aberrant DNA methylation of promoter region CpG islands is associated with gene silencing and serves as an alternative to mutations in the inactivation of tumor suppressor genes in human cancers. We identified a gene TMS1 ( for Target of Methylation-mediated Silencing) that is subject to such epigenetic silencing in a significant proportion of human breast and other cancers. Also known as ASC and PYCARD, TMS1 encodes a bipartite intracellular signaling molecule with proposed roles in apoptosis and inflammation. However, the precise role of this protein in the pathogenesis of breast and other cancers has not been clearly defined. In this study, we examined the role of TMS1/ASC in death receptor signaling. We found that TMS1/ASC is upregulated in response to treatment with TNF-related apoptosis-inducing ligand ( TRAIL) and tumor necrosis factor-alpha (TNF alpha) in breast epithelial cells, but not in human fibroblasts. This upregulation was not dependent on the synthesis of a TNF alpha-regulated intermediate or alterations in mRNA stability, suggesting a direct effect on TMS1/ASC transcription. Induction of TMS1/ASC by TNFa was blocked by co-expression of a dominant negative I kappa B alpha, small interfering RNA-mediated knockdown of RelA/p65, or concurrent treatment with SP600125, indicating a requirement for the nuclear factor-kappa B (NF-kappa B) and jun kinase signaling pathways. Although previous work has suggested that TMS1/ASC may be directly regulated by p53, we found that whereas treatment of breast epithelial cells or normal diploid. broblasts with DNA damaging agents resulted in the stabilization of endogenous p53 and a concomitant increase in p21, it had little impact on the expression of TMS1/ASC mRNA or protein. We further show that whereas TMS1/ASC is not required for TNF alpha or TRAIL-induced activation of NF-kappa B or caspase-8, it can promote caspase-8 activation independently of death receptor-ligand interactions. Taken together, these data suggest that upregulation of TMS1/ASC by TNF alpha and subsequent activation of caspase-8 could function to amplify the apoptotic signal induced by death receptors in some cell types, including breast epithelial cells.	Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA; Emory Univ, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Vertino, PM (corresponding author), Emory Univ, Dept Radiat Oncol, 1365-C Clifton Rd,NE, Atlanta, GA 30322 USA.	pvertin@emory.edu						Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Conway KE, 2000, CANCER RES, V60, P6236; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Furukawa Y, 2005, MOL CANCER RES, V3, P325, DOI 10.1158/1541-7786.MCR-04-0105; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hasegawa M, 2005, J BIOL CHEM, V280, P15122, DOI 10.1074/jbc.M412284200; Horak P, 2005, MOL CANCER RES, V3, P335, DOI 10.1158/1541-7786.MCR-04-0136; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, MOL CELL BIOL, V19, P2021; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430; Li GQ, 2004, J BIOL CHEM, V279, P1123, DOI 10.1074/jbc.M305893200; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7; Masumoto J, 2001, J HISTOCHEM CYTOCHEM, V49, P1269, DOI 10.1177/002215540104901009; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; McConnell BB, 2000, CANCER RES, V60, P6243; McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Moriai R, 2002, ANTICANCER RES, V22, P4163; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Richards N, 2001, J BIOL CHEM, V276, P39320, DOI 10.1074/jbc.M104730200; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shetty S, 2005, MOL CELL BIOL, V25, P5404, DOI 10.1128/MCB.25.13.5404-5416.2005; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Shiohara M, 2002, BIOCHEM BIOPH RES CO, V293, P1314, DOI 10.1016/S0006-291X(02)00384-4; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stehlik C, 2003, J IMMUNOL, V171, P6154, DOI 10.4049/jimmunol.171.11.6154; Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552; Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Tian B, 2005, J BIOL CHEM, V280, P17435, DOI 10.1074/jbc.M500437200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; van Noesel MM, 2002, CANCER RES, V62, P2157; Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yamamoto M, 2004, GENES CELLS, V9, P1055, DOI 10.1111/j.1365-2443.2004.00789.x; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yokoyama T, 2003, CANCER LETT, V202, P101, DOI 10.1016/j.canlet.2003.08.027; Yu JW, 2006, CELL DEATH DIFFER, V13, P236, DOI 10.1038/sj.cdd.4401734; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	66	22	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6948	6958		10.1038/sj.onc.1209684	http://dx.doi.org/10.1038/sj.onc.1209684			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715133				2022-12-17	WOS:000241732300005
J	Neiman, PE; Kimmel, R; Icreverzi, A; Elsaesser, K; Bowers, SJ; Burnside, J; Delrow, J				Neiman, P. E.; Kimmel, R.; Icreverzi, A.; Elsaesser, K.; Bowers, S. -J.; Burnside, J.; Delrow, J.			Genomic instability during myc-induced lymphomagenesis in the bursa of fabricius	ONCOGENE			English	Article						myc oncogene; gene amplification; DNA palindromes	B-CELL DEVELOPMENT; SHORT INVERTED REPEATS; LARGE DNA PALINDROME; GENE AMPLIFICATION; HUMAN CANCERS; HL60 CELLS; CHICKEN; EXPRESSION; CDNA; HAMSTER	Retroviral vector-mediated overexpression of c-myc in embryonic bursal precursors induces multi-staged tumorigenesis beginning with preneoplastic-transformed follicles (TF) and progressing to clonal metastatic B-cell lymphomas. Using a 13K chicken cDNA microarray, specifically enriched for chicken immune system expressed sequence tagged (ESTs), we carried out array-based comparative genomic hybridization (array-CGH) and detected significant DNA copy number change at many loci on most or all chromosomes in both early TF and end-stage lymphomas. Formation of long palindromes, through breakage-fusion-bridge cycles, is thought to play an early role in gene amplification. Employing genome-wide analysis of palindrome formation (GAPF), we detected extensive palindrome formation in early TF and end-stage lymphomas. The population of loci showing amplification by array-CGH was enriched for palindromes detected by GAPF providing strong evidence for genetic instability early in Myc-induced tumorigenesis and further support for the role of palindromes in gene amplification. Comparing gene copy number change and RNA expression changes pro. led on the same cDNA array, we detected very little consistent contribution of gene copy number change to RNA expression changes. Palindromic loci in TF and tumors, however, were expressed, many at high levels, suggesting an abundance of RNA species with long double-stranded segments generated during tumorigenesis.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; Univ Delaware, Dept Anim & Food Sci, Newark, DE USA; Fred Hutchinson Canc Res Ctr, DNA Array Facil, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Delaware; Fred Hutchinson Cancer Center	Neiman, PE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,C2-023, Seattle, WA 98109 USA.	pneiman@fhcrc.org	Nolen, Danielle/A-5250-2010; Crozier, Laura B/C-5891-2011		NATIONAL CANCER INSTITUTE [R01CA020068, R01CA109365] Funding Source: NIH RePORTER; NCI NIH HHS [CA-20068, CA-109365] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boardman PE, 2002, CURR BIOL, V12, P1965, DOI 10.1016/S0960-9822(02)01296-4; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Brown CY, 2004, DEV COMP IMMUNOL, V28, P619, DOI 10.1016/j.dci.2003.09.017; Burnside J, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-13; Butler DK, 1996, CELL, V87, P1115, DOI 10.1016/S0092-8674(00)81805-X; Chang H, 2004, CHROMOSOME RES, V12, P299, DOI 10.1023/B:CHRO.0000021947.17128.96; Ellerman V., 1908, ZENTR BAKTERIOL PARA, V46, P595; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; ESKOLA J, 1974, CELL IMMUNOL, V13, P459, DOI 10.1016/0008-8749(74)90265-2; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Feo S, 1996, ONCOGENE, V13, P1521; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hillier LW, 2004, NATURE, V432, P695, DOI 10.1038/nature03154; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Kittler R, 2004, NATURE, V432, P1036, DOI 10.1038/nature03159; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LOONEY JE, 1987, MOL CELL BIOL, V7, P569, DOI 10.1128/MCB.7.2.569; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; Mai S, 1996, ONCOGENE, V12, P277; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; Mangano R, 1998, ONCOGENE, V17, P2771, DOI 10.1038/sj.onc.1202434; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; NEIMAN P, 1985, P NATL ACAD SCI USA, V82, P222, DOI 10.1073/pnas.82.1.222; NEIMAN P, 1980, J VIROL, V34, P178, DOI 10.1128/JVI.34.1.178-186.1980; NEIMAN P, 2006, REV PROTOCOLS DT40 R; NEIMAN PE, 1975, CELL, V4, P311; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NEIMAN PE, 1994, ADV IMMUNOL, V56, P467, DOI 10.1016/S0065-2776(08)60457-5; Neiman PE, 2003, ONCOGENE, V22, P1073, DOI 10.1038/sj.onc.1206070; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Tanaka H, 2005, NAT GENET, V37, P320, DOI 10.1038/ng1515; Tanaka H, 2002, P NATL ACAD SCI USA, V99, P8772, DOI 10.1073/pnas.132275999; THOMPSON CB, 1987, CELL, V51, P371, DOI 10.1016/0092-8674(87)90633-7; Tlsty TD, 1997, CURR TOP MICROBIOL, V221, P37; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; YASUDA LF, 1991, CELL, V67, P505, DOI 10.1016/0092-8674(91)90525-4; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	42	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2006	25	47					6325	6335		10.1038/sj.onc.1209646	http://dx.doi.org/10.1038/sj.onc.1209646			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16652139				2022-12-17	WOS:000241218200009
J	Glesne, D; Huberman, E				Glesne, D.; Huberman, E.			Smad6 is a protein kinase X phosphorylation substrate and is required for HL-60 cell differentiation	ONCOGENE			English	Article						macrophage differentiation; PrKX; Smad6; HL-60; leukemia	GROWTH-FACTOR-BETA; TUMOR-NECROSIS-FACTOR; MACROPHAGE DIFFERENTIATION; ALPHA(5)BETA(1) INTEGRIN; CATALYTIC SUBUNIT; EXPRESSION; INDUCTION; SEQUENCE; SYSTEM; PRKX	To gain insight into the function of human protein kinase X (PrKX), a signal-transduction protein required for macrophage differentiation, we identified regulatory subunit I alpha of protein kinase A, T54 and Smad6 as partners for this protein using a yeast two-hybrid interaction screen. Interactions between PrKX and these proteins were substantiated by co-immunoprecipitation. Interaction between Smad6 and PrKX was also confirmed in human myeloid HL-60 cells following their phorbol 12-myristate 13-acetate (PMA)-induced differentiation into macrophages. In vitro phosphorylation assays demonstrated that PrKX phosphorylates Smad6 at a serine residue. Mutagenesis of this site resulted in abrogation of PrKX phosphorylation. Both PrKX and Smad6 were shown to be co-localized to the nuclear compartment of HL-60 cells during their macrophage differentiation where PrKX levels are induced and Smad6 protein levels remain relatively constant while levels of serine phosphorylation of Smad6 increase. By using in vitro electrophoretic mobility shift assays and in vivo chromatin immunoprecipitation, we also demonstrate that during macrophage differentiation Smad6 displays an increased binding to the human osteopontin, Id2, and Hex gene promoters, which correlates to an observed increased expression of these genes. Finally, vector-based RNA interference experiments established that both Smad6 and PrKX proteins are required for PMA-induced cell attachment and spreading.	Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA; Argonne Natl Lab, Gene Express & Funct Grp, Argonne, IL 60439 USA	United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory	Huberman, E (corresponding author), Argonne Natl Lab, Biosci Div, 9700 S Cass Ave,Bld 202, Argonne, IL 60439 USA.	elih@anl.gov			NATIONAL CANCER INSTITUTE [R01CA080826] Funding Source: NIH RePORTER; NCI NIH HHS [CA80826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersson G, 1996, CONNECT TISSUE RES, V35, P163, DOI 10.3109/03008209609029188; Atkins K, 1998, J CELL PHYSIOL, V175, P229, DOI 10.1002/(SICI)1097-4652(199805)175:2<229::AID-JCP13>3.0.CO;2-3; Bai ST, 2000, J BIOL CHEM, V275, P8267, DOI 10.1074/jbc.275.12.8267; Bai ST, 2002, J BIOL CHEM, V277, P4176, DOI 10.1074/jbc.M105105200; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Blaschke RJ, 2000, GENOMICS, V64, P187, DOI 10.1006/geno.2000.6116; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; Chiorini JA, 1998, MOL CELL BIOL, V18, P5921, DOI 10.1128/MCB.18.10.5921; COLLART FR, 1990, BLOOD, V75, P570; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Pasquale G, 2003, EMBO J, V22, P1716, DOI 10.1093/emboj/cdg153; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Greenbaum L, 2003, ONCOGENE, V22, P5221, DOI 10.1038/sj.onc.1206723; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; HUBERMAN E, 1982, CARCINOGENESIS, V3, P111, DOI 10.1093/carcin/3.1.111; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; KAMIJO R, 1990, J IMMUNOL, V144, P1311; KLINK A, 1995, HUM MOL GENET, V4, P869, DOI 10.1093/hmg/4.5.869; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Laouar A, 1999, J IMMUNOL, V162, P407; Li XH, 2002, P NATL ACAD SCI USA, V99, P9260, DOI 10.1073/pnas.132051799; LILJESTROM PL, 1985, NUCLEIC ACIDS RES, V13, P7257, DOI 10.1093/nar/13.20.7257; MELENDEZ A, 1995, GENETICS, V141, P1507; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; NISHIKAWA M, 1994, CANCER RES, V54, P4879; Nunes I, 1996, CANCER RES, V56, P495; Orkin SH, 1996, CURR OPIN GENET DEV, V6, P597, DOI 10.1016/S0959-437X(96)80089-X; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Ribardo DA, 2001, J BIOL CHEM, V276, P5467, DOI 10.1074/jbc.M006690200; ROVERA G, 1982, ANN NY ACAD SCI, V397, P211, DOI 10.1111/j.1749-6632.1982.tb43428.x; Rozovskaia T, 2003, P NATL ACAD SCI USA, V100, P7853, DOI 10.1073/pnas.1132115100; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schindelhauer D, 1996, GENOME RES, V6, P1056, DOI 10.1101/gr.6.11.1056; Semizarov D, 1998, P NATL ACAD SCI USA, V95, P15412, DOI 10.1073/pnas.95.26.15412; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; Vanegas N, 2003, LEUKEMIA RES, V27, P607, DOI 10.1016/S0145-2126(02)00231-X; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Xie B, 1998, J BIOL CHEM, V273, P11583, DOI 10.1074/jbc.273.19.11583; Zhang WJ, 2002, J BIOL CHEM, V277, P45435, DOI 10.1074/jbc.M208056200; Zhao FP, 2001, J ENDOTOXIN RES, V7, P53, DOI 10.1179/096805101101532549; Zhao Y, 2003, P NATL ACAD SCI USA, V100, P2426, DOI 10.1073/pnas.0536882100; Zimmermann B, 1999, J BIOL CHEM, V274, P5370, DOI 10.1074/jbc.274.9.5370	56	22	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4086	4098		10.1038/sj.onc.1209436	http://dx.doi.org/10.1038/sj.onc.1209436			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491121				2022-12-17	WOS:000238802400009
J	Ma, W; Xia, X; Stafford, LJ; Yu, C; Wang, F; LeSage, G; Liu, M				Ma, W.; Xia, X.; Stafford, L. J.; Yu, C.; Wang, F.; LeSage, G.; Liu, M.			Expression of GCIP in transgenic mice decreases susceptibility to chemical hepatocarcinogenesis	ONCOGENE			English	Article						GCIP; CCNDBP1; DIP1/HHM; transgenic mouse; hepatocarcinogenesis; diethylnitrosamine; HLH-zipper proteins	LOOP-HELIX PROTEINS; DNA-BINDING PROTEINS; ID PROTEINS; CYCLIN D1; HEPATOCELLULAR-CARCINOMA; CELL-CYCLE; MYELOID DIFFERENTIATION; TRANSCRIPTION FACTORS; NEGATIVE REGULATOR; GENE-EXPRESSION	Transcription factors with helix-loop-helix (HLH) motif play critical roles in controlling the expression of genes involved in lineage commitment, cell fate determination, proliferation, and tumorigenesis. To examine whether the newly identified HLH protein GCIP/CCNDBP1 modulates cell fate determination and plays a role in hepatocyte growth, proliferation, and hepatocarcinogenesis, we generated transgenic mice with human GCIP gene driven by a liver-specific albumin promoter. We demonstrated that in GCIP transgenic mice, the overall liver growth and regeneration occurred normally after liver injury induced by carbon tetrachloride (CCl4). In the diethylnitrosamine (DEN)-induced mouse hepatocarcinogenesis, we demonstrated that overexpression of GCIP in mouse liver suppressed DEN-induced hepatocarcinogenesis at an early stage of tumor development. The number of hepatic adenomas at 24 weeks was significantly lower or not detected in GCIP transgenic male mice compared to the control mice under the same treatment. Although GCIP has little inhibition on the number of hepatic tumors at later stages (40 weeks), hepatocellular tumors in GCIP transgenic mice are smaller and well-differentiated compared to the poorly differentiated tumors in wildtype mice. Furthermore, we demonstrate that GCIP functions as a transcriptional suppressor, regulates the expression of cyclin D1, and inhibits anchorage-independent cell growth and colony formation in HepG2 cells, suggesting a significant role of GCIP in tumor initiation and development.	Texas A&M Univ, Alkek Inst Biosci & Technol, Syst Hlth Sci Ctr, Houston, TX 77030 USA; Texas A&M Univ, Ctr Canc Biol & Nutr, Syst Hlth Sci Ctr, Houston, TX 77030 USA; Texas A&M Univ, Dept Mol & Cellular Med, Syst Hlth Sci Ctr, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77225 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Liu, M (corresponding author), Texas A&M Univ, Alkek Inst Biosci & Technol, Syst Hlth Sci Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamhsc.edu		Ma, Wenbin/0000-0001-8774-7593	NCI NIH HHS [1R01CA106479] Funding Source: Medline; NHLBI NIH HHS [5R01HL064792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106479] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Cooper TA, 2005, CELL, V120, P1, DOI 10.1016/j.cell.2004.12.030; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; Deane NG, 2004, CANCER RES, V64, P1315, DOI 10.1158/0008-5472.CAN-03-1772; Deane NG, 2001, CANCER RES, V61, P5389; DIWAN BA, 1976, CANCER LETT, V1, P249; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Hwang SY, 1997, DEV DYNAM, V209, P217, DOI 10.1002/(SICI)1097-0177(199706)209:2<217::AID-AJA7>3.0.CO;2-L; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kee BL, 2000, IMMUNOL REV, V175, P138, DOI 10.1111/j.1600-065X.2000.imr017514.x; Kenny FS, 1999, CLIN CANCER RES, V5, P2069; Knight B, 2000, J EXP MED, V192, P1809, DOI 10.1084/jem.192.12.1809; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Ledda-Columbano GM, 2002, HEPATOLOGY, V36, P1098, DOI 10.1053/jhep.2002.36159; Lee C, 2005, BRIEF BIOINFORM, V6, P23, DOI 10.1093/bib/6.1.23; Lee GH, 1998, CANCER RES, V58, P1665; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lemmer ER, 2004, CARCINOGENESIS, V25, P1257, DOI 10.1093/carcin/bgh129; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOORE MR, 1981, CANCER RES, V41, P1585; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nakatani T, 2001, JPN J CANCER RES, V92, P249, DOI 10.1111/j.1349-7006.2001.tb01089.x; Natrajan R, 2003, CANCER RES, V63, P7657; Nishida N, 1997, HISTOL HISTOPATHOL, V12, P1019; NISHIDA N, 1994, CANCER RES, V54, P3107; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Pin CL, 2001, J CELL BIOL, V155, P519, DOI 10.1083/jcb.200105060; RECKNAGEL RO, 1989, PHARMACOL THERAPEUT, V43, P139, DOI 10.1016/0163-7258(89)90050-8; Rivera R, 2001, ONCOGENE, V20, P8308, DOI 10.1038/sj.onc.1205091; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Roskams TA, 2003, SEMIN LIVER DIS, V23, P385; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; SHIRAKATA M, 1995, EMBO J, V14, P1766, DOI 10.1002/j.1460-2075.1995.tb07165.x; Sierralta J, 2004, BRAIN RES REV, V47, P105, DOI 10.1016/j.brainresrev.2004.06.002; Sikder H, 2003, CANCER CELL, V4, P291, DOI 10.1016/S1535-6108(03)00245-9; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; SUGIHARA S, 1992, CANCER, V70, P1488, DOI 10.1002/1097-0142(19920915)70:6<1488::AID-CNCR2820700607>3.0.CO;2-J; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Suzui M, 2002, CANCER RES, V62, P3997; Takami T, 2005, GASTROENTEROLOGY, V128, P1369, DOI 10.1053/j.gastro.2005.03.014; Terai S, 2000, HEPATOLOGY, V32, P357, DOI 10.1053/jhep.2000.9092; Theise ND, 2003, HISTOPATHOLOGY, V43, P263, DOI 10.1046/j.1365-2559.2003.01707.x; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; VESSELINOVITCH SD, 1987, TOXICOL PATHOL, V15, P221, DOI 10.1177/019262338701500216; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WROBLEWSKI F, 1959, AM J MED, V27, P911, DOI 10.1016/0002-9343(59)90175-5; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Yao Y, 2000, EXP CELL RES, V257, P22, DOI 10.1006/excr.2000.4884; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092; Zhao XF, 1999, J BIOL CHEM, V274, P1388, DOI 10.1074/jbc.274.3.1388; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	68	22	22	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4207	4216		10.1038/sj.onc.1209450	http://dx.doi.org/10.1038/sj.onc.1209450			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501603				2022-12-17	WOS:000239004800008
J	Wang, P; Greiner, TC; Lushnikova, T; Eischen, CM				Wang, P.; Greiner, T. C.; Lushnikova, T.; Eischen, C. M.			Decreased Mdm2 expression inhibits tumor development induced by loss of ARF	ONCOGENE			English	Article						Mdm2; ARF; p53; transformation; tumor	MYC-INDUCED LYMPHOMAGENESIS; CELL-CYCLE ARREST; P53-INDEPENDENT FUNCTIONS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; SUPPRESSOR PROTEIN; DEFICIENT MICE; DNA-DAMAGE; P53; P19(ARF)	The tumor suppressor p14/p19(ARF) regulates Mdm2, which is known for controlling the p53 tumor suppressor. Here we report that loss of one allele of Mdm2 in cells that lack ARF resulted in a decreased rate of proliferation, fewer chromosomal aberrations, and suppression of Ras-induced transformation. Moreover, a haploinsufficiency of Mdm2 inhibited spontaneous tumor development in ARF-null mice. Remarkably, Mdm2(+/-) ARF(-/-) mice survived an average of 6 months longer than Mdm2(+/-) ARF(-/-) mice. The spectrum of tumors that arose in Mdm2(+/-) ARF(-/-) mice did not significantly differ from those that developed in mice lacking only ARF. However, the extended tumor latency allowed for the emergence of multiple primary tumors in a third of the Mdm2(+/-) ARF(-/-) mice, as compared to the single tumor type that arose in ARF null only mic e. Therefore, a decrease in Mdm2 levels restored regulation of critical cellular processes that are altered during transformation and that occur in the absence of ARF. Our findings also indicate that Mdm2 can function independently from ARF and imply that targeting Mdm2 in tumors that lack ARF expression should be an effective therapeutic approach.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Nebraska, Ctr Med, Dept Pathol & Microbiol, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System	Eischen, CM (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, 600 S 42nd St, Omaha, NE 68198 USA.	ceischen@unmc.edu			NCI NIH HHS [CA098139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2002, CANCER RES, V62, P2184; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1993, ONCOGENE, V8, P1519; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Iwakuma T, 2003, MOL CANCER RES, V1, P993; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KAMB A, 1994, SCIENCE, V264, P440; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUNA RMD, 1995, NATURE, V378, P203; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Matheu A, 2004, GENE DEV, V18, P2736, DOI 10.1101/gad.310304; MAYR GA, 1995, CANCER RES, V55, P2410; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; Moore L, 2003, ONCOGENE, V22, P7831, DOI 10.1038/sj.onc.1206985; O'Leary KA, 2004, MOL CELL BIOL, V24, P186, DOI 10.1128/MCB.24.1.186-191.2004; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	46	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3708	3718		10.1038/sj.onc.1209411	http://dx.doi.org/10.1038/sj.onc.1209411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16491126				2022-12-17	WOS:000238448300010
J	Li, N; Li, H; Cherukuri, P; Farzan, S; Harmes, DC; DiRenzo, J				Li, N; Li, H; Cherukuri, P; Farzan, S; Harmes, DC; DiRenzo, J			TA-p63-gamma regulates expression of Delta N-p63 in a manner that is sensitive to p53	ONCOGENE			English	Article						p63; p53; mammary gland; progenitor; self-renewal	EPITHELIAL STEM-CELLS; P63 GENE-MUTATIONS; BREAST-CANCER; DIFFERENTIAL REGULATION; DEVELOPMENTAL SYNDROMES; PROTEIN-DEGRADATION; MAMMARY-GLAND; TARGET GENES; SELF-RENEWAL; EEC-SYNDROME	Geneticanalysis indicates that TP63 is required for establishment and preservation of self-renewing progenitors within the basal layer of several epithelial structures, however, the specific contributions of transactivating ( TAp63) and dominant-negative (DN-p63) isoforms remain largely undemned. Recent studies have suggested a model in which TA-p63 plays an important role in the establishment of progenitor populations in which expression of Delta Np63 contributes to the preservation of self-renewing capacity. Our previous studies indicate that Delta N-p63 is a transcriptional target of p53, however, the absence of overt epithelial deficiencies in p53-/- mice and reports of increased expression of Delta N-p63 in p53-/- mice suggest p53-independent mechanisms also contribute to expression of DN-p63. Here, we present data indicating that, prolonged loss of p53 leads to the activation of a p53-independent mechanism for transcriptional regulation of DN-p63. This p53-independent mechanism is sensitive to ectopic p53 but not to a p53 mutant that lacks the transactivation domain. We further show that in cells in which p53 is expressed TA-p63-gamma protein is destabilized in a manner that is p53 dependent and sensitive to pharmacologic inhibition of the 26S proteosome. Consistent with this observation, we demonstrate that loss of p53 leads to the stabilization of TA-p63-gamma that is reversible by ectopic p53. Finally, we present evidence that disruption of TA-p63-gamma expression leads to decreased expression of Delta N-p63 and that overexpression of TA-p63c was sufficient to enhance the activity of the Delta N-p63 promoter. Taken together, our studies indicate that TAp63 gamma is capable of activating expression of Delta N-p63 and that this mechanism may account for p53-independent expression of DN-p63.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	DiRenzo, J (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	james.direnzo@dartmouth.edu			NATIONAL CANCER INSTITUTE [R01CA108539] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA108539] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chepko G, 1999, J MAMMARY GLAND BIOL, V4, P35, DOI 10.1023/A:1018752519356; Clarke RB, 2003, CELL PROLIFERAT, V36, P1, DOI 10.1046/j.1365-2184.36.s.1.1.x; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025; DiRenzo J, 2002, CANCER RES, V62, P89; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jerry DJ, 1999, J MAMMARY GLAND BIOL, V4, P177, DOI 10.1023/A:1018777224808; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Koster MI, 2002, J INVEST DERM SYMP P, V7, P41, DOI 10.1046/j.1523-1747.2002.19639.x; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Smith GH, 2001, MICROSC RES TECHNIQ, V52, P190, DOI 10.1002/1097-0029(20010115)52:2<190::AID-JEMT1005>3.0.CO;2-O; Suliman Y, 2001, CANCER RES, V61, P6467; Trosko JE, 2003, ONCOL RES, V13, P353; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Welm AL, 2005, P NATL ACAD SCI USA, V102, P4324, DOI 10.1073/pnas.0500470102; Welm B, 2003, CELL PROLIFERAT, V36, P17, DOI 10.1046/j.1365-2184.36.s.1.3.x; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Ying HQ, 2005, MOL CELL BIOL, V25, P6154, DOI 10.1128/MCB.25.14.6154-6164.2005	40	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2349	2359		10.1038/sj.onc.1209270	http://dx.doi.org/10.1038/sj.onc.1209270			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331262				2022-12-17	WOS:000236764300007
J	Hossini, AM; Geilen, CC; Fecker, LF; Daniel, PT; Eberle, J				Hossini, AM; Geilen, CC; Fecker, LF; Daniel, PT; Eberle, J			A novel Bcl-x splice product, Bcl-x(AK), triggers apoptosis in human melanoma cells without BH3 domain	ONCOGENE			English	Article						Bcl-x; apoptosis; alternative splicing; melanoma; chemotherapeutics	HUMAN MALIGNANT-MELANOMA; CANCER-CELLS; CONDITIONAL EXPRESSION; ANTIAPOPTOTIC PROTEIN; FAMILY PROTEINS; MESSENGER-RNA; IN-VITRO; DEATH; BAX; LINES	Pro- and antiapoptotic proteins of the large Bcl-2 family are critical regulators of apoptosis via the mitochondrial pathway. Whereas antiapoptotic proteins of the family share all four Bcl-2 homology domains (BH1-BH4), proapoptotic members may lack some of these domains, but all so far described proapoptotic Bcl-2 proteins enclose BH3. The bcl-x gene gives rise to several alternative splice products resulting in proteins with distinct functions as the antiapoptotic Bcl-x(L) and proapoptotic Bcl-x(S). Here, we describe a novel Bcl-x splice product of 138 amino acids termed Bcl-x(AK) (Atypical Killer), which encloses the Bcl-2 homology domains BH2 and BH4 as well as the transmembrane domain, but lacks BH1 and BH3. Weak endogenous expression of Bcl-x(AK) was seen in melanoma and other tumor cells. Interestingly, its overexpression by applying a tetracycline-inducible expression system-resulted in significant induction of apoptosis in melanoma cells, which occurred in synergism with drug-induced apoptosis. After exogenous overexpression, Bcl-x(AK) was localized both in mitochondrial and in cytosolic cell fractions. By these findings, a completely new class of Bcl-2-related proteins is introduced, which promotes apoptosis independently from the BH3 domain and implies additional, new mechanisms for apoptosis regulation in melanoma cells.	Charite Univ Med Berlin, Dept Dermatol & Allergy, Skin Canc Ctr, D-12203 Berlin, Germany; Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Eberle, J (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Skin Canc Ctr, Campus Benjamin Franklin,Fabeckstr 60-62, D-12203 Berlin, Germany.	juergen.eberle@charite.de		Eberle, Jurgen/0000-0001-8533-1519				Ban J, 1998, BIOCHEM BIOPH RES CO, V248, P147, DOI 10.1006/bbrc.1998.8907; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BEAN MA, 1975, CANCER RES, V35, P2902; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; BRUGGEN J, 1981, J CANCER RES CLIN, V102, P141, DOI 10.1007/BF00410665; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; DEL PL, 1997, SCIENCE, V278, P687; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Eberle J, 1999, J INVEST DERMATOL, V112, P925, DOI 10.1046/j.1523-1747.1999.00598.x; Eberle J, 2003, ONCOGENE, V22, P9131, DOI 10.1038/sj.onc.1207228; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fecker LF, 2002, J INVEST DERMATOL, V118, P1019, DOI 10.1046/j.1523-1747.2002.01744.x; FULTS D, 1992, J NEUROPATH EXP NEUR, V51, P272, DOI 10.1097/00005072-199205000-00005; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Hipp ML, 1997, ONCOGENE, V15, P791, DOI 10.1038/sj.onc.1201247; HOLZMANN B, 1988, INT J CANCER, V41, P542; Hossini AM, 2003, FEBS LETT, V553, P250, DOI 10.1016/S0014-5793(03)01017-2; HOSSINI AM, 2003, ARCH DERMATOL RES, V294, P499; Hussein MR, 2003, J PATHOL, V199, P275, DOI 10.1002/path.1300; Jin KL, 2001, J NEUROCHEM, V77, P1508, DOI 10.1046/j.1471-4159.2001.00361.x; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kim MR, 2001, FEBS LETT, V505, P179, DOI 10.1016/S0014-5793(01)02816-2; Leech SH, 2000, INT J CANCER, V86, P570, DOI 10.1002/(SICI)1097-0215(20000515)86:4<570::AID-IJC20>3.0.CO;2-T; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; LIAO SK, 1975, J NATL CANCER I, V54, P1037; Lindenboim L, 2000, ONCOGENE, V19, P1783, DOI 10.1038/sj.onc.1203495; Losonczi JA, 2000, BIOCHEMISTRY-US, V39, P11024, DOI 10.1021/bi000919v; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ogata Y, 2003, DRUG NEWS PERSPECT, V16, P446, DOI 10.1358/dnp.2003.16.7.829356; OPPERMANN M, 2005, ONCOGENE; Oxford SME, 2004, CURR MED CHEM, V11, P1031, DOI 10.2174/0929867043455486; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Renshaw SA, 2004, J BIOL CHEM, V279, P2846, DOI 10.1074/jbc.M309769200; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; Schmitt E, 2004, ONCOGENE, V23, P3915, DOI 10.1038/sj.onc.1207554; Schwarz CS, 2002, NEUROREPORT, V13, P2439, DOI 10.1097/00001756-200212200-00013; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	62	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2160	2169		10.1038/sj.onc.1209253	http://dx.doi.org/10.1038/sj.onc.1209253			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288206				2022-12-17	WOS:000236581200003
J	Huang, M; Kamasani, U; Prendergast, GC				Huang, M; Kamasani, U; Prendergast, GC			RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3	ONCOGENE			English	Article						Ras; Rho; Akt; cancer	FARNESYLTRANSFERASE INHIBITORS; GERANYLGERANYLATED RHOB; PROTEIN-KINASE; PHOSPHORYLATION; TRANSFORMATION; GROWTH; CANCER; DEGRADATION; SUPPRESSION; EXPRESSION	The small GTPase RhoB suppresses cancer in part by limiting cell proliferation. However, the mechanisms it uses to achieve this are poorly understood. Recent studies link RhoB to trafficking of Akt, which through its regulation of glycogen synthase kinase-3 (GSK-3) has an important role in controlling the stability of the c-Myc oncoprotein. c-Myc stabilization may be a root feature of human tumorigenesis as it phenocopies an essential contribution of SV40 small T antigen in human cell transformation. In this study we show that RhoB directs efficient turnover of c-Myc in established or transformed mouse fibroblasts and that the attenuation of RhoB which occurs commonly in human cancer is a sufficient cause to elevate c-Myc levels. Increased levels of c-Myc elicited by RhoB deletion increased the proliferation of nullizygous cells, whereas restoring RhoB in null cells decreased the stability of c-Myc and restrained cell proliferation. Mechanistic analyses indicated that RhoB facilitated nuclear accumulation of GSK-3 and GSK-3-mediated phosphorylation of c-Myc T58, the critical site for ubiquitination and degradation of c-Myc. RhoB deletion restricted nuclear localization of GSK-3, reduced T58 phosphorylation, and stabilized c-Myc. These effects were not associated with changes in phosphorylation or localization of Akt, however, differences were observed in phosphorylation and localization of the GSK-3 regulatory Akt-related kinase, serum- and glucocorticoid-inducible protein kinase (SGK). The ability of RhoB to support GSK-3-dependent turnover of c-Myc offers a mechanism by which RhoB acts to limit the proliferation of neoplastically transformed cells.	Lankenau Inst Med Res, Canc Cell Signaling Lab, Wynnewood, PA 19096 USA; Thomas Jefferson Univ, Sch Med, Dept Pathol Anat & Cell Biol, Philadelphia, PA USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Jefferson University	Prendergast, GC (corresponding author), Lankenau Inst Med Res, Canc Cell Signaling Lab, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergastg@mlhs.org			NCI NIH HHS [CA82222, R01 CA100123, CA100123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100123, R01CA082222] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Adnane J, 2002, CLIN CANCER RES, V8, P2225; Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; Alarcon-Vargas D, 2002, ONCOGENE, V21, P4384, DOI 10.1038/sj.onc.1205543; BHATIA K, 1994, BLOOD, V84, P883; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Du W, 1999, MOL CELL BIOL, V19, P1831; Firestone GL, 2003, CELL PHYSIOL BIOCHEM, V13, P1, DOI 10.1159/000070244; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, FEBS LETT, V481, P205, DOI 10.1016/S0014-5793(00)02003-2; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; PULVERER BJ, 1994, ONCOGENE, V9, P59; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sakoda H, 2003, J BIOL CHEM, V278, P25802, DOI 10.1074/jbc.M301127200; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; WANG S, 2004, NOVART FDN SYMP, V259, P245; WANG S, 2004, NOVART FDN SYMP, V259, P285; Wang Shaowen, 2004, Novartis Found Symp, V259, P238; Wang SW, 2003, ONCOGENE, V22, P6204, DOI 10.1038/sj.onc.1206653; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wherlock M, 2004, J CELL SCI, V117, P3221, DOI 10.1242/jcs.01193; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zeng PY, 2003, ONCOGENE, V22, P1124, DOI 10.1038/sj.onc.1206181	48	22	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1281	1289		10.1038/sj.onc.1209174	http://dx.doi.org/10.1038/sj.onc.1209174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247449				2022-12-17	WOS:000235708200001
J	Djafarzadeh, R; Noessner, E; Engelmann, H; Schendel, DJ; Notohamiprodjo, M; von Luettichau, I; Nelson, PJ				Djafarzadeh, R; Noessner, E; Engelmann, H; Schendel, DJ; Notohamiprodjo, M; von Luettichau, I; Nelson, PJ			GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing	ONCOGENE			English	Article						renal cell carcinoma; cell surface engineering; FAS apoptosis; TIMP-1; GPI anchor	TUMOR-INFILTRATING LYMPHOCYTES; TISSUE INHIBITOR; IN-VIVO; MATRIX METALLOPROTEINASES; PANCREATIC-CANCER; EPITHELIAL-CELLS; MEDIATED LYSIS; DEATH; CYTOTOXICITY; APOPTOSIS	The resistance of tumours to immune-mediated lysis has been linked to the biology of matrix metalloproteinases (MMPs), and specically to the cell surface expression of MMPs by the tumour cell. The endogenous tissue inhibitors of metalloproteinases (TIMPs) exhibit diverse physiological/biological functions including the moderation of tumour growth, metastasis and apoptosis. These biologic activities are mediated in part by the stoichiometry of TIMP/MMP/cell surface protein interactions. A glycosylphosphatidylinositol (GPI) anchor was fused to TIMP-1 to focus defined concentrations of this inhibitory protein on the surface of three renal cell carcinoma (RCC) cell lines (RCC-26, RCC-53 and A498) independently of cell surface protein-protein interactions. Exogenously added TIMP-1-GPI efficiently inserted into the RCC cell membrane and dramatically altered the association of MMPs with the cell surface. TIMP-1-GPI treatment inhibited RCC proliferation and rendered the normally FAS-resistant RCC cells sensitive to FAS-induced apoptosis but did not alter perforin-mediated lysis by cytotoxic effector cells. The increased sensitivity to FAS-mediated apoptosis correlated with an alteration in the balance of pro- and antiapoptotic BCL-2-family proteins. By interfering with the proliferative capacity and inducing sensitivity to immune effector mechanisms GPI-anchored TIMP-1 may represent a more effective version of the TIMP-1 protein for therapeutic strategies.	Univ Munich, Med Poliklin, D-80336 Munich, Germany; GSF Inst Mol Immunol, Munich, Germany; Univ Munich, Inst Immunol, D-80336 Munich, Germany; Tech Univ Munich, Childrens Hosp, Med Ctr, D-8000 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Technical University of Munich; University of Munich	Nelson, PJ (corresponding author), Univ Munich, Med Poliklin, Schillerstr 42, D-80336 Munich, Germany.	peter.nelson@med.uni-muenchen.de						Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BARNSTABLE CJ, 1978, BRIT MED BULL, V34, P241, DOI 10.1093/oxfordjournals.bmb.a071504; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; Bloomston M, 2002, J SURG RES, V102, P39, DOI 10.1006/jsre.2001.6318; Bode W, 2003, BIOL CHEM, V384, P863, DOI 10.1515/BC.2003.097; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Brand Karsten, 2002, Current Gene Therapy, V2, P255, DOI 10.2174/1566523024605564; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brown O, 2000, GENE THER, V7, P1947, DOI 10.1038/sj.gt.3301325; Djafarzadeh R, 2004, BIOL CHEM, V385, P655, DOI 10.1515/BC.2004.081; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Frost P, 2003, INT J ONCOL, V22, P431; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GONG JH, 1994, LEUKEMIA, V8, P652; Hemmerlein B, 2004, INT J ONCOL, V24, P1069; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; JOHNSON JP, 1988, IMMUNOBIOLOGY, V178, P275, DOI 10.1016/S0171-2985(88)80071-8; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KIRBY AC, 1995, BIOCHEM BIOPH RES CO, V214, P200, DOI 10.1006/bbrc.1995.2275; Klier CM, 2001, BIOL CHEM, V382, P1405, DOI 10.1515/BC.2001.173; Lang R, 2004, J MOL BIOL, V336, P213, DOI 10.1016/j.jmb.2003.12.022; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; Majid MA, 2002, BRIT J OPHTHALMOL, V86, P97, DOI 10.1136/bjo.86.1.97; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; Milani V, 2005, INT IMMUNOL, V17, P257, DOI 10.1093/intimm/dxh203; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; Rigg AS, 2001, CANCER GENE THER, V8, P869, DOI 10.1038/sj.cgt.7700387; Robertson MJ, 1996, EXP HEMATOL, V24, P406; Sayers TJ, 1998, J IMMUNOL, V161, P3957; Schendel DJ, 2000, GENE THER, V7, P2007, DOI 10.1038/sj.gt.3301349; Schendel DJ, 1997, J MOL MED-JMM, V75, P400, DOI 10.1007/s001090050125; SCHENDEL DJ, 1993, J IMMUNOL, V151, P4209; Seki N, 2002, J IMMUNOL, V168, P3484, DOI 10.4049/jimmunol.168.7.3484; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Span PN, 2004, J PATHOL, V202, P395, DOI 10.1002/path.1528; Trapani JA, 2000, CURR OPIN IMMUNOL, V12, P323, DOI 10.1016/S0952-7915(00)00094-7; Vogelzang NJ, 1998, LANCET, V352, P1691, DOI 10.1016/S0140-6736(98)01041-1; Zacchigna S, 2004, CANCER GENE THER, V11, P73, DOI 10.1038/sj.cgt.7700657	44	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1496	1508		10.1038/sj.onc.1209188	http://dx.doi.org/10.1038/sj.onc.1209188			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261161				2022-12-17	WOS:000235890400007
J	Spillare, EA; Wang, XW; von Kobbe, C; Bohr, VA; Hickson, ID; Harris, CC				Spillare, EA; Wang, XW; von Kobbe, C; Bohr, VA; Hickson, ID; Harris, CC			Redundancy of DNA helicases in p53-mediated apoptosis	ONCOGENE			English	Article						helicases; apoptosis; microinjection	BLOOMS-SYNDROME PROTEIN; WERNERS-SYNDROME GENES; SACCHAROMYCES-CEREVISIAE; GENOMIC INSTABILITY; XERODERMA-PIGMENTOSUM; HOMOLOGOUS RECOMBINATION; FUNCTIONAL INTERACTION; RECQ HELICASES; SYNDROME CELLS; SGS1 MUTANT	A subset of DNA helicases, the RecQ family, has been found to be associated with the p53-mediated apoptotic pathway and is involved in maintaining genomic integrity. This family contains the BLM and WRN helicases, in which germline mutations are responsible for Bloom and Werner syndromes, respectively. TFIIH DNA helicases, XPB and XPD, are also components in this apoptotic pathway. We hypothesized that there may be some redundancy between helicases in their ability to complement the attenuated p53-mediated apoptotic levels seen in cells from individuals with diseases associated with these defective helicase genes. The attenuated apoptotic phenotype in Bloom syndrome cells was rescued not only by ectopic expression of BLM, but also by WRN or XPB, both 30-50 helicases, but not expression of the 50-30 helicase XPD. Overexpression of Sgs1, a WRN/BLM yeast homolog, corrected the reduction in BS cells only, which is consistent with Sgs1 being evolutionarily most homologous to BLM. A restoration of apoptotic levels in cells from WS, XPB or XPD patients was attained only by overexpression of the specific helicase. Our data suggest a limited redundancy in the pathways of these RecQ helicases in p53-induced apoptosis.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; NIA, Lab Mol Gerontol, DHHS, NIH, Baltimore, MD USA; Univ Oxford, John Radcliffe Hosp, Canc Res UK, Weatherall Inst Mol Med, Oxford, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Cancer Research UK; University of Oxford	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, 37 Convent Dr,Bldg 37,Room 3068, Bethesda, MD 20892 USA.	curtis_harris@nih.gov	Wang, Xin Wei/B-6162-2009; Hickson, Ian/AAJ-7548-2020; Bohr, Vilhelm/AAP-5931-2020	Wang, Xin Wei/0000-0001-9735-606X; Hickson, Ian/0000-0002-0583-566X; von Kobbe, Cayetano/0000-0003-3895-3790	NATIONAL CANCER INSTITUTE [Z01BC005795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000726] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [Z01 BC005795-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ajima J, 2002, MUTAT RES-FUND MOL M, V504, P157, DOI 10.1016/S0027-5107(02)00089-1; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; Fairall L, 2001, MOL CELL, V8, P351, DOI 10.1016/S1097-2765(01)00321-5; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Heo SJ, 1999, GENES CELLS, V4, P619, DOI 10.1046/j.1365-2443.1999.00288.x; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Lane D, 2004, CARCINOGENESIS, V25, P1077, DOI 10.1093/carcin/bgh186; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lillard-Wetherell K, 2005, CANCER RES, V65, P5520, DOI 10.1158/0008-5472.CAN-05-0632; Machwe A, 2004, ONCOGENE, V23, P149, DOI 10.1038/sj.onc.1206906; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Nakayama H, 2002, ONCOGENE, V21, P9008, DOI 10.1038/sj.onc.1205959; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; Onoda F, 2000, MUTAT RES-DNA REPAIR, V459, P203, DOI 10.1016/S0921-8777(99)00071-3; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Robles AI, 2001, ACTA ONCOL, V40, P696; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Sanz MM, 2000, AM J HUM GENET, V67, P89; Sanz MM, 2000, CYTOGENET CELL GENET, V91, P217, DOI 10.1159/000056848; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Stavropoulos DJ, 2002, HUM MOL GENET, V11, P3135, DOI 10.1093/hmg/11.25.3135; Tuteja N, 2004, EUR J BIOCHEM, V271, P1849, DOI 10.1111/j.1432-1033.2004.04094.x; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Watt PM, 1996, GENETICS, V144, P935; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; Winkler GS, 2000, J BIOL CHEM, V275, P4258, DOI 10.1074/jbc.275.6.4258; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733	40	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2119	2123		10.1038/sj.onc.1209242	http://dx.doi.org/10.1038/sj.onc.1209242			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288211	Green Accepted			2022-12-17	WOS:000236359700015
J	Stanhill, A; Levin, V; Hendel, A; Shachar, I; Kazanov, D; Arber, N; Kaminski, N; Engelberg, D				Stanhill, A; Levin, V; Hendel, A; Shachar, I; Kazanov, D; Arber, N; Kaminski, N; Engelberg, D			Ha-ras(val12) induces HSP70b transcription via the HSE/HSF1 system, but HSP70b expression is suppressed in Ha-ras(val12)-transformed cells	ONCOGENE			English	Article						ras; HSF1; HSP70b	HEAT-SHOCK FACTOR-1; ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; DNA-BINDING ACTIVITY; FACTOR-I; NEURONAL DIFFERENTIATION; MOLECULAR CHAPERONES; PC12 CELLS; PROGNOSTIC IMPLICATIONS; INCREASING COMPLEXITY	Heat shock proteins (Hsps) are overexpressed in many tumors, but are downregulated in some tumors. To check for a direct effect of Ha-Ras(va112) on HSP70 transcription, we transiently expressed the oncoprotein in Rat1 fibro-blasts and monitored its effect on HSP70b promoter-driven reporter gene. We show that expression of Ha-Ras(va112) induced this promoter. Promoter analysis via systematic deletions and point mutations revealed that Ha-Ras(va112) induces HSP70b transcription via heat shock elements (HSEs). Also, Ha-Ras(va112) induction of HSE-mediated transcription was dramatically reduced in HSF1 -/- cells. Yet, residual effect of Ha-Ras(va112) that was still measured in HSF1 -/- cells suggests that some of the Ha-Ras(va112) effect is Hsf1-independent. When HSF1 -/- cells, stably expressing Ha-Ras(va112), were grown on soft agar only small colonies were formed suggesting a role for heat shock factor 1 (Hsf1) in Ha-Ras(va112)-mediated transformation. Although Ha-ras(Val12) seems to be an inducer of HSP70's expression, we found that in Ha-ras(Va112-)transformed fibroblasts expression of this gene is suppressed. This suppression is correlated with higher sensitivity of Ha-ras(va112)-transformed cells to heat shock. We suggest that Ha-ras(Va112) is involved in Hsf1 activation, thereby inducing the cellular protective response. Cells that repress this response are perhaps those that acquire the capability to further proliferate and become transformed clones.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Chaim Sheba Med Ctr, Dept Funct Genom, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, GI Oncol Unit, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Gastroenterol, IL-69978 Tel Aviv, Israel; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA	Hebrew University of Jerusalem; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Engelberg, D (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	Engelber@mail.ls.huji.ac.il	Hendel, Ayal/GMW-7991-2022	Arber, Nadir/0000-0001-5283-6991; Kaminski, Naftali/0000-0001-5917-4601; Hendel, Ayal/0000-0002-3388-6202				Ahn SG, 2003, GENE DEV, V17, P516, DOI 10.1101/gad.1044503; Ausubel F. M., 2001, CURRENT PROTOCOLS MO; Baler R, 1996, CELL STRESS CHAPERON, V1, P33, DOI 10.1379/1466-1268(1996)001<0033:EFAROH>2.3.CO;2; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Brown JM, 1999, CANCER RES, V59, P1391; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200; Dwyer DS, 1996, NEUROCHEM RES, V21, P659, DOI 10.1007/BF02527722; Engelberg D, 2004, SEMIN CANCER BIOL, V14, P271, DOI 10.1016/j.semcancer.2004.04.006; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Han SI, 2002, FEBS LETT, V515, P141, DOI 10.1016/S0014-5793(02)02459-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hatayama T, 1997, J BIOCHEM-TOKYO, V122, P904; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kaminski N, 2002, AM J RESP CELL MOL, V27, P125, DOI 10.1165/ajrcmb.27.2.f247; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; LI GC, 1995, INT J HYPERTHER, V11, P459, DOI 10.3109/02656739509022483; Li WX, 1996, RADIAT RES, V145, P324, DOI 10.2307/3578988; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mathon NE, 2001, NAT REV CANCER, V1, P203, DOI 10.1038/35106045; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MIVECHI NF, 1995, CANCER RES, V55, P5512; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; Myung Jae-Kyung, 2004, Proteome Sci, V2, P8, DOI 10.1186/1477-5956-2-8; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Santarosa M, 1997, EUR J CANCER, V33, P873, DOI 10.1016/S0959-8049(97)00002-6; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; Stacey D, 2002, CURR OPIN GENET DEV, V12, P44, DOI 10.1016/S0959-437X(01)00262-3; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; TETU B, 1992, CANCER RES, V52, P2325; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; Voellmy R, 2004, PROG NUCLEIC ACID RE, V78, P143, DOI 10.1016/S0079-6603(04)78004-6; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cb.11.110195.002301; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799; Zuo FR, 2002, P NATL ACAD SCI USA, V99, P6292, DOI 10.1073/pnas.092134099	79	22	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1485	1495		10.1038/sj.onc.1209193	http://dx.doi.org/10.1038/sj.onc.1209193			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16278678				2022-12-17	WOS:000235890400006
J	Polak, P; Oren, A; Ben-Dror, I; Steinberg, D; Sapoznik, S; Arditi-Duvdevany, A; Vardimon, L				Polak, P; Oren, A; Ben-Dror, I; Steinberg, D; Sapoznik, S; Arditi-Duvdevany, A; Vardimon, L			The cytoskeletal network controls c-Jun translation in a UTR-dependent manner	ONCOGENE			English	Article						c-Jun; translation control; UTRs; cytoskeletal network; cell density	ACTIVATED PROTEIN-KINASES; MAMMALIAN UV RESPONSE; NECROSIS-FACTOR-ALPHA; GLUCOCORTICOID-RECEPTOR; BINDING PROTEIN; MESSENGER-RNAS; GROWTH-FACTORS; CELL LIFE; INDUCTION; AGENTS	The cytoskeleton is a dynamic network that undergoes restructuring during various cellular events, influencing cell proliferation, differentiation, and apoptosis. Here, we report that accumulation of c-Jun, a member of the AP1 family of transcription factors that play a key role in normal and aberrant cell growth, dramatically increases upon depolymerization of the cytoskeleton, and that, unexpectedly, this increase is controlled translationally. Depolymerization of the actin or microtubule network induces an increase in c-Jun accumulation with no corresponding increase in c-Jun mRNA or in the half-life of the c-Jun protein, but rather in the translatability of its transcript. This increase is mediated by the untranslated regions (UTRs) of c-Jun mRNA, and is not dependent on activated mitogen-activated protein kinase pathways. This novel mechanism of c-Jun regulation might be relevant to physiological conditions in which c-Jun plays a pivotal role.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Vardimon, L (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	vardi@post.tau.ac.il		Polak, Pazit/0000-0001-8363-0734				Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oren A, 1999, MOL CELL BIOL, V19, P1742; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; REISFELD S, 1994, MOL ENDOCRINOL, V8, P1224, DOI 10.1210/me.8.9.1224; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Sehgal A, 2000, ONCOGENE, V19, P2836, DOI 10.1038/sj.onc.1203601; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TARNOWKA MA, 1979, J CELL PHYSIOL, V99, P359, DOI 10.1002/jcp.1040990311; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Xiao DH, 2003, CANCER RES, V63, P6825; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	43	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					665	676		10.1038/sj.onc.1209114	http://dx.doi.org/10.1038/sj.onc.1209114			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16247475				2022-12-17	WOS:000235068800002
J	Boggs, K; Reisman, D				Boggs, K; Reisman, D			Increased p53 transcription prior to DNA synthesis is regulated through a novel regulatory element within the p53 promoter	ONCOGENE			English	Article						p53; transcription; gene expression; cell cycle	BINDING-PROTEIN-BETA; NUCLEAR EXPORT SIGNAL; TUMOR-SUPPRESSOR GENE; LI-FRAUMENI-SYNDROME; KAPPA-B; POTENTIAL MEDIATOR; C/EBP-BETA; EXPRESSION; DAMAGE; MDM2	p53 mRNA levels are tightly regulated during the cell cycle with its transcription being induced prior to DNA synthesis. However, the mechanism controlling this regulation is not well defined. Through characterizing an additional 1000 bp of upstream DNA sequences of the murine p53 gene, we identified new positive and negative regulatory elements. Furthermore, we found a trans-acting factor(s) that binds within a positive cis-acting element (-972/-953) in a manner indicative of regulation during the cell cycle. When Swiss3T3 cells are arrested by serum depletion p53 mRNA levels decrease and binding of this regulatory factor( s) to the promoter is reduced. Upon serum stimulation, the regulatory factor( s) binds the promoter and p53 mRNA levels increase prior to the cells entering S phase. When the factors are experimentally sequestered from the promoter or when the regulatory element is deleted from the promoter, p53 promoter activity is reduced. There is no further reduction in p53 promoter activity upon serum depletion and the kinetics of induction upon serum stimulation is delayed by approximately 5 h. These findings indicate that a factor( s) binding within the -972/-953 regulatory element on the p53 promoter is important for the proper regulation of p53 mRNA expression in response to mitogen stimulation. Our initial findings indicate that a member of the C/EBP family of transcription factors may play a role in this regulation.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Reisman, D (corresponding author), Univ S Carolina, Dept Biol Sci, Coker Life Sci Bldg,Sumter St, Columbia, SC 29208 USA.	reisman@biol.sc.edu						Arnett Brenda, 2003, Mol Cancer, V2, P21, DOI 10.1186/1476-4598-2-21; Balint E, 1996, CANCER RES, V56, P1648; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1999, CANCER RES, V59, P1; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GINSBERG D, 1990, ONCOGENE, V5, P1285; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALE TK, 1995, NUCLEIC ACIDS RES, V23, P663, DOI 10.1093/nar/23.4.663; Hanlon M, 1999, J BIOL CHEM, V274, P14224, DOI 10.1074/jbc.274.20.14224; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Liu L, 1999, MOL CELL BIOL, V19, P1202; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; MIYASHITA T, 1995, CELL, V80, P293; Miyazawa K, 1998, J BIOL CHEM, V273, P7620, DOI 10.1074/jbc.273.13.7620; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; Reisman D, 2001, GENE, V274, P129, DOI 10.1016/S0378-1119(01)00623-0; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sigal A, 2000, CANCER RES, V60, P6788; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; VALEV LV, 2002, J BIOL CHEM, V2111, P42438; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WU HY, 1994, J BIOL CHEM, V269, P20067; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhao RB, 2000, GENE DEV, V14, P981	46	22	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					555	565		10.1038/sj.onc.1209076	http://dx.doi.org/10.1038/sj.onc.1209076			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16158047				2022-12-17	WOS:000234897400007
J	Freeman-Cook, LL; DiMaio, D				Freeman-Cook, LL; DiMaio, D			Modulation of cell function by small transmembrane proteins modeled on the bovine papillomavirus E5 protein	ONCOGENE			English	Review						growth factor receptors; transformation; oncogene; selection; transmembrane domain	FACTOR-BETA-RECEPTOR; GROWTH-FACTOR RECEPTOR; HELIX-HELIX ASSOCIATION; OPEN READING FRAME; MOUSE C127 CELLS; TRANSFORMING PROTEIN; MEMBRANE-PROTEINS; AMINO-ACID; ERYTHROPOIETIN RECEPTOR; PRODUCTIVE INTERACTION	Viruses have been subjected to intense study because of their medical importance and because they can provide fundamental insights into normal and pathological cellular processes. Indeed, much of our knowledge about basic cellular biology and biochemistry was acquired through the study of viruses, and some of medicine's greatest triumphs and challenges involve viruses. Since viruses have evolved to exploit important cell processes, they can provide tools and approaches to manipulate cell function. The small transmembrane E5 protein of bovine papillomavirus type 1 transforms cells by a unique mechanism involving ligand-independent activation of the platelet-derived growth factor beta receptor. Experiments summarized in this review suggest that it may be possible to use the E5 protein as a model to design an entirely new class of small, modular transmembrane proteins with novel biological activities.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	Yale University	DiMaio, D (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.	daniel.dimaio@yale.edu						Adamian L, 2001, J MOL BIOL, V311, P891, DOI 10.1006/jmbi.2001.4908; Bennasroune A, 2004, MOL BIOL CELL, V15, P3464, DOI 10.1091/mbc.E03-10-0753; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; Brosig B, 1998, PROTEIN SCI, V7, P1052; BURKHARDT A, 1987, EMBO J, V6, P2381, DOI 10.1002/j.1460-2075.1987.tb02515.x; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Chen CP, 2002, PROTEIN SCI, V11, P2774, DOI 10.1110/ps.0214502; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Clemons PA, 1999, CURR OPIN CHEM BIOL, V3, P112, DOI 10.1016/S1367-5931(99)80020-9; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; Constantinescu SN, 1999, EMBO J, V18, P3334, DOI 10.1093/emboj/18.12.3334; Constantinescu SN, 2003, J BIOL CHEM, V278, P43755, DOI 10.1074/jbc.M302974200; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; DeGrado WF, 2003, PROTEIN SCI, V12, P647, DOI 10.1110/ps.0236503; DiMaio D, 2000, CYTOKINE GROWTH F R, V11, P283, DOI 10.1016/S1359-6101(00)00012-5; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; Eilers M, 2000, P NATL ACAD SCI USA, V97, P5796, DOI 10.1073/pnas.97.11.5796; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; Freeman-Cook LL, 2005, J MOL BIOL, V345, P907, DOI 10.1016/j.jmb.2004.10.072; Freeman-Cook LL, 2004, J MOL BIOL, V338, P907, DOI 10.1016/j.jmb.2004.03.044; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; George SR, 2003, J PHARMACOL EXP THER, V307, P481, DOI 10.1124/jpet.103.053843; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; HORWITZ BH, 1989, J VIROL, V63, P4515, DOI 10.1128/JVI.63.11.4515-4519.1989; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; Huynh NT, 2003, IMMUNOLOGY, V108, P458, DOI 10.1046/j.1365-2567.2003.01614.x; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; KULKE R, 1992, J VIROL, V66, P505, DOI 10.1128/JVI.66.1.505-511.1992; Lai CC, 2000, J BIOL CHEM, V275, P9832, DOI 10.1074/jbc.275.13.9832; Lai CC, 2005, J VIROL, V79, P1924, DOI 10.1128/JVI.79.3.1924-1929.2005; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; Langosch D, 1998, PROTEINS, V31, P150, DOI 10.1002/(SICI)1097-0134(19980501)31:2<150::AID-PROT5>3.0.CO;2-Q; Leeds JA, 2001, J MOL BIOL, V313, P181, DOI 10.1006/jmbi.2001.5007; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LOFTS FJ, 1993, ONCOGENE, V8, P2813; Manolios N, 1997, NAT MED, V3, P84, DOI 10.1038/nm0197-84; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; Mattoon D, 2001, ONCOGENE, V20, P3824, DOI 10.1038/sj.onc.1204523; MEYER AN, 1994, P NATL ACAD SCI USA, V91, P4634, DOI 10.1073/pnas.91.11.4634; Nappi VM, 2002, J BIOL CHEM, V277, P47149, DOI 10.1074/jbc.M209582200; Nappi VM, 2002, J VIROL, V76, P7976, DOI 10.1128/JVI.76.16.7976-7986.2002; NILSON LA, 1995, J VIROL, V69, P5869, DOI 10.1128/JVI.69.9.5869-5874.1995; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; Partridge AW, 2003, J BIOL CHEM, V278, P22056, DOI 10.1074/jbc.M210685200; Partridge AW, 2002, BIOCHEMISTRY-US, V41, P3647, DOI 10.1021/bi0120502; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4032; RIESE DJ, 1995, ONCOGENE, V10, P1431; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sal-Man N, 2004, J MOL BIOL, V344, P855, DOI 10.1016/j.jmb.2004.09.066; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; STAEBLER A, 1995, J VIROL, V69, P6507, DOI 10.1128/JVI.69.10.6507-6517.1995; Surti T, 1998, PROTEINS, V33, P601; Takeda M, 2002, J VIROL, V76, P1391, DOI 10.1128/JVI.76.3.1391-1399.2002; Tarasova NI, 1999, J BIOL CHEM, V274, P34911, DOI 10.1074/jbc.274.49.34911; Therien AG, 2001, NAT STRUCT BIOL, V8, P597, DOI 10.1038/89631; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Yang JX, 1998, CURR BIOL, V8, P11, DOI 10.1016/S0960-9822(98)70015-6; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	82	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7756	7762		10.1038/sj.onc.1209039	http://dx.doi.org/10.1038/sj.onc.1209039			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299535				2022-12-17	WOS:000233372600011
J	Baldassarre, G; Belletti, B; Battista, S; Nicoloso, MS; Pentimalli, F; Fedele, M; Croce, CM; Fusco, A				Baldassarre, G; Belletti, B; Battista, S; Nicoloso, MS; Pentimalli, F; Fedele, M; Croce, CM; Fusco, A			HMGA1 protein expression sensitizes cells to cisplatin-induced cell death	ONCOGENE			English	Article						HMGA1; BRCA1; knockout; ES cells; apoptosis; DNA damage	NUCLEOTIDE EXCISION-REPAIR; HMGI(Y) PROTEIN; GENE-EXPRESSION; PROSTATE-CANCER; DNA-DAMAGE; BRCA1; CARCINOMA; TRANSFORMATION; CHEMOTHERAPY; APOPTOSIS	HMGA1 proteins belong to a family of nonhistone chromatin proteins able to bind DNA in AT-rich regions and to interact with various transcription factors thus enhancing or inhibiting gene transcription by acting as architectural proteins. Although their expression is very low or absent in many adult tissues, HMGA1 proteins have been frequently found to be upregulated in human cancers and are expressed at high levels during embryogenesis, suggesting they could have a role in highly proliferating cells. We have previously demonstrated that HMGA1 expression in primary breast cancer and mammary carcinoma derived cell lines inversely correlated with BRCA1 expression and that HMGA1 is able to downregulate the expression of BRCA1 gene by binding directly to its promoter region. Being BRCA1 protein expression strictly linked to the DNA repair activity of the cell, we investigated whether HMGA1 expression was able to influence cellular responses to DNA damage. Here, we report that high expression levels of HMGA1 proteins in MCF-7 or mouse embryonic stem cells results in diminished BRCA1 expression and enhanced sensitivity to Cisplatin and Bleomycin. The increased DNA damage-induced cell death in HMGA1-expressing cells is likely due to a diminished cellular DNA repair activity. Therefore, we propose that high expression of HMGA1 protein in human malignant neoplasias, acting on BRCA1 expression, could contribute to the progression of malignant transformation influencing the response of the cells to the damaged DNA.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale, CNR,Fac Med & Chirurg, I-80131 Naples, Italy; Ctr Riferimento Oncol, Div Oncol Sperimentale 2, I-33081 Aviano, Italy; New Jersey Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; NOGEC Naple Oncogenom Ctr, CEINGE, Ctr Biotecnol Avanzate, I-80145 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Aviano (CRO); Jefferson University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; CEINGE Biotecnologie Avanzate	Fusco, A (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale, CNR,Fac Med & Chirurg, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Young, Richard A/F-6495-2012; Battista, Sabrina/AAY-2981-2020; Belletti, Barbara/J-2028-2018; Nicoloso, Milena S/K-6411-2012; Fedele, Monica/C-1417-2015; Pentimalli, Francesca/K-4936-2014; Baldassarre, Gustavo/K-1350-2016	Young, Richard A/0000-0001-8855-8647; Battista, Sabrina/0000-0001-5899-9759; Belletti, Barbara/0000-0003-2249-0285; Nicoloso, Milena S/0000-0003-4231-9303; Fedele, Monica/0000-0002-9171-1312; Pentimalli, Francesca/0000-0003-4740-6801; Baldassarre, Gustavo/0000-0002-9750-8825; Fusco, Alfredo/0000-0003-3332-5197	NATIONAL CANCER INSTITUTE [P01CA076259, P30CA056036] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA76259, P30CA56036] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Battista S, 2003, FASEB J, V17, P1496, DOI 10.1096/fj.02-0977fje; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Buschfort-Papewalis C, 2002, BLOOD, V100, P845, DOI 10.1182/blood-2002-01-0022; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Husain A, 1998, CANCER RES, V58, P1120; ITO M, 2005, J GENE MED, V8; Liu WM, 1999, CANCER RES, V59, P5695; Masciullo V, 2003, CARCINOGENESIS, V24, P1191, DOI 10.1093/carcin/bgg075; Quinn JE, 2003, CANCER RES, V63, P6221; RAM TG, 1993, CANCER RES, V53, P2655; Reed E, 1998, CANCER TREAT REV, V24, P331, DOI 10.1016/S0305-7372(98)90056-1; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Rosen EM, 2001, CANCER INVEST, V19, P396, DOI 10.1081/CNV-100103134; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Takaha N, 2002, CANCER RES, V62, P647; TAMIMI Y, 1993, CANCER RES, V53, P5512; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852	26	22	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6809	6819		10.1038/sj.onc.1208831	http://dx.doi.org/10.1038/sj.onc.1208831			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007157				2022-12-17	WOS:000232527800008
J	Ropke, A; Buhtz, P; Bohm, M; Seger, J; Wieland, I; Allhoff, EP; Wieacker, PF				Ropke, A; Buhtz, P; Bohm, M; Seger, J; Wieland, I; Allhoff, EP; Wieacker, PF			Promoter CpG hypermethylation and downregulation of DICE1 expression in prostate cancer	ONCOGENE			English	Article						DICE1 (DDX26); promoter; hypermethylation; downregulation; prostate cancer	TUMOR-SUPPRESSOR GENE; CARCINOMA CELL-LINE; LASER MICRODISSECTION; CHROMOSOME 13Q14.3; DNA METHYLATION; HIGH-RESOLUTION; BREAST-CANCER; ALLELIC LOSS; LUNG; INACTIVATION	A critical region of loss of heterozygosity on human chromosome 13q14 harbors the tumor suppressor gene DICE1 (DDX26). To elucidate the reduced DICE1 expression in tumor cells, the putative promoter sequence upstream of the DICE1 gene was analysed. This sequence shows a high GC content and is rich in CpG sites and binding sites of transcriptional factors. Promoter activity was identified within three overlapping fragments of the 800 bp sequence upstream of the DICE1 gene. A 13 bp deletion polymorphism detected in the DICE1 promoter region showed a decreased activity compared with the undeleted variant. However, this 13 bp deletion was seen in male control samples and patients with prostate cancer or benign prostatic hyperplasia at similar rates. A reduced DICE1 expression was observed in prostate cancer cell lines DU145 and LNCaP. This downregulation is associated with hypermethylation of the DICE1 promoter. Treatment of both prostate cancer cell lines with 5-azacytidine leads to upregulation of DICE1 expression. Hypermethylation of CpG sites of the DICE1 promoter was observed in four of eight analysed prostate cancers. This study suggests that transcriptional repression of DICE1 is caused by hypermethylation of the DICE1 promoter region in prostate cancer cells.	Univ Magdeburg, Inst Human Genet, D-39120 Magdeburg, Germany; Univ Magdeburg, Inst Pathol, D-39120 Magdeburg, Germany; Univ Magdeburg, Dept Urol, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University; Otto von Guericke University	Wieacker, PF (corresponding author), Univ Magdeburg, Inst Human Genet, Leipziger Str 44, D-39120 Magdeburg, Germany.	peter.wieacker@medizin.uni-magdeburg.de		Wieland, Ilse/0000-0002-8017-3029				Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bohm M, 1997, AM J PATHOL, V151, P63; Bohm M, 1999, ONKOLOGIE, V22, P296, DOI 10.1159/000026978; Deng GR, 2001, ONCOGENE, V20, P7120, DOI 10.1038/sj.onc.1204891; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GIBAS Z, 1984, CANCER GENET CYTOGEN, V11, P399, DOI 10.1016/0165-4608(84)90020-7; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Klein G, 2002, SEMIN CANCER BIOL, V12, P327, DOI 10.1016/S1044-579X(02)00052-4; Kuroki T, 2003, CANCER RES, V63, P3724; Li WJ, 2003, ONCOGENE, V22, P314, DOI 10.1038/sj.onc.1206098; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ogawara K, 1998, INT J CANCER, V79, P312, DOI 10.1002/(SICI)1097-0215(19980821)79:4<312::AID-IJC2>3.0.CO;2-Y; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SOBIN LH, 1997, CLASSIFICATION MALIG, P170; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; Tamura K, 1997, INT J CANCER, V74, P45, DOI 10.1002/(SICI)1097-0215(19970220)74:1<45::AID-IJC8>3.0.CO;2-0; Ueda T, 1999, GENE CHROMOSOME CANC, V24, P183, DOI 10.1002/(SICI)1098-2264(199903)24:3<183::AID-GCC2>3.3.CO;2-A; Watanabe T, 2001, J NEUROPATH EXP NEUR, V60, P1181, DOI 10.1093/jnen/60.12.1181; Wieland I, 2004, ONCOL REP, V12, P207; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Wieland I, 2001, ONCOL RES, V12, P491, DOI 10.3727/096504001108747503; Yang QF, 2002, CLIN CANCER RES, V8, P2890; Yin ZN, 1999, ONCOGENE, V18, P7576, DOI 10.1038/sj.onc.1203203; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	35	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6667	6675		10.1038/sj.onc.1208824	http://dx.doi.org/10.1038/sj.onc.1208824			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007164				2022-12-17	WOS:000232367800008
J	Magrassi, L; Conti, L; Lanterna, A; Zuccato, C; Marchionni, M; Cassini, P; Arienta, C; Cattaneo, E				Magrassi, L; Conti, L; Lanterna, A; Zuccato, C; Marchionni, M; Cassini, P; Arienta, C; Cattaneo, E			Shc3 affects human high-grade astrocytomas survival	ONCOGENE			English	Article						Shc; brain tumors; signal transduction; neuro-oncology; growth control; gliomas	GROWTH-FACTOR RECEPTOR; ANAPLASTIC LYMPHOMA KINASE; CELL-LINE; NEUROTROPHIC FACTOR; GLIOBLASTOMA CELLS; ADAPTER PROTEINS; HUMAN BRAIN; GENE; ACTIVATION; PATHWAY	A selective switch from expression of Shc1 gene to Shc3 occurs with maturation of neuronal precursors into postmitotic neurons. Previous studies showed that in the embryo, Shc1 is maximally expressed in dividing CNS stem cells while it is silenced in mature neurons, where it is replaced by Shc3. Under normal conditions Shc3 is never expressed by glial cells. We now show that in human astrocytomas and glioblastomas, the normal pattern of expression of Shc1/Shc3 is totally subverted, both proteins being present at the same time and in the same cells. Our data indicate that Shc3 is maximally expressed, together with Shc1, in glioblastoma, a highly proliferative tumor with little, if any, indication of neuronal differentiation. In primary cultures of glioblastoma, tumor cells maintain Shc1 expression but downregulate Shc3. Analysis of the phosphorylation status of Shc3 in human glioblastoma tumor samples in vivo indicates that it is tyrosine phosphorylated. Finally, we found that the expression of truncated variants of Shc3 with dominant-negative effects in human high-grade glioma cells that maintain Shc3 expression in vitro leads to a decreased Akt posphorylation and increased apoptosis, thus resulting in impaired survival of the transfected cells. These data suggest that Shc molecules play an important role in glioblastoma cell growth and survival.	Univ Pavia, Dipartimento Chirurg, IRCCS, Policlin S Matteo, I-27100 Pavia, Italy; CNR, IGM, I-27100 Pavia, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, Dept Pharmacol Sci, I-20133 Milan, Italy; Osped Riuniti Bergamo, Dept Neurosurg, I-24100 Bergamo, Italy; Univ Milano Bicocca, Dept Neurosci & Biomed Technol, Monza, Italy	IRCCS Fondazione San Matteo; University of Pavia; Consiglio Nazionale delle Ricerche (CNR); University of Milan; Ospedali Riuniti di Bergamo; University of Milano-Bicocca	Magrassi, L (corresponding author), Univ Pavia, Dipartimento Chirurg, IRCCS, Policlin S Matteo, I-27100 Pavia, Italy.	magrassi@igm.cnr.it	Magrassi, Lorenzo/AAJ-3105-2020; Conti, Luciano/H-4184-2012	Conti, Luciano/0000-0002-2050-9846; Magrassi, Lorenzo/0000-0002-8308-2720; CATTANEO, ELENA/0000-0002-0755-4917; ZUCCATO, CHIARA/0000-0003-1771-3392; lanterna, luigi andrea/0000-0001-9484-4834				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Cattaneo E, 1998, ANTICANCER RES, V18, P2381; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Dirks WG, 2002, INT J CANCER, V100, P49, DOI 10.1002/ijc.10435; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Hecker TP, 2004, ONCOGENE, V23, P3962, DOI 10.1038/sj.onc.1207541; Hecker TP, 2002, CANCER RES, V62, P2699; Lemkine GF, 1999, J DRUG TARGET, V7, P305, DOI 10.3109/10611869909085513; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NIKKHAH G, 1992, J NEURO-ONCOL, V13, P1, DOI 10.1007/BF00172941; Nishiguchi M, 2003, NEUROCHEM INT, V42, P493, DOI 10.1016/S0197-0186(02)00139-0; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; Pandita A, 2004, GENE CHROMOSOME CANC, V39, P29, DOI 10.1002/gcc.10300; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; Pore N, 2003, CANCER RES, V63, P236; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; Rebbaa A, 1997, J BIOL CHEM, V272, P9275; Rubenstein M, 2001, MED ONCOL, V18, P121, DOI 10.1385/MO:18:2:121; Russo C, 2002, J BIOL CHEM, V277, P35282, DOI 10.1074/jbc.M110785200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Su JD, 2003, CANCER RES, V63, P3585; Trinei M, 2000, CANCER RES, V60, P793; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Wiesenhofer B, 2000, ACTA NEUROPATHOL, V99, P131, DOI 10.1007/PL00007416	29	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2005	24	33					5198	5206		10.1038/sj.onc.1208708	http://dx.doi.org/10.1038/sj.onc.1208708			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15870690				2022-12-17	WOS:000230964600006
J	Fujimoto, M; Kitazawa, R; Maeda, S; Kitazawa, S				Fujimoto, M; Kitazawa, R; Maeda, S; Kitazawa, S			Methylation adjacent to negatively regulating AP-1 site reactivates TrkA gene expression during cancer progression	ONCOGENE			English	Article						TrkA; non-CpG islands; methylation; AP-1; pancreatic cancer	NERVE GROWTH-FACTOR; PANCREATIC DUCTAL ADENOCARCINOMA; DNA-METHYLATION; PERINEURAL INVASION; NEUROTROPHIN RECEPTOR; CPG METHYLATION; BINDING; PROLIFERATION; NEUROBLASTOMAS; REPRESSION	Nerve growth factor and its high-affinity receptor TrkA are thought to be involved in the progression of various cancers. This study investigated the mechanism that regulates aberrant or increased TrkA expression in various cancer cell lines and in the course of pancreatic cancer progression. W e found that the negative cis-acting AP-1-like sequence TGAGCGA was located in the 5'-untranslated region of the TrkA gene. Sodium bisulfite mapping revealed that steady-state TrkA expression correlated positively with the accumulation of methylated CpG around the AP-1-like site. Electrophoretic mobility shift assay showed that the AP-1- like site was bound mainly by c-Jun homodimers; the binding was directly blocked by Sss I methylase-induced methylation or by an excess of oligonucleotides containing consensus AP-1 sequences. Consequently, activation of TrkA gene expression by methylation was considered to be caused by the direct interference of c-Jun binding to the negatively regulating AP-1- like site. Further more, the accumulation of methylated CpG around the AP-1- like site was also observed with increased TrkA immunohistochemical staining in cases of advanced pancreatic adenocarcinoma with extensive perineural invasion. Unlike global methylation at CpG islands that leads to gene silencing, specific methylation at non-CpG islands would play a crucial epigenetic role in the versatility and plasticity of TrkA expression during cancer progression.	Kobe Univ, Grad Sch Med, Div Mol Pathol, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Kitazawa, S (corresponding author), Kobe Univ, Grad Sch Med, Div Mol Pathol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kitazawa@med.kobe-u.ac.jp	Kitazawa, Sohei/E-5602-2010	Kitazawa, Sohei/0000-0002-7466-7356				Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOCKMAN DE, 1994, GASTROENTEROLOGY, V107, P219, DOI 10.1016/0016-5085(94)90080-9; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Brellier F, 2004, CANCER RES, V64, P2699, DOI 10.1158/0008-5472.CAN-03-3477; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Eberhart CG, 2001, J NEUROPATH EXP NEUR, V60, P462, DOI 10.1093/jnen/60.5.462; Eden S, 2001, EMBO J, V20, P3518, DOI 10.1093/emboj/20.13.3518; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2001, CANCER RES, V61, P3225; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; George DJ, 1998, PROSTATE, V36, P172, DOI 10.1002/(SICI)1097-0045(19980801)36:3<172::AID-PROS5>3.0.CO;2-J; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Indo Y, 1997, JPN J HUM GENET, V42, P343, DOI 10.1007/BF02766957; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787; Kitazawa S, 2000, LAB INVEST, V80, P275, DOI 10.1038/labinvest.3780031; Kondo T, 2004, J BONE MINER RES, V19, P1411, DOI 10.1359/JBMR.040604; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Ricci A, 2004, AM J RESP CELL MOL, V30, P12, DOI 10.1165/rcmb.2002-0110OC; Sakamoto Y, 2001, ONCOL REP, V8, P477; Schneider MB, 2001, J HISTOCHEM CYTOCHEM, V49, P1205, DOI 10.1177/002215540104901002; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; Tulchinsky EM, 1996, ONCOGENE, V12, P1737; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Yi SQ, 2003, PANCREAS, V27, P225, DOI 10.1097/00006676-200310000-00005; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003; Zhu ZW, 2002, MOL CARCINOGEN, V35, P138, DOI 10.1002/mc.10083; Zhu ZW, 1999, J CLIN ONCOL, V17, P2419, DOI 10.1200/JCO.1999.17.8.2419	36	22	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 28	2005	24	32					5108	5118		10.1038/sj.onc.1208697	http://dx.doi.org/10.1038/sj.onc.1208697			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15870692				2022-12-17	WOS:000230816900010
J	Restle, A; Janz, C; Wiesmuller, L				Restle, A; Janz, C; Wiesmuller, L			Differences in the association of p53 phosphorylated on serine 15 and key enzymes of homologous recombination	ONCOGENE			English	Article						Bloom's syndrome; Mre11; Rad51; Rad52; Rad54; replication fork stalling	STRAND BREAK REPAIR; HOLLIDAY JUNCTIONS; BRANCH MIGRATION; MISMATCH REPAIR; CELL-CYCLE; DNA; COMPLEXES; PROTEINS; RAD51; BRCA1	Phosphorylation of p53 on serine 15 by ATM or ATR is a frequent modi. cation and initiates a cascade of posttranslational modi. cations. To identify possible mechanisms that modulate p53 functions in recombination surveillance, we compared the nuclear localization of p53 phosphorylated on serine 15 (p53pSer15) and the key enzymes of homologous recombination (HR) after replication fork stalling. We demonstrate an almost mutually exclusive subcompartmentalization with Rad52, while p53pSer15 was colocalizing with 40-60% of the Rad51 and Mre11 foci. Therefore, possible sites of p53pSer15-dependent regulation seem to be sites of Rad51- rather than Rad52-dependent HR processes. Remarkably, the association of p53pSer15 with repair complexes containing Rad51 or Mre11 was transient, because less than 20% of the Rad51 and Mre11 foci overlapped with p53pSer15 after 6 h. When we examined colocalization and coimmunoprecipitation of p53pSer15 and the RecQ helicase BLM with recombination surveillance and proapoptotic functions, we observed colocalization within a fraction of approximately 70% of the BLM foci and stable physical interactions until 6 h after replication arrest. Our data suggest that p53pSer15 plays a dual role in the functional interactions with early complexes of Rad51-dependent recombination within distinct nuclear subcompartments.	Univ Frauenklin, D-89075 Ulm, Germany	Ulm University	Wiesmuller, L (corresponding author), Univ Frauenklin, Prittwitzstr 43, D-89075 Ulm, Germany.	lisa.wiesmueller@medizin.uni-ulm.de						Adams MD, 2003, SCIENCE, V299, P265, DOI 10.1126/science.1077198; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Davalos AR, 2003, J CELL BIOL, V162, P1197, DOI 10.1083/jcb.200304016; Digweed M, 2002, CARCINOGENESIS, V23, P1121, DOI 10.1093/carcin/23.7.1121; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; FUCHS B, 1995, ONCOGENE, V10, P789; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Hopfner KP, 2002, CURR OPIN STRUC BIOL, V12, P115, DOI 10.1016/S0959-440X(02)00297-X; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Krejci L, 2003, PROG NUCLEIC ACID RE, V74, P159, DOI 10.1016/S0079-6603(03)01013-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 2003, CANCER RES, V63, P2596; Liu YL, 1999, CURR BIOL, V9, P975, DOI 10.1016/S0960-9822(99)80427-8; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Miyazaki T, 2004, EMBO J, V23, P939, DOI 10.1038/sj.emboj.7600091; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Pedrazzi G, 2003, BIOL CHEM, V384, P1155, DOI 10.1515/BC.2003.128; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Prabhu VP, 2002, J MOL BIOL, V316, P1023, DOI 10.1006/jmbi.2001.5408; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Subramanian D, 2002, NUCLEIC ACIDS RES, V30, P2427, DOI 10.1093/nar/30.11.2427; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Wang Y, 2000, GENE DEV, V14, P927; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Yoon D, 2004, J MOL BIOL, V336, P639, DOI 10.1016/j.jmb.2003.12.050; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	39	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4380	4387		10.1038/sj.onc.1208639	http://dx.doi.org/10.1038/sj.onc.1208639			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806145				2022-12-17	WOS:000229976900007
J	Rodrigue, CM; Porteu, F; Navarro, N; Bruyneel, E; Bracke, M; Romeo, PH; Gespach, C; Garel, MC				Rodrigue, CM; Porteu, F; Navarro, N; Bruyneel, E; Bracke, M; Romeo, PH; Gespach, C; Garel, MC			The cancer chemopreventive agent resveratrol induces tensin, a cell-matrix adhesion protein with signaling and antitumor activities	ONCOGENE			English	Article						focal adhesions; stress fibers; bronectin; cancer cell invasion; resveratrol; K562 and MCF7 cells	RAS-INDUCED CANCERS; THYMOSIN BETA-10; INDUCED APOPTOSIS; TUMOR-CELLS; IN-VITRO; ACTIN; EXPRESSION; CYTOSKELETON; PRODUCT; GRAPES	During a search to identify resveratrol (3,5,4'-trihydroxy-trans-stilbene, RV) target genes in the human erythroleukemic K562 cell line, we show here that the tensin gene and protein levels are remarkably induced by this dietary polyphenol. Tensin, a cell-matrix adhesion protein binding the integrins and cytoskeletal actin. laments also interacts with PI3-kinase and JNK signaling pathways. Tensin induction by RV is associated with increased K562 cell adhesion to fibronectin, cell spreading and actin polymerization. The same responses were observed in the tensin-deficient MCF7 human breast cancer cell line. In K562 and MCF7 cells treated by RV, tensin was found in punctate and intracytoplasmic areas. in MCF7 epithelial cells, induction of tensin is not exclusively associated with plasma membrane-bound vinculin, suggesting a dual localization of tensin in both focal and fibrillar adhesions. pharmacological blockade of PI3-kinase and Rho GTPases/Rho-kinase resulted in selective depletion of focal adhesions, disorganization of tensin localization and disruption of stress fibers. RV increased cell motility and attachment to fibronectin in MCF7 cells submitted to mechanical laminar flow stress, and abrogated estrogen-induced MCF7 cancer cell invasion. Our data support the conclusion that induction of tensin by RV contributes to the chemopreventive and anti-invasive activity of this natural dietary compound in tensin-negative and-deficient leukemic cells or epithelioid cancers.	Hop St Antoine, INSERM, U673, F-75571 Paris, France; Univ Paris 05, Inst Cochin, INSERM,U567, UMR,8104,Dept Hematol, F-75014 Paris, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ghent University; Ghent University Hospital	Gespach, C (corresponding author), Hop St Antoine, INSERM, U673, 184 Rue Faubourg St Antoine, F-75571 Paris, France.	gespach@st-antoine.inserm.fr	PORTEU, Françoise/I-8445-2016; Romeo, Paul-Henri/L-5989-2017	PORTEU, Françoise/0000-0002-2403-4163; Romeo, Paul-Henri/0000-0002-8294-0367				ADLERCREUTZ H, 1992, J STEROID BIOCHEM, V41, P331, DOI 10.1016/0960-0760(92)90359-Q; Ahmad N, 2001, CLIN CANCER RES, V7, P1466; Auger KR, 1996, J BIOL CHEM, V271, P23452, DOI 10.1074/jbc.271.38.23452; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; Cavailles V, 2002, J MOL ENDOCRINOL, V28, P165, DOI 10.1677/jme.0.0280165; Chen HY, 2000, BIOCHEM J, V351, P403, DOI 10.1042/0264-6021:3510403; Chen HY, 2002, P NATL ACAD SCI USA, V99, P733, DOI 10.1073/pnas.022518699; Clement MV, 1998, BLOOD, V92, P996; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; Dong ZG, 2003, MUTAT RES-FUND MOL M, V523, P145, DOI 10.1016/S0027-5107(02)00330-5; Dorrie J, 2001, CANCER RES, V61, P4731; Drexler HG, 1999, LEUKEMIA RES, V23, P207; Entschladen F, 2000, J CANCER RES CLIN, V126, P671, DOI 10.1007/s004320000143; Ferry-Dumazet H, 2002, CARCINOGENESIS, V23, P1327, DOI 10.1093/carcin/23.8.1327; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Golla R, 1997, CELL MOTIL CYTOSKEL, V38, P187, DOI 10.1002/(SICI)1097-0169(1997)38:2<187::AID-CM7>3.0.CO;2-4; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; HALL AK, 1991, J NEUROCHEM, V56, P462, DOI 10.1111/j.1471-4159.1991.tb08173.x; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Levesque JP, 1999, EXP HEMATOL, V27, P579, DOI 10.1016/S0301-472X(98)00069-1; Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516; Maxwell PJ, 2003, CANCER RES, V63, P4602; Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404; Otto AM, 2002, J CANCER RES CLIN, V128, P247, DOI 10.1007/s00432-002-0332-7; Park JW, 2001, CARCINOGENESIS, V22, P1633, DOI 10.1093/carcin/22.10.1633; POKORNA E, 1994, CELL MOTIL CYTOSKEL, V28, P25, DOI 10.1002/cm.970280103; Pozo-Guisado E, 2002, BIOCHEM PHARMACOL, V64, P1375, DOI 10.1016/S0006-2952(02)01296-0; Rodrigue CM, 2001, BRIT J HAEMATOL, V113, P500, DOI 10.1046/j.1365-2141.2001.02746.x; Salesse S, 2002, ONCOGENE, V21, P8605, DOI 10.1038/sj.onc.1206088; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Schneider Y, 2000, CANCER LETT, V158, P85, DOI 10.1016/S0304-3835(00)00511-5; SHIMAMURA R, 1990, BLOOD, V76, P977; Sun HQ, 1996, J BIOL CHEM, V271, P9223, DOI 10.1074/jbc.271.16.9223; Sun NJ, 1998, J NAT PROD, V61, P362, DOI 10.1021/np970488q; Tikoo A, 2000, CANCER J, V6, P162; Tikoo A, 1999, CANCER J SCI AM, V5, P293; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Torgler CN, 2004, DEV CELL, V6, P357, DOI 10.1016/S1534-5807(04)00055-3; Uenobe F, 1997, MUTAT RES-FUND MOL M, V373, P197, DOI 10.1016/S0027-5107(96)00191-1; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang MF, 1999, J AGR FOOD CHEM, V47, P3974, DOI 10.1021/jf990382w; YU FX, 1993, J BIOL CHEM, V268, P502; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zamir E, 2001, J CELL SCI, V114, P3583; Zamir E, 1999, J CELL SCI, V112, P1655	50	22	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3274	3284		10.1038/sj.onc.1208485	http://dx.doi.org/10.1038/sj.onc.1208485			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735708				2022-12-17	WOS:000228881800006
J	Au, PYB; Martin, N; Chau, H; Moemeni, B; Chia, M; Liu, FF; Minden, M; Yeh, WC				Au, PYB; Martin, N; Chau, H; Moemeni, B; Chia, M; Liu, FF; Minden, M; Yeh, WC			The oncogene PDGF-B provides a key switch from cell death to survival induced by TNF	ONCOGENE			English	Article						TNF; PDGF-B; cell survival; NF-kappa B	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; MYC-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; GROWTH-FACTOR; DERMATOFIBROSARCOMA PROTUBERANS; IN-VITRO; ACTIVATION; ALPHA; INDUCTION	Tumor necrosis factor (TNF) induces both cell death and survival signals. NF-kappa B, a transcription factor activated by TNF, is critical for controlling survival signals through trans-activation of downstream target genes. However, few NF-kappa B target survival genes have been identified with direct roles in oncogenesis. We report that platelet-derived growth factor B (PDGF-B), an oncogene and growth factor, is highly induced by TNF in fibroblasts in an NF-kappa B-dependent manner. PDGF-B can rescue NF-kappa B deficient. broblasts from TNF-mediated killing, and inhibition of PDGF-B signaling sensitizes wild-type cells to TNF-induced death. Interestingly, PDGF-B-transformed NIH-3T3 cells are even more highly sensitized to TNF-induced cell death with PDGF-B inhibition. Our results suggest that while normal cells contain multiple TNF-induced survival signals, tumor cells may favor a specific survival gene that is abnormally upregulated in order to evade death signals.	Univ Toronto, Dept Med Biophys, Univ Hlth Network, AMDI cFIFBCR, Toronto, ON M5G 2C1, Canada; Univ Hlth Network, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Yeh, WC (corresponding author), Univ Toronto, Dept Med Biophys, Univ Hlth Network, AMDI cFIFBCR, 620 Univ Ave,Suite 7-706, Toronto, ON M5G 2C1, Canada.	wyeh@uhnres.utoronto.ca		Liu, Fei-Fei/0000-0003-4344-6486; Spence, Tara/0000-0001-7098-4103				Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BEG AA, 1996, SCIENCE, V274, P784; BRUSERUD O, 1995, LEUKEMIA RES, V19, P15, DOI 10.1016/0145-2126(94)00062-F; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; Gibson EM, 2002, CANCER RES, V62, P488; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HELSON L, 1975, NATURE, V258, P731, DOI 10.1038/258731a0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JAATTELA M, 1995, ONCOGENE, V10, P2297; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KALTHOFF H, 1991, ONCOGENE, V6, P1015; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mahboobi S, 2002, J MED CHEM, V45, P1002, DOI 10.1021/jm010988n; Mak TW, 2002, ARTHRITIS RES THER, V4, pS243, DOI 10.1186/ar569; Manley PW, 2002, EUR J CANCER, V38, pS19, DOI 10.1016/S0959-8049(02)80599-8; Manna SK, 2000, J INTERF CYTOK RES, V20, P725, DOI 10.1089/10799900050116435; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Mochizuki Y, 2004, CLIN EXP METASTAS, V21, P39, DOI 10.1023/B:CLIN.0000017181.01474.35; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; Prins John, 1998, Biochemical Society Transactions, V26, pS314; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rudolph D, 2000, GENE DEV, V14, P854; Shimamura T, 2002, EXP CELL RES, V274, P157, DOI 10.1006/excr.2001.5449; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; Sjoblom T, 2001, CANCER RES, V61, P5778; Smith S, 2002, PLACENTA, V23, P322, DOI 10.1053/plac.2001.0783; Suzuki S, 2003, P NATL ACAD SCI USA, V100, P8276, DOI 10.1073/pnas.0932598100; Takeuchi H, 2004, BRIT J CANCER, V90, P1069, DOI 10.1038/sj.bjc.6601605; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	45	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3196	3205		10.1038/sj.onc.1208516	http://dx.doi.org/10.1038/sj.onc.1208516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735680				2022-12-17	WOS:000228728100013
J	Miyake, I; Hakomori, Y; Misu, Y; Nakadate, H; Matsuura, N; Sakamoto, M; Sakai, R				Miyake, I; Hakomori, Y; Misu, Y; Nakadate, H; Matsuura, N; Sakamoto, M; Sakai, R			Domain-specific function of ShcC docking protein in neuroblastoma cells	ONCOGENE			English	Article						ShcC; neuroblastoma; dominant-negative form; SH2 domain; Src family kinase	RECEPTOR TYROSINE KINASE; ADAPTER PROTEIN; CYCLE PROGRESSION; HEMATOPOIETIC-CELLS; SH3 DOMAINS; GROWTH; SRC; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION	ShcC is a family member of the Shc docking proteins that possess two different phosphotyrosine-binding motifs and conduct signals as Grb2-binding substrates of various receptor tyrosine kinases. We have recently shown that some neuroblastoma cell lines, such as NB-39-nu cells, express a protein complex of hyperphosphorylated ShcC and anaplastic lymphoma kinase (ALK), which is self-activated by gene amplification. Here, we demonstrate that the expression of a mutant ShcC lacking Grb2-binding sites, 3YF-ShcC, significantly impaired the survival, differentiation and motility of NB-39-nu cells by blocking the ERK and Akt pathways. On the other hand, cells overexpressing ShcC or 3YF-ShcC, but not a mutant ShcC that lacks SH2, showed decreased anchorage independency and in vivo tumorigenicity, suggesting a novel ShcC-specific suppressive effect through its SH2 domain on cell transformation. Notably, overexpression of ShcC suppressed the sustained phosphorylation of Src family kinase after cell detachment, which might be independent of phosphorylation of Grb2-binding site. It was indicated that the Src/Fyn-Cas pathway is modulated as a target of these suppressive effects by ShcC. Reciprocal change of ShcC expression and phosphorylation observed in malignant neuroblastoma cell lines might be explained by these phosphotyrosine-dependent and - independent functions of ShcC.	Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan; Kitasato Univ, Sch Med, Dept Pediat, Sagamihara, Kanagawa 2288555, Japan; Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1608582, Japan	National Cancer Center - Japan; Kitasato University; Keio University	Sakai, R (corresponding author), Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	rsakai@gan2.res.ncc.go.jp		Sakai, Ryuichi/0000-0001-6833-1103				Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Collins LR, 1999, J CELL BIOL, V147, P1561, DOI 10.1083/jcb.147.7.1561; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; MCNEIL PL, 1985, J CELL BIOL, V101, P372, DOI 10.1083/jcb.101.2.372; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Nakamura T, 1996, ONCOGENE, V13, P1111; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OBryan JP, 1996, J BIOL CHEM, V271, P11787, DOI 10.1074/jbc.271.20.11787; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pelicci G, 1996, ONCOGENE, V13, P633; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; Stevenson LE, 1999, CELL GROWTH DIFFER, V10, P61; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Wang YJ, 2002, J CELL BIOCHEM, V87, P424, DOI 10.1002/jcb.10321; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei L, 2002, J CELL BIOCHEM, V87, P439, DOI 10.1002/jcb.10322; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989	38	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3206	3215		10.1038/sj.onc.1208523	http://dx.doi.org/10.1038/sj.onc.1208523			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735675				2022-12-17	WOS:000228728100014
J	Truong, AHL; Cervi, D; Lee, J; Ben-David, Y				Truong, AHL; Cervi, D; Lee, J; Ben-David, Y			Direct transcriptional regulation of MDM2 by Fli-1	ONCOGENE			English	Article						erythroleukemia; Fli-1; MDM2; Friend Disease; p53	MULV-INDUCED-ERYTHROLEUKEMIAS; MURINE LEUKEMIA-VIRUS; DNA-BINDING; F-MULV; ERYTHROID PROLIFERATION; P53 PROTEIN; ETS FAMILY; DIFFERENTIATION; CELLS; GENE	The Ets transcription factor, Fli-1, has been shown to play a pivotal role in the induction and progression of Friend Murine Leukemia Virus (F-MuLV)-induced erythroleukemia, with its overexpression leading to erythroblast survival, proliferation, and inhibition of terminal differentiation. P53 inactivation is an additional genetic alteration that occurs in late-stage leukemic progression associated with in vivo and in vitro immortalization. Since p53 protein expression levels are low, to undetectable, in primary erythroleukemic cells that express elevated levels of Fli-1, we investigated the potential regulation of p53 by Fli-1. We assessed whether the overexpression of Fli-1 could partially regulate p53 via modulation of its well-established regulator, MDM2. In this paper, we demonstrate that the promoter of MDM2 contains a consensus binding site for Fli-1that is bound by this transcription factor in vitro and in vivo, resulting in MDM2 transcriptional regulation. We further substantiate these observations in vivo by demonstrating a positive correlation in the expression of Fli-1and MDM2, and a negative correlation with p53 in leukemic tissues obtained from mice with Friend Disease. These observations depict a significant function of Fli-1 overexpression in the indirect control of p53, evidently capable of leading to an increasingly aggressive erythroleukemic clone in vivo.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Div Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med Biophys, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Div Mol & Cellular Biol, Res Bldg,Room S-216,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	bendavid@srcl.sunnybrook.utoronto.ca						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; CordonCardo C, 1997, CANCER RES, V57, P1217; Datta NS, 2002, EXP HEMATOL, V30, P158, DOI 10.1016/S0301-472X(01)00780-9; DAVID YB, 1988, ONCOGENE, V3, P179; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; HOWARD JC, 1993, ONCOGENE, V8, P2721; Kawada H, 2001, INT J HEMATOL, V73, P463, DOI 10.1007/BF02994008; Lee CR, 2003, ANTICANCER RES, V23, P2159; Lesault I, 2002, EMBO J, V21, P694, DOI 10.1093/emboj/21.4.694; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MAO XH, 1994, J BIOL CHEM, V269, P18216; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Prasher JM, 2001, ONCOGENE, V20, P2946, DOI 10.1038/sj.onc.1204395; RAO VN, 1993, ONCOGENE, V8, P2167; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	29	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					962	969		10.1038/sj.onc.1208323	http://dx.doi.org/10.1038/sj.onc.1208323			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592502				2022-12-17	WOS:000226749200002
J	Shao, CS; Deng, L; Chen, YP; Kucherlapati, R; Stambrook, PJ; Tischfield, JA				Shao, CS; Deng, L; Chen, YP; Kucherlapati, R; Stambrook, PJ; Tischfield, JA			Mlh1 mediates tissue-specific regulation of mitotic recombination	ONCOGENE			English	Article						Mlh1; mismatch repair; mitotic recombination; point mutation; mouse model	DNA MISMATCH REPAIR; HOMOLOGOUS RECOMBINATION; GENETIC INSTABILITY; MUTATOR PHENOTYPE; APC MUTATIONS; MOUSE GENOME; MICE; CELLS; DEFICIENT; HETEROZYGOSITY	Mitotic recombination (MR) between chromosome homologs in somatic cells is a major pathway to the loss of heterozygosity (LOH), which may cause cancer if tumor suppressor genes are involved. MR can be suppressed by DNA sequence heterology (homeology) in hybrid mice from matings between species or between subspecies. We now report that MR is relatively suppressed in F1 hybrids between inbred strains C57BL/6 and 129S2. The frequency of MR in fibroblasts is lower in F1 hybrid mice than in either of the two parental strains. However, MR in T cells is not affected by strain background. Thus, relatively small genetic differences are capable of restricting MR in a tissue-specific manner. Using Mlh1-deficient mice, we tested the role of mismatch repair in MR in two isogenic cell types. In fibroblasts of C57BL/6 x 129S2 F1 mice, the suppression of MR is alleviated in the absence of MLH1. In contrast, MR is not affected by Mlh1 status in T cells. The frequency of point mutations at the reporter gene loci Aprt and Hprt, on the other hand, is significantly increased in both T cells and fibroblasts of Mlh1(-/-) mice. Thus, different cell types respond differently to MLH1 deficiency, and the contribution of MR to tumorigenesis may be tissue-dependent in the absence of mismatch repair.	Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA; Univ Cincinnati, Coll Med, Dept Anat Cell Biol & Neurobiol, Cincinnati, OH 45267 USA	Rutgers State University New Brunswick; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; University System of Ohio; University of Cincinnati	Shao, CS (corresponding author), Rutgers State Univ, Dept Genet, 604 Allison Rd, Piscataway, NJ 08854 USA.	shao@biology.rutgers.edu; jay@biology.rutgers.edu	Kucherlapati, Raju/ABC-8807-2021; Shao, Changshun/AAD-8977-2022	Shao, Changshun/0000-0003-2618-9342; Tischfield, Jay/0000-0003-3217-8287	NIEHS NIH HHS [R01ES011633] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011633] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Cervantes RB, 2002, P NATL ACAD SCI USA, V99, P3586, DOI 10.1073/pnas.062527199; Datta A, 1996, MOL CELL BIOL, V16, P1085; DeBerardinis RJ, 1998, NAT GENET, V20, P288, DOI 10.1038/3104; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1999, CANCER RES, V59, P1301; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Engle SJ, 1996, P NATL ACAD SCI USA, V93, P5307, DOI 10.1073/pnas.93.11.5307; Haigis KM, 2002, P NATL ACAD SCI USA, V99, P8927, DOI 10.1073/pnas.132275099; Haigis KM, 2003, NAT GENET, V33, P33, DOI 10.1038/ng1055; Hall MC, 2003, NUCLEIC ACIDS RES, V31, P2025, DOI 10.1093/nar/gkg324; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Kuraguchi M, 2000, ONCOGENE, V19, P5755, DOI 10.1038/sj.onc.1203962; Liang L, 2002, MUTAT RES-FUND MOL M, V502, P69, DOI 10.1016/S0027-5107(02)00029-5; LOEB LA, 1991, CANCER RES, V51, P3075; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mohindra A, 2002, HUM MOL GENET, V11, P2189, DOI 10.1093/hmg/11.18.2189; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; Shao CS, 2000, P NATL ACAD SCI USA, V97, P7405, DOI 10.1073/pnas.97.13.7405; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Shao CS, 2002, ONCOGENE, V21, P2840, DOI 10.1038/sj.onc.1205358; Shao CS, 2001, NAT GENET, V28, P169, DOI 10.1038/88897; Shin CY, 2002, DNA REPAIR, V1, P995, DOI 10.1016/S1568-7864(02)00149-0; Shin CY, 2002, ONCOGENE, V21, P1768, DOI 10.1038/sj.onc.1205241; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; Stambrook PJ, 1996, ENVIRON MOL MUTAGEN, V28, P471; Tischfield JA, 2003, NAT GENET, V33, P5, DOI 10.1038/ng0103-5; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252; Wijnhoven SWP, 2003, CARCINOGENESIS, V24, P139, DOI 10.1093/carcin/24.1.139; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	40	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9017	9024		10.1038/sj.onc.1208148	http://dx.doi.org/10.1038/sj.onc.1208148			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15480418				2022-12-17	WOS:000225492800002
J	Ferrer, A; Marce, S; Bellosillo, B; Villamor, N; Bosch, F; Lopez-Guillermo, A; Espinet, B; Sole, F; Montserrat, E; Campo, E; Colomer, D				Ferrer, A; Marce, S; Bellosillo, B; Villamor, N; Bosch, F; Lopez-Guillermo, A; Espinet, B; Sole, F; Montserrat, E; Campo, E; Colomer, D			Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes	ONCOGENE			English	Article						apoptosis; lymphoma; mitoxantrone	TOPOISOMERASE-II; LYMPHOPROLIFERATIVE DISORDERS; AGGRESSIVE VARIANTS; FOLLICULAR LYMPHOMA; MISSENSE MUTATIONS; CYCLE ARREST; IN-VITRO; P53; FLUDARABINE; EXPRESSION	Mantle cell lymphoma (MCL) is a mature B-cell proliferation characterized by the presence of translocation t(11;14)(q13;q32), an aggressive clinical course, and poor response to chemotherapy. The majority of drugs currently used in the treatment of lymphoproliferative disorders induce cell death by triggering apoptosis, but few data concerning drug-induced apoptosis in MCL have been reported. We have analysed the mechanisms of drug-induced cell death in four cell lines with the t(11; 14) and in primary cells from 10 patients with MCL. Mitoxantrone, a topoisomerase II inhibitor, induced a strong cytotoxic effect in three cell lines (JVM-2, REC-1, and Granta 519), and in primary MCL cells. This cytotoxic effect due to apoptosis induction was observed despite the presence of either p53 or ATM abnormalities. However, no cytotoxic effect was detected after incubation with DNA-damaging agents in the NCEB-1 cell line, carrying p53 and ATM alterations, despite the presence of functional mitochondrial machinery. These results support that mitoxantrone can be effective in the treatment of MCL but that this activity requires the integrity of functional DNA-damage response genes.	Univ Barcelona, Hosp Clin, IDIBAPS, Hematopathol Unit,Dept Hematol, E-08036 Barcelona, Spain; Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, Hematopathol Unit,Dept Pathol, E-08036 Barcelona, Spain; Hosp del Mar, Dept Pathol, Lab Cytogenet & Mol Biol, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Colomer, D (corresponding author), Univ Barcelona, Hosp Clin, IDIBAPS, Hematopathol Unit,Dept Hematol, Villarroel 170, E-08036 Barcelona, Spain.	dcolomer@clinic.ub.es	COLOMER, DOLORS/ABG-6894-2020; Solé, Francesc/K-8373-2012; Campo, Elias/AAC-5593-2019; MARCE, Silvia/J-6651-2017; sole, francesc/A-2430-2011; Bosch, Francesc/AAE-7052-2019	Solé, Francesc/0000-0002-3251-2161; Campo, Elias/0000-0001-9850-9793; MARCE, Silvia/0000-0001-9128-6822; Bosch, Francesc/0000-0001-9241-2886; Ana, Ferrer/0000-0002-3381-9472; Espinet, Blanca/0000-0002-4294-8145; COLOMER, DOLORS/0000-0001-7486-8484				Argatoff LH, 1997, BLOOD, V89, P2067, DOI 10.1182/blood.V89.6.2067; Bailly JD, 1997, LEUKEMIA, V11, P1523, DOI 10.1038/sj.leu.2400762; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bellosillo B, 1999, BLOOD, V94, P2836, DOI 10.1182/blood.V94.8.2836.420k35_2836_2843; Bellosillo B, 1998, BRIT J HAEMATOL, V100, P142, DOI 10.1046/j.1365-2141.1998.00520.x; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Bellosillo B, 2001, BLOOD, V98, P2771, DOI 10.1182/blood.V98.9.2771; Bertoni F, 2004, BRIT J HAEMATOL, V124, P130, DOI 10.1046/j.1365-2141.2003.04761.x; Bogner C, 2003, BRIT J HAEMATOL, V122, P260, DOI 10.1046/j.1365-2141.2003.04438.x; Bosch F, 2002, BRIT J HAEMATOL, V119, P976, DOI 10.1046/j.1365-2141.2002.03959.x; Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z; BOSCH F, 1994, BLOOD, V84, P2726; Camacho E, 2002, BLOOD, V99, P238, DOI 10.1182/blood.V99.1.238; Campo E, 1999, SEMIN HEMATOL, V36, P115; Campo E, 2003, HUM PATHOL, V34, P330, DOI 10.1053/hupa.2003.97; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DEISABELLA P, 1991, LIFE SCI, V48, P2195, DOI 10.1016/0024-3205(91)90333-7; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Fang NY, 2003, P NATL ACAD SCI USA, V100, P5372, DOI 10.1073/pnas.0831102100; Fedier A, 2003, ANN ONCOL, V14, P938, DOI 10.1093/annonc/mdg240; Flinn IW, 2000, BLOOD, V96, P71, DOI 10.1182/blood.V96.1.71.013k21_71_75; Hernandez L, 1996, BLOOD, V87, P3351, DOI 10.1182/blood.V87.8.3351.bloodjournal8783351; Hofmann WK, 2001, BLOOD, V98, P787, DOI 10.1182/blood.V98.3.787; Khoury JD, 2003, J PATHOL, V199, P90, DOI 10.1002/path.1254; M'kacher R, 2003, ONCOGENE, V22, P7905, DOI 10.1038/sj.onc.1206826; Martinez N, 2003, CANCER RES, V63, P8226; Molina-Arcas M, 2003, BLOOD, V101, P2328, DOI 10.1182/blood-2002-07-2236; Muller-Hermelink, 2001, PATHOLOGY GENETICS T, P168; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pham LV, 2003, J IMMUNOL, V171, P88, DOI 10.4049/jimmunol.171.1.88; Pinyol M, 2000, AM J PATHOL, V156, P1987, DOI 10.1016/S0002-9440(10)65071-7; Pinyol M, 1997, BLOOD, V89, P272, DOI 10.1182/blood.V89.1.272.272_272_280; Rasheed ZA, 2003, ONCOGENE, V22, P7296, DOI 10.1038/sj.onc.1206935; Reiman T, 2002, LEUKEMIA, V16, P1886, DOI 10.1038/sj.leu.2402579; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; Schlegelberger B, 1999, BLOOD, V94, P3114; Schrader C, 2004, LEUKEMIA, V18, P1200, DOI 10.1038/sj.leu.2403387; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; SolalCeligny P, 1996, J CLIN ONCOL, V14, P514, DOI 10.1200/JCO.1996.14.2.514; Stankovic T, 2004, BLOOD, V103, P291, DOI 10.1182/blood-2003-04-1161; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Xue LY, 2003, EXP CELL RES, V283, P135, DOI 10.1016/S0014-4827(02)00032-0; Zhao WL, 2004, BLOOD, V103, P695, DOI 10.1182/blood-2003-06-1901	46	22	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8941	8949		10.1038/sj.onc.1208084	http://dx.doi.org/10.1038/sj.onc.1208084			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480431				2022-12-17	WOS:000225354600009
J	Macdonald, M; Wan, Y; Wang, W; Roberts, E; Cheung, TH; Erickson, R; Knuesel, MT; Liu, XD				Macdonald, M; Wan, Y; Wang, W; Roberts, E; Cheung, TH; Erickson, R; Knuesel, MT; Liu, XD			Control of cell cycle-dependent degradation of c-Ski proto-oncoprotein by Cdc34	ONCOGENE			English	Article						Cdc34; Ski; SnoN; protein degradation; ubiquitin; cell cycle	TRANSFORMING-GROWTH-FACTOR; HISTONE DEACETYLASE COMPLEX; ANAPHASE-PROMOTING COMPLEX; SKELETAL-MUSCLE; INDUCED TRANSCRIPTION; UBIQUITIN LIGASE; SMAD PROTEINS; CDNA CLONES; IN-VIVO; SNON	It is known that excess amounts of Ski, or any member of its proto-oncoprotein family, causes disruption of the transforming growth factor beta signal transduction pathway, thus causing oncogenic transformation of cells. Previous studies indicate that Ski is a relatively unstable protein whose expression levels can be regulated by ubiquitin-mediated proteolysis. Here, we investigate the mechanism by which the stability of Ski is regulated. We show that the steady-state levels of Ski protein are controlled post-translationally by cell cycle-dependent proteolysis, wherein Ski is degraded during the interphase of the cell cycle but is relatively stable during mitosis. Furthermore, we demonstrate that the ubiquitin-conjugating enzyme Cdc34 mediates cell cycle-dependent Ski degradation both in vitro and in vivo. Overexpression of dominant-negative Cdc34 stabilizes Ski and enhances its ability to antagonize TGF-beta signaling. Our data suggest that regulated proteolysis of Ski is one of the key mechanisms that control the threshold levels of this proto-oncoprotein, and thus prevents epithelial cells from becoming TGF-beta resistant.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	University of Colorado System; University of Colorado Boulder; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Liu, XD (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	xuedong.liu@colorado.edu		LIU, XUEDONG/0000-0001-7209-4964; Knuesel, Matthew/0000-0002-1441-8614	NATIONAL CANCER INSTITUTE [R01CA095527] Funding Source: NIH RePORTER; NCI NIH HHS [CA95527-01, R01 CA095527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; AMBROSE MR, 1995, DNA CELL BIOL, V14, P701, DOI 10.1089/dna.1995.14.701; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BOYER PL, 1993, ONCOGENE, V8, P457; Cohen SB, 1999, NUCLEIC ACIDS RES, V27, P1006, DOI 10.1093/nar/27.4.1006; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; FUMAGALLI S, 1993, MELANOMA RES, V3, P23, DOI 10.1097/00008390-199304000-00004; GRIMES HL, 1993, ONCOGENE, V8, P2863; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jin JP, 2003, CANCER CELL, V3, P517, DOI 10.1016/S1535-6108(03)00145-4; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Luo KX, 2003, J BONE JOINT SURG AM, V85A, P39, DOI 10.2106/00004623-200300003-00008; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Pati D, 1999, MOL CELL BIOL, V19, P5001; PEARSONWHITE S, 1993, NUCLEIC ACIDS RES, V21, P4632, DOI 10.1093/nar/21.19.4632; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; Prunier C, 2003, J BIOL CHEM, V278, P26249, DOI 10.1074/jbc.M304459200; Reed JA, 2001, CANCER RES, V61, P8074; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; Sutrave P, 2000, GENE, V241, P107, DOI 10.1016/S0378-1119(99)00461-8; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672; Zhang F, 2003, CANCER RES, V63, P5005; Zheng GX, 1997, J BIOL CHEM, V272, P31855, DOI 10.1074/jbc.272.50.31855	50	22	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5643	5653		10.1038/sj.onc.1207733	http://dx.doi.org/10.1038/sj.onc.1207733			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15122324				2022-12-17	WOS:000222629500009
J	Nagayama, S; Iiizumi, M; Katagiri, T; Toguchida, J; Nakamura, Y				Nagayama, S; Iiizumi, M; Katagiri, T; Toguchida, J; Nakamura, Y			Identification of PDZK4, a novel human gene with PDZ domains, that is upregulated in synovial sarcomas	ONCOGENE			English	Article						synovial sarcomas; PDZ domain; upregulation; small interfering RNA	SOFT-TISSUE SARCOMAS; PROTEIN; CHEMOTHERAPY; DOXORUBICIN; IFOSFAMIDE; ASSOCIATION; COMPLEXES; SSX; SYT	In an earlier study designed to investigate molecular mechanisms of carcinogenesis in synovial sarcomas (SSs), we applied a cDNA microarray to detect human genes with significantly increased expression in SS cells. Among the genes selected in this way, we identified a novel transcript, subsequently designated PDZK4 (PDZ domain-containing 4), that was specifically upregulated in all of the 13 SS cases we examined. On Northern blots of normal human tissues, the PDZK4 transcript was expressed only in fetal brain. Immmunocytochemical staining of transfected COS7 cells showed that the PDZK4 gene product localized mainly under the plasma membrane. Treatment of human SS cells with small interfering RNA (siRNA) inhibited the expression of PDZK4 and resulted in the suppression of tumor-cell growth. Induction of exogenous PDZK4 expression promoted growth of T98G and COS7 cells in which no endogenous expression of PDZK4 was observed. Taken together, these findings strongly suggest that inappropriate expression of PDZK4 might play an important role in the proliferation of SS cells and that the gene might be a suitable molecular target for designing of novel drugs to treat SS patients.	Univ Tokyo, Inst Med Sci, Mol Med Lab, Human Genet Unit, Tokyo 1088639, Japan; Kyoto Univ, Dept Surg & Surg Basic Sci, Grad Sch Med, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Kyoto 6068507, Japan	University of Tokyo; Kyoto University; Kyoto University	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Mol Med Lab, Human Genet Unit, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp						ANTMAN K, 1993, J CLIN ONCOL, V11, P1276, DOI 10.1200/JCO.1993.11.7.1276; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Edmonson JH, 2002, CANCER, V94, P786, DOI 10.1002/cncr.10259; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV-100102557; Frustaci S, 2001, J CLIN ONCOL, V19, P1238, DOI 10.1200/JCO.2001.19.5.1238; Hirao K, 2000, J BIOL CHEM, V275, P2966, DOI 10.1074/jbc.275.4.2966; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Mizuno K, 2003, J BIOL CHEM, V278, P31240, DOI 10.1074/jbc.M303593200; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nagayama S, 2002, CANCER RES, V62, P5859; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Patel SR, 1998, AM J CLIN ONCOL-CANC, V21, P317, DOI 10.1097/00000421-199806000-00025; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; *SARC MET COLL, 1998, LANCET, V350, P1647; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; van de Rijn M, 1999, AM J CLIN PATHOL, V112, P43; WEISS SW, 2001, ENZINGER WEISSS SOFT; Wunder JS, 1998, J BONE JOINT SURG AM, V80A, P1020, DOI 10.2106/00004623-199807000-00011; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200	25	22	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5551	5557		10.1038/sj.onc.1207710	http://dx.doi.org/10.1038/sj.onc.1207710			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15077175				2022-12-17	WOS:000222588400015
J	Zhou, DJ; Chen, B; Ye, JJ; Chen, SA				Zhou, DJ; Chen, B; Ye, JJ; Chen, SA			A novel crosstalk mechanism between nuclear receptor-mediated and growth factor/Ras-mediated pathways through PNRC-Grb2 interaction	ONCOGENE			English	Article						PNRC; nuclear receptor coactivator; Grb2; growth factor/Ras; signal transduction	ACTIVATED PROTEIN-KINASE; ESTROGEN-RECEPTOR; COACTIVATORS; CELLS; COREPRESSORS; ALPHA-1; BINDING; MOTIF; SH2	It has been demonstrated that proline-rich nuclear receptor coregulatory protein (PNRC) is a nuclear receptor coactivator that interacts with nuclear receptors through an SH3-binding motif located in its C-terminus. In the present report, a physical interaction between PNRC and Grb2 (an adapter protein involved in growth factor/Ras-mediated pathways) has been demonstrated using the GST pull-down assay, the yeast two-hybrid assay, as well as by coimmunoprecipitation. Cotransfection and fluorescence imaging have also confirmed the colocalization of PNRC and Grb2 in mammalian cells. Transient transfection experiments have demonstrated that, by interacting with each other, Grb2 decreases the coactivator activity of PNRC for nuclear receptors, and that PNRC suppresses Grb2-mediated Ras/MAP-kinase activation. Furthermore, it was discovered that HeLa cells overexpressing PNRC grew more slowly when compared to matched controls. Additionally, using a RT-PCR analysis of mRNA on six pairs of cancer/noncancer tissues, PNRC expression was found to be significantly lower in breast cancer tissue than in noncancer tissue. Based on these findings, we believe that PNRC and Grb2, by interacting with each other, can suppress nuclear receptor-mediated regulation and growth factor-mediated regulation in human breast tissue. This is a newly identified crosstalk mechanism for modulating these two important types of regulatory pathways.	Beckman Res Inst City Hope, Dept Surg Res, Duarte, CA 91010 USA; Third Mil Med Univ, Dept Biochem, Chongqing, Peoples R China	City of Hope; Beckman Research Institute of City of Hope; Army Medical University	Chen, SA (corresponding author), Beckman Res Inst City Hope, Dept Surg Res, Duarte, CA 91010 USA.	schen@coh.org			NCI NIH HHS [CA44735] Funding Source: Medline; NIDDK NIH HHS [DK60560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen S, 2001, J BIOL CHEM, V276, P28465, DOI 10.1074/jbc.M102638200; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Gay B, 1999, INT J CANCER, V83, P235, DOI 10.1002/(SICI)1097-0215(19991008)83:2<235::AID-IJC15>3.0.CO;2-B; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NICHOLSON RI, 1996, HORMONES CANC, P227; Ordentlich P, 2001, CURR TOP MICROBIOL, V254, P101; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rauh MJ, 1999, MOL CELL BIOL, V19, P8169; Rooij J, 1997, ONCOGENE, V14, P623; RUSSELL KS, 1992, CANCER RES, V52, P6624; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Verbeek BS, 1997, J PATHOL, V183, P195; Zhou DJ, 2001, NUCLEIC ACIDS RES, V29, P3939, DOI 10.1093/nar/29.19.3939; Zhou DJ, 2000, MOL ENDOCRINOL, V14, P986, DOI 10.1210/me.14.7.986	22	22	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2004	23	31					5394	5404		10.1038/sj.onc.1207695	http://dx.doi.org/10.1038/sj.onc.1207695			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15122321				2022-12-17	WOS:000222491600015
J	Vares, G; Ory, K; Lectard, B; Levalois, C; Altmeyer-Morel, S; Chevillard, S; Lebeau, J				Vares, G; Ory, K; Lectard, B; Levalois, C; Altmeyer-Morel, S; Chevillard, S; Lebeau, J			Progesterone prevents radiation-induced apoptosis in breast cancer cells	ONCOGENE			English	Article						progesterone; apoptosis; breast; cancer	P53 TUMOR-SUPPRESSOR; MAMMARY-GLAND; HORMONAL-REGULATION; GROWTH-INHIBITION; EPITHELIAL-CELLS; MENSTRUAL-CYCLE; CROSS-TALK; DNA-DAMAGE; BCL-2; RECEPTOR	Sex steroid hormones play an essential role in the control of homeostasis in the mammary gland. Although the involvement of progesterone in cellular proliferation and differentiation is well established, its exact role in the control of cell death still remains unclear. As dysregulation of the apoptotic process plays an important role in the pathogenesis of breast cancer, we investigated the regulation of apoptosis by progesterone in various breast cancer cell lines. Our results show that progesterone treatment protects against radiation-induced apoptosis. This prevention appears to be mediated by the progesterone receptor and is unrelated to p53 status. There is also no correlation with the intrinsic hormonal effect on cell proliferation, as the presence of cells in a particular phase of the cell cycle. Surprisingly, progesterone partly allows bypassing of the irradiation-induced growth arrest in G(2)/M in PgR + cells, leading to an increase in cell proliferation after irradiation. One consequence of this effect is a higher rate of chromosome damage in these proliferating progesterone-treated cells compared to what is observed in untreated irradiated cells. We propose that progesterone, by inhibiting apoptosis and promoting the proliferation of cells with DNA damage, potentially facilitates the emergence of genetic mutations that may play a role in malignant transformation.	CEA, DSV, DRR, LCE, F-92265 Fontenay Aux Roses, France	CEA	Lebeau, J (corresponding author), CEA, DSV, DRR, LCE, 60-68 Ave GenLeclerc,BP6, F-92265 Fontenay Aux Roses, France.	lebeau@dsvidf.cea.fr	Vares, Guillaume/S-6530-2019; Vares, Guillaume/A-9257-2011	Vares, Guillaume/0000-0002-6191-9032; Vares, Guillaume/0000-0002-6191-9032; Chevillard, Sylvie/0000-0001-5889-4041				Alkhalaf M, 2002, EUR J CANCER PREV, V11, P481, DOI 10.1097/00008469-200210000-00011; BARDON S, 1987, CANCER RES, V47, P1441; Bernstein L, 2002, J MAMMARY GLAND BIOL, V7, P3, DOI 10.1023/A:1015714305420; Biri A, 2002, MUTAT RES-GEN TOX EN, V521, P113, DOI 10.1016/S1383-5718(02)00217-6; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; FERGUSON DJP, 1981, BRIT J CANCER, V44, P177, DOI 10.1038/bjc.1981.168; Flototto T, 2001, HORM METAB RES, V33, P451, DOI 10.1055/s-2001-16936; Formby B, 1998, ANN CLIN LAB SCI, V28, P360; Formby B, 1999, MOL CELL BIOCHEM, V202, P53, DOI 10.1023/A:1007081021483; Gompel A, 2000, STEROIDS, V65, P593, DOI 10.1016/S0039-128X(00)00172-0; Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; JUENGEL JL, 1993, ENDOCRINOLOGY, V132, P249, DOI 10.1210/en.132.1.249; Kandouz M, 1999, J STEROID BIOCHEM, V69, P463, DOI 10.1016/S0960-0760(99)00069-2; Kao GD, 2001, ONCOGENE, V20, P3486, DOI 10.1038/sj.onc.1204445; Kester HA, 2003, EXP CELL RES, V284, P264, DOI 10.1016/S0014-4827(02)00017-4; Kester HA, 1997, J BIOL CHEM, V272, P16637, DOI 10.1074/jbc.272.26.16637; KirschVolders M, 1997, MUTAT RES-GEN TOX EN, V392, P19, DOI 10.1016/S0165-1218(97)00042-6; Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257; Lanari C, 2002, BREAST CANCER RES, V4, P240, DOI 10.1186/bcr539; Lange CA, 1999, MOL ENDOCRINOL, V13, P829, DOI 10.1210/me.13.6.829; Lebeau J, 2002, ANTICANCER RES, V22, P2161; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin VCL, 2003, AM J PATHOL, V162, P1781, DOI 10.1016/S0002-9440(10)64313-1; LUCIANO AM, 1994, BIOL REPROD, V51, P646, DOI 10.1095/biolreprod51.4.646; LUKIC B, 1987, MUTAT RES, V191, P121, DOI 10.1016/0165-7992(87)90140-0; Lydon JP, 1999, CANCER RES, V59, P4276; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Murdoch WJ, 2002, MOL CELL ENDOCRINOL, V186, P61, DOI 10.1016/S0303-7207(01)00675-X; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; Ory K, 2001, BREAST CANCER RES TR, V68, P187, DOI 10.1023/A:1012288510743; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pecci A, 1997, J BIOL CHEM, V272, P11791, DOI 10.1074/jbc.272.18.11791; ROTELLO RJ, 1992, AM J PATHOL, V140, P449; SABOURIN JC, 1994, INT J CANCER, V59, P1, DOI 10.1002/ijc.2910590102; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; Thordarson G, 2001, CARCINOGENESIS, V22, P1027, DOI 10.1093/carcin/22.7.1027	45	22	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4603	4613		10.1038/sj.onc.1207601	http://dx.doi.org/10.1038/sj.onc.1207601			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064714				2022-12-17	WOS:000221799000010
J	Delva, L; Gallais, I; Guillouf, C; Denis, N; Orvain, C; Moreau-Gachelin, F				Delva, L; Gallais, I; Guillouf, C; Denis, N; Orvain, C; Moreau-Gachelin, F			Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells	ONCOGENE			English	Article						Spi-1/PU.1; TLS; erythroleukemia; transcription factor; splicing interference	RNA-BINDING PROTEIN; HUMAN MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR PU.1; POLYMERASE-II; CHROMOSOMAL TRANSLOCATION; DNA-BINDING; PUTATIVE ONCOGENE; ACTIVATION DOMAIN; TERMINAL DOMAIN; IN-VIVO	The hematopoietic transcription factor Spi-1/PU.1 is an oncoprotein participating to the malignant transformation of proerythroblasts in the Friend erythroleukemia or in the erythroleukemic process developed in spi-1 transgenic mice. Overexpression of Spi-1 in proerythroblasts blocks their differentiation. We have shown that Spi-1 promotes the use of the proximal 5'-splice site during the E1A pre-mRNA splicing and interferes with the effect of TLS (Translocated in LipoSarcoma) in this splicing assay. TLS was identified from chromosomal translocations in human liposarcoma and acute myeloid leukemia. Here, we determine the function of Spi-1 domains in splicing and in the interference with TLS. In transient transfection assays in erythroid cells, we show that the DNA binding domain cooperates with the transactivation domain or the PEST region of Spi-1 to modify the function of TLS in splicing. Interestingly, the 27 C-terminal amino acids, which determine the DNA binding activity of Spi-1, are necessary for the splicing function of Spi-1 as well as for its ability to interfere with TLS. Finally, we demonstrate that in leukemic proerythroblasts overexpressing Spi-1, TLS has lost its splicing effect. Thus, we hypothesize that oncogenic pathways in proerythroblasts may involve the ability of Spi-1 to alter splicing.	Inst Curie, INSERM, U528, Sect Rech, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM, U528, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.	framoreau@curie.fr		DELVA, Laurent/0000-0002-1086-3964				Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Baechtold H, 1999, J BIOL CHEM, V274, P34337, DOI 10.1074/jbc.274.48.34337; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bertrand P, 1999, ONCOGENE, V18, P4515, DOI 10.1038/sj.onc.1203048; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CALVIO C, 1995, RNA, V1, P724; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DELGADO MD, 1994, ONCOGENE, V9, P1723; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; FU XD, 1995, RNA, V1, P663; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Knoop LL, 2001, J BIOL CHEM, V276, P22317, DOI 10.1074/jbc.M008950200; Kuroda M, 2000, EMBO J, V19, P453, DOI 10.1093/emboj/19.3.453; Lerga A, 2001, J BIOL CHEM, V276, P6807, DOI 10.1074/jbc.M008304200; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; OHNO T, 1994, ONCOGENE, V9, P3087; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Perkel JM, 1998, J IMMUNOL, V160, P241; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAYGALLET D, 1995, ONCOGENE, V11, P303; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Wu SP, 1997, EMBO J, V16, P4421, DOI 10.1093/emboj/16.14.4421; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	55	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4389	4399		10.1038/sj.onc.1207578	http://dx.doi.org/10.1038/sj.onc.1207578			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064749				2022-12-17	WOS:000221661300005
J	Han, SY; Iliopoulos, D; Druck, T; Guler, G; Grubbs, CJ; Pereira, M; Zhang, ZQ; You, M; Lubet, RA; Fong, LYY; Huebner, K				Han, SY; Iliopoulos, D; Druck, T; Guler, G; Grubbs, CJ; Pereira, M; Zhang, ZQ; You, M; Lubet, RA; Fong, LYY; Huebner, K			CpG methylation in the Fhit regulatory region: relation to Fhit expression in murine tumors	ONCOGENE			English	Article						CpG island methylation; Fhit promoter; epigenetics; tumor suppressor; gene inactivation; homozygous deletion	DNA METHYLATION; GENE-EXPRESSION; BLADDER-CANCER; LUNG; PROFILE; BREAST; INACTIVATION; BREAKPOINT; CARCINOMA; 3P14.2	To determine if: (1) 5' CpG island methylation is related to Fhit inactivation; (2) there are tumor or carcinogen-specific methylation patterns, we examined 35 CpG sites in the promoter, exon and intron 1 of the mouse Fhit gene. In primary tumors of lung, urinary bladder and tongue, induced by different carcinogens, 15-35% of sites were methylated, with specific methylation patterns associated with each cancer type, suggesting cancer- or tissue-specific methylation patterns. The methylation patterns were associated with reduced Fhit expression, as determined by immunohistochemical analyses. Methylation of rat Fhit 5' CpGs in mammary adenocarcinomas, detected by methylation specific PCR amplification, also correlated with reduced gene expression. Thus, there was an overall association between promoter/exon 1 methylation and decreased Fhit expression. In contrast, in cancer- derived cell lines 70-95% of the CpG sites were methylated. This is the first detailed study of the relationship between Fhit 5' CpG island methylation and Fhit expression in murine tumors, our main models for preclinical cancer studies, and provides evidence that loss of Fhit expression and methylation are correlated in these mouse models and these models will be useful to examine the complex relationships among gene expression, methylation patterns and organ specific city.	Thomas Jefferson Univ, Kimmel Canc Ctr, BLSB 1008, Philadelphia, PA 19107 USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; Med Coll Ohio, Dept Pathol, Toledo, OH 43699 USA; Washington Univ, Dept Surg, St Louis, MO USA; NCI, Div Canc Prevent & Control, DCPC, Rockville, MD 20852 USA; Hacettepe Univ, Dept Pathol, TR-06100 Ankara, Turkey	Jefferson University; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hacettepe University	Huebner, K (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, BLSB 1008, 233 S 10th St, Philadelphia, PA 19107 USA.	K_Huebner@mail.jci.tju.edu	GULER, GULNUR/I-9887-2013; Iliopoulos, Dimitrios/AAE-9106-2019	Fong, Louise/0000-0001-7654-7035	NCI NIH HHS [N01-CN-15128, N01-CN-25007, N01-CN-15113, CA77738, CA56036] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA056036, P01CA077738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Baffa R, 2000, AM J PATHOL, V156, P419, DOI 10.1016/S0002-9440(10)64745-1; BAYLIN SB, 1986, CANCER RES, V46, P2917; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Druck T, 1997, CANCER RES, V57, P504; Druck T, 1998, ONCOL RES, V10, P341; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Esteller M, 2001, CANCER RES, V61, P3225; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Glover TW, 1998, CANCER RES, V58, P3409; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Grubbs CJ, 2000, CANCER RES, V60, P5599; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Ingvarsson S, 1999, CANCER RES, V59, P2682; Kolomietz E, 2003, LEUKEMIA, V17, P1313, DOI 10.1038/sj.leu.2402969; LUBET RA, 2003, UNPUB CARCINOGENESIS; Maruyama R, 2001, CANCER RES, V61, P8659; Nigro JM, 2001, AM J PATHOL, V158, P1253, DOI 10.1016/S0002-9440(10)64076-X; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paz MF, 2003, CANCER RES, V63, P1114; Pekarsky Y, 1998, CANCER RES, V58, P3401; Skopelitou AS, 2001, IN VIVO, V15, P169; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Sozzi G, 1998, CANCER RES, V58, P5032; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Sutherland JE, 2001, MUTAT RES-FUND MOL M, V479, P225, DOI 10.1016/S0027-5107(01)00163-4; Tanaka H, 1998, CANCER RES, V58, P3429; WARY KK, 1993, CANCER RES, V53, P1498; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	33	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3990	3998		10.1038/sj.onc.1207526	http://dx.doi.org/10.1038/sj.onc.1207526			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007387				2022-12-17	WOS:000221382000011
J	Wu, LQ; Zhu, HY; Nie, LH; Maki, CG				Wu, LQ; Zhu, HY; Nie, LH; Maki, CG			A link between p73 transcriptional activity and p73 degradation	ONCOGENE			English	Article						p53; p73; degradation	RING-FINGER DOMAIN; P53-RELATED PROTEIN; ONCOPROTEIN MDM2; UBIQUITIN LIGASE; P53; P63; IDENTIFICATION; ACTIVATION; TRANSACTIVATION; APOPTOSIS	The p53 family of proteins includes three members, p53, p63, and p73. The levels and stability of p53 are controlled in large part by MDM2, which can bind the p53 N-terminus and promote its degradation. Because the MDM2 gene is transcriptionally activated by p53, it forms part of an autoregulatory feedback loop that directly links the transcriptional activity of p53 with its degradation. In contrast, little is known about the mechanisms that control p63 or p73 stability. In the current study, p73 deletion or point mutants that lacked transactivation activity were stable compared to wild-type p73. A naturally occurring p73 variant (DeltaNp73) was also stable compared to wild-type p73. Finally, fusion of the VP16-transactivation domain to an inactive, stable p73 mutant restored transactivation function and rendered the mutant protein unstable. These results demonstrate that p73 transactivation activity is necessary for rapid p73 turnover, and suggest that one or more transcriptional targets of p73 may promote its degradation.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	University of Chicago	Maki, CG (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, 5841 S Maryland Ave,MC1105,Room G-06, Chicago, IL 60637 USA.	cmaki@rover.uchicago.edu			NCI NIH HHS [1R01CA80918-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; MELIKHOV D, 2002, EUR PHYS J C, V2, P1; Miyazaki K, 2003, BIOCHEM BIOPH RES CO, V308, P106, DOI 10.1016/S0006-291X(03)01347-0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Takada N, 1999, CANCER RES, V59, P2810; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	25	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4032	4036		10.1038/sj.onc.1207538	http://dx.doi.org/10.1038/sj.onc.1207538			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021899				2022-12-17	WOS:000221382000016
J	Rae, FK; Martinez, G; Gillinder, KR; Smith, A; Shooter, G; Forrest, AR; Grimmond, SM; Little, MH				Rae, FK; Martinez, G; Gillinder, KR; Smith, A; Shooter, G; Forrest, AR; Grimmond, SM; Little, MH			Anlaysis of complementary expression profiles following WT1 induction versus repression reveals the cholesterol/fatty acid synthetic pathways as a possible major target of WT1	ONCOGENE			English	Article						WT1; mevalonate; cholesterol; expression profiling	TUMOR-SUPPRESSOR GENE; DENSITY-LIPOPROTEIN RECEPTOR; WILMS-TUMOR; ORNITHINE-DECARBOXYLASE; MUTANT PROTEINS; BINDING; CELLS; MUTATIONS; RAS; WILMS-TUMOR-1	The Wilms' tumour suppressor gene, WT1, encodes a zinc-finger protein that is mutated in Wilms' tumours and other malignancies. WT1 is one of the earliest genes expressed during kidney development. WT1 proteins can activate and repress putative target genes in vitro, although the in vivo relevance of such target genes often remains unverified. To better understand the role of WT1 in tumorigenesis and kidney development, we need to identify downstream target genes. In this study, we have expression pro. led human embryonic kidney 293 cells stably transfected to allow inducible WT1 expression and mouse mesonephric M15 cells transfected with a WT1 antisense construct to abolish endogenous expression of all WT1 isoforms to identify WT1-responsive genes. The complementary overlap between the two cell lines revealed a pronounced repression of genes involved in cholesterol biosynthesis by WT1. This pathway is transcriptionally regulated by the sterol responsive element-binding proteins (SREBPs). Here, we provide evidence that the C-terminal end of the WT1 protein can directly interact with SREBP, suggesting that WT1 may modify the transcriptional function of SREBPs via a direct protein-protein interaction. Therefore, the tumour suppressor activities of WT1 may be achieved by repressing the mevalonate pathway, thereby controlling cellular proliferation and promoting terminal differentiation.	Univ Queensland, Queensland Biosci Precinct, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland	Little, MH (corresponding author), Univ Queensland, Queensland Biosci Precinct, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	m.little@imb.uq.edu.au	Little, Melissa H/A-6170-2010; Grimmond, Sean/K-3246-2019; Gillinder, Kevin/I-6224-2013; Smith, Aaron/A-8329-2010; Forrest, Alistair/A-6597-2008; Grimmond, Sean M/J-5304-2016	Little, Melissa H/0000-0003-0380-2263; Grimmond, Sean/0000-0002-8102-7998; Gillinder, Kevin/0000-0002-1221-9718; Forrest, Alistair/0000-0003-4543-1675; Grimmond, Sean M/0000-0002-8102-7998				Bassa BV, 1999, BBA-MOL CELL RES, V1449, P137, DOI 10.1016/S0167-4889(99)00007-5; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Denoyelle C, 2003, CELL SIGNAL, V15, P327, DOI 10.1016/S0898-6568(02)00124-9; DENYS P, 1967, ARCH FR PEDIATR, V24, P729; DRASH A, 1970, J PEDIATR-US, V76, P585, DOI 10.1016/S0022-3476(70)80409-7; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grimmond S, 2000, HUM MOL GENET, V9, P1553, DOI 10.1093/hmg/9.10.1553; Gurates B, 2002, J CLIN ENDOCR METAB, V87, P4369, DOI 10.1210/jc.2002-020522; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; HEWITT SM, 1995, CANCER RES, V55, P5386; Holmes G, 1997, BIOCHEM BIOPH RES CO, V233, P723, DOI 10.1006/bbrc.1997.6545; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; KingUnderwood L, 1996, BLOOD, V87, P2171, DOI 10.1182/blood.V87.6.2171.bloodjournal8762171; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LADANYI M, 1994, CANCER RES, V54, P2837; Ladomery M, 2003, J CELL SCI, V116, P1539, DOI 10.1242/jcs.00324; Ladomery MR, 1999, J BIOL CHEM, V274, P36520, DOI 10.1074/jbc.274.51.36520; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lee TH, 2001, PHYSIOL GENOMICS, V7, P187, DOI 10.1152/physiolgenomics.00046.2001; Li RS, 1999, EXP CELL RES, V247, P257, DOI 10.1006/excr.1998.4361; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; Llorente-Cortes V, 2002, CIRCULATION, V106, P3104, DOI 10.1161/01.CIR.0000041434.28573.0B; Lopez D, 2001, ENDOCRINOLOGY, V142, P5097, DOI 10.1210/en.142.12.5097; LUO XN, 1995, ONCOGENE, V11, P743; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Oda H, 1999, KIDNEY INT, V56, pS2, DOI 10.1046/j.1523-1755.1999.07101.x; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1994, HUM MOL GENET, V3, P1633, DOI 10.1093/hmg/3.9.1633; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; REDDY JC, 1995, J BIOL CHEM, V270, P29976; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Sakakura Y, 2001, BIOCHEM BIOPH RES CO, V286, P176, DOI 10.1006/bbrc.2001.5375; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Sim EUH, 2002, ONCOGENE, V21, P2948, DOI 10.1038/sj.onc.1205373; Simms LA, 1995, EUR J CANCER, V31A, P2270, DOI 10.1016/0959-8049(95)00474-2; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; Valerius MT, 2002, P NATL ACAD SCI USA, V99, P8090, DOI 10.1073/pnas.122229199	56	22	23	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3067	3079		10.1038/sj.onc.1207360	http://dx.doi.org/10.1038/sj.onc.1207360			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15021918				2022-12-17	WOS:000220845200011
J	Schubert, S; Horstmann, S; Bartusel, T; Klempnauer, KH				Schubert, S; Horstmann, S; Bartusel, T; Klempnauer, KH			The cooperation of B-Myb with the coactivator p300 is orchestrated by cyclins A and D1	ONCOGENE			English	Article						B-myb; p300; cyclin A; cyclin D1; acetylation	CBP-INDUCED STIMULATION; CELL-CYCLE; TRANSCRIPTION FACTOR; RETINOBLASTOMA PROTEIN; C-MYB; ESTROGEN-RECEPTOR; MOLECULAR-CLONING; DEPENDENT-KINASE; GENE-EXPRESSION; V-MYB	B-Myb is a highly conserved member of the Myb family of transcription factors whose activity is regulated during the cell cycle. Previous work has shown that the activity of B-Myb is stimulated by cyclin A/Cdk2-dependent phosphorylation whereas interaction of B-Myb with cyclin D1 inhibits its activity. Here, we have investigated the role of p300 as a coactivator for B-Myb. We show that B-Myb-dependent transactivation is stimulated by p300 as a result of interaction between B-Myb and p300. We have mapped the sequences responsible for the interaction of B-Myb and p300 to the E1A-binding region of p300 and the transactivation domain of B-Myb, respectively. Furthermore, our data suggest that phosphorylation of B-Myb stimulates its acetylation by p300 and that the acetylation of B-Myb is necessary for the full stimulation of its transactivation potential by p300. We have also studied the effect of cyclin D1 on the cooperation of B-Myb and p300. Based on our results we propose that cyclin D1 inhibits the activity of B-Myb by interfering with the interaction of B-Myb and p300. The data reported here provide novel insight into the mechanisms by which the activity of B-Myb is regulated during the cell cycle. Taken together they suggest that the coactivator p300 plays an important role in this regulation and that the cooperation of B-Myb and p300 is orchestrated by cyclins A and D1.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de	Buchinger, Sebastian/M-3003-2013	Buchinger, Sebastian/0000-0003-4859-8972				Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARSURA M, 1992, BLOOD, V79, P2708; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BERNARDS R, 1999, BIOCHIM BIOPHYS ACTA, V1424, P17; Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Facchinetti V, 1997, BIOCHEM J, V324, P729, DOI 10.1042/bj3240729; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Horstmann S, 2000, ONCOGENE, V19, P5428, DOI 10.1038/sj.onc.1203937; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; Kamano H, 1995, ONCOGENE, V11, P2575; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Li XL, 2002, MOL CELL BIOL, V22, P3663, DOI 10.1128/MCB.22.11.3663-3673.2002; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200; Robinson C, 1996, ONCOGENE, V12, P1855; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sitzmann J, 1996, ONCOGENE, V12, P1889; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	73	22	23	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1392	1404		10.1038/sj.onc.1207255	http://dx.doi.org/10.1038/sj.onc.1207255			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14973551				2022-12-17	WOS:000189035800006
J	Fan, YJ; Rayet, B; Gelinas, C				Fan, YJ; Rayet, B; Gelinas, C			Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes	ONCOGENE			English	Article						NF-kappa B; Rel; cancer; transformation; transcription	HODGKIN/REED-STERNBERG CELLS; CHICKEN SPLEEN-CELLS; DISEASE TUMOR-CELLS; V-REL; DNA-BINDING; TRANSCRIPTION FACTORS; BREAST-CANCER; CYTOPLASMIC RETENTION; TRANSFORMING ACTIVITY; SELECTIVE ACTIVATION	rel/nf-kappaB genes are amplified, overexpressed, or constitutively activated in many human hematopoietic tumors; however, the molecular mechanisms by which they contribute to tumorigenesis remain to be determined. Here, we explored the oncogenic potential of cellular Rel/NF-kappaB proteins in vitro and in vivo. We show that overexpression of wild-type mouse and human c-rel genes suffices to malignantly transform primary spleen cells in stringent soft agar assays and produce fatal tumors in vivo. In contrast relA and a constitutively active form of IKKbeta did not. Importantly, a hybrid RelA protein with its C-terminal transactivation domain substituted by that of v-Rel was potently oncogenic in vitro and in vivo. The transactivation domain of v-Rel selectively conferred an oncogenic phenotype upon the Rel homology domain (RHD) of RelA, but not to the more divergent RHDs of p50/NF-kappaB1, p52/NF-kappaB2, or RelB. Collectively, our results highlight important differences in the intrinsic oncogenic activity of mammalian c-Rel and RelA proteins, and indicate that critical determinants of their differential oncogenicity reside in their divergent transactivation domains. These findings provide experimental evidence for a role of mammalian Rel/NF-kappaB factors in leukemia/lymphomagenesis in an in vivo animal model, and are consistent with the implication of c-rel in many human lymphomas.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Gelinas, C (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, 679 Hoes Lane, Piscataway, NJ 08854 USA.	gelinas@cabm.rutgers.edu			NCI NIH HHS [CA54999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054999, R29CA054999] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carrasco D, 1997, J EXP MED, V186, P279, DOI 10.1084/jem.186.2.279; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DOUGHERTY JP, 1989, J VIROL, V63, P3209, DOI 10.1128/JVI.63.7.3209-3212.1989; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; Fujii M, 1996, ONCOGENE, V12, P2193; Gapuzan MER, 2002, ONCOGENE, V21, P2484, DOI 10.1038/sj.onc.1205333; Garcia JF, 2003, BLOOD, V101, P681, DOI 10.1182/blood-2002-04-1128; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 1996, ONCOGENE, V13, P1367; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; HOFFMANN A, 2003, IN PRESS EMBO J, V22; Houldsworth J, 1996, BLOOD, V87, P25; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; KUCHARCZAK J, IN PRESS ONCOGENE; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LU D, 1991, ONCOGENE, V6, P1235; MCDONNELL PC, 1992, ONCOGENE, V7, P163; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Ricca A, 2001, BRIT J CANCER, V85, P1914, DOI 10.1054/bjoc.2001.2174; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Rottjakob EM, 1996, J VIROL, V70, P3176, DOI 10.1128/JVI.70.5.3176-3188.1996; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; Wessendorf S, 2003, ONCOGENE, V22, P1425, DOI 10.1038/sj.onc.1206297; White DW, 1996, ONCOGENE, V13, P891; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Zurovec M, 1998, ONCOGENE, V16, P3133, DOI 10.1038/sj.onc.1201860	84	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1030	1042		10.1038/sj.onc.1207221	http://dx.doi.org/10.1038/sj.onc.1207221			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647412				2022-12-17	WOS:000188749900002
J	Saito, T; Tanaka, R; Wataba, K; Kudo, R; Yamasaki, H				Saito, T; Tanaka, R; Wataba, K; Kudo, R; Yamasaki, H			Overexpression of estrogen receptor-alpha gene suppresses gap junctional intercellular communication in endometrial carcinoma cells	ONCOGENE			English	Article						connexin; estrogen; carcinogenesis; endometrial hyperplasia; gap junction; cell adhesion	EPIDERMAL-GROWTH-FACTOR; DOWN-REGULATION; STEROID-HORMONES; CONNEXIN GENES; CANCER-CELLS; MICROSATELLITE INSTABILITY; ISLAND METHYLATION; PROMOTER REGION; BETA-CATENIN; EXPRESSION	Stimulation of the endometrium by estrogens without the differentiating effect of progestins is the primary etiological factor associated with the development of endometrial hyperplasia and adenocarcinoma. However, the correlation between sex steroids and gap junctional intercellular communication (GJIC), which is considered to play an important role in the control of cell growth and differentiation, is not well known in endometrial carcinoma. In this study, we focused on the influence of estrogen and its receptor in connexin (Cx) expression and GJIC in endometrial carcinoma cells, established stable clone IK-ER1 overexpressing ER-alpha to transfect the expression vector and analysed them in various hormonal conditions. The growth of IK-ER1 was accelerated by 17beta-estradiol and the acceleration of the 5-bromo-25-deoxyuridine labeling index was observed. GJIC was assayed by scoring the number of dye-coupled cells after microinjecton of single cells with Lucifer-Yellow, and subcellular localization of Cx26 and Cx32 was analysed by immunocytochemistry. In the presence of estradiol, dye-coupled cells of IK-ER1 were significantly reduced compared to those without estradiol and the reduction was completely inhibited by adding ICI182.780, a pure antiestrogen substrate. Cxs were detected as only small spots by immunocytochemistry, and Western blotting showed that the expression was decreased. These results suggest that activation of ER-alpha by estrogen results in tumor progression by stimulating cell growth and suppressing GJIC via suppression of the expression of Cxs in endometrial carcinogenesis.	Sapporo Med Univ, Sch Med, Dept Obstet & Gynaecol, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Kwansei Gakuin Univ, Sch Sci & Technol, Sanda 6691337, Japan	Sapporo Medical University; Kwansei Gakuin University	Saito, T (corresponding author), Sapporo Med Univ, Sch Med, Dept Obstet & Gynaecol, Chuo Ku, S-1,W-16, Sapporo, Hokkaido 0608543, Japan.	tsaito@sapmed.ac.jp						Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Ali SH, 2000, CANCER RES, V60, P7094; ANZAI Y, 1992, J STEROID BIOCHEM, V42, P449, DOI 10.1016/0960-0760(92)90256-I; Ashihara Koji, 2002, Medical Electron Microscopy, V35, P9, DOI 10.1007/s007950200001; BERCHUCK A, 1995, CANCER, V76, P2034, DOI 10.1002/1097-0142(19951115)76:10+<2034::AID-CNCR2820761321>3.0.CO;2-U; Darnel AD, 1999, J STEROID BIOCHEM, V70, P203, DOI 10.1016/S0960-0760(99)00116-8; Dubina MV, 2002, ONCOGENE, V21, P4992, DOI 10.1038/sj.onc.1205630; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; Fukuchi T, 1998, CANCER RES, V58, P3526; Grummer R, 1999, ENDOCRINOLOGY, V140, P2509, DOI 10.1210/en.140.6.2509; Hanna EA, 1999, CARCINOGENESIS, V20, P1369, DOI 10.1093/carcin/20.7.1369; Heikaus S, 2002, J MOL ENDOCRINOL, V29, P239, DOI 10.1677/jme.0.0290239; Hirai A, 2003, AM J NEPHROL, V23, P172, DOI 10.1159/000070653; HOLINKA CF, 1986, CANCER RES, V46, P2771; Huang RC, 2002, CANCER RES, V62, P2806; JAMIL A, 1991, J MOL ENDOCRINOL, V6, P215, DOI 10.1677/jme.0.0060215; KAMIBAYASHI Y, 1995, CARCINOGENESIS, V16, P1287, DOI 10.1093/carcin/16.6.1287; KLEINMAN D, 1995, ENDOCRINOLOGY, V136, P2531, DOI 10.1210/en.136.6.2531; Klotz LO, 2002, CANCER RES, V62, P4922; KOHLER MF, 1993, AM J OBSTET GYNECOL, V169, P690, DOI 10.1016/0002-9378(93)90644-X; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Krutovskikh V, 1997, HISTOL HISTOPATHOL, V12, P761; KRUTOVSKIKH VA, 1991, CARCINOGENESIS, V12, P1701, DOI 10.1093/carcin/12.9.1701; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X; Laird DW, 1999, CANCER RES, V59, P4104; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; Locke D, 1998, J PATHOL, V186, P343; Loncarek J, 2003, MOL CARCINOGEN, V36, P74, DOI 10.1002/mc.10102; LUKES AS, 1994, CANCER, V73, P2380, DOI 10.1002/1097-0142(19940501)73:9<2380::AID-CNCR2820730922>3.0.CO;2-G; MESNIL M, 1995, CANCER RES, V55, P629; Mizumoto H, 2002, INT J CANCER, V100, P401, DOI 10.1002/ijc.10504; Nei H, 1999, MOL CARCINOGEN, V25, P207, DOI 10.1002/(SICI)1098-2744(199907)25:3<207::AID-MC7>3.3.CO;2-W; Nishida Masato, 2002, Hum Cell, V15, P104, DOI 10.1111/j.1749-0774.2002.tb00105.x; Nishimura M, 2003, CARCINOGENESIS, V24, P1615, DOI 10.1093/carcin/bgg121; Ozog MA, 2002, CANCER RES, V62, P3544; Parc YR, 2000, INT J CANCER, V86, P60, DOI 10.1002/(SICI)1097-0215(20000401)86:1<60::AID-IJC9>3.0.CO;2-3; PETROCELLI T, 1993, ENDOCRINOLOGY, V133, P284, DOI 10.1210/en.133.1.284; RISEK B, 1995, J CELL SCI, V108, P1017; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; Saito T, 1998, ONCOGENE, V17, P1673, DOI 10.1038/sj.onc.1202092; Saito T, 1997, INT J CANCER, V73, P479, DOI 10.1002/(SICI)1097-0215(19971114)73:4<479::AID-IJC4>3.0.CO;2-X; Saito T, 1997, CANCER RES, V57, P375; Saito T, 1997, BIOCHEM BIOPH RES CO, V231, P610, DOI 10.1006/bbrc.1997.6164; Saito T, 2001, INT J CANCER, V93, P317, DOI 10.1002/ijc.1350; SASAKI H, 1993, CANCER RES, V53, P1906; Singal R, 2000, ANTICANCER RES, V20, P59; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Tan LW, 2002, CARCINOGENESIS, V23, P231, DOI 10.1093/carcin/23.2.231; Thenot S, 1999, MOL CELL ENDOCRINOL, V156, P85, DOI 10.1016/S0303-7207(99)00139-2; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; Trosko JE, 2002, CURR DRUG TARGETS, V3, P465, DOI 10.2174/1389450023347371; Trosko JE, 2001, MUTAT RES-FUND MOL M, V480, P219, DOI 10.1016/S0027-5107(01)00181-6; Tsai H, 1996, BIOCHEM BIOPH RES CO, V227, P64, DOI 10.1006/bbrc.1996.1468; Wataba K, 2001, INT J CANCER, V91, P448, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1077>3.0.CO;2-F; WENTZ W B, 1974, Gynecologic Oncology, V2, P362, DOI 10.1016/0090-8258(74)90027-4; Willecke K, 1999, ANN NY ACAD SCI, V883, P302, DOI 10.1111/j.1749-6632.1999.tb08592.x; Yamasaki H, 1999, CANCER DETECT PREV, V23, P273, DOI 10.1046/j.1525-1500.1999.99037.x; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	60	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1109	1116		10.1038/sj.onc.1207215	http://dx.doi.org/10.1038/sj.onc.1207215			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14762440				2022-12-17	WOS:000188749900009
J	Dermott, JM; Ha, JH; Lee, CH; Dhanasekaran, N				Dermott, JM; Ha, JH; Lee, CH; Dhanasekaran, N			Differential regulation of Jun N-terminal kinase and p38MAP kinase by G alpha(12)	ONCOGENE			English	Article						G protein; JNK; p38MAPK; MKK; cell proliferation	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; NH2-TERMINAL KINASE; SYNERGISTIC ACTIVATION; IN-VITRO; MKK4; TRANSFORMATION; SPECIFICITY; FIBROBLASTS; INHIBITION	Based on the findings that the overexpression of the wild-type Galpha(12) (Galpha(12)WT) result in the oncogenic transformation of NIH3T3 cells in a serum-dependent manner, a model system has been established in which the mitogenic and subsequent cell transformation pathways activated by Galpha(12) can be turned on or off by the addition or removal of serum. Using this model system, our previous studies have shown that the stimulation of Galpha(12)WT or the expression of an activated mutant of Galpha(12) (Galpha(12)QL) leads to increased cell proliferation and subsequent oncogenic transformation of NIH3T3 cells, as well as persistent activation of Jun N-terminal kinases (JNKs). In the present studies, we show that the stimulation of Galpha(12)WT or the expression of Galpha(12)QL results in a potent inhibition of p38MAPK, and that the mechanism by which Galpha(12) inhibits p38MAPK activity involves the dual specificity kinases upstream of p38MAPK. The results indicate that Galpha(12) attenuates the activation of MKK3 and MKK4, which are known to stimulate only p38MAPK or p38MAPK and JNK, respectively. The results also suggest that Galpha(12) activates JNKs specifically through the stimulation of the JNK-specific upstream kinase MKK7. These findings demonstrate for the first time that Galpha(12) differentially regulates JNK and p38MAPK by specifically activating MKK7, while inhibiting MKK3 and MKK4 in NIH3T3 cells. Since the stimulation of p38MAPK is often associated with apoptotic responses, our findings suggest that Galpha(12) stimulates cell proliferation and neoplastic transformation of NIH3T3 cells by attenuating p38MAPK-associated apoptotic responses, while activating the mitogenic responses through the stimulation of ERK- and JNK-mediated signaling pathways.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Hanyang Univ, Coll Med, Dept Pharmacol, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Inst Biomed Sci, Seoul 133791, South Korea	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Hanyang University; Hanyang University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.	danny001@temple.edu		HA, Ji Hee/0000-0002-6281-1904	NIGMS NIH HHS [GM49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avdi NJ, 2002, J BIOL CHEM, V277, P40687, DOI 10.1074/jbc.M204455200; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dermott JM, 2002, METHOD ENZYMOL, V344, P298; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; JIANG H, 1993, FEBS LETT, V3, P319; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; VARAPRASAD MVV, 1995, J BIOL CHEM, V270, P18655; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Weston CR, 2002, SCIENCE, V296, P2345, DOI 10.1126/science.1073344; XU N, 1993, P NATL ACAD SCI USA, V90, P11354; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	26	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					226	232		10.1038/sj.onc.1207009	http://dx.doi.org/10.1038/sj.onc.1207009			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712227				2022-12-17	WOS:000187895300023
J	Durr, M; Harder, F; Merkel, A; Bug, G; Henschler, R; Muller, AM				Durr, M; Harder, F; Merkel, A; Bug, G; Henschler, R; Muller, AM			Chimaerism and erythroid marker expression after microinjection of human acute myeloid leukaemia cells into murine blastocysts	ONCOGENE			English	Article						acute myeloid leukaemia (AML); embryonic microenvironment	TERATOCARCINOMA CELLS; EMBRYONAL CARCINOMA; RETINOIC ACID; MOUSE EMBRYOS; STEM-CELLS; DIFFERENTIATION; FUSION; CANCER; LINES; LIVER	It has been suggested that the embryonic microenvironment can control the survival and the transformed phenotype of tumour cells. Here, we addressed the hypothesis that the murine embryonic microenvironment can induce the differentiation of human tumour cells. To examine such interactions, we injected human leukaemic cells into preimplantation murine blastocysts at embryonic day 3.5 of gestation (E3.5). Microinjection of human KG-1 myeloid leukaemia cells and primary human acute myeloid leukaemia (AML) cells led to the generation of chimaeric embryos and adults. We observed that in E12.5 murine embryos, KG-1 cells were preferentially detected in yolk sac and peripheral blood, while primary AML cells mainly seeded the aorta gonad mesonephros region of chimaeric embryos. Analysis of the donor contribution in 15 different adult tissues showed that progeny of primary AML cells seeded to various haematopoietic and non-haematopoietic tissues. Chimaeric embryos and adults showed no apparent tumour formation. Furthermore, analysis of chimaeric E12.5 embryos revealed that the progeny of human KG-1 cells activated erythroid-specific human globin and glycophorin A expression. In summary, our data indicate that human AML cells activate markers of erythroid differentiation after injection into early murine embryos.	Univ Wurzburg, Inst Med Radiat & Cell Res MSZ, D-97078 Wurzburg, Germany; Red Cross Blood Ctr, Inst Transfus Med & Immune Haematol, D-60528 Frankfurt, Germany; Univ Frankfurt, Dept Med 3, D-60590 Frankfurt, Germany	University of Wurzburg; Goethe University Frankfurt	Muller, AM (corresponding author), Univ Wurzburg, Inst Med Radiat & Cell Res MSZ, Versbacherstr 5,D-2, D-97078 Wurzburg, Germany.		Bug, Gesine/H-8827-2013					Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; BARKER JE, 1970, NATURE, V228, P1305, DOI 10.1038/2281305a0; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BRINSTER RL, 1974, J EXP MED, V140, P1049, DOI 10.1084/jem.140.4.1049; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; DRACH J, 1993, CANCER RES, V53, P2100; Geiger H, 1998, CELL, V93, P1055, DOI 10.1016/S0092-8674(00)81210-6; GERSCHENSON M, 1986, P NATL ACAD SCI USA, V83, P7307, DOI 10.1073/pnas.83.19.7307; GOOTWINE E, 1982, NATURE, V299, P63, DOI 10.1038/299063a0; Harder F, 2002, BLOOD, V99, P719, DOI 10.1182/blood.V99.2.719; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; ILLMENSEE K, 1976, P NATL ACAD SCI USA, V73, P549, DOI 10.1073/pnas.73.2.549; JUNGHAHN I, 2001, BLOOD, V98; Kirchhof N, 2002, CELLS TISSUES ORGANS, V171, P77, DOI 10.1159/000057693; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; KOEFFLER HP, 1981, CANCER RES, V41, P919; Li L, 2003, CANCER RES, V63, P2733; Lichtenberger C, 1999, J IMMUNOL METHODS, V227, P75, DOI 10.1016/S0022-1759(99)00076-9; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; MINTZ B, 1975, TERATOMAS DIFFERENTI, P59; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; OUTRAM S, 1988, LEUKEMIA RES, V12, P651, DOI 10.1016/0145-2126(88)90099-9; PAPAIOANNOU VE, 1975, NATURE, V258, P70, DOI 10.1038/258070a0; PIERCE GB, 1979, P NATL ACAD SCI USA, V76, P6649, DOI 10.1073/pnas.76.12.6649; PIERCE GB, 1982, CANCER RES, V42, P1082; PODESTA AH, 1984, P NATL ACAD SCI-BIOL, V81, P7608, DOI 10.1073/pnas.81.23.7608; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBINSON J, 1981, NATURE, V289, P68, DOI 10.1038/289068a0; ROSSANT J, 1985, EXP CELL RES, V156, P213, DOI 10.1016/0014-4827(85)90275-7; SACHS L, 1980, J NATL CANCER I, V65, P675, DOI 10.1093/jnci/65.4.675; SAITO H, 1985, BLOOD, V66, P1233; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; Stevens L C, 1967, Adv Morphog, V6, P1; Tavian M, 1996, BLOOD, V87, P67, DOI 10.1182/blood.V87.1.67.bloodjournal87167; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; TERSTAPPEN LWMM, 1992, LEUKEMIA, V6, P993; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6; WATERS BK, 1986, J EMBRYOL EXP MORPH, V98, P99; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	43	22	27	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9185	9191		10.1038/sj.onc.1207134	http://dx.doi.org/10.1038/sj.onc.1207134			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668800				2022-12-17	WOS:000187149100009
J	Croce, M; De Ambrosis, A; Corrias, MV; Pistoia, V; Occhino, M; Meazza, R; Giron-Michel, J; Azzarone, B; Accolla, RS; Ferrini, S				Croce, M; De Ambrosis, A; Corrias, MV; Pistoia, V; Occhino, M; Meazza, R; Giron-Michel, J; Azzarone, B; Accolla, RS; Ferrini, S			Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells	ONCOGENE			English	Article						HLA class II; CIITA; neuroblastoma; promoter methylation	BARE-LYMPHOCYTE-SYNDROME; HISTOCOMPATIBILITY COMPLEX EXPRESSION; PROMOTER BINDING-PROTEIN; TRANSACTIVATOR CIITA; ANTIGEN PRESENTATION; DERMAL FIBROBLASTS; TROPHOBLAST CELLS; REGULATORY FACTOR; GENE-EXPRESSION; NF-Y	The HLA class II expression is controlled by the transcriptional activator CIITA. The transcription of CIITA is controlled by different promoters, among which promoter-IV is inducible by IFN-gamma. We analysed the regulation of HLA class II molecules by IFN-gamma in a large series of human neuroblastoma cell lines. No induction of surface or intracellular HLA class II molecules and of specific mRNA was observed, in all neuroblastomas, with the exception of a nonprototypic cell line, ACN. In a large subset of neuroblastomas IFN-gamma induced expression of CIITA mRNA, derived from promoter-IV, which was not methylated. In contrast, in another subset of neuroblastomas, CIITA was not inducible by IFN-gamma and CIITA promoter-IV was either completely or partially methylated. Interestingly, the use of DNA demethylating agents restored CIITA gene transcriptional activation by IFN-gamma, but not HLA class II expression. The defect of HLA class II was not related to alterations in RFX or NF-Y transcription factors, as suggested by EMSA or RFX gene transfection experiments. In addition, the transfection of a functional CIITA cDNA failed to induce HLA class II expression in typical neuroblastoma cells. Confocal microscopy and Western blot analysis suggested a defective nuclear translocation and/or reduced protein synthesis in CIITA-transfected NB cells. Altogether, these data point to multiple mechanisms preventing HLA class II expression in the neuroblastoma, either involving CIITA promoter-IV silencing, or acting at the CIITA post-transcriptional level.	Ist Nazl Ric Canc, I-16132 Genoa, Italy; Ist Giannina Gaslini, I-16148 Genoa, Italy; Univ Insubria, Dipartimento Sci Clin & Biol, I-21100 Varese, Italy; Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Insubria; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Ferrini, S (corresponding author), Ctr Biotecnol Avanzate, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.		Giron-Michel, Julien/Q-4503-2018; Croce, Michela/AAA-8966-2020; Giron-michel, Julien/GNP-7299-2022; Meazza, Raffaella/AAC-2425-2019; Corrias, Maria Valeria/E-4571-2011; Azzarone, Bruno/AAH-9251-2019	Giron-Michel, Julien/0000-0001-6613-6099; Croce, Michela/0000-0003-4683-4951; Giron-michel, Julien/0000-0001-6613-6099; Meazza, Raffaella/0000-0003-0242-3157; Corrias, Maria Valeria/0000-0002-7316-0772; Azzarone, Bruno/0000-0002-5962-3849; Accolla, Roberto/0000-0003-2493-7378; Ferrini, Silvano/0000-0001-7254-2616				Accolla RS, 2002, EUR J IMMUNOL, V32, P2783, DOI 10.1002/1521-4141(2002010)32:10<2783::AID-IMMU2783>3.0.CO;2-E; ACCOLLA RS, 1986, J EXP MED, V164, P369, DOI 10.1084/jem.164.1.369; Antunes NL, 2000, J PEDIAT HEMATOL ONC, V22, P315, DOI 10.1097/00043426-200007000-00007; Armstrong TD, 1997, P NATL ACAD SCI USA, V94, P6886, DOI 10.1073/pnas.94.13.6886; Barbieri G, 2002, INT IMMUNOL, V14, P839, DOI 10.1093/intimm/dxf060; Blanck G, 1999, MICROBES INFECT, V1, P913, DOI 10.1016/S1286-4579(99)00226-9; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; BROCKER EB, 1984, J INVEST DERMATOL, V82, P244, DOI 10.1111/1523-1747.ep12260181; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; COOPER MJ, 1990, CANCER RES, V50, P3694; Corrias MV, 2001, TISSUE ANTIGENS, V57, P110, DOI 10.1034/j.1399-0039.2001.057002110.x; Cressman DE, 2001, J IMMUNOL, V167, P3626, DOI 10.4049/jimmunol.167.7.3626; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Garrido F, 2001, ADV CANCER RES, V83, P117, DOI 10.1016/S0065-230X(01)83005-0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOBLIN S, 1997, IMMUNITY, V6, P601; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; KHAN R, 1988, J BIOL CHEM, V263, P14374; LAMPSON LA, 1990, J IMMUNOL, V144, P512; Lennon AM, 1997, IMMUNOGENETICS, V45, P266, DOI 10.1007/s002510050202; Li GX, 2001, MOL CELL BIOL, V21, P4626, DOI 10.1128/MCB.21.14.4626-4635.2001; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Martin BK, 1999, J IMMUNOL, V162, P6663; Meazza R, 2003, EUR J IMMUNOL, V33, P1183, DOI 10.1002/eji.200323712; MORENO CS, 1995, J IMMUNOL, V155, P4313; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Morris AC, 2000, J IMMUNOL, V164, P4143, DOI 10.4049/jimmunol.164.8.4143; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Nagarajan UM, 1999, IMMUNITY, V10, P153, DOI 10.1016/S1074-7613(00)80016-3; Naves R, 2002, INT IMMUNOL, V14, P481, DOI 10.1093/intimm/14.5.481; Nekrep N, 2000, MOL CELL BIOL, V20, P4455, DOI 10.1128/MCB.20.12.4455-4461.2000; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Redwine JM, 2001, AM J PATHOL, V159, P1219, DOI 10.1016/S0002-9440(10)62507-2; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Rodriguez AM, 1997, EUR J IMMUNOL, V27, P45, DOI 10.1002/eji.1830270108; Sartoris S, 1998, J IMMUNOL, V161, P814; SHEENCHEN SM, 1994, SURGERY, V116, P510; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TEMPONI M, 1993, J IMMUNOL METHODS, V161, P239, DOI 10.1016/0022-1759(93)90300-V; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; Tosi G, 2002, EMBO J, V21, P5467, DOI 10.1093/emboj/cdf557; van den Elsen PJ, 2000, HUM IMMUNOL, V61, P850, DOI 10.1016/S0198-8859(00)00159-2; van der Stoep N, 2002, INT J CANCER, V97, P501, DOI 10.1002/ijc.1623	57	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7848	7857		10.1038/sj.onc.1207054	http://dx.doi.org/10.1038/sj.onc.1207054			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586411				2022-12-17	WOS:000186240200015
J	Fagman, H; Larsson, F; Arvidsson, Y; Meuller, J; Nordling, M; Martinson, T; Helmbrecht, K; Brabant, G; Nilsson, M				Fagman, H; Larsson, F; Arvidsson, Y; Meuller, J; Nordling, M; Martinson, T; Helmbrecht, K; Brabant, G; Nilsson, M			Nuclear accumulation of full-length and truncated adenomatous polyposis coli protein in tumor cells depends on proliferation	ONCOGENE			English	Article						APQ beta-catenin; cell-cell adhesion; proliferation; nuclear transport	APC GENE-PRODUCT; BETA-CATENIN; SUPPRESSOR PROTEIN; SUBCELLULAR-LOCALIZATION; CYCLE PROGRESSION; COLORECTAL-CANCER; EPITHELIAL-CELLS; PHOSPHATASE 2A; S-PHASE; MUTATIONS	The adenomatous polyposis coli (APC) tumor suppressor is a nucleocytoplasmic protein. The nuclear accumulation of APC was recently found to vary depending on cell density, suggesting that putative APC function(s) in the nucleus is controlled by the establishment of cell contacts. We report here that the density-dependent redistribution of APC between nucleus and cytoplasm prevails in 6/6 thyroid and colorectal carcinoma cell lines. Moreover, mutated APC lacking known nuclear localization sequences had the similar distribution pattern as the full-length protein. APC invariably accumulated in the nuclei of Ki-67 expressing cells, but was largely cytoplasmic when cell cycle exit was induced by serum starvation or at high cell density. APC colocalized with beta-catenin in the nucleus only in one cell line (SW480). Also, APC maintained a predominantly nuclear position in early confluent states when cytoplasmic beta-catenin was recruited to newly formed adherens-like junctions. The results indicate that nuclear targeting of APC is driven by cell cycle entry rather than altered cell-cell contact. The ability of C-terminally truncated APC to accumulate in the nucleus suggests that nuclear import signals other than NLS1(APC) and NLS2(APC) are functionally important. Residual function(s) of N-terminal APC fragments in tumor cells carrying APC mutations might be beneficial to tumor growth and survival.	Univ Gothenburg, Inst Anat & Cell Biol, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Univ Hosp E, Dept Clin Genet, SE-41685 Gothenburg, Sweden; Hannover Med Sch, Dept Clin Endocrinol, D-30625 Hannover, Germany	University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Hannover Medical School	Fagman, H (corresponding author), Univ Gothenburg, Inst Anat & Cell Biol, Box 420, SE-40530 Gothenburg, Sweden.	henrik.fagman@anatcell.gu.se	Martinsson, Tommy/J-4140-2013	Martinsson, Tommy/0000-0002-9403-3123; Fagman, Henrik/0000-0001-5853-6295; Nordling, Margareta/0000-0002-4047-4994; Larsson, Fredrik/0000-0002-7888-6863				Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brocardo MG, 2001, BIOCHEM BIOPH RES CO, V284, P982, DOI 10.1006/bbrc.2001.5066; Cetta F, 1998, WORLD J SURG, V22, P1231, DOI 10.1007/s002689900550; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Galea MA, 2001, J BIOL CHEM, V276, P45833, DOI 10.1074/jbc.M107149200; GERDES J, 1984, J IMMUNOL, V133, P1710; Hamada F, 2002, NAT CELL BIOL, V4, P208, DOI 10.1038/ncb755; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Homma MK, 2002, P NATL ACAD SCI USA, V99, P5959, DOI 10.1073/pnas.092143199; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Neufeld KL, 2000, EMBO REP, V1, P519; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PROSSER J, 1994, BRIT J CANCER, V70, P841, DOI 10.1038/bjc.1994.408; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Senda T, 1996, BIOCHEM BIOPH RES CO, V223, P329, DOI 10.1006/bbrc.1996.0894; Sieber OM, 2000, MOL MED TODAY, V6, P462; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; vanderLuijt RB, 1997, HUM MUTAT, V9, P7, DOI 10.1002/(SICI)1098-1004(1997)9:1<7::AID-HUMU2>3.0.CO;2-8; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	52	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6013	6022		10.1038/sj.onc.1206731	http://dx.doi.org/10.1038/sj.onc.1206731			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955080				2022-12-17	WOS:000185137800010
J	Prosser, S; Sorokina, E; Pratt, P; Sorokin, A				Prosser, S; Sorokina, E; Pratt, P; Sorokin, A			CrkIII: a novel and biologically distinct member of the Crk family of adaptor proteins	ONCOGENE			English	Article						CrkII; CrkIII; adaptor protein; ERK; MAP kinase	INSULIN-RECEPTOR SUBSTRATE-1; V-CRK; TYROSINE PHOSPHORYLATION; EXPRESSION CLONING; SIGNALING PATHWAYS; SH3 DOMAIN; PC12 CELLS; SRC; RAS; BINDS	As the role for adaptor proteins constantly proliferates, appreciation of their importance has never been higher. The Crk family of adaptor proteins is no exception. Currently comprising four members, v-Crk, CrkI, CrkII and Crk-like protein, we have introduced a fifth member, CrkIII. Cloned by the CORT technique, CrkIII is identical in sequence to CrkII until the second of its two SH3 domains, which is disrupted partway through and results in a nonfunctional domain and a unique C-terminal sequence. We have demonstrated the existence of native CrkIII at the message level using RT-PCR and RNAse protection assays, and at the protein level in mouse fibroblasts. We show that CrkII overexpression is capable of enhancing insulin-stimulated ERK activity, whereas CrkIII is not, thus partially characterizing a novel member of the Crk family and elucidating important effects mediated by the c-terminal SH3 domain.	Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Sorokin, A (corresponding author), Med Coll Wisconsin, Dept Med, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	sorokin@mcw.edu		Sorokin, Andrey/0000-0002-5660-0190	NHLBI NIH HHS [HL10165-01, HL22563] Funding Source: Medline; NIDDK NIH HHS [DK 41684] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010165, R01HL022563, R37HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKUI Y, 1989, ONCOGENE RES, V4, P283; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Smith JJ, 2002, MOL CELL BIOL, V22, P1412, DOI 10.1128/MCB.22.5.1412-1423.2002; Smith JJ, 2000, J CELL BIOL, V151, P1391, DOI 10.1083/jcb.151.7.1391; Sorokin A, 1998, ONCOGENE, V16, P2425, DOI 10.1038/sj.onc.1201781; Sorokin A, 1998, BIOCHEM J, V334, P595, DOI 10.1042/bj3340595; Sraer JD, 1996, KIDNEY INT, V49, P267, DOI 10.1038/ki.1996.38; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VRIESSMITS AMM, 1992, NATURE, V357, P602; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	27	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4799	4806		10.1038/sj.onc.1206714	http://dx.doi.org/10.1038/sj.onc.1206714			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894221				2022-12-17	WOS:000184344600003
J	Edwards, SJ; Hananeia, L; Eccles, MR; Zhang, YF; Braithwaite, AW				Edwards, SJ; Hananeia, L; Eccles, MR; Zhang, YF; Braithwaite, AW			The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions	ONCOGENE			English	Article						p53; proline domain; apoptosis	WILD-TYPE P53; DNA-DAMAGE; TUMOR-SUPPRESSOR; DROSOPHILA P53; GROWTH ARREST; CELLS; HOMOLOG; IDENTIFICATION; TRANSCRIPTION; PROMOTERS	The N-terminal proline-rich domain of human p53 has been shown to be important for the induction of apoptosis. However, the corresponding region in mouse and other species is not highly conserved and has been less well studied. In this paper, we have characterized mutants with deletions in this region of mouse p53. Our results demonstrate that deletions in the proline-rich domain have varying effects on function ranging from no effect to severe impairment of cell death activity, depending on precisely which residues are deleted. We also show that the mutants differ in their ability to transactivate different p53 target promoters. Although we have been able to obtain mutants selectively impaired for apoptosis, our data are not generally consistent with this region being a functional domain. The data are more consistent with the interpretation that the region influences function by altering local protein structure which may affect promoter discrimination.	Univ Otago, Dept Pathol, Dunedin Sch Med, Dunedin, New Zealand	University of Otago	Edwards, SJ (corresponding author), Univ Otago, Dept Pathol, Dunedin Sch Med, Box 913, Dunedin, New Zealand.		Eccles, Michael Roger/AAF-7878-2020	Eccles, Michael Roger/0000-0002-6824-8761; Edwards, Sara/0000-0002-3468-1217				Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Hansen RS, 1996, ONCOGENE, V13, P995; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; JACKSON P, 1993, ONCOGENE, V8, P589; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; PERREM K, 1995, ONCOGENE, V11, P1299; Prives C, 1999, J PATHOL, V187, P112; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; SOUSSI T, 1990, ONCOGENE, V5, P945; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	24	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4517	4523		10.1038/sj.onc.1206726	http://dx.doi.org/10.1038/sj.onc.1206726			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881708				2022-12-17	WOS:000184054700007
J	Olivier, A; Lucie, K; Jean-Francois, R; Christian-Jacques, L; Paule, S				Olivier, A; Lucie, K; Jean-Francois, R; Christian-Jacques, L; Paule, S			Delineation of the domains required for physical and functional interaction of p14(ARF) with human topoisomerase I	ONCOGENE			English	Article						p14(ARF); topoisomerase I; protein interactions; cell cycle	NUCLEOLAR LOCALIZATION; TUMOR-SUPPRESSOR; BETA-TRANSCRIPT; NUCLEAR EXPORT; CELL-LINES; P19(ARF); PROTEIN; MDM2; P53; ARF	We recently reported an interaction between the p14(ARF). protein and human topoisomerase I (Topo 1) resulting in the stimulation of the relaxation activity of Topo 1. Our data showed that the complex between the two proteins was located within the nucleolus. In the present work, we have investigated the regions of p14(ARF). involved in this interaction by using targeted point mutagenesis and deletion mutants. A region encompassing exon 2-encoded sequence was required for physical binding of p14(ARF) to Topo I as well as for stimulatory activity of the enzyme. Exon 1beta-encoded segment was not implicated in the interaction. Moreover, among p14(ARF) point mutants selected for their high conservation among different mammalian species, mutant p14(ARF) (RR87, 88AA) did not stimulate Topo I in spite of its association with the enzyme, suggesting its direct implication in the functional activity of ARE In contrast, one mutant,p14(ARF) (R71A), was more efficient than wild-type protein to activate Topo 1, suggesting that this residue is a key element to modulate Topo I activity. Finally, only ARF-Topo I complexes containing p14(ARF) exon 2 segment were found to be localized in the nucleolus, suggesting that this sulmuclear location is linked to the biological function of the ARF-Topo I complex.	Inst Biol Mol & Ingn Genet, IBMIG, F-86022 Poitiers, France; UFR Pharm, F-51096 Reims, France	Universite de Poitiers; Universite de Reims Champagne-Ardenne	Paule, S (corresponding author), Inst Biol Mol & Ingn Genet, IBMIG, 40 Ave Recteur Pineau, F-86022 Poitiers, France.			Seite, Paule/0000-0002-7809-7610; riou, jean-francois/0000-0002-0055-6506				Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Gazzeri S, 1998, CANCER RES, V58, P3926; GULDNER HH, 1986, CHROMOSOMA, V94, P132, DOI 10.1007/BF00286991; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; KUBBUTAT MH, 1997, NATURE, V6630, P299; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	22	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1945	1954		10.1038/sj.onc.1206214	http://dx.doi.org/10.1038/sj.onc.1206214			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673200				2022-12-17	WOS:000181967700005
J	Rossman, TG; Visalli, MA; Komissarova, EV				Rossman, TG; Visalli, MA; Komissarova, EV			fau and its ubiquitin-like domain (FUBI) transforms human osteogenic sarcoma (HOS) cells to anchorage-independence	ONCOGENE			English	Article						transformation; fau; ubiquitin-like protein; arsenic; hygromycin; ribosomal protein	PROTEIN; ARSENITE; INDUCTION; FUSION; CDNA; GENE; PATHWAYS; SEQUENCE; HOMOLOG; CLONING	Arsenite is the most likely carcinogenic form of arsenic in the environment. Previously, expression cloning for cDNAs whose overexpression confers arsenite-resistance in Chinese hamster V79 cells identified two genes:fau and a novel gene, asr2. The fau gene encodes a ubiquitin-like protein (here called FUBI) fused to the ribosomal S30 protein. Since the expression of the fox sequence (antisense to fau) increased the tumorigenicity of a mouse sarcoma virus, it was proposed that fau might be a tumor suppressor gene. We intended to test its ability to block arsenite-induced transformation of human osteogenic sarcoma (HOS) cells to anchorage-independence. Instead, we found that overexpressing fau itself was able to transform HOS cells. When the two domains were expressed separately, only FUBI was transforming and only the S30 domain conferred arsenite resistance. An incidental finding was the transforming activity of the selectable marker, hyg. FUBI belongs to the ubiquitin-like protein group that is capable of forming conjugates to other proteins, although none have so far been identified. Alternatively, FUBI may act as a substitute or inhibitor of ubiquitin, to which it is most closely related, or to close ubiquitin-like relatives UCRP, FAT10, and/or Nedd8.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; NYU, Sch Med, Inst Canc, Tuxedo Pk, NY 10987 USA	New York University; New York University	Rossman, TG (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	rossman@env.med.nyu.edu		Komissarova, Elena V./0000-0001-6848-0635	NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009252, P42ES010344, P30ES000260] Funding Source: NIH RePORTER; NCI NIH HHS [CA16087] Funding Source: Medline; NIEHS NIH HHS [ES00260, P42 ES10344, R01 ES09252] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baker RT, 1996, J BIOL CHEM, V271, P13549, DOI 10.1074/jbc.271.23.13549; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; Finkel M P, 1976, Recent Results Cancer Res, P92; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hiemstra PS, 1999, J LEUKOCYTE BIOL, V66, P423, DOI 10.1002/jlb.66.3.423; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Huang CS, 2001, MOL CELL BIOCHEM, V222, P29, DOI 10.1023/A:1017974131948; Huang SC, 1998, CARCINOGENESIS, V19, P889, DOI 10.1093/carcin/19.5.889; Hummer BT, 2001, J VIROL, V75, P7774, DOI 10.1128/JVI.75.16.7774-7777.2001; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; KLEMPERER NS, 1989, J BIOL CHEM, V264, P19245; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIN XH, 1994, ENVIRON HEALTH PERSP, V102, P289, DOI 10.2307/3431804; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; LOEB KR, 1992, J BIOL CHEM, V267, P7806; McLaughlin PMJ, 2000, INT J CANCER, V85, P871, DOI 10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O; MICHIELS L, 1993, ONCOGENE, V8, P2537; Miller AC, 1998, ENVIRON HEALTH PERSP, V106, P465, DOI 10.1289/ehp.98106465; Nakamura M, 1999, J BIOL CHEM, V274, P18026, DOI 10.1074/jbc.274.25.18026; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; Nakamura M, 1996, J IMMUNOL, V156, P533; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Potter JL, 1999, J BIOL CHEM, V274, P25061, DOI 10.1074/jbc.274.35.25061; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Ramirez P, 1997, MUTAT RES-REV MUTAT, V386, P291, DOI 10.1016/S1383-5742(97)00018-5; RANI AS, 1992, CARCINOGENESIS, V13, P2021, DOI 10.1093/carcin/13.11.2021; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; REDMAN KL, 1996, BIOCHEM J, V315, P21; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; Rossman TG, 1999, CARCINOGENESIS, V20, P311, DOI 10.1093/carcin/20.2.311; Rossman TG, 2001, ARSENIC EXPOSURE AND HEALTH EFFECTS IV, P285; Sambrook J., 1989, MOL CLONING; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; VOGT B, 2001, MUTAT RES, V478, P59; WANG ZL, 1994, BIOTECHNIQUES, V16, P460; WONG JM, 1993, CANCER RES, V53, P1916; Wright GD, 1998, ADV EXP MED BIOL, V456, P27; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	48	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1817	1821		10.1038/sj.onc.1206283	http://dx.doi.org/10.1038/sj.onc.1206283			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660817				2022-12-17	WOS:000181678200008
J	Ariumi, Y; Ego, T; Kaida, A; Matsumoto, M; Pandolfi, PP; Shimotohno, K				Ariumi, Y; Ego, T; Kaida, A; Matsumoto, M; Pandolfi, PP; Shimotohno, K			Distinct nuclear body components, PML and SMRT, regulate the trans-acting function of HTLV-1 tax oncoprotein	ONCOGENE			English	Article						HTLV-1; tax; PML; SMRT; CBP; nuclear body	CELL LEUKEMIA-VIRUS; ACUTE PROMYELOCYTIC LEUKEMIA; CREB BINDING-PROTEIN; REPLICATION COMPARTMENTS; VIRAL TRANSACTIVATOR; TUMOR SUPPRESSION; COACTIVATOR CBP; TYPE-1 TAX; RAR-ALPHA; BODIES	Several viruses target cellular promyelocytic leukemia (PML)-nuclear bodies (PML-NBs) to induce their disruption, marked morphological changes in these structures or the relocation to PML-NB components to the cytoplasm of infected cells. PML conversely interferes with viral replication. We demonstrate that PML acts as a coactivator for the human T-cell leukemia virus type I (HTLV-1) Tax oncoprotein without direct binding. Tax was identified within interchromatin granule clusters (IGCs)/RNA splicing bodies (SBs), not PML-NBs; Tax expression did not affect PML-NB formation. Moreover, PML and CBP/p300 cooperatively activated Tax-mediated HTLV-1-LTR-dependent gene expression. Interestingly, two PML mutants, PML-RAR and PMLDelta216-331, which fail to form PML-NBs, could also coactivate Tax-mediated trans-acting function but had no effect on retinoic acid receptor (RAR)- or p53-dependent gene expression. In contrast, SMRT (silencing mediator for retinoic acid and thyroid hormone receptors), a nuclear corepressor found within the matrix-associated deacetylase (MAD) nuclear body, relocatized into Tax-associated nuclear bodies upon coexpression with Tax. SMRT coactivated the trans-acting function of Tax through direct binding. Coexpression of SMRT and PML resulted in an additive activation of Tax trans-acting function. Thus, crosstalk between distinct nuclear bodies may control Tax function.	Kyoto Univ, Inst Virus Res, Lab Human Tumor Viruses, Sakyo Ku, Kyoto 6068507, Japan; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Dept Human Genet,Mol Biol Program, New York, NY 10021 USA	Kyoto University; Cornell University; Memorial Sloan Kettering Cancer Center	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Lab Human Tumor Viruses, Sakyo Ku, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp	Ariumi, Yasuo/F-5804-2013					Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Ariumi Y, 2001, BIOCHEM BIOPH RES CO, V287, P556, DOI 10.1006/bbrc.2001.5626; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; Burkham J, 1998, J VIROL, V72, P10100, DOI 10.1128/JVI.72.12.10100-10107.1998; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2633, DOI 10.1073/pnas.96.6.2633; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DOUCAS V, 1996, BIOCHIM BIOPHYS ACTA, V1288, P25; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; MORI K, 1987, J GEN VIROL, V68, P499, DOI 10.1099/0022-1317-68-2-499; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 1999, J VIROL, V73, P5137; NOSAKA T, 1993, EXP CELL RES, V208, P89; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Wang ZG, 1998, SCIENCE, V279, P1547; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	47	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1611	1619		10.1038/sj.onc.1206244	http://dx.doi.org/10.1038/sj.onc.1206244			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642864				2022-12-17	WOS:000181580500003
J	Oo, ML; Senga, T; Thant, AA; Amin, AR; Huang, PY; Mon, NN; Hamaguchi, M				Oo, ML; Senga, T; Thant, AA; Amin, AR; Huang, PY; Mon, NN; Hamaguchi, M			Cysteine residues in the C-terminal lobe of Src: their role in the suppression of the Src kinase	ONCOGENE			English	Article						Src; SH-alkylating agents; inactivation; cysteine; redox	HERBIMYCIN-A; TYROSINE; TRANSFORMATION; MECHANISM	To evaluate the function of cysteine residues of the Src kinase, we constructed a series of Src mutants in which some of cyteines were replaced to alanines. With these mutants, we studied the effect of SH-alkylating agents, N[p-(2-benzimidazolyl)phenyll maleimide (BIPM) and N(9-acridinyl) maleimide (NAM), on their kinase activity. Of 10 cysteine residues scattered over v-Src, either a single mutation at Cys520 or multiple mutations at the four clustered cyteines, Cys483, Cys487, Cys496 and Cys498, yielded clear resistance to the treatment with 10 muM BIPM or 1 mum NAM. In contrast, other cysteines including those in the SH2 domain and those in the catalytic cleft of the kinase domain were dispensable for the inactivation by BIPM and NAM. Similarly, deletion of SH2 and SH3 did not confer the resistance to v-Src, suggesting the inactivation by the SH-alkylating agents is SH2/SH3-independent. Although Cys520-mutated v-Src was resistant to 1 mum NAM, it was inactivated by 5 mum NAM. However, combined mutation including all of Cys483, Cys487, Cys496, Cys498 and Cys520 yielded clear resistance to 5 mum NAM. Among these mutants, those with double mutations in the four clustered cysteines yielded a temperature sensitive phenotype in the transfected cells, whereas Cys520 did not, suggesting that Cys520 has, at least in part, a discrete function. In contrast to v-Src, c-Src, which lacks cysteine at position 520, was resistant to 1 mum NAM but sensitive to 5 mum NAM. While replacement of Phe520 of c-Src to cysteine made it sensitive to 1 mum NAM, double mutation in clustered cysteines again yielded resistance to 5 mum NAM. Taken together, our results strongly suggest that the multiple cysteine residues clustered at the end of the G terminal lobe are critical for the inhibition by the SH-alkylating agents and, thereby, have an allosteric repressor effect on the catalytic activity of Src in a SH2-phosphoTyr527 independent manner.	Nagoya Univ, Sch Med, Lab Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Lab Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.			AMIN, ARM/0000-0001-9144-2960; Mon, Naing Naing/0000-0001-6178-0176				Akhand AK, 1999, J BIOL CHEM, V274, P25821, DOI 10.1074/jbc.274.36.25821; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; FUKAZAWA H, 1990, BIOCHEM BIOPH RES CO, V173, P276, DOI 10.1016/S0006-291X(05)81053-8; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pu MY, 1996, ONCOGENE, V13, P2615; Senga T, 2000, ONCOGENE, V19, P273, DOI 10.1038/sj.onc.1203296; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; SIMPSON RB, 1961, J AM CHEM SOC, V83, P4711, DOI 10.1021/ja01484a005; STRICKS W, 1953, J AM CHEM SOC, V75, P5673, DOI 10.1021/ja01118a060; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; VEILLETTE A, 1993, J BIOL CHEM, V268, P17547; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	18	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1411	1417		10.1038/sj.onc.1206286	http://dx.doi.org/10.1038/sj.onc.1206286			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618767				2022-12-17	WOS:000181360900016
J	Roccato, E; Pagliardini, S; Cleris, L; Canevari, S; Formelli, F; Pierotti, MA; Greco, A				Roccato, E; Pagliardini, S; Cleris, L; Canevari, S; Formelli, F; Pierotti, MA; Greco, A			Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation	ONCOGENE			English	Article						TRK-T3; coiled-coil domain; TFG; NTRK1; oncogenic activation	NERVE GROWTH-FACTOR; TYROSINE KINASE; OLIGOMERIZATION DOMAIN; PROMOTER REGION; PC MOTIF; PROTEIN; DIMERIZATION; RECEPTOR; TERMINUS; MEMBRANE	The TRK-T3 oncoprotein, isolated from a human papillary thyroid tumor, arises from the fusion between the N-terminal domain of the TFG gene and the tyrosine kinase domain of the NTRK1 receptor. The 68 kDa TRKT3 oncoprotein displays a constitutive tyrosine kinase activity resulting in its capability to transform NIH3T3 cells. The TFG portion of TRK-T3 contains a coiled-coil domain, which mediates protein oligomerization essential for the oncogene constitutive activation, and several consensus sites for protein interaction. In this study, we investigate the role of TFG sequences outside the coiled-coil domain on TRK-T3 activation, We constructed four mutants carrying different deletions of TFG sequences and expressed them in mammalian cells. By performing biochemical and biological assays we demonstrated that all the deleted regions are required for TRK-T3 activation, as they are involved in different mechanisms such as protein processing, formation of stable and/or functional complexes, and possible interaction with other proteins. By constructing site-specific mutants, we demonstrated a crucial role for a PB1 domain and a considerable contribution of an SH2-binding motif in TRK-T3 oncogenic activation. This work establishes an important role for TFG sequences outside the coiled-coil domain in the activation of the thyroid TRK-T3 oncogene.	Ist Nazl Tumori, Operat Unit 3, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, Operat Unit 13, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, Operat Unit 11, Dept Expt Oncol, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Greco, A (corresponding author), Ist Nazl Tumori, Operat Unit 3, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.	angela.greco@istitutotumori.mi.it	Pierotti, Marco Alessandro/AAC-4728-2022; Greco, Angela/C-1953-2017; Cleris, Loredana/T-3144-2018	Pierotti, Marco Alessandro/0000-0002-7431-8332; Greco, Angela/0000-0003-2994-0349; Cleris, Loredana/0000-0001-8778-7931				BORRELLO MG, 1994, ONCOGENE, V9, P1661; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; Canu N, 1997, J NEUROCHEM, V68, P1390; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Mathews JM, 2000, J VIROL, V74, P5911, DOI 10.1128/JVI.74.13.5911-5920.2000; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Mencinger M, 1999, BIOCHEM BIOPH RES CO, V257, P67, DOI 10.1006/bbrc.1999.0417; Mencinger M, 1997, GENOMICS, V41, P327, DOI 10.1006/geno.1997.4625; Miranda C, 2001, J CELL PHYSIOL, V186, P35; Monaco C, 2001, ONCOGENE, V20, P599, DOI 10.1038/sj.onc.1204127; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; Roccato E, 2002, BRIT J CANCER, V87, P645, DOI 10.1038/sj.bjc.6600544; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, CURR OPIN GENE DEV, V13, P6711; Terasawa H, 2001, EMBO J, V20, P3947, DOI 10.1093/emboj/20.15.3947; Tong Q, 1997, J BIOL CHEM, V272, P9043	28	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					807	818		10.1038/sj.onc.1206189	http://dx.doi.org/10.1038/sj.onc.1206189			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584559				2022-12-17	WOS:000180864300002
J	Carneiro, C; Jiao, MS; Hu, M; Shaffer, D; Park, M; Pandolfi, PP; Cordon-Cardo, C; Koff, A				Carneiro, C; Jiao, MS; Hu, M; Shaffer, D; Park, M; Pandolfi, PP; Cordon-Cardo, C; Koff, A			p27 deficiency desensitizes Rb-/- cells to signals that trigger apoptosis during pituitary tumor development	ONCOGENE			English	Article						tumorigenesis; p27kip1; Rb; Arf	DEPENDENT KINASE INHIBITOR; PROGNOSTIC-SIGNIFICANCE; GENE-EXPRESSION; GROWTH ARREST; MICE LACKING; P27(KIP1); CANCER; CYCLE; P53; DIFFERENTIATION	Low p27 expression in many human cancers is a prognostic indicator for poor outcome. While analysing the mechanism by which p27 deficiency contributed to tumor development in the Rb+/- mouse model, we identified a role for p27 as a proapoptotic tumor suppressor. We examined the cell cycle and apoptotic response of these pituitary tumor cells to the dopamine analog bromocriptine as well as the expression of Arf and other cell cycle and apoptotic regulators in these tumors. We also examined the expression of Arf and its function in mouse embryo fibroblasts either singly or doubly deficient for Rb and p27. From these studies, we concluded that the absence of p27 disabled the trigger for an Arf-dependent apoptotic response in Rb-/- tumor cells. This suggests a novel mechanism by which the loss of p27 may impact on tumor development.	Mem Sloan Kettering Canc Ctr, Dept Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Koff, A (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Mol Biol, RRL917D,Box 207,1275 York Ave, New York, NY 10021 USA.			Koff, Andrew/0000-0003-3271-3067				Arita J, 1998, NEUROENDOCRINOLOGY, V68, P163, DOI 10.1159/000054362; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CHRONWALL BM, 1987, ENDOCRINOLOGY, V120, P1201, DOI 10.1210/endo-120-3-1201; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Drissi H, 1999, CANCER RES, V59, P3705; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lowenheim H, 1999, P NATL ACAD SCI USA, V96, P4084, DOI 10.1073/pnas.96.7.4084; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; Palmqvist R, 1999, J PATHOL, V188, P18, DOI 10.1002/(SICI)1096-9896(199905)188:1<18::AID-PATH311>3.0.CO;2-T; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Swerdlow RH, 1998, DRUG AGING, V13, P263, DOI 10.2165/00002512-199813040-00002; Tong W, 1998, CELL GROWTH DIFFER, V9, P787; Tsihlias J, 1999, ANNU REV MED, V50, P401; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Yin DL, 1999, J CLIN NEUROSCI, V6, P326, DOI 10.1016/S0967-5868(99)90057-7; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	39	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					361	369		10.1038/sj.onc.1206163	http://dx.doi.org/10.1038/sj.onc.1206163			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545157				2022-12-17	WOS:000180379100005
J	Curino, A; Mitola, DJ; Aaronson, H; McMahon, GA; Raja, K; Keegan, AD; Lawrence, DA; Bugge, TH				Curino, A; Mitola, DJ; Aaronson, H; McMahon, GA; Raja, K; Keegan, AD; Lawrence, DA; Bugge, TH			Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages	ONCOGENE			English	Review						fibrosarcoma; tumor-infiltrating macrophages; plasminogen activator; stroma	RECEPTOR-BOUND UROKINASE; LEWIS LUNG-CARCINOMA; SPONTANEOUS METASTASIS MODEL; SQUAMOUS-CELL CARCINOMA; GENE-INACTIVATED MICE; HUMAN COLON-CANCER; LATENT TGF-BETA; ACTIVATOR INHIBITOR-1; DEFICIENT MICE; BREAST-CANCER	The specific functions of plasminogen, stromal plasminogen activator, stromal plasminogen activator receptor, and stromal plasminogen activator inhibitor in the progression of the murine soft tissue sarcoma, T241 were investigated. Negation of plasminogen to the tumor blunted the orthotopic growth of the sarcoma in syngeneic mice. The reduced tumor growth was associated with a dramatic increase in tumor-infiltrating F4/80-positive macrophages and a diminution of vessel density, but not with obvious differences in fibrin and collagen deposition, or invasiveness of the tumor. Ablation of plasminogen activation by the tumor stroma only modestly impaired the prolonged growth of the sarcoma, suggesting that tumor cell-produced plasminogen activator is sufficient to mediate productive plasminogen activation. Plasminogen facilitated sarcoma progression, angiogenesis, and suppression of macrophage infiltration in the absence of either stromal urokinase plasminogen activator receptor or stromal plasminogen activator inhibitor. These data demonstrate that tumor cell-produced plasminogen activator and host plasminogen cooperate to facilitate soft tissue sarcoma growth and suppress the accumulation of tumor-infiltrating macrophages.	Natl Inst Dent Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Amer Red Cross, Dept Immunol, Rockville, MD 20855 USA; Amer Red Cross, Dept Vasc Biol, Rockville, MD 20855 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); American Red Cross; American Red Cross	Bugge, TH (corresponding author), Natl Inst Dent Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr, Bethesda, MD 20892 USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL055747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL55747, P01 HL54710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEVA DG, 1994, J IMMUNOL, V153, P1674; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BAKER MS, 1990, CANCER RES, V50, P4676; Beck JM, 1999, INFECT IMMUN, V67, P879, DOI 10.1128/IAI.67.2.879-884.1999; Blasi F, 1999, APMIS, V107, P96, DOI 10.1111/j.1699-0463.1999.tb01531.x; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; Bugge TH, 1997, BLOOD, V90, P4522; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; BUGGE TH, 1995, J BIOL CHEM, V270, P16886, DOI 10.1074/jbc.270.28.16886; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Chapman HA, 2001, THROMB HAEMOSTASIS, V86, P124; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; De Petro G, 1998, CANCER RES, V58, P2234; DECLERCK PJ, 1995, THROMB HAEMOSTASIS, V74, P1305; DECLERCK PJ, 1995, J BIOL CHEM, V270, P8397, DOI 10.1074/jbc.270.15.8397; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; DiNapoli MR, 1996, J EXP MED, V183, P1323, DOI 10.1084/jem.183.4.1323; Dublin E, 2000, AM J PATHOL, V157, P1219, DOI 10.1016/S0002-9440(10)64637-8; DUFFY MJ, 1990, CANCER RES, V50, P6827; Elgert KD, 1998, J LEUKOCYTE BIOL, V64, P275, DOI 10.1002/jlb.64.3.275; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1991, SEMIN THROMB HEMOST, V17, P194, DOI 10.1055/s-2007-1002609; FOEKENS JA, 1992, CANCER RES, V52, P6101; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; GANESH S, 1994, CANCER RES, V54, P4065; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; Goguen JD, 2000, METHODS, V21, P179, DOI 10.1006/meth.2000.0989; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; Gutierrez LS, 2000, CANCER RES, V60, P5839; HALL SW, 1991, J BIOL CHEM, V266, P12329; HEARING VJ, 1988, CANCER RES, V48, P1270; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; HIENERT G, 1988, J UROLOGY, V140, P1466, DOI 10.1016/S0022-5347(17)42074-X; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Hudson MA, 1997, J NATL CANCER I, V89, P709, DOI 10.1093/jnci/89.10.709; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; KOBAYASHI H, 1994, INT J CANCER, V57, P727, DOI 10.1002/ijc.2910570520; Kono K, 1996, EUR J IMMUNOL, V26, P1308, DOI 10.1002/eji.1830260620; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lanza F, 1998, BRIT J HAEMATOL, V103, P110; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Leek RD, 2000, J PATHOL, V190, P430, DOI 10.1002/(SICI)1096-9896(200003)190:4<430::AID-PATH538>3.0.CO;2-6; Leek RD, 1996, CANCER RES, V56, P4625; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; List K, 2000, BIOCHEMISTRY-US, V39, P508, DOI 10.1021/bi991701f; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; Martin DC, 1999, J CELL BIOL, V146, P881, DOI 10.1083/jcb.146.4.881; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Min HY, 1996, CANCER RES, V56, P2428; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Morita S, 1998, INT J CANCER, V78, P286, DOI 10.1002/(SICI)1097-0215(19981029)78:3<286::AID-IJC4>3.0.CO;2-R; MUELLER BM, 1995, P NATL ACAD SCI USA, V92, P205, DOI 10.1073/pnas.92.1.205; NEKARDA H, 1994, LANCET, V343, P117, DOI 10.1016/S0140-6736(94)90845-1; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Nielsen BS, 1996, LAB INVEST, V74, P168; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; OHMORI T, 1995, HISTOL HISTOPATHOL, V10, P789; OKA T, 1991, CANCER RES, V51, P3522; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PEDERSEN H, 1994, CANCER RES, V54, P4671; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; PLESNER T, 1994, AM J CLIN PATHOL, V102, P835, DOI 10.1093/ajcp/102.6.835; PLOW EF, 1986, J IMMUNOL, V137, P1910; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PYKE C, 1991, CANCER RES, V51, P4067; PYKE C, 1994, HISTOPATHOLOGY, V24, P131, DOI 10.1111/j.1365-2559.1994.tb01291.x; PYKE C, 1993, CANCER RES, V53, P1911; PYKE C, 1991, AM J PATHOL, V138, P1059; Rabbani SA, 1995, INT J CANCER, V63, P840, DOI 10.1002/ijc.2910630615; Rifkin DB, 1999, APMIS, V107, P80, DOI 10.1111/j.1699-0463.1999.tb01529.x; Rogove AD, 1999, J CELL SCI, V112, P4007; Romisch J, 1999, HAEMOSTASIS, V29, P292; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SAWAYA R, 1988, J NEUROSURG, V68, P73, DOI 10.3171/jns.1988.68.1.0073; Schmidt M, 2000, HEAD NECK-J SCI SPEC, V22, P498, DOI 10.1002/1097-0347(200008)22:5<498::AID-HED9>3.0.CO;2-W; Shapiro RL, 1996, CANCER RES, V56, P3597; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sier CFM, 1998, CANCER RES, V58, P1843; SIMON DI, 1993, BLOOD, V82, P2414; SKRIVER L, 1984, Journal of Cell Biology, V99, P752; Solberg H, 2001, J HISTOCHEM CYTOCHEM, V49, P237, DOI 10.1177/002215540104900211; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Taniguchi T, 1998, CANCER RES, V58, P4461; Wahl LM, 1998, J NATL CANCER I, V90, P1583, DOI 10.1093/jnci/90.21.1583; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; YU H, 1990, CANCER RES, V50, P7623	113	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8830	8842		10.1038/sj.onc.1205951	http://dx.doi.org/10.1038/sj.onc.1205951			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483535				2022-12-17	WOS:000179734400016
J	Mao, L				Mao, L			Recent advances in the molecular diagnosis of lung cancer	ONCOGENE			English	Review						molecular marker; lung cancer; diagnosis; sputum; serum	NONSMALL CELL LUNG; GROWTH-FACTOR RECEPTOR; ABERRANT PROMOTER METHYLATION; BRONCHOALVEOLAR LAVAGE FLUID; GASTRIN-RELEASING-PEPTIDE; CIRCULATING TUMOR-CELLS; CODON 12 MUTATIONS; K-RAS MUTATION; STAGE-I; GENE-EXPRESSION	Despite extensive effort in improvement of diagnosis and treatment of patients with lung cancer in past three decades, the overall survival of patients with the disease remains dismal. Because the development of lung cancer takes a few decades, early diagnosis of the disease or identification of truly high-risk populations may provide us opportunity to successfully cure or prevent the disease. Recent advances in understanding biological basis of lung tumorigenesis provide new tools for detecting malignant cells or the process of malignant transformation and progression. Along with identification of molecular abnormalities in the early lung tumorigenesis, advanced molecular analytic technologies have been emerged, which may facilitate development of rapid and effective methods for early diagnosis and risk assessment. Here, I discuss recent progresses in understanding of early molecular abnormalities in lung cancer, efforts of translating laboratory findings to clinical tests, and prospective of biomarkers in lung cancer diagnosis and risk assessment.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Mao, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	lmao@mdanderson.org	Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358				Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Albanell J, 1997, JNCI-J NATL CANCER I, V89, P1609, DOI 10.1093/jnci/89.21.1609; Allan JM, 2001, INT J CANCER, V91, P359, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1058>3.0.CO;2-E; Aoyagi Y, 2001, CANCER RES, V61, P7950; Bauer C, 2001, CANCER, V92, P822, DOI 10.1002/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bessho A, 2000, ANTICANCER RES, V20, P1149; Brichory F, 2001, CANCER RES, V61, P7908; Brichory FM, 2001, P NATL ACAD SCI USA, V98, P9824, DOI 10.1073/pnas.171320598; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Caballero OL, 2001, GENE CHROMOSOME CANC, V32, P119, DOI 10.1002/gcc.1173; CARBONE DP, 1994, CHEST, V106, pS377, DOI 10.1378/chest.106.6.377S; CERNY T, 1986, BRIT J CANCER, V54, P265, DOI 10.1038/bjc.1986.172; Chen JJW, 2001, CANCER RES, V61, P5223; Chen XQ, 1996, NAT MED, V2, P1033; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; De Luca A, 2000, CLIN CANCER RES, V6, P1439; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; Eerola AK, 1997, J PATHOL, V181, P172; Esteller M, 1999, CANCER RES, V59, P67; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Feng G, 2001, CANCER RES, V61, P7999; Fernandez-Madrid F, 1999, CLIN CANCER RES, V5, P1393; Fielding P, 1999, CLIN CANCER RES, V5, P4048; Fleischhacker M, 2001, ANN NY ACAD SCI, V945, P179; Foa P, 1999, ANTICANCER RES, V19, P3613; GORGOULIS V, 1992, ANTICANCER RES, V12, P1183; Graziano SL, 1999, J CLIN ONCOL, V17, P668, DOI 10.1200/JCO.1999.17.2.668; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Gure AO, 1998, CANCER RES, V58, P1034; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Hibi K, 1998, CANCER RES, V58, P5690; Hirao T, 2001, CANCER RES, V61, P612; Iizasa T, 1998, CANCER IMMUNOL IMMUN, V46, P345, DOI 10.1007/s002620050496; Jang SJ, 2001, CANCER RES, V61, P7959; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Karnak D, 2001, LUNG, V179, P57, DOI 10.1007/s004080000047; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Kong LF, 1998, CANCER LETT, V130, P93, DOI 10.1016/S0304-3835(98)00115-3; Kurusu Y, 1999, SURGERY, V126, P820, DOI 10.1016/S0039-6060(99)70020-6; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; Lee JC, 1998, LUNG CANCER-J IASLC, V21, P99; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Liloglou T, 2001, CANCER RES, V61, P1624; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MAO L, 1994, CANCER RES, V54, P1634; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Miozzo M, 1996, CANCER RES, V56, P2285; Mishina T, 1999, BRIT J CANCER, V80, P1289, DOI 10.1038/sj.bjc.6690500; Mishina T, 2000, CLIN CANCER RES, V6, P11; Mitsudomi T, 1998, JNCI-J NATL CANCER I, V90, P1563, DOI 10.1093/jnci/90.20.1563; Mulshine JL, 2000, CANCER-AM CANCER SOC, V89, P2465; Nakajima E, 2001, INT J ONCOL, V18, P105; Niklinski J, 2001, LUNG CANCER, V34, pS53, DOI 10.1016/S0169-5002(01)00345-2; Nishio M, 1996, J CLIN ONCOL, V14, P497, DOI 10.1200/JCO.1996.14.2.497; Noel-Georis I, 2001, DIS MARKERS, V17, P271, DOI 10.1155/2001/607263; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Oh JMC, 2001, PROTEOMICS, V1, P1303, DOI 10.1002/1615-9861(200110)1:10<1303::AID-PROT1303>3.0.CO;2-2; Oh Y, 1998, ONCOGENE, V17, P1141, DOI 10.1038/sj.onc.1202029; Palmisano WA, 2000, CANCER RES, V60, P5954; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Patz EF, 2000, NEW ENGL J MED, V343, P1627, DOI 10.1056/NEJM200011303432208; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Ponticiello A, 2000, EUR RESPIR J, V15, P547, DOI 10.1034/j.1399-3003.2000.15.20.x; PUJOL JL, 1993, BRIT J CANCER, V67, P1423, DOI 10.1038/bjc.1993.264; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; RICHARDSON GE, 1993, SEMIN ONCOL, V20, P105; Rosell R, 1997, INT J CANCER, V74, P330, DOI 10.1002/(SICI)1097-0215(19970620)74:3<330::AID-IJC17>3.0.CO;2-F; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; RUSCH V, 1993, CANCER RES, V53, P2379; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Salgia R, 2001, ANTICANCER RES, V21, P1241; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; Scott FM, 1997, CLIN CANCER RES, V3, P479; Sekine I, 1997, JPN J CANCER RES, V88, P559, DOI 10.1111/j.1349-7006.1997.tb00419.x; Shriver SP, 2000, JNCI-J NATL CANCER I, V92, P24, DOI 10.1093/jnci/92.1.24; SIEGFRIED JM, 1993, ANAT RECORD, V236, P241, DOI 10.1002/ar.1092360129; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Somers VA, 1998, J CLIN ONCOL, V16, P3061, DOI 10.1200/JCO.1998.16.9.3061; Soria JC, 2002, CANCER RES, V62, P351; Soria JC, 2000, CANCER RES, V60, P4000; Soria JC, 2001, JNCI-J NATL CANCER I, V93, P1257, DOI 10.1093/jnci/93.16.1257; Sozzi G, 2001, CANCER RES, V61, P4675; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Sutedja TG, 2001, LUNG CANCER, V34, P157, DOI 10.1016/S0169-5002(01)00242-2; Takamochi K, 2001, AM J PATHOL, V159, P1941, DOI 10.1016/S0002-9440(10)63041-6; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Tas F, 2000, J EXP CLIN CANC RES, V19, P477; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; Tomizawa Y, 1999, ONCOGENE, V18, P1007, DOI 10.1038/sj.onc.1202384; Tseng JE, 1999, CANCER RES, V59, P4798; Tseng JE, 1999, CANCER RES, V59, P5666; TSUCHIYA E, 1992, CANCER RES, V52, P2478; Usadel H, 2002, CANCER RES, V62, P371; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang L, 2000, CLIN CANCER RES, V6, P2988; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; WEBER S, 1985, J CLIN INVEST, V75, P306, DOI 10.1172/JCI111690; Westra WH, 1996, CANCER RES, V56, P2224; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; Wu WG, 1998, CANCER RES, V58, P4082; Yamaguchi K, 2000, INT J CANCER, V89, P524, DOI 10.1002/1097-0215(20001120)89:6<524::AID-IJC10>3.0.CO;2-O; Yashima K, 1997, CANCER RES, V57, P2373; Zhou X, 2000, CLIN CANCER RES, V6, P559; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	116	22	25	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6960	6969		10.1038/sj.onc.1205564	http://dx.doi.org/10.1038/sj.onc.1205564			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362277				2022-12-17	WOS:000178640200010
J	Preobrazhenska, O; Yakymovych, M; Kanamoto, T; Yakymovych, I; Stoika, R; Heldin, CH; Souchelnytskyi, S				Preobrazhenska, O; Yakymovych, M; Kanamoto, T; Yakymovych, I; Stoika, R; Heldin, CH; Souchelnytskyi, S			BRCA2 and Smad3 synergize in regulation of gene transcription	ONCOGENE			English	Article						BRCA2; Smad3; transcription	GROWTH-FACTOR-BETA; PLASMINOGEN-ACTIVATOR INHIBITOR; CANCER; PROMOTER; PROTEINS; ONCOPROTEIN; FAMILY; COOPERATION; INDUCTION; MUTATIONS	Smad3 is an essential component in the intracellular signaling of transforming growth factor-beta (TGFbeta), which is a potent inhibitor of tumor cell proliferation. BRCA2 is a tumor suppressor involved in early onset of breast, ovarian and prostate cancer. Both Smad3 and BRCA2 possess transcription activation domains. Here, we show that Smad3 and BRCA2 interact functionally and physically. We found that BRCA2 forms a complex with Smad3 in vitro and in vivo, and that both MH1 and MH2 domains of Smad3 contribute to the interaction. TGFbeta1 stimulates interaction of endogenous Smad3 and BRCA2 in non-transfected cells. BRCA2 co-activates Smad3-dependent transcriptional activation of luciferase reporter and expression of plasminogen activator inhibitor-1 (PAM). Smad3 increases the transcriptional activity of BRCA2 fused to the DNA-binding domain (DBD) of Gal4, and reciprocally, BRCA2 co-activates DBD-Gal4-Smad3. Thus, our results show that BRCA2 and Smad3 form a complex and synergize in regulation of transcription.	Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; Ukrainian Acad Sci, Inst Cell Biol, UA-79005 Lvov, Ukraine; Hiroshima Univ, Sch Med, Dept Ophthalmol, Minami Ku, Hiroshima 7348551, Japan	Ludwig Institute for Cancer Research; National Academy of Sciences Ukraine; Institute of Cell Biology of NASU; Hiroshima University	Souchelnytskyi, S (corresponding author), Ludwig Inst Canc Res, Box 595,Husargatan 3, SE-75124 Uppsala, Sweden.	serhiy.souchelnytskyi@licr.uu.se	Souchelnytskyi, Serhiy/G-6491-2011; Souchelnytskyi, Serhiy/J-9446-2014	Souchelnytskyi, Serhiy/0000-0001-8243-9276; Stoika, Rostyslav/0000-0001-5719-2187				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hofmann W, 2000, J CANCER RES CLIN, V126, P487, DOI 10.1007/s004320000140; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; LAIHO M, 1987, J BIOL CHEM, V262, P17467; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nordling M, 1998, CANCER RES, V58, P1372; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Yakmovych I, 2001, FASEB J, V15, P553; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	32	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5660	5664		10.1038/sj.onc.1205732	http://dx.doi.org/10.1038/sj.onc.1205732			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165866				2022-12-17	WOS:000177442000017
J	Stein, T; Crighton, D; Warnock, LJ; Milner, J; White, RJ				Stein, T; Crighton, D; Warnock, LJ; Milner, J; White, RJ			Several regions of p53 are involved in repression of RNA polymerase III transcription	ONCOGENE			English	Article						p53; repression; RNA polymerase III; TFIIIB; transcription	TATA-BINDING-PROTEIN; WILD-TYPE P53; TUMOR SUPPRESSORS; DNA-BINDING; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; FACTOR-TFIIIB; AMINO-ACIDS; DAMAGED DNA	The tumour suppressor p53 has been shown to regulate RNA polymerase (pol) III transcription both in vitro and in vivo. We have characterized the regions of p53 that contribute to this effect. Repression of pol III transcription in vivo does not require residues 13-19 near the N-terminus of p53 that are highly conserved through evolution. However, amino acids 22 and 23 in the adjacent transactivation domain do contribute to the inhibition of pol III activity. Deletions within the central DNA-binding core domain (residues 102-292) of p53 can entirely abolish the repression function in these assays, despite the fact that pol III templates contain no recognized p53 binding site. Deletion or substitution within the C-terminal domain of p53 can also compromise its ability to repress pol III activity in vitro and in transfected cells. These observations reveal that repression of pol III transcription is a complex function involving multiple regions of p53 extending throughout much of the protein.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ York, Dept Biol, YCR Res Grp P53, York YO10 5DD, N Yorkshire, England	University of Glasgow; University of York - UK	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.		Stein, Torsten/G-1147-2012	Stein, Torsten/0000-0002-9946-1549				ABELSON HT, 1974, CELL, V1, P161, DOI 10.1016/0092-8674(74)90107-X; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Brown TRP, 2000, GENE EXPRESSION, V9, P15; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN KV, 1992, SCIENCE, V255, P459; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hong TM, 2001, J BIOL CHEM, V276, P1510, DOI 10.1074/jbc.M008231200; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAUCK JC, 1974, CELL, V3, P171, DOI 10.1016/0092-8674(74)90122-6; Molinari M, 1996, ONCOGENE, V13, P2077; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Okorokov AL, 1999, MOL CELL BIOL, V19, P7501; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SOUSSI T, 1990, ONCOGENE, V5, P945; Stein T, 2002, ONCOGENE, V21, P2961, DOI 10.1038/sj.onc.1205372; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; White R. J., 1998, RNA POLYMERASE 3 TRA; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; White RJ, 1998, INT J ONCOL, V12, P741; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; Zhao RB, 2000, GENE DEV, V14, P981	65	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5540	5547		10.1038/sj.onc.1205739	http://dx.doi.org/10.1038/sj.onc.1205739			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165852				2022-12-17	WOS:000177442000003
J	Taylor, A; Shang, F; Nowell, T; Galanty, Y; Shiloh, Y				Taylor, A; Shang, F; Nowell, T; Galanty, Y; Shiloh, Y			Ubiquitination capabilities in response to neocarzinostatin and H2O2 stress in cell lines from patients with ataxia-telangiectasia	ONCOGENE			English	Article						ATM; ataxia-telangiectasia; ubiquitination; oxidative stress; aging	LENS EPITHELIAL-CELLS; AGE-RELATED DECLINE; OXIDATIVE STRESS; CONJUGATING ENZYMES; ACTIVATING ENZYME; PROTEIN OXIDATION; REDOX REGULATION; GENE-PRODUCT; EYE LENS; ATM	The human genetic disorder ataxia-telangiectasia (A-T) is due to lack of functional ATM, a protein kinase which is involved in cellular responses to DNA double strand breaks (DSBs) and possibly other oxidative stresses, as well as in regulation of several fundamental cellular functions. Studies regarding responses in A-T cells to the induction of DSBs utilize ionizing radiation or radiomimetic chemicals, such as neocarzinostatin (NCS), which induce DNA DSBs. This critical DNA lesion activates many defense systems, such as the cell cycle checkpoints. The cell cycle is also regulated through a timed and coordinated degradation of regulatory proteins via the ubiquitin pathway. Our recent studies indicate that the ubiquitin pathway is influenced by the cellular redox status and that it is the major cellular pathway for removal of oxidized proteins. Accordingly, we hypothesized that the absence of a functional ATM protein might involve perturbations to the ubiquitin pathway as well. We show here that upon treatment with NCS, there was a transient 50-70% increase in endogenous ubiquitin conjugates in A-T and wt lymphoblastoid cells. Ubiquitin conjugation capabilities per se and levels of substrates for conjugation were also similarly enhanced in wt and A-T cells upon NCS treatment. We also compared the ubiquitination response in A-T and wt cells using H2O2 as the stress, in view of preexisting evidence of the effects of H2O2 on ubiquitination capabilities in other types of cells. As with NCS treatment, there was an approximate to45% increase in endogenous ubiquitin conjugates by 2-4 h after exposure to H2O2. Both cell types showed a rapid 50-150% increase in de novo formed I-125-ubiquitin conjugates. As compared with wt cells, unexposed A-T cells had higher endogenous levels of conjugates and enhanced conjugation capability. However, A-T cells mounted a more muted ubiquitination response to the stress. The enhanced ubiquitin conjugation in unstressed A-T cells and attenuated ability of these cells to respond to stress are consistent with the A-T cells being under oxidative stress and with their having an 'aged' phenotype. The indication that ubiquitin conjugate levels and ubiquitin conjugation capabilities are enhanced upon oxidative stress without significant changes in GSSG/GSH ratios indicates that assays of ubiquitination provide a sensitive measure of cellular stress. The data also add support to the impression that potentiated ubiquitination response to mild oxidative stress is a generalizable phenomenon.	Tufts Univ, JM Human Nutr Res Ctr Aging, USDA, Lab Nutr & Vis Res, Boston, MA 02111 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, David & Inez Myers Lab Genet Res, IL-69978 Tel Aviv, Israel	Tufts University; United States Department of Agriculture (USDA); Tel Aviv University; Sackler Faculty of Medicine	Taylor, A (corresponding author), Tufts Univ, JM Human Nutr Res Ctr Aging, USDA, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.	ataylor@hnrc.tufts.edu		Galanty, Yaron/0000-0001-7167-9004	NEI NIH HHS [EY013250] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013250] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adamo AM, 1999, J NEUROSCI RES, V55, P523, DOI 10.1002/(SICI)1097-4547(19990215)55:4<523::AID-JNR12>3.0.CO;2-Q; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; APPLEGATE LA, 1994, J INVEST DERMATOL, V102, P762, DOI 10.1111/1523-1747.ep12377610; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; CIECHANOVER A, 1985, P NATL ACAD SCI USA, V82, P1341, DOI 10.1073/pnas.82.5.1341; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cuervo AM, 2000, J BIOL CHEM, V275, P31505, DOI 10.1074/jbc.M002102200; EDO K, 1991, CHEM PHARM BULL, V39, P170; EISENHAUER DA, 1988, EXP EYE RES, V46, P579, DOI 10.1016/S0014-4835(88)80014-9; Gatei M, 2001, ONCOGENE, V20, P289, DOI 10.1038/sj.onc.1204111; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Haas AL, 1997, FASEB J, V11, P1053, DOI 10.1096/fasebj.11.13.9367340; Haas AL, 1997, FASEB J, V11, P1257; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; JABBEN M, 1989, PLANT PHYSIOL, V90, P380, DOI 10.1104/pp.90.2.380; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kamsler A, 2001, CANCER RES, V61, P1849; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Lenton KJ, 2000, AM J CLIN NUTR, V71, P1194; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MAYER RJ, 1991, J PATHOL, V163, P279, DOI 10.1002/path.1711630402; MULLERTAUBENBERGER A, 1988, J CELL SCI, V90, P51; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Obin M, 1999, J BIOL CHEM, V274, P11789, DOI 10.1074/jbc.274.17.11789; Okada S, 2000, J GASTROENTEROL, V35, P407, DOI 10.1007/s005350050370; Ramanathan M, 1999, NEUROREPORT, V10, P3797, DOI 10.1097/00001756-199912160-00014; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Rotman G, 1997, CANCER SURV, V29, P285; Rybczynska M, 1996, BBA-LIPID LIPID MET, V1302, P231, DOI 10.1016/0005-2760(96)00067-7; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schor NF, 1999, BRAIN RES, V831, P125, DOI 10.1016/S0006-8993(99)01414-6; Shackelford RE, 2001, J BIOL CHEM, V276, P21951, DOI 10.1074/jbc.M011303200; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; SHILOH Y, 1982, BIOCHIM BIOPHYS ACTA, V721, P485, DOI 10.1016/0167-4889(82)90105-7; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Smith D, 1999, J NUTR, V129, P1229, DOI 10.1093/jn/129.6.1229; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Stephen AG, 1996, J BIOL CHEM, V271, P15608, DOI 10.1074/jbc.271.26.15608; Takao N, 2000, FEBS LETT, V472, P133, DOI 10.1016/S0014-5793(00)01422-8; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; TAYLOR A, 1995, MECH AGEING DEV, V79, P33, DOI 10.1016/0047-6374(94)01541-S; TAYLOR A, 1991, IN VITRO CELL DEV B, V27, P287, DOI 10.1007/BF02630905; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; Taylor A., 1999, CRC MOD NUT, V1st, P53; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277	60	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4363	4373		10.1038/sj.onc.1205557	http://dx.doi.org/10.1038/sj.onc.1205557			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080467				2022-12-17	WOS:000176317100002
J	Im, HJ; Craig, TA; Pittelkow, MR; Kumar, R				Im, HJ; Craig, TA; Pittelkow, MR; Kumar, R			Characterization of a novel hexameric repeat DNA sequence in the promoter of the immediate early gene, IEX-1, that mediates 1 alpha,25-dihydroxyvitamin D-3-associated IEX-1 gene repression	ONCOGENE			English	Article						immediate early gene; IEX-1; VDRE; transcriptional suppression	VITAMIN-D-RECEPTOR; TRANSFORMING-GROWTH-FACTOR; RETINOID-X-RECEPTOR; PROTEIN-KINASE-C; MEMBRANE CALCIUM-PUMP; EARLY RESPONSE GENE; FACTOR-BETA 2; 1,25-DIHYDROXYVITAMIN D-3; THYROID-HORMONE; DEFICIENCIES INCREASE	1alpha,25-Dihydroxyvitamin D-3(1alpha,25(OH)(2)D-3), the active metabolite of vitamin D-3, mediates anti-proliferative effects in cells by regulating the expression of 1alpha,25(OH)(2)D-3-responsive genes. The expression of the proliferation-promoting immediate Early gene X-1 (IEX-1) is reduced by 1alpha,25(OH)(2)D-3 through unknown mechanisms. Here we report the presence of a novel inhibitory hexameric repeat DNA response element in the promoter of the human IEX-1 gene that mediates 1alpha,25(OH)(2)D-3-associated IEX-1 gene repression. To localize a vitamin D sensitive DIVA response element we transfected the keratinocyte-like cell line, HaCaT, (referred as HaCaT) with a series of plasmids containing full-length and truncated IEX-1 promoter elements fused to the luciferase reporter gene in the absence or presence of 1alpha,25(OH)(2)D-3, and we performed electrophoretic gel mobility assays in the presence of receptors for 1alpha,25(OH)(2)D-3 (vitamin D receptor, VDR) and 9-cis-retinoic acid (RXRalpha). We mapped a negative response element between nt -405 and -391(15 bp) of the IEX-1 promoter (5'-TGAACC AGG GAGTCA-3') that mediates transcriptional inhibition in response to 1alpha,25(OH)(2)D-3 and which requires expression of both nuclear receptors for 1alpha,25(OH)(2)D-3 and 9-cis-retinoic acid. Our data indicate that the physiological repression of IEX-1 gene expression by 1alpha,25(OH)(2)D-3 is directly mediated by nuclear VDR/RXRalpha heterodimers through a specific transcriptional element.	Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Dermatol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Kumar, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med, 200 1st St SW, Rochester, MN 55905 USA.	rkumar@mayo.edu		Kumar, Rajiv/0000-0003-3497-3057	NCI NIH HHS [CA 015083] Funding Source: Medline; NIAMS NIH HHS [AR27032] Funding Source: Medline; NIDDK NIH HHS [DK25409, DK59505, DK58546, R01 DK025409, R01 DK058546] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027032, R56AR027032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058546, R01DK025409, R01DK059505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER U, 1988, J CLIN ENDOCR METAB, V67, P607, DOI 10.1210/jcem-67-3-607; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CAI Q, 1993, P NATL ACAD SCI USA, V90, P1345, DOI 10.1073/pnas.90.4.1345; Candeliere GA, 1996, MOL CELL BIOL, V16, P584; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Craig TA, 1999, NAT BIOTECHNOL, V17, P1214, DOI 10.1038/70767; Craig TA, 1997, BIOCHEMISTRY-US, V36, P10482, DOI 10.1021/bi970561b; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; Elstner E, 1996, CANCER RES, V56, P3570; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Falzon M, 1996, MOL ENDOCRINOL, V10, P672, DOI 10.1210/me.10.6.672; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GIULIANO AR, 1991, ARCH BIOCHEM BIOPHYS, V285, P261, DOI 10.1016/0003-9861(91)90358-P; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GROSS M, 1986, J BONE MINER RES, V1, P457; Haugen JD, 1996, BIOCHEM BIOPH RES CO, V229, P618, DOI 10.1006/bbrc.1996.1853; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; Herdick M, 2000, J MOL BIOL, V304, P793, DOI 10.1006/jmbi.2000.4267; IM HJ, 2002, J BIOL CHEM     0213; ITIN PH, 1994, ENDOCRINOLOGY, V135, P1793, DOI 10.1210/en.135.5.1793; James SY, 1996, J STEROID BIOCHEM, V58, P395, DOI 10.1016/0960-0760(96)00048-9; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Koszewski NJ, 1999, MOL ENDOCRINOL, V13, P455, DOI 10.1210/me.13.3.455; Koszewski NJ, 2000, J STEROID BIOCHEM, V72, P125, DOI 10.1016/S0960-0760(00)00022-4; Kremer R, 1996, J BIOL CHEM, V271, P16310, DOI 10.1074/jbc.271.27.16310; KUMAR R, 1991, KIDNEY INT, V40, P1177, DOI 10.1038/ki.1991.332; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu SM, 1996, MOL ENDOCRINOL, V10, P206, DOI 10.1210/me.10.2.206; Lutz W, 2000, BIOCHEM BIOPH RES CO, V271, P1, DOI 10.1006/bbrc.2000.2570; Mackey SL, 1996, MOL ENDOCRINOL, V10, P298, DOI 10.1210/me.10.3.298; Mathiasen IS, 1999, CANCER RES, V59, P4848; Mehta RG, 1997, JNCI-J NATL CANCER I, V89, P212, DOI 10.1093/jnci/89.3.212; Narvaez CJ, 1997, ENDOCRINOLOGY, V138, P4690, DOI 10.1210/en.138.11.4690; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; OCONNELL TD, 1995, BIOCHEM BIOPH RES CO, V213, P59, DOI 10.1006/bbrc.1995.2098; PEEHL DM, 1994, CANCER RES, V54, P805; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS DE, 1993, ANTI-CANCER DRUG, V4, P201, DOI 10.1097/00001813-199304000-00012; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; SimboliCampbell M, 1997, BREAST CANCER RES TR, V42, P31, DOI 10.1023/A:1005772432465; SIMBOLICAMPBELL M, 1994, J BIOL CHEM, V269, P3257; Towers TL, 1998, J BIOL CHEM, V273, P10338, DOI 10.1074/jbc.273.17.10338; VANLEEUWEN JPTM, 1992, J BIOL CHEM, V267, P12562; Veenstra TD, 1997, BIOCHEM BIOPH RES CO, V235, P15, DOI 10.1006/bbrc.1997.6718; Veenstra TD, 1998, BIOCHEMISTRY-US, V37, P5988, DOI 10.1021/bi972965+; Veenstra TD, 1998, NAT BIOTECHNOL, V16, P262, DOI 10.1038/nbt0398-262; Veenstra TD, 1998, J AM SOC MASS SPECTR, V9, P8, DOI 10.1016/S1044-0305(97)00229-8; WASSERMAN RH, 1992, GASTROENTEROLOGY, V102, P886, DOI 10.1016/0016-5085(92)90174-W; Wu YH, 1999, BIOCHEMISTRY-US, V38, P2654, DOI 10.1021/bi981944s; Wu YH, 1997, BIOCHEM BIOPH RES CO, V239, P734, DOI 10.1006/bbrc.1997.7544; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900	64	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3706	3714		10.1038/sj.onc.1205450	http://dx.doi.org/10.1038/sj.onc.1205450			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032839				2022-12-17	WOS:000175676000006
J	Shi, PA; Hematti, P; von Kalle, C; Dunbar, CE				Shi, PA; Hematti, P; von Kalle, C; Dunbar, CE			Genetic marking as an approach to studying in vivo hematopoiesis: progress in the non-human primate model	ONCOGENE			English	Article						hematopoietic stem cells; retroviral vectors; in vivo gene tracking; clonality	STEM-CELL FACTOR; COLONY-STIMULATING FACTOR; X-CHROMOSOME INACTIVATION; RHESUS PERIPHERAL-BLOOD; LONG-TERM ENGRAFTMENT; CD34(+) CELLS; COMPETITIVE REPOPULATION; LIFELONG HEMATOPOIESIS; HUMAN INTERLEUKIN-3; CLONAL ANALYSIS	Retroviral insertion site analysis following transplantation of marked hematopoietic stem cells (HSCs) is a powerful method for studying hematopoiesis in vivo. High-level gene transfer efficiency was achieved in murine models in the late 1980s, but early human gene transfer protocols into hematopoietic stem and progenitor cells using the murine methodology showed consistently poor results. The utility of non-human primates as pre-clinical models has since become apparent. Modifications in retroviral transduction conditions have resulted in stable long-term gene transfer efficiency as high as 15-20% to primitive repopulating cells in non-human primate models. This has permitted, for the first time in a large animal model, tracking of individual stem and progenitor cell clones via insertion site analysis, an advantage over competitive transplantation studies, which cannot firmly evaluate the number or life span of individual clones contributing to hematopoiesis. Retroviral tracking studies in mice suggest that stable hematopoiesis may be dominated by a small number of clones, but these studies have been limited by insensitive detection methods, low numbers of transplanted stem cells, and limited life span of immunodeficient mice. Autologous transplantation studies in non-human primates have just begun and have the potential to shed light on controversial issues such as the number of clones contributing to stable hematopoiesis, clonal succession, and lineage commitment, as well as the effect of clinically relevant manipulations such as cytokines, chemotherapy, and radiation on hematopoiesis. These approaches will have significant impact in studying various aspects of stem cell biology including the phenomenon of stem cell plasticity.	NHLBI, Mol Hematopoiesis Sect, Hematol Branch, NIH, Bethesda, MD 20892 USA; Univ Freiburg, Dept Internal Med, D-7800 Freiburg, Germany	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Freiburg	Dunbar, CE (corresponding author), NHLBI, Mol Hematopoiesis Sect, Hematol Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	dunbarc@nhlbi.nih.gov		Shi, Patricia/0000-0002-7954-0055; Dunbar, Cynthia/0000-0002-7645-838X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002339, Z01HL002339] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abkowitz JL, 2000, BLOOD, V96, P3399, DOI 10.1182/blood.V96.10.3399.h8003399_3399_3405; ABKOWITZ JL, 1995, P NATL ACAD SCI USA, V92, P2031, DOI 10.1073/pnas.92.6.2031; ABKOWITZ JL, 1990, P NATL ACAD SCI USA, V87, P9062, DOI 10.1073/pnas.87.22.9062; Abkowitz JL, 1996, NAT MED, V2, P190, DOI 10.1038/nm0296-190; Abkowitz JL, 1998, P NATL ACAD SCI USA, V95, P3862, DOI 10.1073/pnas.95.7.3862; An DS, 2000, J VIROL, V74, P1286, DOI 10.1128/JVI.74.3.1286-1295.2000; ANDERSON WF, 1986, COLD SPRING HARB SYM, V51, P1073, DOI 10.1101/SQB.1986.051.01.125; ANDREWS RG, 1995, BLOOD, V85, P15, DOI 10.1182/blood.V85.1.15.bloodjournal85115; BERENSON RJ, 1988, J CLIN INVEST, V81, P951, DOI 10.1172/JCI113409; BOCK TA, 1995, J EXP MED, V182, P2037, DOI 10.1084/jem.182.6.2037; BODINE DM, 1991, EXP HEMATOL, V19, P206; BODINE DM, 1994, BLOOD, V84, P1482; BOGGS DR, 1982, J CLIN INVEST, V70, P242, DOI 10.1172/JCI110611; Brenner M, 1996, HUM GENE THER, V7, P1927, DOI 10.1089/hum.1996.7.16-1927; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; BROWN CJ, 2000, BLOOD, V95, P2449; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; BURGER H, 1990, BLOOD, V76, P2229; Busque L, 1996, BLOOD, V88, P59; CAPEL B, 1989, P NATL ACAD SCI USA, V86, P4564, DOI 10.1073/pnas.86.12.4564; Cashman JD, 1997, BLOOD, V89, P4307, DOI 10.1182/blood.V89.12.4307; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Champion KM, 1997, BRIT J HAEMATOL, V97, P920, DOI 10.1046/j.1365-2141.1997.1933010.x; Christensen K, 2000, BLOOD, V95, P2449, DOI 10.1182/blood.V95.7.2449.007k06_2449_2451; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; Donahue RE, 1996, BLOOD, V87, P1644, DOI 10.1182/blood.V87.4.1644.bloodjournal8741644; Donahue RE, 2001, HUM GENE THER, V12, P607, DOI 10.1089/104303401300057289; Dorrell C, 2000, BLOOD, V95, P102; Drize NJ, 1996, BLOOD, V88, P2927, DOI 10.1182/blood.V88.8.2927.bloodjournal8882927; Drize NJ, 2001, EXP HEMATOL, V29, P786, DOI 10.1016/S0301-472X(01)00634-8; Dunbar CE, 1996, ANNU REV MED, V47, P11; Dunbar CE, 1996, P NATL ACAD SCI USA, V93, P11871, DOI 10.1073/pnas.93.21.11871; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; Emerson SG, 1996, BLOOD, V87, P3082, DOI 10.1182/blood.V87.8.3082.bloodjournal8783082; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; Gale RE, 1997, BRIT J HAEMATOL, V98, P512, DOI 10.1046/j.1365-2141.1997.2573078.x; Gothot A, 1998, BLOOD, V92, P2641, DOI 10.1182/blood.V92.8.2641.420k36_2641_2649; Greiner DL, 1998, STEM CELLS, V16, P166, DOI 10.1002/stem.160166; Guenechea G, 2001, NAT IMMUNOL, V2, P75, DOI 10.1038/83199; Habibian HK, 1998, J EXP MED, V188, P393, DOI 10.1084/jem.188.2.393; Hanania EG, 1996, P NATL ACAD SCI USA, V93, P15346, DOI 10.1073/pnas.93.26.15346; Hanenberg H, 1996, NAT MED, V2, P876, DOI 10.1038/nm0896-876; HARRISON DE, 1988, P NATL ACAD SCI USA, V85, P822, DOI 10.1073/pnas.85.3.822; HARRISON DE, 1980, BLOOD, V55, P77; HARRISON DE, 1991, BLOOD, V78, P1237; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KANTOFF PW, 1987, J EXP MED, V166, P219, DOI 10.1084/jem.166.1.219; KARLSSON S, 1991, BLOOD, V78, P2481; KAY HEM, 1965, LANCET, V2, P418; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KELLER G, 1990, J EXP MED, V171, P1407, DOI 10.1084/jem.171.5.1407; Kelly PF, 2001, ANN NY ACAD SCI, V938, P262; Kiem HP, 1997, BLOOD, V90, P4638; Kiem HP, 1998, BLOOD, V92, P1878, DOI 10.1182/blood.V92.6.1878.418k39_1878_1886; Kim HJ, 2000, BLOOD, V96, P1; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Lemischka I, 1999, P NATL ACAD SCI USA, V96, P14193, DOI 10.1073/pnas.96.25.14193; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LUSKEY BD, 1992, BLOOD, V80, P396; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Naldini L, 1998, CURR OPIN BIOTECH, V9, P457, DOI 10.1016/S0958-1669(98)80029-3; NASH R, 1988, BLOOD, V72, P2031; NOLTA JA, 1994, BLOOD, V83, P3041, DOI 10.1182/blood.V83.10.3041.3041; Nolta JA, 1996, P NATL ACAD SCI USA, V93, P2414, DOI 10.1073/pnas.93.6.2414; OCHMAN H, 1988, GENETICS, V120, P621; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, ANN NY ACAD SCI, V938, P221; Orlic D, 1996, P NATL ACAD SCI USA, V93, P11097, DOI 10.1073/pnas.93.20.11097; Petzer AL, 1996, J EXP MED, V183, P2551, DOI 10.1084/jem.183.6.2551; Rebel VI, 1999, BLOOD, V93, P2217, DOI 10.1182/blood.V93.7.2217.407a01_2217_2224; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; SNODGRASS R, 1987, EMBO J, V6, P3955, DOI 10.1002/j.1460-2075.1987.tb02737.x; Srour EF, 1999, J HEMATOTHER, V8, P93, DOI 10.1089/106161299320370; Takatoku M, 2001, J CLIN INVEST, V108, P447, DOI 10.1172/JCI12593; Tisdale JF, 1998, BLOOD, V92, P1131, DOI 10.1182/blood.V92.4.1131.416k41_1131_1141; Tonon L, 1998, BRIT J HAEMATOL, V102, P996, DOI 10.1046/j.1365-2141.1998.00867.x; VANBEKKUM DW, 1978, TRANSPL P, V10, P105; vanBeusechem VW, 1996, HUM GENE THER, V7, P1649, DOI 10.1089/hum.1996.7.14-1649; Wu T, 2000, MOL THER, V1, P285, DOI 10.1006/mthe.2000.0034; Yokota T, 1998, BLOOD, V91, P3263, DOI 10.1182/blood.V91.9.3263.3263_3263_3272; Zanjani ED, 1996, INT J HEMATOL, V63, P179; Zhong RK, 1996, J IMMUNOL, V157, P138	86	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3274	3283		10.1038/sj.onc.1205320	http://dx.doi.org/10.1038/sj.onc.1205320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032769				2022-12-17	WOS:000175633300004
J	Folberg-Blum, A; Sapir, A; Shilo, BZ; Oren, M				Folberg-Blum, A; Sapir, A; Shilo, BZ; Oren, M			Overexpression of mouse Mdm2 induces developmental phenotypes in Drosophila	ONCOGENE			English	Article						Mdm2; apoptosis; Drosophila	ONCOPROTEIN MDM2; P53-INDEPENDENT ROLE; S PHASE; P53; EXPRESSION; IDENTIFICATION; REGULATOR; CLEAVAGE; PROMOTES; HOMOLOG	The Mdm2 proto-oncogene is amplified and overexpressed in a variety of tumors. One of the major functions of Mdm2 described to date is its ability to modulate the levels and activity of the tumor suppressor protein p53. Mdm2 binds to the N-terminus of p53 and, through its action as an E3 ubiquitin ligase, targets p53 for rapid proteasomal degradation. Mdm2 can also bind to other cellular proteins such as hNumb, E2F1, Rb and Akt; however, the biological significance of these interactions is less clear. To gain insight into the function of Mdm2 in vivo, we have generated a transgenic Drosophila strain bearing the mouse Mdm2 gene. Ectopic expression of Mdm2, using the UAS/GAL4 system, causes eye and wing phenotypes in the fly. Analysis of wing imaginal discs from third instar larvae showed that expression of Mdm2 induces apoptosis. Crosses did not reveal genetic interactions between Mdm2 and the Drosophila homolog of E2F, Numb and Akt. These transgenic flies may provide a unique experimental model for exploring the molecular interactions of Mdm2 in a developmental context.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il	Sapir, Amir/C-5758-2015	Sapir, Amir/0000-0001-9888-1800; Oren, Moshe/0000-0003-4311-7172; Shilo, Ben Zion/0000-0003-4903-8889	NCI NIH HHS [R01 CA40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkhalaf M, 1999, ONCOGENE, V18, P1419, DOI 10.1038/sj.onc.1202448; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; CHANG HC, 1994, COLD SPRING HARB SYM, V59, P147, DOI 10.1101/SQB.1994.059.01.018; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; GOTTLIEB TM, 2002, IN PRESS ONCOGENE; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAY BA, 1994, DEVELOPMENT, V120, P2121; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	37	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2413	2417		10.1038/sj.onc.1205305	http://dx.doi.org/10.1038/sj.onc.1205305			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948425				2022-12-17	WOS:000174635600014
J	Croxton, R; Ma, YH; Cress, WD				Croxton, R; Ma, YH; Cress, WD			Differences in DNA binding properties between E2F1 and E2F4 specify repression of the Mcl-1 promoter	ONCOGENE			English	Article						apoptosis; DNA binding; E2F1; E2F4; Mcl-1; specificity	S-PHASE ENTRY; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; EXPRESSION PATTERNS; SIGNALING PATHWAY; PROTEIN; FAMILY; LEADS; RB; IDENTIFICATION	E2F1 is a potent inducer of apoptosis whereas its relative, E2F4, generally does not promote cell death. Other work from our laboratory has demonstrated that E2F1 can directly bind and represss the Mcl-1 promoter - contributing to E2F1-mediated apoptosis. Here we show that while E2F1 can repress the Mcl-1 promoter, other members of the E2F family (such as E2F4) cannot. Characterization of the Mcl-1 promoter demonstrates that the -143/+10 region is critical for E2F1-mediated downregulation. We demonstrate that the ability of E2F1 to repress the Mcl-1 promoter correlates with its ability to bind within the required -143/+10 region of this promoter. In contrast, E2F4 is unable to bind to the -143/+10 region of the Mcl-1 promoter. We propose that E2F4 is unable to repress the Mcl-1 promoter primarily as a result of insufficient binding to the essential regulatory region. This is the first evidence of DNA binding specificity among E2F family members that results in differential regulation of a naturally occurring promoter.	H Lee Moffit Comprehens Canc Ctr & Res Inst, Program Mol Oncol, Tampa, FL 33612 USA; Dept Oncol, Tampa, FL 33612 USA; Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Inst Biomol Sci, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Cress, WD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NCI NIH HHS [CA78214] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CROXTON R, 2001, IN PRESS ONCOGENE; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Muller H, 1997, MOL CELL BIOL, V17, P5508; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Wang JM, 1999, MOL CELL BIOL, V19, P6195; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; ZHANG YH, 1995, ONCOGENE, V10, P2085	55	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1563	1570		10.1038/sj.onc.1205232	http://dx.doi.org/10.1038/sj.onc.1205232			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896585				2022-12-17	WOS:000173956800012
J	Kulesza, CA; Van Buskirk, HA; Cole, MD; Reese, JC; Smith, MM; Engel, DA				Kulesza, CA; Van Buskirk, HA; Cole, MD; Reese, JC; Smith, MM; Engel, DA			Adenovirus E1A requires the yeast SAGA histone acetyltransferase complex and associates with SAGA components Gcn5 and Tra1	ONCOGENE			English	Article						gene regulation; transcription; genetics; yeast; adenovirus	TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME ACETYLATION; GENE ACTIVATION; ADA COMPLEX; PCAF; P300; ONCOPROTEIN; EXPRESSION	The budding yeast Saccharomyces cerevisiae was used as a model system to study the function of the adenovirus E1A oncoprotein. Previously we demonstrated that expression of the N-terminal 82 amino acids of E1A in yeast causes pronounced growth inhibition and specifically interferes with SWI/SNF-dependent transcriptional activation. Further genetic analysis identified the yeast transcription factor Adr1 as a high copy suppressor of E1A function. Transcriptional activation by Adr1 requires interaction with co-activator proteins Ada2 and Gcn5, components of histone acetyltransferase complexes including ADA and SAGA. Analysis of mutant alleles revealed that several components of the SAGA complex, including proteins from the Ada, Spt, and Taf classes were required for E1A-induced growth inhibition. Growth inhibition also depended on the Gcn5 histone acetyltransferase, and point mutations within the Gen5 HAT domain rendered cells E1A-resistant. Also required was SAGA component Tra1, a homologue of the mammalian TRRAP protein which is required for c-myc and E1A induced cellular transformation. Additionally, Gcn5 protein could associate with E1A in vitro in a manner that depended on the N-terminal domain of E1A, and Tra1 protein was co-immunoprecipitated with E1A in vivo. These results indicate a strong requirement for intact SAGA complex for E1A to function in yeast, and suggest a role for SAGA-like complexes in mammalian cell transformation.	Univ Virginia, Sch Med, Dept Microbiol & Canc Ctr, Charlottesville, VA 22908 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Virginia; Princeton University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Engel, DA (corresponding author), Univ Virginia, Sch Med, Dept Microbiol & Canc Ctr, Charlottesville, VA 22908 USA.	dae2s@virginia.edu			NCI NIH HHS [CA60675, CA87620] Funding Source: Medline; NIGMS NIH HHS [5T32GM08136, R01 GM058672-05, R01 GM028920, GM28920, R01 GM058672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060675, R01CA060675, R01CA087620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028920, T32GM008136, R01GM058672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Berk AJ, 1998, COLD SPRING HARB SYM, V63, P243, DOI 10.1101/sqb.1998.63.243; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, J BIOL CHEM, V271, P5237; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DYSON N, 1992, CANCER SURV, V12, P161; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Eckner R, 1996, MOL CELL BIOL, V16, P3454; EISENMANN DM, 1994, GENETICS, V137, P647; FASSLER JS, 1988, GENETICS, V118, P203; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HANDA H, 1987, GENE, V58, P127; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; MILLER ME, 1995, ONCOGENE, V11, P1623; Miller ME, 1996, MOL CELL BIOL, V16, P5737; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Peterson CL, 1998, COLD SPRING HARB SYM, V63, P545, DOI 10.1101/sqb.1998.63.545; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Roberts SM, 1997, GENETICS, V147, P451; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493; SIMCHEN G, 1984, P NATL ACAD SCI-BIOL, V81, P2431, DOI 10.1073/pnas.81.8.2431; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; VANDENELSEN P, 1983, VIROLOGY, V128, P377; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; WINSTON F, 1984, GENETICS, V107, P179; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	74	22	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1411	1422		10.1038/sj.onc.1205201	http://dx.doi.org/10.1038/sj.onc.1205201			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857084				2022-12-17	WOS:000173861000011
J	Yamamoto, H; Ochiya, T; Tamamushi, S; Toriyama-Baba, H; Takahama, Y; Hirai, K; Sasaki, H; Sakamoto, H; Saito, I; Iwamoto, T; Kakizoe, T; Terada, M				Yamamoto, H; Ochiya, T; Tamamushi, S; Toriyama-Baba, H; Takahama, Y; Hirai, K; Sasaki, H; Sakamoto, H; Saito, I; Iwamoto, T; Kakizoe, T; Terada, M			HST-1/FGF-4 gene activation induces spermatogenesis and prevents adriamycin-induced testicular toxicity	ONCOGENE			English	Article						FGF-4; spermatogenesis; Cre/lox; testis; transgenic	ADENOVIRUS-MEDIATED TRANSFER; GERM-CELL TUMORS; RECOMBINANT ADENOVIRUS; TRANSFORMING GENE; INDUCED APOPTOSIS; SERTOLI CELLS; STEM-CELLS; GROWTH; LOCALIZATION; EXPRESSION	We previously demonstrated expression of the HST-1/FGF-4 gene in the testis of normal adult animals, which suggests its possible role in spermatogenesis. For an understanding of its functional significance in the testis, conditional transgene expression was used. Precise genetic switches can be efficiently generated in a straightforward manner using adenovirus-carrying Cre recombinase, which means our new strategies promise to contribute substantially to a better and prompt understanding of the functions of genes in vivo by controlling the expression of any gene to any organ at any desired time. Our new method demonstrated for the first time that the specific gain of function of the HST-1/FGF-4 gene in the testis resulted in markedly enhanced spermatogenesis. To further investigate the function and therapeutic potency of HST-1/FGF-4, transgenic mice with enhanced HST-1/FGF-4 expression in the testis were exposed to adriamycin (ADR), an anticancer drug causing severe testicular toxicity. Degree of damage to spermatogenesis was assessed by sperm count, testicular weight, histology, and DNA ploidy. Induced expression of HST-1/FGF-4 markedly enhanced the recovery of ADR-induced testicular damage. Furthermore, adenoviruses carrying the HST-1/FGF-4 gene ameliorated testicular toxicity of ADR. These results with new adenovirus-mediated Cre/lox conditional mice indicated that HST1/FGF-4 could be an important factor for spermatogenesis, presenting a new paradigm to treat impaired fertility.	Natl Canc Ctr, Res Inst, Chuo Ku, Div Genet, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Chuo Ku, Sect Studies Metastasis, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Chuo Ku, Chemotherapy Div, Tokyo 1040045, Japan; Natl Canc Ctr, Natl Canc Ctr, Inst Res, Chuo Ku, Tokyo 1040045, Japan; CLEA Japan Inc, Shizuoka 4190301, Japan; Nara Med Univ, Dept Surg 1, Nara 6348522, Japan; Univ Tokyo, Inst Med Sci, Mol Genet Lab, Minato Ku, Tokyo 1088639, Japan; St Marianna Univ, Sch Med, Dept Urol, Kawasaki, Kanagawa 2168511, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Nara Medical University; University of Tokyo; Saint Marianna University	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Chuo Ku, Div Genet, 1-1 Tsukiji,5 Chome, Tokyo 1040045, Japan.	mterada@ncc.go.jp	Ochiya, Takahiro/AAH-7585-2019					Avarbock MR, 1996, NAT MED, V2, P693, DOI 10.1038/nm0696-693; Cancilla B, 1998, BIOL REPROD, V58, P1138, DOI 10.1095/biolreprod58.5.1138; Ford WCL, 2001, LANCET, V357, P1223, DOI 10.1016/S0140-6736(00)04452-4; GRELL RF, 1980, P NATL ACAD SCI-BIOL, V77, P6720, DOI 10.1073/pnas.77.11.6720; Griswold M D, 1988, Int Rev Cytol, V110, P133; GRISWOLD MD, 1988, OXFORD REV REPROD B, V10, P124; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; Hall SJ, 2000, HUM GENE THER, V11, P1705, DOI 10.1089/10430340050111359; HELLSTROM WJG, 1990, UROLOGY, V35, P321, DOI 10.1016/0090-4295(90)80155-G; Hogan B., 1986, MANIPULATING MOUSE E; Ishii Y, 1997, DEV GROWTH DIFFER, V39, P643; Ivanova M, 1999, THERIOGENOLOGY, V52, P163, DOI 10.1016/S0093-691X(99)00118-1; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Konishi H, 1996, ONCOGENE, V13, P9; LEMARGUERESSEBA.B, 1994, ENDOCRINOLOGY, V1135, P2404; Matsui H, 1993, Eisei Shikenjo Hokoku, P39; Miho Y, 1999, CELL DEATH DIFFER, V6, P463, DOI 10.1038/sj.cdd.4400506; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; OAKBERG EF, 1976, STEM CELLS RENEWING, P287; OCHIYA T, 1995, J CELL BIOL, V130, P997, DOI 10.1083/jcb.130.4.997; Ogawa T, 2000, NAT MED, V6, P29, DOI 10.1038/71496; ORTH JM, 1990, ANAT REC, V226, P320, DOI 10.1002/ar.1092260308; RUSSO A, 1992, ENVIRON MOL MUTAGEN, V19, P125, DOI 10.1002/em.2850190206; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Sharpe Richard M., 1994, P1363; Shinoda K, 1999, ARCH TOXICOL, V73, P274, DOI 10.1007/s002040050617; SIMPKINS H, 1984, BIOCHIM BIOPHYS ACTA, V783, P293, DOI 10.1016/0167-4781(84)90040-X; SIMPKINS H, 1984, CANCER RES, V44, P613; Sjoblom T, 1998, ENVIRON MOL MUTAGEN, V31, P133, DOI 10.1002/(SICI)1098-2280(1998)31:2<133::AID-EM5>3.0.CO;2-N; Steger K, 1998, HISTOCHEM CELL BIOL, V110, P57, DOI 10.1007/s004180050265; STROHMEYER T, 1991, CANCER RES, V51, P1811; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; Takahama Y, 1999, ONCOGENE, V18, P5943, DOI 10.1038/sj.onc.1203171; vanDisselEmiliani FMF, 1996, ENDOCRINOLOGY, V137, P647, DOI 10.1210/en.137.2.647; Wagle A, 2000, J PHARMACOL EXP THER, V295, P889; Werdien D, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.11.e53; Wilkinson DG, 1992, SITU HYBRIDIZATION P; Yamamoto H, 2000, ONCOGENE, V19, P3805, DOI 10.1038/sj.onc.1203752; YOSHIDA T, 1991, METHOD ENZYMOL, V198, P124; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5	47	22	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					899	908		10.1038/sj.onc.1205135	http://dx.doi.org/10.1038/sj.onc.1205135			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840335				2022-12-17	WOS:000173427100005
J	Carraresi, L; Tripodi, SA; Mulder, LCF; Bertini, S; Nuti, S; Schuerfeld, K; Cintorino, M; Bensi, G; Rossini, M; Mora, M				Carraresi, L; Tripodi, SA; Mulder, LCF; Bertini, S; Nuti, S; Schuerfeld, K; Cintorino, M; Bensi, G; Rossini, M; Mora, M			Thymic hyperplasia and lung carcinomas in a line of mice transgenic for keratin 5-driven HPV16 E6/E7 oncogenes	ONCOGENE			English	Article						human Papillomavirus type 16; E6/E7 oncogenes; transgenic mice; lung carcinomas; thymic hyperplasia	HUMAN-PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; E7 ONCOPROTEIN; BRONCHOPULMONARY CARCINOMAS; EPIDERMAL HYPERPLASIA; E6 ONCOPROTEINS; CDK INHIBITORS; HPV-16 E6; EXPRESSION; PROTEIN	Human Papillomavirus type 16 (HPV-16) is the cause of both benign lesions and ano-genital cancers. In HPV-associated cancers the transforming properties of the expressed viral E6 and E7 proteins have been revealed by a number of different assays. We have generated transgenic mice expressing HPV-16 E6/E7 genes under the control of the murine keratin 5 gene promoter, which should confer cell-type specific expression in the basal cells of squamous stratified epithelia. Transgenic mice developed thymic hyperplasia and lung neoplasia with 100% frequency, the thymus showing a size increase at 2 months and reaching the maximum dimension at 6 months, when lung carcinomas appeared. After this time the size of hyperplastic thymi decreased, while malignant formations invaded the mediastinal area. Hepatic metastasis could be also observed in some of the animals at the autopsy and death invariably occurred around 10 - 11 months of age.	Univ Siena, Dept Physiopathol & Expt Med, I-53100 Siena, Italy; Univ Siena, Inst Pathol Anat & Histol, I-53100 Siena, Italy; Chiron Res Ctr, I-53100 Siena, Italy	University of Siena; University of Siena; Novartis	Rossini, M (corresponding author), Univ Siena, Dept Physiopathol & Expt Med, Via Aldo Moro, I-53100 Siena, Italy.	rossini@unisi.it	TRIPODI, SERGIO ANTONIO/AAK-7569-2021					ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; Bol D, 1998, MOL CARCINOGEN, V21, P2, DOI 10.1002/(SICI)1098-2744(199801)21:1<2::AID-MC2>3.0.CO;2-R; Boyer SN, 1996, CANCER RES, V56, P4620; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clavel CE, 2000, CANCER, V88, P1347, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1347::AID-CNCR10>3.0.CO;2-2; COMERFORD SA, 1995, ONCOGENE, V10, P587; Coussens LM, 1996, AM J PATHOL, V149, P1899; Damak S, 1996, MOL CARCINOGEN, V17, P84, DOI 10.1002/(SICI)1098-2744(199610)17:2<84::AID-MC5>3.0.CO;2-T; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eckert RL, 2000, INT J ONCOL, V16, P853; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gao QS, 1999, MOL CELL BIOL, V19, P733; Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008; GRANA X, 1995, ONCOGENE, V11, P573; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; HARPER JW, 1993, CELL, V75, P805; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Hennig EM, 1999, ACTA ONCOL, V38, P639; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Hirayasu T, 1996, J CLIN PATHOL, V49, P810, DOI 10.1136/jcp.49.10.810; Hogan B., 1986, MANIPULATING MOUSE E; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klug DB, 1998, P NATL ACAD SCI USA, V95, P11822, DOI 10.1073/pnas.95.20.11822; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LEDENT C, 1995, ONCOGENE, V10, P1789; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; MISSERO C, 1993, J CELL BIOL, V121, P1109, DOI 10.1083/jcb.121.5.1109; MOLL R, 1989, VIRCHOWS ARCH B, V58, P129, DOI 10.1007/BF02890064; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; Morris G F, 1998, J La State Med Soc, V150, P179; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Ogawa K, 1996, CARCINOGENESIS, V17, P341, DOI 10.1093/carcin/17.2.341; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rodriguez-Puebla ML, 2000, AM J PATHOL, V157, P1039, DOI 10.1016/S0002-9440(10)64616-0; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; Sampietro G, 2000, APPL IMMUNOHISTO M M, V8, P49, DOI 10.1097/00022744-200003000-00008; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; Sunday ME, 1999, ONCOGENE, V18, P4336, DOI 10.1038/sj.onc.1202810; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	83	22	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2001	20	56					8148	8153		10.1038/sj.onc.1205007	http://dx.doi.org/10.1038/sj.onc.1205007			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781829				2022-12-17	WOS:000172396800013
J	Daury, L; Busson, M; Tourkine, N; Casas, F; Cassar-Malek, I; Wrutniak-Cabello, C; Castellazzi, M; Cabello, G				Daury, L; Busson, M; Tourkine, N; Casas, F; Cassar-Malek, I; Wrutniak-Cabello, C; Castellazzi, M; Cabello, G			Opposing functions of ATF2 and Fos-like transcription factors in e-Jun-mediated myogenin expression and terminal differentiation of avian myoblasts	ONCOGENE			English	Article						Jun; Fos; ATF; myoblasts; differentiation; Myogenin	NEGATIVE REGULATOR; GENE MYF-5; V-JUN; MUSCLE; INDUCTION; AP-1; INACTIVATION; STIMULATION; PROMOTER; ELEMENT	With the aim to identify the oncoprotein partners implicated in the c-Jun myogenic influence, we carried out stable transfection experiments of c-Jun and/or ATF2, Fra2, c-Fos overexpression in avian myoblasts. Before induction of differentiation, c-Jun repressed myoblast withdrawal from the cell cycle, as did a TPA treatment. However, after serum removal, unlike TPA, c-Jun significantly stimulated myoblast differentiation. In search for specific partners involved in this dual influence, we found that a reduction in the amounts of c-Fos and Fra2 and an increase in c-Jun proteins occurred at cell confluence, a situation likely to favor cooperation between c-Jun and ATF2 during terminal differentiation. Whereas c-Fos and Fra2 cooperated with c-Jun to abrogate myoblast withdrawal from the cell cycle and terminal differentiation, ATF2 co-expression potentiated the positive myogenic e-Jun influence. In addition, myogenin expression was a positive target of this cooperation and this regulation occurred through a stimulation of myogenin promoter activity: (1) whereas c-Fos or Fra2 co-expression abrogated c-Jun stimulatory activity on this promoter, ATF2 co-expression potentiated this influence; (2) using a dominant negative ATF2 mutant, we established that c-Jun transcriptional activity required functionality of endogenous ATF2. These data suggest that through this dual myogenic influence due to cooperations with different partners, c-Jun is involved in the control of duration of myoblast proliferation and thereafter of fusion efficiency.	INRA, UMR Differenciat Cellulaire & Croissance, Unite Endocrinol Cellulaire, F-34060 Montpellier 1, France; Ecole Normale Super Lyon, INSERM, Unite Virol Humaine, U412, F-69364 Lyon 07, France	INRAE; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Cabello, G (corresponding author), INRA, UMR Differenciat Cellulaire & Croissance, Unite Endocrinol Cellulaire, 2 Pl Viala, F-34060 Montpellier 1, France.	cabello@ensam.inra.fr	, Cassar-Malek/AAW-6386-2020	, Cassar-Malek/0000-0001-7407-1408; Francois, Casas/0000-0002-5535-8195; Daury, Laetitia/0000-0002-1296-7150				ANDAM H, 2001, ONCOGENE, V20, P2453; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CassarMalek I, 1996, J BIOL CHEM, V271, P11392, DOI 10.1074/jbc.271.19.11392; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Hebrok M, 1997, EXP CELL RES, V232, P295, DOI 10.1006/excr.1997.3541; HILL CS, 1986, J CELL BIOL, V103, P2185, DOI 10.1083/jcb.103.6.2185; HIRAYAMA E, 1995, CELL STRUCT FUNCT, V20, P377, DOI 10.1247/csf.20.377; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; Leppa S, 2001, MOL CELL BIOL, V21, P4369, DOI 10.1128/MCB.21.13.4369-4378.2001; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PARK K, 1992, J BIOL CHEM, V267, P10810; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SNEDECOR GW, 1961, STAT METHODS, P534; SU HY, 1991, ONCOGENE, V6, P1759; SULAKHE PV, 1985, FEBS LETT, V186, P281, DOI 10.1016/0014-5793(85)80725-0; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715	34	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2001	20	55					7998	8008		10.1038/sj.onc.1204967	http://dx.doi.org/10.1038/sj.onc.1204967			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753683				2022-12-17	WOS:000172288700009
J	Han, XS; Stewart, JE; Bellis, SL; Benveniste, EN; Ding, Q; Tachibana, K; Grammer, JR; Gladson, CL				Han, XS; Stewart, JE; Bellis, SL; Benveniste, EN; Ding, Q; Tachibana, K; Grammer, JR; Gladson, CL			TGF-beta 1 up-regulates paxillin protein expression in malignant astrocytoma cells: requirement for a fibronectin substrate	ONCOGENE			English	Article						paxillin; TGF-beta 1; fibronectin; integrin alpha 5 beta 1; astrocytoma; astrocytes; glioma; glioblastoma	INTEGRIN; GENE; VITRONECTIN; ACTIVATION; SENESCENCE; MOLECULES; COMPLEX; DOCK180; KINASE; HIC-5	Cytokines can influence the interactions between members of the integrin cell adhesion receptor family and the extracellular matrix thereby potentially affecting cell function and promoting cell adhesion, growth and migration of malignant astrocytoma tumor cells. As malignant astrocytoma cells synthesize TGF-beta1 in vivo, we analysed the effects of TGF-beta1 on signaling events associated with integrin receptor ligation, focusing on the effects on paxillin, a phosphorylated adaptor protein, that acts as a scaffold for signaling molecules recruited to focal adhesions. TGF-beta1 -stimulation of primary astrocytes and serum-starved U-251MG malignant astrocytoma cells attached to fibronectin induced a substantial increase in the levels of paxillin protein (fivefold increase at 2.0 ng/ml) in a dose- and time-dependent manner compared to the levels observed on plating onto fibronectin in the absence of stimulation. In the astrocytoma cells, this resulted in an increase in the pool of tyrosine-phosphorylated paxillin, although it did not appear to alter the extent of phosphorylation of the paxillin molecules. In contrast, in primary astrocytes the protein levels were upregulated in the absence of a parallel increase in phosphorylation. The TGF-beta1-stimulated increase in paxillin levels required ligation of the fibronectin receptor, as it was not induced when the cells were plated onto vitronectin, collagen or laminin. The increase in the pool of paxillin on TGF-beta1 stimulation of the fibronectin-plated astrocytoma cells was associated with an increase in translation, but was not associated with an increase in the steady-state levels of paxillin mRNA. Stimulation with TGF-beta1 on a fibronectin substrate increased subsequent attachment and spreading of U-251MG cells onto fibronectin and, to a lesser extent, vitronectin, but not collagen. Our results indicate that physiologic levels of TGF-beta1 stimulate the expression of paxillin protein at the level of translation through a process that requires engagement of the fibronectin receptor, and promotes attachment and spreading of malignant astrocytoma cells on fibronectin.	Univ Alabama, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Gladson, CL (corresponding author), Univ Alabama, Dept Pathol, Div Neuropathol, LHRB 567,701 S 19th St, Birmingham, AL 35294 USA.				NCI NIH HHS [CA59958, CA75682] Funding Source: Medline; NINDS NIH HHS [NS34856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075682, R01CA059958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENVENISTE EN, 1991, J BIOL CHEM, V266, P18119; Fujita H, 1998, J BIOL CHEM, V273, P26516, DOI 10.1074/jbc.273.41.26516; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gladson CL, 1999, J NEUROPATH EXP NEUR, V58, P1029, DOI 10.1097/00005072-199910000-00001; GLADSON CL, 1995, J CELL SCI, V108, P947; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kjellman C, 2000, INT J CANCER, V89, P251, DOI 10.1002/1097-0215(20000520)89:3<251::AID-IJC7>3.0.CO;2-5; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Pijuan-Thompson V, 1999, EXP CELL RES, V249, P86, DOI 10.1006/excr.1999.4458; PijuanThompson V, 1997, J BIOL CHEM, V272, P2736, DOI 10.1074/jbc.272.5.2736; Riedy MC, 1999, EXP CELL RES, V251, P194, DOI 10.1006/excr.1999.4573; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Wang DY, 2000, J CELL SCI, V113, P4221; Wang HM, 2001, J CELL PHYSIOL, V187, P188, DOI 10.1002/jcp.1068; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	20	22	24	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7976	7986		10.1038/sj.onc.1204996	http://dx.doi.org/10.1038/sj.onc.1204996			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753680				2022-12-17	WOS:000172288700006
J	Yang, LM; Ostrowski, J; Reczek, P; Brown, P				Yang, LM; Ostrowski, J; Reczek, P; Brown, P			The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGF beta and causing cell cycle arrest	ONCOGENE			English	Article						retinoic acid; cell cycle; cyclin-dependent kinase (CDK); CDK inhibitors and normal breast cells; TGF beta; proliferation	MAMMARY EPITHELIAL-CELLS; PHASE-II TRIAL; CANCER CELLS; CARCINOMA CELLS; 13-CIS-RETINOIC ACID; APOPTOSIS INDUCTION; RAR-ALPHA; EXPRESSION; PROLIFERATION; ACTIVATION	We have previously shown that a retinoic acid receptor (RAR) antagonist BMS453, which does not activate RAR-dependent gene transcription in breast cells, inhibits normal breast cell growth. In this study we have investigated the mechanisms by which this retinoid receptor antagonist inhibits cell growth. Both all traits retinoic acid (atRA) and BMS453 inhibited the proliferation of normal breast cell growth without significantly inducing apoptosis. Both retinoids caused a GI block in the cell cycle with an increase in the proportion of cells in G0/G1 and a decrease in the proportion of cells in S phase. We then investigated the effects of the retinoids on molecules that regulate the G1 to S transition. These studies demonstrated that both atRA and BMS453 induce Rb hypophosphorylation and decrease CDK2 kinase activity. We then studied the effect of the retinoids on the expression of CDK inhibitors. atRA and BMS453 increased total p21 protein levels and CDK2-bound p21 protein, but did not change CDK4-bound p21. These results suggest that atRA and BMS453 increase p21, decrease CDK2 kinase activity, which in turn leads to hypophosphorylation of Rb and GI arrest. Because transforming growth factor beta (TGF beta) has been proposed as a mediator of retinoid-induced growth inhibition, we next investigated whether TGF beta mediates the anti-proliferative effect of atRA and BMS453 in normal breast cells. These studies showed that atRA and BMS453 increased total TGF beta activity by 3-5-fold. However, BMS453 increased active TGF beta activity by 33-fold while atRA increased active TGF beta activity by only threefold. These results suggest that BMS453 treatment induces conversion of latent TGF beta to active TGF beta. To investigate whether this increase in active TGF beta mediates the anti-proliferative effects of these retinolds, a TGF beta -blocking antibody was used in an attempt to prevent retinoid-induced growth inhibition. Results from these experiments showed that the anti-TGF beta antibody prevented the inhibition of cell proliferation induced by BMS453, but did not prevent the inhibition of cell proliferation induced by atRA. 2001 These results demonstrate that BMS453 inhibits breast cell growth predominantly through the induction of active TGF beta, while atRA inhibits growth through other mechanisms. These results suggest that retinoid analogs that increase active TGF beta may be promising agents for the prevention of breast cancer.	Baylor Coll Med, Baylor Breast Ctr, Houston, TX 77030 USA; Bristol Myers Squibb Co, Princeton, NJ USA	Baylor College of Medicine; Bristol-Myers Squibb	Brown, P (corresponding author), Baylor Coll Med, Baylor Breast Ctr, 1 Baylor Plaza,MS600, Houston, TX 77030 USA.			Brown, Powel/0000-0002-3398-163X	NCI NIH HHS [R01CA78480] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; CASSIDY J, 1982, EUR J CANCER CLIN ON, V18, P925, DOI 10.1016/0277-5379(82)90239-5; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Fanjul AN, 1998, CANCER RES, V58, P4607; Gangemi RMR, 1996, ANN NY ACAD SCI, V784, P550, DOI 10.1111/j.1749-6632.1996.tb16279.x; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Imai S, 1997, FEBS LETT, V411, P102, DOI 10.1016/S0014-5793(97)00673-X; Jing YK, 1996, DIFFERENTIATION, V60, P109, DOI 10.1046/j.1432-0436.1996.6020109.x; KIM SJ, 1989, J BIOL CHEM, V264, P402; KOJIMA S, 1993, J CELL PHYSIOL, V155, P323, DOI 10.1002/jcp.1041550213; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Langenfeld J, 1996, ONCOGENE, V13, P1983; LEE JS, 1993, J CLIN ONCOL, V11, P959, DOI 10.1200/JCO.1993.11.5.959; LEE PPH, 1995, ENDOCRINOLOGY, V136, P1707, DOI 10.1210/en.136.4.1707; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; Li XS, 1996, CANCER RES, V56, P5055; Lin F, 2000, CANCER RES, V60, P3271; Liu XJ, 1998, CANCER RES, V58, P4752; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Miller VA, 1996, CLIN CANCER RES, V2, P471; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; Nunes I, 1996, CANCER RES, V56, P495; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; ROBERTS AB, 1984, RETINOIDS, V2, P209; Rocha RL, 1996, J NATL CANCER I, V88, P601, DOI 10.1093/jnci/88.9.601; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Sutton LM, 1997, CANCER CHEMOTH PHARM, V40, P335, DOI 10.1007/s002800050666; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Toma S, 1998, ANTICANCER RES, V18, P935; Toma S, 1997, INT J CANCER, V70, P619, DOI 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6; Toma S, 1998, INT J CANCER, V78, P86, DOI 10.1002/(SICI)1097-0215(19980925)78:1<86::AID-IJC14>3.0.CO;2-3; Yang L, 1999, BREAST CANCER RES TR, V56, P277, DOI 10.1023/A:1006219411078; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Zhang YX, 2000, CANCER RES, V60, P2025; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	45	22	24	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					8025	8035		10.1038/sj.onc.1204911	http://dx.doi.org/10.1038/sj.onc.1204911			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753686				2022-12-17	WOS:000172288700012
J	Kato, M; Takeda, K; Kawamoto, Y; Tsuzuki, T; Dai, Y; Nakayama, S; Toriyama, K; Tamada, Y; Takahashi, M; Nakashima, I				Kato, M; Takeda, K; Kawamoto, Y; Tsuzuki, T; Dai, Y; Nakayama, S; Toriyama, K; Tamada, Y; Takahashi, M; Nakashima, I			RET tyrosine kinase enhances hair growth in association with promotion of melanogenesis	ONCOGENE			English	Article						anagen; kit; melanogenesis; RET	MELANOCYTIC TUMOR-DEVELOPMENT; NEUROTROPHIC FACTOR; MALIGNANT-MELANOMA; TRANSGENIC MICE; C-KIT; CYCLE; FOLLICLE; RECEPTOR; INVOLVEMENT; EXPRESSION	We first demonstrated that c-Ret protein is transiently expressed mainly in the inner and outer root sheaths of hair follicles soon after birth in the skin of normal C57BL/6 and BALB/c mice. A longer-lasting expression of activated RET protein overlapped the c-Ret expression with some preferential expression in the outer root sheath in close association with increase in the number of S-100 protein-containing cells in the area and excess melanogenesis in and around hair bulbs in the skin of RFP-RET-transgenic mice on a C57BL/6 background (RFP-RET/B6). Hair follicles in the skin of the transgenic mice continuously showed histology of the anagen phase, and the recovery period for the hair of the transgenic mice after shaving was shortened. Such growth promotion was not observed in the case of white hairs of RFP-RET-transgenic mice on a BALB/c background. These results suggest that RET works to extend the anagen phase in association with upregulation of melanin production.	Nagoya Univ, Grad Sch Med, Grad Dept Immunol, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Pathol, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Nagoya, Aichi 4668550, Japan; Aichi Med Univ, Dept Dermatol, Nagakute, Aichi 48011, Japan	Nagoya University; Nagoya University; Nagoya University; Aichi Medical University	Nakashima, I (corresponding author), Nagoya Univ, Grad Sch Med, Dept Immunol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 466, Japan.		KATO, Masashi/I-7250-2014; 善之, 川本/GPT-3802-2022; TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020	Takahashi, Masahide/0000-0002-2803-2683; Tsuzuki, Toyonori/0000-0002-4855-4366				Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkareva NV, 2000, AM J PATHOL, V156, P1041, DOI 10.1016/S0002-9440(10)64972-3; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; Hansen LA, 1997, AM J PATHOL, V150, P1959; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; IWAMOTO T, 1992, EXP CELL RES, V200, P410, DOI 10.1016/0014-4827(92)90189-F; Jindo T, 1998, J INVEST DERMATOL, V110, P338, DOI 10.1046/j.1523-1747.1998.00144.x; Kato M, 1998, J INVEST DERMATOL, V111, P640, DOI 10.1046/j.1523-1747.1998.00341.x; Kato M, 1998, ONCOGENE, V17, P1885, DOI 10.1038/sj.onc.1202077; Kato M, 1999, ONCOGENE, V18, P837, DOI 10.1038/sj.onc.1202329; Kato M, 2000, MOL BIOL CELL, V11, P93, DOI 10.1091/mbc.11.1.93; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; ORTONNE JP, 1993, J INVEST DERMATOL, V101, pS82, DOI 10.1111/1523-1747.ep12362884; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Peus D, 1996, DERMATOL CLIN, V14, P559, DOI 10.1016/S0733-8635(05)70384-3; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SLOMINSKI A, 1994, J INVEST DERMATOL, V102, P862, DOI 10.1111/1523-1747.ep12382606; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; Takahashi M, 1999, HUM MUTAT, V13, P331, DOI 10.1002/(SICI)1098-1004(1999)13:4<331::AID-HUMU11>3.3.CO;2-R; TAKAHASHI M, 1993, ONCOGENE, V8, P2925	25	22	24	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7536	7541		10.1038/sj.onc.1204918	http://dx.doi.org/10.1038/sj.onc.1204918			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709725				2022-12-17	WOS:000171976900010
J	Lefort, K; Rouault, JP; Tondereau, L; Magaud, JP; Dore, JF				Lefort, K; Rouault, JP; Tondereau, L; Magaud, JP; Dore, JF			The specific activation of gadd45 following UVB radiation requires the POU family gene product N-oct3 in human melanoma cells	ONCOGENE			English	Article						gadd45; melanoma; UVB; UVC; N-oct3	P53-REGULATED PROTEIN GADD45; TRANSCRIPTION FACTOR-BINDING; DNA-BINDING; THYMIDINE DINUCLEOTIDES; ULTRAVIOLET-RADIATION; IONIZING-RADIATION; CYCLE CHECKPOINT; HUMAN SKIN; DOMAIN; P53	Here we report the specific regulation of gadd45 expression in human melanoma cell lines following UVB radiation. This solar wavelength is likely to be involved in melanoma aetiology. We have previously shown that gadd45 expression is strongly enhanced in a p53-independent manner following UVB irradiation, unlike the other p53 target genes studied. Furthermore, gadd45 is specifically activated in melanocytes since its induction in response to UVB, is not observed in other skin cells such as keratinocytes or fibroblasts. To investigate this particular regulation of gadd45, we analysed the UVB-induced response of different gadd45 promoter regions. Thus, a minimal promoter region of 50 bp length, responsible for gadd45 activation in melanoma cell lines following UVB irradiation, was determined. In electrophoretic mobility shift assays (EMSAs), we showed that this region (-106/-56) of the gadd45 promoter which contains two identical octamers, binds the POU family gene products oct-l and N-oct3. Given the specific expression pattern of N-oct3 in melanocyte, we invalidated the expression of this transcription factor in melanoma cells: such an abrogation of N-oct3 protein expression in melanoma cells impeded gadd45 UVB-response. Thus the response of melanocyte to UVB may use an original and previously undescribed pathway.	Ctr Leon Berard, INSERM U453, F-69373 Lyon 08, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Dore, JF (corresponding author), Ctr Leon Berard, INSERM U453, 28 Rue Laennec, F-69373 Lyon 08, France.							ANGUS J, 1995, ONCOGENE, V11, P691; Atillasoy ES, 1998, AM J PATHOL, V152, P1179; Bae I, 1996, CANCER RES, V56, P840; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CARRIER F, 1994, J BIOL CHEM, V269, P32672; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Graunke DM, 1999, NUCLEIC ACIDS RES, V27, P3881, DOI 10.1093/nar/27.19.3881; Haapajarvi T, 1999, CELL GROWTH DIFFER, V10, P163; HALL PA, 1995, ONCOGENE, V10, P2427; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; JACUBOVICH R, 1985, BRIT J CANCER, V51, P335, DOI 10.1038/bjc.1985.45; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Kallassy M, 1997, CANCER RES, V57, P4731; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; RONAI Z, 1994, ENVIRON MOL MUTAGEN, V23, P157, DOI 10.1002/em.2850230302; ROSFJORD E, 1995, BIOCHEM BIOPH RES CO, V212, P847, DOI 10.1006/bbrc.1995.2046; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETLOW RB, 1989, P NATL ACAD SCI USA, V86, P8922, DOI 10.1073/pnas.86.22.8922; Smith AG, 1998, MELANOMA RES, V8, P2, DOI 10.1097/00008390-199802000-00002; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; STURM RA, 1994, PIGM CELL RES, V7, P235, DOI 10.1111/j.1600-0749.1994.tb00055.x; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Takahashi S, 2001, CANCER RES, V61, P1187; THOMSON JAF, 1993, PIGM CELL RES, V6, P13, DOI 10.1111/j.1600-0749.1993.tb00576.x; VERRIJZER CP, 1992, MOL CELL BIOL, V12, P542, DOI 10.1128/MCB.12.2.542; Vigano MA, 1996, NUCLEIC ACIDS RES, V24, P2112, DOI 10.1093/nar/24.11.2112; Wang SQ, 2001, J AM ACAD DERMATOL, V44, P837, DOI 10.1067/mjd.2001.114594; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Westerdahl J, 2000, BRIT J CANCER, V82, P1593; WOLF P, 1994, J NATL CANCER I, V86, P99, DOI 10.1093/jnci/86.2.99; Xiao G, 2000, CANCER RES, V60, P1711; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; ZHAN QM, 1994, CANCER RES, V54, P2755; Zhao HC, 2000, CANCER RES, V60, P6276	50	22	24	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7375	7385		10.1038/sj.onc.1204923	http://dx.doi.org/10.1038/sj.onc.1204923			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704867				2022-12-17	WOS:000171894200010
J	Wonerow, P; Watson, SP				Wonerow, P; Watson, SP			The transmembrane adapter LAT plays a central role in immune receptor signalling	ONCOGENE			English	Article						LAT; T cell receptor signalling; glycolipid-enriched membrane domains (GEMs); adapters; platelets; signal transduction	T-CELL RECEPTOR; PROTEIN-TYROSINE KINASE; NATURAL-KILLER-CELLS; SRC FAMILY KINASES; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; GAMMA-CHAIN; COLLAGEN RECEPTOR; MEMBRANE DOMAINS; GLYCOPROTEIN-VI	The transmembrane adapter LAT (linker for activation of T cells) plays a central role in signalling by ITAM bearing receptors expressed on T cells, natural killer cells, mast cells and platelets. Receptor engagement leads to the phosphorylation of tyrosine residues present in the intracellular domain of LAT and formation of a multiprotein complex with other adapter molecules and enzymes including Grb2, Gads/SLP-76 and PLC gamma isoforms. These signalling events predominantly take place in glycolipid-enriched membrane domains. The constitutive presence of LAT in GEMs enables its function as the main scaffolding protein for the organization of GEM-localized signalling. The study of LAT-deficient mice and LAT-deficient cell lines further emphasizes the importance of LAT for these signalling cascades but also defines the existence of LAT-independent events downstream of the Syk-family kinase-ITAM complex.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Wonerow, P (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423				Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; AZZONI L, 1992, J EXP MED, V176, P1745, DOI 10.1084/jem.176.6.1745; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; Binstadt BA, 1998, J BIOL CHEM, V273, P27518, DOI 10.1074/jbc.273.42.27518; Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Bonilla FA, 2000, P NATL ACAD SCI USA, V97, P1725, DOI 10.1073/pnas.040543597; Bosselut R, 1999, J EXP MED, V190, P1517, DOI 10.1084/jem.190.10.1517; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brdicka T, 1998, BIOCHEM BIOPH RES CO, V248, P356, DOI 10.1006/bbrc.1998.8857; BUDAY L, 1994, J BIOL CHEM, V269, P9019; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; CHAN AC, 1994, J IMMUNOL, V152, P4758; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Debnath J, 1999, MOL CELL BIOL, V19, P1498; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; Galandrini R, 1996, J EXP MED, V183, P179, DOI 10.1084/jem.183.1.179; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; Goitsuka R, 1998, J IMMUNOL, V161, P5804; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; Honda ZI, 2000, MOL CELL BIOL, V20, P1759, DOI 10.1128/MCB.20.5.1759-1771.2000; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Jevremovic D, 1999, J IMMUNOL, V162, P2453; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JUNE CH, 1990, J IMMUNOL, V144, P1591; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kelly ME, 2000, CURR OPIN IMMUNOL, V12, P267, DOI 10.1016/S0952-7915(00)00086-8; Kimura T, 2001, IMMUNOL LETT, V75, P123, DOI 10.1016/S0165-2478(00)00295-9; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Lindholm CK, 1999, J BIOL CHEM, V274, P28050, DOI 10.1074/jbc.274.39.28050; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Liu YM, 1998, BIOCHEM BIOPH RES CO, V245, P684, DOI 10.1006/bbrc.1998.8329; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Marie-Cardine A, 1999, J EXP MED, V189, P1181, DOI 10.1084/jem.189.8.1181; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Motto DG, 1996, MOL CELL BIOL, V16, P2823; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Okada T, 2000, IMMUNITY, V13, P817, DOI 10.1016/S1074-7613(00)00079-0; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Pivniouk VI, 2000, CURR OPIN IMMUNOL, V12, P173, DOI 10.1016/S0952-7915(99)00068-0; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; Sarkar S, 1998, FEBS LETT, V441, P357, DOI 10.1016/S0014-5793(98)01584-1; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schraven B, 1999, IMMUNOL TODAY, V20, P431, DOI 10.1016/S0167-5699(99)01519-4; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stoica B, 1998, J IMMUNOL, V160, P1059; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; TING AT, 1992, J EXP MED, V176, P1751, DOI 10.1084/jem.176.6.1751; Tomlinson MG, 2000, IMMUNOL TODAY, V21, P584, DOI 10.1016/S0167-5699(00)01716-3; Torgersen KM, 2001, CELL SIGNAL, V13, P213, DOI 10.1016/S0898-6568(01)00131-0; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; Welsh M, 1998, ONCOGENE, V16, P891, DOI 10.1038/sj.onc.1201607; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; WILDE J, 2001, CELL SIGN, V13, P1; Wong J, 2000, J BIOL CHEM, V275, P33116, DOI 10.1074/jbc.M004467200; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yamasaki S, 1996, MOL CELL BIOL, V16, P7151; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	99	22	23	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6273	6283		10.1038/sj.onc.1204770	http://dx.doi.org/10.1038/sj.onc.1204770			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607829				2022-12-17	WOS:000171640600002
J	Lomax, M; Fried, M				Lomax, M; Fried, M			Polyoma virus disrupts ARF signaling to p53	ONCOGENE			English	Article						ARF; MDM2; oncogene co-operation; p53; polyoma virus; polyoma virus T-antigens	T-ANTIGEN; MDM2; PROTEIN; P19(ARF); PRODUCT; PHOSPHORYLATION; TRANSFORMATION; ASSOCIATION; DEGRADATION; INHIBITION	Polyoma virus (Py) differs from other small DNA tumor viruses in not encoding a protein that inactivates p53. The complete Py early region encoding the large T-antigen (PyLT), middle T-antigen (PyMT) and small T-antigen (PyST) will transform primary rodent cells and REF52 cells, but PyMT, the main Py oncogene, by itself will only transform these cells when p53 or ARF is inactivated. We have related Py oncogene cooperation with the effects of the Py T-antigens on the ARF-p53 signaling pathway. PyMT activates an ARF-induced p53-mediated block to cell division explaining the inability of PyMT alone to generate dividing transformed cells. In contrast, in REF52 cells transformed by the whole Py early region (PyREF52), ARF is upregulated but p53 is not activated. Thus PyLT and/or PyST negates the PyMT-induced ARF-mediated block to cell division by disrupting the signaling pathway from ARF to p53. Although there is no detectable interaction or co-localization of endogenous ARF (nucleoli) and MDM2 (nucleoplasm) in PyREF52 cells, expression of transfected ectopic ARF results in an MDM2/ARF interaction and sequestration of MDM2 into the nucleoli. Sequestration of MDM2 by ARF in the nucleoli is not essential for a p53 response in REF52 cells as activation of Raf in REF52Raf-ER cells results in an ARF-induced p53-mediated cell cycle block in the absence of a detectable ARF-MDM2 interaction. Py may provide new insights into the cellular ARF-p53 signaling pathway.	Imperial Canc Res Fund, London WC2A 3PX, England; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	Cancer Research UK; University of California System; University of California San Francisco	Fried, M (corresponding author), Imperial Canc Res Fund, Lincolns Inn Fields,POB 123, London WC2A 3PX, England.							CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; CUZIN F, 1984, BIOCHIM BIOPHYS ACTA, V781, P193, DOI 10.1016/0167-4781(84)90084-8; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dilworth S M, 1990, Semin Cancer Biol, V1, P407; DURO D, 1995, ONCOGENE, V11, P21; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kannan K, 2000, INT J ONCOL, V16, P585; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MANSUR CP, 1995, ONCOGENE, V10, P457; MAO L, 1995, CANCER RES, V55, P2995; Mayo LD, 1997, CANCER RES, V57, P5013; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Mor O, 1997, ONCOGENE, V15, P3113, DOI 10.1038/sj.onc.1201549; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	38	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					4951	4960		10.1038/sj.onc.1204717	http://dx.doi.org/10.1038/sj.onc.1204717			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526480				2022-12-17	WOS:000170439800005
J	Dhar, M; Taneja, R				Dhar, M; Taneja, R			Cross-regulatory interaction between Stra13 and USF results in functional antagonism	ONCOGENE			English	Article						yeast two hybrid; basic helix-loop-helix factors; interaction; transcriptional activity; DNA-binding	LOOP-HELIX PROTEINS; MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR; UPSTREAM ELEMENT; GENE; FAMILY; BINDING; ACTIVATION; REPRESSOR; ENHANCER	Transcription factors belonging to the basic helix-loop-helix (bHLH) family are critical regulators of cellular proliferation and differentiation. The functional activity of these proteins can be regulated by heterodimerization through the HLH domain, as a result of formation of functional or non-functional heterodimers. The presence of a leucine zipper in bHLH-leucine zipper (bHLHZip) proteins, however, prevents such heterodimeric interactions via the HLH domain between bHLH and bHLHZip proteins. To identify cellular proteins that directly interact with and modulate transcriptional repression mediated by the bHLH protein Stra13, we carried out a yeast two hybrid screen. The bHLHZip protein USF (Upstream Stimulatory factor) was identified as a Stra13 interacting protein. We demonstrate a direct interaction between Stra13 and USF that is dependent upon the C-terminal repression domain of Stra13 and the DNA-binding domain of USF. Stra13 and USF also colocalize and functionally interact in mammalian cells. Co-expression of USF abrogates Stra13-mediated repression of target genes and conversely, Stra13 inhibits DNA-binding and USF-mediated transactivation. Taken together, our data demonstrate that Stra13 and USF interact physically and functionally, and identify a novel mode of cross regulatory interaction between members of the bHLH and bHLHZip families that abrogates their functional activity.	Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Taneja, R (corresponding author), Mt Sinai Sch Med, Dept Biochem & Mol Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA.		Taneja, Reshma/F-9658-2014	Taneja, Reshma/0000-0002-2151-2094; Reshma, Taneja/0000-0001-6214-6177				Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; Dang CV, 1999, MOL CELL BIOL, V19, P1; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; James P, 1996, GENETICS, V144, P1425; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; Sirito Mario, 1992, Gene Expression, V2, P231; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Wallin JJ, 1999, J BIOL CHEM, V274, P15959, DOI 10.1074/jbc.274.22.15959	25	22	22	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4750	4756		10.1038/sj.onc.1204637	http://dx.doi.org/10.1038/sj.onc.1204637			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498797				2022-12-17	WOS:000170208600015
J	Rodier, A; Rochard, P; Berthet, C; Rouault, JP; Casas, F; Daury, L; Busson, M; Magaud, JP; Wrutniak-Cabello, C; Cabello, G				Rodier, A; Rochard, P; Berthet, C; Rouault, JP; Casas, F; Daury, L; Busson, M; Magaud, JP; Wrutniak-Cabello, C; Cabello, G			Identification of functional domains involved in BTG1 cell localization	ONCOGENE			English	Article						BTG1; NLS; NES; myoblast; cell localization	TRANSCRIPTIONAL REGULATORY COMPLEX; NUCLEAR EXPORT SIGNAL; ARGININE N-METHYLTRANSFERASE; MOLECULAR-CLONING; MESSENGER-RNA; PROTEIN BTG1; LEPTOMYCIN-B; GENE; CRM1; TRANSLOCATION	We have previously shown that BTG1 stimulates myoblast differentiation, In addition, this protein displays a major nuclear localization in confluent myoblasts, decreasing during the early steps of differentiation, and is essentially detected in the cytoplasm of mature myotubes. To identify the domains involved in the cellular trafficking of BTG1, we observed the localization of several BTG1 sequences fused to beta Galactosidase. The highly conserved B box among all members of the BTG family induces a significant nuclear localization of the beta Gal moiety, enhanced by presence of the BTG1 carboxy-terminal sequence. In addition, a functional Nuclear Export Signal (NES) overlaps the B box. Moreover, presence of the first 43 NH2-terminal amino acids reduced the nuclear localization of each chimeric protein tested. Last, the BTG1 amino-terminal domain hears an LxxLL, motif favouring nuclear accumulation, and another region encompassing the A box inhibiting nuclear localization. In contrast to a BTG1 mutant exclusively localized in the cytoplasm, transient expression of a mutant displaying a nuclear Localization enhanced myoblasts withdrawal from the cell cycle and terminal differentiation, thus mimicking the myogenic influence of BTG1, In conclusion, several regions of BTG1 are implicated in its cellular localization, and BTG1 myogenic activity is induced at the nuclear level.	Univ Montpellier 2, ENSAM, INRA,Unite Endocrinol Cellulaire, UMR Differenciat Cellulaire & Croissance, F-34060 Montpellier 1, France; Ctr Leon Berard, INSERM, U453, F-69373 Lyon, France	Arts et Metiers Institute of Technology; INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Cabello, G (corresponding author), Univ Montpellier 2, ENSAM, INRA,Unite Endocrinol Cellulaire, UMR Differenciat Cellulaire & Croissance, 2 Pl Viala, F-34060 Montpellier 1, France.		berthet, cyril/T-4842-2017	berthet, cyril/0000-0003-3166-3141; Francois, Casas/0000-0002-5535-8195; Daury, Laetitia/0000-0002-1296-7150				ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; Bogdan JA, 1998, BIOCHEM J, V336, P471, DOI 10.1042/bj3360471; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen PJ, 2000, DEV BIOL, V217, P77, DOI 10.1006/dbio.1999.9521; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; MARCHAL S, 1993, BIOL CELL, V78, P191, DOI 10.1016/0248-4900(93)90129-3; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; Matsuda S, 1996, ONCOGENE, V12, P705; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; RAJPUROHIT R, 1994, J BIOL CHEM, V269, P1075; RIMOKH R, 1991, GENE CHROMOSOME CANC, V3, P24, DOI 10.1002/gcc.2870030106; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Saka Y, 2000, MECH DEVELOP, V93, P27, DOI 10.1016/S0925-4773(00)00260-4; Snedecor G.W., 1961, STAT METHODS; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	41	22	26	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2691	2703		10.1038/sj.onc.1204398	http://dx.doi.org/10.1038/sj.onc.1204398			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420681				2022-12-17	WOS:000168652600010
J	Okan, E; Drewett, V; Shaw, PE; Jones, P				Okan, E; Drewett, V; Shaw, PE; Jones, P			The small-GTPase RalA activates transcription of the urokinase plasminogen activator receptor (uPAR) gene via an AP1-dependent mechanism	ONCOGENE			English	Article						RalA; c-Src; c-Jun; ATF2; uPAR; Ras	GDP DISSOCIATION STIMULATOR; C-FOS PROMOTER; SIGNALING PATHWAY; PROTEIN-KINASE; CELLULAR-TRANSFORMATION; HA-RAS; CELLS; FAMILY; JUN; PHOSPHORYLATION	The urokinase plasminogen activator receptor (uPAR) focuses extracellular protease activity to the cell surface, modulates cell adhesion and activates intracellular signal transduction pathways. In a range of cancers uPAR expression often has a negative correlation with prognosis, Here we show that uPAR transcription is stimulated by V12 H-Ras, the effector loop mutant V12 H-Ras G37 and constitutively-active RalA 72L, RalA-dependent transcription required the presence of the ATF2-like AP1-site at -70 bp and the c-Jun binding motif at -184 bp in the uPAR promoter. Consistent with this, both Ga14-c-Jun- and Ga14-ATF2-fusion proteins were activated by RalA signalling through phosphorylation of their activation domains at Ser63 and Ser73 of c-Jun or Thr69 and Thr71 of ATF2, A transdominant inhibitory mutant of c-Jun N-terminal kinase (JNK) failed to inhibit uPAR transcription demonstrating that JNK activation is not a prerequisite for RalA-dependent uPAR transcription, A dominant negative inhibitor of c-Src effectively inhibited RalA-dependent uPAR transcription identifying it as a downstream effector in the RalA signalling pathway. These data provide evidence for the existence of a novel signalling pathway that links RalA to the activation of uPAR transcription via a c-Src intermediate and activation of AP1.	Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham	Jones, P (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.			SHAW, Peter/0000-0002-2598-4283				Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Allgayer H, 1999, BRIT J CANCER, V80, P1884, DOI 10.1038/sj.bjc.6690616; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOS JL, 1989, CANCER RES, V49, P4682; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; de Bruyn KMT, 2000, J BIOL CHEM, V275, P29761, DOI 10.1074/jbc.M001160200; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JANKUN J, 1991, CANCER RES, V51, P1221; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kindzelskii AL, 1997, BIOPHYS J, V73, P1777, DOI 10.1016/S0006-3495(97)78208-0; Kindzelskii AL, 1996, J IMMUNOL, V156, P297; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; Koshelnick Y, 1999, THROMB HAEMOSTASIS, V82, P305, DOI 10.1055/s-0037-1615847; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Muller SM, 2000, BIOCHEM BIOPH RES CO, V270, P892, DOI 10.1006/bbrc.2000.2531; Murai H, 1997, J BIOL CHEM, V272, P10483; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Xue W, 1997, CANCER RES, V57, P1682; Yamamoto T, 1999, J BIOCHEM-TOKYO, V126, P799, DOI 10.1093/oxfordjournals.jbchem.a022519; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586	57	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1816	1824		10.1038/sj.onc.1204260	http://dx.doi.org/10.1038/sj.onc.1204260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313929				2022-12-17	WOS:000167908400002
J	Olsen, RJ; Hinrichs, SH				Olsen, RJ; Hinrichs, SH			Phosphorylation of the EWS IQ domain regulates transcriptional activity of the EWS/ATF1 and EWS/FLI1 fusion proteins	ONCOGENE			English	Article						sarcoma; fusion protein; phosphorylation; IQ domain; EWS/ATF1; EWS/FLI1	CLEAR-CELL-SARCOMA; DNA-BINDING; CHIMERIC TRANSCRIPTS; MALIGNANT-MELANOMA; KINASE-C; TRANSLOCATION; INHIBITION; REQUIRES; TRANSACTIVATION; EWS-FLI-1	Specific chromosomal translocations are commonly present in mesenchymal tumors and frequently involve genes encoding transcription factors, The combination of different domains from unrelated genes results in chimeric proteins belie, ed to play a key role in the neoplastic process. The EWS/ATF1 and EWS/FLI1 fusion proteins associated with Clear Cell Sarcoma and Ewing's Sarcoma, respectively, were utilized to study the comparative effect of the EWS component on two different DNA binding partners. A potential regulatory site within the EWS IQ domain at serine266 was identified, and studies were performed to demonstrate that EWS is phosphorylated in cells and phosphorylation of serine266 regulates transcriptional activity. Mutational analysis showed that elimination of phosphorylation significantly reduced DNA binding activity by EMSA and reporter activation in luciferase assays, whereas phosphorylation mimicry resulted in a partial restoration to wild-type levels. Phosphorylation was also observed to mediate cellular compartmentalization. These studies confirm that IQ domain phosphorylation regulates the transcriptional activity of exogenous EWS/ATF1 and EWS/FLI1 and suggests that post-translational modifications may potentiate the neoplastic behavior of fusion proteins in general. Since the IQ domain is incorporated into only a subset of fusion transcripts, these findings may provide insight into the molecular mechanism underlying clinical heterogeneity observed in Ewing's sarcoma.	Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 69198 USA	University of Nebraska System; University of Nebraska Medical Center	Hinrichs, SH (corresponding author), Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 69198 USA.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bosilevac JM, 1998, J BIOL CHEM, V273, P16874, DOI 10.1074/jbc.273.27.16874; Bosilevac JM, 1999, J BIOL CHEM, V274, P34811, DOI 10.1074/jbc.274.49.34811; BRIDGE JA, 1991, CANCER GENET CYTOGEN, V52, P101, DOI 10.1016/0165-4608(91)90059-4; BRIDGE JA, 1990, AM J CLIN PATHOL, V93, P26, DOI 10.1093/ajcp/93.1.26; Bridge Julia A., 1996, Current Opinion in Oncology, V8, P284; Caponigro F, 1997, ANTI-CANCER DRUG, V8, P26, DOI 10.1097/00001813-199701000-00003; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Dohjima T, 2000, BRIT J CANCER, V82, P16, DOI 10.1054/bjoc.1998.0870; FONTES JD, 1993, J VIROL, V67, P4436, DOI 10.1128/JVI.67.7.4436-4441.1993; Fujimura Y, 1996, ONCOGENE, V12, P159; GILCHRIST C, 1995, J BIOCH SCI, V3, P96; Gilchrist CA, 1995, ANTIBODY IMMUNOCONJ, V8, P281; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Li KKC, 1998, ONCOGENE, V16, P1325, DOI 10.1038/sj.onc.1201649; Lin PP, 1999, CANCER RES, V59, P1428; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; ORTEN DJ, 1994, J BIOL CHEM, V269, P32254; Pan S, 1998, ONCOGENE, V16, P1625, DOI 10.1038/sj.onc.1201671; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245; ZOUBEK A, 1994, BRIT J CANCER, V70, P908, DOI 10.1038/bjc.1994.419	32	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 29	2001	20	14					1756	1764		10.1038/sj.onc.1204268	http://dx.doi.org/10.1038/sj.onc.1204268			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313922				2022-12-17	WOS:000167750900008
J	Iwai, N; Kitajima, K; Sakai, K; Kimura, T; Nakano, T				Iwai, N; Kitajima, K; Sakai, K; Kimura, T; Nakano, T			Alteration of cell adhesion and cell cycle properties of ES cells by an inducible dominant interfering Myb mutant	ONCOGENE			English	Article						ES cells; cell adhesion; B-Myb	BETA-1 INTEGRIN GENE; EMBRYONIC STEM-CELLS; B-MYB; C-MYB; HEMATOPOIETIC PROGENITORS; S-PHASE; V-MYB; A-MYB; EXPRESSION; DIFFERENTIATION	The Myb transcription factors, c-Myb, A-Myb, and B-Myb, regulate cell differentiation and/or proliferation. To investigate the role of B-Myb in embryogenesis, we introduced an inducible dominant interfering Myb protein (MERT) into embryonic stem (ES) cells, which express B-Myb as an exclusive member of Myb family. Disruption of normal B-Myb function by the conditional activation of MERT caused a drastic morphological alteration of ES cells and G(1)-S cell cycle arrest. The inhibition of B-Myb function by MERT dissociated tightly packed ES cell colonies into dispersed single cells that subsequently detached from the culture dish. Cell adhesion analyses revealed that suppression of B-Myb function reduced the adhesion with extracellular matrix proteins, such as laminin, collagen, and fibronectin, This reduction was presumably due to decreased cell surface expression of beta1 integrin, Embryoid body formation was also severely retarded by the activation of MERT, This impairment was attributed to reduced expression of E-cadherin, which functions as a homophilic intercellular adhesion molecule. Simultaneously, blocking B-Myb function did not alter the expression of differentiation markers. Our data indicate that B-Myb plays important roles in regulating cell adhesion and cell cycle progression. These results are well consistent with the recent report on the phenotype of B-Myb null mice and show that the regulation of cell adhesion is an important B-Myb function that has not yet been assumed.	Osaka Univ, Microbial Dis Res Inst, Dept Mol Cell Biol, Osaka 5650871, Japan	Osaka University	Nakano, T (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Mol Cell Biol, Yamadaoka 3-1, Osaka 5650871, Japan.			Kimura, Tohru/0000-0001-9227-0996				ARSURA M, 1992, BLOOD, V79, P2708; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FRAMPTON J, 1995, EMBO J, V14, P2866, DOI 10.1002/j.1460-2075.1995.tb07286.x; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; JOYNER AL, 1993, IRL PRESS, V142, P1121; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; Kume A, 1999, STEM CELLS, V17, P226, DOI 10.1002/stem.170226; Larue L, 1996, DEVELOPMENT, V122, P3185; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; Lipsick JS, 1996, ONCOGENE, V13, P223; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu ZJ, 1998, BLOOD, V92, P4700; Lyon JJ, 1996, GENE, V182, P123, DOI 10.1016/S0378-1119(96)00531-8; Manabe R, 1999, J BIOL CHEM, V274, P5919, DOI 10.1074/jbc.274.9.5919; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sitzmann J, 1996, ONCOGENE, V12, P1889; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; White JR, 2000, ONCOGENE, V19, P1196, DOI 10.1038/sj.onc.1203394; WILES MV, 1993, METHOD ENZYMOL, V225, P900; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	41	22	22	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1425	1434		10.1038/sj.onc.1204236	http://dx.doi.org/10.1038/sj.onc.1204236			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313886				2022-12-17	WOS:000167595200003
J	Alberghina, L; Porro, D; Cazzador, L				Alberghina, L; Porro, D; Cazzador, L			Towards a blueprint of the cell cycle	ONCOGENE			English	Article						cell cycle; CDK; CKI; cyclin; budding yeast; cancer	YEAST SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; G1 CYCLINS; FLOW-CYTOMETRY; G2 CYCLINS; GROWTH; G(1); PROGRESSION; PATHWAY; PHASE	The understanding of the organisation of cell cycle events is of utmost importance. to devise effective therapeutic strategies for cancer, In this article we gather evidences from the literature in support of a system model of the cell cycle, in which a growth-sensitive threshold controls entry into S phase and the sequential activation of cyclin-dependent kinases, The cycle is terminated by an End function, that comprises events from the onset of mitosis to cell division and that may also be modulated by the increase of cell size, This blueprint allows quantitative predictions by computer simulations of steady and transitory states. In fact, we show that the proposed control system applies to budding yeast populations during nutritional shift-up and following hyperactivation of the cAMP signalling pathway, Besides the growth-sensitive control system it is shown to apply to mammalian cells both in the exit from quiescence and in active proliferation, The putative molecular determinants that set the threshold controlling S phase entry are consistently altered in cancer cells, Finally, we discuss an input/output analysis based on the simulated behaviour derived from the blueprint as a new tool to investigate the road to cancer.	Univ Milan, Biocca, Dept Biosci & Biotechnol, I-20126 Milan, Italy; Natl Res Council, Inst Syst Sci & Biomed Engn, I-35127 Padua, Italy	University of Milan	Alberghina, L (corresponding author), Univ Milan, Biocca, Dept Biosci & Biotechnol, Pzza Sci 2, I-20126 Milan, Italy.			Alberghina, Lilia/0000-0003-1694-931X; PORRO, DANILO/0000-0001-5723-3700				Alberghina L, 1998, J BACTERIOL, V180, P3864, DOI 10.1128/JB.180.15.3864-3872.1998; ALBERGHINA L, 1977, J THEOR BIOL, V69, P633, DOI 10.1016/0022-5193(77)90372-1; ALBERGHINA L, 1983, BIOSYSTEMS, V16, P297, DOI 10.1016/0303-2647(83)90012-6; ALBERGHINA L, 1993, YEAST, V9, P815, DOI 10.1002/yea.320090802; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Anghileri P, 1999, EXP CELL RES, V250, P510, DOI 10.1006/excr.1999.4531; BARONI MD, 1992, EXP CELL RES, V201, P299, DOI 10.1016/0014-4827(92)90277-F; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; Baserga R., 1976, MULTIPLICATION DIVIS; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Breeden LL, 2000, CURR BIOL, V10, pR586, DOI 10.1016/S0960-9822(00)00634-5; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; COOPER S, 1979, NATURE, V280, P17, DOI 10.1038/280017a0; Futcher B, 1996, YEAST, V12, P1635; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUTCHISON C, 1995, CELL CYCLE CONTROL; Jeoung DI, 1998, MOL CELL BIOL, V18, P433, DOI 10.1128/MCB.18.1.433; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; MARIANI L, 1986, IEE PROC-D, V133, P210, DOI 10.1049/ip-d.1986.0035; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; OConnor PM, 1997, CANCER SURV, V29, P151; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; Palsson BO, 1997, NAT BIOTECHNOL, V15, P3, DOI 10.1038/nbt0197-3; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOMPAYRAC L, 1973, NATURE-NEW BIOL, V241, P133, DOI 10.1038/newbio241133a0; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; Tanaka S, 1996, GENES CELLS, V1, P905, DOI 10.1046/j.1365-2443.1996.d01-213.x; THEVELEIN JM, 1991, MOL MICROBIOL, V5, P1301, DOI 10.1111/j.1365-2958.1991.tb00776.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYSON CB, 1979, J BACTERIOL, V138, P92, DOI 10.1128/JB.138.1.92-98.1979; VANONI M, 1983, J BACTERIOL, V156, P1282, DOI 10.1128/JB.156.3.1282-1291.1983; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZETTERBERG A, 1995, CELL CYCLE CONTROL	44	22	22	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1128	1134		10.1038/sj.onc.1204263	http://dx.doi.org/10.1038/sj.onc.1204263			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314050				2022-12-17	WOS:000167232100013
J	Kumar, A; Jasmin, A; Eby, MT; Chaudhary, PM				Kumar, A; Jasmin, A; Eby, MT; Chaudhary, PM			Cytotoxicity of tumor necrosis factor related apoptosis-inducing ligand towards Ewing's sarcoma cell lines	ONCOGENE			English	Article						Ewing's sarcoma; TRAIL; Apo2L; apoptosis; MRIT; NF-kappa B	NF-KAPPA-B; L929 CELLS; TRAIL; DEATH; ACTIVATION; SENSITIVITY; INHIBITION; RECEPTOR; PATHWAY; FAMILY	Death ligands of the Tumor Necrosis Factor (TNF) family are known to induce apoptosis upon binding to their cognate receptors. However, the clinical utility of these cytokines as anticancer agents has been limited due to unacceptable toxicity. TRAIL is a recently isolated death ligand that possesses selective anti-tumor activity against a number of cancer cell lines without significant systemic toxicity. In this report we present evidence that cell lines derived from Ewing's Sarcoma (ES) are uniformly sensitive to TRAIL-mediated apoptosis. Furthermore, unlike TNF-alpha, treatment with TRAIL fails to induce the anti-apoptotic and pro-inflammatory NF-kappaB pathway in the ES cell lines. Our results suggest that TRAIL may prove to be a useful agent for the treatment of Ewing's sarcoma and related peripheral neuroectodermal tumors.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Kumar, Arvind/B-6094-2009; Chaudhary, Preet/E-1970-2018					Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Griffith TS, 1998, J IMMUNOL, V161, P2833; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HENGERER B, 1996, PROMEGA NOTES, V58, P40; Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Leverkus M, 2000, CANCER RES, V60, P553; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386	18	22	22	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					1010	1014		10.1038/sj.onc.1204154	http://dx.doi.org/10.1038/sj.onc.1204154			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314037				2022-12-17	WOS:000167097000013
J	Inagaki-Ohara, K; Yada, S; Takamura, N; Reaves, M; Yu, XH; Liu, ER; Rooney, I; Nicholas, S; Castro, A; Ware, CF; Green, DR; Lin, T				Inagaki-Ohara, K; Yada, S; Takamura, N; Reaves, M; Yu, XH; Liu, ER; Rooney, I; Nicholas, S; Castro, A; Ware, CF; Green, DR; Lin, T			p53-dependent radiation-induced crypt intestinal epithelial cells apoptosis is mediated in part through TNF-TNFR1 system	ONCOGENE			English	Article						apoptosis; intestinal epithelial cells; p53; TNF	NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; FAS LIGAND EXPRESSION; VERSUS-HOST DISEASE; IN-VIVO; INTRAEPITHELIAL LYMPHOCYTES; GASTROINTESTINAL-TRACT; IONIZING-RADIATION; GAMMA-IRRADIATION; DNA DAMAGE	Radiation induces apoptosis of crypt intestinal epithelial cells (IEC) through a pathway that is largely dependent on p53. However, exactly how p53 mediates IEC apoptosis is unclear, Studies irt vitro suggest that one mechanism by which p53 mediates apoptosis is through its ability to transactivate members of the TNF receptor family of (Death Receptors', Here, we examined the role of one of its member, TNF receptor type 1 (TNFR1), in an in viva model of p53-dependent radiation-induced LEC apoptosis, We demonstrate that mice genetically engineered to be deficient in TNF receptor type 1 (TNFR1(-/-)) and mice injected with TNFR1-fusion chimeric protein (TNFR1-Fc; a competitive inhibitor of TNFR1) were partially protected (30-40%) from p53-dependent radiation-induced IEC apoptosis, However, we found no evidence to support the possibility p53 transcriptionally regulates the expression of TNFR1 nor increases the susceptibility of TEC to TNF-mediated apoptosis, Interestingly, we found that injection of TNF readily induced LEC apoptosis and that radiation induced a p53-dependent increase in the intestinal level of TNF. Furthermore, injection of a neutralizing anti-TNF mAb reduced p53-dependent radiation-induced IEC apoptosis by approximately 60%. Overall, these results suggest that p53-dependent radiation-induced IEC apoptosis is mediated in part through ability of p53 to regulate TNF, which subsequently induces IEC apoptosis through TNFR1.	Northwestern Univ, Sch Med, Dept Med, Gastroenterol Sect, Chicago, IL 60611 USA; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; La Jolla Inst Allergy & Immunol, Div Mol Immunol, San Diego, CA 92121 USA	Northwestern University; La Jolla Institute for Immunology; La Jolla Institute for Immunology	Lin, T (corresponding author), Northwestern Univ, Sch Med, Dept Med, Gastroenterol Sect, Chicago, IL 60611 USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NCI NIH HHS [CA69381] Funding Source: Medline; NIAID NIH HHS [AI 44828] Funding Source: Medline; NIDDK NIH HHS [DK02445, DK56605-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK056605, K08DK002445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; GALLAND RB, 1987, BRIT J SURG, V74, P742, DOI 10.1002/bjs.1800740833; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; Higgins LM, 1999, J IMMUNOL, V162, P486; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; InagakiOhara K, 1997, EUR J IMMUNOL, V27, P2885, DOI 10.1002/eji.1830271121; IWAMOTO KS, 1994, RADIAT RES, V139, P103, DOI 10.2307/3578739; KASTAN MB, 1991, CANCER RES, V51, P6304; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; Lin TS, 1998, J CLIN INVEST, V101, P570, DOI 10.1172/JCI896; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Medvedev AE, 1996, J BIOL CHEM, V271, P9778, DOI 10.1074/jbc.271.16.9778; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MERRITT AJ, 1994, CANCER RES, V54, P614; MIYASHITA T, 1995, CELL, V80, P293; NOVAK JM, 1979, J CLIN GASTROENTEROL, V1, P9, DOI 10.1097/00004836-197903000-00003; Piguet PF, 1998, EUR J IMMUNOL, V28, P3499, DOI 10.1002/(SICI)1521-4141(199811)28:11<3499::AID-IMMU3499>3.0.CO;2-Q; PIGUET PF, 1987, J EXP MED, V166, P1280, DOI 10.1084/jem.166.5.1280; POTTEN CS, 1994, INT J RADIAT BIOL, V65, P71, DOI 10.1080/09553009414550101; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sheikh MS, 1998, CANCER RES, V58, P1593; Shiraishi M, 1998, WORLD J SURG, V22, P491, DOI 10.1007/s002689900422; VAN AD, 1996, SCIENCE, V274, P787; WILLIAMS RO, 1994, P NATL ACAD SCI USA, V91, P2762, DOI 10.1073/pnas.91.7.2762; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	38	22	25	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					812	818		10.1038/sj.onc.1204172	http://dx.doi.org/10.1038/sj.onc.1204172			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314015				2022-12-17	WOS:000166924400004
J	Cohen, SB; Waha, A; Gelman, IH; Vogt, PK				Cohen, SB; Waha, A; Gelman, IH; Vogt, PK			Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts	ONCOGENE			English	Article						oncogenic transformation; differential gene expression; DNA micro-array; tumor suppressor	KINASE-C SUBSTRATE; PROTEIN-KINASE; RETROVIRAL VECTORS; GENE-TRANSFER; EMBRYO CELLS; ACTIVATION; IDENTIFICATION; FOS; SRC; MYC	Line 10T1/2 mouse fibroblast overexpressing the v-Jun oncoprotein mere morphologically altered, grew into multilayered foci in culture and formed colonies when suspended in agar, The growth rate of the v-Jun-transformed 10T1/2 cells was not changed significantly from that of the untransformed parental cells, but the saturation density of the transformed cultures exceeded that of normal controls by a factor of 2, mRNA extracted from v-Jun-transformed 10T1/2 cells was analysed for differential gene expression with DNA micro-array technology. One of the targets downregulated by v-Jun was identified as SSeCKS (Src-suppressed C kinase substrate). Re-expression of SSeCKS in v-Jun-transformed fibroblasts reversed the transformed phenotype of the cells. Their ability to form foci was reduced to background levels, the number and size of agar colonies was lowered by a factor of 10 and the saturation density was significantly diminished. However, expression of SSeCKS had little effect on the morphology of v-Jun-transformed 10T1/2 cells. These data suggest that the SSeCKS protein has growth-attenuating properties. Down-regulation of SSeCKS may be essential for Jun-induced transformation.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Gen Probe Inc, San Diego, CA 92121 USA	Scripps Research Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA42564] Funding Source: Medline; NIDDK NIH HHS [5 T23 DK 07022] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007022] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Alizadeh AA, 2000, CURR OPIN IMMUNOL, V12, P219, DOI 10.1016/S0952-7915(99)00078-3; ALT M, 1993, ONCOGENE, V8, P1421; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P; COLLEDGE WH, 1989, ONCOGENE, V4, P753; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; GRODEN J, 1995, CANCER RES, V55, P1531; Hadman M, 1996, ONCOGENE, V12, P135; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; MORGAN IM, 1994, ONCOGENE, V9, P2793; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; NISHIMURA T, 1988, ONCOGENE, V3, P659; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; Xu JC, 2000, CANCER RES, V60, P1677; ZHANG M, 1995, CANCER RES, V55, P2537	39	22	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					141	146		10.1038/sj.onc.1204077	http://dx.doi.org/10.1038/sj.onc.1204077			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313943				2022-12-17	WOS:000166410900001
J	Blair, DG; Athanasiou, M				Blair, DG; Athanasiou, M			Ets and retroviruses - transduction and activation of members of the Ets oncogene family in viral oncogenesis	ONCOGENE			English	Review						ETS; retrovirus; oncogenesis; E26; F-MuLV; SFFV	MURINE LEUKEMIA-VIRUS; NON-T-CELL; AVIAN ERYTHROBLASTOSIS VIRUS; CHICKEN ERYTHROID-CELLS; V-ETS; TRANSCRIPTION FACTOR; DNA-BINDING; PROVIRAL INTEGRATION; FRIEND-VIRUS; PUTATIVE ONCOGENE	Studies of retroviral-induced oncogenesis in animal systems led to the initial discovery of viral oncogenes and their cellular homologs, and provided critical insights into their role in the neoplastic process. V-ets, the founding member of the ETS oncogene family, was originally identified as part of the fusion oncogene encoded by the avian acute leukemia virus E26 and subsequent analysis of virus induced leukemias led to the initial isolation of two other members of the ETS gene family. PU.1 was identified as a target of insertional activation in the majority of tumors induced by the murine Spleen Focus Forming virus (SFFV), while fli-1 proved to be the target of Friend murine leukemia virus (F-MuLV) in F-MuLV induced erythroleukemia, as well as that of the 10A1 and Graffi viruses. The common features of the erythroid and myeloid diseases induced by these viruses provided the initial demonstration that these and other members of the ETS family play important roles in hematopoietic development as well as disease. This review provides an overview of the role of ETS genes in retrovirally induced neoplasia, their possible mechanisms of action, and how these viral studies relate to current knowledge of the functions of these genes in hematopoiesis.	NCI, Frederick Canc Res & Dev Ctr, Div Basic Sci, Res Lab,Oncogene Mechanisms Sect, Frederick, MD 21702 USA; SAIC, Intramural Res Support Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick	Blair, DG (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Div Basic Sci, Res Lab,Oncogene Mechanisms Sect, Bld 469,Room 102, Frederick, MD 21702 USA.				NCI NIH HHS [N01-CO56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Athanasiou M, 1996, ONCOGENE, V12, P337; Athanasiou M, 2000, LEUKEMIA, V14, P439, DOI 10.1038/sj.leu.2401689; Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; AURIGEMMA RE, 1994, MOL BIOL HAEMATOPOIE, V3, P669; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; BEAR SE, 1989, P NATL ACAD SCI USA, V86, P7495, DOI 10.1073/pnas.86.19.7495; BELLACOSA A, 1994, J VIROL, V68, P2320, DOI 10.1128/JVI.68.4.2320-2330.1994; BELLACOSA A, 1991, MOL CELL BIOL, V11, P2864, DOI 10.1128/MCB.11.5.2864; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERGERON D, 1993, LEUKEMIA, V7, P954; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BERGERON D, 1991, J VIROL, V65, P7, DOI 10.1128/JVI.65.1.7-15.1991; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COFFIN JM, 1997, RETROVIRUSES; DAVID YB, 1988, ONCOGENE, V3, P179; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Delgado MD, 1998, BIOCHEM BIOPH RES CO, V252, P383, DOI 10.1006/bbrc.1998.9587; DELGADO MD, 1994, ONCOGENE, V9, P1723; Denicourt C, 1999, J VIROL, V73, P4439, DOI 10.1128/JVI.73.5.4439-4442.1999; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DOMENGET C, 1992, ONCOGENE, V7, P2231; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; Frykberg L, 1988, Oncogene Res, V3, P313; GARDNER MB, 1978, TUMORS EARLY LIFE MA, P343; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GEGONNE A, 1987, VIROLOGY, V156, P177, DOI 10.1016/0042-6822(87)90450-8; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; Graf T, 1978, DIFFERENTIATION NORM, P625; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Hu NP, 1997, CANCER RES, V57, P4123; Ivanov X, 1962, B I PATHOL COMP ANIM, V9, P5; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JURDIC P, 1987, J VIROL, V61, P3058, DOI 10.1128/JVI.61.10.3058-3065.1987; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KRAUT N, 1995, ONCOGENE, V10, P1027; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LAUTENBERGER JA, 1993, J VIROL, V67, P610, DOI 10.1128/JVI.67.1.610-612.1993; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; OTT D, 1990, J VIROL, V64, P757, DOI 10.1128/JVI.64.2.757-766.1990; OTT DE, 1994, VIROLOGY, V205, P563, DOI 10.1006/viro.1994.1680; OTT DE, 1992, J VIROL, V66, P6107, DOI 10.1128/JVI.66.10.6107-6116.1992; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Rascle A, 1996, MOL CELL BIOL, V16, P6338; RAVELCHAPUIS P, 1991, J VIROL, V65, P3928, DOI 10.1128/JVI.65.7.3928-3931.1991; Rossi F, 1996, CURR BIOL, V6, P866, DOI 10.1016/S0960-9822(02)00610-3; RU M, 1993, J VIROL, V67, P4722, DOI 10.1128/JVI.67.8.4722-4731.1993; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; Ruscetti SK, 1999, INT J BIOCHEM CELL B, V31, P1089, DOI 10.1016/S1357-2725(99)00074-6; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; SETH A, 1990, ONCOGENE, V5, P1761; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sieweke Michael H., 1997, Leukemia (Basingstoke), V11, P486; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; SOTIROV N, 1981, J NATL CANCER I, V66, P1143, DOI 10.1093/jnci/66.6.1143; SPIRO C, 1988, J VIROL, V62, P4129, DOI 10.1128/JVI.62.11.4129-4135.1988; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 1999, MOL CELL BIOL, V19, P121; Tamir A, 1999, MOL CELL BIOL, V19, P4452; TOPOL LZ, 1992, CANCER LETT, V67, P71, DOI 10.1016/0304-3835(92)90010-S; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792; WATSON DK, 1988, ADV GENE TECHNOLOGY, P158; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	101	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6472	6481		10.1038/sj.onc.1204046	http://dx.doi.org/10.1038/sj.onc.1204046			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175363				2022-12-17	WOS:000166595000009
J	Deguin-Chambon, V; Vacher, M; Jullien, M; May, E; Bourdon, JC				Deguin-Chambon, V; Vacher, M; Jullien, M; May, E; Bourdon, JC			Direct transactivation of c-Ha-Ras gene by p53: evidence for its involvement in p53 transactivation activity and p53-mediated apoptosis	ONCOGENE			English	Article						p53 RE; c-Ha-Ras; transactivation; Ras.GTP; p53-stability	PROTEIN-KINASE-C; CELL-CYCLE MACHINERY; TUMOR-SUPPRESSOR P53; WILD-TYPE P53; BINDING-SITE; NEUROBLASTOMA-CELLS; PHORBOL ESTER; FIRST INTRON; T-ANTIGEN; IN-VITRO	p53 protein is a sequence-specific transcriptional activator which induces the expression of a number of cellular genes involved in different metabolic pathways, We report that the computer-selected sequence in human and mouse C-Ha-Ras gene confers to a reporter gene the ability to be directly transactivated by wild-type p53 either ovrespressed or activated in response to a cellular stress. By analysing human transformed cell lines, we showed, at both mRNA and protein level, that the endogenous C-Ha-Ras gene expression is positively regulated by wt p53 protein, The stimulation of c-Ha-Ras gene expression in Saos-2Ts cells by a temperature shift down to the permissive temperature for the p53-wt conformation is associated with a significant increase in the activated form of p21(e-11a-Ras) protein. Furthermore, in human transformed cell lines, the transient expression of a dominant interfering mutant of c-Ha-Ras greatly reduced the ability of p53 to induce apoptosis and inhibited the p53-dependent transactivation. This is due, at least in part, to a decrease in the protein (but not mRNA) level of the transiently expressed p53, indicating that inactivation of p21(e-11a-Ras) signalling pathways led to a specific degradation of p53 protein, We therefore suggest that, by inducing c-Ha-Ras, p53 activates a positive feedback loop that counteracts the negative feedback loop mediated by Mdm2.	CEA, DSV, UMR217 CNRS, Lab Cancerogenese Mol, F-92265 Fontenay Aux Roses, France; Univ Dundee, Dept Biochem, CRC, Cell Transformat Res Grp, Dundee DD1 4HN, Scotland	CEA; University of Dundee	May, E (corresponding author), CEA, DSV, UMR217 CNRS, Lab Cancerogenese Mol, BP6, F-92265 Fontenay Aux Roses, France.		JC, Bourdon/A-4439-2008	JC, Bourdon/0000-0003-4623-9386				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; BROWN K, 1988, MOL CARCINOGEN, V1, P161, DOI 10.1002/mc.2940010304; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CANNON JV, 1990, EMBO J, V9, P1595; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; Delphin C, 1997, EUR J BIOCHEM, V245, P684, DOI 10.1111/j.1432-1033.1997.t01-1-00684.x; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MAY E, 1989, ONCOGENE, V4, P1037; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, V80, P293; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; OMILLI F, 1986, MOL CELL BIOL, V6, P1875, DOI 10.1128/MCB.6.6.1875; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; ROMANO JW, 1989, ONCOGENE, V4, P1483; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAULIAN E, 1995, ONCOGENE, V10, P671; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; SPANDIDOS DA, 1995, INT J ONCOL, V7, P1029; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TEGTMEYER P, 1975, J VIROL, V16, P168, DOI 10.1128/JVI.16.1.168-178.1975; TELLIEZ JB, 1995, MOL CARCINOGEN, V12, P137, DOI 10.1002/mc.2940120305; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; YAMATO K, 1995, ONCOGENE, V11, P1; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YonishRouach E, 1995, ONCOGENE, V11, P2197; Youmell M, 1998, BIOCHEM BIOPH RES CO, V245, P514, DOI 10.1006/bbrc.1998.8471; ZHANG W, 1995, INT J ONCOL, V7, P1021; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	56	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5831	5841		10.1038/sj.onc.1203960	http://dx.doi.org/10.1038/sj.onc.1203960			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127813				2022-12-17	WOS:000165563100001
J	Bondzi, C; Grant, S; Krystal, GW				Bondzi, C; Grant, S; Krystal, GW			A novel assay for the measurement of Raf-1 kinase activity	ONCOGENE			English	Article						Raf-1; activation-specific antibody; kinase assay	ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; MAP KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; BIOLOGICAL-ACTIVITY; V-RAF; TAXOL; RESIDUES; GROWTH	Raf-1 is a serine-threonine protein kinase that functions as a central component of the mitogen-activated protein kinase signal transduction pathway, Raf-1 activity is currently assayed in vitro by either measuring P-32 incorporation into MEK, Raf-1's only characterized substrate, or by using the phosphorylated MEK to initiate a coupled assay culminating in the phosphorylation of myelin basic protein by MAP kinase, These assays are plagued by a potential lack of specificity in the case of the former, and the time consuming and error-prone nature of the later indirect assay, In this report, we demonstrate a novel single step assay for Raf-1 kinase activity based on phosphorylation of recombinant MEK-1, detected using an activation-specific MEK antibody that recognizes MEK only when specifically phosphorylated by Raf-1 on Ser 217 and Ser 221, The assay readily detected stem cell factor-mediated Raf-1 activation, MEK phosphorylation by immunoprecipitated Raf-1 plateaued at 10 min following initiation of the kinase reaction and was completely dependent on the inclusion of Raf-1 There was a linear correlation between the degree of MEK phosphorylation and the amount of Raf-1 protein immunoprecipitated, In addition to detecting growth factor-mediated activation, the assay was also able to detect paclitaxel-mediated Raf-1 activation, This assay is rapid, sensitive, and specific and therefore is a marked improvement over currently utilized techniques.	McGuire VA Med Ctr, Richmond, VA 23249 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol Immunol, Richmond, VA 23249 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23249 USA	Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University; Virginia Commonwealth University	Krystal, GW (corresponding author), McGuire VA Med Ctr, 111K,1201 Broad Rock Blvd, Richmond, VA 23249 USA.				NATIONAL CANCER INSTITUTE [R01CA083705, R01CA063753] Funding Source: NIH RePORTER; NCI NIH HHS [CA83705, CA63753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BHALLA K, 1993, LEUKEMIA, V7, P563; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Krystal GW, 1998, CANCER RES, V58, P4660; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LOU Z, 1997, MOL CELL BIOL, V17, P46; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; MARIAS R, 1995, EMBO J, V14, P3136; OKUDA K, 1992, BLOOD, V79, P2880; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROWINSKY EK, 1988, CANCER RES, V48, P4093; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; Torres K, 1998, CANCER RES, V58, P3620; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	29	22	22	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5030	5033		10.1038/sj.onc.1203862	http://dx.doi.org/10.1038/sj.onc.1203862			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042690				2022-12-17	WOS:000089834300010
J	Sansal, I; Dupont, E; Toru, D; Evrard, C; Rouget, P				Sansal, I; Dupont, E; Toru, D; Evrard, C; Rouget, P			NPDC-1, a regulator of neural cell proliferation and differentiation, interacts with E2F-1, reduces its binding to DNA and modulates its transcriptional activity	ONCOGENE			English	Article						cell proliferation; regulatory genes; regulatory proteins; neural differentiation	TERMINAL DIFFERENTIATION; RETINOBLASTOMA PROTEIN; SKELETAL-MUSCLE; DUAL MECHANISMS; CYCLE ARREST; EXPRESSION; KINASE; PHOSPHORYLATION; INHIBITION; REPRESSION	We have previously identified NPDC-1, a neural factor involved in the control of proliferation and differentiation, and we have shown that the stable introduction of NPDC-1 into transformed cells down-regulates cell proliferation both by increasing the generation time and by suppressing transformed properties. The data presented here indicate that, in vitro, NPDC-1 is able to interact with the transcription factor E2F-1 and some cell cycle proteins, such as D-cyclins and cdk2, In addition, two-hybrid experiments in mammalian cells show that the interaction between NPDC-1 and E2F-1 can also occur in vivo. This interaction reduces the binding of E2F-1 to DNA and its transcriptional activity. Taken together, the data suggest that NPDC-1 could influence cell cycle progression and neural differentiation through its association with E2F-1.	Inst Gustave Roussy, CNRS, UMR 1599, Unite Genet Oncol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Rouget, P (corresponding author), Inst Gustave Roussy, CNRS, UMR 1599, Unite Genet Oncol, PR-1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.							BIOU V, 1988, PROTEIN ENG, V2, P185, DOI 10.1093/protein/2.3.185; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU PY, 1978, ADV ENZYMOLOGY RELAT, V0047, P00145; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Dupont E, 1998, J NEUROSCI RES, V51, P257, DOI 10.1002/(SICI)1097-4547(19980115)51:2<257::AID-JNR14>3.0.CO;2-5; GALIANA E, 1995, P NATL ACAD SCI USA, V92, P1560, DOI 10.1073/pnas.92.5.1560; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; KITAGAWA M, 1995, ONCOGENE, V10, P229; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEMESLEVARLOOT L, 1993, COMPUT APPL BIOSCI, V9, P37; Magae J, 1997, ONCOGENE, V15, P759, DOI 10.1038/sj.onc.1201251; Muller H, 1997, MOL CELL BIOL, V17, P5508; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; UNGER R, 1989, PROTEINS, V5, P355, DOI 10.1002/prot.340050410; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zacksenhaus E, 1996, EMBO J, V15, P5917, DOI 10.1002/j.1460-2075.1996.tb00978.x	35	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2000	19	43					5000	5009		10.1038/sj.onc.1203843	http://dx.doi.org/10.1038/sj.onc.1203843			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042687				2022-12-17	WOS:000089834300007
J	Knapp, JI; Heppner, C; Hickman, AB; Burns, AL; Chandrasekharappa, SC; Collins, FS; Marx, SJ; Spiegel, AM; Agarwal, SK				Knapp, JI; Heppner, C; Hickman, AB; Burns, AL; Chandrasekharappa, SC; Collins, FS; Marx, SJ; Spiegel, AM; Agarwal, SK			Identification and characterization of JunD missense mutants that lack menin binding	ONCOGENE			English	Article						MEN1; menin; JunD; mutagenesis; two-hybrid; tumor suppressor	ENDOCRINE-NEOPLASIA TYPE-1; C-JUN; MUTATION ANALYSIS; ACTIVATED TRANSCRIPTION; GERMLINE MUTATIONS; AP-1 COMPLEX; CELL-GROWTH; GENE; PROTEIN; FOS	Menin, the product of the MEN1 tumor suppressor gene, binds to the AP1 transcription factor JunD and represses JunD transcriptional activity. The effects of human or mouse JunD missense mutations upon menin interaction were studied by random and alanine scanning mutagenesis of the menin binding region of JunD (amino acids 1-70). JunD mutant proteins were tested for menin binding in a reverse yeast two-hybrid assay, and for transcriptional regulation by menin in AP1-reporter assays. Random mutagenesis identified two different mutations that disrupted menin interaction at mouse JunD amino acid 42 (G42E and G42R). Mutation G42A generated by alanine scanning did not affect menin binding, likely reflecting the conserved nature of this amino acid substitution. Furthermore, by size exclusion chromatography menin co-migrated with wild type JunD but not with the JunD mutant tested (G42E). Alanine scanning mutagenesis of residues 30-55 revealed two different amino acids, P41 and P44, of mouse JunD that mere critical for interaction with menin. Mouse JunD missense mutants P41A, G42R, G42E and P44A failed to bind menin and also escaped menin's control over their transcriptional activity. At lower amounts of transfected menin, the transcriptional effect of menin on the mutants P41A, G42R and G42E was changed from repression to activation, similar to that with c-jun, In conclusion, a small N-terminal region of JunD mediates a key difference between JunD and c-jun, and a component of this difference is dependent on JunD binding to menin.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Agarwal, SK (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Room 9C-101,10 Ctr Dr,MSC 1802, Bethesda, MD 20892 USA.		Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043310, ZIEDK043006, Z01DK043006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000062] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Bartsch D, 1998, EUR J ENDOCRINOL, V139, P416, DOI 10.1530/eje.0.1390416; Bassett JHD, 1998, AM J HUM GENET, V62, P232, DOI 10.1086/301729; BERGER I, 1991, ONCOGENE, V6, P561; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Giraud S, 1998, AM J HUM GENET, V63, P455, DOI 10.1086/301953; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Hai N, 1999, EUR J ENDOCRINOL, V141, P475, DOI 10.1530/eje.0.1410475; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; Marx S, 1998, GENETIC BASIS HUMAN, P489; Marx SJ, 1999, RECENT PROG HORM RES, V54, P397; METIVIER C, 1993, ONCOGENE, V8, P2311; Mutch MG, 1999, HUM MUTAT, V13, P175, DOI 10.1002/(SICI)1098-1004(1999)13:3<175::AID-HUMU1>3.0.CO;2-R; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Poncin J, 1999, HUM MUTAT, V13, P54, DOI 10.1002/(SICI)1098-1004(1999)13:1<54::AID-HUMU6>3.0.CO;2-K; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Teh BT, 1998, J CLIN ENDOCR METAB, V83, P2621, DOI 10.1210/jc.83.8.2621; Thepot D, 2000, DEVELOPMENT, V127, P143; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685	36	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4706	4712		10.1038/sj.onc.1203832	http://dx.doi.org/10.1038/sj.onc.1203832			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032020				2022-12-17	WOS:000089528800004
J	Duriez, C; Falette, N; Cortes, U; Moyret-Lalle, C; Puisieux, A				Duriez, C; Falette, N; Cortes, U; Moyret-Lalle, C; Puisieux, A			Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage	ONCOGENE			English	Article						p53; KAI1; p53-transcriptional target; DNA damage	WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; CELLULAR-RESPONSE; BINDING FUNCTION; CANCER; GROWTH; EXPRESSION; PROTEIN; IDENTIFICATION; PROGRESSION	The p53 tumor suppressor protein functions to monitor the integrity of the genome. If a damage is detected, p53 binds tightly to specific sequence elements in the DNA and induces the transactivation of genes involved in various growth regulatory processes such as cell cycle progression, DNA repair and apoptosis, A p53-binding site was recently identified in the promoter region of the metastatic suppressor KAI1 gene, suggesting that this gene was a direct transcriptional target of p53. To test the relevance of this hypothesis, we studied the endogenous KAI1 expression in a series of human cell lines with varying p53 status in response to genotoxic treatment as well as in different cellular models exhibiting an inducible p53 activity. Overall, our data indicate that KAI1 expression is not significantly modulated by p53. This observation provides a direct evidence that the presence of a p53-binding site in regulatory domains is not a sufficient criteria to define a p53-transcriptional target gene.	INSERM, U453, Dept Oncol Fondamentale & Appl, Ctr Leon Berard, F-69008 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Puisieux, A (corresponding author), INSERM, U453, Dept Oncol Fondamentale & Appl, Ctr Leon Berard, 28 Rue Laennec, F-69008 Lyon, France.		Moyret-Lalle, Caroline/G-2742-2013	Moyret-Lalle, Caroline/0000-0002-8359-2018; PUISIEUX, Alain/0000-0002-9938-3798				Adachi M, 1996, CANCER RES, V56, P1751; Bacus SS, 1996, ONCOGENE, V12, P2535; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Guillot C, 1996, CLIN CANCER RES, V2, P1439; Guo XZ, 1998, HEPATOLOGY, V28, P1481, DOI 10.1002/hep.510280606; Guo XZ, 1996, CANCER RES, V56, P4876; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	22	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2461	2464		10.1038/sj.onc.1203580	http://dx.doi.org/10.1038/sj.onc.1203580			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828889				2022-12-17	WOS:000087018400012
J	De Graeve, F; Bahr, A; Chatton, B; Kedinger, C				De Graeve, F; Bahr, A; Chatton, B; Kedinger, C			A murine ATFa-associated factor with transcriptional repressing activity	ONCOGENE			English	Article						transcription; repression; JunD; GTF; RNA polymerase	RNA-POLYMERASE-II; TATA-BINDING PROTEIN; TBP-BINDING; EUKARYOTIC TRANSCRIPTION; MULTIPROTEIN COMPLEXES; ESTROGEN-RECEPTOR; MAMMALIAN-CELLS; IN-VIVO; DNA; FAMILY	The ATFa proteins, which are members of the CREB/ATF family of transcription factors, have previously been shown to interact with the adenovirus Ela oncoprotein and to mediate its transcriptional activity; they heterodimerize with Jun, Fos or related transcription factors, possibly altering their DNA-binding specificity; they also stably bind JNK2, a stress-induced protein kinase. Here we report the identification acid characterization of a novel protein isolated in a yeast two-hybrid screen using the N-terminal half of ATFa as a bait. This 1306-residue protein (mAM, for mouse ATFa-associated Modulator) is rather acidic (pHi 4.5) and contains high proportions of Ser/Thr (21%) and Pro (11%) residues. It colocalizes and interacts with ATFa in mammalian cells, contains a bipartite nuclear localization signal and possesses an ATPase activity. Transfection experiments show that mAM is able to downregulate transcriptional activity, in an ATPase-independent manner. Our results indicate that mAM interacts with several components of the basal transcription machinery (TFIIE and TFIIH), including RNAPII itself. Together, these findings suggest that mAM may be involved in the fine-tuning of ATFa-regulated gene expression, by interfering with the assembly or stability of specific preinitiation transcription complexes.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67400 Illkirch Graffenstaden, Communaute Urba, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chatton, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67400 Illkirch Graffenstaden, Communaute Urba, France.		CHATTON, Bruno/R-3813-2019	DE GRAEVE, Fabienne/0000-0002-3455-7507; CHATTON, Bruno/0000-0003-4515-7119				Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Ashraf SI, 1998, CURR BIOL, V8, pR683, DOI 10.1016/S0960-9822(98)70435-X; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BERGER I, 1994, DNA CELL BIOL, V13, P249, DOI 10.1089/dna.1994.13.249; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bocco JL, 1996, ONCOGENE, V12, P1971; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHATURVEDI SK, 1994, NIMHANS J, V12, P9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen WB, 1999, CANCER LETT, V142, P43, DOI 10.1016/S0304-3835(99)00111-1; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; De Graeve F, 1999, ONCOGENE, V18, P3491, DOI 10.1038/sj.onc.1202723; DECIMO D, 1995, GENE PROBES PRACTICA, V2, P183; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; Goetz J, 1996, J BIOL CHEM, V271, P29589, DOI 10.1074/jbc.271.47.29589; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Jensen RT, 1999, ANN ONCOL, V10, P170, DOI 10.1023/A:1008350517079; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MELLSTROM B, 1991, ONCOGENE, V6, P1959; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Ohkuma Y, 1997, J BIOCHEM-TOKYO, V122, P481; Olave I, 1998, GENE DEV, V12, P1621, DOI 10.1101/gad.12.11.1621; OREILLY DR, 1992, BACULOVIRUS EXPRESSI; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROY R, 1994, J BIOL CHEM, V269, P9826; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; TRATNER I, 1991, ONCOGENE, V6, P2049; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	71	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2000	19	14					1807	1819		10.1038/sj.onc.1203492	http://dx.doi.org/10.1038/sj.onc.1203492			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777215				2022-12-17	WOS:000086292500009
J	Olivo, C; Vanni, C; Mancini, P; Silengo, L; Torrisi, MR; Tarone, G; Defilippi, P; Eva, A				Olivo, C; Vanni, C; Mancini, P; Silengo, L; Torrisi, MR; Tarone, G; Defilippi, P; Eva, A			Distinct involvement of Cdc42 and RhoA GTPases in actin organization and cell shape in untransformed and Dbl oncogene transformed NIH3T3 cells	ONCOGENE			English	Article						Cdc42; RhoA; Dbl oncogene; actin cytoskeleton organization	GUANINE-NUCLEOTIDE EXCHANGE; RAS TRANSFORMATION; SIGNALING PATHWAY; PROTEIN-KINASE; ACTIVATION; FAMILY; CYTOSKELETON; FIBROBLASTS; DOWNSTREAM; ADHESION	The Dbl oncogene is a putative exchange factor for the small GTPases RhoA and Cdc42, which are involved in actin polymerization into stress fibers and filopodia, respectively. We report here that, upon adhesion to fibronectin, Dbl-transformed NIH3T3 cells display a contracted, polygonal shape with a high number of short stress fibers. In contrast, untransformed NIH3T3 cells acquire the characteristic fibroblast morphology and organize a regular mesh of long stress fibers. We show that in Dbl-transformed and in untransformed NIH3T3 cells the different shape and actin cytoskeleton organization observed in the early steps of adhesion involves activation of distinct GTPases, Upon adhesion to fibronectin, cell morphology of Dbl-transformed NIH3T3 cells depends on activation of RhoA and not of Cdc42, In contrast Cdc42 activation is necessary to untransfected NIH3T3 cells to acquire their fibroblast shape. In both Dbl-transformed and in untransformed NIH3T3 cells a basal Rac activation is necessary to support stress fiber organization, while constitutive Rac activation promotes ruffles and lamellipodia formation. As a consequence of RhoA activation, Dbl-transformed cells show high activity of ROCK-alpha and CRIK kinases, two known RhoA effecters. In addition Dbl-transformed and NIH3T3 cells expressing the constitutive active form of RhoA are less motile on fibronectin than cells expressing constitutive active Cdc42, We conclude that in NIH3T3 cells in response to fibronectin the expression of the Dbl oncogene leads to a predominant activation of RhoA which both supports the peculiar cell shape and actin cytoskeleton organization in stress fibers and regulates cell motility.	Univ Turin, Dipartimento Genet Biol & Biochim, I-10126 Turin, Italy; Ist Giannina Gaslini, Mol Biol Lab, I-16148 Genoa, Italy; Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy	University of Turin; University of Genoa; IRCCS Istituto Giannina Gaslini; Sapienza University Rome	Defilippi, P (corresponding author), Univ Turin, Dipartimento Genet Biol & Biochim, Via Santena 5bis, I-10126 Turin, Italy.		DEFILIPPI, Paola/L-2232-2014; Eva, Alessandra/J-8268-2016	Eva, Alessandra/0000-0003-2949-078X; Tarone, Guido/0000-0003-4805-086X; Defilippi, Paola/0000-0001-6427-4906; mancini, patrizia/0000-0003-0556-2056				Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DARTSCH PC, 1994, EUR J CELL BIOL, V63, P316; Defilippi P, 1997, ONCOGENE, V14, P1933, DOI 10.1038/sj.onc.1201027; Defilippi P, 1999, MICROSC RES TECHNIQ, V47, P67, DOI 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.3.CO;2-G; Di Cunto F, 1998, J BIOL CHEM, V273, P29706, DOI 10.1074/jbc.273.45.29706; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKADA CY, 1982, CELL, V29, P33, DOI 10.1016/0092-8674(82)90087-3; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1067; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; TARONE G, 1982, J CELL BIOL, V94, P179, DOI 10.1083/jcb.94.1.179; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; Yron I, 1999, CELL ADHES COMMUN, V7, P1, DOI 10.3109/15419069909034388; ZANGRILLI D, 1995, METHOD ENZYMOL, V256, P347; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	46	22	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1428	1436		10.1038/sj.onc.1203440	http://dx.doi.org/10.1038/sj.onc.1203440			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723134				2022-12-17	WOS:000085942700008
J	Maritano, D; Accornero, P; Bonifaci, N; Ponzetto, C				Maritano, D; Accornero, P; Bonifaci, N; Ponzetto, C			Two mutations affecting conserved residues in the Met receptor operate via different mechanisms	ONCOGENE			English	Article						Met oncogenic mutations; receptor tyrosine kinases	HEPATOCYTE GROWTH-FACTOR; LIGAND-INDEPENDENT ACTIVATION; PROTEIN-TYROSINE KINASES; CELL-LINE; HGF-RECEPTOR; C-KIT; CONSTITUTIVE ACTIVATION; INVASIVE-GROWTH; POINT MUTATION; PROTOONCOGENE	We leave investigated the mechanism by which two oncogenic mutations (M1268T and D1246H/N; Amino-acids are numbered according to Schmidt ct a]., 1999) affecting conserved residues in the catalytic domain of the Met receptor, activate its transforming potential. Both mutations were previously found in tumorigenic forms of the Ret and Kit receptors, respectively, The mutated residues are located either in the P+1 loop (M) or within the activation loop (A-loop) (D), which in a number of receptor tyrosine kinases harbors a pair of tandem tyrosines (Y1252-1253 in Met), Ligand-induced dimerization promotes their phosphorylation, and locks the A-loop into an open conformation. When unphosphorylated, the tandem tyrosines inhibit enzymatic activity by blocking the active site. Upon Y-->F mutation of Y1252-1253, neither ligand binding nor Tpr-mediated dimerization ran release this block. Here we show that the M1268T mutation partially rescues the kinase activity (and the transforming ability) of the Y1252-1253F Tpr-Met mutant, but is completely dependent on dimerization for its effect, In contrast, the two D1246H/N mutants strictly depend on Y1252-1253 for activity. Surprisingly, however, they constitutively activate the isolated cytoplasmic TK domain of Met (Cyto-Met), These data indicate that the two mutations operate via distinct mechanisms.	Univ Turin, Dept Biomed Sci & Oncol, I-10126 Turin, Italy; Amedeo Avogadro Univ, Dept Med Sci, Novara, Italy	University of Turin; University of Eastern Piedmont Amedeo Avogadro	Ponzetto, C (corresponding author), Univ Turin, Dept Biomed Sci & Oncol, C Massimo Azeglio 52, I-10126 Turin, Italy.		Accornero, Paolo/B-1396-2008					Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; HUBBARD SR, 1994, NATURE, V372, P766; Iwashita T, 1996, ONCOGENE, V12, P481; Jeffers M, 1999, ONCOGENE, V18, P5120, DOI 10.1038/sj.onc.1202902; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Lam LPY, 1999, BIOCHEM J, V338, P131, DOI 10.1042/0264-6021:3380131; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LONGATI P, 1994, ONCOGENE, V9, P49; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Park WS, 1999, CANCER RES, V59, P307; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; TSUJIMURA T, 1994, BLOOD, V83, P2619; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; YEE CJ, 1993, BIOCHEMISTRY-US, V32, P7922, DOI 10.1021/bi00082a013; ZHEN Z, 1994, ONCOGENE, V9, P1691; ZHU H, 1994, J BIOL CHEM, V269, P29943	47	22	22	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1354	1361		10.1038/sj.onc.1203431	http://dx.doi.org/10.1038/sj.onc.1203431			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713677				2022-12-17	WOS:000085743800012
J	Takeuchi, S; Cho, SK; Seriu, T; Koike, M; Bartram, CR; Reiter, A; Schrappe, M; Takeuchi, C; Taguchi, H; Koeffler, HP				Takeuchi, S; Cho, SK; Seriu, T; Koike, M; Bartram, CR; Reiter, A; Schrappe, M; Takeuchi, C; Taguchi, H; Koeffler, HP			Identification of three distinct regions of deletion on the long arm of chromosome 11 in childhood acute lymphoblastic leukemia	ONCOGENE			English	Article						LOH; ALL; 11q; MLL; ATM	ATM GENE; SUSCEPTIBILITY; MAP	Cytogenetic analysis of childhood acute lymphoblastic leukemia (ALL) identified deletions of chromosome arm 11q, These observations led us to analyse the loss of heterozygosity (LOH) of chromosome arm 11q in 113 primary childhood ALL samples using 14 microsatellite markers. LOH was found in 18 (16%) patients. Detailed examination identified three distinct regions of deletion. The first region is flanked by D11S901 and D11S1391 at 11q22-23 containing the A TM gene. Mutational analysis suggested that the altered gene in this region is not the ATM gene. The second region is flanked by D11S614 and D11S924 at 11q23 containing the MLL gene, The third region is flanked by D11S1356 and D11S614 at 11q23 containing the MLL gene. All the cases with LOH at MLL locus lacked detectable MLL gene rearrangements. In addition, 20 children have been studied both at initial diagnosis and relapse; none of the individuals who relapsed acquired LOH of 11q, suggesting that 11q deletions were infrequently involved in the progression of childhood ALL. Children with 11q LOH had a good response to induction chemotherapy (P=0.015), These data suggest that alterations of putative tumor suppressor genes on 11q are important events in development of childhood ALL. Our map provides important information toward cloning putative tumor suppressor genes associated with childhood ALL.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany; Hannover Med Sch, Dept Pediat 4, Hannover, Germany; Kochi Med Sch, Dept Med, Kochi 7838505, Japan	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Ruprecht Karls University Heidelberg; Hannover Medical School; Kochi University	Takeuchi, S (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Div Hematol Oncol, Los Angeles, CA 90048 USA.		Schrappe, Martin/A-8109-2010; Schrappe, Martin/ABA-6144-2020	Cho, Steve Kyungrae/0000-0001-8547-8430				JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; JOHANSSON B, 1993, GENE CHROMOSOME CANC, V8, P205, DOI 10.1002/gcc.2870080402; RAIMONDI SC, 1995, BLOOD, V86, P1881, DOI 10.1182/blood.V86.5.1881.bloodjournal8651881; RAIMONDI SC, 1993, BLOOD, V81, P2237; TAKEUCHI S, 1995, CANCER RES, V55, P5377; Takeuchi S, 1998, BRIT J HAEMATOL, V103, P536, DOI 10.1046/j.1365-2141.1998.00993.x; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Vorechovsky I, 1996, CANCER RES, V56, P2726; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	9	22	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7387	7388		10.1038/sj.onc.1203145	http://dx.doi.org/10.1038/sj.onc.1203145			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602495				2022-12-17	WOS:000084119400025
J	Gassmann, MG; Stanzel, A; Werner, S				Gassmann, MG; Stanzel, A; Werner, S			Growth factor-regulated expression of enzymes involved in nucleotide biosynthesis: a novel mechanism of growth factor action	ONCOGENE			English	Article						keratinocyte growth factor; keratinocytes; purine; pyrimidine; nucleotide biosynthesis; salvage pathway	INFLAMMATORY BOWEL-DISEASE; HUMAN KERATINOCYTES; MOLECULAR-CLONING; ADENYLOSUCCINATE LYASE; FACTOR RECEPTOR; CDNA SEQUENCE; HUMAN HOMOLOG; FACTOR-ALPHA; GENE; SYNTHETASE	Keratinocyte growth factor (KGF) is a potent and specific mitogen for epithelial cells, including the keratinocytes of the skin, We investigated the mechanisms of action of KGF by searching for genes which are regulated by this growth factor in cultured human keratinocytes. Using the differential display RT-PCR technology we identified the gene encoding adenylosuccinate lyase [EC 4.3.2.2] as a novel KGF-regulated gene, Adenylosuccinate lyase plays an important role in purine de novo synthesis. To gain further insight into the potential role of nucleotide biosynthesis in the mitogenic effect of KGF, we cloned cDNA fragments of the key regulatory enzymes involved in purine and pyrimidine metabolism (adenylosuccinate synthetase [EC 6.3.4.4], phosphoribosyl pyrophosphate synthetase [EC 2.7.6.1], amidophosphoribosyl transferase [EC 2.4.2.14], hypoxanthine guanine phosphoribosyl transferase [EC 2.4.2.8] and the multifunctional protein CAD which includes the enzymatic activities of carbamoyl-phosphate synthetase II [EC 6.3.5.59], aspartate transcarbamylase [EC 2.1.3.2] and dihydroorotase [EC 3.5.2.3]), Expression of all of these enzymes was upregulated after treatment with KGF and also with epidermal growth factor (EGF), indicating that these mitogens stimulate nucleotide production by induction of these enzymes. To determine a possible in vivo correlation between the expression of KGF, EGF and the enzymes mentioned above, we analysed the expression of the enzymes during cutaneous wound repair, where high levels of these mitogens are present. Indeed, we found a strong mRNA expression of all of these enzymes in the EGF- and KGF-responsive keratinocytes of the hyperproliferative epithelium at the wound edge, indicating that their expression might also be regulated by growth factors during wound healing.	ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Max Planck Society	Werner, S (corresponding author), ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland.			Werner, Sabine/0000-0001-7397-8710				Ashcroft GS, 1997, J ANAT, V190, P351, DOI 10.1046/j.1469-7580.1997.19030351.x; BAUER D, 1994, PCR METH APPL, V4, P97; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brauchle M, 1996, AM J PATHOL, V149, P521; Carrey EA, 1995, BIOCHEM SOC T, V23, P899, DOI 10.1042/bst0230899; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DETMAR M, 1990, ARCH DERMATOL RES, V282, P238, DOI 10.1007/BF00371643; ERNER S, 1998, CYTOKINE GROWTH F R, V9, P153; Finch PW, 1997, AM J PATHOL, V151, P1619; Finch PW, 1996, GASTROENTEROLOGY, V110, P441, DOI 10.1053/gast.1996.v110.pm8566591; FON EA, 1993, CYTOGENET CELL GENET, V64, P201, DOI 10.1159/000133575; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Frank S, 1996, J BIOL CHEM, V271, P24337, DOI 10.1074/jbc.271.40.24337; Frank S, 1997, ONCOGENE, V14, P915, DOI 10.1038/sj.onc.1200905; GAME SM, 1992, INT J CANCER, V52, P461, DOI 10.1002/ijc.2910520322; Gold LI, 1997, AM J PATHOL, V150, P209; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Hubner G, 1996, CYTOKINE, V8, P548, DOI 10.1006/cyto.1996.0074; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; IWAHANA H, 1993, J BIOL CHEM, V268, P7225; IWAHANA H, 1993, BIOCHEM BIOPH RES CO, V190, P192, DOI 10.1006/bbrc.1993.1030; IWAHANA H, 1995, BBA-GENE STRUCT EXPR, V1261, P369, DOI 10.1016/0167-4781(95)00036-G; Iwahana H, 1996, BIOCHEM BIOPH RES CO, V219, P249, DOI 10.1006/bbrc.1996.0213; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KONECKI DS, 1982, NUCLEIC ACIDS RES, V10, P6763, DOI 10.1093/nar/10.21.6763; LIAO WSL, 1986, J BIOL CHEM, V261, P5577; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Ogura R, 1983, Curr Probl Dermatol, V11, P145; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; RAO GN, 1988, EXP CELL RES, V178, P449, DOI 10.1016/0014-4827(88)90413-2; RAO GN, 1988, DNA-J MOLEC CELL BIO, V7, P423, DOI 10.1089/dna.1.1988.7.423; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Schmid P, 1998, AM J PATHOL, V152, P485; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SONODA T, 1991, J BIOCHEM-TOKYO, V109, P361; TODD R, 1991, AM J PATHOL, V138, P1307; TREFZER U, 1991, J INVEST DERMATOL, V97, P911, DOI 10.1111/1523-1747.ep12491668; Voet D VJ, 1990, BIOCHEMISTRY; WENCZAK BA, 1992, J CLIN INVEST, V90, P2392, DOI 10.1172/JCI116130; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WONG LJC, 1995, GENOMICS, V28, P341, DOI 10.1006/geno.1995.1152; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4	49	22	22	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6667	6676		10.1038/sj.onc.1203120	http://dx.doi.org/10.1038/sj.onc.1203120			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597272				2022-12-17	WOS:000083792000006
J	Steegenga, WT; Riteco, N; Bos, JL				Steegenga, WT; Riteco, N; Bos, JL			Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and Delta E1B adenovirus replication in human cells	ONCOGENE			English	Article						p53; adenovirus; E1B; tumor therapy; replication; CPE	P53 MUTATIONS; 55-KILODALTON PROTEIN; TUMOR-SUPPRESSOR; INFECTED CELLS; HUMAN CANCERS; GENE-TRANSFER; ACTIVATION; CYCLE; LINES; RETINOBLASTOMA	An adenovirus mutant lacking the expression of the large E1B protein (Delta E1B) has been reported to replicate selectively in cells lacking the expression of functionally wild-type (wt) p53. Based on these results the Delta E1B or ONYX-015 virus has been proposed to be an oncolytic virus which might be useful to treat p53-deficient tumors. Recently however, contradictory results have been published indicating that p53-dependent cell death is required for productive adenovirus infection. Since there is an urgent need for new methods to treat aggressive, mutant p53-expressing primary tumors and their metastases we carefully examined adenovirus replication in human cells to determine whether or not the Delta E1B virus can be used for tumor therapy. The results we present here show that not all human tumor cell lines take up adenovirus efficiently. In addition, we observed inhibition of the expression of adenovirus early proteins in tumor cells. We present evidence that these two factors rather than the p53 status of the cell determine whether adenovirus infection results in lytic cell death. Furthermore, the results we obtained by infecting a panel of different tumor cell lines show that viral spread of the Delta E1B is strongly inhibited in almost all p53-proficient and -deficient cell lines compared to the,vt virus. We conclude that the efficiency of the Delta E1B virus to replicate efficiently in tumor cells is determined by the ability to infect cells and to express the early adenovirus proteins rather than the status of p53.	Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3508 TA Utrecht, Netherlands	Utrecht University; Utrecht University	Steegenga, WT (corresponding author), Univ Utrecht, Physiol Chem Lab, POB 80042, NL-3508 TA Utrecht, Netherlands.							BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Furuwatari C, 1998, AM J CLIN PATHOL, V110, P368, DOI 10.1093/ajcp/110.3.368; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PELTENBURG LTC, 1994, IMMUNOGENETICS, V40, P54, DOI 10.1007/BF00163964; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; STEEGENGA WT, 1995, VIROLOGY, V212, P543, DOI 10.1006/viro.1995.1512; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; van der Eb A J, 1980, Methods Enzymol, V65, P826; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	34	22	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5032	5043		10.1038/sj.onc.1202886	http://dx.doi.org/10.1038/sj.onc.1202886			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490840				2022-12-17	WOS:000082497100003
J	Chen, WY; Butler, M; Rao, PH; Chaganti, SR; Louie, DC; Dalla-Favera, R; Chaganti, RSK				Chen, WY; Butler, M; Rao, PH; Chaganti, SR; Louie, DC; Dalla-Favera, R; Chaganti, RSK			The t(2;3)(q21;q27) translocation in non-Hodgkin's lymphoma displays BCL6 mutations in the 5 ' regulatory region and chromosomal breakpoints distant from the gene	ONCOGENE			English	Article						BCL6 mutation; 3q27 translocation; NHL	B-CELL LYMPHOMA; GERMINAL-CENTER FORMATION; FINGER ENCODING GENE; C-MYC; 3Q27 TRANSLOCATION; MALIGNANT-LYMPHOMA; BURKITT-LYMPHOMA; ABNORMALITIES; LAZ3/BCL6; PROTEIN	The BCL6 gene, mapped at the chromosomal band 3q27, encodes a POZ/Zinc finger transcription repressor protein, It is frequently activated in Non-Hodgkin's lymphomas (NHL) by translocations with breakpoints clustering in the 5' major breakpoint region (MBR) as well as by mutations in the same region, The translocations lead to BCL6 activation by substitution of promoters of rearranging genes derived from the reciprocal chromosomal partners such as IG. We report the molecular genetic analysis of a novel t(2;3)(q21;q27) translocation subset in NHL comprising three cases without apparent BCL6 involvement in the translocation, Southern blot analysis of tumor DNAs utilizing BCL6 MBR probes revealed no rearrangement in two cases, Two rearranged bands in the third case resulted from a deletion in one allele and a mutation in the other allele, Southern blot analysis of DNA from one of the two tumors without BCL6 rearrangement, using a probe derived from the recently identified alternative breakpoint region (ABR), showed a rearrangement,The ABR is located 200-270 kb telomeric to MBR, Mutations were identified in the previously reported hypermutable region of BCL6 in all three tumors, In one, the mutant allele alone was found to be expressed by RT-PCR analysis of RNA, These results demonstrate the presence of 3q27 translocation breakpoints at a distance from BCL6 suggesting distant breaks that deregulate the gene or involvement of other genes that may be subject to rearrangement.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, Div Oncol, New York, NY 10032 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Columbia University	Chaganti, RSK (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA044029, R01CA066999] Funding Source: NIH RePORTER; NCI NIH HHS [CA44029, CA66999] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akasaka T, 1997, CANCER RES, V57, P7; AXELSON H, 1994, INT J CANCER, V56, P418, DOI 10.1002/ijc.2910560322; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; BASTARD C, 1992, BLOOD, V79, P2527; BENITEZ J, 1992, CANCER GENET CYTOGEN, V59, P68, DOI 10.1016/0165-4608(92)90161-Z; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; Butler M., 1997, Blood, V90, p316A; CHAGANTI SR, 1998, IN PRESS GENES CHROM; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLERY E, 1995, ONCOGENE, V10, P2171; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; GaliegueZouitina S, 1995, CR ACAD SCI III-VIE, V318, P1125; JOOS S, 1992, CANCER RES, V52, P6547; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KONISHI H, 1990, CANCER RES, V50, P2698; KORNBLAU SM, 1991, HEMATOL ONCOL, V9, P63; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Nakamura Y, 1996, LEUKEMIA, V10, P658; OFFIT K, 1989, BLOOD, V74, P1876; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; Seyfert VL, 1996, ONCOGENE, V12, P2331; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TWEEDDALE ME, 1987, BLOOD, V69, P1307; WLODARSKA I, 1995, GENE CHROMOSOME CANC, V14, P1, DOI 10.1002/gcc.2870140102; XU L, 1994, INT J CANCER, V59, P383, DOI 10.1002/ijc.2910590316; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YE BHH, 1993, CANCER RES, V53, P2732	36	22	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1717	1722		10.1038/sj.onc.1202098	http://dx.doi.org/10.1038/sj.onc.1202098			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796700	Green Accepted			2022-12-17	WOS:000076200100009
J	Asso-Bonnet, M; Feuillard, J; Ferreira, V; Bissieres, P; Tarantino, N; Korner, M; Raphael, M				Asso-Bonnet, M; Feuillard, J; Ferreira, V; Bissieres, P; Tarantino, N; Korner, M; Raphael, M			Relationship between I kappa B alpha constitutive expression, TNF alpha synthesis, and apoptosis in EBV-infected lymphoblastoid cells	ONCOGENE			English	Article						NF-kappa B; I kappa B alpha; EBV; TNF alpha	TUMOR-NECROSIS-FACTOR; SIGNAL-BINDING-PROTEIN; VIRUS TRANSFORMING PROTEIN; RBP-J-KAPPA; T-CELL; V-REL; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTION FACTOR; LYMPHOMA PATIENTS; GENE-EXPRESSION	In order to understand the role of NF-KB in EBV transformation we have established stably transfected I kappa B alpha: into lymphoblastoid cells. Two clones were obtained in which the loss of NF-kappa B binding activity correlated with the constitutive expression of the transgenic I kappa B alpha. Protein latency expression was determined by immunocytochemistry. Expression of surface markers, intracytoplasmic content of cytokines cell cycle analysis after BrdU incorporation and DNA staining with propidium iodide were studied by flow cytometry, Percentage of apoptotic cells was determined by in-situ labelling of DNA strand breaks, No significative changes in EBV latency nor in cell surface marker expression was found. In contrast, intracytoplasmic TNF alpha levels were strongly reduced in transfected clones. Furthermore, 30% of I kappa B alpha transfected cells were apoptotic after 8 h of TNF alpha treatment. This correlated with a strong reduction of BrdU incorporation after 24 h of TNF alpha treatment, No effect was seen with non transfected cells or with cells transfected with a control plasmid, Our results suggest that the TNF: gene could be one of the targets of NF-kappa B in EBV infected cells and that NF-kappa B protects EBV-infected cells from apoptosis induced by TNF alpha, which may favour the proliferative effect of this cytokine.	Hop Avicenne, Serv Hematol Biol, F-93009 Bobigny, France; Hop La Pitie Salpetriere, URA 625, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Feuillard, J (corresponding author), Hop Avicenne, Serv Hematol Biol, F-93009 Bobigny, France.		Feuillard, Jean/O-8587-2016	Feuillard, Jean/0000-0001-6223-2454				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Coral S, 1997, CELL GROWTH DIFFER, V8, P581; CORDINGLEY FT, 1988, LANCET, V1, P969; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; Ferreira V, 1998, J BIOL CHEM, V273, P592, DOI 10.1074/jbc.273.1.592; FEUILLARD J, 1995, INT IMMUNOL, V7, P121, DOI 10.1093/intimm/7.1.121; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRILLI M, 1993, INT REV CYTOL, V143, P1; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Houldsworth J, 1996, BLOOD, V87, P25; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; HUEN DS, 1995, ONCOGENE, V10, P549; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JELINEK DF, 1987, J IMMUNOL, V139, P2970; Jochems G J, 1991, Hum Antibodies Hybridomas, V2, P57; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KEHRL JH, 1987, J EXP MED, V166, P786, DOI 10.1084/jem.166.3.786; KIEFF E, 1990, EPSTEINBARR VIRUS IT; Klein SC, 1996, LEUKEMIA RES, V20, P633, DOI 10.1016/0145-2126(96)00029-X; KORNER M, 1990, BIOCHEM J, V265, P547, DOI 10.1042/bj2650547; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Macia J, 1996, LEUKEMIA LYMPHOMA, V20, P481, DOI 10.3109/10428199609052433; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Osnes LTN, 1996, THROMB HAEMOSTASIS, V76, P970; PICKER LJ, 1995, BLOOD, V86, P1408, DOI 10.1182/blood.V86.4.1408.bloodjournal8641408; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Rothenberger S, 1997, ONCOGENE, V14, P2123, DOI 10.1038/sj.onc.1201032; Salles G, 1996, BRIT J HAEMATOL, V93, P352, DOI 10.1046/j.1365-2141.1996.5181059.x; Shackelford RE, 1997, MOL PHARMACOL, V52, P421, DOI 10.1124/mol.52.3.421; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; Sugano N, 1997, J EXP MED, V186, P731, DOI 10.1084/jem.186.5.731; SUNG SSJ, 1988, J EXP MED, V168, P1539, DOI 10.1084/jem.168.5.1539; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Warzocha K, 1997, J CLIN ONCOL, V15, P499, DOI 10.1200/JCO.1997.15.2.499; Warzocha Krzysztof, 1997, Leukemia (Basingstoke), V11, P441; WU F, 1988, J VIROL, V62, P218, DOI 10.1128/JVI.62.1.218-225.1988; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	63	22	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1607	1615		10.1038/sj.onc.1202365	http://dx.doi.org/10.1038/sj.onc.1202365			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794238				2022-12-17	WOS:000076089900013
J	Cipriano, SC; Chen, YQ				Cipriano, SC; Chen, YQ			Insensitivity to growth inhibition by TGF-beta 1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells	ONCOGENE			English	Article						TGF-beta; G(1) arrest; cell cycle; p15(INK4B); p21(WAF1/Cip1/Sdi1); p27(KIP1); prostate cancer	DEPENDENT KINASE INHIBITOR; TGF-BETA; CANCER-CELLS; CYCLE ARREST; POTENTIAL MEDIATOR; SMAD PROTEINS; GENE; PROLIFERATION; DPC4; SUPPRESSION	TGF-beta is a potent growth inhibitor of epithelial cells. However, many transformed cells have lost their sensitivity to this growth inhibitory effect. The molecular mechanism of such insensitivity is not get understood, Here, we have studied the TGF-beta 1 effect on normal human prostate and carcinoma cells. Our results showed that normal cells were sensitive to growth inhibition, whereas tumor cells were not or only minimally inhibited regardless of the concentration of TGF-beta 1 (20 to 80 pM) or time of exposure (1-5 days). p21(WAF/Cip1/Sdi1) and p15(INK4B) but not p27(KIP1) were detectable by Western blotting in normal and tumor cells, TGF-beta 1 treatment increased the association of p21(WAF1/Cip1/Sdi1) with the Cdk2/cyclin E complex in both normal and prostate tumor cells. However, there was no increase in the association of p15(INK4B) nor p27(Kip1) with the Cdk/cyclin complexes, In normal cells, the increase in the association of p21(WAF1/Cip1/Sdi1). With th, Cdk2/cyclin E complex resulted in inhibition of the Cdk2 activity. In contrast, although there was an increase in the association of p21(WAF1/Cip1/Sdi1) With th, Cdk2/cyclin E complex in tumor cells, there was no inhibition of the Cdk2 activity, These results indicate that a lack of inhibition of the Cdk2 activity correlates with insensitivity to TGF-beta 1 in prostate tumor cells.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Chen, YQ (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.		Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708				BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHEN YQ, 1994, CANCER MOL BIOL, V1, P357; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FRANZEN P, 1993, EXP CELL RES, V207, P1, DOI 10.1006/excr.1993.1156; GAO X, 1995, ONCOGENE, V11, P1395; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GRUBECKLOBENSTE.B, 1989, J CLIN INVEST, V8, P764; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Herman JG, 1996, CANCER RES, V56, P722; HUGGETT AC, 1990, CANCER RES, V50, P7468; ICHIJO H, 1990, EXP CELL RES, V187, P263, DOI 10.1016/0014-4827(90)90090-W; IVARONE A, 1997, NATURE, V387, P417; Kim IY, 1996, CANCER RES, V56, P44; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; PIACIBELLO W, 1991, HAEMATOLOGICA, V76, P460; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Schutte M, 1996, CANCER RES, V56, P2527; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILDING G, 1989, MOL CELL ENDOCRINOL, V62, P79, DOI 10.1016/0303-7207(89)90115-9; Wrana J, 1997, NATURE, V388, P28, DOI 10.1038/40290; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	42	22	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1549	1556		10.1038/sj.onc.1202069	http://dx.doi.org/10.1038/sj.onc.1202069			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794232				2022-12-17	WOS:000076089900007
J	Helbing, CC; Wellington, CL; Gogela-Spehar, M; Cheng, T; Pinchbeck, GG; Johnston, RN				Helbing, CC; Wellington, CL; Gogela-Spehar, M; Cheng, T; Pinchbeck, GG; Johnston, RN			Quiescence versus apoptosis: Myc abundance determines pathway of exit from the cell cycle	ONCOGENE			English	Article						apoptosis; c-Myc; cdk2; cell cycle control; quiescence; tetracycline	DEPENDENT PROTEIN-KINASES; C-MYC; GENE-EXPRESSION; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; DNA-REPLICATION; MESSENGER-RNA; GROWTH; FIBROBLASTS	When exposed to diverse growth conditions in vitro, cells can respond by entering states of proliferation, quiescence, differentiation or apoptosis, While the choices among these states can be influenced by proto-oncogene expression, how these disparate outcomes are achieved remains poorly understood. To address these issues, we have generated rodent fibroblast cell lines that harbor a human c-myc gene under the control of a tetracycline-regulated promoter, When Myc-induced cells are deprived of serum growth factors, they rapidly become apoptotic with the onset of apoptosis preceded by a large, transient increase in cdk2 kinase activity that is associated with the induction of cdc25A phosphatase and the later accumulation of p27(Kip1) kinase inhibitor, Surprisingly, serum starvation in the absence of myc overexpression, (which leads to quiescence instead of apoptosis) also causes a marked transient elevation in cdk2 kinase activity, an induction of cdc25A and a delayed increase in p27(Kip1), Transient elevations in cdk2 kinase activity and cdc25A abundance are required for cell cycle progression, but it is evident that these changes also precede entry to either apoptosis or quiescence in serum-starved cells. These findings suggest that the pathways to both quiescence and apoptosis share regulatory machinery with cell cycle control mechanisms. In addition, the abundance of MSc protein can be critical in the choices among these cellular states.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary	Johnston, RN (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.		Johnston, Randal/B-9247-2009	Helbing, Caren/0000-0002-8861-1070				ASKEW DS, 1991, ONCOGENE, V6, P1915; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; Cleveland J L, 1988, Oncogene Res, V3, P357; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FREEMAN RS, 1994, NEURON, V12, P3443; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; GIBSON AW, 1992, BIOCHEM CELL BIOL, V70, P998, DOI 10.1139/o92-143; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HASS R, 1994, CRIT REV ONCOGENESIS, V5, P359, DOI 10.1615/CritRevOncog.v5.i4.20; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Helbing C, 1996, DEV GENET, V18, P223, DOI 10.1002/(SICI)1520-6408(1996)18:3<223::AID-DVG3>3.3.CO;2-T; Helbing CC, 1997, CANCER RES, V57, P1255; HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LEE WH, 1995, ANN NY ACAD SCI, V752, P432, DOI 10.1111/j.1749-6632.1995.tb17453.x; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Mueller Rolf, 1993, Biochimica et Biophysica Acta, V1155, P151; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sambrook J, 1989, MOL CLONING LAB MANU; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1993, ONCOGENE, V8, P1593; VONWEIZSACKER F, 1986, EMBO J, V5, P1521, DOI 10.1002/j.1460-2075.1986.tb04392.x; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WATERS CM, 1991, ONCOGENE, V6, P797; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	77	22	22	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1491	1501		10.1038/sj.onc.1202241	http://dx.doi.org/10.1038/sj.onc.1202241			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794226				2022-12-17	WOS:000076089900001
J	McHenry, JZ; Leon, A; Matthaei, KI; Cohen, DR				McHenry, JZ; Leon, A; Matthaei, KI; Cohen, DR			Overexpression of fra-2 in transgenic mice perturbs normal eye development	ONCOGENE			English	Article						AP-1; fra-2; anterior segment dysgenesis; transgenic	HELIX-ZIPPER PROTEIN; C-FOS; GENE; JUN; TRANSCRIPTION; EXPRESSION; CELLS; PHOSPHORYLATION; TRANSFORMATION; AP-1	The major components of transcription factor AP-1 (Activator Protein 1) are encoded by the two families of genes related to the proto-oncogenes c-fos and c-jun. The fos-related antigen-2 (fra-2) gene is the most recently described member of the Fos family. To determine the oncogenic potential of fra-2, transgenic mice were generated which over-express fra-2 in a number of tissues. No tumours were evident in any transgenic mice up to 18 months of age, although eye development was severely disrupted in these animals. Corneal abnormalities could be observed histologically as early as embryonic day 15.5 and eyelid fusion failed to occur. Adult eyes were characterized by generalized anterior segment dysgenesis similar to that previously reported in transgenic mice over-expressing transforming growth factor alpha (TGF alpha), and occasionally microphthalmia. Expression of fra-2 was shown to increase following TGF alpha. treatment of cells in vitro, suggesting that AP-1 complexes containing Fra-2 contribute to TGF alpha signalling events.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Cell Biol, Canberra, ACT 0200, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Neurosci, Canberra, ACT 0200, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; John Curtin School of Medical Research; Australian National University; John Curtin School of Medical Research	Cohen, DR (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Cell Biol, Canberra, ACT 0200, Australia.		Klaus, Matthaei/D-8691-2011	Cohen, Donna/0000-0002-0419-9542				BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CARRASCO D, 1995, ONCOGENE, V10, P1069; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; FOLETTA VC, 1994, ONCOGENE, V9, P3305; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; GOTZ W, 1995, OPHTHALMIC GENET, V16, P85, DOI 10.3109/13816819509059967; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OEHLER T, 1993, ONCOGENE, V8, P1141; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; RENEKER LXW, 1995, DEVELOPMENT, V121, P1669; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	27	22	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1131	1140		10.1038/sj.onc.1202044	http://dx.doi.org/10.1038/sj.onc.1202044			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764823				2022-12-17	WOS:000075598400008
J	O'Brien, V; Campo, MS				O'Brien, V; Campo, MS			BPV-4 E8 transforms NIH3T3 cells, up-regulates cyclin A and cyclin A-associated kinase activity and de-regulates expression of the cdk inhibitor p27(Kip1)	ONCOGENE			English	Article						BPV-4; cell transformation; cyclin A; cyclin A-associated kinase; E8; p27(Kip1)	BOVINE PAPILLOMAVIRUS TYPE-4; PHASE-TRANSITION; GROWTH-FACTOR; PROTEIN; ONCOPROTEIN; INACTIVATION; FIBROBLASTS; RECEPTOR; GOLGI; BINDS	The E8 open reading frame of Bovine papillomavirus type 4 (BPV-4) encodes a small (42 amino acid) hydrophobic polypeptide localized to cellular membranes and capable of conferring an anchorage-independent (AI) growth phenotype on primary bovine cells co-transfected with BPV-4 E7 ORF and an activated ras gene. To further study the function of E8 independently of other viral gene products, we have expressed it in the murine fibroblast cell line, NIH3T3, Cells expressing E8 are capable of AI growth and escape growth arrest after serum withdrawal. E8 deregulates cyclin A expression, induces transactivation of the human cyclin A gene promoter and increases endogenous protein levels in cells maintained in short-term suspension culture and in low-serum (LS), Both these culture conditions promote downregulation of cyclin A in control cells. In LS growth conditions E8 permits sustained cyclin A-associated kinase activity but not cyclin E-cdk2 activity, Cyclin A-cdk2 activity and, in part, cyclin A gene expression are regulated by the cdk inhibitor p27(Kip1). Expression of this cdk inhibitor is also de-regulated in E8 cells, with high levels being detected under all culture conditions tested. These data suggest that the ability of BPV-4 E8 to transform NIH3T3 cells is associated with upregulation of cyclin A-associated kinase activity and de-regulated expression of the cdk inhibitor p27(Kip1) and does not rely on down-regulation of p27(Kip1) expression. Analysis of E8 mutants indicate that the hydrophilic 'tail' of the molecule (residues 31 - 42) is required for cell transformation, as assessed by anchorage-independent growth, while a form of E8 with expression restricted to the Endoplasmic Reticulum/cis-Golgi membranes by addition of a 'KDEL' retention signal revealed that the sub-cellular localization is an important determinant of E8 biological activity.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	O'Brien, V (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.			O'Brien, Vincent/0000-0002-2418-7768				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CAMPO MS, 1994, CARCINOGENESIS, V15, P1597, DOI 10.1093/carcin/15.8.1597; CARMICHAEL J, 1987, CANCER RES, V47, P943; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GIRARD F, 1991, CELL, V67, P1; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Jackson ME, 1996, INT J ONCOL, V9, P1189; JAGGAR RT, 1990, J GEN VIROL, V71, P3041, DOI 10.1099/0022-1317-71-12-3041; Kramer A, 1996, J BIOL CHEM, V271, P6579; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SETTLEMAN J, 1989, MOL CELL BIOL, V9, P5563, DOI 10.1128/MCB.9.12.5563; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPARKOWSKI J, 1995, EMBO J, V14, P3055, DOI 10.1002/j.1460-2075.1995.tb07308.x; THOME KZ, 1997, MOL CELL BIOL, V17, P407; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZerfassThome K, 1996, ONCOGENE, V13, P2323	33	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					293	301		10.1038/sj.onc.1201937	http://dx.doi.org/10.1038/sj.onc.1201937			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690511				2022-12-17	WOS:000074947500004
J	Doza, YN; Hall-Jackson, CA; Cohen, P				Doza, YN; Hall-Jackson, CA; Cohen, P			Arsenite blocks growth factor induced activation of the MAP kinase cascade, upstream of Ras and downstream of Grb2-Sos	ONCOGENE			English	Article						Raf; MAP kinase kinase (MKK); p70 S6 kinase; mSos; EGF-receptor; stress	MITOGENIC SIGNAL-TRANSDUCTION; PROTEIN-TYROSINE-PHOSPHATASE; L6 MUSCLE-CELLS; NUCLEOTIDE EXCHANGE; PLASMA-MEMBRANE; PC12 CELLS; DOWN-REGULATION; HEAT-SHOCK; RECEPTOR; PATHWAY	Pretreatment of cells with 0.5 mM sodium arsenite (but not other activators of stress-activated MAP kinase cascades) prevents the activation of p21Ras and strongly suppresses the activation of c-Raf and the MAP kinase cascade by a variety of growth factors. Arsenite appears to exert its effect by preventing the guanine nucleotide exchange factor mSos from converting Pas to its active GTP-bound state. Exposure to arsenite may be a simple way of assessing whether Pas plays an essential role in mediating activation of the MAP kinase cascade by extracellular signals.	Univ Dundee, Inst Med Sci, Dept Biochem, MRC Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland	University of Dundee	Cohen, P (corresponding author), Univ Dundee, Inst Med Sci, Dept Biochem, MRC Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland.							ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1995, ONCOGENE, V11, P1327; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DOWNWARD J, 1995, METHOD ENZYMOL, V255, P110; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HUNDAL HS, 1992, ENDOCRINOLOGY, V131, P1165, DOI 10.1210/en.131.3.1165; JOHNSTON D, 1980, J BIOL CHEM, V255, P6975; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TANGUAY RM, 1983, CAN J BIOCHEM CELL B, V61, P414, DOI 10.1139/o83-056; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TRAVERSE S, 1993, ONCOGENE, V8, P3175; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIAO S, 1994, J BIOL CHEM, V269, P21244	41	22	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					19	24		10.1038/sj.onc.1202168	http://dx.doi.org/10.1038/sj.onc.1202168			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671310				2022-12-17	WOS:000074677800003
J	Thomas, J; Leverrier, Y; Marvel, J				Thomas, J; Leverrier, Y; Marvel, J			Bcl-X is the major pleiotropic anti-apoptotic gene activated by retroviral insertion mutagenesis in an IL-3 dependent bone marrow derived cell line	ONCOGENE			English	Article						apoptosis; Bcl-X; IL-3; retroviral insertion mutagenesis	ICE FAMILY PROTEASES; C-ELEGANS; HEMATOPOIETIC-CELLS; DEATH; INTEGRATION; BCL-X(L); MYC; SURVIVAL; SITES; INTERLEUKIN-3	In order to identify genes capable of inhibiting apoptosis induced by different pathways, without inducing proliferation we have performed retroviral insertion mutagenesis in the IL-3 dependent bone marrow derived Baf-3 cell line, Out of 200 mutants obtained in three separate mutagenesis experiments, four mutants were resistant to multiple apoptosis inducing pathways (including growth factor starvation, staurosporine, etoposide and cyclosporin A) and did not proliferate in the absence of IL-3, These four mutants overexpress the bcl-X gene following a retroviral insertion 5' of the translation initiation site, These results indicate that the bcl-X gene is a major pleiotropic anti-apoptotic gene in Baf-3 cells, They also suggest that the Bcl-2 family of genes might be the only one capable of inhibiting apoptosis induced by multiple pathways without inducing cell proliferation.	ENS Lyon, LBMC, CNRS UMR 49 INRA LA 913, F-69364 Lyon 07, France	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Marvel, J (corresponding author), ENS Lyon, LBMC, CNRS UMR 49 INRA LA 913, 46 Allee Italie, F-69364 Lyon 07, France.		marvel, jacqueline/H-8638-2014; LEVERRIER, Yann/M-3767-2014	marvel, jacqueline/0000-0001-6241-459X; LEVERRIER, Yann/0000-0002-4227-5446; Thomas, Joelle/0000-0002-0461-6131				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COFFIN J M, 1991, P645; COSSET FL, 1995, J VIROL, V69, P6314, DOI 10.1128/JVI.69.10.6314-6322.1995; CUYPERS HT, 1984, CELL, V37, P141; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; ENGELMAN A, 1994, BIOESSAYS, V16, P797, DOI 10.1002/bies.950161105; FANG W, 1994, J IMMUNOL, V153, P4388; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Gotoh A, 1997, Curr Opin Hematol, V4, P3; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LEVERRIER Y, 1996, TUMOR BIOL, P176; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Mangeney M, 1996, ONCOGENE, V13, P1441; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MARVEL J, 1994, ONCOGENE, V9, P1117; Mielke C, 1996, BIOCHEMISTRY-US, V35, P2239, DOI 10.1021/bi952393y; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nass SJ, 1996, BIOCHEM BIOPH RES CO, V227, P248, DOI 10.1006/bbrc.1996.1497; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; ROBINSON HL, 1986, J VIROL, V57, P28, DOI 10.1128/JVI.57.1.28-36.1986; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sorensen AB, 1996, J VIROL, V70, P4063; STOCKING C, 1993, GROWTH FACTORS, V8, P197, DOI 10.3109/08977199309011023; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Vairo G, 1996, ONCOGENE, V13, P1511; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	56	22	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1399	1408		10.1038/sj.onc.1201672	http://dx.doi.org/10.1038/sj.onc.1201672			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525739				2022-12-17	WOS:000072572400004
J	Megonigal, MD; Rappaport, EF; Nowell, PC; Lange, BJ; Felix, CA				Megonigal, MD; Rappaport, EF; Nowell, PC; Lange, BJ; Felix, CA			Potential role for wild-type p53 in leukemias with MLL gene translocations	ONCOGENE			English	Article						p53; MLL; DNA topoisomerase II; DNA damage; translocation	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DNA TOPOISOMERASE-II; CHILDRENS-CANCER-GROUP; MUTATIONS; CHILDHOOD; BREAKPOINTS; 11Q23; CELLS; MYELODYSPLASIA	We used single-strand conformation polymorphism (SSCP) analysis of p53 exons 4-8 to screen for possible mutations in 25 pediatric de novo leukemias with translocations of the MLL gene at chromosome band 11q23, Of the 25 patients, 21 were infants. Fifteen cases were acute myeloid leukemia (AML), eight were acute lymphoblastic leukemia (ALL), and two cases were biphenotypic, Nineteen cases were studied at diagnosis and six at time of relapse, p53 mutations were absent in all 19 cases studied at the time of diagnosis. The only mutation was a TGC-->TTC transversion (cys-->phe) at codon 141 in exon 5 in a case of infant ALL at relapse that occurred by subclone evolution after MLL gene translocation, We previously showed that p53 mutations are also absent in pediatric treatment-related leukemias with MLL gene translocations. The absence of p53 mutations at initial transformation may suggest that the anti-apoptotic effect of mutant p53 is not important in leukemias with MLL gene translocations. Alternatively, exogenous DNA damage may be the common feature in treatment-related and de novo cases. Since MLL gene translocations may occur through DNA repair and wild-type p53 is central to DNA repair, the absence of p53 mutations raises the possibility that wild-type p53, not mutant p53, may be important in the genesis of leukemias with these translocations.	Univ Penn, Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania	Felix, CA (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.		Rappaport, Eric/GRO-4051-2022		NCI NIH HHS [CA42232, 1R29CA66140-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA066140, R35CA042232] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413; BODLEY AL, 1993, MOL CELL BIOL, V13, P6190, DOI 10.1128/MCB.13.10.6190; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; BUCKLEY JD, 1989, CANCER RES, V49, P4030; CARBONE D, 1991, ONCOGENE, V6, P1691; Cimino G, 1997, BRIT J HAEMATOL, V96, P308, DOI 10.1046/j.1365-2141.1997.d01-2044.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; DARPA P, 1990, CANCER RES, V50, P6919; DICCIANNI MB, 1994, BLOOD, V84, P3105; FELIX C, UNPUB; Felix CA, 1996, BLOOD, V87, P4376, DOI 10.1182/blood.V87.10.4376.bloodjournal87104376; FELIX CA, 1995, CANCER RES, V55, P4287; FELIX CA, 1995, BLOOD, V85, P3250, DOI 10.1182/blood.V85.11.3250.bloodjournal85113250; FELIX CA, 1994, LEUKEMIA, V8, P963; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FELIX CA, 1992, J CLIN INVEST, V90, P653, DOI 10.1172/JCI115907; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; KASTAN MB, 1991, CANCER RES, V51, P6304; KAWAMURA M, 1995, BLOOD, V85, P2546, DOI 10.1182/blood.V85.9.2546.bloodjournal8592546; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANZA C, 1995, LEUKEMIA, V9, P955; Lanza C, 1996, GENE CHROMOSOME CANC, V15, P48, DOI 10.1002/(SICI)1098-2264(199601)15:1<48::AID-GCC7>3.0.CO;2-4; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Marks DI, 1997, J CLIN ONCOL, V15, P1158, DOI 10.1200/JCO.1997.15.3.1158; MISUDOMI T, 1992, ONCOGENE, V7, P171; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PEDERSENBJERGAARD J, 1995, BLOOD, V86, P3542, DOI 10.1182/blood.V86.9.3542.bloodjournal8693542; POMMIER Y, 1993, CAUSES CONSEQUENCES, P277; PROKOCIMER M, 1994, BLOOD, V84, P2391; PUI CH, 1995, LEUKEMIA, V9, P762; PUI CH, 1990, LANCET, V336, P417, DOI 10.1016/0140-6736(90)91956-B; ROBISON LL, 1989, CANCER, V63, P1904; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; SEVERSON RK, 1993, CANCER EPIDEM BIOMAR, V2, P433; WADA M, 1993, BLOOD, V82, P3163; WINICK NJ, 1993, J CLIN ONCOL, V11, P209, DOI 10.1200/JCO.1993.11.2.209; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608	41	22	23	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1351	1356		10.1038/sj.onc.1201637	http://dx.doi.org/10.1038/sj.onc.1201637			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546437				2022-12-17	WOS:000072422000014
J	Alric, S; Froeschle, A; Piquemal, D; Carnac, G; Bonnieu, A				Alric, S; Froeschle, A; Piquemal, D; Carnac, G; Bonnieu, A			Functional specificity of the two retinoic acid receptor RAR and RXR families in myogenesis	ONCOGENE			English	Article						myogenesis; retinoic acid; RAR; RXR; dominant negative; MyoD	INDUCED GRANULOCYTIC DIFFERENTIATION; EMBRYONAL CARCINOMA-CELLS; NUCLEAR HORMONE RECEPTORS; X-RECEPTOR; MUTANT MICE; SIGNALING PATHWAYS; RESPONSE ELEMENT; THYROID-HORMONE; GENE-REGULATION; MUSCLE-CELLS	In C2 myoblasts, retinoic acid (RA) is an efficient inducer of both growth arrest and differentiation. These RA effects are mediated through at least two classes of retinoic acid receptors (RARs and RXRs), which belong to the nuclear receptor superfamily. To determine the role played by each RAR or RXR family in this model system, we have analysed the effects of RA in C2 myoblasts expressing a dominant negative RAR (dnRAR) or a dominant negative RXR (dnRXR), The stable expression of dnRAR or dnRXR in C2 cells delays the RA-induced growth arrest and differentiation, an effect which is more pronounced in C2-dnRXR myoblasts, Furthermore, the RA-inducible expression of MyoD gene is lost in C2-dnRXR but not in C2-dnRAR cells, indicating that each family of retinoid receptors RAR and RXR may regulate distinct subsets of RA-responsive genes. Finally, using C2 cell lines with different retinoid responsiveness, we provided evidence for a link between the RXR and MyoD families in the process of myogenic differentiation, These results illustrate a critical role for RA-receptors in RA-control of C2 myogenesis and provide tools for studying the function of RA and its receptors during vertebrate development.	INRA, Lab Differenciat Cellulaire & Croissance, F-34060 Montpellier 1, France; Univ Montpellier 2, INSERM, U431, F-34095 Montpellier, France; CNRS, CRBM, Cell Biol Unit, F-34033 Montpellier, France	INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Bonnieu, A (corresponding author), INRA, Lab Differenciat Cellulaire & Croissance, Pl Viala, F-34060 Montpellier 1, France.		Bonnieu, Anne/ABA-7182-2020; Carnac, Gilles/N-6744-2018	Piquemal, David/0000-0002-5870-4276; Carnac, Gilles/0000-0002-3518-8774				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; CARNAC G, 1993, ENDOCRINOLOGY, V133, P2171, DOI 10.1210/en.133.5.2171; CARNAC G, 1993, ONCOGENE, V8, P3103; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN YP, 1991, ROUX ARCH DEV BIOL, V200, P162, DOI 10.1007/BF00190236; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10056, DOI 10.1073/pnas.89.21.10056; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DE LUCA LM, 1991, FASEB J, V5, P2924; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; DOWNES M, 1994, ENDOCRINOLOGY, V134, P2658, DOI 10.1210/en.134.6.2658; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Froeschle A, 1996, ONCOGENE, V12, P411; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRIGNANI F, 1995, CANCER RES, V55, P440; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Gudas Lorraine J., 1994, P443; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; Hofmann Clementine, 1994, P387; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kastner P, 1997, DEVELOPMENT, V124, P313; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KONIECZNY SF, 1989, ONCOGENE, V4, P473; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; KRUYT FAE, 1992, DIFFERENTIATION, V49, P27, DOI 10.1111/j.1432-0436.1992.tb00766.x; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOHNES D, 1995, J STEROID BIOCHEM, V53, P475, DOI 10.1016/0960-0760(95)00094-G; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MONTARRAS D, 1991, NEW BIOL, V3, P592; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NILSEN DA, 1983, P NATL ACAD SCI USA, V80, P5198; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; Sucov HM, 1995, DEVELOPMENT, V121, P3997; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAPSCOTT SJ, 1989, SCIENCE, V245, P532, DOI 10.1126/science.2547249; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WAGNER M, 1992, DEVELOPMENT, V116, P55; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	82	22	22	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					273	282		10.1038/sj.onc.1201484	http://dx.doi.org/10.1038/sj.onc.1201484			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464546				2022-12-17	WOS:000071427100015
J	Nikiforov, MA; Kwek, SSS; Mehta, R; Artwohl, JE; Lowe, SW; Das Gupta, T; Deichman, GI; Gudkov, AV				Nikiforov, MA; Kwek, SSS; Mehta, R; Artwohl, JE; Lowe, SW; Das Gupta, T; Deichman, GI; Gudkov, AV			Suppression of apoptosis by bcl-2 does not prevent p53-mediated control of experimental metastasis and anchorage dependence	ONCOGENE			English	Article						p53; apoptosis; bcl-2; metastasis; anchorage dependence; circulation	PROGNOSTIC-SIGNIFICANCE; P53 MUTATIONS; BREAST-CANCER; EXPRESSION; CELLS; ASSOCIATION; CARCINOMA; TUMORS; GENE; PROGRESSION	Mutations in the p53 tumor suppressor gene are frequently associated with the metastatic stage of tumor progression, Inactivation of p53 was shown to promote metastasis under experimental conditions, To determine the p53 functions that are involved in the control of tumor metastasis, we compared properties of three types of transformed mouse fibroblasts: with intact p53, with p53-mediated apoptosis suppressed by bcl-2 and with p53 inactivated by dominant negative mutants, Although expression of bcl-2 blocked apoptosis in detached cells and increased tumor cell survival in the blood circulation, it was insufficient to affect the ability of p53 to cause cell cycle arrest in detached cells and suppress experimental metastasis. For the suppression of metastasis complete inactivation of p53 was required, We conclude that the apoptotic function of p53 is dispensable for the p53-dependent suppression of experimental metastasis that is presumably achieved by controlling anchorage dependence, These data provide a possible explanation to dramatic differences in values of bcl-2 and mutant p53 as prognostic markers in human cancer.	Univ Illinois, Dept Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Surg Oncol, Chicago, IL 60607 USA; Univ Illinois, Biol Resources Lab, Chicago, IL 60607 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Russian Acad Med Sci, Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cold Spring Harbor Laboratory; Russian Academy of Medical Sciences	Gudkov, AV (corresponding author), Univ Illinois, Dept Mol Genet MC669, 900 S Ashland Ave, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [R21CA062045, R01CA060730] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA60730, R21CA62045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AAS AL, 1996, NAT MED, V2, P811; ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BERTORELLE R, 1995, AM J SURG PATHOL, V19, P463, DOI 10.1097/00000478-199504000-00008; DAMERON KM, 1994, SCIENCE, V265, P1502; DONG ZY, 1994, CANCER RES, V54, P789; Fidler I.J., 1997, CANC PRINCIPLES PRAC; FUGMANN RA, 1977, CANCER RES, V37, P496; GASPARINI G, 1995, CLIN CANCER RES, V1, P189; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HAGUE A, 1994, ONCOGENE, V9, P3367; Herod JJO, 1996, CANCER RES, V56, P2178; HSIAO M, 1994, AM J PATHOL, V145, P702; KASTRINAKIS WV, 1995, ONCOGENE, V11, P647; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARCHETTI A, 1993, CANCER RES, V53, P2846; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Nikiforov MA, 1996, ONCOGENE, V13, P1709; NOONAN KD, 1977, J CELL PHYSIOL, V91, P201, DOI 10.1002/jcp.1040910206; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PROSS HF, 1993, NAT IMMUN, V12, P279; SIERRA A, 1995, INT J CANCER, V60, P5463; THOMPSON TC, 1995, ONCOGENE, V10, P869; TSURUO T, 1981, CANCER RES, V41, P3058; UHLMAN DL, 1994, J NATL CANCER I, V86, P1470, DOI 10.1093/jnci/86.19.1470; ULBRIGHT TM, 1994, MODERN PATHOL, V7, P64; VINDELOV LL, 1988, CYTOMETRY, V3, P323	34	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3007	3012		10.1038/sj.onc.1201723	http://dx.doi.org/10.1038/sj.onc.1201723			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444949				2022-12-17	WOS:000070968000001
J	Baskaran, K; Erfurth, F; Taborn, G; Copeland, NG; Gilbert, DJ; Jenkins, NA; Iannaccone, PM; Domer, PH				Baskaran, K; Erfurth, F; Taborn, G; Copeland, NG; Gilbert, DJ; Jenkins, NA; Iannaccone, PM; Domer, PH			Cloning and developmental expression of the murine homolog of the acute leukemia proto-oncogene AF4	ONCOGENE			English	Article						AF4; MLL; acute leukemia; transcription factor	BONE MORPHOGENETIC PROTEIN-4; DIFFERENTIAL EXPRESSION; PROMYELOCYTIC LEUKEMIA; DROSOPHILA-TRITHORAX; TRANSCRIPTION FACTOR; BINDING DOMAINS; GENE-EXPRESSION; MICE LACKING; DNA-BINDING; ALL-1 GENE	AF4 is the 4q21 gene involved in the acute lymphoblastic leukemia associated t(4;11)(q21;q23) where it forms a fusion gene with MLL, In order to gain insight into AF4's role in leukemogenesis we have studied its functional domains and expression pattern during murine development, We have cloned the murine homolog, Af4. We have demonstrated that 5' half of Af4 encodes a region with transcriptional transactivation activity which is disrupted by the t(4;11) in human leukemias, We have also localized the murine AF4 protein to the nucleus supporting a role for AF4 in transcription, The developmental expression pattern of Af4 was determined in situ hybridization and suggests Af4 plays an important role in the development of the hematopoietic, cardiovascular, skeletal and central nervous systems, A repeating pattern of Af4 expression in development is downregulation with differentiation of a tissue, Among the cell types where this pattern of down-regulation is noted are B-lymphocytes. These findings raise the possibility that the disruption of normal AF4 function by the translocation may contribute to leukemogenesis.	UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,CHILDRENS MEM INST EDUC & RES,CHICAGO,IL 60614; FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702	University of Chicago; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [R29 CA 65911-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA065911] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Chakrabarti L, 1996, HUM MOL GENET, V5, P275, DOI 10.1093/hmg/5.2.275; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN CS, 1993, BLOOD, V82, P1080; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; COLLINS SJ, 1987, BLOOD, V70, P1233; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Fidanza V, 1996, CANCER RES, V56, P1179; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Green EL, 1981, GENETICS PROBABILITY, P77; GRIOGORIADIS AE, 1995, TRENDS GENET, V11, P436; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; HAUANG S, 1992, NATURE, V360, P745; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; KAPPIANPUR AR, 1994, BLOOD, V83, P1200; KEHRL JH, 1995, STEM CELLS, V13, P223, DOI 10.1002/stem.5530130304; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; MITELMAN F, 1992, GENE CHROMOSOME CANC, V5, P57, DOI 10.1002/gcc.2870050109; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OKUDA T, 1996, CELL, V78, P45; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; PUI CH, 1991, BLOOD, V77, P440; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1993, DEVELOPMENT, V118, P47; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sitzmann J, 1995, ONCOGENE, V11, P2273; SPENCE RP, 1988, CANCER RES, V48, P324; STEA B, 1988, INT J RADIAT ONCOL, V15, P1233, DOI 10.1016/0360-3016(88)90209-X; Theiler K, 1989, HOUSE MOUSE ATLAS EM, P78; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; YOUNG PE, 1995, BLOOD, V85, P96, DOI 10.1182/blood.V85.1.96.bloodjournal85196; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735; ZION L, 1995, BLOOD, V86, P2876	57	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1967	1978		10.1038/sj.onc.1201365	http://dx.doi.org/10.1038/sj.onc.1201365			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365243				2022-12-17	WOS:A1997YA87200011
J	Karasaki, H; Obata, M; Ogawa, K; Lee, GH				Karasaki, H; Obata, M; Ogawa, K; Lee, GH			Roles of the Pas1 and Par2 genes in determination of the unique, intermediate susceptibility of BALB/cByJ mice to urethane-induction of lung carcinogenesis: Differential effects on tumor multiplicity, size and Kras2 mutations	ONCOGENE			English	Article						lung tumor; susceptibility gene; interactions; urethane; mouse	HEPATOCARCINOGEN SENSITIVITY LOCI; ADENOMA RESISTANCE LOCUS; HA-RAS GENE; PULMONARY ADENOMA; LIVER-TUMORS; SINGLE-GENE; A/J MICE; MOUSE; ACTIVATION; PROTOONCOGENE	The C3H/HeJ (C3H), A/J and BALB/cByJ (BALB) mouse strains are respectively resistant, sensitive and intermediate regarding the induction of lung tumors by urethane. The phenotypic difference between C3H and A/J is largely determined by the Pas1 (Pulmonary adenoma susceptibility 1) gene an chromosome 6, the A/J allele of which dominantly increases the tumor burden. We recently found Chat BALB mice possess a unique lung tumor resistance gene on chromosome 18, designated Par2 (Pulmonary adenoma resistance 2), which partially, but dominantly suppresses the sensitive phenotype of A/J mice (Oncogene 13: 1599-1604, 1996). It has, however, remained unclear why BALB mice carrying the Par2 gene are significantly more sensitive to urethane-induced lung carcinogenesis than C3H mice that have no dominant lung tumor resistance genes. In the present study, using (C3H x BALB)F-1 x C3H backcross mice treated with urethane, we demonstrated that BALB mice possess the disease allele of the Pas1 gene despite their 15-fold more resistance relative to A/J mice (LOD = 22.6). The BALB Par2 allele only significantly reduced the mean lung tumor multiplicity (LOD=4.4) in the backcross population carrying the BALB allele of Pas1, indicating that the intermediate BALB phenotype may at least in part be the result of interactions between these two dominant genes. While the BALB Pas1 allele increased both the mean multiplicity and size of lung tumors, the BALB Par2 allele affected only the mean tumor multiplicity, implying that they are involved in different stages of multi-step lung carcinogenesis. In addition, we found that 68% of lung tumors from the BALB Pas1-positive backcross mice contained activating point mutations of the KRas2 oncogene, tightly linked to the Pas1 locus, whereas these genetic alterations were absent in tumors from BALB Pas1-negative mice. The Pal2 genotype exhibited no effect on this parameter. Since the activating point mutations mere observed exclusively in the BALB allele as already reported with lung tumors in (C57BL/6J x BALB/cJ)F-1 mice, BALB Pas1 or possibly Kras2 itself may confer selective growth advantage on the affected urethane-initiated lung lesions.	ASAHIKAWA MED COLL,DEPT PATHOL,ASAHIKAWA,HOKKAIDO 078,JAPAN	Asahikawa Medical College								BELINSKY SA, 1989, CANCER RES, V49, P5305; BITTNER J. J., 1938, Public Health Reports, V53, P2197, DOI 10.2307/4582733; BUCHMANN A, 1991, P NATL ACAD SCI USA, V88, P911, DOI 10.1073/pnas.88.3.911; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; CHEN B, 1993, CARCINOGENESIS, V14, P1603, DOI 10.1093/carcin/14.8.1603; Cochran WG., 1989, AMES IOWA STATE U PR, V8; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DEVEREUX TR, 1991, CARCINOGENESIS, V12, P299, DOI 10.1093/carcin/12.2.299; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; DRAGANI TA, 1991, CANCER RES, V51, P6299; Dragani TA, 1996, FASEB J, V10, P865, DOI 10.1096/fasebj.10.8.8666163; DRAGANI TA, 1991, ONCOGENE, V6, P333; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; FIJNEMAN RJA, 1994, ONCOGENE, V9, P1417; Fijneman RJA, 1996, NAT GENET, V14, P465, DOI 10.1038/ng1296-465; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; LEE GH, 1995, GENETICS, V139, P387; LEE GH, 1995, MOL CARCINOGEN, V14, P190, DOI 10.1002/mc.2940140308; LEE GH, 1995, CARCINOGENESIS, V16, P1993, DOI 10.1093/carcin/16.8.1993; MALKINSON AM, 1994, MOL CARCINOGEN, V10, P61, DOI 10.1002/mc.2940100202; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; MASSEY TE, 1995, CARCINOGENESIS, V16, P1065, DOI 10.1093/carcin/16.5.1065; MATZINGER SA, 1994, MOL CARCINOGEN, V11, P42, DOI 10.1002/mc.2940110108; Obata M, 1996, ONCOGENE, V13, P1599; OHMORI H, 1992, CARCINOGENESIS, V13, P851, DOI 10.1093/carcin/13.5.851; RE FC, 1992, MOL CARCINOGEN, V5, P155, DOI 10.1002/mc.2940050211; Strong LC, 1936, J HERED, V27, P21, DOI 10.1093/oxfordjournals.jhered.a104133; SUZUKI Y, 1990, ONCOGENE, V5, P1037; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	38	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1833	1840		10.1038/sj.onc.1201357	http://dx.doi.org/10.1038/sj.onc.1201357			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362450				2022-12-17	WOS:A1997XZ72500010
J	Sobczak, K; Kozlowski, P; Napierala, M; Czarny, J; Wozniak, M; Kapuscinska, M; Losko, M; Koziczak, M; Jasinska, A; Powierska, J; Braczkowski, R; Breborowicz, J; Godlewski, D; Mackiewicz, A; Krzyzosiak, W				Sobczak, K; Kozlowski, P; Napierala, M; Czarny, J; Wozniak, M; Kapuscinska, M; Losko, M; Koziczak, M; Jasinska, A; Powierska, J; Braczkowski, R; Breborowicz, J; Godlewski, D; Mackiewicz, A; Krzyzosiak, W			Novel BRCA1 mutations and more frequent intron-20 alteration found among 236 women from western Poland	ONCOGENE			English	Article						BRCA1; mutations and variants; SSCP-heteroduplex analysis; Polish women; positive family history	BREAST-CANCER SUSCEPTIBILITY; POLYMERASE CHAIN-REACTION; OVARIAN-CANCER; GERMLINE MUTATIONS; RAPID DETECTION; GENE; FAMILIES; P53; DNA; PCR	Three different novel BRCA1 mutations, five independent cases of the same 12 bp insertion-duplication in intron-20 and two novel rare BRCA1 sequence variants were identified among 122 Polish women with positive, in most cases moderate family history of breast and/or ovarian cancer, 80 controls and 34 unselected breast cancer tissue specimens, All mutations and variants were germline. The 4153 delA frameshift mutation, the Tyr105Cys missense mutation and two cases of the alteration in intron-20 were found in the group of healthy women with positive family history. Two other cases of the intronic insertion mere found in unselected controls. Their carriers had no family history of breast or ovarian cancer but other cancers occurred in their families. The 1782 Trp/STOP nonsense mutation and one case of the insertion in intron-20 were first found in tissue specimens of breast cancer patient and breast/ovarian cancer patient, respectively. Their carriers also had no family history of breast or ovarian cancer. The distribution of the insertion in intron-20 in analysed groups and results of RT-PCR experiments suggest a less prominent role for this variant considered earlier a splicing mutation. This study shows also, that more population-oriented research is needed, involving women with less profound or even no family history of breast and ovarian cancer, to better understand the role and significance of different BRCA1 variants and mutations.	POLISH ACAD SCI,INST BIOORGAN CHEM,CANC GENET LAB,PL-61704 POZNAN,POLAND; WIELKOPOLSKA CANC CTR,CANC EPIDEMIOL & PREVENT UNION,PL-61866 POZNAN,POLAND; SILESIAN UNIV,SCH MED,DEPT INTERNAL MED,BYTOM,POLAND; UNIV SCH MED SCI,CHAIR ONCOL,PL-61878 POZNAN,POLAND; UNIV SCH MED SCI,WIELKOPOLSKA CANC CTR,DEPT CANC IMMUNOL,PL-61866 POZNAN,POLAND	Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; Wielkopolskie Centrum Onkologii; Medical University Silesia; Wielkopolskie Centrum Onkologii			Kozlowski, Piotr/I-1860-2019; Woźniak, Marcin/F-2936-2013; Wozniak, Marcin/B-6319-2018	Kozlowski, Piotr/0000-0003-3770-7715; Woźniak, Marcin/0000-0003-4491-3824; Wozniak, Marcin/0000-0002-3213-229X; Sobczak, Krzysztof/0000-0001-8352-9812; Jasinska, Anna/0000-0002-1897-4570				ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FRIEND S, 1995, NAT GENET, V11, P238, DOI 10.1038/ng1195-238; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; Johannsson O, 1996, AM J HUM GENET, V58, P441; Kozlowski P, 1996, NUCLEIC ACIDS RES, V24, P1177, DOI 10.1093/nar/24.6.1177; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P42; Langston AA, 1996, AM J HUM GENET, V58, P881; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1991, LANCET, V338, P82; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SOBCZAK K, 1995, ACTA BIOCHIM POL, V42, P363; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; THOMPSON WD, 1994, CANCER, V74, P279; Wagner TMU, 1996, LANCET, V347, P1263, DOI 10.1016/S0140-6736(96)90781-3; WOOSTER R, 1995, TRENDS GENET, V11, P3, DOI 10.1016/S0168-9525(00)88974-X; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; ZATONSKI WA, 1993, CANC POLAND	32	22	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1773	1779		10.1038/sj.onc.1201360	http://dx.doi.org/10.1038/sj.onc.1201360			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362443	Bronze			2022-12-17	WOS:A1997XZ72500003
J	deBoer, CJ; Vaandrager, JW; vanKrieken, JHJM; Holmes, Z; Kluin, PM; Schuuring, E				deBoer, CJ; Vaandrager, JW; vanKrieken, JHJM; Holmes, Z; Kluin, PM; Schuuring, E			Visualization of mono-allelic chromosomal aberrations 3' and 5' of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization	ONCOGENE			English	Article						11q13; t(11;14); NHL; translocation	MESSENGER-RNA DEGRADATION; HUMAN BREAST-CANCER; UNTRANSLATED REGION; SQUAMOUS-CELL; BCL-1 GENE; OVEREXPRESSION; TRANSLOCATION; AMPLIFICATION; EXPRESSION; PRAD1	In mantle cell lymphoma (MCL), in addition to the characteristic t(11;14)(q13;q32), rearrangements on the 3' side of the cyclin D1 gene have been described. In a series of 32 MCL we found three cases with 3'-rearrangements by Southern blot analysis with a probe representing the 3' untranslated region of the cyclin D1 gene. All three were characterized by the absence of the 4.5 kb transcript, and instead, two cases showed overexpression of the 1.7 kb and a third case (MCLp14) an aberrant 2.5 kb transcript. At the genomic level, fine mapping experiments showed in the 3' untranslated region a 2 kb deletion in MCLp14 and a breakpoint in the other two cases. Fiber FISH analysis showed that in all three cases the 3' aberration co-exists with a regular t(11;14) breakpoint 5' of cyclin D1 on a single allele. Fiber FISH analysis of 16 additional MCL revealed two other such cases with breakpoints 5' and 3' of cyclin D1. These mono-allelic aberrations affecting the cyclin D1 gene suggest that the t(11;14) as a first step switches on transcription, and then sequences in the untranslated region of cyclin D1 are affected to stabilize the message.	LEIDEN UNIV, MED CTR, DEPT PATHOL, NL-2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV, MED CTR, DEPT HEMATOL, NL-2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC			van Krieken, Joannes H J M/D-4138-2009	van Krieken, Joannes H J M/0000-0001-6544-1040				AKIYAMA N, 1994, CANCER RES, V54, P377; Bigoni R, 1996, ONCOGENE, V13, P797; BOSCH F, 1995, BRIT J HAEMATOL, V91, P1025, DOI 10.1111/j.1365-2141.1995.tb05429.x; BOSCH F, 1994, BLOOD, V84, P2726; BROOKES S, 1992, GENE CHROMOSOME CANC, V4, P290, DOI 10.1002/gcc.2870040404; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Courjal F, 1996, INT J CANCER, V69, P247; DEBOER CJ, 1995, BLOOD, V86, P2715, DOI 10.1182/blood.V86.7.2715.bloodjournal8672715; DEBOER CJ, 1995, ONCOGENE, V10, P1833; deBoer CJ, 1997, ANN ONCOL, V8, P109, DOI 10.1023/A:1008207005567; DEBOER CJ, 1993, CANCER RES, V53, P4148; deBoer CJ, 1996, ANN ONCOL, V7, P251; FLORIJN RJ, 1995, HUM MOL GENET, V4, P831, DOI 10.1093/hmg/4.5.831; GILLETT C, 1994, CANCER RES, V54, P1812; HAYASHI T, 1994, INT J HEMATOL, V59, P281; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KLUIN PM, 1996, CURR DIAGN PATHOL, V3, P187; KOMATSU H, 1994, BLOOD, V84, P1226; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; RIMOKH R, 1994, BLOOD, V83, P3689; RIMOKH R, 1993, BLOOD, V81, P3063; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Vaandrager JW, 1997, BLOOD, V89, P349, DOI 10.1182/blood.V89.1.349.349_349_349; WILLIAMS ME, 1994, ANN ONCOL, V5, pS71, DOI 10.1093/annonc/5.suppl_1.S71; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	34	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1599	1603		10.1038/sj.onc.1201320	http://dx.doi.org/10.1038/sj.onc.1201320			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380412				2022-12-17	WOS:A1997XX36900011
J	Lorenzi, MV; Castagnino, P; Chen, Q; Chedid, M; Miki, T				Lorenzi, MV; Castagnino, P; Chen, Q; Chedid, M; Miki, T			Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations	ONCOGENE			English	Article						FGFs; cell transformation; phosphotyrosine; receptor tyrosine kinases; MAP kinases	FMS PROTO-ONCOGENE; TRANSFORMED PHENOTYPE; KINASE-ACTIVITY; POINT MUTATION; K-SAM; EXPRESSION; FGF; DOMAIN; CELLS; CLONING	To assess the effect(s) of the C-terminal domain on FGFR2 function, we engineered a series of mutant FGFR2 cDNAs encoding deletions in the C-terminus of the receptor and compared their growth properties in NIH3T3 fibroblasts, In contrast to FGFR2-WT, receptors with C-terminal truncations induced ligand-independent transformation of NIH3T3 cells and transfectants expressing these mutant receptors efficiently formed colonies in semisolid medium. Introduction of point mutations (Y to F) into the C-terminus of FGFR2 at positions 813, 784 or 780 revealed that these mutant receptors also displayed activities similar to that of C-terminally truncated receptors. C-terminally altered FGF receptors did not show an increase in the basal level of receptor phosphorylation compared to that of FGFR2-WT suggesting that elevated receptor phosphorylation does not underlie the transforming activity of these receptors. Interestingly, expression of transforming FGFR2 derivatives, unlike H-Ras transformed cells, did not result in the activation of the mitogen-activated protein kinases (MAPKs), p42/ERK2 and p44/ERK1, indicating that this pathway is not constitutively active in FGFR2-transformed cells, Finally, we report the overexpression of FGFR2 mRNA and protein in several human tumor cell lines suggesting activation of the receptor in these tumors.			Lorenzi, MV (corresponding author), NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892, USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOU JZ, 1993, PROTEIN SCI, V2, P86; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; ITOH H, 1994, CANCER RES, V54, P3237; KALIMAN P, 1993, BIOCHEMISTRY-US, V32, P9539, DOI 10.1021/bi00088a004; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; LORENZI MV, 1995, ONCOGENE, V10, P2051; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOR O, 1993, CANCER GENET CYTOGEN, V65, P111, DOI 10.1016/0165-4608(93)90217-A; PANG L, 1994, J BIOL CHEM, V269, P10604; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RON D, 1993, J BIOL CHEM, V268, P5388; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SHAOUL E, 1995, ONCOGENE, V10, P1554; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILKIE AOM, 1995, CURR BIOL, V5, P500; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAN GC, 1993, BIOCHEM BIOPH RES CO, V194, P512, DOI 10.1006/bbrc.1993.1849; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	45	22	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					817	826		10.1038/sj.onc.1201242	http://dx.doi.org/10.1038/sj.onc.1201242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266968				2022-12-17	WOS:A1997XQ11700008
J	Corbeil, HB; Branton, PE				Corbeil, HB; Branton, PE			Characterization of an E2F-p130 complex formed during growth arrest	ONCOGENE			English	Review						E2F; p130; growth arrest; cell cycle	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; ADENOVIRUS E1A PROTEINS; CELL-CYCLE ARREST; LARGE T-ANTIGENS; SUSCEPTIBILITY GENE; IN-VIVO; FUNCTIONAL INTERACTIONS; ONCOGENIC ACTIVITY; BINDING PROTEIN	Electrophoretic mobility shift assays were used to analyse the pattern of E2F transcription factor complexes containing pRB and related 'pocket' proteins associated with changes in growth of monkey CV-1 cells. Little change was noted in pRB/E2F complexes following growth arrest or serum stimulation. Serum starvation induced the formation of a novel slowly-migrating p130/E2F complex, termed C7, which was comparable to one reported previously in terminally differentiated C2C12 mouse cells (Corbeil et al., 1995, Oncogene 11, 909-920) and thought to contain one or more additional unidentified proteins. After serum stimulation, C7 complex disappeared in S-phase but returned during mitosis. A major E2F complex containing p107 appeared during S-phase but was undetectable at other times. It appeared likely that regulation of pRB, p107 and p130 occurs by several mechanisms. First, phosphorylation has previously been proposed to be involved. All pRB-related proteins were found to be highly phosphorylated during S-phase when E2F activity was highest, and hypophosphorylated in arrested cells when E2F activity was low. Second, the absolute levels of some members of the RE family varied during the cell cycle. Levels of pRB protein and pRB/E2F complexes changed little; however, the amounts of both p107/E2F and p130/E2F complexes varied according to the overall levels of p107 and p130 proteins. Formation of the novel C7 complex in serum arrested cells suggested a third regulatory mechanism mediated by interactions with additional proteins. Our studies indicated that binding of such proteins with p130/E2F occurred via a site in the 'pocket' similar to that utilized by adenovirus E1A proteins. Such proteins could function as additional regulators of E2F-driven transcription.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University								ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BARBEAU D, 1994, ONCOGENE, V9, P359; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCK V, 1995, ONCOGENE, V11, P31; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; CORBEIL HB, 1994, J VIROL, V68, P6697, DOI 10.1128/JVI.68.10.6697-6709.1994; DAVIES R, 1993, BIOTECHNIQUES, V14, P630; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DYNLACHT BD, 1994, GENE DEV, V8, P2008; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1992, SCIENCE, V255, P87; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FATTAEY AR, 1993, ONCOGENE, V8, P3149; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P65; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7183; JOHNSON DG, 1994, GENE DEV, V8, P1759; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MAYOL X, 1993, ONCOGENE, V8, P2561; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4009; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, TRENDS BIOCHEM SCI, V17, P312; NEVINS JR, 1992, MOL CELL BIOL, V12, P5363; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OTTERSON GA, 1993, ONCOGENE, V8, P949; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sambrook J, 1989, MOL CLONING LAB MANU; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHIMIZU M, 1995, MOL CELL BIOL, V15, P882; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Strober BE, 1996, MOL CELL BIOL, V16, P1576; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; XU M, 1994, MOL CELL BIOL, V14, P420; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	107	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					657	668		10.1038/sj.onc.1201224	http://dx.doi.org/10.1038/sj.onc.1201224			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264406				2022-12-17	WOS:A1997XP68300005
J	Chen, H; Yu, DH; Chinnadurai, G; Karunagaran, D; Hung, MC				Chen, H; Yu, DH; Chinnadurai, G; Karunagaran, D; Hung, MC			Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu	ONCOGENE			English	Article						adenovirus 5 E1A domains; transcriptional repression; neu protooncogene; suppression; transformation	LUNG-CANCER CELLS; OVARIAN-CANCER; TUMOR-SUPPRESSOR; GENE-PRODUCTS; MUTATIONAL ANALYSIS; FUNCTIONAL DOMAINS; C-ERBB-2 ONCOGENE; POINT MUTATION; EXPRESSION; PROTEIN	Overexpression of nea (also known as c-erbB-2 or HER-2) commonly occurs in human cancer and is also known to enchance tumor metastasis and chemoresistance. Our earlier reports showed that the adenovirus 5 E1A can suppresss the neu-mediated transformation by repression of neu. Thus, E1A has the potential to be used as a therapeutic agent against the neu-overexpressing human cancers. However, a serious concern to this approach is that E1A is also capable of immortalizing primary culture cells and can co-operate with ras or E1B oncogenes to transform them. The E1A CR2 domain (amino acid residues 120 to 140) necessary for binding to RB is believed to be required for this oncogenic function. Here, we report that deletion of CR2 region did not affect E1A's capability to repress neu. Interestingly, deletion of the amino acid residues 4 to 25 or 40 to 80 completely disrupted E1A-mediated neu repression. By deleting the amino acid residues from 81 to 185, we have successfully generated a mini-E1A mutant that was sufficient to inhibit neu promoter activity and suppress neu-mediated transformation. The mini-E1A mutant does not contain the CR2 domain that is crucial for RB binding and immortalization, and hence, may serve as a more selective tumor suppressor, and a safes therapeutic agent. It may also be a useful tool to further investigate the molecular mechanism(s) of neu overexpression and E1A-mediated transcriptional repression in cancer cells.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT SURG ONCOL,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,INST MOL VIROL,ST LOUIS,MO 63110	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Washington University (WUSTL)			Hung, Mien-Chie/ABD-5911-2021; Karunagaran, Devarajan/A-8148-2010	Hung, Mien-Chie/0000-0003-4317-4740; Karunagaran, Devarajan/0000-0001-9331-8947; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58880, R01-CA60858] Funding Source: Medline; PHS HHS [16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CORBEIL HB, 1994, J VIROL, V68, P6697, DOI 10.1128/JVI.68.10.6697-6709.1994; DEMILIA J, 1989, ONCOGENE, V4, P1233; DOUGALL WC, 1994, ONCOGENE, V9, P2109; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JELSMA TN, 1988, VIROLOGY, V163, P494, DOI 10.1016/0042-6822(88)90290-5; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORN E, 1986, J VIROL, V57, P765; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Mymryk JS, 1996, ONCOGENE, V13, P1581; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; SAYA H, 1990, MOL CARCINOGEN, V3, P198, DOI 10.1002/mc.2940030406; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WEINER DB, 1990, CANCER RES, V50, P421; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YOKOTA J, 1988, ONCOGENE, V2, P283; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887; ZHANG X, 1989, ONCOGENE, V4, P985; ZHANG YJ, 1995, ONCOGENE, V10, P1947	50	22	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1965	1971		10.1038/sj.onc.1201030	http://dx.doi.org/10.1038/sj.onc.1201030			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150363				2022-12-17	WOS:A1997WV80400009
J	Duprez, E; Tong, JH; Derre, J; Chen, SJ; Berger, R; Chen, Z; Lanotte, M				Duprez, E; Tong, JH; Derre, J; Chen, SJ; Berger, R; Chen, Z; Lanotte, M			JEM-1, a novel gene encoding a leucine-zipper nuclear factor upregulated during retinoid-induced maturation of NB4 promyelocytic leukaemia	ONCOGENE			English	Article						leukaemia; differentiation; retinoids; nuclear factors; cloning	LEUKEMIA-CELL LINE; ACID RECEPTORS; TRANSLOCATION; AP-1; PROLIFERATION; TRANSCRIPTION; PROTEASOME; PROMOTER; RNA	Retinoid-induced proliferation causing hyperleukocytosis is a severe complication of retinoid therapy in t(15;17) acute promyelocytic leukaemia. The molecular basis of this phenomenon is unknown. It is possible that the transiently enhanced cell proliferation results from RA-induction of growth regulatory genes. Using Differential Display of cDNAs from NB4 cells we have identified Jem, a novel gene transcript which is upregulated by retinoids during the early proliferative response in maturating cells but not in resistant cells. A 2.7 kb cDNA was cloned and sequenced. The open reading frame contains a 400 amino acid sequence corresponding to a novel 45 kDa basic protein (pI 8.9). The JEM DNA sequence is detected by FISH on human chromosome 1 at q24. The Jem peptide sequence shows a 'leucine-zipper' dimerisation motif with limited homology to Fos/Jun and ATF/CREB proteins and several putative phosphorylation sites. An atypical basic region may correspond to an unknown DNA-binding domain. The C-terminal end of Jem spans a long stretch featuring a PEST motif. After transfection into COS cells, the Jem protein shows a ponctuated nuclear localisation. We hypothesise that this novel nuclear factor may act as a transcription factor, or coregulator, involved in either cell growth control and/or maturation.	HOP ST LOUIS,INSERM U301,CTR G HAYEM,F-75475 PARIS,FRANCE; RUI JIN HOSP,INST HEMATOL,SHANGHAI,PEOPLES R CHINA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			duprez, estelle a/R-2357-2016					BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIGNAM JDL, 1983, NUCLEIC ACIDS RES, V11, P1495; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Duprez E, 1996, ONCOGENE, V12, P2443; DUPREZ E, 1992, LEUKEMIA, V6, P1281; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; GRIGNANI F, 1994, BLOOD, V83, P10; Gudas Lorraine J., 1994, P443; Hong Waun Ki, 1994, P597; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONES D, 1992, P NATL ACAD SCI USA, V89, P4042, DOI 10.1073/pnas.89.9.4042; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LANOTTE M, 1991, BLOOD, V77, P1080; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Peck Gary L., 1994, P631; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROWLEY JD, 1977, LANCET, V1, P549; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; SAKASHITA A, 1993, BLOOD, V81, P1009; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SIMONSEN CC, 1983, MOL CELL BIOL, V3, P2250, DOI 10.1128/MCB.3.12.2250; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VINSON CR, 1989, SCIENCE, V246, P172; YANGYEN HF, 1991, NEW BIOL, V3, P1206	35	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1563	1570		10.1038/sj.onc.1200995	http://dx.doi.org/10.1038/sj.onc.1200995			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129147				2022-12-17	WOS:A1997WQ54800007
J	Kaufmann, AM; Lichtner, RB; Schirrmacher, V; Khazaie, K				Kaufmann, AM; Lichtner, RB; Schirrmacher, V; Khazaie, K			Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour metastasis	ONCOGENE			English	Article						EGF receptor; retroviral gene transfer; mammary carcinoma; proliferation; apoptosis; metastasis	EPIDERMAL-GROWTH-FACTOR; HUMAN-BREAST-CANCER; CARCINOMA-CELLS; TRANSGENIC MICE; TGF-ALPHA; EXPRESSION; GENES; ACTIVATION; STIMULATION; FIBROBLASTS	The low metastatic MTC (13762NF) rat mammary adenocarcinoma cell line is devoid of epidermal growth factor receptor (EGFR). To test for a link between expression of EGFR and the ability of tumour cells to metastasise from their orthotopic site (spontaneous metastasis), stable subclones of this line (S+) that had been retrovirally transduced to express an ectopic full length HER1 were established and characterised, Proliferation, survival, and response to TGF-alpha were investigated and related to the tumorigenic growth and metastatic properties of the cells, S+ clones responded in vitro to ligand stimulation by growth inhibition and apoptosis, Upon orthotopic inoculation into the mammary fat pad of nude (nu/nu) mice, S+ clones showed retarded growth and apoptosed in situ, while MTC cells or neo(R) control cells showed no signs of apoptosis, Yet, S+ cells exhibited more spontaneous metastasis than the MTC parental cells or neo(R) control cells, Spontaneous metastasis requires cellular detachment (primary site) as well as attachment (secondary site) and growth in target organs, Neither the HER1 mediated increased ECM adhesion nor its negative effect on growth potential explains the observed effect, This is the first direct demonstration of the potential of EGFR to promote spontaneous metastasis of mammary adenocarcinoma cells from their orthotopic site.	GERMAN CANC RES CTR, DIV TUMOR IMMUNOL, D-69120 HEIDELBERG, GERMANY; SCHERING AG, RES LABS, D-13342 BERLIN, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Schering AG				Kaufmann, Andreas/0000-0001-7732-3009				ARMSTRONG DK, 1994, CANCER RES, V54, P5280; BATTAGLIA F, 1988, EUR J CANCER CLIN ON, V24, P1685, DOI 10.1016/0277-5379(88)90068-5; Behrens J, 1992, Semin Cell Biol, V3, P169; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Birchmeier W, 1991, CURR OPIN CELL BIOL, V3, P832, DOI 10.1016/0955-0674(91)90057-6; BOLLA M, 1990, BREAST CANCER RES TR, V16, P97, DOI 10.1007/BF01809293; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CASTELLANI R, 1994, CANCER, V73, P344, DOI 10.1002/1097-0142(19940115)73:2<344::AID-CNCR2820730218>3.0.CO;2-Y; DEAN C, 1994, INT J CANCER, P103; DELARUE JC, 1988, BREAST CANC RES TREA, V11; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HART IR, 1991, BRIT J CANCER, V63, P9, DOI 10.1038/bjc.1991.4; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KAUFMANN AM, 1994, INT J ONCOL, V4, P1149; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KHAZAIE K, 1991, ONCOGENE, V6, P21; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; KOENDERS PG, 1991, CANCER RES, V51, P4544; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LICHTNER RB, 1995, ONCOGENE, V10, P1823; LICHTNER RB, 1992, J BIOL CHEM, V267, P11872; LICHTNER RB, 1988, J CELL PHYSIOL, V137, P285, DOI 10.1002/jcp.1041370211; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARSHALLHEYMAN H, 1994, ONCOGENE, V9, P3655; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MODJTAHEDI H, 1994, CANCER RES, V54, P1695; MORONI MC, 1992, J BIOL CHEM, V267, P2714; NERI A, 1982, J NATL CANCER I, V68, P507; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NICOLSON GL, 1992, ONCOGENE, V7, P1127; NICOLSON GL, 1984, EXP CELL RES, V150, P3, DOI 10.1016/0014-4827(84)90696-7; OSTEROP APRM, 1994, BIOCHEMISTRY-US, V33, P7453, DOI 10.1021/bi00189a053; OZAWA S, 1987, INT J CANCER, V40, P706, DOI 10.1002/ijc.2910400523; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAINSBURY JRC, 1985, LANCET, V1, P364; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHIRRMACHER V, 1985, ADV CANCER RES, V43, P1, DOI 10.1016/S0065-230X(08)60942-2; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207	50	22	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2349	2358						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957076				2022-12-17	WOS:A1996VX10800007
J	Peled, A; Schwartz, D; Elkind, NB; Wolkowicz, R; Li, RZ; Rotter, V				Peled, A; Schwartz, D; Elkind, NB; Wolkowicz, R; Li, RZ; Rotter, V			The role of p53 in the induction of polyploidity of myelomonocytic leukemic M1/2 cells	ONCOGENE			English	Article						wild type p53; mutant p53; giant cells; ploidity	WILD-TYPE P53; C-TERMINAL DOMAIN; DNA-DAMAGE; CYCLE CONTROL; IONIZING-RADIATION; FLOW-CYTOMETRY; SINGLE STRANDS; PROTEIN; REPAIR; GENE	p53 was shown to play a central role in the maintenance of genomic integrity. The present experiments suggest that p53 is involved in the control of cell ploidity. Using a p53 non-producer cell line, M1/2, that was reconstituted to express either wild type or mutant p53 protein, by infection with the temperature sensitive (Ts) p53 Val135 virus, it was found that both loss of wild type p53 or overexpression of mutant p53, may be associated with the generation of cell polyploidity. Overexpression of mutant p53 protein enhanced the appearance of giant cells that further accumulated following gamma-irradiation. Expression of wild type p53 reduced the level of giant cells which accumulated in the parental M1/2 p53 nonproducer cells following gamma-irradiation. This activity of the wild type p53 seems to be mediated by either the reduction in the rate of giant cell generation, as observed in M1/2 derived cell lines expressing low levels of wild type p53 protein or by facilitating their apoptosis, as observed in wild type p53 high-producer cells. The latter conclusion is further supported by the observation that isolated giant cells are directly induced to undergo apoptosis following wild type p53 expression.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AFANASYEV VN, 1993, CYTOMETRY, V14, P603, DOI 10.1002/cyto.990140604; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; BRAIN R, 1994, ONCOGENE, V9, P1775; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FRIEDBERG EC, 1994, BIOESSAYS, V16, P645, DOI 10.1002/bies.950160909; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1995, CANCER RES, V55, P7; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LINDAHL T, 1994, CURR BIOL, V4, P249, DOI 10.1016/S0960-9822(00)00056-7; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PARSHAD R, 1994, CARCINOGENESIS, V15, P33, DOI 10.1093/carcin/15.1.33; Peled A, 1996, CANCER RES, V56, P2148; PELED A, 1995, UNPUB EXPT HEMAT; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; WADEHARPER J, 1993, CELL, V75, P805; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZIPORI D, 1985, BLOOD, V66, P447	49	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1677	1685						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895513				2022-12-17	WOS:A1996VM88700012
J	Zhang, N; Shen, WF; Ho, AD; Lu, M				Zhang, N; Shen, WF; Ho, AD; Lu, M			Three distinct domains in the HOX-11 homeobox oncoprotein are required for optimal transactivation	ONCOGENE			English	Article						homeoprotein; leukemia; oncogene; transactivation	ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING SPECIFICITY; T-CELL LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; TRANSCRIPTION FACTOR; HOX11 GENE; PROTEIN; PROTOONCOGENE; T(10-14)(Q24-Q11); EXTRADENTICLE	HOX-11 (tcl-3) is a homeobox oncogene isolated from the breakpoint region of the t(10;14) chromosomal translocation recurring in T-cell acute lymphoblastic leukemia. Here we demonstrate that the HOX-11 homeoprotein mediates transactivation of reporter genes through various promoters in both mammalian and yeast cells. By deletion analysis, the transactivation domains of HOX-11 have been mapped to three amino acid stretches in the homeoprotein, the glycine-proline-rich region at the amino terminus, the homeodomain and the glutamine-rich region at the carboxyl terminus. The three distinct functional domains of HOX-11 act in concert for optimal transactivation. In addition, the homeodomain of HOX-11 appears to be differentially utilized in a promoter-dependent manner. Our data support the notion that the HOX-11 homeoprotein functions as an oncogenic transcription activator in leukemogenesis.	UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94121 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco								CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROCE CM, 1991, CANCER RES, V51, pS5015; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVELOPMENT, V121, P2909; DUBE ID, 1991, BLOOD, V78, P2996; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAGAN J, 1994, CANCER RES, V54, P226; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; LU M, 1992, NUCLEIC ACIDS RES, V20, P263, DOI 10.1093/nar/20.2.263; LU M, 1994, HUM GENE THER, V5, P203, DOI 10.1089/hum.1994.5.2-203; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; MING L, 1992, ONCOGENE, V7, P1325; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PARK JK, 1992, GENE CHROMOSOME CANC, V4, P32, DOI 10.1002/gcc.2870040105; PEERS B, 1995, MOL CELL BIOL, V15, P7091; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; ZHANG N, 1995, CANCER RES, V55, P1117; ZHANG N, 1993, ONCOGENE, V8, P3265; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	33	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1781	1787						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895525				2022-12-17	WOS:A1996VM88700024
J	Meloche, S; Beatty, BG; Pellerin, J				Meloche, S; Beatty, BG; Pellerin, J			Primary structure, expression and chromosomal locus of a human homolog of rat ERK3	ONCOGENE			English	Article						protein kinase; MAP kinase; gene cloning; chromosomal mapping	ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASES; MAP KINASE; INSITU HYBRIDIZATION; GROWTH-FACTOR; CELLS; DIFFERENTIATION; P44(MAPK); CLONING; FAMILY	We report the cloning and characterization of a human cDNA encoding a novel homolog of rat extracellular signal-regulated kinase 3 (ERK3). The cDNA encodes a predicted protein of 721 amino acids which shares 92% amino acid identity with rat ERK3 over their shared length. Interestingly, the human protein contains a unique extension of 178 amino acids at its carboxy terminal extremity, The human ERK3 protein also displays various degrees of homology to other members of the MAP kinases family, but does not contain the typical TXY regulatory motif between subdomains VII and Vm. Northern blot analysis revealed that ERK3 mRNA is widely distributed in human tissues, with the highest expression detected in skeletal muscle. The human ERK3 gene was mapped by fluorescence lit situ hybridization to chromosome 15q21, a region associated with chromosomal abnormalities in acute nonlymphoblastic leukemias. This information should prove valuable in designing studies to define the cellular function of the ERK3 protein kinase.	UNIV MONTREAL, DEPT PHARMACOL, MONTREAL, PQ H2W 1T8, CANADA; HOSP SICK CHILDREN, DEPT PATHOL, TORONTO, ON M5G 1X8, CANADA	Universite de Montreal; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Meloche, S (corresponding author), HOP HOTEL DIEU, CTR RECH, MONTREAL, PQ H2W 1T8, CANADA.							ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE AL, 1992, GENOMICS, V12, P106, DOI 10.1016/0888-7543(92)90412-L; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUARTE MHO, 1990, CANCER GENET CYTOGEN, V49, P25, DOI 10.1016/0165-4608(90)90160-C; FUKUDA M, 1995, ONCOGENE, V11, P239; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIND L, 1995, HUM MOL GENET, V4, P109, DOI 10.1093/hmg/4.1.109; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; *OMIM, 1996, ONL MEND INH MAN; OWAKI H, 1992, BIOCHEM BIOPH RES CO, V182, P1416, DOI 10.1016/0006-291X(92)91891-S; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUCIU S, 1990, CANCER GENET CYTOGEN, V44, P15, DOI 10.1016/0165-4608(90)90193-E; YUNIS JJ, 1981, NEW ENGL J MED, V305, P135, DOI 10.1056/NEJM198107163050304; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	36	22	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1575	1579						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875998				2022-12-17	WOS:A1996VL38400025
J	Beamish, H; Williams, R; Chen, P; Khanna, KK; Hobson, K; Watters, D; Shiloh, Y; Lavin, M				Beamish, H; Williams, R; Chen, P; Khanna, KK; Hobson, K; Watters, D; Shiloh, Y; Lavin, M			Rapamycin resistance in ataxia-telangiectasia	ONCOGENE			English	Article						ataxia-telangiectasia; rapamycin; Wortmannin; cyclin kinase; cell cycle	CYCLE CHECKPOINT PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; IONIZING-RADIATION; PROTEIN-KINASE; IMMUNOSUPPRESSANT RAPAMYCIN; INDUCED INHIBITION; MAMMALIAN PROTEIN; SERINE RESIDUE; LYMPHOMA-CELLS; S6 KINASE	The gene mutated in the human genetic disorder ataxia-telangiectasia (A-T) has been described recently (Savitsky et al., 1995a) and the complete coding sequence of this gene, ATM, has been reported (Savitsky et al., 1995b). The derived amino acid sequence demonstrates significant homologies to several proteins containing a phosphatidylinositol 3-kinase (PI3-kinase) domain, including the yeast TOR proteins and the human protein FRAP. Since the TOR and FRAP proteins are targets for the immunosuppressive drug rapamycin, we have investigated the effects of this compound on A-T cells. We report here that 3 A-T cell lines are more resistant than control cells to rapamycin's growth inhibiting effects but were more sensitive to the PI3-kinase inhibitor wortmannin. As expected rapamycin (1 nM) inhibited the rate of exit of control cells from G(1) phase but failed to perturb the progression of A-T cells. This difference in cell cycle progress after rapamycin treatment is reflected in ribosomal S6 protein kinase (p70(S6K)) by both a downward mobility shift on SDS-PAGE and inhibition of activity. Furthermore, the G, phase cyclin-dependent kinase, cyclin E-cdk2, was rapidly inhibited in control cells post-treatment, whereas in A-T cells it took considerably longer to observe inhibition. There was no evidence that a GST-FKBP12 fusion protein specifically precipitated the ATM protein in the presence of rapamycin in either cell type. These results demonstrate that the ATM protein is not a direct target for rapamycin but its functional loss renders cells more resistant to this compound.	ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES UNIT,BANCROFT CTR,BRISBANE,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,DEPT SURG,HERSTON,QLD,AUSTRALIA; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 TEL AVIV,ISRAEL	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Tel Aviv University; Sackler Faculty of Medicine			Khanna, Kum Kum/I-1747-2013; Lavin, Martin F/F-5961-2014; Watters, Dianne J/E-6007-2010	Lavin, Martin F/0000-0002-5940-4769; Watters, Dianne J/0000-0002-2555-5825; Khanna, Kum Kum/0000-0001-8650-5381				ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALBERS MW, 1993, ANN NY ACAD SCI, V696, P54; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BIEVER BE, 1990, SCIENCE, V250, P556; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P411; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FAN SJ, 1994, CANCER RES, V54, P5824; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FRAUMENI JF, 1967, JNCI-J NATL CANCER I, V38, P593; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GOTTOFF SP, 1967, AM J DIS CHILD, V114, P617; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HECHT F, 1990, CANC GENET CYTOGENET, V46, P11; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LANGE E, 1995, AM J HUM GENET, V57, P112; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; MORICE WG, 1993, J BIOL CHEM, V268, P3734; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; MUTHUKKUMAR S, 1995, TRANSPLANTATION, V60, P264, DOI 10.1097/00007890-199508000-00010; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PARK BD, 1994, CANCER RES, V54, P896; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; SHILOH Y, 1995, IN PRESS EUR J HUM G; STAN R, 1994, J BIOL CHEM, V269, P32027; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; VI M, 1995, TRENDS BIOCHEM SCI, V20, P303; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	59	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					963	970						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806686				2022-12-17	WOS:A1996VG76600010
J	Saxena, A; Robertson, JT; Ali, IU				Saxena, A; Robertson, JT; Ali, IU			Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas	ONCOGENE			English	Article						malignant astrocytomas; recurrent tumors; p16; p15; CDK4	EPIDERMAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; DEPENDENT KINASES; FACTOR RECEPTOR; HUMAN CANCERS; GLIAL TUMORS; CYCLIN-D; AMPLIFICATION; EXPRESSION; INHIBITORS	Abnormalities in the p16, p15 and CDK4 genes that regulate transition through the G1 phase of the cell cycle have been implicated in the malignant progression of astrocytomas. The results of the present study demonstrate that dysfunction of these genes also occurs during recurrence of glial tumors that were highly malignant at first presentation. Analysis of 10 matched pairs of high grade malignant astrocytomas and their subsequent recurrences identified three distinct groups. The primary and recurrent tumors in Group A did not show structural alterations in the p16, p15 or CDK4 genes, whereas homozygous codeletion of p16 and p15 was observed in both primary and recurrent tumors in Group B. The primary tumors in Group C had a normal profile of p16, p15 and CDK4 at presentation. Upon recurrence, however, the tumors sustained either deletion of p16 alone or codeletion of both p16 and p15 or amplification of CDK4. Analysis of the molecular differences between primary anaplastic astrocytomas/glioblastomas and their subsequent recurrences, which are clinically indistinguishable, may provide better therapeutic options for treatment.	NCI,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; UNIV TENNESSEE,NINDS,NIH,SURG NEUROL BRANCH,MEMPHIS,TN 38119; UNIV TENNESSEE,DEPT NEUROSURG,MEMPHIS,TN 38119	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center								EKSTRAND AJ, 1991, CANCER RES, V51, P2164; ELAZOUZI M, 1989, P NATL ACAD SCI USA, V86, P7186, DOI 10.1073/pnas.86.18.7186; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FLEMING TP, 1992, CANCER RES, V52, P4550; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1990, CANCER RES, V50, P5784; GIANI C, 1994, CANCER RES, V54, P6338; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARBARTH P, 1988, DNA-J MOLEC CELL BIO, V7, P297, DOI 10.1089/dna.1988.7.297; HE J, 1995, CANCER RES, V55, P4833; HERMAN JG, 1995, CANCER RES, V55, P4525; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JAMES CD, 1988, CANCER RES, V48, P5546; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHATIB ZA, 1993, CANCER RES, V53, P5535; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; LUKAS J, 1995, CANCER RES, V55, P4818; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; REED JA, 1995, CANCER RES, V55, P2713; SAXENA A, 1992, CANCER RES, V52, P6716; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0	32	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					661	664						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760309				2022-12-17	WOS:A1996VB32800025
J	Christiansen, JH; Monkley, SJ; Wainwright, BJ				Christiansen, JH; Monkley, SJ; Wainwright, BJ			Murine WNT11 is a secreted glycoprotein that morphologically transforms mammary epithelial cells	ONCOGENE			English	Article						WNT; mammary tumorigenesis; C57MG	PROTO-ONCOGENE INT-1; EXPRESSION; WNT-1; GENE; LINE; GLAND; HYPERPLASIA; PRODUCTS; INVITRO; VECTOR	Wnt genes encode a set of structurally related cell surface glycoproteins that appear to have roles in cell-cell signalling. The ectopic expression of several murine Wnt genes has been implicated in the transformation of mammary epithelial and the onset of mammary tumours. Wnt11 is expressed in the developing embryo in a variety of structures including the dermatome/myotome junction of the somites, the truncus ateriosus region of the heart and limb mesenchyme. Here we report that Wnt11 encodes a glycoprotein that is secreted from expressing cells and becomes associated with the extracellular matrix. In addition, Rat2 fibroblasts expressing WNT11 (which are not morphologically altered themselves) are able to induce the transformation of adjacent C57MG mammary epithelial cells in co-culture experiments. These results suggest that WNT11 functions via a paracrine signalling mechanism to have a direct effect on the morphology and growth characteristics of mammary epithelial cells.	UNIV QUEENSLAND,CTR CELLULAR & MOLEC BIOL,ST LUCIA,QLD 4072,AUSTRALIA	University of Queensland				Monkley, Susan/0000-0001-9174-6278; Wainwright, Brandon/0000-0003-0406-2092; Christiansen, Jeff/0000-0002-8146-1225				ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADLEY RS, 1990, EMBO J, V9, P1565; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; KRUMLAUF R, 1991, GENE TRANSFER EXPRES, P307; KU M, 1993, DEVELOPMENT, V119, P1161; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V23, P311; OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PARR BA, 1993, DEVELOPMENT, V119, P247; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SONNENBERG A, 1986, CANCER RES, V46, P5913; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VANHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	42	22	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2705	2711						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700530				2022-12-17	WOS:A1996UW48700025
J	Masuda, A; Takenaga, K; Kondoh, F; Fukami, H; Utsumi, K; Okayama, H				Masuda, A; Takenaga, K; Kondoh, F; Fukami, H; Utsumi, K; Okayama, H			Role of a signal transduction pathway which controls disassembly of microfilament bundles and suppression of high-molecular-weight tropomyosin expression in oncogenic transformation of NRK cells	ONCOGENE			English	Article						tropomyosin; microfilament bundles; EGF; NRK cells; anchorage-independent growth	EPIDERMAL GROWTH-FACTOR; RAF-1 PROTEIN-KINASE; STRESS FIBERS; FIBROBLASTS; ISOFORM-2; ABILITY; ABSENCE; LINES; MOUSE; ACTIN	Role of disassembly of microfilament bundles and suppression of high-molecular-weight tropomyosin (TM) expression in growth factor- and various oncogene-induced transformation was studied by using NRK cells and its transformation-deficient mutants. In NRK cells which show a transformed phenotype by treatment with EGF and TGF-beta, cellular stress fibers became dissociated by EGF or EGF and TGF-beta combination, whereas TGF-beta alone caused thicker appearance of stress fibers, Accompanying these changes, the expression of TM isoforms 1 and 2 was suppressed by treatment with EGF or EGF and TGF-beta, but elevated by TGF-beta with similar time courses, On the other hand, the transformation-deficient mutant cell Lines, 39-1 and 39-3, did not show the transformed phenotypes by treatment with EGF and TGF-beta. Neither EGF nor EGF and TGF-beta combination affected cellular stress fibers and expression of TM isoforms 1 and 2 in both mutant lines, The relationship between the formation of stress fibers and the expression of TM isoforms was consistent in NRK cells, the mutant lines and their various oncogene-expressing sublines under various culture conditions, NRK cells overexpressing exogenous mouse TM isoform 2 showed markedly decreased susceptibility to EGF-induced dissociation of stress fibers and decreased anchorage-independent growth potential in the presence of EGF and TGF-beta. These results indicate that the transformation-deficient NRK mutant lines, 39-1 and 39-3 have defects in an EGF signal transduction pathway which induces suppression of high-molecular-weight TM expression and disassembly of microfilament bundles and suggested that the activation of the pathway is important for morphological transformation and oncogenic growth in growth factors- and various oncogene-induced transformation of NRK cells.	CHIBA CANC CTR,RES INST,DIV CHEMOTHERAPY,CHUOH KU,CHIBA 260,JAPAN; UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	Chiba Cancer Center; University of Tokyo	Masuda, A (corresponding author), AICHI CANC CTR,RES INST,LAB ULTRASTRUCT RES,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.							BAUM G, 1990, DEV BIOL, V142, P115, DOI 10.1016/0012-1606(90)90155-C; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BISCHEK CB, 1981, CELL, V24, P175; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; GALLOWAY PG, 1990, LAB INVEST, V62, P163; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KUME K, 1992, NEW BIOL, V4, P504; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; Macpherson I, 1969, FUNDAMENTAL TECHNIQU, P214; MASUDA A, 1992, NEW BIOL, V4, P489; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; POLLACK R, 1975, P NATL ACAD SCI USA, V86, P6940; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; TAKENAGA K, 1988, MOL CELL BIOL, V8, P5561, DOI 10.1128/MCB.8.12.5561; TAKENAGA K, 1988, BIOCHEM BIOPH RES CO, V157, P1111, DOI 10.1016/S0006-291X(88)80988-4; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498	36	22	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2081	2088						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668333				2022-12-17	WOS:A1996UP28300006
J	Okimoto, T; Kohno, K; Kuwano, M; Gopas, J; Kung, HF; Ono, M				Okimoto, T; Kohno, K; Kuwano, M; Gopas, J; Kung, HF; Ono, M			Regulation of epidermal growth factor receptor by activated H-ras and V-myc oncogenes in mouse Balb/3T3 cells: Possible roles of AP-1	ONCOGENE			English	Article						H-ras; EGF receptor; AP-1; dominant negative c-jun	DENSITY-LIPOPROTEIN RECEPTOR; TRANSCRIPTION FACTOR AP-1; TUMOR-NECROSIS-FACTOR; MIDDLE T-ANTIGEN; C-FOS GENE; PROTO-ONCOGENE; MALIGNANT TRANSFORMATION; CHEMICAL CARCINOGENS; MOLECULAR-CLONING; TYROSINE KINASE	We previously reported that introduction of H-ras oncogene decreases the epidermal growth factor (EGF) binding activity to cell surface EGF receptor in mouse Balb/3T3, In this study, we have further isolated four H-ras transfectants, four v-myc transfectants and three both H-ras and v-myc (H-ras/v-myc) transfectants of mouse Balb/3T3 cells. In comparison with introduction of v-myc alone or both H-ras and v-myc oncogenes, introduction of H-ras alone resulted in a loss of [I-125]EGF binding activity to the cell surface EGF receptor, RT-PCR analysis also showed much lower levels of EGF receptor gene expression in H-ras transfectants compared to that of parental untransformed cells (Balb-Neo1), v-myc and H-ras/v-myc transfectants, Our results demonstrated the activated binding of a transcription factor, Stat1 p84/p91, which directly interacts with EGF receptor, to c-sis-inducible element (SIE) in both v-myc and H-ras/v-myc transfectants, but not in H-ras transfectants, Among transcription factors which we have analysed, activator protein 1 (AP-1) but not SP-1 was modulated by H-ras. Gel shift assays demonstrated the mobility pattern of TPA-responsive element (TRE) binding complex with AP-1 derived from H-ras transfectants migrated faster than those from Balb-Neo1, v-myc and H-ras/v-myc. Expression of c-Jun and Fra-1 was increased more than threefold in H-ras transfectants compared with Balb-Neo1, v-myc and H-ras/v-myc transfectants, but that of c-Fos, Jun B and SP-1 was unchanged, Both transient and permanent expression of H-ras enhanced AP-1 activity in mouse cells, but further co-introduction of dominant negative c-jun mutant encoding a transcriptionally inactive product inhibited the H-ras dependent AP-1 induction, Transfection of the dominant negative c-jun mutant also restored down-regulation of EGF binding by activated H-ras oncogene, Down-regulation of EGF receptor by activated H-ras and the possible involvement of a transcription factor, AP-1, will be discussed.	KYUSHU UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 81282,JAPAN; SOROKA MED CTR,LAB ONCOL,IL-84101 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,DEPT MICROBIOL & IMMUNOL,IL-84105 BEER SHEVA,ISRAEL; NCI,FREDERICK CANC RES & DEV CTR,LAB BIOCHEM PHYSIOL,FREDERICK,MD 21702	Kyushu University; Ben Gurion University; Soroka Medical Center; Ben Gurion University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Gopas, Jacob/0000-0001-9289-8898				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BROWN PH, 1993, ONCOGENE, V8, P877; CARBONE A, 1991, ONCOGENE, V6, P731; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DELAGE SB, 1994, J BIOL CHEM, V269, P18686; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DONG ZG, 1994, CARCINOGENESIS, V15, P1001, DOI 10.1093/carcin/15.5.1001; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRISCH SM, 1990, ONCOGENE, V5, P75; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GOPAS J, 1992, CELL MOL BIOL, V38, P605; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; JOHNSON AC, 1992, J BIOL CHEM, V267, P1689; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAMADA S, 1994, J BIOL CHEM, V269, P4565; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KURATOMI Y, 1987, J CELL PHYSIOL, V130, P51, DOI 10.1002/jcp.1041300109; LAUTENBERGER JA, 1981, P NATL ACAD SCI-BIOL, V78, P1518, DOI 10.1073/pnas.78.3.1518; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; ONO M, 1988, MOL CELL BIOL, V8, P4190, DOI 10.1128/MCB.8.10.4190; ONO M, 1992, EXP CELL RES, V203, P456, DOI 10.1016/0014-4827(92)90021-Y; ONO M, 1991, CELL GROWTH DIFFER, V2, P317; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHITE S, 1988, J BIOL CHEM, V263, P19286; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STEM DF, 1986, MOL CELL BIOL, V6, P870; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TANIGUCHI S, 1986, JPN J CANCER RES, V77, P1193; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TOMITA K, 1987, J BIOL CHEM, V262, P1398; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; YASUTAKE C, 1987, CANCER RES, V47, P4894	59	22	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1625	1633						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622882				2022-12-17	WOS:A1996UG45800004
J	Walkenhorst, J; Goga, A; Witte, ON; SupertiFurga, G				Walkenhorst, J; Goga, A; Witte, ON; SupertiFurga, G			Analysis of human c-Abl tyrosine kinase activity and regulation in S-pombe	ONCOGENE			English	Article						protein tyrosine kinase; SH3 domain; SH2 domain; autophosphorylation; Abl	FISSION YEAST; BCR-ABL; TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; SH2 DOMAIN; PROTEIN; SRC; GENE; AUTOPHOSPHORYLATION; MUTATIONS	c-Abl protein tyrosine kinase activity is tightly regulated in vertebrate cells. Several mutations, including deletions of the SH3 domain, can activate abl and convert it into an oncogene. To study c-Abl activity in a cellular environment likely to lack specific regulators, we have expressed human c-Abl in Schizosaccharomyces pombe in an inducible fashion. c-Abl, but not a kinase inactive form of the molecule, causes growth arrest followed by death of the cells. Concomitant to Abl expression we observed extensive phosphorylation of endogenous proteins on tyrosine. Mutations in the SH2 domain or in the autophosphorylation site dramatically reduce the ability of Abl to confer the growth arrest phenotype and to phosphorylate endogenous proteins, suggesting a fundamental role of these structures in the activity of the enzyme. An SH3 domain deletion mutant of Abl is equally active as wild type c-Abl in yeast, even under conditions allowing detection of subtle differences. These results demonstrate that there is no intrinsic regulation of c-Abl kinase activity via the SH3 domain and suggest that the inhibitory effect of the SH3 domain observed in mammalian cells is mediated by a factor that is absent in fission yeast. Expression of Abl in S.pombe provides a novel quantitative assay for Abl activity and regulation.	EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	European Molecular Biology Laboratory (EMBL); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles			Superti-Furga, Giulio/AAE-5681-2019; Superti-Furga, Giulio/F-4755-2015	Superti-Furga, Giulio/0000-0002-0570-1768				AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; Koegl M, 1995, ONCOGENE, V11, P2317; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; MATTIONI T, 1995, ONCOGENE, V10, P1325; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; MULLER AJ, 1993, P NATL ACAD SCI USA, V90, P3457, DOI 10.1073/pnas.90.8.3457; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAWYERS CL, 1994, CELL, V77, P1; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	40	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1513	1520						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622867				2022-12-17	WOS:A1996UF07600015
J	Han, DS; PottinClemenceau, C; Imro, MA; Scudeletti, M; Doucet, C; Puppo, F; BroutyBoye, D; Vedrenne, J; Sahraoui, Y; Brailly, H; Poggi, A; Jasmin, C; Azzarone, B; Indiveri, F				Han, DS; PottinClemenceau, C; Imro, MA; Scudeletti, M; Doucet, C; Puppo, F; BroutyBoye, D; Vedrenne, J; Sahraoui, Y; Brailly, H; Poggi, A; Jasmin, C; Azzarone, B; Indiveri, F			IL2 triggers a tumor progression process in a melanoma cell line MELP, derived from a patient whose metastasis increased in size during IL2/INF alpha biotherapy	ONCOGENE			English	Article						human melanomas; IL-2R; tumor progression	RECEPTOR GAMMA-CHAIN; INTERCELLULAR-ADHESION MOLECULE-1; COLONY-STIMULATING FACTOR; HIGH-DOSE INTERLEUKIN-2; FUNCTIONAL INTERLEUKIN-2; GROWTH INHIBITOR; EXPRESSION; FIBROBLASTS; P64	Human melanomas may express both in vivo and in vitro functional IL-Rs and may be expected to directly respond to injected IL2. This may generate biological situations which may be favourable for the patient, but also for tumor progression. Here, we analyse the latter hypothesis. MELP is a melanoma cell line derived from a patient whose metastasis increased in size during IL2 / IFN alpha. biotheraphy. These cells have been characterized in vitro for their phenotype and for their sensitivity to IL2. In vitro MELP cells express an IL2-R alpha(+)beta(+)gamma(-) phenotype and IL2 treatment induces the acquisition of new functional characteristics represented (i) by the increased surface expression of two markers of metastatic evolution (ICAM-1 and by the stable CD44); (ii) induction of the IL2-R gamma, with the appearance of functional IL2-R beta complex, which are also recognized by GM-CSF; (iii) by the inhibition of transcription of a regulatory cytokine such as IL6; (iv) by a differential effect of IL6 on CD44 surface expression in MELP cells treated or not with IL2 (MILG cells); (v) by the acquisition of faster growth rates and appearance of piling up and multilayer cellular organization; (vi) by the development of rapidly growing tumors in nude mice. IL2 induces in MELP cells a tumor progression process that could mimic the metastatic evolution observed in vivo during biotherapy. Therefore, MELP phenotype may help to define a subset of patients in which IL2 therapy may trigger unfavourable evolution.	HOP PAUL BROUSSE,INSERM,U268,F-94807 VILLEJUIF,FRANCE; UNIV GENOA,FAC MED,DIMI,I-16132 GENOA,ITALY; IMMUNOTECH SA,F-13288 MARSEILLE,FRANCE; SAN MARTINO HOSP,DEPT IMMUNOPATHOL ABC,I-16132 GENOA,ITALY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Genoa; University of Genoa; IRCCS AOU San Martino IST			Poggi, Alessandro/K-6664-2016; Azzarone, Bruno/AAH-9251-2019; Indiveri, Francesco/AAE-9086-2020	Poggi, Alessandro/0000-0002-1860-430X; Azzarone, Bruno/0000-0002-5962-3849; Induveri, Francesco/0000-0002-9280-2232				ALILECHE A, 1993, ONCOGENE, V8, P1791; ALTOMONTE M, 1992, NEW ENGL J MED, V327, P959; BENVENISTE EN, 1986, NATURE, V321, P610, DOI 10.1038/321610a0; BIRCH M, 1991, CANCER RES, V51, P6660; BOSCO MC, 1994, BLOOD, V83, P2995, DOI 10.1182/blood.V83.10.2995.2995; BUCKLE AM, 1990, EUR J IMMUNOL, V20, P337, DOI 10.1002/eji.1830200216; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FRASIERSCOTT K, 1988, J CLIN INVEST, V82, P1877, DOI 10.1172/JCI113805; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GREEN JE, 1989, MOL CELL BIOL, V9, P4731, DOI 10.1128/MCB.9.11.4731; HERLYN M, 1990, CLIN EXP METASTAS, V8, P9; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KANAKURA Y, 1993, CANCER RES, V53, P675; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; MORIMOTO K, 1994, BLOOD, V83, P657; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; PLAISANCE S, 1992, INT IMMUNOL, V4, P739, DOI 10.1093/intimm/4.7.739; PLAISANCE S, 1993, INT IMMUNOL, V5, P843; PLAISANCE S, 1993, INT J CANCER, V55, P164, DOI 10.1002/ijc.2910550129; RIMOLDI D, 1993, ANTICANCER RES, V13, P555; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1989, ANN SURG, V210, P474, DOI 10.1097/00000658-198910000-00008; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SINGH RK, 1994, CANCER RES, V54, P3242; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; VOSS SD, 1993, P NATL ACAD SCI USA, V90, P2428, DOI 10.1073/pnas.90.6.2428; WALDMANN TA, 1993, IMMUNOL TODAY, V14, P264, DOI 10.1016/0167-5699(93)90043-K; WEIDMANN E, 1992, CANCER RES, V52, P5963	31	22	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1015	1023						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649792				2022-12-17	WOS:A1996UA88400009
J	Zheng, S; Ramachandran, B; Haigh, JR; Palos, TP; Steger, K; Howard, BD				Zheng, S; Ramachandran, B; Haigh, JR; Palos, TP; Steger, K; Howard, BD			The induction of ret by Wnt-1 in PC12 cells is atypically dependent on continual Wnt-1 expression	ONCOGENE			English	Article						PC12; Wnt-1; ret; neu	NERVE GROWTH-FACTOR; MESSENGER-RNA; NEURONAL DIFFERENTIATION; PHEOCHROMOCYTOMA CELLS; POSSIBLE INVOLVEMENT; INT-1 PROTOONCOGENE; MAMMARY ONCOGENE; GENE; LINE; TRANSFORMATION	Wild type PC12 pheochromocytoma cells that had been infected with a Wnt-1-carrying virus and thus express Wnt-1 (PC12/Wnt-1) are known to acquire the same hat cell phenotype as that of spontaneously occurring PC12 flat cell variants except that the latter do not presently express Wnt-1. Flat cell variants of PC12 cells exhibit markedly altered morphology and gene expression. In order to assess the possibility that the spontaneously occurring flat cell variants could have been induced in wild type PC12 cells by previous transient expression of the cell's endogenous Wnt-1, we have isolated PC12/Wnt-1 cells expressing little or no Wnt-1, In spite of absent Wnt-1 expression, they retained their flat cell morphology, glutamate/aspartate transporter activity, increased neu mRNA levels and lack of both norepinephrine transporter activity and nerve growth factor-induced differentiation, Thus, Wnt-1 expression is not required to maintain the flat cell phenotype, However, we identified one gene, ret, whose mRNA level in PC12 was not only increased by Wnt-1 expression, but whose increased mRNA level was also dependent on continual Wnt-1 expression, This finding suggests that the induction of vet by Wnt-1 can be used to elucidate the Wnt-induced signalling pathway in mammalian cells.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH038633, R01MH038633] Funding Source: NIH RePORTER; NIMH NIH HHS [MH38633] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN JK, 1990, J NEUROCHEM, V55, P559, DOI 10.1111/j.1471-4159.1990.tb04170.x; ANDERSON DJ, 1994, FASEB J, V8, P707, DOI 10.1096/fasebj.8.10.8050669; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOUGALL WC, 1994, ONCOGENE, V9, P2109; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAMETT DC, 1994, FEBS LETT, V351, P335, DOI 10.1016/0014-5793(94)00855-8; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HERZLINGER D, 1994, DEV BIOL, V166, P815, DOI 10.1006/dbio.1994.1360; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; ISSACK PS, 1994, NEUR SOC ABSTR, V20, P1077; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOON RT, 1993, DEVELOPMENT S, V118, P85; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; Pestka S, 1981, Methods Enzymol, V78, P3; RAMACHANDRAN B, 1993, J BIOL CHEM, V268, P23891; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SUGIMOTO Y, 1988, J BIOL CHEM, V263, P12102; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; VONDEIMLING A, 1995, BRAIN PATHOL, V5, P153; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	45	22	25	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					555	562						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637712				2022-12-17	WOS:A1996TV59700012
J	Kushner, DB; Pereira, DS; Liu, XH; Graham, FL; Ricciardi, RP				Kushner, DB; Pereira, DS; Liu, XH; Graham, FL; Ricciardi, RP			The first exon of Ad12 E1A excluding the transactivation domain mediates differential binding of COUP-TF and NF-kappa B to the MHC class I enhancer in transformed cells	ONCOGENE			English	Article						adenovirus; E1A; COUP-TF; NF-kappa B	DNA-BINDING; RAT-CELLS; GENE-EXPRESSION; P65 SUBUNIT; TRANSCRIPTION FACTORS; REL ONCOGENE; ADENOVIRUS-TYPE-12; PROTEINS; P50; REPRESSION	The major histocompatibility complex class I enhancer is the target for adenovirus-12 E1A-mediated down-regulation of class I transcription. In Ad12 transformed rodent cells, the class I enhancer is down-regulated through increased binding of the repressor COUP-TF to the R2 element and decreased binding of the activator NF-kappa B (p50/p65) to the R1 element. The reduced surface levels of class I antigens contribute to the tumorigenic potential of Ad12 transformed cells by favoring their immunoescape from cytotoxic T-lymphocytes. Previous studies using transformed containing hybrid Ad5/Ad12 E1A (plus Ad12 E1B) genes have indicated that sequences within the first exon of the 266R Ad12 E1A gene are required for class I down-regulation and tumorigenesis. In this study we demonstrate that these same sequences, which exclude the Ad12 CR3 transactivation domain, are also required for increased COUP-TF binding to the R2 element and decreased NF-kappa B binding to the R1 element of the class I enhancer. We further show that diminished NF-kappa B binding is not due to a lack of NF-kappa B1-p50 in the nuclei of Ad12 transformed rat cells.	UNIV PENN,SCH DENT MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104; UNIV PENN,GRAD GRP MOLEC BIOL,PHILADELPHIA,PA 19104; MCMASTER UNIV,DEPT BIOL,HAMILTON,ON L8S 4K1,CANADA; MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8S 4K1,CANADA	University of Pennsylvania; University of Pennsylvania; McMaster University; McMaster University				Kushner, David B/0000-0002-6260-5094	NCI NIH HHS [CA-29797] Funding Source: Medline; NIAID NIH HHS [5-T32-AI0735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029797] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKRILL AM, 1988, ONCOGENE, V3, P483; ACKRILL AM, 1989, VIROLOGY, V172, P643, DOI 10.1016/0042-6822(89)90207-9; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EAGER KB, 1985, P NATL ACAD SCI USA, V82, P5525, DOI 10.1073/pnas.82.16.5525; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRAHAM FL, 1974, NATURE, V251, P687, DOI 10.1038/251687a0; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JELINEK T, 1994, J VIROL, V68, P888, DOI 10.1128/JVI.68.2.888-896.1994; JELINEK T, 1992, J VIROL, V66, P4117, DOI 10.1128/JVI.66.7.4117-4125.1992; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; LIU X, 1996, IN PRESS MOL CELL BI, V16; LIU XH, 1994, ONCOGENE, V9, P2183; MEIJER I, 1992, CELL IMMUNOL, V145, P56, DOI 10.1016/0008-8749(92)90312-D; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEREIRA DS, 1995, VIROLOGY, V211, P268, DOI 10.1006/viro.1995.1400; PEREIRA DS, 1994, INT J ONCOL, V5, P1197; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PERRICAUDET M, 1980, NATURE, V288, P174, DOI 10.1038/288174a0; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; QIU YH, 1994, TRENDS ENDOCRIN MET, V5, P234, DOI 10.1016/1043-2760(94)P3081-H; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RAZIUDDIN J A M, 1991, Proceedings of the National Academy of Sciences of the United States of America, V88, P9426; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; TELLING GC, 1994, J VIROL, V68, P877, DOI 10.1128/JVI.68.2.877-887.1994; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; YEWDELL JW, 1988, VIROLOGY, V162, P236, DOI 10.1016/0042-6822(88)90413-8	53	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					143	151						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552385				2022-12-17	WOS:A1996TQ01400018
J	Hansen, R; Reddel, R; Braithwaite, A				Hansen, R; Reddel, R; Braithwaite, A			The transforming oncoproteins determine the mechanism by which p53 suppresses cell transformation: pRb-mediated growth arrest or apoptosis	ONCOGENE			English	Article						p53; retinoblastoma protein; SV40 large T antigen; transformation; cell cycle; apoptosis	WILD-TYPE P53; LARGE T-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; SV40 LARGE-T; ADENOVIRUS E1A PROTEINS; LARGE TUMOR-ANTIGEN; HUMAN-DIPLOID FIBROBLASTS; TRANSCRIPTION FACTOR E2F; SIMIAN VIRUS-40; SUSCEPTIBILITY GENE	To investigate the mechanisms by which p53 suppresses cell transformation, we used the simian virus 40 (SV40) large T antigen (LTag), the adenovirus Ela proteins, and an activated ras protein (EJ-ras), to examine different pathways of transformation for their susceptibility to suppression by p53, While p53 can suppress transformation by various oncoproteins, we have shown that it is unable to suppress the transformation of rat embryo fibroblasts (REFs) by LTag, Interestingly, the function of LTag which enables it to overcome the proliferative effects of p53 is not the binding inactivation of p53, but the binding and inactivation of the pRb family of proteins, This observation indicates that pRb mediates a suppressive effect of p53 on cell transformation, We have also observed that in contrast to LTag, both Ela and EJ-ras cause transformation-related events which are susceptible to suppression by p53, Further studies have revealed that cells expressing Ela are susceptible to p53-mediated apoptosis, while cells expressing EJ-ras are susceptible to p53-induced growth inhibition, We therefore propose that p53 suppresses transformation either by arresting cell growth (mediated by pRb in late G1) or by inducing apoptosis, with the mechanism being determined by the transforming oncoprotein(s).	CHILDRENS MED RES INST,SYDNEY,NSW 2145,AUSTRALIA	Children's Medical Research Institute - Australia; University of Sydney	Hansen, R (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 0200,AUSTRALIA.		Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107				BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DICKMANNS A, 1994, J VIROL, V68, P5496, DOI 10.1128/JVI.68.9.5496-5508.1994; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1989, ONCOGENE, V4, P383; ELDIERY WS, 1993, CELL, V75, P817; ELDIERY WS, 1994, CANCER RES, V54, P1169; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GERSHEY EL, 1979, J VIROL, V30, P76, DOI 10.1128/JVI.30.1.76-83.1979; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hiscott J B, 1980, Cold Spring Harb Symp Quant Biol, V44 Pt 1,, P343; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JACKSON P, 1993, ONCOGENE, V8, P589; JIANG D, 1993, ONCOGENE, V8, P2805; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MACLEAN K, 1994, ONCOGENE, V9, P719; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MORGANBESSER AD, 1994, NATURE, V371, P72; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NEVINS JR, 1992, SCIENCE, V258, P424; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Reed Michael, 1993, Gene Expression, V3, P95; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SEGAWA K, 1993, ONCOGENE, V8, P543; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SOMPAYRAC L, 1992, VIROLOGY, V191, P439, DOI 10.1016/0042-6822(92)90206-5; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	97	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2535	2545						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545110				2022-12-17	WOS:A1995TP18800009
J	GLOVER, HR; BAKER, DA; CELETTI, A; DIBB, NJ				GLOVER, HR; BAKER, DA; CELETTI, A; DIBB, NJ			SELECTION OF ACTIVATING MUTATIONS OF C-FMS IN FDC-P1 CELLS	ONCOGENE			English	Article						C-FMS; C-KIT; FDC-P1; TYROSINE KINASE; ACTIVATING MUTATION	COLONY-STIMULATING FACTOR; DEPENDENT PROTEIN-KINASE; FACTOR-I CSF-1; OP OP MOUSE; V-FMS; ONCOGENE PRODUCT; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; SURFACE EXPRESSION; CATALYTIC SUBUNIT	FDC-P1 haemopoietic cells were used to select mutations of c-fms that constitutively activate the receptor for macrophage-colony stimulating factor (M-CSF or CSF-1), One mutation changed Ser 929 to Gly within a Ser/Gly rich region of the C-terminal tail and a second changed a nearby, highly conserved Leu 926 for Pro. A third mutation (D802V) changed Asp 802 to Val within the alpha L12/beta 9 region of the tyrosine kinase domain, so supporting the crystallographic evidence that this region triggers kinase activation, A c-kit mutation exactly equivalent to D802V was previously identified in a leukamic cell line and was demonstrated here to be transforming. Surprisingly, although D802V potently transformed FDC-P1 cells, it could not induce Rat-2 fibroblast foci, even in the presence of M-CSF. It is suggested that the accelerated receptor degradation induced by D802V may account for its cell specific effect.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CHEM PATHOL,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London; Imperial College London			Celetti, Angela/AAY-7172-2020					BAKER DA, 1994, LEUKEMIA, V8, P141; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CARUANA G, 1993, EXP HEMATOL, V21, P761; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; HADWIGER A, 1986, EMBO J, V5, P689, DOI 10.1002/j.1460-2075.1986.tb04268.x; HALENBECK R, 1989, BIO-TECHNOL, V7, P710, DOI 10.1038/nbt0789-710; HAPEL AJ, 1984, BLOOD, V64, P786; HUNTER T, 1992, COLD SPRING HARB SYM, V57, P25, DOI 10.1101/SQB.1992.057.01.005; KARN J, 1989, ONCOGENE, V4, P773; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MCDONOUGH SK, 1971, CANCER RES, V31, P953; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; POLLARD JW, 1991, DEV BIOL, V48, P273; QUI F, 1988, EMBO J, V7, P1003; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TSUJIMURA T, 1994, BLOOD, V83, P2619; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; WETTERS TV, 1992, EMBO J, V11, P551, DOI 10.1002/j.1460-2075.1992.tb05086.x; WIKTORJEDRZEJCZ.W, 1982, J EXP MED, V156, P1516; WIKTORJEDRZEJCZ.W, 1990, P NATL ACAD SCI USA, V87, P4828; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	52	22	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1347	1356						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478556				2022-12-17	WOS:A1995RY96700016
J	PORCELLINI, A; CIULLO, I; PANNAIN, S; FENZI, G; AVVEDIMENTO, E				PORCELLINI, A; CIULLO, I; PANNAIN, S; FENZI, G; AVVEDIMENTO, E			SOMATIC MUTATIONS IN THE VI-TRANSMEMBRANE SEGMENT OF THE THYROTROPIN RECEPTOR CONSTITUTIVELY ACTIVATE CAMP SIGNALING IN THYROID HYPERFUNCTIONING ADENOMAS	ONCOGENE			English	Article						THYROTROPIN RECEPTOR; CAMP-DEPENDENT TRANSCRIPTION PCR; MUTATIONS; NEOPLASMS GENETICS	PHOSPHATIDYLINOSITOL; ONCOGENE; TUMORS	We have discovered two somatic mutations in the VI transmembrane domain of the thyrotropin receptor gene in thyroid hyperfunctioning adenomas, The mutated amino acid residues are phenylalanine 631 (to cysteine) and threonine 632 (to isoleucine), Cloning and expression of the mutated versions of the receptor in COS cells increased significantly the basal and the TSH-induced cAMP levels compared to the wild type receptor, Moreover, the expression of a reporter gene under the control of the cAMP-inducible promoter, was likewise constitutively activated in cells expressing the 631 and 632 TSH receptor mutants relative to the wild type, These data indicate that the VI transmembrane segment in the TSH receptor and presumably in the other G-protein coupled receptors is a critical domain for the activation of G-protein signalling and that the mutations described here may be the cause of the thyroid hyperfunctioning adenoma.	UNIV REGGIO CALABRIA, FAC MED CATANZARO, DIPARTIMENTO MED SPERIMENTALE, CATANZARO, ITALY; UNIV NAPLES FEDERICO II, FAC MED, DIPARTIMENTO ENDOCRINOL, I-80131 NAPLES, ITALY; UNIV NAPLES FEDERICO II, CTR ENDOCRINOL & ONCOL MOLEC, I-80131 NAPLES, ITALY	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; University of Naples Federico II; University of Naples Federico II			Porcellini, Antonio/E-1900-2011	Porcellini, Antonio/0000-0001-6882-9518				AVVEDIMENTO VE, 1984, BIOCHEM BIOPH RES CO, V122, P472; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1991, BIOCHIMIE, V73, P29, DOI 10.1016/0300-9084(91)90070-H; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P657, DOI 10.1210/jc.79.2.657; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SUAREZ HG, 1991, ONCOGENE, V6, P677; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P109	22	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1089	1093						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566968				2022-12-17	WOS:A1995RX18000011
J	AGARWAL, S; CORBLEY, MJ; ROBERTS, TM				AGARWAL, S; CORBLEY, MJ; ROBERTS, TM			RECONSTITUTION OF SIGNAL-TRANSDUCTION FROM THE MEMBRANE TO THE NUCLEUS IN A BACULOVIRUS EXPRESSION SYSTEM - ACTIVATION OF RAF-1 LEADS TO HYPERMODIFICATION OF C-JUN AND C-FOS VIA MULTIPLE PATHWAYS	ONCOGENE			English	Article						SIGNALING PATHWAYS; KINASES; RAF-1; ERK-1; NUCLEAR ONCOGENES; C-FOS; C-JUN; POSTTRANSLATIONAL MODIFICATIONS	GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN-KINASE; DNA-BINDING ACTIVITY; MAP KINASE; HA-RAS; COMPLEX-FORMATION; GROWTH-FACTORS; INSECT CELLS; S6 KINASE; 3T3 CELLS	We have attempted to dissect signaling pathways involved in transmitting activating signals from the cell surface to the nucleus by reconstituting them in the baculovirus/Sf9 cell system. We have used this system to coexpress different combinations of the critical signaling proteins pp60(v-src), p21(v-ras), Raf-1 and ERK-1 and assayed the effects of resulting signaling cascades on the modifications of coexpressed transcription factors c-jun or c-fos. We observe that activation of ERK-1 via Raf-1 and p21(ras) dependent signals can result in the hyperphosphorylation of c-jun. In contrast, c-fos appears to be the target of two Raf-1 activated modifying signals: one independent of ERK-1 and the other dependent on ERK-1 stimulation. Thus, coexpression of c-fos with pp60(v-src), p21(v-ras) or constitutively active forms of Raf-1 results in a dramatic reduction of its electrophoretic mobility in the absence of coexpressed ERK-1. Activation of this ERK-1-independent pathway together with the ERK-1 dependent pathway that modifies c-jun results in additional modification of c-fos. Our observation of a Raf-1 activated, ERK-independent signaling pathway is consistent with previous reports that constitutively active Raf-1 can, in some cell types, result in transformation or differentiation without activation of ERKs. Our data indicate the presence of multiple Raf-1 activated pathways that lead to modification of transcription factors.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [CA43803] Funding Source: Medline; NICHD NIH HHS [HD24926] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, ONCOGENE, V6, P2179; ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; AHN NG, 1992, CIBA F SYMP, V164, P113; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHUNG J, 1991, P NATL ACAD SCI USA, V58, P4981; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; CURRAN T, 1984, CELL, V36, P259; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEGROOT RP, 1993, ONCOGENE, V8, P841; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Distel R J, 1990, Adv Cancer Res, V55, P37, DOI 10.1016/S0065-230X(08)60467-4; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HERRERA R, 1990, CELL GROWTH DIFFER, V1, P483; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MEEK DW, 1992, BIOCHEM J, V287, P1; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SETH A, 1992, J BIOL CHEM, V267, P24796; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Summers MD, 1987, MANUAL METHODS BACUL; TAYLOR LK, 1994, J BIOL CHEM, V269, P308; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAN MH, 1994, NATURE, V372, P798; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	92	22	23	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					427	438						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7543194				2022-12-17	WOS:A1995RN53000002
J	GALDEMARD, C; BRISON, O; LAVIALLE, C				GALDEMARD, C; BRISON, O; LAVIALLE, C			THE PROTOONCOGENE FGF-3 IS CONSTITUTIVELY EXPRESSED IN TUMORIGENIC, BUT NOT IN NONTUMORIGENIC, CLONES OF A HUMAN COLON-CARCINOMA CELL-LINE	ONCOGENE			English	Article						FGF-3/INT-2; DIFFERENTIAL TRANSCRIPTION; COLON CARCINOMA; MYC AMPLIFICATION	GROWTH-FACTOR FAMILY; C-MYC AMPLIFICATION; HUMAN-BREAST TUMORS; INT-2 GENE; MESSENGER-RNA; HUMAN CANCER; MOUSE; PHENOTYPE; MEMBER; ACID	The human colon carcinoma cell line, SW613-S, is composed of cells with a high-level amplification of the MYC proto-oncogene that are tumorigenic in nude mice and of cells with a low-level amplification of MYC that are not tumorigenic. Transcripts from FGF-3, a member of the fibroblast growth factor gene family, accumulate in cells from tumorigenic clones, but are undetectable in those from non-tumorigenic clones. Nuclear run-on analyses indicate that this differential FGF-3 expression is regulated at the level of transcription initiation. Determination of the structure of the FGF-3 transcripts indicates that they are generated by splicing of the three exons and termination at the single polyadenylation site predicted from the genomic sequence. Their size heterogeneity is due to multiple initiation sites spanning a 700 base-pair long promoter region. FGF-3 is activated in tumors induced in nude mice by MYC-transfected cells from non-tumorigenic clones. However, in most of the cell lines established from these tumors, FGF-3 expression tends to be lost upon in vitro propagation. Thus, in these transfectant cell lines, the presence of exogenous MYC gene copies is not sufficient to activate FGF-3 expression and in vivo growth is also required.	INST GUSTAVE ROUSSY,GENET ONCOL LAB,CNRS,URA 1967,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Lavialle, Christian/O-2329-2019; Lavialle, Christian/B-3775-2009					ADNANE J, 1989, ONCOGENE, V4, P1389; ALI IU, 1989, ONCOGENE, V4, P89; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BROOKES S, 1989, ONCOGENE, V4, P429; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHERIF D, 1989, CHROMOSOMA, V97, P327, DOI 10.1007/BF00371974; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DRON M, 1986, MOL CELL BIOL, V6, P1374, DOI 10.1128/MCB.6.5.1374; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GOLDFARB M, 1991, ONCOGENE, V6, P65; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMONERIE T, 1995, EXP CELL RES, V216, P342, DOI 10.1006/excr.1995.1043; LAVIALLE C, 1988, ONCOGENE, V3, P335; LAVIALLE C, 1990, ONCOGENE, V5, P245; LAVIALLE C, 1989, ANTICANCER RES, V9, P1265; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LISCIA DS, 1989, ONCOGENE, V4, P1219; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MODJTAHEDI N, 1992, INT J CANCER, V52, P483, DOI 10.1002/ijc.2910520325; MODJTAHEDI N, 1985, CANCER RES, V45, P4372; MODJTAHEDI N, 1992, EXP CELL RES, V201, P74, DOI 10.1016/0014-4827(92)90349-D; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURAKAMI A, 1993, NUCLEIC ACIDS RES, V21, P5351, DOI 10.1093/nar/21.23.5351; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; ORNITZ DM, 1992, JNCI-J NATL CANCER I, V84, P887, DOI 10.1093/jnci/84.11.887; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; SUAREZ HG, 1987, ONCOGENE RES, V1, P201; THEILLET C, 1989, ONCOGENE, V4, P915; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; ZHANG GH, 1994, CELL GROWTH DIFFER, V5, P349	46	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2331	2342						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784081				2022-12-17	WOS:A1995RE54300008
J	CHEN, XR; WRIGHT, KL; BERKOWITZ, EA; AZIZKHAN, JC; TING, JPY; LEE, DC				CHEN, XR; WRIGHT, KL; BERKOWITZ, EA; AZIZKHAN, JC; TING, JPY; LEE, DC			PROTEIN INTERACTIONS AT SP1-LIKE SITES IN THE TGF-ALPHA PROMOTER AS VISUALIZED BY IN-VIVO GENOMIC FOOTPRINTING	ONCOGENE			English	Article							GROWTH-FACTOR-ALPHA; LIVER EPITHELIAL-CELLS; CHEMICALLY TRANSFORMED INVITRO; HUMAN-BREAST-CANCER; MESSENGER-RNA; TRANSCRIPTION FACTOR; TRANSGENIC MICE; ANTERIOR-PITUITARY; DEVELOPMENTAL EXPRESSION; HUMAN KERATINOCYTES	Transcription from the rat TGP alpha promoter initiates at two predominant sites (-188 and -58) in a G+C-rich region that does not contain TATA or CAAT motifs. Previous studies using transfected reporter constructs implicated the transcription factor Sp1 in active expression from the promoter, particularly from the -58 site (Chen et al., 1992; Shin et al., 1992). In the present report we have examined the functionality of two adjacent clusters of Sp1-like recognition sites that are located in the upstream portion of the promoter from -300 to -273. A double-stranded oligonucleotide, which spanned this region and contained the putative Sp1 elements, demonstrated similar gel-mobility shifts in the presence of both crude HeLa cells nuclear extract and pure Sp1 protein. Mutations that simultaneously altered several of the overlapping Sp1 elements significantly reduced the gel-mobility shift activity of this oligonncleotide probe and, when introduced into the promoter templates, inhibited transcription in vitro from the proximal -188 start site. To confirm the binding of protein to these sites in cells, we carried out an in vivo genomic footprinting analysis of this portion of the TGF alpha promoter in normal and transformed rat liver epithelial cell lines that express the endogenous gene at varying levels. This analysis revealed clear evidence of protein/DNA interaction at Sp1-like sites in the -300 and -273 region in cells actively expressing the gene but not in a normal, parental cell. line that expressed very low levels of TGF alpha mRNA. Collectively, these results corroborate the functional importance of Sp1 binding elements in the -300 to -273 region, and together with previous findings, indicate that two clusters of Sp1 binding sites respectively determine levels of transcription from the -188 and -58 start sites. Our additional finding that Sp1 mRNA and protein were present at similar levels in normal and transformed cells that expressed the endogenous TGF alpha gene at markedly different levels, suggests that the activity of the TGF alpha promoter could be regulated via the accessibility of Sp1 protein.	UNIV N CAROLINA, SCH MED, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL CANCER INSTITUTE [R01CA048185, R01CA043793] Funding Source: NIH RePORTER; NCI NIH HHS [CA-48185, CA-43793] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BORGUNDVAAG B, 1992, ENDOCRINOLOGY, V130, P3453, DOI 10.1210/en.130.6.3453; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHEN XR, 1992, ONCOGENE, V7, P1805; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1987, CANCER RES, V47, P707; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GODWIN AK, 1990, ONCOGENE, V5, P1231; HAMBURGER AW, 1993, P SOC EXP BIOL MED, V202, P64; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KOHDA D, 1989, BIOCHEMISTRY-US, V28, P953, DOI 10.1021/bi00429a005; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU C, 1988, CANCER RES, V48, P850; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; LYNCH MJ, 1993, CANCER RES, V53, P4041; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCKNIGHT GS, 1977, ANAL BIOCHEM, V78, P86, DOI 10.1016/0003-2697(77)90011-2; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUELLER SG, 1991, MOL ENDOCRINOL, V5, P1439, DOI 10.1210/mend-5-10-1439; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; MURAKAMI H, 1993, CANCER RES, V53, P1719; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RAYMOND VW, 1989, CANCER RES, V49, P3608; ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; SEROOGY KB, 1993, J NEUROCHEM, V60, P1777, DOI 10.1111/j.1471-4159.1993.tb13403.x; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; TAKAGI H, 1993, CANCER RES, V53, P4329; TSAO MS, 1985, CANCER RES, V45, P5139; TSAO MS, 1985, CANCER RES, V45, P5134; TWARDZIK DR, 1982, SCIENCE, V216, P894, DOI 10.1126/science.6177040; TWARDZIK DR, 1983, VIROLOGY, V124, P201, DOI 10.1016/0042-6822(83)90307-0; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WILCOX JN, 1988, J NEUROSCI, V8, P1901; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZIPFEL PA, 1993, CELL GROWTH DIFFER, V4, P637; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	67	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3179	3187						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936640				2022-12-17	WOS:A1994PM65800009
J	BALUDA, MA; REDDY, EP				BALUDA, MA; REDDY, EP			ANATOMY OF AN INTEGRATED AVIAN-MYELOBLASTOSIS PROVIRUS - STRUCTURE AND FUNCTION	ONCOGENE			English	Review							ROUS-SARCOMA VIRUS; AMINO-ACID-SEQUENCE; V-MYB ONCOGENE; DNA-BINDING DOMAIN; RNA TUMOR-VIRUS; MOLONEY MURINE LEUKEMIA; LONG TERMINAL REPEAT; C-MYB; NUCLEOTIDE-SEQUENCE; REVERSE-TRANSCRIPTASE		TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,SCH MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90024	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P30CA012227, P01CA052009, R01CA010197] Funding Source: NIH RePORTER; NCI NIH HHS [CA 12227, CA 10197, CA 52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER F, 1987, J VIROL, V61, P534, DOI 10.1128/JVI.61.2.534-542.1987; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BALUDA MA, 1983, FOLIA BIOL-PRAGUE, V29, P18; BALUDA MA, 1974, COLD SPRING HARB SYM, V39, P869, DOI 10.1101/SQB.1974.039.01.101; BALUDA MA, 1964, NATL CANCER I MONOGR, V17, P449; BEAUDREAU GS, 1960, J NATL CANCER I, V24, P395; BENNETT RP, 1991, J VIROL, V65, P272, DOI 10.1128/JVI.65.1.272-280.1991; BERGMANN DG, 1981, J VIROL, V40, P450, DOI 10.1128/JVI.40.2.450-455.1981; BERGMANN DG, 1980, J VIROL, V34, P366, DOI 10.1128/JVI.34.2.366-372.1980; BEUG H, 1982, EMBO J, V1, P1069, DOI 10.1002/j.1460-2075.1982.tb01298.x; BHOWN AS, 1980, J BIOL CHEM, V255, P6962; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOLOGNESI DP, 1973, VIROLOGY, V56, P549, DOI 10.1016/0042-6822(73)90057-3; BOLOGNESI DP, 1970, VIROLOGY, V42, P1097, DOI 10.1016/0042-6822(70)90357-0; BOWLES NE, 1993, J VIROL, V67, P623, DOI 10.1128/JVI.67.2.623-631.1993; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BURMESTER BR, 1959, JNCI-J NATL CANCER I, V23, P277; BURSTEIN H, 1991, J VIROL, V65, P6165, DOI 10.1128/JVI.65.11.6165-6172.1991; BURSTEIN H, 1992, J VIROL, V66, P1781, DOI 10.1128/JVI.66.3.1781-1785.1992; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; CARLBERG K, 1988, J VIROL, V62, P1617, DOI 10.1128/JVI.62.5.1617-1624.1988; CHEN JH, 1981, VIROLOGY, V110, P128, DOI 10.1016/0042-6822(81)90014-3; CHEN JH, 1974, J VIROL, V13, P340, DOI 10.1128/JVI.13.2.340-346.1974; COFFIN J, 1985, RNA TUMOR VIRUSES, V2, P17; COPELAND TD, 1980, J VIROL, V36, P115, DOI 10.1128/JVI.36.1.115-119.1980; CORDELL B, 1976, J VIROL, V19, P548, DOI 10.1128/JVI.19.2.548-558.1976; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; CRAVEN RC, 1991, J VIROL, V65, P6205, DOI 10.1128/JVI.65.11.6205-6217.1991; CROCHET J, 1986, VIROLOGY, P252; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DETHE G, 1964, JNCI-J NATL CANCER I, V32, P201; DOUGHERTY RM, 1965, VIROLOGY, V27, P351, DOI 10.1016/0042-6822(65)90115-7; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1989, ONCOGENE, V4, P1061; DUESBERG PH, 1980, P NATL ACAD SCI-BIOL, V77, P5120, DOI 10.1073/pnas.77.9.5120; DUPRAZ P, 1993, J VIROL, V67, P3826, DOI 10.1128/JVI.67.7.3826-3834.1993; DUPRAZ P, 1990, J VIROL, V64, P4978, DOI 10.1128/JVI.64.10.4978-4987.1990; EISENMAN RN, 1980, J VIROL, V36, P62, DOI 10.1128/JVI.36.1.62-78.1980; ENGELKE V, 1994, J VIROL, V68, P2752; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; FURUICHI Y, 1975, NATURE, V257, P618, DOI 10.1038/257618a0; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; GONDA TJ, 1981, CELL, V23, P279, DOI 10.1016/0092-8674(81)90292-0; GRANDGENETT D, 1985, J BIOL CHEM, V260, P8243; HACKETT PB, 1982, J VIROL, V41, P527, DOI 10.1128/JVI.41.2.527-534.1982; HALL W. J., 1941, AMER JOUR VET RES, V2, P272; HANAFUSA H, 1963, P NATL ACAD SCI USA, V49, P572, DOI 10.1073/pnas.49.4.572; HANAFUSA H, 1963, P NATL ACAD SCI USA, V49, P576; HIPPENMEYER PJ, 1984, VIROLOGY, V137, P358, DOI 10.1016/0042-6822(84)90228-9; HIZI A, 1977, J BIOL CHEM, V252, P2290; HORTON R, 1991, J VIROL, V65, P1141, DOI 10.1128/JVI.65.3.1141-1148.1991; HOUTS GE, 1978, J VIROL, V25, P546, DOI 10.1128/JVI.25.2.546-552.1978; HUNTER E, 1983, J VIROL, V45, P885, DOI 10.1128/JVI.45.2.885-888.1983; HUNTER E, 1983, J VIROL, V46, P920, DOI 10.1128/JVI.46.3.920-936.1983; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; JASKOLSKI M, 1990, BIOCHEMISTRY-US, V29, P5889, DOI 10.1021/bi00477a002; JENTOFT JE, 1988, P NATL ACAD SCI USA, V85, P7094, DOI 10.1073/pnas.85.19.7094; JOHNSON SP, 1983, J VIROL, V45, P876, DOI 10.1128/JVI.45.2.876-881.1983; JOLIOT V, 1993, VIROLOGY, V195, P812, DOI 10.1006/viro.1993.1436; KAN NC, 1985, VIROLOGY, V145, P323, DOI 10.1016/0042-6822(85)90166-7; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATZ RA, 1988, J VIROL, V62, P528, DOI 10.1128/JVI.62.2.528-533.1988; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KEITH J, 1975, P NATL ACAD SCI USA, V72, P3347, DOI 10.1073/pnas.72.9.3347; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KNIGHT JB, 1994, J VIROL, V68, P4493, DOI 10.1128/JVI.68.7.4493-4502.1994; KUNG HJ, 1975, J VIROL, V16, P397, DOI 10.1128/JVI.16.2.397-411.1975; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIN TH, 1991, J BIOL CHEM, V266, P1635; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LIPSICK JS, 1987, J VIROL, V61, P933, DOI 10.1128/JVI.61.3.933-936.1987; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LIPSICK JS, 1984, CANCER CELLS, V2, P143; LUBAN J, 1994, J VIROL, V68, P3784, DOI 10.1128/JVI.68.6.3784-3793.1994; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAK J, 1994, J VIROL, V68, P2065, DOI 10.1128/JVI.68.4.2065-2072.1994; Maxam A M, 1980, Methods Enzymol, V65, P499; MERIC C, 1986, J VIROL, V60, P450; MERIC C, 1988, J VIROL, V62, P3328; MERREGAERT J, 1987, VIROLOGY, V158, P88, DOI 10.1016/0042-6822(87)90241-8; MISONO KS, 1980, FED P EXP BIOL ABS, V60, P1611; MIZUTANI S, 1971, NATURE-NEW BIOL, V230, P232, DOI 10.1038/newbio230232a0; MOELLING K, 1980, J VIROL, V33, P680, DOI 10.1128/JVI.33.2.680-688.1980; MOMMAERTS EB, 1952, P SOC EXP BIOL MED, V79, P450, DOI 10.3181/00379727-79-19409; MONTELARO RC, 1978, VIROLOGY, V84, P19, DOI 10.1016/0042-6822(78)90215-5; MOSCOVIC.C, 1968, VIROLOGY, V35, P487, DOI 10.1016/0042-6822(68)90278-X; MOSCOVICI C, 1970, VIROLOGY, V42, P61, DOI 10.1016/0042-6822(70)90238-2; MURTI KG, 1981, J VIROL, V37, P411, DOI 10.1128/JVI.37.1.411-419.1981; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PANET A, 1975, J VIROL, V16, P146, DOI 10.1128/JVI.16.1.146-152.1975; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PEARL LH, 1987, NATURE, V328, P482, DOI 10.1038/328482b0; PEPINSKY RB, 1979, J MOL BIOL, V131, P819, DOI 10.1016/0022-2836(79)90203-1; PERBAL B, 1983, J VIROL, V45, P925, DOI 10.1128/JVI.45.3.925-940.1983; PERBAL B, 1982, J VIROL, V44, P586, DOI 10.1128/JVI.44.2.586-594.1982; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; PERBAL B, 1985, J VIROL, V56, P240, DOI 10.1128/JVI.56.1.240-244.1985; PETERS GG, 1980, J VIROL, V36, P692, DOI 10.1128/JVI.36.3.692-700.1980; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; PRESS RD, 1992, J VIROL, V66, P5373, DOI 10.1128/JVI.66.9.5373-5383.1992; REDDY EP, 1981, SCIENCE, V214, P445, DOI 10.1126/science.6170110; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; RUSHLOW KE, 1982, J VIROL, V42, P840, DOI 10.1128/JVI.42.3.840-846.1982; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SAUER RT, 1981, BIOCHEMISTRY-US, V20, P3784, DOI 10.1021/bi00516a018; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SILVA RF, 1982, J VIROL, V44, P422, DOI 10.1128/JVI.44.1.422-425.1982; SORET J, 1988, FEBS LETT, V232, P227, DOI 10.1016/0014-5793(88)80422-8; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; SOUZA LM, 1980, J VIROL, V36, P325, DOI 10.1128/JVI.36.2.325-336.1980; SOUZA LM, 1980, J VIROL, V36, P317, DOI 10.1128/JVI.36.2.317-324.1980; SRIVATSAN ES, 1980, J VIROL, V34, P288, DOI 10.1128/JVI.34.1.288-292.1980; STEWART L, 1990, J VIROL, V64, P5076, DOI 10.1128/JVI.64.10.5076-5092.1990; STEWART L, 1991, J VIROL, V65, P6218, DOI 10.1128/JVI.65.11.6218-6231.1991; STEWART L, 1993, J VIROL, V67, P7582, DOI 10.1128/JVI.67.12.7582-7596.1993; STOBERGRASSER U, 1988, J VIROL, V62, P1093; STOCKING C, 1985, P NATL ACAD SCI USA, V82, P5746, DOI 10.1073/pnas.82.17.5746; SWANSTROM R, 1982, J VIROL, V41, P535, DOI 10.1128/JVI.41.2.535-541.1982; SWANSTROM R, 1981, P NATL ACAD SCI-BIOL, V78, P124, DOI 10.1073/pnas.78.1.124; TAYLOR JM, 1975, VIROLOGY, V65, P248, DOI 10.1016/0042-6822(75)90025-2; TAYLOR JM, 1975, J VIROL, V16, P553, DOI 10.1128/JVI.16.3.553-558.1975; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VOGT VM, 1985, J VIROL, V56, P31, DOI 10.1128/JVI.56.1.31-39.1985; VONDERHELM K, 1977, P NATL ACAD SCI USA, V74, P911; WANG LH, 1976, P NATL ACAD SCI USA, V73, P447, DOI 10.1073/pnas.73.2.447; Waters L C, 1977, Prog Nucleic Acid Res Mol Biol, V20, P131; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WILLS JW, 1983, J CELL BIOCHEM, V23, P81, DOI 10.1002/jcb.240230109; WILLS JW, 1991, J VIROL, V65, P3804, DOI 10.1128/JVI.65.7.3804-3812.1991; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; YAMAMOTO T, 1980, CELL, V22, P787, DOI 10.1016/0092-8674(80)90555-3; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	160	22	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2761	2774						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084581				2022-12-17	WOS:A1994PG82200001
J	BATSCHE, E; LIPP, M; CREMISI, C				BATSCHE, E; LIPP, M; CREMISI, C			TRANSCRIPTIONAL REPRESSION AND ACTIVATION IN THE SAME CELL-TYPE OF THE HUMAN C-MYC PROMOTER BY THE RETINOBLASTOMA GENE PROTEIN - ANTAGONISATION OF BOTH EFFECTS BY SV40 T-ANTIGEN	ONCOGENE			English	Article							ADENOVIRUS E1A PROTEINS; TRANS-ACTIVATION; SUSCEPTIBILITY GENE; RB PROTEIN; PRODUCT; E2F; BINDING; EXPRESSION; GROWTH; CYCLE	The c-myc promoter was investigated as a possible cellular target for SV40 large T (LT) antigen. In fibroblast and epithelial cell lines, the human c-myc promoter was transactivated by LT. This transactivation was dependent of the interaction of LT with the retinoblastoma (RB) protein. The use of deletions and point mutations of the c-myc promoter demonstrated that in both cell, types, the E2F binding sites are necessary for such transactivation. Unexpectedly however, over-expression of RB caused an overall transcriptional activation of the c-myc promoter. We resolved this apparent paradox by demonstrating that this activation is a combination of two antagonistic effects: transcriptional repression mediated by the E2F factor, and transcriptional activation independent of this factor. RB was also found to prevent LT-mediated transactivation, and LT inhibited RB-mediated activation independently of the E2F factor. LT therefore antagonizes both the transcriptional repression and activation mediated by RB.	INST PASTEUR,UNITE TECHNOL CELLULAIRE,F-75724 PARIS 15,FRANCE; MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Lipp, Martin/G-2235-2010	Batsche, Eric/0000-0002-5145-5270				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BORRELLI E, 1986, P NATL ACAD SCI USA, V83, P2846, DOI 10.1073/pnas.83.9.2846; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LIPP M, 1989, ONCOGENE, V4, P535; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEVINS JR, 1992, SCIENCE, V258, P424; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAFFER JD, 1990, P NATL ACAD SCI USA, V77, P5706; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WANG HWH, 1991, MOL CELL BIOL, V11, P288; WASYLYK C, 1986, EMBO J, V5, P553, DOI 10.1002/j.1460-2075.1986.tb04246.x; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YU DH, 1992, J BIOL CHEM, V267, P10203; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	39	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2235	2243						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036009				2022-12-17	WOS:A1994NX62900015
J	SOLDI, R; GRAZIANI, A; BENELLI, R; GHIGO, D; BOSIA, A; ALBINI, A; BUSSOLINO, F				SOLDI, R; GRAZIANI, A; BENELLI, R; GHIGO, D; BOSIA, A; ALBINI, A; BUSSOLINO, F			ONCOSTATIN-M ACTIVATES PHOSPHATIDYLINOSITOL-3-KINASE IN KAPOSIS-SARCOMA CELLS	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; RECEPTOR TYROSINE KINASES; HEPATOCYTE GROWTH-FACTOR; IL-6 SIGNAL TRANSDUCER; POLYOMAVIRUS MIDDLE-T; SH2 DOMAINS; ERYTHROPOIETIN RECEPTOR; PDGF RECEPTOR; BINDING-SITE; PI 3-KINASE	Oncostatin M (OM) is a polypeptide cytokine that induces autocrine and paracrine effects on AIDS-Kaposi's sarcoma (KS) cells (Nair et al., Science, 255, 1430-1432, 1992; Miles et al., Science, 255, 1432-1434, 1992). The signalling pathways underlying this activation are largely unknown. We have found that OM binding to KS cell Lines in vitro identifies a higher affinity binding site (Kd 10-20 pM) with a lower affinity (Kd 1.5 nM), high capacity binding site. The binding of OM to its receptor at the KS cell surface stimulates a rapid tyrosine phosphorylation of multiple proteins, including the p85 regulatory subunit of phosphatidylinositol-3-kinase (PI3K). In addition OM can stimulate the in vivo activation of PI3K and increases the PI3K activity in anti-phosphotyrosine and anti-src kinase family antibody directed immunoprecipitates. Genistein, an inhibitor of tyrosine kinases, inhibits the synthesis of phosphatidylinistol 3,4-biphosphate and the growth of KS cells. Finally, OM enhances tyrosine kinase activity in immune complex kinase assay performed with antibody anti-src kinase family. These data suggest that in KS cells OM can stimulate formation of tyrosine kinase co-ordinate signalling complexes, containing at least src kinase family and PI3K, which can drive the accumulation of the putative second-messengers D3-phosphorylated phosphoinositides.	DIPARTIMENTO GENET BIOL & CHIM MED, I-10100 TURIN, ITALY; DIPARTIMENTO SCI BIOMED & ONCOL, I-10100 TURIN, ITALY; IST NAZL RIC CANC, I-16100 GENOA, ITALY	University of Genoa; IRCCS AOU San Martino IST			graziani, andrea/B-2554-2009; Bussolino, Federico/AES-3951-2022; Graziani, Andrea/AAB-6301-2022; Bussolino, Federico/K-2500-2016	graziani, andrea/0000-0002-6302-2317; Graziani, Andrea/0000-0002-6302-2317; Bussolino, Federico/0000-0002-5348-1341; Ghigo, Dario/0000-0001-6050-1577; Benelli, Roberto/0000-0002-9769-0954; Albini, Adriana/0000-0002-9624-5103				ALBINI A, 1992, INT J ONCOL, V1, P723; AMARAL MC, 1993, J CLIN INVEST, V92, P848, DOI 10.1172/JCI116659; AMREIN KE, 1993, P NATL ACAD SCI USA, V90, P10285, DOI 10.1073/pnas.90.21.10285; ARMES J, 1989, ADV CANCER RES, V53, P73; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGER KR, 1992, J BIOL CHEM, V267, P5408; AUGER RK, 1990, METHODS INOSITIDES R, P155; BROWN TJ, 1993, BLOOD, V82, P33, DOI 10.1182/blood.V82.1.33.bloodjournal82133; BROWN TJ, 1991, J IMMUNOL, V147, P2175; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTER AN, 1992, J BIOL CHEM, V267, P14563; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DADI HK, 1993, J CLIN INVEST, V92, P1559, DOI 10.1172/JCI116736; DAMEN JE, 1993, BLOOD, V81, P3204; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; HAVERKOS HW, 1985, NEW ENGL J MED, V312, P1518; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LINSLEY PS, 1989, J BIOL CHEM, V264, P4282; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RUTGERS JL, 1986, AM J PATHOL, V122, P493; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; THOMPSON PA, 1992, ONCOGENE, V7, P719; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; WEICH HA, 1991, AM J PATHOL, V139, P1251; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	70	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2253	2260						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036010				2022-12-17	WOS:A1994NX62900017
J	CHEN, JM; ZONG, CS; WANG, LH				CHEN, JM; ZONG, CS; WANG, LH			TISSUE AND EPITHELIAL CELL-SPECIFIC EXPRESSION OF CHICKEN PROTOONCOGENE C-ROS IN SEVERAL ORGANS SUGGESTS THAT IT MAY PLAY ROLES IN THEIR DEVELOPMENT AND MATURE FUNCTIONS	ONCOGENE			English	Article							TYROSINE-KINASE RECEPTOR; HUMAN INSULIN-RECEPTOR; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; SEVENLESS PROTEIN; GENE; FAMILY; PROTOONCOGENE; PRODUCTS; MEMBERS	Proto-oncogene c-ros codes for a receptor-type protein tyrosine kinase (PTK) sharing high homology with the Drosophila sevenless protein. Recent studies of c-ros expression in mouse by in situ hybridization showed that c-ros was expressed specifically and transiently in the epithelial cells of late embryonic kidney collecting duct and intestine villi. Those investigators suggested that c-ros may play a role in the development of those organelles. In the present study, we have examined the expression profile of c-ros in chicken by RNAase protection and in situ hybridization with riboprobes. Our results showed that in addition to kidney and intestine, low levels of c-ros mRNA could also be detected in lung, testis, thymus and bursa. Expression of c-ros commences during middle to late embryonic stages in those organs and persists into the adult life. In situ hybridization revealed that expression of c-ros was restricted to the epithelial cells of all the tissues examined including kidney, intestine, bursa, thymus and testis. In kidney c-ros was detected in all the epithelial cells of the collecting ducts, in intestine it was detected in the epithelial cells of villi and the underneath crypts. Our finding of c-ros expression in chicken differs from those in mouse in (1) instead of transient expression during the embryonic stage, expression of c-ros in chicken kidney and intestine persists into the adult life and (2) expression of c-ros in renal collecting ducts is not restricted to its growing tips, instead it is expressed in the entire epithelial layer of the ducts. Our results suggest that c-ros may play a role not only in the initial induction events in the organogenesis, but also in the mature function of those organs.	MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA 29339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN GA, 1959, AM J ANAT, V104, P163, DOI 10.1002/aja.1001040202; BASLER K, 1988, CELL, V54, P299; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BIRCHMEIER C, 1987, P NATL ACAD SCI USA, V84, P9270, DOI 10.1073/pnas.84.24.9270; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P1122; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; CHEN JM, 1991, ONCOGENE, V6, P257; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GILBERT SF, 1991, DEV BIOL, P582; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HART AC, 1993, NATURE, V361, P732, DOI 10.1038/361732a0; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Kratochwil K., 1983, P99; KRESS C, 1990, DEVELOPMENT, V109, P775; LEDOUARIN N, 1968, ANN EMBRYOL MORPHOG, V1, P29; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NORTON PA, 1990, CELL, V61, P15, DOI 10.1016/0092-8674(90)90209-W; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Rolnik V.V., 1970, BIRD EMBRYOLOGY; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; Sambrook J., 1989, MOL CLONING; SHARMA S, 1989, ONCOGENE RES, V5, P91; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; TIEDGE H, 1991, DNA CELL BIOL, V10, P143, DOI 10.1089/dna.1991.10.143; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LH, 1974, J VIROL, V14, P1515, DOI 10.1128/JVI.14.6.1515-1529.1974; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982	35	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					773	780						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108119				2022-12-17	WOS:A1994MW55100012
J	COBB, BS; PARSONS, JT				COBB, BS; PARSONS, JT			REGULATION OF THE CELLULAR SRC PROTEIN-TYROSINE KINASE - INTERACTIONS OF THE CARBOXYL-TERMINAL SEQUENCES RESIDING BETWEEN THE KINASE DOMAIN AND TYROSINE-527	ONCOGENE			English	Article							SH3 DOMAINS; MONOCLONAL-ANTIBODIES; TRANSFORMING PROTEIN; STABLE ASSOCIATION; PP60C-SRC; PHOSPHORYLATION; PP60SRC; BINDING; SITES; GENE	Negative regulation of the cellular Src tyrosine kinase (pp60c-src) is mediated through the phosphorylation of a C-terminal tyrosine residue, Tyr-527. Current models predict that inhibition of c-Src kinase activity results from an interaction of phosphorylated Tyr-527 with the amino terminal SH2 domain. Tyr-527 is located 11 residues C-terminal from the end of the kinase domain. Insertion or deletion of residues within these 11 residues of pp60c-src activates kinase activity and induces morphological transformation. The resultant variant Src proteins also exhibit a reduced level of phosphorylation of Tyr-527. We have used antibodies to phosphotyrosine, susceptibility to tyrosine phosphatases and binding of mutant Src proteins to peptides mimicking the tyrosine phosphorylated C-terminus of pp60c-src to investigate the tyrosine phosphorylated and unphosphorylated forms of such insertion/deletion variants. The reactivity of variant proteins with phosphotyrosine antibodies and the susceptibility of phosphorylated Tyr-527 to tyrosine phosphatases were similar to that of wild type pp60c-src. In addition, the results of binding experiments performed with a C-terminal peptide containing phosphorylated Tyr-527 indicated that only dephosphorylated forms of variant Src proteins bound phospho-peptide. These data suggest that insertion or deletion mutations within the C-terminal region of pp60c-src do not substantially alter the interaction of phosphorylated Tyr-527 with the SH2 domain. Rather, the data are consistent with the hypothesis that the reduction of phosphorylation of Tyr-527 and the accompanying activation of these variants may be due to the action of a tyrosine phosphatase and the ineffecient phosphorylation of Tyr-527 by a regulatory kinase.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NCI NIH HHS [CA 40042, CA 29243] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042, R37CA029243, R01CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1990, SRC FAMILY PROTEIN T, P85; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GENTRY LE, 1983, J BIOL CHEM, V258, P1219; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; MACAULEY A, 1990, New Biologist, V2, P828; MACAULEY A, 1993, ONCOGENE, V8, P117; MCCARLEY DJ, 1987, J VIROL, V61, P1927, DOI 10.1128/JVI.61.6.1927-1937.1987; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARTANEN J, 1991, ONCOGENE, V6, P2013; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SMITH JL, 1983, J CLIN NEURO-OPHTHAL, V3, P3; WILKERSON VW, 1985, J VIROL, V55, P314, DOI 10.1128/JVI.55.2.314-321.1985; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					2897	2903						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692368				2022-12-17	WOS:A1993MC09300002
J	PRONK, GJ; DEVRIESSMITS, AMM; ELLIS, C; BOS, JL				PRONK, GJ; DEVRIESSMITS, AMM; ELLIS, C; BOS, JL			COMPLEX-FORMATION BETWEEN THE P21(RAS) GTPASE-ACTIVATING PROTEIN AND PHOSPHOPROTEINS P62 AND P190 IS INDEPENDENT OF P21(RAS) SIGNALING	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; RAS P21 GTPASE; NIH 3T3 CELLS; GENE-EXPRESSION; MOLECULAR-CLONING; MAP KINASE; GAP; PHOSPHORYLATION; TRANSFORMATION	We have investigated whether complex formation between the p21ras GTPase-activating protein (GAP) and the phosphotyrosine-containing proteins p62 and p190 is dependent on functional p21ras, to test the hypothesis that binding of p21(ras)GTP to GAP enables GAP to associate with these phosphoproteins. The formation of p21(ras)GTP was inhibited by a dominant interfering mutant of p21ras, p21ras(Asn-17), which was introduced with a vaccinia virus expression system. We used NIH3T3 cells in which complex formation between GAP and tyrosine-phosphorylated p62 and p190 can be induced either by v-src transformation, by incubating the cells with the phosphotyrosine phosphatase inhibitor pervanadate or by activation of a growth factor receptor tyrosine kinase. In all cases, expression of p21ras(Asn-17) did not affect the presence or the formation of the GAP-phosphoprotein complexes. To monitor the effectiveness of p21ras inhibition, we measured p21ras-mediated phosphorylation of extracellular signal-regulated kinase 2 (ERK2). In all cases, expression of p21ras(Asn-17) completely blocked signalling to ERK2. From these data we conclude that p21(ras)GTP formation is not essential for complex formation between GAP and tyrosine-phosphorylated p62 and p190, and thus complex formation does not depend on interaction of GAP with p21(ras)GTP.	UNIV UTRECHT,PHYSIOL CHEM LAB,VONDELLAAN 24A,3521 GG UTRECHT,NETHERLANDS; CHESTER BEATTY LABS,LONDON,ENGLAND	Utrecht University; University of London; Institute of Cancer Research - UK								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BULLER RML, 1988, J VIROL, V62, P866, DOI 10.1128/JVI.62.3.866-874.1988; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, UNPUB; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHANG JH, 1993, ONCOGENE, V8, P959; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUBYAK GR, 1980, J BIOL CHEM, V255, P306; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PRONK GJ, 1992, ONCOGENE, V7, P389; PRONK GJ, 1992, J BIOL CHEM, V267, P24508; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHECHTER Y, 1980, NATURE, V284, P556; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TAMURA S, 1983, BIOCHEM BIOPH RES CO, V113, P80, DOI 10.1016/0006-291X(83)90434-5; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	55	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2773	2780						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378086				2022-12-17	WOS:A1993LX34300019
J	MILNER, J; CHAN, YS; MEDCALF, EA; WANG, Y; ECKHART, W				MILNER, J; CHAN, YS; MEDCALF, EA; WANG, Y; ECKHART, W			PARTIALLY TRANSFORMED T3T3 CELLS EXPRESS HIGH-LEVELS OF MUTANT-P53 IN THE WILD-TYPE IMMUNOREACTIVE FORM WITH DEFECTIVE OLIGOMERIZATION	ONCOGENE			English	Article							TUMOR SUPPRESSOR PROTEIN; LARGE T-ANTIGEN; SIMIAN VIRUS-40; MONOCLONAL-ANTIBODIES; P53 PROTEIN; CONFORMATION; GENE; PHOSPHORYLATION; LOCALIZATION; REPLICATION	High levels of wild-type p53 suppress transformed growth of many cell lines and yet murine T3T3 cells shown partially transformed growth despite high endogenous levels of phenotypically 'wild-type' p53. On sequencing T3T3 p53 was found to encode missense mutations at codons 230 and 287 and, although endogenous T3T3 p53 is 'wild type', the protein adopted the mutant phenotype when expressed in vitro. Size fractionation of T3T3 cell lysate indicated monomeric p53 possibly in complex with a low molecular weight protein. When expressed in vitro T3T3 p53 formed dimers and higher order structures. Thus T3T3 cells appear (i) to drive endogenous mutant p53 to adopt conformational epitopes characteristic of the 'wild-type' protein, and (ii) to interfer with normal assembly of p53 quaternary structure. Phosphopeptide mapping of p53 from 3T3x cells, T3T3 cells and SV3T3 cells indicated reduced amino terminal phosphorylation of the mutant p53 phenotype. Alternative splicing of p53 was also detected in 3T3x cells; similar splicing occurs in wild-type p53 (Han & Kulesz-Martin, 1992; Nucl. Acids Res., 20, 1979-1981) and a possible regulatory function is discussed.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; SALK INST BIOL STUDIES,SAN DIEGO,CA 92138	University of Cambridge; Salk Institute					NATIONAL CANCER INSTITUTE [R01CA013884, P30CA014195, R37CA013884] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14195, CA 13884] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADDISON C, 1990, ONCOGENE, V5, P423; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CATHALA G, 1983, DNA CELL BIOL, V2, P339; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1591; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1992, ONCOGENE, V7, P71; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1986, VIROLOGY, V153, P21; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZERRAHN J, 1992, ONCOGENE, V7, P1371	46	22	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					2001	2008						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510941				2022-12-17	WOS:A1993LG68200033
J	KELLIHER, MA; WECKSTEIN, DJ; KNOTT, AG; WORTIS, HH; ROSENBERG, N				KELLIHER, MA; WECKSTEIN, DJ; KNOTT, AG; WORTIS, HH; ROSENBERG, N			ABL ONCOGENES DIRECTLY STIMULATE 2 DISTINCT TARGET-CELLS IN BONE-MARROW FROM 5-FLUOROURACIL-TREATED MICE	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; PRE-B-CELL; BCR-ABL; V-ABL; PHILADELPHIA-CHROMOSOME; MONOCLONAL-ANTIBODIES; PROGENITOR CELLS; GROWTH-FACTORS	Mice reconstituted with BCR/ABL-infected 5-fluorouracil-treated bone marrow are considered a model system for human chronic myelogenous leukemia, a malignancy that arises in hematopoietic stem cells. These animals develop multiple types of hematopoietic tumors, which could arise either from undifferentiated cells that mature during tumor development or from progenitors committed to different lineages. To examine the BCR/ABL-sensitive target celts present in the marrow of mice treated with 5-fluorouracil, we used a single-step in vitro assay. These experiments revealed that both the P210 and P185 BCR/ABL proteins and the related v-abl protein induce lymphoid and myeloid colonies, colony types that mimic two of the prominent types of tumors found in the reconstitution model. The lymphoid colonies were similar to lymphoid colonies found following infection of normal bone marrow with respect to differentiation state and tumorigenicity. The cells in the myeloid colonies were differentiated and non-tumorigenic. Fluorescence-activated cell sorting revealed that most of the lymphoid and myeloid colonies arose from distinct precursors and that the lymphoid colonies arose from B-lineage-committed cells. These data suggest that most of the lymphomas observed in the reconstitution model arise from committed progenitors that are distinct from those involved in the myeloid disease.	TUFTS UNIV, SCH MED, DEPT PATHOL, SC-313, 136 HARRISON AVE, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, GRAD PROGRAM IMMUNOL, BOSTON, MA 02111 USA; NEW ENGLAND MED CTR, DEPT MED, DIV HEMATOL & ONCOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts University; Tufts University; Tufts Medical Center; Tufts University					NCI NIH HHS [CA 33771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA033771, R01CA033771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTERMAN LA, 1990, EUR J IMMUNOL, V20, P1597, DOI 10.1002/eji.1830200728; BOSWELL HS, 1984, J IMMUNOL, V133, P2940; BRUCE J, 1981, J IMMUNOL, V127, P2496; CHUNG SW, 1988, BLOOD, V71, P973; CLARK SS, 1989, ANNU REV MED, V40, P113; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; ENGELMAN A, 1990, MOL CELL BIOL, V10, P4365, DOI 10.1128/MCB.10.8.4365; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HEIMFELD S, 1991, P NATL ACAD SCI USA, V88, P9902, DOI 10.1073/pnas.88.21.9902; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HO MK, 1982, J IMMUNOL, V128, P1221; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KELLER G, 1986, COLD SPRING HARB SYM, V51, P1053, DOI 10.1101/SQB.1986.051.01.122; KELLIHER M, 1991, MOL CELL BIOL, V11, P4710, DOI 10.1128/MCB.11.9.4710; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1991, VIRUSES AFFECT IMMUN, P143; KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.iy.07.040189.000551; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; MCKEARN JP, 1985, EUR J IMMUNOL, V15, P295, DOI 10.1002/eji.1830150316; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MULLERSIEBURG CE, 1986, CELL, V44, P653, DOI 10.1016/0092-8674(86)90274-6; MULLERSIEBURG CE, 1988, J EXP MED, V167, P1825, DOI 10.1084/jem.167.6.1825; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; RAMAKRISHNAN L, 1988, MOL CELL BIOL, V8, P5216, DOI 10.1128/MCB.8.12.5216; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SHEVACH EM, 1989, IMMUNOL TODAY, V10, P195, DOI 10.1016/0167-5699(89)90324-1; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; TIDMARSH GF, 1989, MOL CELL BIOL, V9, P2665, DOI 10.1128/MCB.9.6.2665; VANZANT G, 1984, J EXP MED, V159, P679, DOI 10.1084/jem.159.3.679; Varmus H. E., 1982, RNA TUMOR VIRUSES, P369; WANECK GL, 1986, CELL, V44, P337, DOI 10.1016/0092-8674(86)90768-3; WILLIAMS DE, 1985, J IMMUNOL, V135, P1004; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0	52	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1249	1256						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479746				2022-12-17	WOS:A1993KY32800016
J	DIBATTISTE, D; GOLUBIC, M; STACEY, D; WOLFMAN, A				DIBATTISTE, D; GOLUBIC, M; STACEY, D; WOLFMAN, A			DIFFERENCES IN THE INTERACTION OF P21(C-HA-RAS)-GMP-PNP WITH FULL-LENGTH NEUROFIBROMIN AND GTPASE-ACTIVATING PROTEIN	ONCOGENE			English	Article							RAS P21; TYPE-1 GENE; GROWTH-FACTOR; H-RAS; GAP; PRODUCT; STIMULATION; BINDING; IDENTIFICATION; PURIFICATION	Neurofibromin, the product of the neurofibromatosis type 1 gene, was found to form a stable complex with immobilized p21c-Ha-ras-GMP-PNP (a non-hydrolyzable GTP analog). This complex, detectable as early as 30 min after addition of crude brain extract, is extremely stable, with less than 50% dissociating after 5 h at 4-degrees-C. We interpret this to suggest that the dissociation of full-length neurofibromin from p21c-Ha-ras-GMP-PNP is tightly linked to the hydrolysis of GTP to GDP. Failure to remove a significant proportion of the bound neurofibromin in the presence of EDTA and GDP implies that the binding of neurofibromin to p21c-Ha-ras-GMP-PNP results in the ras protein becoming resistant to guanine nucleotide exchange. Under conditions in which neurofibromin quantitatively binds to p21c-Ha-ras-GMP-PNP, we were unable to detect a complex between p21c-Ha-ras and GAP (GTPase-activating protein). The failure to detect GAP binding to immobilized p21c-Ha-ras-GMP-PNP cannot be explained by the known differences in affinities of the GAP-related domain of neurofibromin and GAP for p21c-Ha-ras-GTP. GAP is, however, able to interact biochemically with immobilized p21c-Ha-ras suggesting a difference in the interaction between GAP and neurofibromin with p21c-Ha-ras-GMP-PNP.	CLEVELAND CLIN FDN,DEPT VASC CELL BIOL & ATHEROSCLEROSIS,9500 EUCLID AVE,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation; Cleveland Clinic Foundation					NCI NIH HHS [CA53436, CA48662] Funding Source: Medline; NIGMS NIH HHS [GM41220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GOLUBIC M, 1992, ONCOGENE, V7, P2151; HALL A, 1986, J BIOL CHEM, V261, P963; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KAPLAN S, 1991, J BIOL CHEM, V266, P18934; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLICHTING I, 1989, P NATL ACAD SCI USA, V86, P7687, DOI 10.1073/pnas.86.20.7687; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WOLFMAN A, 1989, J BIOL CHEM, V264, P10820; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	29	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					637	643						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437847				2022-12-17	WOS:A1993KN00800014
J	LARUE, L; DOUGHERTY, N; BRADL, M; MINTZ, B				LARUE, L; DOUGHERTY, N; BRADL, M; MINTZ, B			MELANOCYTE CULTURE LINES FROM TYR-SV40E TRANSGENIC MICE - MODELS FOR THE MOLECULAR GENETIC EVOLUTION OF MALIGNANT-MELANOMA	ONCOGENE			English	Article							MURINE MELANOCYTES; TUMOR PROGRESSION; PHORBOL ESTER; GROWTH; 12-O-TETRADECANOYLPHORBOL-13-ACETATE; TRANSFORMATION; REQUIREMENT; REPLICATION; MECHANISMS; EXPRESSION	Transgenic Tyr-SV40E mice previously produced on the C57BL/6 inbred-strain background, with SV40 oncogenic sequences specifically expressed in pigment cells, are predisposed to melanoma [Bradl, M., Klein-Szanto, A., Porter, S. & Mintz, B. (1991). Proc. Natl. Acad. Sci. USA, 88, 164-1681. Separate lines of these animals differ genetically only in the number of copies and chromosomal site of integration of the transgene. Skin melanocytes from young mice with no apparent skin lesions were established in continuous culture from hemizygous donors with low, medium and high numbers of transgene copies, and from a homozygous offspring of the low-copy mouse line. The standard culture conditions enable C57BL/6 wild-type melanocytes to become stably immortalized without transformation. The transgenic cell lines all changed over time in an orderly progression. However, with greater numbers of transgene copies, the cells more rapidly displayed shorter doubling times, increased anchorage independence, reduced serum and growth factor requirements, decreased tyrosinase expression and melanin content, increased oncogene expression, and capacity to form malignant melanomas when tested by grafting. Melanocytes with the lowest number of transgene copies were of special interest. They grew more rapidly than the wild-type cells from the outset, but did not become tumorigenic until an apparently small number of still-unknown genetic changes had spontaneously occurred, or until the number of transgene copies was increased slightly by homozygosity. In contrast to the hemizygous low-copy cells, the homozygous counter-parts underwent striking and rapid transformational changes and early conversion to malignancy. Thus such low-copy transgenic melanocyte lines afford an exceptional opportunity for molecular analysis of somatic genetic evolution toward malignant melanoma.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center			Larue, Lionel/I-6532-2016; Larue, Lionel/F-7355-2013	Bradl, Monika/0000-0003-2239-1586	NCI NIH HHS [CA-06927, CA-42560] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R35CA042560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALBINO AP, 1988, ADV PIGMENT CELL RES, P361; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BENNETT DC, 1989, ENVIRON HEALTH PERSP, V80, P49, DOI 10.2307/3430731; Berenblum I, 1941, CANCER RES, V1, P807; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; BRADL M, 1991, P NATL ACAD SCI USA, V88, P6447, DOI 10.1073/pnas.88.15.6447; CHENEVIXTRENCH G, 1990, ONCOGENE, V5, P1187; DOOLEY TP, 1988, ONCOGENE, V3, P531; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HERLYN M, 1987, LAB INVEST, V56, P461; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JAMBROSIC J, 1989, INT J CANCER, V44, P1117, DOI 10.1002/ijc.2910440630; JIMBOW K, 1975, J CELL BIOL, V66, P663, DOI 10.1083/jcb.66.3.663; KATH R, 1989, ANTICANCER RES, V9, P865; KLEINSZANTO A, 1991, P NATL ACAD SCI USA, V88, P169, DOI 10.1073/pnas.88.1.169; LARUE L, 1992, P NATL ACAD SCI USA, V89, P9534, DOI 10.1073/pnas.89.20.9534; McKusick V. A., 1986, MENDELIAN INHERITANC; MELBER K, 1989, CANCER RES, V49, P3650; Mintz B, 1981, Adv Cancer Res, V34, P211, DOI 10.1016/S0065-230X(08)60243-2; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; Romerdahl C A, 1989, Cancer Commun, V1, P209; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; TERAO M, 1989, BIOCHEM BIOPH RES CO, V159, P848, DOI 10.1016/0006-291X(89)90072-7; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WILSON RE, 1989, CANCER RES, V49, P711	35	22	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					523	531						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382353				2022-12-17	WOS:A1993KN00800001
J	ROSSLER, U; ANDRES, AC; REICHMANN, E; SCHMAHL, W; WERENSKIOLD, AK				ROSSLER, U; ANDRES, AC; REICHMANN, E; SCHMAHL, W; WERENSKIOLD, AK			T1, AN IMMUNOGLOBULIN SUPERFAMILY MEMBER, IS EXPRESSED IN H-RAS-DEPENDENT EPITHELIAL TUMORS OF MAMMARY CELLS	ONCOGENE			English	Article							ANTIGEN GENE FAMILY; CARCINOEMBRYONIC ANTIGEN; ONCOGENE EXPRESSION; TRANSGENIC MICE; INDUCTION; GLAND; TRANSCRIPTION; TRANSFORMATION; EMBRYOGENESIS; INVASION	T1 is a glycosylated protein in the carcinoembryonic antigen (CEA) family of tumour marker molecules. It was originally identified by virtue of its transient induction after the expression of p21H-ras in NIH3T3 fibroblasts. Here we show that the T1 gene is activated in mammary adenocarcinomas of transgenic mice harbouring an H-ras transgene under the control of the mammary-specific whey acidic protein (WAP) promoter. By contrast, T1 mRNA was not, or only faintly, detectable in mammary carcinomas of transgenic mice bearing a WAP-myc transgene. Thus, T1 overexpression does not appear to be a general tumour-specific phenomenon. A dependence of T1 gene expression on the action of p21H-ras is suggested by the observation of T1 mRNA in nude mouse tumours generated from H-ras-transformed cultured mammary epithelial cells. Interestingly, activation of the T1 gene is also found during the maturation of the mammary gland (3-4 weeks after birth), whereas it is absent during its terminal differentiation in pregnancy and lactation. This expression pattern suggests a role for the secreted T1 glycoprotein in the phase of epithelial proliferation of the mammary gland. It appears that p21H-ras-induced transformation of mammary epithelial cells mimicks the situation occurring in puberty. In both developmental stages the T1 glycoprotein might affect celt interactions of the proliferating epithelial cells with the surrounding stroma. It might thus promote ductal outgrowth in gland maturation as well as invasive growth of p21H-ras-transformed mammary epithelial cells.	GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,DEPT CELL CHEM,INGOLST LANDSTR 1,W-8042 NEUHERBERG,GERMANY; GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST PATHOL,W-8042 NEUHERBERG,GERMANY; UNIV BERN,INST CLIN CANC RES,CH-3004 BERN,SWITZERLAND; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Bern; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)								ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; ANDRES AC, 1991, ONCOGENE, V6, P771; BEAUCHEMIN N, 1989, CANCER RES, V49, P2017; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; COURNOYER D, 1988, CANCER RES, V48, P3153; GO VLW, 1982, CANCER PHILA S, V30, P2618; GOLD P, 1965, J EXP MED, V121, P439, DOI 10.1084/jem.121.3.439; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; HASLAM SZ, 1989, ENDOCRINOLOGY, V125, P2766, DOI 10.1210/endo-125-5-2766; HUANG JQ, 1990, DEVELOPMENT, V110, P573; INAGUMA Y, 1988, DEV BIOL, V128, P245, DOI 10.1016/0012-1606(88)90288-6; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; KNIGHT CH, 1982, J REPROD FERTIL, V65, P521, DOI 10.1530/jrf.0.0650521; KODELJA V, 1989, J BIOL CHEM, V264, P6906; KRATOCHWIL K, 1969, DEV BIOL, V20, P46, DOI 10.1016/0012-1606(69)90004-9; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; REDMOND SMS, 1988, ONCOGENE, V2, P259; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; ROBINSON SD, 1991, DEVELOPMENT, V113, P867; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; THOMPSON J, 1988, TUMOR BIOL, V9, P63, DOI 10.1159/000217547; THOMPSON JA, 1989, BIOCHEM BIOPH RES CO, V158, P996, DOI 10.1016/0006-291X(89)92821-0; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WERENSKIOLD AK, 1992, EUR J BIOCHEM, V204, P1041, DOI 10.1111/j.1432-1033.1992.tb16726.x; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; ZIMMERMANN W, 1988, CANCER RES, V48, P2500	28	22	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					609	617						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437844				2022-12-17	WOS:A1993KN00800011
J	KELMAN, Z; SIMONCHAZOTTES, D; GUENET, JL; YARDEN, Y				KELMAN, Z; SIMONCHAZOTTES, D; GUENET, JL; YARDEN, Y			THE MURINE VIK GENE (CHROMOSOME-9) ENCODES A PUTATIVE RECEPTOR WITH UNIQUE PROTEIN-KINASE MOTIFS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; NUCLEOSIDE DIPHOSPHATE KINASE; TYROSINE KINASE; DICTYOSTELIUM-DISCOIDEUM; CONSERVED FEATURES; SEQUENCE HOMOLOGY; CATALYTIC DOMAIN; MESSENGER-RNAS; SERINE KINASE; FAMILY	Receptor tyrosine kinases are involved in the regulation of cell growth and may play a central role in embryonic development. We recently developed a polymerase chain reaction (PCR)-based gene cloning procedure that allows selective isolation of genes that encode novel transmembrane tyrosine kinases in tissues of embryonic origin. By employing this protocol on mRNA from a 12.5 day post-coitum mouse placenta, we identified a gene for a putative receptor protein kinase. The deduced amino acid sequence predicts the existence of an approximately 200 amino acid long extracellular domain that shows no similarity to known proteins. The cytoplasmic portion contains a core sequence that is structurally homologous to the tyrosine kinase family. However, a few highly conserved short blocks of sequences, shared by all protein kinases, display variations in the isolated gene. These include the glycine-rich block at the nucleotide-binding cleft and the Asp-Phe-Gly triplet at the substrate recognition site. On the basis of these variations, we named the gene vik for variant in the kinase. Northern analysis revealed two widely expressed transcripts of vik with molecular weights of 3 and 2.5 kb. Chromosomal mapping using restriction fragment length polymorphism localized the gene to murine chromosome 9. The unique structural landmarks of vik at both the extracellular and the cytoplasmic domains suggest novel ligand as well as substrate specificity of the presumed receptor.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; INST PASTEUR, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE	Weizmann Institute of Science; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			YARDEN, YOSEF/K-1467-2012					AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AVNER P, 1988, TRENDS GENET, V4, P18, DOI 10.1016/0168-9525(88)90123-0; BONHOMME F, 1979, CR ACAD SCI D NAT, V289, P545; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P2065, DOI 10.1021/bi00431a015; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHAN J, 1991, ONCOGENE, V6, P1057; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GUENET JL, 1986, CURR TOP MICROBIOL, V127, P109; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; Hogan B., 1986, MANIPULATING MOUSE E; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; Maniatis T., 1982, MOL CLONING; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MONTAGUTELLI X, 1990, J HERED, V81, P490, DOI 10.1093/oxfordjournals.jhered.a111033; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2707; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V86, P8722; ROSNET O, 1991, ONCOGENE, V6, P1641; SAFRAN A, 1990, ONCOGENE, V5, P635; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHOWS TB, 1968, SCIENCE, V160, P1356, DOI 10.1126/science.160.3834.1356; STARK KL, 1991, DEVELOPMENT, V113, P641; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.biochem.59.1.971; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; WILKS A F, 1990, Progress in Growth Factor Research, V2, P97, DOI 10.1016/0955-2235(90)90026-G; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Yarden Y, 1991, CURR OPIN STRUC BIOL, V1, P582, DOI 10.1016/S0959-440X(05)80081-8	56	22	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					37	44						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380921				2022-12-17	WOS:A1993KN00500005
J	APEL, TW; MAUTNER, J; POLACK, A; BORNKAMM, GW; EICK, D				APEL, TW; MAUTNER, J; POLACK, A; BORNKAMM, GW; EICK, D			2 ANTISENSE PROMOTERS IN THE IMMUNOGLOBULIN MU-SWITCH REGION DRIVE EXPRESSION OF C-MYC IN THE BURKITTS-LYMPHOMA CELL-LINE BL67	ONCOGENE			English	Article							HEAVY-CHAIN LOCUS; TRANSCRIPTIONAL ACTIVATION; EPSILON-TRANSCRIPTS; GENE; ENHANCER; INTERLEUKIN-4; SP1; TRANSFORMATION; TRANSLOCATION; MUTATIONS	In the Burkitt's lymphoma (BL) cell line BL67 the first exon of the c-myc gene is fused to the mu-switch region of the immunoglobulin heavy-chain gene (IgH). BL67 cells express IgH/c-myc hybrid RNAs which are initiated in the immunoglobulin locus, transcribed across the chromosomal breakpoint into the first exon of c-myc and spliced using the physiological splice donor and acceptor sites of the c-myc gene. We have isolated cDNAs of these hybrid RNAs and characterized the start points in the Ig heavy-chain gene. Two promoters were identified in the mu-switch region of BL67 cells which give rise to antisense transcription of the mu-gene. These promoters are also active in other BL cell lines, in B cells without Ig translocation and in a T-cell line. Both promoters co-localize with DNAase I-hypersensitive sites. HNF and HSW, in the mu-switch region. The structures of IgH/c-myc hybrid RNAs and of the corresponding promoters are described.	GSF MUNICH,FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,W-8000 MUNICH,GERMANY; UNIV FREIBURG,INST MED MIKROBIOL & HYG,VIROL ABT,W-7800 FREIBURG,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Freiburg								ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FISCHER KD, 1990, NUCLEIC ACIDS RES, V18, P5685, DOI 10.1093/nar/18.19.5685; FRYKBERG L, 1987, ONCOGENE, V1, P415; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GERONDAKIS S, 1990, P NATL ACAD SCI USA, V87, P1581, DOI 10.1073/pnas.87.4.1581; GUBLER U, 1983, GENE, V25, P262; HENNIGHAUSEN L, 1985, NATURE, V314, P289, DOI 10.1038/314289a0; JULIUS MA, 1988, ONCOGENE, V2, P469; KAKKIS E, 1988, NUCLEIC ACIDS RES, V16, P77, DOI 10.1093/nar/16.1.77; KEMP DJ, 1980, P NATL ACAD SCI-BIOL, V77, P7400, DOI 10.1073/pnas.77.12.7400; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LUTZKER S, 1988, MOL CELL BIOL, V8, P1849, DOI 10.1128/MCB.8.4.1849; MILLS FC, 1990, NUCLEIC ACIDS RES, V18, P7305, DOI 10.1093/nar/18.24.7305; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RADCLIFFE G, 1990, MOL CELL BIOL, V10, P382, DOI 10.1128/MCB.10.1.382; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SPENCER CA, 1991, ADV CANCER RES, P1; SYMONDS G, 1989, ONCOGENE, V4, P285; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798	29	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1267	1271						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620543				2022-12-17	WOS:A1992HZ97100003
J	SEGATTO, O; LONARDO, F; HELIN, K; WEXLER, D; FAZIOLI, F; RHEE, SG; DIFIORE, PP				SEGATTO, O; LONARDO, F; HELIN, K; WEXLER, D; FAZIOLI, F; RHEE, SG; DIFIORE, PP			ERBB-2 AUTOPHOSPHORYLATION IS REQUIRED FOR MITOGENIC ACTION AND HIGH-AFFINITY SUBSTRATE COUPLING	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-C-GAMMA; PHOSPHOTYROSINE-CONTAINING PROTEINS; TYROSINE KINASE-ACTIVITY; FACTOR RECEPTOR; EGF RECEPTOR; ONCOGENE PRODUCT; NEU ONCOGENE; 3T3 CELLS; GENE	Autophosphorylation of gp185(erbB-2) in vivo is confined to its carboxy terminus and is required for optimal erbB-2 transforming activity under conditions of receptor overexpression. It remains unresolved, however, to what extent autophosphorylation regulates erhB-2 mitogenic signaling in normal cells, nor is the biochemical basis for such a regulatory function known. To address these issues, we utilized a chimeric molecule encompassing the extracellular domain of the epidermal growth factor (EGF) receptor (EGFR) fused to the transmembrane and intracellular domains of the erbB-2 product. In this EGFR/erbB-2 chimera, erbB-2 kinase activity is regulated by EGF binding. An EGFR/erbB-2 mutant bearing multiple Tyr --> Phe substitutions at erbB-2 autophosphorylation sites (EGFR/erbB-2 5P) displayed markedly reduced phosphotyrosine content following EGF stimulation in comparison with the non-mutated chimera. When expressed in NR6 cells, the EGFR/erhB-2 5P mutant was unable to deliver a sizeable mitogenic signal when activated by EGF at physiological levels. In intact cells, the 5P mutant was still able to stimulate phosphorylation of the gamma-isozyme of phospholipase C (PLC-gamma), a prototype erhB-2 substrate, although with a delayed time course, indicating that the 5P mutation decreased the affinity of the erbB-2 kinase for this substrate. This conclusion was further supported by the inability of the 5P mutant to associate with PLC-gamma in co-immunoprecipitation experiments. We infer that a major role of autophosphorylation is to increase the affinity of the erbB-2 kinase for its cellular substrates, so that, under physiological conditions, autophosphorylation is absolutely required for erbB-2 mitogenic signaling.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1D23,BETHESDA,MD 20892; REGINA ELENA INST CANC RES,I-00158 ROME,ITALY; UNIV COPENHAGEN,INST MICROBIOL,DK-1168 COPENHAGEN,DENMARK; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Copenhagen; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Di Fiore, Pier Paolo/K-2130-2012; Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Di Fiore, Pier Paolo/0000-0002-2252-0950; Helin, Kristian/0000-0003-1975-6097; Segatto, Oreste/0000-0003-2561-1142				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; HALEY JD, 1989, ONCOGENE, V4, P273; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HELIN K, 1991, ONCOGENE, V6, P825; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LONARDO F, 1990, New Biologist, V2, P992; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SORKIN A, 1991, J BIOL CHEM, V266, P8355; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUH PG, 1988, J BIOL CHEM, V263, P14497; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VELU TJ, 1989, MOL CELL BIOL, V9, P1771; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3719	41	22	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1339	1346						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1352397				2022-12-17	WOS:A1992HZ97100012
J	NICOLSON, GL; GALLICK, GE; SPOHN, WH; LEMBO, TM; TAINSKY, MA				NICOLSON, GL; GALLICK, GE; SPOHN, WH; LEMBO, TM; TAINSKY, MA			TRANSFECTION OF ACTIVATED C-H-RASEJ/PSV2NEO OR PSV2NEO GENES INTO RAT MAMMARY CELLS - RAPID STIMULATION OF CLONAL DIVERSIFICATION OF SPONTANEOUS METASTATIC AND CELL-SURFACE PROPERTIES	ONCOGENE			English	Article							NIH 3T3 CELLS; C-HA-RAS; DIFFERENTIAL EXPRESSION; ADENOCARCINOMA CELLS; MONOCLONAL-ANTIBODY; MOLECULAR-WEIGHT; DNA TRANSFECTION; BREAST-CANCER; NIH/3T3 CELLS; FRESH PRIMARY	We examined whether the conversion of benign rat mammary cells to metastatic cells by transfection of c-H-ras(EJ)/pSV2neo or control pSV2neo genes results in rapid stimulation of diversification of cellular phenotypes. Transfection of c-H-ras(EJ) into twice-cloned, stable (> 1 year) rat mammary MTC.4 cells, followed quickly by cell cloning, revealed differences in transfected oncogene copy numbers and expression of p21-(rasEJ) . No correlation between c-H-ras(EJ) copy numbers or the cellular amounts of p21(rasEJ) or total p21ras and spontaneous metastatic potentials was found. By subcloning transfected cells as soon as possible after gene transfer, we found some rearrangements and amplifications of c-H-ras(EJ) and heterogeneous spontaneous metastatic potentials. In addition, the expression of the mammary tumor metastasis-associated cell-surface glycoprotein gp580 on untransfected and transfected MTC.4 cells indicated that the cell populations of higher metastatic potential were also more diverse in their cell-to-cell antigen expression than untransfected or non-metastatic, transfected MTC.4 cells. In contrast, the expression of a putative metastasis-suppressor gene, nm23, was unchanged after transfection and subcloning. Control pSV2neo transfections or calcium phosphate treatment alone also resulted in the generation of cellular heterogeneity, although at an apparently lower frequency than c-H-ras(EJ) transfections, suggesting that transfection of activated, dominantly acting oncogenes, or in some cases control genes, can result in destabilization of transfected cells, rapid diversification and generation of heterogeneity in growth rate, spontaneous metastatic potential and antigen expression.			NICOLSON, GL (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BOX 108,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [R23-CA39803, P30-CA16672, R35-CA44352] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA039803, P30CA016672, R35CA044352] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERG P, 1982, MOL APPL GENET, P327; BERNSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P1726, DOI 10.1073/pnas.82.6.1726; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOLSCHER JGM, 1988, EMBO J, V7, P3361, DOI 10.1002/j.1460-2075.1988.tb03208.x; BONDY GP, 1985, CANCER RES, V45, P6005; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; CARNEY WP, 1986, J CELL BIOCHEM, V32, P207, DOI 10.1002/jcb.240320307; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; CLAIR T, 1987, CANCER RES, V47, P5290; COLLARD JG, 1987, CANCER RES, V47, P754; DEAR TN, 1988, CANCER RES, V48, P5203; DEBORTOLI ME, 1985, BIOCHEM BIOPH RES CO, V127, P699, DOI 10.1016/S0006-291X(85)80218-7; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1989, INT J CANCER, V43, P443, DOI 10.1002/ijc.2910430317; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FRAZIER ML, 1983, MOL CELL BIOCHEM, V56, P113; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLICK GE, 1985, P NATL ACAD SCI USA, V82, P1795, DOI 10.1073/pnas.82.6.1795; GARBISA S, 1987, CANCER RES, V47, P1523; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; HAND PH, 1987, J NATL CANCER I, V79, P59; HILL SA, 1988, J NATL CANCER I, V80, P484, DOI 10.1093/jnci/80.7.484; ICHIKAWA T, 1990, CANCER RES, V50, P6349; KERBEL RS, 1987, P NATL ACAD SCI USA, V84, P1263, DOI 10.1073/pnas.84.5.1263; KURZROCK R, 1986, CANCER RES, V46, P1530; KUZEK T, 1987, P NATL ACAD SCI USA, V84, P4490; KYPRIANOU N, 1990, CANCER RES, V50, P1499; LIOTTA LA, 1988, J NATL CANCER I, V80, P468, DOI 10.1093/jnci/80.7.468; LUNDY J, 1986, J CLIN ONCOL, V4, P1321, DOI 10.1200/JCO.1986.4.9.1321; MAREEL MM, 1986, ANTICANCER RES, V6, P419; MARSHALL CJ, 1988, J CELL SCI S, V10, P157; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NERI A, 1982, J NATL CANCER I, V68, P508; NICOLSON GL, 1984, CANCER METAST REV, V3, P25, DOI 10.1007/BF00047691; NICOLSON GL, 1987, CANCER RES, V47, P1473; NICOLSON GL, 1991, J CELL BIOCHEM, V46, P277, DOI 10.1002/jcb.240460402; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; NICOLSON GL, 1990, ONCOGENE, V5, P747; NORTH SM, 1988, INT J CANCER, V42, P607, DOI 10.1002/ijc.2910420423; OHUCHI N, 1986, CANCER RES, V46, P2511; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; PRICE JE, 1989, CANCER RES, V49, P4274; STECK PA, 1983, EXP CELL RES, V147, P255, DOI 10.1016/0014-4827(83)90208-2; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VANROY FM, 1986, CANCER RES, V46, P4787; VERRELLE P, 1987, ANTICANCER RES, V7, P181; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; WAGHORNE C, 1987, ONCOGENE, V1, P149	51	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1127	1135						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594244				2022-12-17	WOS:A1992HU64200010
J	PATEL, G; MACDONALD, MJ; KHOSRAVIFAR, R; HISAKA, MM; DER, CJ				PATEL, G; MACDONALD, MJ; KHOSRAVIFAR, R; HISAKA, MM; DER, CJ			ALTERNATE MECHANISMS OF RAS ACTIVATION ARE COMPLEMENTARY AND FAVOR AND FORMATION OF RAS-GTP	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; H-RAS; ENCODED PROTEINS; BINDING DOMAIN; P21; GAP; MUTANTS; SIGNAL; CELLS; IDENTIFICATION	The mechanisms of ras activation by mutations in residue 61 and in the NKXD guanine nucleotide-binding consensus sequence (ras residues 116-119) have been evaluated. Weakly transforming mutations that either reduce intrinsic and GTPase-activating protein (GAP)stimulated GTPase activities (61P) or enhance guanine nucleotide exchange rates (116H, 119E) were combined into the same H-ras proteins. The resulting double-mutant proteins exhibited significantly stronger transforming activities than are observed with each individual mutation, suggesting that the consequences of these two different mechanisms of activation favor maintenance of ras in the active form, which is GTP bound. In vivo nucleotide association analysis demonstrated a direct relationship between ras-GTP formation and transforming activity. Although both 61P and 61L mutations result in reduced intrinsic GTPase activity and loss of GAP stimulation in vitro, only H-ras(61L) exhibits strong transforming activity. While H-ras(61L) is found predominantly in the GTP-bound form, H-ras(61P) is predominantly complexed with GDP in vivo. Thus, in vitro GAP stimulation of GTPase activity does not directly correlate with transforming potential, suggesting that other ras-specific regulatory components may also be important in regulating the cycling of ras between GDP- and GTP-bound states.	LA JOLLA CANC RES FDN,10901 N TORREY PINES RD,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute			Khosravi-Far, Roya/C-3789-2008	Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA055008, R01CA052072, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA52072, CA55008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; DER CJ, 1988, ONCOGENE, V3, P105; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PROUD CG, 1986, TRENDS BIOCHEM SCI, V11, P73, DOI 10.1016/0968-0004(86)90269-0; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	39	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					283	288						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549350				2022-12-17	WOS:A1992HG98200012
J	BURNS, PA; JACK, A; NEILSON, F; HADDOW, S; BALMAIN, A				BURNS, PA; JACK, A; NEILSON, F; HADDOW, S; BALMAIN, A			TRANSFORMATION OF MOUSE SKIN ENDOTHELIAL-CELLS INVIVO BY DIRECT APPLICATION OF PLASMID DNA ENCODING THE HUMAN T24 H-RAS ONCOGENE	ONCOGENE			English	Article							BLADDER-CARCINOMA ONCOGENE; MURINE SARCOMA-VIRUS; EMBRYO FIBROBLASTS; TRANSGENIC MICE; TUMOR PROMOTERS; POINT MUTATION; HARVEY; GENE; CARCINOGENESIS; ACTIVATION	Plasmid DNA containing the human T24 H-ras oncogene, with or without viral transcriptional enhancer sequences, was applied to scarified mouse skin, followed by multiple treatments with the tumour promoter 12-O-tetradecanoyl-phorbol-13-acetate. This resulted in the formation of vasoformative tumours histologically characterized as lymphangiosarcomas. All of the animals treated developed cystic fluid-filled swellings. Polymerase chain reaction analysis revealed the presence of human H-ras sequences within the cystic fluid from 3 out of 4 swellings. An endothelial cell line established from the cystic fluid removed from one of these swellings was found to contain human H-ras sequences and to express the mutant human p21ras. Injection of the cell line into nude mice, or adult syngeneic mice, resulted in the formation of aggressive angiosarcomas. Further experiments showed that 12-O-tetradecanol-phorbol-13-acetate promotion is not required for tumour formation and would appear to reduce the yield of tumours. These results indicate that a single application of the human H-ras oncogene is sufficient to induce endothelial cell transformation in vivo, even in the absence of any further promotional stimulus.	UNIV LEEDS, DEPT PATHOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Leeds	BURNS, PA (corresponding author), BEATSON INST CANC RES, CRC BEATSON LABS, GARSCUBE ESTATE, GLASGOW G61 1BD, SCOTLAND.							ARMES J, 1989, ADV CANCER RES, V53, P73; ASSELIN C, 1984, MOL CELL BIOL, V4, P755, DOI 10.1128/MCB.4.4.755; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; DONOGHUE DJ, 1984, NATURE, V308, P748, DOI 10.1038/308748a0; DOTTO GP, 1985, NATURE, V318, P472; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FUNG YKT, 1983, P NATL ACAD SCI-BIOL, V80, P353, DOI 10.1073/pnas.80.2.353; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; HSIAO WLW, 1984, SCIENCE, V226, P552, DOI 10.1126/science.6436974; KATZ L, 1973, J BACTERIOL, V114, P577, DOI 10.1128/JB.114.2.577-591.1973; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAITOH A, 1990, ONCOGENE, V5, P1195; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WILLIAMS RL, 1988, CELL, V52, P121; WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614	29	22	23	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					1973	1978						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945407				2022-12-17	WOS:A1991GX11900005
J	PIERCEALL, WE; ANANTHASWAMY, HN				PIERCEALL, WE; ANANTHASWAMY, HN			TRANSFORMATION OF NIH3T3 CELLS BY TRANSFECTION WITH UV-IRRADIATED HUMAN C-HA-RAS-1 PROTOONCOGENE DNA	ONCOGENE			English	Article							EXPOSED BODY SITES; HUMAN-SKIN CANCERS; RAS GENE; N-RAS; XERODERMA PIGMENTOSUM; ACTIVATED ONCOGENES; AMPLIFICATION; MUTATIONS; TUMORS; CARCINOGENESIS	Our previous studies have shown that human skin cancers occurring on sun-exposed body sites frequently contain G --> T mutations at the second position of Ha-ras codon 12. In this study, we investigated whether the c-Ha-ras-1 proto-oncogene could be activated by in vitro UV-irradiation of pEC plasmid DNA, which contains the 6.6 kb BamHI fragment of the human c-Ha-ras-1 proto-onocogene oncogene. Focus formation and nude mouse tumorigenicity assays showed that UV-irradiated pEC DNA induced morphologic and tumorigenic transformation of NIH3T3 cells in multiple cycles of transfection, whereas unirradiated pEC DNA did not. DNAs from secondary cycle foci and tertiary cycle tumors were analyzed for mutations in Ha-ras codons 12 and 61 using the polymerase chain reaction and synthetic oligonucleotide probes. Eleven of 11 secondary cycle foci analyzed possessed a G --> T mutation at the second position of Ha-ras codon 12. However, the nude mouse tumors exhibited a G --> A mutation at position 1 of the Ha-ras codon 12. These results suggest that in vitro UV irradiation of the c-Ha-ras-1 proto-oncogene DNA can induce mutations that are similar to those found in human skin cancers that originated on sun-exposed body sites.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,BOX 178,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [T32-CA-09598, R01-CA-46523] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046523, T32CA009598] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANANTHASWAMY HN, 1988, J CELL BIOCHEM, V36, P137, DOI 10.1002/jcb.240360205; ANANTHASWAMY HN, 1988, CANCER RES, V48, P3341; ANANTHASWAMY HN, 1989, MOL CARCINOGEN, V2, P298, DOI 10.1002/mc.2940020510; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLUM HF, 1959, CARCINOGENESIS ULTRA; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; Epstein J H, 1978, Natl Cancer Inst Monogr, P13; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FORBES PD, 1981, J INVEST DERMATOL, V77, P139, DOI 10.1111/1523-1747.ep12479351; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUSAIN Z, 1990, ARCH DERMATOL, V126, P324, DOI 10.1001/archderm.126.3.324; KEIJZER W, 1989, CANCER RES, V49, P1229; KRIPKE ML, 1977, CANCER RES, V37, P1395; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; Maniatis T., 1982, MOL CLONING; MARSHALL CJ, 1984, NATURE, V310, P586, DOI 10.1038/310586a0; PADAU RA, 1985, MOL CELL BIOL, V5, P582; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; ROSENSTEIN BS, 1987, PHOTOCHEM PHOTOBIOL, V45, P775, DOI 10.1111/j.1751-1097.1987.tb07881.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Scotto J, 1978, Natl Cancer Inst Monogr, P169; SETLOW JANE K., 1966, CURR TOP RADIAT RES, V2, P195; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SHUKLA VK, 1989, ONCOGENE RES, V5, P121; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRICKLAND P T, 1985, Photochemistry and Photobiology, V41, p110S; SUAREZ HG, 1989, CANCER RES, V49, P1223; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Urbach F, 1969, LONG TERM FIELD MEAS; URBACH F, 1978, NATL CANCER I MONOGR, V50, P5; VANDERLUBBE JLM, 1988, ONCOGENE RES, V3, P9; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOUSDEN KH, 1986, P NATL ACAD SCI USA, V83, P1222, DOI 10.1073/pnas.83.5.1222; WHITE SI, 1988, J INVEST DERMATOL, V91, P407; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0; 1988, NASA1988 OZ TRENDS P	46	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2085	2091						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945413				2022-12-17	WOS:A1991GX11900020
J	NICOLAIEW, N; TRIQUENEAUX, G; DAUTRY, F				NICOLAIEW, N; TRIQUENEAUX, G; DAUTRY, F			ORGANIZATION OF THE HUMAN N-RAS LOCUS - CHARACTERIZATION OF A GENE LOCATED IMMEDIATELY UPSTREAM OF N-RAS	ONCOGENE			English	Article							PROTO-ONCOGENE; MESSENGER-RNA; DROSOPHILA-MELANOGASTER; PROMOTER REGION; EXPRESSION; MOUSE; CDNA; ACTIVATION; SEQUENCE; CLONING	The mammalian ras genes have been implicated in a wide variety of natural and experimental tumors. They code for small GTP binding proteins which are believed to play a central role in the control of cellular proliferation and differentiation. We have investigated the transcriptional organization of the human N-ras locus and characterized a transcription unit located immediately upstream of N-ras, which we designate by NRU for N-ras Upstream. NRU messages contain an open reading frame of 767 amino acids which shows no similarity with the ras proteins and provides no clue to the function of the corresponding protein. Of the order of 150 nucleotides separate the N-ras transcription initiation sites from the last NRU polyadenylation site and the same organization is present in the murine genome. Both genes are simultaneously expressed in all the cell lines and murine tissues we have analysed, and in all cases NRU messages accumulate to a higher level than those of N-ras. The small intergenic distance implies that, during transcription of NRU, RNA polymerases transcribe a substantial part of the N-ras gene, suggesting that this genetic organization participates in the regulation of N-ras expression.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,UA 1158,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	DAUTRY, F (corresponding author), INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,UA 1158,F-94805 VILLEJUIF,FRANCE.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; Berger S.L., 1987, METHODS ENZYMOLOGY, V152; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; CHANG EC, 1982, NATURE, V304, P507; CHANG HY, 1987, ONCOGENE RES, V1, P129; CHARDIN P, 1988, BIOCHIMIE, V70, P865, DOI 10.1016/0300-9084(88)90226-X; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DONIGER J, 1987, ONCOGENE, V1, P331; DONIGER J, 1988, NUCLEIC ACIDS RES, V16, P969, DOI 10.1093/nar/16.3.969; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FIORUCCI G, 1988, BIOCHIM BIOPHYS ACTA, V950, P81, DOI 10.1016/0167-4781(88)90076-0; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HILL SA, 1988, J NATL CANCER I, V80, P484, DOI 10.1093/jnci/80.7.484; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HUMPHREY T, 1988, TRENDS GENET, V4, P243, DOI 10.1016/0168-9525(88)90028-5; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LEWIN B, 1990, GENES, V4; LOWNDES NF, 1989, MOL CELL BIOL, V9, P3758, DOI 10.1128/MCB.9.9.3758; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MCHUGH KM, 1988, MOL CELL BIOL, V8, P5224, DOI 10.1128/MCB.8.12.5224; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; Sambrook J., 1989, MOL CLONING; SCHULZ RA, 1989, GENE DEV, V3, P232, DOI 10.1101/gad.3.2.232; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Weil D, 1988, Oncogene Res, V3, P409; WILLIAMS T, 1988, P NATL ACAD SCI USA, V85, P3527, DOI 10.1073/pnas.85.10.3527; YANICOSTAS C, 1989, MOL CELL BIOL, V9, P2526, DOI 10.1128/MCB.9.6.2526	38	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					721	730						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	2052355				2022-12-17	WOS:A1991GT82500006
J	LEE, JH; LI, YC; DOERRE, S; SISTA, P; BALLARD, DW; GREENE, WC; FRANZA, BR				LEE, JH; LI, YC; DOERRE, S; SISTA, P; BALLARD, DW; GREENE, WC; FRANZA, BR			A MEMBER OF THE SET OF KAPPA-B BINDING-PROTEINS, HIVEN86A, IS A PRODUCT OF THE HUMAN C-REL PROTOONCOGENE	ONCOGENE			English	Note							RECEPTOR-ALPHA-GENE; TRANSCRIPTION FACTOR; CELLULAR PROTEINS; T-CELLS; ENHANCER; NUCLEAR; EXPRESSION; TRANSACTIVATION; ACTIVATION; SEQUENCES	HIVEN86A is an inducible member of a set of cellular proteins that specifically bind to the kappa-B enhancer (Franza et al., 1987; Franza, 1988; Franza, 1990; Ballard et al., 1989; Bohnlein et al., 1988). This enhancer motif has been detected in numerous cellular and viral transcription control domains (Boshart et al., 1985; Sen & Baltimore, 1986; Nabel & Baltimore, 1987). Recently, cDNAs have been cloned (Kieran et al., 1990; Baldwin & Sharp, 1987) that encode the 50 kD DNA binding subunit of murine NF-kappa-B (for review: Leonardo & Baltimore, 1989) and the closely related human kappa binding factor (KBF-1) (Kimura et al., 1986; Baldwin & Sharp, 1987). A 350 amino acid domain at the N-terminus of these proteins was found to be homologous with the v-rel oncogene from the avian reticuloendotheliosis virus, strain T (REV-T), as well as a maternal effect gene, dorsal (Kieran et al., 1990; Ghosh et al., 1990). Dorsal is known to activate transcription of certain Drosophila genes (Rushlow et al., 1987). The v-Rel oncoprotein has been identified as a transcriptional activator (Gelinas & Temin, 1988; Hannink & Temin, 1989; Bull et al., 1990) in certain assay systems and shown to be induced by the tumor promoter, phorbol 12-myristate 13-acetate (PMA) in avian cells (for review: Rice & Gilden, 1988). HIVEN86A is also inducible by PMA (Franza et al., 1987; Franza, 1988; Franza, 1990). We now demonstrate that the protein product of the human c-rel proto-oncogene is structurally identical to HIVEN86A.	COLD SPRING HARBOR LAB,BUNGTOWN RD,POB 100,COLD SPRING HARBOR,NY 11724; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Cold Spring Harbor Laboratory; Duke University; Howard Hughes Medical Institute								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; FRANZA BR, 1988, CONTROL OF HUMAN RETROVIRUS GENE EXPRESSION, P159; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; FRANZA BR, 1990, HUMAN RETROVIRUSES, P181; GARRELS JI, 1989, J BIOL CHEM, V264, P5283; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonardo MJ, 1998, CELL, V58, P227; LISCHWE MA, 1977, J BIOL CHEM, V252, P4976; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; RICE NR, 1988, ONCOGENE HDB, P495; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6	27	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					665	667						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	2030915				2022-12-17	WOS:A1991FR93900024
J	MITCHELL, CD; VENTRIS, JA; WARR, TJ; COWELL, JK				MITCHELL, CD; VENTRIS, JA; WARR, TJ; COWELL, JK			MOLECULAR DEFINITION IN A SOMATIC-CELL HYBRID OF A SPECIFIC 2-13 TRANSLOCATION BREAKPOINT IN CHILDHOOD RHABDOMYOSARCOMA	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY LOCUS; ESTERASE-D GENE; CHROMOSOMAL TRANSLOCATION; ALVEOLAR RHABDOMYOSARCOMA; DNA; FRAGMENTS; SEQUENCES; LINKAGE	A consistent, balanced, reciprocal chromosomal translocation t(2:13) (q35:q14) has been identified in alveolar rhabdomyosarcoma. Somatic cell hybrids have been constructed between rhabdomyosarcoma cell lines carrying the (2:13) translocation and mouse 3T3 cells. One hybrid cell line was shown to have retained the derivative (13:2) chromosome, but segregated the normal chromosome 13 and the derivative (2:13) chromosome. Using available DNA probes from human chromosome 13 we find that the loci for retinoblastoma, esterase D, p7D2, pG24E6.8 and pG14E1.9 lie distally to the 13q14 breakpoint, whereas those for p7F12, pHU10 and pG2E3.1 all lie proximally. Thus we have defined a region of 13q14 of approximately 28 mB which contains the breakpoint associated with this rearrangement.	INST CHILD HLTH,IMPERIAL CANC RES FUND,MOLEC ONCOL LAB,LONDON WC1N 1EH,ENGLAND	Cancer Research UK; University of London; University College London	MITCHELL, CD (corresponding author), INST CHILD HLTH,LEUKAEMIA RES FUND,DEPT HAEMATOL & ONCOL,GUILFORD ST,LONDON WC1N 1EH,ENGLAND.			Cowell, John/0000-0002-2079-5950				BOWCOCK AM, 1987, AM J HUM GENET, V41, P27; BOWCOCK AM, 1988, AM J HUM GENET, V43, P664; CAVENEE W, 1984, AM J HUM GENET, V36, P10; COWELL JK, 1980, J NATL CANCER I, V65, P955; COWELL JK, 1989, CYTOGENET CELL GENET, V52, P1, DOI 10.1159/000132827; COWELL JK, 1986, HUMAN CYTOGENETICS P, P202; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; DRYJA TP, 1984, HUM GENET, V65, P320, DOI 10.1007/BF00291555; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HAYASHI Y, 1988, CANCER GENET CYTOGEN, V30, P343, DOI 10.1016/0165-4608(88)90208-7; HIGGINS MJ, 1990, P NATL ACAD SCI USA, V87, P3415, DOI 10.1073/pnas.87.9.3415; HIGGINS MJ, 1989, MOL CELL BIOL, V9, P1; LEPPERT M, 1987, HUMAN GENE MAPPING, V9; MITCHELL CD, 1988, HUM GENET, V81, P57, DOI 10.1007/BF00283730; MITCHELL CD, 1989, ONCOGENE, V4, P253; MORIYAMA M, 1986, CANCER GENET CYTOGEN, V22, P177, DOI 10.1016/0165-4608(86)90204-9; ROWE D, 1987, BRIT J CANCER, V56, P379, DOI 10.1038/bjc.1987.207; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEFFER H, 1986, HUM GENET, V74, P249, DOI 10.1007/BF00282543; SCHEFFER H, 1986, NUCLEIC ACIDS RES, V14, P3148, DOI 10.1093/nar/14.7.3148; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SQUIRE J, 1986, P NATL ACAD SCI USA, V83, P6573, DOI 10.1073/pnas.83.17.6573; SQUIRE J, 1985, HUM GENET, V70, P291, DOI 10.1007/BF00295364; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; VALENTINE M, 1989, CYTOGENET CELL GENET, V52, P128, DOI 10.1159/000132861; YOUNG BD, 1988, BRIT J CANCER, V58, P58	29	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					89	92						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1992447				2022-12-17	WOS:A1991EY03900012
J	SZENTIRMAY, Z; ISHIZAKA, Y; OHGAKI, H; TAHIRA, T; NAGAO, M; ESUMI, H				SZENTIRMAY, Z; ISHIZAKA, Y; OHGAKI, H; TAHIRA, T; NAGAO, M; ESUMI, H			DEMONSTRATION BY INSITU HYBRIDIZATION OF RET PROTOONCOGENE MESSENGER-RNA IN DEVELOPING PLACENTA DURING MIDTERM OF RAT GESTATION	ONCOGENE			English	Article									NATL CANC CTR,RES INST,DIV BIOCHEM,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN; NATL CANC CTR,RES INST,DIV CARCINOGENESIS,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan; National Cancer Center - Japan								ADAMSON ED, 1981, NATURE, V291, P656, DOI 10.1038/291656a0; ALDEN RH, 1948, AM J ANAT, V83, P143, DOI 10.1002/aja.1000830106; BRESSER J, 1987, GENE ANAL TECH, V4, P89, DOI 10.1016/0735-0651(87)90002-1; CHEGINI N, 1985, J CLIN ENDOCR METAB, V61, P529, DOI 10.1210/jcem-61-3-529; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GUITTENY AF, 1988, J HISTOCHEM CYTOCHEM, V36, P563, DOI 10.1177/36.6.3259249; Hebei R., 1986, ANATOMY EMBRYOLOGY L, P237; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; LARGENT BL, 1988, P NATL ACAD SCI USA, V85, P2864, DOI 10.1073/pnas.85.8.2864; LEONG ASY, 1985, J PATHOL, V146, P313, DOI 10.1002/path.1711460404; LEONG ASY, 1988, J PATHOL, V156, P275, DOI 10.1002/path.1711560402; LOGIN GR, 1986, J HISTOCHEM CYTOCHEM, V34, P381, DOI 10.1177/34.3.3950387; MACBRIDE LJ, 1983, TETRAHEDRON LETT, V24, P245; MARTI R, 1987, J HISTOCHEM CYTOCHEM, V35, P1415, DOI 10.1177/35.12.3680934; METZ J, 1980, ANAT EMBRYOL, V159, P289, DOI 10.1007/BF00317652; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; MULLER R, 1983, EMBO J, V2, P679, DOI 10.1002/j.1460-2075.1983.tb01484.x; PFEIFEROHLSSON S, 1984, CELL, V38, P585, DOI 10.1016/0092-8674(84)90513-0; RENTROP M, 1986, HISTOCHEM J, V18, P271, DOI 10.1007/BF01676237; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; STROMBERG K, 1982, BIOCHEM BIOPH RES CO, V106, P354, DOI 10.1016/0006-291X(82)91117-2; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; UHL GR, 1985, P NATL ACAD SCI USA, V82, P5555, DOI 10.1073/pnas.82.16.5555	31	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					701	705						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2189106				2022-12-17	WOS:A1990DG37400010
J	KESAVAN, P; DAS, P; KERN, J; DAS, M				KESAVAN, P; DAS, P; KERN, J; DAS, M			REGULATION OF STABILITY AND SYNTHESIS OF EGF-RECEPTOR MESSENGER-RNAS ENCODING FOR INTACT AND TRUNCATED RECEPTOR FORMS	ONCOGENE			English	Article									UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Kern, Jeffrey/0000-0001-9709-9622	NATIONAL CANCER INSTITUTE [R01CA043787, P01CA015822] Funding Source: NIH RePORTER; NCI NIH HHS [CA-15822, CA-43787] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; COHEN S, 1982, J BIOL CHEM, V261, P11247; DEPALO L, 1988, CANCER RES, V48, P1105; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; JINNO Y, 1988, NUCLEIC ACIDS RES, V16, P4957, DOI 10.1093/nar/16.11.4957; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Maniatis T., 1982, MOL CLONING; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; ROYCHOUDHURY S, 1988, P NATL ACAD SCI USA, V85, P2014, DOI 10.1073/pnas.85.6.2014; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; THOMPSON KL, 1989, J BIOL CHEM, V264, P3230; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; WELLS A, 1988, MOL CELL BIOL, V8, P4561, DOI 10.1128/MCB.8.10.4561; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YAMAMOTO T, 1986, CANCER RES, V46, P414; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	29	22	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					483	488						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2326077				2022-12-17	WOS:A1990DB85300005
J	RO, J; BRESSER, J; RO, JY; BRASFIELD, F; HORTOBAGYI, G; BLICK, M				RO, J; BRESSER, J; RO, JY; BRASFIELD, F; HORTOBAGYI, G; BLICK, M			SIS PDGF-B EXPRESSION IN BENIGN AND MALIGNANT HUMAN-BREAST LESIONS	ONCOGENE			English	Article									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT CLIN IMMUNOL BIOL THERAPY,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT ANAT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	RO, J (corresponding author), UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT MED ONCOL,1515 HOLCOMBE,BOX 78,HOUSTON,TX 77030, USA.				NCRR NIH HHS [RR5511-25] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARSKY SH, 1982, AM J PATHOL, V108, P276; BOWENPOPE DF, 1983, J CELL BIOL, V96, P679, DOI 10.1083/jcb.96.3.679; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; BRESSER J, 1987, GENE ANAL TECH, V4, P89, DOI 10.1016/0735-0651(87)90002-1; CANALIS E, 1981, METABOLISM, V30, P970, DOI 10.1016/0026-0495(81)90094-9; CHIU IM, 1984, CELL, V37, P123; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; KAO RT, 1984, AM J PATHOL, V115, P109; LIOTTA LA, 1983, LAB INVEST, V49, P636; OWEN AJ, 1982, P NATL ACAD SCI-BIOL, V79, P3203, DOI 10.1073/pnas.79.10.3203; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1985, INT J CANCER, V36, P247, DOI 10.1002/ijc.2910360218; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SEEMAYER TA, 1979, AM J SURG PATHOL, V3, P525, DOI 10.1097/00000478-197912000-00005; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; VANZOELEN EJJ, 1985, MOL CELL BIOL, V5, P2289, DOI 10.1128/MCB.5.9.2289; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	26	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					351	354						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2649848				2022-12-17	WOS:A1989U567600011
J	NOGUCHI, T; GALLAND, F; BATOZ, M; MATTEI, MG; BIRNBAUM, D				NOGUCHI, T; GALLAND, F; BATOZ, M; MATTEI, MG; BIRNBAUM, D			ACTIVATION OF A MCF 2 ONCOGENE BY DELETION OF AMINO-TERMINAL CODING SEQUENCES	ONCOGENE			English	Article									EUROPEAN MOLEC BIOL LAB, MEYERHOFSTR 1 POSTFACH 102209, D-6900 HEIDELBERG, GERMANY; INSERM, U119, F-13009 MARSEILLE, FRANCE	European Molecular Biology Laboratory (EMBL); Institut National de la Sante et de la Recherche Medicale (Inserm)				Birnbaum, Daniel/0000-0001-7920-9883				ANSON DS, 1988, EMBO J, V7, P2795, DOI 10.1002/j.1460-2075.1988.tb03134.x; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; NGUYEN C, 1987, EMBO J, V6, P3285, DOI 10.1002/j.1460-2075.1987.tb02647.x; NOGUCHI T, 1987, EMBO J, V6, P1301, DOI 10.1002/j.1460-2075.1987.tb02368.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; RABIN M, 1987, ONCOGENE RES, V1, P169; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V23, P291, DOI 10.1016/0165-4608(86)90011-7; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	28	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1988	3	6					709	715						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577874				2022-12-17	WOS:A1988R646000014
J	MARTINSSON, T; STAHL, F; POLLWEIN, P; WENZEL, A; LEVAN, A; SCHWAB, M; LEVAN, G				MARTINSSON, T; STAHL, F; POLLWEIN, P; WENZEL, A; LEVAN, A; SCHWAB, M; LEVAN, G			TUMORIGENICITY OF SEWA MURINE CELLS CORRELATES WITH DEGREE OF C-MYC AMPLIFICATION	ONCOGENE			English	Article									GERMAN CANC RES CTR,INST EXPTL PATHOL,D-6900 HEIDELBERG 1,FED REP GER; GOTHENBURG UNIV,DEPT GENET,S-41124 GOTHENBURG,SWEDEN; UNIV LUND,INST GENET,S-22101 LUND,SWEDEN	Helmholtz Association; German Cancer Research Center (DKFZ); University of Gothenburg; Lund University			Martinsson, Tommy/J-4140-2013	Martinsson, Tommy/0000-0002-9403-3123				ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRADLEY JV, 1968, DISTRIBUTION FREE ST, P68; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CREWS S, 1982, SCIENCE, V218, P1319, DOI 10.1126/science.7146913; HAMLIN JL, 1984, INT REV CYTOL, V90, P31, DOI 10.1016/S0074-7696(08)61487-4; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; LEVAN A, 1978, CYTOGENET CELL GENET, V20, P12, DOI 10.1159/000130836; LEVAN G, 1977, HEREDITAS, V86, P75; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARTINSSON T, 1982, HEREDITAS, V97, P123, DOI 10.1111/j.1601-5223.1982.tb00720.x; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANCHEZ O, 1973, LANCET, V2, P269; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; SEABRIGH.M, 1971, LANCET, V2, P971; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; SUMNER AT, 1972, EXP CELL RES, V75, P304, DOI 10.1016/0014-4827(72)90558-7; [No title captured]	25	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					437	441						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078951				2022-12-17	WOS:A1988Q773900012
J	KUPPUSWAMY, M; CHINNADURAI, G				KUPPUSWAMY, M; CHINNADURAI, G			CELL TYPE DEPENDENT TRANSFORMATION BY ADENOVIRUS 5 E1A PROTEINS	ONCOGENE			English	Article									ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,3681 PK AVE,ST LOUIS,MO 63110	Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA033616, R01CA031719] Funding Source: NIH RePORTER; NCI NIH HHS [CA-31719, CA-33616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABISS LE, 1983, P NATL ACAD SCI-BIOL, V80, P1352, DOI 10.1073/pnas.80.5.1352; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GLENN GM, 1985, J VIROL, V56, P66, DOI 10.1128/JVI.56.1.66-74.1985; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1984, ADENOVIRUSES, P339; HALEY KP, 1984, NATL ACAD SCI US, V81, P5743; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HO YS, 1982, VIROLOGY, V122, P109, DOI 10.1016/0042-6822(82)90381-6; HURWITZ DR, 1985, J VIROL, V54, P358, DOI 10.1128/JVI.54.2.358-363.1985; HURWITZ DR, 1985, P NATL ACAD SCI USA, V82, P163, DOI 10.1073/pnas.82.1.163; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KIMELMAN D, 1986, MOL CELL BIOL, V6, P1487, DOI 10.1128/MCB.6.5.1487; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; ROBERTS BE, 1985, J VIROL, V56, P404, DOI 10.1128/JVI.56.2.404-413.1985; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WINBERG G, 1984, EMBO J, V3, P1907, DOI 10.1002/j.1460-2075.1984.tb02066.x; YEE S, 1985, VIROLOGY, V147, P315; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	37	22	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					567	572						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2968533				2022-12-17	WOS:A1988N841500006
J	CHIARUGI, V; PORCIATTI, F; PASQUALI, F; MAGNELLI, L; GIANNELLI, S; RUGGIERO, M				CHIARUGI, V; PORCIATTI, F; PASQUALI, F; MAGNELLI, L; GIANNELLI, S; RUGGIERO, M			POLYPHOSPHOINOSITIDE METABOLISM IS RAPIDLY STIMULATED BY ACTIVATION OF A TEMPERATURE-SENSITIVE MUTANT OF ROUS-SARCOMA VIRUS IN RAT FIBROBLASTS	ONCOGENE			English	Article											CHIARUGI, V (corresponding author), IST PATOL GEN,MOLEC BIOL LAB,VIALE MORGAGNI 50,I-50134 FIRENZE,ITALY.		Magnelli, Lucia/J-7077-2018	Magnelli, Lucia/0000-0003-4585-1450				ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALEMA S, 1987, ADV CANCER RES, V49, P87; BAUDRY M, 1986, NATURE, V319, P329, DOI 10.1038/319329a0; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BERRIIDGE MJ, 1983, BIOCHEM J, V212, P843; BESTERMAN JM, 1986, J BIOL CHEM, V261, P723; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CHIARUGI V, 1985, BIOCHEM BIOPH RES CO, V132, P900, DOI 10.1016/0006-291X(85)91892-3; CHIARUGI VP, 1986, BIOCHEM BIOPH RES CO, V141, P591, DOI 10.1016/S0006-291X(86)80214-5; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HORNE WC, 1981, EUR J BIOCHEM, V120, P295, DOI 10.1111/j.1432-1033.1981.tb05703.x; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; LACAL JC, 1987, IN PRESS SCIENCE; LAPETINA EG, 1985, J BIOL CHEM, V260, P7078; LAPETINA EG, 1987, PHOSPHOINOSITIDES RE, P271; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MACDONALD ML, 1985, P NATL ACAD SCI USA, V82, P3993, DOI 10.1073/pnas.82.12.3993; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PREISS J, 1986, J BIOL CHEM, V261, P8597; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SUGANO S, 1985, MOL CELL BIOL, V5, P2399, DOI 10.1128/MCB.5.9.2399; SUGIMOTO Y, 1985, MOL CELL BIOL, V5, P3194, DOI 10.1128/MCB.5.11.3194; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; VANDERVALK J, 1987, J BIOL CHEM, V262, P2431; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WATSON SP, 1984, J BIOL CHEM, V259, P3199; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7	31	22	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	2	1					37	40						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	L4813	2830581				2022-12-17	WOS:A1987L481300005
J	Wang, F; Liao, Y; Zhang, M; Zhu, Y; Wang, WJ; Cai, HS; Liang, JF; Song, F; Hou, C; Huang, SJ; Zhang, YD; Wang, C; Hou, JS				Wang, Fang; Liao, Yan; Zhang, Ming; Zhu, Yue; Wang, Wenjin; Cai, Hongshi; Liang, Jianfeng; Song, Fan; Hou, Chen; Huang, Shuojin; Zhang, Yadong; Wang, Cheng; Hou, Jinsong			N6-methyladenosine demethyltransferase FTO-mediated autophagy in malignant development of oral squamous cell carcinoma	ONCOGENE			English	Article							METHYLTRANSFERASE METTL3 PROMOTES; DECREASED EXPRESSION; CANCER; RNA; TRANSLATION; METHYLATION; TUMORIGENESIS; PROGRESSION; MTOR; PROLIFERATION	N6-methyladenosine (m(6)A) is the most abundant internal mRNA modification in eukaryotes and plays an important role in tumorigenesis. However, the underlying mechanism remains largely unclear. Here, we established a cell model of rapamycin-induced autophagy to screen m(6)A-modifying enzymes. We found that m(6)A demethylase fat mass and obesity-associated protein (FTO) plays a key role in regulating autophagy and tumorigenesis by targeting the gene encoding eukaryotic translation initiation factor gamma 1 (eIF4G1) in oral squamous cell carcinoma (OSCC). Knocked down of FTO expression in OSCC cell lines, resulting in downregulation of eIF4G1 along with enhanced autophagic flux and inhibition of tumorigenesis. Rapamycin inhibited FTO activity, and directly targeted eIF4G1 transcripts and mediated their expression in an m(6)A-dependent manner. Dual-luciferase reporter and mutagenesis assays confirmed that YTH N6-methyladenosine RNA-binding protein 2 (YTHDF2) targets eIF4G1. Conclusively, after FTO silencing, YTHDF2 captured eIF4G1 transcripts containing m(6)A, resulting in mRNA degradation and decreased expression of eIF4G1 protein, thereby promoting autophagy and reducing tumor occurrence. Therefore, rapamycin may regulate m(6)A levels, determining the autophagic flux of OSCC, thereby affecting the biological characteristics of cancer cells. This insight expands our understanding of the crosstalk between autophagy and RNA methylation in tumorigenesis, which is essential for therapeutic strategy development for OSCC.	[Wang, Fang; Liao, Yan; Zhang, Ming; Zhu, Yue; Wang, Wenjin; Cai, Hongshi; Liang, Jianfeng; Song, Fan; Hou, Chen; Huang, Shuojin; Zhang, Yadong; Wang, Cheng; Hou, Jinsong] Sun Yat Sen Univ, Hosp Stomatol, Dept Oral & Maxillofacial Surg, Guanghua Sch Stomatol, Guangzhou, Peoples R China; [Wang, Fang; Liao, Yan; Zhang, Ming; Zhu, Yue; Wang, Wenjin; Cai, Hongshi; Liang, Jianfeng; Song, Fan; Hou, Chen; Huang, Shuojin; Zhang, Yadong; Wang, Cheng; Hou, Jinsong] Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Wang, C; Hou, JS (corresponding author), Sun Yat Sen Univ, Hosp Stomatol, Dept Oral & Maxillofacial Surg, Guanghua Sch Stomatol, Guangzhou, Peoples R China.; Wang, C; Hou, JS (corresponding author), Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China.	wangch75@mail.sysu.edu.cn; houjs@mail.sysu.edu.cn	wang, fang/GYD-4295-2022		National Natural Science Foundation of China [81874128, 82072994]; Sun Yat-sen University Clinical Research 5010 Program [2015018]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sun Yat-sen University Clinical Research 5010 Program	This work was supported by the National Natural Science Foundation of China (Grant Nos. 81874128 and 82072994); Sun Yat-sen University Clinical Research 5010 Program (Grant No. 2015018).	Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019; Caccamo A, 2010, J BIOL CHEM, V285, P13107, DOI 10.1074/jbc.M110.100420; Cai HS, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01446; Cai XL, 2018, CANCER LETT, V415, P11, DOI 10.1016/j.canlet.2017.11.018; Cao YY, 2016, ONCOTARGET, V7, P24242, DOI 10.18632/oncotarget.8168; Chen GH, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8480762; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; Chen YB, 2012, J SURG ONCOL, V105, P542, DOI 10.1002/jso.22151; Cheung MK, 2013, INT J OBESITY, V37, P744, DOI 10.1038/ijo.2012.77; Comtesse N, 2007, INT J CANCER, V120, P2538, DOI 10.1002/ijc.22585; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Day TA, 2019, CLIN CANCER RES, V25, P1156, DOI 10.1158/1078-0432.CCR-18-2024; Dell'Anno I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144856; Diao PF, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1742-x; Fang WY, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-32; Fang YJ, 2020, ONCOTARGETS THER, V13, P10431, DOI 10.2147/OTT.S266389; Fatscher T, 2014, RNA, V20, P1579, DOI 10.1261/rna.044933.114; Gassen NC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13659-4; Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049; Gulati P, 2013, P NATL ACAD SCI USA, V110, P2557, DOI 10.1073/pnas.1222796110; Hale CM, 2016, AUTOPHAGY, V12, P713, DOI 10.1080/15548627.2016.1147669; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho AS, 2017, J CLIN ONCOL, V35, P3601, DOI 10.1200/JCO.2016.71.1176; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jacob JA, 2017, CLIN CHIM ACTA, V468, P85, DOI 10.1016/j.cca.2017.01.028; Jaiswal PK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0947-2; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Jin SH, 2018, CELL RES, V28, P955, DOI 10.1038/s41422-018-0069-8; Kademani D, 2008, J ORAL MAXIL SURG, V66, P2151, DOI 10.1016/j.joms.2008.06.030; Kao YY, 2019, CANCER LETT, V456, P40, DOI 10.1016/j.canlet.2019.04.028; Ke SD, 2015, GENE DEV, V29, P2037, DOI 10.1101/gad.269415.115; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Li JF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01267-6; Li Y, 2019, DIGEST DIS SCI, V64, P1503, DOI 10.1007/s10620-018-5452-2; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Lin XY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09865-9; Liu L, 2017, ONCOGENE, V36, P5874, DOI 10.1038/onc.2017.193; Liu L, 2020, MOL THER, V28, P2177, DOI 10.1016/j.ymthe.2020.06.024; Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333; Mupparapu Mel, 2018, Dent Clin North Am, V62, P47, DOI 10.1016/j.cden.2017.08.003; Parihar M, 2021, CLIN COLORECTAL CANC, V20, pE61, DOI 10.1016/j.clcc.2020.08.006; Park EH, 2011, EMBO J, V30, P302, DOI 10.1038/emboj.2010.312; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Ramirez-Valle F, 2008, J CELL BIOL, V181, P293, DOI 10.1083/jcb.200710215; Rao SVK, 2013, ASIAN PAC J CANCER P, V14, P5567, DOI 10.7314/APJCP.2013.14.10.5567; Schaefer L, 2017, FEBS J, V284, P10, DOI 10.1111/febs.13963; Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827; Stolz A, 2014, NAT CELL BIOL, V16, P495, DOI 10.1038/ncb2979; Towers CG, 2016, EBIOMEDICINE, V14, P15, DOI 10.1016/j.ebiom.2016.10.034; Tu LX, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-78; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wang XX, 2020, AUTOPHAGY, V16, P1221, DOI 10.1080/15548627.2019.1659617; Weng JQ, 2014, ORAL ONCOL, V50, P983, DOI 10.1016/j.oraloncology.2014.06.020; Won KY, 2010, HUM PATHOL, V41, P107, DOI 10.1016/j.humpath.2009.07.006; Xia Q, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.572904; Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0; Yonekawa T, 2013, ESSAYS BIOCHEM, V55, P105, DOI [10.1042/BSE0550105, 10.1042/bse0550105]; Zanoni DK, 2019, ORAL ONCOL, V90, P115, DOI 10.1016/j.oraloncology.2019.02.001; Zhao W, 2020, MOL THER-NUCL ACIDS, V19, P405, DOI 10.1016/j.omtn.2019.11.022; Zhao Z, 2016, AM J CANCER RES, V6, P2162; Zhou J, 2015, NATURE, V526, P591, DOI 10.1038/nature15377; Zhu X, 2020, ONCOTARGETS THER, V13, P10515, DOI 10.2147/OTT.S266095	66	21	22	3	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3885	3898		10.1038/s41388-021-01820-7	http://dx.doi.org/10.1038/s41388-021-01820-7		MAY 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33972683				2022-12-17	WOS:000648930100003
J	Liu, Y; Tang, TC; Yang, XS; Qin, P; Wang, PS; Zhang, HP; Bai, M; Wu, R; Li, F				Liu, Yang; Tang, Tianchi; Yang, Xiaosheng; Qin, Peng; Wang, Pusen; Zhang, Huiping; Bai, Min; Wu, Rong; Li, Fan			Tumor-derived exosomal long noncoding RNA LINC01133, regulated by Periostin, contributes to pancreatic ductal adenocarcinoma epithelial-mesenchymal transition through the Wnt/beta-catenin pathway by silencing AXIN2	ONCOGENE			English	Article								Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies and rapidly progressive diseases. Exosomes and long noncoding RNAs (lncRNAs) are emerging as vital mediators in tumor cells and their microenvironment. However, the detailed roles and mechanisms of exosomal lncRNAs in PDAC progression remain unknown. Here, we aimed to clarify the clinical significance and mechanisms of exosomal lncRNA 01133 (LINC01133) in PDAC. We analyzed the expression of LINC01133 in PDAC and found that exosomal LINC01133 expression was high and positively correlated with higher TNM stage and poor overall survival rate of PDAC patients. Further research demonstrated that Periostin could increase exosome secretion and then enhance LINC01133 expression. In addition, Periostin increased p-EGFR, p-Erk, and c-myc expression, and c-myc could bind to the LINC01133 promoter region. These findings suggested that LINC01133 can be regulated by Periostin via EGFR pathway activity. We also observed that LINC01133 promoted the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of pancreatic cancer cells. We subsequently evaluated the effect of LINC01133 on the Wnt/beta-catenin pathway and confirmed that LINC01133 can interact with Enhancer Of Zeste Homolog 2 (EZH2) and then promote H3K27 trimethylation. This can further silence AXIN2 and suppress GSK3 activity, ultimately activating beta-catenin. Collectively, these data indicate that exosomal LINC01133 plays an important role in pancreatic tumor progression, and targeting LINC01133 may provide a potential treatment strategy for PDAC.	[Liu, Yang; Bai, Min; Wu, Rong; Li, Fan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ultrasound, Shanghai, Peoples R China; [Tang, Tianchi] Shanghai Jiao Tong Univ, Sch Med, Affiliated Xinhua Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Yang, Xiaosheng] Shanghai Jiao Tong Univ, Dept Neurosurg, Shanghai Peoples Hosp 9, Sch Med, Shanghai, Peoples R China; [Qin, Peng] Shanghai Jiao Tong Univ, Dept Instrument Sci & Engn, Shanghai, Peoples R China; [Wang, Pusen] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Zhang, Huiping] East China Normal Univ, Shanghai Changning Matern & Infant Hlth Hosp, Matern & Infant Hlth Hosp, Dept Ultrasound, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; East China Normal University	Wu, R; Li, F (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ultrasound, Shanghai, Peoples R China.	wurong7111@163.com; medicineli@163.com		Fan, Li/0000-0003-3550-0243	Shanghai Municipal Commission of Health and Family Planning [20184Y0363]; Medical and Engineering Cross-Foundation of Shanghai Jiaotong University [ZH2018QNA21]; Songjiang District Science and Technology Research Projects of Shanghai [19SJKJGG29]; National Natural Science Foundation of China [81571679, 81771838]; Shanghai Natural Science Foundation [19ZR1441500]	Shanghai Municipal Commission of Health and Family Planning; Medical and Engineering Cross-Foundation of Shanghai Jiaotong University; Songjiang District Science and Technology Research Projects of Shanghai; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai)	Funding were provided by Shanghai Municipal Commission of Health and Family Planning (20184Y0363), the Medical and Engineering Cross-Foundation of Shanghai Jiaotong University (ZH2018QNA21), Songjiang District Science and Technology Research Projects of Shanghai (19SJKJGG29), the National Natural Science Foundation of China (Nos. 81571679 and 81771838) and the Shanghai Natural Science Foundation (19ZR1441500).	Bolha L, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/7243968; Danieau G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153751; Ding J, 2018, ONCOGENE, V37, P5037, DOI 10.1038/s41388-018-0175-6; Dong D, 2018, CANCER SCI, V109, P2841, DOI 10.1111/cas.13712; Erkan M, 2012, NAT REV GASTRO HEPAT, V9, P454, DOI 10.1038/nrgastro.2012.115; Feng Y, 2019, CANCER BIOL THER, V20, P1453, DOI 10.1080/15384047.2019.1647058; Foroughi K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123881; Fu YJ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0815-z; Fukushima N, 2008, MODERN PATHOL, V21, P1044, DOI 10.1038/modpathol.2008.77; Gruszka AM, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111403; Han ML, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1145-5; He P, 2018, GASTROENTEROLOGY, V154, P1494, DOI 10.1053/j.gastro.2017.12.005; Huang YK, 2020, AM J CANCER RES, V10, P131; Jin H, 2017, CLIN TRANSL ONCOL, V19, P921, DOI 10.1007/s12094-017-1625-2; Kong JL, 2016, CANCER LETT, V380, P476, DOI 10.1016/j.canlet.2016.07.015; Kumar MM, 2017, CURR TOP MED CHEM, V17, P1750, DOI 10.2174/1568026617666161116144744; Lan B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184332; Liu Y, 2017, ONCOTARGET, V8, P89552, DOI 10.18632/oncotarget.11533; Lu HZ, 2017, CANCER MED-US, V6, P1181, DOI 10.1002/cam4.1064; Makena MR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174242; Murillo-Garzon V, 2017, NAT REV UROL, V14, P683, DOI 10.1038/nrurol.2017.144; Pirogov SA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070668; Ren B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0858-1; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Ruivo CF, 2017, CANCER RES, V77, P6480, DOI 10.1158/0008-5472.CAN-17-0994; Saini F, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050424; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sun QY, 2018, NUCLEIC ACIDS RES, V46, P10405, DOI 10.1093/nar/gky696; Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334; Tandon M, 2019, CANCER RES, V79, P5316, DOI 10.1158/0008-5472.CAN-18-3064; Tang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1128-6; Thomas D, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0927-5; Viotti M, 2018, J CELL BIOL, V217, P763, DOI 10.1083/jcb.201705031; Wang J, 2020, INT J CANCER, V146, P906, DOI 10.1002/ijc.32277; Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841; Ware MJ, 2016, BIOMATERIALS, V108, P129, DOI 10.1016/j.biomaterials.2016.08.041; Wen ZZ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0590-2; Yang XZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0874-1; Zeng FR, 2020, ONCOGENE, V39, P293, DOI 10.1038/s41388-019-0984-2; Zeng HF, 2018, ONCOL RES, V26, P335, DOI 10.3727/096504017X14907375885605; Zhang J, 2015, TUMOR BIOL, V36, P7465, DOI 10.1007/s13277-015-3460-9; Zhang YF, 2018, CANCER LETT, V431, P190, DOI 10.1016/j.canlet.2018.05.027; Zheng YF, 2019, J CELL BIOCHEM, V120, P4172, DOI 10.1002/jcb.27704; Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613	44	21	21	4	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3164	3179		10.1038/s41388-021-01762-0	http://dx.doi.org/10.1038/s41388-021-01762-0		APR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33824474	Green Published, hybrid			2022-12-17	WOS:000637478800003
J	Grossman, JE; Vasudevan, D; Joyce, CE; Hildago, M				Grossman, Joseph E.; Vasudevan, Divya; Joyce, Cailin E.; Hildago, Manuel			Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor	ONCOGENE			English	Editorial Material							EXPRESSION; MECHANISM; ESCAPE		[Grossman, Joseph E.; Vasudevan, Divya; Joyce, Cailin E.] Agenus Inc, Lexington, MA USA; [Hildago, Manuel] Weill Cornell Med, Div Hematol & Med Oncol, New York, NY 10065 USA	Agenus Inc; Cornell University	Hildago, M (corresponding author), Weill Cornell Med, Div Hematol & Med Oncol, New York, NY 10065 USA.	mah4006@med.cornell.edu	; Hidalgo, Manuel/I-4995-2015	Grossman, Joseph/0000-0002-2130-2783; Hidalgo, Manuel/0000-0002-3765-3318				Aggen DH, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0299-1; Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Chung HC, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.5522; Crane C, 2009, J IMMUNOTHER, V32, P585, DOI 10.1097/CJI.0b013e3181a8efe6; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Green MR, 2012, CLIN CANCER RES, V18, P1611, DOI 10.1158/1078-0432.CCR-11-1942; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Guo L, 2019, J IMMUNOTHER, V42, P215, DOI 10.1097/CJI.0000000000000275; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Kefford R, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.3005; Lim SO, 2016, CANCER CELL, V30, P925, DOI 10.1016/j.ccell.2016.10.010; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; Mehra R, 2018, BRIT J CANCER, V119, P153, DOI 10.1038/s41416-018-0131-9; Naumann RW, 2019, J CLIN ONCOL, V37, P2825, DOI 10.1200/JCO.19.00739; O'Malley DM, 2020, ANN ONCOL, V31, pS1164, DOI 10.1016/j.annonc.2020.08.2264; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Pichler R, 2017, ONCOTARGET, V8, P66849, DOI 10.18632/oncotarget.19913; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Twa DDW, 2014, BLOOD, V123, P2062, DOI 10.1182/blood-2013-10-535443; Zhang L, 2018, NATURE, V564, P268, DOI 10.1038/s41586-018-0694-x	23	21	21	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1393	1395		10.1038/s41388-020-01611-6	http://dx.doi.org/10.1038/s41388-020-01611-6		JAN 2021	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33500548	Green Published, hybrid			2022-12-17	WOS:000611934200002
J	Formaggio, N; Rubin, MA; Theurillat, JP				Formaggio, Nicolo; Rubin, Mark A.; Theurillat, Jean-Philippe			Loss and revival of androgen receptor signaling in advanced prostate cancer	ONCOGENE			English	Review							N-MYC; NEUROENDOCRINE DIFFERENTIATION; LINEAGE PLASTICITY; TUMOR-SUPPRESSOR; RESISTANCE; MECHANISMS; EXPRESSION; CELLS; EZH2; ADENOCARCINOMA	Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully implemented in clinical practice. That said, the stronger inhibition of the AR signaling axis has led in recent years to an increase of prostate cancers that de-differentiate into AR-negative disease. Unfortunately, this process is intimately linked with a poor prognosis. Here, we review the molecular mechanisms that enable cancer cells to switch from an AR-positive to an AR-negative disease and efforts to prevent/revert this process and thereby maintain/restore AR-dependence.	[Formaggio, Nicolo; Theurillat, Jean-Philippe] Univ Svizzera Italiana, Inst Oncol Res, Lugano, Switzerland; [Rubin, Mark A.] Univ Bern, Dept BioMed Res, Bern, Switzerland; [Rubin, Mark A.] Univ Bern, Bern Ctr Precis Med, Bern, Switzerland; [Rubin, Mark A.] Inselspital Bern, Bern, Switzerland	Universita della Svizzera Italiana; University of Bern; University of Bern	Theurillat, JP (corresponding author), Univ Svizzera Italiana, Inst Oncol Res, Lugano, Switzerland.; Rubin, MA (corresponding author), Univ Bern, Dept BioMed Res, Bern, Switzerland.; Rubin, MA (corresponding author), Univ Bern, Bern Ctr Precis Med, Bern, Switzerland.; Rubin, MA (corresponding author), Inselspital Bern, Bern, Switzerland.	mark.rubin@dbmr.unibe.ch; jean-philippe.theurillat@ior.usi.ch		Rubin, Mark/0000-0002-8321-9950	Universita della Svizzera italiana	Universita della Svizzera italiana	Open Access funding provided by Universita della Svizzera italiana.	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Akamatsu S, 2015, CELL REP, V12, P922, DOI 10.1016/j.celrep.2015.07.012; Akashi T, 2006, ONCOL REP, V16, P831; Alumkal JJ, 2020, P NATL ACAD SCI USA, V117, P12315, DOI 10.1073/pnas.1922207117; Aparicio AM, 2013, CLIN CANCER RES, V19, P3621, DOI 10.1158/1078-0432.CCR-12-3791; Beltran H, 2019, CLIN CANCER RES, V25, P6916, DOI 10.1158/1078-0432.CCR-19-1423; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2014, CLIN CANCER RES, V20, P2846, DOI 10.1158/1078-0432.CCR-13-3309; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Berger A, 2019, J CLIN INVEST, V129, P3924, DOI 10.1172/JCI127961; Berman-Booty LD, 2015, ENDOCR-RELAT CANCER, V22, pR33, DOI 10.1530/ERC-14-0393; Bernasocchi T, 2020, BIORXIV, DOI [10.1101/2020.07.08.193581, DOI 10.1101/2020.07.08.193581]; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02; Chen WY, 2019, CANCER LETT, V440, P35, DOI 10.1016/j.canlet.2018.10.004; Chlenski A, 2001, PROSTATE, V47, P66; Conteduca V, 2019, EUR J CANCER, V121, P7, DOI 10.1016/j.ejca.2019.08.011; Cyrta J, 2020, BIORXIV, DOI [10.1101/2020.03.06.949131, DOI 10.1101/2020.03.06.949131]; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Dehm SM, 2011, ENDOCR-RELAT CANCER, V18, pR183, DOI 10.1530/ERC-11-0141; Deng J, 1999, MOL BRAIN RES, V71, P23, DOI 10.1016/S0169-328X(99)00147-3; Di Donato M, 2019, CANCERS, V11, DOI 10.3390/cancers11060784; Edwards J, 2003, CLIN CANCER RES, V9, P5271; Epstein JI, 2014, AM J SURG PATHOL, V38, P756, DOI 10.1097/PAS.0000000000000208; Flanagan JJ, 2019, MOL CELL ENDOCRINOL, V493, DOI 10.1016/j.mce.2019.110452; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Flechon A, 2011, ANN ONCOL, V22, P2476, DOI 10.1093/annonc/mdr004; Foster BA, 1997, CANCER RES, V57, P3325; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Gao S, 2016, CELL REP, V17, P966, DOI 10.1016/j.celrep.2016.09.064; Gravina GL, 2010, PROSTATE, V70, P1166, DOI 10.1002/pros.21151; Groner AC, 2016, CANCER CELL, V29, P846, DOI 10.1016/j.ccell.2016.04.012; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Ho LN, 2009, P NATL ACAD SCI USA, V106, P5187, DOI 10.1073/pnas.0812888106; Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Jeter CR, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.41; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Karanikolas BDW, 2010, PROSTATE, V70, P675, DOI 10.1002/pros.21112; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kleb B, 2016, EPIGENETICS-US, V11, P184, DOI 10.1080/15592294.2016.1146851; Kregel S, 2020, NEOPLASIA, V22, P111, DOI 10.1016/j.neo.2019.12.003; Kregel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053701; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Kuwahara A, 2010, DEVELOPMENT, V137, P1035, DOI 10.1242/dev.046417; Kwon OJ, 2020, ONCOGENE, V39, P7142, DOI 10.1038/s41388-020-01487-6; Labrecque MP, 2019, J CLIN INVEST, V129, P4492, DOI 10.1172/JCI128212; Lam HM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00167; Lapuk AV, 2012, J PATHOL, V227, P286, DOI 10.1002/path.4047; Lee JK, 2016, CANCER CELL, V29, P536, DOI 10.1016/j.ccell.2016.03.001; Lin D, 2015, ONCOTARGET, V6, P1806, DOI 10.18632/oncotarget.2809; Linn Douglas E, 2010, Genes Cancer, V1, P908, DOI 10.1177/1947601910388271; Loriot Y, 2009, ANN ONCOL, V20, P703, DOI 10.1093/annonc/mdn694; Lotan TL, 2011, MODERN PATHOL, V24, P820, DOI 10.1038/modpathol.2011.7; Malik V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11054-7; Metzger AL, 2019, PROSTATE, V79, P1457, DOI 10.1002/pros.23864; Mishra R, 2018, J CLIN INVEST, V128, P4472, DOI 10.1172/JCI99397; Mohammad OS, 2017, CANCERS, V9, DOI 10.3390/cancers9120166; Molloy Niamh H, 2011, Cancers (Basel), V3, P510, DOI 10.3390/cancers3010510; Monsef N, 2009, PROSTATE, V69, P909, DOI 10.1002/pros.20934; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Nagakawa O, 2004, ONCOL REP, V12, P837; Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190; Neklesa T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.259; Niederst MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7377; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Paranjape AN, 2016, ONCOGENE, V35, P5963, DOI 10.1038/onc.2015.498; Park JW, 2018, SCIENCE, V362, P91, DOI 10.1126/science.aat5749; Park JW, 2017, MODERN PATHOL, V30, P1262, DOI 10.1038/modpathol.2017.44; Puca L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04495-z; Rafiee MR, 2016, MOL CELL, V64, P624, DOI 10.1016/j.molcel.2016.09.019; Randolph TL, 1997, MODERN PATHOL, V10, P612; Rapp UR, 2008, CELL CYCLE, V7, P45, DOI 10.4161/cc.7.1.5203; Rotinen M, 2018, NAT MED, V24, P1887, DOI 10.1038/s41591-018-0241-1; Saraon Punit, 2014, EJIFCC, V25, P42; Sarkar S, 2017, MOL CANCER RES, V15, P1063, DOI 10.1158/1541-7786.MCR-17-0062; Scaccianoce E, 2003, ONCOL RES, V14, P101, DOI 10.3727/000000003108748658; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Sharp A, 2019, J CLIN INVEST, V129, P192, DOI 10.1172/JCI122819; Sigala S, 2002, EUR J ENDOCRINOL, V147, P407, DOI 10.1530/eje.0.1470407; Small E. J., 2014, ANN ONCOLOGY, V25, piv255; Sotomayor P, 2009, PROSTATE, V69, P401, DOI 10.1002/pros.20895; Stoyanova T, 2013, P NATL ACAD SCI USA, V110, P20111, DOI 10.1073/pnas.1320565110; Tang AQ, 2017, ONCOTARGET, V8, P23937, DOI 10.18632/oncotarget.14893; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teply BA, 2018, LANCET ONCOL, V19, P76, DOI 10.1016/S1470-2045(17)30906-3; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Uysal-Onganer P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-55; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Xiong XZ, 2018, CELL REP, V25, P3006, DOI 10.1016/j.celrep.2018.11.065; Yang XZ, 2005, CANCER RES, V65, P5263, DOI 10.1158/0008-5472.CAN-05-0162; Yoo AS, 2009, NATURE, V460, P642, DOI 10.1038/nature08139; Yu XP, 2009, PROSTATE, V69, P249, DOI 10.1002/pros.20877; Zhang LH, 2020, NEURO-ONCOLOGY, V22, P1797, DOI 10.1093/neuonc/noaa138; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764; Zhang ZD, 2020, CANCER CELL, V37, P584, DOI 10.1016/j.ccell.2020.03.001; Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159-8290.CD-16-1174	105	21	21	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1205	1216		10.1038/s41388-020-01598-0	http://dx.doi.org/10.1038/s41388-020-01598-0		JAN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420371	hybrid, Green Published			2022-12-17	WOS:000607346000016
J	Kan, TT; Wang, W; Ip, PP; Zhou, ST; Wong, AS; Wang, X; Yang, MS				Kan, Tongtong; Wang, Wei; Ip, Philip P.; Zhou, Shengtao; Wong, Alice S.; Wang, Xin; Yang, Mengsu			Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites	ONCOGENE			English	Article							FIBROBLASTS; METASTASIS; DISSEMINATION; TUMORIGENESIS; SUBTYPES	Malignant ascites of epithelial ovarian cancer is a metastatic tumor microenvironment in which large amounts of disseminated single cells (DSCs) and disseminated tumor cell clusters (DTCCs) are commonly observed. The tumor cell clusters are known to be more aggressive than individual tumor cells in cancer metastasis; however, little is known about the mechanism. Applying single-cell epithelial-to-mesenchymal transition (EMT)-related transcriptional analysis in 120 DSCs and 195 intra-cluster cells from 27 DTCCs, we demonstrated that DTCCs were heterogeneous cellular units comprised of epithelial tumor cells, leukocytes, and cancer-associated fibroblasts (CAFs). Through the analysis of intra-DTCC heterogeneity, we identified that CAFs induced EMT of tumor cells via TGF beta signaling within the DTCC microenvironment. The activation of EMT program, in particular the upregulation of ZEB2, enabled the acquisition of additional chemoresistance and metastasis abilities of the intra-DTCC tumor cells, which resulted in the aggressiveness of DTCCs.	[Kan, Tongtong; Wang, Wei; Wang, Xin; Yang, Mengsu] City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China; [Ip, Philip P.] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Peoples R China; [Zhou, Shengtao] Sichuan Univ, West China Hosp, Dept Obstet & Gynecol,Key Lab Birth Defects & Rel, Minist Educ,West China Hosp 2, Chengdu, Peoples R China; [Zhou, Shengtao] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Collaborat Innovat Ctr, Chengdu, Peoples R China; [Wong, Alice S.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Peoples R China; [Yang, Mengsu] City Univ Hong Kong, Shenzhen Res Inst, Key Lab Biochip Technol, Shenzhen, Peoples R China	City University of Hong Kong; University of Hong Kong; Sichuan University; Sichuan University; University of Hong Kong; City University of Hong Kong	Yang, MS (corresponding author), City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China.; Yang, MS (corresponding author), City Univ Hong Kong, Shenzhen Res Inst, Key Lab Biochip Technol, Shenzhen, Peoples R China.	bhmyang@cityu.edu.hk	Ip, Philip/AAV-5995-2021; Wong, Alice/AFJ-4595-2022; Wang, Xin/A-1130-2012	Ip, Philip/0000-0002-0493-9838; Wong, Alice/0000-0002-0676-6475; Wang, Xin/0000-0002-5122-2418	Hong Kong Research Grant Council [CityU_11303815, CRF/1013-15G]; Guangdong Frontier and Key Technology Development Fund of Guangdong Province, PR China [2017B020226001]; Knowledge Innovation Program of Shenzhen Municipality, PR China [JCYJ20150601102053070]	Hong Kong Research Grant Council(Hong Kong Research Grants Council); Guangdong Frontier and Key Technology Development Fund of Guangdong Province, PR China; Knowledge Innovation Program of Shenzhen Municipality, PR China	We thank Maggie K.S. Tang from the School of Biological Sciences, The University of Hong Kong for assistance in delivering ascites samples and ovarian cancer cell lines. This work was supported by grants from the General Research Fund (CityU_11303815) and the Collaborative Research Fund (CRF/1013-15G) of Hong Kong Research Grant Council, the Guangdong Frontier and Key Technology Development Fund (2017B020226001) of Guangdong Province, PR China, and the Knowledge Innovation Program (JCYJ20150601102053070) of Shenzhen Municipality, PR China.	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Ao Z, 2015, CANCER RES, V75, P4681, DOI 10.1158/0008-5472.CAN-15-1633; Au SH, 2016, P NATL ACAD SCI USA, V113, P4947, DOI 10.1073/pnas.1524448113; Ayantunde AA, 2007, ANN ONCOL, V18, P945, DOI 10.1093/annonc/mdl499; Bell DA, 2005, MODERN PATHOL, V18, pS19, DOI 10.1038/modpathol.3800306; Burleson KM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-6; Calon A, 2014, SEMIN CANCER BIOL, V25, P15, DOI 10.1016/j.semcancer.2013.12.008; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Cheung KJ, 2016, SCIENCE, V352, P167, DOI 10.1126/science.aaf6546; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Desoize B, 2000, CRIT REV ONCOL HEMAT, V36, P193, DOI 10.1016/S1040-8428(00)00086-X; Dumont N, 2013, NEOPLASIA, V15, P249, DOI 10.1593/neo.121950; Fang ZD, 2011, BRIEF BIOINFORM, V12, P280, DOI 10.1093/bib/bbr004; FIDLER IJ, 1973, EUR J CANCER, V9, P223, DOI 10.1016/S0014-2964(73)80022-2; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hanley CJ, 2016, ONCOTARGET, V7, P6159, DOI 10.18632/oncotarget.6740; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kim S, 2016, CANCER SCI, V107, P1173, DOI 10.1111/cas.12987; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Krebs MG, 2014, NAT REV CLIN ONCOL, V11, P129, DOI 10.1038/nrclinonc.2013.253; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Maddipati R, 2015, CANCER DISCOV, V5, P1086, DOI 10.1158/2159-8290.CD-15-0120; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Rostami P, 2019, J SCI-ADV MATER DEV, V4, P1, DOI 10.1016/j.jsamd.2019.01.006; RUNYON BA, 1988, HEPATOLOGY, V8, P1104, DOI 10.1002/hep.1840080521; Schelker M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02289-3; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shield K, 2009, GYNECOL ONCOL, V113, P143, DOI 10.1016/j.ygyno.2008.11.032; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Uehara Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128066; VELLIOS F, 1954, AM J CLIN PATHOL, V24, P676, DOI 10.1093/ajcp/24.6.676; Wang MN, 2017, J CANCER, V8, P761, DOI 10.7150/jca.17648; Winter MJ, 2003, AM J PATHOL, V163, P2139, DOI 10.1016/S0002-9440(10)63570-5; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhang SZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep16066; Zhuang JL, 2015, SCI REP-UK, V5, DOI 10.1038/srep11924	47	21	21	3	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4227	4240		10.1038/s41388-020-1288-2	http://dx.doi.org/10.1038/s41388-020-1288-2		APR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32284541				2022-12-17	WOS:000526276600001
J	Zhang, GJ; Tang, X; Liang, L; Zhang, WF; Li, DW; Li, XY; Zhao, DC; Zheng, YQ; Chen, YH; Hao, BT; Wang, K; Tang, N; Ding, KY				Zhang, Guiji; Tang, Xia; Liang, Li; Zhang, Wanfeng; Li, Dewei; Li, Xiaoyuan; Zhao, Dachun; Zheng, Yaqiu; Chen, Yanhong; Hao, Bingtao; Wang, Kai; Tang, Ni; Ding, Keyue			DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR-3; RETROMER COMPLEX; RECURRENT MUTATIONS; TRAFFICKING; EXPRESSION; PREVENTION; SECRETION; TARGETS; GENE; RAS	Liver hepatocellular carcinoma (LIHC) is the second leading cause of cancer mortality worldwide. Although cancer driver genes identified so far have been considered to be saturated or nearly saturated, challenges remain in discovering novel genes underlying carcinogenesis due to significant tumor heterogeneity. Here, in a small cohort of hepatitis B virus (HBV)-associated LIHC, we investigated the transcriptional patterns of tumor-mutated alleles using both whole-exome and RNA sequencing data. A graph clustering of the transcribed tumor-mutated alleles characterized overlapped functional clusters, and thus prioritized potentially novel oncogenes. We validated the function of the potentially novel oncogenes in vitro and in vivo. We showed that a component of the retromer complex-the vacuolar protein sorting-associated protein 35 (VPS35)-promoted the proliferation of hepatoma cell through the PI3K/AKT signaling pathway. In VPS35-knockout hepatoma cells, a significantly reduced distribution of membrane fibroblast growth factor receptor 3 (FGFR3) demonstrated the effects of VPS35 on sorting and trafficking of transmembrane receptor. This study provides insight into the roles of the retromer complex on carcinogenesis and has important implications for the development of personalized therapeutic strategies for LIHC.	[Zhang, Guiji; Tang, Xia; Liang, Li; Zheng, Yaqiu; Wang, Kai; Tang, Ni] Chongqing Med Univ, Affiliated Hosp 2, Inst Viral Hepatitis, Key Lab Mol Biol Infect Dis,Minist Educ,Dept Infe, Chongqing, Peoples R China; [Tang, Xia; Zhang, Wanfeng; Ding, Keyue] Chongqing Med Univ, Sch Basic Med, Dept Bioinformat, Chongqing, Peoples R China; [Li, Dewei] Chongqing Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Chongqing, Peoples R China; [Li, Xiaoyuan] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Oncol, Beijing, Peoples R China; [Zhao, Dachun] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Pathol, Beijing, Peoples R China; [Chen, Yanhong; Hao, Bingtao] Henan Univ, Med Genet Inst Henan Prov, Henan Prov Key Lab Genet Dis & Funct Genom, Zhengzhou Univ,Henan Prov Peoples Hosp,Peoples Ho, Zhengzhou, Henan, Peoples R China	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Henan University; Zhengzhou University	Wang, K; Tang, N (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Inst Viral Hepatitis, Key Lab Mol Biol Infect Dis,Minist Educ,Dept Infe, Chongqing, Peoples R China.; Ding, KY (corresponding author), Chongqing Med Univ, Sch Basic Med, Dept Bioinformat, Chongqing, Peoples R China.	wangkai@cqmu.edu.cn; nitang@cqmu.edu.cn; ding.keyue@gmail.com	Wang, Kai/U-3552-2019; Ding, Keyue/AAH-7228-2019; Hao, Bingtao/G-6648-2011	Wang, Kai/0000-0002-0137-1247; Ding, Keyue/0000-0002-3496-6415; Hao, Bingtao/0000-0003-1997-9338	China National Natural Science Foundation [81672780, 81872270, 81572683, 81602417]; Major National ST program [2017ZX10202203-004]; Recruitment Program of Global Youth Experts in China; program of Artificial Intelligence in Medicine of CQ CSTC [ZHYX2019004]; Natural Science Foundation Project of CQ CSTC [cstc2018jcyjAX0254]; Program for Innovation Team of Higher Education in Chongqing [CXTDX201601015]; Leading Talent Program of CQ CSTC [CSTCCXLJRC201719]; Talent Development Program of CQMU for Postgraduate [BJRC201728]	China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Major National ST program; Recruitment Program of Global Youth Experts in China; program of Artificial Intelligence in Medicine of CQ CSTC; Natural Science Foundation Project of CQ CSTC(Natural Science Foundation Project of CQ CSTC); Program for Innovation Team of Higher Education in Chongqing; Leading Talent Program of CQ CSTC; Talent Development Program of CQMU for Postgraduate	This work was funded by the China National Natural Science Foundation (no. 81672780, KD, nos. 81872270 and 81572683, NT, and 81602417, KW), the Major National S&T program (2017ZX10202203-004 to NT), the Recruitment Program of Global Youth Experts in China (KD), the program of Artificial Intelligence in Medicine of CQ CSTC (ZHYX2019004, KD), Natural Science Foundation Project of CQ CSTC (cstc2018jcyjAX0254 to NT), the Program for Innovation Team of Higher Education in Chongqing (grant no. CXTDX201601015), the Leading Talent Program of CQ CSTC (grant no. CSTCCXLJRC201719 to NT) and Talent Development Program of CQMU for Postgraduate (grant no. BJRC201728).	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; Babu SD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-10; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Belenkaya TY, 2008, DEV CELL, V14, P120, DOI 10.1016/j.devcel.2007.12.003; Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu, 2017, Cell, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Caruso S, 2019, GASTROENTEROLOGY, V157, P760, DOI 10.1053/j.gastro.2019.05.001; Chen KE, 2019, TRAFFIC, V20, P465, DOI 10.1111/tra.12649; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; Cho JY, 2004, P NATL ACAD SCI USA, V101, P609, DOI 10.1073/pnas.2237184100; Cleary SP, 2013, HEPATOLOGY, V58, P1693, DOI 10.1002/hep.26540; Creixell P, 2015, NAT METHODS, V12, P615, DOI [10.1038/NMETH.3440, 10.1038/nmeth.3440]; Cui Y, 2019, J CELL BIOL, V218, P615, DOI 10.1083/jcb.201806153; Deng H, 2013, MOVEMENT DISORD, V28, P569, DOI 10.1002/mds.25430; DING K, 2015, SCI REP UK, V5; Ding L, 2014, NAT REV GENET, V15, P556, DOI 10.1038/nrg3767; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Farmer T, 2019, MOL BIOL CELL, V30, P1138, DOI 10.1091/mbc.E19-01-0044; Farmer T, 2017, J CELL SCI, V130, P2359, DOI 10.1242/jcs.204537; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Franch-Marro X, 2008, NAT CELL BIOL, V10, P170, DOI 10.1038/ncb1678; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Fuse A, 2015, FEBS LETT, V589, P1430, DOI 10.1016/j.febslet.2015.04.040; Gao QZ, 2017, CANCER SCI, V108, P1328, DOI 10.1111/cas.13277; Hanawalt PC, 2008, NAT REV MOL CELL BIO, V9, P958, DOI 10.1038/nrm2549; Haugsten EM, 2005, J CELL SCI, V118, P3869, DOI 10.1242/jcs.02509; Hoshida Y, 2014, J HEPATOL, V61, pS79, DOI 10.1016/j.jhep.2014.07.010; Hsiehchen D, 2018, J HUM GENET, V63, P941, DOI 10.1038/s10038-018-0481-4; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Javidi-Sharifi N, 2015, CANCER RES, V75, P880, DOI 10.1158/0008-5472.CAN-14-0573; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Kasprzak A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061288; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; Liang L, 2016, ONCOTARGET, V7, P38440, DOI 10.18632/oncotarget.9540; McGough IJ, 2014, CURR BIOL, V24, P1670, DOI 10.1016/j.cub.2014.06.024; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Nepusz T, 2012, NAT METHODS, V9, P471, DOI [10.1038/NMETH.1938, 10.1038/nmeth.1938]; Pan Q, 2016, ONCOTARGET, V7, P38487, DOI 10.18632/oncotarget.9555; Paur J, 2015, HEPATOLOGY, V62, P1767, DOI 10.1002/hep.28023; Qiu WH, 2005, WORLD J GASTROENTERO, V11, P5266, DOI 10.3748/wjg.v11.i34.5266; Rao CV, 2017, CARCINOGENESIS, V38, P2, DOI 10.1093/carcin/bgw118; Schulze K, 2016, J HEPATOL, V65, P1031, DOI 10.1016/j.jhep.2016.05.035; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shibata T, 2014, NAT REV GASTRO HEPAT, V11, DOI 10.1038/nrgastro.2014.6; Small SA, 2005, ANN NEUROL, V58, P909, DOI 10.1002/ana.20667; Sondka Z, 2018, NAT REV CANCER, V18, P696, DOI 10.1038/s41568-018-0060-1; Sung WK, 2012, NAT GENET, V44, P765, DOI 10.1038/ng.2295; TANG X, 2019, SCI REP UK, V9; Temkin P, 2017, NEURON, V94, P74, DOI 10.1016/j.neuron.2017.03.020; Totoki Y, 2011, NAT GENET, V43, P464, DOI 10.1038/ng.804; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wang JX, 2015, IEEE ACM T COMPUT BI, V12, P815, DOI 10.1109/TCBB.2014.2361348; Wang J, 2018, TRAFFIC, V19, P578, DOI 10.1111/tra.12574; Yang PT, 2008, DEV CELL, V14, P140, DOI 10.1016/j.devcel.2007.12.004; Zaki N, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-163; Zhang J, 2011, DATA DATABASE, V1, P10; Zheng J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200776; Zhou Mo, 2019, Small GTPases, V10, P20, DOI 10.1080/21541248.2016.1263380; Zhou M, 2016, J CELL BIOL, V214, P445, DOI 10.1083/jcb.201604061	61	21	21	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3229	3244		10.1038/s41388-020-1215-6	http://dx.doi.org/10.1038/s41388-020-1215-6		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32071398				2022-12-17	WOS:000514262700002
J	Jeannot, E; Darrigues, L; Michel, M; Stern, MH; Pierga, JY; Rampanou, A; Melaabi, S; Benoist, C; Bieche, I; Vincent-Salomon, A; El Ayachy, R; Noret, A; Epaillard, N; Cabel, L; Bidard, FC; Proudhon, C				Jeannot, Emmanuelle; Darrigues, Lauren; Michel, Marc; Stern, Marc-Henri; Pierga, Jean-Yves; Rampanou, Aurore; Melaabi, Samia; Benoist, Camille; Bieche, Ivan; Vincent-Salomon, Anne; El Ayachy, Radouane; Noret, Aurelien; Epaillard, Nicolas; Cabel, Luc; Bidard, Francois-Clement; Proudhon, Charlotte			A single droplet digital PCR for ESR1 activating mutations detection in plasma	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; CELL-FREE DNA; BREAST-CANCER; RESISTANCE	Activating mutations in the estrogen receptor 1 (ESR1) gene confer resistance to aromatase inhibitors (AI), and may be targeted by selective estrogen receptor downregulators. We designed a multiplex droplet digital PCR (ddPCR), which combines a drop-off assay, targeting the clustered hotspot mutations found in exon 8, with an unconventional assay interrogating the E380Q mutation in exon 5. We assessed its sensitivity in vitro using synthetic oligonucleotides, harboring E380Q, L536R, Y537C, Y537N, Y537S, or D538G mutations. Further validation was performed on plasma samples from a prospective study and compared with next generation sequencing (NGS) data. The multiplex ESR1-ddPCR showed a high sensitivity with a limit of detection ranging from 0.07 to 0.19% in mutant allele frequency. The screening of plasma samples from patients with AI-resistant metastatic breast cancer identified ESR1 mutations in 29% of them, all mutations being confirmed by NGS. In addition, this test identifies patients harboring polyclonal alterations. Furthermore, the monitoring of circulating tumor DNA using this technique during treatment follow-up predicts the clinical benefit of palbociclib-fulvestrant. The multiplex ESR1-ddPCR detects, in a single reaction, the most frequent ESR1 activating mutations with good sensitivity. This method allows real-time liquid biopsy for ESR1 mutation monitoring in large cohorts of patients.	[Jeannot, Emmanuelle; Darrigues, Lauren; Michel, Marc; Pierga, Jean-Yves; Rampanou, Aurore; Bidard, Francois-Clement; Proudhon, Charlotte] PSL Res Univ, Inst Curie, Circulating Tumor Biomarkers Lab, Inserm CIC 1428, Paris, France; [Jeannot, Emmanuelle; Melaabi, Samia; Benoist, Camille; Bieche, Ivan; Vincent-Salomon, Anne] PSL Res Univ, Inst Curie, Dept Biopathol & Genet, Paris, France; [Stern, Marc-Henri] PSL Res Univ, Inst Curie, INSERM U830, Paris, France; [Pierga, Jean-Yves; El Ayachy, Radouane; Noret, Aurelien; Epaillard, Nicolas; Cabel, Luc; Bidard, Francois-Clement] PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France; [Pierga, Jean-Yves; El Ayachy, Radouane; Noret, Aurelien; Epaillard, Nicolas; Cabel, Luc; Bidard, Francois-Clement] PSL Res Univ, Inst Curie, Dept Med Oncol, St Cloud, France; [Pierga, Jean-Yves] Univ Paris, Paris, France; [Pierga, Jean-Yves] Dept Inst Curie, Med Oncol, Paris, France; [Cabel, Luc; Bidard, Francois-Clement] Versailles St Quentin Univ, Paris Saclay Univ, St Cloud, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay	Proudhon, C (corresponding author), PSL Res Univ, Inst Curie, Circulating Tumor Biomarkers Lab, Inserm CIC 1428, Paris, France.	charlotte.proudhon@curie.fr	Stern, Marc-Henri/A-2728-2011	Stern, Marc-Henri/0000-0002-8100-2272; Proudhon, Charlotte/0000-0002-4649-4574; Michel, Marc/0000-0001-6613-8027	Innovative Medicines Initiative Joint Undertaking [115749]; SIRIC 2 Curie [INCa-DGOS-Inserm_12554]	Innovative Medicines Initiative Joint Undertaking; SIRIC 2 Curie	SIRIC 2 Curie (grant INCa-DGOS-Inserm_12554) and the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115749 (project Cancer-ID). The funding sources of the study had no role in the design of the study, collection, analysis, or interpretation of the data or in the writing of this report.	Bidard FC, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-PD2-06; Bidard FC, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006305; Bidshahri R, 2016, J MOL DIAGN, V18, P190, DOI 10.1016/j.jmoldx.2015.09.003; Carausu M, 2019, EXPERT REV MOL DIAGN, V19, P599, DOI 10.1080/14737159.2019.1631799; Chandarlapaty S, 2016, JAMA ONCOL, V2, P1310, DOI 10.1001/jamaoncol.2016.1279; Chu D, 2016, CLIN CANCER RES, V22, P993, DOI 10.1158/1078-0432.CCR-15-0943; Chung JH, 2017, ANN ONCOL, V28, P2866, DOI 10.1093/annonc/mdx490; Clatot F, 2016, ONCOTARGET, V7, P74448, DOI 10.18632/oncotarget.12950; Decraene C, 2018, JOVE-J VIS EXP, V139, P1; Decraene C, 2018, CLIN CHEM, V64, P317, DOI 10.1373/clinchem.2017.272518; Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI [10.1126/scitranslmed.aab0021, 10.1126/scitranslmed.aac7551]; Gyanchandani R, 2017, ONCOTARGET, V8, P66901, DOI 10.18632/oncotarget.11383; Jeselsohn R, 2014, CLIN CANCER RES, V20, P1757, DOI 10.1158/1078-0432.CCR-13-2332; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Lupini L, 2018, SCI REP, V8, P1; Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197; Niu JX, 2015, ONCOTARGETS THER, V8, P3323, DOI 10.2147/OTT.S92443; O'Leary B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03215-x; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Seki Y, 2016, ONCOLOGIST, V21, P156, DOI 10.1634/theoncologist.2015-0288; Takeshita T, 2017, ONCOTARGET, V8, P52142, DOI 10.18632/oncotarget.18479; Takeshita T, 2015, TRANSL RES, V166, P540, DOI 10.1016/j.trsl.2015.09.003; Toy W, 2017, CANCER DISCOV, V7, P277, DOI 10.1158/2159-8290.CD-15-1523; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Wang PL, 2016, CLIN CANCER RES, V22, P1130, DOI 10.1158/1078-0432.CCR-15-1534	26	21	21	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2987	2995		10.1038/s41388-020-1174-y	http://dx.doi.org/10.1038/s41388-020-1174-y		FEB 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32042112	Green Submitted			2022-12-17	WOS:000512528200003
J	Chen, CL; Gupta, P; Parashar, D; Nair, GG; George, J; Geethadevi, A; Wang, W; Tsaih, SW; Bradley, W; Ramchandran, R; Rader, JS; Chaluvally-Raghavan, P; Pradeep, S				Chen, Changliang; Gupta, Prachi; Parashar, Deepak; Nair, Gopakumar G.; George, Jasmine; Geethadevi, Anjali; Wang, Wei; Tsaih, Shirng-Wern; Bradley, William; Ramchandran, Ramani; Rader, Janet S.; Chaluvally-Raghavan, Pradeep; Pradeep, Sunila			ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis	ONCOGENE			English	Article							STAT3; MUTATIONS; SURVIVAL; PATHWAY; TARGET; GROWTH; HEAD	High-grade serous carcinoma, accounts for up to 70% of all ovarian cases. Furin, a proprotein convertase, is highly expressed in high-grade serous carcinoma of ovarian cancer patients, and its expression is even higher in tumor omentum than in normal omentum, the preferred site of ovarian cancer metastasis. The proteolytic actions of this cellular endoprotease help the maturation of several important precursors of protein substrates and its levels increase the risk of several cancer. We show that furin activates the IGF1R/STAT3 signaling axis in ovarian cancer cells. Conversely, furin knockdown downregulated IGF1R-beta and p-STAT3 (Tyr705) expression. Further, silencing furin reduced tumor cell migration and invasion in vitro and tumor growth and metastasis in vivo. Collectively, our findings show that furin can be an effective therapeutic target for ovarian cancer prevention or treatment.	[Chen, Changliang; Gupta, Prachi; Parashar, Deepak; Nair, Gopakumar G.; George, Jasmine; Geethadevi, Anjali; Tsaih, Shirng-Wern; Bradley, William; Ramchandran, Ramani; Rader, Janet S.; Chaluvally-Raghavan, Pradeep; Pradeep, Sunila] Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA; [Wang, Wei] Case Western Reserve Univ, Metrohlth Med Res Ctr, Cleveland, OH 44106 USA; [Ramchandran, Ramani] Med Coll Wisconsin, Dept Pediat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Rader, Janet S.; Chaluvally-Raghavan, Pradeep; Pradeep, Sunila] Med Coll Wisconsin, Canc Ctr, Milwaukee, WI 53226 USA; [Chaluvally-Raghavan, Pradeep; Pradeep, Sunila] Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Case Western Reserve University; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Pradeep, S (corresponding author), Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA.; Pradeep, S (corresponding author), Med Coll Wisconsin, Canc Ctr, Milwaukee, WI 53226 USA.; Pradeep, S (corresponding author), Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	spradeep@mcw.edu	GEETHADEVI, ANJALI/AAI-3798-2020; GOPINADHAN NAIR, GOPA KUMAR/J-6473-2014; Chen, Chang-Liang/AAO-6738-2021; Parashar, Deepak/T-8609-2017	GEETHADEVI, ANJALI/0000-0001-5486-7919; GOPINADHAN NAIR, GOPA KUMAR/0000-0002-2694-8401; Parashar, Deepak/0000-0002-5062-8950	Ovarian Cancer Research Fund Alliance (OCRFA); Women's Health Research Program (WHRP) in the Department of Obstetrics and Gynecology at the Medical College of Wisconsin (MCW); OCRFA; WHRP; DoD Breast Cancer Research Program [W81XWH-18-1-0024]; Children's Research Institute; NIH grants; Department of OBGYN; Department of Pediatrics;  [1R01CA229907]	Ovarian Cancer Research Fund Alliance (OCRFA); Women's Health Research Program (WHRP) in the Department of Obstetrics and Gynecology at the Medical College of Wisconsin (MCW); OCRFA; WHRP; DoD Breast Cancer Research Program(United States Department of Defense); Children's Research Institute; NIH grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of OBGYN; Department of Pediatrics; 	SP is supported by the Ovarian Cancer Research Fund Alliance (OCRFA) and by research funds from the Women's Health Research Program (WHRP) in the Department of Obstetrics and Gynecology at the Medical College of Wisconsin (MCW). PCR is supported by the 1R01CA229907, OCRFA, and WHRP as well as by the DoD Breast Cancer Research Program (W81XWH-18-1-0024). RR is supported by Children's Research Institute, Department of Pediatrics, Department of OBGYN and funds from NIH grants. Authors acknowledge Dr Anil Sood for providing tissue slides collected from the nude mice, treated with NRG1 siRNA-encapsulated nanoparticle.	Bassi DE, 2003, AM J PATHOL, V162, P439, DOI 10.1016/S0002-9440(10)63838-2; Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Baumann J, 2019, EXP CELL RES, V383, DOI 10.1016/j.yexcr.2019.111503; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chaluvally-Raghavan P, 2016, CELL REP, V15, P1493, DOI 10.1016/j.celrep.2016.04.034; Chaluvally-Raghavan P, 2014, CANCER CELL, V26, P863, DOI 10.1016/j.ccell.2014.10.010; Chen CL, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0902-4; Coleman RL, 2013, NAT REV CLIN ONCOL, V10, P211, DOI 10.1038/nrclinonc.2013.5; Coppola J, 2008, NEOPLASIA, V10, P363, DOI 10.1593/neo.08166; Devarajan E, 2009, CURR MOL MED, V9, P626, DOI 10.2174/156652409788488720; Elster N, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918778297; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fang D, 2017, ONCOGENE, V36, P1546, DOI 10.1038/onc.2016.323; Furtek SL, 2016, ACS CHEM BIOL, V11, P308, DOI 10.1021/acschembio.5b00945; Gaitskell K, 2018, INT J CANCER, V142, P281, DOI 10.1002/ijc.31063; Geethadevi Anjali, 2017, Genes Cancer, V8, P746, DOI 10.18632/genesandcancer.162; Geiger JL, 2016, ORAL ONCOL, V56, P84, DOI 10.1016/j.oraloncology.2015.11.022; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Hassan R, 2004, CLIN CANCER RES, V10, P3937, DOI 10.1158/1078-0432.CCR-03-0801; HORIMOTO T, 1994, J VIROL, V68, P6074, DOI 10.1128/JVI.68.9.6074-6078.1994; Huang GY, 2014, STEM CELLS, V32, P1149, DOI 10.1002/stem.1609; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jaaks P, 2017, INT J CANCER, V141, P654, DOI 10.1002/ijc.30714; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Lee JH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29142-x; Linardou H, 2009, NAT REV CLIN ONCOL, V6, P352, DOI 10.1038/nrclinonc.2009.62; Ma YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033414; Page RE, 2007, CELL ONCOL, V29, P289; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pradeep S, 2015, CANCER CELL, V28, P610, DOI 10.1016/j.ccell.2015.09.008; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Siveen KS, 2014, BBA-REV CANCER, V1845, P136, DOI 10.1016/j.bbcan.2013.12.005; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Wang T, 2007, CANCER RES, V67, P11830, DOI 10.1158/0008-5472.CAN-07-1160; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	40	21	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2921	2933		10.1038/s41388-020-1194-7	http://dx.doi.org/10.1038/s41388-020-1194-7		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32029900	Green Accepted			2022-12-17	WOS:000511540800004
J	Ames, S; Andring, JT; McKenna, R; Becker, HM				Ames, Samantha; Andring, Jacob T.; McKenna, Robert; Becker, Holger M.			CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells	ONCOGENE			English	Article							CARBONIC-ANHYDRASE IX; APPARENT DIFFUSION-COEFFICIENT; XENOPUS-LAEVIS OOCYTES; IMMUNOGLOBULIN SUPERFAMILY; TRANSMEMBRANE HELICES; LACTATE TRANSPORTER; ANCILLARY PROTEIN; PLASMA-MEMBRANE; BASIGIN CD147; EXPRESSION	Tumor cells rely on glycolysis to meet their elevated demand for energy. Thereby they produce significant amounts of lactate and protons, which are exported via monocarboxylate transporters (MCTs), supporting the formation of an acidic microenvironment. The present study demonstrates that carbonic anhydrase IX (CAIX), one of the major acid/base regulators in cancer cells, forms a protein complex with MCT1 and MCT4 in tissue samples from human breast cancer patients, but not healthy breast tissue. Formation of this transport metabolon requires binding of CAIX to the Ig1 domain of the MCT1/4 chaperon CD147 and is required for CAIX-mediated facilitation of MCT1/4 activity. Application of an antibody, directed against the CD147-Ig1 domain, displaces CAIX from the transporter and suppresses CAIX-mediated facilitation of proton-coupled lactate transport. In cancer cells, this "metabolon disruption" results in a decrease in lactate transport, reduced glycolysis, and ultimately reduced cell proliferation. Taken together, the study shows that carbonic anhydrases form transport metabolons with acid/base transporters in human tumor tissue and that these interactions can be exploited to interfere with tumor metabolism and proliferation.	[Ames, Samantha; Becker, Holger M.] Univ Kaiserslautern TUK, Dept Biol, Div Gen Zool, D-67653 Kaiserslautern, Germany; [Andring, Jacob T.; McKenna, Robert] Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; [Becker, Holger M.] Univ Vet Med Hannover, Inst Physiol Chem, D-30559 Hannover, Germany	State University System of Florida; University of Florida; University of Veterinary Medicine Hannover, Foundation	Becker, HM (corresponding author), Univ Kaiserslautern TUK, Dept Biol, Div Gen Zool, D-67653 Kaiserslautern, Germany.	Holger.Becker@tiho-hannover.de	Becker, Holger/AAB-4322-2020		Deutsche Forschungsgemeinschaft [BE 4310/6-1]; Research Initiative BioComp; Lotto-Stiftung Rheinland-Pfalz; FAZIT Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Research Initiative BioComp; Lotto-Stiftung Rheinland-Pfalz; FAZIT Stiftung	We thank Heike Kanapin, Sandra Pfeiffer, HansPeter Schneider, and Patrick Pattar for technical assistance. The work was funded by the Deutsche Forschungsgemeinschaft (to H.M.B.; BE 4310/6-1), the Research Initiative BioComp (to H.M.B), and by stipends from the Lotto-Stiftung Rheinland-Pfalz and the FAZIT Stiftung (to S.A.).	Adams A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-538; Adelroth P, 2004, BBA-BIOENERGETICS, V1655, P102, DOI 10.1016/j.bbabio.2003.10.018; Alvarez BV, 2005, EMBO J, V24, P2499, DOI 10.1038/sj.emboj.7600736; Ames Samantha, 2018, Oncotarget, V9, P27940, DOI 10.18632/oncotarget.25371; Bane AL, 2014, ANN ONCOL, V25, P992, DOI 10.1093/annonc/mdu090; Becker HM, 2004, BIOPHYS J, V86, P235, DOI 10.1016/S0006-3495(04)74099-0; Becker HM, 2014, NEUROMETHODS, V90, P25, DOI 10.1007/978-1-4939-1059-5_2; Becker HM, 2011, P NATL ACAD SCI USA, V108, P3071, DOI 10.1073/pnas.1014293108; Beketic-Oreskovic L, 2011, PATHOL ONCOL RES, V17, P593, DOI 10.1007/s12253-010-9355-6; Belli P, 2015, RADIOL MED, V120, P268, DOI 10.1007/s11547-014-0442-8; Benjamin D, 2018, CELL REP, V25, P3047, DOI 10.1016/j.celrep.2018.11.043; Bonen A, 2000, MED SCI SPORT EXER, V32, P778, DOI 10.1097/00005768-200004000-00010; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Broer S, 1997, J BIOL CHEM, V272, P30096, DOI 10.1074/jbc.272.48.30096; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254; Chen CL, 2010, VIRCHOWS ARCH, V457, P53, DOI 10.1007/s00428-010-0938-0; Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470; Choi JH, 2018, ANN NUCL MED, V32, P389, DOI 10.1007/s12149-018-1259-7; Choi J, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3472; Choi J, 2013, PATHOBIOLOGY, V80, P41, DOI 10.1159/000339513; Cipolla V, 2014, EUR J RADIOL, V83, P2144, DOI 10.1016/j.ejrad.2014.09.015; Currie MJ, 2013, HUM PATHOL, V44, P402, DOI 10.1016/j.humpath.2012.06.004; Debernardi R, 2003, J NEUROSCI RES, V73, P141, DOI 10.1002/jnr.10660; Deitmer JW, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00291; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Forero-Quintero LS, 2019, J BIOL CHEM, V294, P593, DOI 10.1074/jbc.RA118.005536; FOSSUM S, 1991, EUR J IMMUNOL, V21, P671, DOI 10.1002/eji.1830210320; Friedman R, 2005, BIOPHYS J, V89, P768, DOI 10.1529/biophysj.105.058917; Guan X, 2019, AAPS J, V21, DOI 10.1208/s12248-018-0279-5; Guan XW, 2019, AAPS J, V21, DOI 10.1208/s12248-018-0261-2; Gutman M, 2006, PHOTOCH PHOTOBIO SCI, V5, P531, DOI 10.1039/b515887g; Halestrap AP, 2013, MOL ASPECTS MED, V34, P337, DOI 10.1016/j.mam.2012.05.003; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hiremath SA, 2019, MATH BIOSCI ENG, V16, P320, DOI 10.3934/mbe.2019016; Innocenti A, 2009, BIOORG MED CHEM LETT, V19, P5825, DOI 10.1016/j.bmcl.2009.08.088; Jackson VN, 1996, J BIOL CHEM, V271, P861, DOI 10.1074/jbc.271.2.861; Jamali S, 2015, SCI REP-UK, V5, DOI 10.1038/srep13605; Johnson JM, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00027; Kim S, 2013, J BREAST CANCER, V16, P146, DOI 10.4048/jbc.2013.16.2.146; Klier M, 2011, J BIOL CHEM, V286, P27781, DOI 10.1074/jbc.M111.255331; Kuang YH, 2018, HONG KONG MED J, V24, P252, DOI 10.12809/hkmj176865; Kwon JE, 2013, TUMOR BIOL, V34, P115, DOI 10.1007/s13277-012-0518-9; Liu M, 2018, J CLIN PATHOL, V71, P1007, DOI 10.1136/jclinpath-2018-205342; Luz MCD, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040170; Manoharan C, 2006, MOL MEMBR BIOL, V23, P486, DOI 10.1080/09687860600841967; Mboge MY, 2019, BIOCHEM J, V476, P1497, DOI 10.1042/BCJ20190177; Muramatsu T, 2016, J BIOCHEM, V159, P481, DOI 10.1093/jb/mvv127; Nabeshima K, 2006, PATHOL INT, V56, P359, DOI 10.1111/j.1440-1827.2006.01972.x; Noor SI, 2018, ELIFE, V7, DOI 10.7554/eLife.35176; Noor SI, 2017, FEBS J, V284, P149, DOI 10.1111/febs.13964; Noor SI, 2015, J BIOL CHEM, V290, P4476, DOI 10.1074/jbc.M114.624577; Ovens MJ, 2010, BIOCHEM J, V425, P523, DOI 10.1042/BJ20091515; Ozretic P, 2018, INT J BIOL MARKER, V33, P109, DOI 10.5301/ijbm.5000291; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; PASTOREK J, 1994, ONCOGENE, V9, P2877; Pastorek J, 2015, SEMIN CANCER BIOL, V31, P52, DOI 10.1016/j.semcancer.2014.08.002; Pastorekova S, 2004, CANC THER, V2, P245; Pinard MA, 2015, ACTA CRYSTALLOGR F, V71, P1352, DOI 10.1107/S2053230X1501239X; Pinheiro C, 2012, J BIOENERG BIOMEMBR, V44, P127, DOI 10.1007/s10863-012-9428-1; Pinheiro C, 2011, HISTOL HISTOPATHOL, V26, P1279, DOI 10.14670/HH-26.1279; Pinheiro C, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/427694; Pinheiro C, 2010, HISTOPATHOLOGY, V56, P860, DOI 10.1111/j.1365-2559.2010.03560.x; Renner K, 2019, CELL REP, V29, P135, DOI 10.1016/j.celrep.2019.08.068; San Martin A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057712; SRERE PA, 1985, TRENDS BIOCHEM SCI, V10, P109, DOI 10.1016/0968-0004(85)90266-X; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Stridh MH, 2012, J PHYSIOL-LONDON, V590, P2333, DOI 10.1113/jphysiol.2011.220152; Supuran CT, 2017, METABOLITES, V7, DOI 10.3390/metabo7030048; Swietach P, 2010, ONCOGENE, V29, P6509, DOI 10.1038/onc.2010.455; Swietach P, 2019, CANCER METAST REV, V38, P5, DOI 10.1007/s10555-018-09778-x; Tan EY, 2009, BRIT J CANCER, V100, P405, DOI 10.1038/sj.bjc.6604844; Vermeulen JF, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-240; Walter M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1078056; Wilson MC, 2005, J BIOL CHEM, V280, P27213, DOI 10.1074/jbc.M411950200; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Wykoff CC, 2000, CANCER RES, V60, P7075; Yu XL, 2008, J BIOL CHEM, V283, P18056, DOI 10.1074/jbc.M802694200; Zat'ovicova M, 2003, J IMMUNOL METHODS, V282, P117, DOI 10.1016/j.jim.2003.08.011	81	21	22	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1710	1723		10.1038/s41388-019-1098-6	http://dx.doi.org/10.1038/s41388-019-1098-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31723238	Green Submitted			2022-12-17	WOS:000514923000007
J	Kim, YS; Vallur, PG; Jones, VM; Worley, BL; Shimko, S; Shin, DH; Crawford, LC; Chen, CW; Aird, KM; Abraham, T; Shepherd, TG; Warrick, JI; Lee, NY; Phaeton, R; Mythreye, K; Hempel, N				Kim, Yeon Soo; Vallur, Piyushi Gupta; Jones, Victoria M.; Worley, Beth L.; Shimko, Sara; Shin, Dong-Hui; Crawford, LaTaijah C.; Chen, Chi-Wei; Aird, Katherine M.; Abraham, Thomas; Shepherd, Trevor G.; Warrick, Joshua, I; Lee, Nam Y.; Phaeton, Rebecca; Mythreye, Karthikeyan; Hempel, Nadine			Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells	ONCOGENE			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; METABOLISM; ANTIOXIDANT; EXPRESSION; DEACETYLATES; PROGRESSION; ANOIKIS; GROWTH; SOD2	Tumor cells must alter their antioxidant capacity for maximal metastatic potential. Yet the antioxidant adaptations required for ovarian cancer transcoelomic metastasis, which is the passive dissemination of cells in the peritoneal cavity, remain largely unexplored. Somewhat contradicting the need for oxidant scavenging are previous observations that expression of SIRT3, a nutrient stress sensor and regulator of mitochondrial antioxidant defenses, is often suppressed in many primary tumors. We have discovered that this mitochondrial deacetylase is specifically upregulated in a context-dependent manner in cancer cells. SIRT3 activity and expression transiently increased following ovarian cancer cell detachment and in tumor cells derived from malignant ascites of high-grade serous adenocarcinoma patients. Mechanistically, SIRT3 prevents mitochondrial superoxide surges in detached cells by regulating the manganese superoxide dismutase (SOD2). This mitochondrial stress response is under dual regulation by SIRT3. SIRT3 rapidly increases SOD2 activity as an early adaptation to cellular detachment, which is followed by SIRT3-dependent increases in SOD2 mRNA during sustained anchorage-independence. In addition, SIRT3 inhibits glycolytic capacity in anchorage-independent cells thereby contributing to metabolic changes in response to detachment. While manipulation of SIRT3 expression has few deleterious effects on cancer cells in attached conditions, SIRT3 upregulation and SIRT3-mediated oxidant scavenging are required for anoikis resistance in vitro following matrix detachment, and both SIRT3 and SOD2 are necessary for colonization of the peritoneal cavity in vivo. Our results highlight the novel context-specific, pro-metastatic role of SIRT3 in ovarian cancer.	[Kim, Yeon Soo; Vallur, Piyushi Gupta; Jones, Victoria M.; Worley, Beth L.; Shimko, Sara; Shin, Dong-Hui; Crawford, LaTaijah C.; Hempel, Nadine] Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA; [Chen, Chi-Wei; Aird, Katherine M.] Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA USA; [Abraham, Thomas] Penn State Univ, Coll Med, Dept Neural & Behav Sci, Hershey, PA USA; [Shepherd, Trevor G.] Western Univ, Dept Obstet, Mary & John Knight Translat Ovarian Canc Res Unit, London, ON, Canada; [Shepherd, Trevor G.] Western Univ, Dept Gynecol Oncol, Mary & John Knight Translat Ovarian Canc Res Unit, London, ON, Canada; [Shepherd, Trevor G.] Western Univ, Dept Anat & Cell Biol, Mary & John Knight Translat Ovarian Canc Res Unit, London, ON, Canada; [Warrick, Joshua, I] Penn State Univ, Coll Med, Dept Pathol, Hershey, PA USA; [Lee, Nam Y.] Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA; [Phaeton, Rebecca] Penn State Univ, Coll Med, Dept Obstet & Gynecol & Microbiol & Immunol, Hershey, PA USA; [Mythreye, Karthikeyan] Univ South Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; [Mythreye, Karthikeyan] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Arizona; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of South Carolina System; University of South Carolina Columbia; University of Alabama System; University of Alabama Birmingham	Hempel, N (corresponding author), Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA.; Mythreye, K (corresponding author), Univ South Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.; Mythreye, K (corresponding author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.	mythreye@uab.edu; nhempel@psu.edu	Karthikeyan, Mythreye/ABC-7345-2020; Aird, Katherine/AAY-3300-2020; Abraham, Thomas/AAJ-7950-2020	Karthikeyan, Mythreye/0000-0001-5478-0098; Hempel, Nadine/0000-0002-5574-8783; Vallur, Piyushi/0000-0002-1906-7497; Crawford, LaTaijah/0000-0002-5129-3355; Chen, Chi-Wei/0000-0001-8658-055X; Kim, Yeon Soo/0000-0002-9677-374X	NIH [R00CA143229, R01CA230628, S100D018124]; Rivkin Center for Ovarian Cancer; Agilent; Penn State Cancer Institute Developmental Fund Award; DoD Pilot award [W81XWH-16-1-0117]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rivkin Center for Ovarian Cancer; Agilent; Penn State Cancer Institute Developmental Fund Award; DoD Pilot award	This work was supported by NIH grants R00CA143229 (NH), R01CA230628 (NH and KM), S100D018124 (TA), by the Rivkin Center for Ovarian Cancer (NH), an equipment grant from Agilent (NH), and the Penn State Cancer Institute Developmental Fund Award (NH). Collection of ascites was partially supported by DoD Pilot award W81XWH-16-1-0117 (NH).	Alhazzazi TY, 2011, BBA-REV CANCER, V1816, P80, DOI 10.1016/j.bbcan.2011.04.004; Alhazzazi TY, 2011, CANCER-AM CANCER SOC, V117, P1670, DOI 10.1002/cncr.25676; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Bell EL, 2011, ONCOGENE, V30, P2986, DOI 10.1038/onc.2011.37; Cai Q, 2015, ONCOGENE, V34, P3315, DOI 10.1038/onc.2014.264; Chen YH, 2011, EMBO REP, V12, P534, DOI 10.1038/embor.2011.65; Connor KM, 2007, CANCER RES, V67, P10260, DOI 10.1158/0008-5472.CAN-07-1204; Correa RJM, 2012, CARCINOGENESIS, V33, P49, DOI 10.1093/carcin/bgr241; Davison CA, 2013, CANCER RES, V73, P3704, DOI 10.1158/0008-5472.CAN-12-2482; Desouki MM, 2014, HUM PATHOL, V45, P1071, DOI 10.1016/j.humpath.2014.01.004; Dier U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098479; Dong XC, 2016, BIOCHEM BIOPH RES CO, V475, P245, DOI 10.1016/j.bbrc.2016.05.098; Emmings E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010229; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Hemachandra LPMP, 2015, CANCER RES, V75, P4973, DOI 10.1158/0008-5472.CAN-14-3799; Hempel N, 2011, ANTI-CANCER AGENT ME, V11, P191, DOI 10.2174/187152011795255911; Hempel N, 2009, FREE RADICAL BIO MED, V46, P42, DOI 10.1016/j.freeradbiomed.2008.09.020; Hou J, 2018, CANCER RES, V78, P2503, DOI 10.1158/0008-5472.CAN-17-2618; Jiang L, 2016, NATURE, V532, P255, DOI 10.1038/nature17393; Jing EX, 2013, DIABETES, V62, P3404, DOI 10.2337/db12-1650; Kamarajan P, 2012, CANCER-AM CANCER SOC, V118, P5800, DOI 10.1002/cncr.27655; Kenny HA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7220; Kenny TC, 2017, ONCOGENE, V36, P4393, DOI 10.1038/onc.2017.52; Kenny TC, 2019, CELL REP, V27, P2292, DOI 10.1016/j.celrep.2019.04.095; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Kim YS, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6040086; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Li M, 2019, CANCER CELL, V35, P916, DOI 10.1016/j.ccell.2019.05.002; McGlynn LM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131344; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Ozden O, 2014, FREE RADICAL BIO MED, V76, P163, DOI 10.1016/j.freeradbiomed.2014.08.001; Papa L, 2011, J CELL SCI, V124, P1396, DOI 10.1242/jcs.078220; Park HK, 2019, CANCER RES, V79, P1369, DOI 10.1158/0008-5472.CAN-18-2558; Peart TM, 2012, CLIN EXP METASTAS, V29, P293, DOI 10.1007/s10585-011-9451-3; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Rangarajan P, 2015, NEUROSCIENCE, V311, P398, DOI 10.1016/j.neuroscience.2015.10.048; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Sehouli J, 2009, J SURG ONCOL, V99, P424, DOI 10.1002/jso.21288; Shepherd TG, 2006, NAT PROTOC, V1, P2643, DOI 10.1038/nprot.2006.328; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Wei Z, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06812-y; Worley BL, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.11.009; Xiang XY, 2016, INT J ONCOL, V49, P773, DOI 10.3892/ijo.2016.3552; Yang B, 2014, BIOCHEM BIOPH RES CO, V443, P156, DOI 10.1016/j.bbrc.2013.11.068; Yu W, 2016, J BIOL CHEM, V291, P3268, DOI 10.1074/jbc.M115.702076; Zhang CZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051703; Zhou YP, 2018, ONCOTARGETS THER, V11, P2157, DOI 10.2147/OTT.S157836; Zou XH, 2017, CANCER RES, V77, P3990, DOI 10.1158/0008-5472.CAN-16-2393	51	21	21	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1619	1633		10.1038/s41388-019-1097-7	http://dx.doi.org/10.1038/s41388-019-1097-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31723239	Green Submitted, Green Accepted, Green Published			2022-12-17	WOS:000514923000001
J	Manoranjan, B; Chokshi, C; Venugopal, C; Subapanditha, M; Savage, N; Tatari, N; Provias, JP; Murty, NK; Moffat, J; Doble, BW; Singh, SK				Manoranjan, Branavan; Chokshi, Chirayu; Venugopal, Chitra; Subapanditha, Minomi; Savage, Neil; Tatari, Nazanin; Provias, John P.; Murty, Naresh K.; Moffat, Jason; Doble, Bradley W.; Singh, Sheila K.			A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells	ONCOGENE			English	Article							CANCER STEM-CELLS; BETA-CATENIN; NEURAL PROGENITORS; ACTIVATION; CD133; EXPRESSION; AKT; TRANSACTIVATION; DIFFERENTIATION; IDENTIFICATION	Mechanistic insight into signaling pathways downstream of surface receptors has been revolutionized with integrated cancer genomics. This has fostered current treatment modalities, namely immunotherapy, to capitalize on targeting key oncogenic signaling nodes downstream of a limited number of surface markers. Unfortunately, rudimentary mechanistic understanding of most other cell surface proteins has reduced the clinical utility of these markers. CD133 has reproducibly been shown to correlate with disease progression, recurrence, and poor overall survivorship in the malignant adult brain tumor, glioblastoma (GBM). Using several patient-derived CD133(high) and CD133(low) GBMs we describe intrinsic differences in determinants of stemness, which we owe to a CD133-AKT-Wnt signaling axis in which CD133 functions as a putative cell surface receptor for AKT-dependent Wnt activation. These findings may have implications for personalized oncology trials targeting PI3K/AKT or Wnt as both pathways may be activated independent of their canonical drivers, leading to treatment resistance and disease relapse.	[Manoranjan, Branavan] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON L8S 4K1, Canada; [Manoranjan, Branavan; Chokshi, Chirayu; Venugopal, Chitra; Subapanditha, Minomi; Savage, Neil; Tatari, Nazanin; Doble, Bradley W.; Singh, Sheila K.] McMaster Univ, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8S 4K1, Canada; [Manoranjan, Branavan; Chokshi, Chirayu; Tatari, Nazanin; Doble, Bradley W.; Singh, Sheila K.] McMaster Univ, Dept Biochem & Biomed Sci, 1200 Main St West, Hamilton, ON L8N 3Z5, Canada; [Provias, John P.] McMaster Univ, Dept Pathol, 1200 Main St West, Hamilton, ON L8N 3Z5, Canada; [Murty, Naresh K.; Singh, Sheila K.] McMaster Univ, Fac Hlth Sci, Surg, 1200 Main St West, Hamilton, ON L8N 3Z5, Canada; [Moffat, Jason] Univ Toronto, Donnelly Ctr, Toronto, ON M5S 3E1, Canada	McMaster University; McMaster University; McMaster University; McMaster University; McMaster University; University of Toronto	Singh, SK (corresponding author), McMaster Univ, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8S 4K1, Canada.; Singh, SK (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, 1200 Main St West, Hamilton, ON L8N 3Z5, Canada.; Singh, SK (corresponding author), McMaster Univ, Fac Hlth Sci, Surg, 1200 Main St West, Hamilton, ON L8N 3Z5, Canada.	ssingh@mcmaster.ca	Moffat, Jason/AAC-1110-2020; Singh, Sheila K/W-2799-2018; Doble, Bradley/L-7551-2016	Moffat, Jason/0000-0002-5663-8586; Singh, Sheila K/0000-0003-1272-5300; Doble, Bradley/0000-0002-0260-2983; Tatari, Nazanin/0000-0002-0003-6121	Canadian Institutes of Health Research Vanier Canada Graduate Scholarship; Neurosurgical Research and Education Foundation; American Association of Neurological surgeons, Pediatric Section; Ontario Institute for Cancer Research; McMaster University Department of Surgery	Canadian Institutes of Health Research Vanier Canada Graduate Scholarship(Canadian Institutes of Health Research (CIHR)); Neurosurgical Research and Education Foundation; American Association of Neurological surgeons, Pediatric Section; Ontario Institute for Cancer Research; McMaster University Department of Surgery	B.M. is supported by a Canadian Institutes of Health Research Vanier Canada Graduate Scholarship. S.K.S. is supported by the Neurosurgical Research and Education Foundation and American Association of Neurological surgeons, Pediatric Section, the Ontario Institute for Cancer Research, and McMaster University Department of Surgery.	Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Cox CV, 2009, BLOOD, V113, P3287, DOI 10.1182/blood-2008-04-154187; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Hambardzumyan D, 2008, STEM CELL REV, V4, P203, DOI 10.1007/s12015-008-9021-5; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hu BL, 2016, CELL, V167, P1281, DOI 10.1016/j.cell.2016.10.039; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Kim WY, 2009, NAT NEUROSCI, V12, P1390, DOI 10.1038/nn.2408; Lan XY, 2017, NATURE, V549, P227, DOI 10.1038/nature23666; Mak AB, 2012, CELL REP, V2, P951, DOI 10.1016/j.celrep.2012.09.016; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Maw MA, 2000, HUM MOL GENET, V9, P27, DOI 10.1093/hmg/9.1.27; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morris LGT, 2013, NAT GENET, V45, P253, DOI 10.1038/ng.2538; Ng SW, 2009, J BIOL CHEM, V284, P24767, DOI 10.1074/jbc.M109.011692; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pulvirenti T, 2011, CANCER RES, V71, P7280, DOI 10.1158/0008-5472.CAN-11-1531; Rheinbay E, 2013, CELL REP, V3, P1567, DOI 10.1016/j.celrep.2013.04.021; Rossi M, 2011, CANCER BIOL THER, V11, P753, DOI 10.4161/cbt.11.8.14894; Sastre-Perona A, 2016, ONCOTARGET, V7, P49435, DOI 10.18632/oncotarget.10356; Shibahara I, 2013, NEURO-ONCOLOGY, V15, P1151, DOI 10.1093/neuonc/not066; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Taal W, 2014, LANCET ONCOL, V15, P943, DOI 10.1016/S1470-2045(14)70314-6; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Uhrbom L, 2002, CANCER RES, V62, P5551; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wei W, 2016, CANCER CELL, V29, P563, DOI 10.1016/j.ccell.2016.03.012; Wei YY, 2013, P NATL ACAD SCI USA, V110, P6829, DOI 10.1073/pnas.1217002110; Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932; Zhang LY, 2010, PATHOL ONCOL RES, V16, P253, DOI 10.1007/s12253-009-9219-0; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zheng HW, 2010, CANCER CELL, V17, P497, DOI 10.1016/j.ccr.2010.03.020	41	21	21	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1590	1599		10.1038/s41388-019-1086-x	http://dx.doi.org/10.1038/s41388-019-1086-x			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31695152				2022-12-17	WOS:000513289600014
J	Veschi, V; Mangiapane, LR; Nicotra, A; Di Franco, S; Scavo, E; Apuzzo, T; Sardina, DS; Fiori, M; Benfante, A; Colorito, ML; Cocorullo, G; Giuliante, F; Cipolla, C; Pistone, G; Bongiorno, MR; Rizzo, A; Tate, CM; Wu, XH; Rowlinson, S; Stancato, LF; Todaro, M; De Maria, R; Stassi, G				Veschi, Veronica; Mangiapane, Laura R.; Nicotra, Annalisa; Di Franco, Simone; Scavo, Emanuela; Apuzzo, Tiziana; Sardina, Davide S.; Fiori, Micol; Benfante, Antonina; Colorito, Maria L.; Cocorullo, Gianfranco; Giuliante, Felice; Cipolla, Calogero; Pistone, Giuseppe; Bongiorno, Maria Rita; Rizzo, Aroldo; Tate, Courtney M.; Wu, Xiaohua; Rowlinson, Scott; Stancato, Louis F.; Todaro, Matilde; De Maria, Ruggero; Stassi, Giorgio			Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; CONSENSUS MOLECULAR SUBTYPES; STEM-CELLS; COLON-CANCER; MICROSATELLITE-INSTABILITY; EXPRESSION PATTERNS; JUVENILE POLYPOSIS; TGF-BETA; DIFFERENTIATION	Despite intense research and clinical efforts, patients affected by advanced colorectal cancer (CRC) have still a poor prognosis. The discovery of colorectal (CR) cancer stem cell (CSC) as the cell compartment responsible for tumor initiation and propagation may provide new opportunities for the development of new therapeutic strategies. Given the reduced sensitivity of CR-CSCs to chemotherapy and the ability of bone morphogenetic proteins (BMP) to promote colonic stem cell differentiation, we aimed to investigate whether an enhanced variant of BMP7 (BMP7v) could sensitize to chemotherapy-resistant CRC cells and tumors. Thirty-five primary human cultures enriched in CR-CSCs, including four from chemoresistant metastatic lesions, were used for in vitro studies and to generate CR-CSC-based mouse avatars to evaluate tumor growth and progression upon treatment with BMP7v alone or in combination with standard therapy or PI3K inhibitors. BMP7v treatment promotes CR-CSC differentiation and recapitulates the cell differentiation-related gene expression profile by suppressing Wnt pathway activity and reducing mesenchymal traits and survival of CR-CSCs. Moreover, in CR-CSC-based mouse avatars, BMP7v exerts an antiangiogenic effect and sensitizes tumor cells to standard chemotherapy regardless of the mutational, MSI, and CMS profiles. Of note, tumor harboring PIK3CA mutations were affected to a lower extent by the combination of BMP7v and chemotherapy. However, the addition of a PI3K inhibitor to the BMP7v-based combination potentiates PIK3CA-mutant tumor drug response and reduces the metastatic lesion size. These data suggest that BMP7v treatment may represent a useful antiangiogenic and prodifferentiation agent, which renders CSCs sensitive to both standard and targeted therapies.	[Veschi, Veronica; Mangiapane, Laura R.; Nicotra, Annalisa; Di Franco, Simone; Scavo, Emanuela; Apuzzo, Tiziana; Sardina, Davide S.; Benfante, Antonina; Colorito, Maria L.; Cocorullo, Gianfranco; Cipolla, Calogero; Stassi, Giorgio] Univ Palermo, Dept Surg Oncol & Stomatol Sci DICHIRONS, I-90127 Palermo, Italy; [Fiori, Micol] Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy; [Giuliante, Felice; De Maria, Ruggero] Univ Cattolica Sacro Cuore, Ist Patol Gen, I-00168 Rome, Italy; [Giuliante, Felice; De Maria, Ruggero] Fdn Policlin Univ A Gemelli, IRCCS, I-00168 Rome, Italy; [Pistone, Giuseppe; Bongiorno, Maria Rita; Todaro, Matilde] Univ Palermo, Dept Hlth Promot Sci Internal Med & Med Specialti, I-90127 Palermo, Italy; [Rizzo, Aroldo] Osped Riuniti Villa Sofia Cervello, Pathol Unit, Palermo, Italy; [Tate, Courtney M.; Wu, Xiaohua; Rowlinson, Scott; Stancato, Louis F.] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	University of Palermo; Istituto Superiore di Sanita (ISS); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Palermo; Eli Lilly	Stassi, G (corresponding author), Univ Palermo, Dept Surg Oncol & Stomatol Sci DICHIRONS, I-90127 Palermo, Italy.; De Maria, R (corresponding author), Univ Cattolica Sacro Cuore, Ist Patol Gen, I-00168 Rome, Italy.; De Maria, R (corresponding author), Fdn Policlin Univ A Gemelli, IRCCS, I-00168 Rome, Italy.	ruggero.demaria@unicatt.it; giorgio.stassi@unipa.it	todaro, matilde/AAC-1003-2022; Veschi, Veronica/K-4143-2018; Cipolla, Calogero/H-2568-2018; Fiori, Micol Eleonora/J-7295-2016; Sardina, Davide Stefano/AAI-9559-2020; Stassi, Giorgio/AAC-1175-2022; di franco, simone/M-3714-2019; Fiori, Micol E/J-4043-2014; Cocorullo, Gianfranco/L-3744-2016	todaro, matilde/0000-0001-8686-8043; Veschi, Veronica/0000-0002-6379-7366; Cipolla, Calogero/0000-0003-4396-3563; Fiori, Micol Eleonora/0000-0002-1813-7035; Sardina, Davide Stefano/0000-0003-1161-3016; di franco, simone/0000-0002-6217-2161; Fiori, Micol E/0000-0002-1813-7035; Cocorullo, Gianfranco/0000-0003-2660-6724; Giuliante, Felice/0000-0003-2087-2589; Mangiapane, Laura Rosa/0000-0003-4186-0157	AIRC [5x1000 (9979)]	AIRC(Fondazione AIRC per la ricerca sul cancro)	We are thankful to Alessandro Gorgone for technical support, Francesco Calo' for graphics and Tatiana Terranova for editing the manuscript. The research leading to these results has received funding from AIRC under 5x1000 (9979) project-P.I. SG and RDM.	Arends JW, 2000, J PATHOL, V190, P412; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Beck SE, 2006, AM J PHYSIOL-GASTR L, V291, pG135, DOI 10.1152/ajpgi.00482.2005; Brosens LAA, 2011, WORLD J GASTROENTERO, V17, P4839, DOI 10.3748/wjg.v17.i44.4839; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Caja L, 2018, ONCOGENE, V37, P2515, DOI 10.1038/s41388-018-0136-0; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Clevers H, 2013, CELL, V154, P274, DOI 10.1016/j.cell.2013.07.004; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Hemminki A, 2000, GASTROENTEROLOGY, V119, P921, DOI 10.1053/gast.2000.18161; Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162; Irshad S, 2017, J PATHOL, V242, P178, DOI 10.1002/path.4891; Jover R, 2006, GUT, V55, P1819, DOI 10.1136/gut.2006.105627; Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840; Kodach LL, 2008, GASTROENTEROLOGY, V134, P1332, DOI 10.1053/j.gastro.2008.02.059; Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104; Laurila R, 2013, INT J CLIN EXP PATHO, V6, P1400; Linnekamp JF, 2018, CELL DEATH DIFFER, V25, P616, DOI 10.1038/s41418-017-0011-5; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcucci F, 2016, NAT REV DRUG DISCOV, V15, P311, DOI 10.1038/nrd.2015.13; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Qi Z, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13824; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rider CC, 2010, BIOCHEM J, V429, P1, DOI 10.1042/BJ20100305; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Sneddon JB, 2006, P NATL ACAD SCI USA, V103, P14842, DOI 10.1073/pnas.0606857103; Song N, 2016, JAMA ONCOL, V2, P1162, DOI 10.1001/jamaoncol.2016.2314; Swenckl-Underwood B, 2008, PROTEIN EXPRES PURIF, V57, P312, DOI 10.1016/j.pep.2007.09.016; Tate CM, 2012, CELL DEATH DIFFER, V19, P1644, DOI 10.1038/cdd.2012.44; Tate CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125697; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Vermeulen L, 2014, NAT REV CANCER, V14, P468, DOI 10.1038/nrc3744; Vitale I, 2017, MOL CELL, V66, P306, DOI 10.1016/j.molcel.2017.04.006; Zeng YH, 2017, ONCOL REP, V38, P456, DOI 10.3892/or.2017.5662; Zeuner A, 2014, CELL STEM CELL, V15, P692, DOI 10.1016/j.stem.2014.11.012	51	21	22	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					987	1003		10.1038/s41388-019-1047-4	http://dx.doi.org/10.1038/s41388-019-1047-4			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31591478	Green Published, hybrid			2022-12-17	WOS:000511209700003
J	Westrich, JA; Vermeer, DW; Silva, A; Bonney, S; Berger, JN; Cicchini, L; Greer, RO; Song, JI; Raben, D; Slansky, JE; Lee, JH; Spanos, WC; Pyeon, D				Westrich, Joseph A.; Vermeer, Daniel W.; Silva, Alexa; Bonney, Stephanie; Berger, Jennifer N.; Cicchini, Louis; Greer, Robert O.; Song, John I.; Raben, David; Slansky, Jill E.; Lee, John H.; Spanos, William C.; Pyeon, Dohun			CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8(+) T-cell responses by upregulating MHC-I expression	ONCOGENE			English	Article							COMPLEX CLASS-I; CERVICAL INTRAEPITHELIAL NEOPLASIA; IMMUNE; SURVIVAL; TISSUE; INFILTRATION; NEUTROPHILS; CARCINOMA; DEPLETION; PROTECTS	Evasion of the host immune responses is critical for both persistent human papillomavirus (HPV) infection and associated cancer progression. We have previously shown that expression of the homeostatic chemokine CXCL14 is significantly downregulated by the HPV oncoprotein E7 during cancer progression. Restoration of CXCL14 expression in HPV-positive head and neck cancer (HNC) cells dramatically suppresses tumor growth and increases survival through an immune-dependent mechanism in mice. Although CXCL14 recruits natural killer (NK) and T cells to the tumor microenvironment, the mechanism by which CXCL14 mediates tumor suppression through NK and/or T cells remained undefined. Here we report that CD8(+) T cells are required for CXCL14-mediated tumor suppression. Using a CD8(+) T-cell receptor transgenic model, we show that the CXCL14-mediated antitumor CD8 + T-cell responses require antigen specificity. Interestingly, CXCL14 expression restores major histocompatibility complex class I (MHC-I) expression on HPV-positive HNC cells downregulated by HPV, and knockdown of MHC-I expression in HNC cells results in loss of tumor suppression even with CXCL14 expression. These results suggest that CXCL14 enacts antitumor immunity through restoration of MHC-I expression on tumor cells and promoting antigen-specific CD8(+) T-cell responses to suppress HPV-positive HNC.	[Westrich, Joseph A.; Silva, Alexa; Berger, Jennifer N.; Cicchini, Louis; Slansky, Jill E.; Pyeon, Dohun] Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO 80045 USA; [Vermeer, Daniel W.; Spanos, William C.] Sanford Res, Canc Biol Res Ctr, Sioux Falls, SD 57104 USA; [Bonney, Stephanie] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO 80045 USA; [Greer, Robert O.] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO 80045 USA; [Greer, Robert O.] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO 80045 USA; [Greer, Robert O.] Univ Colorado, Sch Dent Med, Div Oral & Maxillofacial Pathol, Aurora, CO 80045 USA; [Song, John I.] Univ Colorado, Sch Med, Dept Otolaryngol, Aurora, CO 80045 USA; [Raben, David] Univ Colorado, Sch Med, Dept Radiat Oncol, Aurora, CO 80045 USA; [Lee, John H.] Chan Soon Shiong Inst Med, El Segundo, CA 90245 USA; [Pyeon, Dohun] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; [Westrich, Joseph A.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Sanford Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Michigan State University; Colorado State University	Pyeon, D (corresponding author), Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO 80045 USA.; Pyeon, D (corresponding author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.	dpyeon@msu.edu		Pyeon, Dohun/0000-0003-1970-844X; Vermeer, Daniel/0000-0002-1501-0418; Slansky, Jill/0000-0003-3820-1724	NIH [R01 DE026125, T32 AI052066]; Immunology and Microbiology Pilot Award; University of Colorado Cancer Center; Colorado Clinical and Translational Sciences Institute; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI052066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE026125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008730] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Immunology and Microbiology Pilot Award; University of Colorado Cancer Center; Colorado Clinical and Translational Sciences Institute; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Ross Kedl, Linda van Dyk, Eric Clambey, Paul Ahlquist, Paul Lambert, Xiao-Jing Wang, and members of the Pyeon laboratory for useful comments and suggestions. This work was supported in part by NIH R01 DE026125 (DP and WCS), NIH T32 AI052066 (JAW), Immunology and Microbiology Pilot Award (DP and JES), grants from the University of Colorado Cancer Center (DP), Colorado Clinical and Translational Sciences Institute (DP, JIS, and ROG), and a generous gift from the Marsico Fund (DR).	Augsten M, 2009, P NATL ACAD SCI USA, V106, P3414, DOI 10.1073/pnas.0813144106; BAL V, 1990, EUR J IMMUNOL, V20, P1893, DOI 10.1002/eji.1830200904; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Cao XT, 2000, J IMMUNOL, V165, P2588, DOI 10.4049/jimmunol.165.5.2588; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chen LM, 2010, J IMMUNOL, V184, P4455, DOI 10.4049/jimmunol.0900525; Cicchini L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03295-7; Cicchini L, 2016, MBIO, V7, DOI 10.1128/mBio.00270-16; Cogliano V, 2005, LANCET ONCOL, V6, P204, DOI 10.1016/S1470-2045(05)70086-3; Cuburu N, 2012, J CLIN INVEST, V122, P4606, DOI 10.1172/JCI63287; Da Silva DM, 2015, PAPILLOMAVIRUS RES, V1, P12, DOI 10.1016/j.pvr.2015.05.001; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; de Oliveira LC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118225; DiMaio D, 2013, VIROLOGY, V445, P99, DOI 10.1016/j.virol.2013.05.006; Farkona S, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0623-5; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Garcia-Lora A, 2003, J CELL PHYSIOL, V195, P346, DOI 10.1002/jcp.10290; Glasner A, 2017, J VIROL, V91, P22; Handisurya A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004314; Hata RI, 2015, SCI REP-UK, V5, DOI 10.1038/srep09083; Herzer K, 2003, J VIROL, V77, P8299, DOI 10.1128/JVI.77.15.8299-8309.2003; Hibma Merilyn H, 2012, Open Virol J, V6, P241, DOI 10.2174/1874357901206010241; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hu CY, 2013, INT J ONCOL, V43, P1487, DOI 10.3892/ijo.2013.2078; Johnston RJ, 2014, CANCER CELL, V26, P923, DOI 10.1016/j.ccell.2014.10.018; Kansy BA, 2017, CANCER RES, V77, P6353, DOI 10.1158/0008-5472.CAN-16-3167; Kim DH, 2011, BIOCHEM BIOPH RES CO, V409, P792, DOI 10.1016/j.bbrc.2011.05.090; Klebanoff CA, 2006, IMMUNOL REV, V211, P214, DOI 10.1111/j.0105-2896.2006.00391.x; Kurth I, 2001, J EXP MED, V194, P855, DOI 10.1084/jem.194.6.855; Kuss-Duerkop SK, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020082; Lee HT, 2017, THERANOSTICS, V7, P855, DOI 10.7150/thno.17558; Liu CQ, 2017, MOL MED REP, V15, P1063, DOI 10.3892/mmr.2017.6102; Lu JC, 2015, J CLIN INVEST, V125, P1839, DOI 10.1172/JCI78437; Lu J, 2016, J INFLAMM-LOND, V13, DOI 10.1186/s12950-015-0109-9; Lyu XJ, 2015, ONCOTARGET, V6, P6656, DOI 10.18632/oncotarget.3169; Maldonado L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007323; Miyamoto C, 2014, BIOMED RES-TOKYO, V35, P381, DOI 10.2220/biomedres.35.381; Moses K, 2016, J LEUKOCYTE BIOL, V99, P811, DOI 10.1189/jlb.1HI0715-289R; Nasman A, 2013, INT J CANCER, V132, P72, DOI 10.1002/ijc.27635; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Pasero C, 2015, ONCOTARGET, V6, P14360, DOI 10.18632/oncotarget.3965; Podolin PL, 2013, AM J PHYSIOL-LUNG C, V304, pL312, DOI 10.1152/ajplung.00152.2012; Ran XW, 2017, DRUG DES DEV THER, V11, P2007, DOI 10.2147/DDDT.S140687; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Shurin GV, 2005, J IMMUNOL, V174, P5490, DOI 10.4049/jimmunol.174.9.5490; Smola Sigrun, 2017, Ther Adv Vaccines, V5, P69, DOI 10.1177/2051013617717914; Su RC, 2001, J IMMUNOL, V167, P4869, DOI 10.4049/jimmunol.167.9.4869; Tardif KD, 2003, J VIROL, V77, P11644, DOI 10.1128/JVI.77.21.11644-11650.2003; Tarek N, 2014, ADV EXP MED BIOL, V804, P341, DOI 10.1007/978-3-319-04843-7_19; Tindle RW, 2002, NAT REV CANCER, V2, P59, DOI 10.1038/nrc700; Trimble CL, 2010, J IMMUNOL, V185, P7107, DOI 10.4049/jimmunol.1002756; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Van Audenaerde JRM, 2018, PHARMACOL THERAPEUT, V189, P31, DOI 10.1016/j.pharmthera.2018.04.003; van der Burg SH, 2002, VIRUS RES, V89, P275, DOI 10.1016/S0168-1702(02)00196-X; Welters MJP, 2018, CLIN CANCER RES, V24, P634, DOI 10.1158/1078-0432.CCR-17-2140; Wente MN, 2008, CANCER LETT, V259, P209, DOI 10.1016/j.canlet.2007.10.021; Westrich JA, 2017, VIRUS RES, V231, P21, DOI 10.1016/j.virusres.2016.11.023; Woo YL, 2008, BJOG-INT J OBSTET GY, V115, P1616, DOI 10.1111/j.1471-0528.2008.01936.x; Woo Y. L., 2008, BJOG, V115, P1621	60	21	24	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2019	38	46					7166	7180		10.1038/s41388-019-0911-6	http://dx.doi.org/10.1038/s41388-019-0911-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JN5HX	31417179	Green Accepted, hybrid			2022-12-17	WOS:000496930500004
J	Huang, W; Hu, H; Zhang, Q; Wu, X; Wei, FX; Yang, F; Gan, L; Wang, N; Yang, XL; Guo, AY				Huang, Wei; Hu, Hui; Zhang, Qiong; Wu, Xian; Wei, Fuxiang; Yang, Fang; Gan, Lu; Wang, Ning; Yang, Xiangliang; Guo, An-Yuan			Regulatory networks in mechanotransduction reveal key genes in promoting cancer cell stemness and proliferation	ONCOGENE			English	Article							EXPRESSION; FIBRIN; GROWTH; ACTIVATION; POPULATION; INHIBITION; CARCINOMA; PATHWAYS; NANOG; COLON	Tumor-repopulating cells (TRCs) are cancer stem cell (CSC)-like cells with highly tumorigenic and self-renewing abilities, which were selected from tumor cells in soft three-dimensional (3D) fibrin gels with unidentified mechanisms. Here we evaluated the transcriptome alteration during TRCs generation in 3D culture and revealed that a variety of molecules related with integrin/membrane and stemness were continuously altered by mechanical environment. Some key regulators such as MYC/STAT3/hsa-miR-199a-5p, were changed in the TRCs generation. They regulated membrane genes and the downstream mechanotransduction pathways such as Hippo/WNT/TGF-beta/PI3K-AKT pathways, thus further affecting the expression of downstream cancer-related genes. By integrating networks for membrane proteins, the WNT pathway and cancer-related genes, we identified key molecules in the selection of TRCs, such as ATF4, SLC3A2, CCT3, and hsa-miR-199a-5p. Silencing ATF4 or CCT3 inhibited the selection and growth of TRCs whereas reduction of SLC3A2 or hsa-miR-199a-5p promoted TRCs growth. Further studies showed that CCT3 promoted cell proliferation and stemness in vitro, while its suppression inhibited TRCs-induced tumor formation. We also contemplated CCT3 as a stemness-related gene. Our findings provide insights in the mechanism of TRCs selection through transcriptome analysis.	[Huang, Wei; Wu, Xian; Gan, Lu; Yang, Xiangliang] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Natl Engn Res Ctr Nanomed, Wuhan 430074, Hubei, Peoples R China; [Hu, Hui; Zhang, Qiong; Guo, An-Yuan] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Hubei Bioinformat & Mol Imaging Key Lab, Key Lab Mol Biophys,Minist Educ, Wuhan 430074, Hubei, Peoples R China; [Wei, Fuxiang; Yang, Fang; Wang, Ning] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Dept Biomed Engn, Wuhan 430074, Hubei, Peoples R China; [Wang, Ning] Univ Illinois, Coll Engn, Dept Mech Sci & Engn, Urbana, IL 61801 USA	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; University of Illinois System; University of Illinois Urbana-Champaign	Yang, XL (corresponding author), Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Natl Engn Res Ctr Nanomed, Wuhan 430074, Hubei, Peoples R China.; Guo, AY (corresponding author), Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Hubei Bioinformat & Mol Imaging Key Lab, Key Lab Mol Biophys,Minist Educ, Wuhan 430074, Hubei, Peoples R China.	yangxl@hust.edu.cn; guoay@hust.edu.cn	Zhang, Qiong/AIC-0940-2022; Zhang, Qiong/GYE-1270-2022	Zhang, Qiong/0000-0001-5001-8434; Wei, Fuxiang/0000-0002-6200-6219; Hu, Hui/0000-0002-9208-1041; Guo, An-Yuan/0000-0002-5099-7465	National Basic Research Program of China [2015CB931802]; National Natural Science Foundation of China (NSFC) [81627901, 81773653, 31822030, 31771458]; Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT) [IRT 13016]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072744] Funding Source: NIH RePORTER	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT)(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge the research funding from National Basic Research Program of China (2015CB931802), National Natural Science Foundation of China (NSFC) [81627901, 81773653, 31822030, and 31771458], and Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT) [No. IRT 13016].	Addla SK, 2008, AM J PHYSIOL-RENAL, V295, pF680, DOI 10.1152/ajprenal.90286.2008; Amini S, 2014, ANAT CELL BIOL, V47, P1, DOI 10.5115/acb.2014.47.1.1; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Bu PC, 2016, CELL STEM CELL, V18, P189, DOI 10.1016/j.stem.2016.01.006; Chen JW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03877-7; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; COSTANTINI V, 1992, CANCER METAST REV, V11, P283, DOI 10.1007/BF01307183; Cui X, 2015, WORLD J GASTROENTERO, V21, P8588, DOI 10.3748/wjg.v21.i28.8588; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Estrach S, 2014, CANCER RES, V74, P6878, DOI 10.1158/0008-5472.CAN-14-0579; Gong J, 2014, RNA BIOL, V11, P1375, DOI 10.1080/15476286.2014.996465; Guo CL, 2016, CELL BIOL INT, V40, P847, DOI 10.1002/cbin.10539; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hamzeh MT, 2015, AM J PHYSIOL-RENAL, V308, pF425, DOI 10.1152/ajprenal.00589.2014; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jung K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-328; Koshizuka K, 2017, CANCER SCI, V108, P1681, DOI 10.1111/cas.13298; Lam WA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-35; Li Y, 2015, CANCER RES, V75, P1191, DOI 10.1158/0008-5472.CAN-14-2615; Lin Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep09653; Liu J, 2012, NAT MATER, V11, P734, DOI [10.1038/NMAT3361, 10.1038/nmat3361]; Lopez-Saavedra A, 2016, CELL CYCLE, V15, P2066, DOI 10.1080/15384101.2016.1198863; Luo YM, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3598542; Malik G, 2010, CANCER RES, V70, P4327, DOI 10.1158/0008-5472.CAN-09-3312; Matsumoto T, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389-017-0009-3; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mobus S, 2015, J HEPATOL, V62, P101, DOI 10.1016/j.jhep.2014.08.016; Morgan JT, 2013, EXP EYE RES, V115, P1, DOI 10.1016/j.exer.2013.06.012; Najafi M, 2019, J CELL PHYSIOL, V234, P8381, DOI 10.1002/jcp.27740; Nimmakayala RK, 2019, BBA-REV CANCER, V1871, P50, DOI 10.1016/j.bbcan.2018.10.006; Ning W, 2017, J PHYS D, V50; Palumbo JS, 2001, HAEMOSTASIS, V31, P11; Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095; Rivera B, 2011, ANN ONCOL, V22, P903, DOI 10.1093/annonc/mdq465; Rysa J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23042-w; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; Shafer B, 2011, DEV CELL, V20, P177, DOI 10.1016/j.devcel.2011.01.002; Shi L, 2010, ONCOTARGET, V1, P22, DOI 10.18632/oncotarget.105; Sironen RK, 2002, BIORHEOLOGY, V39, P111; Sun HF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036808; Susswein LR, 2016, GENET MED, V18, P823, DOI 10.1038/gim.2015.166; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tan YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5619; Tarazona S, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv711; van Sluis GL, 2011, CANCER LETT, V306, P106, DOI 10.1016/j.canlet.2011.02.038; VILADIU P, 1975, SURG GYNECOL OBSTET, V140, P544; Vining KH, 2017, NAT REV MOL CELL BIO, V18, P728, DOI 10.1038/nrm.2017.108; Wang J, 2013, MOL NEUROBIOL, V47, P228, DOI 10.1007/s12035-012-8335-0; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang T, 2015, ONCOTARGET, V6, P30975, DOI 10.18632/oncotarget.5199; Wozniak MA, 2009, NAT REV MOL CELL BIO, V10, P34, DOI 10.1038/nrm2592; Xia HF, 2017, J HISTOCHEM CYTOCHEM, V65, P285, DOI 10.1369/0022155417694872; Zhang HM, 2015, BRIEF BIOINFORM, V16, P45, DOI 10.1093/bib/bbt085; Zhang T, 2003, BIOCHEM J, V376, P457, DOI 10.1042/BJ20030668; Zhang YY, 2016, CANCER LETT, V372, P101, DOI 10.1016/j.canlet.2015.12.029; Zhao YZ, 2015, BLOOD, V126, P2383, DOI 10.1182/blood-2015-03-633354; Zheng J, 2015, ONCOTARGET, V6, P25339, DOI 10.18632/oncotarget.4509	58	21	21	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2019	38	42					6818	6834		10.1038/s41388-019-0925-0	http://dx.doi.org/10.1038/s41388-019-0925-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE5UU	31406247	Green Accepted, hybrid			2022-12-17	WOS:000490758200002
J	Cui, Y; Groth, S; Troutman, S; Carlstedt, A; Sperka, T; Riecken, LB; Kissil, JL; Jin, HC; Morrison, H				Cui, Yan; Groth, Susann; Troutman, Scott; Carlstedt, Annemarie; Sperka, Tobias; Riecken, Lars Bjorn; Kissil, Joseph L.; Jin, Hongchuan; Morrison, Helen			The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; ANCHORAGE-INDEPENDENT GROWTH; NEUROFIBROMATOSIS TYPE-2; PLECKSTRIN HOMOLOGY; STRUCTURAL BASIS; GENE-PRODUCT; P120 RASGAP; FERM DOMAIN; CELLS; INHIBITION	Inactivation of the tumor suppressor NF2/merlin underlies neurofibromatosis type 2 (NF2) and some sporadic tumors. Previous studies have established that merlin mediates contact inhibition of proliferation; however, the exact mechanisms remain obscure and multiple pathways have been implicated. We have previously reported that merlin inhibits Ras and Rac activity during contact inhibition, but how merlin regulates Ras activity has remained elusive. Here we demonstrate that merlin can directly interact with both Ras and p120RasGAP (also named RasGAP). While merlin does not increase the catalytic activity of RasGAP, the interactions with Ras and RasGAP may fine-tune Ras signaling. In vivo, loss of RasGAP in Schwann cells, unlike the loss of merlin, failed to promote tumorigenic growth in an orthotopic model. Therefore, modulation of Ras signaling through RasGAP likely contributes to, but is not sufficient to account for, merlin's tumor suppressor activity. Our study provides new insight into the mechanisms of merlin-dependent Ras regulation and may have additional implications for merlin-dependent regulation of other small GTPases.	[Cui, Yan; Groth, Susann; Carlstedt, Annemarie; Sperka, Tobias; Riecken, Lars Bjorn; Morrison, Helen] Leibniz Inst Aging, Fritz Lipmann Inst, Beutenbergstr 11, D-07745 Jena, Germany; [Troutman, Scott; Kissil, Joseph L.] Scripps Res Inst, Dept Mol Med, 130 Scripps Way, Jupiter, FL 33458 USA; [Jin, Hongchuan] Zhejiang Univ, Med Sch, Sir Run Run Shaw Hosp, Lab Canc Biol,Key Lab Biotherapy, Hangzhou 310016, Zhejiang, Peoples R China	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Scripps Research Institute; Zhejiang University	Cui, Y; Morrison, H (corresponding author), Leibniz Inst Aging, Fritz Lipmann Inst, Beutenbergstr 11, D-07745 Jena, Germany.	yan.cui@leibniz-fli.de; Helen.Morrison@leibniz-fli.de	Morrison, Helen/F-9748-2014	Morrison, Helen/0000-0003-4938-1409; Jin, Hongchuan/0000-0002-6697-3097; Cui, Yan/0000-0002-6522-8343; Riecken, Lars Bjorn/0000-0002-1992-4591	Deutsche Forschungsgemeinschaft [MO 1421/2-1, MO 1421/5-1]; Deutsche Krebshilfe [612000]; National Natural Science Foundation of China [81761138047]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported in part by grants from Deutsche Forschungsgemeinschaft (MO 1421/2-1 and MO 1421/5-1) and Deutsche Krebshilfe (612000) to HM, and from National Natural Science Foundation of China (81761138047) to HJ.	Ahronowitz I, 2007, HUM MUTAT, V28, P1, DOI 10.1002/humu.20393; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; BANSAL R, 1987, J NEUROCHEM, V49, P1902, DOI 10.1111/j.1471-4159.1987.tb02453.x; Bayrak-Toydemir P., 1993, GENEREVIEWS; Bondeva T, 2002, MOL BIOL CELL, V13, P2323, DOI 10.1091/mbc.E02-01-0019; Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; Chinthalapudi K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03648-4; Clucas J, 2014, J CELL SCI, V127, P267, DOI 10.1242/jcs.133108; COLBURN NH, 1978, CANCER RES, V38, P624; Cole BK, 2008, MOL CELL BIOL, V28, P1274, DOI 10.1128/MCB.01139-07; Coll MAL, 2005, ONCOGENE, V24, P1727, DOI 10.1038/sj.onc.1208379; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Drugan JK, 2000, J BIOL CHEM, V275, P35021, DOI 10.1074/jbc.M004386200; Eerola I, 2003, AM J HUM GENET, V73, P1240, DOI 10.1086/379793; Evans DGR, 2009, GENET MED, V11, P599, DOI 10.1097/GIM.0b013e3181ac9a27; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Garcia-Rendueles MER, 2015, CANCER DISCOV, V5, P1178, DOI 10.1158/2159-8290.CD-15-0330; Geissler KJ, 2013, P NATL ACAD SCI USA, V110, P20587, DOI 10.1073/pnas.1222078110; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; Gusella JF, 1999, BBA-REV CANCER, V1423, pM29, DOI 10.1016/S0304-419X(99)00005-0; Hayashi T, 2018, CLIN CANCER RES, V24, P1436, DOI 10.1158/1078-0432.CCR-17-2343; Hennigan RF, 2010, MOL CELL BIOL, V30, P54, DOI 10.1128/MCB.00248-09; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; HOSHINO M, 1988, MOL CELL BIOL, V8, P4169, DOI 10.1128/MCB.8.10.4169; Kang BS, 2002, ACTA CRYSTALLOGR D, V58, P381, DOI 10.1107/S0907444901021175; Kim DI, 2016, MOL BIOL CELL, V27, P1188, DOI 10.1091/mbc.E15-12-0844; Koehler JA, 2001, CELL GROWTH DIFFER, V12, P551; Li QZ, 2007, J MOL BIOL, V365, P1446, DOI 10.1016/j.jmb.2006.10.075; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Li YJ, 2015, CELL RES, V25, P801, DOI 10.1038/cr.2015.69; Lim JY, 2006, BIOCHEM BIOPH RES CO, V340, P1151, DOI 10.1016/j.bbrc.2005.12.122; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lobsiger CS, 2000, GLIA, V30, P290, DOI 10.1002/(SICI)1098-1136(200005)30:3<290::AID-GLIA8>3.0.CO;2-6; Lubeck BA, 2015, J IMMUNOL, V195, P31, DOI 10.4049/jimmunol.1402639; Maertens Ophelia, 2014, Advances in Biological Regulation, V55, P1, DOI 10.1016/j.jbior.2014.04.002; Meier C, 1999, J NEUROSCI, V19, P3847; Mo SP, 2018, BIOCHEM SOC T, V46, P1325, DOI 10.1042/BST20180173; Monje PV, 2009, GLIA, V57, P947, DOI 10.1002/glia.20819; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; Newlaczyl AU, 2017, SCI REP-UK, V7, DOI 10.1038/srep41297; Orthaus S, 2009, NUCLEIC ACIDS RES, V37, P3391, DOI 10.1093/nar/gkp199; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Petrilli AM, 2016, ONCOGENE, V35, P537, DOI 10.1038/onc.2015.125; Riecken LB, 2015, HUM MUTAT, V36, P270, DOI 10.1002/humu.22737; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Sher I, 2012, DEV CELL, V22, P703, DOI 10.1016/j.devcel.2012.03.008; Shimizu T, 2002, J BIOL CHEM, V277, P10332, DOI 10.1074/jbc.M109979200; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Shyu YJ, 2006, BIOTECHNIQUES, V40, P61, DOI 10.2144/000112036; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Sperka T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027511; Suarez-Cabrera C, 2017, CANCER RES, V77, P1357, DOI 10.1158/0008-5472.CAN-16-1586; TIKOO A, 1994, J BIOL CHEM, V269, P23387; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; Wiederhold T, 2004, ONCOGENE, V23, P8815, DOI 10.1038/sj.onc.1208110; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Zhou L, 2016, ONCOGENE, V35, P3443, DOI 10.1038/onc.2015.404	58	21	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2019	38	36					6370	6381		10.1038/s41388-019-0883-6	http://dx.doi.org/10.1038/s41388-019-0883-6			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6EX	31312020	hybrid, Green Published			2022-12-17	WOS:000485776800004
J	Perotti, V; Baldassari, P; Molla, A; Nicolini, G; Bersani, I; Grazia, G; Benigni, F; Maurichi, A; Santinami, M; Anichini, A; Mortarini, R				Perotti, Valentina; Baldassari, Paola; Molla, Alessandra; Nicolini, Gabriella; Bersani, Ilaria; Grazia, Giulia; Benigni, Fabio; Maurichi, Andrea; Santinami, Mario; Anichini, Andrea; Mortarini, Roberta			An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN; MALIGNANT-MELANOMA; CANCER CELLS; PROGRESSION; METASTASIS; EXPRESSION; BREAST; GROWTH; DIFFERENTIATION	Discovery of new actionable targets and functional networks in melanoma is an urgent need as only a fraction of metastatic patients achieves durable clinical benefit by targeted therapy or immunotherapy approaches. Here we show that NFATc2 expression is associated with an EMT-like transcriptional program and with an invasive melanoma phenotype, as shown by analysis of melanoma cell lines at the mRNA and protein levels, interrogation of the TCGA melanoma dataset and characterization of melanoma lesions by immunohistochemistry. Gene silencing or pharmacological inhibition of NFATc2 downregulated EMT-related genes and AXL, and suppressed c-Myc, FOXM1, and EZH2. Targeting of c-Myc suppressed FOXM1 and EZH2, while targeting of FOXM1 suppressed EZH2. Inhibition of c-Myc, or FOXM1, or EZH2 downregulated EMT-related gene expression, upregulated MITF and suppressed migratory and invasive activity of neoplastic cells. Stable silencing of NFATc2 impaired melanoma cell proliferation in vitro and tumor growth in vivo in SCID mice. In NFATc2(+) EZH2(+) melanoma cell lines pharmacological co-targeting of NFATc2 and EZH2 exerted strong anti-proliferative and proapoptotic activity, irrespective of BRAF or NRAS mutations and of BRAF inhibitor resistance. These results provide preclinical evidence for a role of NFATc2 in shaping the EMT-like melanoma phenotype and reveal a targetable vulnerability associated with NFATc2 and EZH2 expression in melanoma cells belonging to different mutational subsets.	[Perotti, Valentina; Baldassari, Paola; Molla, Alessandra; Nicolini, Gabriella; Bersani, Ilaria; Grazia, Giulia; Anichini, Andrea; Mortarini, Roberta] Dept Res, Human Tumors Immunobiol Unit, Milan, Italy; [Benigni, Fabio] HuMabs Biomed, Subsidiary Vir Biotechnol, Bellinzona, Switzerland; [Maurichi, Andrea; Santinami, Mario] Fdn IRCCS, Dept Surg, Melanoma & Sarcoma Unit, Ist Nazl Tumori, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Mortarini, R (corresponding author), Dept Res, Human Tumors Immunobiol Unit, Milan, Italy.	roberta.mortarini@istitutotumori.mi.it	Maurichi, Andrea/AAX-5020-2020; Santinami, Mario/I-3795-2017; Maurichi, Andrea/E-7030-2017; Perotti, Valentina/C-1049-2017; Anichini, Andrea/K-1434-2016	Maurichi, Andrea/0000-0002-6503-5373; Santinami, Mario/0000-0001-8436-4757; Maurichi, Andrea/0000-0002-6503-5373; Perotti, Valentina/0000-0003-4506-2363; Anichini, Andrea/0000-0001-5096-5538	Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) [IG15860]	Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.), grant IG15860 to RM.	Anichini A, 2006, CANCER RES, V66, P6405, DOI 10.1158/0008-5472.CAN-06-0854; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Baumgart S, 2016, MOL CANCER THER, V15, P491, DOI 10.1158/1535-7163.MCT-15-0309; Braig S, 2011, BRIT J CANCER, V105, P231, DOI 10.1038/bjc.2011.226; Caballero FJ, 2007, BIOCHEM PHARMACOL, V73, P1013, DOI 10.1016/j.bcp.2006.12.001; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Ciuffreda L, 2009, NEOPLASIA, V11, P720, DOI 10.1593/neo.09398; Courboulin A, 2011, J EXP MED, V208, P535, DOI 10.1084/jem.20101812; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eriksson J, 2016, ONCOTARGET, V7, P15065, DOI 10.18632/oncotarget.7604; Garay T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117021; Geback T, 2009, BIOTECHNIQUES, V46, P265, DOI 10.2144/000113083; Izumi H, 2015, SURG TODAY, V45, P487, DOI 10.1007/s00595-015-1126-2; Kim SH, 2015, STEM CELL REP, V4, P226, DOI 10.1016/j.stemcr.2014.12.006; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Kreiseder B, 2013, INT J CANCER, V132, P521, DOI 10.1002/ijc.27698; Kudo-Saito C, 2013, CANCER RES, V73, P6185, DOI 10.1158/0008-5472.CAN-13-1364; Liu L, 2016, BJU INT, V117, P351, DOI 10.1111/bju.12702; Lu J, 2015, MOL MED REP, V12, P2668, DOI 10.3892/mmr.2015.3752; Mahmoud F, 2016, CANCER BIOL THER, V17, P579, DOI 10.1080/15384047.2016.1167291; Mann KM, 2004, J CELL BIOL, V165, P483, DOI 10.1083/jcb.200402105; Paluncic J, 2016, BBA-MOL CELL RES, V1863, P770, DOI 10.1016/j.bbamcr.2016.01.025; Parvani JG, 2015, CANCER RES, V75, P2316, DOI 10.1158/0008-5472.CAN-14-3485; Pearlman RL, 2017, CANCER LETT, V391, P125, DOI 10.1016/j.canlet.2017.01.029; Penna I, 2016, ONCOTARGET, V7, P3947, DOI 10.18632/oncotarget.6600; Peres J, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-117; Perotti V, 2016, ONCOGENE, V35, P2862, DOI 10.1038/onc.2015.355; Perotti V, 2012, J INVEST DERMATOL, V132, P2652, DOI 10.1038/jid.2012.179; Rai K, 2015, CANCER DISCOV, V5, P1314, DOI 10.1158/2159-8290.CD-15-0493; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Rastelli L, 2011, INT J ONCOL, V39, P401, DOI 10.3892/ijo.2011.1040; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Schech AJ, 2013, MOL CANCER THER, V12, P1356, DOI 10.1158/1535-7163.MCT-12-0304; Sensi M, 2011, J INVEST DERMATOL, V131, P2448, DOI 10.1038/jid.2011.218; Shankar J, 2010, CANCER RES, V70, P3780, DOI 10.1158/0008-5472.CAN-09-4439; Singh SK, 2011, J BIOL CHEM, V286, P28761, DOI 10.1074/jbc.M110.197533; Tian L, 2016, INT J ONCOL, V48, P783, DOI 10.3892/ijo.2015.3282; Tiffen JC, 2015, ONCOTARGET, V6, P27023, DOI 10.18632/oncotarget.4809; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Wang B, 2012, BIOCHEM BIOPH RES CO, V417, P601, DOI 10.1016/j.bbrc.2011.12.014; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Xu N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059412; Yamamoto K, 2014, MOL CELL, V53, P904, DOI 10.1016/j.molcel.2014.02.028; Yang KK, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0158-1; Yin LL, 2015, J INVEST DERMATOL, V135, P2455, DOI 10.1038/jid.2015.179; Zhang K, 2013, NAT CELL BIOL, V15, P677, DOI 10.1038/ncb2743; Zingg D, 2017, CELL REP, V20, P854, DOI 10.1016/j.celrep.2017.07.007	50	21	22	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4384	4396		10.1038/s41388-019-0729-2	http://dx.doi.org/10.1038/s41388-019-0729-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30710146	Green Published, hybrid			2022-12-17	WOS:000469339100013
J	Choucair, A; Pham, TH; Omarjee, S; Jacquemetton, J; Kassem, L; Tredan, O; Rambaud, J; Marangoni, E; Corbo, L; Treilleux, I; Le Romancer, M				Choucair, Ali; Thuy Ha Pham; Omarjee, Soleilmane; Jacquemetton, Julien; Kassem, Loay; Tredan, Olivier; Rambaud, Juliette; Marangoni, Elisabetta; Corbo, Laura; Treilleux, Isabelle; Le Romancer, Muriel			The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; METHYLATION; RESISTANCE; EXPRESSION; PROMOTES; CHAIN	Aside from its well-known nuclear routes of signaling, estrogen also mediates its effects through cytoplasmic signaling. Estrogen signaling involves numerous posttranslational modifications of its receptor ER alpha, the best known being phosphorylation. Our research group previously showed that upon estrogen stimulation, ER alpha is methylated on residue R260 and forms the mER alpha/Src/PI3K complex, central to the rapid transduction of nongenomic estrogen signals. Regulation of ER alpha signaling via its phosphorylation by growth factors is well recognized, and we wondered whether they could also trigger ER alpha methylation (mER alpha). Here, we found that IGF-1 treatment of MCF-7 cells induced rapid ER alpha methylation by the arginine methyltransferase PRMT1 and triggered the binding of mER alpha to IGF-1R. Mechanistically, we showed that PRMT1 bound constitutively to IGF-1R and that PRMT1 became activated upon IGF-1 stimulation. Moreover, we found that expression or pharmacological inhibition of PRMT1 impaired mER alpha and IGF-1 signaling. Our findings were substantiated in a cohort of breast tumors in which IGF-1R expression was positively correlated with ER alpha/Src and ER alpha/PI3K expression, hallmarks of nongenomic estrogen signaling, reinforcing the link between IGF-1R and mER alpha. Altogether, these results provide a new insight into ER alpha and IGF-1R interference, and open novel perspectives for combining endocrine therapies with PRMT1 inhibitors in ER alpha-positive tumors.	[Choucair, Ali; Thuy Ha Pham; Omarjee, Soleilmane; Jacquemetton, Julien; Rambaud, Juliette; Corbo, Laura; Treilleux, Isabelle; Le Romancer, Muriel] Ctr Rech Cancerol Lyon, INSERM, U1052, Lyon, France; [Choucair, Ali; Thuy Ha Pham; Omarjee, Soleilmane; Jacquemetton, Julien; Rambaud, Juliette; Corbo, Laura; Treilleux, Isabelle; Le Romancer, Muriel] Ctr Rech Cancerol Lyon, CNRS, UMR5286, Lyon, France; [Choucair, Ali; Thuy Ha Pham; Omarjee, Soleilmane; Jacquemetton, Julien; Rambaud, Juliette; Corbo, Laura; Treilleux, Isabelle; Le Romancer, Muriel] Univ Lyon 1, Lyon, France; [Omarjee, Soleilmane] Univ Cambridge, Cambridge Inst, Canc Res UK, Cambridge CB2 0RE, England; [Kassem, Loay] Cairo Univ, Fac Med, Dept Clin Oncol, Cairo, Egypt; [Tredan, Olivier] Ctr Leon Berard, Dept Oncol, Lyon, France; [Marangoni, Elisabetta] Inst Curie, Translat Res Dept, F-75005 Paris, France; [Treilleux, Isabelle] Ctr Leon Berard, Dept Pathol, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Egyptian Knowledge Bank (EKB); Cairo University; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Centre Leon Berard	Le Romancer, M (corresponding author), Ctr Rech Cancerol Lyon, INSERM, U1052, Lyon, France.; Le Romancer, M (corresponding author), Ctr Rech Cancerol Lyon, CNRS, UMR5286, Lyon, France.; Le Romancer, M (corresponding author), Univ Lyon 1, Lyon, France.	muriel.leromancer@lyon.unicancer.fr	Marangoni, Elisabetta/GSO-3945-2022; Tredan, Olivier/N-9794-2017	Marangoni, Elisabetta/0000-0002-3337-6448; Le Romancer, Muriel/0000-0002-8491-4015; Omarjee, Soleilmane/0000-0001-8686-7286; Jacquemetton, Julien/0000-0003-0513-6604; Tredan, Olivier/0000-0001-5881-9383	Fondation ARC Cancer; DGOS; "la ligue contre le cancer", comity of the Saone-et-Loire; INCA; Ministry of Research; ligue nationale contre le cancer	Fondation ARC Cancer; DGOS; "la ligue contre le cancer", comity of the Saone-et-Loire; INCA(Institut National du Cancer (INCA) France); Ministry of Research(Ministry of Research and Technology of the Republic of Indonesia (RISTEK)); ligue nationale contre le cancer(Ligue nationale contre le cancer)	We thank the Fondation ARC Cancer, the INCA and DGOS and "la ligue contre le cancer", comity of the Saone-et-Loire, the Fondation ARC Cancer and DGOS for JJ, and the Ministry of Research and the ligue nationale contre le cancer for financial support to AC.	Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Baserga R, 1997, BBA-REV CANCER, V1332, pF105, DOI 10.1016/S0304-419X(97)00007-3; Becker MA, 2011, MOL ENDOCRINOL, V25, P516, DOI 10.1210/me.2010-0373; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Bianchini L, 1997, J BIOL CHEM, V272, P271; Bouchekioua-Bouzaghou K, 2014, INT J CANCER, V135, P1307, DOI 10.1002/ijc.28781; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chakraborty AK, 2010, BREAST CANCER RES TR, V120, P327, DOI 10.1007/s10549-009-0382-5; Christopoulos PF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0291-7; Cottu P, 2014, CLIN CANCER RES, V20, P4314, DOI 10.1158/1078-0432.CCR-13-3230; Dupont J, 2003, CELL CYCLE, V2, P270, DOI 10.4161/cc.2.4.408; Eram MS, 2016, ACS CHEM BIOL, V11, P772, DOI 10.1021/acschembio.5b00839; Goulet I, 2007, J BIOL CHEM, V282, P33009, DOI 10.1074/jbc.M704349200; Happerfield LC, 1997, J PATHOL, V183, P412; He X, 2010, ONCOGENE, V29, P2238, DOI 10.1038/onc.2009.513; Herrmann F, 2005, J BIOL CHEM, V280, P38005, DOI 10.1074/jbc.M502458200; Herrmann F, 2009, GENES CELLS, V14, P309, DOI 10.1111/j.1365-2443.2008.01266.x; Heskamp S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117745; Infantino S, 2010, J EXP MED, V207, P711, DOI 10.1084/jem.20091303; Ishihara H, 1998, BIOCHEM BIOPH RES CO, V252, P139, DOI 10.1006/bbrc.1998.9621; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Johnston SRD, 2010, CLIN CANCER RES, V16, P1979, DOI 10.1158/1078-0432.CCR-09-1823; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; La Rosa P, 2012, MOL ENDOCRINOL, V26, P762, DOI 10.1210/me.2011-1208; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Liao HW, 2015, J CLIN INVEST, V125, P4529, DOI 10.1172/JCI82826; Lisztwan J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2113; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Poulard C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087982; Poulard C, 2012, EMBO MOL MED, V4, P1200, DOI 10.1002/emmm.201201615; Simpson A, 2017, TARGET ONCOL, V12, P571, DOI 10.1007/s11523-017-0514-5; Soderberg Ola, 2007, Genet Eng (N Y), V28, P85, DOI 10.1007/978-0-387-34504-8_5; Song RXD, 2007, ENDOCRINOLOGY, V148, P4091, DOI 10.1210/en.2007-0240; STEWART AJ, 1992, BRIT J CANCER, V66, P640, DOI 10.1038/bjc.1992.330; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Thordarson G, 2004, BREAST CANCER RES TR, V87, P277, DOI 10.1007/s10549-004-9504-2; Tian J, 2012, J CLIN INVEST, V122, P192, DOI 10.1172/JCI42204; Totta P, 2015, MOL ENDOCRINOL, V29, P739, DOI 10.1210/me.2014-1385; Xu J, 2013, MOL CELL, V51, P5, DOI 10.1016/j.molcel.2013.05.004; Yan SC, 2015, ONCOTARGETS THER, V8, P279, DOI 10.2147/OTT.S74774; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338; Yu ZB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061627; Zhang YH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2883	49	21	21	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4015	4027		10.1038/s41388-019-0694-9	http://dx.doi.org/10.1038/s41388-019-0694-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30692633	Green Published, hybrid			2022-12-17	WOS:000468740200004
J	Ghoshal, A; Rodrigues, LC; Gowda, CP; Elcheva, IA; Liu, ZQ; Abraham, T; Spiegelman, VS				Ghoshal, Archita; Rodrigues, Lucas C.; Gowda, Chethana P.; Elcheva, Irina A.; Liu, Zhenqiu; Abraham, Thomas; Spiegelman, Vladimir S.			Extracellular vesicle-dependent effect of RNA-binding protein IGF2BP1 on melanoma metastasis	ONCOGENE			English	Article							MYC MESSENGER-RNA; CRD-BP; CODING REGION; C-MYC; NICHE FORMATION; EXPRESSION; CELLS; TRANSCRIPTION; BETA-TRCP1; PHENOTYPE	Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is a multifunctional RNA-binding protein with an oncofetal pattern of expression shown to be implicated in the development of a variety of malignancies. In this study, we explored the role and mechanisms of IGF2BP1 in melanoma development and progression. In two different in vivo models, we showed that although genetic deletion or shRNA-mediated suppression of IGF2BP1 did not affect primary tumor formation, it drastically suppressed lung metastasis. Here we demonstrated that extracellular vesicles (EVs) secreted by melanoma cells mediate the effects of IGF2BP1 on metastasis: EVs from the IGF2BP1 knockdown melanoma cells failed to promote metastasis, whereas EVs isolated from IGF2BP1-overexpressed melanoma cells further accelerated EV-induced metastasis. Moreover, the EVs from IGF2BP1 knockdown melanoma cells inhibited fibronectin deposition and accumulation of CD45(+) cells in the lungs compared with control EVs, thus blocking the pre-metastatic niche formation potential of EVs. IGF2BP1 knockdown did not affect size, number, or protein/RNA concentration of secreted EVs or their uptake by recipient cells in vitro or in vivo. However, RNA-sequencing and proteomics analysis of the EVs revealed differential expression in a number of mRNA, proteins, and miRNAs. This suggested that IGF2BP1 is intimately involved in the regulation of the cargo of EVs, thereby affecting the pro-metastatic function of melanoma-derived EVs. To the best of our knowledge, this is the first study that demonstrates the role of RNA-binding protein IGF2BP1 in EV-mediated promotion of melanoma metastasis and may provide novel avenues for the development of metastatic inhibitors.	[Ghoshal, Archita; Rodrigues, Lucas C.; Gowda, Chethana P.; Elcheva, Irina A.; Liu, Zhenqiu; Spiegelman, Vladimir S.] Penn State Univ, Coll Med, Dept Pediat, Div Pediat Hematol Oncol, Hershey, PA 17033 USA; [Abraham, Thomas] Penn State Univ, Coll Med, Dept Neural & Behav Sci, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Spiegelman, VS (corresponding author), Penn State Univ, Coll Med, Dept Pediat, Div Pediat Hematol Oncol, Hershey, PA 17033 USA.	vspiegelman@pennstatehealth.psu.edu	Abraham, Thomas/AAJ-7950-2020; Abraham, Thomas/J-7080-2014	Ghoshal, Archita/0000-0002-9210-3140; Spiegelman, Vladimir S/0000-0003-4847-155X; Abraham, Thomas/0000-0003-0750-8774	NIH [R01 AR063361]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR063361] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was supported in part by the NIH grant R01 AR063361 (VSS). We thank Dr Ze'ev Ronai for the generous gift of reagents and Dr JM Sundstrom for the help with Nanosight (TM) analysis of EVs. We thank Penn State Cancer Institute Genomics Sciences, Penn State College of Medicine Imaging Core, Flow Cytometry Core, and Molecular and Histopathology Core Facilities for help with respective data acquisition and analysis.	Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Bell JL, 2015, J CLIN ONCOL, V33, P1285, DOI 10.1200/JCO.2014.55.9880; Bosenberg M, 2006, GENESIS, V44, P262, DOI 10.1002/dvg.20205; Chen Y, 2017, ONCOGENE, V36, P4692, DOI 10.1038/onc.2017.100; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Craig EA, 2012, PIGM CELL MELANOMA R, V25, P83, DOI 10.1111/j.1755-148X.2011.00921.x; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Dimitriadis E, 2007, INT J CANCER, V121, P486, DOI 10.1002/ijc.22716; Dorayappan KDP, 2018, ONCOGENE, V37, P3806, DOI 10.1038/s41388-018-0189-0; Elcheva I, 2008, ONCOGENE, V27, P5069, DOI 10.1038/onc.2008.141; Elcheva I, 2009, MOL CELL, V35, P240, DOI 10.1016/j.molcel.2009.06.007; Ghoshal A, 2016, MOL CELL BIOCHEM, V418, P119, DOI 10.1007/s11010-016-2738-6; Goswami S, 2015, J BIOL CHEM, V290, P384, DOI 10.1074/jbc.M114.590158; Gupta S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0923-0; Hamilton KE, 2013, CARCINOGENESIS, V34, P2647, DOI 10.1093/carcin/bgt217; Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Iyer SC, 2015, MOL CELL BIOCHEM, V407, P223, DOI 10.1007/s11010-015-2471-6; Jao CY, 2008, P NATL ACAD SCI USA, V105, P15779, DOI 10.1073/pnas.0808480105; Kim T, 2018, MOL CARCINOGEN, V57, P678, DOI 10.1002/mc.22786; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Li WH, 2014, APMIS, V122, P1080, DOI 10.1111/apm.12261; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Lobb RJ, 2017, SEMIN CELL DEV BIOL, V67, P3, DOI 10.1016/j.semcdb.2017.01.004; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839; Noubissi FK, 2009, CANCER RES, V69, P8572, DOI 10.1158/0008-5472.CAN-09-1500; Oberman F, 2007, RNA, V13, P1558, DOI 10.1261/rna.559507; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Sparanese D, 2007, NUCLEIC ACIDS RES, V35, P1209, DOI 10.1093/nar/gkl1148; Stohr N, 2012, CELL ADHES MIGR, V6, P312, DOI 10.4161/cam.20628; Su YL, 2016, ONCOTARGET, V7, P68397, DOI 10.18632/oncotarget.11722; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Wang RJ, 2015, J BIOL CHEM, V290, P8938, DOI 10.1074/jbc.M114.624700; Weidle UH, 2017, CANCER GENOM PROTEOM, V14, P1, DOI 10.21873/cgp.20015; Wen SW, 2016, CANCER RES, V76, P6816, DOI 10.1158/0008-5472.CAN-16-0868	38	21	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4182	4196		10.1038/s41388-019-0797-3	http://dx.doi.org/10.1038/s41388-019-0797-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30936459	Green Accepted			2022-12-17	WOS:000468740200015
J	Zhao, XY; Reebye, V; Hitchen, P; Fan, J; Jiang, HC; Saetrom, P; Rossi, J; Habib, NA; Huang, KW				Zhao, Xiaoyang; Reebye, Vikash; Hitchen, Paul; Fan, Jia; Jiang, Hongchi; Saetrom, Pal; Rossi, John; Habib, Nagy. A.; Huang, Kai-Wen			Mechanisms involved in the activation of C/EBP alpha by small activating RNA in hepatocellular carcinoma	ONCOGENE			English	Article							CELL-CYCLE; BINDING; PROTEIN; BETA; EXPRESSION; CEBPA; REPRESSION; P21; LIP	Hepatocellular carcinoma (HCC) is generally accompanied by high mortality and low cure rate. CCAAT enhancer-binding proteins (CEBPs) are transcriptional regulators that play a key role in maintaining liver function. Altered expression of C/EBP alpha and C/EBP beta occurs in many tumours including HCC. saRNAs are small double-stranded RNAs that enhance target gene expression at the transcriptional level. In this report, we activate CEPBA with saRNAs and suppress CEBPB with siRNAs in cells that represent three different degrees of HCC. We performed functional assays to investigate the effects of enhancing C/EBP alpha and its downstream targets, p21 and albumin across these lines. We also used Mass-spectrometry (MS) subsequent to a ChIP pull-down assay to characterise the components of the protein complex involved in regulating saRNA function. Putative saRNA interacting protein candidates that were identified by MS were knocked-down with siRNAs to investigate its impact on saRNA activity. We confirmed CEBPA-saRNA decreased proliferation and migration in the differentiated lines (HepG3/Hep3B). The undifferentiated line (PLCPRF5) showed saRNA-induced increase in CEBPA but with no loss in proliferation. This effect was reversed when CEBPB was suppressed with CEBPB-siRNA. When interrogating saRNA mode of action; three saRNA interacting proteins, CTR9, HnRNPA2/B1 and DDX5 were identified by MS. Targeted knock-down of these two proteins (by siRNA) abrogated saRNA activity. This study provides insight into how different HCC lines are affected by CEBPA-saRNAs and that endogenous abundance of CEBPB and saRNA accessory proteins may dictate efficacy of CEBPA-saRNA when used in a therapeutic context.	[Zhao, Xiaoyang; Reebye, Vikash; Habib, Nagy. A.] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp, HPB Surg Unit, London W12 0HS, England; [Zhao, Xiaoyang; Fan, Jia] Fudan Univ, Zhongshan Hosp, Dept Surg, Shanghai 200032, Peoples R China; [Zhao, Xiaoyang; Jiang, Hongchi] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Harbin 150001, Heilongjiang, Peoples R China; [Hitchen, Paul] Imperial Coll London, Dept Life Sci, London SW7 2AZ, England; [Saetrom, Pal] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, NO-7489 Trondheim, Norway; [Saetrom, Pal] Norwegian Univ Sci & Technol, Dept Comp Sci, NO-7489 Trondheim, Norway; [Rossi, John] City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Duarte, CA 91010 USA; [Huang, Kai-Wen] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Huang, Kai-Wen] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan; [Huang, Kai-Wen] Natl Taiwan Univ, Grad Inst Clin Med, Taipei, Taiwan	Imperial College London; Fudan University; Harbin Medical University; Imperial College London; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); City of Hope; Beckman Research Institute of City of Hope; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Huang, KW (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan.; Huang, KW (corresponding author), Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan.; Huang, KW (corresponding author), Natl Taiwan Univ, Grad Inst Clin Med, Taipei, Taiwan.	skywing@ntuh.gov.tw	Sætrom, Pål/AAH-1216-2019	Sætrom, Pål/0000-0001-8142-7441; HUANG, KAI-WEN/0000-0001-6375-8714	National Taiwan University Hospital and Imperial College London	National Taiwan University Hospital and Imperial College London	This work was funded by National Taiwan University Hospital and Imperial College London.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Begay V, 2015, J MOL MED, V93, P39, DOI 10.1007/s00109-014-1215-5; Bertran E, 2013, HEPATOLOGY, V58, P2032, DOI 10.1002/hep.26597; Burgess-Beusse BL, 1999, HEPATOLOGY, V29, P597, DOI 10.1002/hep.510290245; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Huan HB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153117; Jakobsen JS, 2013, GENOME RES, V23, P592, DOI 10.1101/gr.146399.112; Kuttippurathu L, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2492-x; LOPEZCABRERA M, 1991, VIROLOGY, V183, P825, DOI 10.1016/0042-6822(91)91019-D; Lourenco AR, 2017, ONCOGENE, V14, P1; Luedde T, 2004, HEPATOLOGY, V40, P356, DOI 10.1002/hep.20333; Ohkoshi S, 2015, WORLD J GASTROENTERO, V21, P12150, DOI 10.3748/wjg.v21.i42.12150; Pabst T, 2009, CLIN CANCER RES, V15, P5303, DOI 10.1158/1078-0432.CCR-08-2941; Portnoy V, 2016, CELL RES, V26, P320, DOI 10.1038/cr.2016.22; Reebye V, 2018, ONCOGENE, V37, P3216, DOI 10.1038/s41388-018-0126-2; Reebye V, 2014, HEPATOLOGY, V59, P216, DOI 10.1002/hep.26669; Tomizawa M, 2002, INT J MOL MED, V9, P597; van der Krieken SE, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/324815; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Voutila J, 2017, MOL THER, V25, P2705, DOI 10.1016/j.ymthe.2017.07.018; Welm AL, 2000, J BIOL CHEM, V275, P27406; Xu L, 2001, CANCER RES, V61, P3176; ZHOU DX, 1991, J BIOL CHEM, V266, P23416; Zuo Y, 2006, J BIOL CHEM, V281, P7960, DOI 10.1074/jbc.M510682200	25	21	21	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3446	3457		10.1038/s41388-018-0665-6	http://dx.doi.org/10.1038/s41388-018-0665-6			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30643190				2022-12-17	WOS:000466610000009
J	Liu, SM; Yin, P; Kujawa, SA; Coon, JS; Okeigwe, I; Bulun, SE				Liu, Shimeng; Yin, Ping; Kujawa, Stacy A.; Coon, John S.; Okeigwe, Ijeoma; Bulun, Serdar E.			Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma	ONCOGENE			English	Article							OSTEOCLAST DIFFERENTIATION; TRANSCRIPTIONAL REGULATION; MEDIATOR; LIGAND; GENE; MUTATIONS; PATHWAY; CANCER	Progesterone and its receptor, PR, are essential for uterine leiomyoma (LM, a.k.a., fibroid) tumorigenesis, but the underlying cellular and molecular mechanisms remain unclear. The receptor activator of NF-kappa B (RANKL) was recently identified as a novel progesterone/PR-responsive gene that plays an important role in promoting LM growth. Here, we used RANKL as a representative gene to investigate how steroid hormone, genetic, and epigenetic signals are integrated to regulate LM stem cell (LSC) function. We demonstrated that RANKL specifically upregulates LSC proliferation through activation of Cyclin D1. RANKL gene transcription was robustly induced by the progesterone agonist R5020, leading to a dramatically higher RANKL expression in LM compared to adjacent myometrial (MM) tissue. MethylCap-Seq revealed a differentially methylated region (DMR) adjacent to the distal PR-binding site (PRBS) 87 kb upstream of the RANKL transcription start site. Hypermethylation of the DMR inhibited recruitment of PR to the adjacent PRBS. Luciferase assays indicated that the DMR and distal PRBS constitute a novel RANKL distal regulatory element that actively regulates RANKL expression. Furthermore, MED12 physically interacts with PR in LM tissue. The interaction between MED12 and PR, binding of PR and MED12 to PRBS, and RANKL gene expression are significantly higher in LM containing a distinct MED12 mutation (G44D) than in LM with wild-type MED12. In summary, our findings suggest that DNA methylation and MED12 mutation together constitute a complex regulatory network that affects progesterone/PR-mediated RANKL gene expression, with an important role in activating stem cell proliferation and fibroid tumor development.	[Liu, Shimeng; Yin, Ping; Kujawa, Stacy A.; Coon, John S.; Okeigwe, Ijeoma; Bulun, Serdar E.] Northwestern Univ, Div Reprod Sci Med, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Bulun, SE (corresponding author), Northwestern Univ, Div Reprod Sci Med, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA.	s-bulun@northwestern.edu			NIH [P01 HD057877]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD057877] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH grant P01 HD057877 to SB.	Acevedo ML, 2003, MOL CELL BIOL, V23, P335, DOI 10.1128/MCB.23.1.335-348.2003; Aranda-Orgilles B, 2016, CELL STEM CELL, V19, P784, DOI 10.1016/j.stem.2016.08.004; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Banaganapalli B, 2016, J CELL BIOCHEM, V117, P2023, DOI 10.1002/jcb.25499; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bonifacino Juan S, 2016, CURR PROTOC CELL BIO, V71; Borahay MA, 2015, MOL MED, V21, P242, DOI 10.2119/molmed.2014.00053; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; Bulun SE, 2013, NEW ENGL J MED, V369, P1344, DOI 10.1056/NEJMra1209993; Catherino WH, 2011, FERTIL STERIL, V95, P9, DOI 10.1016/j.fertnstert.2010.08.049; Chen W, 2007, NUCLEIC ACIDS RES, V35, P6161, DOI 10.1093/nar/gkm661; Delgado-Calle J, 2012, EPIGENETICS-US, V7, P83, DOI 10.4161/epi.7.1.18753; Flaque MCD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3587; Dyson MT, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004158; Faivre EJ, 2008, MOL ENDOCRINOL, V22, P823, DOI 10.1210/me.2007-0437; Fan X, 2004, J CELL BIOCHEM, V93, P807, DOI 10.1002/jcb.20217; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gonzalez-Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495; Hagege H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hsu PY, 2016, ONCOGENE, V35, P2379, DOI 10.1038/onc.2015.298; Hu H, 2014, BREAST CANCER RES TR, V146, P515, DOI 10.1007/s10549-014-3049-9; Hu Y, 2008, BIOCHEM BIOPH RES CO, V370, P440, DOI 10.1016/j.bbrc.2008.03.106; Ikhena DE, 2018, J CLIN ENDOCR METAB, V103, P1842, DOI 10.1210/jc.2017-01585; Ishikawa H, 2010, ENDOCRINOLOGY, V151, P2433, DOI 10.1210/en.2009-1225; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kiesel L, 2016, MATURITAS, V86, P10, DOI 10.1016/j.maturitas.2016.01.001; Kim JJ, 2013, ENDOCR REV, V34, P130, DOI 10.1210/er.2012-1043; Klug M., 2014, EPIGENETICS, V1, P127, DOI DOI 10.4161/EPI.1.3.3327; Klug M, 2006, EPIGENETICS-US, V1, P127, DOI 10.4161/epi.1.3.3327; Li Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1412-9; Makinen N, 2011, SCIENCE, V334, P252, DOI 10.1126/science.1208930; Malik M, 2012, MATRIX BIOL, V31, P389, DOI 10.1016/j.matbio.2012.09.005; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Mittal P, 2015, J CLIN INVEST, V125, P3280, DOI 10.1172/JCI81534; Navarro A, 2014, J CLIN ENDOCR METAB, V99, pE2437, DOI 10.1210/jc.2014-2264; Navarro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033284; Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774; Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Ono M, 2013, P NATL ACAD SCI USA, V110, P17053, DOI 10.1073/pnas.1313650110; Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Renema N, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160150; Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387; Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284; Tanos T, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005654; Turunen M, 2014, CELL REP, V7, P654, DOI 10.1016/j.celrep.2014.03.047; Yin P, 2015, J CLIN ENDOCR METAB, V100, pE601, DOI 10.1210/jc.2014-2134; Yin P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029021	50	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2722	2735		10.1038/s41388-018-0612-6	http://dx.doi.org/10.1038/s41388-018-0612-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30538295	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000464121600004
J	Ahodantin, J; Bou-Nader, M; Cordier, C; Megret, J; Soussan, P; Desdouets, C; Kremsdorf, D				Ahodantin, James; Bou-Nader, Myriam; Cordier, Corinne; Megret, Jerome; Soussan, Patrick; Desdouets, Chantal; Kremsdorf, Dina			Hepatitis B virus X protein promotes DNA damage propagation through disruption of liver polyploidization and enhances hepatocellular carcinoma initiation	ONCOGENE			English	Article							HBX PROTEIN; CELL-DEATH; KINASE; REPLICATION; P38; EXPRESSION; INCREASES; REPAIR; HEPATOCYTES; INHIBITION	Hepatitis B virus X protein (HBx) contributes to Hepatitis B virus (HBV)-related liver cancer. However, its impact on hepatocyte proliferation and genomic stability remains elusive. We studied the role of HBx expression on the progression of cell cycle and liver polyploidization during proliferation and liver carcinogenesis. Full-length HBx transgenic mice (FL-HBx) were developed to investigate liver ploidy as well as hepatocyte proliferation, along normal liver maturation and during cancer initiation (chemical carcinogen treatment). Investigation of postnatal liver development in FL-HBx showed an aberrant G1/S and G2/M transitions, triggered (1) a delay of the formation of hepatocytes binucleation, (2) the early synthesis of polyploidy nuclei (>= 4n) and (3) DNA damage appearance. Moreover, HBV infection during hepatocytes proliferation in a humanized liver mouse model led, to modifications in polyploidy of hepatocytes. In initiation of hepatocellular carcinoma, FL-HBx protein decreased ChK1 phosphorylation, Mre11 and Rad51 expression, upregulated IL-6 expression and impaired apoptosis. This was related to DNA damage accumulation in FL-HBx mice. At day 75 after initiation of hepatocellular carcinoma, FL-HBx mice revealed significant cell cycle changes related to the increased amount of 4n nuclei and of markers of cancer progenitor cells. Finally, PLK1 upregulation and p38/ERK activation in FL-HBx mice were implicated in aberrant polyploidization favoring DNA damage propagation and hepatocyte transformation. In conclusion, our data indicate that FL-HBx protein increases DNA damage through the hijack of hepatocyte polyploidization. That leads to enhancement of hepatocellular carcinoma initiation in an inflammatory context.	[Ahodantin, James; Soussan, Patrick; Kremsdorf, Dina] Inserm U1135 CIMI Paris, Team Persistent Viral Infect, Paris, France; [Ahodantin, James; Soussan, Patrick; Kremsdorf, Dina] Univ Paris 06, Paris, France; [Ahodantin, James; Soussan, Patrick; Kremsdorf, Dina] CNRS, ERL 8255, Paris, France; [Bou-Nader, Myriam; Desdouets, Chantal] INSERM, Inst Cochin, U1016, Paris, France; [Bou-Nader, Myriam; Desdouets, Chantal] CNRS, UMR8104, Paris, France; [Bou-Nader, Myriam; Desdouets, Chantal] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Cordier, Corinne; Megret, Jerome] Inserm US24, CNRS UMS 3633, SFR Necker, Cytometry Core Facil, Paris, France; [Cordier, Corinne; Megret, Jerome] Paris Descartes, Fac Med, Paris, France	UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kremsdorf, D (corresponding author), Inserm U1135 CIMI Paris, Team Persistent Viral Infect, Paris, France.; Kremsdorf, D (corresponding author), Univ Paris 06, Paris, France.; Kremsdorf, D (corresponding author), CNRS, ERL 8255, Paris, France.	dina.kremsdorf@inserm.fr	Ahodantin, James/AAB-7216-2022; Cordier, Corinne/F-9966-2018; soussan, patrick/O-9801-2017; Ahodantin, James/AAK-3326-2020	Ahodantin, James/0000-0003-4405-2593; Cordier, Corinne/0000-0003-4799-6143; soussan, patrick/0000-0003-2706-7371; Ahodantin, James/0000-0003-4405-2593	Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) [AO 2014-1 16032]; Ligue Contre le Cancer [RS16/75-7, 2017 RS17/75-23]; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Pierre et Marie Curie (UPMC); ANRS doctoral grant	Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS)(ANRSFrench National Research Agency (ANR)); Ligue Contre le Cancer(Ligue nationale contre le cancer); Institut National de la Sante et de la Recherche Medicale (Inserm)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite Pierre et Marie Curie (UPMC); ANRS doctoral grant	This work was supported by grants from the Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) (AO 2014-1 16032), Ligue Contre le Cancer (2016, RS16/75-7 and 2017 RS17/75-23), Institut National de la Sante et de la Recherche Medicale (Inserm) and Universite Pierre et Marie Curie (UPMC). J.A. was supported by an ANRS doctoral grant.	Awad MM, 2000, J BIOL CHEM, V275, P38716, DOI 10.1074/jbc.M008040200; Bandopadhyay M, 2016, INFECT AGENTS CANCER, V11, DOI 10.1186/s13027-016-0085-6; Bontron S, 2002, J BIOL CHEM, V277, P38847, DOI 10.1074/jbc.M205722200; Brezillon N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025096; Celton-Morizur S, 2009, J CLIN INVEST, V119, P1880, DOI 10.1172/JCI38677; Chaisaingmongkol J, 2017, CANCER CELL, V32, P57, DOI 10.1016/j.ccell.2017.05.009; Cheng B, 2010, LIVER INT, V30, P319, DOI 10.1111/j.1478-3231.2009.02167.x; Dan Yue, 2016, Sci Rep, V6, P24430, DOI 10.1038/srep24430; Desdouets C, 2015, ONCOTARGET, V6, P8430, DOI 10.18632/oncotarget.3809; Duncan AW, 2012, GASTROENTEROLOGY, V142, P25, DOI 10.1053/j.gastro.2011.10.029; Duncan AW, 2010, NATURE, V467, P707, DOI 10.1038/nature09414; Forgues M, 2003, MOL CELL BIOL, V23, P5282, DOI 10.1128/MCB.23.15.5282-5292.2003; Gentric G, 2015, J CLIN INVEST, V125, P981, DOI 10.1172/JCI73957; Gentric G, 2014, AM J PATHOL, V184, P322, DOI 10.1016/j.ajpath.2013.06.035; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; He GB, 2013, CELL, V155, P384, DOI 10.1016/j.cell.2013.09.031; He ZL, 2009, WORLD J GASTROENTERO, V15, P4177, DOI 10.3748/wjg.15.4177; Kawai H, 2000, HEPATOLOGY, V31, P1246, DOI 10.1053/jhep.2000.7298; Kew MC, 2011, J GASTROEN HEPATOL, V26, P144, DOI 10.1111/j.1440-1746.2010.06546.x; Kim S, 2015, J GEN VIROL, V96, P2242, DOI 10.1099/vir.0.000150; KUDRYAVTSEV BN, 1993, VIRCHOWS ARCH B, V64, P387, DOI 10.1007/BF02915139; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021; Margall-Ducos G, 2007, J CELL SCI, V120, P3633, DOI 10.1242/jcs.016907; Na TY, 2016, ONCOGENE, V35, P5435, DOI 10.1038/onc.2016.82; Pandey V, 2012, J BIOL CHEM, V287, P20545, DOI 10.1074/jbc.M112.359760; Pandit SK, 2013, TRENDS CELL BIOL, V23, P556, DOI 10.1016/j.tcb.2013.06.002; Parrilla A, 2016, CELL CYCLE, V15, P3177, DOI 10.1080/15384101.2016.1249544; Qadri I, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-48; Qiao L, 2001, HEPATOLOGY, V34, P906, DOI 10.1053/jhep.2001.28886; Quetier I, 2015, J GEN VIROL, V96, P614, DOI 10.1099/vir.0.070680-0; Quetier I, 2013, J HEPATOL, V59, P285, DOI 10.1016/j.jhep.2013.03.021; Rakotomalala L, 2008, J BIOL CHEM, V283, P28729, DOI 10.1074/jbc.M802751200; Schmit TL, 2007, MOL CANCER THER, V6, P1920, DOI 10.1158/1535-7163.MCT-06-0781; Studach L, 2010, J BIOL CHEM, V285, P30282, DOI 10.1074/jbc.M109.093963; Studach LL, 2009, HEPATOLOGY, V50, P414, DOI 10.1002/hep.22996; Tarn C, 2002, J VIROL, V76, P9763, DOI 10.1128/JVI.76.19.9763-9772.2002; Tormos AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171738; Toyoda H, 2005, GUT, V54, P297, DOI 10.1136/gut.2004.043893; Wang C, 2012, HEPATOLOGY, V55, P108, DOI 10.1002/hep.24675; Wang SN, 2012, EUR J CLIN INVEST, V42, P1295, DOI 10.1111/eci.12003; Wang YL, 2016, ONCOTARGET, V7, P11284, DOI 10.18632/oncotarget.7022; Wong VWS, 2009, INT J CANCER, V124, P2766, DOI 10.1002/ijc.24281; Wu BK, 2006, BIOCHEM BIOPH RES CO, V340, P916, DOI 10.1016/j.bbrc.2005.12.089; Yun C, 2004, MOL CANCER RES, V2, P159	45	21	25	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2645	2657		10.1038/s41388-018-0607-3	http://dx.doi.org/10.1038/s41388-018-0607-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30538294				2022-12-17	WOS:000463335200014
J	Pan, WW; Moroishi, T; Koo, JH; Guan, KL				Pan, Wei-Wei; Moroishi, Toshiro; Koo, Ja Hyun; Guan, Kun-Liang			Cell type-dependent function of LATS1/2 in cancer cell growth	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PATHWAY; ORGAN SIZE CONTROL; HIPPO PATHWAY; TEAD/TEF FAMILY; YAP; GENE; INACTIVATION; INHIBITION; YAP/TAZ; ROLES	The Hippo pathway controls organ size and tissue homeostasis, and its dysregulation often contributes to tumorigenesis. Extensive studies have shown that the Hippo pathway inhibits cell proliferation, and survival in a cell-autonomous manner. We examined the function of the Hippo pathway kinases LATS1/2 (large tumor suppressor 1 and 2) in cancer cells. As expected, loss of LATS1/2 promotes cancer cell growth in most cell lines. Surprisingly, however, LATS1/2 deletion inhibits the growth of murine MC38 colon cancer cells, especially under detachment conditions. This growth inhibitory effect caused by LATS1/2 deletion is due to uncontrolled activation of Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), the key downstream transcriptional coactivators inhibited by LATS1/2. We identified Wnt inducible signaling pathway protein 2 (Wisp2) and coiled-coil domain containing 80 (Ccdc80) as direct targets of YAP/TAZ. Their expression is selectively induced by LATS1/2 deletion in MC38 cells. Furthermore, deletion of WISP2 and CCDC80 prevents the growth inhibitory effect of LATS1/2 loss in MC38 cells. Our study demonstrates that the function of LATS1/2 in cell growth is cell context dependent, suggesting that LATS1/2 inhibition can be a therapeutic approach for some cancer types.	[Pan, Wei-Wei; Moroishi, Toshiro; Koo, Ja Hyun; Guan, Kun-Liang] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Pan, Wei-Wei; Moroishi, Toshiro; Koo, Ja Hyun; Guan, Kun-Liang] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Pan, Wei-Wei] Jiaxing Univ, Sch Med, Jiaxing 314001, Peoples R China; [Moroishi, Toshiro] Kumamoto Univ, Fac Life Sci, Dept Mol Enzymol, Kumamoto 8608556, Japan; [Moroishi, Toshiro] Kumamoto Univ, Fac Life Sci, Ctr Metab Regulat Hlth Aging, Kumamoto 8608556, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Jiaxing University; Kumamoto University; Kumamoto University	Pan, WW; Guan, KL (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.; Pan, WW; Guan, KL (corresponding author), Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.; Pan, WW (corresponding author), Jiaxing Univ, Sch Med, Jiaxing 314001, Peoples R China.	aidspan@163.com; kuguan@ucsd.edu	Koo, Ja Hyun/GQP-5440-2022; Guan, Kun-Liang/ADK-7088-2022	Koo, Ja Hyun/0000-0001-5738-1105; Moroishi, Toshiro/0000-0001-6419-3882	National Institutes of Health [CA196878, CA217642, GM51586]; National Natural Science Foundation of China [31871402, 81402162]; Natural Science Foundation of Zhejiang Province [LY17H160060]; NATIONAL CANCER INSTITUTE [R35CA196878, R01CA217642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051586] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Zhipeng Meng, Rui Chen, Shenghong Ma, Zhengming Wu, Kimberly C, Lin and Min Luo for technical assistance; JiaYu Chen and Xiangdong Fu for help in bioinformatics analysis. This work was supported by grants from the National Institutes of Health (CA196878, CA217642, and GM51586) to K.L.G. This study was supported by grants from National Natural Science Foundation of China (31871402, 81402162), and the Natural Science Foundation of Zhejiang Province (LY17H160060) to W.W.P.	Baia GS, 2012, MOL CANCER RES, V10, P904, DOI 10.1158/1541-7786.MCR-12-0116; Barreto SC, 2016, J BUON, V21, P1359; Barry ER, 2013, CURR OPIN CELL BIOL, V25, P247, DOI 10.1016/j.ceb.2012.12.006; Barry ER, 2013, NATURE, V493, P106, DOI 10.1038/nature11693; Bommer GT, 2005, J BIOL CHEM, V280, P7962, DOI 10.1074/jbc.M412593200; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cottini F, 2014, NAT MED, V20, P599, DOI 10.1038/nm.3562; Dhar G, 2008, CANCER RES, V68, P4580, DOI 10.1158/0008-5472.CAN-08-0316; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Ferraro A, 2013, J CLIN ENDOCR METAB, V98, P2834, DOI 10.1210/jc.2012-2926; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Herbst A, 2011, ONCOL LETT, V2, P981, DOI 10.3892/ol.2011.356; Huang HY, 2017, CANCER RES, V77, P5769, DOI 10.1158/0008-5472.CAN-17-0449; Ji JF, 2015, BRIT J CANCER, V113, P921, DOI 10.1038/bjc.2015.285; Jiao S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14058; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Murakami H, 2011, CANCER RES, V71, P873, DOI 10.1158/0008-5472.CAN-10-2164; Oh JE, 2015, J NEUROPATH EXP NEUR, V74, P952, DOI 10.1097/NEN.0000000000000238; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; Wang Z, 2017, CANCER RES, V77, P2413, DOI 10.1158/0008-5472.CAN-16-3229; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; Yimlamai D, 2015, J HEPATOL, V63, P1491, DOI 10.1016/j.jhep.2015.07.008; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	39	21	22	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2595	2610		10.1038/s41388-018-0610-8	http://dx.doi.org/10.1038/s41388-018-0610-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531839	Green Submitted, Green Accepted			2022-12-17	WOS:000463335200011
J	Urtishak, KA; Wang, LS; Culjkovic-Kraljacic, B; Davenport, JW; Porazzi, P; Vincent, TL; Teachey, DT; Tasian, SK; Moore, JS; Seif, AE; Jin, SH; Barrett, JS; Robinson, BW; Chen, IML; Harvey, RC; Carroll, MP; Carroll, AJ; Heerema, NA; Devidas, M; Dreyer, ZE; Hilden, JM; Hunger, SP; Willman, CL; Borden, KLB; Felix, CA				Urtishak, Karen A.; Wang, Li-San; Culjkovic-Kraljacic, Biljana; Davenport, James W.; Porazzi, Patrizia; Vincent, Tiffaney L.; Teachey, David T.; Tasian, Sarah K.; Moore, Jonni S.; Seif, Alix E.; Jin, Shenghao; Barrett, Jeffrey S.; Robinson, Blaine W.; Chen, I-Ming L.; Harvey, Richard C.; Carroll, Martin P.; Carroll, Andrew J.; Heerema, Nyla A.; Devidas, Meenakshi; Dreyer, ZoAnn E.; Hilden, Joanne M.; Hunger, Stephen P.; Willman, Cheryl L.; Borden, Katherine L. B.; Felix, Carolyn A.			Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; INITIATION-FACTOR EIF4E; GENE-EXPRESSION; PROGNOSTIC-FACTORS; IMPROVED SURVIVAL; DRUG-RESISTANCE; ANTIVIRAL DRUG; RNA REGULON; CELL-CYCLE; FACTOR 4E	The poor outcomes in infant acute lymphoblastic leukemia (ALL) necessitate new treatments. Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has anticancer properties through EIF4E inhibition, as a potential treatment. We find that ribavirin treatment of actively dividing infant ALL cells on bone marrow stromal cells (BMSCs) at clinically achievable concentrations causes robust proliferation inhibition in proportion with EIF4E expression. Further, we find that ribavirin treatment of KMT2A-rearranged (KMT2A-R) infant ALL cells and the KMT2A-AFF1 cell line RS4:11 inhibits EIF4E, leading to decreases in oncogenic EIF4E-regulated cell growth and survival proteins. In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin-treated RS4:11 cells exhibit impaired EIF4E-dependent nuclear to cytoplasmic export and/or translation of the corresponding mRNAs, as well as reduced phosphorylation of the p-AKT1, p-EIF4EBP1, p-RPS6 and p-EIF4E signaling proteins. This leads to an S-phase cell cycle arrest in RS4:11 cells corresponding to the decreased proliferation. Ribavirin causes nuclear EIF4E to re-localize to the cytoplasm in KMT2A-AFF1 infant ALL and RS4:11 cells, providing further evidence for EIF4E inhibition. Ribavirin slows increases in peripheral blasts in KMT2A-R infant ALL xenograft-bearing mice. Ribavirin cooperates with chemotherapy, particularly L-asparaginase, in reducing live KMT2A-AFF1 infant ALL cells in BMSC co-cultures. This work establishes that EIF4E is broadly elevated across infant ALL and that clinically relevant ribavirin exposures have preclinical activity and effectively inhibit EIF4E in KMT2A-R cases, suggesting promise in EIF4E targeting using ribavirin as a means of treatment.	[Urtishak, Karen A.; Davenport, James W.; Porazzi, Patrizia; Vincent, Tiffaney L.; Teachey, David T.; Tasian, Sarah K.; Seif, Alix E.; Robinson, Blaine W.; Hunger, Stephen P.; Felix, Carolyn A.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Wang, Li-San; Moore, Jonni S.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA; [Culjkovic-Kraljacic, Biljana; Borden, Katherine L. B.] Univ Montreal, IRIC, Dept Pathol & Cell Biol, Montreal, PQ, Canada; [Teachey, David T.; Tasian, Sarah K.; Seif, Alix E.; Barrett, Jeffrey S.; Hunger, Stephen P.; Felix, Carolyn A.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Jin, Shenghao; Carroll, Martin P.] Univ Penn, Div Hematol & Oncol, Perelman Sch Med, Philadelphia, PA USA; [Barrett, Jeffrey S.] Childrens Hosp Philadelphia, Div Clin Pharmacol & Therapeut, Philadelphia, PA 19104 USA; [Chen, I-Ming L.; Harvey, Richard C.; Willman, Cheryl L.] Univ New Mexico Hlth Serv, Dept Pathol, Albuquerque, NM USA; [Chen, I-Ming L.; Harvey, Richard C.; Willman, Cheryl L.] Univ New Mexico Hlth Serv, UNM Canc Ctr, Albuquerque, NM USA; [Carroll, Andrew J.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA; [Heerema, Nyla A.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Devidas, Meenakshi] Dept Biostat, Childrens Oncol Grp, Gainesville, FL USA; [Dreyer, ZoAnn E.] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; [Hilden, Joanne M.] Childrens Hosp Colorado, Aurora, CO USA; [Hilden, Joanne M.] Univ Colorado, Sch Med, Aurora, CO USA; [Urtishak, Karen A.] NewAgeSys Inc, Princeton Jct, NJ USA; [Porazzi, Patrizia] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Barrett, Jeffrey S.] Bill & Melinda Gates Med Res Inst, Cambridge, MA USA; [Robinson, Blaine W.] Leukemia & Lymphoma Soc, Therapy Accelerat Program, Rye Brook, NY USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Universite de Montreal; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of New Mexico; University of New Mexico; University of Alabama System; University of Alabama Birmingham; University System of Ohio; Ohio State University; Children's Oncology Group (COG); Baylor College of Medicine; Texas Children's Cancer Center; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Jefferson University	Felix, CA (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.; Felix, CA (corresponding author), Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.	felix@email.chop.edu	Porazzi, Patrizia/AAA-3151-2020; Devidas, Meenakshi/H-1170-2019; Seif, Alix/B-9918-2013	Devidas, Meenakshi/0000-0002-1099-3478; Teachey, David/0000-0001-7373-8987; Porazzi, Patrizia/0000-0002-1372-7482; Tasian, Sarah/0000-0003-1327-1662; Seif, Alix/0000-0002-1799-2582	Leukemia & Lymphoma Society [SCOR 7372-07]; ASH Bridge Funding Program; CHOP Bridge Funding Program; Eagles Fly for Leukemia; CHOP Hematologic Malignancies Research Fund; SU2C St. Baldrick's Pediatric Dream Team Translational Research [SU2C-AACR-DT1113]; Cookies for Kids' Cancer Foundation; Rally Foundation [K08CA184418]; Hyundai Hope on Wheels Scholar Award [ACS MRSG-12-215-01-LIB]; Canada Research Chair [R01CA098571, R01CA080728]; COG Statistical Center [U10CA98413]; COG Specimen Banking [U24CA114766];  [R01CA198089]; NATIONAL CANCER INSTITUTE [U10CA098413, R01CA080728, R01CA098571, K08CA184418, U10CA180886, R01CA198089, P30CA016520, U10CA180899] Funding Source: NIH RePORTER	Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); ASH Bridge Funding Program; CHOP Bridge Funding Program; Eagles Fly for Leukemia; CHOP Hematologic Malignancies Research Fund; SU2C St. Baldrick's Pediatric Dream Team Translational Research; Cookies for Kids' Cancer Foundation; Rally Foundation; Hyundai Hope on Wheels Scholar Award; Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); COG Statistical Center; COG Specimen Banking; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	CAF, LSW, J.S.B., CLW, MD, and SPH supported by Leukemia & Lymphoma Society SCOR 7372-07. CAF supported by ASH Bridge Funding Program, CHOP Bridge Funding Program, Eagles Fly for Leukemia, and CHOP Hematologic Malignancies Research Fund. C.A.F. and S.K.T. supported by SU2C St. Baldrick's Pediatric Dream Team Translational Research Grant SU2C-AACR-DT1113 (SU2C is a program of Entertainment Industry Foundation administered by AACR). CAF and DTT supported by Cookies for Kids' Cancer Foundation. SKT supported by K08CA184418 and Rally Foundation for Childhood Cancer Research and was ALSF Scholar in Developmental Therapeutics. AES supported by ACS MRSG-12-215-01-LIB and Hyundai Hope on Wheels Scholar Award. MPC supported by R01CA198089. KLBB funded by R01CA098571 and R01CA080728 and holds a Canada Research Chair. Other support provided by U10CA98413 (COG Statistical Center), U24CA114766 (COG Specimen Banking).	Aebi C, 1997, J PEDIATR-US, V130, P612, DOI 10.1016/S0022-3476(97)70246-4; Asano K, 2001, COLD SPRING HARB SYM, V66, P403, DOI 10.1101/sqb.2001.66.403; ASSELIN BL, 1993, J CLIN ONCOL, V11, P1780, DOI 10.1200/JCO.1993.11.9.1780; Assouline S, 2015, HAEMATOLOGICA, V100, pE7, DOI 10.3324/haematol.2014.111245; Assouline S, 2009, BLOOD, V114, P257, DOI 10.1182/blood-2009-02-205153; Barrett D, 2012, PEDIATR DRUGS, V14, P299, DOI 10.2165/11594740-000000000-00000; Barrington-Trimis JL, 2017, INT J CANCER, V140, P1000, DOI 10.1002/ijc.30487; Biondi A, 2006, HAEMATOLOGICA, V91, P534; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Borden KLB, 2016, TRANSLATION, V4, DOI 10.1080/21690731.2016.1220899; Borden KLB, 2010, LEUKEMIA LYMPHOMA, V51, P1805, DOI 10.3109/10428194.2010.496506; Bunpo P, 2010, J NUTR, V140, P2020, DOI 10.3945/jn.110.129197; Bunpo P, 2009, J BIOL CHEM, V284, P32742, DOI 10.1074/jbc.M109.047910; Chapuis N, 2010, LEUKEMIA, V24, P1686, DOI 10.1038/leu.2010.170; Cheok MH, 2006, NAT REV CANCER, V6, P117, DOI 10.1038/nrc1800; Culjkovic B, 2008, J CELL BIOL, V181, P51, DOI 10.1083/jcb.200707018; Culjkovic B, 2006, J CELL BIOL, V175, P415, DOI 10.1083/jcb.200607020; Culjkovic B, 2007, CELL CYCLE, V6, P65, DOI 10.4161/cc.6.1.3688; Culjkovic B, 2009, J ONCOL, V2009, DOI 10.1155/2009/981679; Culjkovic-Kraljacic B, 2016, BLOOD, V127, P858, DOI 10.1182/blood-2015-05-645069; Dai DH, 2017, BIOCHEM BIOPH RES CO, V482, P1259, DOI 10.1016/j.bbrc.2016.12.025; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dordelmann M, 1999, BLOOD, V94, P1209, DOI 10.1182/blood.V94.4.1209.416k05_1209_1217; Dreyer ZE, 2015, PEDIATR BLOOD CANCER, V62, P419, DOI 10.1002/pbc.25322; Dunn LA, 2018, HEAD NECK-J SCI SPEC, V40, P233, DOI 10.1002/hed.24938; Ekins S, 2011, DRUG DISCOV TODAY, V16, P298, DOI 10.1016/j.drudis.2011.02.016; Endres CJ, 2009, J PHARMACOL EXP THER, V331, P287, DOI 10.1124/jpet.109.153130; Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597; FERSTER A, 1994, BRIT J HAEMATOL, V86, P284, DOI 10.1111/j.1365-2141.1994.tb04727.x; Frost BM, 2002, MED PEDIATR ONCOL, V38, P329, DOI 10.1002/mpo.10052; Glue P, 1999, SEMIN LIVER DIS, V19, P17; Groninger E, 2004, CRIT REV ONCOL HEMAT, V52, P173, DOI 10.1016/j.critrevonc.2004.08.007; HALL CB, 1983, NEW ENGL J MED, V308, P1443, DOI 10.1056/NEJM198306163082403; Hijiya N, 2009, CANCER-AM CANCER SOC, V115, P23, DOI 10.1002/cncr.23988; Hilden JM, 2006, BLOOD, V108, P441, DOI 10.1182/blood-2005-07-3011; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513; Hunger SP, 2012, J CLIN ONCOL, V30, P1663, DOI 10.1200/JCO.2011.37.8018; Imamura T, 2002, BRIT J HAEMATOL, V119, P119, DOI 10.1046/j.1365-2141.2002.03803.x; Isakovic AM, 2017, EXP CELL RES, V350, P32, DOI 10.1016/j.yexcr.2016.11.001; Jarvis SM, 1998, BRIT J PHARMACOL, V123, P1587, DOI 10.1038/sj.bjp.0701775; Jedema I, 2004, EXP HEMATOL, V32, P188, DOI 10.1016/j.exphem.2003.11.005; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kang HN, 2012, BLOOD, V119, P1872, DOI 10.1182/blood-2011-10-382861; Kentsis A, 2005, RNA, V11, P1762, DOI 10.1261/rna.2238705; Kentsis A, 2004, P NATL ACAD SCI USA, V101, P18105, DOI 10.1073/pnas.0406927102; KHARE GP, 1973, ANTIMICROB AGENTS CH, V3, P517, DOI 10.1128/AAC.3.4.517; Koren G, 2003, CAN MED ASSOC J, V168, P1289; Kosaka T, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.6_suppl.329; Kosaka T, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e14010; Kraljacic BC, 2011, LEUKEMIA, V25, P1197, DOI 10.1038/leu.2011.57; Krilov LR, 2002, PEDIATR INFECT DIS J, V21, P479, DOI 10.1097/00006454-200205000-00037; KRISHAN A, 1976, CANCER RES, V36, P143; Landon AL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6413; LASKIN OL, 1987, CLIN PHARMACOL THER, V41, P546, DOI 10.1038/clpt.1987.70; Lin CJ, 2009, CANCER RES, V69, P7491, DOI 10.1158/0008-5472.CAN-09-0813; LOWIS SP, 1993, CANCER RES, V53, P4881; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; Manara MC, 2013, CURR PHARM DESIGN, V19, P5344, DOI 10.2174/1381612811319300004; Matsuo Y, 1998, LEUKEMIA RES, V22, P567, DOI 10.1016/S0145-2126(98)00050-2; MCLEOD HL, 1992, BRIT J CANCER, V66, pS23; MCLEOD HL, 1993, CANCER SURV, V17, P253; Mihara K, 2003, BRIT J HAEMATOL, V120, P846, DOI 10.1046/j.1365-2141.2003.04217.x; Moore AS, 2011, J PAEDIATR CHILD H, V47, P875, DOI 10.1111/j.1440-1754.2011.02103.x; Munson ME, 2010, CYTOM PART A, V77A, P909, DOI 10.1002/cyto.a.20935; Ogino A, 2014, ONCOL LETT, V8, P2469, DOI 10.3892/ol.2014.2569; Pessetto ZY, 2013, MOL CANCER THER, V12, P1299, DOI 10.1158/1535-7163.MCT-12-0968; Pettersson F, 2015, CANCER RES, V75, P1102, DOI 10.1158/0008-5472.CAN-14-1996; Pettersson F, 2011, CLIN CANCER RES, V17, P2874, DOI 10.1158/1078-0432.CCR-10-2334; Pieters R, 2007, LANCET, V370, P240, DOI 10.1016/S0140-6736(07)61126-X; Pozarowski Piotr, 2004, Curr Protoc Cell Biol, VChapter 18, DOI [10.1002/0471142956.cy0719s25, 10.1002/0471143030.cb1808s21]; Ramakers-van Woerden NL, 2004, LEUKEMIA, V18, P521, DOI 10.1038/sj.leu.2403253; Reaman GH, 1999, J CLIN ONCOL, V17, P445, DOI 10.1200/JCO.1999.17.2.445; Riner A, 2009, POSTGRAD MED, V121, P139, DOI 10.3810/pgm.2009.05.2014; Rixe O, 2007, CLIN CANCER RES, V13, P7280, DOI 10.1158/1078-0432.CCR-07-2141; Robinson BW, 2008, BRIT J HAEMATOL, V141, P827, DOI 10.1111/j.1365-2141.2008.07100.x; Roederer M, 2011, CYTOM PART A, V79A, P95, DOI 10.1002/cyto.a.21010; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schotte D, 2011, HAEMATOL-HEMATOL J, V96, P703, DOI 10.3324/haematol.2010.026138; Scully RE, 2007, CARDIOVASC TOXICOL, V7, P122, DOI 10.1007/s12012-007-0006-4; Shi FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136746; Sidwell RW, 2005, ANTIVIR RES, V68, P10, DOI 10.1016/j.antiviral.2005.06.003; Smee Donald F., 2004, Antiviral Chemistry & Chemotherapy, V15, P261; Stam RW, 2010, BLOOD, V115, P2835, DOI 10.1182/blood-2009-07-233049; Tan J, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22007; Tan K, 2008, BIOCHEM BIOPH RES CO, V375, P341, DOI 10.1016/j.bbrc.2008.07.163; Teachey DT, 2006, BLOOD, V107, P1149, DOI 10.1182/blood-2005-05-1935; Teng LC, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-63; Topisirovic I, 2005, MOL CELL BIOL, V25, P1100, DOI 10.1128/MCB.25.3.1100-1112.2005; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Topisirovic I, 2009, MOL CELL BIOL, V29, P1152, DOI 10.1128/MCB.01532-08; Trentin L, 2009, EUR J HAEMATOL, V83, P406, DOI 10.1111/j.1600-0609.2009.01305.x; Urtishak KA, 2013, BLOOD, V121, P2689, DOI 10.1182/blood-2012-04-425033; Vallee S, 2000, EUR J PHARMACOL, V404, P49, DOI 10.1016/S0014-2999(00)00596-3; van Leeuwen IMM, 2012, CELL CYCLE, V11, P1851, DOI 10.4161/cc.20254; Volpin F, 2017, ONCOGENE, V36, P3037, DOI 10.1038/onc.2016.457; Volpon L, 2016, P NATL ACAD SCI USA, V113, P5263, DOI 10.1073/pnas.1524291113; Volpon L, 2013, BIOCHEM BIOPH RES CO, V434, P614, DOI 10.1016/j.bbrc.2013.03.125; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; WILLIS RC, 1978, P NATL ACAD SCI USA, V75, P3042, DOI 10.1073/pnas.75.7.3042; Xi CL, 2018, BIOCHEM BIOPH RES CO, V503, P2286, DOI 10.1016/j.bbrc.2018.06.150; Xu K, 2011, BRIEF BIOINFORM, V12, P341, DOI 10.1093/bib/bbr006; Yang CHT, 2017, J CLIN TRANSL HEPATO, V5, P59, DOI 10.14218/JCTH.2016.00053; Yang L, 2008, J CLIN ONCOL, V26, P1932, DOI 10.1200/JCO.2007.13.8404; Zahreddine HA, 2014, NATURE, V511, P90, DOI 10.1038/nature13283	108	21	21	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2241	2262		10.1038/s41388-018-0567-7	http://dx.doi.org/10.1038/s41388-018-0567-7			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30478448	Green Accepted			2022-12-17	WOS:000462588000002
J	Huang, X; Wang, XN; Yuan, XD; Wu, WY; Lobie, PE; Wu, ZS				Huang, Xing; Wang, Xiao-nan; Yuan, Xiao-dong; Wu, Wen-yong; Lobie, Peter E.; Wu, Zhengsheng			XIAP facilitates breast and colon carcinoma growth via promotion of p62 depletion through ubiquitination-dependent proteasomal degradation	ONCOGENE			English	Article							APOPTOSIS PROTEINS; SIGNALING ADAPTER; AUTOPHAGY; CANCER; INHIBITOR; TUMORIGENESIS; BECLIN-1	X-linked inhibitor of apoptosis protein (XIAP) possesses a critical role in promotion of cell survival and maintenance of cellular homeostasis. In cancer, elevated XIAP expression has been associated with malignancy, poor prognosis, and treatment resistance. However, the underlying mechanisms of these effects remain unclear. XIAP has previously been proposed to promote tumor growth through suppression of autophagy. In this study, we examined the expression of XIAP and p62, two critical mediators of autophagy, in breast and colon cancer. We observed a negative correlation between XIAP and p62 expression in normal and cancer tissues of breast and colon, and that the ratio of XIAP and p62 expression determines the cancer phenotype. In vitro, we observed that XIAP interacted with p62 and also that XIAP depletion resulted in increased expression of p62. XIAP functioned as an ubiquitination E3 ligase towards p62 and suppressed p62 expression through ubiquitin-proteasomal degradation. Furthermore, XIAP enhanced cancer cell proliferation, viability, and colony formation in vitro via suppression of p62. In addition, we demonstrated that XIAP-enhanced tumor growth is dependent on depletion of p62 in vivo. Herein, we have therefore delineated a novel mechanism by which XIAP contributes to development and progression of breast and colon carcinoma.	[Huang, Xing] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Key Lab Precis Diag & Treatment Hepatobiliary & P, Hangzhou 310003, Zhejiang, Peoples R China; [Wang, Xiao-nan; Yuan, Xiao-dong; Wu, Zhengsheng] Anhui Med Univ, Dept Pathol, Hefei 230032, Anhui, Peoples R China; [Huang, Xing] Southeast Univ, Inst Life Sci, Key Lab Dev Genes & Human Dis, Nanjing 210096, Jiangsu, Peoples R China; [Wu, Wen-yong] Anhui Med Univ, Dept Gen Surg, Affiliated Hosp 1, Hefei 230032, Anhui, Peoples R China; [Lobie, Peter E.] Tsinghua Univ, Tsinghua Berkeley Shenzhen Inst, Shenzhen, Guangdong, Peoples R China	Zhejiang University; Anhui Medical University; Southeast University - China; Anhui Medical University; Tsinghua University	Huang, X (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Key Lab Precis Diag & Treatment Hepatobiliary & P, Hangzhou 310003, Zhejiang, Peoples R China.; Wu, ZS (corresponding author), Anhui Med Univ, Dept Pathol, Hefei 230032, Anhui, Peoples R China.; Huang, X (corresponding author), Southeast Univ, Inst Life Sci, Key Lab Dev Genes & Human Dis, Nanjing 210096, Jiangsu, Peoples R China.	dr.huangxing@foxmail.com; woozson@yahoo.com	黄, 星/AAB-2241-2019	黄, 星/0000-0002-8886-2777; Wu, Zhengsheng/0000-0002-6616-2745	National Natural Science Foundation of China [81502975, 81472493, 81572305]; China Postdoctoral Science Foundation [2016T90413, 2015M581693]; Jiangsu Planned Projects for Postdoctoral Research Funds [1501002A]; Fundamental Research Funds for the Central Universities [2242016R20027, 2242016K41045]; Anhui provincial academic and technical leader reserve candidate [2016H074]; Key Program of Outstanding Young Talents in Higher Education Institutions of Anhui [gxyqZD2016046]; Shenzhen Development and Reform Commission Subject Construction Project [[2017]1434]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jiangsu Planned Projects for Postdoctoral Research Funds; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Anhui provincial academic and technical leader reserve candidate; Key Program of Outstanding Young Talents in Higher Education Institutions of Anhui; Shenzhen Development and Reform Commission Subject Construction Project	We deeply thank Dr. Bert Vogelstein (Johns Hopkins University) for XIAP<SUP>-/-</SUP> HCT116 and XIAP<SUP>-/-</SUP> DLD1 cell lines, Dr. Noboru Mizushima (The University of Tokyo) for Atg5<SUP>-/-</SUP> MEF cell lines, and Dr. Tao Zhu (University of Science & Technology of China) for breast cell lines. Especially, the author Xing Huang would like to express deepest thanks to Dr. Mian Wu (University of Science & Technology of China) for the technological training and ideological inspiration in his lab. This work was supported by grants from National Natural Science Foundation of China (81502975, 81472493, and 81572305), and China Postdoctoral Science Foundation (2016T90413 and 2015M581693). The research was funded in part by Jiangsu Planned Projects for Postdoctoral Research Funds (1501002A), Fundamental Research Funds for the Central Universities (2242016R20027 and 2242016K41045), Anhui provincial academic and technical leader reserve candidate (#2016H074), Key Program of Outstanding Young Talents in Higher Education Institutions of Anhui (#gxyqZD2016046) and the Shenzhen Development and Reform Commission Subject Construction Project ([2017]1434).	Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014; Fulda S, 2014, CLIN CANCER RES, V20, P289, DOI 10.1158/1078-0432.CCR-13-0227; Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Huang X, 2013, EMBO J, V32, P2204, DOI 10.1038/emboj.2013.133; Hung TH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012202; Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3; Ichimura Y, 2010, SEMIN IMMUNOPATHOL, V32, P431, DOI 10.1007/s00281-010-0220-1; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Komatsu M, 2011, AUTOPHAGY, V7, P1088, DOI 10.4161/auto.7.9.16474; Kong DK, 2010, MOL BIOL CELL, V21, P1335, DOI 10.1091/mbc.E09-09-0818; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Lee HM, 2011, J IMMUNOL, V186, P1248, DOI 10.4049/jimmunol.1001954; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Linares JF, 2011, MOL CELL BIOL, V31, P105, DOI 10.1128/MCB.00620-10; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Merlo P, 2013, EMBO J, V32, P2187, DOI 10.1038/emboj.2013.152; Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006; Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030; Moscat J, 2012, TRENDS BIOCHEM SCI, V37, P230, DOI 10.1016/j.tibs.2012.02.008; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Pandey V, 2010, ENDOCRINOLOGY, V151, P909, DOI 10.1210/en.2009-0979; Puissant A, 2012, AM J CANCER RES, V2, P397; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031; Schlafli AM, 2015, EUR J HISTOCHEM, V59, P137, DOI 10.4081/ejh.2015.2481; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Wu WY, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0108-3	32	21	22	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1448	1460		10.1038/s41388-018-0513-8	http://dx.doi.org/10.1038/s41388-018-0513-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30275562				2022-12-17	WOS:000459945800006
J	Turner, JA; Bemis, JGT; Bagby, SM; Capasso, A; Yacob, BW; Chimed, TS; Van Gulick, R; Lee, H; Tobin, R; Tentler, JJ; Pitts, T; McCarter, M; Robinson, WA; Couts, KL				Turner, Jacqueline A.; Bemis, Judson G. T.; Bagby, Stacey M.; Capasso, Anna; Yacob, Betelehem W.; Chimed, Tugs-Saikhan; Van Gulick, Robert; Lee, Hannah; Tobin, Richard; Tentler, John J.; Pitts, Todd; McCarter, Martin; Robinson, William A.; Couts, Kasey L.			BRAF fusions identified in melanomas have variable treatment responses and phenotypes	ONCOGENE			English	Article							RAF INHIBITOR RESISTANCE; TARGETED THERAPY; GENE FUSIONS; B-RAF; ACTIVATION; DIMERIZATION; MUTATIONS; PATHWAY; TUMORS	Oncogenic BRAF fusions have emerged as an alternate mechanism for BRAF activation in melanomas and other cancers. A number of BRAF fusions with different 5' gene partners and BRAF exon breakpoints have been described, but the effects of different partners and breakpoints on cancer phenotypes and treatment responses has not been well characterized. Targeted RNA sequencing was used to screen 60 melanoma patient-derived xenograft (PDX) models for BRAF fusions. We identified three unique BRAF fusions, including a novel SEPT3-BRAF fusion, occurring in four tumors (4/60, 6.7%), all of which were "pan-negative" (lacking other common mutations) (4/18, 22.2%). The BRAF fusion PDX models showed variable growth rates and responses to MAPK inhibitors in vivo. Overexpression of BRAF fusions identified in our study, as well as other BRAF fusions previously identified in melanomas, resulted in a high degree of variability in 2D proliferation and 3D invasion between the different fusions. While exogenously expressed BRAF fusions all responded to MAPK inhibition in vitro, we observed potential differences in signaling and feedback mechanisms. In summary, BRAF fusions are actionable therapeutic targets, however there are significant differences in phenotypes, treatment responses, and signaling which may be clinically relevant.	[Turner, Jacqueline A.; Bemis, Judson G. T.; Bagby, Stacey M.; Capasso, Anna; Yacob, Betelehem W.; Chimed, Tugs-Saikhan; Van Gulick, Robert; Lee, Hannah; Tentler, John J.; Pitts, Todd; Robinson, William A.; Couts, Kasey L.] Univ Colorado Denver, Dept Med, Div Med Oncol, Aurora, CO 80045 USA; [Lee, Hannah] Univ Colorado Denver, Dept Med, Internal Med Residency Training Program, Aurora, CO USA; [Tobin, Richard; McCarter, Martin] Univ Colorado Denver, Dept Surg, Div Surg Oncol, Aurora, CO USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Couts, KL (corresponding author), Univ Colorado Denver, Dept Med, Div Med Oncol, Aurora, CO 80045 USA.	kasey.couts@ucdenver.edu		Turner, Jacqueline A./0000-0002-6638-1956; Robinson, William/0000-0003-1875-9691	Melanoma Scientific Advisory Board at the University of Colorado; Amy Davis Foundation; Moore Family Foundation; Heidi Horner Foundation; Genomic and Microarray Shared Resource of Colorado's NIH/NCI Cancer Center Support Grant [P30CA046934]; NIH/N CATS CCTSI Grant [UL1 TR001082]; Cancer League of Colorado	Melanoma Scientific Advisory Board at the University of Colorado; Amy Davis Foundation; Moore Family Foundation; Heidi Horner Foundation; Genomic and Microarray Shared Resource of Colorado's NIH/NCI Cancer Center Support Grant; NIH/N CATS CCTSI Grant; Cancer League of Colorado	We thank the patients and their families for donating tissue to the International Melanoma Biorepository and Research Laboratory at the University of Colorado Cancer Center. We thank the Melanoma Scientific Advisory Board at the University of Colorado for their support. The work presented here was supported in part by the Amy Davis Foundation, the Moore Family Foundation, and the Heidi Horner Foundation. Additionally, funding was also provided by the Genomic and Microarray Shared Resource of Colorado's NIH/NCI Cancer Center Support Grant P30CA046934, NIH/N CATS CCTSI Grant UL1 TR001082, and Cancer League of Colorado.	Alatrash G, 2013, EXPERT OPIN DRUG SAF, V12, P631, DOI 10.1517/14740338.2013.795944; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bagby S, 2016, JOVE-J VIS EXP, V115, P54393; Baitei EY, 2009, J PATHOL, V217, P707, DOI 10.1002/path.2496; Baiter M, 2015, DERMATOLOGY, V231, P127, DOI 10.1159/000381849; Botton T, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12148; Brummer T, 2006, ONCOGENE, V25, P6262, DOI 10.1038/sj.onc.1209640; Couts KL, 2013, ONCOGENE, V32, P1959, DOI 10.1038/onc.2012.209; Couts KL, 2018, MOL CANCER THER, V17, P222, DOI 10.1158/1535-7163.MCT-17-0472; Feitelson MA, 2015, SEMIN CANCER BIOL, V35, pS25, DOI 10.1016/j.semcancer.2015.02.006; Fischer A, 2009, J BIOL CHEM, V284, P3183, DOI 10.1074/jbc.M804795200; Fouad YA, 2017, AM J CANCER RES, V7, P1016; Gautschi O, 2015, J THORAC ONCOL, V10, P1451, DOI 10.1097/JTO.0000000000000625; Germann UA, 2017, MOL CANCER THER, V16, P2351, DOI 10.1158/1535-7163.MCT-17-0456; Hennig A, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964-016-0128-z; Hutchinson KE, 2013, CLIN CANCER RES, V19, P6696, DOI 10.1158/1078-0432.CCR-13-1746; Jain P, 2017, ONCOTARGET, V8, P84697, DOI 10.18632/oncotarget.20949; Jiang WG, 2015, SEMIN CANCER BIOL, V35, pS244, DOI 10.1016/j.semcancer.2015.03.008; Kim HS, 2017, ONCOGENE, V36, P3334, DOI 10.1038/onc.2016.486; Klempner SJ, 2016, CANCER DISCOV, V6, P594, DOI 10.1158/2159-8290.CD-15-1192; Lavoie H, 2018, NATURE, V554, P549, DOI 10.1038/nature25478; Li E, 2012, BBA-BIOMEMBRANES, V1818, P183, DOI 10.1016/j.bbamem.2011.08.031; Linnekamp JF, 2015, CANCER RES, V75, P245, DOI 10.1158/0008-5472.CAN-14-2240; Lu HY, 2017, CANCER RES, V77, P3502, DOI 10.1158/0008-5472.CAN-16-2745; Mar VJ, 2015, BRIT J DERMATOL, V173, P76, DOI 10.1111/bjd.13756; McGranahan N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1408; Menzies AM, 2015, PIGM CELL MELANOMA R, V28, P607, DOI 10.1111/pcmr.12388; Ortore MG, 2015, BIOPHYS J, V108, P2896, DOI 10.1016/j.bpj.2015.05.015; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Scolnick JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128916; Sievert AJ, 2013, P NATL ACAD SCI USA, V110, P5957, DOI 10.1073/pnas.1219232110; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Tentler JJ, 2012, NAT REV CLIN ONCOL, V9, P338, DOI 10.1038/nrclinonc.2012.61; Turner J, 2017, PIGM CELL MELANOMA R, V30, P53, DOI 10.1111/pcmr.12560; UEKI K, 1994, J BIOL CHEM, V269, P15756; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Wang L, 2017, J MOL DIAGN, V19, P387, DOI 10.1016/j.jmoldx.2016.11.005; Weiss RH, 1998, AM J PHYSIOL-CELL PH, V274, pC1521, DOI 10.1152/ajpcell.1998.274.6.C1521	40	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1296	1308		10.1038/s41388-018-0514-7	http://dx.doi.org/10.1038/s41388-018-0514-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30254212				2022-12-17	WOS:000459249800011
J	Han, H; Yang, B; Nakaoka, HJ; Yang, JD; Zhao, YF; Le Nguyen, K; Bishara, AT; Mandalia, TK; Wang, WQ				Han, Han; Yang, Bing; Nakaoka, Hiroki J.; Yang, Jiadong; Zhao, Yifan; Le Nguyen, Kathern; Bishara, Amell Taffy; Mandalia, Tejas Krishen; Wang, Wenqi			Hippo signaling dysfunction induces cancer cell addiction to YAP	ONCOGENE			English	Article							ONCOGENE ADDICTION; TISSUE HOMEOSTASIS; PATHWAY; KINASES; INACTIVATION; ONCOPROTEIN; ACTIVATION; INHIBITORS; YAP/TAZ; LATS1/2	Over the past decades, the Hippo has been established as a crucial pathway involved in organ size control and cancer suppression. Dysregulation of Hippo signaling and hyperactivation of its downstream effector YAP are frequently associated with various human cancers. However, the underlying significance of such YAP activation in cancer development and therapy has not been fully characterized. In this study, we reported that the Hippo signaling deficiency can lead to a YAP-dependent oncogene addiction for cancer cells. Through a clinical compound library screen, we identified histone deacetylase (HDAC) inhibitors as putative inhibitors to suppress YAP expression. Importantly, HDAC inhibitors specifically targeted the viability and xenograft tumor growth for the cancer cells in which YAP is constitutively active. Taken together, our results not only establish an active YAP-induced oncogene addiction in cancer cells, but also lay the foundation to develop targeted therapies for the cancers with Hippo dysfunction and YAP activation.	[Han, Han; Yang, Bing; Nakaoka, Hiroki J.; Yang, Jiadong; Zhao, Yifan; Le Nguyen, Kathern; Bishara, Amell Taffy; Mandalia, Tejas Krishen; Wang, Wenqi] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Wang, WQ (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.	wenqiw6@uci.edu	HAN, HAN/AAC-5464-2022; han, han/HDL-7807-2022	HAN, HAN/0000-0003-2222-5270; Wang, Wenqi/0000-0003-4053-5088	American Association for Cancer Research Career Development Award for Translational Breast Cancer Research - Breast Cancer Research Foundation [16-20-26-WANG]; University of California, Irvine Chao Family Comprehensive Cancer Center; NIH [R01 GM126048]; American Cancer Society [RSG-18-009-01-CCG]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM126048] Funding Source: NIH RePORTER	American Association for Cancer Research Career Development Award for Translational Breast Cancer Research - Breast Cancer Research Foundation; University of California, Irvine Chao Family Comprehensive Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs. Steven H Lin and Junjie Chen (MD Anderson Cancer Center) for the clinical compound library. WW is a recipient of an American Association for Cancer Research Career Development Award for Translational Breast Cancer Research supported by the Breast Cancer Research Foundation (16-20-26-WANG). This work was supported by University of California, Irvine Chao Family Comprehensive Cancer Center (Pilot Project 2018) and in part by a NIH grant (R01 GM126048) and a Research Scholar Grant (RSG-18-009-01-CCG) from the American Cancer Society to WW.	Bonilla X, 2016, NAT GENET, V48, P398, DOI 10.1038/ng.3525; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Jung DE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11094-3; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Li Q, 2014, DEV CELL, V31, P291, DOI 10.1016/j.devcel.2014.09.012; Li SX, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.38; Li Y., 2016, COLD SPRING HARB PER, V6; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Meng ZP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9357; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898; Pagliarini R, 2015, EMBO REP, V16, P280, DOI 10.15252/embr.201439949; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Petrilli AM, 2016, ONCOGENE, V35, P537, DOI 10.1038/onc.2015.125; Plouffe SW, 2018, J BIOL CHEM, V293, P11230, DOI 10.1074/jbc.RA118.002715; Plouffe SW, 2016, MOL CELL, V64, P993, DOI 10.1016/j.molcel.2016.10.034; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Wang WQ, 2008, J CELL SCI, V121, P1334, DOI 10.1242/jcs.018176; Wang WQ, 2015, CELL REP, V13, P524, DOI 10.1016/j.celrep.2015.09.014; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhang WQ, 2017, J CELL MOL MED, V21, P2663, DOI 10.1111/jcmm.13182; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zheng YG, 2015, DEV CELL, V34, P642, DOI 10.1016/j.devcel.2015.08.014; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	34	21	21	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2018	37	50					6414	6424		10.1038/s41388-018-0419-5	http://dx.doi.org/10.1038/s41388-018-0419-5			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HE0WA	30068939	Green Accepted, Green Submitted			2022-12-17	WOS:000452989100003
J	Horvat, A; Noto, JM; Ramatchandirin, B; Zaika, E; Palrasu, M; Wei, JX; Schneider, BG; El-Rifai, W; Peek, RM; Zaika, AI				Horvat, Andela; Noto, Jennifer M.; Ramatchandirin, Balamurugan; Zaika, Elena; Palrasu, Manikandan; Wei, Jinxiong; Schneider, Barbara G.; El-Rifai, Wael; Peek, Richard M., Jr.; Zaika, Alexander I.			Helicobacter pylori pathogen regulates p14ARF tumor suppressor and autophagy in gastric epithelial cells	ONCOGENE			English	Article							CAGA PROTEIN; ARF; CANCER; P53; ACTIVATION; HYPERMETHYLATION; DEGRADATION; EXPRESSION; RESPONSES; DOMAIN	Infection with Helicobacter pylori is one of the strongest risk factors for development of gastric cancer. Although these bacteria infect approximately half of the world's population, only a small fraction of infected individuals develops gastric malignancies. Interactions between host and bacterial virulence factors are complex and interrelated, making it difficult to elucidate specific processes associated with H. pylori-induced tumorigenesis. In this study, we found that H. pylori inhibits p14ARF tumor suppressor by inducing its degradation. This effect was found to be strain-specific. Downregulation of p14ARF induced by H. pylori leads to inhibition of autophagy in a p53-independent manner in infected cells. We identified TRIP12 protein as E3 ubiquitin ligase that is upregulated by H. pylori, inducing ubiquitination and subsequent degradation of p14ARF protein. Using isogenic H. pylori mutants, we found that induction of TRIP12 is mediated by bacterial virulence factor CagA. Increased expression of TRIP12 protein was found in infected gastric epithelial cells in vitro and human gastric mucosa of H. pylori-infected individuals. In conclusion, our data demonstrate a new mechanism of ARF inhibition that may affect host-bacteria interactions and facilitate tumorigenic transformation in the stomach.	[Horvat, Andela; Ramatchandirin, Balamurugan; Wei, Jinxiong; Zaika, Alexander I.] Vanderbilt Univ, Dept Surg, Med Ctr, Nashville, TN 37240 USA; [Horvat, Andela; Ramatchandirin, Balamurugan; Wei, Jinxiong; Zaika, Alexander I.] Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Noto, Jennifer M.; Schneider, Barbara G.; Peek, Richard M., Jr.] Vanderbilt Univ, Med Ctr, Div Gastroenterol, Nashville, TN USA; [Zaika, Elena; Palrasu, Manikandan; El-Rifai, Wael; Zaika, Alexander I.] Univ Miami, Dept Surg, Miami, FL 33136 USA; [Zaika, Alexander I.] Miami VA Healthcare Syst, Dept Vet Affairs, Miami, FL 33125 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Miami	Zaika, AI (corresponding author), Vanderbilt Univ, Dept Surg, Med Ctr, Nashville, TN 37240 USA.; Zaika, AI (corresponding author), Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.; Zaika, AI (corresponding author), Univ Miami, Dept Surg, Miami, FL 33136 USA.; Zaika, AI (corresponding author), Miami VA Healthcare Syst, Dept Vet Affairs, Miami, FL 33125 USA.	axz353@med.miami.edu	Ramatchandirin, Balamurugan/AAB-7958-2020	Ramatchandirin, Balamurugan/0000-0003-0390-1878; Horvat, Andela/0000-0002-5771-2434	National Cancer Institute [CA206564, R01 CA138833]; Department of Veterans Affairs [BX002115]; Vanderbilt Ingram Cancer Center [P30 CA68485]; Vanderbilt Digestive Disease Research Center [DK058404]; NATIONAL CANCER INSTITUTE [R01CA077955, P01CA116087, R01CA206564, P30CA068485, R01CA138833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058587, P30DK058404] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002115] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Veterans Affairs(US Department of Veterans Affairs); Vanderbilt Ingram Cancer Center; Vanderbilt Digestive Disease Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	We thank Drs. Maria B. Piazuelo and Alberto G. Delgado for help with tissue processing. This work was supported by grants from the National Cancer Institute CA206564, R01 CA138833, the Department of Veterans Affairs BX002115, Vanderbilt Ingram Cancer Center (P30 CA68485), and the Vanderbilt Digestive Disease Research Center (DK058404). The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Veterans Affairs, National Institutes of Health, Vanderbilt University, or University of Miami Health Centers.	Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069; Argent RH, 2008, J MED MICROBIOL, V57, P145, DOI 10.1099/jmm.0.47465-0; Balaburski GM, 2010, TRENDS CELL BIOL, V20, P363, DOI 10.1016/j.tcb.2010.02.007; Brandt S, 2005, P NATL ACAD SCI USA, V102, P9300, DOI 10.1073/pnas.0409873102; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Budina-Kolomets A, 2013, AUTOPHAGY, V9, P1553, DOI 10.4161/auto.25831; Chen DL, 2010, NATURE, V464, P624, DOI 10.1038/nature08820; de Sablet T, 2011, GUT, V60, P1189, DOI 10.1136/gut.2010.234468; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fox JG, 2003, CANCER RES, V63, P942; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Ko A, 2012, JNCI-J NATL CANCER I, V104, P1660, DOI 10.1093/jnci/djs424; Kodaman N, 2014, P NATL ACAD SCI USA, V111, P1455, DOI 10.1073/pnas.1318093111; Kuo ML, 2004, CELL CYCLE, V3, P1367, DOI 10.4161/cc.3.11.1244; Mauvezin C, 2015, AUTOPHAGY, V11, P1437, DOI 10.1080/15548627.2015.1066957; N'Diaye EN, 2009, EMBO REP, V10, P173, DOI 10.1038/embor.2008.238; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Peek RM, 1999, CANCER RES, V59, P6124; Pimkina J, 2009, AUTOPHAGY, V5, P397, DOI 10.4161/auto.5.3.7782; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Sato F, 2006, CANCER-AM CANCER SOC, V106, P483, DOI 10.1002/cncr.21657; Sherr CJ, 2005, COLD SH Q B, V70, P129, DOI 10.1101/sqb.2005.70.004; Sherr CJ, 2012, WIRES DEV BIOL, V1, P731, DOI 10.1002/wdev.40; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wang XW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2533; Wei JX, 2015, GUT, V64, P1040, DOI 10.1136/gutjnl-2014-307295; Wei JX, 2010, GASTROENTEROLOGY, V139, P1333, DOI 10.1053/j.gastro.2010.06.018; Whitehead RH, 2009, AM J PHYSIOL-GASTR L, V296, pG455, DOI 10.1152/ajpgi.90381.2008; Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1; Zhu YL, 2005, ONCOGENE, V24, P3886, DOI 10.1038/sj.onc.1208551	33	21	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5054	5065		10.1038/s41388-018-0343-8	http://dx.doi.org/10.1038/s41388-018-0343-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29849123	Green Accepted			2022-12-17	WOS:000444405300002
J	Sirinian, C; Papanastasiou, AD; Schizas, M; Spella, M; Stathopoulos, GT; Repanti, M; Zarkadis, IK; King, TA; Kalofonos, HP				Sirinian, Chaido; Papanastasiou, Anastasios D.; Schizas, Michail; Spella, Magda; Stathopoulos, Georgios T.; Repanti, Maria; Zarkadis, Ioannis K.; King, Tari A.; Kalofonos, Haralabos P.			RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-kappa B activation and EGFR signaling	ONCOGENE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; RECEPTOR ACTIVATOR; MAMMARY-CANCER; METASTASIS; TUMORS; EXPRESSION; FAMILY; CELLS; DIFFERENTIATION; PROLIFERATION	The RANK/RANKL axis emerges as a key regulator of breast cancer initiation, progression, and metastasis. RANK-c is a RANK receptor isoform produced through alternative splicing of the TNFRSF11A (RANK) gene and a dominant-negative regulator of RANK-induced nuclear factor-kappa B (NF-kappa B) activation. Here we report that RANK-c transcript is expressed in 3.2% of cases in The Cancer Genome Atlas breast cancer cohort evenly between ER-positive and ER-negative cases. Nevertheless, the ratio of RANK to RANK-c (RANK/RANK-c) is increased in ER-negative breast cancer cell lines compared to ER-positive breast cancer cell lines. In addition, forced expression of RANK-c in ER-negative breast cancer cell lines inhibited stimuli-induced NF-kappa B activation and attenuated migration, invasion, colony formation, and adhesion of cancer cells. Further, RANK-c expression in MDA-MB-231 cells inhibited lung metastasis and colonization in vivo. The RANK-c-mediated inhibition of cancer cell aggressiveness and nuclear factor-kappa B (NF-kappa B) activation in breast cancer cells seems to rely on a RANK-c/TNF receptor-associated factor-2 (TRAF2) protein interaction. This was further confirmed by a mutated RANK-c that is unable to interact with TRAF2 and abolishes the ability to attenuate NF-kappa B activation, migration, and invasion. Additional protein interaction characterization revealed epidermal growth factor receptor (EGFR) as a novel interacting partner for RANK-c in breast cancer cells with a negative effect on EGFR phosphorylation and EGF-dependent downstream signaling pathway activation. Our findings further elucidate the complex molecular biology of the RANKL/RANK system in breast cancer and provide preliminary data for RANK-c as a possible marker for disease progression and aggressiveness.	[Sirinian, Chaido; Papanastasiou, Anastasios D.; Kalofonos, Haralabos P.] Univ Patras, Div Oncol, Dept Med, Clin & Mol Oncol Lab, Patras, Greece; [Schizas, Michail; King, Tari A.] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA; [Spella, Magda; Stathopoulos, Georgios T.] Univ Patras, Dept Physiol, Lab Mol Resp Carcinogenesis, Fac Med, Patras, Greece; [Repanti, Maria] Patras Gen Hosp, Dept Pathol, Patras, Greece; [Zarkadis, Ioannis K.] Univ Patras, Sch Med, Dept Biol, Patras, Greece; [King, Tari A.] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Surg Oncol, Boston, MA USA	University of Patras; Memorial Sloan Kettering Cancer Center; University of Patras; University of Patras; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Papanastasiou, AD (corresponding author), Univ Patras, Div Oncol, Dept Med, Clin & Mol Oncol Lab, Patras, Greece.	apapanasta@upnet.gr	Stathopoulos, Georgios/AAE-6884-2020; Papanastasiou, Anastasios/AAP-5296-2021; Stathopoulos, Georgios/D-6576-2013	Stathopoulos, Georgios/0000-0002-9215-6461	State Scholarships Foundation "IKY Fellowships of Excellence for Postgraduate Studies in Greece-Siemens Programme" [SR 229101]; State Scholarships Foundation [SR 229101]	State Scholarships Foundation "IKY Fellowships of Excellence for Postgraduate Studies in Greece-Siemens Programme"; State Scholarships Foundation	CS is funded by the State Scholarships Foundation "IKY Fellowships of Excellence for Postgraduate Studies in Greece-Siemens Programme" (SR 229101). The research reported was partially funded by the State Scholarships Foundation (SR 229101). The publicly available dataset from the TCGA breast cancer study was retrieved from the TCGA data portal on 05/2017.	Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Blakely CM, 2015, CELL REP, V11, P98, DOI 10.1016/j.celrep.2015.03.012; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Eswaran J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01689; Forootan SS, 2016, INT J ONCOL, V48, P130, DOI 10.3892/ijo.2015.3222; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giannou AD, 2015, J CLIN INVEST, V125, P2317, DOI 10.1172/JCI79840; Gonzalez-Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014-5793(98)01731-1; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lacroix M, 2004, ENDOCR-RELAT CANCER, V11, P497, DOI 10.1677/erc.1.00758; Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992; Lopez-Garcia MA, 2010, HISTOPATHOLOGY, V57, P171, DOI 10.1111/j.1365-2559.2010.03568.x; Marazioti A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071207; Matsuda N, 2017, EXPERT OPIN INV DRUG, V26, P463, DOI 10.1080/13543784.2017.1299707; Melchor L, 2008, ONCOGENE, V27, P3165, DOI 10.1038/sj.onc.1210975; Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Ohtsuka T, 1996, J BIOL CHEM, V271, P1651, DOI 10.1074/jbc.271.3.1651; Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008-5472.CAN-12-0044; Papanastasiou Anastasios D, 2014, Curr Mol Pharmacol, V7, P33; Papanastasiou AD, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3234; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pfitzner BM, 2014, BREAST CANCER RES TR, V145, P307, DOI 10.1007/s10549-014-2955-1; Rennstam K, 2003, CANCER RES, V63, P8861; Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387; Sebestyen E, 2015, NUCLEIC ACIDS RES, V43, P1345, DOI 10.1093/nar/gku1392; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Sigl V, 2016, CELL RES, V26, P761, DOI 10.1038/cr.2016.69; Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063; Sirinian C, 2013, GENE, V525, P124, DOI 10.1016/j.gene.2013.04.075; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; Tanaka Y, 1996, J VIROL, V70, P8508, DOI 10.1128/JVI.70.12.8508-8517.1996; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Weigelt B, 2010, J PATHOL, V220, P263, DOI 10.1002/path.2648; Weigelt B, 2009, NAT REV CLIN ONCOL, V6, P718, DOI 10.1038/nrclinonc.2009.166; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoldi G, 2016, CANCER RES, V76, P5857, DOI 10.1158/0008-5472.CAN-15-2745	48	21	22	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5101	5114		10.1038/s41388-018-0324-y	http://dx.doi.org/10.1038/s41388-018-0324-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29844572				2022-12-17	WOS:000444405300006
J	McClurg, UL; Chit, NCTH; Azizyan, M; Edwards, J; Nabbi, A; Riabowol, KT; Nakjang, S; McCracken, SR; Robson, CN				McClurg, Urszula L.; Chit, Nay C. T. H.; Azizyan, Mahsa; Edwards, Joanne; Nabbi, Arash; Riabowol, Karl T.; Nakjang, Sirintra; McCracken, Stuart R.; Robson, Craig N.			Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12	ONCOGENE			English	Article							DEUBIQUITINATING ENZYME USP12; ANDROGEN RECEPTOR; RESISTANCE; INHIBITORS; MDM2; PHOSPHORYLATION; IDENTIFICATION; UBIQUITINATION; CHEMOTHERAPY; DEGRADATION	The TP53-MDM2-AR-AKT signalling network plays a critical role in the development and progression of prostate cancer. However, the molecular mechanisms regulating this signalling network are not completely defined. By conducting transcriptome analysis, denaturing immunoprecipitations and immunopathology, we demonstrate that the TP53-MDM2-AR-AKT cross-talk is regulated by the deubiquitinating enzyme USP12 in prostate cancer. Our findings explain why USP12 is one of the 12 most commonly overexpressed cancer-associated genes located near an amplified super-enhancer. We find that USP12 deubiquitinates MDM2 and AR, which in turn controls the levels of the TP53 tumour suppressor and AR oncogene in prostate cancer. Consequently, USP12 levels are predictive not only of cancer development but also of patient's therapy resistance, relapse and survival. Therefore, our findings suggest that USP12 could serve as a promising therapeutic target in currently incurable castrate-resistant prostate cancer.	[McClurg, Urszula L.; Chit, Nay C. T. H.; Azizyan, Mahsa; Nakjang, Sirintra; McCracken, Stuart R.; Robson, Craig N.] Newcastle Univ, Northern Inst Canc Res, Newcastle Canc Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [McClurg, Urszula L.] Newcastle Univ, Inst Cell & Mol Biosci, Med Sch, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Edwards, Joanne] Univ Glasgow, Inst Canc Sci, Coll Med Vet & Life Sci, Wolfson Wohl Canc Res Ctr, Glasgow G61 1QH, Lanark, Scotland; [Nabbi, Arash; Riabowol, Karl T.] Univ Calgary, Arnie Charbonneau Canc Inst, Cumming Sch Med, Dept Oncol, Calgary, AB T2N 4N1, Canada; [Nakjang, Sirintra] Newcastle Univ, Bioinformat Support Unit, Fac Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; University of Glasgow; University of Calgary; Newcastle University - UK	McClurg, UL; Robson, CN (corresponding author), Newcastle Univ, Northern Inst Canc Res, Newcastle Canc Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.; McClurg, UL (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Med Sch, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	Urszula.McClurg@ncl.ac.uk; Craig.Robson@ncl.ac.uk	Edwards, Joanne/J-1903-2015	Edwards, Joanne/0000-0002-7192-6906; Nabbi, Arash/0000-0002-3195-7361; McClurg, Urszula/0000-0003-2631-4174	PC UK [PG09-23]; JGWP Foundation [BH142412]; JRE Scientific Committee Charity; Newcastle Healthcare Charity [JG/ML/0414]; Cancer Research UK [C27826/A15994]; Newcastle University	PC UK; JGWP Foundation; JRE Scientific Committee Charity; Newcastle Healthcare Charity; Cancer Research UK(Cancer Research UK); Newcastle University	ULM, SRM and CNR were funded by PC UK (PG09-23), JGWP Foundation (BH142412) and JRE Scientific Committee Charity, Newcastle Healthcare Charity (JG/ML/0414). CNR is supported by Cancer Research UK (C27826/A15994). NCTHC was funded by Newcastle University.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Attard G, 2016, NAT REV UROL, V13, P697, DOI 10.1038/nrurol.2016.212; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Binda O, 2013, EPIGENETICS-US, V8, P177, DOI 10.4161/epi.23416; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Burska UL, 2013, J BIOL CHEM, V288, P32641, DOI 10.1074/jbc.M113.485912; Chen JJ, 2011, CHEM BIOL, V18, P1390, DOI 10.1016/j.chembiol.2011.08.014; Chen MH, 2011, CANCER CELL, V20, P173, DOI 10.1016/j.ccr.2011.07.013; Dexheimer TS, 2014, J MED CHEM, V57, P8099, DOI 10.1021/jm5010495; Dexheimer TS, 2010, PROBE REPORTS NIH MO; Dharadhar S, 2016, J STRUCT BIOL, V196, P437, DOI 10.1016/j.jsb.2016.09.011; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Edwards J, 2003, CLIN CANCER RES, V9, P5271; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Joshi S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1531-3; Kee Y, 2010, J BIOL CHEM, V285, P11252, DOI 10.1074/jbc.M109.095141; Kirkegaard T, 2006, HISTOPATHOLOGY, V48, P787, DOI 10.1111/j.1365-2559.2006.02412.x; Lee JK, 2016, NEURO-ONCOLOGY, V18, P37, DOI 10.1093/neuonc/nov091; Li H, 2016, MOL CELL, V63, P249, DOI 10.1016/j.molcel.2016.05.031; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Liu JB, 2016, INT J ONCOL, V49, P2549, DOI 10.3892/ijo.2016.3752; Lohiya V, 2016, CLIN MED INSIGHTS-ON, V10, P57, DOI 10.4137/CMO.S34535; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo WJ, 2013, BIOINFORMATICS, V29, P1830, DOI 10.1093/bioinformatics/btt285; Marques RB, 2015, EUR UROL, V67, P1177, DOI 10.1016/j.eururo.2014.08.053; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McClurg UL, 2017, NUCLEIC ACIDS RES, V45, P1793, DOI 10.1093/nar/gkw1162; McClurg UL, 2015, ONCOTARGET, V6, P37724, DOI 10.18632/oncotarget.6075; McClurg UL, 2015, ONCOTARGET, V6, P9657, DOI 10.18632/oncotarget.3922; McClurg UL, 2014, ONCOTARGET, V5, P7081, DOI 10.18632/oncotarget.2162; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Mistry H, 2013, MOL CANCER THER, V12, P2651, DOI 10.1158/1535-7163.MCT-13-0103-T; Murai J, 2011, MOL CELL BIOL, V31, P2462, DOI 10.1128/MCB.05058-11; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Poletto M, 2016, NUCLEIC ACIDS RES, V44, P3165, DOI 10.1093/nar/gkw015; Rigas AC, 2007, ONCOGENE, V26, P7611, DOI 10.1038/sj.onc.1210586; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sourisseau T, 2016, CELL CYCLE, V15, P295, DOI 10.1080/15384101.2015.1120918; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Wahi Divya, 2015, Syst Synth Biol, V9, P33, DOI 10.1007/s11693-015-9162-1; Willder JM, 2013, BRIT J CANCER, V108, P139, DOI 10.1038/bjc.2012.480; Xiong XP, 2016, J BIOL CHEM, V291, P25167, DOI 10.1074/jbc.M116.740639; Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r14; Zhang XY, 2016, NAT GENET, V48, P176, DOI 10.1038/ng.3470; Zhang ZQ, 2012, J CANCER RES CLIN, V138, P1231, DOI 10.1007/s00432-012-1193-3	51	21	21	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4679	4691		10.1038/s41388-018-0283-3	http://dx.doi.org/10.1038/s41388-018-0283-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29755129	Green Accepted, Green Submitted			2022-12-17	WOS:000442514400004
J	Zhou, W; Sun, W; Yung, MMH; Dai, S; Cai, YH; Chen, CW; Meng, YX; Lee, JB; Braisted, JC; Xu, YH; Southall, NT; Shinn, P; Huang, XF; Song, ZF; Chen, XL; Kai, Y; Cai, X; Li, ZZ; Hao, Q; Cheung, ANY; Ngan, HYS; Liu, SS; Barak, S; Hao, J; Dai, ZJ; Tzatsos, A; Peng, WQ; Pei, HD; Han, ZY; Chan, DW; Zheng, W; Zhu, WG				Zhou, Wei; Sun, Wei; Yung, Mingo M. H.; Dai, Sheng; Cai, Yihua; Chen, Chi-Wei; Meng, Yunxiao; Lee, Jennifer B.; Braisted, John C.; Xu, Yinghua; Southall, Noel T.; Shinn, Paul; Huang, Xuefeng; Song, Zhangfa; Chen, Xiulei; Kai, Yan; Cai, Xin; Li, Zongzhu; Hao, Qiang; Cheung, Annie N. Y.; Ngan, Hextan Y. S.; Liu, Stephanie S.; Barak, Stephanie; Hao, Jing; Dai, Zhijun; Tzatsos, Alexandros; Peng, Weiqun; Pei, Huadong; Han, Zhiyong; Chan, David W.; Zheng, Wei; Zhu, Wenge			Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance	ONCOGENE			English	Article							OVARIAN-CANCER; MYELOPROLIFERATIVE NEOPLASMS; POLYCYTHEMIA-VERA; MOLECULAR-MECHANISMS; DNA-DAMAGE; STAGE-III; CISPLATIN; MUTATIONS; PACLITAXEL; INHIBITORS	Antineoplastic platinum agents are used in first-line treatment of ovarian cancer, but treatment failure frequently results from platinum drug resistance. Emerging observations suggest a role of reactive oxygen species (ROS) in the resistance of cancer drugs including platinum drugs. However, the molecular link between ROS and cellular survival pathway is poorly understood. Using quantitative high-throughput combinational screen (qHTCS) and genomic sequencing, we show that in platinum-resistant ovarian cancer elevated ROS levels sustain high level of IL-11 by stimulating FRA1-mediated IL-11 expression and increased IL-11 causes resistance to platinum drugs by constitutively activating JAK2-STAT5 via an autocrine mechanism. Inhibition of JAK2 by LY2784544 or IL-11 by anti-IL-11 antibody overcomes the platinum resistance in vitro or in vivo. Significantly, clinic studies also confirm the activated IL-11-JAK2 pathway in platinum-resistant ovarian cancer patients, which highly correlates with poor prognosis. These findings not only identify a novel ROS-IL-11-JAK2-mediated platinum resistance mechanism but also provide a new strategy for using LY2784544- or IL-11-mediated immunotherapy to treat platinum-resistant ovarian cancer.	[Zhou, Wei; Cai, Yihua; Chen, Chi-Wei; Meng, Yunxiao; Lee, Jennifer B.; Cai, Xin; Li, Zongzhu; Hao, Qiang; Hao, Jing; Pei, Huadong; Han, Zhiyong; Zhu, Wenge] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20037 USA; [Zhou, Wei; Dai, Sheng; Huang, Xuefeng; Song, Zhangfa] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Colorectal Surg, Hangzhou 310016, Zhejiang, Peoples R China; [Zhou, Wei; Cai, Yihua; Chen, Chi-Wei; Meng, Yunxiao; Lee, Jennifer B.; Kai, Yan; Cai, Xin; Li, Zongzhu; Hao, Qiang; Tzatsos, Alexandros; Pei, Huadong; Zhu, Wenge] George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA; [Sun, Wei; Dai, Sheng; Braisted, John C.; Southall, Noel T.; Shinn, Paul; Zheng, Wei] Natl Ctr Adv Translat Sci, Natl Inst Hlth, Bethesda, MD 20892 USA; [Yung, Mingo M. H.; Chan, David W.] Univ Hong Kong, LKS Fac Med, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China; [Xu, Yinghua] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Med Oncol, Hangzhou 310016, Zhejiang, Peoples R China; [Chen, Xiulei] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Clin Lab, Hangzhou 310016, Zhejiang, Peoples R China; [Kai, Yan; Peng, Weiqun] George Washington Univ, Columbian Coll Arts & Sci, Dept Phys, Washington, DC 20052 USA; [Cheung, Annie N. Y.; Ngan, Hextan Y. S.; Liu, Stephanie S.] Univ Hong Kong, LKS Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Barak, Stephanie] George Washington Univ, Sch Med & Hlth Sci, Dept Pathol, Washington, DC 20037 USA; [Dai, Zhijun] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Oncol, Xian 710004, Shaanxi, Peoples R China; [Tzatsos, Alexandros] George Washington Univ, Sch Med & Hlth Sci, Dept Anat & Regenerat Biol, Washington, DC 20037 USA	George Washington University; Zhejiang University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS); University of Hong Kong; Zhejiang University; Zhejiang University; George Washington University; University of Hong Kong; George Washington University; Xi'an Jiaotong University; George Washington University	Zhu, WG (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20037 USA.; Zhu, WG (corresponding author), George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA.; Zheng, W (corresponding author), Natl Ctr Adv Translat Sci, Natl Inst Hlth, Bethesda, MD 20892 USA.; Chan, DW (corresponding author), Univ Hong Kong, LKS Fac Med, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China.	dwchan@hku.hk; wzheng@mail.nih.gov; wz6812@gwu.edu	Zheng, Wei/GQQ-8951-2022; /AAI-2516-2019; Zheng, Wei/GOE-5990-2022; Kai, Yan/ABH-8469-2020; YUNG, Mingo Ming Ho/AHB-5775-2022; dai, sheng/AGQ-0059-2022; Chan, David/O-9896-2018; Southall, Noel/H-8991-2012; Dai, Zhi-Jun/O-6826-2014; Cheung, Annie Nga Yin/C-4231-2009	Kai, Yan/0000-0003-3262-4160; YUNG, Mingo Ming Ho/0000-0003-0903-1164; Chan, David/0000-0002-6951-3467; Ngan, Hextan Y S/0000-0003-3945-159X; Chen, Chi-Wei/0000-0001-8658-055X; Southall, Noel/0000-0003-4500-880X; Dai, Zhi-Jun/0000-0001-5209-8626; Peng, Weiqun/0000-0001-5521-9091; dai, sheng/0000-0002-5387-8517; Cheung, Annie Nga Yin/0000-0002-1584-7568	National Institutes of Health [CA177898, CA184717]; McCormick Genomic and Proteomic Center; intramural research program at the National Center for Advancing Translational Sciences (NCATS); American Cancer Society [RSG-13-214-01-DMC]; National Natural Science Foundation of China [81402580]; NATIONAL CANCER INSTITUTE [R01CA184717, R01CA177898, R21CA182662, R03CA212068] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [ZIATR000018, ZICTR000242] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); McCormick Genomic and Proteomic Center; intramural research program at the National Center for Advancing Translational Sciences (NCATS); American Cancer Society(American Cancer Society); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was partially supported by funding from the National Institutes of Health (CA177898 and CA184717 to W. Zhu), the McCormick Genomic and Proteomic Center, and intramural research program at the National Center for Advancing Translational Sciences (NCATS). W Zhu was supported by a Research Scholar Grant, RSG-13-214-01-DMC from the American Cancer Society. This work was supported by the National Natural Science Foundation of China grant 81402580 to W Zhou.	Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Buchert M, 2016, ONCOGENE, V35, P939, DOI 10.1038/onc.2015.150; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025; Di Veroli GY, 2016, BIOINFORMATICS, V32, P2866, DOI 10.1093/bioinformatics/btw230; Ernst M, 2014, CLIN CANCER RES, V20, P5579, DOI 10.1158/1078-0432.CCR-13-2492; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Hanker LC, 2012, ANN ONCOL, V23, P2605, DOI 10.1093/annonc/mds203; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jazaeri AA, 2013, MOL CANCER THER, V12, P1958, DOI 10.1158/1535-7163.MCT-12-1028; Kang MA, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.134; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; LANGDON SP, 1988, CANCER RES, V48, P6166; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Ma L, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.6; Marullo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081162; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Onnis B, 2013, J CLIN INVEST, V123, P1615, DOI 10.1172/JCI59623; Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park CY, 2015, BIOINFORMATICS, V31, P1093, DOI 10.1093/bioinformatics/btu786; Quintas-Cardama A, 2013, CLIN CANCER RES, V19, P1933, DOI 10.1158/1078-0432.CCR-12-0284; Quintas-Cardama A, 2011, NAT REV DRUG DISCOV, V10, P127, DOI 10.1038/nrd3264; Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun W, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.123; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Tasdogan A, 2016, CELL STEM CELL, V19, P752, DOI 10.1016/j.stem.2016.08.007; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tyner JW, 2010, BLOOD, V115, P5232, DOI 10.1182/blood-2009-05-223727; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wu SC, 2015, CANCER CELL, V28, P29, DOI 10.1016/j.ccell.2015.06.005; Yu X, 2012, CANCER CELL, V21, P614, DOI 10.1016/j.ccr.2012.03.042	40	21	23	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3981	3997		10.1038/s41388-018-0238-8	http://dx.doi.org/10.1038/s41388-018-0238-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29662190	Green Accepted, Green Submitted			2022-12-17	WOS:000439101300006
J	Cannataro, VL; Gaffney, SG; Stender, C; Zhao, ZM; Philips, M; Greenstein, AE; Townsend, JP				Cannataro, Vincent L.; Gaffney, Stephen G.; Stender, Carly; Zhao, Zi-Ming; Philips, Mark; Greenstein, Andrew E.; Townsend, Jeffrey P.			Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C	ONCOGENE			English	Article							EGFR T790M MUTATION; ACQUIRED-RESISTANCE; INTRATUMORAL HETEROGENEITY; POPULATION-GENETICS; LUNG CANCERS; RAS; INHIBITORS; THERAPY; MUTANT; GENES	Activating mutations in RAS genes are associated with approximately 20% of all human cancers. New targeted therapies show preclinical promise in inhibiting the KRAS G12C variant. However, concerns exist regarding the effectiveness of such therapies in vivo given the possibilities of existing intratumor heterogeneity or de novo mutation leading to treatment resistance. We performed deep sequencing of 27 KRAS G12-positive lung tumors to determine the prevalence of other oncogenic mutations within KRAS or within commonly mutated downstream genes that could confer resistance at the time of treatment. We also passaged patient-derived xenografts to assess the potential for novel KRAS mutation to arise during subsequent tumor evolution. Furthermore, we estimate the de novo mutation rate in KRAS position 12 and in genes downstream of KRAS. Finally, we present an approach for estimation of the selection intensity for these point mutations that explains their high prevalence in tumors. We find no evidence of heterogeneity that may compromise KRAS G12C targeted therapy within sequenced lung tumors or passaged xenografts. We find that mutations that confer resistance are even less likely to occur downstream of KRAS than to occur within KRAS. Our approach predicts that BRAF V600E would provide the highest fitness advantage for de novo-resistant subclones. Overall, our findings suggest that resistance to targeted therapy of KRAS G12C-positive tumors is unlikely to be present at the time of treatment and, among the de novo mutations likely to confer resistance, mutations in BRAF, a gene with targeted inhibitors presently available, result in subclones with the highest fitness advantage.	[Cannataro, Vincent L.; Gaffney, Stephen G.; Stender, Carly; Zhao, Zi-Ming; Townsend, Jeffrey P.] Yale Univ, Dept Biostat, New Haven, CT 06520 USA; [Philips, Mark] NYU, Sch Med, Dept Med, New York, NY USA; [Philips, Mark] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; [Philips, Mark] NYU, Sch Med, Dept Pharmacol, New York, NY USA; [Greenstein, Andrew E.] Gilead Sci, Foster City, CA USA; [Townsend, Jeffrey P.] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA; [Townsend, Jeffrey P.] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA	Yale University; New York University; New York University; New York University; Gilead Sciences; Yale University; Yale University	Townsend, JP (corresponding author), Yale Univ, Dept Biostat, New Haven, CT 06520 USA.; Townsend, JP (corresponding author), Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA.; Townsend, JP (corresponding author), Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA.	jeffrey.townsend@yale.edu	Townsend, Jeffrey/H-2747-2019	Townsend, Jeffrey/0000-0002-9890-3907; Greenstein, Andrew/0000-0002-1470-1970; Cannataro, Vincent/0000-0002-6364-7747; Gaffney, Stephen/0000-0002-5490-2945; Mark, Philips/0000-0002-1179-8156	Gilead Sciences, Inc.; NATIONAL CANCER INSTITUTE [R01CA116034] Funding Source: NIH RePORTER	Gilead Sciences, Inc.(Gilead Sciences); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was partially funded by Gilead Sciences, Inc.	Al-Mulla F, 1998, J PATHOL, V185, P130, DOI 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M; Alsdorf WH, 2013, EXP MOL PATHOL, V94, P155, DOI 10.1016/j.yexmp.2012.09.016; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Burrell RA, 2014, MOL ONCOL, V8, P1095, DOI 10.1016/j.molonc.2014.06.005; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Bustamante CD, 2005, STAT BIOL HEALTH, P63, DOI 10.1007/0-387-27733-1_4; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Cannataro VL, 2016, EVOL APPL, V9, P565, DOI 10.1111/eva.12361; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214; Cox Adrienne D, 2010, Small GTPases, V1, P2; Desai MM, 2007, CURR BIOL, V17, P385, DOI 10.1016/j.cub.2007.01.072; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Fiala O, 2013, CANCER GENET-NY, V206, P26, DOI 10.1016/j.cancergen.2012.12.003; Fujita Y, 2012, J THORAC ONCOL, V7, P1640, DOI 10.1097/JTO.0b013e3182653d7f; Gerrish PJ, 1998, GENETICA, V102-3, P127, DOI 10.1023/A:1017067816551; Greulich Heidi, 2010, Genes Cancer, V1, P1200, DOI 10.1177/1947601911407324; Grossman RL, 2016, NEW ENGL J MED, V375, P1109, DOI 10.1056/NEJMp1607591; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hashimoto D, 2016, PANCREAS, V45, P1111, DOI 10.1097/MPA.0000000000000624; Hobbs GA, 2016, CANCER CELL, V29, P251, DOI 10.1016/j.ccell.2016.02.015; Huang LH, 2015, ACTA PHARM SIN B, V5, P390, DOI 10.1016/j.apsb.2015.07.001; Hunter JC, 2014, P NATL ACAD SCI USA, V111, P8895, DOI 10.1073/pnas.1404639111; Innan H, 2004, P NATL ACAD SCI USA, V101, P10667, DOI 10.1073/pnas.0401720101; Izar B, 2014, J THORAC ONCOL, V9, P1363, DOI 10.1097/JTO.0000000000000266; Kadara H, 2017, ANN ONCOL, V28, P75, DOI 10.1093/annonc/mdw436; Keats JJ, 2012, BLOOD, V120, P1067, DOI 10.1182/blood-2012-01-405985; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204; Lloyd MC, 2016, CANCER RES, V76, P3136, DOI 10.1158/0008-5472.CAN-15-2962; Mao CQ, 2014, MOL THER, V22, P964, DOI 10.1038/mt.2014.18; McCormick F, 2015, CLIN CANCER RES, V21, P1797, DOI 10.1158/1078-0432.CCR-14-2662; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Montalvo SK, 2017, FUTURE ONCOL, V13, P263, DOI 10.2217/fon-2016-0363; Moran PAP, 1958, MATH P CAMBRIDGE PHI, V54, P60, DOI DOI 10.1017/S0305004100033193; Mulloy R, 2007, CANCER RES, V67, P2325, DOI 10.1158/0008-5472.CAN-06-4293; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nadal E, 2014, J THORAC ONCOL, V9, P1513, DOI 10.1097/JTO.0000000000000305; Ohashi K, 2012, P NATL ACAD SCI USA, V109, pE2127, DOI 10.1073/pnas.1203530109; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Parsons TL, 2007, THEOR POPUL BIOL, V72, P121, DOI 10.1016/j.tpb.2006.11.004; Patricelli MP, 2016, CANCER DISCOV, V6, P316, DOI 10.1158/2159-8290.CD-15-1105; Porta M, 2009, MUTAT RES-REV MUTAT, V682, P83, DOI 10.1016/j.mrrev.2009.07.003; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Roberts PJ, 2013, J CLIN ONCOL, V31, P1112, DOI 10.1200/JCO.2012.43.0454; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Rozhok AI, 2016, TRENDS CANCER, V2, P552, DOI 10.1016/j.trecan.2016.09.004; SAWYER SA, 1992, GENETICS, V132, P1161; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schildhaus HU, 2015, CLIN CANCER RES, V21, P907, DOI 10.1158/1078-0432.CCR-14-0450; Schmitt MW, 2016, NAT REV CLIN ONCOL, V13, P335, DOI 10.1038/nrclinonc.2015.175; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Shima F, 2013, P NATL ACAD SCI USA, V110, P8182, DOI 10.1073/pnas.1217730110; Singh H, 2015, J CLIN ONCOL, V33, P3650, DOI 10.1200/JCO.2015.62.1052; Stewart EL, 2015, TRANSL LUNG CANCER R, V4, P67, DOI 10.3978/j.issn.2218-6751.2014.11.06; Suda K, 2009, J THORAC ONCOL, V4, P1, DOI 10.1097/JTO.0b013e3181913c9f; Svaton M, 2016, ANTICANCER RES, V36, P1077; Tougeron D, 2013, ANN ONCOL, V24, P1267, DOI 10.1093/annonc/mds620; Vilarinho S, 2014, GASTROENTEROLOGY, V146, pS495; Visscher M, 2016, CURR OPIN CHEM BIOL, V30, P61, DOI 10.1016/j.cbpa.2015.11.004; Westover KD, 2016, CANCER DISCOV, V6, P233, DOI 10.1158/2159-8290.CD-16-0092; Wilson CY, 2016, DRUG DISCOV TODAY, V21, P1915, DOI 10.1016/j.drudis.2016.08.002; Xiong Y, 2017, ACS MED CHEM LETT, V8, P61, DOI 10.1021/acsmedchemlett.6b00373; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Yun C- H, 2016, P NATL ACAD SCI USA, V105, P2070; Zienolddiny S, 2006, CARCINOGENESIS, V27, P560, DOI 10.1093/carcin/bgi232; Ziogas DE, 2016, BIOMARK MED, V10, P681, DOI 10.2217/bmm-2016-0044	73	21	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2444	2455		10.1038/s41388-017-0105-z	http://dx.doi.org/10.1038/s41388-017-0105-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29453361	Green Submitted			2022-12-17	WOS:000431386000008
J	Di Costanzo, A; Del Gaudio, N; Conte, L; Dell'Aversana, C; Vermeulen, M; de The, H; Migliaccio, A; Nebbioso, A; Altucci, L				Di Costanzo, Antonella; Del Gaudio, Nunzio; Conte, Lidio; Dell'Aversana, Carmela; Vermeulen, Michiel; de The, Hugues; Migliaccio, Antimo; Nebbioso, Angela; Altucci, Lucia			The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia	ONCOGENE			English	Article							SUBEROYLANILIDE HYDROXAMIC ACID; POLYCOMB GROUP PROTEINS; HISTONE H3; SUMOYLATION; CANCER; CHROMODOMAIN; REPRESSION; TARGET; CELLS; TUMORIGENESIS	Polycomb group (PcG) proteins regulate transcription, playing a key role in stemness and differentiation. Deregulation of PcG members is known to be involved in cancer pathogenesis. Emerging evidence suggests that CBX2, a member of the PcG protein family, is overexpressed in several human tumors, correlating with lower overall survival. Unraveling the mechanisms regulating CBX2 expression may thus provide a promising new target for anticancer strategies. Here we show that the HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia. We identify CBX4 and RNF4 as the E3 SUMO and E3 ubiquitin ligase, respectively, and describe the specific molecular mechanism regulating CBX2 protein stability. Finally, we show that CBX2-depleted leukemic cells display impaired proliferation, underscoring its critical role in regulating leukemia cell tumorogenicity. Our results show that SAHA affects CBX2 stability, revealing a potential SAHA-mediated anti-leukemic activity though SUMO2/3 pathway.	[Di Costanzo, Antonella; Del Gaudio, Nunzio; Conte, Lidio; Dell'Aversana, Carmela; Migliaccio, Antimo; Nebbioso, Angela; Altucci, Lucia] Univ Campania Luigi Vanvitelli, Dept Biochem Biophys & Gen Pathol, Vico L De Crecchio 7, I-80138 Naples, Italy; [Vermeulen, Michiel] Radboud Univ Nijmegen, Dept Mol Biol, Fac Sci, Radboud Inst Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; [de The, Hugues] Hop St Louis, Inst Univ Hematol, INSERM Unite Mixte Rech 944, Equipe Labellisee Ligue Natl Canc, Paris 10, France	Universita della Campania Vanvitelli; Radboud University Nijmegen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Di Costanzo, A; Altucci, L (corresponding author), Univ Campania Luigi Vanvitelli, Dept Biochem Biophys & Gen Pathol, Vico L De Crecchio 7, I-80138 Naples, Italy.	antonella.dicostanzo@unina.it; lucia.altucci@unicampania.it	NEBBIOSO, ANGELA/GVS-1294-2022; Dell'Aversana, Carmela/P-7829-2018; Vermeulen, Michiel/C-8883-2013; Altucci, Lucia/S-8031-2019; Migliaccio, Antimo/AAB-3376-2019	Dell'Aversana, Carmela/0000-0001-6588-698X; Vermeulen, Michiel/0000-0003-0836-6894; Migliaccio, Antimo/0000-0002-4197-2055; Conte, Lidio/0000-0002-9520-1344; altucci, lucia/0000-0002-7312-5387; Del Gaudio, Nunzio/0000-0003-3691-443X	Blueprint [282510]; EPIGEN (MIUR-CNR); MIUR [PRIN2012ZHN9YH, 20152TE5PK]; AIRC [17217]; COST EPICHEMBIO [CM1406]	Blueprint; EPIGEN (MIUR-CNR)(Consiglio Nazionale delle Ricerche (CNR)); MIUR(Ministry of Education, Universities and Research (MIUR)); AIRC(Fondazione AIRC per la ricerca sul cancro); COST EPICHEMBIO(European Cooperation in Science and Technology (COST))	Blueprint (282510), EPIGEN (MIUR-CNR); MIUR (PRIN2012ZHN9YH; 20152TE5PK), AIRC (17217); COST EPICHEMBIO CM1406.	Bawa-Khalfe Tasneem, 2010, Genes Cancer, V1, P748; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Clermont PL, 2014, BRIT J CANCER, V111, P1663, DOI 10.1038/bjc.2014.474; Clermont PL, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0182-9; Dell'Aversana C, 2017, LEUKEMIA, V31, P2315, DOI 10.1038/leu.2017.64; Di Costanzo A, 2011, J CELL PHYSIOL, V226, P2189, DOI 10.1002/jcp.22553; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eifler K, 2015, TRENDS BIOCHEM SCI, V40, P779, DOI 10.1016/j.tibs.2015.09.006; Enserink JM, 2015, CELL DIV, V10, DOI 10.1186/s13008-015-0010-1; Forzati F, 2012, J CLIN INVEST, V122, P612, DOI 10.1172/JCI58620; Frank CL, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0065-5; Fujikawa D, 2016, BLOOD, V127, P1790, DOI 10.1182/blood-2015-08-662593; Grau DJ, 2011, GENE DEV, V25, P2210, DOI 10.1101/gad.17288211; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Hatano A, 2010, BIOCHEM BIOPH RES CO, V397, P93, DOI 10.1016/j.bbrc.2010.05.074; Ismail IH, 2012, NUCLEIC ACIDS RES, V40, P5497, DOI 10.1093/nar/gks222; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kaustov L, 2011, J BIOL CHEM, V286, P521, DOI 10.1074/jbc.M110.191411; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lee SH, 2013, CANCER LETT, V335, P397, DOI 10.1016/j.canlet.2013.02.051; Li B, 2007, BIOCHEM J, V405, P369, DOI 10.1042/BJ20061873; Li J, 2014, CANCER CELL, V25, P118, DOI 10.1016/j.ccr.2013.12.008; Meulmeester E, 2008, MOL CELL, V30, P610, DOI 10.1016/j.molcel.2008.03.021; Neff T, 2012, P NATL ACAD SCI USA, V109, P5028, DOI 10.1073/pnas.1202258109; Niessen HEC, 2009, EPIGENET CHROMATIN, V2, DOI 10.1186/1756-8935-2-10; Portanova P, 2008, INT J ONCOL, V33, P325, DOI 10.3892/ijo_00000012; Ren CY, 2015, CHEM BIOL, V22, P161, DOI 10.1016/j.chembiol.2014.11.021; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Riising EM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002704; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schwartz YB, 2013, NAT REV GENET, V14, P853, DOI 10.1038/nrg3603; Simhadri C, 2014, J MED CHEM, V57, P2874, DOI 10.1021/jm401487x; Smits AH, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks941; Stielow C, 2014, NUCLEIC ACIDS RES, V42, P3044, DOI 10.1093/nar/gkt1317; Tatham MH, 2009, NAT PROTOC, V4, P1363, DOI 10.1038/nprot.2009.128; Uzunova K, 2007, J BIOL CHEM, V282, P34167, DOI 10.1074/jbc.M706505200; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; van den Boom V, 2016, CELL REP, V14, P332, DOI 10.1016/j.celrep.2015.12.034; van den Boom V, 2013, BLOOD, V121, P2452, DOI 10.1182/blood-2012-08-451666; Wang W, 2015, MED RES REV, V35, P1220, DOI 10.1002/med.21358; Wu Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep09520; Zhang L, 2017, CELL DEATH DIFFER, V24, P1530, DOI 10.1038/cdd.2017.29; Zhao J, 2007, CELL MOL LIFE SCI, V64, P3017, DOI 10.1007/s00018-007-7137-4	47	21	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2559	2572		10.1038/s41388-018-0143-1	http://dx.doi.org/10.1038/s41388-018-0143-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29467492	Green Published, hybrid			2022-12-17	WOS:000431873400008
J	Lin, J; Ma, JC; Yang, J; Yin, JY; Chen, XX; Guo, H; Wen, XM; Zhang, TJ; Qian, W; Qian, J; Deng, ZQ				Lin, J.; Ma, J. -C.; Yang, J.; Yin, J. -Y.; Chen, X. -X.; Guo, H.; Wen, X. -M.; Zhang, T. -J.; Qian, W.; Qian, J.; Deng, Z. -Q.			Arresting of miR-186 and releasing of H19 by DDX43 facilitate tumorigenesis and CML progression	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; LONG NONCODING RNA; CANCER-CELLS; DOWN-REGULATION; STEM-CELLS; POOR SURVIVAL; GENOME-WIDE; EXPRESSION; METASTASIS; MICRORNAS	Cancer-testis (CT) antigens, rarely in normal tissues except testis, are expressed in many tumor types. In recent years, DDX43 has been shown to be expressed in several malignancies. However, the role of DDX43 during tumorigenesis is not well established. In the present study, we explored the function of DDX43 in chronic myeloid leukemia (CML). We found that DDX43 overexpression in CML cell lines enhanced survival and colony formation, inhibited cell apoptosis, promoted tumorigenesis, and CML progression. In contrast, silencing of DDX43 inhibited cell survival and tumorigenesis. Upregulated H19 and downregulated miR-186 were identified in DDX43-transfected cells. Furthermore, we demonstrated that miR-186 targeted DDX43, and overexpressed miR-186 increased apoptosis and decreased cell survival. We also showed that DDX43 regulated the expression of H19 through demethylation and silencing H19 inhibited cell survival. Taken together, these results indicate that DDX43 provides critical support to the progression of CML by enhancing cell survival, colony formation, and inhibiting cell apoptosis, thereby implicating DDX43 as a potential therapeutic target in CML.	[Lin, J.; Ma, J. -C.; Yin, J. -Y.; Guo, H.; Wen, X. -M.; Deng, Z. -Q.] Jiangsu Univ, Affiliated Peoples Hosp, Dept Cent Lab, Zhenjiang, Jiangsu, Peoples R China; [Lin, J.; Ma, J. -C.; Guo, H.; Wen, X. -M.; Zhang, T. -J.; Qian, J.; Deng, Z. -Q.] Key Lab Precis Diag & Treatment Hematol Malignanc, Zhenjiang, Jiangsu, Peoples R China; [Yang, J.; Chen, X. -X.; Zhang, T. -J.; Qian, J.] Jiangsu Univ, Affiliated Peoples Hosp, Dept Hematol, Zhenjiang, Jiangsu, Peoples R China; [Qian, W.] Jiangsu Univ, Affiliated Peoples Hosp, Dept Otolaryngol, Zhenjiang, Jiangsu, Peoples R China	Jiangsu University; Jiangsu University; Jiangsu University	Deng, ZQ (corresponding author), Jiangsu Univ, Affiliated Peoples Hosp, Dept Cent Lab, Zhenjiang, Jiangsu, Peoples R China.; Qian, J; Deng, ZQ (corresponding author), Key Lab Precis Diag & Treatment Hematol Malignanc, Zhenjiang, Jiangsu, Peoples R China.; Qian, J (corresponding author), Jiangsu Univ, Affiliated Peoples Hosp, Dept Hematol, Zhenjiang, Jiangsu, Peoples R China.	qianjun0007@hotmail.com; zqdeng2002@163.com		Qian, Jun/0000-0001-7697-2875	National Natural Science Foundation of China [81172592, 81270630]; Medical Innovative Team of "Ke Jiao Qiang Wei" Project of Jiangsu Province [CXTDB2017002]; six talent peaks project in Jiangsu Province [2015-WSN-115]; China Postdoctoral Science Foundation [2016M601747]; Jiangsu Provincial "Innovative & entrepreneurial talent team" Program	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Innovative Team of "Ke Jiao Qiang Wei" Project of Jiangsu Province; six talent peaks project in Jiangsu Province; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jiangsu Provincial "Innovative & entrepreneurial talent team" Program	This study was supported by National Natural Science Foundation of China (81172592, 81270630), Medical Innovative Team of "Ke Jiao Qiang Wei" Project of Jiangsu Province (CXTDB2017002), six talent peaks project in Jiangsu Province (2015-WSN-115), China Postdoctoral Science Foundation (2016M601747), and Jiangsu Provincial "Innovative & entrepreneurial talent team" Program.	Adams SP, 2002, LEUKEMIA, V16, P2238, DOI 10.1038/sj.leu.2402732; Bernaudo S, 2016, ONCOGENE, V35, P4816, DOI 10.1038/onc.2016.15; Cai JC, 2013, CANCER RES, V73, P756, DOI 10.1158/0008-5472.CAN-12-2651; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Chen Q, 2013, GENET TEST MOL BIOMA, V17, P508, DOI 10.1089/gtmb.2012.0530; Chen Q, 2012, BRIT J HAEMATOL, V158, P293, DOI 10.1111/j.1365-2141.2012.09138.x; Chen Qin, 2011, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V19, P1171; Conigliaro A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0426-x; Cui GH, 2014, TUMOR BIOL, V35, P8933, DOI 10.1007/s13277-014-2168-6; Dey BK, 2014, GENE DEV, V28, P491, DOI 10.1101/gad.234419.113; Erdmann K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-82; Fanale D, 2012, ONCOGENE, V31, P2121, DOI 10.1038/onc.2011.408; Ferrer G, 2013, LEUKEMIA LYMPHOMA, V54, P2016, DOI 10.3109/10428194.2012.763123; Giustacchini A, 2017, NAT MED, V23, P692, DOI 10.1038/nm.4336; Hehlmann R, 2007, LANCET, V370, P342, DOI 10.1016/S0140-6736(07)61165-9; Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Lee DF, 2015, CELL, V161, P240, DOI 10.1016/j.cell.2015.02.045; Li HL, 2013, CARCINOGENESIS, V34, P2145, DOI 10.1093/carcin/bgt158; Liggins Amanda P, 2010, Cancer Immun, V10, P8; Lin J, 2014, LEUKEMIA RES, V38, P601, DOI 10.1016/j.leukres.2014.02.012; Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033; Ma JC, 2014, CELL PHYSIOL BIOCHEM, V34, P2266, DOI 10.1159/000369669; Martelange V, 2000, CANCER RES, V60, P3848; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; Raveh E, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0458-2; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Rokavec M, 2017, CANCER RES, V77, P1854, DOI 10.1158/0008-5472.CAN-16-3236; Savona M, 2008, NAT REV CANCER, V8, P341, DOI 10.1038/nrc2368; Si XX, 2016, ONCOTARGET, V7, P81452, DOI 10.18632/oncotarget.13263; Sidaway Peter, 2016, Nat Rev Clin Oncol, V13, P135, DOI 10.1038/nrclinonc.2016.13; Song YF, 2017, HEPATOLOGY, V66, P1183, DOI 10.1002/hep.29209; Vennin C, 2015, ONCOTARGET, V6, P29209, DOI 10.18632/oncotarget.4976; Wang Q, 2017, ONCOTARGET, V8, P2558, DOI 10.18632/oncotarget.13708; Wang W, 2015, BLOOD, V126, P1699, DOI 10.1182/blood-2015-05-646489; Zhang TJ, 2016, CLIN LAB, V62, P113, DOI 10.7754/Clin.Lab.2015.150606; Zheng J, 2015, ONCOTARGET, V6, P25339, DOI 10.18632/oncotarget.4509; Zheng PS, 2004, FASEB J, V18, P754, DOI 10.1096/fj.03-0545fje; Zhou JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10221; Zhou JD, 2018, J CELL PHYSIOL, V233, P2444, DOI 10.1002/jcp.26119; Zhou W, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9557; Zhu X, 2016, ONCOGENE, V35, P323, DOI 10.1038/onc.2015.84	42	21	21	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2432	2443		10.1038/s41388-018-0146-y	http://dx.doi.org/10.1038/s41388-018-0146-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29449695	hybrid, Green Published			2022-12-17	WOS:000431386000007
J	Orth, M; Unger, K; Schoetz, U; Belka, C; Lauber, K				Orth, M.; Unger, K.; Schoetz, U.; Belka, C.; Lauber, K.			Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2	ONCOGENE			English	Article							PANCREATIC-CANCER CELLS; X-RAY-SENSITIVITY; KINASE AURORA-A; LUNG-CANCER; INDUCTION CHEMOTHERAPY; RADIATION SENSITIZER; CLONOGENIC SURVIVAL; COLORECTAL-CANCER; TUMOR-GROWTH; HELA-CELLS	Taxane-based radiochemotherapy is a central treatment option for various cancer entities in locally advanced stages. The therapeutic synergism of this combined modality approach due to taxane-mediated radiosensitization of cancer cells is well-known. However, the underlying molecular mechanisms remain largely elusive, and mechanism-derived predictive markers of taxane-based radiochemotherapy are currently not available. Here, we show that clinically relevant doses of Paclitaxel, the prototype taxane, stimulate a tripolar mode of mitosis leading to chromosomal missegregation and aneuploidization rather than interfering with cell cycle progression. This distinct mitotic phenotype was interlinked with Paclitaxel-mediated radiosensitization via overexpression of mitotic Aurora kinase A (AURKA) and its cofactor TPX2 whose knockdown rescued the bipolar mode of cell division and largely attenuated the radiosensitizing effects of Paclitaxel. In the cancer genome atlas (TCGA) lung adenocarcinoma cohort, high expression levels of AURKA and TPX2 were associated with specifically improved overall survival upon taxane-based radiochemotherapy, but not in case of non-taxane-based radiochemotherapy, chemo- or radiotherapy only. Thus, our data provide insights into Paclitaxel-mediated radiosensitization on a mechanistic and molecular level and identify AURKA and TPX2 as the first potential mechanism-based, predictive markers of taxane-based radiochemotherapy.	[Orth, M.; Schoetz, U.; Belka, C.; Lauber, K.] Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Marchioninistr 15, D-81377 Munich, Germany; [Orth, M.; Unger, K.; Schoetz, U.; Belka, C.; Lauber, K.] German Res Ctr Environm Hlth GmbH, Helmholtz Ctr Munich, Clin Cooperat Grp Personalized Radiotherapy Head, Neuherberg, Germany; [Orth, M.; Belka, C.; Lauber, K.] German Canc Consortium DKTK, Munich, Germany; [Orth, M.] German Canc Res Ctr, Heidelberg, Germany; [Unger, K.] Helmholtz Ctr Munich, Res Unit Radiat Cytogenet, Neuherberg, Germany; [Belka, C.] German Ctr Lung Res DZL, Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Lauber, K (corresponding author), Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Marchioninistr 15, D-81377 Munich, Germany.	kirsten.lauber@med.uni-muenchen.de	Unger, Kristian/F-3730-2018; Orth, Michael/AAQ-7299-2021	Unger, Kristian/0000-0002-0374-2320; Orth, Michael/0000-0002-4608-7151; Schotz, Ulrike/0000-0001-8118-3977	grants of the Friedrich-Baur-Stiftung; Verein zur Forderung von Wissenschaft und Forschung	grants of the Friedrich-Baur-Stiftung; Verein zur Forderung von Wissenschaft und Forschung	We thank Olaf Stemmann for the stably transfected HeLa cell line and the centrin antibody, and Oliver J. Gruss for TPX2 antisera. This work was supported by grants of the Friedrich-Baur-Stiftung and the Verein zur Forderung von Wissenschaft und Forschung to MO and CB.	Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Asteriti IA, 2010, BBA-REV CANCER, V1806, P230, DOI 10.1016/j.bbcan.2010.08.001; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Bian ML, 2010, SCI CHINA LIFE SCI, V53, P1322, DOI 10.1007/s11427-010-4086-1; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Choy H, 2001, Expert Opin Pharmacother, V2, P963, DOI 10.1517/14656566.2.6.963; Choy H, 2001, CRIT REV ONCOL HEMAT, V37, P237, DOI 10.1016/S1040-8428(00)00112-8; Demidenko ZN, 2008, ONCOGENE, V27, P4402, DOI 10.1038/onc.2008.82; Dey S, 2003, CLIN CANCER RES, V9, P1557; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; Eberhardt WEE, 2015, J CLIN ONCOL, V33, P4194, DOI 10.1200/JCO.2015.62.6812; Ernst A, 2015, CANCER LETT, V365, P211, DOI 10.1016/j.canlet.2015.05.024; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137; Garrido G, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00088; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Giubettini M, 2011, J CELL SCI, V124, P113, DOI 10.1242/jcs.075457; Goldenson B, 2015, ONCOGENE, V34, P537, DOI 10.1038/onc.2014.14; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Hata T, 2005, CANCER RES, V65, P2899, DOI 10.1158/0008-5472.CAN-04-3981; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; HORWITZ SB, 1986, ANN NY ACAD SCI, V466, P733, DOI 10.1111/j.1749-6632.1986.tb38455.x; Huber RM, 2006, J CLIN ONCOL, V24, P4397, DOI 10.1200/JCO.2005.05.4163; Janssen A, 2011, ONCOGENE, V30, P2799, DOI 10.1038/onc.2011.30; Kinzel L, 2016, ONCOTARGET, V7, P43199, DOI 10.18632/oncotarget.9774; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Kurdoglu B, 1999, CLIN CANCER RES, V5, P2580; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; LIEBMANN J, 1994, J NATL CANCER I, V86, P441, DOI 10.1093/jnci/86.6.441; Lin Y, 2012, BRIT J CANCER, V107, P1692, DOI 10.1038/bjc.2012.450; Manfredi MG, 2011, CLIN CANCER RES, V17, P7614, DOI 10.1158/1078-0432.CCR-11-1536; Martens-de Kemp SR, 2013, CLIN CANCER RES, V19, P1994, DOI 10.1158/1078-0432.CCR-12-2539; Mazumdar A, 2009, HEAD NECK-J SCI SPEC, V31, P625, DOI 10.1002/hed.21007; Mhaidat NM, 2007, MOL CANCER THER, V6, P752, DOI 10.1158/1535-7163.MCT-06-0564; Mignogna C, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0238-7; Morgan-Lappe SE, 2007, CANCER RES, V67, P4390, DOI 10.1158/0008-5472.CAN-06-4132; Neumayer G, 2014, CELL MOL LIFE SCI, V71, P3027, DOI 10.1007/s00018-014-1582-7; Panier S, 2013, NAT REV MOL CELL BIO, V14, P661, DOI 10.1038/nrm3659; Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005; Scharer CD, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-79; Sehdev V, 2013, CANCER-AM CANCER SOC, V119, P904, DOI 10.1002/cncr.27801; Sillars-Hardebol AH, 2012, GUT, V61, P1568, DOI 10.1136/gutjnl-2011-301153; SINCLAIR WK, 1966, RADIAT RES, V29, P450, DOI 10.2307/3572025; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; STEREN A, 1993, GYNECOL ONCOL, V50, P89, DOI 10.1006/gyno.1993.1169; TERASIMA T, 1963, SCIENCE, V140, P490, DOI 10.1126/science.140.3566.490; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Unkel S, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0584-z; Wang H, 2016, ONCOGENE, V35, P2011, DOI 10.1038/onc.2015.304; Warner SL, 2009, CLIN CANCER RES, V15, P6519, DOI 10.1158/1078-0432.CCR-09-0077; Xu J, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-200; Yang G, 2010, CLIN CANCER RES, V16, P3171, DOI 10.1158/1078-0432.CCR-09-3171; Zasadil LM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007965; Zullo KM, 2015, CLIN CANCER RES, V21, P4097, DOI 10.1158/1078-0432.CCR-15-0033	54	21	21	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					52	62		10.1038/onc.2017.304	http://dx.doi.org/10.1038/onc.2017.304			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869599				2022-12-17	WOS:000422625000006
J	Ding, D; Huang, H; Jiang, W; Yu, W; Zhu, H; Liu, J; Saiyin, H; Wu, J; Huang, H; Jiang, S; Yu, L				Ding, D.; Huang, H.; Jiang, W.; Yu, W.; Zhu, H.; Liu, J.; Saiyin, H.; Wu, J.; Huang, H.; Jiang, S.; Yu, L.			Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway	ONCOGENE			English	Article							CELL LUNG-CANCER; IDENTIFICATION; GENES	Hepatocellular carcinoma (HCC) is a major health threat worldwide. Although the involvement of reticulocalbin-2 (RCN2) in cell differentiation has been reported, its function in oncogenesis is poorly understood. Here, we showed that RCN2 was upregulated in tumors compared with adjacent non-tumorous tissues in HCC patients and RCN2 expression clinically correlated with tumor size, disease recurrence and survival rate. Both knockdown and knockout of RCN2 significantly inhibited HCC cell proliferation by inducing G1/S transition arrest and downregulating cyclin D1 expression, while the proliferative ability was restored in knockout HCC cells with exogenously expressed RCN2. Mechanistically, we demonstrated that RCN2 interacted with the epidermal growth factor receptor (EGFR). Knockout of RCN2 in HCC cells not only inhibited activation of the EGFR-ERK pathway by blocking EGF-mediated EGFR dimerization and internalization but also suppressed cell proliferation and EGFR phosphorylation under long exposure to EGF. We further showed that knockout of RCN2 inhibited EGFR phosphorylation, Ki-67 expression and tumor growth in nude mice. Moreover, we demonstrated that RCN2 knockout sensitized HCC cells to tyrosine kinase inhibitors, including erlotinib, lapatinib and sunitinib. Taken together, our results indicate that RCN2 plays a pivotal role in HCC cell proliferation and tumor growth presumably through regulating activation of the EGFR-ERK pathway. Our work also suggests that RCN2 is a potential therapeutic target of HCC.	[Ding, D.; Huang, H.; Yu, W.; Zhu, H.; Saiyin, H.; Wu, J.; Jiang, S.; Yu, L.] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; [Jiang, W.] Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Shanghai Med Coll, Shanghai, Peoples R China; [Zhu, H.] Fudan Univ, Sch Life Sci, Key Lab Med Mol Virol, Minist Educ Hlth, Shanghai, Peoples R China; [Liu, J.] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Ctr Reprod Med,Shanghai Key Lab Assisted Reprod &, Shanghai, Peoples R China; [Huang, H.] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN USA	Fudan University; Fudan University; Fudan University; Shanghai Jiao Tong University; Mayo Clinic	Jiang, S; Yu, L (corresponding author), Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.	smjiang@fudan.edu.cn; longyu@fudan.edu.cn		Saiyin, Hexige/0000-0003-2993-6817; Ding, Donglin/0000-0003-2339-7349	National Key Science and Technology Project of China [2013ZX10002010]; National Basic Research Program of China (973 Program) [2013CB910504]	National Key Science and Technology Project of China; National Basic Research Program of China (973 Program)(National Basic Research Program of China)	We are thankful to Professor Jiahuai Han at Xiamen University for providing RCN2 cDNA. We thank Dr Suqin Shen, Longjiang Liu and Huazheng Yu at Fudan University for their technical support. This study was supported by National Key Science and Technology Project of China (2013ZX10002010), National Basic Research Program of China (973 Program, 2013CB910504).	Cavallo F, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-S4-S7; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Foerster S, 2013, PROTEOMICS, V13, P3131, DOI 10.1002/pmic.201300154; Giribaldi G, 2013, J PROTEOMICS, V91, P385, DOI 10.1016/j.jprot.2013.07.018; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hirano T, 2005, INT J CANCER, V117, P460, DOI 10.1002/ijc.21172; Honore B, 2009, BIOESSAYS, V31, P262, DOI 10.1002/bies.200800186; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jiang W., 2015, CELL CYCLE HEPATOCEL, V34, P4460, DOI DOI 10.1038/onc.2014.373; Kharbanda A, 2014, CLIN CANCER RES, V20, P5423, DOI 10.1158/1078-0432.CCR-13-3168; Kishi T, 2007, P NATL ACAD SCI USA, V104, P17418, DOI 10.1073/pnas.0704951104; Lakadamyali M, 2006, CELL, V124, P997, DOI 10.1016/j.cell.2005.12.038; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Li LJ, 2010, P NATL ACAD SCI USA, V107, P1402, DOI 10.1073/pnas.0905657107; Liu ZD, 1997, BIOCHEM BIOPH RES CO, V231, P283, DOI 10.1006/bbrc.1997.6083; Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]; Llovet JM, 2014, CLIN CANCER RES, V20, P2072, DOI 10.1158/1078-0432.CCR-13-0547; Ludvigsen M, 2009, PROTEOMICS, V9, P5267, DOI 10.1002/pmic.200900321; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Manichaikul A, 2011, AM J PHYSIOL-HEART C, V301, pH1056, DOI 10.1152/ajpheart.00366.2011; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Nimmrich I, 2000, CANCER LETT, V160, P37, DOI 10.1016/S0304-3835(00)00553-X; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868; Villanueva A, 2013, NAT REV GASTRO HEPAT, V10, P34, DOI 10.1038/nrgastro.2012.199; von Zastrow M, 2007, CURR OPIN CELL BIOL, V19, P436, DOI 10.1016/j.ceb.2007.04.021; Wang RY, 2013, GASTROENTEROLOGY, V145, P1436, DOI 10.1053/j.gastro.2013.08.009; Wang ZC, 2015, HEPATOLOGY, V62, P1201, DOI 10.1002/hep.27911; Wu YM, 2011, CANCER RES, V71, P7270, DOI 10.1158/0008-5472.CAN-11-1161; Yu LR, 2000, ELECTROPHORESIS, V21, P3058, DOI 10.1002/1522-2683(20000801)21:14<3058::AID-ELPS3058>3.0.CO;2-U	32	21	24	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6691	6700		10.1038/onc.2017.230	http://dx.doi.org/10.1038/onc.2017.230			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28745317				2022-12-17	WOS:000416780800004
J	Li, J; Hu, SB; Wang, LY; Zhang, X; Zhou, X; Yang, B; Li, JH; Xiong, J; Liu, N; Li, Y; Wu, YZ; Zheng, QC				Li, J.; Hu, S. B.; Wang, L. Y.; Zhang, X.; Zhou, X.; Yang, B.; Li, J. H.; Xiong, J.; Liu, N.; Li, Y.; Wu, Y. Z.; Zheng, Q. C.			Autophagy-dependent generation of Axin2+cancer stem-like cells promotes hepatocarcinogenesis in liver cirrhosis	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA CELLS; SIGNALING PATHWAY; LUNG-CANCER; AXIN2; IDENTIFICATION; PHENOTYPE; TRAITS; EPCAM	Autophagy is a pathophysiological phenomenon in liver cirrhosis that can further progress into hepatocarcinoma. Liver cancer stem cells (CSCs) are believed to initiate hepatocarcinogenesis. To investigate the precise mechanism related to the origin of CSCs in liver cirrhosis and hepatocarcinogenesis, we labeled Axin2+ hepatic cells with EGFP in Axin2Cre;Rosa26EGFP transgenic rats, and then stratified clinical and rat liver cirrhosis samples by autophagy flux. Clinical follow-up and lineage tracing in transgenic rat liver cirrhosis revealed that while Axin2/EGFP+ hepatic cells were present in normal livers and cirrhotic livers without aberrant autophagy, hepatic Axin2/EGFP+CD90+ cells were generated exclusively in cirrhotic livers with aberrant autophagy and promoted hepatocarcinogenesis. Aberrant autophagy in liver cirrhosis resulted in hepatocyte growth factor (HGF) expression, leading to activation of Met/JNK and Met/STAT3 signaling in sorted hepatic Axin2/EGFP+ cells and their transition into Axin2/EGFP+ CD90+ cells that possess CSC properties. In a transgenic rat liver cirrhosis model, induction or inhibition of autophagy in cirrhotic livers by systemic administration of rapamycin or chloroquine or transfection with Atg3- and Atg7-shRNAs significantly induced or suppressed HGF expression, which in turn increased or reduced generation of EGFP+CD90+ hepatic cells by activating or inactivating Met/JNK and Met/STAT3 signaling, thereby promoting or preventing hepatocarcinogenesis. Systemic treatment with HGF-shRNA, SP600125 or stattic also reduced generation of EGFP(Axin2)+ hepatic cell-originated CD90+ CSCs in aberrant autophagic cirrhotic livers by inactivating HGF/Met/JNK or HGF/Met/STAT3 signaling, further preventing hepatocarcinogenesis. These data suggest that activation of Met/JNK and Met/STAT3 signaling in Axin2+ hepatic cells via autophagy-dependent HGF expression and the resultant generation of Axin2+CD90+ CSCs is a major mechanism of hepatocarcinogenesis in cirrhotic livers.	[Li, J.; Liu, N.; Li, Y.] Chongqing Canc Inst & Hosp & Canc Ctr, Dept Urol Oncol Surg, HanYu Rd 181, Chongqing 400030, Peoples R China; [Hu, S. B.; Wang, L. Y.; Zhou, X.; Xiong, J.; Zheng, Q. C.] Huazhong Univ Sci & Technol, Union Hosp, Dept Hepatobiliary Surg, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Zhang, X.] Third Mil Med Univ, Inst Hepatobiliary Surg, Southwest Hosp, Chongqing, Peoples R China; [Yang, B.] Southern Med Univ, Zhujiang Hosp, Dept Hepatobiliary Surg 2, Coinnovat Ctr Organ Failure Res,State Key Lab Org, Guangzhou, Guangdong, Peoples R China; [Li, J. H.] Huazhong Univ Sci & Technol, Union Hosp, Dept Gastroenterol, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Wu, Y. Z.] Chongqing Canc Inst & Hosp & Canc Ctr, Dept Radiotherapy, Chongqing, Peoples R China	Huazhong University of Science & Technology; Army Medical University; Southern Medical University - China; Huazhong University of Science & Technology	Li, J (corresponding author), Chongqing Canc Inst & Hosp & Canc Ctr, Dept Urol Oncol Surg, HanYu Rd 181, Chongqing 400030, Peoples R China.	herrleej@foxmail.com			National Natural Science Foundation of China [81400674]; China Scholarship Council [201508500057]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Scholarship Council(China Scholarship Council)	This work was supported by the National Natural Science Foundation of China under Grant (No. 81400674) and China Scholarship Council under Grant (No. 201508500057) to JL.	Bourdeau V, 2016, AUTOPHAGY, V12, P1965, DOI 10.1080/15548627.2016.1214779; Bowman AN, 2013, P NATL ACAD SCI USA, V110, P7324, DOI 10.1073/pnas.1305411110; Cao L, 2015, ONCOTARGET, V6, P6627, DOI 10.18632/oncotarget.3113; Capone F, 2014, WORLD J GASTROENTERO, V20, P9261, DOI 10.3748/wjg.v20.i28.9261; Cecchi F, 2010, EUR J CANCER, V46, P1260, DOI 10.1016/j.ejca.2010.02.028; Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012; Chai S, 2016, HEPATOLOGY, V64, P2062, DOI 10.1002/hep.28821; Fang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9640; Gong LY, 2016, J PATHOL, V240, P184, DOI 10.1002/path.4767; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Kitanaka Chifumi, 2013, Genes Cancer, V4, P388, DOI 10.1177/1947601912474892; Kowalik MA, 2016, ONCOTARGET, V7, P5788, DOI 10.18632/oncotarget.6810; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lim XH, 2016, P NATL ACAD SCI USA, V113, pE1498, DOI 10.1073/pnas.1601599113; Liu D, 2016, ONCOTARGET, V7, P40704, DOI 10.18632/oncotarget.9930; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Martins-Neves SR, 2016, J CELL PHYSIOL, V231, P876, DOI 10.1002/jcp.25179; Oikawa T, 2016, HEPATOLOGY, V64, P645, DOI 10.1002/hep.28485; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Sakai K, 2015, ONCOL LETT, V9, P405, DOI 10.3892/ol.2014.2702; Song WQ, 2014, CANCER RES, V74, P2444, DOI 10.1158/0008-5472.CAN-13-2136; Song YJ, 2013, CANCER LETT, V339, P70, DOI 10.1016/j.canlet.2013.07.021; Terris B, 2010, J HEPATOL, V52, P280, DOI 10.1016/j.jhep.2009.10.026; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Wang B, 2015, NATURE, V524, P180, DOI 10.1038/nature14863; Wang X, 2016, J HEPATOL, V64, P1283, DOI 10.1016/j.jhep.2016.01.019; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Wiegand J, 2013, DTSCH ARZTEBL INT, V110, P85, DOI 10.3238/arztebl.2013.0085; Wu GY, 2015, ONCOTARGET, V6, P28882, DOI 10.18632/oncotarget.4921; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang ZF, 2008, HEPATOLOGY, V47, P919, DOI 10.1002/hep.22082; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Zhang XZ, 2016, PROCEEDINGS 2016 IEEE INTERNATIONAL CONFERENCE ON INDUSTRIAL TECHNOLOGY (ICIT), P2016, DOI 10.1109/ICIT.2016.7475077; Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004	36	21	21	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6725	6737		10.1038/onc.2017.272	http://dx.doi.org/10.1038/onc.2017.272			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28783177	Green Published, hybrid			2022-12-17	WOS:000416780800007
J	Tao, T; Yang, X; Zheng, J; Feng, D; Qin, Q; Shi, X; Wang, Q; Zhao, C; Peng, Z; Liu, H; Jiang, WG; He, J				Tao, T.; Yang, X.; Zheng, J.; Feng, D.; Qin, Q.; Shi, X.; Wang, Q.; Zhao, C.; Peng, Z.; Liu, H.; Jiang, W. G.; He, J.			PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation	ONCOGENE			English	Article							TYROSINE-PHOSPHATASE SHP-1; BREAST-CANCER; CLEAR-CELL; COLORECTAL-CANCER; TARGETED THERAPY; PROTEIN; EXPRESSION; GROWTH; TUMORIGENESIS; SURVIVAL	Renal cell carcinoma (RCC) is one of the most aggressive urologic cancers, however, the mechanism on supporting RCC carcinogenesis is still not clear. By using gene expression profile analysis and functional clustering, PDZ domain-containing 1 (PDZK1) was revealed to be downregulated in human clear cell renal cell carcinoma (ccRCC) samples, which was also verified in several independent public ccRCC data sets. Using PDZK1 overexpression and knockdown models in ccRCC cell lines, we demonstrated that PDZK1 inhibited cell proliferation, cell cycle G1/S phase transition, cell migration and invasion, indicating a tumor-suppressor role in the development and progression of ccRCC. Our study further demonstrated that PDZK1 inhibited cell proliferation and migration of ccRCC via targeting SHP-1. PDZK1 was further identified to suppress cell proliferation by blocking SHP-1 phosphorylation at Tyr536 via inhibition of the association between SHP-1 and PLC beta 3, and then retarding Akt phosphorylation and promoting STAT5 phosphorylation in ccRCC cells. Moreover, the inhibitive effects of PDZK1 on SHP-1 phosphorylation and the tumor growth were verified in vivo by xenograft tumor studies. Accordingly, PDZK1 expression was negatively correlated with SHP-1 activation and phosphorylation, advanced pathologic stage, tumor weight and size, and prognosis of ccRCC patients. These findings have provided first lines of evidences that PDZK1 expression is negatively correlated with SHP-1 activation and poor clinical outcomes in ccRCC. PDZK1 was identified as a novel tumor suppressor in ccRCC by negating SHP-1 activity.	[Tao, T.; Yang, X.; Zheng, J.; Qin, Q.; Shi, X.; Wang, Q.; Zhao, C.; Peng, Z.; Liu, H.; He, J.] Capital Med Univ, Dept Biochem & Mol Biol, 10 Xitoutiao, Beijing 100069, Peoples R China; [Yang, X.; Zheng, J.; Qin, Q.; Liu, H.; He, J.] Capital Med Univ, Beijing Int Cooperat Base Sci & Technol China UK, Beijing Key Lab Canc Invas & Metastasis Res, Beijing, Peoples R China; [Feng, D.] Shanxi Med Univ, Hosp 1, Dept Intervent Radiol, Taiyuan, Shanxi, Peoples R China; [Jiang, W. G.] Cardiff Univ, Cardiff China Med Res Collaborat, Sch Med, Heath Pk, Cardiff, S Glam, Wales	Capital Medical University; Capital Medical University; Shanxi Medical University; Cardiff University	Liu, H; He, J (corresponding author), Capital Med Univ, Dept Biochem & Mol Biol, 10 Xitoutiao, Beijing 100069, Peoples R China.	hualh08@ccmu.edu.cn; jq_he@ccmu.edu.cn	jiang, wen/GYI-9662-2022; Jiang, Wen G./AAF-1876-2020; Jiang, Wen G/B-1293-2010	Jiang, Wen G./0000-0002-3283-1111; Jiang, Wen G/0000-0002-3283-1111	National Natural Science Foundation of the People's Republic of China [81472409, 81572333]; Beijing Natural Science Foundation Program; Beijing Municipal Commission of Education [KZ201710025015]; Project of High-level Teachers in Beijing Municipal Universities [IDHT20170516]; Beijing BaiQianWan Talents Program	National Natural Science Foundation of the People's Republic of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation Program(Beijing Natural Science Foundation); Beijing Municipal Commission of Education(Beijing Municipal Commission of Education); Project of High-level Teachers in Beijing Municipal Universities; Beijing BaiQianWan Talents Program	This work was supported by the National Natural Science Foundation of the People's Republic of China (No. 81472409, 81572333); Beijing Natural Science Foundation Program and Scientific Research Key Program of Beijing Municipal Commission of Education (KZ201710025015); Support Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan (IDHT20170516); Beijing BaiQianWan Talents Program (2017-2018).	Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Caceres W, 2011, P R HEALTH SCI J, V30, P73; Calvo E, 2016, CANCER TREAT REV, V50, P109, DOI 10.1016/j.ctrv.2016.09.002; Ciccarese C, 2016, CANCER TREAT REV, V49, P37, DOI 10.1016/j.ctrv.2016.07.003; Cooper SJ, 2010, ONCOGENE, V29, P2905, DOI 10.1038/onc.2010.64; Du Y, 2016, ONCOTARGET, V7, P41885, DOI 10.18632/oncotarget.9628; Eyre NS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001130; Gardiol D, 2012, FEBS J, V279, P3529, DOI 10.1111/j.1742-4658.2012.08685.x; Ghosh MG, 2000, CANCER RES, V60, P6367; Golebiewska U, 2010, CRIT REV BIOCHEM MOL, V45, P97, DOI 10.3109/10409231003598812; Inoue J, 2004, AM J PATHOL, V165, P71, DOI 10.1016/S0002-9440(10)63276-2; Kanamori M, 2003, J BIOL CHEM, V278, P38758, DOI 10.1074/jbc.M306324200; Kim JK, 2012, J BIOL CHEM, V287, P21012, DOI 10.1074/jbc.M111.337865; Klatte T, 2007, CLIN CANCER RES, V13, P7388, DOI 10.1158/1078-0432.CCR-07-0411; Kroeze SGC, 2010, CANCER BIOMARK, V7, P261, DOI 10.3233/CBM-2010-0195; Li HL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0162-x; Ljungberg B, 2011, EUR UROL, V60, P615, DOI 10.1016/j.eururo.2011.06.049; Lopez-Beltran A, 2006, EUR UROL, V49, P798, DOI 10.1016/j.eururo.2005.11.035; Ma Q, 2015, ONCOTARGET, V6, P35851, DOI 10.18632/oncotarget.5323; Moch H, 2015, CURR DRUG TARGETS, V16, P125, DOI 10.2174/1389450116666150126110632; Montano X, 2009, ONCOGENE, V28, P3787, DOI 10.1038/onc.2009.143; Polette M, 2005, CANCER RES, V65, P7691, DOI 10.1158/0008-5472.CAN-04-4230; Poole AW, 2005, CELL SIGNAL, V17, P1323, DOI 10.1016/j.cellsig.2005.05.016; Rathmell WK, 2008, EXPERT REV ANTICANC, V8, P63, DOI 10.1586/14737140.8.1.63; Rodriguez-Ubreva FJ, 2010, ONCOGENE, V29, P345, DOI 10.1038/onc.2009.329; Saponaro C, 2014, CANCER BIOMARK, V14, P177, DOI 10.3233/CBM-130329; Sharma Y, 2016, FUTURE ONCOL, V12, P1287, DOI 10.2217/fon-2015-0057; Sooman L, 2014, TUMOR BIOL, V35, P4479, DOI 10.1007/s13277-013-1590-5; Stebbing J, 2014, ONCOGENE, V33, P939, DOI 10.1038/onc.2013.80; Subbaiah VK, 2011, BIOCHEM J, V439, P195, DOI 10.1042/BJ20110903; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun LC, 2016, FASEB J, V30, P578, DOI 10.1096/fj.15-275586; Walsh DR, 2015, PHARMACOL REV, V67, P656, DOI 10.1124/pr.115.010728; Xiao WB, 2010, BLOOD, V116, P6003, DOI 10.1182/blood-2010-05-283937; Yao S, 2015, J PATHOL, V236, P65, DOI 10.1002/path.4502; Zheng JF, 2017, EBIOMEDICINE, V15, P62, DOI 10.1016/j.ebiom.2016.12.003	36	21	22	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6119	6131		10.1038/onc.2017.199	http://dx.doi.org/10.1038/onc.2017.199			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692056	Green Accepted			2022-12-17	WOS:000414249800006
J	Spolverini, A; Fuchs, G; Bublik, DR; Oren, M				Spolverini, A.; Fuchs, G.; Bublik, D. R.; Oren, M.			let-7b and let-7c microRNAs promote histone H2B ubiquitylation and inhibit cell migration by targeting multiple components of the H2B deubiquitylation machinery	ONCOGENE			English	Article							BREAST-CANCER; TUMOR-SUPPRESSOR; LUNG-CANCER; CHROMATIN MODIFICATIONS; MESENCHYMAL TRANSITION; DOWN-REGULATION; POOR-PROGNOSIS; SELF-RENEWAL; MONOUBIQUITINATION; EXPRESSION	Monoubiquitylation of histone H2B (H2Bub1) is catalyzed mainly by the RNF20/RNF40 complex and erased by multiple deubiquitylating enzymes (DUBs). H2Bub1 influences many aspects of chromatin function, including transcription regulation and DNA repair. Cancer cells often display reduced levels of H2Bub1, and this reduction may contribute to cancer progression. The let-7 family of microRNAs (miRNAs) comprises multiple members with reported tumor-suppressive features, whose expression is frequently downregulated in cancer. We now report that let-7b and let-7c can positively regulate cellular H2Bub1 levels. Overexpression of let-7b and let-7c in a variety of non-transformed and cancer-derived cell lines results in H2Bub1 elevation. The positive effect of let-7b and let-7c on H2Bub1 levels is achieved through targeting of multiple mRNAs, coding for distinct components of the H2B deubiquitylation machinery. Specifically, let-7b and let-7c bind directly and inhibit the mRNAs encoding the DUBs USP42 and USP44, and also the mRNA encoding the adapter protein ATXN7L3, which is part of the DUB module of the SAGA complex. RNF20 knockdown (KD) strongly reduces H2Bub1 levels and increases the migration of non-transformed mammary epithelial cells and breast cancer-derived cells. Remarkably, overexpression of let-7b, which partly counteracts the effect of RNF20 KD on H2Bub1 levels, also reverses the pro-migratory effect of RNF20 KD. Likewise, ATXN7L3 KD also increases H2Bub1 levels and reduces cell migration, and this anti-migratory effect is abolished by simultaneous KD of RNF20. Together, our findings uncover a novel function of let-7 miRNAs as regulators of H2B ubiquitylation, suggesting an additional mechanism whereby these miRNAs can exert their tumor-suppressive effects.	[Spolverini, A.; Fuchs, G.; Bublik, D. R.; Oren, M.] Weizmann Inst Sci, Dept Mol Cell Biol, POB 26,234 Herzl St, IL-7610001 Rehovot, Israel	Weizmann Institute of Science	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, POB 26,234 Herzl St, IL-7610001 Rehovot, Israel.	moshe.oren@weizmann.ac.il		Oren, Moshe/0000-0003-4311-7172	Dr Miriam and Sheldon G. Adelson Medical Research Foundation; European Research Council [293438]; Center of Excellence grant from the Israel Science Foundation; Robert Bosch Foundation [11.5.8000.0094]; Moross Integrated Cancer Center	Dr Miriam and Sheldon G. Adelson Medical Research Foundation; European Research Council(European Research Council (ERC)European Commission); Center of Excellence grant from the Israel Science Foundation; Robert Bosch Foundation; Moross Integrated Cancer Center	We thank Ofra Golani from the Bioinformatics Unit of the Weizmann Institute for expert help with image analysis; Yonit Hoffman and Gali Brand for help with data analysis; and Sharath Chandra Arandkar and Ohad Tarcic for valuable discussions. This study was supported in part by the Dr Miriam and Sheldon G. Adelson Medical Research Foundation, grant 293438 (RUBICAN) from the European Research Council, a Center of Excellence grant from the Israel Science Foundation, the Robert Bosch Foundation (project 11.5.8000.0094) and the Moross Integrated Cancer Center. MO is incumbent of the Andre Lwoff chair in molecular biology.	Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Atanassov BS, 2016, MOL CELL, V62, P558, DOI 10.1016/j.molcel.2016.03.030; Atanassov BS, 2011, FEBS LETT, V585, P2016, DOI 10.1016/j.febslet.2010.10.042; Audia JE, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019521; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Blank M, 2012, NAT MED, V18, P227, DOI 10.1038/nm.2596; Chandrasekharan MB, 2009, P NATL ACAD SCI USA, V106, P16686, DOI 10.1073/pnas.0907862106; Chen DL, 2015, ONCOTARGET, V6, P10868, DOI 10.18632/oncotarget.3451; Chernikova SB, 2012, CANCER RES, V72, P2111, DOI 10.1158/0008-5472.CAN-11-2209; Chiu SC, 2014, CELL TRANSPLANT, V23, P459, DOI 10.3727/096368914X678418; Cole AJ, 2015, ENDOCR-RELAT CANCER, V22, pT19, DOI 10.1530/ERC-14-0185; Cui SY, 2013, MOL CANCER RES, V11, P699, DOI 10.1158/1541-7786.MCR-13-0019-T; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dawson SJ, 2013, EMBO J, V32, P617, DOI 10.1038/emboj.2013.19; Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Fierz B, 2011, NAT CHEM BIOL, V7, P113, DOI [10.1038/nchembio.501, 10.1038/NCHEMBIO.501]; Fuchs G, 2014, BBA-GENE REGUL MECH, V1839, P694, DOI 10.1016/j.bbagrm.2014.01.002; Fuchs G, 2012, MOL CELL, V46, P662, DOI 10.1016/j.molcel.2012.05.023; Gambari R, 2016, INT J ONCOL, V49, P5, DOI 10.3892/ijo.2016.3503; Garcia AI, 2011, EMBO MOL MED, V3, P279, DOI 10.1002/emmm.201100136; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005; Haakensen VD, 2016, INT J CANCER, V139, P1117, DOI 10.1002/ijc.30142; Han X, 2015, CANCER GENE THER, V22, P122, DOI 10.1038/cgt.2014.75; Hausser J, 2013, GENOME RES, V23, P604, DOI 10.1101/gr.139758.112; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hock AK, 2014, J BIOL CHEM, V289, P34862, DOI 10.1074/jbc.M114.589267; Hu J, 2015, LUNG CANCER, V88, P239, DOI 10.1016/j.lungcan.2015.02.019; Hu XW, 2013, MOL CANCER RES, V11, P240, DOI 10.1158/1541-7786.MCR-12-0432; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jansen MPHM, 2012, BREAST CANCER RES TR, V133, P937, DOI 10.1007/s10549-011-1877-4; Johnsen SA, 2012, FEBS LETT, V586, P1592, DOI 10.1016/j.febslet.2012.04.002; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Jusufovic E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045577; Kari V, 2011, CELL CYCLE, V10, P3495, DOI 10.4161/cc.10.20.17769; Karpiuk O, 2012, MOL CELL, V46, P705, DOI 10.1016/j.molcel.2012.05.022; Kim J, 2005, MOL CELL, V20, P759, DOI 10.1016/j.molcel.2005.11.012; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lal A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002363; Lan XJ, 2016, CELL REP, V17, P2382, DOI 10.1016/j.celrep.2016.10.076; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lang G, 2011, MOL CELL BIOL, V31, P3734, DOI 10.1128/MCB.05231-11; Lee H, 2016, PROTEIN CELL, V7, P100, DOI 10.1007/s13238-015-0212-y; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Ma L, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0773-7; Majid S, 2013, CLIN CANCER RES, V19, P73, DOI 10.1158/1078-0432.CCR-12-2952; Melling N, 2016, PATHOL ONCOL RES, V22, P95, DOI 10.1007/s12253-015-9977-9; Minsky N, 2008, NAT CELL BIOL, V10, P483, DOI 10.1038/ncb1712; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005; Moyal L, 2011, MOL CELL, V41, P529, DOI 10.1016/j.molcel.2011.02.015; Nakamura K, 2011, MOL CELL, V41, P515, DOI 10.1016/j.molcel.2011.02.002; Olive V, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005813; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Prenzel T, 2011, CANCER RES, V71, P5739, DOI 10.1158/0008-5472.CAN-11-1896; Reczko M, 2012, BIOINFORMATICS, V28, P771, DOI 10.1093/bioinformatics/bts043; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Schultz J, 2008, CELL RES, V18, P549, DOI 10.1038/cr.2008.45; Shema E, 2008, GENE DEV, V22, P2664, DOI 10.1101/gad.1703008; Shema E, 2011, MOL CELL, V42, P477, DOI 10.1016/j.molcel.2011.03.011; Song QC, 2014, ONCOL REP, V31, P1263, DOI 10.3892/or.2014.2989; Stahlhut C, 2015, CELL CYCLE, V14, P2171, DOI 10.1080/15384101.2014.1003008; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sun X, 2016, CANCER GENE THER, V23, P83, DOI 10.1038/cgt.2016.3; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tang B, 2015, ONCOTARGET, V6, P12654, DOI 10.18632/oncotarget.3705; Tarcic O, 2017, CELL DEATH DIFFER, V24, P694, DOI 10.1038/cdd.2016.126; Tarcic O, 2016, CELL REP, V14, P1462, DOI 10.1016/j.celrep.2016.01.020; Tommasi S, 2016, ONCOTARGET, V7, P80363, DOI 10.18632/oncotarget.10345; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Urasaki Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036775; van der Knaap JA, 2005, MOL CELL, V17, P695, DOI 10.1016/j.molcel.2005.02.013; Wang E, 2013, P NATL ACAD SCI USA, V110, P3901, DOI 10.1073/pnas.1301045110; Wang PY, 2013, FEBS LETT, V587, P2675, DOI 10.1016/j.febslet.2013.07.004; Wang TZ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0402-5; Wang XR, 2012, ONCOL LETT, V3, P955, DOI 10.3892/ol.2012.609; Wang ZJ, 2013, WORLD J GASTROENTERO, V19, P8099, DOI 10.3748/wjg.v19.i44.8099; Wang ZJ, 2015, HUM PATHOL, V46, P1006, DOI 10.1016/j.humpath.2015.04.001; Wei XM, 2011, NAT GENET, V43, P442, DOI 10.1038/ng.810; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhang F, 2011, MOL CELL, V41, P384, DOI 10.1016/j.molcel.2011.01.024; Zhang XY, 2008, MOL CELL, V29, P102, DOI 10.1016/j.molcel.2007.12.015; Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023389; Zhang YX, 2011, J CANCER RES CLIN, V137, P1245, DOI 10.1007/s00432-011-0998-9; Zhang ZP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-124; Zhao BT, 2014, CANCER LETT, V342, P43, DOI 10.1016/j.canlet.2013.08.030; Zhao YC, 2011, BREAST CANCER RES TR, V127, P69, DOI 10.1007/s10549-010-0972-2; Zhao YM, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a025064; Zhao Y, 2008, MOL CELL, V29, P92, DOI 10.1016/j.molcel.2007.12.011; Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025	99	21	22	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5819	5828		10.1038/onc.2017.187	http://dx.doi.org/10.1038/onc.2017.187			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28604753	Green Accepted			2022-12-17	WOS:000413292900004
J	Weng, CC; Hawse, JR; Subramaniam, M; Chang, VHS; Yu, WCY; Hung, WC; Chen, LT; Cheng, KH				Weng, C-C; Hawse, J. R.; Subramaniam, M.; Chang, V. H. S.; Yu, W. C. Y.; Hung, W-C; Chen, L-T; Cheng, K-H			KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras(G12D) p53(flox/flox) model	ONCOGENE			English	Article							INDUCIBLE EARLY GENE; TGF-BETA; MESENCHYMAL TRANSITION; TUMOR SUPPRESSION; CELL-MIGRATION; CANCER; GROWTH; RECEPTOR; EXPRESSION; CXCR4	Kruppel-like transcription factor 10 (KLF10), also named as TIEG1, plays essential roles in mediating transforming growth factor beta (TGF beta) signaling and has been shown to function as a tumor suppressor in multiple cancer types. However, its roles in mediating cancer progression in vivo have yet to be fully characterized. Here, we have employed two well-characterized Pdx-1CreLSL-Kras(G12D) and Pdx-1CreLSL-Kras(G12D)p53(L/L) pancreatic cancer models to ablate KLF10 expression and determine the impact of KLF10 deletion on tumor development and progression. We show that loss of KLF10 cooperates with Kras(G12D) leading to an invasive and widely metastatic phenotype of pancreatic ductal adenocarcinoma (PDAC). Mechanistically, loss of KLF10 in PDAC is shown to increase distant metastases and cancer stemness through activation of SDF-1/CXCR4 and AP-1 pathways. Furthermore, we demonstrate that targeting the SDF-1/CXCR4 pathway in the context of KLF10 deletion substantially suppresses PDAC progression suggesting that inhibition of this pathway represents a novel therapeutic strategy for PDAC treatment.	[Weng, C-C; Cheng, K-H] Natl Sun Yat Sen Univ, Inst Biomed Sci, 70 Lien Hai Rd, Kaohsiung 80424, Taiwan; [Hawse, J. R.; Subramaniam, M.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA; [Chang, V. H. S.] Taipei Med Univ, Coll Med Sci & Technol, Program Translat Med, Taipei, Taiwan; [Yu, W. C. Y.; Hung, W-C; Chen, L-T; Cheng, K-H] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; [Hung, W-C] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Inst Basic Med Sci, Tainan, Taiwan; [Chen, L-T] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan; [Cheng, K-H] Kaohsiung Med Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung, Taiwan	National Sun Yat Sen University; Mayo Clinic; Taipei Medical University; National Health Research Institutes - Taiwan; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; Kaohsiung Medical University	Chen, LT; Cheng, KH (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, 70 Lien Hai Rd, Kaohsiung 80424, Taiwan.	leochen@nhri.org.tw; khcheng@faculty.nsysu.edu.tw			Ministry of Science and Technology, Taiwan ROC [MOST 104-2320-B-110-003, 105-2320-B-110-004, MOST 101-2628-B-400-003-MY2, MOST 105-2321-B-400-010]; Kaohsiung Medical University, Kaohsiung, Taiwan [KMU-TP104G00, KMU-TP105G00]; National Institutes of Health, USA [R01 DE14036]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014036] Funding Source: NIH RePORTER	Ministry of Science and Technology, Taiwan ROC(Ministry of Science and Technology, Taiwan); Kaohsiung Medical University, Kaohsiung, Taiwan; National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by grants MOST 104-2320-B-110-003 and 105-2320-B-110-004 (to KH Cheng), MOST 101-2628-B-400-003-MY2 (to LT Chen) and MOST 105-2321-B-400-010 (to LT Chen and KH Cheng) from the Ministry of Science and Technology, Taiwan ROC, and grants KMU-TP104G00, KMU-TP105G00 (to KH Cheng) from Kaohsiung Medical University, Kaohsiung, Taiwan, and grant R01 DE14036 (to JRH and MS) from the National Institutes of Health, USA.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Cao ZX, 2009, J BIOL CHEM, V284, P24914, DOI 10.1074/jbc.M109.000059; Chang VHS, 2012, AM J PATHOL, V181, P423, DOI 10.1016/j.ajpath.2012.04.025; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Cui K, 2011, J SURG RES, V171, P143, DOI 10.1016/j.jss.2010.03.001; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Devine SM, 2004, J CLIN ONCOL, V22, P1095, DOI 10.1200/JCO.2004.07.131; Dubrovsky L, 2014, BLOOD, V123, P3296, DOI 10.1182/blood-2014-01-549022; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gu HJ, 2008, CLIN CANCER RES, V14, P3627, DOI 10.1158/1078-0432.CCR-07-4808; Hawse JR, 2008, BONE, V42, P1025, DOI 10.1016/j.bone.2008.02.004; Hawse JR, 2008, MOL ENDOCRINOL, V22, P1579, DOI 10.1210/me.2007-0253; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Iacopetta BJ, 1998, J PATHOL, V184, P390; Im KS, 2017, VET COMP ONCOL, V15, P315, DOI 10.1111/vco.12165; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jiang L, 2009, CANCER LETT, V274, P101, DOI 10.1016/j.canlet.2008.09.017; Jin W, 2012, MOL CELL BIOL, V32, P50, DOI 10.1128/MCB.06152-11; Johnsen SA, 2002, ONCOGENE, V21, P5783, DOI 10.1038/sj.onc.1205681; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mukherjee D, 2013, AM J CANCER RES, V3, P46; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nervi B, 2009, BLOOD, V113, P6206, DOI 10.1182/blood-2008-06-162123; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Papadakis KA, 2015, AM J PHYSIOL-CELL PH, V308, pC362, DOI 10.1152/ajpcell.00262.2014; Romero-Gallo J, 2005, ONCOGENE, V24, P3028, DOI 10.1038/sj.onc.1208475; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Singh S, 2004, LAB INVEST, V84, P1666, DOI 10.1038/labinvest.3700181; Sioletic S, 2014, J PATHOL, V234, P190, DOI 10.1002/path.4379; Spittau B, 2012, CELL TISSUE RES, V347, P65, DOI 10.1007/s00441-011-1186-6; Spittau G, 2010, J NEUROSCI RES, V88, P2017, DOI 10.1002/jnr.22364; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Subramaniam M, 2010, BIOFACTORS, V36, P8, DOI 10.1002/biof.67; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Tau KR, 1998, ENDOCRINOLOGY, V139, P1346, DOI 10.1210/en.139.3.1346; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	55	21	21	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5532	5543		10.1038/onc.2017.155	http://dx.doi.org/10.1038/onc.2017.155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28581520				2022-12-17	WOS:000411960500009
J	Han, B; Kpark, H; Ching, T; Panneerselvam, J; Wang, H; Shen, Y; Zhang, J; Li, L; Che, R; Garmire, L; Fei, P				Han, B.; KPark, H.; Ching, T.; Panneerselvam, J.; Wang, H.; Shen, Y.; Zhang, J.; Li, L.; Che, R.; Garmire, L.; Fei, P.			Human DBR1 modulates the recycling of snRNPs to affect alternative RNA splicing and contributes to the suppression of cancer development	ONCOGENE			English	Article							DISTINCT METABOLIC SIGNATURE; HUMAN BLADDER-CANCER; TUMOR-SUPPRESSOR; BRANCH POINT; DEBRANCHING ENZYME; DNA-DAMAGE; SPLICEOSOME; PATHWAY; FANCD2; COMPLEX	The contribution of RNA processing to tumorigenesis is understudied. Here, we report that the human RNA debranching enzyme (hDBR1), when inappropriately regulated, induces oncogenesis by causing RNA processing defects, for example, splicing defects. We found that wild-type p53 and hypoxia-inducible factor 1 co-regulate hDBR1 expression, and insufficient hDBR1 leads to a higher rate of exon skipping. Transcriptomic sequencing confirmed the effect of hDBR1 on RNA splicing, and metabolite profiling supported the observation that neoplasm is triggered by a decrease in hDBR1 expression both in vitro and in vivo. Most importantly, when modulating the expression of hDBR1, which was found to be generally low in malignant human tissues, higher expression of hDBR1 only affected exon-skipping activity in malignant cells. Together, our findings demonstrate previously unrecognized regulation and functions of hDBR1, with immediate clinical implications regarding the regulation of hDBR1 as an effective strategy for combating human cancer.	[Han, B.; Panneerselvam, J.; Shen, Y.; Li, L.; Che, R.; Fei, P.] Univ Hawaii, Canc Ctr, Div Canc Biol, 701 Ilalo St, Honolulu, HI 96813 USA; [KPark, H.; Wang, H.; Zhang, J.] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Rochester, MN USA; [Ching, T.; Garmire, L.; Fei, P.] Univ Hawaii, Canc Ctr, Div Epidemiol, Honolulu, HI 96813 USA; [Li, L.] Xuzhou Med Coll, Canc Inst, Xuzhou, Peoples R China	Cancer Research Center of Hawaii; University of Hawaii System; Mayo Clinic; Cancer Research Center of Hawaii; University of Hawaii System; Xuzhou Medical University	Fei, P (corresponding author), Univ Hawaii, Canc Ctr, Div Canc Biol, 701 Ilalo St, Honolulu, HI 96813 USA.	Pfei@cc.hawaii.edu		HAN, BING/0000-0002-0818-409X; li, liantao/0000-0002-8788-2880; Ching, Travers/0000-0002-5577-3516	NIH [R01CA136532, R01CA188251]; Chinese National Science Foundation (CNSF) [81372171]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD084633] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA071789, R01CA136532, R01CA188251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K01ES025434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103457] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM012373] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chinese National Science Foundation (CNSF)(National Natural Science Foundation of China (NSFC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	This study was supported in part by NIH grants (R01CA136532 and R01CA188251) to PF and Chinese National Science Foundation (CNSF#81372171) to PF. We thank Dr Alberto R Kornblihtt (Universidad de Buenos Aires, Argentina) for providing the FN-EDI reporter construct.	Azubel M, 2004, MOL CELL, V15, P833, DOI 10.1016/j.molcel.2004.07.022; Barrett SP, 2015, ELIFE, V4, DOI 10.7554/eLife.07540; Bischof O, 2015, IUBMB LIFE, V67, P255, DOI 10.1002/iub.1373; Bitton DA, 2014, GENOME RES, V24, P1169, DOI 10.1101/gr.166819.113; Carstens RP, 2014, MOL CELL, V54, P903, DOI 10.1016/j.molcel.2014.06.014; Chan SP, 2003, SCIENCE, V302, P279, DOI 10.1126/science.1086602; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; Clark NE, 2016, P NATL ACAD SCI USA, V113, P14727, DOI 10.1073/pnas.1612729114; Clerte C, 2009, BIOCHEMISTRY-US, V48, P2063, DOI 10.1021/bi8016872; Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012; Fourmann JB, 2013, GENE DEV, V27, P413, DOI 10.1101/gad.207779.112; Frye M, 2016, DEVELOPMENT, V143, P3871, DOI 10.1242/dev.136556; Fu DC, 2013, CELL CYCLE, V12, P803, DOI 10.4161/cc.23755; Gao KP, 2008, NUCLEIC ACIDS RES, V36, P2257, DOI 10.1093/nar/gkn073; Han B, 2017, ONCOTARGET, V8, P22490, DOI 10.18632/oncotarget.14989; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hube F, 2017, NUCLEIC ACIDS RES, V45, P4768, DOI 10.1093/nar/gkw1341; Ilagan JO, 2013, RNA, V19, P400, DOI 10.1261/rna.034223.112; Kataoka N, 2013, SCI REP-UK, V3, DOI 10.1038/srep01090; Kataoka N, 2009, MOL CELL BIOL, V29, P3243, DOI 10.1128/MCB.00360-09; Kock KH, 2015, NUCLEIC ACIDS RES, V43, P6568, DOI 10.1093/nar/gkv617; Kol G, 2005, HUM MOL GENET, V14, P1559, DOI 10.1093/hmg/ddi164; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lee Y, 2015, ANNU REV BIOCHEM, V84, P291, DOI 10.1146/annurev-biochem-060614-034316; Li ZL, 2016, OXID MED CELL LONGEV, V2016, P12, DOI DOI 10.1007/S10529-016-2066-7; Matera AG, 2014, NAT REV MOL CELL BIO, V15, P108, DOI 10.1038/nrm3742; Moore MJ, 2010, CELL, V142, P625, DOI 10.1016/j.cell.2010.07.019; Munoz MJ, 2009, CELL, V137, P708, DOI 10.1016/j.cell.2009.03.010; Nam K, 1997, MOL CELL BIOL, V17, P809, DOI 10.1128/MCB.17.2.809; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Ohi MD, 2007, P NATL ACAD SCI USA, V104, P3195, DOI 10.1073/pnas.0611591104; Panneerselvam J, 2016, J PROTEOME RES, V15, P1333, DOI 10.1021/acs.jproteome.6b00076; Panneerselvam J, 2014, ONCOTARGET, V5, P1326, DOI 10.18632/oncotarget.1796; Panneerselvam J, 2013, ONCOTARGET, V4, P1416, DOI 10.18632/oncotarget.1217; Panneerselvam J, 2012, CELL CYCLE, V11, P2947, DOI 10.4161/cc.21400; Park HK, 2011, CELL CYCLE, V10, P2574, DOI 10.4161/cc.10.15.15923; Park HK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013313; Pastuszak AW, 2011, NUCLEIC ACIDS RES, V39, P2344, DOI 10.1093/nar/gkq1046; Qiu YP, 2014, CLIN CANCER RES, V20, P2136, DOI 10.1158/1078-0432.CCR-13-1939; Qiu YP, 2013, INT J MOL SCI, V14, P8047, DOI 10.3390/ijms14048047; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; SHARP PA, 1987, SCIENCE, V238, P729, DOI 10.1126/science.2445035; Sullenger BA, 2016, SCIENCE, V352, P1417, DOI 10.1126/science.aad8709; Svoronos AA, 2016, CANCER RES, V76, P3666, DOI 10.1158/0008-5472.CAN-16-0359; Wahl MC, 2015, CELL, V161, P1474, DOI 10.1016/j.cell.2015.05.050; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Ward AJ, 2010, J PATHOL, V220, P152, DOI 10.1002/path.2649; Yoshimoto R, 2009, NUCLEIC ACIDS RES, V37, P891, DOI 10.1093/nar/gkn1002; Zheng SM, 2015, CELL, V161, P762, DOI 10.1016/j.cell.2015.03.020	52	21	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5382	5391		10.1038/onc.2017.150	http://dx.doi.org/10.1038/onc.2017.150			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28504715	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000411382100005
J	Xin, B; Yamamoto, M; Fujii, K; Ooshio, T; Chen, X; Okada, Y; Watanabe, K; Miyokawa, N; Furukawa, H; Nishikawa, Y				Xin, B.; Yamamoto, M.; Fujii, K.; Ooshio, T.; Chen, X.; Okada, Y.; Watanabe, K.; Miyokawa, N.; Furukawa, H.; Nishikawa, Y.			Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways	ONCOGENE			English	Article							C-MYC; HEPATOCELLULAR-CARCINOMA; SLEEPING-BEAUTY; IN-VIVO; SOMATIC INTEGRATION; TRANSPOSON SYSTEM; N-RAS; CANCER; CELLS; MICE	MYC activation at modest levels has been frequently found in hepatocellular carcinoma. However, its significance in hepatocarcinogenesis has remained obscure. Here we examined the role of Myc activation in mouse liver tumours induced by hepatocytic expression of myristoylated AKT (AKT) and/or mutant HRAS(V12) (HRAS) via transposon-mediated gene integration. AKT or HRAS alone required 5 months to induce liver tumours, whereas their combination generated hepatocellular carcinoma within 8 weeks. Co-introduction of AKT and HRAS induced lipid-laden preneoplastic cells that grew into nodules composed of tumour cells with or without intracytoplasmic lipid, with the latter being more proliferative and associated with spontaneous Myc expression. AKT/HRAS-induced tumorigenesis was almost completely abolished when MadMyc, a competitive Myc inhibitor, was expressed simultaneously. The Tet-On induction of MadMyc in preneoplastic cells significantly inhibited the progression of AKT/HRAS-induced tumours; its induction in transformed cells suppressed their proliferative activity with alterations in lipid metabolism and protein translation. Transposon-mediated Myc overexpression facilitated tumorigenesis by AKT or HRAS, and when it was co-introduced with AKT and HRAS, diffusely infiltrating tumours without lipid accumulation developed as early as 2 weeks. Examination of the dose-responses of Myc in the enhancement of AKT/HRAS-induced tumorigenesis revealed that a reduction to one-third retained enhancing effect but three-times greater introduction damped the process with increased apoptosis. Myc overexpression suppressed the mRNA expression of proteins involved in the synthesis of fatty acids, and when combined with HRAS introduction, it also suppressed the mRNA expression of proteins involved in their degradation. Finally, the MYC-positive human hepatocellular carcinoma was characterized by the cytoplasm devoid of lipid accumulation, prominent nucleoli and a higher proliferative activity. Our results demonstrate that in hepatocarcinogenesis induced by both activated AKT and HRAS, activation of endogenous Myc is an enhancing factor and adequate levels of Myc deregulation further facilitate the process with alterations in cellular metabolism.	[Xin, B.; Yamamoto, M.; Fujii, K.; Ooshio, T.; Chen, X.; Okada, Y.; Watanabe, K.; Nishikawa, Y.] Asahikawa Med Univ, Dept Pathol, Div Tumor Pathol, Higashi 2-1-1-1, Asahikawa, Hokkaido 0788510, Japan; [Watanabe, K.; Furukawa, H.] Asahikawa Med Univ, Dept Surg, Div Gastroenterol & Gen Surg, Asahikawa, Hokkaido, Japan; [Miyokawa, N.] Asahikawa Med Univ, Dept Surg Pathol, Asahikawa, Hokkaido, Japan	Asahikawa Medical College; Asahikawa Medical College; Asahikawa Medical College	Nishikawa, Y (corresponding author), Asahikawa Med Univ, Dept Pathol, Div Tumor Pathol, Higashi 2-1-1-1, Asahikawa, Hokkaido 0788510, Japan.	nishikwa@asahikawa-med.ac.jp		Xin, Bing/0000-0002-8644-2429	Ministry of Education, Culture, Sports, Science, and Technology of Japan [26870025, 18590362, 21590426, 24390092]; Grants-in-Aid for Scientific Research [15K15107] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (#26870025 to MY; #18590362, #21590426 and #24390092 to YN). We thank Mr Yoshiyasu Satake for animal care and Ms Ema Yamatomi, Ms Hiroko Chiba, and Ms Aya Kitano for secretarial assistance. We are also grateful to the staff of the Department of Pathology, Asahikawa Medical University Hospital for generous help.	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Akita H, 2014, CANCER RES, V74, P5903, DOI 10.1158/0008-5472.CAN-14-0527; Antonov A, 2014, ONCOTARGET, V5, P11004, DOI 10.18632/oncotarget.2668; Bell JB, 2007, NAT PROTOC, V2, P3153, DOI 10.1038/nprot.2007.471; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006; Carlson CM, 2005, P NATL ACAD SCI USA, V102, P17059, DOI 10.1073/pnas.0502974102; Carroll M, 2013, J INTERF CYTOK RES, V33, P227, DOI 10.1089/jir.2012.0142; Castellano E, 2007, ONCOGENE, V26, P917, DOI 10.1038/sj.onc.1209845; Castellano E, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r123; Chen X, 2015, CANCER SCI, V106, P972, DOI 10.1111/cas.12700; Chow EKH, 2012, HEPATOLOGY, V56, P1331, DOI 10.1002/hep.25776; Coulouarn C, 2006, HEPATOLOGY, V44, P1003, DOI 10.1002/hep.21293; De Ponti A, 2015, CANCER LETT, V369, P396, DOI 10.1016/j.canlet.2015.09.005; Diersch S, 2016, ONCOGENE, V35, P3880, DOI 10.1038/onc.2015.437; Factor VM, 1998, J BIOL CHEM, V273, P15846, DOI 10.1074/jbc.273.25.15846; FUJIWARA Y, 1993, CANCER RES, V53, P857; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Ho C, 2012, HEPATOLOGY, V55, P833, DOI 10.1002/hep.24736; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Poortinga G, 2015, ONCOGENE, V34, P403, DOI 10.1038/onc.2014.13; Qu AJ, 2014, J HEPATOL, V60, P331, DOI 10.1016/j.jhep.2013.09.024; Ren JW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153863; SANDGREN EP, 1989, ONCOGENE, V4, P715; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Stein TJ, 2011, LIVER INT, V31, P1298, DOI 10.1111/j.1478-3231.2011.02596.x; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Wahlstrom T, 2015, BBA-GENE REGUL MECH, V1849, P563, DOI 10.1016/j.bbagrm.2014.07.004; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Zhang YX, 2014, MOL ENDOCRINOL, V28, P116, DOI 10.1210/me.2013-1268; Zhu JD, 2008, P NATL ACAD SCI USA, V105, P6584, DOI 10.1073/pnas.0802785105; Zirath H, 2013, P NATL ACAD SCI USA, V110, P10258, DOI 10.1073/pnas.1222404110; Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061	48	21	21	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5087	5097		10.1038/onc.2017.114	http://dx.doi.org/10.1038/onc.2017.114			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481866	Green Published, hybrid, Green Submitted			2022-12-17	WOS:000409371100001
J	Raja, E; Komuro, A; Tanabe, R; Sakai, S; Ino, Y; Saito, N; Todo, T; Morikawa, M; Aburatani, H; Koinuma, D; Iwata, C; Miyazono, K				Raja, E.; Komuro, A.; Tanabe, R.; Sakai, S.; Ino, Y.; Saito, N.; Todo, T.; Morikawa, M.; Aburatani, H.; Koinuma, D.; Iwata, C.; Miyazono, K.			Bone morphogenetic protein signaling mediated by ALK-2 and DLX2 regulates apoptosis in glioma-initiating cells	ONCOGENE			English	Article							ACTIVATING ACVR1 MUTATIONS; RECEPTOR KINASE INHIBITOR; CANCER STEM-CELLS; NEURONAL DIFFERENTIATION; TRANSCRIPTION FACTORS; MALIGNANT GLIOMA; VALPROIC ACID; I RECEPTORS; GLIOBLASTOMA; PATHWAY	Bone morphogenetic protein (BMP) signaling exerts antitumor activities in glioblastoma; however, its precise mechanisms remain to be elucidated. Here, we demonstrated that the BMP type I receptor ALK-2 (encoded by the ACVR1 gene) has crucial roles in apoptosis induction of patient-derived glioma-initiating cells (GICs), TGS-01 and TGS-04. We also characterized a BMP target gene, Distal-less homeobox 2 (DLX2), and found that DLX2 promoted apoptosis and neural differentiation of GICs. The tumor-suppressive effects of ALK-2 and DLX2 were further confirmed in a mouse orthotopic transplantation model. Interestingly, valproic acid (VPA), an anti-epileptic compound, induced BMP2, BMP4, ACVR1 and DLX2 mRNA expression with a concomitant increase in phosphorylation of Smad1/5. Consistently, we showed that treatment with VPA induced apoptosis of GICs, whereas silencing of ALK-2 or DLX2 expression partially suppressed it. Our study thus reveals BMP-mediated inhibitory mechanisms for glioblastoma, which explains, at least in part, the therapeutic effects of VPA.	[Raja, E.; Komuro, A.; Tanabe, R.; Sakai, S.; Morikawa, M.; Koinuma, D.; Iwata, C.; Miyazono, K.] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; [Ino, Y.; Todo, T.] Univ Tokyo, Inst Med Sci, Div Innovat Canc Therapy, Tokyo, Japan; [Saito, N.] Univ Tokyo, Grad Sch Med, Dept Neurosurg, Tokyo, Japan; [Aburatani, H.] Univ Tokyo, Res Ctr Adv Sci & Technol RCAST, Genome Sci Div, Tokyo, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Morikawa, Masato/D-1932-2011; Koinuma, Daizo/Y-8716-2018	Morikawa, Masato/0000-0002-6191-7176; Koinuma, Daizo/0000-0001-5611-2122; Todo, Tomoki/0000-0003-0523-8010	Ministry of Education, Culture, Sports and Technology of Japan (MEXT) [KAKENHI 22112002]; Japan Society for the Promotion of Science (JSPS) [24390070, 15H05774]; Ministry of Health, Labour and Welfare of Japan [201220012C]; JSPS; Naito Foundation; Grants-in-Aid for Scientific Research [15H05774] Funding Source: KAKEN	Ministry of Education, Culture, Sports and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Naito Foundation(Naito Memorial Foundation); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Y Kakiuchi for animal care. This work was supported by Grants-in-Aid for Scientific Research (KAKENHI 22112002) from the Ministry of Education, Culture, Sports and Technology of Japan (MEXT) and Scientific Research (B) and (S) (24390070 and 15H05774, respectively, KM) from the Japan Society for the Promotion of Science (JSPS), Grant-in-Aid from the Ministry of Health, Labour and Welfare of Japan (201220012C), the JSPS Core-to-Core Program 'Cooperative International Framework in TGF-beta Family Signalling', and a grant from the Naito Foundation.	Andrews GL, 2003, MOL CELL NEUROSCI, V23, P107, DOI 10.1016/S1044-7431(03)00016-2; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Bezecny P, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0985-5; Buczkowicz P, 2014, NAT GENET, V46, P451, DOI 10.1038/ng.2936; Cai J, 2015, STEM CELL REP, V5, P963, DOI 10.1016/j.stemcr.2015.10.020; Caren H, 2015, STEM CELL REP, V5, P829, DOI 10.1016/j.stemcr.2015.09.014; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choe Y, 2013, J NEUROSCI, V33, P6766, DOI 10.1523/JNEUROSCI.0128-13.2013; Davis H, 2016, CYTOKINE GROWTH F R, V27, P81, DOI 10.1016/j.cytogfr.2015.11.009; Dey D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1090; Du Y, 2010, DIFFERENTIATION, V79, P84, DOI 10.1016/j.diff.2009.10.003; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; Fontebasso AM, 2014, NAT GENET, V46, P462, DOI 10.1038/ng.2950; Frew AJ, 2009, CANCER LETT, V280, P125, DOI 10.1016/j.canlet.2009.02.042; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ghanem N, 2012, J NEUROSCI, V32, P8219, DOI 10.1523/JNEUROSCI.1344-12.2012; Guichet PO, 2013, GLIA, V61, P225, DOI 10.1002/glia.22429; Hallahan AR, 2003, NAT MED, V9, P1033, DOI 10.1038/nm904; Hide T, 2009, CANCER RES, V69, P7953, DOI 10.1158/0008-5472.CAN-09-2006; Hoshino Y, 2015, AM J PATHOL, V185, P1457, DOI 10.1016/j.ajpath.2015.01.011; Hover LD, 2016, NEURO-ONCOLOGY, V18, P928, DOI 10.1093/neuonc/nov310; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Hu WX, 2015, CELL STEM CELL, V17, P204, DOI 10.1016/j.stem.2015.07.006; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Jones C, 2012, NAT REV CLIN ONCOL, V9, P400, DOI 10.1038/nrclinonc.2012.87; Katagiri T, 2016, COLD SPRING HARB PER, V8; Kendall SE, 2005, MOL CELL BIOL, V25, P7711, DOI 10.1128/MCB.25.17.7711-7724.2005; Kodama Y, 2015, NUCLEIC ACIDS RES, V43, pD18, DOI 10.1093/nar/gku1120; Krauze AV, 2015, INT J RADIAT ONCOL, V92, P986, DOI 10.1016/j.ijrobp.2015.04.038; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Li H, 2014, J CELL BIOCHEM, V115, P2004, DOI 10.1002/jcb.24872; Liu S, 2016, ONCOTARGET, V7, P17920, DOI 10.18632/oncotarget.7472; Liu S, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-52; Liu XS, 2012, NEUROSCIENCE, V220, P313, DOI 10.1016/j.neuroscience.2012.06.012; Mehta S, 2011, CANCER CELL, V19, P359, DOI 10.1016/j.ccr.2011.01.035; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Mizutani A, 2016, ONCOGENE, V35, P3514, DOI 10.1038/onc.2015.412; Mohedas AH, 2013, ACS CHEM BIOL, V8, P1291, DOI 10.1021/cb300655w; Moon BS, 2009, EXP MOL MED, V41, P116, DOI 10.3858/emm.2009.41.2.014; Panchision DM, 2001, GENE DEV, V15, P2094, DOI 10.1101/gad.894701; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Park GT, 2001, FEBS LETT, V496, P60, DOI 10.1016/S0014-5793(01)02398-5; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Podkowa M, 2013, MOL CELL NEUROSCI, V57, P83, DOI 10.1016/j.mcn.2013.10.005; Sakurai T, 2016, ONCOGENE, V35, P5000, DOI 10.1038/onc.2016.35; Santra M, 2006, CANCER RES, V66, P11726, DOI 10.1158/0008-5472.CAN-06-1978; Savary K, 2013, ONCOGENE, V32, P5409, DOI 10.1038/onc.2013.67; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Su ZD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4338; Taylor KR, 2014, NAT GENET, V46, P457, DOI 10.1038/ng.2925; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Weller M, 2013, NEURO-ONCOLOGY, V15, P4, DOI 10.1093/neuonc/nos273; Wu XW, 2010, CANCER RES, V70, P2718, DOI 10.1158/0008-5472.CAN-09-3631; Yan K, 2014, GENE DEV, V28, P1085, DOI 10.1101/gad.235515.113; Yu PB, 2008, J BIOL CHEM, V283, P3877, DOI 10.1074/jbc.M706797200; Zhou ZM, 2011, CANCER BIOTHER RADIO, V26, P77, DOI 10.1089/cbr.2010.0857	59	21	22	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					4963	4974		10.1038/onc.2017.112	http://dx.doi.org/10.1038/onc.2017.112			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459464				2022-12-17	WOS:000408768800002
J	Zhao, J; Wang, Y; Mu, C; Xu, Y; Sang, J				Zhao, J.; Wang, Y.; Mu, C.; Xu, Y.; Sang, J.			MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells	ONCOGENE			English	Article							NOTCH SIGNALING PATHWAY; STEM-CELLS; CANCER/TESTIS ANTIGENS; GENE-EXPRESSION; C-JUN; PROTEIN; FAMILY; RESISTANCE; PHENOTYPE; MIGRATION	Melanoma-associated antigen A1 (MAGEA1) is member of the MAGE gene family that is expressed in male germ line cells and placenta under normal physiological conditions. Although MAGEA1's expression levels have been evaluated as one of the cancer testis (CT) antigens for immunotherapy in melanoma and several other cancers, its functional role and signaling mechanisms are largely unknown. In this study, we examined the functional involvement and signaling mechanisms of MAGEA1 in breast and ovarian cancer cells. Inhibitory effects of MAGEA1 on cell proliferation and migration were observed using both gain-of-(MAGEA1 overexpression) and loss-of-(siRNA interference) function approaches in breast (MCF-7 and MDA-MB-231) and ovarian (SKOV3 and SKOV3ip) cancer cell lines. We revealed a novel interaction between MAGEA1 and the intracellular segment of NOTCH1 receptor (NICD1). MAGEA1 reduced NICD1's stability by promoting the ubiquitin modification of NICD1. MAGEA1 also interacted with FBXW7, a subunit of E3 ubiquitin protein ligase complex SCF, and the latter was functionally involved in NICD1 ubiquitination and degradation. In addition, siRNA interference of FBXW7 reversed the inhibitory effect of MAGEA1 on migration and proliferation of MCF-7 and MDA-MB-231 cells. These newly discovered MAGEA1-NICD1 and MAGEA1-FBXW7 interactions have potential clinical implications in breast and ovarian cancer treatment.	[Zhao, J.; Wang, Y.; Mu, C.; Xu, Y.; Sang, J.] Beijing Normal Univ, Coll Life Sci, Key Lab Cell Proliferat & Regulat, 19 XinJieKouWai St, Beijing 100875, Peoples R China; [Xu, Y.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA	Beijing Normal University; Indiana University System; Indiana University Bloomington	Xu, Y; Sang, J (corresponding author), Beijing Normal Univ, Coll Life Sci, Key Lab Cell Proliferat & Regulat, 19 XinJieKouWai St, Beijing 100875, Peoples R China.	xu2@iupui.edu; jlsang@bnu.edu.cn			National Basic Research Program of China [2007CB914401]; National High Technology Research and Development Program of China [2006AA02Z4A6]; Mary Fendrich-Hulman Charitable Trust Fund	National Basic Research Program of China(National Basic Research Program of China); National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); Mary Fendrich-Hulman Charitable Trust Fund	This work was supported in part by The National Basic Research Program of China (Grant no. 2007CB914401) and the National High Technology Research and Development Program of China (Grant no. 2006AA02Z4A6) to JS; as well as in part by the Mary Fendrich-Hulman Charitable Trust Fund to YX. We would like to thank Kevin McClelland for editing the manuscript.	Abd-Elsalam EA, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0285-0; Acar A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2498764; Askew EB, 2009, J BIOL CHEM, V284, P34793, DOI 10.1074/jbc.M109.065979; Bao B, 2011, CANCER LETT, V307, P26, DOI 10.1016/j.canlet.2011.03.012; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bolos V, 2013, BREAST CANCER RES, V15, P15; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brzozowa-Zasada M, 2016, WSPOLCZESNA ONKOL, V20, P267, DOI 10.5114/wo.2016.61845; Daudi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104099; De Plaen E, 1999, GENOMICS, V55, P176, DOI 10.1006/geno.1998.5638; Doyle JM, 2010, MOL CELL, V39, P963, DOI 10.1016/j.molcel.2010.08.029; Ladelfa MF, 2012, CANCER LETT, V325, P11, DOI 10.1016/j.canlet.2012.05.031; Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gillespie AM, 1999, CANCER TREAT REV, V25, P219, DOI 10.1053/ctrv.1999.0126; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hao JQ, 2015, ONCOTARGET, V6, P42028, DOI 10.18632/oncotarget.5973; Heasley LE, 2006, MOL CELLS, V21, P167; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hu YY, 2012, ADV EXP MED BIOL, V727, P186, DOI 10.1007/978-1-4614-0899-4_14; Kim HL, 2001, CANCER RES, V61, P2833; Kitade S, 2016, CANCER SCI, V107, P1399, DOI 10.1111/cas.13026; Kloudova K, 2016, ONCOTARGET, V7, P46120, DOI 10.18632/oncotarget.10028; Kozakova L, 2015, CELL CYCLE, V14, P920, DOI 10.1080/15384101.2014.1000112; Laduron S, 2004, NUCLEIC ACIDS RES, V32, P4340, DOI 10.1093/nar/gkh735; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; Marcar L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127713; Marcar L, 2010, CANCER RES, V70, P10362, DOI 10.1158/0008-5472.CAN-10-1341; Matkovic B, 2011, CROAT MED J, V52, P171, DOI 10.3325/cmj.2011.52.171; Minges JT, 2013, J BIOL CHEM, V288, P1939, DOI 10.1074/jbc.M112.428409; Monte M, 2006, P NATL ACAD SCI USA, V103, P11160, DOI 10.1073/pnas.0510834103; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Otte M, 2001, CANCER RES, V61, P6682; Peche LY, 2012, CELL DEATH DIFFER, V19, P926, DOI 10.1038/cdd.2011.173; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Pui CH, 2009, CANCER CELL, V15, P85, DOI 10.1016/j.ccr.2009.01.007; Saha SK, 2017, ONCOGENE, V36, P332, DOI 10.1038/onc.2016.221; She QB, 2002, CANCER RES, V62, P1343; Shukla G, 2017, CURR STEM CELL RES T, V12, P207, DOI 10.2174/1574888X11666161028143224; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; TRAVERSARI C, 1992, IMMUNOGENETICS, V35, P145, DOI 10.1007/BF00185107; Tseng HY, 2012, CARCINOGENESIS, V33, P1871, DOI 10.1093/carcin/bgs236; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Wang D, 2016, BIOCHEM BIOPH RES CO, V473, P959, DOI 10.1016/j.bbrc.2016.03.161; WEINBERGER M, 1989, ARTHRITIS RHEUM, V32, P1577, DOI 10.1002/anr.1780321212; Weon JL, 2015, CURR OPIN CELL BIOL, V37, P1, DOI 10.1016/j.ceb.2015.08.002; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Zhang SQ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-163; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	54	21	22	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5023	5034		10.1038/onc.2017.131	http://dx.doi.org/10.1038/onc.2017.131			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459460				2022-12-17	WOS:000408768800007
J	Schaefer, SM; Segalada, C; Cheng, PF; Bonalli, M; Parfejevs, V; Levesque, MP; Dummer, R; Nicolis, SK; Sommer, L				Schaefer, S. M.; Segalada, C.; Cheng, P. F.; Bonalli, M.; Parfejevs, V.; Levesque, M. P.; Dummer, R.; Nicolis, S. K.; Sommer, L.			Sox2 is dispensable for primary melanoma and metastasis formation	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; CANCER STEM-CELLS; INITIATING CELLS; TRANSCRIPTION FACTOR; CUTANEOUS MELANOMA; MOUSE MODEL; EXPRESSION; TUMORIGENICITY; NEUROGENESIS; MAINTENANCE	Tumor initiation and metastasis formation in many cancers have been associated with emergence of a gene expression program normally active in embryonic or organ-specific stem cells. In particular, the stem cell transcription factor Sox2 is not only expressed in a variety of tumors, but is also required for their formation. Melanoma, the most aggressive skin tumor, derives from melanocytes that during development originate from neural crest stem cells. While neural crest stem cells do not express Sox2, expression of this transcription factor has been reported in melanoma. However, the role of Sox2 in melanoma is controversial. To study the requirement of Sox2 for melanoma formation, we therefore performed CRISPR-Cas9-mediated gene inactivation in human melanoma cells. In addition, we conditionally inactivated Sox2 in a genetically engineered mouse model, in which melanoma spontaneously develops in the context of an intact stroma and immune system. Surprisingly, in both models, loss of Sox2 did neither affect melanoma initiation, nor growth, nor metastasis formation. The lack of a tumorigenic role of Sox2 in melanoma might reflect a distinct stem cell program active in neural crest stem cells and during melanoma formation.	[Schaefer, S. M.; Segalada, C.; Bonalli, M.; Parfejevs, V.; Sommer, L.] Univ Zurich, Inst Anat, Winterthurerstr 190, CH-8057 Zurich, Switzerland; [Cheng, P. F.; Levesque, M. P.; Dummer, R.] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland; [Nicolis, S. K.] Univ Milano Bicocca, Dept Biotechnol & Biosci, Milan, Italy	University of Zurich; University of Zurich; University Zurich Hospital; University of Milano-Bicocca	Sommer, L (corresponding author), Univ Zurich, Inst Anat, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	lukas.sommer@anatom.uzh.ch	Cheng, Phil/AAN-8567-2021	Cheng, Phil/0000-0003-2940-006X; NICOLIS, SILVIA KIRSTEN/0000-0003-0378-3808; Parfejevs, Vadims/0000-0002-1836-3999; Segalada, Corina/0000-0003-4187-4145	Swiss National Science Foundation (SNF); University Research Priority Program (URPP) 'Translational Cancer Research' Biobank; Swiss Cancer League; AIRC; Telethon	Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); University Research Priority Program (URPP) 'Translational Cancer Research' Biobank; Swiss Cancer League; AIRC(Fondazione AIRC per la ricerca sul cancro); Telethon(Fondazione Telethon)	We thank Annika Klug for help with hematoxylin and eosin stainings and Jessica Hausel for assistance in histology. We would like to thank Daniel Zingg for his help with statistical analysis. Further, we acknowledge the advice by the Cancer Biology PhD program of the University of Zurich. This work was supported by the Swiss National Science Foundation (SNF), the University Research Priority Program (URPP) 'Translational Cancer Research' Biobank, and the Swiss Cancer League. Work in the Nicolis laboratory was supported by AIRC and Telethon.	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Basu-Roy U, 2010, CELL DEATH DIFFER, V17, P1345, DOI 10.1038/cdd.2010.57; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; BUTTNER P, 1995, CANCER-AM CANCER SOC, V75, P2499, DOI 10.1002/1097-0142(19950515)75:10<2499::AID-CNCR2820751016>3.0.CO;2-8; Buzaid AC, 1997, J CLIN ONCOL, V15, P1039, DOI 10.1200/JCO.1997.15.3.1039; Bylund M, 2003, NAT NEUROSCI, V6, P1162, DOI 10.1038/nn1131; Carrasco-Garcia E, 2016, AM J CANCER RES, V6, P701; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cesarini V, ONCOGENE; Chen PL, 2013, MODERN PATHOL, V26, P44, DOI 10.1038/modpathol.2012.132; Civenni G, 2011, CANCER RES, V71, P3098, DOI 10.1158/0008-5472.CAN-10-3997; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Driskell RR, 2009, DEVELOPMENT, V136, P2815, DOI 10.1242/dev.038620; Favaro R, 2014, CANCER RES, V74, P1833, DOI 10.1158/0008-5472.CAN-13-1942; Favaro R, 2009, NAT NEUROSCI, V12, P1248, DOI 10.1038/nn.2397; Ferone G, 2016, CANCER CELL, V30, P519, DOI 10.1016/j.ccell.2016.09.001; Ferri ALM, 2004, DEVELOPMENT, V131, P3805, DOI 10.1242/dev.01204; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Girouard SD, 2012, LAB INVEST, V92, P362, DOI 10.1038/labinvest.2011.188; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Kareta MS, 2015, CELL STEM CELL, V16, P39, DOI 10.1016/j.stem.2014.10.019; Kaufman CK, 2016, SCIENCE, V351, DOI 10.1126/science.aad2197; Laga AC, 2011, EXP DERMATOL, V20, P339, DOI 10.1111/j.1600-0625.2011.01247.x; Laga AC, 2010, AM J PATHOL, V176, P903, DOI 10.2353/ajpath.2010.090495; Li H, 2012, CELL STEM CELL, V11, P845, DOI 10.1016/j.stem.2012.09.014; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Miyagi S, 2008, FEBS LETT, V582, P2811, DOI 10.1016/j.febslet.2008.07.011; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Sarkar A, 2016, CELL REP, V16, P1929, DOI 10.1016/j.celrep.2016.07.034; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Shakhova O, 2013, CANCER LETT, V338, P74, DOI 10.1016/j.canlet.2012.10.009; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Taranova OV, 2006, GENE DEV, V20, P1187, DOI 10.1101/gad.1407906; Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665; Vanner RJ, 2014, CANCER CELL, V26, P33, DOI 10.1016/j.ccr.2014.05.005; Wakamatsu Y, 2004, DEV DYNAM, V229, P74, DOI 10.1002/dvdy.10498; Weina K, 2016, PIGM CELL MELANOMA R, V29, P453, DOI 10.1111/pcmr.12483; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051; Zipser MC, 2011, PIGM CELL MELANOMA R, V24, P326, DOI 10.1111/j.1755-148X.2010.00823.x	45	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4516	4524		10.1038/onc.2017.55	http://dx.doi.org/10.1038/onc.2017.55			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368416	Green Accepted			2022-12-17	WOS:000406806000013
J	Gupta, R; Yang, Q; Dogra, SK; Wajapeyee, N				Gupta, R.; Yang, Q.; Dogra, S. K.; Wajapeyee, N.			Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progression	ONCOGENE			English	Article							APOPTOSIS INDUCTION; WT1 EXPRESSION; METABOLISM; PATHWAY; SHMT1; SUPPRESSORS; CARCINOMA; CELLS; PROLIFERATION; POLYMORPHISMS	High-grade serous (HGS) ovarian cancer accounts for 90% of all ovarian cancer-related deaths. However, factors that drive HGS ovarian cancer tumor growth have not been fully elucidated. In particular, comprehensive analysis of the metabolic requirements of ovarian cancer tumor growth has not been performed. By analyzing The Cancer Genome Atlas mRNA expression data for HGS ovarian cancer patient samples, we observed that six enzymes of the folic acid metabolic pathway were overexpressed in HGS ovarian cancer samples compared with normal ovary samples. Systematic knockdown of all six genes using short hairpin RNAs (shRNAs) and follow-up functional studies demonstrated that serine hydroxymethyl transferase 1 (SHMT1) was necessary for ovarian cancer tumor growth and cell migration in culture and tumor formation in mice. SHMT1 promoter analysis identified transcription factor Wilms tumor 1 (WT1) binding sites, and WT1 knockdown resulted in reduced SHMT1 transcription in ovarian cancer cells. Unbiased large-scale metabolomic analysis and transcriptome-wide mRNA expression profiling identified reduced levels of several metabolites of the amino sugar and nucleotide sugar metabolic pathways, including sialic acid N-acetylneuraminic acid (Neu5Ac), and downregulation of pro-oncogenic cytokines interleukin-6 and 8 (IL-6 and IL-8) as unexpected outcomes of SHMT1 loss. Overexpression of either IL-6 or IL-8 partially rescued SHMT1 loss-induced tumor growth inhibition and migration. Supplementation of culture medium with Neu5Ac stimulated expression of IL-6 and IL-8 and rescued the tumor growth and migratory phenotypes of ovarian cancer cells expressing SHMT1 shRNAs. In agreement with the ovarian tumor-promoting role of Neu5Ac, treatment with Neu5Ac-targeting glycomimetic P-3Fax-Neu5Ac blocked ovarian cancer growth and migration. Collectively, these results demonstrate that SHMT1 controls the expression of pro-oncogenic inflammatory cytokines by regulating sialic acid Neu5Ac to promote ovarian cancer tumor growth and migration. Thus, targeting of SHMT1 and Neu5Ac represents a precision therapy opportunity for effective HGS ovarian cancer treatment.	[Gupta, R.; Yang, Q.; Wajapeyee, N.] Yale Univ, Sch Med, Dept Pathol, LH-214A,310 Cedar St, New Haven, CT 06510 USA; [Dogra, S. K.] ASTAR, Singapore Inst Clin Sci, Brenner Ctr Mol Med, Singapore, Singapore	Yale University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Institute for Clinical Sciences (SICS)	Wajapeyee, N (corresponding author), Yale Univ, Sch Med, Dept Pathol, LH-214A,310 Cedar St, New Haven, CT 06510 USA.	Narendra.Wajapeyee@yale.edu	Dogra, Shaillay Kumar/K-7073-2015		National Institutes of Health [R21CA197758-01, R21CA191364-01, R01CA196566-01A1, R01CA200919-01, R41 (1R41CA195908-01A1)]; American Cancer Society [128347-RSG-15-212-01-TBG]; NATIONAL CANCER INSTITUTE [R21CA195077, R21CA197758, R41CA195908, R01CA200919, R21CA191364, R01CA196566] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the following grants from the National Institutes of Health: R21CA197758-01 (to NW), R21CA191364-01 (to NW), R01CA196566-01A1 (to NW), R01CA200919-01 (to NW) and R41 (1R41CA195908-01A1) (to NW). NW is also supported by a research scholar grant from the American Cancer Society (128347-RSG-15-212-01-TBG).	Alvero AB, 2014, ONCOTARGET, V5, P8703, DOI 10.18632/oncotarget.2367; Bahari G, 2016, CELL MOL BIOL, V62, P45; Bull C, 2015, ACS NANO, V9, P733, DOI 10.1021/nn5061964; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Chen B, 2016, SCI REP-UK, V6, DOI 10.1038/srep30404; Forloni M, 2016, CELL REP, V16, P457, DOI 10.1016/j.celrep.2016.05.087; Gao B, 2016, J GENE MED, V49, P1325; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haneklaus M, 2015, IMMUNOL REV, V265, P53, DOI 10.1111/imr.12285; Huang WH, 2016, INT J ONCOL, V48, P1125, DOI 10.3892/ijo.2016.3318; Kohnz RA, 2016, ACS CHEM BIOL, V11, P2131, DOI 10.1021/acschembio.6b00433; Lane AN, 2015, NUCLEIC ACIDS RES, V43, P2466, DOI 10.1093/nar/gkv047; Lin L, 2014, CANCER DISCOV, V4, P1168, DOI 10.1158/2159-8290.CD-13-0747; Liu ZY, 2014, ANTICANCER RES, V34, P2331; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Masoodi M, 2015, BBA-MOL CELL BIOL L, V1851, P503, DOI 10.1016/j.bbalip.2014.09.023; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Miranda F, 2016, CANCER CELL, V30, P273, DOI 10.1016/j.ccell.2016.06.020; Pabalan N, 2013, INT J COLORECTAL DIS, V28, P925, DOI 10.1007/s00384-013-1639-3; Paone A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.482; Pearce OMT, 2016, GLYCOBIOLOGY, V26, P111, DOI 10.1093/glycob/cwv097; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Succi M, 2014, MOL BIOL REP, V41, P581, DOI 10.1007/s11033-013-2895-6; Tania M, 2010, CURR ONCOL, V17, P6; Vachharajani VT, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/8167273; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Wajapeyee N, 2006, J BIOL CHEM, V281, P16207, DOI 10.1074/jbc.M600539200; Wang YW, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0065-z; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Williams SJ, 2009, GYNECOL ONCOL, V112, P637, DOI 10.1016/j.ygyno.2008.11.015; Wu SJ, 2016, TUMOR BIOL, V37, P5193, DOI 10.1007/s13277-015-4369-z; Yamamoto S, 2007, VIRCHOWS ARCH, V451, P27, DOI 10.1007/s00428-007-0433-4; Yang LF, 2014, MOL SYST BIOL, V10, DOI 10.1002/msb.20134892; Zhang SY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2218-0	42	21	21	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4014	4024		10.1038/onc.2017.37	http://dx.doi.org/10.1038/onc.2017.37			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288142	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000405379900007
J	Ma, X; Meng, Z; Jin, L; Xiao, Z; Wang, X; Tsark, WM; Ding, L; Gu, Y; Zhang, J; Kim, B; He, M; Gan, X; Shively, JE; Yu, H; Xu, R; Huang, W				Ma, X.; Meng, Z.; Jin, L.; Xiao, Z.; Wang, X.; Tsark, W. M.; Ding, L.; Gu, Y.; Zhang, J.; Kim, B.; He, M.; Gan, X.; Shively, J. E.; Yu, H.; Xu, R.; Huang, W.			CAMK2 gamma in intestinal epithelial cells modulates colitis-associated colorectal carcinogenesis via enhancing STAT3 activation	ONCOGENE			English	Article							CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; CRITICAL REGULATOR; TARGETING STAT3; IMMUNE CELLS; COLON-CANCER; MOUSE MODEL; RISK; EXPRESSION	Inflammation is one of the major risk factors for cancer. Here, we show that calcium/calmodulin-dependent protein kinase II gamma (CAMK2 gamma) in intestinal epithelial cells (IECs) modulates inflammatory signals and promotes colitis-associated cancer (CAC) in mice. We have identified CAMK2 gamma as a downstream target of colitis-induced WNT5A signaling. Furthermore, we have shown that CAMK2 gamma protects against intestine tissue injury by increasing IEC survival and proliferation. Calcium/calmodulin-dependent protein kinase II gamma knockout mice displayed reduced CAC. Furthermore, we used bone marrow transplantation to reveal that CAMK2 gamma in IECs, but not immune cells, was crucial for its effect on CAC. Consistently, transgenic over-expression of CAMK2 gamma in IECs accelerated CAC development. Mechanistically, CAMK2 gamma in IECs enhanced epithelial signal transducer and activator of transcription 3 (STAT3) activation to promote survival and proliferation of colonic epithelial cells during CAC development. These results thus identify a new molecular mechanism mediated by CAMK2 gamma in IECs during CAC development, thereby providing a potential new therapeutic target for CAC.	[Ma, X.; Meng, Z.; Jin, L.; Xiao, Z.; Wang, X.; Ding, L.; Gu, Y.; Zhang, J.; Kim, B.; Gan, X.; Xu, R.; Huang, W.] City Hope Natl Med Ctr, Diabet & Metab Res Inst, Dept Diabet Complicat & Metab, Mol & Cellular Biol Canc Program, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Ma, X.; Kim, B.; Huang, W.] City Hope Natl Med Ctr, Irell & Manella Grad Sch Biol Sci, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Jin, L.] Xiamen Univ, Innovat Ctr Cell Signaling Network, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China; [Xiao, Z.] Fujian Med Univ, Teaching Hosp, Fujian Prov Canc Hosp, Fujian Prov Key Lab Tumor Biotherapy,Dept Clin La, Fuzhou, Fujian, Peoples R China; [Wang, X.] Cleveland Clin, Robert J Tomsich Inst Pathol & Lab Med, Cleveland, OH 44106 USA; [Tsark, W. M.] City Hope Natl Med Ctr, Transgen Mouse Core, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Zhang, J.; Xu, R.] Zhejiang Univ, Sch Med, Affiliated Hosp 2,Dept Hematol, China Natl Minist Educ,Key Lab Canc Prevent & Int, Hangzhou, Zhejiang, Peoples R China; [He, M.] Guangxi Med Univ, Sch Publ Hlth, Nanning, Guangxi, Peoples R China; [Shively, J. E.] City Hope Natl Med Ctr, Dept Immunol, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Yu, H.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Immunotherapeut & Tumor Immunol, Duarte, CA 91010 USA	City of Hope; City of Hope; Xiamen University; Fujian Medical University; Cleveland Clinic Foundation; City of Hope; Zhejiang University; Guangxi Medical University; City of Hope; City of Hope; Beckman Research Institute of City of Hope	Xu, R; Huang, W (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Diabet & Metab Dis Res, 1500 E Duarte Rd, Duarte, CA 91010 USA.	zrxyk10@zju.edu.cn; whuang@coh.org	Ma, Xiaoxiao/AFB-9086-2022	Ma, Xiaoxiao/0000-0001-8661-5660; YU, Hua/0000-0003-0931-1000	National Natural Science Foundation of China [81270601, 81328016]; State Key Laboratory of Cellular Stress Biology, Xiamen University [SKLCSB2016KF002]; National Cancer Institute of the National Institutes of Health [P30CA33572];  [2NCI R01-CA139158]; NATIONAL CANCER INSTITUTE [P30CA033572, R01CA139158] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Cellular Stress Biology, Xiamen University; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Johannes Backs for providing the Camk2 gamma KO mice. We thank Dr Richard Ermel and the Animal Resource Center for the technical resources. We thank the pathologists from the City of Hope Pathology Core Lab for sample processing and analysis. We thank Dr Fong-Fong Chu and Dr Mei Kong at City of Hope for discussion. We also thank Dr Nancy Linford for providing editing assistance. This work is supported in part by 2NCI R01-CA139158, the National Natural Science Foundation of China (81270601 and 81328016) and the Open Research Fund of State Key Laboratory of Cellular Stress Biology, Xiamen University (SKLCSB2016KF002). Research reported in this publication was also supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572.	Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; Backs J, 2010, P NATL ACAD SCI USA, V107, P81, DOI 10.1073/pnas.0912658106; Blanpain C, 2013, NAT CELL BIOL, V15, P126, DOI 10.1038/ncb2657; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Brandl K, 2010, P NATL ACAD SCI USA, V107, P19967, DOI 10.1073/pnas.1014669107; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Bui JD, 2000, CELL, V100, P457, DOI 10.1016/S0092-8674(00)80681-9; Chassaing Benoit, 2014, Curr Protoc Immunol, V104, DOI 10.1002/0471142735.im1525s104; Cui WW, 2007, NUCLEIC ACIDS RES, V35, pD805, DOI 10.1093/nar/gkl767; De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; del Reino P, 2014, CANCER RES, V74, P6150, DOI 10.1158/0008-5472.CAN-14-0870; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Foersch S, 2014, CELL MOL LIFE SCI, V71, P3523, DOI 10.1007/s00018-014-1636-x; Furtek SL, 2016, ACS CHEM BIOL, V11, P308, DOI 10.1021/acschembio.5b00945; Gibson RM, 2005, BBA-BIOMEMBRANES, V1714, P56, DOI 10.1016/j.bbamem.2005.05.014; GILLEN CD, 1994, GUT, V35, P1590, DOI 10.1136/gut.35.11.1590; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gu Y, 2012, BLOOD, V120, P4829, DOI 10.1182/blood-2012-06-434894; Gupta J, 2014, CANCER CELL, V25, P484, DOI 10.1016/j.ccr.2014.02.019; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang WD, 2011, NATURE, V470, P414, DOI 10.1038/nature09703; Huang W, 2009, MOL CELL, V35, P48, DOI 10.1016/j.molcel.2009.05.023; Hughes KR, 2011, INFLAMM BOWEL DIS, V17, P213, DOI 10.1002/ibd.21353; Jess T, 2012, CLIN GASTROENTEROL H, V10, P639, DOI 10.1016/j.cgh.2012.01.010; Kortylewski M, 2009, NAT BIOTECHNOL, V27, P925, DOI 10.1038/nbt.1564; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Lakatos PL, 2008, WORLD J GASTROENTERO, V14, P3937, DOI 10.3748/wjg.14.3937; Lasry A, 2016, NAT IMMUNOL, V17, P230, DOI 10.1038/ni.3384; Levanen B, 2011, RESP MED, V105, P282, DOI 10.1016/j.rmed.2010.11.018; Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013; Liu XG, 2008, BLOOD, V112, P4961, DOI 10.1182/blood-2008-03-144022; Lo RKH, 2003, J BIOL CHEM, V278, P52154, DOI 10.1074/jbc.M307299200; Meng ZP, 2013, MOL CANCER THER, V12, P2067, DOI 10.1158/1535-7163.MCT-13-0314; Neufert C, 2013, J CLIN INVEST, V123, P1428, DOI 10.1172/JCI63748; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; Nguyen A, FEBS LETT; Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617; Planell N, 2013, GUT, V62, P967, DOI 10.1136/gutjnl-2012-303333; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017; Robles AI, 2016, GASTROENTEROLOGY, V150, P931, DOI 10.1053/j.gastro.2015.12.036; Rubin DC, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00107; Saleh M, 2011, NAT REV IMMUNOL, V11, P9, DOI 10.1038/nri2891; Sato A, 2015, SCI REP-UK, V5, DOI 10.1038/srep10536; Si JT, 2008, CANCER RES, V68, P3733, DOI 10.1158/0008-5472.CAN-07-2509; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Solomon L., 2010, COMP CLIN PATH, V19, P235, DOI [10.1007/s00580-010-0979-4, DOI 10.1007/S00580-010-0979-4]; Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x; Thaker AI, 2012, JOVE-J VIS EXP, DOI 10.3791/4100; Timmins JM, 2009, J CLIN INVEST, V119, P2925, DOI 10.1172/JCI38857; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Trinchieri G, 2012, ANNU REV IMMUNOL, V30, P677, DOI 10.1146/annurev-immunol-020711-075008; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Van Der Kraak L, 2015, WORLD J GASTROENTERO, V21, P11688, DOI 10.3748/wjg.v21.i41.11688; von Roon AC, 2007, DIS COLON RECTUM, V50, P839, DOI 10.1007/s10350-006-0848-z; Wang Y, 2015, BIOMED RES INT, V2015, P6, DOI DOI 10.1128/MBI0.01280-15; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41; Wotherspoon A C, 2000, Curr Gastroenterol Rep, V2, P494, DOI 10.1007/s11894-000-0014-z; Yashiro M, 2014, WORLD J GASTROENTERO, V20, P16389, DOI 10.3748/wjg.v20.i44.16389; Yue P, 2009, EXPERT OPIN INV DRUG, V18, P45, DOI [10.1517/13543780802565791, 10.1517/13543780802565791 ]; Zhao C, 2013, CARCINOGENESIS, V34; Zhao L, 2016, CIRC RES, V118, P1918, DOI 10.1161/CIRCRESAHA.116.308688	67	21	22	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4060	4071		10.1038/onc.2017.16	http://dx.doi.org/10.1038/onc.2017.16			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28319059	Green Accepted			2022-12-17	WOS:000405379900011
J	Zhao, B; Hu, W; Kumar, S; Gonyo, P; Rana, U; Liu, Z; Wang, B; Duong, WQ; Yang, Z; Williams, CL; Miao, QR				Zhao, B.; Hu, W.; Kumar, S.; Gonyo, P.; Rana, U.; Liu, Z.; Wang, B.; Duong, W. Q.; Yang, Z.; Williams, C. L.; Miao, Q. R.			The Nogo-B receptor promotes Ras plasma membrane localization and activation	ONCOGENE			English	Article							UNDECAPRENYL PYROPHOSPHATE SYNTHASE; MAMMARY EPITHELIAL-CELLS; HUMAN BREAST-CANCER; H-RAS; K-RAS; MALIGNANT-TRANSFORMATION; DRUG-RESISTANCE; FAMILY PROTEINS; PDE-DELTA; IN-VITRO	The localization of prenylated Ras at the plasma membrane promotes activation of Ras by receptor tyrosine kinases and stimulates oncogenic signaling by mutant Ras. The Nogo-B receptor (NgBR) is a transmembrane receptor that contains a conserved hydrophobic pocket. Here, we demonstrate that the NgBR promotes the membrane accumulation of Ras by directly binding prenylated Ras at the plasma membrane. We show that NgBR knockdown diminishes the membrane localization of Ras in multiple cell types. NgBR overexpression in NIH-3T3 fibroblasts increases membrane-associated Ras, induces the transformed phenotype in vitro, and promotes the formation of fibrosarcoma in nude mice. NgBR knockdown in human breast cancer cells reduces Ras membrane localization, inhibits epidermal growth factor (EGF)-stimulated Ras signaling and diminishes tumorigenesis of xenografts in nude mice. Our data demonstrate that NgBR is a unique receptor that promotes accumulation of prenylated Ras at the plasma membrane and promotes EGF pathways.	[Zhao, B.; Hu, W.; Rana, U.; Liu, Z.; Wang, B.; Duong, W. Q.; Miao, Q. R.] Med Coll Wisconsin, Dept Surg, Childrens Res Inst, Div Pediat Surg, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Zhao, B.; Hu, W.; Kumar, S.; Rana, U.; Liu, Z.; Wang, B.; Duong, W. Q.; Miao, Q. R.] Med Coll Wisconsin, Dept Pathol, Childrens Res Inst, Div Pediat Pathol, Milwaukee, WI 53226 USA; [Zhao, B.] Chinese Acad Sci, Dalian Inst Chem Phys, Key Lab Separat Sci, Dalian, Liaoning, Peoples R China; [Gonyo, P.; Williams, C. L.; Miao, Q. R.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Wang, B.] China Japan Friendship Hosp, Dept Pathol, Beijing, Peoples R China; [Yang, Z.] Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI USA	Medical College of Wisconsin; Medical College of Wisconsin; Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; Medical College of Wisconsin; China-Japan Friendship Hospital; Wayne State University	Miao, QR (corresponding author), Med Coll Wisconsin, Dept Surg & Pathol, Childrens Res Inst, Div Pediat Surg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.; Miao, QR (corresponding author), Med Coll Wisconsin, Dept Surg & Pathol, Childrens Res Inst, Div Pediat Pathol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	qmiao@mcw.edu	Miao, Qing/K-3186-2019	Miao, Qing/0000-0002-3125-1238; Duong, William/0000-0002-2879-8590	Division of Pediatric Surgery, Medical College of Wisconsin (MCW); AHA [SDG 0730079N]; NIH [R01HL108938, R01 CA188871, R01HL128647]; American Cancer Society [86-004-26]; Kathy Duffey Fogarty Award for breast cancer research; Children's Hospital of Wisconsin Research Institute Pilot Innovative Research Grant; AHA postdoctoral fellowship [13POST13940002, 11POST5690035]; China State Key Basic Research Program [2016YFA0501401]; Hundred Talents Program of CAS; Rock River Cancer Research Foundation; Division of Pediatric Pathology, Medical College of Wisconsin; Advancing a Healthier Wisconsin endowment; Wisconsin Breast Cancer Showhouse (WBCS); We Care Fund; NATIONAL CANCER INSTITUTE [R01CA188871] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL108938, R01HL128647] Funding Source: NIH RePORTER	Division of Pediatric Surgery, Medical College of Wisconsin (MCW); AHA(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Kathy Duffey Fogarty Award for breast cancer research; Children's Hospital of Wisconsin Research Institute Pilot Innovative Research Grant; AHA postdoctoral fellowship(American Heart Association); China State Key Basic Research Program; Hundred Talents Program of CAS(Chinese Academy of Sciences); Rock River Cancer Research Foundation; Division of Pediatric Pathology, Medical College of Wisconsin; Advancing a Healthier Wisconsin endowment; Wisconsin Breast Cancer Showhouse (WBCS); We Care Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr John Hancock at University of Texas Health Science Center at Houston generously provided pEGFP-C1 vector. This work is supported in part by start-up funds from Division of Pediatric Surgery and Division of Pediatric Pathology, Medical College of Wisconsin (MCW) and Advancing a Healthier Wisconsin endowment to MCW, AHA SDG 0730079N, NIH R01HL108938, Wisconsin Breast Cancer Showhouse (WBCS), Institutional Research Grant # 86-004-26 from the American Cancer Society, We Care Fund, Kathy Duffey Fogarty Award for breast cancer research, State of Wisconsin Tax Check-off program for breast & prostate cancer research and Children's Hospital of Wisconsin Research Institute Pilot Innovative Research Grant to QRM., AHA postdoctoral fellowship 13POST13940002 and 11POST5690035, China State Key Basic Research Program Grant 2016YFA0501401 and the support from the Hundred Talents Program of CAS to BZ. Additional support was provided by NIH R01 CA188871 (CLW), the Rock River Cancer Research Foundation (CLW), and the Nancy Laning Sobczak, PhD., Breast Cancer Research Award (CLW), NIH R01HL128647 (ZY).	Abramovitz A, 2012, BIOCHEMISTRY-US, V51, P715, DOI 10.1021/bi201211v; Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255; Belanis L, 2008, MOL BIOL CELL, V19, P1404, DOI 10.1091/mbc.E07-10-1053; Bernhard EJ, 1998, CANCER RES, V58, P1754; Brunsveld L, 2009, BBA-BIOMEMBRANES, V1788, P273, DOI 10.1016/j.bbamem.2008.08.006; Buday L, 2008, BBA-REV CANCER, V1786, P178, DOI 10.1016/j.bbcan.2008.05.001; Chandra A, 2012, NAT CELL BIOL, V14, P148, DOI 10.1038/ncb2394; Chang SY, 2004, PROTEIN SCI, V13, P971, DOI 10.1110/ps.03519904; Chen APC, 2005, BIOCHEM J, V386, P169, DOI 10.1042/BJ20040785; CLARK R, 1988, CANCER RES, V48, P4689; Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214; DATI C, 1991, INT J CANCER, V47, P833, DOI 10.1002/ijc.2910470607; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; Dong CY, 2016, ONCOTARGET, V7, P8850, DOI 10.18632/oncotarget.7091; GUNZBURG WH, 1988, CARCINOGENESIS, V9, P1849, DOI 10.1093/carcin/9.10.1849; Guo RT, 2005, J BIOL CHEM, V280, P20762, DOI 10.1074/jbc.M502121200; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Harrison KD, 2011, EMBO J, V30, P2490, DOI 10.1038/emboj.2011.147; Hoffman GR, 2000, CELL, V102, P403, DOI 10.1016/S0092-8674(00)00045-3; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kelly KJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1309, DOI 10.1152/ajpcell.00353.2002; Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432-1033.2002.03014.x; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Miao RQ, 2006, P NATL ACAD SCI USA, V103, P10997, DOI 10.1073/pnas.0602427103; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; Nancy V, 2002, J BIOL CHEM, V277, P15076, DOI 10.1074/jbc.M109983200; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Nyati MK, 2006, NAT REV CANCER, V6, P876, DOI 10.1038/nrc1953; Omerovic J, 2007, CELL MOL LIFE SCI, V64, P2575, DOI 10.1007/s00018-007-7133-8; Omerovic J, 2009, FEBS J, V276, P1817, DOI 10.1111/j.1742-4658.2009.06928.x; Parish CA, 1997, BIOCHEMISTRY-US, V36, P2686, DOI 10.1021/bi961844r; Park EJ, 2016, EMBO REP, V17, P167, DOI 10.15252/embr.201540789; Park EJ, 2014, CELL METAB, V20, P448, DOI 10.1016/j.cmet.2014.06.016; Pechlivanis M, 2006, BBA-PROTEINS PROTEOM, V1764, P1914, DOI 10.1016/j.bbapap.2006.09.017; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Prior IA, 2012, SEMIN CELL DEV BIOL, V23, P145, DOI 10.1016/j.semcdb.2011.09.002; Rana U, 2016, DEV BIOL, V410, P190, DOI 10.1016/j.ydbio.2015.12.023; REDMOND SMS, 1988, ONCOGENE, V2, P259; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Rocks O, 2006, CURR OPIN CELL BIOL, V18, P351, DOI 10.1016/j.ceb.2006.06.007; Rotblat B, 2004, MOL CELL BIOL, V24, P6799, DOI 10.1128/MCB.24.15.6799-6810.2004; Rotblat B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011991; Roy S, 2005, MOL CELL BIOL, V25, P6722, DOI 10.1128/MCB.25.15.6722-6733.2005; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Schmick M, 2015, TRENDS CELL BIOL, V25, P190, DOI 10.1016/j.tcb.2015.02.004; Shalom-Feuerstein R, 2008, CANCER RES, V68, P6608, DOI 10.1158/0008-5472.CAN-08-1117; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Sylvester PW, 2011, METHODS MOL BIOL, V716, P157, DOI 10.1007/978-1-61779-012-6_9; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Toulany M, 2006, CLIN CANCER RES, V12, P4119, DOI 10.1158/1078-0432.CCR-05-2454; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Wang B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078083; WATSON DMA, 1991, BREAST CANCER RES TR, V17, P161, DOI 10.1007/BF01806365; Weise K, 2013, FARADAY DISCUSS, V161, P549, DOI 10.1039/c2fd20100c; Williams CL, 2003, CELL SIGNAL, V15, P1071, DOI 10.1016/S0898-6568(03)00098-6; Wright LP, 2006, J LIPID RES, V47, P883, DOI 10.1194/jlr.R600004-JLR200; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zhao B, BLOOD, V116, P5423; Zhao BF, 2015, J PROTEOMICS, V112, P38, DOI 10.1016/j.jprot.2014.08.007; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	71	21	22	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3406	3416		10.1038/onc.2016.484	http://dx.doi.org/10.1038/onc.2016.484			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28068323	Green Accepted			2022-12-17	WOS:000403340700005
J	Steinhauser, K; Kloble, P; Kreis, NN; Ritter, A; Friemel, A; Roth, S; Reichel, JM; Michaelis, J; Rieger, MA; Louwen, F; Oswald, F; Yuan, J				Steinhaeuser, K.; Kloeble, P.; Kreis, N-N; Ritter, A.; Friemel, A.; Roth, S.; Reichel, J. M.; Michaelis, J.; Rieger, M. A.; Louwen, F.; Oswald, F.; Yuan, J.			Deficiency of RITA results in multiple mitotic defects by affecting microtubule dynamics	ONCOGENE			English	Article							CENTROMERE-ASSOCIATED KINESIN; TUMOR-SUPPRESSOR P53; KINASE 1 INHIBITORS; ALPHA-TUBULIN; POSTTRANSLATIONAL MODIFICATIONS; FLUORESCENT-PROBES; CANCER-CELLS; SPINDLE; ACETYLATION; ACETYLTRANSFERASE	Deregulation of mitotic microtubule (MT) dynamics results in defective spindle assembly and chromosome missegregation, leading further to chromosome instability, a hallmark of tumor cells. RBP-J interacting and tubulin-associated protein (RITA) has been identified as a negative regulator of the Notch signaling pathway. Intriguingly, deregulated RITA is involved in primary hepatocellular carcinoma and other malignant entities. We were interested in the potential molecular mechanisms behind its involvement. We show here that RITA binds to tubulin and localizes to various mitotic MT structures. RITA coats MTs and affects their structures in vitro as well as in vivo. Tumor cell lines deficient of RITA display increased acetylated alpha-tubulin, enhanced MT stability and reduced MT dynamics, accompanied by multiple mitotic defects, including chromosome misalignment and segregation errors. Re-expression of wild-type RITA, but not RITA.tub ineffectively binding to tubulin, restores the phenotypes, suggesting that the role of RITA in MT modulation is mediated via its interaction with tubulin. Mechanistically, RITA interacts with tubulin/histone deacetylase 6 (HDAC6) and its suppression decreases the binding of the deacetylase HDAC6 to tubulin/MTs. Furthermore, the mitotic defects and increased MT stability are also observed in RITA(-/-) mouse embryonic fibroblasts. RITA has thus a novel role in modulating MT dynamics and its deregulation results in erroneous chromosome segregation, one of the major reasons for chromosome instability in tumor cells.	[Steinhaeuser, K.; Kreis, N-N; Ritter, A.; Friemel, A.; Roth, S.; Louwen, F.; Yuan, J.] Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany; [Kloeble, P.; Oswald, F.] Univ Med Ctr Ulm, Dept Internal Med 1, Ctr Internal Med, Ulm, Germany; [Reichel, J. M.; Michaelis, J.] Ulm Univ, Inst Biophys, Ulm, Germany; [Rieger, M. A.] Goethe Univ Frankfurt, Dept Hematol Oncol, Frankfurt, Germany; [Rieger, M. A.] German Canc Consortium DKTK, Heidelberg, Germany; [Rieger, M. A.] German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Ulm University; Ulm University; Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Yuan, J (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	yuan@em.uni-frankfurt.de	Kreis, Nina-Naomi/AAF-5407-2019; Rieger, Michael A/L-8324-2017; Ritter, Andreas/AAX-3938-2020; Ritter, Andreas/ABB-6348-2020; Oswald, Franz/AAO-9584-2020	Kreis, Nina-Naomi/0000-0003-4304-0160; Rieger, Michael A/0000-0002-4158-5872; Ritter, Andreas/0000-0002-5955-859X; Michaelis, Jens/0000-0002-2739-4172; Yuan, Juping/0000-0003-0694-0565	Deutsche Forschungsgemeinschaft [SFB1074/A3]; BMBF (research nucleus SyStAR); International Graduate School in Molecular Medicine, Ulm, Germany [GSC270]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BMBF (research nucleus SyStAR)(Federal Ministry of Education & Research (BMBF)); International Graduate School in Molecular Medicine, Ulm, Germany	We thank Dr L Wordeman, University of Washington, and Dr A Bird, MPI, Dortmund, Germany, for their critical manuscript reading and valuable comments. The work was supported by the Deutsche Forschungsgemeinschaft (SFB1074/A3 to FO), the BMBF (research nucleus SyStAR to FO). PK was supported by the International Graduate School in Molecular Medicine, Ulm, Germany (GSC270).	Akella JS, 2010, NATURE, V467, P218, DOI 10.1038/nature09324; Akhmanova A, 2010, J CELL SCI, V123, P3415, DOI 10.1242/jcs.062414; Bakhoum SF, 2012, J CLIN INVEST, V122, P1138, DOI 10.1172/JCI59954; Bates M, 2007, SCIENCE, V317, P1749, DOI 10.1126/science.1146598; Brouhard GJ, 2014, J CELL BIOL, V207, P323, DOI 10.1083/jcb.201407095; CAMBRAYDEAKIN MA, 1987, CELL MOTIL CYTOSKEL, V8, P284, DOI 10.1002/cm.970080309; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Eckerdt F, 2005, J BIOL CHEM, V280, P36575, DOI 10.1074/jbc.M504548200; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Gadde S, 2004, CURR BIOL, V14, pR797, DOI 10.1016/j.cub.2004.09.021; Giustiniani J, 2009, CELL SIGNAL, V21, P529, DOI 10.1016/j.cellsig.2008.12.004; Goshima G, 2010, ANNU REV CELL DEV BI, V26, P21, DOI 10.1146/annurev-cellbio-100109-104006; Heilemann M, 2008, ANGEW CHEM INT EDIT, V47, P6172, DOI 10.1002/anie.200802376; Hoogendoorn E, 2014, SCI REP-UK, V4, DOI 10.1038/srep03854; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; Janke C, 2011, NAT REV MOL CELL BIO, V12, P773, DOI 10.1038/nrm3227; Kreis NN, 2010, ONCOGENE, V29, P5591, DOI 10.1038/onc.2010.290; Kreis NN, 2014, ONCOGENE, V33, P5716, DOI 10.1038/onc.2013.518; Kreis NN, 2015, ONCOTARGET, V6, P6611, DOI 10.18632/oncotarget.2844; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; Luders J, 2006, NAT CELL BIOL, V8, P137, DOI 10.1038/ncb1349; Magiera MM, 2013, METHOD CELL BIOL, V115, P247, DOI 10.1016/B978-0-12-407757-7.00016-5; Manning AL, 2008, CURR OPIN CELL BIOL, V20, P101, DOI 10.1016/j.ceb.2007.11.004; MARUTA H, 1986, J CELL BIOL, V103, P571, DOI 10.1083/jcb.103.2.571; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Meunier S, 2011, NAT CELL BIOL, V13, P1406, DOI 10.1038/ncb2372; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Miyake Y, 2016, NAT CHEM BIOL, V12, P748, DOI 10.1038/nchembio.2140; Muschol-Steinmetz C, 2016, CELL CYCLE, V15, P827, DOI 10.1080/15384101.2016.1149273; Muschol-Steinmetz C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073337; Nguyen HL, 1999, J CELL SCI, V112, P1813; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Pakala SB, 2012, J BIOL CHEM, V287, P40560, DOI 10.1074/jbc.M112.399576; Penela P, 2014, CURR OPIN CELL BIOL, V27, P10, DOI 10.1016/j.ceb.2013.10.005; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Ritter A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00186; Ritter A, 2015, CELL CYCLE, V14, P3755, DOI 10.1080/15384101.2015.1068481; Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929; Sanhaji M, 2014, ONCOTARGET, V5, P3130, DOI 10.18632/oncotarget.1861; Sanhaji M, 2013, CELL CYCLE, V12, P1340, DOI 10.4161/cc.24573; Sanhaji M, 2012, CELL CYCLE, V11, P543, DOI 10.4161/cc.11.3.19076; Sanhaji M, 2010, MOL CELL BIOL, V30, P2594, DOI 10.1128/MCB.00098-10; Sharma N, 2011, MOL BIOL CELL, V22, P806, DOI 10.1091/mbc.E10-03-0269; Shida T, 2010, P NATL ACAD SCI USA, V107, P21517, DOI 10.1073/pnas.1013728107; Song YY, 2015, TRENDS CELL BIOL, V25, P125, DOI 10.1016/j.tcb.2014.10.004; Soppina V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048204; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Wacker SA, 2011, EMBO J, V30, P43, DOI 10.1038/emboj.2010.289; Wang B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4479; Wang HH, 2014, BIOCHEM BIOPH RES CO, V454, P71, DOI 10.1016/j.bbrc.2014.10.023; Wang HH, 2012, ONCOL RES, V20, P437, DOI 10.3727/096504013X13685487925059; WEBSTER DR, 1989, J CELL SCI, V92, P57; Yount AL, 2015, EXP CELL RES, V334, P70, DOI 10.1016/j.yexcr.2014.12.015	56	21	21	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2146	2159		10.1038/onc.2016.372	http://dx.doi.org/10.1038/onc.2016.372			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27721410				2022-12-17	WOS:000399782500010
J	Daly, CS; Shaw, P; Ordonez, LD; Williams, GT; Quist, J; Grigoriadis, A; Van Es, JH; Clevers, H; Clarke, AR; Reed, KR				Daly, C. S.; Shaw, P.; Ordonez, L. D.; Williams, G. T.; Quist, J.; Grigoriadis, A.; Van Es, J. H.; Clevers, H.; Clarke, A. R.; Reed, K. R.			Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumorigenesis in murine mammary epithelium	ONCOGENE			English	Article							ADENOMATOUS-POLYPOSIS-COLI; PRIMARY BREAST CANCERS; BETA-CATENIN; TUMOR-SUPPRESSOR; E-CADHERIN; C-MYC; CYTOPLASMIC LOCALIZATION; MESENCHYMAL TRANSITION; GENE PROMOTER; FREQUENT LOSS	Aberrant Wnt signaling within breast cancer is associated with poor prognosis, but regulation of this pathway in breast tissue remains poorly understood and the consequences of immediate or long-term dysregulation remain elusive. The exact contribution of the Wnt-regulating proteins adenomatous polyposis coli (APC) and APC2 in the pathogenesis of human breast cancer are ill-defined, but our analysis of publically available array data sets indicates that tumors with concomitant low expression of both proteins occurs more frequently in the 'triple negative' phenotype, which is a subtype of breast cancer with particularly poor prognosis. We have used mouse transgenics to delete Apc and/or Apc2 from mouse mammary epithelium to elucidate the significance of these proteins in mammary homeostasis and delineate their influences on Wnt signaling and tumorigenesis. Loss of either protein alone failed to affect Wnt signaling levels or tissue homeostasis. Strikingly, concomitant loss led to local disruption of beta-catenin status, disruption in epithelial integrity, cohesion and polarity, increased cell division and a distinctive form of ductal hyperplasia with 'squamoid' ghost cell nodules in young animals. Upon aging, the development of Wnt activated mammary carcinomas with squamous differentiation was accompanied by a significantly reduced survival. This novel Wnt-driven mammary tumor model highlights the importance of functional redundancies existing between the Apc proteins both in normal homeostasis and in tumorigenesis.	[Daly, C. S.; Shaw, P.; Ordonez, L. D.; Clarke, A. R.; Reed, K. R.] Cardiff Univ, Sch Biosci, European Canc Stem Cell Res Inst, Hadyn Ellis Bldg,Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales; [Williams, G. T.] Cardiff Univ, Sch Med, Div Canc & Genet, Cardiff, S Glam, Wales; [Quist, J.; Grigoriadis, A.] Kings Coll London, Guys Hosp London, Breast Canc Now Unit, London, England; [Quist, J.; Grigoriadis, A.] Kings Coll London, Guys Hosp London, Canc Bioinformat, London, England; [Van Es, J. H.; Clevers, H.] Netherlands Inst Dev Biol, Hubrecht Lab, Utrecht, Netherlands	Cardiff University; Cardiff University; University of London; King's College London; University of London; King's College London; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Reed, KR (corresponding author), Cardiff Univ, Sch Biosci, European Canc Stem Cell Res Inst, Hadyn Ellis Bldg,Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales.	ReedKR@Cardiff.ac.uk	van+Es, Johan/ABD-5411-2021; Reed, Karen/B-8813-2011	Reed, Karen/0000-0002-7467-1718; Grigoriadis, Anita/0000-0003-3434-201X	Biotechnology and Biomedical Sciences Research Council; Cancer Research UK [C1295/A15937]; Wales Gene Park; NIHR Biomedical Research Centre at Guy's and St Thomas; Breast Cancer NOW; Cancer Research UK [15937] Funding Source: researchfish	Biotechnology and Biomedical Sciences Research Council; Cancer Research UK(Cancer Research UK); Wales Gene Park; NIHR Biomedical Research Centre at Guy's and St Thomas; Breast Cancer NOW; Cancer Research UK(Cancer Research UK)	This project was funded by Biotechnology and Biomedical Sciences Research Council and Cancer Research UK (ARC Program grant C1295/A15937). GTW is supported by the Wales Gene Park. Jelmar Quist is funded by a PhD studentship from the NIHR Biomedical Research Centre at Guy's and St Thomas. Anita Grigoriadis is supported by Breast Cancer NOW (former Breakthrough Breast Cancer Research). We thank Luke Bradshaw, Oro Asby, Bridget Allen and Elaine Taylor for assistance with mouse husbandry. We would also like to thank Mark Bishop and Matthew Zverev for technical support and genotyping and Derek Scarborough and Marc Isaacs for their assistance in histology.	Ahmed Y, 2002, DEVELOPMENT, V129, P1751; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Bray K, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3487; Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; Gallagher RCJ, 2002, ONCOGENE, V21, P6446, DOI 10.1038/sj.onc.1205892; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hassanein AM, 2003, AM J CLIN PATHOL, V120, P732, DOI 10.1309/EALEG7LD6W7167PX; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Ho KYK, 1999, HISTOPATHOLOGY, V35, P249; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Irshad S, 2011, CURR OPIN ONCOL, V23, P566, DOI 10.1097/CCO.0b013e32834bf8ae; Jarrett CR, 2001, CANCER RES, V61, P7978; Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853; Jonsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2; KASHIWABA M, 1994, J CANCER RES CLIN, V120, P727, DOI 10.1007/BF01194271; Khalil S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033421; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lesko AC, 2014, CURR DRUG TARGETS, V15, P90, DOI 10.2174/1389450114666131108155418; Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lopez-Knowles E, 2010, CANCER EPIDEM BIOMAR, V19, P301, DOI 10.1158/1055-9965.EPI-09-0741; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Mohinta S, 2007, FRONT BIOSCI-LANDMRK, V12, P4020, DOI 10.2741/2368; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; Neese RA, 2002, P NATL ACAD SCI USA, V99, P15345, DOI 10.1073/pnas.232551499; Nelson S, 2013, J CELL SCI, V126, P873, DOI 10.1242/jcs.100479; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Reichert M, 2000, J BIOL CHEM, V275, P9492, DOI 10.1074/jbc.275.13.9492; Roberts DM, 2012, MOL BIOL CELL, V23, P2041, DOI 10.1091/mbc.E11-11-0965; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sarrio D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197; Schlosshauer PW, 2000, MODERN PATHOL, V13, P1066, DOI 10.1038/modpathol.3880196; Schneikert J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068072; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; Sobottka SB, 2000, J NEURO-ONCOL, V49, P187, DOI 10.1023/A:1006442024874; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Tanaka A, 2007, J ORAL PATHOL MED, V36, P400, DOI 10.1111/j.1600-0714.2007.00550.x; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Van der Auwera I, 2008, BRIT J CANCER, V99, P1735, DOI 10.1038/sj.bjc.6604705; van der Meer M, 2001, TRANSGENIC RES, V10, P399, DOI 10.1023/A:1012244404020; van Es JH, 1999, CURR BIOL, V9, P105, DOI 10.1016/S0960-9822(99)80024-4; Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; Watkins J, 2015, CANCER DISCOV, V5, P488, DOI 10.1158/2159-8290.CD-14-1092; Williams TM, 2006, AM J PATHOL, V169, P1784, DOI 10.2353/ajpath.2006.060590; Yang TL, 2004, GENE CHROMOSOME CANC, V41, P250, DOI 10.1002/gcc.20080; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zardawi SJ, 2009, HISTOL HISTOPATHOL, V24, P385, DOI 10.14670/HH-24.385	63	21	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1793	1803		10.1038/onc.2016.342	http://dx.doi.org/10.1038/onc.2016.342			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27694902	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000398128900005
J	Demir, O; Ieong, PU; Amaro, RE				Demir, Oe; Ieong, P. U.; Amaro, R. E.			Full-length p53 tetramer bound to DNA and its quaternary dynamics	ONCOGENE			English	Article							TUMOR-SUPPRESSOR P53; C-TERMINAL DOMAIN; MOLECULAR-DYNAMICS; MUTANT P53; BINDING DOMAIN; ELECTRON-MICROSCOPY; PROTEIN; REACTIVATION; RESTORATION; ELEMENTS	P53 is a major tumor suppressor that is mutated and inactivated in similar to 50% of all human cancers. Thus, reactivation of mutant p53 using small molecules has been a long sought-after anticancer therapeutic strategy. Full structural characterization of the full-length oligomeric p53 is challenging because of its complex architecture and multiple highly flexible regions. To explore p53 structural dynamics, here we developed a series of atomistic integrative models with available crystal structures of the full-length p53 (fl-p53) tetramer bound to three different DNA sequences: a p21 response element, a puma response element and a nonspecific DNA sequence. Explicitly solvated, all-atom molecular dynamics simulations of the three complexes (totaling nearly 1 mu s of aggregate simulation time) yield final structures consistent with electron microscopy maps and, for the first time, show the direct interactions of the p53 C-terminal with DNA. Through a collective principal component analysis, we identify sequence-dependent differential quaternary binding modes of the p53 tetramer interfacing with DNA. Additionally, L1 loop dynamics of fl-p53 in the presence of DNA is revealed, and druggable pockets of p53 are identified via solvent mapping to aid future drug discovery studies.	[Demir, Oe; Ieong, P. U.; Amaro, R. E.] Univ Calif San Diego, Dept Chem & Biochem, 3234 Urey Hall,9500 Gilman Dr,MC 0332, La Jolla, CA 92103 USA; [Ieong, P. U.; Amaro, R. E.] Univ Calif San Diego, Natl Biomed Computat Resource, San Diego, CA 92103 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Amaro, RE (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 3234 Urey Hall,9500 Gilman Dr,MC 0332, La Jolla, CA 92103 USA.	ramaro@ucsd.edu		Demir, Ozlem/0000-0002-3317-4731	University of California Cancer Research Coordinating Committee award and NIH Innovator award [DP2-007237]; National Biomedical Computation Resource [NIH P41, GM103426]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103426] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD007237] Funding Source: NIH RePORTER	University of California Cancer Research Coordinating Committee award and NIH Innovator award; National Biomedical Computation Resource; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Mikel Valle for kindly providing the three-dimensional cryo-EM maps in 2011 Melero et al. article, and Steffen Lindert, Rob Swift, Clarisse Ricci, Lane Votapka, Jacob Durrant and Elizabeth Villa for helpful discussions. This work was supported by the University of California Cancer Research Coordinating Committee award and NIH Innovator award DP2-007237. Computing time on Stampede and Comet supercomputers was provided through the NSF XSEDE supercomputer resources grant RAC CHE060073N (to REA). Additional support from the National Biomedical Computation Resource NIH P41 GM103426 is acknowledged.	Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Altintas I, 2004, 16TH INTERNATIONAL CONFERENCE ON SCIENTIFIC AND STATISTICAL DATABASE MANAGEMENT, PROCEEDINGS, P423; [Anonymous], 2015, MAESTR VERS 10 4; Arlt C, 2015, PROTEOMICS, V15, P2746, DOI 10.1002/pmic.201400549; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Bochkareva E, 2005, P NATL ACAD SCI USA, V102, P15412, DOI 10.1073/pnas.0504614102; Case D. A., 2015, AMBER 2015; D'Abramo M, 2016, ONCOGENE, V35, P3272, DOI 10.1038/onc.2015.388; Darden T, 1999, STRUCT FOLD DES, V7, pR55, DOI 10.1016/S0969-2126(99)80033-1; Durrant JD, 2014, J CHEM THEORY COMPUT, V10, P5047, DOI 10.1021/ct500381c; Emamzadah S, 2014, J MOL BIOL, V426, P936, DOI 10.1016/j.jmb.2013.12.020; Emamzadah S, 2011, MOL CANCER RES, V9, P1493, DOI 10.1158/1541-7786.MCR-11-0351; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; Friedler A, 2005, STRUCTURE, V13, P629, DOI 10.1016/j.str.2005.01.020; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hupp TR, 1999, CELL MOL LIFE SCI, V55, P88, DOI 10.1007/s000180050272; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jacobs SA, 2002, NAT STRUCT BIOL, V9, P833, DOI 10.1038/nsb861; Janert P.K., 2010, GNUPLOT ACTION UNDER; Joerger AC, 2015, STRUCTURE, V23, P2246, DOI 10.1016/j.str.2015.10.016; Joerger AC, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000919; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Lavery R, 2009, NUCLEIC ACIDS RES, V37, P5917, DOI 10.1093/nar/gkp608; Leith JS, 2012, P NATL ACAD SCI USA, V109, P16552, DOI 10.1073/pnas.1120452109; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lim KW, 2009, J AM CHEM SOC, V131, P4301, DOI 10.1021/ja807503g; Liu XR, 2013, NUCLEIC ACIDS RES, V41, P6034, DOI 10.1093/nar/gkt305; Lowe ED, 2002, BIOCHEMISTRY-US, V41, P15625, DOI 10.1021/bi0268910; Lukman S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080221; Ma BY, 2007, NUCLEIC ACIDS RES, V35, P2986, DOI 10.1093/nar/gkm192; Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; Melero R, 2011, P NATL ACAD SCI USA, V108, P557, DOI [10.1073/pnas.1015520107, 10.1073/pnas.101S520107]; Molecular Operating Environment (MOE), 2016, H3A 2R7; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Natan E, 2011, J MOL BIOL, V409, P358, DOI 10.1016/j.jmb.2011.03.047; Ngan CH, 2012, NUCLEIC ACIDS RES, V40, pW271, DOI 10.1093/nar/gks441; Pang YP, 1999, J MOL MODEL, V5, P196, DOI 10.1007/s008940050119; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Petty TJ, 2011, EMBO J, V30, P2167, DOI 10.1038/emboj.2011.127; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; R-Core-Team, 2015, LANG ENV STAT COMP; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; Tafvizi A, 2011, P NATL ACAD SCI USA, V108, P563, DOI 10.1073/pnas.1016020107; Tidow H, 2007, P NATL ACAD SCI USA, V104, P12324, DOI 10.1073/pnas.0705069104; Trabuco LG, 2008, STRUCTURE, V16, P673, DOI 10.1016/j.str.2008.03.005; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Viadiu H, 2000, MOL CELL, V5, P889, DOI 10.1016/S1097-2765(00)80329-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Votapka LW, 2013, COMMUN COMPUT PHYS, V13, P256, DOI 10.4208/cicp.170711.111111s; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wassman CD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2361; Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wiman KG, 2007, ADV CANCER RES, V97, P321, DOI 10.1016/S0065-230X(06)97014-6; Yu X, 2012, CANCER CELL, V21, P614, DOI 10.1016/j.ccr.2012.03.042	63	21	23	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1451	1460		10.1038/onc.2016.321	http://dx.doi.org/10.1038/onc.2016.321			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27641333	Green Accepted			2022-12-17	WOS:000395862500013
J	Cidre-Aranaz, F; Grunewald, TGP; Surdez, D; Garcia-Garcia, L; Lazaro, JC; Kirchner, T; Gonzalez-Gonzalez, L; Sastre, A; Garcia-Miguel, P; Lopez-Perez, SE; Monzon, S; Delattre, O; Alonso, J				Cidre-Aranaz, F.; Gruenewald, T. G. P.; Surdez, D.; Garcia-Garcia, L.; Lazaro, J. Carlos; Kirchner, T.; Gonzalez-Gonzalez, L.; Sastre, A.; Garcia-Miguel, P.; Lopez-Perez, S. E.; Monzon, S.; Delattre, O.; Alonso, J.			EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma	ONCOGENE			English	Article							FIBROBLAST-GROWTH-FACTOR; MOLECULAR PATHOGENESIS; EWS/FLI1 ONCOPROTEIN; DOWN-REGULATION; TARGET GENES; EXPRESSION; MIGRATION; INVASION; RECEPTOR; FUSION	Ewing sarcoma is characterized by chromosomal translocations fusing the EWS gene with various members of the ETS family of transcription factors, most commonly FLI1. EWS-FLI1 is an aberrant transcription factor driving Ewing sarcoma tumorigenesis by either transcriptionally inducing or repressing specific target genes. Herein, we showed that Sprouty 1 (SPRY1), which is a physiological negative feedback inhibitor downstream of fibroblast growth factor (FGF) receptors (FGFRs) and other RAS-activating receptors, is an EWS-FLI1 repressed gene. EWS-FLI1 knockdown specifically increased the expression of SPRY1, while other Sprouty family members remained unaffected. Analysis of SPRY1 expression in a panel of Ewing sarcoma cells showed that SPRY1 was not expressed in Ewing sarcoma cell lines, suggesting that it could act as a tumor suppressor gene in these cells. In agreement, induction of SPRY1 in three different Ewing sarcoma cell lines functionally impaired proliferation, clonogenic growth and migration. In addition, SPRY1 expression inhibited extracellular signal-related kinase/mitogen-activated protein kinase (MAPK) signaling induced by serum and basic FGF (bFGF). Moreover, treatment of Ewing sarcoma cells with the potent FGFR inhibitor PD-173074 reduced bFGF-induced proliferation, colony formation and in vivo tumor growth in a dose-dependent manner, thus mimicking SPRY1 activity in Ewing sarcoma cells. Although the expression of SPRY1 was low when compared with other tumors, SPRY1 was variably expressed in primary Ewing sarcoma tumors and higher expression levels were significantly associated with improved outcome in a large patient cohort. Taken together, our data indicate that EWS-FLI1-mediated repression of SPRY1 leads to unrestrained bFGF-induced cell proliferation, suggesting that targeting the FGFR/MAPK pathway can constitute a promising therapeutic approach for this devastating disease.	[Cidre-Aranaz, F.; Garcia-Garcia, L.; Lazaro, J. Carlos; Gonzalez-Gonzalez, L.; Lopez-Perez, S. E.; Monzon, S.; Alonso, J.] Inst Salud Carlos III, Inst Invest Enfermedades Raras, Unidad Tumores Solidos Infantiles, Ctra Majadahonda Pozuelo Km 2, Majadahonda Madrid 28220, Spain; [Gruenewald, T. G. P.; Surdez, D.; Delattre, O.] Genet & Biol Canc Inst Curie Res Ctr, INSERM U830, Paris, France; [Gruenewald, T. G. P.] Ludwig Maximilians Univ Munchen, Inst Pathol, Lab Pediat Sarcoma Biol, Munich, Germany; [Sastre, A.; Garcia-Miguel, P.] Hosp Infantil Univ La Paz, Unidad Hematooncol Pediat, Madrid, Spain; [Monzon, S.] Inst Salud Carlos III, CIBERER U758, Madrid, Spain	Instituto de Salud Carlos III; Instituto de Investigacion de Enfermedades Raras (IIER); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; University of Munich; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III	Alonso, J (corresponding author), Inst Salud Carlos III, Inst Invest Enfermedades Raras, Unidad Tumores Solidos Infantiles, Ctra Majadahonda Pozuelo Km 2, Majadahonda Madrid 28220, Spain.	fjalonso@isciii.es	Grünewald, Thomas G. P./O-2317-2013; Monzon, Sara/AAG-2909-2021; Alonso, Javier/B-6012-2013; Surdez, Didier/ABG-4565-2020	Grünewald, Thomas G. P./0000-0003-0920-7377; Monzon, Sara/0000-0002-0740-6324; Alonso, Javier/0000-0002-6287-8391; delattre, olivier/0000-0002-8730-2276; Cidre Aranaz, Florencia/0000-0002-0246-7179; GARCIA, LAURA/0000-0002-8585-849X; Gonzalez-Gonzalez, Laura/0000-0003-0372-2650	Asociacion Pablo Ugarte and Miguelanez SA; ASION-La Hucha de Tomas; Fundacion La Sonrisa de Alex; Instituto de Salud Carlos III [PI12/00816, RTICC RD12/0036/0027]; Verein zur Forderung von Wissenschaft und Forschung an der Medizinischen Fakultat der LMU Munchen (WiFoMed); Daimler and Benz Foundation; LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative; Mehr LEBEN fur krebskranke Kinder-Bettina-Brau-Stiftung; Walter Schulz Foundation; German Cancer Aid [DKH-111886, DKH-70112257]; Ligue Nationale Contre Le Cancer (Equipe labellisee); European PROVABES grant; Reinhard Frank Foundation; Fritz Thyssen Foundation [FTH-40.15.0.030MN]; European ASSET grant; European EEC FP7 grant	Asociacion Pablo Ugarte and Miguelanez SA; ASION-La Hucha de Tomas; Fundacion La Sonrisa de Alex; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Verein zur Forderung von Wissenschaft und Forschung an der Medizinischen Fakultat der LMU Munchen (WiFoMed); Daimler and Benz Foundation; LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative; Mehr LEBEN fur krebskranke Kinder-Bettina-Brau-Stiftung; Walter Schulz Foundation; German Cancer Aid(Deutsche Krebshilfe); Ligue Nationale Contre Le Cancer (Equipe labellisee)(Ligue nationale contre le cancer); European PROVABES grant; Reinhard Frank Foundation; Fritz Thyssen Foundation; European ASSET grant; European EEC FP7 grant	FC-A, LG-G, JCL, AS, PG-M, SEL-P, SM and JA are supported by Asociacion Pablo Ugarte and Miguelanez SA, ASION-La Hucha de Tomas, Fundacion La Sonrisa de Alex and Instituto de Salud Carlos III (PI12/00816 and Spanish Cancer Network RTICC RD12/0036/0027). TGPG is supported by a grant from 'Verein zur Forderung von Wissenschaft und Forschung an der Medizinischen Fakultat der LMU Munchen (WiFoMed)', the Daimler and Benz Foundation in cooperation with the Reinhard Frank Foundation, by LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative, the 'Mehr LEBEN fur krebskranke Kinder-Bettina-Brau-Stiftung', the Walter Schulz Foundation, the Fritz Thyssen Foundation (FTH-40.15.0.030MN) and by the German Cancer Aid (DKH-111886 and DKH-70112257). The 'Genetics and Biology of Cancers' team (TGPG, DS and OD) is supported by grants from the Ligue Nationale Contre Le Cancer (Equipe labellisee). This work was also supported by the European PROVABES, ASSET and EEC FP7 grants. We also thank the following associations for their invaluable support: the Societe Francaise des Cancers de l'Enfant, Courir pour Mathieu, Dans les pas du Geant, Olivier Chape, Les Bagouzamanon, Enfants et Sante and les Amis de Claire. We thank Dr S Navarro (University of Valencia, Valencia, Spain) and Dr TJ Triche (Children's Hospital Los Angeles, Los Angeles, USA) for providing us with Ewing sarcoma cell lines A4573 and TTC-466, respectively.	Agelopoulos K, 2015, CLIN CANCER RES, V21, P4935, DOI 10.1158/1078-0432.CCR-14-2744; Agra N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066281; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bilke S, 2013, GENOME RES, V23, P1797, DOI 10.1101/gr.151340.112; Bottcher RT, 2005, ENDOCR REV, V26, P63, DOI 10.1210/er.2003-0040; Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457; Carrillo J, 2007, CLIN CANCER RES, V13, P2429, DOI 10.1158/1078-0432.CCR-06-1762; Chalkiadaki G, 2009, INT J BIOCHEM CELL B, V41, P1323, DOI 10.1016/j.biocel.2008.11.008; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; Cidre-Aranaz F, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00162; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fritzsche S, 2006, ENDOCR-RELAT CANCER, V13, P839, DOI 10.1677/erc.1.01190; Garcia-Aragoncillo E, 2008, ONCOGENE, V27, P6034, DOI 10.1038/onc.2008.203; Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256; Grohar PJ, 2013, PHARMACOL THERAPEUT, V137, P216, DOI 10.1016/j.pharmthera.2012.10.004; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Grunewald TGP, 2015, NAT GENET, V47, P1073, DOI 10.1038/ng.3363; Grunewald TGP, 2012, MOL CANCER RES, V10, P52, DOI 10.1158/1541-7786.MCR-11-0524; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Kamura S, 2010, BRIT J CANCER, V103, P370, DOI 10.1038/sj.bjc.6605775; Kovar H, 1997, ONCOGENE, V15, P2225, DOI 10.1038/sj.onc.1201397; Kovar H, 2003, ONCOGENE, V22, P3193, DOI 10.1038/sj.onc.1206391; Kovar H, 2014, EXPERT OPIN THER TAR, V18, P1315, DOI 10.1517/14728222.2014.947963; Kwabi-Addo B, 2004, CANCER RES, V64, P4728, DOI 10.1158/0008-5472.CAN-03-3759; Kwabi-Addo B, 2009, EPIGENETICS, V4, P54, DOI 10.4161/epi.4.1.7400; Ladenstein R, 2010, J CLIN ONCOL, V28, P3284, DOI 10.1200/JCO.2009.22.9864; Liu XZ, 2014, ADV MATER INTERFACES, V1, DOI 10.1002/admi.201300053; Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207; Macia A, 2012, ONCOGENE, V31, P3961, DOI 10.1038/onc.2011.556; Mackintosh C, 2010, CANCER BIOL THER, V9, P655, DOI 10.4161/cbt.9.9.11511; Masoumi-Moghaddam S, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-61; Mekkawy AH, 2014, TUMOR BIOL, V35, P5037, DOI 10.1007/s13277-014-1665-y; Mendiola M, 2006, INT J CANCER, V118, P1381, DOI 10.1002/ijc.21578; Minowada G, 1999, DEVELOPMENT, V126, P4465; Navarro D, 2010, CARCINOGENESIS, V31, P394, DOI 10.1093/carcin/bgp317; Postel-Vinay S, 2012, NAT GENET, V44, P323, DOI 10.1038/ng.1085; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Surdez D, 2012, CANCER RES, V72, P4494, DOI 10.1158/0008-5472.CAN-12-0371; Terada N, 2014, J CELL BIOCHEM, V115, P1505, DOI 10.1002/jcb.24805; Tirode F, 2014, CANCER DISCOV, V4, P1342, DOI 10.1158/2159-8290.CD-14-0622; Tomazou EM, 2015, CELL REP, V10, P1082, DOI 10.1016/j.celrep.2015.01.042; Touat M, 2015, CLIN CANCER RES, V21, P2684, DOI 10.1158/1078-0432.CCR-14-2329; Wiles ET, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059369; Willier S, 2013, BIOL CELL, V105, P317, DOI 10.1111/boc.201300011; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; Yue PYK, 2010, J BIOMOL SCREEN, V15, P427, DOI 10.1177/1087057110361772; Zhao Z, 2010, GENE DEV, V24, P1389, DOI 10.1101/gad.1940710; Zhu LM, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00230	52	21	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					766	776		10.1038/onc.2016.244	http://dx.doi.org/10.1038/onc.2016.244			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27375017	Green Accepted			2022-12-17	WOS:000394168200004
J	Khan, S; Sikander, M; Ebeling, MC; Ganju, A; Kumari, S; Yallapu, MM; Hafeez, BB; Ise, T; Nagata, S; Zafar, N; Behrman, SW; Wan, JY; Ghimire, HM; Sahay, P; Pradhan, P; Chauhan, SC; Jaggi, M				Khan, S.; Sikander, M.; Ebeling, M. C.; Ganju, A.; Kumari, S.; Yallapu, M. M.; Hafeez, B. B.; Ise, T.; Nagata, S.; Zafar, N.; Behrman, S. W.; Wan, J. Y.; Ghimire, H. M.; Sahay, P.; Pradhan, P.; Chauhan, S. C.; Jaggi, M.			MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression	ONCOGENE			English	Article							FOCAL ADHESION KINASE; CELL-MIGRATION; PROTEIN-KINASE; OVARIAN-CANCER; SURVIVAL; MUCINS; EXPRESSION; MOTILITY; GROWTH; ROLES	Although MUC13, a transmembrane mucin, is aberrantly expressed in pancreatic ductal adenocarcinoma (PDAC) and generally correlates with increased expression of HER2, the underlying mechanism remains poorly understood. Herein, we found that MUC13 co-localizes and interacts with HER2 in PDAC cells (reciprocal co-immunoprecipitation, immunofluorescence, proximity ligation, co-capping assays) and tissues (immunohistofluorescence). The results from this study demonstrate that MUC13 functionally interacts and activates HER2 at p1248 in PDAC cells, leading to stimulation of HER2 signaling cascade, including ERK1/2, FAK, AKT and PAK1 as well as regulation of the growth, cytoskeleton remodeling and motility, invasion of PDAC cells-all collectively contributing to PDAC progression. Interestingly, all of these phenotypic effects of MUC13-HER2 co-localization could be effectively compromised by depleting MUC13 and mediated by the first and second EGF-like domains of MUC13. Further, MUC13-HER2 co-localization also holds true in PDAC tissues with a strong functional correlation with events contributing to increased degree of disorder and cancer aggressiveness. In brief, findings presented here provide compelling evidence of a functional ramification of MUC13-HER2: this interaction could be potentially exploited for targeted therapeutics in a subset of patients harboring an aggressive form of PDAC.	[Khan, S.; Sikander, M.; Ganju, A.; Kumari, S.; Yallapu, M. M.; Hafeez, B. B.; Chauhan, S. C.; Jaggi, M.] Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Canc Res Bldg,19 South Manassas,Ave Suite 226, Memphis, TN 38163 USA; [Khan, S.; Sikander, M.; Ganju, A.; Kumari, S.; Yallapu, M. M.; Hafeez, B. B.; Chauhan, S. C.; Jaggi, M.] Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, Memphis, TN 38163 USA; [Ebeling, M. C.] Sanford Res, Canc Biol Res Ctr, Sioux Falls, SD USA; [Ise, T.; Nagata, S.] Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Ctr Drug Design Res, Ibaraki, Osaka, Japan; [Zafar, N.] Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA; [Behrman, S. W.] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; [Wan, J. Y.] Univ Tennessee, Ctr Hlth Sci, Dept Biostat & Epidemiol, Memphis, TN 38163 USA; [Ghimire, H. M.; Sahay, P.; Pradhan, P.] Univ Memphis, Dept Phys, Memphis, TN 38152 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Sanford Health; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Memphis	Chauhan, SC; Jaggi, M (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Canc Res Bldg,19 South Manassas,Ave Suite 226, Memphis, TN 38163 USA.	schauha1@uthsc.edu; mjaggi@uthsc.edu	Nagata, Satoshi/B-5781-2008; Ganju, Aditya/AAM-3757-2021; Ganju, Aditya/AAK-4870-2021	Ganju, Aditya/0000-0003-1258-0105; Nagata, Satoshi/0000-0001-9156-5215	National Institutes of Health [R01 CA142736, U01 CA162106A, R01 EB003682, K22CA174841]; Department of Defense [PC130870]; College of Pharmacy Dean's Seed/Instrument Grants of the University of Tennessee Health Science Center; Grants of the University of Memphis; Herb Kosten Foundation [UT 14-0558]; NATIONAL CANCER INSTITUTE [K22CA174841, R01CA142736, U01CA162106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB003682] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); College of Pharmacy Dean's Seed/Instrument Grants of the University of Tennessee Health Science Center; Grants of the University of Memphis; Herb Kosten Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was partially supported by grants from the National Institutes of Health (R01 CA142736 to SCC, U01 CA162106A to SCC and MJ; R01 EB003682 to PP; K22CA174841 to MMY), the Department of Defense (PC130870 to SCC and MJ), the College of Pharmacy 2014 and 2015 Dean's Seed/Instrument Grants of the University of Tennessee Health Science Center (to SCC, MJ and MMY) and Grants of the University of Memphis (to PP). We acknowledge the Herb Kosten Foundation for pancreatic cancer research support (UT 14-0558 to SCC). We are also thankful to Cathy Christopherson for editorial assistance.	Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chauhan SC, 2012, MOL CANCER THER, V11, P24, DOI 10.1158/1535-7163.MCT-11-0598; Chauhan SC, 2009, J OVARIAN RES, V2, DOI 10.1186/1757-2215-2-21; Chauhan SC, 2009, CANCER RES, V69, P765, DOI 10.1158/0008-5472.CAN-08-0587; Damania D, 2010, BIOPHYS J, V99, P989, DOI 10.1016/j.bpj.2010.05.023; Grothey A, 2000, ONCOGENE, V19, P4864, DOI 10.1038/sj.onc.1203838; Guddo F, 1998, J CLIN PATHOL, V51, P667, DOI 10.1136/jcp.51.9.667; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Jaggi M, 2005, CANCER RES, V65, P483; Jonckheere Nicolas, 2008, Critical Reviews in Oncogenesis, V14, P177; Kar G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000601; Kaur S, 2013, NAT REV GASTRO HEPAT, V10, P607, DOI 10.1038/nrgastro.2013.120; Khan S, 2014, ONCOTARGET, V5, P7599, DOI 10.18632/oncotarget.2281; Khan S, 2012, MOL CARCINOGEN, V51, P679, DOI 10.1002/mc.20821; Koos B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8294; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Maher DM, 2011, MOL CANCER RES, V9, P531, DOI 10.1158/1541-7786.MCR-10-0443; Parry S, 2001, BIOCHEM BIOPH RES CO, V283, P715, DOI 10.1006/bbrc.2001.4775; Paszek MJ, 2014, NATURE, V511, P319, DOI 10.1038/nature13535; Pradhan P, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/2/026012; Pradhan P, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3524523; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Senapati S, 2010, TRENDS BIOCHEM SCI, V35, P236, DOI 10.1016/j.tibs.2009.10.003; Settleman J, 2015, ONCOTARGET, V6, P588, DOI 10.18632/oncotarget.3036; Subramanian H, 2009, CANCER RES, V69, P5357, DOI 10.1158/0008-5472.CAN-08-3895; Subramanian H, 2008, P NATL ACAD SCI USA, V105, P20118, DOI 10.1073/pnas.0804723105; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200	29	21	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					491	500		10.1038/onc.2016.218	http://dx.doi.org/10.1038/onc.2016.218			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27321183	Green Accepted			2022-12-17	WOS:000394166700006
